PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Meiling-Wesse, K; Barth, H; Voss, C; Eskelinen, EL; Epple, UD; Thumm, M				Meiling-Wesse, K; Barth, H; Voss, C; Eskelinen, EL; Epple, UD; Thumm, M			Atg21 is required for effective recruitment of Atg8 to the preautophagosomal structure during the Cvt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLE TARGETING PATHWAY; PRE-AUTOPHAGOSOMAL STRUCTURE; SACCHAROMYCES-CEREVISIAE; YEAST VACUOLE; MAMMALIAN-CELLS; CYTOPLASM; PROTEIN; MEMBRANE; COMPLEX; TRANSPORT	Atg21 and Atg18 are homologue yeast proteins. Whereas Atg18 is essential for the Cvt pathway and autophagy, a lack of Atg21 only blocks the Cvt pathway. Our proteinase protection experiments now demonstrate that growing atg21Delta cells fail to form proaminopeptidase I-containing Cvt vesicles. Quantitative measurement of autophagy in starving atg21Delta cells showed only 35% of the wild-type rate. This suggests that Atg21 plays a nonessential role in improving the fidelity of autophagy. The intracellular localization of Atg21 is unique among the Atg proteins. In cells containing multiple vacuoles, Atg21-yellow fluorescent protein clearly localizes to the vertices of the vacuole junctions. Cells with a single vacuole show most of the protein at few perivacuolar punctae. This distribution pattern is reminiscent to the Vps class C( HOPS) ( homotypic fusion and vacuolar protein sorting) protein complex. In growing cells, Atg21 is required for effective recruitment of Atg8 to the preautophagosomal structure. Consistently, the covalent linkage of Atg8 to the lipid phosphatidylethanolamine is significantly retarded. Lipidated Atg8 is supposed to act during the elongation of autophagosome precursors. However, despite the reduced autophagic rate and the retardation of Atg8 lipidation, electron microscopy of starved atg21Delta ypt7Delta double mutant cells demonstrates the formation of normally sized autophagosomes with an average diameter of 450 nm.	Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37073 Gottingen, Germany; Univ Kiel, Inst Biochem, D-24118 Kiel, Germany	University of Gottingen; University of Kiel	Thumm, M (corresponding author), Univ Gottingen, Ctr Biochem & Mol Cell Biol, Heinrich Dueker Weg 12, D-37073 Gottingen, Germany.	mthumm@uni-goettingen.de	Thumm, Michael/A-8033-2015; Eskelinen, Eeva-Liisa/AAF-3496-2019	Eskelinen, Eeva-Liisa/0000-0003-0006-7785; Thumm, Michael/0000-0003-3238-4857				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Barth H, 2002, FEBS LETT, V512, P173, DOI 10.1016/S0014-5793(02)02252-4; Barth H, 2001, FEBS LETT, V508, P23, DOI 10.1016/S0014-5793(01)03016-2; Campbell CL, 1998, J CELL SCI, V111, P2455; Del Roso A, 2003, EXP GERONTOL, V38, P519, DOI 10.1016/S0531-5565(03)00002-0; Dove SK, 2004, EMBO J, V23, P1922, DOI 10.1038/sj.emboj.7600203; Epple UD, 2003, J BIOL CHEM, V278, P7810, DOI 10.1074/jbc.M209309200; Georgakopoulos T, 2001, YEAST, V18, P1155, DOI 10.1002/yea.764; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Leber R, 2001, J BIOL CHEM, V276, P29210, DOI 10.1074/jbc.M101438200; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Meiling-Wesse K, 2002, FEBS LETT, V530, P174, DOI 10.1016/S0014-5793(02)03456-7; Meiling-Wesse K, 2002, FEBS LETT, V526, P71, DOI 10.1016/S0014-5793(02)03119-8; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Nice DC, 2002, J BIOL CHEM, V277, P30198, DOI 10.1074/jbc.M204736200; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Pan XZ, 2000, MOL BIOL CELL, V11, P2445, DOI 10.1091/mbc.11.7.2445; Prescianotto-Baschong C, 2002, TRAFFIC, V3, P37, DOI 10.1034/j.1600-0854.2002.30106.x; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ravikumar B, 2003, HUM MOL GENET, V12, P985, DOI 10.1093/hmg/ddg109; Reggiori F, 2003, J BIOL CHEM, V278, P5009, DOI 10.1074/jbc.M210436200; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Thumm M, 2002, MOL CELL, V10, P1257, DOI 10.1016/S1097-2765(02)00794-3; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; Thumm M, 2000, MICROSC RES TECHNIQ, V51, P563, DOI 10.1002/1097-0029(20001215)51:6<563::AID-JEMT6>3.0.CO;2-8; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Wurmser AE, 2002, J CELL BIOL, V158, P761, DOI 10.1083/jcb.200112050; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	56	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37741	37750		10.1074/jbc.M401066200	http://dx.doi.org/10.1074/jbc.M401066200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15194695	hybrid			2022-12-27	WOS:000223554600066
J	Seong, YM; Choi, JY; Park, HJ; Kim, KJ; Ahn, SG; Seong, GH; Kim, IK; Kang, S; Rhim, H				Seong, YM; Choi, JY; Park, HJ; Kim, KJ; Ahn, SG; Seong, GH; Kim, IK; Kang, S; Rhim, H			Autocatalytic processing of HtrA2/Omi is essential for induction of caspase-dependent cell death through antagonizing XIAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE OMI/HTRA2; ESCHERICHIA-COLI; APOPTOSIS PROTEINS; RAPID PURIFICATION; INTRAMEMBRANE PROTEOLYSIS; MAMMALIAN PROTEIN; STRUCTURAL BASIS; CYTOCHROME-C; PDZ DOMAINS; HTRA FAMILY	A mature form of nuclear-encoded mitochondrial serine protease HtrA2/Omi is pivotal in regulating apoptotic cell death; however, the underlying mechanism of the processing event of HtrA2/Omi and its relevant biological function remain to be clarified. Here, we describe that HtrA2/Omi is autocatalytically processed to the 36-kDa protein fragment, which is required for the cytochrome c-dependent caspase activation along with neutralizing XIAP-mediated inhibition of caspases through interaction with XIAP, eventually promoting apoptotic cell death. We have shown that the autocatalytic processing of HtrA2/Omi occurs via an intermolecular event, demonstrated by incubating an in vitro translated HtrA2/Omi (S306A) mutant with the enzymatically active glutathione S-transferase-HtrA2/Omi protein. Using N-terminal amino acid sequencing and mutational analysis, we identified that the autocatalytic cleavage site is the carboxyl side of alanine 133 of HtrA2/ Omi, resulting in exposure of an inhibitor of apoptosis protein binding motif in its N terminus. Our study provides evidence that the autocatalytic processing of HtrA2/ Omi is crucial for regulating HtrA2/ Omi-mediated apoptotic cell death.	Catholic Univ Korea, Catholic Res Inst Med Sci, Res Inst Mol Genet, Seoul 137701, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biomed Sci, Seoul 137701, South Korea; Sangmyung Univ, Dept Biol, Seoul 110743, South Korea	Catholic University of Korea; Korea University; Catholic University of Korea; Catholic University of Korea; Sang Myung University	Kang, S (corresponding author), Catholic Univ Korea, Catholic Res Inst Med Sci, Res Inst Mol Genet, 505 Banpo Dong, Seoul 137701, South Korea.	skang@korea.ac.kr; hrhim@catholic.ac.kr						Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Choi JY, 2002, BIOTECHNOL APPL BIOC, V36, P33, DOI 10.1042/BA20020004; Cilenti L, 2003, J BIOL CHEM, V278, P11489, DOI 10.1074/jbc.M212819200; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Jones CH, 2002, J BACTERIOL, V184, P5762, DOI 10.1128/JB.184.20.5762-5771.2002; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kipp RA, 2002, BIOCHEMISTRY-US, V41, P7344, DOI 10.1021/bi0121454; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Martins LM, 2002, CELL DEATH DIFFER, V9, P699, DOI 10.1038/sj.cdd.4401044; Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Park HJ, 2003, BIOTECHNOL LETT, V25, P1597, DOI 10.1023/A:1025630013679; RHIM H, 1993, J VIROL, V67, P1110, DOI 10.1128/JVI.67.2.1110-1121.1993; RHIM HS, 1993, PROTEIN EXPRES PURIF, V4, P24, DOI 10.1006/prep.1993.1004; Savopoulos JW, 2000, PROTEIN EXPRES PURIF, V19, P227, DOI 10.1006/prep.2000.1240; Seong YM, 2004, PROTEIN EXPRES PURIF, V33, P200, DOI 10.1016/j.pep.2003.10.002; Sik A, 2004, J BIOL CHEM, V279, P15323, DOI 10.1074/jbc.M313756200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	53	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37588	37596		10.1074/jbc.M401408200	http://dx.doi.org/10.1074/jbc.M401408200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201285	hybrid			2022-12-27	WOS:000223554600050
J	Wang, YG; Nnakwe, C; Lane, WS; Modesti, M; Frank, KM				Wang, YG; Nnakwe, C; Lane, WS; Modesti, M; Frank, KM			Phosphorylation and regulation of DNA ligase IV stability by DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; RAY-SENSITIVE MUTANTS; END-JOINING PROTEINS; HAMSTER OVARY CELL; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; XRCC4 PROTEIN; CANCER SUSCEPTIBILITY; GENOMIC INSTABILITY; EMBRYONIC LETHALITY	DNA ligase IV (Lig4), x-ray cross-complementation group 4 (XRCC4), and DNA-dependent protein kinase (DNA-PK) are essential mammalian nonhomologous end joining proteins used for V(D)J recombination and DNA repair. Previously a Lig4 peptide was reported to be an in vitro substrate for DNA-PK, but the phosphorylation state of Lig4 protein in vivo is not known. In this study, we report that a full-length Lig4 construct was expressed as a phosphoprotein in the cell. Also the full-length Lig4 protein, in complex with XRCC4, was an in vitro substrate for DNA-PK. Using tandem mass spectrometry, we identified a DNA-PK phosphorylation site at Thr-650 in human Lig4 and a potential second phosphorylation site at Ser-668 or Ser-672. Phosphorylation of Lig4 per se was not required for Lig4 DNA end joining activity. Substitution of these amino acids with alanine, individually or in combination, led to changes in Lig4 protein stability of mouse Lig4. The phosphomimetic mutation S650D returned Lig4 stability to that of the wild-type protein. Furthermore DNA-PK was found to negatively regulate Lig4 protein stability. Our results suggest that Lig4 stability is regulated by multiple factors, including interaction with XRCC4, phosphorylation status, and possibly Lig4 conformation.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; Erasmus Med Ctr, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	University of Chicago; Harvard University; Erasmus University Rotterdam; Erasmus MC	Frank, KM (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.	kfrank@uchicago.edu	Modesti, Mauro/D-6258-2017	Modesti, Mauro/0000-0002-4964-331X	NIAID NIH HHS [K08 AI01428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Brady N, 2003, CANCER RES, V63, P1798; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Fu YP, 2003, CANCER RES, V63, P2440; Fukumura R, 1998, J BIOL CHEM, V273, P13058, DOI 10.1074/jbc.273.21.13058; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Grawunder U, 2001, CURR OPIN IMMUNOL, V13, P186, DOI 10.1016/S0952-7915(00)00203-X; Hamer G, 2003, BIOL REPROD, V68, P717, DOI 10.1095/biolreprod.102.008920; HAN J, 2003, CARCINOGENESIS; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Hsu HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Kuschel B, 2002, HUM MOL GENET, V11, P1399, DOI 10.1093/hmg/11.12.1399; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Lee KJ, 2002, J IMMUNOL, V169, P3413, DOI 10.4049/jimmunol.169.6.3413; Lee Y, 2002, CANCER RES, V62, P6395; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; Mauldin SK, 2002, NUCLEIC ACIDS RES, V30, P4075, DOI 10.1093/nar/gkf529; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Modesti M, 2003, J MOL BIOL, V334, P215, DOI 10.1016/j.jmb.2003.09.031; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Przewloka MR, 2003, MOL BIOL CELL, V14, P685, DOI 10.1091/mbc.e01-11-0117; Roddam PL, 2002, J MED GENET, V39, P900, DOI 10.1136/jmg.39.12.900; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Yu YP, 2003, DNA REPAIR, V2, P1239, DOI 10.1016/S1568-7864(03)00143-5; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	67	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37282	37290		10.1074/jbc.M401217200	http://dx.doi.org/10.1074/jbc.M401217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15194694	hybrid			2022-12-27	WOS:000223554600012
J	Chastain, PD; Bowers, JL; Lee, DG; Bell, SP; Griffith, JD				Chastain, PD; Bowers, JL; Lee, DG; Bell, SP; Griffith, JD			Mapping subunit location on the Saccharomyces cerevisiae origin recognition complex free and bound to DNA using a novel nanoscale biopointer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL ELEMENTS; PROTEIN COMPLEXES; ATPASE ACTIVITY; REPLICATION; BINDING; BIOTINYLATION; SUBSTRATE; DOMAIN; CELLS; SITE	The Saccharomyces cerevisiae origin recognition complex (ORC) is composed of six subunits and is an essential component in the assembly of the replication apparatus. To probe the organization of this multiprotein complex by electron microscopy, each subunit was tagged on either its C or N terminus with biotin and assembled into a complex with the five other unmodified subunits. A nanoscale biopointer consisting of a short DNA duplex with streptavidin at one end was used to map the location of the N and C termini of each subunit. These observations were made using ORC free in solution and bound to the ARS1 origin of replication. This mapping confirms and extends previous studies mapping the sites of subunit interaction with origin DNA. In particular, we provide new information concerning the stoichiometry of the ORC-ARS1 complex and the changes in conformation that are associated with DNA binding by ORC. This versatile, new approach to mapping protein structure has potential for many applications.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA	University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu	Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788; Bell, Stephen/0000-0002-2876-610X	NIGMS NIH HHS [GM 19014, GM 31819, GM 53229] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819, R01GM053229] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BERLINER E, 1994, J BIOL CHEM, V269, P8610; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Duffy S, 1998, ANAL BIOCHEM, V262, P122, DOI 10.1006/abio.1998.2770; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Stenlund A, 2003, NAT REV MOL CELL BIO, V4, P777, DOI 10.1038/nrm1226; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652	19	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36354	36362		10.1074/jbc.M403501200	http://dx.doi.org/10.1074/jbc.M403501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15201282	Green Published, hybrid			2022-12-27	WOS:000223453600025
J	Ronning, DR; Vissa, V; Besra, GS; Belisle, JT; Sacchettini, JC				Ronning, DR; Vissa, V; Besra, GS; Belisle, JT; Sacchettini, JC			Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTIVE IMMUNITY; PROTEIN; FIBRONECTIN; EXPRESSION; MECHANISM; RESIDUES; EFFICACY; VACCINES; COMPLEX; H37RV	The maintenance of the highly hydrophobic cell wall is central to the survival of Mycobacterium tuberculosis within its host environment. The antigen 85 proteins (85A, 85B, and 85C) of M. tuberculosis help maintain the integrity of the cell wall 1) by catalyzing the transfer of mycolic acids to the cell wall arabinogalactan and 2) through the synthesis of trehalose dimycolate (cord factor). Additionally, these secreted proteins allow for rapid invasion of alveolar macrophages via direct interactions between the host immune system and the invading bacillus. Here we describe two crystal structures: the structure of antigen 85C co-crystallized with octylthioglucoside as substrate, resolved to 2.0 Angstrom, and the crystal structure of antigen 85A, which was solved at a resolution of 2.7 Angstrom. The structure of 85C with the substrate analog identifies residues directly involved in substrate binding. Elucidation of the antigen 85A structure, the last of the three antigen 85 homologs to be solved, shows that the active sites of the three antigen 85 proteins are virtually identical, indicating that these share the same substrate. However, in contrast to the high level of conservation within the substrate-binding site and the active site, surface residues disparate from the active site are quite variable, indicating that three antigen 85 enzymes are needed to evade the host immune system.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Texas A&M University System; Texas A&M University College Station; University of Birmingham; Colorado State University	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.	sacchett@tamu.edu	Belisle, John T/B-8944-2017	Belisle, John T/0000-0002-2539-2798; Besra, Gurdyal/0000-0002-5605-0395; Ronning, Donald/0000-0003-2583-8849	NCRR NIH HHS [RR 07707] Funding Source: Medline; NIGMS NIH HHS [GM 62410] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; Anderson DH, 2001, J MOL BIOL, V307, P671, DOI 10.1006/jmbi.2001.4461; Armitige LY, 2000, INFECT IMMUN, V68, P767, DOI 10.1128/IAI.68.2.767-778.2000; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DRENTH J, 1994, PRINCIPLES PROTEIN X, P71; Fikrig E, 2000, J IMMUNOL, V164, P5344, DOI 10.4049/jimmunol.164.10.5344; Harth G, 2002, P NATL ACAD SCI USA, V99, P15614, DOI 10.1073/pnas.242612299; Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamath AT, 2000, CLIN EXP IMMUNOL, V120, P476, DOI 10.1046/j.1365-2249.2000.01240.x; Kamath AT, 1999, INFECT IMMUN, V67, P1702; Mariani F, 2000, GENE, V253, P281, DOI 10.1016/S0378-1119(00)00249-3; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Miki K, 2004, INFECT IMMUN, V72, P2014, DOI 10.1128/IAI.72.4.2014-2021.2004; Naito M, 2000, BIOCHEM J, V347, P725, DOI 10.1042/0264-6021:3470725; Naito M, 1998, J BIOL CHEM, V273, P2905, DOI 10.1074/jbc.273.5.2905; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; Puech V, 2002, MOL MICROBIOL, V44, P1109, DOI 10.1046/j.1365-2958.2002.02953.x; ROCHE PW, 1994, INFECT IMMUN, V62, P5319, DOI 10.1128/IAI.62.12.5319-5326.1994; Ronning DR, 2000, NAT STRUCT BIOL, V7, P141; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; van Putten JPM, 1998, MOL MICROBIOL, V29, P369, DOI 10.1046/j.1365-2958.1998.00951.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	31	72	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36771	36777		10.1074/jbc.M400811200	http://dx.doi.org/10.1074/jbc.M400811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192106	hybrid			2022-12-27	WOS:000223453600078
J	Andreishcheva, EN; Kunkel, JP; Gemmill, TR; Trimble, RB				Andreishcheva, EN; Kunkel, JP; Gemmill, TR; Trimble, RB			Five genes involved in biosynthesis of the pyruvylated Gal beta 1,3-epitope in Schizosaccharomyces pombe N-linked glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							AMYLOID-P COMPONENT; XANTHAN GUM BIOSYNTHESIS; MADS-BOX-FAMILY; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; FISSION YEAST; CELL-SURFACE; CRYSTAL-STRUCTURE; CAPSULAR POLYSACCHARIDE; PYRUVATE ACETAL	The N-linked galactomannans of Schizosaccharomyces pombe have pyruvylated Galbeta1,3- (PvGal) caps on a portion of the Galalpha1,2- residues in their outer chains (Gemmill, T. R., and Trimble, R. B. (1998) Glycobiology 8, 1087-1095). PvGal biosynthesis was investigated by ethyl methanesulfonate mutagenesis of S. pombe, followed by the isolation of cells devoid of negatively charged N-glycans by Q-Sepharose exclusion and failure to bind human serum amyloid P component, which acts as a lectin for terminal PvGal residues. Mutant glycans were characterized by lectin binding, saccharide composition, exoglycosidase sensitivity, and NMR spectroscopy. Restoration of the cell surface negative charge by complementation with an S. pombe genomic library led to the identification of five genes involved in PvGal biosynthesis, which we designated pvg1-pvg5. Pvg1p may be a pyruvyltransferase, since NMR of pvg1(-) mutant N-glycans revealed the absence of only the pyruvyl moiety. Pvg2p-Pvg5p are crucial for attachment of the Galbeta1,3- residue that becomes pyruvylated. Pvg3p is predicted to be a member of the beta1,3-galactosyltransferase family, and Pvg3p-green fluorescent protein labeling was consistent with Golgi localization. Predicted Pvg1p and Pvg3p functions imply that Galbeta1,3- is added to the galactomannans and is then pyruvylated in situ, rather than by an en bloc addition of PvGalbeta1,3- caps to the outer chain. Pvg4p-green fluorescent protein targeted to the nucleus, and its sequence contains a MADS-box DNA-binding and dimerization domain; however, it does not appear to solely control transcription of the other identified genes. Pvg2p and/or Pvg5p may contribute to an enzyme complex. Whereas a functional role for the PvGal epitope in S. pombe remains unclear, it is nonessential for either cell growth or mating under laboratory conditions.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Trimble, RB (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, C-547,POB 509, Albany, NY 12201 USA.	trimble@wadsworth.org			NIGMS NIH HHS [GM23900] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C, 1993, EXPT FISSION YEAST L; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Alvarez-Buylla ER, 2000, P NATL ACAD SCI USA, V97, P5328, DOI 10.1073/pnas.97.10.5328; Alviano CS, 1999, GLYCOCONJUGATE J, V16, P545, DOI 10.1023/A:1007078106280; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; ARAKI S, 1991, EUR J BIOCHEM, V198, P689, DOI 10.1111/j.1432-1033.1991.tb16068.x; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bahler J, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P13; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BEBAULT GM, 1973, J BACTERIOL, V113, P1345, DOI 10.1128/JB.113.3.1345-1347.1973; Becker A, 1998, APPL MICROBIOL BIOT, V50, P145, DOI 10.1007/s002530051269; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOSSIO JC, 1986, BIOCHEM BIOPH RES CO, V134, P205, DOI 10.1016/0006-291X(86)90548-6; Bossio JC, 1996, CELL MOL BIOL, V42, P737; Breton C, 2002, BIOCHEM SOC SYMP, V69, P23; Burke D., 2000, METHODS YEAST GENETI; Cerantola S, 2000, FEMS MICROBIOL LETT, V185, P243, DOI 10.1016/S0378-1097(00)00099-9; CHANDRASEKARAN R, 1994, CARBOHYD RES, V261, P279, DOI 10.1016/0008-6215(94)84024-5; CHAPPELL TG, 1994, MOL BIOL CELL, V5, P519, DOI 10.1091/mbc.5.5.519; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Chiovitti A, 1997, CARBOHYD RES, V299, P229, DOI 10.1016/S0008-6215(97)00017-7; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Cutler JE, 2001, MED MYCOL, V39, P75, DOI 10.1080/714030992; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; Fraysse N, 2003, EUR J BIOCHEM, V270, P1365, DOI 10.1046/j.1432-1033.2003.03492.x; GARDIOL AE, 1986, J BACTERIOL, V168, P1459, DOI 10.1128/jb.168.3.1459-1462.1986; GARDIOL AE, 1987, J BACTERIOL, V169, P1161, DOI 10.1128/jb.169.3.1161-1167.1987; Gemmill TR, 1998, GLYCOBIOLOGY, V8, P1087, DOI 10.1093/glycob/8.11.1087; Gemmill TR, 1996, J BIOL CHEM, V271, P25945, DOI 10.1074/jbc.271.42.25945; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; Gemmill TR, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P405; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7033, DOI 10.1128/jb.175.21.7033-7044.1993; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; HA YW, 1991, FEMS MICROBIOL LETT, V78, P49, DOI 10.1016/0378-1097(91)90253-7; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HART GW, 1995, ADV EXP MED BIOL, V376, P115; HASSLER RA, 1990, BIOTECHNOL PROGR, V6, P182, DOI 10.1021/bp00003a003; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hennet T, 2002, CELL MOL LIFE SCI, V59, P1081, DOI 10.1007/s00018-002-8489-4; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HIND CRK, 1985, BIOCHEM J, V225, P107, DOI 10.1042/bj2250107; HUANG KM, 1995, MOL BIOL CELL, V6, P485, DOI 10.1091/mbc.6.5.485; IELPI L, 1981, BIOCHEM BIOPH RES CO, V102, P1400, DOI 10.1016/S0006-291X(81)80167-2; Jamai A, 2002, MOL CELL BIOL, V22, P5741, DOI 10.1128/MCB.22.16.5741-5752.2002; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; Jung US, 2002, MOL MICROBIOL, V46, P781, DOI 10.1046/j.1365-2958.2002.03198.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Kojima H, 1999, BIOSCI BIOTECH BIOCH, V63, P1970, DOI 10.1271/bbb.63.1970; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; Leslie MR, 1998, CARBOHYD RES, V309, P95, DOI 10.1016/S0008-6215(98)00103-7; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MACHLERBAUER A, 2003, NUCLEIC ACIDS RES, V31, P383; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; MARZOCCA MP, 1991, J BACTERIOL, V173, P7519, DOI 10.1128/jb.173.23.7519-7524.1991; Mata J, 2003, GENOME RES, V13, P2686, DOI 10.1101/gr.1420903; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Mesnage S, 2000, EMBO J, V19, P4473, DOI 10.1093/emboj/19.17.4473; Miyata M, 1997, ANTON LEEUW INT J G, V71, P207, DOI 10.1023/A:1000166426509; Mo Y, 2001, J MOL BIOL, V314, P495, DOI 10.1006/jmbi.2001.5138; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakai K, 2000, ADV PROTEIN CHEM, V54, P277, DOI 10.1016/S0065-3233(00)54009-1; Neiman AM, 1997, GENETICS, V145, P637; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nielsen O, 1996, MOL GEN GENET, V253, P387, DOI 10.1007/s004380050335; Parolis LAS, 1996, CARBOHYD RES, V293, P101, DOI 10.1016/0008-6215(96)00190-5; Peng XA, 2001, APPL ENVIRON MICROB, V67, P3413, DOI 10.1128/AEM.67.8.3413-3417.2001; REASON AJ, 1992, J BIOL CHEM, V267, P16911; Sadykov M. R., 1998, Molekulyarnaya Biologiya (Moscow), V32, P797; Sambrook J., MOL CLONING LAB MANU; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Schaffer C, 2001, EUR J BIOCHEM, V268, P857, DOI 10.1046/j.1432-1327.2001.01961.x; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SILVER RP, 1988, REV INFECT DIS, V10, pS282; Soares RMA, 2000, BBA-GEN SUBJECTS, V1474, P262, DOI 10.1016/S0304-4165(00)00003-9; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; SWAMY MJ, 1991, CARBOHYD RES, V213, P59; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Tanaka N, 1999, J BACTERIOL, V181, P1356, DOI 10.1128/JB.181.4.1356-1359.1999; Tanaka N, 2001, YEAST, V18, P903, DOI 10.1002/yea.740; Thompson D, 2002, J MOL BIOL, V320, P1081, DOI 10.1016/S0022-2836(02)00514-4; TRIMBLE RB, 1987, METHOD ENZYMOL, V138, P763; URBANIKSYPNIEWSKA T, 1992, ACTA BIOCHIM POL, V39, P177; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Verostek MF, 2000, ANAL BIOCHEM, V278, P111, DOI 10.1006/abio.1999.4433; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; West AG, 1997, MOL CELL BIOL, V17, P2876, DOI 10.1128/MCB.17.5.2876; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yabana N, 1996, MOL CELL BIOL, V16, P3420; Yoko-o T, 2001, FEBS LETT, V489, P75, DOI 10.1016/S0014-5793(01)02082-8; ZIEGLER FD, 1994, J BIOL CHEM, V269, P12527	109	28	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35644	35655		10.1074/jbc.M403574200	http://dx.doi.org/10.1074/jbc.M403574200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15173185	hybrid			2022-12-27	WOS:000223303400061
J	Bae, E; Sakai, T; Mosher, DF				Bae, E; Sakai, T; Mosher, DF			Assembly of exogenous fibronectin by fibronectin-null cells is dependent on the adhesive substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVELY SPLICED EIIIB; PLASMA FIBRONECTIN; ALPHA(5)BETA(1) INTEGRIN; LYSOPHOSPHATIDIC ACID; VASCULAR DEVELOPMENT; ISOFORM DISTRIBUTION; MATRIX ADHESIONS; FOCAL ADHESIONS; MOUSE EMBRYOS; V-SEGMENT	The role of endogenously synthesized fibronectin (FN) in assembly was studied with cells lacking or expressing FN. Cells were cultured as homogeneous or mixed populations on surfaces coated with different matrix proteins. Compared with FN-expressing cells, FN-null cells poorly assembled exogenous plasma FN (pFN) when adhered to vitronectin or the recombinant cell-binding domain (III7-10) of FN. Vitronectin had a suppressive effect that was overcome by co-adsorbed pFN or laminin-1 but not by soluble FN. In co-cultures of FN-expressing cells and FN-null cells, endogenous FN was preferentially assembled around FN-expressing cells regardless of the adhesive ligand. If the adhesive ligand was vitronectin, exogenous pFN assembled preferentially around cells expressing cellular FN or recombinant EDa- or EDa+ FN. In co-cultures on vitronectin of FN-null cells and beta(1) integrin subunit-null cells, fibrils of cellular FN and pFN were preferentially deposited by FN-null (beta(1)-expressing) cells immediately adjacent to (FN-secreting) beta(1)-null cells. In co-cultures on vitronectin of FN-null cells and beta(1)-null cells expressing a chimera with the extracellular domain of beta(1) and the cytoplasmic domain of beta(3), preferential assembly was by the chimera-expressing cells. These results indicate that the adhesive ligand is a determinant of FN assembly by cells not secreting endogenous FN (suppressive if vitronectin, non-suppressive but non-supportive if III7-10, supportive if pFN or laminin-1) and suggest that efficient interaction of freshly secreted cellular FN with a beta(1) integrin, presumably alpha(5)beta(1), substitutes for integrin-mediated adherence to a preformed matrix of laminin-1 or pFN to support assembly of FN.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Mosher, DF (corresponding author), Rm 4285,Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	dfmosher@wisc.edu			NHLBI NIH HHS [HL 21644] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOTA S, 1994, J BIOL CHEM, V269, P24756; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CARNEMOLLA B, 1987, FEBS LETT, V215, P269, DOI 10.1016/0014-5793(87)80160-6; Chen F, 1996, J BIOL CHEM, V271, P9084, DOI 10.1074/jbc.271.15.9084; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; DUFOUR S, 1991, EXP CELL RES, V193, P331, DOI 10.1016/0014-4827(91)90104-3; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Francis SE, 2002, ARTERIOSCL THROM VAS, V22, P927, DOI 10.1161/01.ATV.0000016045.93313.F2; Fukuda T, 2002, CANCER RES, V62, P5603; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1990, J CELL BIOL, V110, P833, DOI 10.1083/jcb.110.3.833; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hocking DC, 1999, J BIOL CHEM, V274, P27257, DOI 10.1074/jbc.274.38.27257; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1990, SPRINGER SERIES MOL, P24; Ilic D, 1997, J CELL SCI, V110, P401; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; Li FY, 2003, BIOPHYS J, V84, P1252, DOI 10.1016/S0006-3495(03)74940-6; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1989, FIBRONECTIN, P163; Mosher, 1989, FIBRONECTIN, P1; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Ohashi T, 1999, P NATL ACAD SCI USA, V96, P2153, DOI 10.1073/pnas.96.5.2153; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; Peters JH, 1996, CELL ADHES COMMUN, V4, P127, DOI 10.3109/15419069609010767; Peters JH, 1996, CELL ADHES COMMUN, V4, P103, DOI 10.3109/15419069609010766; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Sakai T, 2003, NATURE, V423, P876, DOI 10.1038/nature01712; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; Sottile J, 2000, J CELL SCI, V113, P4287; THIERY JP, 1989, FIBRONECTIN, P181; Tomasini-Johansson BR, 2001, J BIOL CHEM, V276, P23430, DOI 10.1074/jbc.M103467200; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wierzbicka-Patynowski I, 2002, J BIOL CHEM, V277, P19703, DOI 10.1074/jbc.M200270200; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhang QH, 1999, J BIOL CHEM, V274, P368, DOI 10.1074/jbc.274.1.368; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	58	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35749	35759		10.1074/jbc.M406283200	http://dx.doi.org/10.1074/jbc.M406283200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199047	hybrid			2022-12-27	WOS:000223303400074
J	Boopathi, E; Lenka, N; Prabu, SK; Fang, JK; Wilkinson, F; Atchison, M; Giallongo, A; Avadhani, NG				Boopathi, E; Lenka, N; Prabu, SK; Fang, JK; Wilkinson, F; Atchison, M; Giallongo, A; Avadhani, NG			Regulation of murine cytochrome c oxidase Vb gene expression during Myogenesis - YY-1 and heterogeneous nuclear ribonucleoprotein D-like protein (JKTBP1) reciprocally regulate transcription activity by physical interaction with the BERF-1/ZBP-89 factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SUBUNIT-IV GENE; MUSCLE-SPECIFIC ENHANCER; ZINC-FINGER PROTEIN; G-RICH-BOX; BINDING PROTEIN; NUCLEOTIDE-SEQUENCE; STRUCTURAL ORGANIZATION; AFFINITY-CHROMATOGRAPHY; CATALYTIC-ACTIVITY	A transcription suppressor element (sequence -481 to -320) containing a G-rich motif (designated GTG) and a newly identified CAT-rich motif (designated CATR) was previously shown to modulate expression of the mouse cytochrome c oxidase Vb gene during myogenesis. Here, we show that the GTG element is critical for transcription activation in both undifferentiated and differentiated myocytes. Mutations of the CATR motif abolished transcription repression in myoblasts while limiting transcription activation in differentiated myotubes, suggesting contrasting functional attributes of this DNA motif at different stages of myogenesis. Results show that the activity of the transcription suppressor motif is modulated by an orchestrated interplay between ubiquitous transcription factors: ZBP-89, YY-1, and a member of the heterogeneous nuclear ribonucleoprotein D-like protein (also known as JKTBP1) family. In undifferentiated muscle cells, GTG motif-bound ZBP-89 physically and functionally interacted with CATR motif-bound YY-1 to mediate transcription repression. In differentiated myotubes, heterogeneous nuclear ribonucleoprotein D-like protein/JKTBP1 bound to the CATR motif exclusive of YY-1 and interacted with ZBP-89 in attenuating repressor activity, leading to transcription activation. Our results show a novel mechanism of protein factor switching in transcription regulation of the cytochrome c oxidase Vb gene during myogenesis.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; CNR, Ist Biomed & Immunol Mol, I-90146 Palermo, Italy	University of Pennsylvania; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR)	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Lenka, Nibedita/ABX-3824-2022; Giallongo, Agata/ABD-1103-2020	Giallongo, Agata/0000-0001-9998-4481; Wilkinson, Frank/0000-0001-6003-3478; Ettickan, Boopathi/0000-0001-9431-7719	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049683] Funding Source: NIH RePORTER; NIDDK NIH HHS [T-32 DKO7708] Funding Source: Medline; NIGMS NIH HHS [GM49683] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akagi T, 2000, GENE, V245, P267, DOI 10.1016/S0378-1119(00)00032-9; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; Basu A, 1997, J BIOL CHEM, V272, P5899, DOI 10.1074/jbc.272.9.5899; BASU A, 1993, J BIOL CHEM, V268, P4188; BASU A, 1990, BIOCHIM BIOPHYS ACTA, V1087, P98, DOI 10.1016/0167-4781(90)90128-O; BASU A, 1991, J BIOL CHEM, V266, P15450; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; Bemark M, 1998, J BIOL CHEM, V273, P18881, DOI 10.1074/jbc.273.30.18881; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; Camasamudram V, 2003, EUR J BIOCHEM, V270, P1128, DOI 10.1046/j.1432-1033.2003.03461.x; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; CARTER RS, 1994, J BIOL CHEM, V269, P4381; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FEO S, 1995, MOL CELL BIOL, V15, P5991; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Lee I, 2001, BIOL CHEM, V382, P1629, DOI 10.1515/BC.2001.198; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1994, ONCOGENE, V9, P1047; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Lenka N, 1996, J BIOL CHEM, V271, P30281, DOI 10.1074/jbc.271.47.30281; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LIU XD, 1995, GENE DEV, V9, P1766, DOI 10.1101/gad.9.14.1766; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Mikheev AM, 2000, NUCLEIC ACIDS RES, V28, P3762, DOI 10.1093/nar/28.19.3762; Min CH, 1996, NUCLEIC ACIDS RES, V24, P3806, DOI 10.1093/nar/24.19.3806; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; PARHAM P, 1983, METHOD ENZYMOL, V92, P110; Park H, 2003, BLOOD, V101, P894, DOI 10.1182/blood-2002-03-0680; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Remington MC, 1997, BIOCHEM BIOPH RES CO, V237, P230, DOI 10.1006/bbrc.1997.7119; Rushlow WJ, 1999, NEUROSCIENCE, V94, P637, DOI 10.1016/S0306-4522(99)00342-5; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Sucharov C, 1995, GENE EXPRESSION, V5, P93; SUSKE G, 1988, DNA-J MOLEC CELL BIO, V7, P163, DOI 10.1089/dna.1988.7.163; TAANMAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P283, DOI 10.1016/0167-4781(91)90027-J; THOMPSON CC, 1991, SCIENCE, V253, P742; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tsuchiya N, 1998, J BIOCHEM-TOKYO, V123, P499; Vijayasarathy C, 1998, BBA-BIOMEMBRANES, V1371, P71, DOI 10.1016/S0005-2736(97)00278-2; Vijayasarathy C, 2003, EUR J BIOCHEM, V270, P871, DOI 10.1046/j.1432-1033.2003.03447.x; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691	71	18	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35242	35254		10.1074/jbc.M403160200	http://dx.doi.org/10.1074/jbc.M403160200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190078	hybrid			2022-12-27	WOS:000223303400015
J	Sansen, S; De Ranter, CJ; Gebruers, K; Brijs, K; Courtin, CM; Delcour, JA; Rabijns, A				Sansen, S; De Ranter, CJ; Gebruers, K; Brijs, K; Courtin, CM; Delcour, JA; Rabijns, A			Structural basis for inhibition of Aspergillus niger xylanase by Triticum aestivum xylanase inhibitor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; XIP-I; 3-DIMENSIONAL STRUCTURE; CELL-WALLS; PROTEIN; WHEAT; CRYSTALLIZATION; IDENTIFICATION; ENDOXYLANASES	Plants developed a diverse battery of defense mechanisms in response to continual challenges by a broad spectrum of pathogenic microorganisms. Their defense arsenal includes inhibitors of cell wall-degrading enzymes, which hinder a possible invasion and colonization by antagonists. The structure of Triticum aestivum xylanase inhibitor-I (TAXI-I), a first member of potent TAXI-type inhibitors of fungal and bacterial family 11 xylanases, has been determined to 1.7-Angstrom resolution. Surprisingly, TAXI-I displays structural homology with the pepsin-like family of aspartic proteases but is proteolytically nonfunctional, because one or more residues of the essential catalytical triad are absent. The structure of the TAXI-I.Aspergillus niger xylanase I complex, at a resolution of 1.8 Angstrom, illustrates the ability of tight binding and inhibition with subnanomolar affinity and indicates the importance of the C-terminal end for the differences in xylanase specificity among different TAXI-type inhibitors.	Katholieke Univ Leuven, Lab Analyt Chem & Med Physicochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Food Chem Lab, B-3001 Louvain, Belgium	KU Leuven; KU Leuven	Rabijns, A (corresponding author), Katholieke Univ Leuven, Lab Analyt Chem & Med Physicochem, E van Evenstr 4, B-3000 Louvain, Belgium.	Anja.rabijns@pharm.kuleuven.ac.be	Courtin, Christophe M/Q-1916-2016; DELCOUR, Jan A/P-4182-2017; Delcour, Jan A/A-7636-2013; Gebruers, Kurt/AAW-8622-2021	Courtin, Christophe M/0000-0002-1203-9063; DELCOUR, Jan A/0000-0003-2954-1022; Gebruers, Kurt/0000-0003-4720-1515				ALBERSHEIM P, 1971, P NATL ACAD SCI USA, V68, P1815, DOI 10.1073/pnas.68.8.1815; BAILEY D, 1994, PROTEIN SCI, V3, P2129, DOI 10.1002/pro.5560031126; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bento I, 1998, ACTA CRYSTALLOGR D, V54, P991, DOI 10.1107/S0907444998001048; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUGBEE WM, 1993, PHYTOPATHOLOGY, V83, P63, DOI 10.1094/Phyto-83-63; CAMPBELL RL, 1993, P 2 TRICEL S TRICH R, P63; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Christophersen C, 1997, STARCH-STARKE, V49, P5, DOI 10.1002/star.19970490104; Christov LP, 1999, PROCESS BIOCHEM, V34, P511, DOI 10.1016/S0032-9592(98)00117-4; Courtin CM, 1999, J AGR FOOD CHEM, V47, P1870, DOI 10.1021/jf981178w; Debyser W, 1997, J AM SOC BREW CHEM, V55, P153; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Fierens K, 2003, FEBS LETT, V540, P259, DOI 10.1016/S0014-5793(03)00276-X; Flatman R, 2002, BIOCHEM J, V365, P773, DOI 10.1042/BJ20020168; Gebruers K, 2002, J ENZYM INHIB MED CH, V17, P61, DOI 10.1080/14756360290018611; Gebruers K, 2001, BIOCHEM J, V353, P239, DOI 10.1042/0264-6021:3530239; Green JA, 1998, REV REPROD, V3, P62; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ingelbrecht JA, 2001, CEREAL CHEM, V78, P721, DOI 10.1094/CCHEM.2001.78.6.721; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krengel U, 1996, J MOL BIOL, V263, P70, DOI 10.1006/jmbi.1996.0556; LESLIE AG, 1992, JNT CCP4 ESF EACMB N, V26; MATTHEWS BW, 1974, J MOL BIOL, V82, P513, DOI 10.1016/0022-2836(74)90245-9; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payan F, 2004, J BIOL CHEM, V279, P36029, DOI 10.1074/jbc.M404225200; Payan F, 2003, BIOCHEM J, V372, P399, DOI 10.1042/BJ20021802; Prusky D, 2003, MOL PLANT PATHOL, V4, P509, DOI [10.1046/j.1364-3703.2003.00196.x, 10.1046/J.1364-3703.2003.00196.X]; Qin Q, 2003, PLANT J, V34, P327, DOI 10.1046/j.1365-313X.2003.01726.x; Ramalho-Santos M, 1998, EUR J BIOCHEM, V255, P133, DOI 10.1046/j.1432-1327.1998.2550133.x; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Rouau X, 1998, J CEREAL SCI, V28, P63, DOI 10.1006/jcrs.1997.0180; Sansen S, 2004, ACTA CRYSTALLOGR D, V60, P555, DOI 10.1107/S0907444903029330; SATOH S, 1992, PLANTA, V188, P432, DOI 10.1007/BF00192811; Suurnakki A, 1997, Adv Biochem Eng Biotechnol, V57, P261; TORRONEN A, 1994, EMBO J, V13, P2493, DOI 10.1002/j.1460-2075.1994.tb06536.x; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; WALTON JD, 1994, PLANT PHYSIOL, V104, P1113, DOI 10.1104/pp.104.4.1113; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; Wu SSH, 2002, J BIOL CHEM, V277, P49055, DOI 10.1074/jbc.M208804200; Xie S, 1997, P NATL ACAD SCI USA, V94, P12809, DOI 10.1073/pnas.94.24.12809; Yang J, 1999, ACTA CRYSTALLOGR D, V55, P625, DOI 10.1107/S0907444998013961	47	104	108	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36022	36028		10.1074/jbc.M404212200	http://dx.doi.org/10.1074/jbc.M404212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15166216	hybrid			2022-12-27	WOS:000223303400104
J	Bjelke, JR; Christensen, J; Branner, S; Wagtmann, N; Olsen, C; Kanstrup, AB; Rasmussen, HB				Bjelke, JR; Christensen, J; Branner, S; Wagtmann, N; Olsen, C; Kanstrup, AB; Rasmussen, HB			Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROPELLER DOMAIN; PROLYL OLIGOPEPTIDASE; SERINE PROTEASES; DPP-IV; CRYSTAL-STRUCTURE; CD26; INHIBITION; IV/CD26; LOCALIZATION; EXPRESSION	Human dipeptidyl peptidase IV (DPP- IV) is a ubiquitously expressed type II transmembrane serine protease. It cleaves the penultimate positioned prolyl bonds at the N terminus of physiologically important peptides such as the incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic peptide. In this study, we have characterized different active site mutants. The Y547F mutant as well as the catalytic triad mutants S630A, D708A, and H740L showed less than 1% wild type activity. X-ray crystal structure analysis of the Y547F mutant revealed no overall changes compared with wild type apoDPP-IV, except the ablation of the hydroxyl group of Tyr(547) and a water molecule positioned in close proximity to Tyr(547). To elucidate further the reaction mechanism, we determined the crystal structure of DPP- IV in complex with diisopropyl fluorophosphate, mimicking the tetrahedral intermediate. The kinetic and structural findings of the tyrosine residue are discussed in relation to the catalytic mechanism of DPP- IV and to the inhibitory mechanism of the 2-cyanopyrrolidine class of potent DPP- IV inhibitors, proposing an explanation for the specificity of this class of inhibitors for the S9b family among serine proteases.	Novo Nordisk AS, Prot Struct, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Prot Sci, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Canc & Immunobiol, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Med Chem, DK-2880 Bagsvaerd, Denmark; Univ Copenhagen, Panum Inst, Inst Med Biochem & Genet, DK-2200 Copenhagen, Denmark	Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; University of Copenhagen	Rasmussen, HB (corresponding author), Novo Nordisk AS, Prot Struct, Novo Alle, DK-2880 Bagsvaerd, Denmark.	hbrm@novonordisk.com						Abbott CA, 2000, EUR J BIOCHEM, V267, P6140, DOI 10.1046/j.1432-1327.2000.01617.x; Abbott CA, 1999, FEBS LETT, V458, P278, DOI 10.1016/S0014-5793(99)01166-7; ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; Abbott CA., 2002, ECTOPEPTIDASES CD13A, P171; Ahren B, 2004, J CLIN ENDOCR METAB, V89, P2078, DOI 10.1210/jc.2003-031907; Ahren B, 2002, DIABETES CARE, V25, P869, DOI 10.2337/diacare.25.5.869; ASBOTH B, 1983, BIOCHEMISTRY-US, V22, P117, DOI 10.1021/bi00270a017; BERNARD AM, 1994, BIOCHEMISTRY-US, V33, P15204, DOI 10.1021/bi00254a032; Brandt W, 2000, ADV EXP MED BIOL, V477, P97; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARTER P, 1991, BIOCHEMISTRY-US, V30, P6142, DOI 10.1021/bi00239a009; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; DukeCohan JS, 1996, J IMMUNOL, V156, P1714; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Hiramatsu H, 2003, BIOCHEM BIOPH RES CO, V302, P849, DOI 10.1016/S0006-291X(03)00258-4; Holst JJ, 2001, SCAND J CLIN LAB INV, V61, P75, DOI 10.1080/713783697; Holst JJ, 1998, DIABETES, V47, P1663, DOI 10.2337/diabetes.47.11.1663; HOPSUHAV.VK, 1966, HISTOCHEMISTRY, V7, P197, DOI 10.1007/BF00577838; Hughes TE, 1999, BIOCHEMISTRY-US, V38, P11597, DOI 10.1021/bi990852f; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; Lambeir AM, 1997, BBA-PROTEIN STRUCT M, V1340, P215, DOI 10.1016/S0167-4838(97)00045-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Oefner C, 2003, ACTA CRYSTALLOGR D, V59, P1206, DOI 10.1107/S0907444903010059; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Reva B, 2002, PROTEINS, V47, P180, DOI 10.1002/prot.10076; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Szeltner Z, 2000, PROTEIN SCI, V9, P353; Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001	35	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34691	34697		10.1074/jbc.M405400200	http://dx.doi.org/10.1074/jbc.M405400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175333	hybrid			2022-12-27	WOS:000223134800074
J	Dave V; Childs, T; Whitsett, JA				Dave, V; Childs, T; Whitsett, JA			Nuclear factor of activated T cells regulates transcription of the surfactant protein D gene (Sftpd) via direct interaction with thyroid transcription factor-1 in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; ALVEOLAR MACROPHAGES; RAT ALVEOLAR; SP-A; BINDING PROTEIN; HOST-DEFENSE; DEVELOPMENTAL EXPRESSION; TRANSGENIC MICE; INNATE IMMUNITY; MESSENGER-RNA	Surfactant protein D (SP-D) plays critical roles in host defense, surfactant homeostasis, and pulmonary immunomodulation. Here, we identify a role of nuclear factor of activated T cells (NFATs) in regulation of murine SP-D gene (Sftpd) transcription. An NFAT-dependent enhancer modulated by NFATs or calcineurin and sensitive to cyclosporin was identified in the Sftpd promoter. Ionomycin and phorbol 12-myristate 13-acetate further increased the activity of this enhancer, whereas VIVIT, a potent NFAT inhibitor peptide, selectively interfered with the calcineurin-NFAT interaction and abolished enhancer function. Gel supershift and DNase I protection assays identified DNA elements that bind NFAT in the Sftpd promoter. Calcineurin and NFATc3 proteins were detected in the embryonic and adult mouse lung epithelium, and the mRNA expression profiles of the NFATs were similar in immortalized mouse lung epithelial cells and alveolar epithelial type II cells. NFATc3 and TTF-1 activated the Sftpd promoter, synergized transcription, co-immunoprecipitated from mouse lung epithelial cells, and physically interacted in vitro. Components of the calcineurin/NFAT pathway were identified in respiratory epithelial cells of the lung that potentially augment rapid assembly of a multiprotein transcription complex on Sftpd promoter inducing SP-D expression.	Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Dave V (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, 4403,3333 Burnet Ave, Cincinnati, OH 45229 USA.	davev0@cchmc.org	Dave, Vrushank/K-5262-2012	Dave, Vrushank/0000-0003-4044-2658	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063329] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63329] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderibigbe AO, 1999, AM J RESP CELL MOL, V20, P219, DOI 10.1165/ajrcmb.20.2.3348; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bachurski CJ, 2003, MOL CELL BIOL, V23, P9014, DOI 10.1128/MCB.23.24.9014-9024.2003; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Clark H, 2002, J IMMUNOL, V169, P2892, DOI 10.4049/jimmunol.169.6.2892; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Crestani B, 1998, J IMMUNOL, V160, P4596; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; Dave V, 2000, MOL CELL BIOL, V20, P7673, DOI 10.1128/MCB.20.20.7673-7684.2000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; Haidaris PJS, 1997, BLOOD, V89, P873; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; He YC, 2002, J BIOL CHEM, V277, P19530, DOI 10.1074/jbc.M201126200; He YC, 2000, J BIOL CHEM, V275, P31051, DOI 10.1074/jbc.M003499200; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Homer RJ, 2002, AM J PHYSIOL-LUNG C, V283, pL52, DOI 10.1152/ajplung.00438.2001; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V278, pL75, DOI 10.1152/ajplung.2000.278.1.L75; Ikegami M, 2001, AM J PHYSIOL-LUNG C, V281, pL697, DOI 10.1152/ajplung.2001.281.3.L697; Jain-Vora S, 1998, INFECT IMMUN, V66, P4229; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Mannervik M, 1999, BIOESSAYS, V21, P267, DOI 10.1002/(SICI)1521-1878(199904)21:4<267::AID-BIES1>3.3.CO;2-3; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; Mason RJ, 2002, AM J PHYSIOL-LUNG C, V282, pL249, DOI 10.1152/ajplung.00027.2001; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; OGASAWARA Y, 1992, LIFE SCI, V50, P1761, DOI 10.1016/0024-3205(92)90059-X; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200; PARK KM, 2004, J BIOL CHEM; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reid KBM, 1998, IMMUNOBIOLOGY, V199, P200, DOI 10.1016/S0171-2985(98)80027-2; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; Suck Dietrich, 1994, Journal of Molecular Recognition, V7, P65, DOI 10.1002/jmr.300070203; Tino MJ, 1999, AM J PHYSIOL-LUNG C, V276, pL164, DOI 10.1152/ajplung.1999.276.1.L164; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Whitsett J, 1998, NAT GENET, V20, P7, DOI 10.1038/1654; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wong CJ, 1996, PEDIATR RES, V39, P930, DOI 10.1203/00006450-199606000-00002; Wright JR, 2003, J CLIN INVEST, V111, P1453, DOI 10.1172/JCI200318650; Wright JR, 2001, AM J RESP CELL MOL, V24, P513, DOI 10.1165/ajrcmb.24.5.f208; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Xu XS, 1998, AM J RESP CELL MOL, V18, P168, DOI 10.1165/ajrcmb.18.2.2824; Yan C, 2001, J BIOL CHEM, V276, P21686, DOI 10.1074/jbc.M011378200; Yang MCW, 2003, EUR RESPIR J, V22, P28, DOI 10.1183/09031936.03.00117702; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	73	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34578	34588		10.1074/jbc.M404296200	http://dx.doi.org/10.1074/jbc.M404296200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173172	hybrid			2022-12-27	WOS:000223134800062
J	Hidaka, S; Konecke, V; Osten, L; Witzgall, R				Hidaka, S; Konecke, V; Osten, L; Witzgall, R			PIGEA-14, a novel coiled-coil protein affecting the intracellular distribution of polycystin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-DISEASE PROTEIN; CATION CHANNEL; PKD2; GENE; IDENTIFICATION; INTERACTS	Employing a yeast two-hybrid screen with the COOH terminus of polycystin-2, one of the proteins mutated in patients with polycystic kidney disease, we were able to isolate a novel protein that we call PIGEA-14 ( polycystin-2 interactor, Golgi- and endoplasmic reticulum-associated protein with a molecular mass of 14 kDa). Molecular modeling only predicts a coiled-coil motif, but no other functional domains, in PIGEA-14. In a subsequent two-hybrid screen using PIGEA-14 as a bait, we found GM130, a component of the cis-compartment of the Golgi apparatus. Co-expression of the PIGEA-14 and PKD2 cDNAs in LLC-PK1 and HeLa cells resulted in a redistribution of PIGEA-14 and polycystin-2 to the trans-Golgi network, which suggests that PIGEA-14 plays an important role in regulating the intracellular location of polycystin-2 and possibly other intracellular proteins. Our results also indicate that the intracellular trafficking of polycystin-2 is regulated both at the level of the endoplasmic reticulum and that of the trans-Golgi network.	Univ Regensburg, Inst Mol & Cellular Anat, D-93053 Regensburg, Germany	University of Regensburg	Witzgall, R (corresponding author), Univ Regensburg, Inst Mol & Cellular Anat, Univ Str 31, D-93053 Regensburg, Germany.	ralph.witzgall@vkl.uni-regensburg.de		Witzgall, Ralph/0000-0002-5283-4846				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Deltas CC, 2001, HUM MUTAT, V18, P13, DOI 10.1002/humu.1145; DONG YH, 1993, NUCLEIC ACIDS RES, V21, P771, DOI 10.1093/nar/21.3.771; GAI Y, 1999, J BIOL CHEM, V274, P28557; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Gallagher AR, 2002, CELL MOL LIFE SCI, V59, P682, DOI 10.1007/s00018-002-8457-z; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315	24	55	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35009	35016		10.1074/jbc.M314206200	http://dx.doi.org/10.1074/jbc.M314206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194699	hybrid			2022-12-27	WOS:000223134800113
J	Kilian, K; Dernedde, J; Mueller, EC; Bahr, I; Tauber, R				Kilian, K; Dernedde, J; Mueller, EC; Bahr, I; Tauber, R			The interaction of protein kinase C isozymes alpha, iota, and theta with the cytoplasmic domain of L-selectin is modulated by phosphorylation of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; TYROSINE PHOSPHORYLATION; ADHESION MOLECULE-1; HUMAN NEUTROPHILS; PKC; ASSOCIATION; INTEGRINS; BINDING; IDENTIFICATION; LYMPHOCYTES	The leukocyte adhesion molecule L-selectin has an important role in the initial steps of leukocyte extravasation during inflammation and lymphocyte homing. Its cytoplasmic domain is involved in signal transduction after L-selectin cross-linking and in the regulation of receptor binding activity in response to intracellular signals. However, the signaling events occurring at the level of the receptor are largely unknown. This study therefore addressed the question of whether protein kinases associate with the cytoplasmic domain of the receptor and mediate its phosphorylation. Using a glutathione S-transferase fusion protein of the L-selectin cytoplasmic domain, we isolated a kinase activity from cellular extracts of the human leukemic Jurkat T-cell line that phosphorylated L-selectin on serine residues. This kinase showed characteristics of the protein kinase C (PKC) family. Moreover, the Ca2+-independent PKC isozymes theta and iota were found associated with the cytoplasmic domain of L-selectin. Pseudosubstrate inhibitors of these isozymes abolished phosphorylation of the cytoplasmic domain, demonstrating that these kinases are responsible for the phosphorylation. Analysis of proteins specifically bound to the phosphorylated cytoplasmic tail of L-selectin revealed that PKCalpha and -theta are strongly associated with the phosphorylated cytoplasmic domain of L-selectin. Binding of these isozymes to L-selectin was also found in intact cells after phorbol ester treatment inducing serine phosphorylation of the receptor. Furthermore, stimulation of Jurkat T-cells by CD3 cross-linking induced association of PKCalpha and -theta with L-selectin, indicating a role of these kinases in the regulation of L-selectin through the T-cell receptor complex. The phosphorylation-regulated association of PKC isozymes with the cytoplasmic domain of L-selectin indicates an important role of this kinase family in L-selectin signal transduction.	Charite, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany; Schering AG, Prot Chem, D-13342 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kilian, K (corresponding author), Charite, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany.	karin.kilian@charite.de	Dernedde, Jens/H-4097-2017	Dernedde, Jens/0000-0001-5319-7677				Brenner B, 1997, BIOCHEM BIOPH RES CO, V231, P802, DOI 10.1006/bbrc.1997.6191; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Brenner B, 1997, IMMUNOLOGY, V92, P214, DOI 10.1046/j.1365-2567.1997.00336.x; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Evans SS, 1999, J IMMUNOL, V162, P3615; Fagerholm S, 2002, J BIOL CHEM, V277, P1728, DOI 10.1074/jbc.M106856200; Fieger C B, 2001, Biochim Biophys Acta, V1524, P75; Giblin PA, 1997, J IMMUNOL, V159, P3498; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; Ivetic A, 2002, J BIOL CHEM, V277, P2321, DOI 10.1074/jbc.M109460200; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KANSAS GS, 1992, APMIS, V100, P287, DOI 10.1111/j.1699-0463.1992.tb00874.x; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; LAUDANNA C, 1994, J BIOL CHEM, V269, P4021; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; Meller N, 1999, CELL IMMUNOL, V193, P185, DOI 10.1006/cimm.1999.1478; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MURAKAWA Y, 1992, J IMMUNOL, V148, P1771; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Sikorski MA, 1996, CELL ADHES COMMUN, V4, P355, DOI 10.3109/15419069609010778; SIMON SI, 1995, J IMMUNOL, V155, P1502; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tsang YTM, 1997, J IMMUNOL, V159, P4566; Valmu L, 1999, EUR J IMMUNOL, V29, P2107, DOI 10.1002/(SICI)1521-4141(199907)29:07<2107::AID-IMMU2107>3.0.CO;2-T; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1	47	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34472	34480		10.1074/jbc.M405916200	http://dx.doi.org/10.1074/jbc.M405916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192100	hybrid			2022-12-27	WOS:000223134800049
J	Xu, CQ; Brone, B; Wicher, D; Bozkurt, O; Lu, WY; Huys, I; Han, YH; Tytgat, J; Van Kerkhove, E; Chi, CW				Xu, CQ; Brone, B; Wicher, D; Bozkurt, O; Lu, WY; Huys, I; Han, YH; Tytgat, J; Van Kerkhove, E; Chi, CW			BmBKTx1, a novel Ca2+-activated K+ channel blocker purified from the Asian scorpion Buthus martensi Karsch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; MAXI-K; LOCUSTA-MIGRATORIA; BINDING-SITES; LEIUROTOXIN-I; CHARYBDOTOXIN; TOXINS; NEURONS; PURIFICATION; IBERIOTOXIN	BmBKTx1 is a novel short chain toxin purified from the venom of the Asian scorpion Buthus martensi Karsch. It is composed of 31 residues and is structurally related to SK toxins. However, when tested on the cloned rat SK2 channel, it only partially inhibited rSK2 currents, even at a concentration of 1 muM. To screen for other possible targets, BmBKTx1 was then tested on isolated metathoracic dorsal unpaired median neurons of Locusta migratoria, in which a wide variety of ion channels are expressed. The results suggested that BmBKTx1 could specifically block voltage-gated Ca2+-activated K+ currents (BK-type). This was confirmed by testing the BmBKTx1 effect on the alpha subunits of BK channels of the cockroach (pSlo), fruit fly (dSlo), and human (hSlo), heterologously expressed in HEK293 cells. The IC50 for channel blocking by BmBKTx1 was 82 nM for pSlo and 194 nM for dSlo. Interestingly, BmBKTx1 hardly affected hSlo currents, even at concentrations as high as 10 muM, suggesting that the toxin might be insect specific. In contrast to most other scorpion BK blockers that also act on the Kv1.3 channel, BmBKTx1 did not affect this channel as well as other Kv channels. These results show that BmBKTx1 is a novel kind of blocker of BK-type Ca2+-activated K+ channels. As the first reported toxin active on the Drosophila Slo channel dSlo, it will also greatly facilitate studying the physiological role of BK channels in this model organism.	Chinese Acad Sci, Grad Sch,Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Limburgs Univ Ctr, Ctr Milieukunde CMK, Physiol Lab, B-3590 Diepenbeek, Belgium; Saxon Acad Sci, Res Grp Neurohormonal Mech, D-07743 Jena, Germany; Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA; Univ Louvain, Toxicol Lab, B-3000 Louvain, Belgium; Tongji Univ, Inst Prot Res, Shanghai 200092, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Hasselt University; University System of Maryland; University of Maryland Baltimore; Tongji University	Chi, CW (corresponding author), Chinese Acad Sci, Grad Sch,Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China.	chi@sunm.shcnc.ac.cn	Huys, Isabelle/M-8673-2016; Tytgat, Jan/F-1560-2010; Lu, Wuyuan/B-2268-2010; Lu, Wuyuan/J-8452-2017; Van Kerkhove, Emmy/H-6358-2016	Lu, Wuyuan/0000-0003-1318-9968; Xu, Chenqi/0000-0002-4968-6782; Tytgat, Jan/0000-0003-1778-6022; Brone, Bert/0000-0002-4851-9480				Ahluwalia J, 2004, NATURE, V427, P853, DOI 10.1038/nature02356; AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ASHBY G., 1972, UFAW HDB CARE MANAGE, P582; Ashcroft FM, 2000, ION CHANNELS DIS; AUGUSTE P, 1992, BIOCHEMISTRY-US, V31, P648, DOI 10.1021/bi00118a003; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Brone B, 2003, J INSECT PHYSIOL, V49, P171, DOI 10.1016/S0022-1910(02)00263-9; Cai Z, 2004, BIOCHEMISTRY-US, V43, P3764, DOI 10.1021/bi035412+; Corona M, 2002, FEBS LETT, V532, P121, DOI 10.1016/S0014-5793(02)03652-9; de la Vega RCR, 2003, TRENDS PHARMACOL SCI, V24, P222, DOI 10.1016/S0165-6147(02)00080-4; Derst C, 2003, EUR J NEUROSCI, V17, P1197, DOI 10.1046/j.1460-9568.2003.02550.x; FLINN JP, 1995, INT J PEPT PROT RES, V45, P320; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Gao YD, 2003, PROTEINS, V52, P146, DOI 10.1002/prot.10341; GIANGIACOMO KM, 1993, BIOCHEMISTRY-US, V32, P2363, DOI 10.1021/bi00060a030; Giangiacomo KM, 2000, BIOCHEMISTRY-US, V39, P6115, DOI 10.1021/bi992865z; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; GROLLEAU F, 1995, J NEUROPHYSIOL, V73, P160, DOI 10.1152/jn.1995.73.1.160; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huys I, 2002, EUR J BIOCHEM, V269, P1854, DOI 10.1046/j.1432-1033.2002.02833.x; MUNUJOS P, 1995, BIOCHEMISTRY-US, V34, P10771, DOI 10.1021/bi00034a009; Myers MP, 2000, NEUROPHARMACOLOGY, V39, P11, DOI 10.1016/S0028-3908(99)00074-X; NOVICK J, 1991, BIOPHYS J, V59, P78; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; RomiLebrun R, 1997, BIOCHEMISTRY-US, V36, P13473, DOI 10.1021/bi971044w; RomiLebrun R, 1997, EUR J BIOCHEM, V245, P457, DOI 10.1111/j.1432-1033.1997.00457.x; SABATIER JM, 1994, INT J PEPT PROT RES, V43, P486; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; SCHNEIDER MJ, 1989, FEBS LETT, V250, P433, DOI 10.1016/0014-5793(89)80771-9; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schroeder N, 2002, FEBS LETT, V527, P298, DOI 10.1016/S0014-5793(02)03256-8; Shakkottai VG, 2001, J BIOL CHEM, V276, P43145, DOI 10.1074/jbc.M106981200; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Tytgat J, 1996, FEBS LETT, V390, P280, DOI 10.1016/0014-5793(96)00674-6; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wang CG, 2001, EUR J BIOCHEM, V268, P2480, DOI 10.1046/j.1432-1327.2001.02132.x; WEGENER JW, 1992, J INSECT PHYSIOL, V38, P237, DOI 10.1016/0022-1910(92)90124-V; Wicher D, 2001, PROG NEUROBIOL, V64, P431, DOI 10.1016/S0301-0082(00)00066-6; Wickenden AD, 2002, PHARMACOL THERAPEUT, V94, P157, DOI 10.1016/S0163-7258(02)00201-2; Wu JJ, 2002, BIOCHEMISTRY-US, V41, P2844, DOI 10.1021/bi011367z; Zeng XH, 2003, NAT STRUCT BIOL, V10, P448, DOI 10.1038/nsb932	43	33	37	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34562	34569		10.1074/jbc.M312798200	http://dx.doi.org/10.1074/jbc.M312798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15178692	hybrid			2022-12-27	WOS:000223134800060
J	Zou, ZY; Chung, B; Nguyen, T; Mentone, S; Thomson, B; Biemesderfer, D				Zou, ZY; Chung, B; Nguyen, T; Mentone, S; Thomson, B; Biemesderfer, D			Linking receptor-mediated endocytosis and cell signaling - Evidence for regulated intramembrane proteolysis of megalin in proximal tubule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; RENAL BRUSH-BORDER; HEYMANN NEPHRITIS; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; SOLUBLE FORM; MEMBRANE; CLEAVAGE; GP330	Megalin, a member of the low density lipoprotein receptor gene family, is required for efficient protein absorption in the proximal tubule. Recent studies have shown that the low density lipoprotein receptor-related protein, another member of this gene family, is proteolytically processed by gamma-secretase implying a role for low density lipoprotein receptor-related protein in a Notch-like signaling pathway. This pathway has been shown to involve: 1) metalloprotease-mediated ectodomain shedding and gamma-secretase-mediated intramembrane proteolysis of some receptors. Experiments were performed to determine whether megalin undergoes similar processing. By immunocytochemistry, immunoblotting, and a fluorogenic enzyme assay presenilin-1 ( required for gamma-secretase activity) and gamma-secretase activity were found in the brush border of proximal kidney tubules where megalin is localized. Using a fluorogenic peptide containing an amyloid precursor protein gamma-secretase cleavage site and Compound E, a specific gamma-secretase inhibitor, we found high levels of gamma-secretase activity in renal brush border membrane vesicles. Immunoblotting analysis of renal microsomes and opossum kidney proximal tubule (OKP) cells using antibodies directed to the cytosolic domain of megalin showed a 35-40-kDa, membrane-associated, carboxyl-terminal fragment of megalin (MCTF). When cells were incubated with 200 nM phorbol 12-myristate 13-acetate, the appearance of the MCTF increased 2.5-fold and was blocked by metalloprotease inhibitors. When the cells were incubated with gamma-secretase inhibitor Compound E, it caused a 2-fold increase in MCTF. Finally, incubating the cells with 1 muM vitamin D-binding protein resulted in a 25% increase in the appearance of the MCTF. In summary, the MCTF is produced by protein kinase C regulated, metalloprotease-mediated ectodomain shedding and is the substrate for gamma-secretase. We postulate that the enzymatic processing of megalin represents part of a novel ligand-dependent signaling pathway in the proximal tubule that links receptor-mediated endocytosis with cell signaling.	Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Biemesderfer, D (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 333 Cedar St,TAC S255,POB 208029, New Haven, CT 06520 USA.	daniel.biemesderfer@yale.edu			NIDDK NIH HHS [DK 543933] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; BACHINSKY DR, 1993, AM J PATHOL, V143, P598; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; Biemesderfer D, 2001, J BIOL CHEM, V276, P10161, DOI 10.1074/jbc.M008098200; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BIEMESDERFER D, 1997, AM J PHYSIOL, V273, P289; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Campbell WA, 2003, J NEUROCHEM, V85, P1563, DOI 10.1046/j.1471-4159.2003.01799.x; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; CZEKAY RP, 1995, J CELL SCI, V108, P1433; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Farquhar MG, 1996, AM J PATHOL, V148, P1331; GRASSL SM, 1986, J BIOL CHEM, V261, P8778; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; KERJASCHKI D, 1987, J EXP MED, V166, P109, DOI 10.1084/jem.166.1.109; KERJASCHKI D, 1992, P NATL ACAD SCI USA, V89, P11179, DOI 10.1073/pnas.89.23.11179; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KERJASCHKI D, 1990, VIRCHOWS ARCH B, V58, P253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; LOWRY OH, 1951, J BIOL CHEM, V193, P265; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MAY P, 2003, SCI STKE; MCCLEAN W, 1973, J HISTOCHEM CYTOCHEM, V22, P1077; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; Orth SR, 1998, NEW ENGL J MED, V338, P1202, DOI 10.1056/NEJM199804233381707; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Rutherford PA, 1997, EXP NEPHROL, V5, P490; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	46	125	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34302	34310		10.1074/jbc.M405608200	http://dx.doi.org/10.1074/jbc.M405608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180987	hybrid			2022-12-27	WOS:000223134800029
J	Junutula, JR; Schonteich, E; Wilson, GM; Peden, AA; Scheller, RH; Prekeris, R				Junutula, JR; Schonteich, E; Wilson, GM; Peden, AA; Scheller, RH; Prekeris, R			Molecular characterization of Rab11 interactions with members of the family of Rab11-interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; CANINE KIDNEY-CELLS; BETA-CATENIN; MEMBRANE TRAFFICKING; RECYCLING ENDOSOME; BINDING-PROTEINS; IDENTIFICATION; COMPLEX; DOMAIN; RAB25	The Rab11 subfamily of GTPases plays an important role in vesicle trafficking from endosomes to the plasma membrane. At least six Rab11 effectors ( family of Rab11-interacting proteins (FIPs)) have been shown to interact with Rab11 and are hypothesized to regulate various membrane trafficking pathways such as transferrin recycling, cytokinesis, and epidermal growth factor trafficking. In this study, we characterized interactions of FIPs with the Rab11 GTPase using isothermal titration calorimetric studies and mutational analysis. Our data suggest that FIPs cannot differentiate between GTP-bound Rab11a and Rab11b in vitro ( 50 - 100 nM affinity) and in vivo. We also show that, although FIPs interact with the GDP-bound form of Rab11 in vitro, the binding affinity (> 1000 nM) is not sufficient for FIP and GDP-bound Rab11 interactions to occur in vivo. Mutational analysis revealed that both the conserved hydrophobic patch and Tyr(628) are important for the GTP-dependent binding of Rab11 to FIPs. The entropy and enthalpy analyses suggest that binding to Rab11a/b may induce conformational changes in FIPs.	Univ Colorado, Hlth Sci Ctr, Dept Cellular & Dev Biol, Sch Med, Denver, CO 80262 USA; Genentech Inc, San Francisco, CA 94080 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Roche Holding; Genentech	Prekeris, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Cellular & Dev Biol, Sch Med, Rm 4520,B111,4200 E 9th Ave, Denver, CO 80262 USA.	Rytis.Prekeris@uchsc.edu	Junutula, Jagath Reddy/ABD-4753-2020	Junutula, Jagath Reddy/0000-0002-5942-4428; Peden, Andrew/0000-0003-0144-7712	NIDDK NIH HHS [DK064380] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064380] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Christoforidis S, 2000, METHODS, V20, P403, DOI 10.1006/meth.2000.0953; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; EKLOF SK, 2001, EMBO J, V20, P6203; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; Goldenring JR, 2001, METHOD ENZYMOL, V329, P225; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; Hickson GRX, 2003, MOL BIOL CELL, V14, P2908, DOI 10.1091/mbc.E03-03-0160; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Junutula JR, 2004, MOL BIOL CELL, V15, P2218, DOI 10.1091/mbc.E03-10-0777; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Knapp S, 2001, J MOL BIOL, V306, P1179, DOI 10.1006/jmbi.2001.4463; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Lindsay AJ, 2002, J BIOL CHEM, V277, P27193, DOI 10.1074/jbc.M200757200; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Meyers JM, 2002, J BIOL CHEM, V277, P49003, DOI 10.1074/jbc.M205728200; PEDEN AA, 2004, IN PRESS MOL BIOL CE; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Prekeris Rytis, 2003, ScientificWorldJournal, V3, P870; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	35	74	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33430	33437		10.1074/jbc.M404633200	http://dx.doi.org/10.1074/jbc.M404633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173169	hybrid			2022-12-27	WOS:000223039700051
J	Michaely, P; Li, WP; Anderson, RGW; Cohen, JC; Hobbs, HH				Michaely, P; Li, WP; Anderson, RGW; Cohen, JC; Hobbs, HH			The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; ULTRATHIN FROZEN-SECTIONS; FAMILIAL HYPERCHOLESTEROLEMIA; MOLECULAR-MECHANISMS; CYTOPLASMIC DOMAIN; HUMAN-FIBROBLASTS; CLATHRIN ADAPTER; ENDOCYTOSIS; AP-2; CATABOLISM	ARH is an adaptor protein required for efficient endocytosis of low density lipoprotein (LDL) receptors (LDLRs) in selected tissues. Individuals lacking ARH (ARH(-/-)) have severe hypercholesterolemia due to impaired hepatic clearance of LDL. Immortalized lymphocytes, but not fibroblasts, from ARH-deficient subjects fail to internalize LDL. To further define the role of ARH in LDLR function, we compared the subcellular distribution of the LDLR in lymphocytes from normal and ARH(-/-) subjects. In normal lymphocytes LDLRs were predominantly located in intracellular compartments, whereas in ARH(-/-) cells the receptors were almost exclusively on the plasma membrane. Biochemical assays and quantification of LDLR by electron microscopy indicated that ARH(-/-) lymphocytes had >20-fold more LDLR on the cell surface and a similar to27-fold excess of LDLR outside of coated pits. The accumulation of LDLR on the cell surface was not due to failure of receptors to localize in coated pits since the number of LDLRs in coated pits was similar in ARH(-/-) and normal cells. Despite the dramatic increase in cell surface receptors, LDL binding was only 2-fold higher in the ARH(-/-) lymphocytes. These findings indicate that ARH is required not only for internalization of the LDL.LDLR complex but also for efficient binding of LDL to the receptor and suggest that ARH stabilizes the associations of the receptor with LDL and with the invaginating portion of the budding pit, thereby increasing the efficiency of LDL internalization.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75290 USA.	Helen.Hobbs@utsouthwestern.edu			NHLBI NIH HHS [HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Arca M, 2002, LANCET, V359, P841, DOI 10.1016/S0140-6736(02)07955-2; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Boll W, 2002, TRAFFIC, V3, P590, DOI 10.1034/j.1600-0854.2002.30808.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; Cohen JC, 2003, CURR OPIN LIPIDOL, V14, P121, DOI 10.1097/00041433-200304000-00002; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; ESSER V, 1988, J BIOL CHEM, V263, P13282; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Licht SS, 2003, BIOCHEMISTRY-US, V42, P2916, DOI 10.1021/bi026059v; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LOUIE LG, 1991, AM J HUM GENET, V48, P637; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Soutar AK, 2003, ARTERIOSCL THROM VAS, V23, P1963, DOI 10.1161/01.ATV.0000094410.66558.9A; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802; ZULIANI G, 1995, EUR J CLIN INVEST, V25, P322, DOI 10.1111/j.1365-2362.1995.tb01709.x	40	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34023	34031		10.1074/jbc.M405242200	http://dx.doi.org/10.1074/jbc.M405242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166224	hybrid			2022-12-27	WOS:000223039700114
J	Sarkar, A; Sreenivasan, Y; Ramesh, GT; Manna, SK				Sarkar, A; Sreenivasan, Y; Ramesh, GT; Manna, SK			beta-D-glucoside suppresses tumor necrosis factor-induced activation of nuclear transcription factor kappa B but potentiates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; GLUTATHIONE LEVELS; HYDROGEN-PEROXIDE; FACTOR-ALPHA; INHIBITION; MANGIFERIN; CYTOKINE; KINASE; OVEREXPRESSION; CELLS	Mangiferin, a natural polyphenol is known to exhibit anti-inflammatory, antioxidant, and antiviral effects. However the molecular mechanism underlying these effects has not been well characterized. Because NF-kappaB plays an important role in these processes, it is possible that mangiferin modulates NF-kappaB activation. Our results show that mangiferin blocks tumor necrosis factor (TNF)- induced NF-kappaB activation and NF-kappaB-dependent genes like ICAM1 and COX2. The effect was mediated through inhibition of IKK activation and subsequent blocking of phosphorylation and degradation of IkappaBalpha. In addition, mangiferin inhibits TNF-induced p65 phosphorylation as well as translocation to the nucleus and also inhibits NF-kappaB activation induced by other inflammatory agents like PMA, ceramide, and SA-LPS. Mangiferin, similar to the other known antioxidants, NAC and PDTC, inhibits TNF-induced reactive oxygen intermediate (ROI) generation. Since intracellular glutathione (GSH) levels are known to modulate NF-kappaB levels, we measured the levels of GSH. Mangiferin enhances glutathione level by almost 2-fold more than other antioxidants, and at the same time it decreases the levels of GSSG and increases the activity of catalase. Depletion of GSH by buthionine sulfoximine led to a significant reversal of mangiferin effect. Hence mangiferin with its ability to inhibit NF-kappaB and increase the intracellular GSH levels may prove to be a potent drug for anti-inflammatory and antioxidant therapy. Mangiferin-mediated down-regulation of NF-kappaB also potentiates chemotherapeutic agent-mediated cell death, suggesting a role in combination therapy for cancer.	Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India; Texas So Univ, Dept Biol, Houston, TX 77004 USA	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Texas Southern University	Manna, SK (corresponding author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.	manna@www.cdfd.org.in						ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Aucamp J, 1997, ANTICANCER RES, V17, P4381; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BEERS RF, 1952, J BIOL CHEM, V195, P133; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; CHENGUANG F, 2003, J BIOL CHEM, V278, P2072; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; Collins AR, 1999, BIOESSAYS, V21, P238, DOI 10.1002/(SICI)1521-1878(199903)21:3<238::AID-BIES8>3.0.CO;2-3; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Damianaki A, 2000, J CELL BIOCHEM, V78, P429, DOI 10.1002/1097-4644(20000901)78:3<429::AID-JCB8>3.0.CO;2-M; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Futakuchi M, 1998, EUR J CANCER PREV, V7, P153; Garcia D, 2002, INT IMMUNOPHARMACOL, V2, P797, DOI 10.1016/S1567-5769(02)00018-8; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Guha S, 1996, CHEMOTHERAPY, V42, P443, DOI 10.1159/000239478; Hutter D, 2000, J CELL PHYSIOL, V183, P45, DOI 10.1002/(SICI)1097-4652(200004)183:1<45::AID-JCP6>3.3.CO;2-G; Ichiki H, 1998, BIOL PHARM BULL, V21, P1389, DOI 10.1248/bpb.21.1389; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kumar A, 1999, METHOD ENZYMOL, V300, P339; LEVESQUE A, 1995, CYTOMETRY, V20, P181, DOI 10.1002/cyto.990200211; Li H, 1998, BIOL PHARM BULL, V21, P1322, DOI 10.1248/bpb.21.1322; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEYER A, 1994, EUR RESPIR J, V7, P431, DOI 10.1183/09031936.94.07030431; Miura T, 2001, PHYTOMEDICINE, V8, P85, DOI 10.1078/0944-7113-00009; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; Moreira RRD, 2001, BIOL PHARM BULL, V24, P201, DOI 10.1248/bpb.24.201; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NUNN CJ, 1991, FOOD CHEM TOXICOL, V29, P73, DOI 10.1016/0278-6915(91)90070-N; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; Saccani A, 2000, P NATL ACAD SCI USA, V97, P2761, DOI 10.1073/pnas.97.6.2761; Sanchez GM, 2000, PHARMACOL RES, V42, P565, DOI 10.1006/phrs.2000.0727; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Shi MJ, 2004, AM J HYPERTENS, V17, P450, DOI 10.1016/j.amjhyper.2003.12.019; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; WATTENBERG LW, 1980, CANCER RES, V40, P2820; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yoshimi N, 2001, CANCER LETT, V163, P163, DOI 10.1016/S0304-3835(00)00678-9; Young IS, 2001, J CLIN PATHOL, V54, P176, DOI 10.1136/jcp.54.3.176; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	62	104	108	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33768	33781		10.1074/jbc.M403424200	http://dx.doi.org/10.1074/jbc.M403424200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161907	hybrid			2022-12-27	WOS:000223039700086
J	Zhai, L; Chaturvedi, D; Cumberledge, S				Zhai, L; Chaturvedi, D; Cumberledge, S			Drosophila Wnt-1 undergoes a hydrophobic modification and is targeted to lipid rafts, a process that requires porcupine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARITY GENE PORCUPINE; WINGLESS PROTEIN; CHOLESTEROL MODIFICATION; ENDOPLASMIC-RETICULUM; SONIC HEDGEHOG; TOUT-VELU; MEMBRANE; PALMITOYLATION; SECRETION; CELLS	Wnt signaling pathways regulate many developmental responses; however, little is known about how Wnt ligands function on a biochemical level. Recent studies have shown that Wnt-3a is palmitoylated before secretion. Here we report that Drosophila Wnt-1 ( Wingless) also undergoes a lipid modification. Lipidation occurs in the endoplasmic reticulum and is dependent on Porcupine, a putative O-acyltransferase. After modification, DWnt-1 partitions as a membrane-anchored protein and is sorted into lipid raft detergent-insoluble microdomains. Lipidation, raft targeting, and secretion can be blocked by the addition of 2-bromopalmitate, a competitive inhibitor of O-acyltransferase activity. Based on these results we propose a model whereby lipidation targets Wnt-1 to secretory vesicles that deliver the ligand to specialized microdomains at the cell surface where it can be packaged for secretion.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Cumberledge, S (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.	susanc@biochem.umass.edu	vkg, testridreg/B-8565-2016	vkg, testridreg/0000-0002-1508-5647; g, vvk/0000-0003-1538-7589				Arias AM, 2003, NAT REV MOL CELL BIO, V4, P321, DOI 10.1038/nrm1078; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Caricasole A, 2002, GENE, V288, P147, DOI 10.1016/S0378-1119(02)00467-5; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; COLEMAN RA, 1992, BIOCHIM BIOPHYS ACTA, V1125, P203, DOI 10.1016/0005-2760(92)90046-X; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gallet A, 2003, DEV CELL, V4, P191, DOI 10.1016/S1534-5807(03)00031-5; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Jeong J, 2002, J CLIN INVEST, V110, P591, DOI 10.1172/JCI200216506; JONES HE, 1992, LIPIDS, V27, P984, DOI 10.1007/BF02535576; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; Patterson SI, 2002, BIOL RES, V35, P139, DOI 10.4067/S0716-97602002000200005; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Tanaka K, 2003, CELL BIOL INT, V27, P549, DOI 10.1016/S1065-6995(03)00080-5; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Vilas GL, 2004, BIOCHEM J, V377, P121, DOI 10.1042/BJ20030951; Vincent JP, 2002, TRENDS CELL BIOL, V12, P57, DOI 10.1016/S0962-8924(01)02227-9; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; White T, 1998, ANAL BIOCHEM, V258, P109, DOI 10.1006/abio.1997.2545; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648	44	189	201	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33220	33227		10.1074/jbc.M403407200	http://dx.doi.org/10.1074/jbc.M403407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166250	hybrid			2022-12-27	WOS:000223039700027
J	Ho, YS; Xiong, Y; Ma, WC; Spector, A; Ho, DS				Ho, YS; Xiong, Y; Ma, WC; Spector, A; Ho, DS			Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; GLUTATHIONE-PEROXIDASE; HYPOCATALASEMIC MOUSE; HYDROGEN-PEROXIDE; MITOCHONDRIAL-FUNCTION; ANTIOXIDANT DEFENSE; OXIDATIVE STRESS; EPITHELIAL-CELLS; BLOOD CATALASE; RAT LENSES	Catalase plays a major role in cellular antioxidant defense by decomposing hydrogen peroxide, thereby preventing the generation of hydroxyl radical by the Fenton reaction. The degree of catalase deficiency in acatalasemic and hypocatalasemic mice varies from tissue to tissue. They therefore may not be suitable for studying the function of this enzyme in certain models of oxidant-mediated tissue injury. We sought to generate a new line of catalase null mice by the gene targeting technique. The mouse catalase (Cat or Cas1) gene was disrupted by replacing parts of intron 4 and exon 5 with a neomycin resistance cassette. Homozygous Cat knockout mice, which are completely deficient in catalase expression, develop normally and show no gross abnormalities. Slices of liver and lung and lenses from the knockout mice exhibited a retarded rate in decomposing extracellular hydrogen peroxide compared with those of wild-type mice. However, mice deficient in catalase were not more vulnerable to hyperoxia-induced lung injury; nor did their lenses show any increased susceptibility to oxidative stress generated by photochemical reaction, suggesting that the antioxidant function of catalase in these two models of oxidant injury is negligible. Further studies showed that cortical injury from physical impact caused a significant decrease in NAD-linked electron transfer activities and energy coupling capacities in brain mitochondria of Cat knockout mice but not wild-type mice. The observed decrease in efficiency of mitochondrial respiration may be a direct result of an increase in mitochondrion-associated calcium, which is secondary to the increased oxidative stress. These studies suggest that the role of catalase in antioxidant defense is dependent on the type of tissue and the model of oxidant-mediated tissue injury.	Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA	Wayne State University; Wayne State University; Columbia University	Ho, YS (corresponding author), Wayne State Univ, Inst Environm Hlth Sci, 2727 2nd Ave,Rm 4000, Detroit, MI 48201 USA.	yho@wayne.edu		Xiong, Ye/0000-0001-9770-6031	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056421, R01HL063317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AEBI H, 1968, BIOCHEM GENET, V2, P245, DOI 10.1007/BF01474764; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARNHOLD J, 1991, J BIOLUM CHEMILUM, V6, P189, DOI 10.1002/bio.1170060309; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BERG JM, 2002, BIOCHEMISTRY-US, P205; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; Eaton JW, 1995, METABOLIC MOL BASES, P2371; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; FEINSTEI.RN, 1967, ARCH BIOCHEM BIOPHYS, V120, P165, DOI 10.1016/0003-9861(67)90609-1; FEINSTEIN RN, 1967, ARCH BIOCHEM BIOPHYS, V122, P338, DOI 10.1016/0003-9861(67)90203-2; FEINSTEIN RN, 1966, GENETICS, V53, P923; FEINSTEIN RN, 1968, BIOCHEM GENET, V1, P277, DOI 10.1007/BF00485182; FEINSTEIN RN, 1968, SCIENCE, V159, P638, DOI 10.1126/science.159.3815.638; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; Flohe L, 2003, BIOFACTORS, V19, P3, DOI 10.1002/biof.5520190102; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; FREEMAN BA, 1984, ENVIRON HEALTH PERSP, V56, P51; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; JONES GL, 1976, ARCH BIOCHEM BIOPHYS, V173, P463, DOI 10.1016/0003-9861(76)90283-6; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; Keilin D, 1936, PROC R SOC SER B-BIO, V119, P141, DOI 10.1098/rspb.1936.0003; KEILIN D, 1945, BIOCHEM J, V39, P293, DOI 10.1042/bj0390293; Lee C. P., 1993, V2, P41; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINDAUSHEPARD BA, 1993, FREE RADICAL BIO MED, V15, P581, DOI 10.1016/0891-5849(93)90160-V; MAKINO N, 1994, J BIOL CHEM, V269, P1020; Mueller S, 1997, BLOOD, V90, P4973, DOI 10.1182/blood.V90.12.4973.4973_4973_4978; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; OSHINO N, 1973, BIOCHEM J, V131, P555, DOI 10.1042/bj1310555; Povlishock J T, 1992, Hum Cell, V5, P345; RADI R, 1991, J BIOL CHEM, V266, P22028; RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D; REIMER DL, 1994, GENOMICS, V21, P325, DOI 10.1006/geno.1994.1273; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; SHAFFER JB, 1990, BIOCHEM BIOPH RES CO, V173, P1043, DOI 10.1016/S0006-291X(05)80891-5; SHAFFER JB, 1987, J BIOL CHEM, V262, P12908; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Spector A, 1996, EXP EYE RES, V62, P521, DOI 10.1006/exer.1996.0063; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; SPECTOR A, 1993, P NATL ACAD SCI USA, V90, P7485, DOI 10.1073/pnas.90.16.7485; SPERANZA MJ, 1993, J BIOL CHEM, V268, P19039; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; SUZUKI K, 1991, ACTA MED OKAYAMA, V45, P363; Takahara S., 1948, J OTORHINOLARYNG SOC, V51, P163; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Wang DH, 2001, BBA-GENE STRUCT EXPR, V1522, P217, DOI 10.1016/S0167-4781(01)00316-5; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang H, 2003, AM J HYPERTENS, V16, P1, DOI 10.1016/S0895-7061(02)03086-8; YOO JH, 1994, J CLIN INVEST, V93, P297, DOI 10.1172/JCI116959	66	276	290	2	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32804	32812		10.1074/jbc.M404800200	http://dx.doi.org/10.1074/jbc.M404800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15178682	hybrid			2022-12-27	WOS:000222849700100
J	Tanaka, K; Russell, P				Tanaka, K; Russell, P			Cds1 phosphorylation by Rad3-Rad26 kinase is mediated by forkhead-associated domain interaction with Mrc1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; LI-FRAUMENI-SYNDROME; FISSION YEAST; FHA DOMAIN; SCHIZOSACCHAROMYCES-POMBE; REPLICATION STRESS; S-PHASE; RECOMBINATIONAL REPAIR; PROTEIN-KINASE; IN-VITRO	The protein kinase Cds1 is an effector of the replication checkpoint in the fission yeast Schizosaccharomyces pombe. Cds1 is required to stabilize stalled replication forks, and it helps to prevent the onset of mitosis until the genome is fully replicated. Mrc1 (mediator of the replication checkpoint-1) and Rad3-Rad26 kinase are required for Cds1 activation, but exactly how Mrc1 mediates Cds1 activation is unknown. Here we show that Mrc1 is required for the initial threonine 11 phosphorylation of Cds1 by Rad3-Rad26. Mrc1 specifically interacts with the forkhead-associated (FHA) domain of Cds1 in yeast two-hybrid assays. Mutations in the FHA domain that abolish this interaction also eliminate Thr-11 phosphorylation of Cds1. Weak Thr-11 phosphorylation of a "kinase-dead" mutant of Cds1 is rescued by co-expression of wild type Cds1. The requirement for Mrc1 in the replication checkpoint can be partially eliminated by expression of a Rad26-Cds1 fusion protein. These findings suggest that recognition of Mrc1 by the FHA domain of Cds1 serves to recruit Cds1 to Rad3-Rad26. This interaction mediates the initial Thr-11 phosphorylation of Cds1 by Rad3-Rad26 with subsequent intermolecular phosphorylation events leading to full activation of Cds1.	Shimane Univ, Fac Life & Environm Sci, Dept Appl Biosci & Biotechnol, Matsue, Shimane 6908504, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Shimane University; Scripps Research Institute; Scripps Research Institute	Tanaka, K (corresponding author), Shimane Univ, Fac Life & Environm Sci, Dept Appl Biosci & Biotechnol, 1060 Nishikawatsu, Matsue, Shimane 6908504, Japan.	ktanaka@life.shimane-u.ac.jp	Tanaka, Katsunori/F-8086-2010	Tanaka, Katsunori/0000-0001-9692-0968	NIGMS NIH HHS [GM59447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059447] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Bashkirov VI, 2003, MOL CELL BIOL, V23, P1441, DOI 10.1128/MCB.23.4.1441-1452.2003; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Boddy MN, 2003, MOL CELL BIOL, V23, P5939, DOI 10.1128/MCB.23.16.5939-5946.2003; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; KEENEY JB, 1994, GENETICS, V136, P849; KIM JS, 1993, PROTEIN SCI, V2, P348; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee SB, 2001, CANCER RES, V61, P8062; Lee SJ, 2003, MOL CELL BIOL, V23, P6300, DOI 10.1128/MCB.23.17.6300-6314.2003; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 2000, J CELL SCI, V113, P3889; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tanaka K, 2001, MOL CELL BIOL, V21, P3398, DOI 10.1128/MCB.21.10.3398-3404.2001; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	50	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32079	32086		10.1074/jbc.M404834200	http://dx.doi.org/10.1074/jbc.M404834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173168	hybrid			2022-12-27	WOS:000222849700012
J	Bric, A; Radebaugh, CA; Paule, MR				Bric, A; Radebaugh, CA; Paule, MR			Photocross-linking of the RNA polymerase I preinitiation and immediate postinitiation complexes - Implications for promoter recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION-FACTOR; LARGE-SCALE PREPARATION; ACANTHAMOEBA-CASTELLANII; FACTOR TIF; STRUCTURAL BASIS; DNA; SUBUNIT; YEAST; BINDING; ELONGATION	The architecture of eukaryotic rRNA transcription complexes was analyzed, revealing facts significant to the RNA polymerase (pol) I initiation process. Functional initiation and elongation complexes were mapped by site-specific photocross-linking to template DNA. Polymerase I is recruited to the promoter via protein-protein interactions with DNA-bound transcription initiation factor-IB. The latter's TATA-binding protein (TBP) and TAFs photocross-link to the promoter from - 78 to + 10 relative to the tis ( + 1). Although TBP does not bind DNA using its TATA-binding saddle, it does photocross-link to a 22-bp sequence that does not resemble a TATA box. Only TAF(I)96 ( the mammalian TAF(I)68, yeast Rrn7p homolog) overlaps significantly with the DNA interaction cleft of pol I based on modeling to the pol II crystal structure. None of the pol I-specific subunits that are localized on the lips of the cleft (A49 and A34.5) or the pol I-specific stalk (A43 and A14) cross-link to DNA. Pol I does not extend significantly upstream of the promoter-proximal border of the factor complex ( - 11 to - 14), and similarly in the promoter proximal elongation complex, the enzyme does not contact DNA upstream of its normal exit from the cleft.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Paule, MR (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	mpaule@lamar.colostate.edu			NIGMS NIH HHS [GM22580] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022580] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Khouri AM, 2002, MOL CELL BIOL, V22, P750, DOI 10.1128/MCB.22.3.750-761.2002; ALKHOURI AM, 2002, IN PRESS MOL CELL BI, V22; Aprikian P, 2001, MOL CELL BIOL, V21, P4847, DOI 10.1128/MCB.21.15.4847-4855.2001; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BARTHOLOMEW B, 1994, J BIOL CHEM, V269, P18090; BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BATEMAN E, 1988, MOL CELL BIOL, V8, P1940, DOI 10.1128/MCB.8.5.1940; BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; Bischler N, 2002, EMBO J, V21, P4136, DOI 10.1093/emboj/cdf392; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; Boukhgalter B, 2002, GENE, V291, P187, DOI 10.1016/S0378-1119(02)00597-8; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DALESSIO JM, 1979, J BIOL CHEM, V254, P4085; DALESSIO JM, 1979, J BIOL CHEM, V254, P1282; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Geiss GK, 1997, J BIOL CHEM, V272, P29243, DOI 10.1074/jbc.272.46.29243; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GONG XL, 1995, MOL CELL BIOL, V15, P4956; Kahl BF, 2000, J MOL BIOL, V299, P75, DOI 10.1006/jmbi.2000.3743; KAHL BF, 2001, DNA PROTEIN INTERACT, P63; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; Marilley M, 2002, MOL GENET GENOMICS, V267, P781, DOI 10.1007/s00438-002-0708-z; Milkereit P, 1997, BIOL CHEM, V378, P1433, DOI 10.1515/bchm.1997.378.12.1433; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; PAULE MR, 1991, MOL CELL BIOCHEM, V104, P119, DOI 10.1007/BF00229811; Perna Peter J., 1992, Gene Expression, V2, P71; Peyroche E, 2002, P NATL ACAD SCI USA, V99, P14670, DOI 10.1073/pnas.232580799; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; Radebaugh CA, 1998, J BIOL CHEM, V273, P27708, DOI 10.1074/jbc.273.42.27708; Radebaugh CA, 1997, J BIOL CHEM, V272, P3141, DOI 10.1074/jbc.272.6.3141; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SPINDLER SR, 1978, J BIOL CHEM, V253, P4669; SPINDLER SR, 1978, J BIOL CHEM, V253, P6242; Travers A, 2000, PRACT APPROACH SER, P229; WONG JM, 1992, GENE, V117, P91, DOI 10.1016/0378-1119(92)90494-A; Wooddell CI, 2000, BIOCHEMISTRY-US, V39, P13405, DOI 10.1021/bi0014249; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	47	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31259	31267		10.1074/jbc.M311828200	http://dx.doi.org/10.1074/jbc.M311828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15161919	hybrid			2022-12-27	WOS:000222726800045
J	Chen, C; Ko, Y; Delannoy, M; Ludtke, SJ; Chiu, W; Pedersen, PL				Chen, C; Ko, Y; Delannoy, M; Ludtke, SJ; Chiu, W; Pedersen, PL			Mitochondrial ATP synthasome - Three-dimensional structure by electron microscopy of the ATP synthase in complex formation with carriers for P-i and ADP/ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; PROTEIN; RESOLUTION; INTERMEDIATE; F-1-ATPASE; MECHANISM	The terminal steps involved in making ATP in mitochondria require an ATP synthase (F0F1) comprised of two motors, a phosphate carrier (PIC), and an adenine nucleotide carrier (ANC). Under mild conditions, these entities sub-fractionate as an ATP synthase/PIC/ANC complex or "ATP synthasome" (Ko, Y. H., Delannoy, M, Hullihen, J., Chiu, W., and Pedersen, P. L. ( 2003) J. Biol. Chem. 278, 12305 - 12309). As a first step toward obtaining three-dimensional information about this large complex or "metabolon" and the locations of PIC and ANC therein, we dispersed ATP synthasomes into single complexes and visualized negatively stained images by electron microscopy ( EM) that showed clearly the classical headpiece, central stalk, and basepiece. Parallel immuno-EM studies revealed the presence of PIC and ANC located non-centrally in the basepiece, and other studies implicated an ATP synthase/PIC/ANC stoichiometry near 1: 1: 1. Single ATP synthasome images ( 7506) were boxed, and, using EMAN software, a three-dimensional model was obtained at a resolution of 23 Angstrom. Significantly, the basepiece is oblong and contains two domains, the larger of which connects to the central stalk, whereas the smaller appears as an extension. Docking studies with known structures together with the immuno-EM studies suggest that PIC or ANC may be located in the smaller domain, whereas the other transporter resides nearby in the larger domain. Collectively, these finding support a mechanism in which the entry of the substrates ADP and Pi into mitochondria, the synthesis of ATP on F-1, and the release and exit of ATP are very localized and highly coordinated events.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Baylor College of Medicine	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	ppederse@jhmi.edu	Ludtke, Steven/A-4478-2008	Ludtke, Steven/0000-0002-1903-1574	NCI NIH HHS [CA 10951] Funding Source: Medline; NCRR NIH HHS [P41RR02250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Belogrudov GI, 2002, J BIOL CHEM, V277, P6097, DOI 10.1074/jbc.M111256200; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BLOCK MR, 1982, BIOCHEM BIOPH RES CO, V109, P471, DOI 10.1016/0006-291X(82)91745-4; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; CATTERAL.WA, 1973, J BIOL CHEM, V248, P7427; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; Hardy AW, 2003, J BIOENERG BIOMEMBR, V35, P389, DOI 10.1023/A:1027363012727; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; JACOBS EE, 1956, J BIOL CHEM, V223, P147; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaplan RS, 2001, J MEMBRANE BIOL, V179, P165, DOI 10.1007/s002320010046; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Oster G, 1999, STRUCTURE, V7, pR67, DOI 10.1016/S0969-2126(99)80046-X; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P423, DOI 10.1023/A:1005652605340; Pedersen PL, 1999, J BIOENERG BIOMEMBR, V31, P291, DOI 10.1023/A:1005453700533; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	36	167	168	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31761	31768		10.1074/jbc.M401353200	http://dx.doi.org/10.1074/jbc.M401353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15166242	hybrid			2022-12-27	WOS:000222726800102
J	Wackett, LP				Wackett, LP			Evolution of enzymes for the metabolism of new chemical inputs into the environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GLUTATHIONE S-TRANSFERASES; DICHLOROMETHANE DEHALOGENASE; ATRAZINE CHLOROHYDROLASE; CATABOLIC PLASMID; COMPLETE SEQUENCE; 4-OXALOCROTONATE TAUTOMERASE; BACTERIAL; ADENOSINE; DEAMINASE; MECHANISM		Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA; Univ Minnesota, Inst Biotechnol, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Wackett, LP (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA.	wackett@biosci.cbs.umn.edu						Alexander M., 1999, BIODEGRADATION BIORE, P17; Anandarajah K, 2000, BIOCHEMISTRY-US, V39, P5303, DOI 10.1021/bi9923813; Araujo ASF, 2003, CHEMOSPHERE, V52, P799, DOI 10.1016/S0045-6535(03)00266-2; Badia J, 1998, J BIOL CHEM, V273, P8376, DOI 10.1074/jbc.273.14.8376; BAER HP, 1966, MOL PHARMACOL, V2, P67; BAR HP, 1966, BIOCHEM BIOPH RES CO, V24, P584, DOI 10.1016/0006-291X(66)90361-5; BLOCKI FA, 1994, J BIOL CHEM, V269, P8826; BLUMER M, 1976, SCI AM, V234, P35; BROWN MP, 1988, SCIENCE, V240, P1674, DOI 10.1126/science.3132740; CHAKRABARTY AM, 1968, P NATL ACAD SCI USA, V60, P168, DOI 10.1073/pnas.60.1.168; Chen G, 2003, RES MICROBIOL, V154, P393, DOI 10.1016/S0923-2508(03)00082-2; CHEN YM, 1989, J BACTERIOL, V171, P6097, DOI 10.1128/jb.171.11.6097-6105.1989; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Copley SD, 2003, DEHALOGENATION: MICROBIAL PROCESSES AND ENVIRONMENTAL APPLICATIONS, P227; GALLI R, 1982, EXPERIENTIA, V38, P1378; GALLI R, 1988, J GEN MICROBIOL, V134, P943; Gisi D, 1999, ARCH TOXICOL, V73, P71, DOI 10.1007/s002040050589; Greated A, 2002, ENVIRON MICROBIOL, V4, P856, DOI 10.1046/j.1462-2920.2002.00305.x; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Igloi GL, 2003, J BACTERIOL, V185, P1976, DOI 10.1128/JB.185.6.1976-1986.2003; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kayser MF, 2001, J BACTERIOL, V183, P5209, DOI 10.1128/JB.183.17.5209-5212.2001; Kayser MF, 2000, J BACTERIOL, V182, P5433, DOI 10.1128/JB.182.19.5433-5439.2000; KOHLERSTAUB D, 1985, J BACTERIOL, V162, P676, DOI 10.1128/JB.162.2.676-681.1985; LAROCHE SD, 1991, J BACTERIOL, V173, P6714, DOI 10.1128/jb.173.21.6714-6721.1991; Martinez B, 2001, J BACTERIOL, V183, P5684, DOI 10.1128/JB.183.19.5684-5697.2001; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; ORSER CS, 1993, J BACTERIOL, V175, P2640, DOI 10.1128/JB.175.9.2640-2644.1993; Poelarends GJ, 1998, APPL ENVIRON MICROB, V64, P2931; Poelarends GJ, 2000, J BACTERIOL, V182, P2191, DOI 10.1128/JB.182.8.2191-2199.2000; Poelarends GJ, 2001, J BACTERIOL, V183, P4269, DOI 10.1128/JB.183.14.4269-4277.2001; RAILLARD SA, 2001, CHEM BIOL, V125, P1; RHEINWAL.JG, 1973, P NATL ACAD SCI USA, V70, P885, DOI 10.1073/pnas.70.3.885; Romine MF, 1999, J BACTERIOL, V181, P1585, DOI 10.1128/JB.181.5.1585-1602.1999; Sadowsky MJ, 1998, J BACTERIOL, V180, P152, DOI 10.1128/JB.180.1.152-158.1998; Salama F, 1999, ASTROPHYS J, V526, P265, DOI 10.1086/307978; SCHOLTZ R, 1988, J BACTERIOL, V170, P5698, DOI 10.1128/jb.170.12.5698-5704.1988; Seffernick JL, 2000, APPL ENVIRON MICROB, V66, P4247, DOI 10.1128/AEM.66.10.4247-4252.2000; Seffernick JL, 2002, BIOCHEMISTRY-US, V41, P14430, DOI 10.1021/bi020415s; Seffernick JL, 2001, J BACTERIOL, V183, P2405, DOI 10.1128/JB.183.8.2405-2410.2001; Seffernick JL, 2001, BIOCHEMISTRY-US, V40, P12747, DOI 10.1021/bi011293r; Sephton MA, 2002, NAT PROD REP, V19, P292, DOI 10.1039/b103775g; Sota M, 2003, J BACTERIOL, V185, P6741, DOI 10.1128/JB.185.22.6741-6745.2003; STEIERT JG, 1986, BIOCHEM BIOPH RES CO, V141, P825, DOI 10.1016/S0006-291X(86)80247-9; Stivers JT, 1996, PROTEIN SCI, V5, P729; Stourman NV, 2003, BIOCHEMISTRY-US, V42, P11048, DOI 10.1021/bi035016r; Tauch A, 2003, MOL GENET GENOMICS, V268, P570, DOI 10.1007/s00438-002-0785-z; Thorsted PA, 1998, J MOL BIOL, V282, P969, DOI 10.1006/jmbi.1998.2060; Tiedje James M., 1993, Biodegradation, V4, P231, DOI 10.1007/BF00695971; Top EM, 2000, HORIZONTAL GENE POOL, P249; Veerkamp W., 1981, MICROBIAL DEGRADATIO; Vuilleumier S, 2002, APPL MICROBIOL BIOT, V58, P138, DOI 10.1007/s00253-001-0836-0; Wackett LP, 2002, APPL MICROBIOL BIOT, V58, P39, DOI 10.1007/s00253-001-0862-y; Whitman CP, 2002, ARCH BIOCHEM BIOPHYS, V402, P1, DOI 10.1016/S0003-9861(02)00052-8; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Wyndham R. Campbell, 1994, Biodegradation, V5, P323, DOI 10.1007/BF00696468; YANG RSH, 1986, RESIDUE REV, V97, P19; 1972, NATURE, V240, P319	60	42	42	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41259	41262		10.1074/jbc.R400014200	http://dx.doi.org/10.1074/jbc.R400014200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15187076	hybrid			2022-12-27	WOS:000224075500001
J	Vargas, GA; von Zastrow, M				Vargas, GA; von Zastrow, M			Identification of a novel endocytic recycling signal in the D1 dopamine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN LUTROPIN RECEPTOR; C-TERMINAL TAIL; OPIOID RECEPTORS; CYTOPLASMIC TAIL; CARBOXYL TAIL; DESENSITIZATION; TRAFFICKING; PHOSPHORYLATION; MOTIF	A critical event determining the functional consequences of G protein-coupled receptor ( GPCR) endocytosis is the molecular sorting of internalized receptors between divergent recycling and degradative membrane pathways. The D1 dopamine receptor recycles rapidly and efficiently to the plasma membrane after agonist-induced endocytosis and is remarkably resistant to proteolytic down-regulation. Whereas the mechanism mediating agonist-induced endocytosis of D1 receptors has been investigated in some detail, little is known about how receptors are sorted after endocytosis. We have identified a sequence present in the carboxyl-terminal cytoplasmic domain of the human D1 dopamine receptor that is specifically required for the efficient recycling of endocytosed receptors back to the plasma membrane. This sequence is distinct from previously identified membrane trafficking signals and is located in a proximal portion of the carboxyl-terminal cytoplasmic domain, in contrast to previously identified GPCR recycling signals present at the distal tip. Nevertheless, fusion of this sequence to the carboxyl terminus of a chimeric mutant delta opioid neuropeptide receptor is sufficient to re-route internalized receptors from lysosomal to recycling membrane pathways, defining this sequence as a bona fide endocytic recycling signal that can function in both proximal and distal locations. These results identify a novel sorting signal controlling the endocytic trafficking itinerary of a physiologically important dopamine receptor, provide the first example of such a sorting signal functioning in a proximal portion of the carboxyl-terminal cytoplasmic domain, and suggest the existence of a diverse array of sorting signals in the GPCR superfamily that mediate subtype-specific regulation of receptors via endocytic membrane trafficking.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vargas, GA (corresponding author), Univ Calif San Francisco, Dept Psychiat, N-216 Genetech Hall,600 16th St, San Francisco, CA 94143 USA.	gvargas@itsa.ucsf.edu						Ariano MA, 1997, SYNAPSE, V27, P313, DOI 10.1002/(SICI)1098-2396(199712)27:4<313::AID-SYN5>3.3.CO;2-0; Barboi AC, 1999, CLIN NEUROPHARMACOL, V22, P184; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; Chaar ZY, 2001, J NEUROCHEM, V79, P1047, DOI 10.1046/j.1471-4159.2001.00648.x; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Dumartin B, 1998, J NEUROSCI, V18, P1650; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Galet C, 2004, MOL ENDOCRINOL, V18, P434, DOI 10.1210/me.2003-0293; Galet C, 2003, MOL ENDOCRINOL, V17, P411, DOI 10.1210/me.2002-0161; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEIN L, 1994, J BIOL CHEM, V269, P27719; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nestler EJ, 1997, NATURE, V385, P578, DOI 10.1038/385578a0; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Wang W, 2003, J BIOL CHEM, V278, P36848, DOI 10.1074/jbc.M301540200	35	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37461	37469		10.1074/jbc.M401034200	http://dx.doi.org/10.1074/jbc.M401034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15192107	hybrid			2022-12-27	WOS:000223554600034
J	Mukamel, Z; Kimchi, A				Mukamel, Z; Kimchi, A			Death-associated protein 3 localizes to the mitochondria and is involved in the process of mitochondrial fragmentation during cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-RECEPTOR; RIBOSOMAL-PROTEINS; APOPTOSIS; YEAST; DAP3; DYNAMICS; MEDIATOR; IDENTIFICATION; MORPHOLOGY; DIVISION	Death-associated protein 3 (DAP3) was previously isolated in our laboratory as a positive mediator of cell death. It is a 46-kDa protein containing a GTP binding domain that was shown to be essential for the induction of cell death. DAP3 functions downstream of the receptor signaling complex, and its death-promoting effects depend on caspase activity. Recent reports have suggested that DAP3 is localized to the mitochondria, but no functional significance of this localization has been reported so far. Here, we study the sub-cellular localization and cellular function of human DAP3 (hDAP3). We found that hDAP3 is localized to the mitochondria and, in contrast to cytochrome c, is not released to the cytoplasm following several cell death signals. Overexpression of hDAP3 induced dramatic changes in the mitochondrial structure involving increased fragmentation of the mitochondria. Both the mitochondrial localization of hDAP3 and its GTP-binding activity were essential for the fragmentation. The punctiform mitochondrial morphology was similar to that observed upon treatment of HeLa cells with staurosporine. In fact, reduction of endogenous hDAP3 protein by RNA interference partially attenuated staurosporine-induced mitochondrial fission. Thus, hDAP3 is a necessary component in the molecular pathway that culminates in fragmented mitochondria, probably reflecting its involvement in the fission process. These results, for the first time, provide a specific functional role for hDAP3 in mitochondrial maintenance.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il						Berger T, 2000, J CELL SCI, V113, P3603; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hulkko SM, 2000, BIOCHEM J, V349, P885, DOI 10.1042/bj3490885; Hulkko SM, 2002, BIOCHEM BIOPH RES CO, V295, P749, DOI 10.1016/S0006-291X(02)00713-1; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Messerschmitt M, 2003, J CELL BIOL, V160, P553, DOI 10.1083/jcb.200211113; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Morgan CJ, 2001, BIOCHEM BIOPH RES CO, V280, P177, DOI 10.1006/bbrc.2000.4119; Saveanu C, 2001, J BIOL CHEM, V276, P15861, DOI 10.1074/jbc.M010864200; Schulke N, 1999, J BIOL CHEM, V274, P22847, DOI 10.1074/jbc.274.32.22847; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J	24	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36732	36738		10.1074/jbc.M400041200	http://dx.doi.org/10.1074/jbc.M400041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15175341	hybrid			2022-12-27	WOS:000223453600073
J	Rayes, D; De Rosa, MAJ; Bartos, M; Bouzat, C				Rayes, D; De Rosa, MAJ; Bartos, M; Bouzat, C			Molecular basis of the differential sensitivity of nematode and mammalian muscle to the anthelmintic agent levamisole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHANNEL CURRENTS; ACETYLCHOLINE-RECEPTORS; AGONIST BINDING; ASCARIS MUSCLE; MUTATION; DOMAIN; INHIBITION; ACTIVATION; MECHANISM; PYRANTEL	Levamisole is an anthelmintic agent that exerts its therapeutic effect by acting as a full agonist of the nicotinic receptor (AChR) of nematode muscle. Its action at the mammalian muscle AChR has not been elucidated to date despite its wide use as an anthelmintic in humans and cattle. By single channel and macroscopic current recordings, we investigated the interaction of levamisole with the mammalian muscle AChR. Levamisole activates mammalian AChRs. However, single channel openings are briefer than those activated by acetylcholine (ACh) and do not appear in clusters at high concentrations. The peak current induced by levamisole is about 3% that activated by ACh. Thus, the anthelmintic acts as a weak agonist of the mammalian AChR. Levamisole also produces open channel blockade of the AChR. The apparent affinity for block (190 muM at -70 mV) is similar to that of the nematode AChR, suggesting that differences in channel activation kinetics govern the different sensitivity of nematode and mammalian muscle to anthelmintics. To identify the structural basis of this different sensitivity, we performed mutagenesis targeting residues in the alpha subunit that differ between vertebrates and nematodes. The replacement of the conserved alphaGly-153 with the homologous glutamic acid of nematode AChR significantly increases the efficacy of levamisole to activate channels. Channel activity takes place in clusters having two different kinetic modes. The kinetics of the high open probability mode are almost identical when the agonist is ACh or levamisole. It is concluded that alphaGly-153 is involved in the low efficacy of levamisole to activate mammalian muscle AChRs.	UNS, CONICET, Inst Invest Bioquim Bahia Blanca, Bahia Blanca, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the South	Bouzat, C (corresponding author), UNS, CONICET, Inst Invest Bioquim Bahia Blanca, CC857,Camino La Carrindanga Km 7-B8000FWB, Bahia Blanca, Buenos Aires, Argentina.	inbouzat@criba.edu.ar	, Diego/AAH-4523-2020	DE ROSA, MARIA JOSE/0000-0002-2149-6127	FIC NIH HHS [1R03 TW 01185-01] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001185] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ACEVES J, 1970, BRIT J PHARMACOL, V38, P602, DOI 10.1111/j.1476-5381.1970.tb10601.x; Akk G, 2000, BRIT J PHARMACOL, V130, P249, DOI 10.1038/sj.bjp.0703335; AMADOR M, 1991, SYNAPSE, V7, P207, DOI 10.1002/syn.890070305; ATCHISON WD, 1992, TOXICOL APPL PHARM, V112, P133, DOI 10.1016/0041-008X(92)90289-5; Bouzat C, 2000, J GEN PHYSIOL, V115, P663, DOI 10.1085/jgp.115.5.663; Bouzat C, 1998, MOL PHARMACOL, V54, P146, DOI 10.1124/mol.54.1.146; Bouzat C, 2002, BIOPHYS J, V82, P1920, DOI 10.1016/S0006-3495(02)75541-0; BOUZAT C, 1994, NEURON, V13, P1395, DOI 10.1016/0896-6273(94)90424-3; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Corringer PJ, 1998, J NEUROSCI, V18, P648; Dilger JP, 1997, J GEN PHYSIOL, V109, P401, DOI 10.1085/jgp.109.3.401; DILGER JP, 1992, MOL PHARMACOL, V41, P127; Engel AG, 2002, MOL NEUROBIOL, V26, P347, DOI 10.1385/MN:26:2-3:347; Evans AM, 1996, BRIT J PHARMACOL, V118, P1127, DOI 10.1111/j.1476-5381.1996.tb15515.x; Fleming JT, 1997, J NEUROSCI, V17, P5843; Grutter T, 2003, EMBO J, V22, P1990, DOI 10.1093/emboj/cdg197; Gumilar F, 2003, NEUROPHARMACOLOGY, V45, P964, DOI 10.1016/S0028-3908(03)00247-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARROW ID, 1985, PESTIC SCI, V16, P662, DOI 10.1002/ps.2780160612; Hoekstra R, 1997, MOL BIOCHEM PARASIT, V84, P179, DOI 10.1016/S0166-6851(96)02793-4; Le Novere N, 1999, NUCLEIC ACIDS RES, V27, P340, DOI 10.1093/nar/27.1.340; Levandoski MM, 2003, EUR J PHARMACOL, V471, P9, DOI 10.1016/S0014-2999(03)01796-5; LEWIS JA, 1980, NEUROSCIENCE, V5, P967, DOI 10.1016/0306-4522(80)90180-3; LIU Y, 1993, SYNAPSE, V13, P57, DOI 10.1002/syn.890130108; Martin R.J., 1991, Parasitology, V102, P41; Martin RJ, 1996, PARASITOLOGY, V113, pS137, DOI 10.1017/S0031182000077945; NARANJO D, 1993, SCIENCE, V260, P1811, DOI 10.1126/science.8511590; NEHER E, 1983, J PHYSIOL-LONDON, V339, P663, DOI 10.1113/jphysiol.1983.sp014741; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; PRINCE RJ, 1998, NICOTINIC ACETYLCHOL, P31; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Rayes D, 2001, NEUROPHARMACOLOGY, V41, P238, DOI 10.1016/S0028-3908(01)00057-0; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; ROBERTSON SJ, 1993, BRIT J PHARMACOL, V108, P170, DOI 10.1111/j.1476-5381.1993.tb13458.x; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Spitzmaul G, 2001, MOL PHARMACOL, V60, P235, DOI 10.1124/mol.60.2.235; Spitzmaul GF, 1999, NEUROREPORT, V10, P2175, DOI 10.1097/00001756-199907130-00032; Wang HL, 2000, J GEN PHYSIOL, V116, P449, DOI 10.1085/jgp.116.3.449; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; Wiley LJ, 1996, GENE, V182, P97, DOI 10.1016/S0378-1119(96)00520-3	42	24	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36372	36381		10.1074/jbc.M403096200	http://dx.doi.org/10.1074/jbc.M403096200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15201284	hybrid, Green Published			2022-12-27	WOS:000223453600027
J	Soriano, ME; Nicolosi, L; Bernardi, P				Soriano, ME; Nicolosi, L; Bernardi, P			Desensitization of the permeability transition pore by cyclosporin A prevents activation of the mitochondrial apoptotic pathway and liver damage by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; ARACHIDONIC-ACID; FACTOR RECEPTOR; GD3 GANGLIOSIDE; INNER MEMBRANE; CYCLOPHILIN; RESISTANT; CERAMIDE; INJURY	We studied the effects of cyclosporin A (CsA) administration 1) on the properties of the permeability transition pore (PTP) in mitochondria isolated from the liver and 2) on the susceptibility to hepatotoxicity induced by lipopolysaccharide of Escherichia coli (LPS) plus D-galactosamine (D-GalN) in rats. CsA exerted a marked PTP inhibition ex vivo, with an effect that peaked between 2 and 9 h of drug treatment and decayed with an apparent half-time of about 13 h. Administration of LPS plus D-GalN to naive rats caused the expected increased serum levels of tumor necrosis factor (TNF)-alpha, liver inflammation with BID cleavage, activation of caspase 3, appearance of terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling-positive nuclei, and release of alanine aminotransferase and aspartate aminotransferase into the bloodstream. Treatment with CsA before or within 5 h of the administration of LPS plus D-GalN protected rats from hepatotoxicity despite the normal increase of serum TNF-alpha and BID cleavage. These results indicate that CsA prevents the hepatotoxic effects of TNF-alpha by blocking the mitochondrial proapoptotic pathway through inhibition of the PTP and provides a viable strategy for the treatment of liver diseases that depend on increased production and/or liver sensitization to TNF-alpha.	Univ Padua, Inst Neurosci, Consiglio Nazl Ric, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine	Bernardi, P (corresponding author), Univ Padua, Inst Neurosci, Consiglio Nazl Ric, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	bernardi@bio.unipd.it	Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736; Soriano, Maria Eugenia/0000-0002-7971-2961	Telethon [GGP02123] Funding Source: Medline	Telethon(Fondazione Telethon)		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; CROMPTON M, 1988, BIOCHEM J, V255, P357; Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002; DECKER K, 1974, REV PHYSIOL BIOCH P, V71, P77, DOI 10.1007/BFb0027661; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gramaglia D, 2004, CELL DEATH DIFFER, V11, P342, DOI 10.1038/sj.cdd.4401326; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kawakami T, 2000, HEPATOL RES, V18, P284, DOI 10.1016/S1386-6346(00)00088-7; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P10014, DOI 10.1073/pnas.1633614100; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krauskopf A, 2003, J BIOL CHEM, V278, P41685, DOI 10.1074/jbc.M301181200; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1998, Rev Physiol Biochem Pharmacol, V133, P109; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malagarie-Cazenave S, 2004, J BIOL CHEM, V279, P18648, DOI 10.1074/jbc.M314294200; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Mari M, 2004, J CLIN INVEST, V113, P895, DOI 10.1172/JCI200419852; Nguyen NSD, 1999, FREE RADICAL BIO MED, V27, P1267, DOI 10.1016/S0891-5849(99)00160-4; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Penzo D, 2004, J BIOL CHEM, V279, P25219, DOI 10.1074/jbc.M310381200; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WALSH CT, 1992, J BIOL CHEM, V267, P13115; Wasaki S, 1997, LIVER, V17, P107; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YOSHIBA M, 1995, J GASTROENTEROL, V30, P67, DOI 10.1007/BF01211377; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200	65	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36803	36808		10.1074/jbc.M405297200	http://dx.doi.org/10.1074/jbc.M405297200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15201276	hybrid			2022-12-27	WOS:000223453600082
J	Mimura, H; Nakanishi, Y; Hirono, M; Maeshima, M				Mimura, H; Nakanishi, Y; Hirono, M; Maeshima, M			Membrane topology of the H+-pyrophosphatase of Streptomyces coelicolor determined by cysteine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING INORGANIC PYROPHOSPHATASE; METAL-TETRACYCLINE/H+ ANTIPORTER; PROTON-PUMPING PYROPHOSPHATASE; SUBSTRATE-BINDING SITE; RHODOSPIRILLUM-RUBRUM; ESCHERICHIA-COLI; TERMINAL REGION; ANION-EXCHANGER; RESIDUES; INHIBITION	The H+-translocating pyrophosphatase (H+-PPase) is a proton pump that is found in a wide variety of organisms. It consists of a single polypeptide chain that is thought to possess between 14 and 17 transmembrane domains. To determine the topological arrangement of its conserved motifs and transmembrane domains, we carried out a cysteine-scanning analysis by determining the membrane topology of cysteine substitution mutants of Streptomyces coelicolor H+-PPase expressed in Escherichia coli using chemical reagents. First, we prepared a synthetic DNA that encoded the enzyme and constructed a functional cysteine-less mutant by substituting the four cysteine residues. We then introduced cysteine residues individually into 42 sites in its hydrophilic regions and N- and C-terminal segments. Thirty-six of the mutant enzymes retained both pyrophosphatase and H+-translocating activities. Analysis of 29 of these mutant forms using membrane-permeable and - impermeable sulfhydryl reagents revealed that S. coelicolor H+-PPase contains 17 transmembrane domains and that several conserved segments, such as the substrate-binding domains, are exposed to the cytoplasm. Four essential serine residues that were located on the cytoplasmic side were also identified. A marked characteristic of the S. coelicolor enzyme is a long additional sequence that includes a transmembrane domain at the C terminus. We propose that the basic structure of H+-PPases has 16 transmembrane domains with several large cytoplasmic loops containing functional motifs.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan	Nagoya University	Maeshima, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan.	maeshima@agr.nagoya-u.ac.jp	Maeshima, Masayoshi/D-3073-2013	Maeshima, Masayoshi/0000-0002-1611-5481				Baltscheffsky M, 1999, FEBS LETT, V452, P121, DOI 10.1016/S0014-5793(99)00617-1; Belogurov GA, 2002, J BIOL CHEM, V277, P49651, DOI 10.1074/jbc.M210341200; Belogurov GA, 2002, J BIOL CHEM, V277, P22209, DOI 10.1074/jbc.M202951200; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Gaxiola RA, 2001, P NATL ACAD SCI USA, V98, P11444, DOI 10.1073/pnas.191389398; GordonWeeks R, 1996, PLANT PHYSIOL, V111, P195, DOI 10.1104/pp.111.1.195; Kamiya T, 2004, J BIOL CHEM, V279, P812, DOI 10.1074/jbc.M309726200; Kimura T, 1997, J BIOL CHEM, V272, P580; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; Maeshima M, 2001, ANNU REV PLANT PHYS, V52, P469, DOI 10.1146/annurev.arplant.52.1.469; MAESHIMA M, 1991, EUR J BIOCHEM, V196, P11, DOI 10.1111/j.1432-1033.1991.tb15779.x; McIntosh MT, 2002, INT J PARASITOL, V32, P1, DOI 10.1016/S0020-7519(01)00325-3; Nakanishi Y, 2003, J BIOCHEM, V134, P615, DOI 10.1093/jb/mvg184; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; Perez-Castineira JR, 2002, P NATL ACAD SCI USA, V99, P15914, DOI 10.1073/pnas.242625399; Perez-Castineira JR, 2002, BIOCHEM BIOPH RES CO, V294, P567, DOI 10.1016/S0006-291X(02)00517-X; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Saliba KJ, 2003, J BIOL CHEM, V278, P5605, DOI 10.1074/jbc.M208648200; Schultz A, 2003, BBA-BIOENERGETICS, V1607, P141, DOI 10.1016/j.bbabio.2003.09.003; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Takasu A, 1997, J BIOCHEM-TOKYO, V122, P883, DOI 10.1093/oxfordjournals.jbchem.a021837; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200	34	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35106	35112		10.1074/jbc.M406264200	http://dx.doi.org/10.1074/jbc.M406264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187077	hybrid			2022-12-27	WOS:000223134800123
J	Tzeng, YL; Datta, A; Ambrose, K; Lo, M; Davies, JK; Carlson, RW; Stephens, DS; Kahler, CM				Tzeng, YL; Datta, A; Ambrose, K; Lo, M; Davies, JK; Carlson, RW; Stephens, DS; Kahler, CM			The misR/misS two-component regulatory system influences inner core structure and immunotype of lipooligosaccharide in Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; ENTERICA SEROVAR TYPHIMURIUM; LIPID-A; SALMONELLA-TYPHIMURIUM; POLYMYXIN-B; PSEUDOMONAS-AERUGINOSA; PHASE-VARIATION; SEROGROUP-B; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI	Lipooligosaccharide (LOS) of Neisseria meningitidis is the major inflammatory mediator that contributes to meningococcal pathogenesis. Variable attachments to the HepII residue of the LOS inner core together with the alpha-chain heterogeneity result in immunologically distinct LOS structures, which may be selected for during human infection. Lpt-3, a phosphoethanolamine ( PEA) transferase, and LgtG, a glucosyltransferase, mediate the substitution of PEA or glucose at the O-3 position of HepII in L3 or L2 LOS immunotypes, respectively. Inactivation of a two-component response regulator, encoded by NMB0595, in N. meningitidis strain NMB resulted in the loss of all PEA decorations on the LOS inner core expressed by the NMB0595 mutant. When compared with the parental strain NMB that predominantly expresses L2 immunotype LOS and other minor LOS structures, the NMB0595 mutant expresses a pure population of a novel LOS structure completely substituted at the HepII O-3 position with glucose, but lacking other PEA decorations on the inner core. Quantitative real time PCR experiments showed increased transcription of lgtG in the NMB0595 mutant, and no significant change in lpt-3 transcription. Inactivation of lgtG resulted in LOS inner cores without glucose, but these structures, even though the lpt-3 transcription was unaffected, also lacked the O-3-linked PEA. Consistently, a double mutation of lgtG and misR in strain NMB yielded a LOS structure without PEA or Glc substitution of HepII. These data indicated a new pathway for the regulation of LOS inner core structure in N. meningitidis through an environmental sensing two-component regulatory system, named misR( NMB0595)/misS(NMB0594) for regulator and sensor of the meningococcal inner core structure.	Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Decatur, GA 30033 USA; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Monash University; University System of Georgia; University of Georgia	Tzeng, YL (corresponding author), Woodruff Mem Bldg,Rm 2107,1639 Pierce Dr, Atlanta, GA 30322 USA.	ytzeng@emory.edu	Kahler, Charlene M/H-5159-2014; Stephens, David S/A-8788-2012	Kahler, Charlene M/0000-0003-4322-3055; DATTA, ANUP/0000-0002-3796-6891	NIAID NIH HHS [AI 33157] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerjee A, 1998, P NATL ACAD SCI USA, V95, P10872, DOI 10.1073/pnas.95.18.10872; Bearson BL, 1998, J BACTERIOL, V180, P2409, DOI 10.1128/JB.180.9.2409-2417.1998; Berrington AW, 2002, FEMS IMMUNOL MED MIC, V34, P267, DOI 10.1016/S0928-8244(02)00369-3; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; BRANDTZAEG P, 1992, MICROB PATHOGENESIS, V13, P423, DOI 10.1016/0882-4010(92)90010-L; Cai SJ, 2002, J BIOL CHEM, V277, P24155, DOI 10.1074/jbc.M110715200; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Cox AD, 2003, J BACTERIOL, V185, P3270, DOI 10.1128/JB.185.11.3270-3277.2003; Cox AD, 2002, CARBOHYD RES, V337, P1435, DOI 10.1016/S0008-6215(02)00161-1; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; De Wulf P, 2000, MICROBIOL-UK, V146, P247, DOI 10.1099/00221287-146-2-247; DUNN KLR, 1995, MICROB PATHOGENESIS, V18, P81, DOI 10.1016/S0882-4010(95)90085-3; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; Ernst RK, 2001, MICROBES INFECT, V3, P1327, DOI 10.1016/S1286-4579(01)01494-0; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; Gidney MAJ, 2004, INFECT IMMUN, V72, P559, DOI 10.1128/IAI.72.1.559-569.2004; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1177/09680519010070011001; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Hitchen PG, 2002, MOL MICROBIOL, V44, P1637, DOI 10.1046/j.1365-2958.2002.02990.x; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Hyytiainen H, 2003, MOL MICROBIOL, V50, P795, DOI 10.1046/j.1365-2958.2003.03729.x; JANIK A, 1976, J CLIN MICROBIOL, V4, P71; Jennings MP, 1999, MICROBIOL-UK, V145, P3013, DOI 10.1099/00221287-145-11-3013; Johnson CR, 2001, MOL MICROBIOL, V39, P1345, DOI 10.1111/j.1365-2958.2001.02324.x; JONES DM, 1992, MICROB PATHOGENESIS, V13, P219, DOI 10.1016/0882-4010(92)90022-G; Kahler CM, 1998, INFECT IMMUN, V66, P5939, DOI 10.1128/IAI.66.12.5939-5947.1998; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Kahler CM, 1996, J BACTERIOL, V178, P1265, DOI 10.1128/jb.178.5.1265-1273.1996; Kogan G, 1997, CARBOHYD RES, V298, P191, DOI 10.1016/S0008-6215(96)00305-9; Macfarlane ELA, 2000, MICROBIOL-SGM, V146, P2543, DOI 10.1099/00221287-146-10-2543; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; McPhee JB, 2003, MOL MICROBIOL, V50, P205, DOI 10.1046/j.1365-2958.2003.03673.x; MENARD R, 1993, J BACTERIOL, V175, P5899; MICHON F, 1990, J BIOL CHEM, V265, P7243; Monteiro MA, 2003, CARBOHYD RES, V338, P2905, DOI 10.1016/j.carres.2003.08.014; Moskowitz SM, 2004, J BACTERIOL, V186, P575, DOI 10.1128/JB.186.2.575-579.2004; NATH K, 1990, NUCLEIC ACIDS RES, V18, P6462, DOI 10.1093/nar/18.21.6462; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Plested JS, 1999, INFECT IMMUN, V67, P5417, DOI 10.1128/IAI.67.10.5417-5426.1999; Plested JS, 2003, J INFECT DIS, V187, P1223, DOI 10.1086/368360; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahman MM, 1998, CARBOHYD RES, V307, P311; Rahman MM, 2001, GLYCOBIOLOGY, V11, P703, DOI 10.1093/glycob/11.8.703; Ram S, 2003, J BIOL CHEM, V278, P50853, DOI 10.1074/jbc.M308364200; Richardson AR, 2001, MOL MICROBIOL, V40, P645, DOI 10.1046/j.1365-2958.2001.02408.x; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Snyder LAS, 2001, J BACTERIOL, V183, P1233, DOI 10.1128/JB.183.4.1233-1241.2001; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Tamayo R, 2002, INFECT IMMUN, V70, P6770, DOI 10.1128/IAI.70.12.6770-6778.2002; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thomas CJ, 1999, J BIOL CHEM, V274, P29624, DOI 10.1074/jbc.274.42.29624; Tzeng YL, 2002, J BIOL CHEM, V277, P24103, DOI 10.1074/jbc.M200931200; VANPUTTEN JPM, 1995, MOL MICROBIOL, V16, P847; Yethon JA, 2000, INFECT IMMUN, V68, P4485, DOI 10.1128/IAI.68.8.4485-4491.2000; Zhou DG, 1996, GENE, V171, P133, DOI 10.1016/0378-1119(96)00103-5	64	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35053	35062		10.1074/jbc.M401433200	http://dx.doi.org/10.1074/jbc.M401433200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173178	hybrid			2022-12-27	WOS:000223134800118
J	Wei, ZY; Zhang, P; Zhou, ZC; Cheng, ZJ; Wan, M; Gong, WM				Wei, ZY; Zhang, P; Zhou, ZC; Cheng, ZJ; Wan, M; Gong, WM			Crystal structure of human eIF3k, the first structure of eIF3 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION; COMPLEX; BINDING; DOMAIN; RECOGNITION; YEAST; INTERACTS; MODEL; CORE; FOKI	eIF3k, the smallest subunit of eukaryotic initiation factor 3 (eIF3), interacts with several other subunits of eIF3 and the 40 S ribosomal subunit. eIF3k is conserved among high eukaryotes, including mammals, insects, and plants, and it is ubiquitously expressed in human tissues. Interestingly, eIF3k does not exist in some species of yeast. Thus, eIF3k may play a unique regulatory role in higher organisms. Here we report the crystal structure of human eIF3k, the first high-resolution structure of an eIF3 component. This novel structure contains two distinct domains, a HEAT ( named for Huntington, elongation factor 3, A subunit of protein phosphatase 2A, target of rapamycin) repeat-like HAM ( HEAT analogous motif) domain and a winged-helix-like WH domain. Through structural comparison and sequence conservation analysis, we show that eIF3k has three putative protein-binding surfaces and has potential RNA binding activity. The structure provides key information for understanding the structure and function of the eIF3 complex.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Gong, WM (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	wgong@sun5.ibp.ac.cn	Wei, Zhiyi/C-4315-2014; Wei, Zhiyi/N-9995-2019; Wei, Zhiyi/B-5001-2010; Cheng, zhongjun/D-6929-2011	Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrade MA, 2001, J STRUCT BIOL, V134, P117, DOI 10.1006/jsbi.2001.4392; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Green JB, 2003, MOL CELL, V11, P1537, DOI 10.1016/S1097-2765(03)00178-3; Groft CM, 1998, P NATL ACAD SCI USA, V95, P9117, DOI 10.1073/pnas.95.16.9117; GROVES MR, 1999, P NATL ACAD SCI USA, V86, P8669; He H, 2003, MOL CELL BIOL, V23, P5431, DOI 10.1128/MCB.23.15.5431-5445.2003; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim TH, 2001, TRENDS PLANT SCI, V6, P379, DOI 10.1016/S1360-1385(01)02015-5; Kobe B, 1999, STRUCTURE, V7, pR91, DOI 10.1016/S0969-2126(99)80060-4; KORADI R, 1998, PDB NEWSLETT, V84, P5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841; Selmer M, 2002, EMBO J, V21, P4145, DOI 10.1093/emboj/cdf408; Sinha SC, 2003, J BACTERIOL, V185, P4087, DOI 10.1128/JB.185.14.4087-4098.2003; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200	47	48	49	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34983	34990		10.1074/jbc.M405158200	http://dx.doi.org/10.1074/jbc.M405158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180986	hybrid			2022-12-27	WOS:000223134800110
J	Perez-Marin, MC; Lopez-Rubio, JS; Murillo, FJ; Elias-Arnanz, M; Padmanabhan, S				Perez-Marin, MC; Lopez-Rubio, JS; Murillo, FJ; Elias-Arnanz, M; Padmanabhan, S			The N terminus of Myxococcus xanthus CarA repressor is an autonomously folding domain that mediates physical and functional interactions with both operator DNA and antirepressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-INDUCED CAROTENOGENESIS; SIGMA-FACTOR CARQ; THERMODYNAMIC ANALYSIS; STRUCTURAL STABILITY; CAROTENOID SYNTHESIS; CRYSTAL-STRUCTURE; BINDING DOMAINS; RNA-POLYMERASE; TRANSCRIPTION; GENE	Expression of the Myxococcus xanthus carB operon, which encodes the majority of the enzymes involved in light-induced carotenogenesis, is down-regulated in the dark by the CarA repressor binding to its bipartite operator. CarS, produced on illumination, relieves repression of carB by physically interacting with CarA to dismantle CarA-DNA complexes. Here, we demonstrate that the N- and C-terminal portions of CarA are organized as distinct structural and functional domains. Specifically, we show that the 78 N- terminal residues of CarA, CarA( Nter), form a monomeric, highly helical, autonomously folding unit with significant structural stability. Significantly, CarA( Nter) houses both the operator and CarS binding specificity determinants of CarA. CarA( Nter) binds operator with a lower affinity than whole CarA, and the CarA( Nter)-CarS complex has a 1: 1 stoichiometry. In vitro, sufficiently high concentrations of CarA( Nter) block M. xanthus RNA polymerase-promoter binding, and this is relieved by CarS. In vivo, substitution of the gene carA by that for CarA( Nter) results in constitutive expression of carB just as in a carA-deleted background. However, re-engineering the latter strain to overexpress CarA( Nter) restores repression of carB. Thus, the 78-residue N- terminal portion of CarA is an autonomously folded, dual function domain that orchestrates specific DNA-protein and protein-protein interactions and, when overexpressed, can be functionally competent in vivo.	Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain	University of Murcia	Elias-Arnanz, M (corresponding author), Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain.	melias@um.es; padhu@um.es	Padmanabhan, S./E-8943-2017; Elías-Arnanz, Montserrat/H-4707-2015; lopez-rubio, jose juan/A-4509-2014	Elías-Arnanz, Montserrat/0000-0003-1980-3092; Padmanabhan, S./0000-0002-8772-0152; lopez-rubio, jose juan/0000-0002-0555-1122				ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; AVERY L, 1983, MOL GEN GENET, V191, P99, DOI 10.1007/BF00330896; BALSALOBRE JM, 1989, THESIS U MURCIA MURC; BOTELLA JA, 1995, EUR J BIOCHEM, V233, P238, DOI 10.1111/j.1432-1033.1995.238_1.x; BRETSCHER AP, 1978, J BACTERIOL, V133, P763, DOI 10.1128/JB.133.2.763-768.1978; Browning DF, 2003, MOL MICROBIOL, V48, P237, DOI 10.1046/j.1365-2958.2003.03431.x; Cayuela ML, 2003, J BACTERIOL, V185, P3527, DOI 10.1128/JB.185.12.3527-3537.2003; Cervantes M, 2002, J BACTERIOL, V184, P2215, DOI 10.1128/JB.184.8.2215-2224.2002; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; Cole J L, 1999, J Biomol Tech, V10, P163; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Felitsky DJ, 2003, BIOCHEMISTRY-US, V42, P2202, DOI 10.1021/bi0270992; Fontes M, 2003, MOL MICROBIOL, V47, P561, DOI 10.1046/j.1365-2958.2003.03319.x; FONTES M, 1993, EMBO J, V12, P1265, DOI 10.1002/j.1460-2075.1993.tb05771.x; Godsey MH, 2001, J BIOL CHEM, V276, P47178, DOI 10.1074/jbc.M105819200; Goodwin T.W, 1980, BIOCH CAROTENOIDS, V1; Gorham HC, 1996, MOL MICROBIOL, V19, P171, DOI 10.1046/j.1365-2958.1996.360888.x; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; Hodgson D, 1993, MYXOBACTERIA, VII, P157; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; Julien B, 2000, P NATL ACAD SCI USA, V97, P9098, DOI 10.1073/pnas.97.16.9098; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Lopez-Rubio JJ, 2004, J BIOL CHEM, V279, P28945, DOI 10.1074/jbc.M403459200; Lopez-Rubio JJ, 2002, J BIOL CHEM, V277, P7262, DOI 10.1074/jbc.M110351200; Martinez-Argudo I, 1998, MOL MICROBIOL, V30, P883, DOI 10.1046/j.1365-2958.1998.01129.x; MCGOWAN SJ, 1993, MOL MICROBIOL, V10, P713, DOI 10.1111/j.1365-2958.1993.tb00943.x; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; Moreno AJ, 2001, J BACTERIOL, V183, P557, DOI 10.1128/JB.183.2.557-569.2001; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NICOLAS FJ, 1994, GENE DEV, V8, P2375, DOI 10.1101/gad.8.19.2375; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PACE CN, 1990, PROTEIN STRUCTURE PR, P331; Padmanabhan S, 2001, J BIOL CHEM, V276, P41566, DOI 10.1074/jbc.M106352200; Padmanabhan S, 1999, BIOCHEMISTRY-US, V38, P15536, DOI 10.1021/bi991757+; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; Rau W., 1988, PLANT PIGMENTS, P231; Rohl CA, 1997, BIOCHEMISTRY-US, V36, P8435, DOI 10.1021/bi9706677; RUIZVAZQUEZ R, 1993, MOL MICROBIOL, V10, P25, DOI 10.1111/j.1365-2958.1993.tb00900.x; RUIZVAZQUEZ R, 1984, J BACTERIOL, V160, P818; Sambrook J., 2001, MOL CLONING LAB MANU, V3; SCHMID FX, 1990, PROTEIN STRUCTURE PR, P261; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Walkinshaw MD, 2002, MOL CELL, V9, P187, DOI 10.1016/S1097-2765(02)00435-5; ZHELEZNOVAHELDW.EE, 2001, NATURE, V409, P378	50	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33093	33103		10.1074/jbc.M405225200	http://dx.doi.org/10.1074/jbc.M405225200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15163666	hybrid			2022-12-27	WOS:000223039700011
J	Pesce, A; Nardini, M; Ascenzi, P; Geuens, E; Dewilde, S; Moens, L; Bolognesi, M; Riggs, AF; Hale, A; Deng, PC; Nienhaus, GU; Olson, JS; Nienhaus, K				Pesce, A; Nardini, M; Ascenzi, P; Geuens, E; Dewilde, S; Moens, L; Bolognesi, M; Riggs, AF; Hale, A; Deng, PC; Nienhaus, GU; Olson, JS; Nienhaus, K			Thr-E11 regulates O-2 affinity in Cerebratulus lacteus mini-hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DIOXYGENASE; SPERM-WHALE MYOGLOBIN; LIGAND-BINDING; STRUCTURAL DYNAMICS; HEME-PROTEINS; NONVERTEBRATE HEMOGLOBINS; CRYSTAL-STRUCTURE; DISTAL POCKET; OXYGEN; GLOBIN	The mini-hemoglobin from Cerebratulus lacteus (CerHb) belongs to a class of globins containing the polar Tyr-B10/Gln-E7 amino acid pair that normally causes low rates of O-2 dissociation and ultra-high O-2 affinity, which suggest O2 sensing or NO scavenging functions. CerHb, however, has high rates of O-2 dissociation (k(O2) = 200 - 600 s(-1)) and moderate O-2 affinity (K-O2 approximate to 1 muM(-1)) as a result of a third polar amino acid in its active site, Thr-E11. When Thr-E11 is replaced by Val, k(O2) decreases 1000-fold and K-O2 increases 130-fold at pH 7.0, 20 degreesC. The mutation also shifts the stretching frequencies of both heme-bound and photodissociated CO, indicating marked changes of the electrostatic field at the active site. The crystal structure of Thr-E11 --> Val CerHbO(2) at 1.70 Angstrom resolution is almost identical to that of the wildtype protein ( root mean square deviation of 0.12 Angstrom). The dramatic functional and spectral effects of the Thr-E11 --> Val mutation are due exclusively to changes in the hydrogen bonding network in the active site. Replacing Thr-E11 with Val "frees" the Tyr-B10 hydroxyl group to rotate toward and donate a strong hydrogen bond to the heme-bound ligand, causing a selective increase in O-2 affinity, a decrease of the rate coefficient for O-2 dissociation, a 40 cm(-1) decrease in nu(CO) of heme-bound CO, and an increase in ligand migration toward more remote intermediate sites.	Univ Ulm, Dept Biophys, D-89081 Ulm, Germany; Univ Genoa, Dept Phys, INFM, I-16146 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16146 Genoa, Italy; Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Roma Tre, Interdept Lab Electron Microscopy, I-00146 Rome, Italy; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Natl Inst Canc Res, Struct Biol Unit, I-16132 Genoa, Italy; Univ Texas, Neurobiol Sect, Austin, TX 78712 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	Ulm University; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Genoa; University of Genoa; Roma Tre University; Roma Tre University; University of Antwerp; University of Genoa; IRCCS AOU San Martino IST; University of Texas System; University of Texas Austin; Rice University; Rice University; University of Illinois System; University of Illinois Urbana-Champaign	Nienhaus, K (corresponding author), Univ Ulm, Dept Biophys, Albert Einstein Allee 11, D-89081 Ulm, Germany.	Karin.Nienhaus@physik.uni-ulm.de	Pesce, Alessandra/A-3660-2015; Bolognesi, Martino/B-7924-2017; Nienhaus, Gerd Ulrich/G-8698-2012; Nardini, Marco/B-7842-2017	Bolognesi, Martino/0000-0002-9253-5170; Nienhaus, Gerd Ulrich/0000-0002-5027-3192; Nardini, Marco/0000-0002-3718-2165; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERDING N, 1976, SCIENCE, V192, P1002, DOI 10.1126/science.1273579; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERENDZEN J, 1990, P NATL ACAD SCI USA, V87, P1, DOI 10.1073/pnas.87.1.1; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; Bourgeois D, 2003, P NATL ACAD SCI USA, V100, P8704, DOI 10.1073/pnas.1430900100; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; CHALAZON.N, 1966, CR SOC BIOL, V160, P1020; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; Das TK, 2000, BIOCHEMISTRY-US, V39, P837, DOI 10.1021/bi9922087; Das TK, 2004, J BIOL CHEM, V279, P10433, DOI 10.1074/jbc.M309590200; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Franzen S, 2002, J AM CHEM SOC, V124, P13271, DOI 10.1021/ja017708d; Frey AD, 2003, FEMS MICROBIOL REV, V27, P525, DOI 10.1016/S0168-6445(03)00056-1; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Giangiacomo L, 2001, BIOCHEMISTRY-US, V40, P9311, DOI 10.1021/bi0101143; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Godecke A, 2003, J BIOL CHEM, V278, P21761, DOI 10.1074/jbc.M302573200; Goldberg DE, 1999, CHEM REV, V99, P3371, DOI 10.1021/cr970152l; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hernandez-Urzua E, 2003, J BIOL CHEM, V278, P34975, DOI 10.1074/jbc.M303629200; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Kundu S, 2003, BIOPHYS J, V84, P3931, DOI 10.1016/S0006-3495(03)75121-2; Kundu S, 2003, PROTEINS, V50, P239, DOI 10.1002/prot.10277; Kundu S, 2002, PROTEINS, V46, P268, DOI 10.1002/prot.10048; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; LAMB DC, 2000, J PHYS ORG CHEM, V13, P1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NIENHAUS GU, 1994, BIOCHEMISTRY-US, V33, P13413, DOI 10.1021/bi00249a030; Nienhaus K, 2003, J BIOL CHEM, V278, P42532, DOI 10.1074/jbc.M306888200; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9633, DOI 10.1021/bi034787s; Olson J S, 1981, Methods Enzymol, V76, P631; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Pesce A, 2002, STRUCTURE, V10, P725, DOI 10.1016/S0969-2126(02)00763-3; Pesce A, 2001, J MOL BIOL, V309, P1153, DOI 10.1006/jmbi.2001.4731; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; Raushel FM, 2003, ACCOUNTS CHEM RES, V36, P539, DOI 10.1021/ar020047k; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Spiro TG, 2001, ACCOUNTS CHEM RES, V34, P137, DOI 10.1021/ar000108j; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Vandergon TL, 1998, J BIOL CHEM, V273, P16998, DOI 10.1074/jbc.273.27.16998; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; YOUNG RD, 1984, J CHEM PHYS, V81, P3730, DOI 10.1063/1.448124; [No title captured]	81	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33662	33672		10.1074/jbc.M403597200	http://dx.doi.org/10.1074/jbc.M403597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161908	hybrid			2022-12-27	WOS:000223039700076
J	Zhang, ZX; Melia, TJ; He, F; Yuan, C; McGough, A; Schmid, MF; Wensel, TG				Zhang, ZX; Melia, TJ; He, F; Yuan, C; McGough, A; Schmid, MF; Wensel, TG			How a g protein binds a membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP PHOSPHODIESTERASE ACTIVATION; HELICAL IMAGE-RECONSTRUCTION; HETEROTRIMERIC G-PROTEIN; GAMMA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; BETA-GAMMA; ELECTRON CRYSTALLOGRAPHY; CRYOELECTRON MICROSCOPY; PHOSPHOLIPID-BILAYERS; ALPHA-SUBUNITS	Heterotrimeric G proteins interact with receptors and effectors at the membrane-cytoplasm interface. Structures of soluble forms have not revealed how they interact with membranes. We have used electron crystallography to determine the structure in ice of a helical array of the photoreceptor G protein, transducin, bound to the surface of a tubular lipid bilayer. The protein binds to the membrane with a very small area of contact, restricted to two points, between the surface of the protein and the surface of the lipids. Fitting the x-ray structure into the membrane-bound structure reveals one membrane contact near the lipidated Ggamma C terminus and Galpha N terminus, and another near the Galpha C terminus. The narrowness of the tethers to the lipid bilayer provides flexibility for the protein to adopt multiple orientations on the membrane, and leaves most of the G protein surface area available for protein-protein interactions.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	twensel@bcm.tmc.edu		Wensel, Theodore/0000-0003-3518-9352; Schmid, Michael/0000-0003-1077-5750	NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02250] Funding Source: Medline; NEI NIH HHS [EY07981] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; AvilaSakar AJ, 1996, BIOPHYS J, V70, P57, DOI 10.1016/S0006-3495(96)79597-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brand SH, 1996, AM J PHYSIOL-CELL PH, V270, pC1362, DOI 10.1152/ajpcell.1996.270.5.C1362; Busconi L, 1997, BIOCHEM J, V323, P239, DOI 10.1042/bj3230239; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; DeRosier D, 1999, J MOL BIOL, V289, P159, DOI 10.1006/jmbi.1999.2677; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; Dietrich A, 1996, BIOCHEMISTRY-US, V35, P15174, DOI 10.1021/bi960305j; Diraviyam K, 2003, J MOL BIOL, V328, P721, DOI 10.1016/S0022-2836(03)00325-5; DOUGHERTY MT, 1998, MICROSC MICROANAL, V4, P452; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FUKADA Y, 1995, METHOD ENZYMOL, V250, P91; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; Fukami A, 1965, J Electron Microsc (Tokyo), V14, P112; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Hamm H E, 1990, Biochem Soc Symp, V56, P35; Hedin EMK, 2002, BIOCHEMISTRY-US, V41, P14185, DOI 10.1021/bi020158r; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; Jian XY, 2001, J BIOL CHEM, V276, P48518, DOI 10.1074/jbc.M107129200; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; Melia TJ, 1999, J STRUCT BIOL, V128, P119, DOI 10.1006/jsbi.1999.4151; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; Rossmann MG, 2001, J STRUCT BIOL, V136, P190, DOI 10.1006/jsbi.2002.4435; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TOYOSHIMA C, 1989, ULTRAMICROSCOPY, V30, P439, DOI 10.1016/0304-3991(89)90076-4; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; Valentine KG, 2003, BIOCHEMISTRY-US, V42, P6333, DOI 10.1021/bi0206816; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1989, BIOCHEM BIOPH RES CO, V159, P651, DOI 10.1016/0006-291X(89)90044-2; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wu XW, 2003, J STRUCT BIOL, V141, P63, DOI 10.1016/S1047-8477(02)00570-1; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	61	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33937	33945		10.1074/jbc.M403404200	http://dx.doi.org/10.1074/jbc.M403404200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173184	hybrid			2022-12-27	WOS:000223039700104
J	Berka, V; Wu, G; Yeh, HC; Palmer, G; Tsai, AL				Berka, V; Wu, G; Yeh, HC; Palmer, G; Tsai, AL			Three different oxygen-induced radical species in endothelial nitric-oxide synthase oxygenase domain under regulation by L-arginine and tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE SPECTROSCOPY; SUPEROXIDE GENERATION; STRUCTURAL-CHARACTERIZATION; HYDROGEN-PEROXIDE; CYTOCHROME-C; HEME DOMAIN; EPR; REDUCTION; DYSFUNCTION; EXPRESSION	Endothelial nitric-oxide synthase ( eNOS) plays important roles in vascular physiology and homeostasis. Whether eNOS catalyzes nitric oxide biosynthesis or the synthesis of reactive oxygen species such as superoxide, hydrogen peroxide, and peroxynitrite is dictated by the bioavailability of tetrahydrobiopterin (BH4) and L-arginine during eNOS catalysis. The effect of BH4 and L-arginine on oxygen-induced radical intermediates has been investigated by single turnover rapid-freeze quench and EPR spectroscopy using the isolated eNOS oxygenase domain (eNOS(ox)). Three distinct radical intermediates corresponding to >50% of the heme were observed during the reaction between ferrous eNOS(ox) and oxygen. BH4-free eNOS(ox) produced the superoxide radical very efficiently in the absence of L-arginine. L-Arginine decreased the formation rate of superoxide by an order of magnitude but not its final level or EPR line shape. For BH4-containing eNOS(ox), only a stoichiometric amount of BH4 radical was produced in the presence of L-arginine, but in its absence a new radical was obtained. This new radical could be either a peroxyl radical of BH4 or an amino acid radical was in the vicinity of the heme. Formation of this new radical is very rapid, >150 s(-1), and it was subsequently converted to a BH4 radical. The trapping of the superoxide radical by cytochrome c in the reaction of BH4(-) eNOS(ox) exhibited a limiting rate of similar to15 s(-1), the time for the superoxide radical to leave the heme pocket and reach the protein surface; this reveals a general problem of the regular spin-trapping method in determining radical formation kinetics. Cytochrome c failed to trap the new radical species. Together with other EPR characteristics, our data strongly support the conclusion that this new radical is not a superoxide radical or a mixture of superoxide and biopterin radicals. Our study points out distinct roles of BH4 and L-arginine in regulating eNOS radical intermediates. BH4 prevented superoxide formation by chemical conversions of the Fe(II)O-2 intermediate, and L-arginine delayed superoxide formation by electronic interaction with the heme-bound oxygen.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77225 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77225 USA.	Ah-lim.Tsai@uth.tmc.edu			NIGMS NIH HHS [GM56818, GM55807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056818] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT JE, 1968, T FARADAY SOC, V64, P3200, DOI 10.1039/tf9686403200; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; Berka V, 1998, BIOCHEMISTRY-US, V37, P6136, DOI 10.1021/bi980133l; Bouloumie A, 1997, HYPERTENSION, V30, P934, DOI 10.1161/01.HYP.30.4.934; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; DeGray JA, 1997, J BIOL CHEM, V272, P2359; Du M, 2003, J BIOL CHEM, V278, P6002, DOI 10.1074/jbc.M209606200; FELDMANN HJ, 1993, RADIOTHER ONCOL, V26, P38, DOI 10.1016/0167-8140(93)90024-3; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; Hiner ANP, 2001, EUR J BIOCHEM, V268, P3091, DOI 10.1046/j.1432-1327.2001.02208.x; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; JANZEN EG, 1984, METHOD ENZYMOL, V105, P188; KNOWLES PF, 1969, BIOCHEM J, V111, P53, DOI 10.1042/bj1110053; KOPPENOL WH, 1976, BIOCHIM BIOPHYS ACTA, V449, P157, DOI 10.1016/0005-2728(76)90130-4; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; Kuzkaya N, 2003, J BIOL CHEM, V278, P22546, DOI 10.1074/jbc.M302227200; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; PALMER G, 1964, J BIOL CHEM, V239, P2657; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Reddy SG, 1998, BIOCHEMISTRY-US, V37, P558, DOI 10.1021/bi972086n; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Svistunenko DA, 2001, BBA-PROTEIN STRUCT M, V1546, P365, DOI 10.1016/S0167-4838(01)00157-1; Szabo C, 1996, CIRC RES, V78, P1051, DOI 10.1161/01.RES.78.6.1051; Tsai AL, 1998, ANAL BIOCHEM, V264, P165, DOI 10.1006/abio.1998.2774; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Vasquez-Vivar J, 2003, FREE RADICAL RES, V37, P121, DOI 10.1080/1071576021000040655; Vasquez-Vivar J, 2002, BIOCHEM J, V362, P733, DOI 10.1042/0264-6021:3620733; Vasquez-Vivar J, 2001, FREE RADICAL BIO MED, V31, P975, DOI 10.1016/S0891-5849(01)00680-3; WANG JL, 1993, J BIOL CHEM, V268, P22255; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; YANEZ J, 1987, J PHYS CHEM-US, V91, P487, DOI 10.1021/j100286a044	46	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32243	32251		10.1074/jbc.M404044200	http://dx.doi.org/10.1074/jbc.M404044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166218	hybrid			2022-12-27	WOS:000222849700032
J	Joseph, JD; Daigle, SN; Means, AR				Joseph, JD; Daigle, SN; Means, AR			PINA is essential for growth and positively influences NIMA function in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; DEPENDENT PROLINE ISOMERIZATION; CELL-CYCLE; BINDING-PROTEIN; CA2+/CALMODULIN-DEPENDENT KINASE; SACCHAROMYCES-CEREVISIAE; PREMATURE MITOSIS; NUCLEAR DIVISION; CYCLOPHILIN-A; GENE	The phospho-Ser/Thr-directed prolyl-isomerase Pin1 was originally identified in vertebrate systems as a negative regulator of NIMA, a Ser/Thr protein kinase that regulates the G(2)/M transition in Aspergillus nidulans. Here we explore the physiological roles of the Pin1 orthologue, PINA, in A. nidulans and evaluate the relevance of the interaction of PINA with NIMA in this fungus. We find pinA to be an essential gene in A. nidulans. In addition, when PINA levels are reduced 50-fold the cells grow at a reduced rate. Upon germination under conditions that repress PINA expression, the cells are delayed in the interphase activation of NIMXcdc2, whereas they traverse the other phases of the cell cycle at a similar rate to controls. These results indicate that a marked reduction of PINA results in a lengthening of G(1). Additionally, PINA repression increases the rate at which the cells enter mitosis following release from a hydroxyurea arrest without altering the sensitivity of the fungus to agents that activate the replication or DNA damage checkpoints. In contrast to predictions based on Pin1, the physical interaction between PINA and NIMA is primarily dependent upon the prolylisomerase domain of PINA and the C-terminal 303 amino acids of NIMA. Finally, reduction of PINA levels exacerbates the nimA5 temperature-sensitive mutant, whereas overexpression of PINA decreases the severity of this mutation, results that are consistent with a positive genetic interaction between PINA and NIMA. Thus, although PINA is essential and positively regulates NIMA function, A. nidulans is most sensitive to a reduction in PINA concentration in G(1) rather than in G(2)/M.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	means001@mc.duke.edu			NCI NIH HHS [CA82845] Funding Source: Medline; NIDDK NIH HHS [2T32DK07568-13] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atchison FW, 2003, BIOL REPROD, V69, P1989, DOI 10.1095/biolreprod.103.020859; Atchison FW, 2003, DEVELOPMENT, V130, P3579, DOI 10.1242/dev.00584; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Dayton JS, 1997, J BIOL CHEM, V272, P3223, DOI 10.1074/jbc.272.6.3223; Dayton JS, 1996, MOL BIOL CELL, V7, P1511, DOI 10.1091/mbc.7.10.1511; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; De Souza CPC, 1999, MOL BIOL CELL, V10, P3661, DOI 10.1091/mbc.10.11.3661; Devasahayam G, 2002, GENETICS, V160, P37; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Fujimori F, 2001, BIOCHEM BIOPH RES CO, V289, P181, DOI 10.1006/bbrc.2001.5925; GUTHRIE C, 2002, METHOD ENZYMOL, P351; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS SD, 1994, GENETICS, V136, P517; Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508; Huang HK, 2001, J CELL SCI, V114, P3779; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; Jacobs DM, 2003, J BIOL CHEM, V278, P26174, DOI 10.1074/jbc.M300796200; JAMES SW, 1995, J CELL SCI, V108, P3485; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Joseph James D, 2003, Prog Cell Cycle Res, V5, P477; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; LU KP, 1992, MOL ENDOCRINOL, V6, P365, DOI 10.1210/me.6.3.365; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1993, METH MOL G, V2, P255; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Miyashita H, 2003, ONCOL REP, V10, P455; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; RASMUSSEN C, 1994, EMBO J, V13, P3917, DOI 10.1002/j.1460-2075.1994.tb06703.x; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Uchida T, 2003, CHEM BIOL, V10, P15, DOI 10.1016/S1074-5521(02)00310-1; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; You H, 2002, J CELL BIOCHEM, V84, P211, DOI 10.1002/jcb.10037; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	57	18	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32373	32384		10.1074/jbc.M405415200	http://dx.doi.org/10.1074/jbc.M405415200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15178679	hybrid			2022-12-27	WOS:000222849700050
J	Kowanetz, K; Crosetto, N; Haglund, K; Schmidt, MHH; Heldin, CH; Dikic, I				Kowanetz, K; Crosetto, N; Haglund, K; Schmidt, MHH; Heldin, CH; Dikic, I			Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; UBA DOMAIN; UBIQUITIN; PROTEINS; COMPLEX; DEGRADATION; MONOUBIQUITYLATION; MONOUBIQUITINATION; IDENTIFICATION; PATHWAY	The ubiquitin (Ub) ligase Cbl plays a critical role in attenuation of receptor tyrosine kinase (RTK) signaling by inducing ubiquitination of RTKs and promoting their sorting for endosomal degradation. Herein, we describe the identification of two novel Cbl-interacting proteins, p70 and Clip4 ( recently assigned the names Sts-1 and Sts-2, respectively), that inhibit endocytosis of epidermal growth factor receptor ( EGFR) and platelet-derived growth factor receptor. Sts-1 and Sts-2 contain SH3 domains that interacted with Cbl, Ub-associated domains, which bound directly to mono-Ub or to the EGFR/Ub chimera as well as phosphoglycerate mutase domains that mediated oligomerization of Sts-1/2. Ligand-induced recruitment of Sts-1/Sts-2 into activated EGFR complexes led to inhibition of receptor internalization, reduction in the number of EGFR-containing endocytic vesicles, and subsequent block of receptor degradation followed by prolonged activation of mitogenic signaling pathways. On the other hand, interference with Sts-1/Sts-2 functions diminished ligand-induced receptor degradation, cell proliferation, and oncogenic transformation in cultured fibroblasts. We suggest that Sts-1 and Sts-2 represent a novel class of Ub-binding proteins that regulate RTK endocytosis and control growth factor-induced cellular functions.	Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Goethe University Frankfurt; Ludwig Institute for Cancer Research	Dikic, I (corresponding author), Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	ivan.dikic@biochem2.de	Schmidt, Mirko H. H./ABI-6650-2020; Dikic, Ivan/O-4650-2015; Haglund, Kaisa/B-3927-2017	Schmidt, Mirko H. H./0000-0001-7411-8835; Dikic, Ivan/0000-0001-8156-9511; Haglund, Kaisa/0000-0002-7946-3299				Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; BACHE KG, 2003, J BIOL CHEM, V27, P27; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Carpino N, 2002, MOL CELL BIOL, V22, P7491, DOI 10.1128/MCB.22.21.7491-7500.2002; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; FESHCHENKO EA, IN PRESS ONCOGENE; Gagny B, 2000, J CELL SCI, V113, P3309; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Jedrzejas MJ, 2000, PROG BIOPHYS MOL BIO, V73, P263, DOI 10.1016/S0079-6107(00)00007-9; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; SORKIN A, 1993, BIOESSAYS, V6, P375; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Soubeyran P, 2003, BIOCHEM J, V370, P29, DOI 10.1042/BJ20021539; Szymkiewicz I, 2004, FEBS LETT, V565, P33, DOI 10.1016/j.febslet.2004.03.100; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Usuba T, 2001, INT J CANCER, V94, P662, DOI 10.1002/ijc.1524; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wattenhofer M, 2001, HUM GENET, V108, P140, DOI 10.1007/s004390000453; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939	33	96	99	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32786	32795		10.1074/jbc.M403759200	http://dx.doi.org/10.1074/jbc.M403759200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159412	hybrid			2022-12-27	WOS:000222849700098
J	Maxwell, MJ; Yuan, YP; Anderson, KE; Hibbs, ML; Salem, HH; Jackson, SP				Maxwell, MJ; Yuan, YP; Anderson, KE; Hibbs, ML; Salem, HH; Jackson, SP			SHIP1 and Lyn kinase negatively regulate integrin alpha(IIb)beta(3) signaling in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; VON-WILLEBRAND-FACTOR; PHOSPHOLIPASE C-GAMMA; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE 3-KINASE; INTEGRIN ALPHA(IIB)BETA(3); TYROSINE PHOSPHORYLATION; GLYCOPROTEIN IB/V/IX; CALCIUM SIGNALS; STIMULATED PLATELETS	Integrin alpha(IIb)beta(3) plays a critical role in platelet function, promoting a broad range of functional responses including platelet adhesion, spreading, aggregation, clot retraction, and platelet procoagulant function. Signaling events operating downstream of this receptor (outside-in signaling) are important for these responses; however the mechanisms negatively regulating integrin alpha(IIb)beta(3) signaling remain ill-defined. We demonstrate here a major role for the Src homology 2 domain-containing inositol 5-phosphatase (SHIP1) and Src family kinase, Lyn, in this process. Our studies on murine SHIP1 knockout platelets have defined a major role for this enzyme in regulating integrin alpha(IIb)beta(3)-dependent phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) accumulation, necessary for a cytosolic calcium response and platelet spreading. SHIP1 phosphorylation and PtdIns( 3,4,5) P3 metabolism is partially regulated through Lyn kinase, resulting in an enhanced calcium flux and spreading response in Lyn-deficient mouse platelets. Analysis of platelet adhesion dynamics under physiological blood flow conditions revealed an important role for SHIP1 in regulating platelet adhesion on fibrinogen. Specifically, SHIP1-dependent PtdIns(3,4,5)P-3 metabolism down-regulates the stability of integrin alpha(IIb)beta(3)-fibrinogen adhesive bonds, leading to a decrease in the proportion of platelets forming shear-resistant adhesion contacts. These studies define a major role for SHIP1 and Lyn as negative regulators of integrin alpha(IIb)beta(3) adhesive and signaling function.	Monash Univ, Box Hill Hosp, Dept Med, Australian Ctr Blood Dis, Melbourne, Vic 3128, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia	Box Hill Hospital; Monash University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Jackson, SP (corresponding author), Monash Univ, Box Hill Hosp, Dept Med, Australian Ctr Blood Dis, Melbourne, Vic 3128, Australia.	Shaun.Jackson@med.monash.edu.au	Hibbs, Margaret L/D-7013-2011; Maxwell, Mhairi/G-5492-2011	Hibbs, Margaret L/0000-0002-3751-6751; Anderson, Karen/0000-0002-7394-6660; Jackson, Shaun/0000-0002-4750-1991				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Baran CP, 2003, J BIOL CHEM, V278, P38628, DOI 10.1074/jbc.M305021200; Choudhri TF, 1998, J CLIN INVEST, V102, P1301, DOI 10.1172/JCI3338; Cicmil M, 2002, BLOOD, V99, P137, DOI 10.1182/blood.V99.1.137; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Giuriato S, 2000, BIOCHEM J, V348, P107, DOI 10.1042/0264-6021:3480107; Giuriato S, 2003, BIOCHEM J, V376, P199, DOI 10.1042/BJ20030581; Goncalves I, 2003, J BIOL CHEM, V278, P34812, DOI 10.1074/jbc.M306504200; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; JAKOBSEN E, 1974, THROMB RES, V4, P499, DOI 10.1016/0049-3848(74)90227-8; Jones KL, 2001, BLOOD, V98, P1456, DOI 10.1182/blood.V98.5.1456; Kottirsch G, 1997, BIOORG MED CHEM LETT, V7, P727, DOI 10.1016/S0960-894X(97)00095-4; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; Nakamura K, 2002, BLOOD, V100, P3374, DOI 10.1182/blood-2002-03-0787; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; NEWMAN PJ, 1997, J CLIN INVEST, V100, P25; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Phillips DR, 2001, THROMB HAEMOSTASIS, V86, P246; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Saint-Dic D, 2001, J BIOL CHEM, V276, P21192, DOI 10.1074/jbc.M008336200; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varon D, 1998, BLOOD, V91, P500, DOI 10.1182/blood.V91.2.500.500_500_507; Watanabe N, 2003, BLOOD, V102, P541, DOI 10.1182/blood-2002-11-3327; Wonerow P, 2003, J BIOL CHEM, V278, P37520, DOI 10.1074/jbc.M305077200; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	63	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32196	32204		10.1074/jbc.M400746200	http://dx.doi.org/10.1074/jbc.M400746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166241	hybrid			2022-12-27	WOS:000222849700026
J	Rodriguez, JM; Ruiz-Sala, P; Ugarte, M; Penalva, MA				Rodriguez, JM; Ruiz-Sala, P; Ugarte, M; Penalva, MA			Fungal metabolic model for type I 3-methylglutaconic aciduria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ASPERGILLUS-NIDULANS; MOLECULAR-BASIS; GENE; IDENTIFICATION; ALKAPTONURIA; MUTATIONS; AUH; PEROXISOMES; LYASE	Aspergillus nidulans catabolizes Leu to acetyl-CoA and acetoacetate through a pathway homologous to that used by humans. Fungal hlyA encodes a bifunctional polypeptide comprising the last two enzymes in this pathway, 3-methylglutaconyl-CoA hydratase and 3-hydroxy-3-methylglutaryl-CoA lyase. hlyA transcription is specifically induced by Leu. A DeltahlyA mutation removing the complete 3-methylglutaconyl-CoA hydratase C-terminal domain prevents growth on Leu but not on lactose or other amino acids and, in agreement with the predicted enzyme function, leads to Leu-dependent accumulation of 3-methylglutaconic acid in the culture supernatant. These data represent a formal demonstration in vivo of the specific involvement of 3-methylglutaconyl-CoA hydratase in Leu catabolism. Type I 3-methylglutaconic aciduria patients deficient in 3-methylglutaconyl-CoA hydratase show urinary excretion of 3-methylglutaconic acid and, in contrast to the other three types of methylglutaconic acidurias, 3-hydroxy-isovaleric acid excretion. Gas chromatography-mass spectrometry analysis revealed an accumulation of both diagnostic compounds in DeltahlyA culture supernatants, illustrating that the metabolic consequences of equivalent inborn errors of metabolism are conserved from fungi to humans. Using our fungal type I 3-methylglutaconic aciduria model, we show that metabolites accumulating in the deficient strain are toxic, although less so than those accumulating in a DeltamccB strain deficient for the upstream enzyme 3-methylcrotonyl-CoA carboxylase. Diagnostic metabolite accumulation is Leu concentration-dependent, in agreement with the ability of Leu intake restriction to reduce the levels of offending metabolites. DeltamccB and DeltahlyA mutations show additive Leu toxicities. The double mutant accumulates 3-methylglutaconic acid, which can therefore be synthesized through 3-methylcrotonyl-CoA carboxylase-dependent and -independent reactions.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, Madrid 28040, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol, Madrid 28034, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Penalva, MA (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Ramiro de Maeztu 9, Madrid 28040, Spain.	penalva@cib.csic.es	Penalva, Miguel A/G-2295-2015	Penalva, Miguel A/0000-0002-3102-2806; Ruiz-Sala, Pedro/0000-0003-1785-4988				Anikster Y, 2001, AM J HUM GENET, V69, P1218, DOI 10.1086/324651; ARMITT S, 1970, FEBS LETT, V7, P231, DOI 10.1016/0014-5793(70)80168-5; ARMITT S, 1971, FEBS LETT, V12, P276, DOI 10.1016/0014-5793(71)80198-9; Ashmarina LI, 1999, J LIPID RES, V40, P70; Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Brennan LE, 1999, GENE, V228, P85, DOI 10.1016/S0378-1119(99)00003-7; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; DURAN M, 1982, J PEDIATR-US, V101, P551, DOI 10.1016/S0022-3476(82)80698-7; EDMOND J, 1974, J BIOL CHEM, V249, P66; Fernandez-Canon JM, 1998, J BIOL CHEM, V273, P329, DOI 10.1074/jbc.273.1.329; FERNANDEZCANON JM, 1995, J BIOL CHEM, V270, P21199, DOI 10.1074/jbc.270.36.21199; FERNANDEZCANON JM, 1995, P NATL ACAD SCI USA, V92, P9132, DOI 10.1073/pnas.92.20.9132; FernandezCanon JM, 1996, NAT GENET, V14, P19, DOI 10.1038/ng0996-19; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Gallardo ME, 2001, AM J HUM GENET, V68, P334, DOI 10.1086/318202; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Ijlst L, 2002, AM J HUM GENET, V71, P1463, DOI 10.1086/344712; KORNBERG HL, 1966, BIOCHEM J, V99, P1; Ly TBN, 2003, HUM MUTAT, V21, P401, DOI 10.1002/humu.10202; Penalva MA, 2001, FUNGAL GENET BIOL, V34, P1, DOI 10.1006/fgbi.2001.1284; Rodriguez JM, 2000, HUM MOL GENET, V9, P2341, DOI 10.1093/oxfordjournals.hmg.a018927; Rodriguez JM, 2004, J BIOL CHEM, V279, P4578, DOI 10.1074/jbc.M310055200; Scriver CR, 1999, TRENDS GENET, V15, P267, DOI 10.1016/S0168-9525(99)01761-8; Sweetman L., 2001, METABOLIC MOL BASES, P2125; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; Vaz FM, 2003, J BIOL CHEM, V278, P43089, DOI 10.1074/jbc.M305956200; Walsh R, 1999, J INHERIT METAB DIS, V22, P251, DOI 10.1023/A:1005573819137; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804	31	9	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32385	32392		10.1074/jbc.M313044200	http://dx.doi.org/10.1074/jbc.M313044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15181004	hybrid, Green Published			2022-12-27	WOS:000222849700051
J	Tanaka, Y; Tsumoto, K; Yasutake, Y; Umetsu, M; Yao, M; Fukada, H; Tanaka, I; Kumagai, I				Tanaka, Y; Tsumoto, K; Yasutake, Y; Umetsu, M; Yao, M; Fukada, H; Tanaka, I; Kumagai, I			How oligomerization contributes to the thermostability of an Archaeon protein - Protein L-isoaspartyl-O-methyltransferase from Sulfolobus tokodaii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORIBOSYL ANTHRANILATE ISOMERASE; CRYSTAL-STRUCTURE; PYROCOCCUS-FURIOSUS; HYPERTHERMOPHILIC ARCHAEON; THERMAL-STABILITY; REPAIR METHYLTRANSFERASE; POSSIBLE DETERMINANTS; THERMOTOGA-MARITIMA; CITRATE SYNTHASE; DIMER INTERFACE	To study how oligomerization may contribute to the thermostability of archaeon proteins, we focused on a hexameric protein, protein L-isoaspartyl-O-methyltransferase from Sulfolobus tokodaii (StoPIMT). The crystal structure shows that StoPIMT has a distinctive hexameric structure composed of monomers consisting of two domains: an S-adenosylmethionine-dependent methyltransferase fold domain and a C-terminal alpha-helical domain. The hexameric structure includes three interfacial contact regions: major, minor, and coiled-coil. Several C-terminal deletion mutants were constructed and characterized. The hexameric structure and thermostability were retained when the C-terminal alpha-helical domain (Tyr(206)-Thr(231)) was deleted, suggesting that oligomerization via coiled-coil association using the C-terminal alpha-helical domains did not contribute critically to hexamerization or to the increased thermostability of the protein. Deletion of three additional residues located in the major contact region, Tyr(203)-Asp(204)-Asp(205), led to a significant decrease in hexamer stability and chemico/thermostability. Although replacement of Thr(146) and Asp(204), which form two hydrogen bonds in the interface in the major contact region, with Ala did not affect hexamer formation, these mutations led to a significant decrease in thermostability, suggesting that two residues in the major contact region make significant contributions to the increase in stability of the protein via hexamerization. These results suggest that cooperative hexamerization occurs via interactions of "hot spot" residues and that a couple of interfacial hot spot residues are responsible for enhancing thermostability via oligomerization.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Div Appl Biochem, Osaka 5998531, Japan	Tohoku University; Hokkaido University; Osaka Metropolitan University	Tsumoto, K (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.	tsumoto@mail.tains.tohoku.ac.jp	yao, min/F-5287-2011; Yasutake, Yoshiaki/H-8079-2018	yao, min/0000-0003-1687-5904; Yasutake, Yoshiaki/0000-0002-4521-7516; Tanaka, Yoshikazu/0000-0002-7893-3236				Arndt KM, 2001, J MOL BIOL, V312, P221, DOI 10.1006/jmbi.2001.4915; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bennett EJ, 2003, BIOCHEMISTRY-US, V42, P12844, DOI 10.1021/bi034891+; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRITTON KL, 1995, EUR J BIOCHEM, V229, P688, DOI 10.1111/j.1432-1033.1995.tb20515.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; Chakravarty S, 2002, BIOCHEMISTRY-US, V41, P8152, DOI 10.1021/bi025523t; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; GEIGER T, 1987, J BIOL CHEM, V262, P785; Griffith SC, 2001, J MOL BIOL, V313, P1103, DOI 10.1006/jmbi.2001.5095; Hart DJ, 2001, J MOL BIOL, V310, P563, DOI 10.1006/jmbi.2001.4724; Hatanaka H, 1997, J MOL BIOL, V268, P922, DOI 10.1006/jmbi.1997.1001; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; Li T, 2003, J MOL BIOL, V325, P1031, DOI 10.1016/S0022-2836(02)01285-8; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Loladze VV, 1999, BIOCHEMISTRY-US, V38, P16419, DOI 10.1021/bi992271w; Ogasahara K, 2003, J BIOL CHEM, V278, P8922, DOI 10.1074/jbc.M210893200; Ogasahara K, 2001, EUR J BIOCHEM, V268, P3233, DOI 10.1046/j.1432-1327.2001.02220.x; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; RUSSELL RJM, 1994, STRUCTURE, V2, P1157, DOI 10.1016/S0969-2126(94)00118-9; Ryttersgaard C, 2002, J BIOL CHEM, V277, P10642, DOI 10.1074/jbc.M200229200; Sanchez-Ruiz JM, 2001, TRENDS BIOTECHNOL, V19, P132, DOI 10.1016/S0167-7799(00)01548-1; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SCHUMANN J, 1993, PROTEIN SCI, V2, P1612, DOI 10.1002/pro.5560021007; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; Skinner MM, 2000, STRUCTURE, V8, P1189, DOI 10.1016/S0969-2126(00)00522-0; Smith CD, 2002, PROTEIN SCI, V11, P625, DOI 10.1110/ps.37802; SPASSOV VZ, 1995, PROTEIN SCI, V4, P1516, DOI 10.1002/pro.5560040809; Sterner R, 1996, PROTEIN SCI, V5, P2000, DOI 10.1002/pro.5560051006; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tahirov TH, 1998, J MOL BIOL, V284, P101, DOI 10.1006/jmbi.1998.2146; Tanaka Y, 2004, FEBS LETT, V556, P167, DOI 10.1016/S0014-5793(03)01402-9; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thapar N, 2002, J BIOL CHEM, V277, P1058, DOI 10.1074/jbc.M108261200; Thoma R, 2000, STRUCTURE, V8, P265, DOI 10.1016/S0969-2126(00)00106-4; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; Tsumoto K, 1998, J IMMUNOL METHODS, V219, P119, DOI 10.1016/S0022-1759(98)00127-6; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; Vogt G, 1997, FOLD DES, V2, pS40, DOI 10.1016/S1359-0278(97)00062-X; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433	58	66	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32957	32967		10.1074/jbc.M404405200	http://dx.doi.org/10.1074/jbc.M404405200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169774	hybrid			2022-12-27	WOS:000222849700116
J	Boehning, D; Sedaghat, L; Sedlak, TW; Snyder, SH				Boehning, D; Sedaghat, L; Sedlak, TW; Snyder, SH			Heme oxygenase-2 is activated by calcium-calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; AKT-DEPENDENT PHOSPHORYLATION; NUCLEUS-TRACTUS-SOLITARII; CARBON-MONOXIDE; GLUTAMATE RECEPTORS; ENDOTHELIAL-CELLS; PENILE ERECTION; NEUROTRANSMISSION; ANTAGONISTS; ARTERIOLES	The heme oxygenase family of enzymes catalyzes the metabolism of heme to biliverdin, ferrous iron, and carbon monoxide (CO). At least two isoforms exist, heme oxygenase-1 (HO1) and heme oxygenase-2 (HO2), which are encoded by separate genes. HO2 is selectively enriched in neurons, and substantial evidence suggests that HO2-derived CO functions as a neurotransmitter/ neuromodulator. However, a molecular mechanism for the rapid activation of HO2 during neuronal activity has not been described. Through a yeast two-hybrid screen we identified calmodulin as a potential regulator of HO2 activity. Calmodulin binds with nanomolar affinity to HO2 in a calcium-dependent manner via a canonical 1 - 10 motif, resulting in a 3-fold increase in catalytic activity. Mutations within this motif block calmodulin binding and calcium-dependent stimulation of enzyme activity in vitro and in intact cells. The calcium mobilizing agents ionomycin and glutamate stimulate endogenous HO2 activity in primary cortical cultures, establishing in vivo relevance. Calcium-calmodulin provides a mechanism for rapid and transient activation of HO2 during neuronal activity.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St,813 WBSB, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu	Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922	NIDA NIH HHS [DA-000266, DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NINDS NIH HHS [NS-043850] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agullo L, 1997, EUR J PHARMACOL, V323, P119, DOI 10.1016/S0014-2999(97)00019-8; ASANO M, 1989, J PHARMACOL EXP THER, V251, P764; Baranano DE, 2000, J BIOL CHEM, V275, P15166, DOI 10.1074/jbc.275.20.15166; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fiumana E, 2003, AM J PHYSIOL-HEART C, V284, pH1073, DOI 10.1152/ajpheart.00881.2002; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hurt KJ, 2002, P NATL ACAD SCI USA, V99, P4061, DOI 10.1073/pnas.052712499; Leffler CW, 2003, AM J PHYSIOL-HEART C, V285, pH74, DOI 10.1152/ajpheart.01081.2002; LEINDERSZUFALL T, 1995, J NEUROPHYSIOL, V74, P1498, DOI 10.1152/jn.1995.74.4.1498; Li XQ, 2002, EUR J PHARMACOL, V450, P43, DOI 10.1016/S0014-2999(02)02051-4; Lin CH, 2004, J PHARMACOL EXP THER, V308, P1213, DOI 10.1124/jpet.103.060186; Lo WC, 2002, EUR J PHARMACOL, V454, P39, DOI 10.1016/S0014-2999(02)02480-9; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Parfenova H, 2003, J CEREBR BLOOD F MET, V23, P190, DOI 10.1097/01.WCB.000004823561824.C4; Robinson JS, 2002, AM J PHYSIOL-HEART C, V282, pH2371, DOI 10.1152/ajpheart.00911.2001; Sampaio-Maia B, 2001, CELL BIOL INT, V25, P245, DOI 10.1006/cbir.2000.0639; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; Watkins CC, 2004, P NATL ACAD SCI USA, V101, P2631, DOI 10.1073/pnas.0308695100; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Zufall F, 1997, J NEUROSCI, V17, P2703	30	69	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30927	30930		10.1074/jbc.C400222200	http://dx.doi.org/10.1074/jbc.C400222200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15175337	hybrid			2022-12-27	WOS:000222726800004
J	Jenkins, CE; Swiatoniowski, A; Issekutz, AC; Lin, TJ				Jenkins, CE; Swiatoniowski, A; Issekutz, AC; Lin, TJ			Pseudomonas aeruginosa exotoxin A induces human mast cell apoptosis by a caspase-8 and -3-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; DIPHTHERIA-TOXIN; CYSTIC-FIBROSIS; TRANSENDOTHELIAL MIGRATION; DNA FRAGMENTATION; PROTEIN-SYNTHESIS; EPITHELIAL-CELLS; CHIMERIC PROTEIN; DEATH; RECEPTOR	Mast cells play an important role in both allergy and innate immunity. Recently, we demonstrated an active interaction between human mast cells and Pseudomonas aeruginosa leading to the production of multiple cytokines. Here, we show that both primary cultured human cord blood-derived mast cells and the human mast cell line HMC-1 undergo apoptosis as determined by single-stranded DNA (ssDNA) formation after stimulation with P. aeruginosa exotoxin A (ETA), a major toxin produced by this bacterium. ETA-induced ssDNA formation was completely inhibited by Z-VAD (where Z is benzyloxycarbonyl), which blocks multiple caspases, suggesting a role for caspases in this process. Active caspase-3 formation in mast cells after an ETA challenge was detected by both Western blotting and flow cytometry analysis. ETA-induced caspase-3 activity in human mast cells was demonstrated by the detection of a characteristic 23 kDa product of D4-GDI (where GDI is guanine nucleotide dissociation inhibitor), an endogenous caspase-3 substrate. Interestingly, a specific caspase-8 inhibitor, Z-IETD-fmk (where fmk is fluoromethyl ketone), blocked ETA-induced cleavage of D4-GDI, but a caspase-9 inhibitor (Z-LEHD-fmk) did not. Treatment of mast cells with caspase-3 inhibitor Z-DEVD-fmk or caspase-8 inhibitor Z-IETD-fmk reduced the generation of ssDNA induced by ETA, suggesting a role for caspase-8 and -3 in ETA-induced mast cell apoptosis. Furthermore, treatment of mast cells with ETA induced decreases of the short form and a long form (p43) of Fas-associated death domain protein (FADD)-like interleukin-1beta-converting enzyme (FLICE) (caspase-8)-inhibitory proteins (FLIPs), which are endogenous caspase-8 inhibitors. Taken together, these results suggest that ETA-induced mast cell apoptosis involves down-regulation of antiapoptotic proteins, FLIPs, and activation of caspase-8 and -3 pathways.	Dalhousie Univ, Dept Pediat, IWK Hlth Ctr, Halifax, NS B3J 3G9, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3J 3G9, Canada	Dalhousie University; Dalhousie University	Lin, TJ (corresponding author), Dalhousie Univ, Dept Pediat, IWK Hlth Ctr, 5850 Univ Ave, Halifax, NS B3J 3G9, Canada.	tong-jun.lin@dal.ca						Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Boudreau RTM, 2002, J BIOL CHEM, V277, P5322, DOI 10.1074/jbc.M108623200; CROSS AS, 1980, J INFECT DIS, V142, P538, DOI 10.1093/infdis/142.4.538; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Fishman A, 1997, EUR J IMMUNOL, V27, P486, DOI 10.1002/eji.1830270220; Fishman A, 2000, CLIN EXP IMMUNOL, V119, P398, DOI 10.1046/j.1365-2249.2000.01151.x; FOX B, 1981, J CLIN PATHOL, V34, P1333, DOI 10.1136/jcp.34.12.1333; Frankfurt OS, 2001, J HISTOCHEM CYTOCHEM, V49, P369, DOI 10.1177/002215540104900311; Gallant CV, 2000, MICROBIOL-SGM, V146, P1891, DOI 10.1099/00221287-146-8-1891; Gommerman JL, 1998, BLOOD, V91, P1891, DOI 10.1182/blood.V91.6.1891.1891_1891_1900; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Hamood AN, 1996, J SURG RES, V61, P425, DOI 10.1006/jsre.1996.0140; HIRAKATA Y, 1993, INFECT IMMUN, V61, P2468, DOI 10.1128/IAI.61.6.2468-2473.1993; JAFFARBANDJEE MC, 1995, J CLIN MICROBIOL, V33, P924, DOI 10.1128/JCM.33.4.924-929.1995; Kawakami M, 2002, MOL CANCER THER, V1, P999; Keppler-Hafkemeyer A, 2000, INT J CANCER, V87, P86, DOI 10.1002/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I; Keppler-Hafkemeyer A, 1998, BIOCHEMISTRY-US, V37, P16934, DOI 10.1021/bi980995m; KOCH C, 1993, LANCET, V341, P1065, DOI 10.1016/0140-6736(93)92422-P; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; Komatsu N, 1998, J BIOCHEM-TOKYO, V124, P1038, DOI 10.1093/oxfordjournals.jbchem.a022197; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin TJ, 2003, INFECT IMMUN, V71, P365, DOI 10.1128/IAI.71.1.365-373.2003; Lin TJ, 2002, J IMMUNOL, V169, P4522, DOI 10.4049/jimmunol.169.8.4522; Lin TJ, 2001, INT ARCH ALLERGY IMM, V124, P142, DOI 10.1159/000053693; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; McHugh L, 2002, J BIOL CHEM, V277, P34383, DOI 10.1074/jbc.M205456200; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; MOEHRING JM, 1988, J BIOL CHEM, V263, P3840; MORIMOTO H, 1992, J IMMUNOL, V149, P2089; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; Park BS, 2000, IMMUNOL INVEST, V29, P51, DOI 10.3109/08820130009060877; Park HI, 2001, LIFE SCI, V69, P553, DOI 10.1016/S0024-3205(01)01140-7; PERENTESIS JP, 1992, BIOFACTORS, V3, P173; Plotkowski MC, 2002, AM J RESP CELL MOL, V26, P617, DOI 10.1165/ajrcmb.26.5.4489; Schumann J, 1998, J IMMUNOL, V161, P5745; Schumann J, 2000, IMMUNOL LETT, V74, P165, DOI 10.1016/S0165-2478(00)00240-6; Shelburne CP, 2001, IMMUNOL REV, V179, P82, DOI 10.1034/j.1600-065X.2001.790109.x; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; WICK MJ, 1990, MOL MICROBIOL, V4, P527, DOI 10.1111/j.1365-2958.1990.tb00620.x; Yoshikawa H, 2000, J IMMUNOL, V165, P6262, DOI 10.4049/jimmunol.165.11.6262	50	55	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37201	37207		10.1074/jbc.M405594200	http://dx.doi.org/10.1074/jbc.M405594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205454	hybrid			2022-12-27	WOS:000223453600124
J	Mongrand, S; Morel, J; Laroche, J; Claverol, S; Carde, JP; Hartmann, MA; Bonneu, M; Simon-Plas, F; Lessire, R; Bessoule, JJ				Mongrand, S; Morel, J; Laroche, J; Claverol, S; Carde, JP; Hartmann, MA; Bonneu, M; Simon-Plas, F; Lessire, R; Bessoule, JJ			Lipid rafts in higher plant cells - Purification and characterization of triton X-100-insoluble microdomains from tobacco plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-LAYER CHROMATOGRAPHY; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; CARBONIC-ANHYDRASE; PROTEIN; ARABIDOPSIS; STEROLS; ELONGATION; BINDING; PHOSPHOLIPIDS	A large body of evidence from the past decade supports the existence of functional microdomains in membranes of animal and yeast cells, which play important roles in protein sorting, signal transduction, or infection by pathogens. They are based on the dynamic clustering of sphingolipids and cholesterol or ergosterol and are characterized by their insolubility, at low temperature, in nonionic detergents. Here we show that similar microdomains also exist in plant plasma membrane isolated from both tobacco leaves and BY2 cells. Tobacco lipid rafts were found to be greatly enriched in a sphingolipid, identified as glycosylceramide, as well as in a mixture of stigmasterol, sitosterol, 24-methylcholesterol, and cholesterol. Phospho- and glycoglycerolipids of the plasma membrane were largely excluded from lipid rafts. Membrane proteins were separated by one- and two-dimensional gel electrophoresis and identified by tandem mass spectrometry or use of specific antibody. The data clearly indicate that tobacco microdomains are able to recruit a specific set of the plasma membrane proteins and exclude others. We demonstrate the recruitment of the NADPH oxidase after elicitation by cryptogein and the presence of the small G protein NtRac5, a negative regulator of NADPH oxidase, in lipid rafts.	Univ Bordeaux 2, Lab Biogenese Membranaire, CNRS, FRE 2694, Bordeaux, France; Univ Bourgogne, INRA, UMR 692, Phytopharm Lab, F-21065 Dijon, France; Univ Bordeaux 2, Univ Bordeaux 1, INRA, UMR 6191,Inst Biol Vegetale Mol, F-33883 Villenave Dornon, France; Univ Strasbourg, CNRS, UPR 2357, Inst Biol Mol Plantes, F-67083 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; INRAE; Universite de Bourgogne; INRAE; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mongrand, S (corresponding author), Univ Bordeaux 2, Lab Biogenese Membranaire, CNRS, FRE 2694, 146 Rue Leo Saignat,BP 33076, Bordeaux, France.	sebastien.mongrand@biomemb.u-bordeaux2.fr						Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; Assossou O, 2003, FEMS MICROBIOL LETT, V224, P161, DOI 10.1016/S0378-1097(03)00479-8; Bagnat M, 2002, BIOL CHEM, V383, P1475, DOI 10.1515/BC.2002.169; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Berczi Alajos, 2003, Acta Biologica Szegediensis, V47, P7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bohn M, 2001, ARCH BIOCHEM BIOPHYS, V387, P35, DOI 10.1006/abbi.2000.2224; BOUCHEPILLON S, 1994, PLANT PHYSIOL, V105, P691, DOI 10.1104/pp.105.2.691; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Clouse SD, 2002, PLANT CELL, V14, P1995, DOI 10.1105/tpc.140930; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; FETT JP, 1994, PLANT PHYSIOL, V105, P707, DOI 10.1104/pp.105.2.707; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Garcia A, 2003, BIOCHIMIE, V85, P727, DOI 10.1016/j.biochi.2003.09.005; GRONEWALD JW, 1982, PHYTOCHEMISTRY, V21, P859, DOI 10.1016/0031-9422(82)80080-0; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hartmann MA, 1998, TRENDS PLANT SCI, V3, P170, DOI 10.1016/S1360-1385(98)01233-3; HARTMANN MA, 1983, PLANT SCI LETT, V30, P239, DOI 10.1016/0304-4211(83)90223-7; JACINTO T, 1993, PLANT PHYSIOL, V103, P1393, DOI 10.1104/pp.103.4.1393; JUGUELIN H, 1986, DEV BRAIN RES, V25, P249, DOI 10.1016/0165-3806(86)90214-2; Kawamura Y, 2003, PLANT J, V36, P141, DOI 10.1046/j.1365-313X.2003.01864.x; Klahre U, 1998, PLANT CELL, V10, P1677, DOI 10.1105/tpc.10.10.1677; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; LARSSON C, 1994, METHOD ENZYMOL, V228, P451; Lindsey K, 2003, TRENDS PLANT SCI, V8, P521, DOI 10.1016/j.tplants.2003.09.012; Luche S, 2003, PROTEOMICS, V3, P249, DOI 10.1002/pmic.200390037; MACALA LJ, 1983, J LIPID RES, V24, P1243; MARTIN H, 1994, J NEUROCHEM, V63, P2259; MOORE AL, 1983, ISOLATION MEMBRANES, P153; Morel J, 2004, PLANT J, V37, P282, DOI 10.1046/j.1365-313X.2003.01957.x; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Peskan T, 2000, EUR J BIOCHEM, V267, P6989, DOI 10.1046/j.1432-1327.2000.01776.x; Rahier A., 1989, ANAL STEROLS OTHER B, P223, DOI [10.1016/B978-0-12-515445-1.50016-1, DOI 10.1016/B978-0-12-515445-1.50016-1]; Reymond P, 1996, PLANT CELL, V8, P2265, DOI 10.1105/tpc.8.12.2265; ROSENBERRY TL, 1989, J BIOL CHEM, V264, P7096; Rumeau D, 1996, PLANTA, V199, P79, DOI 10.1007/BF00196884; RYAN CA, 1991, ANNU REV PLANT PHYS, V42, P651, DOI 10.1146/annurev.pp.42.060191.003251; Santoni V, 1999, BIOCHIMIE, V81, P655, DOI 10.1016/S0300-9084(99)80122-9; Schindelman G, 2001, GENE DEV, V15, P1115, DOI 10.1101/gad.879101; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Simon-Plas F, 2002, PLANT J, V31, P137, DOI 10.1046/j.1365-313X.2002.01342.x; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; Sperling P, 2003, BBA-MOL CELL BIOL L, V1632, P1, DOI 10.1016/S1388-1981(03)00033-7; Sullards MC, 2000, J MASS SPECTROM, V35, P347, DOI 10.1002/(SICI)1096-9888(200003)35:3<347::AID-JMS941>3.0.CO;2-3; TAKAHASHI T, 1995, GENE DEV, V9, P97, DOI 10.1101/gad.9.1.97; van Duyl BY, 2003, FEBS LETT, V547, P101, DOI 10.1016/S0014-5793(03)00678-1; VITIELLO F, 1978, J CHROMATOGR, V166, P637, DOI 10.1016/S0021-9673(00)95654-1; WHITEHEART SW, 1989, J BIOL CHEM, V264, P14334; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; YANG W, 1994, J BIOL CHEM, V269, P3852; Zheng XJ, 2003, J INVEST DERMATOL, V121, P1487, DOI 10.1111/j.1523-1747.2003.12614.x	58	372	394	0	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36277	36286		10.1074/jbc.M403440200	http://dx.doi.org/10.1074/jbc.M403440200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15190066	hybrid			2022-12-27	WOS:000223453600016
J	Torra, IP; Freedman, LP; Garabedian, MJ				Torra, IP; Freedman, LP; Garabedian, MJ			Identification of DRIP205 as a coactivator for the farnesoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; ORPHAN NUCLEAR RECEPTOR; VITAMIN-D-RECEPTOR; BILE-ACID; THYROID-HORMONE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; TRAP220 COMPONENT; RESPONSE ELEMENT	Farnesoid X receptor (FXR) is a bile acid sensor that regulates the expression of a number of genes the products of which control bile acid and cholesterol homeostasis; however, the role of DRIP205 in FXR-mediated gene regulation remains unexplored. In this study we demonstrate that DRIP205 binds FXR in a ligand-dependent manner in vitro and in vivo. Glutathione S-transferase pull-down assays showed that DRIP205 binds FXR in response to bile acid ligands in a dose-dependent fashion and that the potency of this interaction is associated with the ability of the ligand to activate FXR. In addition, the FXR-DRIP205 interaction required the presence of an intact LXXLL nuclear receptor box 1 (N-terminal) motif of DRIP205. In gel shift assays FXR was also able to recruit DRIP205 in the context of a DNA-bound FXR/RXR (retinoid X receptor) heterodimer. In transient transfection assays, DRIP205 efficiently enhanced a bile acid-activated FXRE-driven reporter gene in a dose-dependent manner in cells overexpressing FXR/RXR, demonstrating that DRIP205 enhances FXR-mediated transactivation. By contrast, an FXRW469A mutant in the activation function 2 domain that does not bind to DRIP205 was unable to activate ligand-stimulated FXR transcription, indicating that DRIP205 is recruited to activation function 2 of FXR. Requirement for the FXR/RXR heterodimer in the DRIP205-FXR interaction was evaluated using an RXR heterodimerization-deficient FXR mutant (FXRL433R). FXRL433R was not able to bind to DRIP205 and failed to enhance an FXRE-driven reporter gene. In addition, DRIP205 was unable to induce FXR-mediated transactivation in the absence of RXR overexpression, indicating that FXR heterodimerization with RXR is required for coactivation by DRIP205. Finally, in HepG2 cells, overexpression or reduction of DRIP205 levels modulated the induction of endogenous FXR target gene mRNA expression by ligand. Together, these results demonstrate that DRIP205 acts as a bona fide coactivator of FXR and underscore the importance of DRIP205 in modulating the bile acid response of FXR target genes.	NYU, Sch Med, Dept Microbiol & Urol, New York, NY 10016 USA; Merck Res Labs, Dept Mol Endocrinol, W Point, PA 19486 USA	New York University; Merck & Company	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol & Urol, 550 1st Ave,MSB 235, New York, NY 10016 USA.	garabm01@med.nyu.edu		Pineda Torra, Ines/0000-0002-7349-2208				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; Barbier O, 2003, GASTROENTEROLOGY, V124, P1926, DOI 10.1016/S0016-5085(03)00388-3; Bonazzi A, 2000, J BIOL CHEM, V275, P2837, DOI 10.1074/jbc.275.4.2837; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Cavarretta ITR, 2002, MOL ENDOCRINOL, V16, P253, DOI 10.1210/me.16.2.253; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Claudel T, 2002, J CLIN INVEST, V109, P961; Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Huang L, 2003, J BIOL CHEM, V278, P51085, DOI 10.1074/jbc.M308321200; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kassam A, 2003, J BIOL CHEM, V278, P10028, DOI 10.1074/jbc.M208312200; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; Love MW, 1998, CURR OPIN LIPIDOL, V9, P225, DOI 10.1097/00041433-199806000-00007; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Maeda Y, 2002, MOL ENDOCRINOL, V16, P1502, DOI 10.1210/me.16.7.1502; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Malik S, 2002, MOL CELL BIOL, V22, P5626, DOI 10.1128/MCB.22.15.5626-5637.2002; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Torra IP, 2003, MOL ENDOCRINOL, V17, P259, DOI 10.1210/me.2002-0120; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zhang JC, 1999, MOL ENDOCRINOL, V13, P1130, DOI 10.1210/me.13.7.1130; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	54	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36184	36191		10.1074/jbc.M405126200	http://dx.doi.org/10.1074/jbc.M405126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15187081	hybrid			2022-12-27	WOS:000223453600005
J	Cao, J; Semenova, MM; Solovyan, VT; Han, JH; Coffey, ET; Courtney, MJ				Cao, J; Semenova, MM; Solovyan, VT; Han, JH; Coffey, ET; Courtney, MJ			Distinct requirements for p38 alpha and c-jun N-terminal kinase stress-activated protein kinases in different forms of apoptotic neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; DNA LOOP DOMAINS; CELL-DEATH; SYMPATHETIC NEURONS; CASPASE ACTIVATION; MOUSE HIPPOCAMPUS; CEREBRAL-ISCHEMIA; P38; JNK; INHIBITION	The stress-activated protein kinases c-Jun-activated kinase (JNK) and p38 are implicated in neuronal apoptosis. Early studies in cell lines suggested a requirement for both in the apoptosis induced by withdrawal of nerve growth factor. However, studies in neuronal cells typically implicate JNK but not p38 in apoptosis. In some cases, p38 is implicated, but the role of JNK is undefined. It remains unclear whether p38 and JNK have differing roles dependent on cell type, apoptotic stimulus, or mechanism of cell death or whether they are redundant and each sufficient to induce identical forms of cell death. We investigate the relative roles of these protein kinases in different death mechanisms in a single system, cultured cerebellar granule neurons. Apoptosis induced by withdrawal of trophic support and glutamate are mechanistically different in terms of caspase activation, DNA fragmentation profile, chromatin morphology, and dependence on de novo gene expression. Caspase-independent apoptosis induced by glutamate is accompanied by strong activation of p38, and dominant negatives and inhibitors of the p38 pathway prevent this apoptosis. In contrast, withdrawal of trophic support induces caspase-dependent death accompanied by JNK-dependent phosphorylation of c-Jun, and inhibition of JNK is sufficient to prevent the death induced by withdrawal of trophic support. Inhibition of p38 does not block withdrawal of trophic support-induced death, nor does inhibition of JNK block glutamate-induced death. We propose that mechanistically different forms of apoptosis have differing requirements for p38 and JNK activities in neurons and demonstrate that only inhibition of the appropriate kinase will prevent neurons from undergoing apoptosis.	Univ Kuopio, AI Virtanen Inst, Dept Neurobiol, FIN-70211 Kuopio, Finland; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Abo Akad, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Univ Turku, FIN-20521 Turku, Finland	University of Eastern Finland; Scripps Research Institute; Abo Akademi University; University of Turku	Courtney, MJ (corresponding author), Univ Kuopio, AI Virtanen Inst, Dept Neurobiol, Neulaniementie 2,POB 1627, FIN-70211 Kuopio, Finland.	courtney@messi.uku.fi	Courtney, Michael J/D-6648-2016; Han, J/G-4671-2010	Courtney, Michael J/0000-0001-8693-3933; Coffey, Eleanor/0000-0002-9717-5610				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Armstrong RC, 1997, J NEUROSCI, V17, P553; BALAZS R, 1990, NEUROSCIENCE, V37, P251, DOI 10.1016/0306-4522(90)90211-L; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bezvenyuk Z, 2000, MOL BRAIN RES, V81, P191, DOI 10.1016/S0169-328X(00)00174-1; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Castilho RF, 1998, J NEUROSCI, V18, P10277; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Coffey ET, 2000, J NEUROSCI, V20, P7602; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; COURTNEY MJ, 1992, J NEUROCHEM, V59, P983, DOI 10.1111/j.1471-4159.1992.tb08339.x; Courtney MJ, 1997, J NEUROSCI, V17, P4201; Didenko VV, 2002, MOL MED, V8, P347, DOI 10.1007/BF03402015; Eilers A, 1998, J NEUROSCI, V18, P1713; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fukuda T, 1999, NEUROSCI RES, V33, P49, DOI 10.1016/S0168-0102(98)00111-4; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; GOLD K, 2003, P NATL ACAD SCI USA, V100, P15434; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; HELLER C, 1989, NUCLEIC ACIDS RES, V17, P5989, DOI 10.1093/nar/17.15.5989; Hongisto V, 2003, MOL CELL BIOL, V23, P6027, DOI 10.1128/MCB.23.17.6027-6036.2003; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kikuchi M, 2000, J NEUROSCI, V20, P5037; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LINDQVIST C, 1995, CELL IMMUNOL, V165, P71, DOI 10.1006/cimm.1995.1188; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; Schwarzschild MA, 1999, J NEUROCHEM, V72, P2248, DOI 10.1046/j.1471-4159.1999.0722248.x; Sheldon RA, 2001, NEUROSCI LETT, V304, P165, DOI 10.1016/S0304-3940(01)01788-8; Solovyan VT, 2002, J BIOL CHEM, V277, P21458, DOI 10.1074/jbc.M110621200; Watson A, 1998, J NEUROSCI, V18, P751; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhao M, 1999, MOL CELL BIOL, V19, P21	51	93	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35903	35913		10.1074/jbc.M402353200	http://dx.doi.org/10.1074/jbc.M402353200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192112	hybrid			2022-12-27	WOS:000223303400091
J	Kampf, JP; Kleinfeld, AM				Kampf, JP; Kleinfeld, AM			Fatty acid transport in adipocytes monitored by imaging intracellular free fatty acid levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; FLIP-FLOP; BINDING-PROTEIN; RAT ADIPOCYTES; OLEIC-ACID; LONG; DIFFERENTIATION; EXPRESSION; MECHANISM; DIFFUSION	Transport of free fatty acids (FFA) across the adipocyte plasma membrane is critical for maintaining homeostasis. To determine the membrane's role in regulating transport we describe here the first measurements of the intracellular (unbound) FFA concentration ([FFA(i)]) and their use in monitoring transport of FFA across 3T3F442A adipocytes. [FFA(i)] was measured by microinjecting cells with ADIFAB, a fluorescently labeled fatty acid-binding protein that is used to measure unbound FFA levels. We used ratio fluorescence microscopy of intracellular ADIFAB to image unbound FFA levels and determined the time course of [FFA(i)] in response to changing the extracellular unbound FFA concentration ([FFA(o)]). [FFA(o)] was clamped at defined levels using complexes of FFA and bovine serum albumin. We show that FFA influx is slow, requiring about 300 s to reach steady state (rate constant similar to0.02 s(-1)) and saturable (K-o similar to 200 nM). Efflux is twice as fast as influx, for zero [FFA(o)], but decreases with increasing [FFA(o)]. Surprisingly, at steady state [FFA(i)] is 2-5-fold (average 2-fold) greater than [FFA(o)] and this [FFA(i)]/[FFA(o)] gradient is abolished by depleting cellular ATP. Our results indicate that FFA transport across adipocyte membranes is highly regulated, involving an ATP-driven pump and a mechanism for gating efflux that is sensitive to [FFA(o)]. These characteristics are well described by a membrane carrier model but are not consistent with FFA transport across the membrane's lipid phase. We suggest that these characteristics are important in regulating circulating FFA levels by the adipocyte.	Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Torrey Pines Institute for Molecular Studies, California	Kleinfeld, AM (corresponding author), Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA.	akleinfeld@tpims.org		Kampf, James/0000-0003-3050-3998	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058762] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58762] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Apple F.S., 2004, CLIN PROTEOMICS, V1, P41, DOI [10.1385/CP:1:1:041, DOI 10.1385/CP:1:1:041]; Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; Carlsson M, 2000, ARTERIOSCL THROM VAS, V20, P1588, DOI 10.1161/01.ATV.20.6.1588; Caserta F, 2001, AM J PHYSIOL-ENDOC M, V280, pE238, DOI 10.1152/ajpendo.2001.280.2.E238; Civelek VN, 1996, P NATL ACAD SCI USA, V93, P10139, DOI 10.1073/pnas.93.19.10139; Cupp D, 2004, BIOCHEMISTRY-US, V43, P4473, DOI 10.1021/bi036335l; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Hamilton JA, 2003, CURR OPIN LIPIDOL, V14, P263, DOI 10.1097/00041433-200306000-00006; Hamilton JA, 1998, J LIPID RES, V39, P467; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; Jouven X, 2001, CIRCULATION, V104, P756, DOI 10.1161/hc3201.094151; Kamp F, 2003, J BIOL CHEM, V278, P7988, DOI 10.1074/jbc.M206648200; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; Kleinfeld AM, 1998, BIOCHEMISTRY-US, V37, P8011, DOI 10.1021/bi980301+; Kleinfeld AM, 2000, J MEMBRANE BIOL, V175, P79, DOI 10.1007/s002320001056; Leyssens A, 1996, J PHYSIOL-LONDON, V496, P111, DOI 10.1113/jphysiol.1996.sp021669; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; Nielsen S, 2003, J CLIN INVEST, V111, P981, DOI [10.1172/JCI16253, 10.1172/JCI200316253]; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J LIPID RES, V36, P229; RICHIERI GV, 1995, ANAL BIOCHEM, V229, P256, DOI 10.1006/abio.1995.1410; Richieri GV, 1999, MOL CELL BIOCHEM, V192, P87, DOI 10.1023/A:1006878421990; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; STORCH J, 1991, J BIOL CHEM, V266, P13473; STORCH J, 1989, J BIOL CHEM, V264, P10527; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; Stump DD, 2001, J LIPID RES, V42, P509; Thomas RM, 2002, BIOCHEMISTRY-US, V41, P1591, DOI 10.1021/bi011555p; Trigatti BL, 1996, BIOCHEM J, V313, P487, DOI 10.1042/bj3130487; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; WEISS TF, 1996, CELLULAR BIOPHYSICS, P360; Zakim D, 2000, J MEMBRANE BIOL, V176, P101, DOI 10.1007/s002320001080; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P16055, DOI 10.1021/bi961685b; ZHOU SL, 1992, J BIOL CHEM, V267, P14456	42	39	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35775	35780		10.1074/jbc.M403630200	http://dx.doi.org/10.1074/jbc.M403630200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199061	hybrid			2022-12-27	WOS:000223303400077
J	Todaka, H; Taniguchi, J; Satoh, J; Mizuno, A; Suzuki, M				Todaka, H; Taniguchi, J; Satoh, J; Mizuno, A; Suzuki, M			Warm temperature-sensitive transient receptor potential vanilloid 4 (TRPV4) plays an essential role in thermal hyperalgesia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING TRPV4; CAPSAICIN-RECEPTOR; INFLAMMATORY HYPERALGESIA; CUTANEOUS THERMORECEPTORS; PAIN; HEAT; CARRAGEENAN; EXPRESSION; ACTIVATION; SENSATION	Animals sense various ranges of temperatures by cutaneous thermal stimuli. Transient receptor potential vanilloid 4 (TRPV4) is a cation channel activated at a warm temperature (over 30 degreesC) in exogenously expressed cells. We found in the present study that TRPV4 is essential in thermal hyperalgesia at a warm temperature in vivo. TRPV4-/- and TRPV4+/+ mice exhibited the same latency of escape from 35-50 degreesC hotplates. Neuronal activity in the femoral nerve, however, revealed that the number and activity level of neurons decreased in response to a warm temperature in TRPV4-/- mice. TRPV4-/- mice displayed a significantly longer latency to escape from the plates at 35-45 degreesC when hyperalgesia was induced by carrageenan without changes in foot volumes. TRPV4 therefore determines the sensitivity rather than the threshold of painful heat detection and plays an essential role in thermal hyperalgesia.	Jichi Med Sch, Dept Pharmacol, Div Mol Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, Div Mol Pharmacol, 3311-1 YAkushiji, Minami Kawachi, Tochigi 3290498, Japan.							Adelson DW, 1997, J NEUROPHYSIOL, V77, P2989, DOI 10.1152/jn.1997.77.6.2989; Alessandri-Haber N, 2004, J NEUROSCI, V24, P4444, DOI 10.1523/JNEUROSCI.0242-04.2004; Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; ATANABE H, 2003, NATURE, V424, P434; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; DIROSA M, 1972, J PHARM PHARMACOL, V24, P89, DOI 10.1111/j.2042-7158.1972.tb08940.x; HARDY JD, 1951, SCIENCE, V114, P149, DOI 10.1126/science.114.2954.149; HENSEL H, 1960, J PHYSIOL-LONDON, V153, P113, DOI 10.1113/jphysiol.1960.sp006522; IGGO A, 1969, J PHYSIOL-LONDON, V200, P403, DOI 10.1113/jphysiol.1969.sp008701; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Mansikka H, 2002, NEUROSCIENCE, V113, P339, DOI 10.1016/S0306-4522(02)00189-6; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Nackley AG, 2003, NEUROSCIENCE, V119, P747, DOI 10.1016/S0306-4522(03)00126-X; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Quartilho A, 2003, ANESTHESIOLOGY, V99, P955, DOI 10.1097/00000542-200310000-00031; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Suzuki M, 2003, J BIOL CHEM, V278, P51448, DOI 10.1074/jbc.M308212200; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tao F, 2003, NEUROSCIENCE, V120, P847, DOI 10.1016/S0306-4522(03)00362-2; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Wu WP, 2002, NEUROSCIENCE, V114, P523, DOI 10.1016/S0306-4522(02)00273-7; Zhang LP, 2001, PAIN, V89, P265, DOI 10.1016/S0304-3959(00)00378-X	28	136	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35133	35138		10.1074/jbc.M406260200	http://dx.doi.org/10.1074/jbc.M406260200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15187078	hybrid			2022-12-27	WOS:000223303400003
J	Lee, GE; Yu, EY; Cho, CH; Lee, J; Muller, MT; Chung, IK				Lee, GE; Yu, EY; Cho, CH; Lee, J; Muller, MT; Chung, IK			DNA-protein kinase catalytic subunit-interacting protein KIP binds telomerase by interacting with human telomerase reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-STRAND OVERHANG; MAMMALIAN TELOMERASE; LENGTH MAINTENANCE; IMMORTAL CELLS; CANCER; PKCS; GENE; IDENTIFICATION; REPLICATION; REPEATS	Telomere homeostasis, a process that is essential for continued cell proliferation and genomic stability, is regulated by endogenous telomerase and a collection of associated proteins. In this paper, a protein called KIP ( previously reported as a protein that binds specifically to DNA-dependent protein kinase), has been identified as a telomerase-regulating activity based on the following pieces of evidence. First, complexes between KIP and the catalytic subunit of telomerase ( hTERT) were identified using the yeast two-hybrid technique. Second, antibodies specific to KIP immunoprecipitate human telomerase in cell-free extracts. Third, immunolocalization experiments demonstrate that KIP is a nuclear protein that co-localizes with hTERT in cells. Fourth, KIP binds to hTERT both in vitro and in vivo in the absence of human telomerase RNA or telomeric DNA, thus defining the catalytic subunit of telomerase as the site of physical interaction. Fifth, co-immunoprecipitation experiments suggest that KIP-hTERT complexes form readily in cells and that overexpression of KIP in telomerase-positive cells increases endogenous telomerase activity. Finally, continued overexpression of KIP ( 60 population doublings) resulted in cells with elongated telomeres; thus, KIP directly or indirectly stimulates telomerase activity through hTERT and contributes to telomere lengthening. The collective data in this paper suggest that KIP plays a positive role in telomere length maintenance and/or regulation and may represent a novel target for anti-cancer drug development.	Yonsei Univ, Dept Biol & Mol Aging Res Ctr, Seoul 120749, South Korea; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	Yonsei University; State University System of Florida; University of Central Florida	Chung, IK (corresponding author), Yonsei Univ, Dept Biol, Coll Sci, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@yonsei.ac.kr			NATIONAL CANCER INSTITUTE [R01CA098214] Funding Source: NIH RePORTER; NCI NIH HHS [CA 98214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chai WH, 2002, J BIOL CHEM, V277, P47242, DOI 10.1074/jbc.M208542200; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Danska JS, 1996, MOL CELL BIOL, V16, P5507; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hande P, 1999, GENOMICS, V56, P221, DOI 10.1006/geno.1998.5668; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Kim JH, 2003, BIOCHEM J, V373, P523, DOI 10.1042/BJ20030363; Kim JH, 2003, MOL PHARMACOL, V63, P1117, DOI 10.1124/mol.63.5.1117; Kim JH, 2002, MOL CELLS, V13, P228; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Liu Y, 2000, MOL CELL BIOL, V20, P8178, DOI 10.1128/MCB.20.21.8178-8184.2000; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Saito T, 1999, MAMM GENOME, V10, P315, DOI 10.1007/s003359900994; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	40	41	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34750	34755		10.1074/jbc.M401843200	http://dx.doi.org/10.1074/jbc.M401843200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190070	hybrid, Green Published			2022-12-27	WOS:000223134800081
J	Reiser, J; Oh, J; Shirato, I; Asanuma, K; Hug, A; Mundel, TM; Honey, K; Ishidoh, K; Kominami, E; Kreidberg, JA; Tomino, Y; Mundel, P				Reiser, J; Oh, J; Shirato, I; Asanuma, K; Hug, A; Mundel, TM; Honey, K; Ishidoh, K; Kominami, E; Kreidberg, JA; Tomino, Y; Mundel, P			Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha(3) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL SEGMENTAL GLOMERULOSCLEROSIS; ALPHA-3-BETA-1 INTEGRIN; MICE LACKING; AMINONUCLEOSIDE NEPHROSIS; EXTRACELLULAR-MATRIX; GLOMERULAR PROTEIN; PROCATHEPSIN-L; IN-VITRO; EXPRESSION; NEPHRIN	Podocyte foot process effacement and disruption of the slit diaphragm are typically associated with glomerular proteinuria and can be induced in rats by the injection of puromycin aminonucleoside. Here, we show that the induction of puromycin aminonucleoside nephrosis involves podocyte migration conducted by a coordinated interplay between the cysteine protease cathepsin L and alpha(3) integrin. Puromycin aminonucleoside treatment up-regulates cathepsin L expression in podocytes in vivo as well as expression and enzymatic activity of cathepsin L in podocytes in vitro. Isolated podocytes from mice lacking cathepsin L are protected from cell puromycin aminonucleoside-induced cell detachment. The functional significance of cathepsin L expression was underscored by the observation that puromycin aminonucleoside-induced cell migration was slowed down in cathepsin L-deficient podocytes and by the preservation of cell-cell contacts and expression of vital slit diaphragm protein CD2AP. Cathepsin L expression and activity were induced in podocytes lacking alpha(3) integrin. Similarly, acute functional inhibition of alpha(3) integrin in wild type podocytes with a blocking antibody increased the expression of cathepsin L activity. Downregulation of alpha(3) integrin protected against puromycin aminonucleoside-induced podocyte detachment. In summary, these data establish that podocyte foot process effacement is a migratory event involving a novel interplay between cathepsin L and alpha(3) integrin.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Juntendo Univ, Dept Med, Tokyo 1138421, Japan; Juntendo Univ, Dept Biochem, Tokyo 1138421, Japan; Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; Univ Munster, Dept Surg, D-48149 Munster, Germany; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Juntendo University; Juntendo University; Ruprecht Karls University Heidelberg; University of Munster; University of Washington; University of Washington Seattle; Harvard University; Boston Children's Hospital	Mundel, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Div Nephrol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	mundel@aecom.yu.edu	Kominami, Eiki/D-3802-2009; Hug, Andreas/O-5508-2014	Hug, Andreas/0000-0002-7764-1813	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK064236, R01DK057683] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 057683, DK 064236] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1992, AM J PATHOL, V141, P571; Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; Asanuma K, 2002, KIDNEY INT, V62, P822, DOI 10.1046/j.1523-1755.2002.00539.x; AUTHIER F, 1995, J BIOL CHEM, V270, P15798, DOI 10.1074/jbc.270.26.15798; BARICOS WH, 1991, ARCH BIOCHEM BIOPHYS, V288, P468, DOI 10.1016/0003-9861(91)90222-5; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Cheng ZZ, 2003, KIDNEY INT, V63, P107, DOI 10.1046/j.1523-1755.2003.00726.x; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Honey K, 2002, NAT IMMUNOL, V3, P1069, DOI 10.1038/ni844; Inokuchi S, 1996, KIDNEY INT, V50, P1278, DOI 10.1038/ki.1996.439; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; JAT PS, 1991, P NATL ACAD SCI US, V88; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; KRETZLER M, 1996, AM J PHYSIOL, V271, P770; Levicar N, 2003, CANCER GENE THER, V10, P141, DOI 10.1038/sj.cgt.7700546; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; NAKAMURA T, 1991, LAB INVEST, V64, P640; NISHIMURA Y, 1989, ARCH BIOCHEM BIOPHYS, V271, P400, DOI 10.1016/0003-9861(89)90289-0; Ohashi K, 2003, BBA-PROTEINS PROTEOM, V1649, P30, DOI 10.1016/S1570-9639(03)00152-3; Raats CJI, 2000, AM J PATHOL, V156, P1749, DOI 10.1016/S0002-9440(10)65046-8; Regele HM, 2000, J AM SOC NEPHROL, V11, P403, DOI 10.1681/ASN.V113403; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Reiser J, 2000, KIDNEY INT, V57, P2035, DOI 10.1046/j.1523-1755.2000.00070.x; Saleem MA, 2002, AM J PATHOL, V161, P1459, DOI 10.1016/S0002-9440(10)64421-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Van den Berg JG, 2000, J AM SOC NEPHROL, V11, P413, DOI 10.1681/ASN.V113413; Van Noorden CJF, 1998, CLIN EXP METASTAS, V16, P159; Wagner LA, 1999, EUR J IMMUNOL, V29, P2530, DOI 10.1002/(SICI)1521-4141(199908)29:08<2530::AID-IMMU2530>3.0.CO;2-2; Wang ZM, 1999, J CELL SCI, V112, P2925; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; WHITESIDE C, 1989, LAB INVEST, V61, P650	44	138	150	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34827	34832		10.1074/jbc.M401973200	http://dx.doi.org/10.1074/jbc.M401973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15197181	hybrid			2022-12-27	WOS:000223134800091
J	Hu, YC; Yeh, SY; Yeh, SD; Sampson, ER; Huang, JT; Li, P; Hsu, CL; Ting, HJ; Lin, HK; Wang, L; Kim, E; Ni, J; Chang, CS				Hu, YC; Yeh, SY; Yeh, SD; Sampson, ER; Huang, JT; Li, P; Hsu, CL; Ting, HJ; Lin, HK; Wang, L; Kim, E; Ni, J; Chang, CS			Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-RECEPTOR; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONES; ESTROGEN-RECEPTOR; COMPLEMENTARY-DNA; AGONIST ACTIVITY	Androgen receptor (AR)-associated coregulator 70 (ARA70) was the first identified AR coregulator. However, its molecular mechanism and biological relevance to prostate cancer remain unclear. Here we show that ARA70 interacts with and promotes AR activity via the consensus FXXLF motif within the ARA70-N2 domain ( amino acids 176 - 401). However, it does not promote AR activity via the classic LXXLL motif located at amino acids 92 - 96, although this classic LXXLL motif is important for ARA70 to interact with other receptors, such as PPARgamma. The molecular mechanisms by which ARA70 enhances AR transactivation involve the increase of AR expression, protein stability, and nuclear translocation. Furthermore, ARA70 protein is more frequently detected in prostate cancer specimens (91.74%) than in benign tissues (64.64%, p < 0.0001). ARA70 expression is also increased in high-grade prostate cancer tissues as well as the hormone-refractory LNCaP xenografts and prostate cancer cell lines. Because ARA70 can promote the antiandrogen hydroxyflutamide (HF)-enhanced AR transactivation, the increased ARA70 expression in hormone-refractory prostate tumors may confer the development of HF withdrawal syndrome, commonly diagnosed in patients with the later stages of prostate cancer. Because ARA70-N2 containing the AR-interacting FXXLF motif without coactivation function can suppress HF-enhanced AR transactivation in the hormone-refractory LNCaP cells, using the ARA70-N2 inhibitory peptide at the hormone refractory stage to battle the HF withdrawal syndrome may become an alternative strategy to treat prostate cancer.	Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Taipei Med Univ, Dept Urol, Taipei 105, Taiwan	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Texas System; UTMD Anderson Cancer Center; Taipei Medical University	Chang, CS (corresponding author), Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Hu, Yueh-Chiang/AAX-2370-2020	Huang, Jiaoti/0000-0003-1195-1998; Chang, Chawnshang/0000-0001-8510-3516; Hu, Yueh-Chiang/0000-0002-7992-0525; Ting, Huei-Ju/0000-0003-3709-5755	NIDDK NIH HHS [DK067686, DK60905] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905, R01DK067686] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOULNIK I, 2000, KEYST S NUCL REC SUP; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Culig Z, 2003, UROLOGY, V62, P21, DOI 10.1016/S0090-4295(03)00698-8; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gregory CW, 1998, CANCER RES, V58, P5718; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Hu YC, 2002, J BIOL CHEM, V277, P33571, DOI 10.1074/jbc.M203531200; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Mitchell SH, 1999, CANCER RES, V59, P5892; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; PAYNE AH, 1990, BIOL REPROD, V42, P399, DOI 10.1095/biolreprod42.3.399; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Rahman MM, 2003, J BIOL CHEM, V278, P19619, DOI 10.1074/jbc.M210941200; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Thin TH, 2002, J BIOL CHEM, V277, P36499, DOI 10.1074/jbc.M202824200; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Truica CI, 2000, CANCER RES, V60, P4709; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1997, LANCET, V349, P852, DOI 10.1016/S0140-6736(05)61756-4; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287	64	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33438	33446		10.1074/jbc.M401781200	http://dx.doi.org/10.1074/jbc.M401781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166229	hybrid			2022-12-27	WOS:000223039700052
J	Galgani, M; De Rosa, V; De Simone, S; Leonardi, A; D'Oro, U; Napolitani, G; Masci, AM; Zappacosta, S; Racioppi, L				Galgani, M; De Rosa, V; De Simone, S; Leonardi, A; D'Oro, U; Napolitani, G; Masci, AM; Zappacosta, S; Racioppi, L			Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REGULATES CYTOKINE PRODUCTION; NECROSIS-FACTOR-ALPHA; IN-VIVO; PROSTAGLANDIN E-2; C-JUN; ACTIVATION; MATURATION; INTERLEUKIN-12; RECEPTOR	Immature dendritic cells (iDCs) can be instructed to polarize the immune response toward a noninflammatory pathway by mediators that increase the intracellular concentration of cAMP. This phenomenon is associated with the ability of the cyclic nucleoside to inhibit the release of pro-inflammatory cytokines without affecting the differentiation process of the dendritic cells (DCs). Here we investigated the ability of cAMP to modulate the endotoxin signaling by exposing DCs to exogenous 8-bromium-cyclic AMP in the presence or absence of H89, a selective inhibitor of the protein kinase A, one of the major molecular targets of the cyclic nucleoside. cAMP affects the early lipopolysaccharide-induced signaling cascade dissociating the activation of NF-kappaB, p38, and ERK pathways from the stimulation of c-Src and Lyn kinases. This phenomenon was prevented by H89. The pharmacological block of Src-like tyrosine kinases induces comparable results confirming the involvement of this family of enzymes in the mechanism controlling the release of cytokines in human monocyte-derived iDCs. We propose that the cAMP-protein kinase A-dependent pathway regulates the functional plasticity of iDCs by gating the Toll-like receptor signaling at the level of Src-like kinases.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Endocrinol & Oncol Sperimentale, Naples, Italy; Chiron Vaccines, Siena, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Novartis	Racioppi, L (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, 5 Via S Pansini, I-80131 Naples, Italy.	racioppi@unina.it	leonardi, antonio/A-2887-2009; racioppi, luigi/AGB-8665-2022; racioppi, luigi/GNP-0349-2022; De Rosa, Veronica/K-6534-2016	leonardi, antonio/0000-0001-8636-9623; racioppi, luigi/0000-0002-9207-6752; De Rosa, Veronica/0000-0002-9477-0991; Galgani, Mario/0000-0001-8414-1676; Masci, Anna Maria/0000-0003-1940-6740				Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brocker T, 1997, J EXP MED, V185, P541, DOI 10.1084/jem.185.3.541; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; D'Amico G, 2000, NAT IMMUNOL, V1, P387, DOI 10.1038/80819; Delgado M, 2000, J IMMUNOL, V165, P3051, DOI 10.4049/jimmunol.165.6.3051; Finkelman FD, 1996, J IMMUNOL, V157, P1406; Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kalinski P, 1998, J IMMUNOL, V161, P2804; Kalinski P, 1997, J IMMUNOL, V159, P28; Kalinski P, 2001, BLOOD, V97, P3466, DOI 10.1182/blood.V97.11.3466; Kambayashi T, 2001, J LEUKOCYTE BIOL, V70, P903; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lanzavecchia A, 2001, CURR OPIN IMMUNOL, V13, P291, DOI 10.1016/S0952-7915(00)00218-1; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Mann J, 2002, J BIOL CHEM, V277, P17125, DOI 10.1074/jbc.M109250200; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakamura I, 2002, J IMMUNOL, V168, P5103, DOI 10.4049/jimmunol.168.10.5103; Napolitani G, 2003, EUR J IMMUNOL, V33, P2832, DOI 10.1002/eji.200324073; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schwartz JH, 2001, P NATL ACAD SCI USA, V98, P13482, DOI 10.1073/pnas.251533998; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; Wilkin F, 2002, EUR J IMMUNOL, V32, P2409, DOI 10.1002/1521-4141(200209)32:9<2409::AID-IMMU2409>3.0.CO;2-H; Wilkin F, 2001, J IMMUNOL, V166, P7172, DOI 10.4049/jimmunol.166.12.7172; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	46	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32507	32514		10.1074/jbc.M403355200	http://dx.doi.org/10.1074/jbc.M403355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166249	hybrid			2022-12-27	WOS:000222849700065
J	Tchen, CR; Brook, M; Saklatvala, J; Clark, AR				Tchen, CR; Brook, M; Saklatvala, J; Clark, AR			The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AU-RICH-ELEMENT; ZINC-FINGER PROTEINS; COLONY-STIMULATING FACTOR; EARLY-RESPONSE GENES; T-CELL-ACTIVATION; FACTOR-ALPHA; POSTTRANSCRIPTIONAL REGULATION; TNF-ALPHA; SIGNALING CASCADE	Tristetraprolin (TTP) is an mRNA-destabilizing protein that negatively regulates the expression of proinflammatory mediators such as tumor necrosis factor alpha, granulocyte/macrophage colony-stimulating factor, and cyclooxygenase 2. Here we investigate the regulation of TTP expression in the mouse macrophage cell line RAW264.7. We show that TTP mRNA is expressed in a biphasic manner following stimulation of cells with lipopolysaccharide and that the second phase of expression, like the first, is dependent on mitogen-activated protein kinase (MAPK) p38. MAPK p38 acts through a downstream kinase to stabilize TTP mRNA, and this stabilization is mediated by an adenosine/uridine-rich region at the 3'-end of the TTP 3'-untranslated region. Hence TTP is post-transcriptionally regulated in a similar manner to several proinflammatory genes. We also demonstrate that TTP is able to bind to its own 3'-untranslated region and negatively regulate its own expression, forming a feedback loop to limit expression levels.	Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol Div, London W6 8LH, England	Imperial College London; University of Oxford	Clark, AR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol Div, 1 Aspenlea Rd, London W6 8LH, England.	andy.clark@ic.ac.uk	Clark, Andrew/AAN-4043-2021; Brook, Matthew/I-5828-2019	Brook, Matthew/0000-0003-1245-7385; Clark, Andy/0000-0003-4996-8322				Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Cao HP, 2003, ARCH BIOCHEM BIOPHYS, V412, P106, DOI 10.1016/S0003-9861(03)00012-2; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chrestensen CA, 2004, J BIOL CHEM, V279, P10176, DOI 10.1074/jbc.M310486200; Clark A, 2000, ARTHRITIS RES, V2, P172, DOI 10.1186/ar83; Clark AR, 2003, FEBS LETT, V546, P37, DOI 10.1016/S0014-5793(03)00439-3; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Fairhurst AM, 2003, ARTHRITIS RES THER, V5, pR214, DOI 10.1186/ar778; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; Johnson BA, 2002, ONCOGENE, V21, P4237, DOI 10.1038/sj.onc.1205526; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; MA QF, 1994, ONCOGENE, V9, P3329; Maclean KN, 1998, BRIT J BIOMED SCI, V55, P184; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Ogawa K, 2003, J BIOL CHEM, V278, P30373, DOI 10.1074/jbc.M304856200; Phillips K, 2004, P NATL ACAD SCI USA, V101, P2011, DOI 10.1073/pnas.0400148101; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Shim J, 2002, MOL CELLS, V14, P323; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Sully G, 2004, BIOCHEM J, V377, P629, DOI 10.1042/BJ20031484; Suzuki K, 2003, J EXP MED, V198, P1717, DOI 10.1084/jem.20031701; Tabara H, 1999, DEVELOPMENT, V126, P1; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; Yu H, 2003, J BIOL CHEM, V278, P13912, DOI 10.1074/jbc.M213027200; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	67	122	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32393	32400		10.1074/jbc.M402059200	http://dx.doi.org/10.1074/jbc.M402059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15187092	hybrid			2022-12-27	WOS:000222849700052
J	Xu, MG; Zhao, MW; Wang, ED				Xu, MG; Zhao, MW; Wang, ED			Leucyl-tRNA synthetase from the hyperthermophilic bacterium Aquifex aeolicus recognizes minihelices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC-CODE; AMINO-ACID; ENZYMATIC AMINOACYLATION; NUCLEOTIDE DETERMINANTS; ACCEPTOR STEM; DISCRIMINATION; ISOLEUCINE; SUBSTRATE; LEUCINE	Aminoacylation of the minihelix mimicking the amino acid acceptor arm of tRNA has been demonstrated in more than 10 aminoacyl-tRNA synthetase systems. Although Escherichia coli or Homo sapiens cytoplasmic leucyl-tRNA synthetase (LeuRS) is unable to charge the cognate minihelix or microhelix, we show here that minihelix(Leu) is efficiently charged by Aquifex aeolicus synthetase, the only known heterodimeric LeuRS (alphabeta-LeuRS). Aminoacylation of minihelices is strongly dependent on the presence of the A73 identity nucleotide and greatly stimulated by destabilization of the first base pair as reported for the E. coli isoleucyl-tRNA synthetase and methionyl-tRNA synthetase systems. In the E. coli LeuRS system, the anticodon of tRNA(Leu) is not important for recognition by the synthetase. However, the addition of RNA helices that mimic the anticodon domain stimulates minihelix(Leu) charging by alphabeta-LeuRS, indicating possible domain-domain communication within alphabeta-LeuRS. The leucine-specific domain of alphabeta-LeuRS is responsible for minihelix recognition. To ensure accurate translation of the genetic code, LeuRS functions to hydrolyze misactivated amino acids (pretransfer editing) and misaminoacylated tRNA (post-transfer editing). In contrast to tRNA(Leu), minihelix(Leu) is unable to induce posttransfer editing even upon the addition of the anticodon domain of tRNA. Therefore, the context of tRNA is crucial for the editing of mischarged products. However, the minihelix(Leu) cannot be misaminoacylated, perhaps because of the tRNA-independent pretransfer editing activity of alphabeta-LeuRS.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Wang, ED (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	edwang@sibs.ac.cn						Alexander RW, 1998, P NATL ACAD SCI USA, V95, P12214, DOI 10.1073/pnas.95.21.12214; ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; de Pouplana LR, 2000, CELL MOL LIFE SCI, V57, P865, DOI 10.1007/PL00000729; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DIETRICH A, 1990, NUCLEIC ACIDS RES, V18, P2589; Du X, 2003, NUCLEIC ACIDS RES, V31, P2865, DOI 10.1093/nar/gkg382; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Farrow MA, 1999, BIOCHEMISTRY-US, V38, P16898, DOI 10.1021/bi9920782; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; FRUGIER M, 1994, EMBO J, V13, P2218, DOI 10.1002/j.1460-2075.1994.tb06499.x; Fukai S, 2003, RNA, V9, P100, DOI 10.1261/rna.2760703; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Gouda M, 2002, FEBS LETT, V518, P139, DOI 10.1016/S0014-5793(02)02675-3; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; KHAN AS, 1988, SCIENCE, V241, P74, DOI 10.1126/science.2455342; Korencic D, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf104; Larkin DC, 2002, NUCLEIC ACIDS RES, V30, P2103, DOI 10.1093/nar/30.10.2103; Li Y, 1999, PROTEIN EXPRES PURIF, V16, P355, DOI 10.1006/prep.1999.1083; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; Metzger AU, 1997, NUCLEIC ACIDS RES, V25, P4551, DOI 10.1093/nar/25.22.4551; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Nordin BE, 2003, BIOCHEMISTRY-US, V42, P12989, DOI 10.1021/bi035052q; Nordin BE, 2002, J BIOL CHEM, V277, P20510, DOI 10.1074/jbc.M202023200; Nordin BE, 1999, J BIOL CHEM, V274, P6835, DOI 10.1074/jbc.274.11.6835; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; NUREKI O, 1993, TRANSLATIONAL APPARATUS, P59; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RIBAS DPL, 2001, J BIOL CHEM, V276, P6881; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; Sankaranarayanan R, 2001, ACTA BIOCHIM POL, V48, P323; Schimmel P, 1996, P NATL ACAD SCI USA, V93, P4521, DOI 10.1073/pnas.93.10.4521; Shi PY, 1998, RNA, V4, P276; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Steer BA, 1999, J BIOL CHEM, V274, P35601, DOI 10.1074/jbc.274.50.35601; Tardif KD, 2002, NUCLEIC ACIDS RES, V30, P2538, DOI 10.1093/nar/30.11.2538; Tocchini-Valentini G, 2000, J MOL BIOL, V298, P779, DOI 10.1006/jmbi.2000.3694; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Xu MG, 2002, J BIOL CHEM, V277, P41590, DOI 10.1074/jbc.M205126200; Zhao MW, 2003, BIOCHEMISTRY-US, V42, P7694, DOI 10.1021/bi027394m	53	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32151	32158		10.1074/jbc.M403018200	http://dx.doi.org/10.1074/jbc.M403018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161932	hybrid			2022-12-27	WOS:000222849700021
J	Kalatskaya, I; Schussler, S; Blaukat, A; Muller-Esterl, W; Jochum, M; Proud, D; Faussner, A				Kalatskaya, I; Schussler, S; Blaukat, A; Muller-Esterl, W; Jochum, M; Proud, D; Faussner, A			Mutation of tyrosine in the conserved NPXXY sequence leads to constitutive phosphorylation and internalization, but not signaling, of the human B-2 bradykinin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; HUMAN FIBROBLASTS; ACTIVATION; IDENTIFICATION; SEQUESTRATION; TRAFFICKING; PATHWAY; BINDING; STATE	Although the G protein-coupled receptors (GPCRs) share a similar seven-transmembrane domain structure, only a limited number of amino acid residues is conserved in their protein sequences. One of the most highly conserved sequences is the NPXXY motif located at the cytosolic end of the transmembrane region-7 of many GPCRs, particularly of those belonging to the family of the rhodopsin/beta-adrenergic-like receptors. Exchange of Tyr(305) in the corresponding NPLVY sequence of the bradykinin B-2 receptor (B2R) for Ala resulted in a mutant, termed Y305A, that internalized [H-3] bradykinin (BK) almost as rapidly as the wild-type (wt) B2R. However, receptor sequestration of the mutant after stimulation with BK was clearly reduced relative to the wt B2R. Confocal fluorescence microscopy revealed that, in contrast to the B2R-enhanced green fluorescent protein chimera, the Y305A-enhanced green fluorescent protein chimera was predominantly located intracellularly even in the absence of BK. Two-dimensional phosphopeptide analysis showed that the mutant Y305A constitutively exhibited a phosphorylation pattern similar to that of the BK-stimulated wt B2R. Ligand-independent Y305A internalization was demonstrated by the uptake of rhodamine-labeled antibodies directed to a tag sequence at the N terminus of the mutant receptor. Co-immunoprecipitation revealed that Y305A is precoupled to G(q/11) without activating the G protein because the basal accumulation rate of inositol phosphate was unchanged as compared with wt B2R. We conclude, therefore, that the Y305A mutation of B2R induces a receptor conformation which is prone to ligand-independent phosphorylation and internalization. The mutated receptor binds to, but does not activate, its cognate heterotrimeric G protein G(q/11), thereby limiting the extent of ligand-independent receptor internalization.	Univ Munich, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany; Heidelberg Univ, Inst Pharmakol, D-69120 Heidelberg, Germany; Goethe Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of Munich; Ruprecht Karls University Heidelberg; Goethe University Frankfurt; University of Calgary	Faussner, A (corresponding author), Univ Munich, Klin Chem & Klin Biochem Abt, Nussbaumstr 20, D-80336 Munich, Germany.	alexander.faussner@med.uni-muenchen.de		Kalatskaya, Irina/0000-0002-1663-859X				Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Bouley R, 2003, AM J PHYSIOL-CELL PH, V285, pC750, DOI 10.1152/ajpcell.00477.2002; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; FAUSSNER A, 1991, J BIOL CHEM, V266, P9442; FAUSSNER A, 2003, AM J PHYSIOL, V284, pH1909; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gabilondo AM, 1996, EUR J PHARMACOL, V307, P243, DOI 10.1016/0014-2999(96)00247-6; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; Rosendorff A, 2000, MOL BRAIN RES, V84, P90, DOI 10.1016/S0169-328X(00)00227-8; Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Wang JF, 1997, MOL PHARMACOL, V52, P306, DOI 10.1124/mol.52.2.306	28	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31268	31276		10.1074/jbc.M401796200	http://dx.doi.org/10.1074/jbc.M401796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15161928	hybrid			2022-12-27	WOS:000222726800046
J	Sinsheimer, R				Sinsheimer, R			Early steps on the DNA ladder - A recollection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							3-DIMENSIONAL FOURIER SYNTHESIS; DEOXYRIBONUCLEIC-ACID; ENZYMATIC-SYNTHESIS		Univ Calif Santa Barbara, Dept Mol Cell & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Sinsheimer, R (corresponding author), Univ Calif Santa Barbara, Dept Mol Cell & Dev Biol, Santa Barbara, CA 93106 USA.	sinsheim@lifesci.ucsb.edu						Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; BENBOW RM, 1971, J VIROL, V7, P549, DOI 10.1128/JVI.7.5.549-558.1971; Chargaff E, 1955, NUCLEIC ACIDS, P307; CHEO PC, 1959, P NATL ACAD SCI USA, V45, P305, DOI 10.1073/pnas.45.3.305; COHN WE, 1950, J AM CHEM SOC, V72, P1471, DOI 10.1021/ja01160a012; CULLIS AF, 1962, PROC R SOC LON SER-A, V265, P161, DOI 10.1098/rspa.1962.0002; FIERS W, 1962, J MOL BIOL, V5, P424, DOI 10.1016/S0022-2836(62)80031-X; FREIFELDER D, 1964, SCIENCE, V146, P254, DOI 10.1126/science.146.3641.254; FRIESEN BS, 1959, J MOL BIOL, V1, P321, DOI 10.1016/S0022-2836(59)80013-9; GOULIAN M, 1967, P NATL ACAD SCI USA, V58, P2321, DOI 10.1073/pnas.58.6.2321; GUTHRIE GD, 1960, J MOL BIOL, V2, P297, DOI 10.1016/S0022-2836(60)80026-5; HOLLAENDER A., 1941, Cold Spring Harbor Symposia on Quantitative Biology, V9, P179; HOPKINS GR, 1955, BIOCHIM BIOPHYS ACTA, V17, P476, DOI 10.1016/0006-3002(55)90410-8; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; KLEINSCHMIDT ALBRECHT K., 1963, SCIENCE, V142, P961, DOI 10.1126/science.142.3594.961; LEHMAN IR, 1958, P NATL ACAD SCI USA, V44, P1191, DOI 10.1073/pnas.44.12.1191; Loofbourow JR, 1940, REV MOD PHYS, V12, P0267, DOI 10.1103/RevModPhys.12.267; MIRSKY AE, 1946, J GEN PHYSIOL, V30, P117, DOI 10.1085/jgp.30.2.117; NORTHROP TG, 1954, J CHEM PHYS, V22, P703, DOI 10.1063/1.1740154; PAULING L, 1953, P NATL ACAD SCI USA, V39, P84, DOI 10.1073/pnas.39.2.84; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SANGER F, 1952, ADV PROTEIN CHEM, V7, P1, DOI 10.1016/S0065-3233(08)60017-0; Sertic V, 1935, CR SOC BIOL, V119, P1270; SINSHEIMER RL, 1955, BIOCHIM BIOPHYS ACTA, V18, P13, DOI 10.1016/0006-3002(55)90003-2; SINSHEIMER RL, 1952, J BIOL CHEM, V198, P293; SINSHEIMER RL, 1952, J AM CHEM SOC, V74, P283, DOI 10.1021/ja01121a531; SINSHEIMER RL, 1957, RADIAT RES, V6, P121, DOI 10.2307/3570592; SINSHEIMER RL, 1956, P NATL ACAD SCI USA, V42, P502, DOI 10.1073/pnas.42.8.502; SINSHEIMER RL, 1954, SCIENCE, V120, P551, DOI 10.1126/science.120.3119.551; SINSHEIMER RL, 1954, RADIAT RES, V1, P505, DOI 10.2307/3570217; SINSHEIMER RL, 1951, SCIENCE, V114, P42, DOI 10.1126/science.114.2950.42; SINSHEIMER RL, 1959, J MOL BIOL, V1, P43, DOI 10.1016/S0022-2836(59)80006-1; SINSHEIMER RL, 1954, J BIOL CHEM, V208, P445; SINSHEIMER RL, 1959, J MOL BIOL, V1, P37, DOI 10.1016/S0022-2836(59)80005-X; SINSHEIMER ROBERT L., 1962, JOUR MOLECULAR BIOL, V4, P142, DOI 10.1016/S0022-2836(62)80047-3; Stadler LJ, 1942, GENETICS, V27, P84; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	38	1	1	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40247	40251		10.1074/jbc.X400004200	http://dx.doi.org/10.1074/jbc.X400004200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15169775	hybrid			2022-12-27	WOS:000223916800001
J	Reynolds, PR; Mucenski, ML; Le Cras, TD; Nichols, WC; Whitsett, JA				Reynolds, PR; Mucenski, ML; Le Cras, TD; Nichols, WC; Whitsett, JA			Midkine is regulated by hypoxia and causes pulmonary vascular remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; GROWTH-FACTOR MIDKINE; SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; LUNG MORPHOGENESIS; TRANSGENIC MICE; TRANSCRIPTION FACTORS; MOUSE EMBRYOGENESIS; HIGH-ALTITUDE; BETA-CATENIN	Midkine (MK) is expressed in a precise temporal-spatial pattern during lung morphogenesis; however, its role in pulmonary homeostasis is unknown. Increased MK staining and mRNA expression were observed in the lungs of hypoxia-susceptible CAST/eiJ mice during hypoxia. MK expression was induced by hypoxia in cell lines in vitro. Because the transcription factor hypoxia-inducible factor-1alpha (HIF-1alpha) modulates cellular responses to hypoxia, we tested whether increased expression of MK in the lung was mediated by HIF-1alpha. HIF-1alpha enhanced the transcription of MK, acting on HIF-1alpha regulatory elements located in the MK gene promoter. Site-directed mutagenesis of the 3' HIF response element in the MK promoter blocked the stimulatory effects of HIF-1alpha. To directly assess the role of MK on lung morphogenesis, transgenic mice were generated in which MK was expressed in the respiratory epithelial cells of the developing lung. MK increased muscularization of small pulmonary arteries, increasing alpha-smooth muscle actin and caldesmon staining and the expression of myocardin. MK directly enhanced the expression of myocardin and the smooth muscle-specific genes alpha-smooth muscle actin, calponin, and SM-22 in vascular smooth muscle precursor cells. Expression of MK in the respiratory epithelium is regulated by hypoxia and HIF-1alpha. These data provide a model wherein the respiratory epithelium responds to hypoxia via HIF-1alpha-dependent regulation of MK, enhancing myocardin expression to influence pulmonary vascular gene expression.	Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Pulm Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Human Genet, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Whitsett, JA (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org		Le Cras, Timothy/0000-0001-8538-2703; Reynolds, Paul/0000-0002-0931-3025	NHLBI NIH HHS [HL 75770, HL 72058, HL 56387, HL 38859] Funding Source: Medline; NICHD NIH HHS [HD 07463] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, R01HL038859, P50HL056387, P01HL072058, R37HL038859, R01HL075770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akeson AL, 2000, DEV DYNAM, V217, P11, DOI 10.1002/(SICI)1097-0177(200001)217:1<11::AID-DVDY2>3.0.CO;2-L; Arakawa E, 2000, FEBS LETT, V481, P193, DOI 10.1016/S0014-5793(00)01995-5; Arrigoni FI, 2003, CIRCULATION, V107, P1195, DOI 10.1161/01.CIR.0000051466.00227.13; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Choudhuri R, 1997, CANCER RES, V57, P1814; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; GHARMA ZW, 2003, CLEVE CLIN J MED S1, V70, P2; Gorenflo M, 2003, CARDIOL YOUNG, V13, P219, DOI 10.1017/S1047951103000453; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kaplan F, 2003, AM J RESP CELL MOL, V28, P33, DOI 10.1165/rcmb.2002-0047OC; Kulikova N, 2003, J MUSCLE RES CELL M, V24, P7, DOI 10.1023/A:1024843409429; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; Le Cras TD, 2003, AM J PHYSIOL-LUNG C, V285, pL1046, DOI 10.1152/ajplung.00045.2003; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Llorente-Cortes V, 2002, CIRCULATION, V106, P3104, DOI 10.1161/01.CIR.0000041434.28573.0B; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Niermeyer S, 2003, HIGH ALT MED BIOL, V4, P225, DOI 10.1089/152702903322022820; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RABINOVITCH M, 1979, AM J PHYSIOL, V236, P818; Reynolds PR, 2003, DEV DYNAM, V227, P227, DOI 10.1002/dvdy.10304; Rossi GP, 2002, CARDIOVASC RES, V55, P178, DOI 10.1016/S0008-6363(02)00400-5; Schoene RB, 1999, ADV EXP MED BIOL, V474, P47; Schweizer L, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-4; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shibata Y, 2002, MOL CELL BIOL, V22, P6788, DOI 10.1128/MCB.22.19.6788-6796.2002; Takada T, 1997, J BIOCHEM-TOKYO, V122, P453; Thomas BJ, 2003, EUR J PHARMACOL, V477, P153, DOI 10.1016/j.ejphar.2003.08.015; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; Toriyama K, 1997, DIFFERENTIATION, V61, P161, DOI 10.1046/j.1432-0436.1997.6130161.x; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; Veyssier-Belot C, 1999, CARDIOVASC RES, V44, P274, DOI 10.1016/S0008-6363(99)00230-8; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; YU H, 1993, J HYPERTENS, V11, P1347, DOI 10.1097/00004872-199312000-00005; Zaidi SHE, 2002, CIRCULATION, V105, P516, DOI 10.1161/hc0402.102866; Zhu H, 2002, NEPHROL DIAL TRANSPL, V17, P3, DOI 10.1093/ndt/17.suppl_1.3	51	119	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37124	37132		10.1074/jbc.M405254200	http://dx.doi.org/10.1074/jbc.M405254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15197188	hybrid			2022-12-27	WOS:000223453600116
J	Villafuerte, BC; Phillips, LS; Rane, MJ; Zhao, WD				Villafuerte, BC; Phillips, LS; Rane, MJ; Zhao, WD			Insulin-response element-binding protein 1 - A novel Akt substrate involved in transcriptional action of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; FORKHEAD; IDENTIFICATION; FKHR; PHOSPHORYLATION; TRANSDUCTION; RECOGNITION; METABOLISM; CLEAVAGE; CLONING	Although the cis-acting elements that mediate the actions of insulin on gene transcription have been defined for a significant number of genes, the transcription factors responsible for the transactivation of these target sequences remain unknown. In this report, we identified a novel transcription factor that binds and transactivates the insulin-response elements of the insulin-like growth factor-binding protein-3 and other insulin responsive genes. This factor is a target of insulin signal transduction downstream of the phosphatidylinositol 3'-kinase/protein kinase B (Akt) pathway. Akt phosphorylates this factor in vivo and in vitro. Changes in expression level, phosphorylation, and nuclear translocation modulate the transactivation effects of the factor, and its expression is decreased in conditions of diabetes and insulin deficiency. Identification of a novel target of Akt that appears to mediate signals specific for insulin action should provide further insight into the mechanism of insulin action at the genomic level.	Univ Louisville, Dept Med, Div Endocrinol & Metab, Louisville, KY 40202 USA; Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Atlanta, GA 30322 USA; Univ Louisville, Dept Med, Div Nephrol, Louisville, KY 40202 USA	University of Louisville; Emory University; University of Louisville	Villafuerte, BC (corresponding author), Univ Louisville, Dept Med, Div Endocrinol & Metab, Louisville, KY 40202 USA.	bcvill01@louisville.edu			NIDDK NIH HHS [DK 52965] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052965] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; Baker NE, 2000, BIOESSAYS, V22, P264, DOI 10.1002/(SICI)1521-1878(200003)22:3<264::AID-BIES8>3.0.CO;2-M; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Estienne V, 1999, J BIOL CHEM, V274, P35313, DOI 10.1074/jbc.274.50.35313; Heldin CH, 2001, SCIENCE, V294, P2111, DOI 10.1126/science.1067628; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kimble J, 1998, TRENDS BIOCHEM SCI, V23, P353, DOI 10.1016/S0968-0004(98)01263-8; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Krammer A, 1999, P NATL ACAD SCI USA, V96, P1351, DOI 10.1073/pnas.96.4.1351; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Lim SP, 2000, J VIROL, V74, P1632, DOI 10.1128/JVI.74.4.1632-1640.2000; Marino-Buslje C, 1998, FEBS LETT, V441, P331, DOI 10.1016/S0014-5793(98)01509-9; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; SCHMID RM, 1992, AM J PHYSIOL, V262, pG971, DOI 10.1152/ajpgi.1992.262.6.G971; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; Unterman T., 1995, Progress in Growth Factor Research, V6, P119, DOI 10.1016/0955-2235(95)00020-8; Villafuerte BC, 1996, MOL ENDOCRINOL, V10, P622, DOI 10.1210/me.10.6.622; VILLAFUERTE BC, 1994, ENDOCRINOLOGY, V134, P2044, DOI 10.1210/en.134.5.2044; Villafuerte BC, 1997, J BIOL CHEM, V272, P5024, DOI 10.1074/jbc.272.8.5024; VILLAFUERTE BC, 1991, DIABETES, V40, P837, DOI 10.2337/diabetes.40.7.837; Zhu JL, 1999, ENDOCRINOLOGY, V140, P4761, DOI 10.1210/en.140.10.4761; Zhu JL, 2000, MOL CELL ENDOCRINOL, V164, P205, DOI 10.1016/S0303-7207(00)00207-0	40	20	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36650	36659		10.1074/jbc.M404349200	http://dx.doi.org/10.1074/jbc.M404349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194686	hybrid			2022-12-27	WOS:000223453600064
J	Ahn, SK; Shenoy, SK; Wei, HJ; Lefkowitz, RJ				Ahn, SK; Shenoy, SK; Wei, HJ; Lefkowitz, RJ			Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; MAP KINASE; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT DEGRADATION; CLATHRIN ADAPTER; TRANSDUCTION; INTERNALIZATION; BETA-ARRESTIN-2; ENDOCYTOSIS	The seven-membrane-spanning angiotensin II type 1A receptor activates the mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 (ERK1/2) by distinct pathways dependent on either G protein (likely G(q)/G(11)) or beta-arrestin2. Here we sought to distinguish the kinetic and spatial patterns that characterize ERK1/2 activated by these two mechanisms. We utilized beta-arrestin RNA interference, the protein kinase C inhibitor Ro-31-8425, a mutant angiotensin II receptor (DRY/AAY), and a mutant angiotensin II peptide (SII-angiotensin), which are incapable of activating G proteins, to isolate the two pathways in HEK-293 cells. G protein-dependent activation was rapid (peak<2 min), quite transient (t(1/2) similar to 2 min), and led to nuclear translocation of the activated ERK1/2 as assessed by confocal microscopy. In contrast, beta-arrestin2-dependent activation was slower (peak 5-10 min), quite persistent with little decrement noted out to 90 min, and entirely confined to the cytoplasm. Moreover, ERK1/2 activated via beta-arrestin2 accumulated in a pool of cytoplasmic endosomal vesicles that also contained the internalized receptors and beta-arrestin. Such differential regulation of the temporal and spatial patterns of ERK1/2 activation via these two pathways strongly implies the existence of distinct physiological endpoints.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R01HL070631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 70631, R01 HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; Gaborik Z, 2003, ENDOCRINOLOGY, V144, P2220, DOI 10.1210/en.2002-0135; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LEE RM, 1992, J BIOL CHEM, V267, P1088; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; RAY LB, 1988, J BIOL CHEM, V263, P12721; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100	40	404	414	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35518	35525		10.1074/jbc.M405878200	http://dx.doi.org/10.1074/jbc.M405878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205453	hybrid			2022-12-27	WOS:000223303400046
J	Gorr, TA; Tomita, T; Wappner, P; Bunn, HF				Gorr, TA; Tomita, T; Wappner, P; Bunn, HF			Regulation of Drosophila hypoxia-inducible factor (HIF) activity in SL2 cells - Identification of a hypoxia-induced variant isoform of the HIF alpha homolog gene similar	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BHLH-PAS PROTEIN; TUMOR-SUPPRESSOR PROTEIN; ARYL-HYDROCARBON RECEPTOR; LOOP-HELIX PROTEIN; DNA METHYLATION; ERYTHROPOIETIN GENE; CNS MIDLINE; TRANSCRIPTIONAL REGULATION; DEGRADATION DOMAIN; FACTOR 1-ALPHA	Although hypoxia-inducible factor-alpha (HIFalpha) subunit-specific hydroxylation and proteolytic breakdown explain the binary switch between the presence (hypoxia) and absence (normoxia) of HIFs, little is known of the mechanisms that fine-tune HIF activity under constant, rather than changing, oxygen tensions. Here, we report that the Drosophila HIFalpha homolog, the basic helix-loop-helix/PAS protein Sima ((Sim) under bar il (a) under barr), in hypoxic cultures of SL2 cells is expressed in full-length (fl) and splice variant (sv) isoforms. The following evidence supports the role of flSima as functional HIFalpha and the role of SL2 HIF as a transcriptional activator or suppressor. The pO(2) dependence of Sima abundance matched that of HIF activity. HIF-dependent changes in candidate target gene expression were detected through variously effective stimuli: hypoxia (strong) > iron chelation, e. g. desferrioxamine (moderate) much greater than transition metals, e. g. cobalt similar or equal to normoxia (ineffective). Sima overexpression augmented hypoxic induction or suppression of different targets. In addition to the full-length exon 1-12 transcript yielding the 1510-amino acid HIFalpha homolog, the sima gene also expressed, specifically under hypoxia, an exon 1-7/12 splice variant, which translated into a 426-amino acid Sima truncation termed svSima. svSima contains basic helix-loop-helix and PAS sequences identical to those of flSima, but, because of deletion of exons 8-11, lacks the oxygen-dependent degradation domain and nuclear localization signals. Overexpressed svSima failed to transactivate reporter genes. However, it attenuated HIF (Sima.Tango)-stimulated reporter expression in a dose-dependent manner. Thus, svSima has the potential to regulate Drosophila HIF function under steady and hypoxic pO(2) by creating a cytosolic sink for the Sima partner protein Tango.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, Boston, MA 02115 USA; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Consejo Nacl Invest Cient & Tecn, Inst Leloir, RA-1405 Buenos Aires, DF, Argentina	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires	Bunn, HF (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, 221 Longwood Ave, Boston, MA 02115 USA.	hfbunn@rics.bwh.harvard.edu		Gorr, Thomas/0000-0002-6023-4234; Tomita, Takeshi/0000-0001-6815-2244; Wappner, Pablo/0000-0003-1517-0742	NIDDK NIH HHS [R01 DK41234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbuShumays RL, 1997, DEV GENET, V20, P11, DOI 10.1002/(SICI)1520-6408(1997)20:1<11::AID-DVG2>3.0.CO;2-C; Bacon NCM, 1998, BIOCHEM BIOPH RES CO, V249, P811, DOI 10.1006/bbrc.1998.9234; BELL J, 1988, MOL CELL BIOL, V8, P91, DOI 10.1128/MCB.8.1.91; Bruening W, 1999, CANCER RES, V59, P4973; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Burmester T, 1999, MOL BIOL EVOL, V16, P1809, DOI 10.1093/oxfordjournals.molbev.a026093; CHADWICK LEIGH E., 1940, PHYSIOL ZOOL, V13, P398; CHUNG YT, 1990, MOL CELL BIOL, V10, P6172, DOI 10.1128/MCB.10.12.6172; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; CSIK L., 1939, ZEITSCHR VERGLEICH PHYSIOL, V27, P304; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DiGregorio PJ, 2001, J BIOL CHEM, V276, P1930, DOI 10.1074/jbc.M003911200; Douglas RM, 2001, AM J PHYSIOL-REG I, V280, pR1555, DOI 10.1152/ajpregu.2001.280.5.R1555; Ebert BL, 1999, BLOOD, V94, P1864; Emmons RB, 1999, DEVELOPMENT, V126, P3937; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gorr TA, 2004, J BIOL CHEM, V279, P36038, DOI 10.1074/jbc.M403981200; GORR TA, 2003, OXYGEN SENSING RESPO, P175; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grieshaber M K, 1994, Rev Physiol Biochem Pharmacol, V125, P43, DOI 10.1007/BFb0030909; GUANG LW, 1993, P NATL ACAD SCI USA, V90, P4304; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Haddad GG, 2000, J APPL PHYSIOL, V88, P1481, DOI 10.1152/jappl.2000.88.4.1481; Hankeln T, 2002, J BIOL CHEM, V277, P29012, DOI 10.1074/jbc.M204009200; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Jiang L, 2003, MOL CELL BIOL, V23, P5625, DOI 10.1128/MCB.23.16.5625-5637.2003; Keister M., 1974, P469; KLAGSBRUN M, 1976, CANCER RES, V36, P110; Krishnan SN, 1997, J INSECT PHYSIOL, V43, P203, DOI 10.1016/S0022-1910(96)00084-4; Kunert N, 2003, DEVELOPMENT, V130, P5083, DOI 10.1242/dev.00716; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Ledent V, 2001, GENOME RES, V11, P754, DOI 10.1101/gr.177001; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LOCKE M, 1958, Q J MICROSC SCI, V99, P373; LONG EO, 1980, J MOL BIOL, V138, P873, DOI 10.1016/0022-2836(80)90070-4; LOUDON C, 1988, J INSECT PHYSIOL, V34, P97, DOI 10.1016/0022-1910(88)90160-6; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Lyko F, 2001, TRENDS GENET, V17, P169, DOI 10.1016/S0168-9525(01)02234-X; Ma E, 1999, MOL BRAIN RES, V73, P11, DOI 10.1016/S0169-328X(99)00224-7; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mazure NM, 2002, CANCER RES, V62, P1158; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; Peyrefitte S, 2001, MECH DEVELOP, V104, P99, DOI 10.1016/S0925-4773(01)00360-4; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ward MP, 1998, DEVELOPMENT, V125, P1599; Wegener G., 1988, OXYGEN SENSING TISSU, P13, DOI [10.1007/978-3-642-83444-8_2, DOI 10.1007/978-3-642-83444-8_2]; WEGENER G, 1993, SURVIVING HYPOXIA ME, P417; Wenger RH, 2000, J EXP BIOL, V203, P1253; WENGER RH, 1997, BIOL CHEM, V378, P1; WHARTON KA, 1994, DEVELOPMENT, V120, P3563; WIGGLESWORTH VB, 1954, Q J MICROSC SCI, V95, P115; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	87	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36048	36058		10.1074/jbc.M405077200	http://dx.doi.org/10.1074/jbc.M405077200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169765	hybrid			2022-12-27	WOS:000223303400107
J	Banci, L; Bertini, I; Cantini, F; Ciofi-Baffoni, S; Gonnelli, L; Mangani, S				Banci, L; Bertini, I; Cantini, F; Ciofi-Baffoni, S; Gonnelli, L; Mangani, S			Solution structure of Cox11, a novel type of beta-immunoglobulin-like fold involved in Cu-B site formation of cytochrome C oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; TORSION ANGLE DYNAMICS; COPPER CHAPERONE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; NMR STRUCTURE; SUPEROXIDE-DISMUTASE; REGULATORY DOMAIN; BACILLUS-SUBTILIS; PROTEIN NMR	Cytochrome c oxidase assembly process involves many accessory proteins including Cox11, which is a copper-binding protein required for Cu incorporation into the Cu-B site of cytochrome c oxidase. In a genome wide search, a number of Cox11 homologs are found in all of the eukaryotes with complete genomes and in several Gram-negative bacteria. All of them possess a highly homologous soluble domain and contain an N-terminal fragment that anchors the protein to the membrane. An anchor-free construct of 164 amino acids was obtained from Sinorhizobium meliloti, and the first structure of this class of proteins is reported here. The apoform has an immunoglobulin-like fold with a novel type of beta-strand organization. The copper binding motif composed of two highly conserved cysteines is located on one side of the beta-barrel structure. The apoprotein is monomeric in the presence of dithiothreitol, whereas it dimerizes in the absence of the reductant. When copper(I) binds, NMR and extended x-ray absorption fine structure (EXAFS) data indicate a dimeric protein state with two thiolates bridging two copper(I) ions. The present results advance the knowledge on the poorly understood molecular aspects of cytochrome c oxidase assembly.	Univ Florence, CERM, Magnet Resonance Ctr, I-50019 Florence, Italy; Univ Florence, Dept Chem, I-50019 Florence, Italy; Univ Siena, Dept Chem, I-53100 Siena, Italy	University of Florence; University of Florence; University of Siena	Bertini, I (corresponding author), Univ Florence, CERM, Magnet Resonance Ctr, Via L Sacconi 6, I-50019 Florence, Italy.	ivanobertini@cerm.unifi.it	Ciofi-Baffoni, Simone/AAH-9778-2021; Cantini, Francesca/O-1220-2015	Cantini, Francesca/0000-0003-0526-6732; BANCI, LUCIA/0000-0003-0562-5774; Ciofi Baffoni, Simone/0000-0002-2376-3321				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; ATKINSON ER, 1985, INORG CHIM A-ART LET, V100, P285, DOI 10.1016/S0020-1693(00)85299-8; Banci L, 2003, BIOCHEMISTRY-US, V42, P2467, DOI 10.1021/bi0205810; Banci L, 2002, EUR J BIOCHEM, V269, P1905, DOI 10.1046/j.1432-1033.2002.02840.x; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Bertinia I, 2003, J BIOMOL NMR, V26, P355, DOI 10.1023/A:1024092421649; Binsted N, 1996, J SYNCHROTRON RADIAT, V3, P185, DOI 10.1107/S0909049596005651; BLACKBURN NJ, 1989, INORG CHEM, V28, P1349, DOI 10.1021/ic00306a027; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Bullock TL, 1996, J MOL BIOL, V263, P284, DOI 10.1006/jmbi.1996.0575; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; Einstein A, 1956, INVESTIGATIONS THEOR; Eisses JF, 2000, BIOCHEMISTRY-US, V39, P7337, DOI 10.1021/bi000690j; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; LYTLE FW, 1989, PHYS REV B, V11, P2795; Mattatall NR, 2000, J BIOL CHEM, V275, P28802, DOI 10.1074/jbc.M002741200; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; PARNES JR, 1989, ADV IMMUNOL, V44, P265; Pearlman DA, 1997, AMBER 5 0; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; PETTIFER RF, 1985, J APPL CRYSTALLOGR, V18, P404, DOI 10.1107/S0021889885010627; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; Stokes G. G., 1856, T CAMBRIDGE PHILOS S, V9, P5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Zamoyska R, 1998, CURR OPIN IMMUNOL, V10, P82, DOI 10.1016/S0952-7915(98)80036-8	64	83	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34833	34839		10.1074/jbc.M403655200	http://dx.doi.org/10.1074/jbc.M403655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181013	hybrid			2022-12-27	WOS:000223134800092
J	Erler, I; Hirnet, D; Wissenbach, U; Flockerzi, V; Niemeyer, BA				Erler, I; Hirnet, D; Wissenbach, U; Flockerzi, V; Niemeyer, BA			Ca2+-selective transient receptor potential V channel architecture and function require a specific ankyrin repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; K+ CHANNELS; VANILLOID RECEPTOR-1; CAT-LIKE; TRPV6; EXPRESSION; PROTEIN; ASSOCIATION; COMPLEX; DOMAIN	Transient receptor potential (TRP) proteins form cation-conducting ion channels with currently 28 known genes encoding TRP channel monomers in mammals. These monomers are thought to coassemble to form homo- or heterotetrameric channels, but the signals governing their assembly are unknown. Within the TRPV subgroup, TRPV5 and TRPV6 show exclusive calcium selectivity and play an important role in calcium uptake. To identify signals that mediate assembly of functional TRPV6, we screened domains for self-association using co-immunoprecipitation, sucrose gradient centrifugation, bacterial two-hybrid assays, and patch clamp analysis. Of the two identified interaction domains within the N-terminal region, we showed that the first domain encompassing the third ankyrin repeat is the stringent requirement for physical assembly of TRPV6 subunits and when transferred to an unrelated protein enables its interaction with TRPV6. Deletion of this repeat or mutation of critical residues within this repeat rendered nonfunctional channels that do not co-immunoprecipitate or form tetramers. Suppression of dominant-negative inhibitors of TRPV6-specific currents was achieved by deletion of ankyrin (ANK) 3. We propose that the third ANK repeat initiates a molecular zippering process that proceeds past the fifth ANK repeat and creates an intracellular anchor that is necessary for functional subunit assembly.	Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany	Saarland University	Niemeyer, BA (corresponding author), Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, Geb 46, D-66421 Homburg, Germany.	barbara.niemeyer@uniklinik-saarland.de	Niemeyer, Barbara A./AAL-8972-2021	Niemeyer, Barbara A./0000-0002-6963-0575				Amiri H, 2003, CELL CALCIUM, V33, P463, DOI 10.1016/S0143-4160(03)00061-7; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Fixemer T, 2003, ONCOGENE, V22, P7858, DOI 10.1038/sj.onc.1206895; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Hirnet D, 2003, CELL CALCIUM, V33, P509, DOI 10.1016/S0143-4160(03)00066-6; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Jahnel R, 2001, EUR J BIOCHEM, V268, P5489, DOI 10.1046/j.1432-1033.2001.02500.x; Jonas-Straube E, 2001, J BIOL CHEM, V276, P24654, DOI 10.1074/jbc.M100153200; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mery L, 2002, J CELL SCI, V115, P3497; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MONTELL C, 2001, SCI STKE, V90, P1; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Peng JB, 2000, BIOCHEM BIOPH RES CO, V278, P326, DOI 10.1006/bbrc.2000.3716; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Sheng ZF, 1997, BIOCHEMISTRY-US, V36, P15501; Strang C, 2003, J BIOL CHEM, V278, P31361, DOI 10.1074/jbc.M304268200; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200	30	101	108	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34456	34463		10.1074/jbc.M404778200	http://dx.doi.org/10.1074/jbc.M404778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192090	hybrid			2022-12-27	WOS:000223134800047
J	Hermit, MB; Greenwood, JR; Brauner-Osborne, H				Hermit, MB; Greenwood, JR; Brauner-Osborne, H			Mutation-induced quisqualic acid and ibotenic acid affinity at the metabotropic glutamate receptor subtype 4 - Ligand selectivity results from a synergy of several amino acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; MGLUR4 SUBTYPE; ACTIVATION; MUTAGENESIS; EXPRESSION; POCKET; RAT	The metabotropic glutamate receptors (mGluRs) are key modulators of excitatory neurotransmission in the central nervous system. The eight mGluR subtypes are seven trans-membrane-spanning proteins that possess a large extracellular amino-terminal domain in which the endogenous ligand binding pocket resides. In this study, we have identified four non-conserved amino acid residues that are essential for differentiating mGluR1 from mGluR4. Our approach has been to increase the affinity of the classic mGluR1 agonists, quisqualic acid and ibotenic acid, at mGluR4 by making various point mutations that mimicked mGluR1 residues. Based on ligand docking to homology models, the non-conserved residues, Lys-74, Glu-287, Ser-313, and Lys-317, were chosen for the mutational studies and all of the mutations proved capable of partially or completely restoring the affinities of the ligands. In particular, the mutations K74Y and K317R induced dramatic triple-order-of-magnitude increases in the affinity of ibotenic acid at mGluR4, making the affinity equivalent to that of mGluR1. Furthermore, the affinity of quisqualic acid at mGluR4 was increased to the same level as mGluR1 by the two double mutations, K74Y/K317R and K74Y/E287G. Advanced analysis of ligand conformation and docking procedures were used for the interpretation of these results. The study shows that mGluR subtype selectivity results from a complex interplay of residues shaping the binding pocket, rather than being attributable to a single specific ligand-receptor interaction.	Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark	University of Copenhagen	Brauner-Osborne, H (corresponding author), Danish Univ Pharmaceut Sci, Dept Med Chem, Univ Pk 2, DK-2100 Copenhagen, Denmark.	hbo@molpharm.net	Bräuner-Osborne, Hans/D-7260-2011	Bräuner-Osborne, Hans/0000-0001-9495-7388				Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Brauner-Osborne H, 2000, J MED CHEM, V43, P2609, DOI 10.1021/jm000007r; Brauner-Osborne H, 1998, EUR J PHARMACOL, V350, P311, DOI 10.1016/S0014-2999(98)00246-5; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Eriksen L, 1995, BRIT J PHARMACOL, V116, P3279, DOI 10.1111/j.1476-5381.1995.tb15136.x; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hermit MB, 2004, EUR J PHARMACOL, V486, P241, DOI 10.1016/j.ejphar.2003.12.033; Holscher C, 1999, NEUROSCI BIOBEHAV R, V23, P399, DOI 10.1016/S0149-7634(98)00045-1; Jensen AA, 2000, EUR J PHARMACOL, V397, P247, DOI 10.1016/S0014-2999(00)00283-1; Jin RS, 2002, BIOCHEMISTRY-US, V41, P15635, DOI 10.1021/bi020583k; Kowal D, 1998, NEUROPHARMACOLOGY, V37, P179, DOI 10.1016/S0028-3908(98)00011-2; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Malherbe P, 2001, MOL PHARMACOL, V60, P944, DOI 10.1124/mol.60.5.944; Mathiesen JM, 2003, BRIT J PHARMACOL, V138, P1026, DOI 10.1038/sj.bjp.0705159; Monastyrskaia K, 1999, BRIT J PHARMACOL, V128, P1027, DOI 10.1038/sj.bjp.0702885; MOTULSKY H, 1997, CURRENT PROTOCOLS NE; Mutel V, 2000, J NEUROCHEM, V75, P2590, DOI 10.1046/j.1471-4159.2000.0752590.x; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pagano A, 2001, J NEUROSCI, V21, P1189; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Rosemond E, 2002, J BIOL CHEM, V277, P7333, DOI 10.1074/jbc.M110476200; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; THOMSEN C, 1993, BRAIN RES, V619, P22, DOI 10.1016/0006-8993(93)91592-G; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Yao Y, 2003, J NEUROCHEM, V86, P947, DOI 10.1046/j.1471-4159.2003.01906.x	32	16	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34811	34817		10.1074/jbc.M404109200	http://dx.doi.org/10.1074/jbc.M404109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184361	hybrid			2022-12-27	WOS:000223134800089
J	Kennedy, MN; Mullen, GED; Leifer, CA; Lee, C; Mazzoni, A; Dileepan, KN; Segal, DM				Kennedy, MN; Mullen, GED; Leifer, CA; Lee, C; Mazzoni, A; Dileepan, KN; Segal, DM			A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL LIPOPOLYSACCHARIDE; DENDRITIC CELLS; CUTTING EDGE; TLR4; ENDOTOXIN; CONFERS; MICE; RESPONSIVENESS; RECOGNITION; EXPRESSION	MD-2, a glycoprotein that is essential for the innate response to lipopolysaccharide (LPS), binds to both LPS and the extracellular domain of Toll-like receptor 4 (TLR4). Following synthesis, MD-2 is either secreted directly into the medium as a soluble, active protein, or binds directly to TLR4 in the endoplasmic reticulum before migrating to the cell surface. Here we investigate the function of the secreted form of MD-2. We show that secreted MD-2 irreversibly loses activity over a 24-h period at physiological temperature. LPS, but not lipid A, prevents this loss in activity by forming a stable complex with MD-2, in a CD14-dependent process. Once formed, the stable MD-2 . LPS complex activates TLR4 in the absence of CD14 or free LPS indicating that the activating ligand of TLR4 is the MD-2 . LPS complex. Finally we show that the MD-2 . LPS complex, but not LPS alone, induces epithelial cells, which express TLR4 but not MD-2, to secrete interleukin-6 and interleukin-8. We propose that the soluble MD-2 . LPS complex plays a crucial role in the LPS response by activating epithelial and other TLR4(+)/MD-2(-) cells in the inflammatory microenvironment.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Kansas, Med Ctr, Dept Med, Kansas City, KS 66160 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Kansas; University of Kansas Medical Center	Segal, DM (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B36, Bethesda, MD 20892 USA.	dave_segal@nih.gov			NATIONAL CANCER INSTITUTE [Z01BC009254, Z01BC009255, ZIABC009254, ZICBC009255] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Abreu MT, 2003, J ENDOTOXIN RES, V9, P322, DOI 10.1179/096805103225002593; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kawasaki K, 2001, J IMMUNOL, V166, P11, DOI 10.4049/jimmunol.166.1.11; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; Muroi M, 2002, INFECT IMMUN, V70, P3546, DOI 10.1128/IAI.70.7.3546-3550.2002; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Talreja J, 2003, FASEB J, V17, pC57; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955	29	95	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34698	34704		10.1074/jbc.M405444200	http://dx.doi.org/10.1074/jbc.M405444200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175334	hybrid			2022-12-27	WOS:000223134800075
J	Mandard, S; Zandbergen, F; Tan, NS; Escher, P; Patsouris, D; Koenig, W; Kleemann, R; Bakker, A; Veenman, F; Wahli, W; Muller, M; Kersten, S				Mandard, S; Zandbergen, F; Tan, NS; Escher, P; Patsouris, D; Koenig, W; Kleemann, R; Bakker, A; Veenman, F; Wahli, W; Muller, M; Kersten, S			The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOPOIETIN-LIKE PROTEIN-4; NECROSIS-FACTOR-ALPHA; ADIPOCYTE DIFFERENTIATION; PROPROTEIN CONVERTASES; LIPOPROTEIN-LIPASE; LIPID-METABOLISM; SECRETORY FACTOR; IN-VIVO; GENE; EXPRESSION	The fasting-induced adipose factor (FIAF, ANGPTL4, PGAR, HFARP) was previously identified as a novel adipocytokine that was up-regulated by fasting, by peroxisome proliferator-activated receptor agonists, and by hypoxia. To further characterize FIAF, we studied regulation of FIAF mRNA and protein in liver and adipose cell lines as well as in human and mouse plasma. Expression of FIAF mRNA was up-regulated by peroxisome proliferator-activated receptor alpha( PPARalpha) and PPARbeta/delta agonists in rat and human hepatoma cell lines and by PPARgamma and PPARbeta/delta agonists in mouse and human adipocytes. Transactivation, chromatin immunoprecipitation, and gel shift experiments identified a functional PPAR response element within intron 3 of the FIAF gene. At the protein level, in human and mouse blood plasma, FIAF was found to be present both as the native protein and in a truncated form. Differentiation of mouse 3T3-L1 adipocytes was associated with the production of truncated FIAF, whereas in human white adipose tissue and SGBS adipocytes, only native FIAF could be detected. Interestingly, truncated FIAF was produced by human liver. Treatment with fenofibrate, a potent PPARalpha agonist, markedly increased plasma levels of truncated FIAF, but not native FIAF, in humans. Levels of both truncated and native FIAF showed marked interindividual variation but were not associated with body mass index and were not influenced by prolonged semistarvation. Together, these data suggest that FIAF, similar to other adipocytokines such as adiponectin, may partially exert its function via a truncated form.	Univ Wageningen & Res Ctr, Div Human Nutr, Nutr Metab & Genom Grp, NL-6700 EV Wageningen, Netherlands; Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Univ Basel, Pharmazentrum, Inst Physiol, CH-4056 Basel, Switzerland; Univ Ulm, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany; TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands	Wageningen University & Research; University of Lausanne; University of Basel; Ulm University; Netherlands Organization Applied Science Research; Maastricht University	Kersten, S (corresponding author), Univ Wageningen & Res Ctr, Div Human Nutr, Nutr Metab & Genom Grp, POB 8129, NL-6700 EV Wageningen, Netherlands.	sander.kersten@wur.nl	Muller, Michael/M-5724-2019; Wahli, Walter/I-3194-2019; Kersten, Sander/A-1116-2011; Tan, Nguan Soon/A-2220-2011; Muller, Michael/B-5795-2008; Wahli, Walter/B-1398-2009; Mandard, Stéphane/J-4800-2019	Muller, Michael/0000-0002-5930-9905; Kersten, Sander/0000-0003-4488-7734; Tan, Nguan Soon/0000-0003-0136-7341; Muller, Michael/0000-0002-5930-9905; Wahli, Walter/0000-0002-5966-9089; Mandard, Stéphane/0000-0002-7298-821X				Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Banerjee RR, 2001, J BIOL CHEM, V276, P25970, DOI 10.1074/jbc.M103109200; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Chen J, 2002, J ENDOCRINOL, V175, P499, DOI 10.1677/joe.0.1750499; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; Croissandeau G, 2002, J CELL SCI, V115, P1203; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; FREDERICH RC, 1992, HYPERTENSION, V19, P339, DOI 10.1161/01.HYP.19.4.339; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Ge HF, 2004, J BIOL CHEM, V279, P2038, DOI 10.1074/jbc.M307583200; Hansmannel F, 2003, BIOCHEM BIOPH RES CO, V311, P149, DOI 10.1016/j.bbrc.2003.09.185; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hukshorn CJ, 2003, AM J CLIN NUTR, V77, P771, DOI 10.1093/ajcn/77.4.771; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Mars M, 2003, INT J OBESITY, V27, P574, DOI 10.1038/sj.ijo.0802266; Ono M, 2003, J BIOL CHEM, V278, P41804, DOI 10.1074/jbc.M302861200; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V301, P604, DOI 10.1016/S0006-291X(02)03058-9; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Trayhurn P, 2000, AM J PHYSIOL-REG I, V279, pR2329, DOI 10.1152/ajpregu.2000.279.6.R2329; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	40	219	230	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34411	34420		10.1074/jbc.M403058200	http://dx.doi.org/10.1074/jbc.M403058200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190076	hybrid, Green Published			2022-12-27	WOS:000223134800042
J	Kennedy, KA; Gachelet, EG; Traxler, B				Kennedy, KA; Gachelet, EG; Traxler, B			Evidence for multiple pathways in the assembly of the Escherichia coli maltose transport complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ACETYLCHOLINE-RECEPTOR; INSERTION MUTANTS; MEMBRANE-PROTEINS; SYSTEM; ABC; PURIFICATION; MALFGK(2); SITES	We used the maltose transport complex MalFGK(2) of the Escherichia coli cytoplasmic membrane as a model for the study of the assembly of hetero-oligomeric membrane protein complexes. Analysis of other membrane protein complexes has led to a general model in which a unique, ordered pathway is followed from subunit monomers to a final oligomeric structure. In contrast, the studies reported here point to a fundamentally different mode for assembly of this transporter. Using coimmunoprecipitation and quantification of interacting partners, we found that all subunits of the maltose transport complex efficiently form heteromeric complexes in vivo. The pairwise complexes were stable over time, suggesting that they all represent assembly intermediates for the final MalFGK(2) transporter. These results indicate that several paths can lead to assembly of this oligomer. We also characterized MalF and MalG mutants that caused reduced association between some or all of the subunits of the complex with this assay. The mutant analysis highlights some important motifs for subunit contacts and suggests that the promiscuous interactions between these Mal proteins contribute to the efficiency of complex assembly. The behaviors of the wild type and mutant proteins in the co-immunoprecipitations support a model of multiple assembly pathways for this complex.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Traxler, B (corresponding author), Univ Washington, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	btraxler@u.washington.edu						AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Kennedy KA, 1999, J BIOL CHEM, V274, P6259, DOI 10.1074/jbc.274.10.6259; Landmesser H, 2002, BBA-BIOMEMBRANES, V1565, P64, DOI 10.1016/S0005-2736(02)00506-0; Lee MH, 1999, J BACTERIOL, V181, P6108, DOI 10.1128/JB.181.19.6108-6113.1999; Lippincott J, 1997, J BACTERIOL, V179, P1337, DOI 10.1128/jb.179.4.1337-1343.1997; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Nelson BD, 1998, J BACTERIOL, V180, P2507, DOI 10.1128/JB.180.9.2507-2514.1998; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852	25	12	12	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33290	33297		10.1074/jbc.M403796200	http://dx.doi.org/10.1074/jbc.M403796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15192116	hybrid			2022-12-27	WOS:000223039700035
J	Wu, CCN; Lee, JD; Raz, E; Corr, M; Carson, DA				Wu, CCN; Lee, JD; Raz, E; Corr, M; Carson, DA			Necessity of oligonucleotide aggregation for toll-like receptor 9 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHODIESTER CPG OLIGONUCLEOTIDES; DEOXYRIBOGUANOSINE RUN CONJUGATION; NF-KAPPA-B; IMMUNOSTIMULATORY DNA; BACTERIAL-DNA; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE; ANTIPROLIFERATIVE ACTIVITY; SIGNAL-TRANSDUCTION; DENDRITIC CELLS; PROTEIN-KINASE	Toll-like receptor 9 (TLR9), a member of the interleukin-1 (IL-1) family of pathogen-associated molecular pattern receptors, is activated by unmethylated CpG-containing sequences in bacterial DNA or synthetic oligonucleotides (ODNs) in the endosomal compartment. The stimulation of an IL-1 response is thought to require the aggregation of its receptor. By analogy, we postulated that the potency of a TLR9 ligand should depend first on its ability to enter cells and gain access to TLR9 and second on its capacity to form a multimeric complex capable of cross-linking these receptors. Previously, we selected from a random library a series of phosphodiester ODNs with enhanced ability to permeate cells. Here, we studied the structural requirements for these penetrating ODNs to elicit a functional TLR9 response, as assessed by cytokine production from bone marrow-derived mouse mononuclear cells. The presence of a prototypic murine immunostimulatory DNA hexameric sequence (purine-purine-CG-pyrimidine-pyrimidine) in the ODNs was not sufficient for stimulation. In addition, the TLR9-activating ODNs had to have the ability to form aggregates and often to form secondary structures near the core CpG motifs. Multimerization was promoted by the presence of a guanine-rich 3'-terminus. The phosphodiester ODNs with CpG motifs that did not aggregate antagonized the effects of the multimeric TLR9 activators. These findings suggest that an optimal TLR9 agonist needs to contain a spatially distinct multimerization domain and a receptor binding CpG domain. This concept may prove useful for the design of new TLR9-modulating agents.	Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wu, CCN (corresponding author), 9500 Gilman Dr,0663, La Jolla, CA 92093 USA.	c5wu@ucsd.edu		Lee, Jongdae/0000-0002-6270-4658	NIAID NIH HHS [AI56453, AI40682] Funding Source: Medline; NIAMS NIH HHS [AR44850, AR07567] Funding Source: Medline; NIGMS NIH HHS [GM23200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI056453, P01AI040682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR044850, T32AR007567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Ballas ZK, 2001, J IMMUNOL, V167, P4878, DOI 10.4049/jimmunol.167.9.4878; Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Benimetskaya L, 1997, NUCLEIC ACIDS RES, V25, P2648, DOI 10.1093/nar/25.13.2648; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Bhagat L, 2003, BIOCHEM BIOPH RES CO, V300, P853, DOI 10.1016/S0006-291X(02)02943-1; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; COSSUM PA, 1993, J PHARMACOL EXP THER, V267, P1181; Dabbagh K, 2003, CURR OPIN INFECT DIS, V16, P199, DOI 10.1097/00001432-200306000-00003; Dalpke AH, 2002, IMMUNOLOGY, V106, P102, DOI 10.1046/j.1365-2567.2002.01410.x; Dapic V, 2002, BIOCHEMISTRY-US, V41, P3676, DOI 10.1021/bi0119520; Elias F, 2003, J IMMUNOL, V171, P3697, DOI 10.4049/jimmunol.171.7.3697; Fearon K, 2003, EUR J IMMUNOL, V33, P2114, DOI 10.1002/eji.200323948; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P706, DOI 10.1067/mai.2002.129122; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Ishii KJ, 2002, J EXP MED, V196, P269, DOI 10.1084/jem.20020773; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Kandimalla ER, 2001, BIOORGAN MED CHEM, V9, P807, DOI 10.1016/S0968-0896(00)00316-3; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Lederman S, 1996, ANTISENSE NUCLEIC A, V6, P281, DOI 10.1089/oli.1.1996.6.281; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Lee SW, 2000, J IMMUNOL, V165, P3631, DOI 10.4049/jimmunol.165.7.3631; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Magone MT, 2000, EUR J IMMUNOL, V30, P1841, DOI 10.1002/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E; Marshall JD, 2003, J LEUKOCYTE BIOL, V73, P781, DOI 10.1189/jlb.1202630; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Park Y, 2001, J ALLERGY CLIN IMMUN, V108, P570; Prasad V, 1999, ANTIMICROB AGENTS CH, V43, P2689, DOI 10.1128/AAC.43.11.2689; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Shen WY, 2002, ANTISENSE NUCLEIC A, V12, P155, DOI 10.1089/108729002760220752; Suzuki K, 1999, EUR J BIOCHEM, V260, P855, DOI 10.1046/j.1432-1327.1999.00233.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Underhill DM, 2003, EUR J IMMUNOL, V33, P1767, DOI 10.1002/eji.200324037; Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Werling D, 2003, VET IMMUNOL IMMUNOP, V91, P1, DOI 10.1016/S0165-2427(02)00228-3; Wu CCN, 2003, HUM GENE THER, V14, P849, DOI 10.1089/104303403765701141; YAMAMOTO T, 1994, ANTISENSE RES DEV, V4, P119, DOI 10.1089/ard.1994.4.119; Yu D, 2000, BIOORG MED CHEM LETT, V10, P2585, DOI 10.1016/S0960-894X(00)00537-0; Yu D, 2001, BIOORG MED CHEM LETT, V11, P2263, DOI 10.1016/S0960-894X(01)00418-8; Zimmermann S, 2003, VACCINE, V21, P990, DOI 10.1016/S0264-410X(02)00550-9; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	55	73	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33071	33078		10.1074/jbc.M311662200	http://dx.doi.org/10.1074/jbc.M311662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184382	hybrid			2022-12-27	WOS:000223039700008
J	Popovici, C; Conchonaud, F; Birnbaum, D; Roubin, R				Popovici, C; Conchonaud, F; Birnbaum, D; Roubin, R			Functional phylogeny relates LET-756 to fibroblast growth factor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR FGF; C-ELEGANS; CAENORHABDITIS-ELEGANS; SKELETAL DISORDERS; HOMOLOGOUS FACTORS; SIGNAL SEQUENCE; RECEPTOR; SECRETION; GENE; EXPRESSION	Fibroblast growth factors (FGFs) are secreted regulatory proteins involved in various developmental processes. In vertebrates, the FGF superfamily comprises 22 members. In non-vertebrates, six FGF genes have been identified in Ciona intestinalis, three in Drosophila melanogaster, and two (let-756 and egl-17) in Caenorhabditis elegans. The core of LET-756 shares a 30-50% sequence identity with the various members of the superfamily. The relationships between vertebrate and non-vertebrate FGFs are not clear. We made chimeric FGFs by replacing the core region of LET-756 by the cores of various mammalian, fly, and worm FGFs. LET-756 deleted in its core region was no longer able to rescue the lethal phenotype of a let-756 null mutant, and only chimeras containing the cores of FGFs 9, 16, and 20 showed rescue capacity. This core contains an internal motif of six amino acid residues (EFISIA) whose deletion or mutation abolished both the rescue activity and FGF secretion in the supernatant of transfected COS-1 cells. Chimera containing the core of C. intestinalis FGF9/16/20, a potential ortholog of FGF9 lacking the complete EFISIA motif, was not able to rescue the lethal phenotype or be secreted. However, the introduction of the EFISIA motif restored both activities. The data show that the EFISIA motif in the core of LET-756 is essential for its biological activity and that FGFs 9, 16, and 20, which contain that motif, are functionally close to LET-756 and may be evolutionary related. This non-classical mode of secretion using an internal motif is conserved throughout evolution.	Marseille Canc Res Inst, UMR599, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Mol Oncol Lab, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Roubin, R (corresponding author), Marseille Canc Res Inst, UMR599, INSERM, 27 Bd Lei Roure, F-13009 Marseille, France.	roubin@marseille.inserm.fr	POPOVICI, Cornel/A-2027-2009	POPOVICI, Cornel/0000-0001-8226-3127; Birnbaum, Daniel/0000-0001-7920-9883				Bertrand V, 2003, CELL, V115, P615, DOI 10.1016/S0092-8674(03)00928-0; Bulow HE, 2004, NEURON, V42, P367, DOI 10.1016/S0896-6273(04)00246-6; Burdine RD, 1997, P NATL ACAD SCI USA, V94, P2433, DOI 10.1073/pnas.94.6.2433; Colvin JS, 1999, DEV DYNAM, V216, P72; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; Garces A, 2000, J NEUROSCI RES, V60, P1, DOI 10.1002/(SICI)1097-4547(20000401)60:1<1::AID-JNR1>3.0.CO;2-P; GOLDFARB M, 2001, SCI STKE; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Goodman SJ, 2003, DEVELOPMENT, V130, P3757, DOI 10.1242/dev.00604; Huang P, 2004, DEVELOPMENT, V131, P2595, DOI 10.1242/dev.01135; Kim HS, 2001, CYTOGENET CELL GENET, V93, P131, DOI 10.1159/000056965; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Miyakawa K, 1999, J BIOL CHEM, V274, P29352, DOI 10.1074/jbc.274.41.29352; Miyakawa K, 2003, J BIOL CHEM, V278, P35718, DOI 10.1074/jbc.M300690200; Ohmachi S, 2000, BIOCHEM BIOPH RES CO, V277, P355, DOI 10.1006/bbrc.2000.3675; Olsen SK, 2003, J BIOL CHEM, V278, P34226, DOI 10.1074/jbc.M303183200; Ornitz DM, 2001, GENOME BIOL, V2; Popovici C, 2001, BIOCHEM BIOPH RES CO, V288, P362, DOI 10.1006/bbrc.2001.5794; Revest JM, 2000, J BIOL CHEM, V275, P8083, DOI 10.1074/jbc.275.11.8083; Roubin R, 1999, ONCOGENE, V18, P6741, DOI 10.1038/sj.onc.1203074; Satou Y, 2002, DEV GENES EVOL, V212, P432, DOI 10.1007/s00427-002-0266-8; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Stathopoulos A, 2004, GENE DEV, V18, P687, DOI 10.1101/gad.1166404; Stewart HI, 1998, MOL GEN GENET, V260, P280, DOI 10.1007/PL00013816; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Wood WB, 1998, NEMATODE CAENORHABDI	31	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40146	40152		10.1074/jbc.M405795200	http://dx.doi.org/10.1074/jbc.M405795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15199049	hybrid			2022-12-27	WOS:000223791500113
J	Expert-Bezancon, A; Sureau, A; Durosay, P; Salesse, R; Groeneveld, H; Lecaer, JP; Marie, J				Expert-Bezancon, A; Sureau, A; Durosay, P; Salesse, R; Groeneveld, H; Lecaer, JP; Marie, J			hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; MUSCLE-SPECIFIC EXON; SECONDARY STRUCTURE; ALTERNATIVE EXON; BINDING-SITES; A/B PROTEINS; HIV-1 TAT; 5'-SPLICE-SITE SELECTION; COOPERATIVE BINDING; SILENCER ELEMENT/	Mutually exclusive splicing of exons 6A and 6B from the chicken beta-tropomyosin gene involves numerous regulatory sequences. Previously, we identified a G-rich intronic sequence (S3) downstream of exon 6B. This element consists of six G-rich motifs, mutations of which abolish splicing of exon 6B. In this paper, we investigated the cellular factors that bind to this G-rich element. By using RNA affinity chromatography, we identified heterogeneous nuclear ribonucleoprotein (hnRNP) A1, the SR proteins ASF/SF2 and SC35, and hnRNP F/H as specific components that are assembled onto the G-rich element. By using hnRNP A1-depleted HeLa nuclear extract and add-back experiments, we show that hnRNP A1 has a negative effect on splicing of exon 6B. In agreement with in vitro data, artificial recruitment of hnRNP A1, as a fusion with the MS2 coat protein, also represses splicing of exon 6B ex vivo. In contrast, ASF/SF2 and SC35 activate splicing of exon 6B. As observed with other systems, hnRNP A1 counteracts the stimulating effect of the SR proteins. Moreover, cross-linking experiments show that both ASF/SF2 and SC35 are able to displace binding of hnRNP A1 to the G-rich element, suggesting that the binding sites for these proteins are overlapping. These data indicate that the G-rich sequence is a composite element that acts as an enhancer or as a silencer, depending on which proteins bind to them.	Univ Paris 06, Lab Propre Associe, Ctr Genet Mol, CNRS,UPR 2167, F-91198 Gif Sur Yvette, France; INRA, Unite Recepteur & Commun, F-78352 Jouy En Josas, France; Ecole Super Phys & Chim Ind Ville Paris, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Marie, J (corresponding author), Univ Paris 06, Lab Propre Associe, Ctr Genet Mol, CNRS,UPR 2167, F-91198 Gif Sur Yvette, France.	marie@cgm.cnrs-gif.fr	Sureau, Alain/M-1998-2017	Sureau, Alain/0000-0003-1523-0207				ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; BALVAY L, 1992, NUCLEIC ACIDS RES, V20, P3987, DOI 10.1093/nar/20.15.3987; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BLACK DL, 1995, RNA, V1, P763; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Carlo T, 2000, MOL CELL BIOL, V20, P3988, DOI 10.1128/MCB.20.11.3988-3995.2000; Carlo T, 1996, RNA, V2, P342; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Damgaard CK, 2002, RNA, V8, P1401, DOI 10.1017/S1355838202023075; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Domsic JK, 2003, MOL CELL BIOL, V23, P8762, DOI 10.1128/MCB.23.23.8762-8772.2003; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENGELBRECHT J, 1992, J MOL BIOL, V227, P108, DOI 10.1016/0022-2836(92)90685-D; Expert-Bezancon A, 2002, J BIOL CHEM, V277, P16614, DOI 10.1074/jbc.M201083200; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; FU XD, 1995, RNA, V1, P663; GALLEGO ME, 1992, MOL CELL BIOL, V12, P5415, DOI 10.1128/MCB.12.12.5415; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hastings ML, 2001, RNA, V7, P859, DOI 10.1017/S1355838201002084; Hutchison S, 2002, J BIOL CHEM, V277, P29745, DOI 10.1074/jbc.M203633200; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Miriami E, 2003, NUCLEIC ACIDS RES, V31, P1974, DOI 10.1093/nar/gkg279; MOORE MJ, 1993, RNA WORLD, V13, P303; Nasim FUH, 2002, RNA, V8, P1078, DOI 10.1017/S1355838202024056; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Rooke N, 2003, MOL CELL BIOL, V23, P1874, DOI 10.1128/MCB.23.6.1874-1884.2003; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIRANDPUGNET P, 1995, J MOL BIOL, V251, P591, DOI 10.1006/jmbi.1995.0458; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Tange TO, 2001, EMBO J, V20, P5748; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	61	67	69	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38249	38259		10.1074/jbc.M405377200	http://dx.doi.org/10.1074/jbc.M405377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208309	hybrid			2022-12-27	WOS:000223684100024
J	Datta, A; Nag, A; Pan, W; Hay, N; Gartel, AL; Colamonici, O; Mori, Y; Raychaudhuri, P				Datta, A; Nag, A; Pan, W; Hay, N; Gartel, AL; Colamonici, O; Mori, Y; Raychaudhuri, P			Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; CELL-CYCLE PROGRESSION; C-MYC; ORNITHINE-DECARBOXYLASE; EMBRYO FIBROBLASTS; GROWTH ARREST; ONCOGENIC RAS; MDM2; P19(ARF); P14(ARF)	The tumor suppressor protein ARF (alternate reading frame) inhibits MDM2 to stabilize and activate the functions of p53. Here we provide evidence for an additional activity of ARF that attenuates cell cycle progression independently of p53 activation. We show that ARF interacts with c-Myc independently of MDM2 or p53. Consequently, ARF relocalizes c-Myc from the nucleoplasm to the nucleolus. Binding and relocalization by ARF correlate with an inhibition of the c-Myc-activated transcription in both p53-positive and -negative cells. Using inducible cell lines, we show that the wild type ARF, but not a mutant, inhibits expression of the c-Myc-induced genes before inhibiting S phase. Moreover, ARF inhibits Myc-induced progression into S phase in cells lacking p53 or expressing a defective p53, indicating that ARF inhibits the S phase stimulatory function of c-Myc independently of p53. Our results strongly suggest that c-Myc is a bona fide target of ARF and that ARF attenuates c-Myc independently of the ARF-p53 axis.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Rheumatol Sect, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	Pradip@uic.edu			NCI NIH HHS [CA 55079, CA 88863, CA 100035] Funding Source: Medline; NIGMS NIH HHS [GM 54709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100035, R01CA088863, R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Esteller M, 2000, CANCER RES, V60, P129; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Groth A, 2000, J BIOL CHEM, V275, P27473; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENGYUN F, 2000, J BIOL CHEM, V275, P8945; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1; Silva J, 2001, ONCOGENE, V20, P4586, DOI 10.1038/sj.onc.1204617; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	103	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36698	36707		10.1074/jbc.M312305200	http://dx.doi.org/10.1074/jbc.M312305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15199070	hybrid			2022-12-27	WOS:000223453600069
J	Gellhaus, A; Dong, XS; Propson, S; Maass, K; Klein-Hitpass, L; Kibschull, M; Traub, O; Willecke, K; Perbal, B; Lye, SJ; Winterhager, E				Gellhaus, A; Dong, XS; Propson, S; Maass, K; Klein-Hitpass, L; Kibschull, M; Traub, O; Willecke, K; Perbal, B; Lye, SJ; Winterhager, E			Connexin43 interacts with NOV - A possible mechanism for negative regulation of cell growth in choriocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; CCN FAMILY; INTERCELLULAR COMMUNICATION; INDUCIBLE EXPRESSION; POTENTIAL ROLE; GLIOMA-CELLS; GENE; MOUSE; DIFFERENTIATION; TRANSFECTION	The gap junction protein connexin43 (Cx43) is thought to be involved in growth control in several tissues. Using the doxycycline inducible tet-on system, we generated human malignant trophoblast Jeg3 cells transfected with either Cx40, Cx43, or C-terminal truncated Cx43 (trCx43). Cx43, but not Cx40 or trCx43, displayed a reduced cell growth of Jeg3 cells in vitro and tumor growth in nude mice, suggesting a role of the C terminus of Cx43 in growth regulation. Using gene array analysis, the growth regulator NOV (CCN3), a member of the CCN gene family, was found to be up-regulated only in the Cx43-transfected cells. Validation by reverse transcriptase-PCR confirmed an up-regulation of the NOV transcript exclusively upon Cx43 induction. In contrast to Cx40 or trCx43, induction of Cx43 led to a switch in localization of NOV from the nucleus to the cell membrane, where it is colocalized with Cx43. Coimmunoprecipitation showed a binding of NOV to the C terminus of Cx43 in vitro as well as in transfected cells. Jeg3 cells transfected only with NOV revealed that NOV itself acts as a growth regulator. We suggest that Cx43 is able to regulate cell growth via an up-regulation of NOV transcription, a change in localization of the NOV protein and a binding of NOV to the C terminus of Cx43.	Univ Hosp Essen, Inst Anat, D-45122 Essen, Germany; Univ Hosp Essen, Inst Cell Biol, D-45122 Essen, Germany; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Physiol, Toronto, ON M5G 1X5, Canada; Univ Bonn, Inst Genet, D-53117 Bonn, Germany; Univ Paris, UFR Biochim, Lab Oncol Virale & Mol, F-75005 Paris, France	University of Duisburg Essen; University of Duisburg Essen; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Bonn; UDICE-French Research Universities; Universite Paris Cite	Winterhager, E (corresponding author), Univ Hosp Essen, Inst Anat, 55 Hufelandstr, D-45122 Essen, Germany.	e.winterhager@uni-essen.de	Lye, Stephen J/E-7269-2013	Lye, Stephen J/0000-0002-3305-4406; Maass, Karen/0000-0001-9815-841X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042558] Funding Source: NIH RePORTER; NICHD NIH HHS [1R01 HD 42558-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; Chevalier G, 1998, AM J PATHOL, V152, P1563; Cronier L, 2003, BIOL REPROD, V69, P1472, DOI 10.1095/biolreprod.103.016360; Cronier L, 2002, MOL HUM REPROD, V8, P1005, DOI 10.1093/molehr/8.11.1005; Czyz J, 2000, EXP CELL RES, V255, P40, DOI 10.1006/excr.1999.4760; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; Durig J, 2003, BLOOD, V101, P2748, DOI 10.1182/blood-2002-09-2683; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Ellis PD, 2003, J VASC RES, V40, P234, DOI 10.1159/000071887; Fernstrom MJ, 2002, EXP MOL PATHOL, V73, P54, DOI 10.1006/exmp.2002.2436; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; Frendo JL, 2003, J CELL SCI, V116, P3413, DOI 10.1242/jcs.00648; Gabriel HD, 2001, EUR J BIOCHEM, V268, P1749, DOI 10.1046/j.1432-1327.2001.02040.x; Giepmans BNG, 2001, CURR BIOL, V11, P1364, DOI 10.1016/S0960-9822(01)00424-9; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gramsch B, 2001, EXP CELL RES, V264, P397, DOI 10.1006/excr.2000.5145; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; Hellmann P, 1996, PFLUG ARCH EUR J PHY, V432, P501, DOI 10.1007/s004240050162; Hellmann P, 1999, EXP CELL RES, V246, P480, DOI 10.1006/excr.1998.4332; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; King TJ, 2000, CARCINOGENESIS, V21, P1097, DOI 10.1093/carcin/21.6.1097; King TJ, 2002, MOL CARCINOGEN, V35, P29, DOI 10.1002/mc.10071; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; McLeod TL, 2001, CELL COMMUN ADHES, V8, P441, DOI 10.3109/15419060109080767; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Olbina G, 2003, MOL CANCER RES, V1, P690; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; PATTILLO RA, 1968, SCIENCE, V159, P1467, DOI 10.1126/science.159.3822.1467; Peebles KA, 2003, CARCINOGENESIS, V24, P651, DOI 10.1093/carcin/bgg008; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Perbal B, 1999, J CLIN PATHOL-MOL PA, V52, P84, DOI 10.1136/mp.52.2.84; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Scholz G, 1996, MOL CELL BIOL, V16, P481; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Sohl G, 2003, CELL COMMUN ADHES, V10, P173, DOI 10.1080/15419060390262877; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; TRAUB O, 1994, EUR J CELL BIOL, V64, P101; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; WINTERHAGER E, 1991, EUR J CELL BIOL, V55, P133; Winterhager E, 1999, PLACENTA, V20, P627, DOI 10.1053/plac.1999.0434; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Yamasaki H, 1999, NOVART FDN SYMP, V219, P241; YAMASAKI H, 1991, ENVIRON HEALTH PERSP, V93, P191, DOI 10.2307/3431188; YUE H, 2001, NUCLEIC ACIDS RES, V29, P1; Zhang YW, 2003, J BIOL CHEM, V278, P44852, DOI 10.1074/jbc.M305072200; Zhang YW, 2003, CANCER RES, V63, P1623; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	64	124	136	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36931	36942		10.1074/jbc.M404073200	http://dx.doi.org/10.1074/jbc.M404073200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15181016	hybrid			2022-12-27	WOS:000223453600096
J	Aihara, K; Azuma, H; Akaike, M; Ikeda, Y; Yamashita, M; Sudo, T; Hayashi, H; Yamada, Y; Endoh, F; Fujimura, M; Yoshida, T; Yamaguchi, H; Hashizume, S; Kato, M; Yoshimura, K; Yamamoto, Y; Kato, S; Matsumoto, T				Aihara, K; Azuma, H; Akaike, M; Ikeda, Y; Yamashita, M; Sudo, T; Hayashi, H; Yamada, Y; Endoh, F; Fujimura, M; Yoshida, T; Yamaguchi, H; Hashizume, S; Kato, M; Yoshimura, K; Yamamoto, Y; Kato, S; Matsumoto, T			Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-FACTOR; 1,25-DIHYDROXYVITAMIN D-3; ANTITHROMBIN DEFICIENCY; WHOLE-BLOOD; EXPRESSION; CELLS; AGGREGATION; RICKETS	Vitamin D metabolites influence the expression of various genes involved in calcium homeostasis, cell differentiation, and regulation of the immune system. Expression of these genes is mediated by the activation of the nuclear vitamin D receptor (VDR). Previous studies have shown that a hormonally active form of vitamin D, 1alpha,25-dihydroxyvitamin D3, exerts anticoagulant effects in cultured monocytic cells. To clarify whether activation of VDR plays any antithrombotic actions in vivo, hemostatic/thrombogenic systems were examined in normocalcemic VDR knock-out (KO) mice on a high calcium diet and compared with wild type and hypocalcemic VDRKO mice that were fed a regular diet. Platelet aggregation was enhanced significantly in normocalcemic VDRKO mice compared with wild type and hypocalcemic VDRKO mice. Aortic endothelial nitric-oxide (NO) synthase expression and urinary NOx excretions were reduced in hypocalcemic VDRKO mice, but not in normocalcemic VDRKO mice. Northern blot and RT-PCR analyses revealed that the gene expression of antithrombin in the liver as well as that of thrombomodulin in the aorta, liver and kidney was down-regulated in hypo- and normocalcemic VDRKO mice. Whereas tissue factor mRNA expression in the liver and kidney was up-regulated in VDRKO mice regardless of plasma calcium level. Furthermore, VDRKO mice manifested an exacerbated multi-organ thrombus formation after exogenous lipopolysaccharide injection regardless of the calcemic conditions. These results demonstrate that activation of nuclear VDR elicits antithrombotic effects in vivo, and suggest that the VDR system may play a physiological role in the maintenance of antithrombotic homeostasis.	Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan; Univ Tokushima, Grad Sch Med, Dept Pathol, Tokushima 7708503, Japan; Otsuka Pharmaceut Co Ltd, Inst New Drug Discovery 1, Tokushima 7710192, Japan; TSL Inc, Higashimatuyama Lab, Anat & Mol Div, Higashimatsuyama, Saitama, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Tokushima University; Tokushima University; Otsuka Pharmaceutical; University of Tokyo	Aihara, K (corresponding author), Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	aihara@clin.med.tokushima-u.ac.jp	Aihara, Ken-ichi/AEE-8245-2022	Aihara, Ken-ichi/0000-0001-8906-0920; Ikeda, Yasumasa/0000-0003-4318-7349				ABRAMS C, 1991, THROMB HAEMOSTASIS, V65, P467; Asakura H, 2001, THROMB HAEMOSTASIS, V85, P287; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Endo I, 2003, ENDOCRINOLOGY, V144, P5138, DOI 10.1210/en.2003-0502; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Koyama T, 1998, BLOOD, V92, P160, DOI 10.1182/blood.V92.1.160.413k16_160_167; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; Loscalzo J, 2000, Trans Am Clin Climatol Assoc, V111, P158; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mathieu C, 2001, J BONE MINER RES, V16, P2057, DOI 10.1359/jbmr.2001.16.11.2057; MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; NIELSEN HK, 1991, SEMIN THROMB HEMOST, V17, P250; Niessen RWLM, 1996, BIOCHEM J, V318, P263, DOI 10.1042/bj3180263; Ohsawa M, 2000, CIRCULATION, V102, P2867; Ozeki Y, 2001, THROMB RES, V101, P65, DOI 10.1016/S0049-3848(00)00377-7; POLLER L, 1988, THROMB HAEMOSTASIS, V60, P18; Sudo T, 2003, PLATELETS, V14, P239, DOI 10.1080/0953710031000118885; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Verhagen AMG, 1998, J AM SOC NEPHROL, V9, P755; Yamada K, 1997, J NEUROCHEM, V68, P1234; Yanada M, 2002, BLOOD, V99, P2455, DOI 10.1182/blood.V99.7.2455; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	27	189	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35798	35802		10.1074/jbc.M404865200	http://dx.doi.org/10.1074/jbc.M404865200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205460	hybrid			2022-12-27	WOS:000223303400080
J	Bohme, I; Rabe, H; Luddens, H				Bohme, I; Rabe, H; Luddens, H			Four amino acids in the alpha subunits determine the gamma-aminobutyric acid sensitivities of GABA(A) receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A RECEPTORS; BINDING; PHARMACOLOGY; CELLS; HIPPOCAMPAL; AFFINITY; CHANNELS; DOMAIN; SITES	GABA(A) receptors, mediators of fast inhibitory neurotransmission, are heteropentameric assemblies from a large array of subunits. Differences in the sensitivity of receptor subtypes to endogenous GABA may permit subunit-dependent finely tuned responsiveness to the same GABAergic inputs. Using both radioligand binding and electrophysiology combined with mutagenesis, we identified a domain of four amino acids within the alpha subunits that mediates the distinct sensitivities to GABA allowing their selective switch between alphabeta3gamma2 combinations. Replacing this domain in alpha3 by the corresponding segments of alpha1-alpha5 resulted in mutant receptors displaying the GABA EC50 values of the respective wild-type receptors. Vice versa, the alpha3 motif forced the low sensitivity to GABA of alpha3 upon alpha1beta3gamma2, alpha4beta3gamma2, and alpha5beta3gamma2. Binding of the GABA agonist [H-3] muscimol was not affected by the exchange of the motif between alpha1 and alpha3 subunits. Thus, the equilibrium binding pocket is maintained upon replacement of the four amino acids. Taken together our data suggest that the identified motifs contribute to a structure involved in the transduction of the binding signal rather than to the binding itself.	Univ Mainz, Dept Psychiat, Mol Biol Lab, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Luddens, H (corresponding author), Univ Mainz, Dept Psychiat, Mol Biol Lab, Untere Zahlbacher Str 8, D-55131 Mainz, Germany.	lueddens@uni-mainz.de						Barnard EA, 1998, PHARMACOL REV, V50, P291; Baur R, 2003, J NEUROCHEM, V87, P325, DOI 10.1046/j.1471-4159.2003.01982.x; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brickley SG, 1999, J NEUROSCI, V19, P2960; Costa E, 1998, ANNU REV PHARMACOL, V38, P321, DOI 10.1146/annurev.pharmtox.38.1.321; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; DUCIC I, 1995, J PHARMACOL EXP THER, V272, P438; EBERT B, 1994, MOL PHARMACOL, V46, P957; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Fritschy JM, 1998, NEUROSCI LETT, V249, P99, DOI 10.1016/S0304-3940(98)00397-8; Gingrich KJ, 1995, J PHYSIOL-LONDON, V489, P529, DOI 10.1113/jphysiol.1995.sp021070; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartvig L, 2000, J NEUROCHEM, V75, P1746, DOI 10.1046/j.1471-4159.2000.0751746.x; Holden JH, 2002, J BIOL CHEM, V277, P18785, DOI 10.1074/jbc.M111778200; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; KORPI ER, 1993, MOL PHARMACOL, V44, P87; KORPI ER, 1992, EUR J PHARMACOL, V211, P427, DOI 10.1016/0014-2999(92)90402-P; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LUDDENS H, 1995, J NEUROSCI, V15, P6957; Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165-0173(98)00052-6; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Nusser Z, 1998, J NEUROSCI, V18, P1693; Nusser Z, 1996, P NATL ACAD SCI USA, V93, P11939, DOI 10.1073/pnas.93.21.11939; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; Saxena NC, 1996, MOL PHARMACOL, V49, P567; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8	36	43	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35193	35200		10.1074/jbc.M405653200	http://dx.doi.org/10.1074/jbc.M405653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199051	hybrid			2022-12-27	WOS:000223303400009
J	Chen, ZJ; Rogge, G; Hague, C; Alewood, D; Colless, B; Lewis, RJ; Minneman, KP				Chen, ZJ; Rogge, G; Hague, C; Alewood, D; Colless, B; Lewis, RJ; Minneman, KP			Subtype-selective noncompetitive or competitive inhibition of human alpha(1)-adrenergic receptors by rho-TIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1D)-ADRENERGIC RECEPTOR; CELL-SURFACE EXPRESSION; ARTERIAL BLOOD-PRESSURE; PHASE PEPTIDE-SYNTHESIS; ALPHA(1B)-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; CARDIAC-HYPERTROPHY; MOLECULAR-CLONING; RAT-BRAIN; ALPHA(1A)-ADRENERGIC RECEPTOR	The 19-amino acid conopeptide (rho-TIA) was shown previously to antagonize noncompetitively alpha(1B)-adrenergic receptors (ARs). Because this is the first peptide ligand for these receptors, we compared its interactions with the three recombinant human alpha(1)-AR subtypes (alpha(1A), alpha(1B), and alpha(1D)). Radioligand binding assays showed that rho-TIA was 10-fold selective for human alpha(1B)- over alpha(1A)- and alpha(1D)-ARs. As observed with hamster alpha(1B)-ARs, rho-TIA decreased the number of binding sites (B-max) for human alpha(1B)-ARs without changing affinity (K-D), and this inhibition was unaffected by the length of incubation but was reversed by washing. However, rho-TIA had opposite effects at human alpha(1A)-ARs and alpha(1D)-ARs, decreasing KD without changing Bmax, suggesting it acts competitively at these subtypes. rho-TIA reduced maximal NE-stimulated [H-3] inositol phosphate formation in HEK293 cells expressing human alpha(1B)-ARs but competitively inhibited responses in cells expressing alpha(1A)- or alpha(1D)-ARs. Truncation mutants showed that the amino-terminal domains of alpha(1B)- or alpha(1D)-ARs are not involved in interaction with rho-TIA. Alanine-scanning mutagenesis of rho-TIA showed F18A had an increased selectivity for alpha(1B)-ARs, and F18N also increased subtype selectivity. I8A had a slightly reduced potency at alpha(1B)-ARs and was found to be a competitive, rather than noncompetitive, inhibitor in both radioligand and functional assays. Thus rho-TIA noncompetitively inhibits alpha(1B)-ARs but competitively inhibits the other two subtypes, and this selectivity can be increased by mutation. These differential interactions do not involve the receptor amino termini and are not because of the charged nature of the peptide, and isoleucine 8 is critical for its noncompetitive inhibition at alpha(1B)-ARs.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Xenome Ltd, Indooroopilly, Qld 4068, Australia	Emory University	Minneman, KP (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	kminneman@pharm.emory.edu	Lewis, Richard J/E-8674-2013; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Lewis, Richard/0000-0003-3470-923X				ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BOER R, 1989, EUR J PHARM-MOLEC PH, V172, P131, DOI 10.1016/0922-4106(89)90004-7; Burcelin R, 2004, J BIOL CHEM, V279, P1108, DOI 10.1074/jbc.M307788200; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; Chalothorn D, 2002, MOL PHARMACOL, V61, P1008, DOI 10.1124/mol.61.5.1008; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Drouin C, 2002, J NEUROSCI, V22, P2873, DOI 10.1523/JNEUROSCI.22-07-02873.2002; ESBENSHADE TA, 1995, MOL PHARMACOL, V47, P977; FOGLAR R, 1995, EUR J PHARM-MOLEC PH, V288, P201, DOI 10.1016/0922-4106(95)90195-7; GOETZ AS, 1995, EUR J PHARMACOL, V272, pR5, DOI 10.1016/0014-2999(94)00751-R; Gonzalez-Cabrera PJ, 2003, MOL PHARMACOL, V63, P1104, DOI 10.1124/mol.63.5.1104; GREENGRASS P, 1979, EUR J PHARMACOL, V55, P323, DOI 10.1016/0014-2999(79)90202-4; GROSS G, 1988, EUR J PHARMACOL, V151, P333, DOI 10.1016/0014-2999(88)90819-9; Hague C, 2004, J BIOL CHEM, V279, P15541, DOI 10.1074/jbc.M314014200; Hague C, 2004, J PHARMACOL EXP THER, V309, P388, DOI 10.1124/jpet.103.060509; Hague C, 2003, LIFE SCI, V74, P411, DOI 10.1016/j.lfs.2003.07.008; HAN C, 1987, MOL PHARMACOL, V32, P505; Hancock AA, 1996, DRUG DEVELOP RES, V39, P54; Hawtin SR, 2000, BIOCHEMISTRY-US, V39, P13524, DOI 10.1021/bi0013400; HENRY JA, 1993, BIOORG MED CHEM LETT, V3, P949, DOI 10.1016/S0960-894X(00)80698-8; HIRASAWA A, 1993, BIOCHEM BIOPH RES CO, V195, P902, DOI 10.1006/bbrc.1993.2130; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; Hruby VJ, 2003, LIFE SCI, V73, P699, DOI 10.1016/S0024-3205(03)00390-4; Hruby VJ, 2002, NAT REV DRUG DISCOV, V1, P847, DOI 10.1038/nrd939; Leppik RA, 2000, MOL PHARMACOL, V57, P436, DOI 10.1124/mol.57.3.436; Lin G, 2001, CIRC RES, V89, P343, DOI 10.1161/hh1601.095912; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MINNEMAN KP, 1983, MOL PHARMACOL, V23, P359; MORROW AL, 1985, EUR J PHARMACOL, V109, P285, DOI 10.1016/0014-2999(85)90432-7; MORROW AL, 1986, MOL PHARMACOL, V29, P321; O'Connell TD, 2003, J CLIN INVEST, V111, P1783, DOI 10.1172/JCI200316100; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Piascik MT, 2001, J PHARMACOL EXP THER, V298, P403; Pupo AS, 2003, EUR J PHARMACOL, V462, P1, DOI 10.1016/S0014-2999(03)01292-5; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Rokosh DG, 2002, P NATL ACAD SCI USA, V99, P9474, DOI 10.1073/pnas.132552699; Romeo G, 2003, J MED CHEM, V46, P2877, DOI 10.1021/jm0307741; Saha S, 1998, J PEPT RES, V52, P112; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; Sharpe IA, 2003, J BIOL CHEM, V278, P34451, DOI 10.1074/jbc.M305410200; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Tanoue A, 2002, J CLIN INVEST, V109, P765, DOI 10.1172/JCI200214001; Tanoue A, 2002, LIFE SCI, V71, P2207, DOI 10.1016/S0024-3205(02)02012-X; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Vecchione C, 2002, CIRCULATION, V105, P1700, DOI 10.1161/01.CIR.0000012750.08480.55; WALKER P, 1994, J BIOL CHEM, V269, P2863; Waugh DJJ, 1999, J PHARMACOL EXP THER, V291, P1164; XIE YB, 1990, J BIOL CHEM, V265, P21411; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Zhao MM, 1996, MOL PHARMACOL, V50, P1118; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8; Zuscik MJ, 2001, J BIOL CHEM, V276, P13738, DOI 10.1074/jbc.M008693200; Zuscik MJ, 2000, NAT MED, V6, P1388, DOI 10.1038/82207	60	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35326	35333		10.1074/jbc.M403703200	http://dx.doi.org/10.1074/jbc.M403703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194691	hybrid			2022-12-27	WOS:000223303400025
J	Payan, F; Leone, P; Porciero, S; Furniss, C; Tahir, T; Williamson, G; Durand, A; Manzanares, P; Gilbert, HJ; Juge, N; Roussel, A				Payan, F; Leone, P; Porciero, S; Furniss, C; Tahir, T; Williamson, G; Durand, A; Manzanares, P; Gilbert, HJ; Juge, N; Roussel, A			The dual nature of the wheat xylanase protein inhibitor XIP-I - Structural basis for the inhibition of family 10 and family 11 xylanases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-ENZYME INTERMEDIATE; TRITICUM-AESTIVUM; 3-DIMENSIONAL STRUCTURE; ALPHA-AMYLASE; SPECIFICITY; SUBSTRATE; BINDING; IDENTIFICATION; SEQUENCE	The xylanase inhibitor protein I (XIP-I) from wheat Triticum aestivum is the prototype of a novel class of cereal protein inhibitors that inhibit fungal xylanases belonging to glycoside hydrolase families 10 (GH10) and 11 (GH11). The crystal structures of XIP-I in complex with Aspergillus nidulans (GH10) and Penicillium funiculosum (GH11) xylanases have been solved at 1.7 and 2.5 Angstrom resolution, respectively. The inhibition strategy is novel because XIP-I possesses two independent enzyme-binding sites, allowing binding to two glycoside hydrolases that display a different fold. Inhibition of the GH11 xylanase is mediated by the insertion of an XIP-I Pi-shaped loop (Lalpha(4)beta(5)) into the enzyme active site, whereas residues in the helix alpha7 of XIP-I, pointing into the four central active site subsites, are mainly responsible for the reversible inactivation of GH10 xylanases. The XIP-I strategy for inhibition of xylanases involves substrate-mimetic contacts and interactions occluding the active site. The structural determinants of XIP-I specificity demonstrate that the inhibitor is able to interact with GH10 and GH11 xylanases of both fungal and bacterial origin. The biological role of the xylanase inhibitors is discussed in light of the present structural data.	Inst Food Res, Inst Food Res, Norwich NR4 7UA, Norfolk, England; CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; CSIC, Inst Agroquim & Tecnol Alimentos, Valencia 46100, Spain; Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Fac Sci & Tech St Jerome, INRA, UMR 1111, Inst Mediterraneen Rech Nutr, F-13397 Marseille, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); Newcastle University - UK; INRAE; UDICE-French Research Universities; Aix-Marseille Universite	Juge, N (corresponding author), Inst Food Res, Inst Food Res, Colney Lane, Norwich NR4 7UA, Norfolk, England.	nathalie.juge@bbsrc.ac.uk	Williamson, Gary/AAE-9665-2019; Manzanares, Paloma/H-2873-2012	Williamson, Gary/0000-0002-5624-6267; Manzanares, Paloma/0000-0001-5036-9787; Juge, Nathalie/0000-0001-8515-1315; Tahir, Tariq/0000-0002-3992-6877				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Belshaw NJ, 2002, APPL MICROBIOL BIOT, V60, P455, DOI 10.1007/s00253-002-1141-2; Biely P, 1997, J BIOTECHNOL, V57, P151, DOI 10.1016/S0168-1656(97)00096-5; Bishop JG, 2000, P NATL ACAD SCI USA, V97, P5322, DOI 10.1073/pnas.97.10.5322; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coutinho PM, 1999, ROY SOC CH, P3; De Lorenzo G, 2002, CURR OPIN PLANT BIOL, V5, P295, DOI 10.1016/S1369-5266(02)00271-6; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; Elliott GO, 2003, J CEREAL SCI, V37, P187, DOI 10.1006/jcrs.2002.0493; Fierens K, 2003, FEBS LETT, V540, P259, DOI 10.1016/S0014-5793(03)00276-X; Flatman R, 2002, BIOCHEM J, V365, P773, DOI 10.1042/BJ20020168; Furniss CSM, 2002, BBA-PROTEINS PROTEOM, V1598, P24, DOI 10.1016/S0167-4838(02)00366-7; Garcia-Vallve S, 2000, MOL BIOL EVOL, V17, P352, DOI 10.1093/oxfordjournals.molbev.a026315; Gebruers K, 2004, BBA-PROTEINS PROTEOM, V1696, P213, DOI 10.1016/j.bbapap.2003.08.013; Gebruers K, 2001, BIOCHEM J, V353, P239, DOI 10.1042/0264-6021:3530239; Jeffries TW, 1996, CURR OPIN BIOTECH, V7, P337, DOI 10.1016/S0958-1669(96)80041-3; Juge N, 2004, BBA-PROTEINS PROTEOM, V1696, P203, DOI 10.1016/j.bbapap.2003.08.014; Krengel U, 1996, J MOL BIOL, V263, P70, DOI 10.1006/jmbi.1996.0556; Kulkarni N, 1999, FEMS MICROBIOL REV, V23, P411, DOI 10.1111/j.1574-6976.1999.tb00407.x; MacCabe AP, 1996, GENE, V175, P29, DOI 10.1016/0378-1119(96)00116-3; McLauchlan WR, 1999, BIOCHEM J, V338, P441, DOI 10.1042/0264-6021:3380441; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payan F, 2003, BIOCHEM J, V372, P399, DOI 10.1042/BJ20021802; Roussel A, 1991, SILICON GRAPHICS GEO, P86; Sabini E, 2001, ACTA CRYSTALLOGR D, V57, P1344, DOI 10.1107/S0907444901010873; Sabini E, 1999, CHEM BIOL, V6, P483, DOI 10.1016/S1074-5521(99)80066-0; Sansen S, 2004, J BIOL CHEM, V279, P36022, DOI 10.1074/jbc.M404212200; Sapag A, 2002, J BIOTECHNOL, V95, P109, DOI 10.1016/S0168-1656(02)00002-0; Sato Y, 1999, GENE, V238, P93, DOI 10.1016/S0378-1119(99)00321-2; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; Tahir TA, 2002, J BIOL CHEM, V277, P44035, DOI 10.1074/jbc.M205657200; TORRONEN A, 1994, EMBO J, V13, P2493, DOI 10.1002/j.1460-2075.1994.tb06536.x; WIEGAND G, 1995, J MOL BIOL, V247, P99, DOI 10.1006/jmbi.1994.0125; [No title captured]	38	101	109	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36029	36037		10.1074/jbc.M404225200	http://dx.doi.org/10.1074/jbc.M404225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15181003	Green Published, hybrid			2022-12-27	WOS:000223303400105
J	Singh, P; Salih, M; Leddy, JJ; Tuana, BS				Singh, P; Salih, M; Leddy, JJ; Tuana, BS			The muscle-specific calmodulin-dependent protein kinase assembles with the glycolytic enzyme complex at the sarcoplasmic reticulum and modulates the activity of glyceraldehyde-3-phosphate dehydrogenase in a Ca2+/calmodulin-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; 3-PHOSPHOGLYCERATE KINASE; ANCHORING PROTEIN; ALPHA-KAP; CA2+; PHOSPHORYLATION; RECEPTOR; BINDING; FORM	The skeletal muscle specific Ca2+/calmodulin-dependent protein kinase (CaMKIIbeta(M)) is localized to the sarcoplasmic reticulum (SR) by an anchoring protein, alphaKAP, but its function remains to be defined. Protein interactions of CaMKIIbeta(M) indicated that it exists in complex with enzymes involved in glycolysis at the SR membrane. The kinase was found to complex with glycogen phosphorylase, glycogen debranching enzyme, glyceraldehyde-3- phosphate dehydrogenase (GAPDH), and creatine kinase in the SR membrane. CaMKIIbeta(M) was also found to assemble with aldolase A, GAPDH, enolase, lactate dehydrogenase, creatine kinase, pyruvate kinase, and phosphorylase b kinase from the cytosolic fraction. The interacting proteins were substrates of CaMKIIbeta(M), and their phosphorylation was enhanced in a Ca2+- and calmodulin (CaM)-dependent manner. The CaMKIIbeta(M) could directly phosphorylate GAPDH and markedly increase (similar to3.4-fold) its activity in a Ca2+/CaM-dependent manner. These data suggest that the muscle CaMKIIbeta(M) isoform may serve to assemble the glycogen-mobilizing and glycolytic enzymes at the SR membrane and specifically modulate the activity of GAPDH in response to calcium signaling. Thus, the activation of CaMKIIbeta(M) in response to calcium signaling would serve to modulate GAPDH and thereby ATP and NADH levels at the SR membrane, which in turn will regulate calcium transport processes.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Tuana, BS (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	btuana@uottawa.ca						Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; Benfenati F, 1996, MOL BRAIN RES, V40, P297, DOI 10.1016/0169-328X(96)00053-8; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Cherednichenko G, 2004, CIRC RES, V94, P478, DOI 10.1161/01.RES.0000115554.65513.7C; CONNELLY PA, 1987, J BIOL CHEM, V262, P10154; CUENDA A, 1993, BIOCHEM BIOPH RES CO, V196, P1127, DOI 10.1006/bbrc.1993.2368; CUENDA A, 1995, J BIOL CHEM, V270, P11998, DOI 10.1074/jbc.270.20.11998; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HEILMEYER LMG, 1990, MOL CELL BIOCHEM, V99, P111; HELMREICH E, 1964, P NATL ACAD SCI USA, V52, P647, DOI 10.1073/pnas.52.3.647; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Ikemoto A, 2003, J BIOL CHEM, V278, P5929, DOI 10.1074/jbc.M211617200; IMAMURA K, 1982, BIOCHEM J, V131, P223; Jona I, 2001, PFLUG ARCH EUR J PHY, V441, P729, DOI 10.1007/s004240000484; Laver DR, 2001, J PHYSIOL-LONDON, V537, P763; LEDDY JJ, 1993, BIOCHEM J, V295, P849, DOI 10.1042/bj2950849; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LORCA T, 1994, BBA-MOL CELL RES, V1223, P325, DOI 10.1016/0167-4889(94)90091-4; MACLENNAN DH, 1984, ADV CYCLIC NUCL PROT, V17, P393; MALHOTRA OP, 1995, EUR J BIOCHEM, V227, P556, DOI 10.1111/j.1432-1033.1995.tb20424.x; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; Nadeau OW, 1997, J BIOL CHEM, V272, P26202, DOI 10.1074/jbc.272.42.26202; NARANG S, 1974, COMP BIOCHEM PHYSIOL, V49, P477, DOI 10.1016/0305-0491(74)90183-7; Nori A, 2003, BIOCHEM J, V370, P873, DOI 10.1042/BJ20021624; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; Stange M, 2003, J BIOL CHEM, V278, P51693, DOI 10.1074/jbc.M310406200; SUKHODOLETS MV, 1988, FEBS LETT, V238, P161, DOI 10.1016/0014-5793(88)80248-5; TOMPA P, 1990, BIOCHEM INT, V20, P487; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; WEBER JP, 1982, BIOCHEMISTRY-US, V21, P4189, DOI 10.1021/bi00260a042; Xu KY, 1998, J HISTOCHEM CYTOCHEM, V46, P419, DOI 10.1177/002215549804600401; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88; Yasykova MY, 2000, BIOCHEMISTRY-MOSCOW+, V65, P1192; Zhu XS, 2004, CELL CALCIUM, V35, P165, DOI 10.1016/j.ceca.2003.09.002; Zima AV, 2004, J PHYSIOL-LONDON, V555, P727, DOI 10.1113/jphysiol.2003.055848; Zima AV, 2003, FEBS LETT, V547, P32, DOI 10.1016/S0014-5793(03)00664-1	47	63	63	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35176	35182		10.1074/jbc.M402282200	http://dx.doi.org/10.1074/jbc.M402282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199064	hybrid			2022-12-27	WOS:000223303400007
J	Zhu, PP; Patterson, A; Stadler, J; Seeburg, DP; Sheng, M; Blackstone, C				Zhu, PP; Patterson, A; Stadler, J; Seeburg, DP; Sheng, M; Blackstone, C			Intra- and intermolecular domain interactions of the C-terminal GTPase effector domain of the multimeric dynamin-like GTPase Drp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RATE-LIMITING STEP; MITOCHONDRIAL DIVISION; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; MEDIATED ENDOCYTOSIS; OUTER-MEMBRANE; PROTEIN DLP1; MXA GTPASE; FISSION; YEAST	Mammalian Drp1 is a dynamin-like GTPase required for mitochondrial fission. Although it exists primarily as a cytosolic homo-tetramer in vivo, it can also self-assemble into higher order structures on the mitochondrial outer membrane, where it is required for proper mitochondrial division. Functional studies and sequence comparisons have revealed four different structural domains in Drp1, comprising N-terminal GTP-binding, middle, insert B, and C-terminal GTPase effector (GED) domains. Here we describe an intramolecular interaction within Drp1 between the GED and the N-terminal GTP-binding and middle domains. A point mutation (K679A) within the C-terminal GED domain inhibits this intramolecular association, without affecting the formation of Drp1 tetramers or the intermolecular associations among isolated C-terminal domains. Mutant Drp1 K679A exhibits impaired GTPase activity, and when overexpressed in mammalian cells it decreases mitochondrial division. Sedimentation experiments indicate that the K679A mutation either increases Drp1 complex formation or, more likely, decreases complex disassembly as compared with wild-type Drp1. Taken together, these data suggest that the C-terminal GED domain is important for stimulation of GTPase activity, formation and stability of higher order complexes, and efficient mitochondrial division.	NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA; NIH, NIH George Washington Univ Grad Partnerships Prog, Bethesda, MD 20892 USA; MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN	Blackstone, C (corresponding author), NINDS, Cellular Neurol Unit, NIH, Bldg 35,Rm 2C-913,9000 Rockville Pike, Bethesda, MD 20892 USA.	blackstc@ninds.nih.gov	Patterson, Andrew/G-3852-2012; Patterson, Andrew/ABF-1575-2020	Patterson, Andrew/0000-0003-2073-0070; Patterson, Andrew/0000-0003-2073-0070				Accola MA, 2002, J BIOL CHEM, V277, P21829, DOI 10.1074/jbc.M201641200; Blackstone C, 2003, BIOCHEM BIOPH RES CO, V305, P345, DOI 10.1016/S0006-291X(03)00767-8; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Di Paolo C, 1999, J BIOL CHEM, V274, P32071, DOI 10.1074/jbc.274.45.32071; Fekkes P, 2000, J CELL BIOL, V151, P333, DOI 10.1083/jcb.151.2.333; Fukushima NH, 2001, MOL BIOL CELL, V12, P2756, DOI 10.1091/mbc.12.9.2756; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Howng SL, 2004, BIOCHEM BIOPH RES CO, V314, P766, DOI 10.1016/j.bbrc.2003.12.172; Imoto M, 1998, J CELL SCI, V111, P1341; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Klockow B, 2002, EMBO J, V21, P240, DOI 10.1093/emboj/21.3.240; Kochs G, 2002, J BIOL CHEM, V277, P14172, DOI 10.1074/jbc.M200244200; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Muhlberg AB, 2000, METHODS, V20, P475, DOI 10.1006/meth.2000.0960; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shin HW, 1999, J BIOL CHEM, V274, P2780, DOI 10.1074/jbc.274.5.2780; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; van der Bliek AM, 2000, J CELL BIOL, V151, pF1, DOI 10.1083/jcb.151.2.F1; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2001, CURR BIOL, V11, pR67, DOI 10.1016/S0960-9822(01)00011-2; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922; Zhu PP, 2003, J BIOL CHEM, V278, P49063, DOI 10.1074/jbc.M306702200	47	157	161	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35967	35974		10.1074/jbc.M404105200	http://dx.doi.org/10.1074/jbc.M404105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208300	hybrid			2022-12-27	WOS:000223303400098
J	Wang, HH; Cronan, JE				Wang, HH; Cronan, JE			Functional replacement of the FabA and FabB proteins of Escherichia coli fatty acid synthesis by Enterococcus faecalis FabZ and FabF homologues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; HYDROXYDECANOYL THIOESTER DEHYDRASE; MEMBRANE-LIPID-COMPOSITION; CRYSTAL-STRUCTURE; SYNTHASE-I; STREPTOCOCCUS-PNEUMONIAE; CONDENSING ENZYMES; BIOSYNTHESIS; GENE; TRANSCRIPTION	The anaerobic unsaturated fatty acid synthetic pathway of Escherichia coli requires two specialized proteins, FabA and FabB. However, the fabA and fabB genes are found only in the Gram-negative alpha- and gamma-proteobacteria, and thus other anaerobic bacteria must synthesize these acids using different enzymes. We report that the Gram-positive bacterium Enterococcus faecalis encodes a protein, annotated as FabZ1, that functionally replaces the E. coli FabA protein, although the sequence of this protein aligns much more closely with E. coli FabZ, a protein that plays no specific role in unsaturated fatty acid synthesis. Therefore E. faecalis FabZ1 is a bifunctional dehydratase/isomerase, an enzyme activity heretofore confined to a group of Gram-negative bacteria. The FabZ2 protein is unable to replace the function of E. coli FabZ, although FabZ2, a second E. faecalis FabZ homologue, has this ability. Moreover, an E. faecalis FabF homologue (FabF1) was found to replace the function of E. coli FabB, whereas a second FabF homologue was inactive. From these data it is clear that bacterial fatty acid biosynthetic pathways cannot be deduced solely by sequence comparisons.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NIAID NIH HHS [AI 15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Altabe SG, 2003, J BACTERIOL, V185, P3228, DOI 10.1128/JB.185.10.3228-3231.2003; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BLOCH K, 1971, ENZYMES, P441; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Chang YY, 1999, MOL MICROBIOL, V33, P249, DOI 10.1046/j.1365-2958.1999.01456.x; Choi-Rhee E, 2003, J BIOL CHEM, V278, P30806, DOI 10.1074/jbc.M302507200; CRONAN JE, 1974, P NATL ACAD SCI USA, V71, P3758, DOI 10.1073/pnas.71.9.3758; CRONAN JE, 1972, J BACTERIOL, V112, P206, DOI 10.1128/JB.112.1.206-211.1972; CRONAN JE, 1973, J BIOL CHEM, V248, P1188; CRONAN JE, 1969, J BACTERIOL, V100, P601, DOI 10.1128/JB.100.2.601-604.1969; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GUERRA DJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P336, DOI 10.1016/0003-9861(90)90339-Z; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; Hoang TT, 1997, J BACTERIOL, V179, P5326, DOI 10.1128/jb.179.17.5326-5332.1997; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; KASS LR, 1968, J BIOL CHEM, V243, P3223; Lai CY, 2003, J BIOL CHEM, V278, P51494, DOI 10.1074/jbc.M308638200; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Marrakchi H, 2002, J BIOL CHEM, V277, P44809, DOI 10.1074/jbc.M208920200; Moche M, 2001, J MOL BIOL, V305, P491, DOI 10.1006/jmbi.2000.4272; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MONTGOMERIE JZ, 1973, J BACTERIOL, V115, P73, DOI 10.1128/JB.115.1.73-75.1973; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; Olsen JG, 2001, STRUCTURE, V9, P233, DOI 10.1016/S0969-2126(01)00583-4; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; Price AC, 2003, J BACTERIOL, V185, P4136, DOI 10.1128/JB.185.14.4136-4143.2003; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Rock C O, 1981, Methods Enzymol, V72, P397; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; SILBERT DF, 1967, P NATL ACAD SCI USA, V58, P1579, DOI 10.1073/pnas.58.4.1579; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; von Wettstein-Knowles P, 2000, BIOCHEM SOC T, V28, P601, DOI 10.1042/BST0280601; Wang HH, 2003, J BACTERIOL, V185, P4930, DOI 10.1128/JB.185.16.4930-4937.2003; WILKINS PO, 1982, ARCH MICROBIOL, V132, P211, DOI 10.1007/BF00508733	48	82	94	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34489	34495		10.1074/jbc.M403874200	http://dx.doi.org/10.1074/jbc.M403874200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194690	hybrid			2022-12-27	WOS:000223134800051
J	Wang, XHL; Herzog, B; Waltner-Law, M; Hall, RK; Shiota, M; Granner, DK				Wang, XHL; Herzog, B; Waltner-Law, M; Hall, RK; Shiota, M; Granner, DK			The synergistic effect of dexamethasone and all-trans-retinoic acid on hepatic phosphoenolpyruvate carboxykinase gene expression involves the coactivator p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; INSULIN-RESPONSE SEQUENCES; NUCLEAR HORMONE-RECEPTORS; RNA-POLYMERASE-II; ACCESSORY FACTORS; GLUCOCORTICOID RESPONSE; PEPCK GENE; COUP-TF; PROMOTER; TRANSCRIPTION	Activation of phosphoenolpyruvate carboxykinase ( PEPCK) gene transcription in response to all-transretinoic acid ( RA) or a glucocorticoid such as dexamethasone (Dex) requires a distinct arrangement of DNA-response elements and their cognate transcription activators on the gene promoter. Two of the accessory factor-binding elements involved in the Dex response (gAF1 and gAF3) coincide with the DNA-response elements involved in the RA response. We demonstrate here that the combination of Dex/RA has a synergistic effect on endogenous PEPCK gene expression in rat hepatocytes and H4IIE hepatoma cells. Reporter gene studies show that the gAF3 element and one of the two glucocorticoid receptor-binding elements (GR1) are most important for this effect. Chromatin immunoprecipitation assays revealed that when H4IIE cells were treated with Dex/RA, ligand-activated retinoic acid receptors ( retinoic acid receptor/ retinoid X receptor) and glucocorticoid receptors are recruited to this gene promoter, as are the transcription coregulators p300, CREB-binding protein, p/CIP, and SRC-1. Notably, the recruitment of p300 and RNA polymerase II to the PEPCK promoter is increased by the combined Dex/RA treatment compared with Dex or RA treatment alone. The functional importance of p300 in the Dex/RA response is illustrated by the observation that selective reduction of this coactivator, but not that of CREB-binding protein, abolishes the synergistic effect in H4IIE cells.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035107, P30DK020593, R01DK035107, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20593, DK 35107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Herzog B, 2004, MOL ENDOCRINOL, V18, P807, DOI 10.1210/mg.2003-0384; Kung AL, 2000, GENE DEV, V14, P272; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; NAKASHATRI H, 1994, J BIOL CHEM, V269, P890; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Schweizer M, 2002, BIOCHEM SOC T, V30, P1070, DOI 10.1042/BST0301070; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Scribner KB, 2003, J NUTR, V133, P4112, DOI 10.1093/jn/133.12.4112; Stafford JM, 2001, J BIOL CHEM, V276, P39885, DOI 10.1074/jbc.M105370200; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; Ugai H, 1999, J MOL MED, V77, P481, DOI 10.1007/s001099900021; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Veitia RA, 2003, BIOL REV, V78, P149, DOI 10.1017/S1464793102006036; Waltner-Law M, 2003, J BIOL CHEM, V278, P10427, DOI 10.1074/jbc.M211846200; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074	37	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34191	34200		10.1074/jbc.M403455200	http://dx.doi.org/10.1074/jbc.M403455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15166231	hybrid			2022-12-27	WOS:000223134800017
J	Drummelsmith, J; Girard, I; Trudel, N; Ouellette, M				Drummelsmith, J; Girard, I; Trudel, N; Ouellette, M			Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; TRYPANOSOMA-BRUCEI; DRUG-RESISTANCE; VISCERAL LEISHMANIASIS; 3'-UNTRANSLATED REGION; GENE AMPLIFICATION; ACID-METABOLISM; REDUCTASE; MECHANISMS; TARENTOLAE	Leishmania is a trypanosomatid parasite causing serious disease and displaying resistance to various drugs. Here, we present comparative proteomic analyses of Leishmania major parasites that have been either shocked with or selected in vitro for high level resistance to the model antifolate drug methotrexate. Numerous differentially expressed proteins were identified by these experiments. Some were associated with the stress response, whereas others were found to be overexpressed due to genetic linkage to primary resistance mediators present on DNA amplicons. Several proteins not previously associated with resistance were also identified. The role of one of these, methionine adenosyltransferase, was confirmed by gene transfection and metabolite analysis. After a single exposure to low levels of methotrexate, L. major methionine adenosyltransferase transfectants could grow at high concentrations of the drug. Methotrexate resistance was also correlated to increased cellular S-adenosylmethionine levels. The folate and S-adenosylmethionine regeneration pathways are intimately connected, which may provide a basis for this novel resistance phenotype. This thorough comparative proteomic analysis highlights the variety of responses required for drug resistance to be achieved.	Univ Laval, Infect Dis Res Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University	Ouellette, M (corresponding author), CHUQ, Infect Dis Res Ctr, Pavillon CHUL,2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	marc.ouellette@crchul.ulaval.ca	Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646				BARAK AJ, 1984, J AM COLL NUTR, V3, P93; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; Boucher N, 2002, J BIOL CHEM, V277, P19511, DOI 10.1074/jbc.M200500200; BROCHU C, 2004, IN RPESS CELL STRESS; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; Cash P, 1999, ELECTROPHORESIS, V20, P2259, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2259::AID-ELPS2259>3.0.CO;2-F; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Drummelsmith J, 2003, MOL CELL PROTEOMICS, V2, P146, DOI 10.1074/mcp.M200085-MCP200; El Fadili A, 2004, J BIOL CHEM, V279, P18575, DOI 10.1074/jbc.M400652200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FORSTHOEFEL NR, 1995, PLANT PHYSIOL, V108, P1185, DOI 10.1104/pp.108.3.1185; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gaskin AA, 2002, J VET INTERN MED, V16, P34, DOI 10.1892/0891-6640(2002)016&lt;0034:VLIANY&gt;2.3.CO;2; Goldberg B, 1999, ARCH BIOCHEM BIOPHYS, V364, P13, DOI 10.1006/abbi.1999.1098; Guimond C, 2003, NUCLEIC ACIDS RES, V31, P5886, DOI 10.1093/nar/gkg806; Haimeur A, 1999, MOL MICROBIOL, V34, P726, DOI 10.1046/j.1365-2958.1999.01634.x; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Kabututu Z, 2003, INT J PARASITOL, V33, P219, DOI 10.1016/S0020-7519(02)00253-9; Kashiwagi H, 2000, Hum Cell, V13, P135; Kishi T, 2000, CANCER-AM CANCER SOC, V89, P925, DOI 10.1002/1097-0142(20000815)89:4<925::AID-CNCR28>3.0.CO;2-W; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Kundig C, 1999, NUCLEIC ACIDS RES, V27, P3653, DOI 10.1093/nar/27.18.3653; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MAGI B, 2004, IN PRESS CELL DEATH; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; MATTHEWS RG, 1982, ADV ENZYME REGUL, V20, P123, DOI 10.1016/0065-2571(82)90012-7; McAtee CP, 2001, PROTEOMICS, V1, P516, DOI 10.1002/1615-9861(200104)1:4<516::AID-PROT516>3.3.CO;2-F; Ouellette M, 1998, ADV EXP MED BIOL, V456, P99; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; PAJARES MA, 1994, BIOCHEM J, V303, P949, DOI 10.1042/bj3030949; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PHELOUZAT MA, 1995, BIOCHEM J, V305, P133, DOI 10.1042/bj3050133; Prasad J, 2003, APPL ENVIRON MICROB, V69, P917, DOI 10.1128/AEM.69.2.917-925.2003; PRIEST JW, 1994, MOL BIOCHEM PARASIT, V65, P291, DOI 10.1016/0166-6851(94)90080-9; Quijada L, 2000, MOL BIOCHEM PARASIT, V110, P79, DOI 10.1016/S0166-6851(00)00258-9; REFSUM H, 1989, CLIN PHARMACOL THER, V46, P510, DOI 10.1038/clpt.1989.179; Reguera RM, 2002, J BIOL CHEM, V277, P3158, DOI 10.1074/jbc.M105512200; RHEE MS, 1992, MOL PHARMACOL, V42, P909; Richard D, 2002, J BIOL CHEM, V277, P29460, DOI 10.1074/jbc.M204796200; Saas J, 2000, J BIOL CHEM, V275, P2745, DOI 10.1074/jbc.275.4.2745; Soto M, 2003, PARASITOLOGY, V127, P95, DOI 10.1017/S0031182003003445; Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Walker J, 1997, INT J PARASITOL, V27, P883, DOI 10.1016/S0020-7519(97)00039-8; Wang JY, 1997, ARCH BIOCHEM BIOPHYS, V342, P197, DOI 10.1006/abbi.1997.0126; Wang W, 2001, J CHROMATOGR B, V762, P59, DOI 10.1016/S0378-4347(01)00341-3; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833	54	53	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33273	33280		10.1074/jbc.M405183200	http://dx.doi.org/10.1074/jbc.M405183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15190060	hybrid			2022-12-27	WOS:000223039700033
J	Chan, AYM; Soltys, CLM; Young, ME; Proud, CG; Dyck, JRB				Chan, AYM; Soltys, CLM; Young, ME; Proud, CG; Dyck, JRB			Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; LEFT-VENTRICULAR HYPERTROPHY; ELONGATION-FACTOR-2 KINASE; PHOSPHORYLATION SITE; MAMMALIAN TARGET; GAMMA(2) SUBUNIT; RAPAMYCIN; GROWTH; MTOR; AKT	A necessary mediator of cardiac myocyte enlargement is protein synthesis, which is controlled at the levels of both translation initiation and elongation. Eukaryotic elongation factor-2 (eEF2) mediates the translocation step of peptide-chain elongation and is inhibited through phosphorylation by eEF2 kinase. In addition, p70S6 kinase can regulate protein synthesis by phosphorylating eEF2 kinase or via phosphorylation of ribosomal protein S6. We have recently shown that eEF2 kinase is also controlled by phosphorylation by AMP-activated protein kinase ( AMPK), a key regulator of cellular energy homeostasis. Moreover, the mammalian target of rapamycin has also been shown to be inhibited, indirectly, by AMPK, thus leading to the inhibition of p70S6 kinase. Although AMPK activation has been shown to modulate protein synthesis, it is unknown whether AMPK could also be a regulator of cardiac hypertrophic growth. Therefore, we investigated the role of AMPK activation in regulating protein synthesis during both phenylephrine- and Akt-induced cardiac hypertrophy. Metformin and 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside were used to activate AMPK in neonatal rat cardiac myocytes. Activation of AMPK significantly decreased protein synthesis induced by phenylephrine treatment or by expression of constitutively active Akt. Activation of AMPK also resulted in decreased p70S6 kinase phosphorylation and increased phosphorylation of eEF2, suggesting that inhibition of protein synthesis involves the eEF2 kinase/eEF2 axis and/or the p70S6 kinase pathway. Together, our data suggest that the inhibition of protein synthesis by pharmacological activation of AMPK may be a key regulatory mechanism by which hypertrophic growth can be controlled.	Univ Alberta, Heritage Med Res Ctr 474, Fac Med, Dept Pediat,Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Fac Med, Dept Pharmacol, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Texas, Hlth Sci Ctr, Brown Fdn Inst Mol Med, Houston, TX 77030 USA; Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Alberta; University of Alberta; University of Texas System; University of Texas Health Science Center Houston; University of Dundee	Dyck, JRB (corresponding author), Univ Alberta, Heritage Med Res Ctr 474, Fac Med, Dept Pediat,Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada.	Jason.Dyck@UAlberta.ca		Proud, Christopher/0000-0003-0704-6442; Dyck, Jason/0000-0002-7045-2884				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALLARD MF, 1991, AM J PHYSIOL, V267, pH742; Arad M, 2003, CIRCULATION, V107, P2850, DOI 10.1161/01.CIR.0000075270.13497.2B; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Diggle TA, 2001, BIOCHEM J, V353, P621, DOI 10.1042/0264-6021:3530621; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403; Hannan RD, 2003, CLIN EXP PHARMACOL P, V30, P517, DOI 10.1046/j.1440-1681.2003.03873.x; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Krieg T, 2002, AM J PHYSIOL-HEART C, V283, pH2322, DOI 10.1152/ajpheart.00474.2002; Lehman John J, 2002, Heart Fail Rev, V7, P175; Lorell BH, 2000, CIRCULATION, V102, P470; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MULLANE K, 1993, CARDIOVASC RES, V27, P43, DOI 10.1093/cvr/27.1.43; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Proud CG, 2004, BIOCHEM BIOPH RES CO, V313, P429, DOI 10.1016/j.bbrc.2003.07.015; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; Richey PA, 1998, J SPORT SCI, V16, P129; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Soltys CLM, 2002, AM J PHYSIOL-HEART C, V283, pH1056, DOI 10.1152/ajpheart.00275.2002; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Tian R, 2001, CIRCULATION, V104, P1664, DOI 10.1161/hc4001.097183; Wang LJ, 2002, FEBS LETT, V531, P285, DOI 10.1016/S0014-5793(02)03536-6; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Xia Y, 2003, J BIOL CHEM, V278, P13143, DOI 10.1074/jbc.M208500200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	59	267	286	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32771	32779		10.1074/jbc.M403528200	http://dx.doi.org/10.1074/jbc.M403528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159410	hybrid			2022-12-27	WOS:000222849700096
J	Graham, ME; Barclay, JW; Burgoyne, RD				Graham, ME; Barclay, JW; Burgoyne, RD			Syntaxin/Munc18 interactions in the late events during vesicle fusion and release in exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NSF ATPASE ACTIVITY; PROTEIN-KINASE-C; SNARE COMPLEX; MEMBRANE-FUSION; NSEC-1 MUNC-18; ALPHA-SNAP; LATE STEPS; CHROMAFFIN; DOCKING; 1A	The SNARE proteins, syntaxin, SNAP-25, and VAMP, form part of the core machinery for membrane fusion during regulated exocytosis. Additional proteins are required to account for the speed, spatial restriction, and tight control of exocytosis and a key role is played by members of the Sec1/Munc18 family of proteins that have been implicated either in vesicle docking or fusion itself through their interactions with the corresponding syntaxin. Using amperometry to assay the kinetics of single vesicle fusion/release events in adrenal chromaffin cells, the effect of expression of syntaxin 1A mutants was examined. Overexpression of wild-type syntaxin or its cytoplasmic domain had no effect on the kinetics of release during single exocytotic events although the cytoplasmic domain reduced the frequency of exocytosis. In contrast, expression of either an open syntaxin 1A or the I233A mutant resulted in increased quantal size and a slowing of the kinetics of release. The wild-type and mutant syntaxins were overexpressed to a similar extent and the only common defect shown by the syntaxin 1A mutants was reduced binding to Munc18-1. These results are consistent with a role for Munc18-1 in controlling the late stages of exocytosis by binding to and limiting the availability of syntaxin in its open conformation. Modification of the Munc18-1/syntaxin 1A interaction would therefore be a key mechanism for the regulation of quantal size.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liv.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Barclay, Jeff W/0000-0003-4320-2094				Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BRENNER S, 1974, GENETICS, V77, P71; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Craig TJ, 2003, J NEUROCHEM, V86, P1450, DOI 10.1046/j.1471-4159.2003.01955.x; CRAIG TJ, 2004, IN PRESS J BIOCH BIO; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2001, J CELL SCI, V114, P4397; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Graham ME, 1997, J NEUROCHEM, V69, P2369; Grote E, 2000, J CELL BIOL, V151, P439, DOI 10.1083/jcb.151.2.439; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; Haynes LP, 1998, FEBS LETT, V436, P1, DOI 10.1016/S0014-5793(98)01088-6; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Matos MF, 2000, EUR J CELL BIOL, V79, P377, DOI 10.1078/0171-9335-00063; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2002, J BIOL CHEM, V277, P9375, DOI 10.1074/jbc.M111729200; Munson M, 2000, NAT STRUCT BIOL, V7, P894; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pothos EN, 2002, J PHYSIOL-LONDON, V542, P453, DOI 10.1113/jphysiol.2002.018630; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rowe J, 2001, J CELL SCI, V114, P3323; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sombers LA, 2004, J NEUROSCI, V24, P303, DOI 10.1523/JNEUROSCI.1119-03.2004; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang CT, 2003, NATURE, V424, P943, DOI 10.1038/nature01857; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Wu MN, 2001, EUR J CELL BIOL, V80, P196, DOI 10.1078/0171-9335-00143; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	56	52	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32751	32760		10.1074/jbc.M400827200	http://dx.doi.org/10.1074/jbc.M400827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175344	hybrid			2022-12-27	WOS:000222849700094
J	Cherukuri, A; Carter, RH; Brooks, S; Bornmann, W; Finn, R; Dowd, CS; Pierce, SK				Cherukuri, A; Carter, RH; Brooks, S; Bornmann, W; Finn, R; Dowd, CS; Pierce, SK			B cell signaling is regulated by induced palmitoylation of CD81	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; LIPID RAFTS; ANTIGEN RECEPTOR; SACCHAROMYCES-CEREVISIAE; ENRICHED MICRODOMAINS; MEMBRANE MICRODOMAIN; TETRASPANIN PROTEINS; CD19/CD21 COMPLEX; ANCHORED PROTEINS; FATTY-ACIDS	Signaling through the B cell antigen receptor (BCR) is amplified and prolonged by coligation of the BCR to the CD19/CD21/CD81 coreceptor complex. Coligation is induced during immune responses by the simultaneous binding of complement-tagged antigens to the complement receptor, CD21, and to the BCR. Enhanced signaling is due in part to the ability of the CD19/CD21/CD81 complex to stabilize the BCR in sphingolipid- and cholesterol-rich membrane microdomains termed lipid rafts. The tetraspanin CD81 is essential for the raft-stabilizing function of the coreceptor. Here we show that coligation of the BCR and the CD19/CD21/CD81 complex leads to selective, rapid, and reversible palmitoylation of CD81 and that palmitoylation is necessary for the raft stabilizing function of the CD19/CD21/CD81 complex. Inducible palmitoylation may represent a novel mechanism by which tetraspanins function to facilitate lipid raft-dependent receptor signaling.	NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Univ Alabama, Dept Med & Microbiol, Birmingham, AL 35294 USA; Mem Sloan Kettering Canc Ctr, Radiochem Core Facil, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Alabama System; University of Alabama Birmingham; Memorial Sloan Kettering Cancer Center	Pierce, SK (corresponding author), NIAID, Immunogenet Lab, NIH, Twinbrook 2,12441 Parklawn Dr,Rm 200B,MSC 8180, Rockville, MD 20852 USA.	spierce@nih.gov						Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brooks SR, 2000, J IMMUNOL, V164, P3123, DOI 10.4049/jimmunol.164.6.3123; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Cheng PC, 2001, J IMMUNOL, V166, P3693, DOI 10.4049/jimmunol.166.6.3693; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cherukuri A, 2004, J IMMUNOL, V172, P370, DOI 10.4049/jimmunol.172.1.370; Cherukuri A, 2001, IMMUNITY, V14, P169; Clark KL, 2004, J BIOL CHEM, V279, P19401, DOI 10.1074/jbc.M312626200; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Gidwani A, 2001, BIOCHEMISTRY-US, V40, P12422, DOI 10.1021/bi010496c; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; KNAPP FF, 1984, J MED CHEM, V27, P94, DOI 10.1021/jm00367a021; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Liang XQ, 2002, J BIOL CHEM, V277, P33032, DOI 10.1074/jbc.M204607200; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Maecker HT, 2000, HYBRIDOMA, V19, P15, DOI 10.1089/027245700315752; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; MASON DY, 1991, J IMMUNOL, V147, P2474; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Micchelli CA, 2002, DEVELOPMENT, V129, P843; Nakao F, 2002, CIRC RES, V91, P953, DOI 10.1161/01.RES.0000042702.04920.BF; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Weintraub BC, 2000, J EXP MED, V191, P1443, DOI 10.1084/jem.191.8.1443; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	51	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31973	31982		10.1074/jbc.M404410200	http://dx.doi.org/10.1074/jbc.M404410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15161911	hybrid			2022-12-27	WOS:000222726800126
J	Hu, HZ; Gu, QH; Wang, CB; Colton, CK; Tang, JS; Kinoshita-Kawada, M; Lee, LY; Wood, JD; Zhu, MX				Hu, HZ; Gu, QH; Wang, CB; Colton, CK; Tang, JS; Kinoshita-Kawada, M; Lee, LY; Wood, JD; Zhu, MX			2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; CAPSAICIN-RECEPTOR; CA2+ RELEASE; ION-CHANNEL; VANILLOID RECEPTOR-1; TRPC3 CHANNELS; ENTRY; 2-APB; HEAT; SENSITIVITY	The transient receptor potential (TRP) superfamily contains a large number of proteins encoding cation permeable channels that are further divided into TRPC (canonical), TRPM (melastatin), and TRPV (vanilloid) subfamilies. Among the six TRPV members, TRPV1, TRPV2, TRPV3, and TRPV4 form heat-activated cation channels, which serve diverse functions ranging from nociception to osmolality regulation. Although chemical activators for TRPV1 and TRPV4 are well documented, those for TRPV2 and TRPV3 are lacking. Here we show that in the absence of other stimuli, 2-aminoethoxydiphenyl borate (2APB) activates TRPV1, TRPV2, and TRPV3, but not TRPV4, TRPV5, and TRPV6 expressed in HEK293 cells. In contrast, 2APB inhibits the activity of TRPC6 and TRPM8 evoked by 1-oleolyl-2-acetyl-sn-glycerol and menthol, respectively. In addition, low levels of 2APB strongly potentiate the effect of capsaicin, protons, and heat on TRPV1 as well as that of heat on TRPV3 expressed in Xenopus oocytes. In dorsal root ganglia neurons, supra-additive stimulations were evoked by 2APB and capsaicin or 2APB and acid. Our data suggest the existence of a common activation mechanism for TRPV1, TRPV2, and TRPV3 that may serve as a therapeutic target for pain management and treatment for diseases caused by hypersensitivity and temperature misregulation.	Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Kentucky, Med Ctr, Dept Physiol, Lexington, KY 40536 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University of Kentucky; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Wood, JD (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 304 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	wood.13@osu.edu; zhu.55@osu.edu		Hu, Hongzhen/0000-0002-8967-7522; Lee, Lu-Yuan/0000-0001-8306-2845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL067379, R01HL067379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042183] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67379] Funding Source: Medline; NIDDK NIH HHS [DK057075] Funding Source: Medline; NINDS NIH HHS [NS42183] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Lemonnier L, 2004, FEBS LETT, V556, P121, DOI 10.1016/S0014-5793(03)01387-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2003, BIOCHEM J, V376, P667, DOI 10.1042/BJ20031345; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; McIntyre P, 2001, BRIT J PHARMACOL, V132, P1084, DOI 10.1038/sj.bjp.0703918; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Tsuzuki K, 2004, J NEUROSCI, V24, P762, DOI 10.1523/JNEUROSCI.4658-03.2004; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	52	372	410	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35741	35748		10.1074/jbc.M404164200	http://dx.doi.org/10.1074/jbc.M404164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194687	hybrid			2022-12-27	WOS:000223303400073
J	Kovacs, M; Toth, J; Hetenyi, C; Malnasi-Csizmadia, A; Sellers, JR				Kovacs, M; Toth, J; Hetenyi, C; Malnasi-Csizmadia, A; Sellers, JR			Mechanism of blebbistatin inhibition of myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; RABBIT SKELETAL-MUSCLE; TRYPTOPHAN RESIDUE; NEURITE OUTGROWTH; MOTOR DOMAIN; BINDING; ACTIN; CONTRACTION; TRANSITION; RESOLUTION	Blebbistatin is a recently discovered small molecule inhibitor showing high affinity and selectivity toward myosin II. Here we report a detailed investigation of its mechanism of inhibition. Blebbistatin does not compete with nucleotide binding to the skeletal muscle myosin subfragment-1. The inhibitor preferentially binds to the ATPase intermediate with ADP and phosphate bound at the active site, and it slows down phosphate release. Blebbistatin interferes neither with binding of myosin to actin nor with ATP-induced actomyosin dissociation. Instead, it blocks the myosin heads in a products complex with low actin affinity. Blind docking molecular simulations indicate that the productive blebbistatin-binding site of the myosin head is within the aqueous cavity between the nucleotide pocket and the cleft of the actin-binding interface. The property that blebbistatin blocks myosin II in an actin-detached state makes the compound useful both in muscle physiology and in exploring the cellular function of cytoplasmic myosin II isoforms, whereas the stabilization of a specific myosin intermediate confers a great potential in structural studies.	NIH, Mol Cardiol Lab, NHLBI, Bethesda, MD 20892 USA; Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Eotvos Lorand University	Sellers, JR (corresponding author), NIH, Mol Cardiol Lab, NHLBI, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.	sellersj@nhlbi.nih.gov	Csizmadia, András Málnási/K-7632-2018; Kovacs, Mihaly/A-6841-2011; Hetenyi, Csaba/G-5249-2010	Csizmadia, András Málnási/0000-0002-2430-8398; Hetenyi, Csaba/0000-0002-8013-971X; Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004234, Z01HL004234] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Brown J, 2003, J HISTOCHEM CYTOCHEM, V51, P421, DOI 10.1177/002215540305100403; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Hetenyi C, 2002, PROTEIN SCI, V11, P1729, DOI 10.1110/ps.0202302; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; LIMOUZE J, 2004, IN PRESS J MUSCLE RE; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; OKAMOTO Y, 1985, J BIOCHEM-TOKYO, V98, P1143, DOI 10.1093/oxfordjournals.jbchem.a135365; Onishi H, 2000, P NATL ACAD SCI USA, V97, P11203, DOI 10.1073/pnas.200362897; Ostap EM, 2002, J MUSCLE RES CELL M, V23, P305, DOI 10.1023/A:1022047102064; Park S, 2000, BIOCHEMISTRY-US, V39, P11732, DOI 10.1021/bi000945t; Sellers J. R., 1999, MYOSINS; Shaw MA, 2003, BIOCHEMISTRY-US, V42, P6128, DOI 10.1021/bi026964f; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Urbanke C, 2001, BIOCHEM J, V358, P165, DOI 10.1042/0264-6021:3580165; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wylie SR, 2003, MOL BIOL CELL, V14, P4654, DOI 10.1091/mbc.E03-03-0187; Wylie SR, 1998, P NATL ACAD SCI USA, V95, P12967, DOI 10.1073/pnas.95.22.12967; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yumura S, 2003, INT REV CYTOL, V224, P173, DOI 10.1016/S0074-7696(05)24005-6	31	693	704	5	79	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35557	35563		10.1074/jbc.M405319200	http://dx.doi.org/10.1074/jbc.M405319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205456	hybrid			2022-12-27	WOS:000223303400051
J	Patenge, N; Elkin, SK; Oettinger, MA				Patenge, N; Elkin, SK; Oettinger, MA			ATP-dependent remodeling by SWI/SNF and ISWI proteins stimulates V(D)J cleavage of 5 S arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLATION; CHROMATIN-STRUCTURE; NUCLEOSOMAL DNA; TRANSCRIPTION FACTORS; PHD FINGER; GENE; RECOMBINATION; RAG2; ACCESSIBILITY; CELL	Control of V(D)J recombination is critical for the generation of a fully developed immune repertoire. The molecular mechanisms underlying the regulation of antigen receptor gene assembly are beginning to be revealed. Here we studied the influence of chromatin modifications on V(D)J cleavage of a polynucleosomal substrate, in which V(D)J cleavage is greatly reduced compared with naked DNA. ATP-dependent remodeling by human SWI/SNF (hSWI/SNF) in the presence of HMG1 led to a substantial increase of cleavage by the recombination activation gene (RAG) proteins. Either BRG1, the ATPase subunit of hSWI/SNF, or SNF2h, the ATPase of human ISWI complexes, was capable of stimulating V(D)J cleavage of the array, although these remodelers act by different mechanisms. No effect of histone hyperacetylation was detectable in this system. As is observed on naked DNA, in the presence of core RAG1, the full-length RAG2 protein proved to be more active than core RAG2 on these polynucleosomal arrays, reinforcing the importance of the RAG2 C-terminal domain for efficient recombination. Comparison of 5 S array cleavage by the RAG proteins or by the restriction enzyme HhaI after remodeling by hSWI/SNF suggested that RAG proteins and HhaI might have different requirements for maximal accessibility of the substrate.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Oettinger, MA (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Wellman 10,50 Blossom St, Boston, MA 02114 USA.	oettinger@frodo.mgh.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48026] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Agata Y, 2001, J EXP MED, V193, P873, DOI 10.1084/jem.193.7.873; Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P1209, DOI 10.1073/pnas.0237043100; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; Angelin-Duclos C, 1998, MOL CELL BIOL, V18, P6253, DOI 10.1128/MCB.18.11.6253; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Baumann M, 2003, EMBO J, V22, P5197, DOI 10.1093/emboj/cdg487; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; Carruthers LM, 1999, METHOD ENZYMOL, V304, P19; Cherry SR, 1999, P NATL ACAD SCI USA, V96, P10788, DOI 10.1073/pnas.96.19.10788; Chowdhury D, 2001, EMBO J, V20, P6394, DOI 10.1093/emboj/20.22.6394; COTE J, 1995, METHODS MOL GEN, V6, P102; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Elkin SK, 2003, EMBO J, V22, P1931, DOI 10.1093/emboj/cdg184; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Golding A, 1999, EMBO J, V18, P3712, DOI 10.1093/emboj/18.13.3712; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kirch SA, 1998, EMBO J, V17, P4881, DOI 10.1093/emboj/17.16.4881; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; Langst G, 2001, J CELL SCI, V114, P2561; LEWIS SM, 1994, ADV IMMUNOL, V56, P127; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Maes J, 2001, J IMMUNOL, V167, P866, DOI 10.4049/jimmunol.167.2.866; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; McBlane F, 2000, CURR BIOL, V10, P483, DOI 10.1016/S0960-9822(00)00449-8; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Morshead KB, 2003, P NATL ACAD SCI USA, V100, P11577, DOI 10.1073/pnas.1932643100; Narlikar GJ, 2001, MOL CELL, V8, P1219, DOI 10.1016/S1097-2765(01)00412-9; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OwenHughes T, 1996, EMBO J, V15, P4702, DOI 10.1002/j.1460-2075.1996.tb00847.x; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tripathi R, 2002, J IMMUNOL, V168, P2316, DOI 10.4049/jimmunol.168.5.2316; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; VanGent DC, 1996, CURR TOP MICROBIOL, V217, P1; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; Ye SK, 2001, IMMUNITY, V15, P813, DOI 10.1016/S1074-7613(01)00230-8	70	41	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35360	35367		10.1074/jbc.M405790200	http://dx.doi.org/10.1074/jbc.M405790200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201272	hybrid			2022-12-27	WOS:000223303400029
J	Tikunova, SB; Davis, JP				Tikunova, SB; Davis, JP			Designing calcium-sensitizing mutations in the regulatory domain of cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNESIUM BINDING-SITES; CA2+ BINDING; EF-HAND; STRUCTURAL TRANSITION; CONFORMATIONAL CHANGE; TARGET RECOGNITION; N-DOMAIN; EXCHANGE; AFFINITY; MG2+	Cardiac troponin C belongs to the EF-hand superfamily of calcium-binding proteins and plays an essential role in the regulation of muscle contraction and relaxation. To follow calcium binding and exchange with the regulatory N-terminal domain (N-domain) of human cardiac troponin C, we substituted Phe at position 27 with Trp, making a fluorescent cardiac troponin C-F27W. Trp(27) accurately reported the kinetics of calcium association and dissociation of the N-domain of cardiac troponin C-F27W. To sensitize the N-domain of cardiac troponin C-F27W to calcium, we individually substituted the hydrophobic residues Phe(20), Val(44), Met(45), Leu(48), and Met(81) with polar Gln. These mutations were designed to increase the calcium affinity of the N-domain of cardiac troponin C by facilitating the movement of helices B and C (BC unit) away from helices N, A, and D (NAD unit). As anticipated, these selected hydrophobic residue substitutions increased the calcium affinity of the regulatory domain of cardiac troponin C-F27W similar to2.1-15.2-fold. Surprisingly, the increased calcium affinity caused by the hydrophobic residue substitutions was largely due to faster calcium association rates (2.6-8.7-fold faster) rather than to slower calcium dissociation rates (1.2-2.9-fold slower). The regulatory N-domains of cardiac troponin C-F27W and its mutants were also able to bind magnesium competitively and with physiologically relevant affinities (1.2-2.7 mM). The design of calcium-sensitizing cardiac troponin C mutants presented in this work enhances the understanding of how to control cation binding properties of EF-hand proteins and ultimately their structure and physiological function.	Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Tikunova, SB (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 209 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	tikunova1@hotmail.com			NHLBI NIH HHS [HL073600] Funding Source: Medline; NIAMS NIH HHS [AR20792] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020792] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ababou A, 2001, BIOCHEMISTRY-US, V40, P12719, DOI 10.1021/bi010405b; Ababou A, 2001, PROTEIN SCI, V10, P301, DOI 10.1110/ps.33601; Allen K, 2000, J APPL PHYSIOL, V88, P180, DOI 10.1152/jappl.2000.88.1.180; Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; Arteaga GM, 2002, ANN MED, V34, P248, DOI 10.1080/078538902320322510; BEST PM, 1977, J PHYSIOL-LONDON, V265, P1; Black DJ, 2000, BIOCHEMISTRY-US, V39, P13831, DOI 10.1021/bi001106+; BLACK DJ, 2001, BIOPHYS J, V80, P408; Browne JP, 1997, BIOCHEMISTRY-US, V36, P9550, DOI 10.1021/bi970460d; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; Davis JP, 2004, J BIOL CHEM, V279, P17348, DOI 10.1074/jbc.M314095200; Davis JP, 2002, J BIOL CHEM, V277, P49716, DOI 10.1074/jbc.M208488200; Davis JP, 1999, BIOCHEMISTRY-US, V38, P4235, DOI 10.1021/bi982495z; de Tombe PP, 1998, CARDIOVASC RES, V37, P367, DOI 10.1016/S0008-6363(97)00275-7; DONALDSON SKB, 1978, J GEN PHYSIOL, V71, P645, DOI 10.1085/jgp.71.6.645; Dong WJ, 1996, J BIOL CHEM, V271, P688, DOI 10.1074/jbc.271.2.688; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; Erhardt Leif R, 2003, Ital Heart J, V4 Suppl 2, p27S; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; Gillis TE, 2003, BIOCHEMISTRY-US, V42, P6418, DOI 10.1021/bi0340494; Gillis TE, 2003, AM J PHYSIOL-CELL PH, V284, pC1176, DOI 10.1152/ajpcell.00339.2002; Gillis TE, 2000, AM J PHYSIOL-REG I, V279, pR1707, DOI 10.1152/ajpregu.2000.279.5.R1707; Gomes AV, 2002, IUBMB LIFE, V54, P323, DOI 10.1080/15216540216037; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; Hazard AL, 1998, PROTEIN SCI, V7, P2451, DOI 10.1002/pro.5560071123; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; HONGO K, 1994, JPN J PHYSIOL, V44, P357, DOI 10.2170/jjphysiol.44.357; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kragelund BB, 1998, BIOCHEMISTRY-US, V37, P8926, DOI 10.1021/bi9726436; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; Malmendal A, 1998, J BIOL CHEM, V273, P28994, DOI 10.1074/jbc.273.44.28994; Moyes CD, 1996, BIOCHEMISTRY-US, V35, P11756, DOI 10.1021/bi9607057; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; OGAWA Y, 1985, J BIOCHEM-TOKYO, V97, P1011, DOI 10.1093/oxfordjournals.jbchem.a135143; Ohki SY, 1997, BIOCHEMISTRY-US, V36, P4309, DOI 10.1021/bi962759m; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POTTER JD, 1975, J BIOL CHEM, V250, P4628; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; Rupp H, 1982, Adv Myocardiol, V3, P455; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SOLARO RJ, 1976, CIRC RES, V39, P8, DOI 10.1161/01.RES.39.1.8; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; Tikunova SB, 2004, BIOPHYS J, V86, p394A; Tikunova SB, 2002, BIOCHEMISTRY-US, V41, P6697, DOI 10.1021/bi011763h; Tikunova SB, 2001, BIOCHEMISTRY-US, V40, P3348, DOI 10.1021/bi0021333; Wang ST, 1998, BIOCHEMISTRY-US, V37, P14539, DOI 10.1021/bi9814641	61	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35341	35352		10.1074/jbc.M405413200	http://dx.doi.org/10.1074/jbc.M405413200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205455	hybrid			2022-12-27	WOS:000223303400027
J	Carvalho, AL; Goyal, A; Prates, JAM; Bolam, DN; Gilbert, HJ; Pires, VMR; Ferreira, LMA; Planas, A; Romao, MJ; Fontes, CMGA				Carvalho, AL; Goyal, A; Prates, JAM; Bolam, DN; Gilbert, HJ; Pires, VMR; Ferreira, LMA; Planas, A; Romao, MJ; Fontes, CMGA			The family 11 carbohydrate-binding module of Clostridium thermocellum Lic26A-Cel5E accommodates beta-1,4- and beta-1,3-1,4-mixed linked glucans at a single binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; LIGAND-BINDING; AFFINITY ELECTROPHORESIS; SEQUENCE; COMPLEX; RECOGNITION; DOMAINS; OLIGOSACCHARIDES; IDENTIFICATION; SPECIFICITY	Modular glycoside hydrolases that attack recalcitrant polymers generally contain noncatalytic carbohydrate-binding modules (CBMs), which play a critical role in the action of these enzymes by localizing the appended catalytic domains onto the surface of insoluble polysaccharide substrates. Type B CBMs, which recognize single polysaccharide chains, display ligand specificities that are consistent with the substrates hydrolyzed by the associated catalytic domains. In enzymes that contain multiple catalytic domains with distinct substrate specificities, it is unclear how these different activities influence the evolution of the ligand recognition profile of the appended CBM. To address this issue, we have characterized the properties of a family 11 CBM (CtCBM11) in Clostridium thermocellum Lic26A-Cel5E, an enzyme that contains GH5 and GH26 catalytic domains that display beta-1,4- and beta-1,3 -1,4-mixed linked endoglucanase activity, respectively. Here we show that CtCBM11 binds to both beta-1,4- and beta-1,3-1,4-mixed linked glucans, displaying K-a values of 1.9 x 10(5), 4.4 x 10(4), and 2 x 10(3) M-1 for Glc-beta1,4-Glc-beta1,4-Glc- beta1,3-Glc, Glc-beta1,4-Glc-beta1,4-Glc-beta1,4-Glc, and Glc-beta1,3-Glc- beta1,4-Glc-beta1,3-Glc, respectively, demonstrating that CBMs can display a preference for mixed linked glucans. To determine whether these ligands are accommodated in the same or diverse sites in CtCBM11, the crystal structure of the protein was solved to a resolution of 1.98 Angstrom. The protein displays a beta-sandwich with a concave side that forms a potential binding cleft. Site-directed mutagenesis revealed that Tyr(22), Tyr(53), and Tyr(129), located in the putative binding cleft, play a central role in the recognition of all the ligands recognized by the protein. We propose, therefore, that CtCBM11 contains a single ligand-binding site that displays affinity for both beta-1,4- and beta-1,3 - 1,4-mixed linked glucans.	Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal; Univ Tecn Lisboa, Ctr Interdisciplinar Invest Sanidade Anim, Fac Med Vet, P-1300744 Lisbon, Portugal; Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Ramon Llull, Biochem Lab, Inst Quim Sarria, Barcelona 08017, Spain	Universidade Nova de Lisboa; Universidade de Lisboa; Newcastle University - UK; Universitat Ramon Llull; Institut Quimic de Sarria	Romao, MJ (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal.	mromao@dq.fct.unl.pt; cafontes@fmv.utl.pt	Carvalho, Ana Luísa/G-5638-2011; Pires, Virginia/J-4799-2013; Prates, José A M/K-9934-2013; Romao, Maria J/A-4115-2013; UCIBIO, U Cienc Biom Apl/F-7948-2017; PLANAS, ANTONI/I-4803-2015	Carvalho, Ana Luísa/0000-0002-3824-0240; Pires, Virginia/0000-0003-1307-3797; Prates, José A M/0000-0003-1032-5987; Romao, Maria J/0000-0002-3004-0543; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; PLANAS, ANTONI/0000-0001-7073-3320; Ferreira, Luis/0000-0002-3543-9166; Fontes, Carlos/0000-0002-1219-9753; Bolam, David/0000-0003-0314-3122				Abou-Hachem M, 2002, BIOCHEMISTRY-US, V41, P5720, DOI 10.1021/bi012094a; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bolam DN, 2004, J BIOL CHEM, V279, P22953, DOI 10.1074/jbc.M313317200; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Coutinho PM, 1999, ROY SOC CH, P3; COWTAN K, 1994, JOINT CCP4 ESF EACBM, V31; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; Faijes M, 2003, BIOCHEMISTRY-US, V42, P13304, DOI 10.1021/bi030131n; Gilbert HJ, 2002, ROY SOC CH, P89, DOI 10.1039/9781847550323-00089; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JAMAL S, 2004, IN PRESS STRUCTURE; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Malburg SRC, 1997, APPL ENVIRON MICROB, V63, P2449, DOI 10.1128/AEM.63.6.2449-2453.1997; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pearson WR, 1998, J MOL BIOL, V276, P71, DOI 10.1006/jmbi.1997.1525; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; ROUSSEL A, 1991, TURBO FRODO SILICON, P86; Shoham Y, 1999, TRENDS MICROBIOL, V7, P275, DOI 10.1016/S0966-842X(99)01533-4; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Sulzenbacher G, 1999, BIOCHEMISTRY-US, V38, P4826, DOI 10.1021/bi982648i; Sunna A, 2001, BIOCHEM J, V356, P791, DOI 10.1042/0264-6021:3560791; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tomme P, 2000, ENZYME MICROB TECH, V27, P453, DOI 10.1016/S0141-0229(00)00246-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; WOOD TM, 1988, METHOD ENZYMOL, V160, P19; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; YAGUE E, 1990, GENE, V89, P61, DOI 10.1016/0378-1119(90)90206-7	43	84	91	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34785	34793		10.1074/jbc.M405867200	http://dx.doi.org/10.1074/jbc.M405867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192099	hybrid			2022-12-27	WOS:000223134800086
J	Hormann, F; Kuchler, M; Sveshnikov, D; Oppermann, U; Li, Y; Soll, J				Hormann, F; Kuchler, M; Sveshnikov, D; Oppermann, U; Li, Y; Soll, J			Tic32, an essential component in chloroplast biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER ENVELOPE MEMBRANE; SHORT-CHAIN DEHYDROGENASES/REDUCTASES; PROTEIN IMPORT MACHINERY; 11-CIS RETINOL DEHYDROGENASE; ARABIDOPSIS-THALIANA; PRECURSOR PROTEINS; REVERSE GENETICS; BINDING PROTEIN; REDOX STATE; TRANSLOCATION	Chloroplast protein import across the inner envelope is facilitated by the translocon of the inner envelope of chloroplasts (Tic). Here we have identified Tic32 as a novel subunit of the Tic complex. Tic32 can be purified from solubilized inner envelope membranes by chromatography on Tic110 containing affinity matrix. Co-immunoprecipitation experiments using either Tic32 or Tic110 antisera indicated a tight association between these polypeptides as well as with other Tic subunits, e. g. Tic40, Tic22, or Tic62, whereas the outer envelope protein Toc75 was not found in this complex. Chemical cross-linking suggests that Tic32 is involved late in the overall translocation process, because both the precursor form as well as the mature form of Rubisco small subunit can be detected. We were unable to isolate Arabidopsis null mutants of the attic32 gene, indicating that Tic32 is essential for viability. Deletion of the attic32 gene resulted in early seed abortion because the embryo was unable to differentiate from the heart stage to the torpedo stage. The homology of Tic32 to short-chain dehydrogenases suggests a dual role of Tic32 in import, one as a regulatory component and one as an important subunit in the assembly of the entire complex.	Univ Munich, Dept Biol & Plant Biochem, D-80638 Munich, Germany; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Max Planck Inst Plant Breeding, D-50829 Cologne, Germany	University of Munich; Karolinska Institutet; Max Planck Society	Soll, J (corresponding author), Univ Munich, Dept Biol & Plant Biochem, Menzinger Str 67, D-80638 Munich, Germany.	soll@uni-muenchen.de	Li, Yong/A-6283-2011	Li, Yong/0000-0003-2651-8791				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; Bahring R, 2001, J BIOL CHEM, V276, P22923, DOI 10.1074/jbc.M100483200; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; Chen XJ, 2002, PLANT CELL, V14, P641, DOI 10.1105/tpc.010336; Cheng WH, 2002, PLANT CELL, V14, P2723, DOI 10.1105/tpc.006494; Chou ML, 2003, EMBO J, V22, P2970, DOI 10.1093/emboj/cdg281; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; Heins L, 2002, EMBO J, V21, P2616, DOI 10.1093/emboj/21.11.2616; Hiltbrunner A, 2001, BIOCHEM CELL BIOL, V79, P629, DOI 10.1139/bcb-79-5-629; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; Hirohashi T, 2001, PLANT PHYSIOL, V125, P2154, DOI 10.1104/pp.125.4.2154; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Inaba T, 2003, J BIOL CHEM, V278, P38617, DOI 10.1074/jbc.M306367200; Jelic M, 2002, BIOL CHEM, V383, P1875, DOI 10.1515/BC.2002.211; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Keegstra K, 1999, CURR OPIN PLANT BIOL, V2, P471, DOI 10.1016/S1369-5266(99)00021-7; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kim J, 2003, PLANT CELL PHYSIOL, V44, P85, DOI 10.1093/pcp/pcg013; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kuchler M, 2002, EMBO J, V21, P6136, DOI 10.1093/emboj/cdf621; Liu CM, 1998, PLANT J, V16, P21, DOI 10.1046/j.1365-313x.1998.00268.x; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NADA A, 2004, IN PRESS J CELL SCI; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oswald O, 2001, P NATL ACAD SCI USA, V98, P2047, DOI 10.1073/pnas.021449998; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; Pfannschmidt T, 2001, J BIOL CHEM, V276, P36125, DOI 10.1074/jbc.M105701200; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Rogl H, 1998, FEBS LETT, V432, P21, DOI 10.1016/S0014-5793(98)00825-4; Rosso MG, 2003, PLANT MOL BIOL, V53, P247, DOI 10.1023/B:PLAN.0000009297.37235.4a; Rylott EL, 2003, J BIOL CHEM, V278, P21370, DOI 10.1074/jbc.M300826200; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; Sessions A, 2002, PLANT CELL, V14, P2985, DOI 10.1105/tpc.004630; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1999, J CELL SCI, V112, P549; Soll J, 2002, CURR OPIN PLANT BIOL, V5, P529, DOI 10.1016/S1369-5266(02)00296-0; Stahl T, 1999, J BIOL CHEM, V274, P37467, DOI 10.1074/jbc.274.52.37467; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; Sun YJ, 2002, NAT STRUCT BIOL, V9, P95, DOI 10.1038/nsb744; Sveshnikova N, 2000, P NATL ACAD SCI USA, V97, P4973, DOI 10.1073/pnas.080491597; THEG SM, 1989, J BIOL CHEM, V264, P6730; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	61	78	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34756	34762		10.1074/jbc.M402817200	http://dx.doi.org/10.1074/jbc.M402817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180984	hybrid, Green Published			2022-12-27	WOS:000223134800082
J	Ivetic, A; Florey, O; Deka, J; Haskard, DO; Ager, A; Ridley, AJ				Ivetic, A; Florey, O; Deka, J; Haskard, DO; Ager, A; Ridley, AJ			Mutagenesis of the ezrin-radixin-moesin binding domain of L-selectin tail affects shedding, microvillar positioning, and leukocyte tethering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INTERCELLULAR-ADHESION MOLECULE-3; CYTOPLASMIC DOMAIN; HUMAN NEUTROPHILS; DOWN-REGULATION; SUBCELLULAR-LOCALIZATION; GLYCOPROTEIN LIGAND-1; T-LYMPHOCYTES; ERM PROTEINS; IN-VIVO	L-selectin is a cell adhesion molecule that mediates the initial capture ( tethering) and subsequent rolling of leukocytes along ligands expressed on endothelial cells. We have previously identified ezrin and moesin as novel binding partners of the 17-amino acid L-selectin tail, but the biological role of this interaction is not known. Here we identify two basic amino acid residues within the L-selectin tail that are required for binding to ezrin-radixin-moesin (ERM) proteins: arginine 357 and lysine 362. L-selectin mutants defective for ERM binding show reduced localization to microvilli and decreased phorbol 12-myristate 13-acetate-induced shedding of the L-selectin ectodomain. Cells expressing these L-selectin mutants have reduced tethering to the L-selectin ligand P-selectin glycoprotein ligand-1, but rolling velocity on P-selectin glycoprotein ligand-1 is not affected. These results suggest that ERM proteins are required for microvillar positioning of L-selectin and that this is important both for leukocyte tethering and L-selectin shedding.	Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England; Hammersmith Hosp, BHF Cardiovasc Med Unit, Imperial Coll, London W12 0NN, England; Natl Inst Med Res, Div Prot Structure, London NW7 1AA, England; Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; Imperial College London; MRC National Institute for Medical Research; MRC National Institute for Medical Research; University of London; University College London	Ivetic, A (corresponding author), Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	aleks@ludwig.ucl.ac.uk		Ridley, Anne/0000-0001-8186-5708; Florey, Oliver/0000-0002-1075-7424; Ager, Ann/0000-0002-5763-8908; Ivetic, Aleksandar/0000-0001-9844-6518				Alexander SR, 2000, J LEUKOCYTE BIOL, V67, P415, DOI 10.1002/jlb.67.3.415; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; BORREGAARD N, 1994, J LEUKOCYTE BIOL, V56, P80, DOI 10.1002/jlb.56.1.80; Brenner B, 1997, BIOCHEM BIOPH RES CO, V231, P802, DOI 10.1006/bbrc.1997.6191; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Brenner B, 1998, EXP CELL RES, V243, P123, DOI 10.1006/excr.1998.4146; Brenner B, 1997, IMMUNOLOGY, V92, P214, DOI 10.1046/j.1365-2567.1997.00336.x; Condon TP, 2001, ANTISENSE NUCLEIC A, V11, P107, DOI 10.1089/108729001750171353; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; Fors BP, 2001, J IMMUNOL, V167, P3642, DOI 10.4049/jimmunol.167.7.3642; Gal I, 2003, J BIOL CHEM, V278, P11150, DOI 10.1074/jbc.M210661200; Gamulescu MA, 2003, PLATELETS, V14, P211, DOI 10.1080/0953710031000118830; Gomez-Gaviro MV, 2002, J BIOL CHEM, V277, P38212, DOI 10.1074/jbc.M205142200; Ivetic A, 2004, IMMUNOLOGY, V112, P165, DOI 10.1111/j.1365-2567.2004.01882.x; Ivetic A, 2002, J BIOL CHEM, V277, P2321, DOI 10.1074/jbc.M109460200; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; Khan AI, 2003, INFLAMMATION, V27, P265, DOI 10.1023/A:1026056525755; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; LEY K, 1993, BLOOD, V82, P1632; Malhotra R, 1996, BIOCHEM J, V320, P589, DOI 10.1042/bj3200589; Malhotra R, 1997, BIOESSAYS, V19, P919, DOI 10.1002/bies.950191012; Malhotra R, 1997, CHEM BIOL, V4, P543, DOI 10.1016/S1074-5521(97)90240-4; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Serrador JM, 2002, J BIOL CHEM, V277, P10400, DOI 10.1074/jbc.M110694200; Serrador JM, 2002, EUR J IMMUNOL, V32, P1560, DOI 10.1002/1521-4141(200206)32:6<1560::AID-IMMU1560>3.0.CO;2-U; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; SZABO A, 1995, CURR OPIN STRUC BIOL, V5, P699, DOI 10.1016/0959-440X(95)80064-6; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Turutin DV, 2003, FEBS LETT, V536, P241, DOI 10.1016/S0014-5793(03)00061-9; Urzainqui A, 2002, IMMUNITY, V17, P401, DOI 10.1016/S1074-7613(02)00420-X; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228; Zhao L C, 2001, Dev Immunol, V8, P267, DOI 10.1155/2001/91831; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200	55	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33263	33272		10.1074/jbc.M312212200	http://dx.doi.org/10.1074/jbc.M312212200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178693	hybrid			2022-12-27	WOS:000223039700032
J	Kalin, N; Fernandes, J; Hrafnsdottir, S; van Meer, G				Kalin, N; Fernandes, J; Hrafnsdottir, S; van Meer, G			Natural phosphatidylcholine is actively translocated across the plasma membrane to the surface of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; MDR3 P-GLYCOPROTEIN; INTACT HUMAN-ERYTHROCYTES; RED-BLOOD-CELLS; TRANSBILAYER MOVEMENT; FLIP-FLOP; MULTIDRUG TRANSPORTER; LIPID ASYMMETRY; CARNITINE PALMITOYLTRANSFERASE; INTRACELLULAR-TRANSPORT	The cell surface of eukaryotic cells is enriched in choline phospholipids, whereas the aminophospholipids are concentrated at the cytosolic side of the plasma membrane by the activity of one or more P-type ATPases. Lipid translocation has been investigated mostly by using short chain lipid analogs because assays for endogenous lipids are inherently complicated. In the present paper, we optimized two independent assays for the translocation of natural phosphatidylcholine (PC) to the cell surface based on the hydrolysis of outer leaflet phosphoglycerolipids by exogenous phospholipase A(2) and the exchange of outer leaflet PC by a transfer protein. We report that PC reached the cell surface in the absence of vesicular traffic by a pathway that involved translocation across the plasma membrane. In erythrocytes, PC that was labeled at the inside of the plasma membrane was translocated to the cell surface with a half-time of 30 min. This translocation was probably mediated by an ATPase, because it required ATP and was vanadate-sensitive. The inhibition of PC translocation by glibenclamide, an inhibitor of various ATP binding cassette transporters, and its reduction in erythrocytes from both Abcb1a/1b and Abcb4 knockout mice, suggest the involvement of ATP binding cassette transporters in natural PC cell surface translocation. The relative importance of the outward translocation of PC as compared with the well characterized fast inward translocation of phosphatidylserine for the overall asymmetric phospholipid organization in plasma membranes remains to be established.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Membrane Enzymol, NL-3584 CH Utrecht, Netherlands	Utrecht University	Kalin, N (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Membrane Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	nanette.kaelin@dlr.de	van Meer, Gerrit/AAH-1560-2021	van Meer, Gerrit/0000-0002-5976-6436				Allen JD, 2000, CANCER RES, V60, P5761; Allen JD, 2002, MOL CANCER THER, V1, P417; ANDRICK C, 1991, BIOCHIM BIOPHYS ACTA, V1064, P235, DOI 10.1016/0005-2736(91)90307-T; ARDUINI A, 1992, J BIOL CHEM, V267, P12673; BERR F, 1993, J BIOL CHEM, V268, P3976; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Bosch I, 1997, BIOCHEMISTRY-US, V36, P5685, DOI 10.1021/bi962728r; CLASSEN J, 1989, J MEMBRANE BIOL, V111, P169, DOI 10.1007/BF01871780; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; CONNOR J, 1992, J BIOL CHEM, V267, P19412; Contreras FX, 2003, J BIOL CHEM, V278, P37169, DOI 10.1074/jbc.M303206200; CRAIN RC, 1980, BIOCHIM BIOPHYS ACTA, V620, P37, DOI 10.1016/0005-2760(80)90182-4; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Devaux PF, 2000, BIOCHIMIE, V82, P497, DOI 10.1016/S0300-9084(00)00209-1; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Ernest S, 1999, J AM SOC NEPHROL, V10, P2306; Farge E, 1999, AM J PHYSIOL-CELL PH, V276, pC725, DOI 10.1152/ajpcell.1999.276.3.C725; FARGE E, 1992, BIOPHYS J, V61, P347, DOI 10.1016/S0006-3495(92)81841-6; Farge E, 1995, BIOPHYS J, V69, P2501, DOI 10.1016/S0006-3495(95)80120-7; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fuchs M, 1997, AM J PHYSIOL-GASTR L, V273, pG1312, DOI 10.1152/ajpgi.1997.273.6.G1312; Golstein PE, 1999, PFLUG ARCH EUR J PHY, V437, P652, DOI 10.1007/s004240050829; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Haest CWM, 1997, BBA-BIOMEMBRANES, V1325, P17, DOI 10.1016/S0005-2736(96)00239-8; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Huang ZH, 2004, BBA-BIOMEMBRANES, V1660, P155, DOI 10.1016/j.bbamem.2003.11.010; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kamp D, 1998, BBA-BIOMEMBRANES, V1372, P91, DOI 10.1016/S0005-2736(98)00049-2; Kamp D, 2001, BIOCHEMISTRY-US, V40, P9438, DOI 10.1021/bi0107492; Kamp H H, 1974, Methods Enzymol, V32, P140; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; MIDDELKOOP E, 1986, BIOCHIM BIOPHYS ACTA, V855, P421, DOI 10.1016/0005-2736(86)90087-8; MORROT G, 1986, P NATL ACAD SCI USA, V83, P6863, DOI 10.1073/pnas.83.18.6863; MYHER JJ, 1989, LIPIDS, V24, P396, DOI 10.1007/BF02535147; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PLAGEMANN PGW, 1985, BIOCHIM BIOPHYS ACTA, V817, P51, DOI 10.1016/0005-2736(85)90067-7; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Pomorski T, 1999, BIOCHEMISTRY-US, V38, P142, DOI 10.1021/bi981244n; Raggers RJ, 2001, BIOCHEM J, V357, P859, DOI 10.1042/0264-6021:3570859; RAMSAY RR, 1991, BIOCHEM J, V275, P685, DOI 10.1042/bj2750685; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; RAWYLER A, 1985, BIOCHEMISTRY-US, V24, P1777, DOI 10.1021/bi00328a031; RENOOIJ W, 1977, BIOCHIM BIOPHYS ACTA, V470, P465, DOI 10.1016/0005-2736(77)90137-7; RENOOIJ W, 1976, EUR J BIOCHEM, V61, P53, DOI 10.1111/j.1432-1033.1976.tb09996.x; Romsicki Y, 2001, BIOCHEMISTRY-US, V40, P6937, DOI 10.1021/bi0024456; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHWICHTENHOVEL C, 1992, BIOCHIM BIOPHYS ACTA, V1111, P35, DOI 10.1016/0005-2736(92)90271-M; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SLEIGHT RG, 1989, J CELL SCI, V93, P363; SMIT JJM, 1994, LAB INVEST, V71, P638; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TILLEY L, 1986, FEBS LETT, V194, P21, DOI 10.1016/0014-5793(86)80044-8; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; van der Bijl P, 1996, BIOCHEM J, V317, P589, DOI 10.1042/bj3170589; van Helvoort A, 1997, J CELL SCI, V110, P75; VAN MEER G, 1980, EUR J BIOCHEM, V103, P283; VAN MEER G, 1982, J CELL BIOCHEM, V19, P193, DOI 10.1002/jcb.240190209; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; VERMEULEN WP, 1996, THESIS U UTRECHT UTR; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9	76	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33228	33236		10.1074/jbc.M401751200	http://dx.doi.org/10.1074/jbc.M401751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175345	Green Published, hybrid			2022-12-27	WOS:000223039700028
J	Li, LT; Kaplan, J				Li, LT; Kaplan, J			A mitochondrial-vacuolar signaling pathway in yeast that affects iron and copper metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; DEFICIENT STRAIN; CARRIER PROTEIN; FRATAXIN; HOMOLOG; GENE; ACCUMULATION; REGULON; CCC1	Mitochondria utilize iron, but the transporters that mediate mitochondrial iron uptake and efflux are largely unknown. Cells with a deletion in the vacuolar iron/manganese transporter Ccc1p are sensitive to high iron. Overexpression of MRS3 or MRS4 suppresses the high iron sensitivity of Deltaccc1 cells. MRS3 and MRS4 have recently been suggested to encode mitochondrial iron transporters. We demonstrate that deletion of MRS3 and MRS4 severely affects cellular and mitochondrial metal homeostasis, including a reduction in cytosolic and mitochondrial iron acquisition. We show that vacuolar iron transport is increased in Deltamrs3Deltamrs4 cells, resulting in decreased cytosolic iron and activation of the iron-sensing transcription factor Aft1p. Activation of Aft1p leads to increased expression of the high affinity iron transport system and increased iron uptake. Deletion of CCC1 in Deltamrs3Deltamrs4 cells restores cellular and mitochondrial iron homeostasis to near normal levels. Deltamrs3Deltamrs4 cells also show increased resistance to cobalt but decreased resistance to copper and cadmium. These phenotypes are also corrected by deletion of CCC1 in Deltamrs3Deltamrs4 cells. Decreased copper resistance in Deltamrs3Deltamrs4 cells results from activation of Aft1p by Ccc1p-mediated iron depletion, as deletion of CCC1 or AFT1 in Deltamrs3Deltamrs4 cells restores copper resistance. These results suggest that deletion of mitochondrial proteins can alter vacuolar metal homeostasis. The data also indicate that increased expression of the AFT1-regulated gene(s) can disrupt copper homeostasis.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu			NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052380, R01DK030534] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA 42014] Funding Source: Medline; NIDDK NIH HHS [R01-DK30534, R01-DK52380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Chen OS, 2004, J BIOL CHEM, V279, P29513, DOI 10.1074/jbc.M403209200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; Kaplan RS, 2001, J MEMBRANE BIOL, V179, P165, DOI 10.1007/s002320010046; Kumar A, 2002, METHOD ENZYMOL, V350, P219, DOI 10.1016/S0076-6879(02)50965-4; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Lesuisse E, 2004, BIOCHEM J, V378, P599, DOI 10.1042/BJ20031387; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; Moore DD, 1995, GLOB MOB SURV; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Nyhus KJ, 2002, MED MYCOL, V40, P581, DOI 10.1080/mmy.40.6.581.591; Portnoy ME, 2002, BIOCHEM J, V362, P119, DOI 10.1042/bj3620119; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Vozza A, 2004, J BIOL CHEM, V279, P20850, DOI 10.1074/jbc.M313610200; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	29	86	88	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33653	33661		10.1074/jbc.M403146200	http://dx.doi.org/10.1074/jbc.M403146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161905	hybrid			2022-12-27	WOS:000223039700075
J	Lobo, IA; Mascia, MP; Trudell, JR; Harris, RA				Lobo, IA; Mascia, MP; Trudell, JR; Harris, RA			Channel gating of the glycine receptor changes accessibility to residues implicated in receptor potentiation by alcohols and anesthetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; TRYPTOPHAN SCANNING MUTAGENESIS; MEMBRANE-SPANNING SEGMENT; ACTIVATED CL-CURRENT; ACETYLCHOLINE-RECEPTOR; TRANSMEMBRANE DOMAIN; SECONDARY STRUCTURE; ION CHANNELS; M2-M3 LOOP; GABA(A)	The glycine receptor is a target for both alcohols and anesthetics, and certain amino acids in the alpha1 subunit transmembrane segments (TM) are critical for drug effects. Introducing larger amino acids at these positions increases the potency of glycine, suggesting that introducing larger residues, or drug molecules, into the drug-binding cavity facilitates channel opening. A possible mechanism for these actions is that the volume of the cavity expands and contracts during channel opening and closing. To investigate this hypothesis, mutations for amino acids in TM1 (I229C) and TM2 (G256C, T259C, V260C, M263C, T264C, S267C, S270C) and TM3 (A288C) were individually expressed in Xenopus laevis oocytes. The ability of sulfhydryl-specific alkyl methanethiosulfonate (MTS) compounds of different lengths to covalently react with introduced cysteines in both the closed and open states of the receptor was determined. S267C was accessible to short chain (C3 - C8) MTS in both open and closed states, but was only accessible to longer chain (C10 - C16) MTS compounds in the open state. Reaction with S267C was faster in the open state. I229C and A288C showed state-dependent reaction with MTS only in the presence of agonist. M263C and S270C were also accessible to MTS labeling. Mutated residues more intracellular than M263C did not react, indicating a floor of the cavity. These data demonstrate that the conformational changes accompanying channel gating increase accessibility to amino acids critical for drug action in TM1, TM2, and TM3, which may provide a mechanism by which alcohols and anesthetics can act on glycine ( and likely other) receptors.	Univ Texas, Waggoner Ctr Alcohol & Addict Res, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Neurobiol Sect, Austin, TX 78712 USA; Univ Cagliari, Dept Expt Biol, Inst Neurosci, CNR, I-09123 Cagliari, Italy; Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Consiglio Nazionale delle Ricerche (CNR); University of Cagliari; Stanford University	Lobo, IA (corresponding author), Univ Texas, Waggoner Ctr Alcohol & Addict Res, Inst Mol & Cellular Biol, Austin, TX 78712 USA.	dirgni@mail.utexas.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, R37AA006399, R01AA013378, F31AA013778] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA13778, AA13378, AA06399] Funding Source: Medline; NIGMS NIH HHS [GM47818] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguayo LG, 1996, J PHARMACOL EXP THER, V279, P1116; AGUAYO LG, 1994, J PHARMACOL EXP THER, V270, P61; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bali M, 2004, MOL PHARMACOL, V65, P68, DOI 10.1124/mol.65.1.68; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Bertaccini E, 2002, PROTEIN ENG, V15, P443, DOI 10.1093/protein/15.6.443; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; CELENTANO JJ, 1988, BRAIN RES, V455, P377, DOI 10.1016/0006-8993(88)90098-4; Colman A., 1984, TRANSCRIPTION TRANSL, P49; Eggers ED, 2000, J NEUROPHYSIOL, V84, P2409, DOI 10.1152/jn.2000.84.5.2409; ENGBLOM AC, 1991, J NEUROCHEM, V57, P384, DOI 10.1111/j.1471-4159.1991.tb03764.x; Findlay GS, 2002, J PHARMACOL EXP THER, V300, P526, DOI 10.1124/jpet.300.2.526; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; Greenblatt Eric P., 1999, Anesthesiology (Hagerstown), V91, pA807; Guzman GR, 2003, BIOCHEMISTRY-US, V42, P12243, DOI 10.1021/bi034764d; Hara K, 2002, ANESTHESIOLOGY, V97, P1512, DOI 10.1097/00000542-200212000-00025; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; LANGOSCH D, 1995, HDB RECEPTORS CHANNE, P291; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; LOBO IA, 2004, IN PRESS J NEUROCHEM; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1996, MOL PHARMACOL, V50, P402; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Raines DE, 2001, ANESTHESIOLOGY, V95, P470, DOI 10.1097/00000542-200108000-00032; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; Sonner JM, 2003, ANESTH ANALG, V97, P718, DOI 10.1213/01.ANE.0000081063.76651.33; Spencer RH, 2002, ANNU REV BIOPH BIOM, V31, P207, DOI 10.1146/annurev.biophys.31.082901.134329; Tang P, 2002, BIOPHYS J, V83, P252, DOI 10.1016/S0006-3495(02)75166-7; TRUDELL JR, 2004, IN PRESS J MOL GRAPH; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Williams DB, 2000, MOL PHARMACOL, V58, P1129, DOI 10.1124/mol.58.5.1129; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Williams DB, 2002, J NEUROSCI, V22, P7417; Williams DB, 2001, NEUROPHARMACOLOGY, V41, P539, DOI 10.1016/S0028-3908(01)00099-5; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23; Ye JH, 2001, J PHARMACOL EXP THER, V296, P77; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	50	52	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33919	33927		10.1074/jbc.M313941200	http://dx.doi.org/10.1074/jbc.M313941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169788	hybrid			2022-12-27	WOS:000223039700102
J	Sirikantaramas, S; Morimoto, S; Shoyama, Y; Ishikawa, Y; Wada, Y; Shoyama, Y; Taura, F				Sirikantaramas, S; Morimoto, S; Shoyama, Y; Ishikawa, Y; Wada, Y; Shoyama, Y; Taura, F			The gene controlling marijuana psychoactivity - Molecular cloning and heterologous expression of Delta(1)-tetrahydrocannabinolic acid synthase from Cannabis sativa L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERBERINE BRIDGE ENZYME; COVALENTLY BOUND FLAVIN; FIR ABIES-GRANDIS; FUNCTIONAL EXPRESSION; 6-HYDROXY-D-NICOTINE OXIDASE; CDNA ISOLATION; TETRAHYDROCANNABINOLIC ACID; ALKALOID BIOSYNTHESIS; MONOTERPENE SYNTHASES; ARTHROBACTER-OXIDANS	Delta(1)-Tetrahydrocannabinolic acid ( THCA) synthase is the enzyme that catalyzes oxidative cyclization of cannabigerolic acid into THCA, the precursor of Delta(1)-tetrahydrocannabinol. We cloned a novel cDNA (GenBank(TM) accession number AB057805) encoding THCA synthase by reverse transcription and polymerase chain reactions from rapidly expanding leaves of Cannabis sativa. This gene consists of a 1635-nucleotide open reading frame, encoding a 545-amino acid polypeptide of which the first 28 amino acid residues constitute the signal peptide. The predicted molecular weight of the 517-amino acid mature polypeptide is 58,597 Da. Interestingly, the deduced amino acid sequence exhibited high homology to berberine bridge enzyme from Eschscholtzia californica, which is involved in alkaloid biosynthesis. The liquid culture of transgenic tobacco hairy roots harboring the cDNA produced THCA upon feeding of cannabigerolic acid, demonstrating unequivocally that this gene encodes an active THCA synthase. Overexpression of the recombinant THCA synthase was achieved using a baculovirus-insect expression system. The purified recombinant enzyme contained covalently attached FAD cofactor at a molar ratio of FAD to protein of 1: 1. The mutant enzyme constructed by changing His-114 of the wild-type enzyme to Ala-114 exhibited neither absorption characteristics of flavoproteins nor THCA synthase activity. Thus, we concluded that the FAD binding residue is His-114 and that the THCA synthase reaction is FAD-dependent. This is the first report on molecular characterization of an enzyme specific to cannabinoid biosynthesis.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan	Kyushu University	Taura, F (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan.	taura@phar.kyushu-u.ac.jp	Sirikantaramas, Supaart/E-3239-2010; Sirikantaramas, Supaart/AAF-7376-2020	Sirikantaramas, Supaart/0000-0003-0330-0845				Baker D, 2003, LANCET NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; BARZU O, 1983, FEBS LETT, V153, P280, DOI 10.1016/0014-5793(83)80624-3; Bird DA, 2001, PLANTA, V213, P888, DOI 10.1007/s004250100582; Bohlmann J, 1997, J BIOL CHEM, V272, P21784, DOI 10.1074/jbc.272.35.21784; Bohlmann J, 1999, ARCH BIOCHEM BIOPHYS, V368, P232, DOI 10.1006/abbi.1999.1332; BRANDSCH R, 1987, EUR J BIOCHEM, V167, P315, DOI 10.1111/j.1432-1033.1987.tb13338.x; BRUHMULLER M, 1972, EUR J BIOCHEM, V29, P143, DOI 10.1111/j.1432-1033.1972.tb01968.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; DECKER KF, 1993, ANNU REV NUTR, V13, P17, DOI 10.1146/annurev.nu.13.070193.000313; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; FABIAN J, 1965, J BACTERIOL, V89, P921; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hoelscher DJ, 2003, PHYTOCHEMISTRY, V62, P1081, DOI 10.1016/S0031-9422(02)00674-X; KIMURA M, 1970, EXPERIENTIA, V26, P819, DOI 10.1007/BF02114192; KOZIOL J., 1971, Methods in Enzymology, V18B, P253, DOI 10.1016/S0076-6879(71)18089-5; KUTCHAN TM, 1994, PHYTOCHEMISTRY, V35, P353, DOI 10.1016/S0031-9422(00)94763-0; KUTCHAN TM, 1995, J BIOL CHEM, V270, P24475, DOI 10.1074/jbc.270.41.24475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUCH L, 1990, J BIOL CHEM, V265, P12761; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; Mechoulam R, 2000, CURR PHARM DESIGN, V6, P1313, DOI 10.2174/1381612003399509; MECHOULAM R, 1970, SCIENCE, V168, P1159, DOI 10.1126/science.168.3936.1159; MECHOULAM R, 1969, J CHEM SOC CHEM COMM, P343, DOI 10.1039/c29690000343; MECHOULAM R, 1969, TETRAHEDRON LETT, V10, P5349; Phillips MA, 2003, ARCH BIOCHEM BIOPHYS, V411, P267, DOI 10.1016/S0003-9861(02)00746-4; SHOYAMA Y, 1975, PHYTOCHEMISTRY, V14, P2189, DOI 10.1016/S0031-9422(00)91096-3; Singer T P, 1978, Methods Enzymol, V53, P397; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; STEFFENS P, 1985, PHYTOCHEMISTRY, V24, P2577, DOI 10.1016/S0031-9422(00)80672-X; TAURA F, 1995, PHYTOCHEMISTRY, V39, P457, DOI 10.1016/0031-9422(94)00887-Y; TAURA F, 1995, J AM CHEM SOC, V117, P9766, DOI 10.1021/ja00143a024; Taura F, 1996, J BIOL CHEM, V271, P17411, DOI 10.1074/jbc.271.29.17411; TURNER CE, 1980, J NAT PROD, V43, P169, DOI 10.1021/np50008a001; VANHAUTE E, 1983, EMBO J, V2, P411, DOI 10.1002/j.1460-2075.1983.tb01438.x; WHITE FF, 1980, J BACTERIOL, V141, P1134, DOI 10.1128/JB.141.3.1134-1141.1980; Wise ML, 1998, J BIOL CHEM, V273, P14891, DOI 10.1074/jbc.273.24.14891; YAMAUCHI T, 1967, CHEM PHARM BULL, V15, P1075; Yuba A, 1996, ARCH BIOCHEM BIOPHYS, V332, P280, DOI 10.1006/abbi.1996.0343	46	182	207	1	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39767	39774		10.1074/jbc.M403693200	http://dx.doi.org/10.1074/jbc.M403693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15190053	hybrid			2022-12-27	WOS:000223791500070
J	Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR				Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR			Glycoprotein hormone assembly in the endoplasmic reticulum - I. The glycosylated end of human alpha-subunit loop 2 is threaded through a beta-subunit hole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; STIMULATING-HORMONE; DISULFIDE BONDS; PROTEIN; RECEPTOR; BINDING; CHORIOGONADOTROPIN; FOLLITROPIN; LUTROPIN; SECRETION	Glycoprotein hormone heterodimers are stabilized by their unusual structures in which a glycosylated loop of the alpha-subunit straddles a hole in the beta-subunit. This hole is formed when a cysteine at the end of a beta-subunit strand known as the "seatbelt" becomes "latched" by a disulfide to a cysteine in the beta-subunit core. The heterodimer is stabilized in part by the difficulty of threading the glycosylated end of the alpha-subunit loop 2 through this hole, a phenomenon required for subunit dissociation. Subunit combination in vitro, which occurs by the reverse process, can be accelerated by removing the alpha-subunit oligosaccharide. In cells, heterodimer assembly was thought to occur primarily by a mechanism in which the seatbelt is wrapped around the alpha-subunit after the subunits dock. Here we show that this "wrap-around" process can be used to assemble disulfide crosslinked human choriogonadotropin analogs that contain an additional alpha-subunit cysteine, but only if the normal beta-subunit latch site has been removed. Normally, the seatbelt is latched before the subunits dock and assembly is completed when the glycosylated end of alpha-subunit loop 2 is threaded beneath the seatbelt. The unexpected finding that most assembly of human choriogonadotropin, human follitropin, and human thyrotropin heterodimers occurs in this fashion, indicates that threading may be an important phenomenon during protein folding and macromolecule assembly in the endoplasmic reticulum. We suggest that the unusual structures of the glycoprotein hormones makes them useful for identifying factors that influence this process in living cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, R01HD038547, R37HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD14907, HD38547] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernard MP, 2004, ANAL BIOCHEM, V327, P278, DOI 10.1016/j.ab.2003.12.029; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN C, 1987, BIOTECHNIQUES, V6, P632; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lorenz IC, 2002, J VIROL, V76, P5480, DOI 10.1128/JVI.76.11.5480-5491.2002; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1987, J BIOL CHEM, V262, P16920; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; Moyle WR, 1998, CHEM BIOL, V5, P241, DOI 10.1016/S1074-5521(98)90617-2; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P35437, DOI 10.1074/jbc.M403053200; Xing YN, 2004, J BIOL CHEM, V279, P35458, DOI 10.1074/jbc.M403055200; Xing YN, 2003, BIOCHEM BIOPH RES CO, V303, P201, DOI 10.1016/S0006-291X(03)00322-X; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; Xing YN, 2001, PROTEIN SCI, V10, P226, DOI 10.1110/ps.25901	26	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35426	35436		10.1074/jbc.M403052200	http://dx.doi.org/10.1074/jbc.M403052200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15161918	hybrid			2022-12-27	WOS:000223303400036
J	Xu, JF; Liao, K				Xu, JF; Liao, K			Protein kinase B/AKT 1 plays a pivotal role in insulin-like growth factor-1 receptor signaling induced 3T3-L1 adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; MITOTIC CLONAL EXPANSION; B C-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; CELL-SURVIVAL; NEGATIVE REGULATION; FACTOR FKHR; ADIPOGENESIS; PREADIPOCYTES	During 3T3-L1 preadipocyte differentiation induction, the insulin-stimulated insulin-like growth factor-1 (IGF-1) receptor signal is responsible for the induction of adipocyte differentiation. Treatment with inhibitors of phosphatidylinositol 3-kinase, LY294002 or wortmannin, leads to the complete blockade of adipocyte differentiation in 3T3-L1 preadipocytes. Of the three factors (1-methyl-3-isobutylxanthine, dexamethasone, and insulin) inducing 3T3-L1 preadipocyte differentiation, only insulin was able to activate the phosphatidylinositol 3-kinase-protein kinase B/Akt signal cascade. In 3T3-L1 preadipocytes, protein kinase B/Akt 1 RNA interference not only suppressed the expression of protein kinase B/Akt 1 but also blocked hormone-induced adipocyte differentiation. In these protein kinase B/Akt 1 RNA interference cells, the signal molecules upstream of protein kinase B/Akt 1, such as IGF-1 receptor and insulin receptor substrate-1, were normally activated by insulin stimulation, whereas insulin-stimulated phosphorylation of forkhead transcription factor (FKHR), which is a downstream molecule of PKB/Akt 1, was blocked. Thus, protein kinase B/Akt 1 is an important signal mediator in IGF-1 receptor signal cascade for inducing adipocyte differentiation.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Liao, K (corresponding author), Shanghai Inst Biochem & Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	kliao@sibs.ac.cn						Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Blair LAC, 1999, J NEUROSCI, V19, P1940; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cho KJ, 2003, J BIOL CHEM, V278, P34823, DOI 10.1074/jbc.M210747200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FONT DE, 1997, MOL CELL BIOL, V17, P6068; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hansen JB, 2002, J BIOL CHEM, V277, P26335, DOI 10.1074/jbc.M203870200; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Jin SH, 2000, J BIOL CHEM, V275, P34344, DOI 10.1074/jbc.M004927200; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LeRoith D, 1997, ENDOCRINE, V7, P103, DOI 10.1007/BF02778074; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Sorisky A, 1996, OBES RES, V4, P9, DOI 10.1002/j.1550-8528.1996.tb00507.x; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225	49	167	175	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35914	35922		10.1074/jbc.M402297200	http://dx.doi.org/10.1074/jbc.M402297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192111	hybrid			2022-12-27	WOS:000223303400092
J	Alonso, AD; Mederlyova, A; Novak, M; Grundke-Iqbal, I; Iqbal, K				Alonso, AD; Mederlyova, A; Novak, M; Grundke-Iqbal, I; Iqbal, K			Promotion of hyperphosphorylation by frontotemporal dementia tau mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ABNORMALLY PHOSPHORYLATED-TAU; R406W HUMAN TAU; V337M HUMAN TAU; PROTEIN-TAU; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; NEUROBLASTOMA-CELLS; FTDP-17 MUTATIONS; P301L TAU	Mutations in the tau gene are known to cosegregate with the disease in frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). However, the molecular mechanism by which these mutations might lead to the disease is not understood. Here, we show that four of the FTDP-17 tau mutations, R406W, V337M, G272V, and P301L, result in tau proteins that are more favorable substrates for phosphorylation by brain protein kinases than the wild-type, largest four-repeat protein tau4L and tau4L more than tau3L. In general, at all the sites studied, mutant tau proteins were phosphorylated faster and to a higher extent than tau4L and tau4L > tau3L. The most dramatic difference found was in the rate and level of phosphorylation of tau4L(R406W) at positions Ser-396, Ser-400, Thr-403, and Ser-404. Phosphorylation of this mutant tau was 12 times faster and 400% greater at Ser-396 and less than 30% at Ser-400, Thr-403, and Ser-404 than phosphorylation of tau4L. The mutated tau proteins polymerized into filaments when 4-6 mol of phosphate per mol of tau were incorporated, whereas wild-type tau required similar to10 mol of phosphate per mol of protein to self-assemble. Mutated and wild-type tau proteins were able to sequester normal tau upon incorporation of similar to4 mol of phosphate per mol of protein, which was achieved at as early as 30 min of phosphorylation in the case of mutant tau proteins. These findings taken together suggest that the mutations in tau might cause neurodegeneration by making the protein a more favorable substrate for hyperphosphorylation.	New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; Slovak Acad Sci, Inst Neuroimmunol, Bratislava 84246, Slovakia	Institute for Basic Research in Developmental Disabilities; Slovak Academy of Sciences	Iqbal, K (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	iqbalk@worldnet.att.net			FIC NIH HHS [TW 00507] Funding Source: Medline; NIA NIH HHS [AG 19158] Funding Source: Medline; NINDS NIH HHS [MN/NS 31862] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019158] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; ALONSO AD, 1995, MOL BRAIN RES, V31, P194, DOI 10.1016/0169-328X(95)00051-S; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Alonso AD, 2001, J BIOL CHEM, V276, P37967; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bird TD, 1999, BRAIN, V122, P741, DOI 10.1093/brain/122.4.741; Crowther RA, 2000, J STRUCT BIOL, V130, P271, DOI 10.1006/jsbi.2000.4270; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Fath T, 2002, J NEUROSCI, V22, P9733; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goldbaum O, 2003, J NEUROSCI, V23, P8872; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1998, BRAIN RES, V464, P43; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; Ho L, 2001, NEUROSCI LETT, V310, P1, DOI 10.1016/S0304-3940(01)02044-4; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; Janssen JC, 2002, NEUROLOGY, V58, P1161, DOI 10.1212/WNL.58.8.1161; Jicha GA, 1999, NEUROSCI LETT, V260, P153, DOI 10.1016/S0304-3940(98)00980-X; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KOPKE E, 1993, J BIOL CHEM, V268, P24374; KREMER L, 1988, ANAL BIOCHEM, V175, P91, DOI 10.1016/0003-2697(88)90365-X; Krishnamurthy PK, 2004, J BIOL CHEM, V279, P7893, DOI 10.1074/jbc.M311203200; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Mack TGA, 2001, NEUROSCIENCE, V108, P701, DOI 10.1016/S0306-4522(01)00434-1; Matsumura N, 1999, AM J PATHOL, V154, P1649, DOI 10.1016/S0002-9440(10)65420-X; Miyamoto K, 2001, ANN NEUROL, V50, P117, DOI 10.1002/ana.1083; Nacharaju P, 1999, FEBS LETT, V447, P195, DOI 10.1016/S0014-5793(99)00294-X; Perez M, 2001, BIOCHEMISTRY-US, V40, P5983, DOI 10.1021/bi002961w; Perez M, 2000, J NEUROCHEM, V74, P2583, DOI 10.1046/j.1471-4159.2000.0742583.x; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SINGH TJ, 1995, FEBS LETT, V358, P267, DOI 10.1016/0014-5793(94)01445-7; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Tanemura K, 2001, NEUROBIOL DIS, V8, P1036, DOI 10.1006/nbdi.2001.0439; Tanemura K, 2002, J NEUROSCI, V22, P133, DOI 10.1523/JNEUROSCI.22-01-00133.2002; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; WILSON DM, 1995, J BIOL CHEM, V270, P24306, DOI 10.1074/jbc.270.41.24306; WISNIEWSKI HM, 1984, J NEUROPATH EXP NEUR, V43, P643, DOI 10.1097/00005072-198411000-00008; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Yoshida H, 2002, J NEUROCHEM, V80, P548, DOI 10.1046/j.0022-3042.2001.00729.x	62	231	246	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34873	34881		10.1074/jbc.M405131200	http://dx.doi.org/10.1074/jbc.M405131200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190058	hybrid			2022-12-27	WOS:000223134800097
J	Hellwig, N; Plant, TD; Janson, W; Schafer, M; Schultz, GN; Schaefer, M				Hellwig, N; Plant, TD; Janson, W; Schafer, M; Schultz, GN; Schaefer, M			TRPV1 acts as proton channel to induce acidification in nociceptive neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; PROTEIN-KINASE-C; CAPSAICIN RECEPTOR; INTRACELLULAR PH; ION CHANNELS; VANILLOID RECEPTOR-1; HIPPOCAMPAL-NEURONS; CALCIUM CURRENT; CELLS; VR1	The low extracellular pH of inflamed or ischemic tissues enhances painful sensations by sensitizing and activating the vanilloid receptor 1 (TRPV1). We report here that activation of TRPV1 results in a marked intracellular acidification in nociceptive dorsal root ganglion neurons and in a heterologous expression system. A characterization of the underlying mechanisms revealed a Ca2+-dependent intracellular acidification operating at neutral pH and an additional as yet unrecognized direct proton conductance through the poorly selective TRPV1 pore operating in acidic extracellular media. Large organic cations permeate through the activated TRPV1 pore even in the presence of physiological concentrations of Na+, Mg2+, and Ca2+. The wide pore and the unexpectedly high proton permeability of TRPV1 point to a proton hopping permeation mechanism along the water-filled channel pore. In acidic media, the high relative proton permeability through TRPV1 defines a novel proton entry mechanism in nociceptive neurons.	Charite Univ Med Berlin, Dept Pharmacol, D-14195 Berlin, Germany; Charite Univ Med Berlin, Dept Anaesthesiol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schaefer, M (corresponding author), Charite Univ Med Berlin, Dept Pharmacol, Campus Benjamin Franklin,Thielallee 67-73, D-14195 Berlin, Germany.	schae@zedat.fu-berlin.de	Schäfer, Michael/AAB-1395-2020	Schaefer, Michael/0000-0002-1581-706X				Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; DeCoursey TE, 2003, NATURE, V422, P531, DOI 10.1038/nature01523; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; DeCoursey TE, 1997, J GEN PHYSIOL, V109, P415, DOI 10.1085/jgp.109.4.415; Dedov VN, 2001, NEUROSCIENCE, V103, P219, DOI 10.1016/S0306-4522(00)00540-6; DIXON DB, 1993, NEURON, V11, P267, DOI 10.1016/0896-6273(93)90183-R; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; HARTLEY Z, 1993, J NEUROSCI, V13, P4690; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; IRWIN RP, 1994, J NEUROSCI, V14, P1352, DOI 10.1523/JNEUROSCI.14-03-01352.1994; JANCSO G, 1990, NEUROSCIENCE, V39, P501, DOI 10.1016/0306-4522(90)90286-D; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kiss L, 1999, J NEUROPHYSIOL, V81, P1839, DOI 10.1152/jn.1999.81.4.1839; Kuzhikandathil EV, 2001, J NEUROSCI, V21, P8697, DOI 10.1523/JNEUROSCI.21-22-08697.2001; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Meyer TM, 2000, NEUROREPORT, V11, P33, DOI 10.1097/00001756-200001170-00007; Meyers JR, 2003, J NEUROSCI, V23, P4054; MIRONOV SL, 1991, PFLUG ARCH EUR J PHY, V419, P138, DOI 10.1007/BF00372999; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Paalasmaa P, 1996, J NEUROPHYSIOL, V75, P2354, DOI 10.1152/jn.1996.75.6.2354; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; TORNQUIST K, 1992, ENDOCRINOLOGY, V130, P717, DOI 10.1210/en.130.2.717; Trapp S, 1996, NEUROREPORT, V7, P2000, DOI 10.1097/00001756-199608120-00029; VAUGHANJONES RD, 1983, NATURE, V301, P522, DOI 10.1038/301522a0; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Vulcu SD, 2004, NEUROSCIENCE, V125, P861, DOI 10.1016/j.neuroscience.2004.02.032; WANG GJ, 1994, J NEUROPHYSIOL, V72, P2563, DOI 10.1152/jn.1994.72.6.2563; WERTH JL, 1994, J NEUROSCI, V14, P348; WU ML, 1999, AM J PHYSIOL, V277, P717; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	50	118	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34553	34561		10.1074/jbc.M402966200	http://dx.doi.org/10.1074/jbc.M402966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173182	hybrid			2022-12-27	WOS:000223134800059
J	Chung, J; Yoon, SO; Lipscomb, EA; Mercurio, AM				Chung, J; Yoon, SO; Lipscomb, EA; Mercurio, AM			The met receptor and alpha(6)beta(4) integrin can function independently to promote carcinoma invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; ALPHA-6-BETA-4 INTEGRIN; CHEMOTACTIC MIGRATION; CELL MIGRATION; BETA 4; GROWTH; HEMIDESMOSOMES; ACTIVATION; ADHESION; METASTASIS	It has been proposed that a constitutive, physical association of the Met receptor and the alpha(6)beta(4) integrin exists on the surface of invasive carcinoma cells and that hepatocyte growth factor (HGF)-mediated invasion is dependent on alpha(6)beta(4) (Trusolino, L., Bertotti, A., and Comoglio, P. M. (2001) Cell 107, 643-654). The potential significance of these results prompted us to re-examine this hypothesis. Using three different carcinoma cell lines that express both Met and alpha(6)beta(4), we were unable to detect the constitutive association of these receptors by co-immunoprecipitation. Moreover, carcinoma cells that lacked expression of alpha(6)beta(4) exhibited Met-dependent invasion toward HGF, and increasing Met expression by viral infection of these cells enhanced invasion without inducing alpha(6)beta(4) expression. Although expression of alpha(6)beta(4) in such cells enhanced their invasion to HGF, it also enhanced their ability to invade toward other chemoattractants such as lysophosphatidic acid, and this latter invasion was not inhibited by a function-blocking Met antibody. Finally, depletion of beta(4) by RNA interference in invasive carcinoma cells that express both receptors reduced the ability of these cells to invade toward HGF by similar to25%, but it did not abrogate their invasion. These data argue that the invasive function of Met can be independent of alpha(6)beta(4) and that alpha(6)beta(4) has a generic influence on the invasion of carcinoma cells that is not specific to Met.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mercurio, AM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Res N,330 Brookline Ave, Boston, MA 02215 USA.	amercuri@caregroup.harvard.edu			NCI NIH HHS [CA80789, R01 CA080789] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080789] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Ke S, 2003, CANCER RES, V63, P7870; Lipscomb EA, 2003, CLIN EXP METASTAS, V20, P569, DOI 10.1023/A:1025819521707; Mercurio A M, 2001, Surg Oncol Clin N Am, V10, P313; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Mercurio AM, 2001, J MAMMARY GLAND BIOL, V6, P299, DOI 10.1023/A:1011323608064; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Tantivejkul K, 2003, ANTICANCER RES, V23, P3681; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366	28	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32287	32293		10.1074/jbc.M403809200	http://dx.doi.org/10.1074/jbc.M403809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161909	hybrid			2022-12-27	WOS:000222849700038
J	Jensik, PJ; Huggenvik, JI; Collard, MW				Jensik, PJ; Huggenvik, JI; Collard, MW			Identification of a nuclear export signal and protein interaction domains in deformed epidermal autoregulatory factor-1 (DEAF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID MODULATORY ELEMENT; SAND DOMAIN; LIM DOMAIN; GENE; SEQUENCE; BINDING; LMO4; TRANSCRIPTION; REPRESSION; DROSOPHILA	Deformed epidermal autoregulatory factor-1 (DEAF-1) is a DNA-binding protein required for embryonic development and linked to clinical depression and suicidal behavior in humans. Although primarily nuclear, cytoplasmic localization of DEAF-1 has been observed, and this suggests the presence of a nuclear export signal (NES). Using a series of fluorescent fusion proteins, an NES with a novel spacing of leucines (LXLX6LLX5LX2L) was identified near the COOH-terminal MYND domain at amino acids 454-476. The NES was leptomycin B-sensitive and mutation of the leucine residues decreased or eliminated nuclear export activity. In vitro pull downs and an in vivo fluorescent protein interaction assay identified a DEAF-1/DEAF-1 protein interaction domain within the NES region. DNA binding had been previously mapped to a positively charged surface patch in the novel DNA binding fold called the "SAND" domain. A second protein-protein interaction domain was identified at amino acids 243-306 that contains the DNA-binding SAND domain and also an adjacent zinc binding motif and a monopartite nuclear localization signal (NLS). Deletion of these adjacent sequences or mutation of the conserved cysteines or histidine in the zinc binding motif not only inhibits protein interaction but also eliminates DNA binding, demonstrating that DEAF-1 protein-protein interaction is required for DNA recognition. The identification of an NES and NLS provides a basis for the control of DEAF-1 subcellular localization and function, whereas the requirement of protein-protein interaction by the SAND domain appears to be unique among this class of transcription factors.	So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Collard, MW (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.	mcollard@siumed.edu			NCI NIH HHS [CA89438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chen HH, 2002, DEVELOPMENT, V129, P4879; Chen J, 2002, J BIOL CHEM, V277, P22053, DOI 10.1074/jbc.M202311200; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gibson TJ, 1998, TRENDS BIOCHEM SCI, V23, P242, DOI 10.1016/S0968-0004(98)01231-6; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Huggenvik JI, 1998, MOL ENDOCRINOL, V12, P1619, DOI 10.1210/me.12.10.1619; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Jensik P, 2002, J COMP PHYSIOL B, V172, P569, DOI 10.1007/s00360-002-0285-9; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Lemonde S, 2003, J NEUROSCI, V23, P8788; Lo Surdo P, 2003, MOL ENDOCRINOL, V17, P1283, DOI 10.1210/me.2002-0409; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Luque CM, 2003, J BIOL CHEM, V278, P2686, DOI 10.1074/jbc.M201521200; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Manne U, 2001, CLIN CANCER RES, V7, P3495; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; Veraksa A, 2002, GENESIS, V33, P67, DOI 10.1002/gene.10090; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Zeng HW, 1998, J BIOL CHEM, V273, P17756, DOI 10.1074/jbc.273.28.17756	38	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32692	32699		10.1074/jbc.M400946200	http://dx.doi.org/10.1074/jbc.M400946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161925	hybrid			2022-12-27	WOS:000222849700088
J	Lee, HT; Lee, JG; Na, M; Kay, EDP				Lee, HT; Lee, JG; Na, M; Kay, EDP			FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; RETROCORNEAL FIBROUS MEMBRANE; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; COLLAGEN-SYNTHESIS; EPITHELIAL-CELLS; POLYMORPHONUCLEAR LEUKOCYTES; INFLAMMATORY CYTOKINES; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS	Our previous work demonstrated that both polymorphonuclear leukocytes (PMNs) and protein fractions released from PMNs induced de novo synthesis of fibroblast growth factor 2 (FGF-2), which in turn becomes the direct mediator of endothelial mesenchymal transformation observed in corneal endothelial cells (CECs). To identify the protein factor, we used ProteinChip Array technology. Protein fractions obtained from the conditioned medium released by PMNs were resolved by two-dimensional electrophoresis with immobilized pH gradient strips. Most of the protein spots, with molecular masses of 17 kDa, were sequentially subjected to in-gel trypsin digestion and mass spectrometry. The 17-kDa peptide band was identified as interleukin-1beta (IL-1beta). Biological activities of IL-1beta were further determined; IL-1beta altered the shape of CECs from polygonal to fibroblastic morphologies in a time- and dose-dependent manner, whereas neutralizing IL-1beta antibody, neutralizing antibody to FGF-2, and LY294002 blocked the action of IL-1beta. IL-1beta greatly increased the levels of FGF-2 mRNA in a time- and dose-dependent manner; IL-1beta stimulated expression of all isoforms of FGF-2. IL-1beta initially induced nuclear accumulation of FGF-2 and facilitated translocation of FGF-2 to plasma membrane and extracellular matrix. IL-1beta activated phosphatidylinositol (PI) 3-kinase, the enzyme activity of which was greatly stimulated after a 5-min exposure to IL-1beta. This early and rapid activation of PI 3-kinase greatly enhanced FGF-2 production in CECs; pretreatment with LY294002 hampered the induction activity of IL-1beta. These observations suggest that IL-1beta takes part in endothelial to mesenchymal transformation of CECs through its inductive potential on FGF-2 via the action of PI 3-kinase.	Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA	Doheny Eye Institute; University of Southern California; University of Southern California	Kay, EDP (corresponding author), Univ So Calif, Keck Sch Med, Doheny Eye Inst, 1450 San Pablo St,DVRC 203, Los Angeles, CA 90033 USA.	ekay@usc.edu	谭, 德华 德/D-1910-2009		NEI NIH HHS [EY06431, EY03040] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006431, P30EY003040] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; Arndt PG, 2004, J BIOL CHEM, V279, P10883, DOI 10.1074/jbc.M309901200; BROWN SI, 1966, ARCH OPHTHALMOL-CHIC, V75, P518; Caputo E, 2003, ANAL BIOCHEM, V321, P116, DOI 10.1016/S0003-2697(03)00361-0; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Cronauer MV, 1999, AM J PATHOL, V155, P1977, DOI 10.1016/S0002-9440(10)65516-2; Cubitt CL, 2001, INVEST OPHTH VIS SCI, V42, P701; Daniels JT, 2000, INVEST OPHTH VIS SCI, V41, P3754; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1991, BLOOD, V77, P1627; Faris M, 1998, AIDS, V12, P19, DOI 10.1097/00002030-199801000-00003; Gu X, 1998, INVEST OPHTH VIS SCI, V39, P2252; Gu X, 1996, INVEST OPHTH VIS SCI, V37, P2326; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Kay E P, 1998, Mol Vis, V4, P22; KAY EDP, 1994, INVEST OPHTH VIS SCI, V35, P2427; KAY EP, 1982, J BIOL CHEM, V257, P7116; KAY EP, 1984, INVEST OPHTH VIS SCI, V25, P502; KAY EP, 1993, INVEST OPHTH VIS SCI, V34, P663; KAY EP, 1982, INVEST OPHTH VIS SCI, V22, P200; KAY EP, 1985, J BIOL CHEM, V260, P5139; Ko MHK, 2002, MOL VIS, V8, P1; Leak LV, 2004, PROTEOMICS, V4, P753, DOI 10.1002/pmic.200300573; Lee HT, 2003, MOL VIS, V9, P624; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P1521, DOI 10.1167/iovs.02-0637; Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200; Leung EW, 2000, MOL VIS, V6, P15; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; McDermott AM, 2003, INVEST OPHTH VIS SCI, V44, P1859, DOI 10.1167/iovs.02-0787; Merchant M, 2000, ELECTROPHORESIS, V21, P1164, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1164::AID-ELPS1164>3.0.CO;2-0; MICHELS RG, 1972, INVEST OPHTH VISUAL, V11, P822; Mohri M, 2002, INVEST OPHTH VIS SCI, V43, P3190; Moore JE, 2002, INVEST OPHTH VIS SCI, V43, P2905; Narita Y, 2002, CANCER RES, V62, P6764; Neumann D, 2002, EUR J IMMUNOL, V32, P3689, DOI 10.1002/1521-4141(200212)32:12<3689::AID-IMMU3689>3.0.CO;2-X; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; PSHENICHKIN SP, 1994, J NEUROCHEM, V63, P419; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Sobue T, 2001, BIOCHEM BIOPH RES CO, V286, P33, DOI 10.1006/bbrc.2001.5343; TAMURA M, 1993, J BIOL CHEM, V268, P8140; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Yano K, 2001, J BONE MINER METAB, V19, P365, DOI 10.1007/s007740170006; Yoshida S, 2003, LAB INVEST, V83, P927, DOI 10.1097/01.LAB.0000075642.11787.83; Zhang JF, 2002, FEBS LETT, V521, P180, DOI 10.1016/S0014-5793(02)02872-7	54	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32325	32332		10.1074/jbc.M405208200	http://dx.doi.org/10.1074/jbc.M405208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173165	hybrid			2022-12-27	WOS:000222849700043
J	Xia, H; Nho, RS; Kahm, J; Kleidon, J; Henke, CA				Xia, H; Nho, RS; Kahm, J; Kleidon, J; Henke, CA			Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta(1) integrin viability signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; TYROSINE KINASES; CELL-SURVIVAL; ENDOTHELIAL-CELLS; SHEAR-STRESS; APOPTOSIS; INTEGRIN; PHOSPHORYLATION; 3-KINASE; PP125(FAK)	The beta(1) integrin, functioning as a mechanoreceptor, senses a mechanical stimulus generated during collagen matrix contraction and down-regulates the phosphatidylinositol 3-kinase (PI3K)/Akt survival signal triggering apoptosis. The identities of integrin-associated signal molecules in the focal adhesion complex that are responsible for propagating beta1 integrin viability signals in response to collagen matrix contraction are not known. Here we show that in response to collagen contraction focal adhesion kinase (FAK) is dephosphorylated. In contrast, enforced activation of beta(1) integrin by anti-beta(1) integrin antibody, which protects fibroblasts from apoptosis, preserves FAK phosphorylation. We demonstrate that ligation of beta(1) integrin by type I collagen or by enforced activation of beta(1) integrin by antibody promotes phosphorylation of FAK, p85 subunit of PI3K, and serine 473 of Akt. Wortmannin inhibited Akt but not FAK phosphorylation in response to enforced activation of beta(1) integrin by antibody. Blocking FAK by pharmacologic inhibition or by dominant negative FAK attenuated phosphorylation of p85 subunit of PI3K and Akt. Dominant negative FAK augmented fibroblast apoptosis during collagen contraction, and this was associated with diminished Akt activity. Constitutively active FAK augmented levels of p85 subunit of PI3K and Akt phosphorylation, and fibroblasts were protected from apoptosis. Our data identify a novel role for FAK, functioning upstream of PI3K/Akt, in transducing a beta(1) integrin viability signal in collagen matrices.	Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Henke, CA (corresponding author), Univ Minnesota, Dept Med, 420 Delaware St SE,Box 276, Minneapolis, MN 55455 USA.	henke002@umn.edu						Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Crouch DH, 1996, ONCOGENE, V12, P2689; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Fluck J, 1998, J INVEST DERMATOL, V110, P153, DOI 10.1046/j.1523-1747.1998.00095.x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mortier E, 2001, CELL SIGNAL, V13, P901, DOI 10.1016/S0898-6568(01)00226-1; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yamada KM, 2001, J CELL SCI, V114, P2375	37	273	280	4	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					33024	33034		10.1074/jbc.M313265200	http://dx.doi.org/10.1074/jbc.M313265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166238	hybrid			2022-12-27	WOS:000222849700122
J	Chiarini, R; Moran, O; Revoltella, RP				Chiarini, R; Moran, O; Revoltella, RP			Identification of an antigenic domain near the C terminus of human granulocyte-macrophage colony-stimulating factor and its spatial localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GM-CSF; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PULMONARY ALVEOLAR PROTEINOSIS; GROWTH-FACTORS; ALPHA-CHAIN; BETA-CHAIN; SYNTHETIC PEPTIDES; MOLECULAR-DYNAMICS; IL-5 RECEPTORS; ANTIBODIES	The goal of this study was to map an epitope on the human granulocyte-macrophage colony-stimulating factor (hGM-CSF) at its C terminus, a region whose integrity is fundamental in maintaining the normal function of this molecule. Residues including the fourth alpha-helix (D, 103 - 116) were analyzed for their role in the interaction with antibodies (Abs) raised against the protein. Five peptides homologous to different segments of the C terminus of hGM-CSF were synthesized. Peptide-(102 121) included the same residues of the alpha-helix D and the next five amino acids toward the C terminus; peptide[ E108A]-( 102 - 121) introduced the mutation E108A in order to verify the role of acidic residues; peptide-[C96A]( 93 - 110) encompassed the beta-sheet 2 and half of the alpha-helix D; peptide-[C121A]-( 110 - 127) included the second half of the alpha-helix D and the C terminus of hGM-CSF; peptide-( 13 - 31)- Gly-Pro-Gly-(103 - 116) included both the alpha-helices A and D connected by the tripeptide Gly-Pro-Gly, which allows the original antiparallel orientation of the two alpha-helices to be maintained. Both anti-protein and anti-peptide-( 102 - 121) antibodies, capable of neutralizing the stimulatory activity of hGM-CSF in the bone marrow colony-forming assays, recognized a specific epitope in the C terminus of hGM-CSF. Molecular modeling estimated the surface accessibility of hGM-CSF and the stability of the synthetic peptides in aqueous solution. Altogether, our results showed that the immunogenic region includes part of the alpha-helix D and the residues 116 - 120, which are external to this helix and particularly exposed on the protein surface, confirming the feasible participation of this region in antibody binding.	CNR, Ist Tecnol Biomed, I-56100 Pisa, Italy; CNR, Ist Biofis, I-16149 Genoa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Revoltella, RP (corresponding author), CNR, Ist Tecnol Biomed, Via G Moruzzi 1, I-56100 Pisa, Italy.	r.revoltella@imd.pi.cnr.it	Moran, Oscar/W-4277-2019					ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAGLEY CJ, 1995, J LEUKOCYTE BIOL, V57, P739, DOI 10.1002/jlb.57.5.739; BALDWIN GC, 1988, P NATL ACAD SCI USA, V85, P2763, DOI 10.1073/pnas.85.8.2763; BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; BEFFY P, 1994, HYBRIDOMA, V13, P457, DOI 10.1089/hyb.1994.13.457; BEFFY P, 1994, FUND CLIN IMMUNOL, V2, P53; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Case D. A., 2002, AMBER 7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; CORTI A, 1992, MOL IMMUNOL, V29, P471, DOI 10.1016/0161-5890(92)90004-H; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GRABSTEIN KH, 1986, SCIENCE, V232, P506, DOI 10.1126/science.3083507; GRIBBEN JG, 1990, LANCET, V335, P434, DOI 10.1016/0140-6736(90)90665-R; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; Hubbard S. J., 1993, NACESS COMPUTER PROG; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; KAUSHANSKY K, 1993, BLOOD, V82, P3229; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; Khanjari F, 2003, THORAX, V58, P645, DOI 10.1136/thorax.58.7.645; Kitamura T, 1999, J EXP MED, V190, P875, DOI 10.1084/jem.190.6.875; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; Kontsek P, 1997, CYTOKINE, V9, P550, DOI 10.1006/cyto.1997.0200; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; MELLSTEDT H, 1994, J INTERFERON RES, V14, P179, DOI 10.1089/jir.1994.14.179; MEROPOL NJ, 1991, HYBRIDOMA, V10, P433, DOI 10.1089/hyb.1991.10.433; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1986, BLOOD, V67, P257; METCALF D, 1984, HAEMOPOIETIC COLONY; Modrowski D, 1997, J CELL PHYSIOL, V170, P35; MOONEN P, 1987, P NATL ACAD SCI USA, V84, P4428, DOI 10.1073/pnas.84.13.4428; Mueller MM, 1999, AM J PATHOL, V155, P1557, DOI 10.1016/S0002-9440(10)65472-7; NICOLA NA, 1992, CANCER RES, V52, P2012; Noli N, 1997, J PEPT SCI, V3, P323, DOI 10.1002/(SICI)1099-1387(199709)3:5<323::AID-PSC108>3.0.CO;2-5; RAGNHAMMAR P, 1994, BLOOD, V84, P4078, DOI 10.1182/blood.V84.12.4078.bloodjournal84124078; REVOLTELLA R P, 1992, Pharmacological Research, V26, P192, DOI 10.1016/1043-6618(92)90660-4; Revoltella RP, 1997, LEUKEMIA LYMPHOMA, V26, P29, DOI 10.3109/10428199709058597; Revoltella RP, 1998, BIOTHERAPY, V10, P321, DOI 10.1007/BF02678552; Revoltella RP, 1999, BIOSENS BIOELECTRON, V14, P555, DOI 10.1016/S0956-5663(99)00034-2; Revoltella RP, 2000, CELL IMMUNOL, V204, P114, DOI 10.1006/cimm.2000.1704; REVOLTELLA RP, 1995, AR SER S PUBL, P463; SUE JM, 1983, P NATL ACAD SCI-BIOL, V80, P3651, DOI 10.1073/pnas.80.12.3651; Svenson M, 1998, BLOOD, V91, P2054, DOI 10.1182/blood.V91.6.2054.2054_2054_2061; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Uchida K, 2004, BLOOD, V103, P1089, DOI 10.1182/blood-2003-05-1565; VARSHNEY A, 1994, IEEE COMPUT GRAPH, V14, P19, DOI 10.1109/38.310720; Vispo NS, 1999, HYBRIDOMA, V18, P251, DOI 10.1089/027245799315907; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WEGMANN TG, 1989, TRANSPLANT P, V21, P566; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	63	0	0	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37908	37917		10.1074/jbc.M404663200	http://dx.doi.org/10.1074/jbc.M404663200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201279	hybrid			2022-12-27	WOS:000223554600084
J	Quinn, SJ; Bai, M; Brown, EM				Quinn, SJ; Bai, M; Brown, EM			pH sensing by the calcium-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTOR; EXTRACELLULAR CALCIUM; CA2+-SENSING RECEPTOR; PARATHYROID-HORMONE; PROTONATION SITE; NMDA RECEPTOR; CA2+ CHANNELS; RAT; EXPRESSION; POLYAMINES	The calcium-sensing receptor (CaR) is activated by small changes in the ionic extracellular calcium concentration (Ca-o) within the physiological range, allowing the parathyroid gland to regulate serum Cao; however, the CaR is also distributed in a number of other tissues where it may sense other endogenous agonists and modulators. CaR agonists are polycationic molecules, and our previous studies suggest that charged residues in the extracellular domain of the CaR are critical for receptor activation through electrostatic interactions. Therefore, pH could also potentially modulate CaR activation by its polycationic agonists. Changes in the concentration of extracellular H+ substantially altered the activation of the CaR by Ca-o and other CaR agonists. The effects of external pH on the CaR's sensitivity to its agonists were observed for both acidic and basic deviations from physiological pH of 7.4, with increases in pH rendering the receptor more sensitive to activation by Cao and decreases in pH producing the converse effect. At pH values more acidic than 5.5, CaR sensitivity to its agonists showed some recovery. Changes in the intracellular pH could not account for the effects of external pH on CaR sensitivity to its agonists. Other G-protein-coupled receptors, which are endogenously expressed in human embryonic kidney 293 cells, showed little change in activity with alterations in external pH or effects opposite those found for the CaR. Extracellular pH directly alters the CaR in the case of Ca-o and Mg-o activation; however, the charges on many organic and inorganic agonists are pH-dependent. Activating CaR mutations show reduced pH(o) modulation, suggesting a molecular mechanism for increased CaR activity at physiological pHo. Several CaR-expressing tissues, including regions of the stomach, the kidney, bone, and the brain, could potentially use the CaR as a sensor for pH and acid-base status.	Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Quinn, SJ (corresponding author), Brigham & Womens Hosp, Div Endocrine, 221 Longwood Ave, Boston, MA 02115 USA.	squinn@rics.bwh.harvard.edu	Centeno, Patricia Pacios/O-8368-2016		NIDDK NIH HHS [DK41415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041415] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baes C.F., 1976, HYDROLYSIS CATIONS, DOI 10.1002/bbpc.19770810252; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BICHARA M, 1990, J CLIN INVEST, V86, P430, DOI 10.1172/JCI114729; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Burgess J., 1999, IONS SOLUTION BASIC, P62; Chen XH, 1997, J BIOL CHEM, V272, P30002, DOI 10.1074/jbc.272.48.30002; Chen XH, 1996, J GEN PHYSIOL, V108, P363, DOI 10.1085/jgp.108.5.363; Cheng I, 1999, GASTROENTEROLOGY, V116, P118, DOI 10.1016/S0016-5085(99)70235-0; Cima RR, 1997, AM J PHYSIOL-GASTR L, V273, pG1051, DOI 10.1152/ajpgi.1997.273.5.G1051; Emanuel RL, 1996, MOL ENDOCRINOL, V10, P555, DOI 10.1210/me.10.5.555; GARRETT JE, 1995, ENDOCRINOLOGY, V136, P5202, DOI 10.1210/en.136.11.5202; Houillier P, 1996, KIDNEY INT, V50, P987, DOI 10.1038/ki.1996.400; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; McLarnon SJ, 2002, BIOCHEM BIOPH RES CO, V297, P71, DOI 10.1016/S0006-291X(02)02133-2; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; PULLAN LM, 1992, J NEUROCHEM, V59, P2087; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; Ray JM, 1997, J CLIN INVEST, V99, P2328, DOI 10.1172/JCI119413; Reector FC., 1986, KIDNEY, P551; REYNOLDS IJ, 1988, EUR J PHARMACOL, V151, P103, DOI 10.1016/0014-2999(88)90697-8; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; ROCK DM, 1995, ANNU REV PHARMACOL, V35, P463; Rogers KV, 1997, BRAIN RES, V744, P47, DOI 10.1016/S0006-8993(96)01070-0; ROMANO C, 1994, NEUROPHARMACOLOGY PO, P81; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SANDS JM, 1997, J CLIN INVEST, V99, P1917; SHEPHERD RM, 1992, AM J PHYSIOL, V262, pC182, DOI 10.1152/ajpcell.1992.262.1.C182; STIM JA, 1994, MINER ELECTROL METAB, V20, P60; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; Valtin H, 1983, RENAL FUNCTION	34	114	118	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37241	37249		10.1074/jbc.M404520200	http://dx.doi.org/10.1074/jbc.M404520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201280	hybrid			2022-12-27	WOS:000223554600008
J	Gorr, TA; Cahn, JD; Yamagata, H; Bunn, HF				Gorr, TA; Cahn, JD; Yamagata, H; Bunn, HF			Hypoxia-induced synthesis of hemoglobin in the crustacean Daphnia magna is hypoxia-inducible factor-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; RECEPTOR NUCLEAR TRANSLOCATOR; BHLH-PAS PROTEIN; DROSOPHILA-MELANOGASTER; WATER-FLEA; FACTOR-I; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENTS; DNA-BINDING; LACTATE-DEHYDROGENASE	Of the four known globin genes that exist in the freshwater crustacean Daphnia magna, several are individually induced by hypoxia, lending pale normoxic animals a visible red color when challenged by oxygen deprivation. The promoter regions of the Daphnia globin genes each contain numerous hypoxia response elements (HREs) as potential binding sites for hypoxia-inducible factors (HIFs). Daphnia HIF, bound to human HRE sequences, was detected in extracts from hypoxic (red), but not normoxic (pale), animals. Taking advantage of the phylogenetically conserved HIF/HRE recognition, we employed heterologous transfections of HIF-expressing human and Drosophila cells to model HIF signaling in Daphnia. These experiments revealed that three functional HREs within the promoter of the D. magna globin-2 gene cooperate for maximal hypoxic induction of a downstream luciferase reporter gene. Two of these three cis-elements, at promoter positions -258 and -107, are able to specifically bind human, Drosophila, or Daphnia HIF complexes in vitro. The same two sites are also necessary for maximal induction of reporter transcription under low oxygen tension in the presence of either endogenous human or overexpressed Drosophila HIF proteins. The third motif of the globin-2 gene promoter, a CACGTG palindrome at position -146, functions as a docking site for an unknown constitutive transcription factor. In human cells, this -146 complex interferes with HIF occupancy at the adjacent -107 HRE and thus controls the extent of HIF-mediated hypoxic activation of the downstream target.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, Boston, MA 02115 USA; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Environm Sci, Lab Environm & Mol Biol, Tokyo 1920392, Japan	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tokyo University of Pharmacy & Life Sciences	Bunn, HF (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, 221 Longwood Ave, Boston, MA 02115 USA.	hfbunn@rics.bwh.harvard.edu		Gorr, Thomas/0000-0002-6023-4234	NIDDK NIH HHS [R01 DK041234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECHER B, 2002, THESIS U MUNSTER MUN; BECK I, 1991, J BIOL CHEM, V266, P15563; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BROOKS JL, 1957, MEM CONN ACAD ARTS S, V13, P30; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CHANDLER ANN, 1954, PROC ZOOL SOC LONDON, V124, P625; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Dewilde S, 1999, MOL BIOL EVOL, V16, P1208, DOI 10.1093/oxfordjournals.molbev.a026211; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ebert BL, 1999, BLOOD, V94, P1864; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FOX HM, 1948, PROC R SOC SER B-BIO, V135, P195, DOI 10.1098/rspb.1948.0006; FOX HM, 1950, NATURE, V166, P609, DOI 10.1038/166609a0; FOX HM, 1949, NATURE, V164, P59, DOI 10.1038/164059a0; FOX HM, 1953, PROC R SOC SER B-BIO, V141, P179, DOI 10.1098/rspb.1953.0034; FOX HM, 1949, PROC R SOC SER B-BIO, V136, P388, DOI 10.1098/rspb.1949.0032; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gorr TA, 2004, J BIOL CHEM, V279, P36048, DOI 10.1074/jbc.M405077200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUANG LW, 1993, P NATL ACAD SCI USA, V90, P4304; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hebert PDN, 1999, J MOL EVOL, V49, P769, DOI 10.1007/PL00006599; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; ILAN E, 1982, BIOCHEM J, V207, P297, DOI 10.1042/bj2070297; Jelkmann W, 1996, ANN ANAT, V178, P391, DOI 10.1016/S0940-9602(96)80124-5; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Kato K, 2001, GENE, V273, P41, DOI 10.1016/S0378-1119(01)00569-8; Kimura S, 1999, J BIOL CHEM, V274, P10649, DOI 10.1074/jbc.274.15.10649; KOBAYASHI M, 1988, PHYSIOL ZOOL, V61, P415, DOI 10.1086/physzool.61.5.30161263; KOBAYASHI M, 1994, COMP BIOCHEM PHYS A, V107, P127; KOBAYASHI M, 1990, COMP BIOCHEM PHYS A, V97, P513; KOBAYASHI M, 1982, COMP BIOCHEM PHYS A, V72, P247, DOI 10.1016/0300-9629(82)90040-8; KOBAYASHI M, 1981, COMP BIOCHEM PHYS A, V69, P679; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Ledent V, 2001, GENOME RES, V11, P754, DOI 10.1101/gr.177001; Ma E, 1999, MOL BRAIN RES, V73, P11, DOI 10.1016/S0169-328X(99)00224-7; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mazure NM, 2002, CANCER RES, V62, P1158; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; PENNAK RW, 1989, FRESH WATER INVERTEB, P386; Peters R.H., 1987, Memorie dell'Istituto Italiano di Idrobiologia Dott Marco de Marchi, V45, P193; Peyrefitte S, 2001, MECH DEVELOP, V104, P99, DOI 10.1016/S0925-4773(01)00360-4; Pirow R, 2001, J EXP BIOL, V204, P3425; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; REMANE A, 1980, SYSTEMATISCHE ZOOLOG, P260; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; SWAMMERDAM J, 1758, BOOK NATURE HIST INS, P39; Swanson HI, 1999, NUCLEIC ACIDS RES, V27, P3205, DOI 10.1093/nar/27.15.3205; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Tokishita S, 1997, GENE, V189, P73, DOI 10.1016/S0378-1119(96)00836-0; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; WENGER RH, 1997, BIOL CHEM, V378, P1; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Zeis B, 2003, BIOL CHEM, V384, P1133, DOI 10.1515/BC.2003.126; Zeis B, 2003, COMP BIOCHEM PHYS B, V134, P243, DOI 10.1016/S1096-4959(02)00253-1	69	86	93	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36038	36047		10.1074/jbc.M403981200	http://dx.doi.org/10.1074/jbc.M403981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169764	hybrid			2022-12-27	WOS:000223303400106
J	Horng, YC; Cobine, PA; Maxfield, AB; Carr, HS; Winge, DR				Horng, YC; Cobine, PA; Maxfield, AB; Carr, HS; Winge, DR			Specific copper transfer from the Cox17 metallochaperone to both Sco1 and Cox11 in the assembly of yeast cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL; PROTEIN; CHAPERONE; GENE; PURIFICATION; TRAFFICKING; SITES; CCS	The assembly of the copper sites in cytochrome c oxidase involves a series of accessory proteins, including Cox11, Cox17, and Sco1. The two mitochondrial inner membrane proteins Cox11 and Sco1 are thought to be copper donors to the Cu-B and Cu-A sites of cytochrome oxidase, respectively, whereas Cox17 is believed to be the copper donor to Sco1 within the intermembrane space. In this report we show Cox17 is a specific copper donor to both Sco1 and Cox11. Using in vitro studies with purified proteins, we demonstrate direct copper transfer from CuCox17 to Sco1 or Cox11. The transfer is specific because no transfer occurs to heterologous proteins, including bovine serum albumin and carbonic anhydrase. In addition, a C57Y mutant of Cox17 fails to transfer copper to Sco1 but is competent for copper transfer to Cox11. The in vitro transfer studies were corroborated by a yeast cytoplasm expression system. Soluble domains of Sco1 and Cox11, lacking the mitochondrial targeting sequence and transmembrane domains, were expressed in the yeast cytoplasm. Metallation of these domains was strictly dependent on the co-expression of Cox17. Thus, Cox17 represents a novel copper chaperone that delivers copper to two proteins.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Cobine, Paul/AAH-6619-2020; Winge, Dennis/G-3611-2010; Cobine, Paul A/G-3107-2011; Horng, Yih-Chern/I-6682-2018	Cobine, Paul/0000-0001-6012-0985; Cobine, Paul A/0000-0001-6012-0985; Horng, Yih-Chern/0000-0001-9558-3189	NCI NIH HHS [5P30-CA-42014] Funding Source: Medline; NIDDK NIH HHS [T32 DK07115] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Cobine PA, 2004, J BIOL CHEM, V279, P14447, DOI 10.1074/jbc.M312693200; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; GELLER BL, 1982, ARCH BIOCHEM BIOPHYS, V213, P109, DOI 10.1016/0003-9861(82)90445-3; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990	31	210	220	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35334	35340		10.1074/jbc.M404747200	http://dx.doi.org/10.1074/jbc.M404747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199057	hybrid			2022-12-27	WOS:000223303400026
J	Ruiz, PA; Kim, SC; Sartor, RB; Haller, D				Ruiz, PA; Kim, SC; Sartor, RB; Haller, D			15-deoxy-Delta(12,14)-prostaglandin J(2)-mediated ERK signaling inhibits gram-negative bacteria-induced RelA phosphorylation and interleukin-6 gene expression in intestinal epithelial cells through modulation of protein phosphatase 2A activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; LUMINAL BACTERIA; P65 SUBUNIT; KINASE; COLITIS; J(2); INFLAMMATION; ALPHA	We have previously shown that non-pathogenic Gram-negative Bacteroides vulgatus induces transient RelA phosphorylation (Ser-536), NF-kappaB activity, and proinflammatory gene expression in native and intestinal epithelial cell (IEC) lines. We now demonstrate that 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) but not prostaglandin E-2 inhibits lipopolysaccharide (LPS) (B. vulgatus)/LPS (Escherichia coli)-induced RelA phosphorylation and interleukin-6 gene expression in the colonic epithelial cell line CMT-93. This inhibitory effect of 15d-PGJ(2) was mediated independently of LPS-induced IkappaBalpha phosphorylation/degradation and RelA nuclear translocation as well as RelA DNA binding activity. Interestingly, although B. vulgatus induced nuclear expression of peroxisome proliferator-activated receptor gamma(PPARgamma) in native epithelium of monoassociated Fisher rats, PPARgamma-specific knock-down in CMT-93 cells using small interference RNA failed to reverse the inhibitory effects of PPARgamma agonist 15d-PGJ(2), suggesting PPARgamma-independent mechanisms. In addition, 15dPGJ(2) but not the synthetic high affinity PPARgamma ligand rosiglitazone triggered ERK1/2 phosphorylation in IEC, and most importantly, MEK1 inhibitor PD98059 reversed the inhibitory effect of 15dPGJ(2) on LPS-induced RelA phosphorylation and interleukin-6 gene expression. Calyculin A, a specific phosphoserine/phosphothreonine phosphatase inhibitor increased the basal phosphorylation of RelA and reversed the inhibitory effect of 15d-PGJ(2) on LPS-induced RelA phosphorylation. We further demonstrated in co-immunoprecipitation experiments that 15d-PGJ(2) triggered protein phosphatase 2A activity, which directly dephosphorylated RelA in LPS-stimulated CMT-93 cells. We concluded that 15d-PGJ(2) may help to control NF-kappaB signaling and normal intestinal homeostasis to the enteric microflora by modulating RelA phosphorylation in IEC through altered protein phosphatase 2A activity.	Tech Univ Munich, Ctr Nutr & Food Res Immunobiol Nutr, D-35350 Freising Weihenstephan, Germany; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	Technical University of Munich; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Haller, D (corresponding author), Tech Univ Munich, Ctr Nutr & Food Res Immunobiol Nutr, D-35350 Freising Weihenstephan, Germany.	haller@wzw.tum.de		Ruiz-Castro, Pedro Antonio/0000-0001-7528-1474; Haller, Dirk/0000-0002-6977-4085	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, R01DK053347] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34987, R01 DK53347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ardite E, 1998, BRIT J PHARMACOL, V124, P431, DOI 10.1038/sj.bjp.0701887; Auwerx J, 2002, AM J PHYSIOL-GASTR L, V282, pG581, DOI 10.1152/ajpgi.00508.2001; Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Dubuquoy L, 2003, GASTROENTEROLOGY, V124, P1265, DOI 10.1016/S0016-5085(03)00271-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gordon JI, 1997, AM J PHYSIOL-GASTR L, V273, pG565, DOI 10.1152/ajpgi.1997.273.3.G565; Guyton K, 2001, J LEUKOCYTE BIOL, V69, P631; Haller D, 2004, J PEDIATR GASTR NUTR, V38, P123, DOI 10.1097/00005176-200402000-00004; Haller D, 2003, J BIOL CHEM, V278, P23851, DOI 10.1074/jbc.M300075200; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hinz B, 2003, BIOCHEM BIOPH RES CO, V302, P415, DOI 10.1016/S0006-291X(03)00195-5; Huang WC, 2002, EXP CELL RES, V277, P192, DOI 10.1006/excr.2002.5546; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Katayama K, 2003, GASTROENTEROLOGY, V124, P1315, DOI 10.1016/S0016-5085(03)00262-2; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rath HC, 1999, INFECT IMMUN, V67, P2969, DOI 10.1128/IAI.67.6.2969-2974.1999; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saubermann LJ, 2002, INFLAMM BOWEL DIS, V8, P330, DOI 10.1097/00054725-200209000-00004; SAVAGE DC, 1968, J EXP MED, V127, P67, DOI 10.1084/jem.127.1.67; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Shkoda A, 2004, GASTROENTEROLOGY, V126, pA8; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Tanaka T, 2001, CANCER RES, V61, P2424; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	59	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36103	36111		10.1074/jbc.M405032200	http://dx.doi.org/10.1074/jbc.M405032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199053	Green Published, hybrid			2022-12-27	WOS:000223303400112
J	Wu, YL; Hooks, SB; Harden, TK; Dohlman, HG				Wu, YL; Hooks, SB; Harden, TK; Dohlman, HG			Dominant-negative inhibition of pheromone receptor signaling by a single point mutation in the G protein alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; NUCLEOTIDE SPECIFICITY; ADENYLYL-CYCLASE; RGS PROTEINS; YEAST; MUTANT; BINDING; RAS; MECHANISM; GENE	In yeast, two different constitutive mutants of the G protein alpha subunit have been reported. Gpa1(Q323L) cannot hydrolyze GTP and permanently activates the pheromone response pathway. Gpa1(N388D) was also proposed to lack GTPase activity, yet it has an inhibitory effect on pheromone responsiveness. We have characterized this inhibitory mutant (designated Galpha(ND)) and found that it binds GTP, interacts with G protein betagamma subunits, and exhibits full GTPase activity in vitro. Although pheromone leads to dissociation of the receptor from wild-type G protein, the same treatment promotes stable association of the receptor with Galpha(ND). We conclude that agonist binding to the receptor promotes the formation of a nondissociable complex with Galpha(ND), and in this manner prevents activation of the endogenous wild-type G protein. Dominant-negative mutants may be useful in matching specific receptors and their cognate G proteins and in determining mechanisms of G protein signaling specificity.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	hdohlman@med.unc.edu		Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [P01-GM65533, F32-GM66561, P01 GM065533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM065533, F32GM066561] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, J BIOL CHEM, V273, P28597, DOI 10.1074/jbc.273.44.28597; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Batlle M, 2003, J CELL SCI, V116, P701, DOI 10.1242/jcs.00266; Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Cismowski MJ, 2001, BIOCHEM BIOPH RES CO, V284, P247, DOI 10.1006/bbrc.2001.4959; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Dohlman HG, 2002, ANNU REV PHYSIOL, V64, P129, DOI 10.1146/annurev.physiol.64.081701.133448; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Grishina G, 2000, MOL PHARMACOL, V57, P1081; Guo M, 2003, MOL CELL, V12, P517, DOI 10.1016/S1097-2765(03)00307-1; Harashima T, 2002, MOL CELL, V10, P163, DOI 10.1016/S1097-2765(02)00569-5; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hoffman GA, 2002, METHOD ENZYMOL, V344, P617; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KURJAN J, 1991, GENE DEV, V5, P475, DOI 10.1101/gad.5.3.475; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1992, J BIOL CHEM, V267, P1212; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; Metodiev MV, 2002, SCIENCE, V296, P1483, DOI 10.1126/science.1070540; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OSAWA S, 1991, J BIOL CHEM, V266, P4673; PARKER EM, 1991, J BIOL CHEM, V266, P519; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; Robishaw JD, 2004, CURR OPIN CELL BIOL, V16, P206, DOI 10.1016/j.ceb.2004.02.007; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SIKORSKI RS, 1989, GENETICS, V122, P19; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stratton HF, 1996, MOL CELL BIOL, V16, P6325; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183; Yu B, 2000, J BIOL CHEM, V275, P71, DOI 10.1074/jbc.275.1.71; Yun CW, 1997, BIOCHEM BIOPH RES CO, V240, P287, DOI 10.1006/bbrc.1997.7649; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002; Zhou Jianlong, 1999, Cell Biochemistry and Biophysics, V30, P193, DOI 10.1007/BF02738067	61	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35287	35297		10.1074/jbc.M404896200	http://dx.doi.org/10.1074/jbc.M404896200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15197187	Green Published, hybrid			2022-12-27	WOS:000223303400020
J	Xin, CY; Ren, SY; Kleuser, B; Shabahang, S; Eberhardt, W; Radeke, H; Schafer-Korting, M; Pfeilschifter, J; Huwiler, A				Xin, CY; Ren, SY; Kleuser, B; Shabahang, S; Eberhardt, W; Radeke, H; Schafer-Korting, M; Pfeilschifter, J; Huwiler, A			Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL MESANGIAL CELLS; PROTEIN-COUPLED RECEPTORS; NITRIC-OXIDE SYNTHASE; TGF-BETA; EXPERIMENTAL GLOMERULONEPHRITIS; KINASE CASCADE; PROSTAGLANDIN SYNTHESIS; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE; EXPRESSION	Exposure of renal mesangial cells to sphingosine 1-phosphate (S1P) leads to a rapid and transient activation of the mitogen- and stress-activated protein kinases but also the protein kinase B. Here, we show that S1P also induces phosphorylation of Smad proteins, which are members of the transforming growth factor-beta (TGF-beta) signaling device. However, Smad phosphorylation occurred more slowly with a maximal effect after 20-30 min of S1P stimulation when compared with the rapid activation of the MAPKs. Interestingly, Smad phosphorylation is increased by pertussis toxin, which is in contrast to the complete inhibition of S1P-induced MAPK phosphorylation by pertussis toxin. TGF-beta is a potent anti-inflammatory cytokine, which in mesangial cells attenuates the expression of (i) inducible nitric-oxide synthase (iNOS) caused by interleukin (IL)-1beta, (ii) secreted phospholipase A(2) (sPLA(2)), and (iii) matrix metalloproteinase-9 (MMP-9). These gene products are also down-regulated by S1P in a concentration-dependent manner. Furthermore, the expression of connective tissue growth factor is enhanced by both TGF-beta(2) and S1P. These effects of S1P are not mediated by the MAPK cascade as neither pertussis toxin nor the MAPK cascade inhibitor U0126 are able to reverse this inhibition. Overexpression of the inhibitory Smad-7 or down-regulation of co-Smad-4 lead to a reversal of the blocking effect of S1P on IL-1beta-induced NO release. Moreover, down-regulating the TGF-beta receptor type II by the siRNA technique or antagonizing the S1P(3) receptor subtype with suramin abrogates S1P-stimulated Smad phosphorylation. In summary, our data show that S1P trans-activates the TGF-beta receptor and triggers activation of Smads followed by activation of connective tissue growth factor gene transcription and inhibition of IL-1 1beta-induced expression of iNOS, sPLA2, and MMP-9.	Univ Frankfurt Klinikum, Pharmazentrum, D-60590 Frankfurt, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Free University of Berlin	Huwiler, A (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Huwiler@em.uni-frankfurt.de	Radeke, Heinfried H/E-3772-2013	Radeke, Heinfried H/0000-0002-4499-2510; Kleuser, Burkhard/0000-0002-1888-9595				Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Cheng JF, 2002, EXP BIOL MED, V227, P943, DOI 10.1177/153537020222701102; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; DING A, 1990, J IMMUNOL, V145, P940; Eberhardt W, 2000, KIDNEY INT, V57, P59, DOI 10.1046/j.1523-1755.2000.00808.x; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; Franitza S, 2002, EUR J IMMUNOL, V32, P193, DOI 10.1002/1521-4141(200201)32:1<193::AID-IMMU193>3.0.CO;2-H; Frey RS, 1997, CANCER RES, V57, P628; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hartner A, 2003, J MOL MED-JMM, V81, P32, DOI 10.1007/s00109-002-0403-x; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; HUWILER A, 1995, BIOCHEM J, V305, P777, DOI 10.1042/bj3050777; Im DS, 2003, TRENDS PHARMACOL SCI, V24, P2, DOI 10.1016/S0165-6147(02)00012-3; KASHGARIAN M, 1992, KIDNEY INT, V41, P524, DOI 10.1038/ki.1992.74; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Madry H, 2001, J MOL MED-JMM, V79, P184, DOI 10.1007/s001090000186; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Manggau M, 2001, J INVEST DERMATOL, V117, P1241, DOI 10.1046/j.0022-202x.2001.01496.x; MARTI HP, 1994, AM J PATHOL, V144, P82; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; MUHL H, 1992, FEBS LETT, V301, P190, DOI 10.1016/0014-5793(92)81245-H; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pages G, 2000, ANN NY ACAD SCI, V902, P187; PFEILSCHIFTER J, 1989, EUR J CLIN INVEST, V19, P347, DOI 10.1111/j.1365-2362.1989.tb00241.x; PFEILSCHIFTER J, 1989, BIOCHEM BIOPH RES CO, V159, P385, DOI 10.1016/0006-291X(89)90003-X; PFEILSCHIFTER J, 1990, BIOCHEM J, V270, P269, DOI 10.1042/bj2700269; PFEILSCHIFTER J, 1994, NEWS PHYSIOL SCI, V9, P271, DOI 10.1152/physiologyonline.1994.9.6.271; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PFEILSCHIFTER J, 1986, BIOCHEM J, V234, P125, DOI 10.1042/bj2340125; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; Sato M, 2003, J BIOL CHEM, V278, P9276, DOI 10.1074/jbc.M211529200; Schiffer M, 2000, KIDNEY INT, V58, pS45, DOI 10.1046/j.1523-1755.2000.07708.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Vogler R, 2003, J INVEST DERMATOL, V120, P693, DOI 10.1046/j.1523-1747.2003.12096.x; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	66	160	165	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35255	35262		10.1074/jbc.M312091200	http://dx.doi.org/10.1074/jbc.M312091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192102	hybrid			2022-12-27	WOS:000223303400016
J	Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR				Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR			Glycoprotein hormone assembly in the endoplasmic reticulum - III. The seatbelt and its latch site determine the assembly pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HUMAN CHORIOGONADOTROPIN; SALMON GONADOTROPINS; STIMULATING-HORMONE; BIOLOGICAL-ACTIVITY; BETA-SUBUNIT; GTH-II; PROTEIN; FOLLITROPIN; LUTROPIN	Vertebrate glycoprotein hormone heterodimers are stabilized by a strand of their beta-subunits known as the "seatbelt" that is wrapped around loop 2 of their alpha-subunits (alpha2). The cysteine that terminates the seatbelt is "latched" by a disulfide to a cysteine in beta-subunit loop 1 (beta1) of all vertebrate hormones except some teleost follitropins (teFSH), wherein it is latched to a cysteine in the beta-subunit NH2 terminus. As reported here, teFSH analogs of human choriogonadotropin (hCG) are assembled by a pathway in which the subunits dock before the seatbelt is latched; assembly is completed by wrapping the seatbelt around loop alpha2 and latching it to the NH2 terminus. This differs from hCG assembly, which occurs by threading the glycosylated end of loop alpha2 beneath the latched seatbelt through a hole in the beta-subunit. The seatbelt is the part of the beta-subunit that has the greatest influence on biological function. Changes in its sequence during the divergence of lutropins, follitropins, and thyrotropins and the speciation of teleost fish may have impeded heterodimer assembly by a threading mechanism, as observed when the hCG seatbelt was replaced with its salmon FSH counterpart. Whereas wrapping is less efficient than threading, it may have facilitated natural experimentation with the composition of the seatbelt during the co-evolution of glycoprotein hormones and their receptors. Migration of the seatbelt latch site to the NH2-terminal end of the beta-subunit would have facilitated teFSH assembly by a wraparound mechanism and may have contributed also to its ability to distinguish lutropin and follitropin receptors.	Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			NICHD NIH HHS [HD38547, HD14907] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038547, R01HD014907, R37HD014907] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALOJ SM, 1973, ARCH BIOCHEM BIOPHYS, V159, P497, DOI 10.1016/0003-9861(73)90480-3; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; Campbell RK, 1997, NAT BIOTECHNOL, V15, P439, DOI 10.1038/nbt0597-439; CHEN F, 1991, J BIOL CHEM, V266, P6904; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; GarciaHernandez MP, 1997, GEN COMP ENDOCR, V106, P389, DOI 10.1006/gcen.1997.6887; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Li MD, 1998, J ENDOCRINOL, V156, P529, DOI 10.1677/joe.0.1560529; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SLAUGHTER S, 1995, MOL CELL ENDOCRINOL, V112, P21, DOI 10.1016/0303-7207(95)03579-V; SWANSON P, 1991, BIOL REPROD, V44, P29, DOI 10.1095/biolreprod44.1.29; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P35437, DOI 10.1074/jbc.M403053200; Xing YN, 2004, J BIOL CHEM, V279, P35426, DOI 10.1074/jbc.M403052200; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; YAN LG, 1992, BIOL REPROD, V47, P418, DOI 10.1095/biolreprod47.3.418	20	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35449	35457		10.1074/jbc.M403054200	http://dx.doi.org/10.1074/jbc.M403054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15161904	hybrid			2022-12-27	WOS:000223303400038
J	Butchbach, MER; Tian, GL; Guo, H; Lin, CLG				Butchbach, MER; Tian, GL; Guo, H; Lin, CLG			Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains - Importance for excitatory amino acid transporter localization and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; NICOTINIC ACETYLCHOLINE-RECEPTOR; AFFINITY GLUTAMATE TRANSPORTER; INTERACTING PROTEIN GTRAP3-18; KINASE-C-ALPHA; HIPPOCAMPAL-NEURONS; RAT-BRAIN; EAAC1; MEMBRANE; SUBTYPE	In the present study, we investigated the role of membrane cholesterol in the function of glutamate transporters. Depletion of membrane cholesterol by methyl-beta-cyclodextrin resulted in reduced Na+-dependent glutamate uptake in primary cortical cultures. Glial glutamate transporter EAAT2-mediated uptake was more sensitive to this effect. Cell surface biotinylation and immunostaining experiments revealed that the loss of cholesterol significantly altered the trafficking of EAAT2 to the plasma membrane as well as their membrane distribution. These effects were also observed in neuronal glutamate transporter EAAT3 but to a lesser extent. Furthermore, the treatment of mouse brain plasma membrane vesicles with methyl-beta-cyclodextrin resulted in a significant reduction in glutamate uptake, suggesting that cholesterol depletion has a direct effect on the function of the glutamate transporters. Plasma membrane cholesterol is localized within discreet microdomains known as lipid rafts. Analyses of purified lipid raft microdomains revealed that a large portion of total EAAT2 and a minor portion of total EAAT1, EAAT3, and EAAT4 were associated with lipid rafts. Artificial aggregation of lipid rafts in vivo resulted in the formation of larger EAAT2-immunoreactive clusters on the cell surface. The purified lipid raft-associated fractions were capable of Na+-dependent glutamate uptake. Our data suggest that the glutamate transporters, especially EAAT2, are associated with cholesterol-rich lipid raft microdomains of the plasma membrane and that the association with these cholesterol-rich microdomains is important for excitatory amino acid transporter localization and function.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Neurosci Grad Studies Program, Columbus, OH 43210 USA; Ohio State Univ, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lin, CLG (corresponding author), Ohio State Univ, Dept Neurosci, 4198 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	lin.492@osu.edu	Lin, Chien-liang G/E-3513-2011	Butchbach, Matthew/0000-0003-2912-6400	NIMH NIH HHS [MH 598005] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Becher A, 2001, J NEUROCHEM, V79, P787, DOI 10.1046/j.1471-4159.2001.00614.x; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Bruses JL, 2001, J NEUROSCI, V21, P504, DOI 10.1523/JNEUROSCI.21-02-00504.2001; Butchbach MER, 2002, GENE, V292, P81, DOI 10.1016/S0378-1119(02)00669-8; Butchbach MER, 2003, J NEUROCHEM, V84, P891, DOI 10.1046/j.1471-4159.2003.01588.x; Canolle B, 2004, J NEUROCHEM, V88, P1521, DOI 10.1046/j.1471-4159.2003.02301.x; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Cheng CL, 2002, J NEUROSCI, V22, P10643; Coco S, 1997, EUR J NEUROSCI, V9, P1902, DOI 10.1111/j.1460-9568.1997.tb00757.x; Conti F, 1998, CEREB CORTEX, V8, P108, DOI 10.1093/cercor/8.2.108; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Daniels KK, 1998, NEUROCHEM RES, V23, P103, DOI 10.1023/A:1022413823183; Davis KE, 1998, J NEUROSCI, V18, P2475; Duan SM, 1999, J NEUROSCI, V19, P10193; Eckert GP, 2003, BRAIN RES, V962, P144, DOI 10.1016/S0006-8993(02)03986-0; Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2; Gonzalez MI, 2003, J NEUROSCI, V23, P5589; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; Hering H, 2003, J NEUROSCI, V23, P3262; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Maekawa S, 2003, BBA-BIOMEMBRANES, V1610, P261, DOI 10.1016/S0005-2736(03)00023-3; Marchand S, 2002, J NEUROSCI, V22, P8891; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Poitry-Yamate CL, 2002, J NEUROCHEM, V82, P987, DOI 10.1046/j.1471-4159.2002.01075.x; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Shayakul C, 1997, AM J PHYSIOL-RENAL, V273, pF1023, DOI 10.1152/ajprenal.1997.273.6.F1023; SHOUFFANI A, 1990, J BIOL CHEM, V265, P6002; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; Suzuki T, 2001, MOL BRAIN RES, V89, P20, DOI 10.1016/S0169-328X(01)00051-1; Swanson RA, 1997, J NEUROSCI, V17, P932; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4	48	132	133	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34388	34396		10.1074/jbc.M403938200	http://dx.doi.org/10.1074/jbc.M403938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187084	hybrid			2022-12-27	WOS:000223134800039
J	Choudhary, S; Sommers, JA; Brosh, RM				Choudhary, S; Sommers, JA; Brosh, RM			Biochemical and kinetic characterization of the DNA helicase and exonuclease activities of Werner syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECQ HELICASE; SYNDROME CELLS; S-PHASE; HOMOLOGOUS RECOMBINATION; REPLICATION ARREST; REPAIR PROCESSES; SYNDROME GENE; POLYMERASE-I; WRN HELICASE; INVITRO	The WRN gene, defective in the premature aging and genome instability disorder Werner syndrome, encodes a protein with DNA helicase and exonuclease activities. In this report, cofactor requirements for WRN catalytic activities were examined. WRN helicase performed optimally at an equimolar concentration ( 1 mM) of Mg2+ and ATP with a K-m of 140 muM for the ATP-Mg2+ complex. The initial rate of WRN helicase activity displayed a hyperbolic dependence on ATP-Mg2+ concentration. Mn2+ and Ni2+ substituted for Mg2+ as a cofactor for WRN helicase, whereas Fe2+ or Cu2+ ( 10 muM) profoundly inhibited WRN unwinding in the presence of Mg2+. Zn2+ ( 100 muM) was preferred over Mg2+ as a metal cofactor for WRN exonuclease activity and acts as a molecular switch, converting WRN from a helicase to an exonuclease. Zn2+ strongly stimulated the exonuclease activity of a WRN exonuclease domain fragment, suggesting a Zn2+ binding site in the WRN exonuclease domain. A fluorometric assay was used to study WRN helicase kinetics. The initial rate of unwinding increased with WRN concentration, indicating that excess enzyme over DNA substrate improved the ability of WRN to unwind the DNA substrate. Under presteady state conditions, the burst amplitude revealed a 1: 1 ratio between WRN and DNA substrate, suggesting an active monomeric form of the helicase. These are the first reported kinetic parameters of a human RecQ unwinding reaction based on real time measurements, and they provide mechanistic insights into WRN-catalyzed DNA unwinding.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	BroshR@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000741, ZIAAG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Cobb JA, 2002, FEBS LETT, V529, P43, DOI 10.1016/S0014-5793(02)03269-6; Cui S, 2003, J BIOL CHEM, V278, P1424, DOI 10.1074/jbc.M209407200; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Harrigan JA, 2003, BIOCHIMIE, V85, P1185, DOI 10.1016/j.biochi.2003.10.006; Hartwig A, 2002, ENVIRON HEALTH PERSP, V110, P797, DOI 10.1289/ehp.02110s5797; Hartwig A, 2002, TOXICOL LETT, V127, P47, DOI 10.1016/S0378-4274(01)00482-9; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Jin YH, 2003, NAT GENET, V34, P326, DOI 10.1038/ng1172; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marians KJ, 2000, STRUCTURE, V8, pR227, DOI 10.1016/S0969-2126(00)00539-6; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSON SW, 1986, J BIOL CHEM, V261, P169; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Singleton MR, 2003, EMBO J, V22, P4579, DOI 10.1093/emboj/cdg441; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; Tanaka Y, 2004, FEBS LETT, V556, P167, DOI 10.1016/S0014-5793(03)01402-9; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7; Xu HQ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng070; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	56	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34603	34613		10.1074/jbc.M401901200	http://dx.doi.org/10.1074/jbc.M401901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187093	hybrid			2022-12-27	WOS:000223134800065
J	Jeong, HG; Youn, CK; Cho, HJ; Kim, SH; Kim, MH; Kim, HB; Chang, IY; Lee, YS; Chung, MH; You, HJ				Jeong, HG; Youn, CK; Cho, HJ; Kim, SH; Kim, MH; Kim, HB; Chang, IY; Lee, YS; Chung, MH; You, HJ			Metallothionein-III prevents gamma-ray-induced 8-oxoguanine accumulation in normal and hOGG1-depleted cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-INHIBITORY FACTOR; ALZHEIMERS-DISEASE BRAIN; OXIDATIVE DNA-DAMAGE; MESSENGER-RNA; ZINC-METALLOTHIONEIN; FREE-RADICALS; IONIZING-RADIATION; NEURITE FORMATION; CORTICAL-NEURONS; STRAND BREAKS	Metallothioneins (MT) play an important biological role in preventing oxidative damage to cells. We have previously demonstrated that the efficiency of the protective effect of MT-III against the DNA degradation from oxidative damage was much higher than that of MT-I/II. As an extension of the latter investigation, this study aimed to assess the ability of MT-III to suppress 8-oxoguanine (8-oxoG), which is one of the major base lesions formed after an oxidative attack to DNA and the mutant frequency of the HPRT gene in human fibroblast GM00637 cells upon exposure to gamma-rays. We found that human MT-III expression decreased the level of 8-oxoG and mutation frequency in the gamma-irradiated cells. Using an 8-oxoguanine DNA glycosylase (OGG1)-specific siRNAs, we also found that MT-III expression resulted in the suppression of the gamma-radiation-induced 8-oxoG accumulation and mutation in the OGG1-depleted cells. Moreover, the down-regulation of MT in human neuroblastoma SKNSH cells induced by MT-specific siRNA led to a significant increase in the 8-oxoG level, after exposure to gamma-irradiation. These results suggest that under the conditions of gamma-ray oxidative stress, MT-III prevents the gamma-radiation-induced 8-oxoG accumulation and mutation in normal and hOGG1-depleted cells, and this suppression might, at least in part, contribute to the anti-carcinogenic and neuroprotective role of MT-III.	Chosun Univ, Res Ctr Prot MAt, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; Korea Canc Ctr Hosp, Lab Radiat Effect, Seoul 139706, South Korea; Seoul Natl Univ, Sch Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; National Cancer Center - Korea (NCC); Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Res Ctr Prot MAt, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@chosun.ac.kr		Chang, In-Youb/0000-0002-8911-7541; KIM, HONGBEUM/0000-0001-9434-0708; You, Ho Jin/0000-0002-0530-4017				ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1; Aschner M, 1998, NEUROTOXICOLOGY, V19, P653; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; BEERS RF, 1952, J BIOL CHEM, V195, P133; Bogdanov MB, 2001, J NEUROCHEM, V79, P1246, DOI 10.1046/j.1471-4159.2001.00689.x; Brooks PJ, 2000, NEUROCHEM INT, V37, P403, DOI 10.1016/S0197-0186(00)00051-6; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; BURKITT MJ, 1990, FREE RADICAL RES COM, V10, P265, DOI 10.3109/10715769009149895; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Cai L, 1998, CHEM-BIOL INTERACT, V115, P141, DOI 10.1016/S0009-2797(98)00069-6; Cai L, 1999, TOXICOLOGY, V132, P85, DOI 10.1016/S0300-483X(98)00150-4; Cai L, 2003, TOXICOL LETT, V136, P193, DOI 10.1016/S0378-4274(02)00359-4; Cai L, 1996, MUTAT RES-GENET TOX, V369, P233, DOI 10.1016/S0165-1218(96)90028-2; Carrasco J, 2003, NEUROBIOL DIS, V13, P22, DOI 10.1016/S0969-9961(03)00015-9; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Ceballos D, 2003, CELL MOL LIFE SCI, V60, P1209, DOI 10.1007/s00018-003-3047-2; CHAPMAN JD, 1973, RADIAT RES, V56, P291, DOI 10.2307/3573667; Chen HN, 2001, DIABETES, V50, P2040, DOI 10.2337/diabetes.50.9.2040; Chen Y, 2002, BIOCHEMISTRY-US, V41, P8360, DOI 10.1021/bi020030+; CHENG KC, 1992, J BIOL CHEM, V267, P166; Cherian MG, 2000, CELL MOL BIOL, V46, P347; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; Chung RS, 2002, EXP NEUROL, V178, P1, DOI 10.1006/exnr.2002.8017; Durnam D M, 1987, Experientia Suppl, V52, P457; EICHHOLTZWIRTH H, 1993, BRIT J CANCER, V67, P1001, DOI 10.1038/bjc.1993.183; Erickson JC, 1997, J NEUROSCI, V17, P1271; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Glaab WE, 1999, MUTAT RES-FUND MOL M, V427, P67, DOI 10.1016/S0027-5107(99)00091-3; Greenstock C L, 1987, Free Radic Res Commun, V2, P233, DOI 10.3109/10715768709065288; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Hogg N, 1998, SEMIN REPROD ENDOCR, V16, P241, DOI 10.1055/s-2007-1016284; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; Iida T, 2002, ACTA NEUROPATHOL, V103, P20, DOI 10.1007/s004010100418; Irie Y, 2003, BRAIN RES, V960, P228, DOI 10.1016/S0006-8993(02)03891-X; Irie Y, 2001, BIOCHEM BIOPH RES CO, V282, P416, DOI 10.1006/bbrc.2001.4594; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Jin RX, 2002, CARCINOGENESIS, V23, P81, DOI 10.1093/carcin/23.1.81; Jourdan E, 2002, ARCH BIOCHEM BIOPHYS, V405, P170, DOI 10.1016/S0003-9861(02)00401-0; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; KAGIMOTO O, 1991, J RADIAT RES, V32, P417, DOI 10.1269/jrr.32.417; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Kondo Y, 1999, CARCINOGENESIS, V20, P1625, DOI 10.1093/carcin/20.8.1625; KOROPATNICK J, 1989, RADIAT RES, V119, P356, DOI 10.2307/3577626; Kramer KK, 1996, TOXICOL APPL PHARM, V141, P1; Kramer KK, 1996, TOXICOL APPL PHARM, V136, P94, DOI 10.1006/taap.1996.0011; Lazo JS, 1998, CHEM-BIOL INTERACT, V112, P255, DOI 10.1016/S0009-2797(97)00165-8; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lee MR, 2004, J BIOL CHEM, V279, P9857, DOI 10.1074/jbc.M311132200; Levadoux M, 1999, J BIOL CHEM, V274, P34961, DOI 10.1074/jbc.274.49.34961; Liu Philip K., 2001, Current Topics in Medicinal Chemistry, V1, P483, DOI 10.2174/1568026013394688; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lyras L, 1997, J NEUROCHEM, V68, P2061; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mei N, 2003, ENVIRON MOL MUTAGEN, V41, P332, DOI 10.1002/em.10165; MELLOFILHO AC, 1988, BIOCHEM J, V256, P475, DOI 10.1042/bj2560475; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168; Miura T, 1997, LIFE SCI, V60, pPL301; Montoliu C, 2000, J NEUROCHEM, V75, P266, DOI 10.1046/j.1471-4159.2000.0750266.x; Nagano T, 2000, J CELL PHYSIOL, V185, P440, DOI 10.1002/1097-4652(200012)185:3<440::AID-JCP15>3.0.CO;2-N; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2003, CELL MOL LIFE SCI, V60, P185, DOI 10.1007/s000180300013; Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5; Perry G, 2002, FREE RADICAL BIO MED, V33, P1475, DOI 10.1016/S0891-5849(02)01113-9; Puttaparthi K, 2002, J NEUROSCI, V22, P8790; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RENAN MJ, 1989, RADIAT RES, V120, P442, DOI 10.2307/3577795; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; ROOTS R, 1975, RADIAT RES, V64, P306, DOI 10.2307/3574267; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Rossman TG, 1998, MUTAT RES-FUND MOL M, V402, P103, DOI 10.1016/S0027-5107(97)00287-X; Rossman TG, 1997, MUTAT RES-FUND MOL M, V373, P75, DOI 10.1016/S0027-5107(96)00192-3; Sakamoto T, 2003, NEUROREPORT, V14, P2147, DOI 10.1097/00001756-200312020-00003; SANCHEZRAMOS JR, 1994, NEURODEGENERATION, V3, P197; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SATOH M, 1993, CANCER RES, V53, P4767; SHIRAISHI N, 1986, TOXICOL APPL PHARM, V85, P128, DOI 10.1016/0041-008X(86)90106-7; Sogawa CA, 2000, BRAIN RES, V853, P310, DOI 10.1016/S0006-8993(99)02284-2; Suzuki JS, 2003, CARCINOGENESIS, V24, P1123, DOI 10.1093/carcin/bgg052; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UCHIDA Y, 1989, BRAIN RES, V481, P190, DOI 10.1016/0006-8993(89)90503-9; UCHIDA Y, 1988, BIOCHEM BIOPH RES CO, V150, P1263, DOI 10.1016/0006-291X(88)90765-6; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Y, 2002, J BIOL CHEM, V277, P32353, DOI 10.1074/jbc.M111263200; Uchida Yoko, 1994, Biological Signals, V3, P211; Vukovic V, 2000, INT J RADIAT BIOL, V76, P757, DOI 10.1080/09553000050028904; WAALKES MP, 1985, FUND APPL TOXICOL, V5, P473, DOI 10.1016/0272-0590(85)90094-6; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamada M, 1996, BRAIN RES, V735, P257, DOI 10.1016/0006-8993(96)00586-0; You HJ, 2002, FEBS LETT, V521, P175, DOI 10.1016/S0014-5793(02)02870-3; You HJ, 2002, BBA-GEN SUBJECTS, V1573, P33, DOI 10.1016/S0304-4165(02)00325-2; Yu WH, 2001, BRAIN RES, V894, P37, DOI 10.1016/S0006-8993(00)03196-6	103	27	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34138	34149		10.1074/jbc.M402530200	http://dx.doi.org/10.1074/jbc.M402530200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190073	hybrid			2022-12-27	WOS:000223134800011
J	Nomura, K; Kato, J; Takiguchi, N; Ohtake, H; Kuroda, A				Nomura, K; Kato, J; Takiguchi, N; Ohtake, H; Kuroda, A			Effects of inorganic polyphosphate on the proteolytic and DNA-binding activities of Lon in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; PROTEIN-DEGRADATION; ION PROTEASE; SITE; LA; PURIFICATION; SYSTEM; OVERPRODUCTION; BACTERIAL; DOMAIN	Lon belongs to a unique group of proteases that bind to DNA and is involved in the regulation of several important cellular functions, including adaptation to nutritional downshift. Previously, we revealed that inorganic polyphosphate ( polyP) increases in Escherichia coli in response to amino acid starvation and that it stimulates the degradation of free ribosomal proteins by Lon. In this work, we examined the effects of polyP on the proteolytic and DNA-binding activities of Lon. An order-of-addition experiment suggested that polyP first binds to Lon, which stimulates Lon-mediated degradation of ribosomal proteins. A polyP-binding assay using Lon deletion mutants showed that the polyP-binding site of Lon is localized in the ATPase domain. Because the same ATPase domain also contains the DNA-binding site, polyP can compete with DNA for binding to Lon. In fact, an equimolar amount of polyP almost completely inhibited DNA-Lon complex formation, suggesting that Lon binds to polyP with a higher affinity than it binds to DNA. Collectively, our results showed that polyP may control the cellular activity of Lon not only as a protease but also as a DNA-binding protein.	Hiroshima Univ, Dept Mol Biotechnol, Hiroshima 7398530, Japan; Osaka Univ, Dept Biotechnol, Osaka 5650871, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan	Hiroshima University; Osaka University; Japan Science & Technology Agency (JST)	Kuroda, A (corresponding author), Hiroshima Univ, Dept Mol Biotechnol, Hiroshima 7398530, Japan.	akuroda@hiroshima-u.ac.jp	Takiguchi, Noboru/F-3419-2014; Kato, Junichi/S-1469-2018	Takiguchi, Noboru/0000-0001-7266-0276; Kato, Junichi/0000-0003-0279-8813				AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; CACHIA C, 1991, J CHROMATOGR, V539, P343, DOI 10.1016/S0021-9673(01)83943-1; CHARETTE MF, 1984, J BACTERIOL, V158, P195, DOI 10.1128/JB.158.1.195-201.1984; CHIN DT, 1988, J BIOL CHEM, V263, P11718; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Ebel W, 1999, J BACTERIOL, V181, P2236, DOI 10.1128/JB.181.7.2236-2243.1999; Fu GK, 1997, J BIOL CHEM, V272, P534; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; GOFF SA, 1987, J BIOL CHEM, V262, P4508; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HUA SS, 1975, J BACTERIOL, V122, P510, DOI 10.1128/JB.122.2.510-517.1975; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Kuroda A, 1997, J BIOL CHEM, V272, P21240, DOI 10.1074/jbc.272.34.21240; Kuroda A, 2001, SCIENCE, V293, P705, DOI 10.1126/science.1061315; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; Rotanova TV, 2002, VOP MED KHIM, V48, P541; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; SONEZAKI S, 1994, APPL MICROBIOL BIOT, V42, P313; SONEZAKI S, 1995, APPL MICROBIOL BIOT, V43, P304; Sonezaki S, 1995, APPL MICROBIOL BIOT, V44, P484; WICKSTROM E, 1988, METHOD ENZYMOL, V164, P238; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7	30	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34406	34410		10.1074/jbc.M404725200	http://dx.doi.org/10.1074/jbc.M404725200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187082	Green Submitted, hybrid			2022-12-27	WOS:000223134800041
J	Prince, WS; McCormick, LM; Wendt, DJ; Fitzpatrick, PA; Schwartz, KL; Aguilera, AI; Koppaka, V; Christianson, TM; Vellard, MC; Pavloff, N; Lemontt, JF; Qin, MM; Starr, CM; Bu, GJ; Zankel, TC				Prince, WS; McCormick, LM; Wendt, DJ; Fitzpatrick, PA; Schwartz, KL; Aguilera, AI; Koppaka, V; Christianson, TM; Vellard, MC; Pavloff, N; Lemontt, JF; Qin, MM; Starr, CM; Bu, GJ; Zankel, TC			Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSISTED CARBOHYDRATE ELECTROPHORESIS; HEPARAN-SULFATE PROTEOGLYCANS; ENZYME REPLACEMENT THERAPY; CULTURED HUMAN-FIBROBLASTS; COMPLEMENT-TYPE REPEATS; HAMSTER OVARY CELLS; LDL RECEPTOR; PLASMINOGEN-ACTIVATOR; LIGAND-BINDING; BETA-GLUCURONIDASE	Enzyme replacement therapy for lysosomal storage disorders depends on efficient uptake of recombinant enzyme into the tissues of patients. This uptake is mediated by oligosaccharide receptors including the cation-independent mannose 6-phosphate receptor and the mannose receptor. We have sought to exploit alternative receptor systems that are independent of glycosylation but allow for efficient delivery to the lysosome. Fusions of the human lysosomal enzymes alpha-L-iduronidase or acid alpha-glucosidase with the receptor-associated protein were efficiently endocytosed by lysosomal storage disorder patient fibroblasts, rat C6 glioma cells, mouse C2C12 myoblasts, and recombinant Chinese hamster ovary cells expressing individual members of the low-density lipoprotein receptor family. Uptake of the fusions exceeded that of phosphorylated enzyme in all cases, often by an order of magnitude or greater. Uptake was specifically mediated by members of the low-density lipoprotein receptor protein family and was followed by delivery of the fusions to the lysosome. The advantages of the lipoprotein receptor system over oligosaccharide receptor systems include more efficient cellular delivery and the potential for transcytosis of ligands across tight endothelia, including the blood-brain barrier.	BioMarin Pharmaceut Inc, Novato, CA 94949 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Physiol, St Louis, MO 63110 USA	BioMarin Pharmaceutical Inc.; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Zankel, TC (corresponding author), BioMarin Pharmaceut Inc, Novato, CA 94949 USA.	tzankel@bmrn.com						Andersen OM, 2000, J BIOL CHEM, V275, P21017, DOI 10.1074/jbc.M000507200; Andersen OM, 2001, BIOCHEMISTRY-US, V40, P15408, DOI 10.1021/bi0110692; Argraves WS, 2001, FRONT BIOSCI, V6, pD406, DOI 10.2741/Argraves; BARTON RW, 1971, J BIOL CHEM, V246, P7773; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; Bu GJ, 2001, INT REV CYTOL, V209, P79; BU GJ, 1993, J BIOL CHEM, V268, P13002; Chun JT, 1999, EXP NEUROL, V157, P194, DOI 10.1006/exnr.1999.7052; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Fuller M, 1995, EUR J BIOCHEM, V234, P903, DOI 10.1111/j.1432-1033.1995.903_a.x; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; Green I, 2003, TRENDS PHARMACOL SCI, V24, P213, DOI 10.1016/S0165-6147(03)00076-2; Hague C, 1998, ELECTROPHORESIS, V19, P2612, DOI 10.1002/elps.1150191508; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; Kakkis ED, 2002, EXPERT OPIN INV DRUG, V11, P675, DOI 10.1517/13543784.11.5.675; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; Kakkis ED, 2001, MOL GENET METAB, V72, P199, DOI 10.1006/mgme.2000.3140; LeBowitz JH, 2004, P NATL ACAD SCI USA, V101, P3083, DOI 10.1073/pnas.0308728100; Li YH, 2002, BIOCHEMISTRY-US, V41, P4921, DOI 10.1021/bi011894i; Li YH, 2001, MOL NEUROBIOL, V23, P53; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Marino M, 2000, J BIOL CHEM, V275, P7125, DOI 10.1074/jbc.275.10.7125; Marino M, 2001, J AM SOC NEPHROL, V12, P637, DOI 10.1681/ASN.V124637; Marzolo MP, 2003, TRAFFIC, V4, P273, DOI 10.1034/j.1600-0854.2003.00081.x; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; Migliorini MM, 2003, J BIOL CHEM, V278, P17986, DOI 10.1074/jbc.M212592200; MURRAY GJ, 1987, METHOD ENZYMOL, V149, P25; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Obunike JC, 2001, J BIOL CHEM, V276, P8934, DOI 10.1074/jbc.M008813200; PAN W, 2004, IN PRESS J CELL SCI; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; Sands MS, 2001, J BIOL CHEM, V276, P43160, DOI 10.1074/jbc.M107778200; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; Starr CM, 1996, J CHROMATOGR A, V720, P295, DOI 10.1016/0021-9673(95)00749-0; TROUSSARD AA, 1995, J BIOL CHEM, V270, P17068, DOI 10.1074/jbc.270.29.17068; Van Hove JLK, 1997, BIOCHEM MOL BIOL INT, V43, P613; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242; Yang HW, 1998, PEDIATR RES, V43, P374, DOI 10.1203/00006450-199803000-00011; Zhao KW, 1997, J BIOL CHEM, V272, P22758, DOI 10.1074/jbc.272.36.22758; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	53	37	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35037	35046		10.1074/jbc.M402630200	http://dx.doi.org/10.1074/jbc.M402630200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15170390	hybrid			2022-12-27	WOS:000223134800116
J	Tominaga, K; Kondo, C; Kagata, T; Hishida, T; Nishizuka, M; Imagawa, M				Tominaga, K; Kondo, C; Kagata, T; Hishida, T; Nishizuka, M; Imagawa, M			The novel gene fad158, having a transmembrane domain and leucine-rich repeat, stimulates adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE 3T3-L1 CELLS; PPAR-GAMMA; INSULIN-RESISTANCE; EARLY-STAGE; ADIPOGENESIS; EXPRESSION; OBESITY; PROTEIN; REGULATOR; PROMOTES	Adipocyte differentiation is known to be regulated by a complex array of genes known as master regulators. Using a subtraction method, we previously isolated 102 genes that are expressed in the early stage of adipocyte differentiation. One of these genes named fad158 (factor for adipocyte differentiation 158) seems to be a novel gene, since there is no significantly similar gene listed in databases. Both mouse and human fad158 encode 803 amino acids and contain 4 transmembrane regions and 8 leucine-rich repeat motifs. Expression of fad158 was induced at an early stage in differentiating 3T3-L1 cells and was observed in the skeletal muscle. When the expression was knocked down with an antisense method in 3T3-L1 cells, the accumulation of oil droplets was reduced. Moreover, on overexpression of fad158 in NIH-3T3 cells, which are fibroblasts and do not usually differentiate into adipocytes, stable transformants accumulated oil droplets and showed an elevated expression of adipocyte marker genes, indicating that these cells had differentiated into mature adipocytes. fad158 has the ability to regulate adipocyte differentiation positively, especially at an early stage.	Nissui Pharmaceut Co Ltd, Div Res, Ibaraki 3070036, Japan		Imagawa, M (corresponding author), Nagoya City Univ, Dept Biol Mol, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Aichi 4678603, Japan.	imagawa@phar.nagoya-cu.ac.jp						Check E, 2002, NATURE, V417, P106, DOI 10.1038/417106a; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVID V, 1993, J BIOL CHEM, V268, P9585; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Imagawa M, 1999, BIOCHEM BIOPH RES CO, V254, P299, DOI 10.1006/bbrc.1998.9937; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kitamura A, 2001, BIOCHEM BIOPH RES CO, V287, P435, DOI 10.1006/bbrc.2001.5577; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Nishizuka M, 2002, BIOCHEM J, V361, P629, DOI 10.1042/0264-6021:3610629; Nishizuka M, 2003, J BIOL CHEM, V278, P15279, DOI 10.1074/jbc.M211479200; Nishizuka M, 2001, J BIOL CHEM, V276, P29625, DOI 10.1074/jbc.C100272200; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Shimba S, 2003, BIOL PHARM BULL, V26, P1266; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Ward CW, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-4; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	36	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34840	34848		10.1074/jbc.M312927200	http://dx.doi.org/10.1074/jbc.M312927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184384	hybrid			2022-12-27	WOS:000223134800093
J	Choudhury, AD; XuO, H; Baer, R				Choudhury, AD; XuO, H; Baer, R			Ubiquitination and proteasomal degradation the BRCA1 tumor suppressor is regulated during cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; DIRECTED DNA-REPAIR; BREAST-CANCER; POLYUBIQUITIN CHAINS; HOMOLOGOUS RECOMBINATION; SUBCELLULAR-LOCALIZATION; BRCA1/BARD1 HETERODIMER; NUCLEAR PHOSPHOPROTEIN; GENETIC INSTABILITY; LIGASE ACTIVITY	The BRCA1 tumor suppressor and the BARD1 protein form a stable heterodimeric complex that can catalyze the formation of polyubiquitin chains. Expression of BRCA1 fluctuates in a cell cycle-dependent manner, such that low steady-state levels of BRCA1 gene products are found in resting cells and early G(1) cycling cells and high levels in S and G(2) phase cells. Although transcriptional activation of the BRCA1 gene can account for induction of BRCA1 expression at the G(1)/S transition, the mechanisms by which BRCA1 is down-regulated during cell cycle progression have not been addressed. Here we show that the steady-state levels of BRCA1 protein remain elevated throughout mitosis but begin to decline at the M/G(1) transition. This decline in BRCA1 levels coincides with the appearance of proteasome-sensitive ubiquitin conjugates of BRCA1 at the onset of G(1). Formation of these conjugates occurs throughout G(1) and S, but not in cells arrested in prometaphase by nocodazole. The proteasome-sensitive ubiquitin conjugates of BRCA1 appear to be distinct from BRCA1 autoubiquitination products and are probably catalyzed by the action of other cellular E3 ligases. Interestingly, co-expression of BARD1 inhibits the formation of these conjugates, suggesting that BARD1 serves to stabilize BRCA1 expression in part by reducing proteasome-sensitive ubiquitination of BRCA1 polypeptides. In summary, these data indicate that the cell cycle-dependent pattern of BRCA1 expression is determined in part by ubiquitin-dependent proteasomal degradation.	Columbia Univ, Inst Canc Genet, Dept Pathol, New York, NY 10032 USA	Columbia University	Baer, R (corresponding author), Columbia Univ, Inst Canc Genet, Dept Pathol, 1150 St Nicholas Ave, New York, NY 10032 USA.	rb670@columbia.edu		Choudhury, Atish/0000-0001-9344-6631	NATIONAL CANCER INSTITUTE [P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [CA97403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen YM, 1996, CANCER RES, V56, P3168; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Ferris DK, 1998, BIOCHEM BIOPH RES CO, V252, P340, DOI 10.1006/bbrc.1998.9648; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Le Page F, 2000, CANCER RES, V60, P5548; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Moynahan ME, 2001, CANCER RES, V61, P4842; Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Ohta T, 2004, ONCOGENE, V23, P2079, DOI 10.1038/sj.onc.1207371; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Westermark UK, 2003, MOL CELL BIOL, V23, P7926, DOI 10.1128/MCB.23.21.7926-7936.2003; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	56	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33909	33918		10.1074/jbc.M403646200	http://dx.doi.org/10.1074/jbc.M403646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166217	hybrid			2022-12-27	WOS:000223039700101
J	Degot, S; Le Hir, H; Alpy, F; Kedinger, V; Stoll, I; Wendling, C; Seraphin, B; Rio, MC; Tomasetto, C				Degot, S; Le Hir, H; Alpy, F; Kedinger, V; Stoll, I; Wendling, C; Seraphin, B; Rio, MC; Tomasetto, C			Association of the breast cancer protein MLN51 with the Exon junction complex via its speckle localizer and RNA binding module	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MAMMALIAN-CELLS; NUCLEAR EXPORT; DEPENDENT MANNER; GENE-EXPRESSION; DROSOPHILA; COMPONENT; DOMAINS; IDENTIFICATION; RECEPTOR	MLN51 is a nucleocytoplasmic shuttling protein that is overexpressed in breast cancer. The function of MLN51 in mammals remains elusive. Its fly homolog, named barentsz, as well as the proteins mago nashi and tsunagi have been shown to be required for proper oskar mRNA localization to the posterior pole of the oocyte. Magoh and Y14, the human homologs of mago nashi and tsunagi, are core components of the exon junction complex (EJC). The EJC is assembled on spliced mRNAs and plays important roles in post-splicing events including mRNA export, nonsense-mediated mRNA decay, and translation. In the present study, we show that human MLN51 is an RNA-binding protein present in ribonucleoprotein complexes. By co-immunoprecipitation assays, endogenous MLN51 protein is found to be associated with EJC components, including Magoh, Y14, and NFX1/TAP, and subcellular localization studies indicate that MLN51 transiently co-localizes with Magoh in nuclear speckles. Moreover, we demonstrate that MLN51 specifically associates with spliced mRNAs in co-precipitation experiments, both in the nucleus and in the cytoplasm, at the position where the EJC is deposited. Most interesting, we have identified a region within MLN51 sufficient to bind RNA, to interact with Magoh and spliced mRNA, and to address the protein to nuclear speckles. This conserved region of MLN51 was therefore named SELOR for speckle localizer and RNA binding module. Altogether our data demonstrate that MLN51 associates with EJC in the nucleus and remains stably associated with mRNA in the cytoplasm, suggesting that its overexpression might alter mRNA metabolism in cancer.	Univ Strasbourg 1, CNRS,UPR 6520, INSERM,U596, Dept Pathol Mol,Inst Genet & Biol Mol & Cellulair, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; CNRS, UPR 2167, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Tomasetto, C (corresponding author), IGBMC, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	cat@igbmc.u-strasbg.fr	Alpy, Fabien/H-8941-2016; Tomasetto, Catherine Laure/J-2783-2014; Alpy, Fabien/ABD-5893-2020	Alpy, Fabien/0000-0002-0526-0720; Tomasetto, Catherine Laure/0000-0002-1811-5848; Alpy, Fabien/0000-0002-0526-0720; Seraphin, Bertrand/0000-0002-5168-1921; Le Hir, Herve/0000-0001-7964-9221				Allain FHT, 2000, J MOL BIOL, V303, P227, DOI 10.1006/jmbi.2000.4118; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Bertrandy S, 1999, HUM MOL GENET, V8, P775, DOI 10.1093/hmg/8.5.775; Bieche I, 1996, CANCER RES, V56, P3886; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; Corbin F, 1997, HUM MOL GENET, V6, P1465, DOI 10.1093/hmg/6.9.1465; Degot S, 2002, ONCOGENE, V21, P4422, DOI 10.1038/sj.onc.1205611; Degot Sebastien, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P365; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Ducret C, 1999, MOL CELL BIOL, V19, P7076; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hyman E, 2002, CANCER RES, V62, P6240; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; LINDBERG U, 1974, J MOL BIOL, V86, P451, DOI 10.1016/0022-2836(74)90030-8; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Macchi P, 2003, J NEUROSCI, V23, P5778; Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265; Martin SG, 2003, DEVELOPMENT, V130, P4201, DOI 10.1242/dev.00630; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Plewniak F, 2003, NUCLEIC ACIDS RES, V31, P3829, DOI 10.1093/nar/gkg518; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; Severt WL, 1999, J CELL SCI, V112, P3691; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4; van Eeden FJM, 2001, J CELL BIOL, V154, P511, DOI 10.1083/jcb.200105056; Wagner S, 2003, P NATL ACAD SCI USA, V100, P3269, DOI 10.1073/pnas.0438055100; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100; Yoon DW, 1997, IMMUNITY, V6, P571, DOI 10.1016/S1074-7613(00)80345-3; Zhao XF, 1998, GENOMICS, V47, P319, DOI 10.1006/geno.1997.5126; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	57	87	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33702	33715		10.1074/jbc.M402754200	http://dx.doi.org/10.1074/jbc.M402754200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166247	hybrid			2022-12-27	WOS:000223039700080
J	Okunande, GW; Miller, ML; Pyne, GJ; Sutliff, RL; O'Connor, KT; Neumann, JC; Andringa, A; Miller, DA; Prasad, V; Doetschman, T; Paul, RJ; Shull, GE				Okunande, GW; Miller, ML; Pyne, GJ; Sutliff, RL; O'Connor, KT; Neumann, JC; Andringa, A; Miller, DA; Prasad, V; Doetschman, T; Paul, RJ; Shull, GE			Targeted ablation of plasma membrane Ca2+-ATPase (PMCA) 1 and 4 indicates a major housekeeping function for PMCA1 and a critical role in hyperactivated sperm motility and male fertility for PMCA4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CALCIUM-PUMP; ISOFORM 2; CA-2+-TRANSPORTING ATPASE; NULL MUTATION; MOUSE SPERM; CA2+ PUMP; GENE; MICE; APOPTOSIS	The relative importance of plasma membrane Ca2+-ATPase (PMCA) 1 and PMCA4 was assessed in mice carrying null mutations in their genes (Atp2b1 and Atp2b4). Loss of both copies of the gene encoding PMCA1 caused embryolethality, whereas heterozygous mutants had no overt disease phenotype. Despite widespread and abundant expression of PMCA4, PMCA4 null (Pmca4(-/-)) mutants exhibited no embryolethality and appeared outwardly normal. Loss of PMCA4 impaired phasic contractions and caused apoptosis in portal vein smooth muscle in vitro; however, this phenotype was dependent on the mouse strain being employed. Pmca4(-/-) mice on a Black Swiss background did not exhibit the phenotype unless they also carried a null mutation in one copy of the Pmca1 gene. Pmca4(-/-) male mice were infertile but had normal spermatogenesis and mating behavior. Pmca4(-/-) sperm that had not undergone capacitation exhibited normal motility but could not achieve hyperactivated motility needed to traverse the female genital tract. Ultrastructure of the motility apparatus in Pmca4(-/-) sperm tails was normal, but an increased incidence of mitochondrial condensation indicated Ca2+ overload. Immunoblotting and immuno- histochemistry showed that PMCA4 is the most abundant isoform in testis and sperm and that it is localized to the principle piece of the sperm tail, which is also the location of the major Ca2+ channel (CatSper) required for sperm motility. These results are consistent with an essential housekeeping or developmental function for PMCA1, but not PMCA4, and show that PMCA4 expression in the principle piece of the sperm tail is essential for hyperactivated motility and male fertility.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, R01HL061974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61974, TGHL07382] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; Eddy E. M., 1994, P29; GARCIA ML, 1999, FRONT BIOSCI, V4, P869; GREEB J, 1989, J BIOL CHEM, V264, P18569; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; Meyer JW, 2002, AM J PHYSIOL-HEART C, V283, pH1846, DOI 10.1152/ajpheart.00083.2002; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; SCHUH K, 2004, J BIOL CHEM; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Street VA, 1998, NAT GENET, V19, P390, DOI 10.1038/1284; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; SUAREZ SS, 1987, J EXP ZOOL, V244, P331, DOI 10.1002/jez.1402440218; Sutliff RL, 1999, ENDOCRINOLOGY, V140, P2077, DOI 10.1210/en.140.5.2077; Takahashi K, 1999, BIOCHEM BIOPH RES CO, V261, P773, DOI 10.1006/bbrc.1999.1102; Wennemuth G, 2003, J GEN PHYSIOL, V122, P115, DOI 10.1085/jgp.200308839; Woo AL, 2000, J BIOL CHEM, V275, P20693, DOI 10.1074/jbc.M002323200; YANAGIMACHI R, 1994, PHYSL REPROD, V0002, P00189; Zacharias DA, 1999, BBA-GEN SUBJECTS, V1428, P397, DOI 10.1016/S0304-4165(99)00058-6	29	244	256	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33742	33750		10.1074/jbc.M404628200	http://dx.doi.org/10.1074/jbc.M404628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178683	hybrid			2022-12-27	WOS:000223039700083
J	Foley, JD; Rosenbaum, H; Griep, AE				Foley, JD; Rosenbaum, H; Griep, AE			Temporal regulation of VEID-7-amino-4-trifluoromethylcoumarin cleavage activity and caspase-6 correlates with organelle loss during lens development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER CELL-DIFFERENTIATION; TERMINAL DIFFERENTIATION; DNA FRAGMENTATION; CYSTEINE PROTEASE; EPITHELIAL-CELLS; CYCLE REGULATION; APOPTOSIS; INHIBITION; ACTIVATION; DEGRADATION	Lens fiber cell differentiation involves extensive reconstruction of the cell's architecture, including the degradation and elimination of all membrane-bound organelles via a process that has been likened to apoptosis. Using caspase reporter assays under conditions in which nonspecific cleavage of the reporter peptides by the proteasome has been inhibited, we investigated whether any specific caspase activities are temporally correlated with this process of organelle loss. Extracts from neonatal mouse lenses contained strong VEID-7-amino-4-trifluoromethylcoumarin (AFC) and minor IETD-AFC and LEVD-AFC cleavage activities, but no DEVD-AFC cleavage activity. Further testing suggested that the VEID-AFC and IETD-AFC cleavage activities were likely due to the same enzyme. In lens extracts from rat embryos, VEID-AFC cleavage activity increased during the period when organelles are eliminated, between embryonic days 15.5 and 18.5, whereas procaspase-6 protein levels decreased, suggesting that this enzyme is responsible for VEID-AFC cleavage. By contrast, in extracts from alphaAE7 transgenic mouse lenses in which apoptosis was induced, strong DEVD-AFC cleavage activity and activated caspase-3 protein were detected. Thus, within the same tissue, different caspase activities can predominate depending on the context, normal differentiation versus apoptosis. These results highlight the difference between normal fiber cell differentiation and apoptosis and the capacity of the lens to differentially regulate these two processes.	Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Griep, AE (corresponding author), Univ Wisconsin, Sch Med, Dept Anat, 1300 Univ Ave, Madison, WI 53706 USA.	aegriep@wisc.edu	Griep, Anne/ABA-9636-2020		NEI NIH HHS [EY09091] Funding Source: Medline; NICHD NIH HHS [HD1007477] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009091] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andersson M, 2000, INVEST OPHTH VIS SCI, V41, P2623; Andersson M, 1998, EXP EYE RES, V67, P231, DOI 10.1006/exer.1998.0519; APPLEBY DW, 1977, P NATL ACAD SCI USA, V74, P5579, DOI 10.1073/pnas.74.12.5579; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; Bassnett S, 1999, J CELL SCI, V112, P2155; Bassnett S, 2002, EXP EYE RES, V74, P1, DOI 10.1006/exer.2001.1111; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fenteany G, 1996, CHEM BIOL, V3, P905, DOI 10.1016/S1074-5521(96)90179-9; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; GRIEP A E, 1990, New Biologist, V2, P727; He HY, 1998, DEV DYNAM, V211, P26, DOI 10.1002/(SICI)1097-0177(199801)211:1<26::AID-AJA3>3.0.CO;2-9; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jordan JF, 2001, GRAEF ARCH CLIN EXP, V239, P613, DOI 10.1007/s004170100332; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Kobayashi T, 1996, J BIOCHEM, V120, P699; Kuszak JR, 1995, INT REV CYTOL, V163, P305, DOI 10.1016/S0074-7696(08)62213-5; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V45, P271; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishi O, 2001, CURR EYE RES, V23, P192, DOI 10.1076/ceyr.23.3.192.5462; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; *PROM CORP, 2003, TECHN B PROM CORP, V248; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shang F, 1999, EXP EYE RES, V68, P179, DOI 10.1006/exer.1998.0576; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Stolen CM, 1997, DEVELOPMENT, V124, P4009; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tamada Y, 2000, BIOCHEM BIOPH RES CO, V275, P300, DOI 10.1006/bbrc.2000.3298; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; WAGNER BJ, 1986, EXP EYE RES, V43, P1141, DOI 10.1016/0014-4835(86)90091-6; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Yao K, 2003, CHINESE MED J-PEKING, V116, P1034; Yoshizawa K, 2000, TOXICOL PATHOL, V28, P555, DOI 10.1177/019262330002800408; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122	60	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32142	32150		10.1074/jbc.M313683200	http://dx.doi.org/10.1074/jbc.M313683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161922	hybrid			2022-12-27	WOS:000222849700020
J	Hirose, M; Kitano, J; Nakajima, Y; Moriyoshi, K; Yanagi, S; Yamamura, H; Muto, T; Jingami, H; Nakanishi, S				Hirose, M; Kitano, J; Nakajima, Y; Moriyoshi, K; Yanagi, S; Yamamura, H; Muto, T; Jingami, H; Nakanishi, S			Phosphorylation and recruitment of Syk by immunoreceptor tyrosine-based activation motif-based phosphorylation of tamalin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; TRANSDUCING ADAPTER MOLECULE; CELL SIGNAL-TRANSDUCTION; ANTIGEN-RECEPTOR; PHOSPHOLIPASE-C; B-CELLS; PROTEIN; KINASES; DOMAIN; ITAM	Tamalin is a scaffold protein that forms a multiple protein assembly including metabotropic glutamate receptors (mGluRs) and several postsynaptic and protein-trafficking scaffold proteins in distinct mode of protein-protein association. In the present investigation, we report that tamalin possesses a typical immunoreceptor tyrosine-based activation motif (ITAM), which enables Syk kinase to be recruited and phosphorylated by the Src family kinases. Coimmunoprecipitation analysis of rat brain membrane fractions showed that tamalin is present in a multimolecular protein assembly comprising not only mGluR1 but also c-Src, Fyn, and a protein phosphatase, SHP-2. The protein association of both tamalin and c-Src, as determined by truncation analysis of mGluR1 in COS-7 cells, occurred at the carboxyl-terminal tail of mGluR1. Mutation analysis of tyrosine with phenylalanine in COS-7 cells revealed that paired tyrosines at the ITAM sequence of tamalin are phosphorylated preferentially by c-Src and Fyn, and this phosphorylation can recruit Syk kinase and enables it to be phosphorylated by the Src family kinases. The phosphorylated tyrosines at the ITAM sequence of tamalin were highly susceptible to dephosphorylation by protein-tyrosine phosphatases in COS-7 cells. Importantly, tamalin was endogenously phosphorylated and associated with Syk in retinoic acid-treated P19 embryonal carcinoma cells that undergo neuron-like differentiation. The present investigation demonstrates that tamalin is a novel signaling molecule that possesses a PDZ domain and a PDZ binding motif and mediates Syk signaling in an ITAM-based fashion.	Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Kyoto 6068501, Japan; Kobe Univ, Grad Sch Med, Dept Genome Sci, Chuo Ku, Kobe, Hyogo 6500017, Japan; Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan	Kyoto University; Kyoto University; Kobe University	Nakanishi, S (corresponding author), Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	snakanis@phy.med.kyoto-u.ac.jp						BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Heidinger V, 2002, J NEUROSCI, V22, P5452; Heuss C, 1999, NAT NEUROSCI, V2, P1070, DOI 10.1038/15996; Husi H, 2001, TRENDS NEUROSCI, V24, P259, DOI 10.1016/S0166-2236(00)01792-6; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; Kitano J, 2003, J BIOL CHEM, V278, P14762, DOI 10.1074/jbc.M300184200; Kitano J, 2002, J NEUROSCI, V22, P1280, DOI 10.1523/JNEUROSCI.22-04-01280.2002; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; Miah SMS, 2004, MOL CELL BIOL, V24, P71, DOI 10.1128/MCB.24.1.71-83.2004; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsujimura T, 2001, FEBS LETT, V489, P129, DOI 10.1016/S0014-5793(01)02097-X; Urzainqui A, 2002, IMMUNITY, V17, P401, DOI 10.1016/S1074-7613(02)00420-X; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	41	27	27	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32308	32315		10.1074/jbc.M400547200	http://dx.doi.org/10.1074/jbc.M400547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173175	hybrid			2022-12-27	WOS:000222849700041
J	Peng, Y; Kang, Q; Luo, Q; Jiang, W; Si, WK; Liu, BA; Luu, HH; Park, JK; Li, XM; Luo, J; Montag, AG; Haydon, RC; He, TC				Peng, Y; Kang, Q; Luo, Q; Jiang, W; Si, WK; Liu, BA; Luu, HH; Park, JK; Li, XM; Luo, J; Montag, AG; Haydon, RC; He, TC			Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ID PROTEINS; GENE; REGULATORS; INDUCTION; RECEPTORS; IDENTIFICATION; EXPRESSION; SYSTEM; CANCER	Bone morphogenetic proteins (BMPs) belong to the TGF-beta superfamily and play an important role in development and in many cellular processes. We have found that BMP-2, BMP-6, and BMP-9 induce the most potent osteogenic differentiation of mesenchymal stem cells. Expression profiling analysis has revealed that the Inhibitors of DNA binding/differentiation (Id)-1, Id-2, and Id-3 are among the most significantly up-regulated genes upon BMP-2, BMP-6, or BMP-9 stimulation. Here, we sought to determine the functional role of these Id proteins in BMP-induced osteoblast differentiation. We demonstrated that the expression of Id-1, Id-2, and Id-3 genes was significantly induced at the early stage of BMP-9 stimulation and returned to basal levels at 3 days after stimulation. RNA interference-mediated knockdown of Id expression significantly diminished the BMP-9-induced osteogenic differentiation of mesenchymal progenitor cells. Surprisingly, a constitutive overexpression of these Id genes also inhibited osteoblast differentiation initiated by BMP-9. Furthermore, we demonstrated that BMP-9-regulated Id expression is Smad4-dependent. Overexpression of the three Id genes was shown to promote cell proliferation that was coupled with an inhibition of osteogenic differentiation. Thus, our findings suggest that the Id helix-loop-helix proteins may play an important role in promoting the proliferation of early osteoblast progenitor cells and that Id expression must be down-regulated during the terminal differentiation of committed osteoblasts, suggesting that a balanced regulation of Id expression may be critical to BMP-induced osteoblast lineage-specific differentiation of mesenchymal stem cells.	Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Funct Genom Facil, Chicago, IL 60637 USA; Chongqing Univ Med Sci, Childrens Hosp, Chongqing 400016, Peoples R China; Catholic Univ Korea, Coll Med, St Pauls Hosp, Dept Surg, Seoul 130709, South Korea	University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago; Chongqing Medical University; Catholic University of Korea	He, TC (corresponding author), Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, 5841 S Maryland Ave,MC3079, Chicago, IL 60637 USA.	tche@surgery.bsd.uchicago.edu	Liu, Bernard/A-3687-2012; Liu, Bernard Arthur/AAR-4915-2021	Liu, Bernard/0000-0003-3060-3120; Liu, Bernard Arthur/0000-0003-3060-3120	NCCIH NIH HHS [F05 AT002014-01] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT002014] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; Chen C, 2003, NAT BIOTECHNOL, V21, P294, DOI 10.1038/nbt795; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Helm GA, 2000, J NEUROSURG, V92, P191, DOI 10.3171/spi.2000.92.2.0191; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; KANG Q, 2004, IN PRESS GENE THER; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kingsley D M, 2001, Novartis Found Symp, V232, P213; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lopez-Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Norton JD, 2000, J CELL SCI, V113, P3897; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744; Ploemacher RE, 1999, LEUKEMIA, V13, P428, DOI 10.1038/sj.leu.2401363; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Rosen V, 1996, ANN NY ACAD SCI, V785, P59, DOI 10.1111/j.1749-6632.1996.tb56244.x; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; URIST MR, 1987, CLIN ORTHOP RELAT R, P295; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600-0722.1998.tb02170.x; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	45	179	192	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32941	32949		10.1074/jbc.M403344200	http://dx.doi.org/10.1074/jbc.M403344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161906	hybrid			2022-12-27	WOS:000222849700114
J	Damdimopoulos, AE; Miranda-Vizuete, A; Treuter, E; Gustafsson, JA; Spyrou, G				Damdimopoulos, AE; Miranda-Vizuete, A; Treuter, E; Gustafsson, JA; Spyrou, G			An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTORS ER-ALPHA; INDUCED CELL-DEATH; NF-KAPPA-B; GENE-EXPRESSION; RETINOIC ACID; TRANSCRIPTION FACTORS; OXIDOREDUCTASE KDRF; HISTONE ACETYLATION; NUCLEAR RECEPTORS; REDOX REGULATION	The selenoprotein thioredoxin reductase (TrxR1) is an integral part of the thioredoxin system. It serves to transfer electrons from NADPH to thioredoxin leading to its reduction. Interestingly, recent work has indicated that thioredoxin reductase can regulate the activity of transcription factors such as p53, hypoxia-inducible factor, and AP-1. Here, we describe that an alternative splicing variant of thioredoxin reductase (TrxR1b) containing an LXXLL peptide motif, is implicated in direct binding to nuclear receptors. In vitro interaction studies revealed direct interaction of the TrxR1b with the estrogen receptors alpha and beta. Confocal microscopy analysis showed nuclear colocalization of the TrxR1b with both estrogen receptor alpha and beta in estradiol-17beta-treated cells. Transcriptional studies demonstrated that TrxR1b can affect estrogen-dependent gene activation differentially at classical estrogen response elements as compared with AP-1 response elements. Based on these results, we propose a model where thioredoxin reductase directly influences the estrogen receptor-coactivator complex assembly on non-classical estrogen response elements such as AP-1. In summary, our results suggest that TrxR1b is an important modulator of estrogen signaling.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Spyrou, G (corresponding author), Acad Athens, Inst Biomed Res, Dept Biochem, Soranou Cfesiou 4, Athens 11527, Greece.	giannis.spyrou@cbt.ki.se	IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189; Treuter, Eckardt/0000-0002-4147-8989				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Akiyama TE, 2002, MOL ENDOCRINOL, V16, P707, DOI 10.1210/me.16.4.707; Arteel GE, 1999, CHEM RES TOXICOL, V12, P264, DOI 10.1021/tx980223r; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; Bjornstrom L, 2002, J BIOL CHEM, V277, P48479, DOI 10.1074/jbc.C200570200; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Glass CK, 2000, GENE DEV, V14, P121; HAINAUT P, 1993, CANCER RES, V53, P4469; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Karimpour S, 2002, ONCOGENE, V21, P6317, DOI 10.1038/sj.onc.1205749; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Koishi R, 1997, J BIOL CHEM, V272, P2570; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Ma XR, 2002, J BIOL CHEM, V277, P22460, DOI 10.1074/jbc.M202286200; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; MirandaVizuete A, 1997, BIOCHEM J, V325, P287, DOI 10.1042/bj3250287; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Osborne S A, 2001, BMC Genomics, V2, P10, DOI 10.1186/1471-2164-2-10; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200	55	44	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38721	38729		10.1074/jbc.M402753200	http://dx.doi.org/10.1074/jbc.M402753200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15199063	hybrid			2022-12-27	WOS:000223684100082
J	Tsubery, H; Mironchik, M; Fridkin, M; Shechter, Y				Tsubery, H; Mironchik, M; Fridkin, M; Shechter, Y			Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ETHYLENE GLYCOL)-MODIFIED PROTEINS; HEPATITIS-C; HALF-LIFE; EXENDIN-4; DELIVERY; RECEPTOR; PEGYLATION; INSULIN; DESIGN; 1,6-ELIMINATION	Polyethylene glycol (PEG)-conjugated therapeutic peptides/proteins have been shown to exhibit clinical properties superior to those of their corresponding unmodified parent molecules. However, the desirable pharmacological features gained by protein PEGylation become irrelevant if conjugates are inactivated or cannot reach their target tissues. Here we describe the design and synthesis of MAL-FMS-OSU. This bifunctional agent enables PEG chains to be linked to peptides and proteins through a slowly hydrolysable chemical bond. PEG-FMS-peptide/protein conjugates thus formed undergo spontaneous hydrolysis at a slow rate upon incubation at pH 8.5, 37 degreesC with a t(1/2) value of 8 - 14 +/- 2 h, generating the unmodified parent molecule. The validity of this approach was studied with exendin-4 and human growth hormone. A single subcutaneous administration of PEG(40,000)-FMS- exendin-4 facilitated a prolonged and stable reduction in glucose levels in mice (t(1/2) = 30 +/- 2 h) and exceeded the effect obtained by the same dose of the native hormone by 7 - 8 times.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Fridkin, M (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.	mati.fridkin@weizmann.ac.il; y.shechter@weizmann.ac.il						Albericio F, 2001, SYNTHETIC COMMUN, V31, P225, DOI 10.1081/SCC-100000203; Bailon P, 1998, PHARM SCI TECHNOL TO, V1, P352, DOI 10.1016/S1461-5347(98)00086-8; Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; Benet L., 1990, PHARMACOL BASIS THER, P3; DELGADO C, 1992, CRIT REV THER DRUG, V9, P249; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1994, PEPTIDES, V15, P453, DOI 10.1016/0196-9781(94)90204-6; FUERTGES F, 1990, J CONTROL RELEASE, V11, P139, DOI 10.1016/0168-3659(90)90127-F; Fung W.-J., 1997, POLYM PREPRINT, V38, P565; GERMAN AJ, 1987, FEBS LETT, V223, P361; Gershonov E, 1999, DIABETES, V48, P1437, DOI 10.2337/diabetes.48.7.1437; Gershonov E, 2000, J MED CHEM, V43, P2530, DOI 10.1021/jm990533m; GOKE R, 1993, J BIOL CHEM, V268, P19650; Greenwald RB, 2000, J MED CHEM, V43, P475, DOI 10.1021/jm990498j; Greenwald RB, 1999, J MED CHEM, V42, P3657, DOI 10.1021/jm990166e; KATRE NV, 1993, ADV DRUG DELIVER REV, V10, P91, DOI 10.1016/0169-409X(93)90005-O; Lee S, 2001, BIOCONJUGATE CHEM, V12, P163, DOI 10.1021/bc000064z; NUCCI ML, 1991, ADV DRUG DELIVER REV, V6, P133, DOI 10.1016/0169-409X(91)90037-D; Reddy KR, 2002, ADV DRUG DELIVER REV, V54, P571, DOI 10.1016/S0169-409X(02)00028-5; Reddy KR, 2000, ANN PHARMACOTHER, V34, P915, DOI 10.1345/aph.10054; Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4; SCHEPP W, 1994, EUR J PHARM-MOLEC PH, V269, P183, DOI 10.1016/0922-4106(94)90085-X; Shechter Y, 2003, BIOCHEM BIOPH RES CO, V305, P386, DOI 10.1016/S0006-291X(03)00715-0; Shechter Y, 2001, DRUG FUTURE, V26, P669, DOI 10.1358/dof.2001.026.07.858711; Shechter Y, 2001, P NATL ACAD SCI USA, V98, P1212, DOI 10.1073/pnas.98.3.1212; TSUSHIMA T, 1980, BIOCHEM J, V187, P479, DOI 10.1042/bj1870479; Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9; Working PK, 1997, ACS SYM SER, V680, P45; Zalipsky S, 1999, BIOCONJUGATE CHEM, V10, P703, DOI 10.1021/bc990031n	29	70	135	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38118	38124		10.1074/jbc.M405155200	http://dx.doi.org/10.1074/jbc.M405155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15190059	hybrid			2022-12-27	WOS:000223684100009
J	Dai, Y; Rahmani, M; Corey, SJ; Dent, P; Grant, S				Dai, Y; Rahmani, M; Corey, SJ; Dent, P; Grant, S			A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; T(14/18) LYMPHOMA-CELLS; BCR-ABL ONCOGENE; KINASE INHIBITOR PD180970; COLONY-STIMULATING FACTOR; CYTOCHROME-C RELEASE; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; BLAST CRISIS; PHOSPHATIDYLINOSITOL 3-KINASE	The relationship between the Src kinase Lyn and Bcl-2 expression was examined in chronic myelogenous leukemia cells (K562 and LAMA84) displaying a Bcr/Abl-independent form of imatinib mesylate resistance. K562-R and LAMA-R cells that were markedly resistant to induction of mitochondrial dysfunction ( e. g. loss of mitochondrial membrane potential, Bax translocation, cytochrome c, and apoptosis-inducing factor release) and apoptosis by imatinib mesylate exhibited a pronounced reduction in expression of Bcr/ Abl, Bcl-x(L), and STAT5 but a striking increase in levels of activated Lyn. Whereas basal expression of Bcl-2 protein was very low in parental cells, imatinib-resistant cells displayed a marked increase in Bcl-2 mRNA and/or protein levels. Treatment of LAMA-R cells with the Src kinase inhibitor PP2 significantly reduced Lyn activation as well as Bcl-2 mRNA and protein levels. Transient or stable transfection of LAMA84 or K562 cells with a constitutively active Lyn (Y508F), but not with a kinase-dead mutant (K275D), significantly increased Bcl-2 protein expression and protected cells from lethality of imatinib mesylate. Ectopic expression of Bcl-2 protected K562 and LAMA84 cells from imatinib mesylate- and PP2-mediated lethality. Conversely, interference with Bcl-2 function by co-administration of the small molecule Bcl-2 inhibitor HA14-1 or down-regulation of Bcl-2 expression by small interfering RNA or antisense strategies significantly increased mitochondrial dysfunction and apoptosis induced by imatinib mesylate and the topoisomerase inhibitor VP-16 in LAMA-R cells. In marked contrast, these interventions had little effect in parental LAMA84 cells that display low basal levels of Bcl-2. Together, these findings indicate that activation of Lyn in leukemia cells displaying a Bcr/ Abl-independent form of imatinib mesylate resistance plays a functional role in Bcl-2 up-regulation and provide a theoretical basis for the development of therapeutic strategies targeting Bcl-2 in such a setting.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Texas System; UTMD Anderson Cancer Center	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu	Dai, Yun/AAG-4040-2019	Dai, Yun/0000-0003-2285-0818; Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753, R01CA100866, R01CA088906, P01CA072955] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100866, CA 63753, CA 72955, CA 93738, CA 88906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bates RC, 2001, CANCER RES, V61, P5275; Brumatti G, 2003, FEBS LETT, V541, P57, DOI 10.1016/S0014-5793(03)00299-0; Canitrot Y, 2003, BLOOD, V102, P2632, DOI 10.1182/blood-2002-10-3207; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cirinna M, 2000, BLOOD, V96, P3915, DOI 10.1182/blood.V96.12.3915.h8003915_3915_3921; Dai Y, 2001, CANCER RES, V61, P5106; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Donato NJ, 2004, CANCER RES, V64, P672, DOI 10.1158/0008-5472.CAN-03-1484; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Katagiri K, 1996, J BIOL CHEM, V271, P11557, DOI 10.1074/jbc.271.19.11557; La Rosee P, 2002, CANCER RES, V62, P7149; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Lickliter JD, 2003, LEUKEMIA, V17, P2074, DOI 10.1038/sj.leu.2403102; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Nieborowska-Skorska M, 2000, ONCOGENE, V19, P4117, DOI 10.1038/sj.onc.1203754; Nimmanapalli R, 2003, CANCER RES, V63, P5126; Nimmanapalli R, 2002, CANCER RES, V62, P5761; Nimmanapalli R, 2003, BLOOD, V101, P3236, DOI 10.1182/blood-2002-08-2675; Ptasznik A, 2002, J EXP MED, V196, P667, DOI 10.1084/jem.20020519; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shangary S, 2003, EXP CELL RES, V289, P67, DOI 10.1016/S0014-4827(03)00234-9; Sinha S, 2001, EXP HEMATOL, V29, P746, DOI 10.1016/S0301-472X(01)00647-6; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; Tauchi T, 2003, CLIN CANCER RES, V9, P4267; von Bubnoff N, 2003, CANCER RES, V63, P6395; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wei S, 1996, J IMMUNOL, V157, P5155; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Yamaguchi H, 2002, CANCER RES, V62, P466; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Yu CR, 2002, CLIN CANCER RES, V8, P2976	60	213	219	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34227	34239		10.1074/jbc.M402290200	http://dx.doi.org/10.1074/jbc.M402290200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175350	hybrid			2022-12-27	WOS:000223134800021
J	Korber, P; Horz, W				Korber, P; Horz, W			In vitro assembly of the characteristic chromatin organization at the yeast PHO5 promoter by a replication-independent extract system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; POSITIONED NUCLEOSOMES; TRANSCRIPTIONAL ACTIVATION; DNA-REPLICATION; MMTV PROMOTER; MINICHROMOSOMES; RECONSTITUTION; MAINTENANCE; REPRESSION; DISRUPTION	An extensive set of analyses of the yeast PHO5 gene, mostly performed in vivo, has made this gene a model for the role of chromatin structure in gene regulation. In the repressed state, the PHO5 promoter shows a characteristic chromatin organization with four positioned nucleosomes and a short hypersensitive site. So far the basis for this nucleosome positioning has remained unresolved. We have therefore decided to complement the in vivo studies by an in vitro approach. As a first step, we have asked whether the characteristic PHO5 promoter chromatin structure depends on the cellular context including replication or higher order nuclear chromatin organization or whether it can be reconstituted in vitro in a cell-free system. To this end we have established an in vitro chromatin assembly system based on yeast extracts. It is capable of generating extensive regular nucleosomal arrays with physiological spacing. Assembly requires supplementation with exogenous histones and is dependent on energy leading to chromatin with dynamic properties due to ATP-dependent activities of the extract. Using the PHO5 promoter sequence as template in this replication independent system, we obtain a nucleosomal pattern over the PHO5 promoter region that is very similar to the in vivo pattern of the repressed state. This shows that the chromatin structure at the PHO5 promoter represents a self-organizing system in cell-free yeast extracts and provides a promising substrate for in vitro studies with a direct in vivo correlate.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Munich	Horz, W (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	hoerz@bio.med.unimuenchen.de	Korber, Philipp/AAN-7633-2021	Korber, Philipp/0000-0001-7526-6549				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Belikov S, 2001, EMBO J, V20, P2802, DOI 10.1093/emboj/20.11.2802; Blank TA, 1996, J MOL BIOL, V260, P1, DOI 10.1006/jmbi.1996.0377; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Gregory PD, 1999, METH MOL B, V119, P417; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; HORZ W, 1980, J MOL BIOL, V144, P305, DOI 10.1016/0022-2836(80)90093-5; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Robinson KM, 2003, MOL CELL BIOL, V23, P7937, DOI 10.1128/MCB.23.22.7937-7946.2003; Schultz MC, 1999, METHODS, V17, P161, DOI 10.1006/meth.1998.0727; Schultz MC, 1997, P NATL ACAD SCI USA, V94, P9034, DOI 10.1073/pnas.94.17.9034; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Terrell AR, 2002, J BIOL CHEM, V277, P31038, DOI 10.1074/jbc.M204662200; THOMA F, 1988, CELL, V55, P945, DOI 10.1016/0092-8674(88)90240-1; TOH EA, 1974, J BACTERIOL, V120, P608; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Venditti P, 1998, NUCLEIC ACIDS RES, V26, P3657, DOI 10.1093/nar/26.16.3657; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x	41	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35113	35120		10.1074/jbc.M405446200	http://dx.doi.org/10.1074/jbc.M405446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192097	hybrid			2022-12-27	WOS:000223134800124
J	Kim, H; Li, Q; Hempstead, BL; Madri, JA				Kim, H; Li, Q; Hempstead, BL; Madri, JA			Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; RAT-BRAIN; EXPRESSION; RECEPTORS; SURVIVAL; ANGIOGENESIS; VEGF; PHOSPHORYLATION; INVOLVEMENT; NEURONS	Brain-derived neurotrophic factor (BDNF) is expressed by endothelial cells. We investigated the characteristics of BDNF expression by brain-derived endothelial cells and tested the hypothesis that BDNF serves paracrine and autocrine functions affecting the vasculature of the central nervous system. In addition to expressing TrkB and p75(NTR) and BDNF under normoxic conditions, these cells increased their expression of BDNF under hypoxia. While the expression of TrkB is unaffected by hypoxia, TrkB exhibits a base-line phosphorylation under normoxic conditions and an increased phosphorylation when BDNF is added. TrkB phosphorylation is decreased when endogenous BDNF is sequestered by soluble TrkB. Exogenous BDNF elicits robust angiogenesis and survival in three-dimensional cultures of these endothelial cells, while sequestration of endogenous BDNF caused significant apoptosis. The effects of BDNF engagement of TrkB appears to be mediated via the phosphatidylinositol ( PI) 3-kinase-Akt pathway. Modulation of BDNF levels directly correlate with Akt phosphorylation and inhibitors of PI 3-kinase abrogate the BDNF responses. BDNF-mediated effects on endothelial cell survival/apoptosis correlated directly with activation of caspase 3. These endothelial cells also express p75(NTR) and respond to its preferred ligand, pro-nerve growth factor (pro-NGF), by undergoing apoptosis. These data support a role for neurotrophins signaling in the dynamic maintenance/differentiation of central nervous system endothelia.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA	Yale University; Cornell University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.	drhkim@kosin.ac.kr; joseph.madri@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058130, P01HL059312, P50HL059312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK055389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035476] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59312, HL-58130] Funding Source: Medline; NIDDK NIH HHS [P01-DK-55389] Funding Source: Medline; NINDS NIH HHS [P01-NS-035476] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Chow J, 2001, DEV BRAIN RES, V130, P123, DOI 10.1016/S0165-3806(01)00220-6; Curristin SM, 2002, P NATL ACAD SCI USA, V99, P15729, DOI 10.1073/pnas.232568799; DONOVAN MJ, 1995, AM J PATHOL, V147, P309; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hiltunen JO, 1996, CIRC RES, V79, P930, DOI 10.1161/01.RES.79.5.930; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Ilan N, 1998, J CELL SCI, V111, P3621; Ilan N, 2003, LAB INVEST, V83, P1105, DOI 10.1097/01.LAB.0000083531.84403.8B; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kim I, 2001, FASEB J, V15, P126, DOI 10.1096/fj.01-0556fje; KOLBECK R, 1994, EUR J BIOCHEM, V225, P995, DOI 10.1111/j.1432-1033.1994.0995b.x; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; Ment LR, 1997, IN VITRO CELL DEV-AN, V33, P684; Ment LR, 1997, DEV BRAIN RES, V100, P52, DOI 10.1016/S0165-3806(97)00012-6; Miyata K, 2001, NEUROSCIENCE, V105, P571, DOI 10.1016/S0306-4522(01)00225-1; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Ricci A, 2000, J VASC RES, V37, P355, DOI 10.1159/000025751; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Ruprecht K, 2002, NEUROSCI LETT, V330, P175, DOI 10.1016/S0304-3940(02)00778-4; Saarelainen T, 2000, MOL CELL NEUROSCI, V16, P87, DOI 10.1006/mcne.2000.0863; SCARISBRICK IA, 1993, J NEUROSCI, V13, P875; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Sobue G, 1998, NEUROCHEM RES, V23, P821, DOI 10.1023/A:1022434209787; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Solowiej A, 2003, AM J PATHOL, V162, P953, DOI 10.1016/S0002-9440(10)63890-4; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Stanzani L, 2001, CEREBROVASC DIS, V12, P240, DOI 10.1159/000047710; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; Tucker KL, 2001, NAT NEUROSCI, V4, P29, DOI 10.1038/82868; Wang SY, 2000, AM J PATHOL, V157, P1247, DOI 10.1016/S0002-9440(10)64640-8; Yanamoto H, 2000, BRAIN RES, V877, P331, DOI 10.1016/S0006-8993(00)02718-9; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	53	161	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33538	33546		10.1074/jbc.M404115200	http://dx.doi.org/10.1074/jbc.M404115200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169782	hybrid			2022-12-27	WOS:000223039700062
J	Koike, M; Kose, S; Furuta, M; Taniguchi, N; Yokoya, F; Yoneda, Y; Imamoto, N				Koike, M; Kose, S; Furuta, M; Taniguchi, N; Yokoya, F; Yoneda, Y; Imamoto, N			beta-catenin shows an overlapping sequence requirement but distinct molecular interactions for its bidirectional passage through nuclear pores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAN-INDEPENDENT MANNER; IMPORTIN-BETA; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN IMPORT; RNA EXPORT; TARGETING COMPLEX; GTP HYDROLYSIS; LIVING CELLS; DROSOPHILA; MECHANISM	beta-Catenin is an example of a typical molecule that can be translocated bidirectionally through nuclear pore complexes (NPCs) on its own in a facilitated manner. In this work the nuclear import and export of beta-catenin were examined to compare the sequence requirement of this molecule and to determine whether molecular interactions required for its bidirectional NPC passage are distinct or not. Deletion analysis of beta-catenin revealed that armadillo repeats 10-12 and the C terminus comprise the minimum region necessary for nuclear migration activity. Further dissection of this fragment showed that the C terminus tail plays an essential role in nuclear migration. The region of beta-catenin required for export substantially overlapped the region required for import. Therefore, the NPC translocation of beta-catenin is apparently reversible, which is consistent with findings reported previously. However, different translocating molecules blocked nuclear import and export of beta-catenin differentially. The data herein indicate that beta-catenin shows an overlapping sequence requirement for its import and export but that bidirectional movement through the NPC proceeds through distinct molecular interactions.	RIKEN, Discovery Res Inst, Cellular Dynam Lab, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Osaka 5650871, Japan	RIKEN; Osaka University	Imamoto, N (corresponding author), RIKEN, Discovery Res Inst, Cellular Dynam Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	nimamoto@riken.jp	Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Gallet A, 1999, EMBO J, V18, P2208, DOI 10.1093/emboj/18.8.2208; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Hurt E, 2000, J BIOL CHEM, V275, P8361, DOI 10.1074/jbc.275.12.8361; Imamoto N, 2000, CELL STRUCT FUNCT, V25, P207, DOI 10.1247/csf.25.207; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kose S, 1999, J BIOL CHEM, V274, P3946, DOI 10.1074/jbc.274.7.3946; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lee SJ, 2000, J MOL BIOL, V302, P251, DOI 10.1006/jmbi.2000.4055; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Neufeld KL, 2000, EMBO REP, V1, P519; Polakis P, 2000, GENE DEV, V14, P1837; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Tago K, 2000, GENE DEV, V14, P1741; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	51	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34038	34047		10.1074/jbc.M405821200	http://dx.doi.org/10.1074/jbc.M405821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173161	hybrid			2022-12-27	WOS:000223039700116
J	Lee, TH; Shank, J; Cusson, N; Kelliher, MA				Lee, TH; Shank, J; Cusson, N; Kelliher, MA			The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced I kappa B kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TNF RECEPTOR; CELL-DEATH; RECRUITMENT; COMPLEX; DOMAIN; IKK; SIGNAL; ENZYME; CYLD	The death domain kinase Rip1 is recruited to the tumor necrosis factor receptor type 1 and mediates the IkappaB kinase and p38 MAP kinase pathways. In response to tumor necrosis factor-alpha (TNF-alpha), we find Rip1 phosphorylated and ubiquitinated, suggesting that Rip1 phosphorylation may stimulate its ubiquitination. To address the contribution of the kinase activity of Rip1 to its ubiquitination and to TNF-alpha signaling, we introduced wild type Rip1 and a kinase-inactive form of Rip1, Rip1D138N, into rip1-/- murine embryonic fibroblast cells by retroviral infection. TNF-alpha-induced ubiquitination of Rip1 is observed in Rip1D138N cells, supporting the argument that Rip1 autophosphorylation is not required for Rip1 ubiquitination. TNF-alpha-induced Ikk and p38 MAP kinase activation is normal, and the Rip1D138N cells are resistant to TNF-alpha-induced cell death, indicating that the kinase activity of Rip1 is not required to mediate its antiapoptotic functions. In the absence of Traf2, TNF-alpha-induced ubiquitination of Rip1 is impaired, suggesting that Traf2 may be the E3 ubiquitin ligase responsible for the TNF-alpha-dependent, ubiquitination of Rip1. Finally, recruitment of the ubiquitinated Tak1 complex is dependent on the presence of Rip1, suggesting that Rip1 ubiquitination rather than its phosphorylation is critical in signaling.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Lazare Res Bldg, Worcester, MA 01605 USA.	Michelle.Kelliher@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061298] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061298, GM61298] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; MEYLAN E, 2004, NAT IMMUNOL; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	25	201	212	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33185	33191		10.1074/jbc.M404206200	http://dx.doi.org/10.1074/jbc.M404206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175328	hybrid			2022-12-27	WOS:000223039700022
J	Ricci, G; Turella, P; De Maria, F; Antonini, G; Nardocci, L; Board, PG; Parker, MW; Carbonelli, MG; Federici, G; Caccuri, AM				Ricci, G; Turella, P; De Maria, F; Antonini, G; Nardocci, L; Board, PG; Parker, MW; Carbonelli, MG; Federici, G; Caccuri, AM			Binding and kinetic mechanisms of the zeta class glutathione transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICHLOROACETIC ACID; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; MIXED DISULFIDE; ACTIVE-SITE; P1-1; POLYMORPHISM; THIOREDOXIN; CATALYSIS; ENZYME	The Zeta class of glutathione transferases (GSTs) has only recently been discovered and hence has been poorly characterized. Here we investigate the substrate binding and kinetic mechanisms of the human Zeta class GSTZ1c-1c by means of pre-steady state and steady-state experiments and site-directed mutagenesis. Binding of GSH occurs at a very low rate compared with that observed for the more recently evolved GSTs ( Alpha, Mu, and Pi classes). Moreover, the single step binding mechanism observed in this enzyme is reminiscent of that found for the Theta class enzyme, whereas the Alpha, Mu, and Pi classes have adopted a multistep binding mechanism. Replacement of Cys(16) with Ala increases the rate of GSH release from the active site causing a 10-fold decrease of affinity toward GSH. Cys(16) also plays a crucial role in co-substrate binding; the mutant enzyme is unable to bind the carcinogenic substrate dichloroacetic acid in the absence of GSH. However, both substrate binding and GSH activation are not rate-limiting in catalysis. A peculiarity of the hGSTZ1c-1c is the half-site activation of bound GSH. This suggests a primitive monomer-monomer interaction that, in the recently diverged GSTP1-1, gives rise to a sophisticated cooperative mechanism that preserves the catalytic efficiency of this GST under stress conditions.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Rome, Dept Biol, I-00146 Rome, Italy; Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Azienda Osp San Camillo Forlanini, I-00149 Rome, Italy; Childrens Hosp IRCCS, I-00165 Rome, Italy	University of Rome Tor Vergata; Sapienza University Rome; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research; Azienda Ospedaliera San Camillo-Forlanini	Caccuri, AM (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Viale Ric Sci, I-00133 Rome, Italy.	caccuri@uniroma2.it	CACCURI, ANNA MARIA/AFU-2643-2022; Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138; CACCURI, ANNA MARIA/0000-0002-3756-4163; Ricci, Giorgio/0000-0002-7108-2846; Antonini, Giovanni/0000-0002-2115-8961				Anandarajah K, 2000, BIOCHEMISTRY-US, V39, P5303, DOI 10.1021/bi9923813; Anderson WB, 2002, CHEM RES TOXICOL, V15, P1387, DOI 10.1021/tx025553x; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Blackburn AC, 2000, PHARMACOGENETICS, V10, P49, DOI 10.1097/00008571-200002000-00007; Blackburn AC, 2001, PHARMACOGENETICS, V11, P671, DOI 10.1097/00008571-200111000-00005; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOARD PG, 2003, BIOCHEM J, V374, P737; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; Caccuri AM, 2002, BIOCHEMISTRY-US, V41, P4686, DOI 10.1021/bi0158425; Caccuri AM, 2002, J BIOL CHEM, V277, P18777, DOI 10.1074/jbc.M201137200; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; Lantum HBM, 2002, CHEM RES TOXICOL, V15, P957, DOI 10.1021/tx010095y; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Polekhina G, 2001, BIOCHEMISTRY-US, V40, P1567, DOI 10.1021/bi002249z; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 2003, BIOCHEM J, V376, P71, DOI 10.1042/BJ20030860; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Segel, 1975, ENZYME KINETICS BEHA, P274; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Tong Z, 1998, BIOCHEM J, V331, P371, DOI 10.1042/bj3310371; Tzeng HF, 2000, CHEM RES TOXICOL, V13, P231, DOI 10.1021/tx990175q	26	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33336	33342		10.1074/jbc.M404631200	http://dx.doi.org/10.1074/jbc.M404631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173170	hybrid			2022-12-27	WOS:000223039700040
J	Van Liempt, E; Imberty, A; Bank, CMC; Van Vliet, SJ; Van Kooyk, Y; Geijtenbeek, TBH; Van Die, I				Van Liempt, E; Imberty, A; Bank, CMC; Van Vliet, SJ; Van Kooyk, Y; Geijtenbeek, TBH; Van Die, I			Molecular basis of the differences in binding properties of the highly related C-type lectins DC-SIGN and L-SIGN to Lewis x trisaccharide and Schistosoma mansoni egg antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-3; HUMAN DENDRITIC CELLS; SELECTIVE RECOGNITION; ENDOTHELIAL-CELLS; (ICAM-3)-GRABBING NONINTEGRIN; TRANS-INFECTION; CUTTING EDGE; RECEPTOR; PROTEIN; VIRUS	The dendritic cell-specific C-type lectin DC-SIGN functions as a pathogen receptor that recognizes Schistosoma mansoni egg antigens through its major glycan epitope Galbeta1,4(Fucalpha1,3) GlcNAc (Le(x)). Here we report that L-SIGN, a highly related homologue of DC-SIGN found on liver sinusoidal endothelial cells, binds to S. mansoni egg antigens but not to the Le(x) epitope. L-SIGN does bind the Lewis antigens Le(a), Le(b), and Le(y), similar as DC-SIGN. A specific mutation in the carbohydrate recognition domain of DC-SIGN ( V351G) abrogates binding to all Lewis antigens. In L-SIGN Ser(363) is present at the corresponding position of Val(351) in DC-SIGN. Replacement of this Ser into Val resulted in a "gain of function" L-SIGN mutant that binds to Le(x), and shows increased binding to the other Lewis antigens. These data indicate that Val(351) is important for the fucose specificity of DC-SIGN. Molecular modeling and docking of the different Lewis antigens in the carbohydrate recognition domains of L-SIGN, DC-SIGN, and their mutant forms, demonstrate that Val(351) in DC-SIGN creates a hydrophobic pocket that strongly interacts with the Fucalpha1,3/4-GlcNAc moiety of the Lewis antigens. The equivalent amino acid residue Ser(363) in L-SIGN creates a hydrophilic pocket that prevents interaction with Fucalpha1,3-GlcNAc in Le(x) but supports interactions with the Fucalpha1,4-GlcNAc moiety in Le(a) and Le(b) antigens. These data demonstrate for the first time that DC-SIGN and L-SIGN differ in their carbohydrate binding profiles and will contribute to our understanding of the functional roles of these C-type lectin receptors, both in recognition of pathogen and self-glycan antigens.	VU Univ Med Ctr, Dept Mol Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands; Univ Grenoble 1, CNRS, CERMAV, F-38041 Grenoble 9, France	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Van Die, I (corresponding author), VU Univ Med Ctr, FdG, Dept Mol Cell Biol & Immunol, Postbus 7057, NL-1007 MB Amsterdam, Netherlands.	im.vandie@vumc.nl	Van Vliet, Sandra/AAO-9534-2020; Geijtenbeek, Teunis/C-2229-2009; Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527; Van Kooyk, Yvette/0000-0001-5997-3665; van Vliet, Sandra/0000-0003-1811-2687				Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cambi A, 2003, EUR J IMMUNOL, V33, P532, DOI 10.1002/immu.200310029; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Colmenares M, 2004, J IMMUNOL, V172, P1186, DOI 10.4049/jimmunol.172.2.1186; Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200; Engering A, 2004, AM J PATHOL, V164, P1587, DOI 10.1016/S0002-9440(10)63717-0; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200; Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Knolle PA, 2000, IMMUNOL REV, V174, P21, DOI 10.1034/j.1600-0528.2002.017408.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; Nyame AK, 2003, EXP PARASITOL, V104, P1, DOI 10.1016/S0014-4894(03)00110-3; Okano M, 2001, J IMMUNOL, V167, P442, DOI 10.4049/jimmunol.167.1.442; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Su SV, 2004, J BIOL CHEM, V279, P19122, DOI 10.1074/jbc.M400184200; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Van Die I, 2004, TRENDS GLYCOSCI GLYC, V16, P265, DOI 10.4052/tigg.16.265; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052	41	86	87	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33161	33167		10.1074/jbc.M404988200	http://dx.doi.org/10.1074/jbc.M404988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184372	Green Published, hybrid			2022-12-27	WOS:000223039700019
J	Shi, YX; Latifi, T; Cromie, MJ; Groisman, EA				Shi, YX; Latifi, T; Cromie, MJ; Groisman, EA			Transcriptional control of the antimicrobial peptide resistance ugtL gene by the Salmonella PhoP and SlyA regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; ESCHERICHIA-COLI; 2-COMPONENT SYSTEM; MOLECULAR CHARACTERIZATION; POLYMYXIN RESISTANCE; VIRULENCE; REGULON; IDENTIFICATION; ACTIVATOR; EXPRESSION	The PhoP/PhoQ two-component system is a master regulator that governs the ability of Salmonella to cause a lethal infection in mice, the adaptation to low Mg2+ environments, and resistance to a variety of antimicrobial peptides. We have recently established that the PhoP-activated ugtL gene is required for resistance to the antimicrobial peptides magainin 2 and polymyxin B. Here we report that ugtL transcription requires not only the PhoP protein but also the virulence regulatory protein SlyA. The PhoP protein footprinted two regions of the ugtL promoter, mutation of either one of which was sufficient to abolish ugtL transcription. Although the SlyA protein is a transcriptional activator of the ugtL gene, it footprinted the ugtL promoter at a region located downstream of the transcription start site. The PhoP protein footprinted the slyA promoter, indicating that it controls slyA transcription directly. The slyA mutant was hypersensitive to magainin 2 and polymyxin B, suggesting that the virulence attenuation exhibited by slyA mutants may be caused by hypersensitivity to antimicrobial peptides. We propose that the PhoP and SlyA proteins control ugtL transcription using a feed-forward loop design.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Groisman, EA (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Campus Box 8230, St Louis, MO 63110 USA.	groisman@borcim.wustl.edu			NIAID NIH HHS [AI49561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049561] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Castelli ME, 2003, J BIOL CHEM, V278, P23579, DOI 10.1074/jbc.M303042200; Chamnongpol S, 2003, J MOL BIOL, V325, P795, DOI 10.1016/S0022-2836(02)01268-8; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis R., 1980, ADV BACTERIAL GENETI; Eguchi Y, 2004, J BACTERIOL, V186, P3006, DOI 10.1128/JB.186.10.3006-3014.2004; Ellermeier CD, 2002, GENE, V290, P153, DOI 10.1016/S0378-1119(02)00551-6; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; GALAN JE, 1989, MICROB PATHOGENESIS, V6, P433, DOI 10.1016/0882-4010(89)90085-5; Garmendia J, 2003, MICROBIOL-SGM, V149, P2385, DOI 10.1099/mic.0.26397-0; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hilbert F, 1999, J BACTERIOL, V181, P2158, DOI 10.1128/JB.181.7.2158-2165.1999; Kato A, 2003, P NATL ACAD SCI USA, V100, P4706, DOI 10.1073/pnas.0836837100; Kox LFF, 2000, EMBO J, V19, P1861, DOI 10.1093/emboj/19.8.1861; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lejona S, 2003, J BACTERIOL, V185, P6287, DOI 10.1128/JB.185.21.6287-6294.2003; LIBBY SJ, 1994, P NATL ACAD SCI USA, V91, P489, DOI 10.1073/pnas.91.2.489; Mangan S, 2003, J MOL BIOL, V334, P197, DOI 10.1016/j.jmb.2003.09.049; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Minagawa S, 2003, J BACTERIOL, V185, P3696, DOI 10.1128/JB.185.13.3696-3702.2003; Montagne M, 2001, J BACTERIOL, V183, P1787, DOI 10.1128/JB.183.5.1787-1791.2001; Munson GP, 2000, MOL MICROBIOL, V36, P1391, DOI 10.1046/j.1365-2958.2000.01957.x; Norte VA, 2003, J BACTERIOL, V185, P3508, DOI 10.1128/JB.185.12.3508-3514.2003; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; Qi Y, 1998, MOL MICROBIOL, V28, P1187, DOI 10.1046/j.1365-2958.1998.00882.x; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Shi YX, 2004, MOL MICROBIOL, V53, P229, DOI 10.1111/j.1365-2958.2004.04107.x; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; Soncini FC, 1996, J BACTERIOL, V178, P6796, DOI 10.1128/jb.178.23.6796-6801.1996; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; Stapleton MR, 2002, J BIOL CHEM, V277, P17630, DOI 10.1074/jbc.M110178200; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Yamamoto K, 2002, MOL MICROBIOL, V45, P423, DOI 10.1046/j.1365-2958.2002.03017.x	40	89	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38618	38625		10.1074/jbc.M406149200	http://dx.doi.org/10.1074/jbc.M406149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208313	hybrid			2022-12-27	WOS:000223684100069
J	Ben-Zvi, A; De los Rios, P; Dietler, G; Goloubinoff, P				Ben-Zvi, A; De los Rios, P; Dietler, G; Goloubinoff, P			Active solubilization and refolding of stable protein aggregates by cooperative unfolding action of individual Hsp70 chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; SUBSTRATE-BINDING; ESCHERICHIA-COLI; COMMON MECHANISM; DNAK; DISAGGREGATION; IMPLIES; FORM	Hsp70 is a central molecular chaperone that passively prevents protein aggregation and uses the energy of ATP hydrolysis to solubilize, translocate, and mediate the proper refolding of proteins in the cell. Yet, the molecular mechanism by which the active Hsp70 chaperone functions are achieved remains unclear. Here, we show that the bacterial Hsp70 ( DnaK) can actively unfold misfolded structures in aggregated polypeptides, leading to gradual disaggregation. We found that the specific unfolding and disaggregation activities of individual DnaK molecules were optimal for large aggregates but dramatically decreased for small aggregates. The active unfolding of the smallest aggregates, leading to proper global refolding, required the cooperative action of several DnaK molecules per misfolded polypeptide. This finding suggests that the unique ATP-fueled locking/unlocking mechanism of the Hsp70 chaperones can recruit random chaperone motions to locally unfold misfolded structures and gradually disentangle stable aggregates into refoldable proteins.	Univ Lausanne, Dept Biol Mol Vegetale, CH-1015 Lausanne, Switzerland; Ecole Polytech Fed Lausanne, ITPSB, Lab Biophys Stat, CH-1015 Lausanne, Switzerland; Ecole Polytech Fed Lausanne, IPMCSB, Lab Phys Mat Vivante, CH-1015 Lausanne, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Goloubinoff, P (corresponding author), Univ Lausanne, Dept Biol Mol Vegetale, CH-1015 Lausanne, Switzerland.	Pierre.Goloubinoff@ie-bpv.unil.ch	De Los Rios, Paolo/B-2456-2010; EPFL, LBS/B-3567-2010; BEN-ZVI, ANAT/F-1674-2012	De Los Rios, Paolo/0000-0002-5394-5062; BEN-ZVI, ANAT/0000-0003-2477-6519; Goloubinoff, Pierre/0000-0002-4802-0807				Ben-Zvi AP, 2002, J BIOL CHEM, V277, P49422, DOI 10.1074/jbc.M209163200; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Buczynski G, 2001, J BIOL CHEM, V276, P27231, DOI 10.1074/jbc.M100237200; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HERENDEEN SL, 1979, J BACTERIOL, V139, P185, DOI 10.1128/JB.139.1.185-194.1979; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	26	79	83	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37298	37303		10.1074/jbc.M405627200	http://dx.doi.org/10.1074/jbc.M405627200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201275	hybrid			2022-12-27	WOS:000223554600014
J	Humphries, LA; Dangelmaier, C; Sommer, K; Kipp, K; Kato, RM; Griffith, N; Bakman, I; Turk, CW; Daniel, JL; Rawlings, DJ				Humphries, LA; Dangelmaier, C; Sommer, K; Kipp, K; Kato, RM; Griffith, N; Bakman, I; Turk, CW; Daniel, JL; Rawlings, DJ			Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase C gamma Src homology 2-Src homology 3 linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL RECEPTOR; ANTIGEN RECEPTOR; CA2+ MOBILIZATION; ACTIVATION; RESIDUES; BTK; C-GAMMA-2; SYK; LYMPHOCYTES; EXPRESSION	Tyrosine phosphorylation of phospholipase Cgamma2 (PLCgamma2) is a crucial activation switch that initiates and maintains intracellular calcium mobilization in response to B cell antigen receptor (BCR) engagement. Although members from three distinct families of nonreceptor tyrosine kinases can phosphorylate PLCgamma in vitro, the specific kinase(s) controlling BCR-dependent PLCgamma activation in vivo remains unknown. Bruton's tyrosine kinase (Btk)-deficient human B cells exhibit diminished inositol 1,4,5-trisphosphate production and calcium signaling despite a normal inducible level of total PLCgamma2 tyrosine phosphorylation. This suggested that Btk might modify a critical subset of residues essential for PLCgamma2 activity. To evaluate this hypothesis, we generated site-specific phosphotyrosine antibodies recognizing four putative regulatory residues within PLCgamma2. Whereas all four sites were rapidly modified in response to BCR engagement in normal B cells, Btk-deficient B cells exhibited a marked reduction in phosphorylation of the Src homology 2 (SH2)-SH3 linker region sites, Tyr(753) and Tyr(759). Phosphorylation of both sites was restored by expression of Tec, but not Syk, family kinases. In contrast, phosphorylation of the PLCgamma2 carboxyl- terminal sites, Tyr(1197) and Tyr(1217), was unaffected by the absence of functional Btk. Together, these data support a model whereby Btk/Tec kinases control sustained calcium signaling via site-specific phosphorylation of key residues within the PLCgamma2 SH2-SH3 linker.	Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90095 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19122 USA; Max Planck Inst Psychiat Mol Cellular & Clin Prot, D-80804 Munich, Germany	University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Max Planck Society	Rawlings, DJ (corresponding author), Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA.	drawling@u.washington.edu	Rawlings, David/CAI-4751-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037091] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA081140] Funding Source: NIH RePORTER; NCI NIH HHS [CA81140] Funding Source: Medline; NICHD NIH HHS [HD37091] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ellmeier W, 2000, J EXP MED, V192, P1611, DOI 10.1084/jem.192.11.1611; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Forssell J, 2000, SCAND J IMMUNOL, V52, P30; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; Genevier HC, 1997, CLIN EXP IMMUNOL, V110, P386, DOI 10.1046/j.1365-2249.1997.4581478.x; Hashimoto A, 2000, J IMMUNOL, V165, P1738, DOI 10.4049/jimmunol.165.4.1738; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HEMPEL WM, 1991, J IMMUNOL, V146, P3713; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kouro T, 2001, INT IMMUNOL, V13, P485, DOI 10.1093/intimm/13.4.485; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Law CL, 1996, MOL CELL BIOL, V16, P1305; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Ozdener F, 2002, MOL PHARMACOL, V62, P672, DOI 10.1124/mol.62.3.672; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Perez-Villar JJ, 1999, J IMMUNOL, V163, P6435; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Rodriguez R, 2003, BIOCHEM J, V374, P269, DOI 10.1042/BJ20021778; Rodriguez R, 2001, J BIOL CHEM, V276, P47982, DOI 10.1074/jbc.M107577200; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Setoguchi R, 1998, IMMUNOL LETT, V64, P109, DOI 10.1016/S0165-2478(98)00086-8; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Watanabe D, 2001, J BIOL CHEM, V276, P38595, DOI 10.1074/jbc.M103675200; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7	59	84	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37651	37661		10.1074/jbc.M311985200	http://dx.doi.org/10.1074/jbc.M311985200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15184383	hybrid			2022-12-27	WOS:000223554600056
J	Sitko, JC; Guevara, CI; Cacalano, NA				Sitko, JC; Guevara, CI; Cacalano, NA			Tyrosine-phosphorylated SOCS3 interacts with the Nck and Crk-L adapter proteins and regulates Nck activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHYSIOLOGICAL NEGATIVE REGULATOR; STIMULATING FACTOR-RECEPTOR; ALDRICH SYNDROME PROTEIN; SRC HOMOLOGY-3 DOMAIN; EXCHANGE FACTOR C3G; SH3 DOMAIN; SIGNAL-TRANSDUCTION; DOCKING PROTEIN; CONSTITUTIVE EXPRESSION	Suppressors of cytokine signaling ( SOCS) are negative feedback inhibitors of cytokine and growth factor signal transduction. Although the affect of SOCS proteins on the Jak-STAT pathway has been well characterized, their role in the regulation of other signaling modules is not well understood. In the present study, we demonstrate that SOCS3 physically interacts with the SH2/SH3-containing adapter proteins Nck and Crk-L, which are known to couple activated receptors to multiple downstream signaling pathways and the actin cytoskeleton. Our data show that the SOCS3/Nck and SOCS3/Crk-L interactions depend on tyrosine phosphorylation of SOCS3 Tyr(221) within the conserved SOCS box motif and intact SH2 domains of Nck and Crk-L. Furthermore, SOCS3 Tyr(221) forms a YXXP motif, which is a consensus binding site for the Nck and Crk-L SH2 domains. Expression of SOCS3 in NIH3T3 cells induces constitutive recruitment of a Nck-GFP fusion protein to the plasma membrane and constitutive tyrosine phosphorylation of endogenous Nck. Our findings suggest that SOCS3 regulates multiple cytokine and growth factor-activated signaling pathways by acting as a recruitment factor for adapter proteins.	Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci, Dept Radiat Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cacalano, NA (corresponding author), Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci, Dept Radiat Oncol, Rm B3-133, Los Angeles, CA 90095 USA.	ncacalano@mednet.ucla.edu						Abramson J, 2003, EUR J IMMUNOL, V33, P85, DOI 10.1002/immu.200390011; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Aoki S, 2004, ANTI-CANCER DRUG, V15, P363, DOI 10.1097/00001813-200404000-00009; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; Lock P, 1999, J BIOL CHEM, V274, P22775, DOI 10.1074/jbc.274.32.22775; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Martelli MP, 2001, J BIOL CHEM, V276, P45654, DOI 10.1074/jbc.M105777200; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; NICHOLS GL, 1994, BLOOD, V84, P2912; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Pramatarova A, 2003, MOL CELL BIOL, V23, P7210, DOI 10.1128/MCB.23.20.7210-7221.2003; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Ronn SG, 2002, MOL ENDOCRINOL, V16, P2124, DOI 10.1210/me.2002-0082; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 1996, ONCOGENE, V12, P839; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; TENHOEVE J, 1994, BLOOD, V84, P1731; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; van Dijk TB, 2000, BLOOD, V96, P3406; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V310, P1188, DOI 10.1016/j.bbrc.2003.09.140; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	96	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37662	37669		10.1074/jbc.M404007200	http://dx.doi.org/10.1074/jbc.M404007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15173187	hybrid			2022-12-27	WOS:000223554600057
J	Young, GD; Murphy-Ullrich, JE				Young, GD; Murphy-Ullrich, JE			Molecular interactions that confer latency to transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; ACTIVATION; THROMBOSPONDIN-1; SUPPRESSION; MECHANISMS; FIBROSIS; PEPTIDE	A major point of regulation of transforming growth factor-beta (TGF-beta) function is through control of activation of the latent TGF-beta complex, which consists of the latency associated peptide (LAP) secreted in non-covalent association with mature TGF-beta. Activation involves proteolysis, dissociation, or altered binding of LAP. However, the mechanism by which LAP confers latency to TGF-beta is poorly understood. Previously, we identified a conserved sequence near the N terminus of LAP as a site of thrombospondin-1 (TSP1) binding to the latent complex. Now we show that expression of the TGF-beta1-latent complex deleted in the TSP1 binding site ((LSKL)-L-54) of LAP (DeltaLSKL LAP) results in secretion of LAP, but not of mature TGF- beta. DeltaLSKL LAP also fails to bind soluble or immobilized TGF-beta1. Consistent with an inability to bind the mature domain, DeltaLSKL LAP is unable to confer latency to TGF-beta, suggesting that the LSKL sequence is important, not only for TSP1 binding and activation, but also for binding to the mature domain. We identified the sequence (RKPK)-R-94 in the receptor-binding region of mature TGF-beta1 as the binding site for LAP. Peptides of the RKPK sequence bind LAP and inhibit LAP/TGF-beta association. RKPK peptides also activate latent TGF-beta, presumably by disrupting LAP-mature TGF-beta interactions. These studies provide a molecular basis for both latency and activation by TSP1 through the LSKL sequence of LAP binding to the RKPK sequence of mature TGF-beta.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Cell Adhes & Matrix Res Ctr, Med Sci Training Program, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Murphy-Ullrich, JE (corresponding author), Univ Alabama, Dept Pathol, Volker Hall 668,1670 Univ Blvd, Birmingham, AL 35294 USA.	murphy@path.uab.edu			NCRR NIH HHS [C06 RR15490] Funding Source: Medline; NHLBI NIH HHS [R01 HL050061, HL50061] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Burmester JK, 1998, GROWTH FACTORS, V15, P231, DOI 10.3109/08977199809002119; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dumont N, 2002, DIFFERENTIATION, V70, P574, DOI 10.1046/j.1432-0436.2002.700910.x; Gressner AM, 2003, J HEPATOL, V39, P856, DOI 10.1016/S0168-8278(03)00432-X; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; Wolfraim LA, 2002, J IMMUNOL METHODS, V266, P7, DOI 10.1016/S0022-1759(02)00090-X; Zhang Y, 2003, J INVEST DERMATOL, V121, P713, DOI 10.1046/j.1523-1747.2003.12517.x	20	82	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38032	38039		10.1074/jbc.M405658200	http://dx.doi.org/10.1074/jbc.M405658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208302	hybrid			2022-12-27	WOS:000223554600097
J	Agapova, LS; Volodina, JL; Chumakov, PM; Kopnin, BP				Agapova, LS; Volodina, JL; Chumakov, PM; Kopnin, BP			Activation of Ras-Ral pathway attenuates p53-independent DNA damage G(2) checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; SIGNALING PATHWAYS; GENE AMPLIFICATION; CROSS-LINKING; KINASE; CANCER; PROTEIN; ONCOGENE; GTPASES; PHOSPHORYLATION	Earlier we have found that in p53-deficient cells the expression of activated Ras attenuates the DNA damage-induced arrest in G(1) and G(2). In the present work we studied Ras-mediated effects on the G(2) checkpoint in two human cell lines, MDAH041 immortalized fibroblasts and Saos-2 osteosarcoma cells. The transduction of the H-Ras mutants that retain certain functions (V12S35, V12G37, and V12C40 retain the ability to activate Raf or RalGDS or phosphatidylinositol 3-kinase, respectively) as well as the activated or dominant-negative mutants of RalA (V23 and N28, respectively) has revealed that the activation of Ras-RalGEFs-Ral pathway was responsible for the attenuation of the G(2) arrest induced by ethyl metanesulfonate or doxorubicin. Noteworthy, the activated RalA V23N49 mutant, which cannot interact with RLIP76/RalBP1 protein, one of the best studied Ral effectors, retained the ability to attenuate the DNA damage-induced G(2) arrest. Activation of the Ras-Ral signaling affected neither the level nor the intracellular localization of cyclin B1 and CDC2 but interfered with the CDC2 inhibitory phosporylation at Tyr(15) and the decrease in the cyclin B/CDC2 kinase activity in damaged cells. The revealed function of the Ras-Ral pathway may contribute to the development of genetic instability in neoplastic cells.	Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Cleveland Clinic Foundation; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Kopnin, BP (corresponding author), Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia.	bkopnin@yahoo.com	Kopnin, Boris/R-8240-2019; Volodina, Yulia L/AGE-9354-2022	Kopnin, Boris/0000-0003-3100-2212; Volodina, Yulia L/0000-0003-4388-3344; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Archer Herbert, 2002, Methods Mol Biol, V189, P67; Awasthi S, 2003, INT J CANCER, V106, P635, DOI 10.1002/ijc.11260; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Boettner B, 2002, GENE DEV, V16, P2033, DOI 10.1101/gad.1020602; BOS JL, 1989, CANCER RES, V49, P4682; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Cullen PJ, 2001, CURR BIOL, V11, pR342, DOI 10.1016/S0960-9822(01)00189-0; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; ICHIKAWA T, 1990, CANCER RES, V50, P6349; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kellogg DR, 2003, J CELL SCI, V116, P4883, DOI 10.1242/jcs.00908; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kimura ET, 2003, CANCER RES, V63, P1454; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Luce RA, 2001, METHOD ENZYMOL, V340, P396; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Oxford G, 2003, CANCER LETT, V189, P117, DOI 10.1016/S0304-3835(02)00510-4; Peitl P, 2002, MUTAGENESIS, V17, P67, DOI 10.1093/mutage/17.1.67; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Poon RYC, 2002, ENCY CANC, P393; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; RAK J, 1995, CANCER RES, V55, P4575; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosse C, 2003, J BIOL CHEM, V278, P30597, DOI 10.1074/jbc.M302191200; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2269, DOI 10.1016/0006-2952(94)90265-8; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; WANI MA, 1994, CANCER RES, V54, P2504; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yamazaki Y, 2001, BIOCHEM BIOPH RES CO, V280, P868, DOI 10.1006/bbrc.2000.4233; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	73	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36382	36389		10.1074/jbc.M405007200	http://dx.doi.org/10.1074/jbc.M405007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208305	hybrid			2022-12-27	WOS:000223453600028
J	Clarke, TA; Im, SC; Bidwai, A; Waskell, L				Clarke, TA; Im, SC; Bidwai, A; Waskell, L			The role of the length and sequence of the linker domain of cytochrome b(5) in stimulating cytochrome P4502B4 catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; ENDOPLASMIC-RETICULUM; SUBSTRATE-BINDING; ESCHERICHIA-COLI; MEMBRANE; PROTEIN; EXPRESSION; METABOLISM; ALIGNMENT; REDUCTASE	Cytochrome b(5) (cyt b(5)) is a 15-kDa amphipathic protein with a cytosolic amino-terminal catalytic heme domain, which is anchored to the microsomal membrane by a hydrophobic transmembrane alpha-helix at its carboxyl terminus. These two domains are connected by an similar to15-amino acid linker domain, Ser(90)-Asp(104), which has been modified by site-directed mutagenesis to investigate whether the length or sequence of the linker influences the ability of cyt b(5) to bind ferric cytochrome P450 2B4 and donate an electron to oxyferrous (cyt P450 2B4), thereby stimulating catalysis. Because shortening the linker by 8 or more amino acids markedly inhibited the ability of cyt b(5) to bind cyt P450 2B4 and stimulate catalysis by this isozyme, it is postulated 7 amino acids are sufficient to allow a productive interaction. All mutant cyts b(5) except the protein lacking the entire 15-amino acid linker inserted normally into the microsomal membrane. Alternatively, lengthening the linker by 16 amino acids, reversing the sequence of the amino acids in the linker, and mutating conserved linker residues did not significantly alter the ability of cyt b(5) to interact with cyt P450 2B4. A model for the membrane-bound cyt b(5)-cyt P450 complex is presented.	Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48105 USA; Vet Affairs Med Res Ctr, Ann Arbor, MI 48105 USA; Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England	University of Michigan System; University of Michigan; University of East Anglia	Waskell, L (corresponding author), Univ Michigan, Dept Anesthesiol, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.	waskell@umich.edu	clarke, tom/D-1837-2009	clarke, tom/0000-0002-6234-1914	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Altuve A, 2001, BIOCHEMISTRY-US, V40, P9469, DOI 10.1021/bi010636i; Arnesano F, 1998, BIOCHEMISTRY-US, V37, P173, DOI 10.1021/bi971896w; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Banci L, 2000, EUR J BIOCHEM, V267, P755, DOI 10.1046/j.1432-1327.2000.01054.x; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Creighton T. E., 1993, PROTEINS STRUCTURES; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; Durley RCE, 1996, ACTA CRYSTALLOGR D, V52, P65, DOI 10.1107/S0907444995007827; Estabrook R W, 1978, Methods Enzymol, V52, P212; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIORDANO SJ, 1993, BIOCHIM BIOPHYS ACTA, V1172, P95, DOI 10.1016/0167-4781(93)90274-H; GRUENKE LD, 1995, J BIOL CHEM, V270, P24707, DOI 10.1074/jbc.270.42.24707; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; Jayasinghe S, 2001, J MOL BIOL, V312, P927, DOI 10.1006/jmbi.2001.5008; Mathews K., 1990, BIOCHEMISTRY; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mulrooney SB, 2000, PROTEIN EXPRES PURIF, V19, P173, DOI 10.1006/prep.2000.1228; Muskett FW, 1996, J MOL BIOL, V258, P172, DOI 10.1006/jmbi.1996.0241; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; Park JY, 2003, J MED CHEM, V46, P1645, DOI 10.1021/jm020538a; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; RodriguezMaranon MJ, 1996, BIOCHEMISTRY-US, V35, P16378, DOI 10.1021/bi961895o; Schenkman JB, 2003, PHARMACOL THERAPEUT, V97, P139, DOI 10.1016/S0163-7258(02)00327-3; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; SLIGAR SG, 1979, BIOCHEM BIOPH RES CO, V90, P925, DOI 10.1016/0006-291X(79)91916-8; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STRITTMATTER P, J BIOL CHEM, V247, P7188; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2000, J INORG BIOCHEM, V81, P183, DOI 10.1016/S0162-0134(00)00102-1; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842	40	34	35	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36809	36818		10.1074/jbc.M406055200	http://dx.doi.org/10.1074/jbc.M406055200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194706	hybrid			2022-12-27	WOS:000223453600083
J	Lima, WF; Nichols, JG; Wu, HJ; Prakash, TP; Migawa, MT; Wyrzykiewicz, TK; Bhat, B; Crooke, ST				Lima, WF; Nichols, JG; Wu, HJ; Prakash, TP; Migawa, MT; Wyrzykiewicz, TK; Bhat, B; Crooke, ST			Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-H; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; WOBBLE POSITION; DNA; OLIGONUCLEOTIDES; SPECIFICITY; BINDING; DUPLEX; ENZYME	Human RNase H1 cleaves RNA exclusively in an RNA/DNA duplex; neither double-strand DNA nor double-strand RNA is a viable substrate. Previous studies suggest that the helical geometry and sugar conformation of the DNA and RNA may play a role in the selective recognition of the heteroduplex substrate by the enzyme. We systematically evaluated the influence of sugar conformation, minor groove bulk, and conformational flexibility of the heteroduplex on enzyme efficiency. Modified nucleotides were introduced into the oligodeoxyribonucleotide at the catalytic site of the heteroduplex and consisted of southern, northern, and eastern biased sugars with and without 2'-substituents, non-hydrogen bonding base modifications, abasic de-oxyribonucleotides, intranucleotide hydrocarbon linkers, and a ganciclovir-modified deoxyribonucleotide. Heteroduplexes containing modifications exhibiting strong northern or southern conformational biases with and without a bulky 2'-substituent were cleaved at a significantly slower rate than the unmodified substrate. Modifications imparting the greatest degree of conformational flexibility were the poorest substrates, resulting in dramatically slower cleavage rates for the ribonucleotide opposing the modification and the surrounding ribonucleotides. Finally, modified heteroduplexes containing modifications predicted to mimic the sugar pucker and conformational flexibility of the deoxyribonucleotide exhibited cleavage rates comparable with those of the unmodified substrate. These data suggest that sugar conformation, minor groove width, and the relative positions of the intra- and internucleotide phosphates are the crucial determinants in the selective recognition of the heteroduplex substrate by human RNase H1 and offer immediate steps to improve the performance of DNA-like antisense oligonucleotides.	ISIS Pharmaceut, Dept Biol Mol & Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Lima, WF (corresponding author), ISIS Pharmaceut, Dept Biol Mol & Struct, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	wlima@isisph.com						AGRIS PF, 1992, J AM CHEM SOC, V114, P2652, DOI 10.1021/ja00033a044; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; CERRITELLI SM, 1995, RNA, V1, P246; Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1; CONNOLLY BA, 1989, NUCLEIC ACIDS RES, V17, P4957, DOI 10.1093/nar/17.13.4957; Crouch R. J., 1982, NUCLEASES, P211; Denisov AY, 2001, NUCLEIC ACIDS RES, V29, P4284, DOI 10.1093/nar/29.21.4284; Detmer K, 2003, EUR J ORG CHEM, V2003, P1837, DOI 10.1002/ejoc.200200641; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; Egli M, 1996, BIOCHEMISTRY-US, V35, P8489, DOI 10.1021/bi9607214; Evans SP, 1999, J MOL BIOL, V291, P661, DOI 10.1006/jmbi.1999.2971; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FRASER A, 1993, J HETEROCYCLIC CHEM, V30, P1277, DOI 10.1002/jhet.5570300518; HALL KB, 1991, BIOCHEMISTRY-US, V30, P1795, DOI 10.1021/bi00221a010; Ikeda H, 1998, NUCLEIC ACIDS RES, V26, P2237, DOI 10.1093/nar/26.9.2237; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; IWAI S, 1995, FEBS LETT, V368, P315, DOI 10.1016/0014-5793(95)00683-Z; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1991, J BIOL CHEM, V266, P11621; Kanazaki M, 2000, J AM CHEM SOC, V122, P2422, DOI 10.1021/ja9934706; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 2003, J BIOL CHEM, V278, P49860, DOI 10.1074/jbc.M306543200; Lima WF, 2003, J BIOL CHEM, V278, P14906, DOI 10.1074/jbc.M211279200; Lima WF, 2001, METHOD ENZYMOL, V341, P430, DOI 10.1016/S0076-6879(01)41168-2; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; Saenger W., 1984, PRINCIPLES NUCL ACID; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; SCHMIT C, 1994, BIOORG MED CHEM LETT, V4, P1969, DOI 10.1016/S0960-894X(01)80545-X; SIERZPUTOWSKAGRACZ H, 1987, J AM CHEM SOC, V109, P7171, DOI 10.1021/ja00257a044; SPROAT BS, 1985, OLIGONUCLEOTIDE SYNT, P83; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; TRAPANE TL, 1994, J AM CHEM SOC, V116, P8412, DOI 10.1021/ja00097a077; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Waga T, 1996, NUCLEOS NUCLEOT, V15, P287, DOI 10.1080/07328319608002385; Wilds CJ, 2000, NUCLEIC ACIDS RES, V28, P3625, DOI 10.1093/nar/28.18.3625; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 2004, J BIOL CHEM, V279, P17181, DOI 10.1074/jbc.M311683200; Wu HJ, 2001, J BIOL CHEM, V276, P23547, DOI 10.1074/jbc.M009676200; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YONEDA N, 1991, TETRAHEDRON, V47, P5329, DOI 10.1016/S0040-4020(01)80970-4; ZHU LM, 1995, BIOCHEMISTRY-US, V34, P2372, DOI 10.1021/bi00007a033	52	65	69	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36317	36326		10.1074/jbc.M405035200	http://dx.doi.org/10.1074/jbc.M405035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205459	hybrid			2022-12-27	WOS:000223453600021
J	Ro, HA; Carson, JH				Ro, HA; Carson, JH			pH microdomains in oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-II; FLUORESCENCE CORRELATION SPECTROSCOPY; RENAL PROXIMAL TUBULE; H+ ION MOBILITY; NA+/H+ EXCHANGER; EXTRACELLULAR PH; EPITHELIAL-CELL; CYTOPLASMIC PH; TRANSPORT; COTRANSPORTER	Oligodendrocytes (OLs) are cells that produce myelin in the central nervous system. Here we use ratiometric pH indicator dye to analyze intracellular pH in OLs in culture. The results reveal alkaline microdomains, which predominate in the perikaryon and proximal dendrites, and acidic microdomains, which predominate in distal dendrites. Spatial nonuniformity of pH is generated by differential subcellular distribution of Na+/H+ exchanger (NHE), which is localized in a punctate distribution in the perikaryon and proximal processes, Na+/HCO3- cotransporter (NBC), which is localized in a punctate distribution in distal dendrites, and carbonic anhydrase isotype II (CAII), which is colocalized with either NHE or NBC. Inhibition of NHE activity by amiloride inhibits regeneration of alkaline microdomains after cytoplasmic acidification, whereas the inhibition of CAII activity with ethoxyzolamide inhibits acidification of dendrites. Fluorescence correlation spectroscopy analysis of CAII microinjected into OLs reveals freely diffusing protein throughout the cell as well as protein associated predominantly with NHE in the perikaryon and predominantly with NBC in the dendrites. Alkaline and acidic microdomains could be generated by transport metabolons consisting of CAII associated with NHE or NBC, respectively. This study provides the first evidence for pH microdomains in cells and describes a mechanism for how they are generated.	Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA	University of Connecticut	Carson, JH (corresponding author), Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA.	jcarson@nso2.uchc.edu			NCRR NIH HHS [RR 13186] Funding Source: Medline; NINDS NIH HHS [NS 15190] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR013186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015190, R56NS015190] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113; Boussouf A, 2000, J NEUROSCI RES, V59, P731, DOI 10.1002/(SICI)1097-4547(20000315)59:6<731::AID-JNR5>3.0.CO;2-G; Boussouf A, 1997, GLIA, V19, P74, DOI 10.1002/(SICI)1098-1136(199701)19:1<74::AID-GLIA8>3.0.CO;2-A; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; Cammer W, 1996, J NEUROIMMUNOL, V67, P131; CAMMER W, 1995, J NEUROSCI RES, V40, P451, DOI 10.1002/jnr.490400404; Cammer WB, 2000, EXS, V90, P475; Carson J H, 2001, Results Probl Cell Differ, V34, P69; Cavet ME, 1999, AM J PHYSIOL-CELL PH, V277, pC1111, DOI 10.1152/ajpcell.1999.277.6.C1111; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1988, NEUROSCIENCE, V27, P941, DOI 10.1016/0306-4522(88)90197-2; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; IVES HE, 1983, J BIOL CHEM, V258, P3513; Joseph D, 2002, AM J PHYSIOL-LUNG C, V282, pL675, DOI 10.1152/ajplung.00330.2001; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; Levin MK, 2004, DIFFERENTIATION, V72, P1, DOI 10.1111/j.1432-0436.2004.07201002.x; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Masereel B, 2003, EUR J MED CHEM, V38, P547, DOI 10.1016/S0223-5234(03)00100-4; MOODY W, 1984, ANNU REV NEUROSCI, V7, P257; Noel J, 2003, BIOCHEMISTRY-US, V42, P15361, DOI 10.1021/bi035296a; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; Ridderstrale Y, 2000, J NEUROCYTOL, V29, P263, DOI 10.1023/A:1026571704422; ROBELLO M, 1994, NEUROSCIENCE, V61, P833, DOI 10.1016/0306-4522(94)90406-5; SMART SC, 1995, J AM COLL CARDIOL, V26, P1365, DOI 10.1016/0735-1097(95)00326-6; Spitzer KW, 2002, J PHYSIOL-LONDON, V541, P159, DOI 10.1113/jphysiol.2001.013268; Sterling D, 2001, JOP, V2, P165; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Sterling D, 2002, AM J PHYSIOL-CELL PH, V283, pC1522, DOI 10.1152/ajpcell.00115.2002; Stewart AK, 1999, J PHYSIOL-LONDON, V516, P209, DOI 10.1111/j.1469-7793.1999.209aa.x; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Vaughan-Jones RD, 2002, J PHYSIOL-LONDON, V541, P139, DOI 10.1113/jphysiol.2001.013267; VERKMAN AS, 1987, BIOPHYS J, V51, P533, DOI 10.1016/S0006-3495(87)83379-9; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; VOET D, 1995, BIOCHEMISTRY-US, P353; WALZ W, 1989, CAN J PHYSIOL PHARM, V67, P577, DOI 10.1139/y89-092; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	39	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37115	37123		10.1074/jbc.M403099200	http://dx.doi.org/10.1074/jbc.M403099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192115	hybrid			2022-12-27	WOS:000223453600115
J	Bichsel, SJ; Tamaskovic, R; Stegert, MR; Hemmings, BA				Bichsel, SJ; Tamaskovic, R; Stegert, MR; Hemmings, BA			Mechanism of activation of NDR (nuclear Dbf2-related) protein kinase by the hMOB1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; MITOTIC EXIT-NETWORK; CELL-CYCLE; GENE ENCODES; YEAST; MORPHOGENESIS; DROSOPHILA; MOB1; DBF2; PHOSPHORYLATION	NDR (nuclear Dbf2-related) kinase belongs to a family of kinases that is highly conserved throughout the eukaryotic world. We showed previously that NDR is regulated by phosphorylation and by the Ca2+-binding protein, S100B. The budding yeast relatives of Homo sapiens NDR, Cbk1, and Dbf2, were shown to interact with Mob2 (Mps one binder 2) and Mob1, respectively. This interaction is required for the activity and biological function of these kinases. In this study, we show that hMOB1, the closest relative of yeast Mob1 and Mob2, stimulates NDR kinase activity and interacts with NDR both in vivo and in vitro. The point mutations of highly conserved residues within the N-terminal domain of NDR reduced NDR kinase activity as well as human MOB1 binding. A novel feature of NDR kinases is an insert within the catalytic domain between subdomains VII and VIII. The amino acid sequence within this insert shows a high basic amino acid content in all of the kinases of the NDR family known to interact with MOB proteins. We show that this sequence is autoinhibitory, and our data indicate that the binding of human MOB1 to the N-terminal domain of NDR induces the release of this autoinhibition.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	Brian.Hemmings@fmi.ch						Baillat G, 2002, J BIOL CHEM, V277, P18961, DOI 10.1074/jbc.M108818200; Balasubramanian MK, 1998, GENETICS, V149, P1265; Bhattacharya S, 2003, BIOCHEMISTRY-US, V42, P14416, DOI 10.1021/bi035089a; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Cong JL, 2001, DEVELOPMENT, V128, P2793; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Du LL, 2002, MOL BIOL CELL, V13, P503, DOI 10.1091/mbc.01-07-0365; Durrenberger F, 1999, MOL GEN GENET, V261, P281, DOI 10.1007/s004380050968; Geng W, 2000, GENETICS, V156, P1817; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hirata D, 2002, EMBO J, V21, P4863, DOI 10.1093/emboj/cdf495; Hou MC, 2003, J CELL SCI, V116, P125, DOI 10.1242/jcs.00206; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Moreno CS, 2001, J BIOL CHEM, V276, P24253, DOI 10.1074/jbc.M102398200; Ponchon L, 2004, J MOL BIOL, V337, P167, DOI 10.1016/j.jmb.2004.01.010; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stavridi ES, 2003, STRUCTURE, V11, P1163, DOI 10.1016/S0969-2126(03)00182-5; Stegert MR, 2004, J BIOL CHEM, V279, P23806, DOI 10.1074/jbc.M402472200; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	38	109	116	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35228	35235		10.1074/jbc.M404542200	http://dx.doi.org/10.1074/jbc.M404542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15197186	hybrid			2022-12-27	WOS:000223303400013
J	Fedoroff, OY; Townson, SA; Golovanov, AP; Baron, M; Avis, JM				Fedoroff, OY; Townson, SA; Golovanov, AP; Baron, M; Avis, JM			The structure and dynamics of tandem WW domains in a negative regulator of notch signaling, suppressor of deltex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAINS; PROTEIN; RECOGNITION; COMPLEX; KINASE; NEDD4; GENE; IDENTIFICATION; SPECIFICITY; RELAXATION	WW domains mediate protein recognition, usually though binding to proline-rich sequences. In many proteins, WW domains occur in tandem arrays. Whether or how individual domains within such arrays cooperate to recognize biological partners is, as yet, poorly characterized. An important question is whether functional diversity of different WW domain proteins is reflected in the structural organization and ligand interaction mechanisms of their multiple domains. We have determined the solution structure and dynamics of a pair of WW domains (WW3-4) from a Drosophila Nedd4 family protein called Suppressor of deltex (Su(dx)), a regulator of Notch receptor signaling. We find that the binding of a type 1 PPPY ligand to WW3 stabilizes the structure with effects propagating to the WW4 domain, a domain that is not active for ligand binding. Both WW domains adopt the characteristic triple-stranded beta-sheet structure, and significantly, this is the first example of a WW domain structure to include a domain ( WW4) lacking the second conserved Trp ( replaced by Phe). The domains are connected by a flexible linker, which allows a hingelike motion of domains that may be important for the recognition of functionally relevant targets. Our results contrast markedly with those of the only previously determined three-dimensional structure of tandem WW domains, that of the rigidly oriented WW domain pair from the RNA-splicing factor Prp40. Our data illustrate that arrays of WW domains can exhibit a variety of higher order structures and ligand interaction mechanisms.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Victoria Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester	Avis, JM (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.	J.Avis@umist.ac.uk	Fedorov, Oleg Y./B-6412-2014; Golovanov, Alexander P./ABN-0572-2022	Fedorov, Oleg Y./0000-0001-9004-1815; Golovanov, Alexander P./0000-0002-8592-3984				Angers A, 2004, J BIOL CHEM, V279, P11471, DOI 10.1074/jbc.M309934200; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bayer E, 2003, J BIOL CHEM, V278, P26183, DOI 10.1074/jbc.M300721200; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Braddock DT, 2001, J AM CHEM SOC, V123, P8634, DOI 10.1021/ja016234f; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; BUSSEAU I, 1994, GENETICS, V136, P585; Carper WR, 1997, J PHYS CHEM A, V101, P3246, DOI 10.1021/jp963338h; Cornell M, 1999, GENETICS, V152, P567; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Daragan VA, 1997, PROG NUCL MAG RES SP, V31, P63, DOI 10.1016/S0079-6565(97)00006-X; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Fostier M, 1998, GENETICS, V150, P1477; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hu H, 2004, PROTEOMICS, V4, P643, DOI 10.1002/pmic.200300632; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 1998, BIOCHEM CELL BIOL, V76, P341, DOI 10.1139/bcb-76-2-3-341; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; KESSLER H, 1988, ANGEW CHEM INT EDIT, V27, P490, DOI 10.1002/anie.198804901; Kim S, 2001, BIOCHEMISTRY-US, V40, P6776, DOI 10.1021/bi002700m; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Mazaleyrat SL, 2003, DEV BIOL, V255, P363, DOI 10.1016/S0012-1606(02)00086-6; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PENG JW, 1994, METHOD ENZYMOL, V239, P563; Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Wintjens R, 2001, J BIOL CHEM, V276, P25150, DOI 10.1074/jbc.M010327200; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	55	30	33	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34991	35000		10.1074/jbc.M404987200	http://dx.doi.org/10.1074/jbc.M404987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173166	hybrid			2022-12-27	WOS:000223134800111
J	Geoffroy, K; Wiernsperger, N; Lagarde, M; El Bawab, S				Geoffroy, K; Wiernsperger, N; Lagarde, M; El Bawab, S			Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SPHINGOSINE 1-PHOSPHATE; INDUCE APOPTOSIS; GROWTH-FACTOR; STRESS; METABOLISM; ACTIVATION; ALBUMIN; SPHINGOSINE-1-PHOSPHATE; INTERLEUKIN-1-BETA	Advanced glycation end-products ( AGE) are generated by chronic hyperglycaemia and may cause diabetic microvascular complications such as diabetic nephropathy. Many factors influence the development of diabetic nephropathy; however, dysregulation of mesangial cell ( MC) proliferation appears to play an early and crucial role. In this study, we investigated the effects of AGE on rat MC proliferation and the involvement of sphingolipids in the AGE response. Results show a bimodal effect of AGE on MC proliferation. Thus, low AGE concentrations (< 1 mu M) induced a significant increase (+26%) of MC proliferation, whereas higher concentrations (10 mu M) markedly reduced it (-24%). In parallel, AGE exerted biphasic effects on neutral ceramidase expression and activity. Low AGE concentrations increased neutral ceramidase activity and expression, whereas high AGE concentrations showed opposite effects. Surprisingly, neutral ceramidase modulation did not result in changes of ceramide levels. However, the AGE (10 mu M)-inhibitory effect on MC proliferation was associated with accumulation of sphingosine and was specifically prevented by blocking glucosylceramide synthesis, suggesting that the high AGE concentration effects are mediated by sphingosine and/or glycolipids. On the other hand, treatment of cells with low AGE concentrations led to an increase of sphingosine kinase activity and sphingosine-1-phosphate production that drove the increase of MC proliferation. Interestingly, in glomeruli isolated from streptozotocin-diabetic rats, a time-dependent modulation of ceramidase activity was observed as compared with controls. These results suggest that AGE regulate MC growth by modulating neutral ceramidase and endogenous sphingolipids.	Inst Natl Sci Appl, INSERM, UMR 585, MERCK Sante,Diabet Microangiopathy Res Unit, F-69621 Villeurbanne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon	El Bawab, S (corresponding author), Inst Natl Sci Appl, INSERM, UMR 585, MERCK Sante,Diabet Microangiopathy Res Unit, Bldg L Pasteur,20 Ave A Einstein, F-69621 Villeurbanne, France.	samer.elbawab@merck.fr						Bendayan M, 1998, KIDNEY INT, V54, P438, DOI 10.1046/j.1523-1755.1998.00030.x; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; CHAO R, 1992, J BIOL CHEM, V267, P23459; Chen S, 2001, KIDNEY INT, V59, P673, DOI 10.1046/j.1523-1755.2001.059002673.x; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; DANZE PM, 1987, CLIN CHIM ACTA, V166, P143, DOI 10.1016/0009-8981(87)90416-5; Denis U, 2002, FREE RADICAL BIO MED, V33, P236, DOI 10.1016/S0891-5849(02)00879-1; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; el Bawab Samer, 2002, Subcell Biochem, V36, P187; Feliers D, 2002, DIABETES, V51, P3290, DOI 10.2337/diabetes.51.11.3290; Forbes JM, 2003, J AM SOC NEPHROL, V14, pS254, DOI 10.1097/01.ASN.0000077413.41276.17; Franzen R, 2002, FEBS LETT, V532, P441, DOI 10.1016/S0014-5793(02)03727-4; Franzen R, 2002, J BIOL CHEM, V277, P46184, DOI 10.1074/jbc.M204034200; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Gennero I, 2002, J BIOL CHEM, V277, P12724, DOI 10.1074/jbc.M108933200; Hanafusa N, 2002, NEPHROL DIAL TRANSPL, V17, P580, DOI 10.1093/ndt/17.4.580; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; KENNEDY L, 1981, DIABETOLOGIA, V21, P94; Kim YS, 2001, J LAB CLIN MED, V138, P59, DOI 10.1067/mlc.2001.115494; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Ling X, 2001, LAB INVEST, V81, P845, DOI 10.1038/labinvest.3780294; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mene P, 2001, J NEPHROL, V14, P198; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Min JK, 2002, ANAL BIOCHEM, V303, P167, DOI 10.1006/abio.2002.5579; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Natalizio A, 2001, BIOCHEM BIOPH RES CO, V281, P78, DOI 10.1006/bbrc.2001.4295; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Olivera A, 2000, METHOD ENZYMOL, V311, P215; Perry DK, 2000, METHOD ENZYMOL, V312, P22; RASCH R, 1983, DIABETOLOGIA, V25, P280, DOI 10.1007/BF00279944; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; Sakurai S, 2003, J AM SOC NEPHROL, V14, pS259, DOI 10.1097/01.ASN.0000077414.59717.74; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sugiyama S, 1996, NEPHROL DIAL TRANSPL, V11, P91; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Tanji N, 2000, J AM SOC NEPHROL, V11, P1656, DOI 10.1681/ASN.V1191656; Tettamanti G, 2003, BIOCHIMIE, V85, P423, DOI 10.1016/S0300-9084(03)00047-6; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; Wolf G, 2000, KIDNEY INT, V58, pS59, DOI 10.1046/j.1523-1755.2000.07710.x; WU VY, 1995, BIOCHEM BIOPH RES CO, V207, P521, DOI 10.1006/bbrc.1995.1219; Yamagishi S, 2002, J BIOL CHEM, V277, P20309, DOI 10.1074/jbc.M202634200; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139	58	91	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34343	34352		10.1074/jbc.M403273200	http://dx.doi.org/10.1074/jbc.M403273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184394	hybrid			2022-12-27	WOS:000223134800034
J	Dimcheff, DE; Faasse, MA; McAtee, FJ; Portis, JL				Dimcheff, DE; Faasse, MA; McAtee, FJ; Portis, JL			Endoplasmic reticulum (ER) stress induced by a neurovirulent mouse retrovirus is associated with prolonged BiP binding and retention of a viral protein in the ER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; INDUCED SPONGIFORM NEURODEGENERATION; C RNA VIRUS; CELL-DEATH; ECOTROPIC RETROVIRUS; OXIDATIVE STRESS; GENE-EXPRESSION; PRION PROTEIN; WILD MICE; DISEASE	Some murine retroviruses cause a spongiform neurodegenerative disease exhibiting pathology resembling that observed in transmissible spongiform encephalopathies. The neurovirulence of these "spongiogenic retroviruses" is determined by the sequence of their respective envelope proteins, although the mechanisms of neurotoxicity are not understood. We have studied a highly neurovirulent virus called FrCas(E) that causes a rapidly progressive form of this disease. Recently, transcriptional markers of endoplasmic reticulum ( ER) stress were detected during the early preclinical period in the brains of FrCas(E)-infected mice. In contrast, ER stress was not observed in mice infected with an avirulent virus, F43, which carries a different envelope gene, suggesting a role for ER stress in disease pathogenesis. Here we have examined in NIH 3T3 cells the cause of this cellular stress response. The envelope protein of F43 bound BiP, a major ER chaperone, transiently and was processed normally through the secretory pathway. In contrast, the envelope protein of FrCasE bound to BiP for a prolonged period, was retained in the ER, and was degraded by the proteasome. Furthermore, engagement of the FrCasE envelope protein by ER quality control pathways resulted in decreased steady-state levels of this protein, relative to that of F43, both in NIH 3T3 cells and in the brains of infected mice. Thus, the ER stress induced by FrCasE appears to be initiated by inefficient folding of its viral envelope protein, suggesting that the neurodegenerative disease caused by this virus represents a protein misfolding disorder.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Portis, JL (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, 903 S 4th St, Hamilton, MT 59840 USA.	jportis@nih.gov	Faasse, Mark/AAD-4049-2019	Faasse, Mark/0000-0002-1524-7239	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000086, Z01AI000086] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ANDREWS JM, 1974, J NEUROPATH EXP NEUR, V33, P285, DOI 10.1097/00005072-197404000-00007; Askovic S, 2000, J VIROL, V74, P465, DOI 10.1128/JVI.74.1.465-473.2000; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CZUB S, 1994, LAB INVEST, V70, P711; DESGROSEILLERS L, 1984, J VIROL, V52, P356, DOI 10.1128/JVI.52.2.356-363.1984; Dimcheff DE, 2003, J VIROL, V77, P12617, DOI 10.1128/JVI.77.23.12617-12629.2003; Fujisawa R, 1998, J VIROL, V72, P5619, DOI 10.1128/JVI.72.7.5619-5625.1998; GARDNER MB, 1973, JNCI-J NATL CANCER I, V51, P1243, DOI 10.1093/jnci/51.4.1243; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Jousse C, 2004, BIOCHEM BIOPH RES CO, V313, P447, DOI 10.1016/j.bbrc.2003.07.020; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim HT, 2004, LAB INVEST, V84, P816, DOI 10.1038/labinvest.3700104; KLEMENT V, 1976, J NATL CANCER I, V57, P1169, DOI 10.1093/jnci/57.5.1169; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Liu N, 2002, J NEUROVIROL, V8, P318, DOI 10.1080/13550280290100699; Lobigs M, 2003, IMMUNOL CELL BIOL, V81, P217, DOI 10.1046/j.1440-1711.2003.01161.x; LUI N, 2004, J NEUROVIROL, V10, P189; LYNCH WP, 1991, NEURON, V7, P365, DOI 10.1016/0896-6273(91)90289-C; Lynch WP, 1996, J VIROL, V70, P8896, DOI 10.1128/JVI.70.12.8896-8907.1996; LYNCH WP, 1995, J VIROL, V69, P1408, DOI 10.1128/JVI.69.3.1408-1419.1995; Lynch WP, 2000, J VIROL, V74, P1558, DOI 10.1128/JVI.74.3.1558-1565.2000; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; MASUDA M, 1992, J VIROL, V66, P2798, DOI 10.1128/JVI.66.5.2798-2806.1992; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mollace V, 2001, TRENDS NEUROSCI, V24, P411, DOI 10.1016/S0166-2236(00)01819-1; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; PORTIS JL, 1990, J VIROL, V64, P1648, DOI 10.1128/JVI.64.4.1648-1656.1990; Portis JL, 2001, ADV VIRUS RES, V56, P3, DOI 10.1016/S0065-3527(01)56003-0; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SHIKOVA E, 1993, J VIROL, V67, P1137, DOI 10.1128/JVI.67.3.1137-1147.1993; Swanstrom R., 1997, P263; SWARZ JR, 1981, NEUROPATH APPL NEURO, V7, P365, DOI 10.1111/j.1365-2990.1981.tb00239.x; SZUREK PF, 1990, J VIROL, V64, P467, DOI 10.1128/JVI.64.2.467-475.1990; Terro F, 2002, J NEUROSCI RES, V69, P530, DOI 10.1002/jnr.10312; Tobisawa S, 2003, BIOCHEM BIOPH RES CO, V303, P496, DOI 10.1016/S0006-291X(03)00353-X; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Vallat-Decouvelaere AV, 2003, J NEUROPATH EXP NEUR, V62, P475, DOI 10.1093/jnen/62.5.475; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Wilt SG, 2000, J NEUROSCI RES, V62, P440, DOI 10.1002/1097-4547(20001101)62:3<440::AID-JNR14>3.3.CO;2-D; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	57	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33782	33790		10.1074/jbc.M403304200	http://dx.doi.org/10.1074/jbc.M403304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178688	hybrid			2022-12-27	WOS:000223039700087
J	Khurana, B; Kristie, TM				Khurana, B; Kristie, TM			A protein sequestering system reveals control of cellular programs by the transcriptional coactivator HCF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; LEUCINE-ZIPPER PROTEIN; DNA-DAMAGE; C1 HCF; VP16-INDUCED COMPLEX; ATF3 INDUCTION; HOMEO DOMAIN; VP16; PROLIFERATION; FAMILY	The mammalian transcriptional coactivator HCF-1 is a critical component of the multiprotein herpes simplex virus immediate early gene enhancer core complex. The protein has also been implicated in basic cellular processes such as cell-cycle progression, transcriptional coactivation, and mRNA processing. Functions have been attributed to HCF-1 primarily from analyses of protein-protein interactions and from the cell-cycle-arrested phenotype of an HCF-1 temperature-sensitive mutant. However, neither the mechanisms involved nor specific cellular transcriptional targets have been identified. As the protein is essential for cell viability and proliferation, a genetic system was developed to specifically sequester the nuclear factor in the cell cytoplasm in a regulated manner. This approach exhibits no significant cell toxicity yet clearly demonstrates the requirement of available nuclear HCF-1 for herpes simplex virus immediate early gene expression during productive infection. Additionally, cellular transcriptional events were identified that contribute to understanding the functions ascribed to the protein and implicate the protein in events that impact the regulation of critical cellular processes.	NIH, Viral Dis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Kristie, TM (corresponding author), NIH, Viral Dis Lab, Bldg 4,Rm 131,4 Ctr Dr, Bethesda, MD 20892 USA.	thomas_Kristie@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000711, Z01AI000711] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe T, 2003, BIOCHEM BIOPH RES CO, V310, P1168, DOI 10.1016/j.bbrc.2003.09.143; Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ajuh P, 2002, EMBO J, V21, P6590, DOI 10.1093/emboj/cdf652; Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Beverdam A, 2002, GENESIS, V34, P221, DOI 10.1002/gene.10156; Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Finch JS, 2002, J CANCER RES CLIN, V128, P3, DOI 10.1007/s00432-001-0298-x; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; Julien E, 2003, EMBO J, V22, P2360, DOI 10.1093/emboj/cdg242; Kanamori M, 2003, J BIOL CHEM, V278, P38758, DOI 10.1074/jbc.M306324200; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Liu Y, 1999, GENE DEV, V13, P1692, DOI 10.1101/gad.13.13.1692; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2003, J BIOL CHEM, V278, P51116, DOI 10.1074/jbc.M303470200; Luciano RL, 2002, P NATL ACAD SCI USA, V99, P13403, DOI 10.1073/pnas.202200399; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Myung K, 1998, P NATL ACAD SCI USA, V95, P7664, DOI 10.1073/pnas.95.13.7664; Myung K, 1997, EMBO J, V16, P3172, DOI 10.1093/emboj/16.11.3172; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nicolas M, 2003, BIOCHEM J, V371, P265, DOI 10.1042/BJ20021166; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; Roizman Bernard, 1996, P1043; Scarr RB, 2000, MOL CELL BIOL, V20, P3568, DOI 10.1128/MCB.20.10.3568-3575.2000; Scarr RB, 2002, ONCOGENE, V21, P5245, DOI 10.1038/sj.onc.1205647; Simone C, 2002, ONCOGENE, V21, P4158, DOI 10.1038/sj.onc.1205511; SYVAOJA JE, 1990, BIOESSAYS, V12, P533, DOI 10.1002/bies.950121106; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; VOGEL JL, 2001, ENCY MOL MED, V1, P732; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	59	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33673	33683		10.1074/jbc.M401255200	http://dx.doi.org/10.1074/jbc.M401255200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15190068	hybrid			2022-12-27	WOS:000223039700077
J	Qi, C; Kashireddy, P; Zhu, YWT; Rao, SM; Zhu, YJ				Qi, C; Kashireddy, P; Zhu, YWT; Rao, SM; Zhu, YJ			Null mutation of peroxisome proliferator-activated receptor-interacting protein in mammary glands causes defective mammopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PROGESTERONE-RECEPTOR; COACTIVATOR PRIP; BINDING PROTEIN; ESTROGEN; GENE; DIFFERENTIATION; EXPRESSION; MICE; TUMORIGENESIS	To investigate the role of nuclear receptor coactivator peroxisome proliferator-activated receptor-interacting protein ( PRIP) in mammary gland development, we generated a conditional null mutation of PRIP in mammary glands. In PRIP-deficient mammary glands, the elongation of ducts during puberty was not affected, but the numbers of ductal branches were decreased, a condition that persisted long after puberty, indicating that the potential of ductal branching was impaired. During pregnancy, PRIP-deficient mammary glands exhibited decreased alveolar density. The lactating PRIP-deficient glands contained scant lobuloalveoli with many adipocytes, whereas the wild type glands were composed of virtually no adipocytes but mostly lobuloalveoli. As a result, PRIP mammary-deficient glands could not produce enough milk to nurse all the pups during lactation. The ductal branching of mammary glands in response to estrogen treatment was attenuated in PRIP mutant glands. Whereas the proliferation index was similar between wild type and PRIP-deficient glands, increased apoptosis was observed in PRIP-deficient glands. PRIP-deficient glands expressed increased amphiregulin, transforming growth factor-alpha, and betacellulin mRNA as compared with wild type glands. The differentiated function of PRIP-deficient mammary epithelial cells was largely intact, as evidenced by the expression of abundant beta-casein, whey acidic protein (WAP), and WDNM1 mRNA. We conclude that PRIP is important for normal mammary gland development.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Zhu, YJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E chicago Ave, Chicago, IL 60611 USA.	y-zhu2@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA088898, R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84472, CA 88898] Funding Source: Medline; NIEHS NIH HHS [K08 ES 00356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2002, J MAMMARY GLAND BIOL, V7, P39, DOI 10.1023/A:1015718406329; Brisken C, 2000, GENE DEV, V14, P650; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Charpentier AH, 2000, CANCER RES, V60, P5977; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gallahan D, 1996, CANCER RES, V56, P1775; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Medina D, 2001, CANCER LETT, V169, P1, DOI 10.1016/S0304-3835(01)00507-9; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Murphy LC, 2002, BIOMED PHARMACOTHER, V56, P65, DOI 10.1016/S0753-3322(01)00157-3; Nass SJ, 1999, HEMATOL ONCOL CLIN N, V13, P311, DOI 10.1016/S0889-8588(05)70058-7; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; YANG J, 1980, P NATL ACAD SCI-BIOL, V77, P2088, DOI 10.1073/pnas.77.4.2088; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2003, J BIOL CHEM, V278, P1986, DOI 10.1074/jbc.C200634200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	40	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33696	33701		10.1074/jbc.M401266200	http://dx.doi.org/10.1074/jbc.M401266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161927	hybrid			2022-12-27	WOS:000223039700079
J	Sato, S; Fujita, N; Tsuruo, T				Sato, S; Fujita, N; Tsuruo, T			Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; RNA INTERFERENCE; C ISOFORMS; ACTIVATION; PHOSPHORYLATION; BINDING; RAF; IDENTIFICATION; MEK; INHIBITION	The phosphatidylinositide-3-OH kinase/3-phosphoinositide-dependent protein kinase-1 (PDK1)/Akt and the Raf/mitogen-activated protein kinase (MAPK/ERK) kinase (MEK)/mitogen-activated protein kinase ( MAPK) pathways have central roles in the regulation of cell survival and proliferation. Despite their importance, however, the cross-talk between these two pathways has not been fully understood. Here we report that PDK1 promotes MAPK activation in a MEK-dependent manner. In vitro kinase assay revealed that the direct targets of PDK1 in the MAPK pathway were the upstream MAPK kinases MEK1 and MEK2. The identified PDK1 phosphorylation sites in MEK1 and MEK2 are Ser(222) and Ser(226), respectively, and are known to be essential for full activation. To date, these sites are thought to be phosphorylated by Raf kinases. However, PDK1 gene silencing using small interference RNA demonstrates that PDK1 is associated with maintaining the steady-state phosphorylated MEK level and cell growth. The small interference RNA-mediated down-regulation of PDK1 attenuated maximum MEK and MAPK activities but could not prolong MAPK signaling duration. Stable and transient expression of constitutively active MEK1 overcame these effects. Our results suggest a novel cross-talk between the phosphatidylinositide-3-OH kinase/PDK1/Akt pathway and the Raf/MEK/MAPK pathway.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cioca DP, 2003, CANCER GENE THER, V10, P125, DOI 10.1038/sj.cgt.7700544; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Corbit KC, 2000, MOL CELL BIOL, V20, P5392, DOI 10.1128/MCB.20.15.5392-5403.2000; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	43	87	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33759	33767		10.1074/jbc.M402055200	http://dx.doi.org/10.1074/jbc.M402055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175348	hybrid			2022-12-27	WOS:000223039700085
J	Cordeiro, Y; Kraineva, J; Ravindra, R; Lima, LMTR; Gomes, MPB; Foguel, D; Winter, R; Silva, JL				Cordeiro, Y; Kraineva, J; Ravindra, R; Lima, LMTR; Gomes, MPB; Foguel, D; Winter, R; Silva, JL			Hydration and packing effects on prion folding and beta-sheet conversion - High pressure spectroscopy and pressure perturbation calorimetry studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL TRANSITIONS; SECONDARY STRUCTURE; SCRAPIE PRION; HYDROSTATIC-PRESSURE; ALPHA-HELICES; NMR STRUCTURE; PROTEIN; AGGREGATION; STABILITY; FTIR	The main hypothesis for prion diseases proposes that the cellular protein (PrPC) can be altered into a misfolded, beta-sheet-rich isoform (PrPSc), which undergoes aggregation and triggers the onset of transmissible spongiform encephalopathies. Here, we compare the stability against pressure and the thermomechanical properties of the alpha-helical and beta-sheet conformations of recombinant murine prion protein, designated as alpha-rPrP and beta-rPrP, respectively. High temperature induces aggregates and a large gain in intermolecular antiparallel beta-sheet (beta-rPrP), a conformation that shares structural similarity with PrPSc.alpha-rPrP is highly stable, and only pressures above 5 kilobars (1 kilobar = 100 MegaPascals) cause reversible denaturation, a process that leads to a random and turn-rich conformation with concomitant loss of alpha-helix, as measured by Fourier transform infrared spectroscopy. In contrast, aggregates of beta-rPrP are very sensitive to pressure, undergoing transition into a dissociated species that differs from the denatured form derived from alpha-rPrP. The higher susceptibility to pressure of beta-rPrP can be explained by its less hydrated structure. Pressure perturbation calorimetry supports the view that the accessible surface area of alpha-rPrP is much higher than that of alpha-rPrP, which explains the lower degree of hydration of alpha-rPrP. Our findings shed new light on the mechanism of prion conversion and show how water plays a prominent role. Our results allow us to propose a volume and free energy diagram of the different species involved in the conversion and aggregation. The existence of different folded conformations as well as different denatured states of PrP may explain the elusive character of its conversion into a pathogenic form.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil; Univ Dortmund, Dept Chem, D-44227 Dortmund, Germany; Univ Fed Rio de Janeiro, Fac Farm, Dept Medicamentos, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Dortmund University of Technology; Universidade Federal do Rio de Janeiro	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Macromol, Av Bauhinia 400,Bloco E S10, BR-21941590 Rio De Janeiro, Brazil.	Jerson@bioqmed.ufrj.br	Silva, Jerson/J-8984-2014; Lima, Luis Mauricio/AAL-2098-2021; Gomes, Mariana/A-6618-2013; SILVA, JERSON Lima/GRF-1442-2022; Cordeiro, Yraima/J-7619-2012	Silva, Jerson/0000-0001-9523-9441; SILVA, JERSON Lima/0000-0001-9523-9441; Cordeiro, Yraima/0000-0003-4278-212X; Winter, Roland/0000-0002-3512-6928; Foguel, Debora/0000-0001-7312-7115; TR Lima, Luis Mauricio/0000-0001-6020-0504				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200; Apetri AC, 2003, J BIOL CHEM, V278, P22187, DOI 10.1074/jbc.M302130200; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Brown P, 2003, P NATL ACAD SCI USA, V100, P6093, DOI 10.1073/pnas.1031826100; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 2003, NATURE, V425, P673, DOI 10.1038/425673a; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cohen FE, 1999, J MOL BIOL, V293, P313, DOI 10.1006/jmbi.1999.2990; Cordeiro Y, 2004, J BIOL CHEM, V279, P5346, DOI 10.1074/jbc.M312262200; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Dzwolak W, 2003, BIOCHEMISTRY-US, V42, P11347, DOI 10.1021/bi034879h; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; Foguel D, 2003, P NATL ACAD SCI USA, V100, P9831, DOI 10.1073/pnas.1734009100; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Herberhold H, 2003, J MOL BIOL, V330, P1153, DOI 10.1016/S0022-2836(03)00657-0; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; Inouye H, 1998, J STRUCT BIOL, V122, P247, DOI 10.1006/jsbi.1998.3998; Ishimaru D, 2003, BIOCHEMISTRY-US, V42, P9022, DOI 10.1021/bi034218k; ISMAIL AA, 1992, BIOCHIM BIOPHYS ACTA, V1121, P183, DOI 10.1016/0167-4838(92)90353-F; Jamin N, 2002, FEBS LETT, V529, P256, DOI 10.1016/S0014-5793(02)03353-7; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kuwata K, 2002, BIOCHEMISTRY-US, V41, P12277, DOI 10.1021/bi026129y; Lin LN, 2002, ANAL BIOCHEM, V302, P144, DOI 10.1006/abio.2001.5524; Martins SM, 2003, J BIOL CHEM, V278, P50449, DOI 10.1074/jbc.M307354200; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; OLIVEIRA AC, 1994, J MOL BIOL, V240, P184, DOI 10.1006/jmbi.1994.1433; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Panick G, 1999, BIOCHEMISTRY-US, V38, P6512, DOI 10.1021/bi982825f; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ravindra R, 2003, CHEMPHYSCHEM, V4, P359, DOI 10.1002/cphc.200390062; Rezaei H, 2002, J MOL BIOL, V322, P799, DOI 10.1016/S0022-2836(02)00856-2; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Royer CA, 2002, BBA-PROTEIN STRUCT M, V1595, P201, DOI 10.1016/S0167-4838(01)00344-2; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Torrent J, 2003, BIOCHEMISTRY-US, V42, P1318, DOI 10.1021/bi0269916; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; WONG PTT, 1985, APPL SPECTROSC, V39, P733, DOI 10.1366/0003702854250176; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	51	99	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32354	32359		10.1074/jbc.M404295200	http://dx.doi.org/10.1074/jbc.M404295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173173	hybrid			2022-12-27	WOS:000222849700047
J	Wang, L; Lin, HK; Hu, YC; Xie, SZ; Yang, L; Chang, CS				Wang, L; Lin, HK; Hu, YC; Xie, SZ; Yang, L; Chang, CS			Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; KINASE 3-BETA; CANCER CELLS; CYCLIN D1; C-MYC; NUCLEAR EXPORT; HEAT-SHOCK; PHOSPHORYLATION; INSULIN; INHIBITION	Androgens play important roles in the growth of normal prostate and prostate cancer via binding to the androgen receptor (AR). In addition to androgens, AR activity can also be modulated by selective growth factors and/or kinases. Here we report a new kinase signaling pathway by showing that AR transactivation was repressed by wild type glycogen synthase kinase 3beta (GSK3beta) or constitutively active S9A-GSK3beta in a dose-dependent manner. In contrast, the catalytically inactive kinase mutant GSK3beta showed little effect on the AR transactivation. The suppression of AR transactivation by GSK3beta was abolished by the GSK3beta inhibitor lithium chloride. The in vitro kinase assay showed that GSK3beta prefers to phosphorylate the amino terminus of AR that may lead to the suppression of activation function 1 activity located in the NH2-terminal region of AR. GSK3beta interrupted the interaction between the NH2 and COOH termini of AR, and overexpression of the constitutively active form of GSK3beta, S9A-GSK3beta, reduced the androgen-induced prostate cancer cell growth in stably transfected CWR22R cells. Together, our data demonstrated that GSK3beta may function as a repressor to suppress AR-mediated transactivation and cell growth, which may provide a new strategy to modulate the AR-mediated prostate cancer growth.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Hu, Yueh-Chiang/AAX-2370-2020	Hu, Yueh-Chiang/0000-0002-7992-0525; Chang, Chawnshang/0000-0001-8510-3516	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Balaji KC, 1997, UROLOGY, V50, P1007, DOI 10.1016/S0090-4295(97)00390-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen Y, 1998, ONCOGENE, V16, P1913, DOI 10.1038/sj.onc.1201719; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Cohen P, 1978, Biochem Soc Symp, P69; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; CULIG Z, 1995, EUR UROL, V27, P45; CULIG Z, 1994, CANCER RES, V54, P5474; DEGROOT RP, 1993, ONCOGENE, V8, P841; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; KOKONTIS J, 1994, CANCER RES, V54, P1566; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lau KF, 1999, J PEPT RES, V54, P85, DOI 10.1034/j.1399-3011.1999.00083.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Miyoshi Y, 2000, PROSTATE, V43, P225, DOI 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Papasozomenos SC, 2002, P NATL ACAD SCI USA, V99, P1140, DOI 10.1073/pnas.032646799; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Torres MA, 1999, MOL CELL BIOL, V19, P1427; Truica CI, 2000, CANCER RES, V60, P4709; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; Wen Y, 2000, CANCER RES, V60, P6841; WOODGETT JR, 2001, SCI STKE; Yang L, 2003, BIOCHEM BIOPH RES CO, V305, P462, DOI 10.1016/S0006-291X(03)00792-7; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	57	78	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32444	32452		10.1074/jbc.M313963200	http://dx.doi.org/10.1074/jbc.M313963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15178691	hybrid			2022-12-27	WOS:000222849700058
J	Cetin, S; Ford, HR; Sysko, LR; Agarwal, C; Wang, J; Neal, MD; Baty, C; Apodaca, G; Hackam, DJ				Cetin, S; Ford, HR; Sysko, LR; Agarwal, C; Wang, J; Neal, MD; Baty, C; Apodaca, G; Hackam, DJ			Endotoxin inhibits intestinal epithelial restitution through activation of Rho-GTPase and increased focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; NECROTIZING ENTEROCOLITIS; ENTEROCYTE PROLIFERATION; BINDING PROTEIN; GROWTH-FACTOR; KAPPA-B; LIPOPOLYSACCHARIDE; MD-2	Diseases of gut inflammation such as neonatal necrotizing enterocolitis (NEC) result after an injury to the mucosal lining of the intestine, leading to translocation of bacteria and endotoxin ( lipopolysaccharide). Intestinal mucosal defects are repaired by the process of intestinal restitution, during which enterocytes migrate from healthy areas to sites of injury. In an animal model of NEC, we determined that intestinal restitution was significantly impaired compared with control animals. We therefore sought to determine the mechanisms governing enterocyte migration under basal conditions and after an endotoxin challenge. Here we show that the cytoskeletal reorganization and stress fiber formation required for migration in IEC-6 enterocytes requires RhoA. Enterocytes were found to express the endotoxin receptor Toll-like receptor 4, which served to bind and internalize lipopolysaccharide. Strikingly, endotoxin treatment significantly inhibited intestinal restitution, as measured by impaired IEC-6 cell migration across a scraped wound. Lipopolysaccharide was found to increase RhoA activity in a phosphatidylinositol 3-kinase-dependent manner, leading to an increase in phosphorylation of focal adhesion kinase and an enhanced number of focal adhesions. Importantly, endotoxin caused a progressive, RhoA-dependent increase in cell matrix tension/contractility, which correlated with the observed impairment in enterocyte migration. We therefore conclude that endotoxin inhibits enterocyte migration through a RhoA-dependent increase in focal adhesions and enhanced cell adhesiveness, which may participate in the impaired restitution observed in experimental NEC.	Childrens Hosp Pittsburgh, Div Pediat Surg, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hackam, DJ (corresponding author), Childrens Hosp Pittsburgh, Div Pediat Surg, Dept Surg, Rm 4A-486 DeSoto Wing,3705 5th Ave, Pittsburgh, PA 15213 USA.	david.hackam@chp.edu	Neal, Matthew/GMW-5601-2022	Neal, Matthew/0000-0001-8931-6236; Hackam, David/0000-0001-5195-8807	NIAID NIH HHS [R01 AI-49473-01, R01-AI-14032-20] Funding Source: Medline; NIDDK NIH HHS [R01 DK51970-06] Funding Source: Medline; NIGMS NIH HHS [K08 GM65583-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014032, R01AI049473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051970] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Amer MD, 2004, BIOL NEONATE, V85, P159, DOI 10.1159/000075306; Atabai K, 2002, AM J PHYSIOL-LUNG C, V283, pL163, DOI 10.1152/ajplung.00396.2001; Basson MD, 2001, LIFE SCI, V69, P3005, DOI 10.1016/S0024-3205(01)01408-4; Berseth CL, 2003, PEDIATRICS, V111, P529, DOI 10.1542/peds.111.3.529; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Burridge K, 1999, SCIENCE, V283, P2028, DOI 10.1126/science.283.5410.2028; Bury RG, 2001, COCHRANE DB SYST REV, V2001, pCD000405, DOI DOI 10.1002/14651858.CD000405; Campbell BH, 2003, J BIOMECH, V36, P137, DOI 10.1016/S0021-9290(02)00325-1; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; de Plaen IG, 2002, IMMUNOLOGY, V106, P577, DOI 10.1046/j.1365-2567.2002.01453.x; Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725-200102000-00014; Duffy LC, 2001, ADV EXP MED BIOL, V501, P519; Ewer AK, 2004, GUT, V53, P207, DOI 10.1136/gut.2003.024521; Forsythe RM, 2002, SHOCK, V17, P180, DOI 10.1097/00024382-200203000-00004; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; Guthrie Scott O, 2003, J Perinatol, V23, P278, DOI 10.1038/sj.jp.7210892; Hackam D. J., 2002, SURG INFECT LARCHMT, V3, P23, DOI DOI 10.1089/10962960260496316; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halpern MD, 2003, AM J PHYSIOL-GASTR L, V284, pG695, DOI 10.1152/ajpgi.00353.2002; Han XN, 2004, SHOCK, V21, P261, DOI 10.1097/01.shk.0000112346.38599.10; Hirabayashi T, 2000, EUR J BIOCHEM, V267, P2525, DOI 10.1046/j.1432-1327.2000.01258.x; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Houle VM, 2000, PEDIATR RES, V48, P497, DOI 10.1203/00006450-200010000-00013; Kafetzis DA, 2003, CURR OPIN INFECT DIS, V16, P349, DOI 10.1097/00001432-200308000-00007; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Lavelle J, 2002, AM J PHYSIOL-RENAL, V283, pF242, DOI 10.1152/ajprenal.00307.2001; Le Roy D, 2001, J IMMUNOL, V167, P2759, DOI 10.4049/jimmunol.167.5.2759; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Longo WE, 1998, MEDIAT INFLAMM, V7, P85, DOI 10.1080/09629359891225; Mammen JMV, 2003, CRIT CARE MED, V31, pS532, DOI 10.1097/01.CCM.0000081429.89277.AF; Medvedev AE, 2003, J ENDOTOXIN RES, V9, P60, DOI 10.1179/096805103125001360; Mercer BM, 1997, JAMA-J AM MED ASSOC, V278, P989, DOI 10.1001/jama.278.12.989; Mishima S, 1997, ARCH SURG-CHICAGO, V132, P1190; Nadler EP, 2000, J SURG RES, V92, P71, DOI 10.1006/jsre.2000.5877; Nieuwenhuijzen GAP, 1996, J ANAT, V189, P537; Noerr Barbara, 2003, Adv Neonatal Care, V3, P107; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; Potoka DA, 2003, AM J PHYSIOL-GASTR L, V285, pG861, DOI 10.1152/ajpgi.00412.2002; Potoka DA, 2002, WORLD J SURG, V26, P806, DOI 10.1007/s00268-002-4056-2; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Suzuki M, 2003, INFECT IMMUN, V71, P3503, DOI 10.1128/IAI.71.6.3503-3511.2003; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wang Q, 1998, J SURG RES, V76, P27, DOI 10.1006/jsre.1998.5288	62	107	114	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24592	24600		10.1074/jbc.M313620200	http://dx.doi.org/10.1074/jbc.M313620200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15169791	hybrid			2022-12-27	WOS:000221702500089
J	Phillips, JD; Whitby, FG; Warby, CA; Labbe, P; Yang, C; Pflugrath, JW; Ferrara, JD; Robinson, H; Kushner, JP; Hill, CP				Phillips, JD; Whitby, FG; Warby, CA; Labbe, P; Yang, C; Pflugrath, JW; Ferrara, JD; Robinson, H; Kushner, JP; Hill, CP			Crystal structure of the oxygen-dependant coproporphyrinogen oxidase (Hem13p) of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III OXIDASE; HEREDITARY COPROPORPHYRIA; ESCHERICHIA-COLI; ACTIVE-SITE; IN-HOUSE; CHOLESTEROL OXIDASE; RADICAL SAM; T-FOLD; SEQUENCE; PROTEIN	Coproporphyrinogen oxidase (CPO) is an essential enzyme that catalyzes the sixth step of the heme biosynthetic pathway. Unusually for heme biosynthetic enzymes, CPO exists in two evolutionarily and mechanistically distinct families, with eukaryotes and some prokaryotes employing members of the highly conserved oxygen-dependent CPO family. Here, we report the crystal structure of the oxygen-dependent CPO from Saccharomyces cerevisiae (Hem13p), which was determined by optimized sulfur anomalous scattering and refined to a resolution of 2.0 Angstrom. The protein adopts a novel structure that is quite different from predicted models and features a central flat seven-stranded antiparallel sheet that is flanked by helices. The dimeric assembly, which is seen in different crystal forms, is formed by packing of helices and a short isolated strand that forms a beta-ladder with its counterpart in the partner subunit. The deep active-site cleft is lined by conserved residues and has been captured in open and closed conformations in two different crystal forms. A substratesized cavity is completely buried in the closed conformation by the similar to8-Angstrom movement of a helix that forms a lid over the active site. The structure therefore suggests residues that likely play critical roles in catalysis and explains the deleterious effect of many of the mutations associated with the disease hereditary coproporphyria.	Univ Utah, Sch Med, Dept Med, Div Hematol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Paris 07, CNRS, Inst Jacques Monod, Lab Biochim Porphyrines, F-75251 Paris 5, France; Rigaku Mol Struct Corp, The Woodlands, TX 77381 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; United States Department of Energy (DOE); Brookhaven National Laboratory	Hill, CP (corresponding author), Univ Utah, Sch Med, Dept Med, Div Hematol, 4C416 SOM,50 N 1900 E, Salt Lake City, UT 84132 USA.	chris@biochem.utah.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020503, R37DK020503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056775] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20503, R01 DK020503] Funding Source: Medline; NIGMS NIH HHS [GM56775, R01 GM056775] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOGARD M, 1989, EUR J BIOCHEM, V181, P417, DOI 10.1111/j.1432-1033.1989.tb14741.x; Breckau D, 2003, J BIOL CHEM, V278, P46625, DOI 10.1074/jbc.M308553200; CAMADRO JM, 1986, EUR J BIOCHEM, V156, P579, DOI 10.1111/j.1432-1033.1986.tb09617.x; Colloc'h N, 2002, FEBS LETT, V526, P5, DOI 10.1016/S0014-5793(02)03123-X; Colloc'h N, 2000, PROTEINS, V39, P142, DOI 10.1002/(SICI)1097-0134(20000501)39:2<142::AID-PROT4>3.0.CO;2-X; Coulombe R, 2001, J BIOL CHEM, V276, P30435, DOI 10.1074/jbc.M104103200; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; Daimon M, 1997, HUM GENET, V99, P199, DOI 10.1007/s004390050338; Debreczeni JE, 2003, ACTA CRYSTALLOGR D, V59, P2125, DOI 10.1107/S0907444903018973; Debreczeni JE, 2003, ACTA CRYSTALLOGR D, V59, P393, DOI 10.1107/S0907444902020917; ELDER GH, 1978, BIOCHEM J, V169, P205, DOI 10.1042/bj1690205; ELDER GH, 1978, BIOCHEM J, V172, P345, DOI 10.1042/bj1720345; ELDER GH, 1978, BIOCHEM J, V169, P215, DOI 10.1042/bj1690215; FUJITA H, 1994, HUM MOL GENET, V3, P1807, DOI 10.1093/hmg/3.10.1807; GRANDCHAMP B, 1978, BIOCHEM J, V176, P97, DOI 10.1042/bj1760097; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Jones MA, 2002, J BIOCHEM, V131, P201, DOI 10.1093/oxfordjournals.jbchem.a003088; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohno H, 1996, BBA-PROTEIN STRUCT M, V1292, P156, DOI 10.1016/0167-4838(95)00188-3; KRUSE E, 1995, PLANTA, V196, P796, DOI 10.1007/BF01106776; Labbe P, 1997, METHOD ENZYMOL, V281, P367; LAMORIL J, 1995, HUM MOL GENET, V4, P275, DOI 10.1093/hmg/4.2.275; Lamoril J, 2001, AM J HUM GENET, V68, P1130, DOI 10.1086/320118; Lamoril J, 1997, HUM MUTAT, V9, P78; Lario PI, 2003, J MOL BIOL, V326, P1635, DOI 10.1016/S0022-2836(03)00054-8; Lash TD, 2002, BIOORG MED CHEM LETT, V12, P451, DOI 10.1016/S0960-894X(01)00774-0; Lash TD, 2001, J ORG CHEM, V66, P3753, DOI 10.1021/jo001697+; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Martasek P, 1998, SEMIN LIVER DIS, V18, P25, DOI 10.1055/s-2007-1007137; MARTASEK P, 1994, HUM MOL GENET, V3, P477, DOI 10.1093/hmg/3.3.477; Martasek P, 1997, CELL MOL BIOL, V43, P47; Medlock AE, 1996, J BIOL CHEM, V271, P32507, DOI 10.1074/jbc.271.51.32507; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Olsen JG, 2004, ACTA CRYSTALLOGR D, V60, P618, DOI 10.1107/S0907444904002598; Olsen JG, 2004, ACTA CRYSTALLOGR D, V60, P250, DOI 10.1107/S0907444903025927; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Phillips JD, 2003, EMBO J, V22, P6225, DOI 10.1093/emboj/cdg606; Ramagopal UA, 2003, ACTA CRYSTALLOGR D, V59, P868, DOI 10.1107/S0907444903005663; Rosipal R, 1999, HUM MUTAT, V13, P44, DOI 10.1002/(SICI)1098-1004(1999)13:1<44::AID-HUMU5>3.0.CO;2-Q; SANO S, 1966, J BIOL CHEM, V241, P5276; SANO S, 1961, J BIOL CHEM, V236, P1173; Schreiber WE, 1997, HUM MUTAT, V10, P196; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wiman A, 2002, J HUM GENET, V47, P407, DOI 10.1007/s100380200059; Yang C, 2003, ACTA CRYSTALLOGR D, V59, P1943, DOI 10.1107/S0907444903018547; Yoshinaga T, 1997, METHOD ENZYMOL, V281, P355; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	55	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38960	38968		10.1074/jbc.M406050200	http://dx.doi.org/10.1074/jbc.M406050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15194705	hybrid			2022-12-27	WOS:000223684100110
J	Bassett, MH; Suzuki, T; Sasano, H; de Vries, CJM; Jimenez, PT; Carr, BR; Rainey, WE				Bassett, MH; Suzuki, T; Sasano, H; de Vries, CJM; Jimenez, PT; Carr, BR; Rainey, WE			The orphan nuclear receptor NGFIB regulates transcription of 3 beta-hydroxysteroid dehydrogenase - Implications for the control of adrenal functional zonation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN-FETAL; STEROID 21-HYDROXYLASE; FACTOR-I; EXPRESSION; CELLS; GENE; ISOMERASE; CORTEX; STEROIDOGENESIS	3beta-Hydroxysteroid dehydrogenase type 2 (HSD3B2) is a steroid-metabolizing enzyme that is essential for adrenal production of mineralocorticoids and glucocorticoids. Thus, HSD3B2 is expressed at high levels in the glomerulosa and fasciculata, where these steroids are produced. In contrast, the production of dehydroepiandrosterone ( DHEA) and DHEA sulfate in the adrenal reticularis is inversely correlated with the expression of HSD3B2. The reasons for the zonal expression of HSD3B2 are not known but represent an important aspect in the biochemical zonation of the adrenal. Using microarray, real time reverse transcriptase- PCR, immunohistochemistry, and HSD3B2 promoter analysis, we demonstrate that the NGFIB family of nuclear hormone receptors plays a critical part in the regulation of HSD3B2 transcription and may play an important role in the functional zonation of the adrenal gland. Microarray analysis of cortisol-versus DHEA sulfate-producing adrenal tissue demonstrated that NGIFB paralleled expression of HSD3B2 with expression much higher in cortisol-producing adrenal tissue; this observation was also demonstrated using real time reverse transcriptase-PCR analysis. In addition, immunohistochemistry confirmed that within adult and fetal adrenal gland NGFIB expression paralleled expression of HSD3B2. Transient transfections into H295R adrenal cells demonstrated that NGFIB family members enhanced HSD3B2 reporter activity but had no effect on a 17alpha-hydroxylase (CYP17) promoter construct. Deletion and mutational analyses of the 5'-flanking region of the HSD3B2 gene identified a consensus NGFIB response element that bound NGFIB in mobility shift assays. Infection of cultured human adrenal cells with adenovirus-containing NGFIB increased cortisol production by 8-fold and increased expression of HSD3B2 mRNA 26-fold over that observed in mock-infected cells. In primary cultures of adrenal cells, ACTH, an activator of HSD3B2, rapidly induced expression of NGFIB. These results suggest that NGFIB plays a crucial role in adrenal zonation by regulating HSD3B2 gene transcription.	Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol, Dallas, TX 75390 USA; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808575, Japan; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tohoku University; University of Amsterdam; Academic Medical Center Amsterdam	Rainey, WE (corresponding author), Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	braine@mednet.swmed.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007190, P50HD011149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043140, R01DK069950, R29DK043140] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11149, T32-HD07190] Funding Source: Medline; NIDDK NIH HHS [DK069950, DK43140] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Bandoh S, 1997, J NEUROENDOCRINOL, V9, P3, DOI 10.1046/j.1365-2826.1997.00571.x; Bassett MH, 2004, MOL ENDOCRINOL, V18, P279, DOI 10.1210/me.2003-0005; Bassett MH, 2002, J MOL ENDOCRINOL, V28, P125, DOI 10.1677/jme.0.0280125; Bird IM, 1998, ENDOCR RES, V24, P345, DOI 10.3109/07435809809032614; BYRNE GC, 1986, J CLIN ENDOCR METAB, V62, P413, DOI 10.1210/jcem-62-2-413; CHANG SF, 1995, MOL ENDOCRINOL, V9, P1330, DOI 10.1210/me.9.10.1330; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Conley AJ, 1997, BIOL REPROD, V56, P789, DOI 10.1095/biolreprod56.4.789; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; DOODY KM, 1990, ENDOCRINOLOGY, V126, P2487, DOI 10.1210/endo-126-5-2487; Endoh A, 1996, J CLIN ENDOCR METAB, V81, P3558, DOI 10.1210/jc.81.10.3558; FUJIEDA K, 1982, J CLIN ENDOCR METAB, V54, P89, DOI 10.1210/jcem-54-1-89; Gell JS, 1998, J CLIN ENDOCR METAB, V83, P3695, DOI 10.1210/jc.83.10.3695; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Hanley NA, 2001, MOL ENDOCRINOL, V15, P57, DOI 10.1210/me.15.1.57; Jimenez P, 2003, ENDOCRINOLOGY, V144, P4285, DOI 10.1210/en.2003-0472; LACK EE, 1990, PATHOLOGY ADRENAL GL, P1; Le Roy C, 2000, ENDOCRINOLOGY, V141, P1599, DOI 10.1210/en.141.5.1599; LeersSucheta S, 1997, J BIOL CHEM, V272, P7960, DOI 10.1074/jbc.272.12.7960; LU L, 2004, IN PRESS J CLIN ENDO; Maruyama K, 1998, INT J ONCOL, V12, P1237; MASON JI, 1993, J STEROID BIOCHEM, V47, P151, DOI 10.1016/0960-0760(93)90069-9; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Narasaka T, 2001, MOL CELL ENDOCRINOL, V174, P111, DOI 10.1016/S0303-7207(00)00445-7; PARKER CR, 1995, ENDOCR RES, V21, P69, DOI 10.3109/07435809509030422; Rainey WE, 2001, J ENDOCRINOL, V171, P209, DOI 10.1677/joe.0.1710209; SASANO H, 1990, ENDOCR PATHOL, V1, P739; Sasano Hironobu, 1990, Endocr Pathol, V1, P94, DOI 10.1007/BF02915624; SIMARD J, 1991, J BIOL CHEM, V266, P14842; SIMONIAN MH, 1984, J CLIN ENDOCR METAB, V59, P643, DOI 10.1210/jcem-59-4-643; STANKOVIC AK, 1994, MOL CELL ENDOCRINOL, V99, P145, DOI 10.1016/0303-7207(94)90002-7; Suzuki T, 2000, CLIN ENDOCRINOL, V53, P739, DOI 10.1046/j.1365-2265.2000.01144.x; Wang WY, 2001, MOL CELL ENDOCRINOL, V173, P127, DOI 10.1016/S0303-7207(00)00404-4; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	39	106	107	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37622	37630		10.1074/jbc.M405431200	http://dx.doi.org/10.1074/jbc.M405431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208301	hybrid			2022-12-27	WOS:000223554600053
J	Hu, WH; Mo, XM; Walters, WM; Brambilla, R; Bethea, JR				Hu, WH; Mo, XM; Walters, WM; Brambilla, R; Bethea, JR			TNAP, a novel repressor of NF-kappa B-inducing kinase, suppresses NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; GENE-EXPRESSION; IKK-ALPHA; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL REGULATION; TRANSACTIVATION DOMAIN; MEDIATED DELIVERY; NF-KAPPA-B2 P100; CELL ACTIVATION; BINDING-SITE	NF-kappaB- inducing kinase (NIK) has been implicated as an essential component of NF-kappaB activation. However, the regulatory mechanism of NIK signaling remains elusive. We have identified a novel NIK interacting protein, TNAP ( for (T) under bar RAFs and (N) under bar IK- (a) under bar ssociated (p) under bar rotein). In mammalian cells, TNAP physically interacts with NIK, TRAF2, and TRAF3 but not IKK1 or IKK2. TNAP specifically inhibits NF-kappaB activation induced by tumor necrosis factor (TNF)-alpha, TNF receptor 1, TRADD, RIP, TRAF2, and NIK but does not affect IKK1- and IKK2-mediated NF-kappaB activation. Knockdown of TNAP by lentiviral-mediated small interference RNA potentiates TNF-alpha-induced NF-kappaB activation. TNAP suppresses NIK kinase activity and subsequently reduces p100 processing, p65 phosphorylation, and IkappaBalpha degradation. These data suggest that TNAP is a repressor of NIK activity and regulates both the classical and alternative NF-kappaB signaling pathways.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Max Delbrueck Ctr Mol Med, D-13122 Berlin, Germany	University of Miami; University of Miami; University of Miami; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Bethea, JR (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terr, Miami, FL 33136 USA.	jbethea@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037130] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37130] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bethea JR, 1997, J IMMUNOL, V158, P5815; Bethea JR, 1998, J NEUROSCI, V18, P3251; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; ERMEULEN L, 2003, EMBO J, V22, P1313; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Fotin-Mleczek M, 2004, J BIOL CHEM, V279, P677, DOI 10.1074/jbc.M310969200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ha YJ, 2004, J IMMUNOL, V172, P231, DOI 10.4049/jimmunol.172.1.231; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Haxhinasto SA, 2004, J BIOL CHEM, V279, P2575, DOI 10.1074/jbc.M310628200; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hu WH, 2002, J NEUROCHEM, V81, P36, DOI 10.1046/j.1471-4159.2002.00788.x; Hu WH, 1999, J NEUROTRAUM, V16, P85, DOI 10.1089/neu.1999.16.85; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Kajiura F, 2004, J IMMUNOL, V172, P2067, DOI 10.4049/jimmunol.172.4.2067; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Li XG, 2001, BIOCHEM BIOPH RES CO, V286, P587, DOI 10.1006/bbrc.2001.5442; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsumoto M, 2002, J IMMUNOL, V169, P1151, DOI 10.4049/jimmunol.169.3.1151; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Miyamoto S, 2004, MOL CELL, V13, P763, DOI 10.1016/S1097-2765(04)00158-3; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nho CW, 2004, J BIOL CHEM, V279, P26019, DOI 10.1074/jbc.M309022200; Nishitsuji H, 2004, MICROBES INFECT, V6, P76, DOI 10.1016/j.micinf.2003.10.009; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Patke A, 2004, CURR OPIN IMMUNOL, V16, P251, DOI 10.1016/j.coi.2004.01.007; Perkins ND, 2003, ONCOGENE, V22, P7553, DOI 10.1038/sj.onc.1207139; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Scherr M, 2003, CELL CYCLE, V2, P251, DOI 10.4161/cc.2.3.376; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Smith C, 2001, J IMMUNOL, V167, P5895, DOI 10.4049/jimmunol.167.10.5895; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; TAKADA Y, 2004, J BIOL CHEM; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Van den Haute C, 2003, HUM GENE THER, V14, P1799, DOI 10.1089/104303403322611809; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xie P, 2004, J EXP MED, V199, P661, DOI 10.1084/jem.20031255; Yamada T, 2000, J IMMUNOL, V165, P804, DOI 10.4049/jimmunol.165.2.804; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	96	29	31	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35975	35983		10.1074/jbc.M405699200	http://dx.doi.org/10.1074/jbc.M405699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208311	hybrid			2022-12-27	WOS:000223303400099
J	Price, LS; Hajdo-Milasinovic, A; Zhao, J; Zwartkruis, FJT; Collard, JG; Bos, JL				Price, LS; Hajdo-Milasinovic, A; Zhao, J; Zwartkruis, FJT; Collard, JG; Bos, JL			Rap1 regulates E-cadherin-mediated cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; DOWN-REGULATION; SMALL GTPASE; CYCLIC-AMP; MDCK CELLS; RHO FAMILY; ACTIVATION; RAS; PROTEIN; EXPRESSION	The small GTPase Rap is best characterized as a critical regulator of integrin-mediated cell adhesion, although its mechanism of action is not understood. Rap also influences the properties of other cell-surface receptors and biological processes, although whether these are a consequence of effects on integrins is not clear. We show here that Rap also plays an important role in the regulation of cadherin-mediated cell-cell adhesion in epithelial cells. Expression of constitutively active Rap1A restored cadherin-mediated cell-cell contacts in mesenchymal Ras-transformed Madin-Darby canine kidney cells, resulting in reversion to an epithelial phenotype. Activation of endogenous Rap via the Rap exchange factor Epac1 also antagonized hepatocyte growth factor-induced disruption of adherens junctions. Inhibition of Rap signaling resulted in disruption of epithelial cell-cell contacts. Rap activity was required for adhesion of cells to recombinant E-cadherin extracellular domains, i.e. in the absence of integrin-mediated adhesion. These findings suggest that Rap signaling positively contributes to cadherin-mediated adhesion and that this occurs independently of effects on integrin-mediated adhesion. Our results imply that Rap may function in a broader manner to regulate the function of cell-surface adhesion receptors.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute	Price, LS (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Stratenum Bldg,Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	l.s.price@med.uu.nl						Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bos JL, 2003, BIOCHEM SOC T, V31, P83, DOI 10.1042/bst0310083; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CLARK P, 1994, J CELL SCI, V107, P1265; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gimond C, 1999, J CELL BIOL, V147, P1325, DOI 10.1083/jcb.147.6.1325; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; Michiels F, 2000, METHOD ENZYMOL, V325, P295; Noe V, 1999, BIOCHEM SOC SYMP, V65, P43; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	47	170	174	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35127	35132		10.1074/jbc.M404917200	http://dx.doi.org/10.1074/jbc.M404917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15166221	hybrid			2022-12-27	WOS:000223303400002
J	Stojanovic, A; Stitham, J; Hwa, J				Stojanovic, A; Stitham, J; Hwa, J			Critical role of transmembrane segment zinc binding in the structure and function of rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINITIS-PIGMENTOSA; CRYSTAL-STRUCTURE; THERMAL-STABILITY; WATER-MOLECULES; DISULFIDE BOND; METHYL-GROUP; GLYCINE 121; HELICES 3; A-BETA; AGGREGATION	Zinc deficiency and retinitis pigmentosa are both important factors resulting in retinal dysfunction and night blindness. In this study, we address the critical biochemical and structural relevance of zinc ions in rhodopsin and examine whether zinc deficiency can lead to rhodopsin dysfunction. We report the identification of a high-affinity zinc coordination site within the transmembrane domain of rhodopsin, coordinated by the side chains of two highly conserved residues, Glu(122) in transmembrane helix III and His(211) in transmembrane helix V. We also demonstrate that this zinc coordination is critical for rhodopsin folding, 11-cis-retinal binding, and the stability of the chromophore-receptor interaction, defects of which are observed in retinitis pigmentosa. Furthermore, a cluster of retinitis pigmentosa mutations is localized within and around this zinc binding site. Based on these studies, we believe that improvement in zinc binding to rhodopsin at this site within the transmembrane domain may be a pharmacological approach for the treatment of select retinitis pigmentosa mutations. Transmembrane coordination of zinc may also be an important common principle across G-protein-coupled receptors.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Med, Cardiol Sect, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Hwa, J (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	John.Hwa@Dartmouth.edu						Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; Beck M, 1998, BIOCHEMISTRY-US, V37, P7630, DOI 10.1021/bi9801560; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Crow JP, 1997, J NEUROCHEM, V69, P1936; del Valle LJ, 2003, J BIOL CHEM, V278, P4719, DOI 10.1074/jbc.M210760200; Elam JS, 2003, J BIOL CHEM, V278, P21032, DOI 10.1074/jbc.M300484200; Finefrock AE, 2003, J AM GERIATR SOC, V51, P1143, DOI 10.1046/j.1532-5415.2003.51368.x; Furutani Y, 2003, BIOCHEMISTRY-US, V42, P9619, DOI 10.1021/bi034592k; Gerlach LO, 2003, BIOCHEMISTRY-US, V42, P710, DOI 10.1021/bi0264770; Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Han M, 1996, J BIOL CHEM, V271, P32330, DOI 10.1074/jbc.271.50.32330; Han M, 1997, P NATL ACAD SCI USA, V94, P13442, DOI 10.1073/pnas.94.25.13442; Han M, 1998, BIOCHEMISTRY-US, V37, P538, DOI 10.1021/bi972060w; Han M, 1996, J BIOL CHEM, V271, P32337, DOI 10.1074/jbc.271.50.32337; Han M, 1997, J BIOL CHEM, V272, P23081, DOI 10.1074/jbc.272.37.23081; Holst B, 2003, ANN NY ACAD SCI, V994, P1, DOI 10.1111/j.1749-6632.2003.tb03156.x; Holst B, 2002, J BIOL CHEM, V277, P47662, DOI 10.1074/jbc.M202103200; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 1999, P NATL ACAD SCI USA, V96, P1932, DOI 10.1073/pnas.96.5.1932; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; Lynch T, 2000, EXP GERONTOL, V35, P445, DOI 10.1016/S0531-5565(00)00112-1; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Schetz JA, 1997, J NEUROCHEM, V68, P1990; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SHUSTER TA, 1992, BIOCHEM J, V282, P123, DOI 10.1042/bj2820123; Stojanovic A, 2003, J BIOL CHEM, V278, P39020, DOI 10.1074/jbc.M303625200; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; SUNG CH, 1993, J BIOL CHEM, V268, P26645; Swaminath G, 2003, J BIOL CHEM, V278, P352, DOI 10.1074/jbc.M206424200; Swaminath G, 2002, MOL PHARMACOL, V61, P65, DOI 10.1124/mol.61.1.65; TAM SW, 1976, BIOCHEM BIOPH RES CO, V72, P302, DOI 10.1016/0006-291X(76)90994-3; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5; WEITZ CJ, 1992, NEURON, V8, P465, DOI 10.1016/0896-6273(92)90274-H	46	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35932	35941		10.1074/jbc.M403821200	http://dx.doi.org/10.1074/jbc.M403821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194703	hybrid			2022-12-27	WOS:000223303400094
J	Borras, C; Esteve, JM; Vina, JR; Sastre, J; Vina, J; Pallardo, FV				Borras, C; Esteve, JM; Vina, JR; Sastre, J; Vina, J; Pallardo, FV			Glutathione regulates telomerase activity in 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; MITOCHONDRIAL-DNA; OXIDATIVE DAMAGE; CANCER-CELLS; IN-VITRO; PROTEINS	Changes in telomerase activity have been associated either with cancer, when activity is increased, or with cell cycle arrest when it is decreased. We report that glutathione, a physiological antioxidant present at high intracellular concentrations, regulates telomerase activity in cells in culture. Telomerase activity increases in 3T3 fibroblasts before exponential cell growth. The peak of telomerase activity takes place 24 h after plating and coincides with the maximum levels of glutathione in the cells. When cells are treated with buthionine sulfoximine, which decreases glutathione levels in cells, telomerase activity decreases by 60%, and cell growth is delayed. Glutathione depletion inhibits expression of E2F4 and Id2, which regulate the cell cycle. When glutathione levels are restored after incubation with glutathione monoethylester, telomerase activity and the cell cycle-related proteins return to control values. To discover the effect of glutathione redox status on the telomerase multicomplex structure, we incubated protein extracts from fibroblasts with different glutathione redox buffers. Telomerase activity is maximal under reduced conditions i.e. when the reduced/oxidized glutathione ratio is high. Consequently glutathione concentration parallels telomerase activity. These results underscore the main role of glutathione in the control of telomerase activity and of the cell cycle.	Univ Valencia, Dept Physiol, Sch Med, Valencia 46010, Spain; Univ Valencia, Sch Med, Dept Biochem, Valencia 46010, Spain	University of Valencia; University of Valencia	Pallardo, FV (corresponding author), Univ Valencia, Dept Physiol, Sch Med, Avda Blasco Ibanez 17, Valencia 46010, Spain.	pallardo@uv.es	Viña, Juan R/ABE-5698-2021; Vina, Jose/AAB-3069-2021; Pallardo, Federico V./T-1156-2017; borras, consuelo/Y-3407-2019	Viña, Juan R/0000-0002-4035-3615; Vina, Jose/0000-0001-9709-0089; Pallardo, Federico V./0000-0003-3715-1980; borras, consuelo/0000-0003-4606-1792				BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2526; Coppe JP, 2003, EXP CELL RES, V285, P131, DOI 10.1016/S0014-4827(03)00014-4; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; EGGLESTON LV, 1974, BIOCHEM J, V138, P425, DOI 10.1042/bj1380425; Esteve JM, 1999, FASEB J, V13, P1055, DOI 10.1096/fasebj.13.9.1055; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hayakawa N, 1999, BIOCHEMISTRY-US, V38, P11501, DOI 10.1021/bi982829k; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; KORNBERG A, 1969, SCIENCE, V163, P1410, DOI 10.1126/science.163.3874.1410; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; VINA J, 1978, BIOCHEM J, V170, P711, DOI 10.1042/bj1700711; Xiao XD, 2003, EXP MOL PATHOL, V75, P238, DOI 10.1016/S0014-4800(03)00092-3	21	61	63	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34332	34335		10.1074/jbc.M402425200	http://dx.doi.org/10.1074/jbc.M402425200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184392	hybrid			2022-12-27	WOS:000223134800032
J	Ji, CY; Wang, Y; Guo, XP; Hartson, S; Jiang, HB				Ji, CY; Wang, Y; Guo, XP; Hartson, S; Jiang, HB			A pattern recognition serine proteinase triggers the prophenoloxidase activation cascade in the tobacco hornworm, Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO ACTIVATION; PRO-PHENOL-OXIDASE; INSECT; HEMOLYMPH; EXPRESSION; PROTEASE; DEFENSE; TOLL; MELANIZATION; COLEOPTERAN	A serine proteinase cascade in insect hemolymph mediates prophenoloxidase activation, a defense mechanism against pathogen or parasite infection. Little is known regarding its initiating proteinase or how this enzyme is activated in response to invading microorganisms. We have isolated from the tobacco hornworm, Manduca sexta, a cDNA encoding a modular protein designated hemolymph proteinase 14 ( HP14). It contains five low density lipoprotein receptor class A repeats, a Sushi domain, a unique Cys-rich region, and a proteinase-catalytic domain. The HP14 mRNA exists in fat body and hemocytes of the naive larvae, and its level increases significantly at 24 h after a bacterial challenge. We expressed proHP14 with a carboxyl-terminal hexahistidine tag in a baculovirus/insect cell system and detected the recombinant protein in two forms. The 87-kDa protein was primarily intracellular, whereas the 75-kDa form was present in the medium. Interaction with peptidoglycan resulted in proteolytic processing of the purified zymogen and generation of an amidase activity. Supplementation of hemolymph with proHP14 greatly enhanced prophenoloxidase activation in response to Micrococcus luteus. These data suggest that proHP14 is a pattern recognition protein that binds to bacteria and autoactivates and triggers the prophenoloxidase activation system in the hemolymph of M. sexta.	Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Oklahoma State University System; Oklahoma State University - Stillwater	Jiang, HB (corresponding author), Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA.	haobo@okstate.edu	Jiang, Haobo/A-6519-2008	Jiang, Haobo/0000-0003-1357-1315	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058634] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashida Masaaki, 1998, P135; BIERI S, 1995, BIOCHEMISTRY-US, V34, P13059, DOI 10.1021/bi00040a017; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; Chou KC, 1997, J PROTEIN CHEM, V16, P765, DOI 10.1023/A:1026363816730; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Danielli A, 2000, P NATL ACAD SCI USA, V97, P7136, DOI 10.1073/pnas.97.13.7136; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gorman MJ, 2000, GENE, V251, P9, DOI 10.1016/S0378-1119(00)00181-5; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Iwanaga S, 1998, J BIOCHEM, V123, P1; Ji CY, 2003, PROTEIN EXPRES PURIF, V29, P235, DOI 10.1016/S1046-5928(03)00020-2; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; WANG Y, 1995, INSECT MOL BIOL, V4, P113, DOI 10.1111/j.1365-2583.1995.tb00015.x; Yau YH, 2001, ANTIMICROB AGENTS CH, V45, P2820, DOI 10.1128/AAC.45.10.2820-2825.2001; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1; Yu XQ, 2002, INSECT BIOCHEM MOLEC, V32, P1287, DOI 10.1016/S0965-1748(02)00091-7	37	65	71	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34101	34106		10.1074/jbc.M404584200	http://dx.doi.org/10.1074/jbc.M404584200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190055	hybrid			2022-12-27	WOS:000223134800006
J	Nishimura, H; Kim, E; Nakanishi, T; Baba, T				Nishimura, H; Kim, E; Nakanishi, T; Baba, T			Possible function of the ADAM1a/ADAM2 fertilin complex in the appearance of ADAM3 on the sperm surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; POLY(A) POLYMERASE; EGG FUSION; 2 ISOFORMS; PROTEIN; CYRITESTIN; FAMILY; GENE; SPERMATOGENESIS; LOCALIZATION	In mouse, two different isoforms of ADAM1 (fertilin alpha), ADAM1a and ADAM1b, are produced in the testis. ADAM1a is localized within the endoplasmic reticulum of testicular germ cells, whereas epididymal sperm contain only ADAM1b on the plasma membrane. In this study, we show that the loss of ADAM1a results in the male infertility because of the severely impaired ability of sperm to migrate from the uterus into the oviduct through the uterotubal junction. However, epididymal sperm of ADAM1a-deficient mice were capable of fertilizing cumulus-intact, zona pellucida-intact eggs in vitro despite the delayed dispersal of cumulus cells and the reduced adhesion/binding to the zona pellucida. Among testis (sperm)-specific proteins examined, only the level of ADAM3 (cyritestin) was strongly reduced in ADAM1a-deficient mouse sperm. Moreover, the appearance of ADAM3 on the sperm surface was dependent on the formation of a fertilin protein complex between ADAM1a and ADAM2 (fertilin beta) in testicular germ cells, although no direct interaction between the fertilin complex and ADAM3 was found. These results suggest that ADAM1a/ADAM2 fertilin may be implicated in the selective transport of specific sperm proteins including ADAM3 from the endoplasmic reticulum of testicular germ cells onto the cell surface. These proteins then can participate in sperm migration into the oviduct, the dispersal of cumulus cells, and sperm binding to the zona pellucida.	Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba	Baba, T (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.	acroman@sakura.cc.tsukuba.ac.jp						Baba D, 2002, J BIOL CHEM, V277, P30310, DOI 10.1074/jbc.M204596200; BABA T, 1994, J BIOL CHEM, V269, P10133; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ikawa M, 2001, DEV BIOL, V240, P254, DOI 10.1006/dbio.2001.0462; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Kashiwabara S, 2002, SCIENCE, V298, P1999, DOI 10.1126/science.1074632; Kashiwabara S, 2000, DEV BIOL, V228, P106, DOI 10.1006/dbio.2000.9894; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; Kim E, 2003, BIOCHEM BIOPH RES CO, V304, P313, DOI 10.1016/S0006-291X(03)00588-6; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; Linder B, 1997, DEV GROWTH DIFFER, V39, P243; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Nishimura H, 2002, GENE, V291, P67, DOI 10.1016/S0378-1119(02)00540-1; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; PHELPS BM, 1990, J CELL BIOL, V111, P1839, DOI 10.1083/jcb.111.5.1839; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; SIBONY M, 1993, HYPERTENSION, V21, P827, DOI 10.1161/01.HYP.21.6.827; SUAREZ SS, 1987, BIOL REPROD, V36, P203, DOI 10.1095/biolreprod36.1.203; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Waters SI, 1997, BIOL REPROD, V56, P1245, DOI 10.1095/biolreprod56.5.1245; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105	35	144	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34957	34962		10.1074/jbc.M314249200	http://dx.doi.org/10.1074/jbc.M314249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194697	hybrid			2022-12-27	WOS:000223134800107
J	Reszko, AE; Kasumov, T; David, F; Thomas, KR; Jobbins, KA; Cheng, JF; Lopaschuk, GD; Dyck, JRB; Diaz, M; Des Rosiers, C; Stanley, WC; Brunengraber, H				Reszko, AE; Kasumov, T; David, F; Thomas, KR; Jobbins, KA; Cheng, JF; Lopaschuk, GD; Dyck, JRB; Diaz, M; Des Rosiers, C; Stanley, WC; Brunengraber, H			Regulation of Malonyl-CoA concentration and turnover in the normal heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ISCHEMIC-HEART; COENZYME-A; PYRUVATE; MUSCLE; ASSAY	The goal of this study was to test the relationship between malonyl-CoA concentration and its turnover measured in isolated rat hearts perfused with (NaHCO3)-C-13. This turnover is a direct measurement of the flux of acetyl-CoA carboxylation in the intact heart. It also reflects the rate of malonyl-CoA decarboxylation, i.e. the only known fate of malonyl-CoA in the heart. Conditions were selected to result in stable malonyl-CoA concentrations ranging from 1.5 to 5 nmol.g wet weight(-1). The malonyl-CoA concentration was directly correlated with the turnover of malonyl-CoA, ranging from 0.7 to 4.2 nmol.min(-1).g wet weight(-1) (slope = 0.98, r(2) = 0.94). The V-max activities of acetyl-CoA carboxylase and of malonyl-CoA decarboxylase exceeded the rate of malonyl-CoA turnover by 2 orders of magnitude and did not correlate with either concentration or turnover of malonyl-CoA. However, conditions of perfusion that increased acetylCoA supply resulted in higher turnover and concentration, demonstrating that malonyl-CoA turnover is regulated by the supply of acetyl-CoA. The only condition where the activity of malonyl-CoA decarboxylase regulated malonyl-CoA kinetics was when the enzyme was pharmacologically inhibited, resulting in increased malonyl-CoA concentration and decreased turnover. Our data show that, in the absence of enzyme inhibitors, the rate of acetyl-CoA carboxylation is the main determinant of the malonyl-CoA concentration in the heart.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Chugai Pharma USA LLC, San Diego, CA 92121 USA; Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2S2, Canada; Univ Montreal, Dept Nutr, Montreal, PQ H3C 3J7, Canada	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Alberta; University of Alberta; Universite de Montreal	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxb8@cwru.edu	Rosiers, Christine Des/O-6285-2014	Dyck, Jason/0000-0002-7045-2884; Cheng, Jie-Fei/0000-0002-5902-0490	NHLBI NIH HHS [P01 HL 74237] Funding Source: Medline; NIDDK NIH HHS [DK 07319, R01 DK 35543] Funding Source: Medline; NIGMS NIH HHS [P50 GM 66309] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM066309] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; DANIEL WW, 1999, BIOSTATISTICS FDN AN, P633; Dyck JRB, 2004, CIRC RES, V94, pE78, DOI 10.1161/01.RES.0000129255.19569.8f; Dyck JRB, 2002, J MOL CELL CARDIOL, V34, P1099, DOI 10.1006/jmcc.2002.2060; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; HOLM S, 1979, SCAND J STAT, V6, P65; Kerner J, 2002, ANAL BIOCHEM, V306, P283, DOI 10.1006/abio.2002.5696; Longnus SL, 2001, AM J PHYSIOL-HEART C, V281, pH1561, DOI 10.1152/ajpheart.2001.281.4.H1561; LOPASCHUK GD, 1994, J BIOL CHEM, V269, P25871; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; Panchal AR, 2000, AM J PHYSIOL-HEART C, V279, pH2390, DOI 10.1152/ajpheart.2000.279.5.H2390; Poirier M, 2002, AM J PHYSIOL-HEART C, V283, pH1379, DOI 10.1152/ajpheart.00244.2002; Reszko AE, 2004, J BIOL CHEM, V279, P19574, DOI 10.1074/jbc.M400162200; Reszko AE, 2001, ANAL BIOCHEM, V298, P69, DOI 10.1006/abio.2001.5349; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Stanley WC, 1996, J MOL CELL CARDIOL, V28, P905, DOI 10.1006/jmcc.1996.0085; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	18	36	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34298	34301		10.1074/jbc.M405488200	http://dx.doi.org/10.1074/jbc.M405488200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181001	hybrid			2022-12-27	WOS:000223134800028
J	Santiveri, CM; Perez-Canadillas, JM; Vadivelu, MK; Allen, MD; Rutherford, TJ; Watkins, NA; Bycroft, M				Santiveri, CM; Perez-Canadillas, JM; Vadivelu, MK; Allen, MD; Rutherford, TJ; Watkins, NA; Bycroft, M			NMR structure of the alpha-hemoglobin stabilizing protein - Insights into conformational heterogeneity and binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME RECYCLING FACTOR; CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; ALIGNMENT; ISOMERIZATION; DOMAIN; ITK; MACROMOLECULES; PREDICTION; PROGRAM	The structure of alpha-hemoglobin stabilizing protein (AHSP), a molecular chaperone for free alpha-hemoglobin, has been determined using NMR spectroscopy. The protein native state shows conformational heterogeneity attributable to the isomerization of the peptide bond preceding a conserved proline residue. The two equally populated cis and trans forms both adopt an elongated antiparallel three alpha-helix bundle fold but display major differences in the loop between the first two helices and at the C terminus of helix 3. Proline to alanine single point mutation of the residue Pro-30 prevents the cis/trans isomerization. The structure of the P30A mutant is similar to the structure of the trans form of AHSP in the loop 1 region. Both the wild-type AHSP and the P30A mutant bind to alpha-hemoglobin, and the wild-type conformational heterogeneity is quenched upon complex formation, suggesting that just one conformation is the active form. Changes in chemical shift observed upon complex formation identify a binding interface comprising the C terminus of helix 1, the loop 1, and the N terminus of helix 2, with the exposed residues Phe-47 and Tyr-51 being attractive targets for molecular recognition. The characteristics of this interface suggest that AHSP binds at the intradimer alpha(1)beta(1) interface in tetrameric HbA.	MRC, Ctr Prot Engn, Cambridge CB2 2QH, England; Univ Cambridge, Dept Hematol, Div Transfus Med, Cambridge CB2 2PT, England	University of Cambridge; University of Cambridge	Bycroft, M (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	mb10031@cus.cam.ac.uk	Pérez-Cañadillas, Jose Manuel/AAN-1864-2020; Bycroft, Mark/D-9446-2017; Perez-Canadillas, Jose M/J-5748-2013	Perez-Canadillas, Jose M/0000-0002-8266-5502; Bycroft, Mark/0000-0002-0673-2216; Santiveri, Clara M./0000-0001-6095-7224				Andreotti AH, 2003, BIOCHEMISTRY-US, V42, P9515, DOI 10.1021/bi0350710; Antonini E, 1971, FRONT BIOL, V21, P1; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Breheny PJ, 2003, J AM CHEM SOC, V125, P15706, DOI 10.1021/ja0375380; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Helgstrand M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kim KK, 2000, EMBO J, V19, P2362, DOI 10.1093/emboj/19.10.2362; Kong Y, 2003, BLOOD, V102, p46A; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lerche MH, 1999, J MAGN RESON, V140, P259, DOI 10.1006/jmre.1999.1820; Luzzatto L, 2002, NATURE, V417, P703, DOI 10.1038/417703a; Mallis RJ, 2002, NAT STRUCT BIOL, V9, P900, DOI 10.1038/nsb864; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nakano H, 2003, J BIOL CHEM, V278, P3427, DOI 10.1074/jbc.M208098200; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERUTZ MF, 1982, NATURE, V295, P535, DOI 10.1038/295535a0; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; Song JK, 2003, BIOCHEMISTRY-US, V42, P6380, DOI 10.1021/bi034053f; Toyoda T, 2000, RNA, V6, P1432, DOI 10.1017/S1355838200001060; Viprakasit V, 2004, BLOOD, V103, P3296, DOI 10.1182/blood-2003-11-3957; WUTHRICH K, 1986, NMR PROTEIN NUCL ACI, P263; Yoshida T, 2001, BIOCHEMISTRY-US, V40, P2387, DOI 10.1021/bi002474g; Yuan XM, 1998, PROTEIN SCI, V7, P2127, DOI 10.1002/pro.5560071009; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	38	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34963	34970		10.1074/jbc.M405016200	http://dx.doi.org/10.1074/jbc.M405016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15178680	hybrid			2022-12-27	WOS:000223134800108
J	Voss, AA; Lango, J; Ernest-Russell, M; Morin, D; Pessah, IN				Voss, AA; Lango, J; Ernest-Russell, M; Morin, D; Pessah, IN			Identification of hyperreactive cysteines within ryanodine receptor type 1 by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; MALIGNANT HYPERTHERMIA FAMILIES; CENTRAL CORE DISEASE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; NITRIC-OXIDE; REDOX SENSOR; SULFHYDRYL-REAGENTS; POLYACRYLAMIDE-GELS	The skeletal-type ryanodine receptor (RyR1) undergoes covalent adduction by nitric oxide (NO), redox-induced shifts in cation regulation, and non-covalent interactions driven by the transmembrane redox potential that enable redox sensing. Tight redox regulation of RyR1 is thought to be primarily mediated through highly reactive (hyperreactive) cysteines. Of the 100 cysteines per subunit of RyR1, similar to25-50 are reduced, with 6 - 8 considered hyperreactive. Thus far, only Cys-3635, which undergoes selective adduction by NO, has been identified. In this report, RyR1-enriched junctional sarcoplasmic reticulum is labeled with 7-diethylamino-3(4'-maleimidylphenyl)-4-methylcoumarin (CPM, 1 pmol/mug of protein) in the presence of 10 mM Mg2+, conditions previously shown to selectively label hyperreactive sulfhydryls and eliminate redox sensing. The CPM-adducted RyR1 is separated by gel electrophoresis and subjected to in-gel tryptic digestion. Isolation of CPM-adducted peptides is achieved by analytical and microbore high-performance liquid chromatography utilizing fluorescence and UV detection. Subsequent analysis using two direct and one tandem mass spectrometry methods results in peptide masses and sequence data that, compared with the known primary sequence of RyR1, enable unequivocal identification of CPM-adducted cysteines. This work is the first to directly identify seven hyperreactive cysteines: 1040, 1303, 2436, 2565, 2606, 2611, and 3635 of RyR1. In addition to Cys-3635, the nitrosylation site, six additional cysteines may contribute toward redox regulation of the RyR1 complex.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Pessah, IN (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIAMS NIH HHS [2R01 AR 43140] Funding Source: Medline; NIEHS NIH HHS [2P42 ES 04699, 1P01 ES 11269, ES 07059, T32 ES007059] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007059, P01ES011269, P42ES004699] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; ALEMAN M, 2004, IN PRESS MUSCLE NERV; Aracena P, 2003, J BIOL CHEM, V278, P42927, DOI 10.1074/jbc.M306969200; Baker ML, 2002, P NATL ACAD SCI USA, V99, P12155, DOI 10.1073/pnas.182058899; Barone V, 1999, J MED GENET, V36, P115; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Brandt A, 1999, HUM MOL GENET, V8, P2055, DOI 10.1093/hmg/8.11.2055; Bull R, 2003, AM J PHYSIOL-CELL PH, V285, pC119, DOI 10.1152/ajpcell.00296.2002; Butterfield DA, 2001, MECH AGEING DEV, V122, P945, DOI 10.1016/S0047-6374(01)00249-4; Donoso P, 2000, BIOPHYS J, V79, P279, DOI 10.1016/S0006-3495(00)76290-4; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Eager KR, 1997, AM J PHYSIOL-CELL PH, V272, pC1908, DOI 10.1152/ajpcell.1997.272.6.C1908; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feng W, 1999, MOL PHARMACOL, V55, P821; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Feng W, 2002, METHOD ENZYMOL, V353, P240; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Floyd RA, 1992, ANN NEUROL, V32, P22; Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685; Ignarro LJ, 2002, J CARDIAC SURG, V17, P301; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; KEATING KE, 1994, HUM MOL GENET, V3, P1855, DOI 10.1093/hmg/3.10.1855; Koesling D, 1999, METHODS, V19, P485, DOI 10.1006/meth.1999.0891; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manning BM, 1998, HUM MUTAT, V11, P45, DOI 10.1002/(SICI)1098-1004(1998)11:1<45::AID-HUMU7>3.0.CO;2-K; MANZONI O, 1993, J NEUROCHEM, V61, P368, DOI 10.1111/j.1471-4159.1993.tb03580.x; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; Oba T, 2002, AM J PHYSIOL-CELL PH, V282, pC684, DOI 10.1152/ajpcell.01273.2000; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Pessah IN, 2002, FRONT BIOSCI-LANDMRK, V7, pA72, DOI 10.2741/pessah; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; Ruffert H, 2002, ANAESTHESIST, V51, P904, DOI 10.1007/s00101-002-0390-x; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIGAL E, 1994, ANN NY ACAD SCI, V714, P211, DOI 10.1111/j.1749-6632.1994.tb12046.x; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46	49	66	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34514	34520		10.1074/jbc.M404290200	http://dx.doi.org/10.1074/jbc.M404290200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15197184	hybrid			2022-12-27	WOS:000223134800054
J	Kakizaki, I; Kojima, K; Takagaki, K; Endo, M; Kannagi, R; Ito, M; Maruo, Y; Sato, H; Yasuda, T; Mita, S; Kimata, K; Itano, N				Kakizaki, I; Kojima, K; Takagaki, K; Endo, M; Kannagi, R; Ito, M; Maruo, Y; Sato, H; Yasuda, T; Mita, S; Kimata, K; Itano, N			A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-XYLOSIDE; UDP-GLUCURONOSYLTRANSFERASE UGT1A6; MOLECULAR-CLONING; IN-VITRO; PERICELLULAR MATRIX; ACID; EXPRESSION; SULFATE; GROWTH; CELLS	Specific inhibitors of hyaluronan (HA) biosynthesis can be valuable therapeutic agents to prevent cancer invasion and metastasis. We have found previously that 4-methylumbelliferone (MU) inhibits HA synthesis in human skin fibroblasts and in group C Streptococcus. In this paper, the inhibition mechanism in mammalian cells was investigated using rat 3Y1 fibroblasts stably expressing HA synthase (HAS) 2. Exposure of the transfectants to the inhibitor resulted in significant reduction of HA biosynthesis and matrix formation. The evaluation of HAS transcripts and analysis of cell-free HA synthesis demonstrated the post-transcriptional suppression of HAS activity by MU. Most interesting, the post-transcriptional suppression of HAS activity was also observed using p-nitrophenol, a well known substrate for UDP-glucuronyltransferases (UGT). We investigated whether the inhibition was exerted by the glucuronidation of MU using both high pressure liquid chromatography and TLC analyses. The production of MU-glucuronic acid (GlcUA) was consistent with the inhibition of HA synthesis in HAS transfectants. MU-GlcUA was also detected at a similar level in control cells, suggesting that the glucuronidation was mediated by an endogenous UGT. Elevated levels of UGT significantly enhanced the inhibitory effects of MU. In contrast, the inhibition by MU was diminished to the control level when an excess of UDP-GlcUA was added to the cell-free HA synthesis system. We propose a novel mechanism for the MU-mediated inhibition of HA synthesis involving the glucuronidation of MU by endogenous UGT resulting in a depletion of UDP-GlcUA.	Hirosaki Univ, Sch Med, Dept Biochem, Hirosaki, Aomori 0368562, Japan; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan; Shiga Univ Med Sci, Core Res Evolut Sci & Technol, Japan Sci & Technol Agcy, Shiga, Japan; Shiga Univ Med Sci, Dept Internal Med 2, Shiga, Japan; Shiga Univ Med Sci, Dept Pediat, Shiga, Japan; Shiga Univ Med Sci, Dept Biol, Shiga, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan	Hirosaki University; Aichi Cancer Center; Japan Science & Technology Agency (JST); Shiga University of Medical Science; Shiga University of Medical Science; Shiga University of Medical Science; Shiga University of Medical Science; Osaka University; Aichi Medical University	Itano, N (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	itano@amugw.aichi-med-u.ac.jp	Kakizaki, Ikuko/AAO-5489-2020; Kannagi, Reiji/Q-6459-2018	Kakizaki, Ikuko/0000-0002-6702-5830; Kannagi, Reiji/0000-0003-4202-2921				AUGUST EM, 1993, ONCOL RES, V5, P415; Bock-Hennig BS, 2002, BIOCHEM PHARMACOL, V63, P123, DOI 10.1016/S0006-2952(01)00833-4; CHICHIBU K, 1989, CLIN CHIM ACTA, V181, P317, DOI 10.1016/0009-8981(89)90237-4; Ciotti M, 1997, PHARMACOGENETICS, V7, P485, DOI 10.1097/00008571-199712000-00007; ElMaradny E, 1997, HUM REPROD, V12, P1080; ENDO Y, 2000, PROGR TRANSPLANTATIO, P1; GOLDBERG RL, 1983, J BIOL CHEM, V258, P7041; GRESSNER AM, 1991, BIOCHEM PHARMACOL, V42, P1987, DOI 10.1016/0006-2952(91)90599-Z; GRESSNER AM, 1991, EXP MOL PATHOL, V55, P143, DOI 10.1016/0014-4800(91)90049-4; Hanioka N, 2001, J PHARMACEUT BIOMED, V25, P65, DOI 10.1016/S0731-7085(00)00491-X; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; Itano N, 1999, CANCER RES, V59, P2499; Ito M, 2002, EUR J CLIN PHARMACOL, V58, P11, DOI 10.1007/s00228-001-0417-2; Jacobson A, 2002, INT J CANCER, V102, P212, DOI 10.1002/ijc.10683; Kakizaki I, 2002, EUR J BIOCHEM, V269, P5066, DOI 10.1046/j.1432-1033.2002.03217.x; Kamst E, 1999, BIOCHEMISTRY-US, V38, P4045, DOI 10.1021/bi982531u; Kanou M, 2002, FUND CLIN PHARMACOL, V16, P513, DOI 10.1046/j.1472-8206.2002.00097.x; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KNUDSON W, 1991, J CELL SCI, V99, P227; Kosaki R, 1999, CANCER RES, V59, P1141; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; LEVESQUE H, 1994, ATHEROSCLEROSIS, V105, P51, DOI 10.1016/0021-9150(94)90007-8; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Liu NF, 2001, CANCER RES, V61, P5207; MATUOKA K, 1985, CELL BIOL INT REP, V9, P577, DOI 10.1016/0309-1651(85)90023-2; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Nakamura T, 1997, BIOCHEM MOL BIOL INT, V43, P263; NAKAMURA T, 1995, BIOCHEM BIOPH RES CO, V208, P470, DOI 10.1006/bbrc.1995.1362; Ouzzine M, 2000, MOL PHARMACOL, V58, P1609, DOI 10.1124/mol.58.6.1609; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; PLEBANI M, 1991, CLIN BIOCHEM, V24, P219, DOI 10.1016/0009-9120(91)80013-S; Radominska-Pandya A, 2002, ARCH BIOCHEM BIOPHYS, V399, P37, DOI 10.1006/abbi.2001.2743; Satoh T, 2000, J GASTROEN HEPATOL, V15, P402, DOI 10.1046/j.1440-1746.2000.02164.x; Simpson MA, 2002, J BIOL CHEM, V277, P10050, DOI 10.1074/jbc.M110069200; SMITH TJ, 1990, J CLIN ENDOCR METAB, V70, P655, DOI 10.1210/jcem-70-3-655; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; TAKAGAKI K, 1992, GLYCOCONJUGATE J, V9, P174, DOI 10.1007/BF00731162; TAKEDA S, 1981, J PHARMACOBIO-DYNAM, V4, P724, DOI 10.1248/bpb1978.4.724; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Ueki N, 2000, BBA-MOL CELL RES, V1495, P160, DOI 10.1016/S0167-4889(99)00161-5; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEISSMANN B, 1954, J AM CHEM SOC, V76, P1753, DOI 10.1021/ja01636a010; Yada T, 2003, J BIOL CHEM, V278, P39711, DOI 10.1074/jbc.M304421200; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; ZAHAREVITZ DW, 1993, BIOCHEM MOL BIOL INT, V31, P627; ZIMMERMAN CL, 1991, J CHROMATOGR-BIOMED, V563, P83, DOI 10.1016/0378-4347(91)80279-L	54	202	206	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33281	33289		10.1074/jbc.M405918200	http://dx.doi.org/10.1074/jbc.M405918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15190064	hybrid			2022-12-27	WOS:000223039700034
J	Nielsen, FS; Sauer, J; Backlund, J; Voldborg, B; Gregorius, K; Mouritsen, S; Bratt, T				Nielsen, FS; Sauer, J; Backlund, J; Voldborg, B; Gregorius, K; Mouritsen, S; Bratt, T			Insertion of foreign T cell epitopes in human tumor necrosis factor alpha with minimal effect on protein structure and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; BINDING; SPECIFICITY; RECOGNITION; RECEPTORS; BLOCKING; ANTIBODY; THERAPY	To create a human therapeutic vaccine able to circumvent self-tolerance against tumor necrosis factor (TNF) alpha, foreign T helper epitopes were inserted into human TNFalpha, with minimal effect on the native three-dimensional structure. TNFalpha variants were screened for solubility, structural stability, biological activity, and after immunization, for eliciting inhibitory antibodies. The longest and most flexible loop in TNFalpha, also designated loop 3, is the only region that is not involved in intra- or intermolecular interactions and therefore constitute an attractive insertion site. However, the extension of the flexible loop by epitope insertions destabilized the TNFalpha molecule. Therefore, two cysteines were introduced to form a stabilizing disulfide bond between loops 2 and 3. In a second design approach, three TNFalpha monomers were linked by two T cell epitopes and expressed as a single chain TNFalpha trimer. TNFalpha variants that were expressed as soluble proteins also had a conserved tertiary structure, as determined by circular dichroism. The biological activity of the TNFalpha variants was of the same magnitude as human TNFalpha in cellular assays. Introduction of three separate single-point mutations (D143N, A145R, or Y87S) diminished the cytotoxicity of the mutated variants 50 - 800-fold compared with native TNFalpha. Antisera from mice immunized with the different TNFalpha variants were able to cross-react with native human TNFalpha and to inhibit TNFalpha signaling via the TNF receptors in vitro, suggesting that the structural binding epitopes of native human TNFalpha and thus the native conformation were conserved in the constructed vaccine candidates.	Pharmexa AS, DK-2970 Horsholm, Denmark; ALK Abello AS, DK-2970 Horsholm, Denmark; PreciSense AS, DK-2970 Horsholm, Denmark	ALK-Abello AS	Nielsen, FS (corresponding author), Pharmexa AS, Kogle Alle 6, DK-2970 Horsholm, Denmark.	fn@pharmexa.com		Voldborg, Bjorn Gunnar/0000-0002-7005-1642				*ABB LAB, 2003, 03A64063161 ABB LAB; ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; ASHER A, 1987, J IMMUNOL, V138, P963; Bodmer JL, 2000, J BIOL CHEM, V275, P20632, DOI 10.1074/jbc.M909721199; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; CORTI A, 1992, MOL IMMUNOL, V29, P471, DOI 10.1016/0161-5890(92)90004-H; Dalum I, 1999, NAT BIOTECHNOL, V17, P666, DOI 10.1038/10878; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Feldman M, 1998, TRANSPLANT P, V30, P4126, DOI 10.1016/S0041-1345(98)01365-7; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Girolomoni Giampiero, 2002, Curr Opin Investig Drugs, V3, P1590; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; Lochs H, 1999, Z GASTROENTEROL, V37, P509; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; Machold KP, 2003, EXPERT OPIN BIOL TH, V3, P351, DOI 10.1517/14712598.3.2.351; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MEAGER A, 1991, J IMMUNOL METHODS, V144, P141, DOI 10.1016/0022-1759(91)90239-C; Narhi LO, 1996, BIOCHEMISTRY-US, V35, P11447, DOI 10.1021/bi952766v; NARHI LO, 1987, BIOCHEM BIOPH RES CO, V147, P740, DOI 10.1016/0006-291X(87)90992-2; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PAQUET A, 1994, J CHROMATOGR A, V667, P125, DOI 10.1016/0021-9673(94)89060-9; Saks S, 1992, Immunol Ser, V56, P567; SMITH RA, 1987, J BIOL CHEM, V262, P6951; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; YANG SC, 1991, CANCER RES, V51, P3669; Yung R L, 2001, Curr Opin Investig Drugs, V2, P216; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	30	9	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33593	33600		10.1074/jbc.M403072200	http://dx.doi.org/10.1074/jbc.M403072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173183	hybrid			2022-12-27	WOS:000223039700068
J	Oliva, JL; Zarich, N; Martinez, N; Jorge, R; Castrillo, A; Azanedo, M; Garcia-Vargas, S; Gutierrez-Eisman, S; Juarranz, A; Bosca, L; Gutkind, JS; Rojas, JM				Oliva, JL; Zarich, N; Martinez, N; Jorge, R; Castrillo, A; Azanedo, M; Garcia-Vargas, S; Gutierrez-Eisman, S; Juarranz, A; Bosca, L; Gutkind, JS; Rojas, JM			The P34G mutation reduces the transforming activity of K-ras and N-ras in NIH 3T3 cells but not of H-ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; EXCHANGE FACTORS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOPLASMIC-RETICULUM; BINDING PROTEIN; ACTIVATE RAF-1; GROWTH; MEMBRANE; PATHWAY	Ras proteins (H-, N-, and K-Ras) operate as molecular switches in signal transduction cascades controlling cell proliferation, differentiation, or apoptosis. The interaction of Ras with its effectors is mediated by the effector-binding loop, but different data about Ras location to plasma membrane subdomains and new roles for some docking/scaffold proteins point to signaling specificities of the different Ras proteins. To investigate the molecular mechanisms for these specificities, we compared an effector loop mutation (P34G) of three Ras isoforms ( H-, N-, and K-Ras4B) for their biological and biochemical properties. Although this mutation diminished the capacity of Ras proteins to activate the Raf/ERK and the phosphatidylinositol 3-kinase/AKT pathways, the H- Ras V12G34 mutant retained the ability to cause morphological transformation of NIH 3T3 fibroblasts, whereas both the N- Ras V12G34 and the K-Ras4B V12G34 mutants were defective in this biological activity. On the other hand, although both the N- Ras V12G34 and the K-Ras4B V12G34 mutants failed to promote activation of the Ral-GDS/Ral A/PLD and the Ras/Rac pathways, the H- Ras V12G34 mutant retained the ability to activate these signaling pathways. Interestingly, the P34G mutation reduced specifically the N- Ras and K-Ras4B in vitro binding affinity to Ral-GDS, but not in the case of H- Ras. Thus, independently of Ras location to membrane subdomains, there are marked differences among Ras proteins in the sensitivity to an identical mutation ( P34G) affecting the highly conserved effector-binding loop.	Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biol Celular, Madrid 28220, Spain; Univ Complutense, Fac Farm, Ctr Mixto CSIC UCM, Inst Bioquim, E-28040 Madrid, Spain; Univ Autonoma Madrid, Fac Biol, Dept Biol, E-28049 Madrid, Spain; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Rojas, JM (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biol Celular, Carretera Majadohonda Pozuelo,Km 2, Madrid 28220, Spain.	jmrojas@isciii.es	juarranz, angeles/L-2446-2013; Bosca, Lisardo/A-2059-2008; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Rojas, José M/D-3718-2018	juarranz, angeles/0000-0002-6574-2887; Bosca, Lisardo/0000-0002-0253-5469; Gutkind, J. Silvio/0000-0002-5150-4482; Rojas, José M/0000-0002-5383-3482; Zarich, Natasha/0000-0003-1058-6191	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Caloca MJ, 2003, J BIOL CHEM, V278, P33465, DOI 10.1074/jbc.M302807200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Jaumot M, 2002, J BIOL CHEM, V277, P272, DOI 10.1074/jbc.M108423200; Jorge B, 2002, J BIOL CHEM, V277, P44171, DOI 10.1074/jbc.M204423200; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Li WQ, 2000, GENE DEV, V14, P895; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Millan O, 2003, ONCOGENE, V22, P477, DOI 10.1038/sj.onc.1206179; Murphy GA, 2002, J BIOL CHEM, V277, P9966, DOI 10.1074/jbc.M109059200; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rojas Jose M., 2002, Current Genomics, V3, P295, DOI 10.2174/1389202023350381; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Rudolph MG, 2001, J BIOL CHEM, V276, P23914, DOI 10.1074/jbc.M011600200; Selfors LM, 1998, P NATL ACAD SCI USA, V95, P6903, DOI 10.1073/pnas.95.12.6903; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIROUZU M, 1994, ONCOGENE, V9, P2153; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; Stang S, 1997, MOL CELL BIOL, V17, P3047, DOI 10.1128/MCB.17.6.3047; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	42	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33480	33491		10.1074/jbc.M404058200	http://dx.doi.org/10.1074/jbc.M404058200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15181015	hybrid, Green Submitted, Green Published			2022-12-27	WOS:000223039700057
J	Turner, LJ; Nicholls, S; Hall, A				Turner, LJ; Nicholls, S; Hall, A			The activity of the Plexin-A1 receptor is regulated by Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-CONE COLLAPSE; INHIBITORY GUIDANCE CUE; BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; AXON GUIDANCE; SEMAPHORIN RECEPTOR; ACTIVATING RHO; GTPASES; CDC42; AUTOINHIBITION	Plexins constitute a large family of transmembrane proteins that act as receptors for the semaphorin family of ligands. They are best known for their role in growth cone guidance, although they also are widely expressed outside the nervous system. Plexins are thought to control axon guidance by modifying the growth cone cytoskeleton, and Rho GTPases have been strongly implicated in this response. However, the exact contribution of Rho proteins is unclear. Sema3A/Plexin-A1-induced growth cone collapse, for example, requires Rac activity, which is a surprising result given that this GTPase is usually associated with membrane protrusions. We show here that Sema3A-induced collapse of COS-7 cells expressing Plexin-A1 also requires Rac but not Rho activity and that the cytoplasmic tail of Plexin-A1 interacts directly with activated Rac. However, collapse induced by a constitutively activated version of Plexin-A1 does not require Rac. We propose a novel function for Rac, namely that it acts upstream of Plexin-A1 during semaphoring-induced collapse, to regulate the activity of the receptor.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, Cell Biol Unit, Canc Res UK,Oncogene & Signal Transduct Grp, London WC1E 6BT, England	University of London; University College London; Cancer Research UK; University of London; University College London	Hall, A (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	alan.hall@ucl.ac.uk						Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Challacombe JF, 1996, J CELL SCI, V109, P2031; Challacombe JF, 1997, J NEUROSCI, V17, P3085; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Eickholt BJ, 1997, MOL CELL NEUROSCI, V9, P358, DOI 10.1006/mcne.1997.0636; Fan XP, 2003, NEURON, V40, P113, DOI 10.1016/S0896-6273(03)00591-9; Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jin Z, 1997, J NEUROSCI, V17, P6256; Jurney WM, 2002, J NEUROSCI, V22, P6019; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohm B, 2000, MECH DEVELOP, V93, P95, DOI 10.1016/S0925-4773(00)00269-0; Rohm B, 2000, FEBS LETT, V486, P68, DOI 10.1016/S0014-5793(00)02240-7; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TANAKA E, 1995, J CELL BIOL, V128, P127, DOI 10.1083/jcb.128.1.127; Tu H, 1999, MOL CELL BIOL, V19, P602; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Williamson T, 1996, P NATL ACAD SCI USA, V93, P15221, DOI 10.1073/pnas.93.26.15221; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zanata SM, 2002, J NEUROSCI, V22, P471, DOI 10.1523/JNEUROSCI.22-02-00471.2002; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng JQ, 1996, J NEUROSCI, V16, P1140	51	77	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33199	33205		10.1074/jbc.M402943200	http://dx.doi.org/10.1074/jbc.M402943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15187088	hybrid			2022-12-27	WOS:000223039700024
J	Duvvuri, M; Gong, YP; Chatterji, D; Krise, JP				Duvvuri, M; Gong, YP; Chatterji, D; Krise, JP			Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMES; DRUGS; LIPOPHILICITY; MITOCHONDRIA; DISPOSITION; DOXORUBICIN	A number of organelles contained within mammalian cells have been implicated in the selective sequestration of chemical entities including drug molecules. Specifically, weakly basic molecules have been shown to selectively associate with either the mitochondrial compartment or lysosomes; however, the structural basis for this differentiation has not been understood. To investigate this, we have identified a series of seven weakly basic compounds, all with pK(alpha) near neutrality, which have different sequestration sites within the multidrug-resistant HL-60 human leukemic cell line. Three of the compounds were selectively sequestered into the mitochondria of the cells, whereas the remainder were predominantly localized within lysosomes. Using specific chemical inhibitors to disrupt either mitochondrial or lysosomal accumulation capacity, we demonstrated that accumulation of these compounds into respective organelles are not competitive processes. Comparison of the permeability characteristics of these compounds as a function of pH revealed striking differences that correlate with the intracellular sequestration site. Only those compounds with significantly reduced permeability in the ionized state relative to the un-ionized state had the capacity to accumulate within lysosomes. Alternatively, those compounds with relatively pH-insensitive permeability selectively accumulated into mitochondria. Using novel quantitative assays for assaying drug accumulation into subcellular organelles, we demonstrated a correlation between these permeability characteristics and the lysosomal versus mitochondrial accumulation capacity of these compounds. Together, these results suggest that the selective accumulations of weakly basic compounds in either lysosomes and mitochondria occur via exclusive pathways governed by a unique permeability parameter.	Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Krise, JP (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA.	krise@ku.edu						Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Binaschi M., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P113, DOI 10.2174/1568011013354723; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Diettrich O, 1998, FEBS LETT, V441, P369, DOI 10.1016/S0014-5793(98)01578-6; Duvvuri M, 2004, PHARM RES-DORDR, V21, P26, DOI 10.1023/B:PHAM.0000012148.12516.3f; FORD T, 1994, ANAL BIOCHEM, V220, P360, DOI 10.1006/abio.1994.1350; Gong YP, 2003, J BIOL CHEM, V278, P50234, DOI 10.1074/jbc.M306606200; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P483; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; Moriyama Y, 1996, J EXP BIOL, V199, P1447; Reymond F, 1999, CHEM-EUR J, V5, P39, DOI 10.1002/(SICI)1521-3765(19990104)5:1<39::AID-CHEM39>3.3.CO;2-V; Rivory LP, 1996, CANCER CHEMOTH PHARM, V38, P439, DOI 10.1007/s002800050508; Rottenberg H, 1979, Methods Enzymol, V55, P547; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; SKOVSGAARD T, 1990, TRANSPORT MULTIDRUG, P209; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100	19	82	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32367	32372		10.1074/jbc.M400735200	http://dx.doi.org/10.1074/jbc.M400735200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15181006	Green Published, hybrid			2022-12-27	WOS:000222849700049
J	Jepson, BJN; Anderson, LJ; Rubio, LM; Taylor, CJ; Butler, CS; Flores, E; Herrero, A; Butt, JN; Richardson, DJ				Jepson, BJN; Anderson, LJ; Rubio, LM; Taylor, CJ; Butler, CS; Flores, E; Herrero, A; Butt, JN; Richardson, DJ			Tuning a nitrate reductase for function - The first spectropotentiometric characterization of a bacterial assimilatory nitrate reductase reveals novel redox properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SYNECHOCOCCUS SP PCC-7942; PROTEIN FILM VOLTAMMETRY; ESCHERICHIA-COLI; PARACOCCUS-DENITRIFICANS; THIOSPHAERA-PANTOTROPHA; AZOTOBACTER-VINELANDII; NITRITE REDUCTASES; ELECTRON-TRANSFER; FERREDOXIN	Bacterial cytoplasmic assimilatory nitrate reductases are the least well characterized of all of the subgroups of nitrate reductases. In the present study the ferredoxin-dependent nitrate reductase NarB of the cyanobacterium Synechococcus sp. PCC 7942 was analyzed by spectropotentiometry and protein film voltammetry. Metal and acid-labile sulfide analysis revealed nearest integer values of 4: 4: 1 (iron/sulfur/molybdenum)/molecule of NarB. Analysis of dithionite-reduced enzyme by low temperature EPR revealed at 10 K the presence of a signal that is characteristic of a [4Fe-4S](1+) cluster. EPR-monitored potentiometric titration of NarB revealed that this cluster titrated as an n = 1 Nernstian component with a midpoint redox potential (E-m) of -190 mV. EPR spectra collected at 60 K revealed a Mo(V) signal termed "very high g" with g(av) = 2.0047 in air-oxidized enzyme that accounted for only 10-20% of the total molybdenum. This signal disappeared upon reduction with dithionite, and a new "high g" species (g(av) = 1.9897) was observed. In potentiometric titrations the high g Mo( V) signal developed over the potential range of -100 to -350 mV (E-m Mo6+/5+ = -150 mV), and when fully developed, it accounted for 1 mol of Mo(V)/mol of enzyme. Protein film voltammetry of NarB revealed that activity is turned on at potentials below -200 mV, where the cofactors are predominantly [4Fe-4S](1+) and Mo5+. The data suggests that during the catalytic cycle nitrate will bind to the Mo5+ state of NarB in which the enzyme is minimally two-electron-reduced. Comparison of the spectral properties of NarB with those of the membrane-bound and periplasmic respiratory nitrate reductases reveals that it is closely related to the periplasmic enzyme, but the potential of the molybdenum center of NarB is tuned to operate at lower potentials, consistent with the coupling of NarB to low potential ferredoxins in the cell cytoplasm.	Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ Sevilla, CSIC, Inst Bioquim Vegetale & Fotosintesis, E-41092 Seville, Spain; Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of East Anglia; University of East Anglia; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Newcastle University - UK	Richardson, DJ (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	d.richardson@uea.ac.uk	Flores, Enrique/L-2007-2014; Flores, Enrique/M-8407-2019; Butt, Julea/E-2133-2011; Richardson, David J/E-2275-2011; Rubio, Luis M./B-5827-2009; Herrero, Antonia/B-7246-2015	Flores, Enrique/0000-0001-7605-7343; Flores, Enrique/0000-0001-7605-7343; Butt, Julea/0000-0002-9624-5226; Rubio, Luis M./0000-0003-1596-2475; Herrero, Antonia/0000-0003-1071-6590				Anderson LJ, 2001, BIOCHEMISTRY-US, V40, P11294, DOI 10.1021/bi002706b; Arnoux P, 2003, NAT STRUCT BIOL, V10, P928, DOI 10.1038/nsb994; BENNETT B, 1994, EUR J BIOCHEM, V226, P789, DOI 10.1111/j.1432-1033.1994.00789.x; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; BOTTIN H, 1992, BIOCHIM BIOPHYS ACTA, V1101, P48, DOI 10.1016/0167-4838(92)90465-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON J, 1994, FEBS LETT, V345, P76, DOI 10.1016/0014-5793(94)00445-5; Butler CS, 2002, BIOCHEM J, V363, P817, DOI 10.1042/0264-6021:3630817; Butler CS, 1999, BIOCHEMISTRY-US, V38, P9000, DOI 10.1021/bi990402n; Butt JN, 2002, BIOELECTROCHEMISTRY, V56, P17, DOI 10.1016/S1567-5394(02)00049-X; CRASKE A, 1986, EUR J BIOCHEM, V158, P429, DOI 10.1111/j.1432-1033.1986.tb09771.x; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; EADY RR, 1987, BIOCHEM J, V244, P197, DOI 10.1042/bj2440197; Ellington MJK, 2002, J BACTERIOL, V184, P4767, DOI 10.1128/JB.184.17.4767-4774.2002; Elliott SJ, 2004, BIOCHEMISTRY-US, V43, P799, DOI 10.1021/bi035869j; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; Flores E., 1994, MOL BIOL CYANOBACTER, VVol 1, P487; Frangioni B, 2004, J AM CHEM SOC, V126, P1328, DOI 10.1021/ja0384072; GANGESWARAN R, 1993, BIOCHEM J, V289, P335, DOI 10.1042/bj2890335; Gangeswaran R, 1996, BIOCHEM J, V317, P103, DOI 10.1042/bj3170103; Hirasawa M, 2004, BBA-BIOENERGETICS, V1608, P155, DOI 10.1016/j.bbabio.2003.11.006; Jormakka M, 2004, STRUCTURE, V12, P95, DOI 10.1016/j.str.2003.11.020; LARA C, 1987, J BACTERIOL, V169, P4376, DOI 10.1128/jb.169.9.4376-4378.1987; LIN JT, 1993, J BACTERIOL, V175, P2370, DOI 10.1128/JB.175.8.2370-2378.1993; Lin JT, 1998, ADV MICROB PHYSIOL, V39, P1; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; LUQUE I, 1994, BBA-BIOENERGETICS, V1184, P296, DOI 10.1016/0005-2728(94)90236-4; Magalon A, 1998, BIOCHEMISTRY-US, V37, P7363, DOI 10.1021/bi972858f; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MIKAMI B, 1984, BIOCHIM BIOPHYS ACTA, V791, P294, DOI 10.1016/0167-4838(84)90340-6; OGAWA KI, 1995, J BACTERIOL, V177, P1409, DOI 10.1128/jb.177.5.1409-1413.1995; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; Potter LC, 1999, BIOCHEM J, V344, P77, DOI 10.1042/0264-6021:3440077; Rasmussen T, 2000, BIOCHEMISTRY-US, V39, P12753, DOI 10.1021/bi001811i; Richardson DJ, 2001, CELL MOL LIFE SCI, V58, P165, DOI 10.1007/PL00000845; Rubio LM, 1998, J BACTERIOL, V180, P1200, DOI 10.1128/JB.180.5.1200-1206.1998; Rubio LM, 1999, FEBS LETT, V462, P358, DOI 10.1016/S0014-5793(99)01556-2; Rubio LM, 1996, PLANT MOL BIOL, V30, P845, DOI 10.1007/BF00019017; Rubio LM, 2002, PHOTOSYNTH RES, V72, P13, DOI 10.1023/A:1016078700839	39	67	70	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32212	32218		10.1074/jbc.M402669200	http://dx.doi.org/10.1074/jbc.M402669200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166246	hybrid			2022-12-27	WOS:000222849700028
J	Schelling, P; Claus, MT; Johner, R; Marquez, VE; Schulz, GE; Scapozza, L				Schelling, P; Claus, MT; Johner, R; Marquez, VE; Schulz, GE; Scapozza, L			Biochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; QUANTITATIVE-DETERMINATION; BIOLOGICAL-ACTIVITY; BRAIN-TUMORS; ACTIVE-SITE; THERAPY; GANCICLOVIR; NUCLEOSIDE; SUICIDE; ACYCLOVIR	Two analogs of the natural nucleoside dT featuring a pseudosugar with fixed conformation in place of the deoxyribosyl residue ( carbathymidine analogs) were biochemically and structurally characterized for their acceptance by both human cytosolic thymidine kinase isoenzyme 1 (hTK1) and herpes simplex virus type 1 thymidine kinase (HSV1 TK) and subsequently tested in cell proliferation assays. 3'-exo-Methanocarbathymidine ((South)-methanocarbathymidine (S)-MCT), which is a substrate for HSV1 TK, specifically inhibited growth of HSV1 TK-transduced human osteosarcoma cells with an IC50 value in the range of 15 muM without significant toxicity toward both hTK1-negative (TK-) and non-transduced cells. 2'-exo-Methanocarbathymidine ((North)-methanocarbathymidine (N)-MCT), which is a weak substrate for hTK1 and a substantial one for HSV1 TK, induced a specific growth inhibition in HSV1 TK-transfected cells comparable to that of (S)-MCT and ganciclovir. A growth inhibition activity was also observed with (N)-MCT and ganciclovir in non-transduced cells in a cell line-dependent manner, whereas TK- cells were not affected. The presented 1.95-Angstrom crystal structure of the complex (S)-MCT.HSV1 TK explains both the more favorable binding affinity and catalytic turnover of (S)-MCT for HSV1 TK over the North analog. Additionally the plasticity of the active site of the enzyme is addressed by comparing the binding of (North)- and (South)- carbathymidine analogs. The presented study of these two potent candidate prodrugs for HSV1 TK gene-directed enzyme prodrug therapy suggests that (S)-MCT may be even safer to use than its North counterpart ( N)-MCT.	ETH, Inst Pharmaceut Sci, CH-8057 Zurich, Switzerland; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; NCI, Med Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Freiburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Scapozza, L (corresponding author), ETH, Inst Pharmaceut Sci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	Leonardo.Scapozza@pharma.ethz.ch	Marquez, Victor/AAP-3549-2021	Scapozza, Leonardo/0000-0003-1079-648X	NATIONAL CANCER INSTITUTE [Z01BC006174, ZIABC006174] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGBARIA R, 1994, MOL PHARMACOL, V45, P777; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bennett MS, 1999, FEBS LETT, V443, P121, DOI 10.1016/S0014-5793(98)01619-6; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Block A, 1997, PANCREAS, V15, P25, DOI 10.1097/00006676-199707000-00004; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Champness JN, 1998, PROTEINS, V32, P350, DOI 10.1002/(SICI)1097-0134(19980815)32:3<350::AID-PROT10>3.0.CO;2-8; CHEN MS, 1978, J BIOL CHEM, V253, P1325; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; Degreve B, 2001, MOL PHARMACOL, V59, P285, DOI 10.1124/mol.59.2.285; Drake RR, 1999, J BIOL CHEM, V274, P37186, DOI 10.1074/jbc.274.52.37186; DREUSICKE D, 1986, FEBS LETT, V208, P301, DOI 10.1016/0014-5793(86)81037-7; Drobyski WR, 2003, J IMMUNOL, V170, P3046, DOI 10.4049/jimmunol.170.6.3046; Fillat C., 2003, Current Gene Therapy, V3, P13, DOI 10.2174/1566523033347426; Gerber S, 1996, BIOCHEM BIOPH RES CO, V225, P263, DOI 10.1006/bbrc.1996.1164; Haynes P, 1996, MUTAT RES-GENET TOX, V369, P65, DOI 10.1016/S0165-1218(96)90049-X; Herman JR, 1999, HUM GENE THER, V10, P1239, DOI 10.1089/10430349950018229; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Iwayama S, 1998, ANTIMICROB AGENTS CH, V42, P1666, DOI 10.1128/AAC.42.7.1666; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOST LM, 1992, J IMMUNOL METHODS, V147, P153, DOI 10.1016/S0022-1759(12)80003-2; Kohn DB, 2003, MOL THER, V8, P180, DOI 10.1016/S1525-0016(03)00212-0; Kokoris MS, 2000, ANTICANCER RES, V20, P959; Kokoris MS, 1999, GENE THER, V6, P1415, DOI 10.1038/sj.gt.3300966; Kussmann-Gerber S, 1999, NUCLEOS NUCLEOT, V18, P311, DOI 10.1080/15257779908043078; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marquez VE, 2004, J AM CHEM SOC, V126, P543, DOI 10.1021/ja037929e; Marquez VE, 1998, J AM CHEM SOC, V120, P2780, DOI 10.1021/ja973535+; Marquez VE, 1999, NUCLEOS NUCLEOT, V18, P521, DOI 10.1080/15257779908041487; Marquez VE, 1996, J MED CHEM, V39, P3739, DOI 10.1021/jm960306+; MORGAN SJ, 1994, KULTUR TIERISCHER ZE, P63; Mu L, 2000, BIOCHEMISTRY-US, V39, P11205, DOI 10.1021/bi001090n; Noy R, 2002, MOL CANCER THER, V1, P585; Ono N, 1998, ANTIMICROB AGENTS CH, V42, P2095, DOI 10.1128/AAC.42.8.2095; Perozzo R, 2000, J BIOL CHEM, V275, P16139, DOI 10.1074/jbc.M000509200; Pilger BD, 1999, J BIOL CHEM, V274, P31967, DOI 10.1074/jbc.274.45.31967; Prota A, 2000, BIOCHEMISTRY-US, V39, P9597, DOI 10.1021/bi000668q; PROTA A, 1999, STRUCTURE ELUCIDATIO, P61; Qasim W, 2002, GENE THER, V9, P824, DOI 10.1038/sj.gt.3301690; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Russ P, 2003, J MED CHEM, V46, P5045, DOI 10.1021/jm030241s; Saenger W., 1984, PRINCIPLES NUCL ACID, P51; Schelling P, 2001, ANAL BIOCHEM, V295, P82, DOI 10.1006/abio.2001.5191; Sekiyama T, 1998, J MED CHEM, V41, P1284, DOI 10.1021/jm9705869; Siddiqui MA, 1996, NUCLEOS NUCLEOT, V15, P235, DOI 10.1080/07328319608002382; Stockhammer G, 1997, J MOL MED, V75, P300, DOI 10.1007/s001090050116; Sulpizi M, 2001, J BIOL CHEM, V276, P21692, DOI 10.1074/jbc.M010223200; Terazaki Y, 2003, HEPATOLOGY, V37, P155, DOI 10.1053/jhep.2003.50018; Thust R, 1996, ANTIVIR RES, V31, P105, DOI 10.1016/0166-3542(96)00961-8; Thust R, 2000, CANCER GENE THER, V7, P107, DOI 10.1038/sj.cgt.7700106; Tiberghien P, 2001, BLOOD, V97, P63, DOI 10.1182/blood.V97.1.63; WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8; Wild K, 1997, PROTEIN SCI, V6, P2097; Yazawa K, 2002, WORLD J SURG, V26, P783, DOI 10.1007/s00268-002-4053-5	59	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32832	32838		10.1074/jbc.M313343200	http://dx.doi.org/10.1074/jbc.M313343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15163659	hybrid			2022-12-27	WOS:000222849700103
J	Schulz, JM; Watson, AL; Sanders, R; Ross, KL; Thoden, JB; Holden, HM; Fridovich-Keil, JL				Schulz, JM; Watson, AL; Sanders, R; Ross, KL; Thoden, JB; Holden, HM; Fridovich-Keil, JL			Determinants of function and substrate specificity in human UDP-galactose 4 '-epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIMERASE-DEFICIENCY GALACTOSEMIA; N-ACETYLGLUCOSAMINE 4-EPIMERASE; ESCHERICHIA-COLI; ACTIVE-SITE; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; HUMAN UDP-GALACTOSE-4-EPIMERASE; GALE GENE; GLUCOSE; YEAST; IDENTIFICATION	UDP-galactose 4'-epimerase (GALE) interconverts UDP-galactose and UDP-glucose in the final step of the Leloir pathway. Unlike the Escherichia coli enzyme, human GALE (hGALE) also efficiently interconverts a larger pair of substrates: UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine. The basis of this differential substrate specificity has remained obscure. Recently, however, x-ray crystallographic data have both predicted essential active site residues and suggested that differential active site cleft volume may be a key factor in determining GALE substrate selectivity. We report here a direct test of this hypothesis. In brief, we have created four substituted alleles: S132A, Y157F, S132A/Y157F, and C307Y-hGALE. While the first three substitutions were predicted to disrupt catalytic activity, the fourth was predicted to reduce active site cleft volume, thereby limiting entry or rotation of the larger but not the smaller substrate. All four alleles were expressed in a null-background strain of Saccharomyces cerevisiae and characterized in terms of activity with regard to both UDP-galactose and UDP-N-acetylgalactosamine. The S132A/Y157F and C307Y-hGALE proteins were also overexpressed in Pichia pastoris and purified for analysis. In all forms tested, the Y157F, S132A, and Y157F/S132A-hGALE proteins each demonstrated a complete loss of activity with respect to both substrates. In contrast, the C307Y-hGALE demonstrated normal activity with respect to UDP-galactose but complete loss of activity with respect to UDP-N-acetylgalactosamine. Together, these results serve to validate the wild-type hGALE crystal structure and fully support the hypothesis that residue 307 acts as a gatekeeper mediating substrate access to the hGALE active site.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Grad Program Nutr & Hlth Sci, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Emory University; Emory University; Emory University; University of Wisconsin System; University of Wisconsin Madison	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Human Genet, Rm 325-2 Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	jfridov@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46403] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bengoechea JA, 2002, J BACTERIOL, V184, P4277, DOI 10.1128/JB.184.15.4277-4287.2002; BUBECK P, 1993, NUCLEIC ACIDS RES, V21, P3601, DOI 10.1093/nar/21.15.3601; Christacos NC, 2000, MOL GENET METAB, V70, P272, DOI 10.1006/mgme.2000.3019; DARROW RA, 1968, BIOCHEMISTRY-US, V7, P1645, DOI 10.1021/bi00845a005; DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2; Dormann P, 1998, PLANT J, V13, P641, DOI 10.1046/j.1365-313X.1998.00067.x; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; Fry BN, 2000, INFECT IMMUN, V68, P2594, DOI 10.1128/IAI.68.5.2594-2601.2000; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Holton J. B., 2000, METABOLIC MOL BASES, P1553; Ishiyama N, 2004, J BIOL CHEM, V279, P22635, DOI 10.1074/jbc.M401642200; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; Maceratesi P, 1998, MOL GENET METAB, V63, P26, DOI 10.1006/mgme.1997.2645; Maceratesi Patrizia, 1996, American Journal of Human Genetics, V59, pA204; MALEY F, 1959, BIOCHIM BIOPHYS ACTA, V31, P577, DOI 10.1016/0006-3002(59)90047-2; METZGER M, 1994, J BACTERIOL, V176, P450, DOI 10.1128/JB.176.2.450-459.1994; PILLER F, 1983, J BIOL CHEM, V258, P774; Potter MD, 1996, INFECT IMMUN, V64, P855, DOI 10.1128/IAI.64.3.855-860.1996; Quimby BB, 1996, J BIOL CHEM, V271, P26835, DOI 10.1074/jbc.271.43.26835; Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517; Roper JR, 2003, MOL BIOCHEM PARASIT, V132, P47, DOI 10.1016/j.molbiopara.2003.07.002; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; Smits HP, 1998, ANAL BIOCHEM, V261, P36, DOI 10.1006/abio.1998.2714; Soldo B, 2003, GENE, V319, P65, DOI 10.1016/S0378-1119(03)00793-5; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P10685, DOI 10.1021/bi9704313; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 2002, J BIOL CHEM, V277, P27528, DOI 10.1074/jbc.M204413200; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; Wang L, 2002, J BACTERIOL, V184, P2620, DOI 10.1128/JB.184.10.2620-2625.2002; WILSON DB, 1969, J BIOL CHEM, V244, P2132; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263; Xu DQ, 2003, J BACTERIOL, V185, P5419, DOI 10.1128/JB.185.18.5419-5430.2003; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P961, DOI 10.1002/pro.5560010801	45	52	53	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32796	32803		10.1074/jbc.M405005200	http://dx.doi.org/10.1074/jbc.M405005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175331	hybrid			2022-12-27	WOS:000222849700099
J	Yamada, S; Busse, M; Ueno, M; Kelly, OG; Skarnes, WC; Sugahara, K; Kusche-Gullberg, M				Yamada, S; Busse, M; Ueno, M; Kelly, OG; Skarnes, WC; Sugahara, K; Kusche-Gullberg, M			Embryonic fibroblasts with a gene trap mutation in Ext1 produce short heparan sulfate chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; TUMOR SUPPRESSORS EXT1; GLUCURONYL C5-EPIMERASE; FUNCTIONAL-ANALYSIS; NEONATAL LETHALITY; GOLGI-APPARATUS; TOUT-VELU; BIOSYNTHESIS; FAMILY; PROTEOGLYCANS	Mutational defects in either EXT1 or EXT2 genes cause multiple exostoses, an autosomal hereditary human disorder. The EXT1 and EXT2 genes encode glycosyltransferases that play an essential role in heparan sulfate chain elongation. In this study, we have analyzed heparan sulfate synthesized by primary fibroblast cell cultures established from mice with a gene trap mutation in Ext1. The gene trap mutation results in embryonic lethality, and homozygous mice die around embryonic day 14. Metabolic labeling and immunohistochemistry revealed that Ext1 mutant fibroblasts still produced small amounts of heparan sulfate. The domain structure of the mutant heparan sulfate was conserved, and the disaccharide composition was similar to that of wild type heparan sulfate. However, a dramatic difference was seen in the polysaccharide chain length. The average molecular sizes of the heparan sulfate chains from wild type and Ext1 mutant embryonic fibroblasts were estimated to be around 70 and 20 kDa, respectively. These data suggest that not only the sulfation pattern but also the length of the heparan sulfate chains is a critical determinant of normal mouse development.	Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Uppsala University; Kobe Pharmaceutical University; University of California System; University of California Berkeley	Kusche-Gullberg, M (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Marion.Kusche@imbim.uu.se	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; COOK A, 1993, AM J HUM GENET, V53, P71; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Hagner-McWhirter A, 2000, GLYCOBIOLOGY, V10, P159, DOI 10.1093/glycob/10.2.159; Han C, 2004, DEVELOPMENT, V131, P1563, DOI 10.1242/dev.01051; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V268, P860, DOI 10.1006/bbrc.2000.2219; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; KURE S, 1986, J IMMUNOL, V137, P3900; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin X, 1998, BIOCHEM BIOPH RES CO, V248, P738, DOI 10.1006/bbrc.1998.9050; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SOLOMON L, 1963, J BONE JOINT SURG BR, V45, P292, DOI 10.1302/0301-620X.45B2.292; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Takei Y, 2004, DEVELOPMENT, V131, P73, DOI 10.1242/dev.00913; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Wei G, 2000, J BIOL CHEM, V275, P27733; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	47	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32134	32141		10.1074/jbc.M312624200	http://dx.doi.org/10.1074/jbc.M312624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161920	hybrid			2022-12-27	WOS:000222849700019
J	Nilsen, N; Nonstad, U; Khan, N; Knetter, CF; Akira, S; Sundan, A; Espevik, T; Lien, E				Nilsen, N; Nonstad, U; Khan, N; Knetter, CF; Akira, S; Sundan, A; Espevik, T; Lien, E			Lipopolysaccharide and double-stranded RNA up-regulate toll-like receptor 2 independently of myeloid differentiation factor 88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMANIZED ANTI-CD4 ANTIBODY; INNATE IMMUNE-SYSTEM; BETA-GLUCAN RECEPTOR; CUTTING EDGE; PATTERN-RECOGNITION; GENE EXPRESSIONS; CELL ACTIVATION; DOWN-REGULATION; T-CELLS	Toll-like receptor 2 (TLR2) is a signaling receptor for a variety of microbial products, including bacterial lipoproteins and peptidoglycan, and is central in initiating immune responses toward Gram-positive bacteria, spirochetes, and mycobacteria. The mechanisms behind regulation of TLR2 protein expression are still not well understood. By using a newly developed monoclonal antibody against mouse TLR2, we detected TLR2 protein expression on macrophages, neutrophils, and dendritic cells. Endogenous macrophage TLR2 localized mostly to the cell membrane, with particular accumulation around phagosomes containing zymosan. Treatment of macrophages with the TLR2 antibody diminished cellular response to lipoproteins and down-regulated membrane TLR2. Marked up-regulation of surface TLR2 was observed on macrophages in response to whole bacteria, lipoproteins, lipopolysaccharide, poly(I-C) (double-stranded RNA), R848, and CpG DNA, and this up-regulation appeared to be a very sensitive marker for the presence of microbial products. Up-regulation of TLR2 in response to stimuli correlated with an increased response to secondary lipoprotein exposure following a low concentration of primary lipoprotein challenge. By comparison, exposure to a larger primary challenge induced a hyporeactive state. Most interestingly, lipopolysaccharide- and double-stranded RNA-induced upregulation of surface TLR2 in macrophages was found to be MyD88-independent, whereas the up-regulation in response to lipoproteins, R848, and CpG DNA was absent in MyD88-deficient cells. We conclude that complex mechanisms regulate expression and signaling via TLR2. Up-regulation of TLR2 in the presence of low, yet clinically relevant amounts of microbial products may be an important mechanism by which the immune system boosts its response to a beginning infection.	Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Dept Med, Worcester, MA 01605 USA; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7489 Trondheim, Norway; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan	University of Massachusetts System; University of Massachusetts Worcester; Norwegian University of Science & Technology (NTNU); Osaka University	Lien, E (corresponding author), Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Dept Med, 364 Plantat St,Lazare Res Bldg 311, Worcester, MA 01605 USA.	Egil.Lien@umassmed.edu	Akira, Shizuo/C-3134-2009; Nilsen, Nadra/G-5592-2017	Nilsen, Nadra/0000-0003-0407-1060	NIAID NIH HHS [R01 AI57588] Funding Source: Medline; NIDDK NIH HHS [5 P30 DK32520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; BARTHOLOMEW M, 1995, IMMUNOLOGY, V85, P41; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Brett SJ, 1997, IMMUNOLOGY, V91, P346, DOI 10.1046/j.1365-2567.1997.00265.x; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Delude RL, 1998, J IMMUNOL, V161, P3001; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heine H, 1999, J IMMUNOL, V162, P6971; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HENRICSON BE, 1993, INFECT IMMUN, V61, P2325, DOI 10.1128/IAI.61.6.2325-2333.1993; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; HOEE K, 2003, NATURE, V424, P743; HOGAN MM, 1987, J IMMUNOL, V139, P3697; Hoshino K, 1999, J IMMUNOL, V162, P3749; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lien E, 2003, NAT IMMUNOL, V4, P1162, DOI 10.1038/ni1203-1162; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Liu T, 2002, INFECT IMMUN, V70, P6638, DOI 10.1128/IAI.70.12.6638-6645.2002; Matsuguchi T, 2000, BLOOD, V95, P1378, DOI 10.1182/blood.V95.4.1378.004k08_1378_1385; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Min R, 2002, BRIT J HAEMATOL, V118, P495, DOI 10.1046/j.1365-2141.2002.03635.x; MOREL P, 1992, CELL IMMUNOL, V145, P287, DOI 10.1016/0008-8749(92)90332-J; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Okada T, 2003, EUR J IMMUNOL, V33, P1012, DOI 10.1002/eji.200323616; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 2003, GENES IMMUN, V4, P87, DOI 10.1038/sj.gene.6363937; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Schjetne KW, 2003, J IMMUNOL, V171, P32, DOI 10.4049/jimmunol.171.1.32; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Weighardt H, 2004, EUR J IMMUNOL, V34, P558, DOI 10.1002/eji.200324714; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; ZHANG XK, 1993, J EXP MED, V177, P511, DOI 10.1084/jem.177.2.511	70	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39727	39735		10.1074/jbc.M405027200	http://dx.doi.org/10.1074/jbc.M405027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15190057	hybrid			2022-12-27	WOS:000223791500065
J	Garcin, ED; Bruns, CM; Lloyd, SJ; Hosfield, DJ; Tiso, M; Gachhui, R; Stuehr, DJ; Tainer, JA; Getzoff, ED				Garcin, ED; Bruns, CM; Lloyd, SJ; Hosfield, DJ; Tiso, M; Gachhui, R; Stuehr, DJ; Tainer, JA; Getzoff, ED			Structural basis for isozyme-specific regulation of electron transfer in nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITORY CONTROL ELEMENT; REDUCTASE DOMAIN; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURES; OXYGENASE DOMAIN; TRANSFER COMPLEX; NO SYNTHASE; CALMODULIN; BINDING; ISOFORMS	Three nitric-oxide synthase (NOS) isozymes play crucial, but distinct, roles in neurotransmission, vascular homeostasis, and host defense, by catalyzing Ca2+/calmodulin-triggered NO synthesis. Here, we address current questions regarding NOS activity and regulation by combining mutagenesis and biochemistry with crystal structure determination of a fully assembled, electron-supplying, neuronal NOS reductase dimer. By integrating these results, we structurally elucidate the unique mechanisms for isozyme-specific regulation of electron transfer in NOS. Our discovery of the autoinhibitory helix, its placement between domains, and striking similarities with canonical calmodulin-binding motifs, support new mechanisms for NOS inhibition. NADPH, isozyme-specific residue Arg(1400), and the C-terminal tail synergistically repress NOS activity by locking the FMN binding domain in an electron-accepting position. Our analyses suggest that calmodulin binding or C-terminal tail phosphorylation frees a large scale swinging motion of the entire FMN domain to deliver electrons to the catalytic module in the holoenzyme.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Syrrx Inc, San Diego, CA 92121 USA; Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Scripps Research Institute; Scripps Research Institute; Cleveland Clinic Foundation	Getzoff, ED (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,MB4, La Jolla, CA 92037 USA.	edg@scripps.edu	Tainer, John/GWQ-4878-2022; Garcin, Elsa D/C-1556-2013	Tainer, John/0000-0003-1659-2429; Garcin, Elsa D/0000-0003-0501-8421	NHLBI NIH HHS [R01HL58883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andoh T, 2002, ANN NY ACAD SCI, V962, P1, DOI 10.1111/j.1749-6632.2002.tb04051.x; Aoyagi M, 2003, EMBO J, V22, P766, DOI 10.1093/emboj/cdg078; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Brunner K, 1998, BIOCHEMISTRY-US, V37, P17545, DOI 10.1021/bi981138l; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 2003, BIOCHEM SOC T, V31, P502, DOI 10.1042/bst0310502; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Hall DA, 2001, P NATL ACAD SCI USA, V98, P9521, DOI 10.1073/pnas.171168898; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Kobayashi K, 2001, J BIOL CHEM, V276, P39864, DOI 10.1074/jbc.M102537200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; Li HY, 2002, BIOCHEMISTRY-US, V41, P13868, DOI 10.1021/bi020417c; Lowe PN, 1996, BIOCHEM J, V314, P55, DOI 10.1042/bj3140055; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Munro AW, 2002, TRENDS BIOCHEM SCI, V27, P250, DOI 10.1016/S0968-0004(02)02086-8; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Rosenfeld RJ, 2002, BIOCHEMISTRY-US, V41, P13915, DOI 10.1021/bi026313j; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SMITH WW, 1977, J MOL BIOL, V117, P195, DOI 10.1016/0022-2836(77)90031-6; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	56	233	237	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37918	37927		10.1074/jbc.M406204200	http://dx.doi.org/10.1074/jbc.M406204200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208315	hybrid			2022-12-27	WOS:000223554600085
J	Bianchi, C; Genova, ML; Castelli, GP; Lenaz, G				Bianchi, C; Genova, ML; Castelli, GP; Lenaz, G			The mitochondrial respiratory chain is partially organized in a supercomplex assembly - Kinetic evidence using flux control analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; CYTOCHROME-C OXIDOREDUCTASE; BOVINE HEART-MITOCHONDRIA; COENZYME-Q REDUCTASE; COMPLEX-I; ELECTRON-TRANSPORT; OXIDATIVE-PHOSPHORYLATION; PARACOCCUS-DENITRIFICANS; SUBMITOCHONDRIAL PARTICLES; OXIDASE SUPERCOMPLEX	The model of the respiratory chain in which the enzyme complexes are independently embedded in the lipid bilayer of the inner mitochondrial membrane and connected by randomly diffusing coenzyme Q and cytochrome c is mostly favored. However, multicomplex units can be isolated from mammalian mitochondria, suggesting a model based on direct electron channeling between complexes. Kinetic testing using metabolic flux control analysis can discriminate between the two models: the former model implies that each enzyme may be rate-controlling to a different extent, whereas in the latter, the whole metabolic pathway would behave as a single supercomplex and inhibition of any one of its components would elicit the same flux control. In particular, in the absence of other components of the oxidative phosphorylation apparatus (i.e. ATP synthase, membrane potential, carriers), the existence of a supercomplex would elicit a flux control coefficient near unity for each respiratory complex, and the sum of all coefficients would be well above unity. Using bovine heart mitochondria and submitochondrial particles devoid of substrate permeability barriers, we investigated the flux control coefficients of the complexes involved in aerobic NADH oxidation (I, III, IV) and in succinate oxidation (II, III, IV). Both Complexes I and III were found to be highly rate-controlling over NADH oxidation, a strong kinetic evidence suggesting the existence of functionally relevant association between the two complexes, whereas Complex IV appears randomly distributed. Moreover, we show that Complex II is fully rate-limiting for succinate oxidation, clearly indicating the absence of substrate channeling toward Complexes III and IV.	Univ Bologna, Dipartimento Biochim G Moruzzi, I-40126 Bologna, Italy	University of Bologna	Lenaz, G (corresponding author), Univ Bologna, Dipartimento Biochim G Moruzzi, Via Irnerio 48, I-40126 Bologna, Italy.	lenaz@biocfarm.unibo.it	Genova, Maria Luisa/H-6921-2012; Lenaz, Giorgio/B-5751-2013	Genova, Maria Luisa/0000-0002-9176-3630; 				BECHMANN G, 1992, EUR J BIOCHEM, V208, P315, DOI 10.1111/j.1432-1033.1992.tb17189.x; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Bianchi C, 2003, BIOFACTORS, V18, P3, DOI 10.1002/biof.5520180202; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; BRAND MD, 1994, EUR J BIOCHEM, V226, P819, DOI 10.1111/j.1432-1033.1994.00819.x; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CHANCE B, 1955, NATURE, V176, P250, DOI 10.1038/176250a0; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; ESPOSTI MD, 1993, BIOCHEM BIOPH RES CO, V190, P1090, DOI 10.1006/bbrc.1993.1161; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Eubel H, 2004, PLANT PHYSIOL, V134, P1450, DOI 10.1104/pp.103.038018; EUBEL H, 2003, PLANT PHYSIOL, V133, P1; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; GENOVA ML, 1995, BIOCHEM J, V311, P105, DOI 10.1042/bj3110105; Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1; Gutman M, 1985, COENZYME Q, P215; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Hatefi Y, 1978, Methods Enzymol, V53, P21; Hatefi Y, 1978, Methods Enzymol, V53, P48; HATEFI Y, 1961, BIOCHIM BIOPHYS ACTA, V52, P106, DOI 10.1016/0006-3002(61)90908-8; Hatefi Y, 1978, Methods Enzymol, V53, P3; HATEFI Y, 1962, J BIOL CHEM, V237, P1676; HERON C, 1978, BIOCHEM J, V174, P791, DOI 10.1042/bj1740791; HOCHLI M, 1976, P NATL ACAD SCI USA, V73, P1636, DOI 10.1073/pnas.73.5.1636; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; *JAND SCI SOFTW, 1995, SIGM PLOT SCI GRAPH; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; KHOLODENKO BN, 1993, FEBS LETT, V320, P71, DOI 10.1016/0014-5793(93)81660-R; KROGER A, 1973, EUR J BIOCHEM, V34, P358, DOI 10.1111/j.1432-1033.1973.tb02767.x; LENAZ G, 1986, J BIOENERG BIOMEMBR, V18, P369, DOI 10.1007/BF00743011; Lenaz G, 2001, FEBS LETT, V509, P151, DOI 10.1016/S0014-5793(01)03172-6; Matsson M, 2001, J BIOENERG BIOMEMBR, V33, P99, DOI 10.1023/A:1010744330092; Moreno-Sanchez R, 1999, EUR J BIOCHEM, V264, P427, DOI 10.1046/j.1432-1327.1999.00621.x; Niebisch A, 2003, J BIOL CHEM, V278, P4339, DOI 10.1074/jbc.M210499200; RAGAN CI, 1978, BIOCHEM J, V174, P783, DOI 10.1042/bj1740783; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; Schagger H, 2001, J BIOL CHEM, V276, P37861; SCHWERZMANN K, 1986, J CELL BIOL, V102, P97, DOI 10.1083/jcb.102.1.97; Singer T P, 1979, Methods Enzymol, V55, P454; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SONE N, 1987, J BIOL CHEM, V262, P15386; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; Vanderkooi G, 1978, MOL BIOL MEMBRANES, P25; Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8; VONJAGOW G, 1986, BIOCHEMISTRY-US, V25, P775, DOI 10.1021/bi00352a006; YU L, 1982, J BIOL CHEM, V257, P2016; zawa T, 1987, BIOENERGETICS STRUCT, P101	52	197	202	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36562	36569		10.1074/jbc.M405135200	http://dx.doi.org/10.1074/jbc.M405135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205457	hybrid			2022-12-27	WOS:000223453600052
J	Campbell, SE; Tandon, NN; Woldegiorgis, G; Luiken, JJFP; Glatz, JFC; Bonen, A				Campbell, SE; Tandon, NN; Woldegiorgis, G; Luiken, JJFP; Glatz, JFC; Bonen, A			A novel function for fatty acid translocase (FAT)/CD36 - Involvement in long chain fatty acid transfer into the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MITOCHONDRIA; CONTRACTILE ACTIVITY; MALONYL-COA; CELL-FREE; CPT-I; OXIDATION; PROTEIN; INTERMYOFIBRILLAR; TRANSPORT; RAT	Fatty acid translocase (FAT)/CD36 is a long chain fatty acid transporter present at the plasma membrane, as well as in intracellular pools of skeletal muscle. In this study, we assessed the unexpected presence of FAT/CD36 in both subsarcolemmal and intermyofibril fractions of highly purified mitochondria. Functional assessments demonstrated that the mitochondria could bind C-14-labeled palmitate, but could only oxidize it in the presence of carnitine. However, the addition of sulfo-N-succinimidyl oleate, a known inhibitor of FAT/CD36, resulted in an 87 and 85% reduction of palmitate oxidation in subsarcolemmal and intermyofibril fractions, respectively. Further studies revealed that maximal carnitine palmitoyltransferase I (CPTI) activity in vitro was inhibited by succinimidyl oleate (42 and 48% reduction). Interestingly, CPTI immunoprecipitated with FAT/CD36, indicating a physical pairing. Tissue differences in mitochondrial FAT/CD36 protein follow the same pattern as the capacity for fatty acid oxidation (heart >> red muscle > white muscle). Additionally, chronic stimulation of hindlimb muscles (7 days) increased FAT/CD36 expression and also resulted in a concomitant increase in mitochondrial FAT/CD36 content (46 and 47% increase). Interestingly, with acute electrical stimulation of hindlimb muscles (30 min), FAT/CD36 expression was not altered, but there was an increase in the mitochondrial content of FAT/CD36 compared with the non-stimulated control limb (35 and 37% increase). Together, these data suggest a role for FAT/CD36 in mitochondrial long chain fatty acid uptake and demonstrate system flexibility to match FAT/CD36 mitochondrial content with an increased capacity for fatty acid oxidation, possibly involving translocation of FAT/CD36 to the mitochondria.	Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada; Otsuka Amer Pharmaceut Inc, Thrombosis & Vasc Biol Lab, Rockville, MD 20850 USA; Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Maastricht Univ, Dept Mol Genet, NL-6200 MD Maastricht, Netherlands	University of Guelph; Maastricht University	Bonen, A (corresponding author), Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada.	abonen@uoguelph.ca						Bezaire V, 2004, AM J PHYSIOL-ENDOC M, V286, pE85, DOI 10.1152/ajpendo.00237.2003; BONAS B, 2003, AM J PHYSIOL, V285, pE481; Bonen A, 2000, J BIOL CHEM, V275, P14501, DOI 10.1074/jbc.275.19.14501; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; Chilibeck PD, 2002, INT J SPORTS MED, V23, P33, DOI 10.1055/s-2002-19269; COGSWELL AM, 1993, AM J PHYSIOL, V264, pC383, DOI 10.1152/ajpcell.1993.264.2.C383; Connor MK, 2000, J APPL PHYSIOL, V88, P1601, DOI 10.1152/jappl.2000.88.5.1601; Coort SLM, 2002, MOL CELL BIOCHEM, V239, P213, DOI 10.1023/A:1020539932353; Coyle EF, 1997, AM J PHYSIOL-ENDOC M, V273, pE268, DOI 10.1152/ajpendo.1997.273.2.E268; Dean D, 2000, DIABETES, V49, P1295, DOI 10.2337/diabetes.49.8.1295; Eaton S, 2001, BIOCHEM BIOPH RES CO, V285, P537, DOI 10.1006/bbrc.2001.5201; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Febbraio M, 2002, MOL CELL BIOCHEM, V239, P193, DOI 10.1023/A:1020515210972; Glatz JFC, 2002, CURR OPIN CLIN NUTR, V5, P365, DOI 10.1097/00075197-200207000-00003; GLATZ JFC, 1984, BIOCHIM BIOPHYS ACTA, V794, P454, DOI 10.1016/0005-2760(84)90012-2; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hoppel C, 2001, ARCH BIOCHEM BIOPHYS, V392, P321, DOI 10.1006/abbi.2001.2463; Jimenez M, 2002, EUR J BIOCHEM, V269, P2878, DOI 10.1046/j.1432-1033.2002.02953.x; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Luiken JJFP, 1999, LIPIDS, V34, pS169, DOI 10.1007/BF02562278; Luiken JJFP, 2002, AM J PHYSIOL-ENDOC M, V282, pE491, DOI 10.1152/ajpendo.00419.2001; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; Odland LM, 1996, AM J PHYSIOL-ENDOC M, V270, pE541, DOI 10.1152/ajpendo.1996.270.3.E541; Odland LM, 1998, AM J PHYSIOL-REG I, V274, pR894, DOI 10.1152/ajpregu.1998.274.4.R894; Schleiff E, 1999, J CELL BIOL, V145, P973, DOI 10.1083/jcb.145.5.973; Sidossis LS, 1996, AM J PHYSIOL-ENDOC M, V270, pE733, DOI 10.1152/ajpendo.1996.270.4.E733; Spriet LL, 2002, MED SCI SPORT EXER, V34, P1477, DOI 10.1097/00005768-200209000-00013; Starritt EC, 2000, AM J PHYSIOL-ENDOC M, V278, pE462, DOI 10.1152/ajpendo.2000.278.3.E462; Takahashi M, 1996, J BIOL CHEM, V271, P27285, DOI 10.1074/jbc.271.44.27285; TANAKA T, 1995, J MOL CELL CARDIOL, V27, P1613, DOI 10.1016/S0022-2828(95)90557-X; VEERKAMP JH, 1983, BIOCHIM BIOPHYS ACTA, V753, P399, DOI 10.1016/0005-2760(83)90064-4; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	38	202	212	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36235	36241		10.1074/jbc.M400566200	http://dx.doi.org/10.1074/jbc.M400566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15161924	hybrid			2022-12-27	WOS:000223453600011
J	Yoo, YG; Lee, MO				Yoo, YG; Lee, MO			Hepatitis B virus X protein induces expression of Fas ligand gene through enhancing transcriptional activity of early growth response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UP-REGULATION; TRANSACTIVATOR PROTEIN; NUCLEAR-FACTOR; T-LYMPHOCYTES; ACTIVATION; PROMOTER; CELLS; MECHANISM; APOPTOSIS; SITES	FasL expressed in tumor cells plays an important role in the escape from immune surveillance by inducing apoptosis in T-cells bearing Fas. Since the Fas/FasL signaling pathway requires transcriptional induction of the FasL gene, elucidation of the precise mechanisms underlying regulation of FasL gene expression may provide useful molecular insights on tumor progression. We and others (Shin, E. C., Shin, J. S., Park, J. H., Kim, H., and Kim, S. J. (1999) Int. J. Cancer 82, 587-591; Lee, M. O., Kang, H. J., Cho, H., Shin, E. C., Park, J. H., and Kim, S. J. (2001) Biochem. Biophys. Res. Commun. 288, 1162-1168) have previously reported that hepatitis B virus X protein (HBx) plays a role in the induction of FasL expression in hepatitis B virus-associated hepatoma. In the present study, we analyzed the potential cis- and trans-acting factors that regulate FasL promoter. We found that HBx induced activity of the reporter containing FasL promoter through binding site for Egr but not through NFAT or SP-1, which are known as strong activators of the FasL promoter in T-cells. Transient expression of antisense Egr-2 and antisense Egr-3 abolished expression of FasL, which further confirmed the role of Egr in the HBx-mediated FasL expression. Also we observed that HBx increased the transcriptional activity of Egr-2 and Egr-3 by enhancing expression as well as the transactivation function of these proteins. HBx interacted with Egr-2 and Egr-3 in vivo and enhanced binding of Egr to the co-activator, cAMP-response element-binding protein-binding protein, which may explain the molecular mechanism by which HBx induced the transactivation function of Egr. Finally, we found that the carboxyl terminus of HBx was necessary and sufficient for FasL induction as well as activation of Egr. Taken together, our results show a novel mechanism by which HBx induces FasL gene expression that is mediated by enhancing transcriptional activity of Egr-2 and Egr-3.	Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea	Sejong University	Lee, MO (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea.	molee@sejong.ac.kr						Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; Carretero M, 2002, VIROLOGY, V299, P288, DOI 10.1006/viro.2002.1526; Chan HM, 2001, J CELL SCI, V114, P2363; Chiou SH, 2001, J IMMUNOL, V167, P4098, DOI 10.4049/jimmunol.167.7.4098; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Gottlob K, 1998, CANCER RES, V58, P3566; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; Kong HJ, 2003, HEPATOLOGY, V38, P1258, DOI 10.1053/jhep.2003.50451; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lee MO, 2002, J HEPATOL, V37, P380, DOI 10.1016/S0168-8278(02)00181-2; Lee MO, 2002, EUR J BIOCHEM, V269, P1162, DOI 10.1046/j.1432-1033.2002.02748.x; Lee MO, 2001, BIOCHEM BIOPH RES CO, V288, P1162, DOI 10.1006/bbrc.2001.5910; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Mages HW, 1998, MOL CELL BIOL, V18, P7157, DOI 10.1128/MCB.18.12.7157; Matsui K, 1998, J IMMUNOL, V161, P3469; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; O'Connell J, 1998, J PATHOL, V186, P240; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; Ruggieri A, 2003, VIRUS RES, V97, P103, DOI 10.1016/j.virusres.2003.08.004; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Shin EC, 1999, INT J CANCER, V82, P587, DOI 10.1002/(SICI)1097-0215(19990812)82:4<587::AID-IJC19>3.0.CO;2-9; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Yang YL, 2002, J BIOL CHEM, V277, P19482, DOI 10.1074/jbc.M201687200; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yun CW, 2000, ONCOGENE, V19, P5163, DOI 10.1038/sj.onc.1203896; Zauli G, 1999, BLOOD, V93, P1000, DOI 10.1182/blood.V93.3.1000.403a12_1000_1010	50	41	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36242	36249		10.1074/jbc.M401290200	http://dx.doi.org/10.1074/jbc.M401290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15173177	hybrid, Green Submitted			2022-12-27	WOS:000223453600012
J	Dreuw, A; Radtke, S; Pflanz, S; Lippok, BE; Heinrich, PC; Hermanns, HM				Dreuw, A; Radtke, S; Pflanz, S; Lippok, BE; Heinrich, PC; Hermanns, HM			Characterization of the signaling capacities of the novel gp130-like cytokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN-M RECEPTOR; TYROSINE KINASE JAK1; TRANSDUCTION PATHWAY; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; PROTEIN-KINASE; ACTIVATION; INTERLEUKIN-6	The gp130-like receptor (GPL) is a recently cloned member of the family of type I cytokine receptors. The name reflects its close relationship to gp130, the common receptor subunit of the interleukin (IL)-6-type cytokines. Indeed, the recently proposed ligand for GPL, IL-31, is closely related to the IL-6-type cytokines oncostatin M, leukemia inhibitory factor, and cardiotrophin-1. The second signal transducing receptor for IL-31 seems to be the oncostatin M receptor beta (OSMRbeta). The present study characterizes in depth the molecular mechanisms underlying GPL-mediated signal transduction. GPL is a strong activator of STAT3 and STAT5, whereas STAT1 is only marginally tyrosine-phosphorylated. We identify tyrosine residues 652 and 721 in the cytoplasmic region of the longest isoform of GPL (GPL745) as the major STAT5- and STAT3-activating sites, respectively. Additionally, we demonstrate Jak1 binding to GPL and its activation in heteromeric complexes with the OSMRbeta but also in a homomeric receptor complex. Most interesting, unlike OSMRbeta and gp130, GPL is insufficient to mediate ERK1/2 phosphorylation. We propose that this is due to a lack of recruitment of the tyrosine phosphatase SHP-2 or the adaptor protein Shc to the cytoplasmic domain of GPL.	Rhein Westfal TH Aachen, Univ Klinikum, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Hermanns, HM (corresponding author), Rhein Westfal TH Aachen, Univ Klinikum, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	heinrich@rwth-aachen.de						AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; DILLON S, 2003, EUR CYTOKINE NETW, V14, P223; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; Gross Jane A., 2003, European Cytokine Network, V14, P109; Grotzinger J, 2002, BBA-MOL CELL RES, V1592, P215, DOI 10.1016/S0167-4889(02)00316-6; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Szalai C, 2000, GENE, V243, P161, DOI 10.1016/S0378-1119(99)00536-3; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wiederkehr-Adam M, 2003, J BIOL CHEM, V278, P16117, DOI 10.1074/jbc.M300261200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	66	73	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36112	36120		10.1074/jbc.M401122200	http://dx.doi.org/10.1074/jbc.M401122200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194700	hybrid			2022-12-27	WOS:000223303400113
J	Kinoshita, Y; Johnson, EM				Kinoshita, Y; Johnson, EM			Site-specific loading of an MCM protein complex in a DNA replication initiation zone upstream of the c-MYC gene in the HeLa cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; MINICHROMOSOME MAINTENANCE PROTEINS; MCM4,6,7 HELICASE ACTIVITY; PUR-ALPHA; S-PHASE; SACCHAROMYCES-CEREVISIAE; RETINOBLASTOMA PROTEIN; HUMAN ORC; BINDING; PHOSPHORYLATION	The MCM proteins participate in an orderly association, beginning with the origin recognition complex, that culminates in the initiation of chromosomal DNA replication. Among these, MCM proteins 4, 6, and 7 constitute a subcomplex that reportedly possesses DNA helicase activity. Little is known about DNA sequences initially bound by these MCM proteins or about their cell cycle distribution in the chromatin. We have determined the locations of certain MCM and associated proteins by chromatin immunoprecipitation (ChIP) in a zone of initiation of DNA replication upstream of the c-MYC gene in the HeLa cell cycle. MCM7 and its clamp-loading partner Cdc6 are highly specifically colocalized by ChIP and re-ChIP in G(1) and early S on a 198-bp segment located near the center of the initiation zone. ChIP and Re-ChIP colocalizes MCM7 and ORC1 to the same segment specifically in late G(1). MCM proteins 6 and 7 can be coimmunoprecipitated throughout the cell cycle, whereas MCM4 is reduced in the complex in late S and G(2), reappearing upon mitosis. MCM7 is not visualized by immunohistochemistry on metaphase chromosomes. MCM7 is recruited to multiple sites in chromatin in S and G(2), at which time it is not detected with ORC1. The rate of dissemination is surprisingly slow and is unlikely to be simply attributed to progression with replication forks. Results indicate sequence-specific loading of MCM proteins onto DNA in late G(1) followed by a recruitment to multiple sites in chromatin subsequent to replication.	CUNY Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, DH Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Johnson, EM (corresponding author), CUNY Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, Box 1194 Pathol, New York, NY 10029 USA.	edward.johnson@mssm.edu			NCI NIH HHS [R01-CA55219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrow MG, 2002, J BIOL CHEM, V277, P2702, DOI 10.1074/jbc.M108118200; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Barr SM, 2001, J CELL BIOCHEM, V81, P621, DOI 10.1002/jcb.1099; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BERBERICH S, 1995, J MOL BIOL, V245, P92, DOI 10.1006/jmbi.1994.0010; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; Daniel DC, 2001, J GEN VIROL, V82, P1543, DOI 10.1099/0022-1317-82-7-1543; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Dziak R, 2003, J BIOL CHEM, V278, P27372, DOI 10.1074/jbc.M301110200; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; ISHIMI Y, 1994, MOL CELL BIOL, V14, P6489, DOI 10.1128/MCB.14.10.6489; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Johnson EM, 2003, NUCLEIC ACIDS RES, V31, P2915, DOI 10.1093/nar/gkg395; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; KARN J, 1974, J BIOL CHEM, V249, P667; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Khalili K, 2003, MOL CELL BIOL, V23, P6857, DOI 10.1128/MCB.23.19.6857-6875.2003; KORNBERG A, 1992, DNA REPLICATION, P206; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Liu GQ, 2003, MOL CELL BIOL, V23, P1832, DOI 10.1128/MCB.23.5.1832-1842.2003; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohta S, 2003, J BIOL CHEM, V278, P41535, DOI 10.1074/jbc.M307535200; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Schaarschmidt D, 2002, NUCLEIC ACIDS RES, V30, P4176, DOI 10.1093/nar/gkf532; Sclafani RA, 2000, J CELL SCI, V113, P2111; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	51	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35879	35889		10.1074/jbc.M401640200	http://dx.doi.org/10.1074/jbc.M401640200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190069	hybrid			2022-12-27	WOS:000223303400089
J	Shah, R; Coleman, CS; Mir, K; Baldwin, J; Van Etten, JL; Grishin, NV; Pegg, AE; Stanley, BA; Phillips, MA				Shah, R; Coleman, CS; Mir, K; Baldwin, J; Van Etten, JL; Grishin, NV; Pegg, AE; Stanley, BA; Phillips, MA			Paramecium bursaria chlorella virus-1 encodes an unusual arginine decarboxylase that is a close homolog of eukaryotic ornithine decarboxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; CATALYTIC IRREVERSIBLE INHIBITION; AMINO-ACID DECARBOXYLASES; ACTIVE-SITE RESIDUES; X-RAY-STRUCTURE; TRYPANOSOMA-BRUCEI; ALPHA-DIFLUOROMETHYLORNITHINE; MOLECULAR-MECHANISMS; ANGSTROM RESOLUTION; LEISHMANIA-DONOVANI	Paramecium bursaria chlorella virus (PBCV-1) is a large double-stranded DNA virus that infects chlorella-like green algae. The virus encodes a homolog of eukaryotic ornithine decarboxylase (ODC) that was previously demonstrated to be capable of decarboxylating L-ornithine. However, the active site of this enzyme contains a key amino acid substitution (Glu for Asp) of a residue that interacts with the delta-amino group of ornithine analogs in the x-ray structures of ODC. To determine whether this active-site change affects substrate specificity, kinetic analysis of the PBCV-1 decarboxylase (PBCV-1 DC) on three basic amino acids was undertaken. The k(cat)/K-m for L-arginine is 550-fold higher than for either L-ornithine or L-lysine, which were decarboxylated with similar efficiency. In addition, alpha-difluoromethylarginine was a more potent inhibitor of the enzyme than alpha-difluoromethylornithine. Mass spectrometric analysis demonstrated that inactivation was consistent with the formation of a covalent adduct at Cys(347). These data demonstrate that PBCV-1 DC should be reclassified as an arginine decarboxylase. The eukaryotic ODCs, as well as PBCV-1 DC, are only distantly related to the bacterial and plant arginine decarboxylases from their common beta/alpha-fold class; thus, the finding that PBCV-1 DC prefers L-arginine to L-ornithine was unexpected based on evolutionary analysis. Mutational analysis was carried out to determine whether the Asp-to-Glu substitution at position 296 (position 332 in Trypanosoma brucei ODC) conferred the change in substrate specificity. This residue was found to be an important determinant of substrate binding for both L-arginine and L-ornithine, but it is not sufficient to encode the change in substrate preference.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	margaret.phillips@UTSouthwestern.edu	Stanley, Bruce/R-9856-2019	Stanley, Bruce/0000-0003-1338-2928	NCI NIH HHS [R37 CA18138] Funding Source: Medline; NCRR NIH HHS [P20RR15635] Funding Source: Medline; NIAID NIH HHS [R01 AI34432] Funding Source: Medline; NIGMS NIH HHS [GM32441] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA018138] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BITONTI AJ, 1987, BIOCHEM J, V242, P69, DOI 10.1042/bj2420069; BROWN MR, 1992, J EXP MAR BIOL ECOL, V161, P91, DOI 10.1016/0022-0981(92)90192-D; Coleman CS, 2004, BIOCHEM J, V379, P849, DOI 10.1042/BJ20040035; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; COLIGAN JE, 1996, CURRENT PROTOCOLS PR, V2; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Hanfrey C, 2002, J BIOL CHEM, V277, P44131, DOI 10.1074/jbc.M206161200; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Jackson LK, 2003, J BIOL CHEM, V278, P22037, DOI 10.1074/jbc.M300188200; Jeffrey CJ, 2000, PROTEIN ENG, V13, P105; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; Kaiser A, 1999, VIROLOGY, V263, P254, DOI 10.1006/viro.1999.9972; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Li F, 1998, EXP PARASITOL, V88, P255, DOI 10.1006/expr.1998.4237; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MOMANY C, 1995, PROTEIN SCI, V4, P849; Morehead TA, 2002, VIROLOGY, V301, P165, DOI 10.1006/viro.2002.1573; Morgan DML, 1999, MOL BIOTECHNOL, V11, P229, DOI 10.1007/BF02788682; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x; OBrien TG, 1997, CANCER RES, V57, P2630; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; Osterman AL, 1997, BIOCHEMISTRY-US, V36, P4558, DOI 10.1021/bi962916h; Osterman AL, 1999, BIOCHEMISTRY-US, V38, P11814, DOI 10.1021/bi9906221; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; Park JH, 2003, J BIOL CHEM, V278, P32683, DOI 10.1074/jbc.M304247200; PEGG AE, 1994, BIOCHEM SOC T, V22, P846, DOI 10.1042/bst0220846; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1979, BIOCHIM BIOPHYS ACTA, V568, P416, DOI 10.1016/0005-2744(79)90310-3; PEGG AE, 1995, J CELL BIOCHEM, P132; Pei JM, 2003, BIOINFORMATICS, V19, P427, DOI 10.1093/bioinformatics/btg008; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; POULIN R, 1992, J BIOL CHEM, V267, P150; Rajagopalan PTR, 2002, BIOCHEMISTRY-US, V41, P12618, DOI 10.1021/bi026369d; Ray SS, 2002, STRUCTURE, V10, P1499, DOI 10.1016/S0969-2126(02)00880-8; Roberts SC, 2002, J BIOL CHEM, V277, P5902, DOI 10.1074/jbc.M110118200; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Takatsuka Y, 2000, J BACTERIOL, V182, P6732, DOI 10.1128/JB.182.23.6732-6741.2000; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Tome ME, 1997, BIOL SIGNAL, V6, P150; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; White WH, 2001, J BIOL CHEM, V276, P10794, DOI 10.1074/jbc.M009804200	53	28	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35760	35767		10.1074/jbc.M405366200	http://dx.doi.org/10.1074/jbc.M405366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190062	hybrid			2022-12-27	WOS:000223303400075
J	Werner, ED; Lee, JS; Hansen, L; Yuan, MS; Shoelson, SE				Werner, ED; Lee, JS; Hansen, L; Yuan, MS; Shoelson, SE			Insulin resistance due to phosphorylation of insulin receptor substrate-1 at Serine 302	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; TYROSINE PHOSPHORYLATION; SERINE/THREONINE PHOSPHORYLATION; FACTOR-ALPHA; METABOLIC SYNDROME; TARGETED DISRUPTION; DIABETES-MELLITUS; SIGNALING CASCADE	Inhibitory serine phosphorylation is a potential molecular mechanism for insulin resistance. We have developed a new variant of the yeast two-hybrid method, referred to as disruptive yeast tri-hybrid (Y3H), to identify inhibitory kinases and sites of phosphorylation in insulin receptors (IR) and IR substrates, IRS-1. Using IR and IRS-1 as bait and prey, respectively, and c-Jun NH2-terminal kinase (JNK1) as the disruptor, we now show that phosphorylation of IRS-1 Ser-307, a previously identified site, is necessary but not sufficient for JNK1-mediated disruption of IR/IRS-1 binding. We further identify a new phosphorylation site, Ser-302, and show that this too is necessary for JNK1-mediated disruption. Seven additional kinases potentially linked to insulin resistance similarly block IR/IRS-1 binding in the disruptive Y3H, but through distinct Ser-302- and Ser-307-independent mechanisms. Phosphospecific antibodies that recognize sequences surrounding Ser(P)-302 or Ser(P)-307 were used to determine whether the sites were phosphorylated under relevant conditions. Phosphorylation was promoted at both sites in Fao hepatoma cells by reagents known to promote Ser/Thr phosphorylation, including the phorbol ester phorbol 12-myristate 13-acetate, anisomycin, calyculin A, and insulin. The antibodies further showed that Ser(P)-302 and Ser(P)-307 are increased in animal models of obesity and insulin resistance, including genetically obese ob/ob mice, diet-induced obesity, and upon induction of hyperinsulinemia. These findings demonstrate that phosphorylation at both Ser-302 and Ser-307 is necessary for JNK1-mediated inhibition of the IR/IRS-1 interaction and that Ser-302 and Ser-307 are phosphorylated in parallel in cultured cells and in vivo under conditions that lead to insulin resistance.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Lee, JS (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	Jongsoon.Lee@joslin.harvard.edu; Steven.Shoelson@joslin.harvard.edu	Lee, Jongsoon/AAG-1674-2020	Lee, Jongsoon/0000-0002-0891-5059	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045943, P30DK036836, R21DK063225, F32DK009393, R01DK043123] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45943, DK43123, DK63225, DK36836, DK09393] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; DHEPAGANON S, 2004, IN PRESS NAT STRUCT; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FREIDENBERG GR, 1988, J CLIN INVEST, V82, P1398, DOI 10.1172/JCI113744; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Harlow E., 1988, ANTIBODIES LAB MANUA; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hartman ME, 2001, BIOCHEM BIOPH RES CO, V280, P776, DOI 10.1006/bbrc.2000.4214; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hotamisligil GS, 2000, INT J OBESITY, V24, pS23, DOI 10.1038/sj.ijo.0801497; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; LAM K, 1994, J BIOL CHEM, V269, P20648; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; *NAT DIAB DAT GROU, 1994, DIAB AM; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Radziuk J, 2000, J CLIN ENDOCR METAB, V85, P4426, DOI 10.1210/jc.85.12.4426; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; Spranger J, 2003, DIABETES, V52, P812, DOI 10.2337/diabetes.52.3.812; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	80	178	181	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35298	35305		10.1074/jbc.M405203200	http://dx.doi.org/10.1074/jbc.M405203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199052	hybrid, Green Published			2022-12-27	WOS:000223303400021
J	Comegys, MM; Lin, SH; Rand, D; Britt, D; Flanagan, D; Callanan, H; Brilliant, K; Hixson, DC				Comegys, MM; Lin, SH; Rand, D; Britt, D; Flanagan, D; Callanan, H; Brilliant, K; Hixson, DC			Two variable regions in carcinoembryonic antigen-related cell adhesion molecule1 N-terminal domains located in or next to monoclonal antibody and adhesion epitopes show evidence of recombination in rat but not in human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; BILIARY GLYCOPROTEIN ISOFORMS; C-CAM; PLASMA-MEMBRANE; GENE FAMILY; HEPATOCELLULAR CARCINOMAS; TUMOR-SUPPRESSOR; ECTO-ATPASE; CEA FAMILY; INTERCELLULAR-ADHESION	In this paper, we have characterized the structure, evolutionary origin, and function of rat and human carcinoembryonic antigen-related cell adhesion molecule1 (CEACAM1) multifunctional Ig-like cell adhesion proteins that are expressed by many epithelial tissues. Restriction enzyme digestion reverse transcriptase-PCR analysis identified three cDNAs encoding novel CEACAM1 N-domains. Comparative sequence analysis showed that human and rat CEACAM1 N-domains segregated into two groups differing in similarity to rat CEACAM1(a)-4L and human CEACAM1. Sequence variability analysis indicated that both human and rat N-domains possessed two variable regions, and one contained a major adhesive epitope. Recombination analysis showed that the group of rat but not human N-domains with high sequence similarity was derived at least in part by recombination. Binding assays revealed that three monoclonal antibodies with strong reactivity for the CEACAM1(a)-4L N-domain showed no reactivity with CEACAM1(b)-4S, an allele with a different N-domain sequence. CEACAM1(b)-4S displayed adhesive activity efficiently blocked by a synthetic peptide corresponding to the adhesive epitope in CEACAM1(a)-4L. Blocking analysis also showed that the adhesive epitope for rat CEACAM1 was located downstream from the equivalent human and mouse epitopes. Glycosylation analysis demonstrated O-linked sugars on rat CEACAM1(b)-4S from COS-1 cells. However, this was not the alteration responsible for the lack of monoclonal antibody reactivity. When considered together with previous studies, our findings suggest an inverse relationship between functionality and amino acid sequence similarity to CEACAM1. Like IgG, the N-domain of CEACAM1 appears to tolerate 10 - 15% sequence diversification without loss of function but begins to show either altered specificity or diminished functionality at higher levels.	Brown Univ, Rhode Isl Hosp, Dept Med, Div Hematol & Oncol, Providence, RI 02903 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Texas System; UTMD Anderson Cancer Center; Brown University	Hixson, DC (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Med, Div Hematol & Oncol, 593 Eddy St, Providence, RI 02903 USA.	dhixson@lifespan.org			NATIONAL CANCER INSTITUTE [R01CA042714] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064856] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42714] Funding Source: Medline; NCRR NIH HHS [1P20 RR 17695] Funding Source: Medline; NIMH NIH HHS [NIMH 64856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BAUM O, 1995, EUR J BIOCHEM, V228, P316; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1999, EXP CELL RES, V252, P243; BECKER A, 1986, EUR J CELL BIOL, V39, P417; BLOCHBERGER TC, 1989, J BIOL CHEM, V264, P20718; Bos MP, 1999, J EXP MED, V190, P331, DOI 10.1084/jem.190.3.331; Bos MP, 2002, INFECT IMMUN, V70, P1715, DOI 10.1128/IAI.70.4.1715-1723.2002; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; Comegys MM, 1999, ONCOGENE, V18, P3261, DOI 10.1038/sj.onc.1202666; *CTR BIOL SEQ AN, NETOGLYC SOFTW; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; DVEKSLER GS, 1995, J VIROL, V69, P543, DOI 10.1128/JVI.69.1.543-546.1995; EDLUND M, 1993, EUR J BIOCHEM, V213, P1109, DOI 10.1111/j.1432-1033.1993.tb17860.x; Estrera VT, 1999, BIOCHEM BIOPH RES CO, V263, P797, DOI 10.1006/bbrc.1999.1443; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; FARIS RA, 1990, CANCER RES, V50, P4755; Finkenzeller D, 2000, MOL CELL BIOL, V20, P7140, DOI 10.1128/MCB.20.19.7140-7145.2000; Finkenzeller D, 2003, MOL CELL BIOL, V23, P272, DOI 10.1128/MCB.23.1.272-279.2003; GILBERT G, 1999, SEQPUP SOFTWARE VERS; Hammarstrom S, 1998, CELL ADHES COMMUN S, V5, P1; HAYES GR, 1992, GLYCOBIOLOGY, V2, P355, DOI 10.1093/glycob/2.4.355; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1989, CANCER RES, V49, P6788; Hixson DC, 2000, EXP MOL PATHOL, V68, P152, DOI 10.1006/exmp.2000.2302; HIXSON DC, 1983, CANCER RES, V43, P3874; HIXSON DC, 1985, CANCER RES, V45, P5049; HSIEH JT, 1995, CANCER RES, V55, P190; Huang XL, 1997, BIOCHEMISTRY-US, V36, P10846, DOI 10.1021/bi9703655; Huang YQ, 1997, J CELL BIOL, V138, P143, DOI 10.1083/jcb.138.1.143; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Hughes AL, 1997, BIOESSAYS, V19, P777, DOI 10.1002/bies.950190907; *I MOL EV GEN, MEGA SOFTW; Kannicht C, 1999, GLYCOBIOLOGY, V9, P897, DOI 10.1093/glycob/9.9.897; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; Kleinerman DI, 1996, CANCER RES, V56, P3431; KODELJA V, 1989, J BIOL CHEM, V264, P6906; Kunath T, 1995, ONCOGENE, V11, P2375; Kuroki M, 2001, J LEUKOCYTE BIOL, V70, P543; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Liang TC, 1996, ARCH BIOCHEM BIOPHYS, V329, P208, DOI 10.1006/abbi.1996.0210; Lim YP, 1996, CANCER RES, V56, P3934; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; Lin SH, 1998, BIOCHEM BIOPH RES CO, V245, P472, DOI 10.1006/bbrc.1998.8381; McCaw SE, 2003, MOL MICROBIOL, V49, P623, DOI 10.1046/j.1365-2958.2003.03591.x; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; MCENTIRE KD, 1989, CANCER RES, V49, P6795; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOWERY J, 1991, HEPATOLOGY, V13, P47; NAGEL G, 1993, EUR J BIOCHEM, V214, P27, DOI 10.1111/j.1432-1033.1993.tb17892.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PINTER A, 1988, J VIROL, V62, P1016, DOI 10.1128/JVI.62.3.1016-1021.1988; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; Popp A, 1999, CELL MICROBIOL, V1, P169, DOI 10.1046/j.1462-5822.1999.00017.x; Rao PV, 1997, VIROLOGY, V229, P336, DOI 10.1006/viro.1997.8446; ROSENBERG M, 1993, CANCER RES, V53, P4938; Rozas J, 1997, COMPUT APPL BIOSCI, V13, P307; RUDERT F, 1989, J MOL EVOL, V29, P126, DOI 10.1007/BF02100111; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SIGAL SH, 1994, HEPATOLOGY, V19, P999; Sippel CJ, 1996, J BIOL CHEM, V271, P33095, DOI 10.1074/jbc.271.51.33095; Taheri M, 2000, J BIOL CHEM, V275, P26935; Tan KM, 2002, EMBO J, V21, P2076, DOI 10.1093/emboj/21.9.2076; TEIXEIRA AM, 1994, BLOOD, V84, P211; Turbide C, 1997, CANCER RES, V57, P2781; Virji M, 1999, MOL MICROBIOL, V34, P538, DOI 10.1046/j.1365-2958.1999.01620.x; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; Watt SM, 2001, BLOOD, V98, P1469, DOI 10.1182/blood.V98.5.1469; Wessner DR, 1998, J VIROL, V72, P1941, DOI 10.1128/JVI.72.3.1941-1948.1998; Wikstrom K, 1996, EXP CELL RES, V227, P360, DOI 10.1006/excr.1996.0285; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YANG L, 1993, HEPATOLOGY, V18, P357, DOI 10.1016/0270-9139(93)90019-J; Zimmermann W, 1998, CELL ADHES COMMUN S, V5, P31	82	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35063	35078		10.1074/jbc.M404431200	http://dx.doi.org/10.1074/jbc.M404431200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184366	hybrid			2022-12-27	WOS:000223134800119
J	Karacsonyi, C; Knorr, R; Fulbier, A; Lindner, R				Karacsonyi, C; Knorr, R; Fulbier, A; Lindner, R			Association of major histocompatibility complex II with cholesterol- and sphingolipid-rich membranes precedes peptide loading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; T-CELL RESPONSES; LIPID RAFTS; INVARIANT CHAIN; ANTIGEN PRESENTATION; EARLY ENDOSOMES; IN-VIVO; HLA-DM; B-CELL; TETRASPAN MICRODOMAINS	Major histocompatibility complex class II protein (MHC II) molecules present antigenic peptides to CD4-positive T-cells. Efficient T cell stimulation requires association of MHC II with membrane microdomains organized by cholesterol and glycosphingolipids or by tetraspanins. Using detergent extraction at 37 degreesC combined with a modified flotation assay, we investigated the sequence of events leading to the association of MHC II with cholesterol- and glycosphingolipid-rich membranes (DRMs) that are distinct from tetraspanins. We find two stages of association of MHC II with DRMs. In stage one, complexes of MHC II and invariant chain, a chaperone involved in MHC II transport, enter DRMs in the Golgi stack. In early endosomes, these complexes are almost quantitatively associated with DRMs. Upon transport to late endocytic compartments, MHC II-bound invariant chain is stepwise proteolyzed to the MHC class II-associated invariant chain peptide ( CLIP) that remains MHC II-bound and retains a preference for DRMs. At the transition between the two stages, CLIP is exchanged against processed antigens, and the resulting MHC II-peptide complexes are transported to the cell surface. In the second stage, MHC II shows a lower overall association with DRMs. However, surface MHC II molecules occupied with peptides that induce resistance to denaturation by SDS are enriched in DRMs relative to SDS-sensitive MHC II-peptide complexes. Likewise, MHC II molecules loaded with long-lived processing products of hen-egg lysozyme containing the immunodominant epitope 48 - 61 show a very high preference for DRMs. Thus after an initial mainly intracellular stage of high DRM association, MHC II moves to a second stage in which its preference for DRMs is modulated by bound peptides.	Hannover Med Sch, Dept Cell Biol, Ctr Anat, D-30625 Hannover, Germany	Hannover Medical School	Lindner, R (corresponding author), Carl Neuberg Str 1, D-30625 Hannover, Germany.	rli@zellbiologie.mh-hannover.de	Lindner, Robert/AAO-9538-2020	Lindner, Robert/0000-0002-6421-5778				ADAMS TE, 1983, IMMUNOLOGY, V50, P613; Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; Becart S, 2003, J CELL SCI, V116, P2565, DOI 10.1242/jcs.00449; Bouillon M, 2003, J BIOL CHEM, V278, P7099, DOI 10.1074/jbc.M211566200; Brachet V, 1999, MOL BIOL CELL, V10, P2891, DOI 10.1091/mbc.10.9.2891; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brugger B, 2004, J BIOL CHEM, V279, P7530, DOI 10.1074/jbc.M310207200; Busch R, 2000, CURR OPIN IMMUNOL, V12, P99, DOI 10.1016/S0952-7915(99)00057-6; Castellino F, 1998, J IMMUNOL, V161, P4048; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cherukuri A, 2004, J IMMUNOL, V172, P370, DOI 10.4049/jimmunol.172.1.370; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Denzer K, 2000, J CELL SCI, V113, P3365; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Dolan BP, 2004, J IMMUNOL, V172, P907, DOI 10.4049/jimmunol.172.2.907; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GLIMCHER LH, 1985, J IMMUNOL, V135, P3542; Goebel J, 2002, HUM IMMUNOL, V63, P813, DOI 10.1016/S0198-8859(02)00458-5; Hammond C, 1998, J IMMUNOL, V161, P3282; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hiltbold EM, 2003, J IMMUNOL, V170, P1329, DOI 10.4049/jimmunol.170.3.1329; Huby RDJ, 1999, J BIOL CHEM, V274, P22591, DOI 10.1074/jbc.274.32.22591; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KOCH S, 1983, TRANSPLANTATION, V36, P177, DOI 10.1097/00007890-198308000-00013; Kropshofer H, 2002, NAT IMMUNOL, V3, P61, DOI 10.1038/ni750; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANIER LL, 1982, HYBRIDOMA, V1, P125, DOI 10.1089/hyb.1.1982.1.125; Lindner R, 2002, TRAFFIC, V3, P133, DOI 10.1034/j.1600-0854.2002.030206.x; Lindner R, 1996, EMBO J, V15, P6910, DOI 10.1002/j.1460-2075.1996.tb01083.x; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; NABAVI N, 1989, J IMMUNOL, V142, P1444; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; Pond L, 1999, J BIOL CHEM, V274, P18049, DOI 10.1074/jbc.274.25.18049; PULVERTAFT RJV, 1964, LANCET, V1, P238; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SCHAFER PH, 1994, IMMUNITY, V1, P699, DOI 10.1016/1074-7613(94)90040-X; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Setterblad N, 2003, J LEUKOCYTE BIOL, V74, P40, DOI 10.1189/jlb.0103045; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Verreck FAW, 2001, EUR J IMMUNOL, V31, P1029, DOI 10.1002/1521-4141(200104)31:4<1029::AID-IMMU1029>3.0.CO;2-Q; Vogt AB, 2002, IMMUNOL REV, V189, P136, DOI 10.1034/j.1600-065X.2002.18912.x; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574	67	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34818	34826		10.1074/jbc.M404608200	http://dx.doi.org/10.1074/jbc.M404608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184367	hybrid			2022-12-27	WOS:000223134800090
J	Martin, CC; Oeser, JK; O'Brien, RM				Martin, CC; Oeser, JK; O'Brien, RM			Differential regulation of islet-specific glucose-6-phosphatase catalytic subunit-related protein gene transcription by Pax-6 and Pdx-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; GLUCAGON GENE; PAIRED-DOMAIN; IN-VIVO; GLUCOSE-METABOLISM; INSULIN PROMOTER; CONTROL ELEMENT; BETA-CELLS; T-CELLS; EXPRESSION	Islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) is selectively expressed in islet beta cells and is a major autoantigen in a mouse model of type I diabetes. The analysis of IGRP-chloramphenicol acetyltransferase ( CAT) fusion gene expression through transient transfection of islet-derived betaTC-3 cells revealed that a promoter region, located between - 273 and - 254, is essential for high IGRP-CAT fusion gene expression. The sequence of this promoter region does not match that for any known islet-enriched transcription factor. However, data derived from gel retardation assays, a modified ligation-mediated polymerase chain reaction in situ footprinting technique and a SDS-polyacrylamide separation/renaturation procedure led to the hypothesis that this protein might be Pax-6, a conclusion that was confirmed by gel supershift assays. Additional experiments revealed a second non-consensus Pax-6 binding site in the - 306/ - 274 IGRP promoter region. Pax-6 binding to these elements is unusual in that it appears to require both its homeo and paired domains. Interestingly, loss of Pax-6 binding to the - 273/ - 246 element is compensated by Pax-6 binding to the - 306/ - 274 element and vice versa. Gel retardation assays revealed that another islet-enriched transcription factor, namely Pdx-1, binds four non-consensus elements in the IGRP promoter. However, mutation of these elements has little effect on IGRP fusion gene expression. Although chromatin immunoprecipitation assays show that both Pax-6 and Pdx-1 bind to the IGRP promoter within intact cells, in contrast to the critical role of these factors in beta cell-specific insulin gene expression, IGRP gene transcription appears to require Pax-6 but not Pdx-1.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 761 PRB MRB II, Nashville, TN 37232 USA.	richard.obrien@vanderbilt.edu			NCI NIH HHS [5T32 CA 09385-17] Funding Source: Medline; NIDDK NIH HHS [P60 DK 20593, DK 61645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK061645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Bischof LJ, 2001, DIABETES, V50, P502, DOI 10.2337/diabetes.50.3.502; Bonner-Weir S, 2000, J MOL ENDOCRINOL, V24, P297, DOI 10.1677/jme.0.0240297; Bramblett DE, 2000, ADV PHARMACOL, V47, P255; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; Ebert DH, 1999, DIABETES, V48, P543, DOI 10.2337/diabetes.48.3.543; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Frigeri C, 2004, DIABETES, V53, P1754, DOI 10.2337/diabetes.53.7.1754; Gannon M, 2001, DEV BIOL, V238, P185, DOI 10.1006/dbio.2001.0359; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; Hutton JC, 2003, P NATL ACAD SCI USA, V100, P8626, DOI 10.1073/pnas.1633447100; Jun HS, 2002, CELL MOL LIFE SCI, V59, P1892, DOI 10.1007/PL00012512; Jun S, 1996, DEVELOPMENT, V122, P2639; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; Liblau RS, 2002, IMMUNITY, V17, P1, DOI 10.1016/S1074-7613(02)00338-2; Lieberman SM, 2003, P NATL ACAD SCI USA, V100, P8384, DOI 10.1073/pnas.0932778100; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Martin CC, 2003, BIOCHEM J, V371, P675, DOI 10.1042/BJ20021585; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; Maxam A M, 1980, Methods Enzymol, V65, P499; McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Notkins AL, 2002, J BIOL CHEM, V277, P43545, DOI 10.1074/jbc.R200012200; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Petrolonis AJ, 2004, J BIOL CHEM, V279, P13976, DOI 10.1074/jbc.M307756200; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Winter William E, 2002, Diabetes Technol Ther, V4, P817, DOI 10.1089/152091502321118838; Yamaoka T, 1999, INT J MOL MED, V3, P247; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	59	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34277	34289		10.1074/jbc.M404830200	http://dx.doi.org/10.1074/jbc.M404830200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180990	hybrid			2022-12-27	WOS:000223134800026
J	Wu, SY; Tan, MJ; Hu, YY; Wang, JL; Scheuner, D; Kaufman, RJ				Wu, SY; Tan, MJ; Hu, YY; Wang, JL; Scheuner, D; Kaufman, RJ			Ultraviolet light activates NF kappa B through translational inhibition of I kappa B alpha synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; UNFOLDED PROTEIN RESPONSE; GENE-EXPRESSION; UV-RADIATION; KINASE; INITIATION; TRANSCRIPTION; GCN2; PERK; RNA	UV light induces a delayed and prolonged (3-20 h) activation of NFkappaB when compared with the immediate and acute (10-90 min) activation of NFkappaB in response to tumor necrosis factor alpha treatment. In the early phase (3-12 h) of NFkappaB activation, UV light reduces inhibitor of NFkappaB (IkappaB) through an IkappaB kinase-independent, but polyubiquitin-dependent, pathway. However, the mechanism for the UV light-induced reduction of IkappaB and activation of NFkappaB is not known. In this report, we show that UV light down-regulates the total amount of IkappaB through decreasing IkappaB mRNA translation. Our data show that UV light inhibits translation of IkappaB in wildtype mouse embryo fibroblasts (MEFS/S) and that this inhibition is prevented in MEFA/A cells in which the phosphorylation site, Ser-51 in the eukaryotic translation initiation factor 2 alpha-subunit, is replaced with a non-phosphorylatable Ala (S51A). Our data also show that UV light-induced NFkappaB activation is delayed in MEFA/A cells and in an MCF-7 cell line that is stably transfected with a trans-dominant negative mutant protein kinase-like endoplasmic reticulum kinase (PERK). These results suggest that UV light-induced eukaryotic translation initiation factor 2 alpha-subunit phosphorylation translationally inhibits new IkappaB synthesis. Without a continuous supply of newly synthesized IkappaB, the existing IkappaB is degraded through a polyubiquitin-dependent proteasomal pathway leading to NFkappaB activation. Based upon our results, we propose a novel mechanism by which UV light regulates early phase NFkappaB activation by means of an ER-stress-induced translational inhibition pathway.	Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA; Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA; Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University System of Ohio; Ohio University; University System of Ohio; Ohio University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Wu, SY (corresponding author), Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA.	wus1@ohio.edu	Wu, Shiyong/I-3359-2013	Wu, Shiyong/0000-0002-4104-4160	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042394] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 86926] Funding Source: Medline; NIDDK NIH HHS [R01 DK 42394] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Faggioli L, 1997, BIOCHEM BIOPH RES CO, V233, P507, DOI 10.1006/bbrc.1997.6489; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Marbach I, 2001, J BIOL CHEM, V276, P16944, DOI 10.1074/jbc.M100383200; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PRICE NT, 1991, BIOCHEM BIOPH RES CO, V176, P993, DOI 10.1016/0006-291X(91)90380-P; Raine DA, 1998, FEBS LETT, V436, P343, DOI 10.1016/S0014-5793(98)01163-6; RANU RS, 1979, BIOCHEM BIOPH RES CO, V91, P1437, DOI 10.1016/0006-291X(79)91227-0; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Sood R, 2000, GENETICS, V154, P787; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	28	113	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34898	34902		10.1074/jbc.M405616200	http://dx.doi.org/10.1074/jbc.M405616200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184376	hybrid			2022-12-27	WOS:000223134800100
J	Xie, ZC; Romano, DM; Kovacs, DM; Tanzi, RE				Xie, ZC; Romano, DM; Kovacs, DM; Tanzi, RE			Effects of RNA interference-mediated silencing of gamma-secretase complex components on cell sensitivity to caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; CALCIUM HOMEOSTASIS; BETA-APP; PRESENILIN-1; NICASTRIN; CLEAVAGE; APH-1; MUTATIONS; PEN-2	Familial Alzheimer's disease mutations in the presenilin 1 gene (PSEN1) have been previously shown to potentiate caspase activation and apoptosis in transfected cells and transgenic mice. However, the mechanism underlying this effect is not known. We set out to determine whether cellular sensitivity to caspase activation could be affected by modulating presenilin 1 (PS1) processing. PS1 processing was altered using RNA interference (RNAi) aimed at silencing the expression of the genes encoding the four components of the gamma-secretase complex, PSEN1, APH-1, PEN-2, and nicastrin. RNAi for these genes was carried out in naive H4 human neuroglioma cells, as well as H4 cell lines overexpressing either wild-type PSEN1 or the Familial Alzheimer's disease mutant PSEN1-Delta9 (PS1-mutant), that were induced to undergo apoptosis. In wildtype PSEN1 cells, RNAi for PEN-2, as expected, increased levels of full-length PS1 (PS1-FL) and decreased PS1 endoproteolysis. This was accompanied by potentiated caspase-3 activation in response to an apoptotic stimulus. In contrast, nicastrin RNAi, which only decreased levels of PS1-amino-terminal fragment and did not affect PS1-FL levels, had no effect on caspase-3 activation during apoptosis. Surprisingly, in the PS1-mutant cells, RNAi for PEN-2 ( and APH-1) did not increase but instead reduced the levels of PS1-FL deleted for exon 9. In turn, this was accompanied by attenuated caspase-3 activation in response to an apoptotic stimulus. Finally, in naive H4 cells, PSEN1 RNAi also attenuated caspase-3 activation in response to an apoptotic stimulus. Collectively, these findings indicate that cellular sensitivity to caspase activation correlates with overall PS1 protein levels, particularly with levels of FL-PS1.	Massachusetts Gen Hosp, MassGen Inst Neurogenet Dis, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Tanzi, RE (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Genet & Aging Res Unit, 114 16th St,C3009, Charlestown, MA 02129 USA.	tanzi@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060009, R37MH060009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005134, R01AG014713] Funding Source: NIH RePORTER; NIA NIH HHS [AG 00294-17, P50 AG 05134, AG 014713-07] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07592] Funding Source: Medline; NIMH NIH HHS [MH 60009-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Barnes NY, 1998, J NEUROSCI, V18, P5869; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; Chan SL, 2002, NEUROBIOL DIS, V11, P2, DOI 10.1006/nbdi.2002.0542; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Holtzman DM, 1997, NAT MED, V3, P954, DOI 10.1038/nm0997-954; Kim TW, 1997, CURR OPIN NEUROBIOL, V7, P683, DOI 10.1016/S0959-4388(97)80089-X; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kovacs DM, 1999, J NEUROCHEM, V73, P2278, DOI 10.1046/j.1471-4159.1999.0732278.x; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Mattson MP, 2000, J NEUROSCI, V20, P1358; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Raina AK, 2003, PROG NEURO-PSYCHOPH, V27, P251, DOI 10.1016/S0278-5846(03)00020-4; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sisodia SS, 2001, TRENDS NEUROSCI, V24, pS2, DOI 10.1016/S0166-2236(00)01987-1; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1998, NEUROBIOL AGING, V19, pS23, DOI 10.1016/S0197-4580(98)00041-4; Xie ZC, 2004, NEURODEGENER DIS, V1, P29, DOI 10.1159/000076667; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	47	26	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34130	34137		10.1074/jbc.M401094200	http://dx.doi.org/10.1074/jbc.M401094200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184387	hybrid			2022-12-27	WOS:000223134800010
J	Revington, M; Holder, TM; Zuiderweg, ERP				Revington, M; Holder, TM; Zuiderweg, ERP			NMR study of nucleotide-induced changes in the nucleotide binding domain of Thermus thermophilus Hsp70 chaperone DnaK - Implications for the allosteric mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; SUBSTRATE-BINDING; SECONDARY STRUCTURE; EXCHANGE FACTOR; ATPASE DOMAIN; COMPLEX; CYCLE; TRANSITION; MUTATIONS	We present an NMR investigation of the nucleotide-dependent conformational properties of a 44-kDa nucleotide binding domain (NBD) of an Hsp70 protein. Conformational changes driven by ATP binding and hydrolysis in the N-terminal NBD are believed to allosterically regulate substrate affinity in the C-terminal substrate binding domain. Several crystal structures of Hsc70 NBDs in different nucleotide states have, however, not shown significant structural differences. We have previously reported the NMR assignments of the backbone resonances of the NBD of the bacterial Hsp70 homologue Thermus thermophilus DnaK in the ADP-bound state. In this study we show, by assigning the NBD with the ATP/transition state analogue, ADP.AlFx, bound, that it closely mimics the ATP-bound state. Chemical shift difference mapping of the two nucleotide states identified differences in a cluster of residues at the interface between subdomains 1A and 1B. Further analysis of the spectra revealed that the ATP state exhibited a single conformation, whereas the ADP state was in slow conformational exchange between a form similar to the ATP state and another state unique to the ADP-bound form. A model is proposed of the allosteric mechanism based on the nucleotide state altering the balance of a dynamic equilibrium between the open and closed states. The observed chemical shift perturbations were concentrated in an area close to a previously described J-domain binding channel, confirming the importance of that region in the allosteric mechanism.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zuiderweg, ERP (corresponding author), Univ Michigan, Div Biophys Res, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	zuiderwe@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063027] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63027] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; Chaudhry C, 2003, EMBO J, V22, P4877, DOI 10.1093/emboj/cdg477; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Farr CD, 1998, J BIOL CHEM, V273, P9744, DOI 10.1074/jbc.273.16.9744; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Harrison C, 2003, CELL STRESS CHAPERON, V8, P218, DOI 10.1379/1466-1268(2003)008<0218:GANEFF>2.0.CO;2; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Houry WA, 2001, CURR PROTEIN PEPT SC, V2, P227, DOI 10.2174/1389203013381134; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Klostermeier D, 1998, J MOL BIOL, V279, P841, DOI 10.1006/jmbi.1998.1816; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1998, BIOL CHEM, V379, P261; McElroy C, 2002, J MOL BIOL, V323, P463, DOI 10.1016/S0022-2836(02)00940-3; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; Osipiuk J, 1997, BBA-GENE STRUCT EXPR, V1353, P253, DOI 10.1016/S0167-4781(97)00071-7; Reid KL, 1996, CELL STRESS CHAPERON, V1, P127, DOI 10.1379/1466-1268(1996)001<0127:PIBMOT>2.3.CO;2; REVINGTON M, 2004, IN PRESS J BIOLMOL N; *ROCH APPL SCI, 2003, BIOCH CAT, P303; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Shi L, 1996, BIOCHEMISTRY-US, V35, P3297, DOI 10.1021/bi951984l; Sitkoff D, 1997, J AM CHEM SOC, V119, P12262, DOI 10.1021/ja9721430; Slepenkov SV, 2003, FEBS LETT, V539, P100, DOI 10.1016/S0014-5793(03)00207-2; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	52	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33958	33967		10.1074/jbc.M313967200	http://dx.doi.org/10.1074/jbc.M313967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175340	hybrid			2022-12-27	WOS:000223039700106
J	Lundequist, A; Tchougounova, E; Abrink, M; Pejler, G				Lundequist, A; Tchougounova, E; Abrink, M; Pejler, G			Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of angiotensin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN; TISSUE; GENERATION; EXPRESSION; ENZYME; MICE	The octapeptide angiotensin II (Ang II) exerts a wide range of effects on the cardiovascular system but has also been implicated in the regulation of cell proliferation, fibrosis, and apoptosis. Ang II is formed by cleavage of Ang I by angiotensin-converting enzyme, but there is also evidence for non-angiotensin-converting enzyme-dependent conversion of Ang I to Ang II. Here we address the role of mast cell proteases in Ang II production by using two different mouse strains lacking mast cell heparin or mouse mast cell protease 4 (mMCP-4), the chymase that may be the functional homologue to human chymase. Ang I was added to ex vivo cultures of peritoneal cells, and the generation of Ang II and other metabolites was analyzed. Activation of mast cells resulted in marked increases in both the formation and subsequent degradation of Ang II, and both of these processes were strongly reduced in heparin-deficient peritoneal cells. In the mMCP-4(-/-) cell cultures no reduction in the rate of Ang II generation was seen, but the formation of Ang-(5-10) was completely abrogated. Addition of a carboxypeptidase A (CPA) inhibitor to wild type cells caused complete inhibition of the formation of Ang-(1-9) and Ang-(1-7) but did not inhibit Ang II formation. However, when the CPA inhibitor was added to them MCP-4(-/-) cultures, essentially complete inhibition of Ang II formation was obtained. Taken together, the results of this study indicate that mast cell chymase and CPA have key roles in both the generation and degradation of Ang II.	Swedish Univ Agr Sci, Biomed Ctr, Dept Mol Biosci, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences	Pejler, G (corresponding author), Swedish Univ Agr Sci, Biomed Ctr, Dept Mol Biosci, Box 575, S-75123 Uppsala, Sweden.	Gunnar.Pejler@bmc.uu.se	Åbrink, Magnus/AAK-8346-2020	Abrink, Magnus/0000-0002-1335-3927				Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Caughey GH, 2002, MOL IMMUNOL, V38, P1353, DOI 10.1016/S0161-5890(02)00087-1; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; COLE KR, 1991, BIOCHEMISTRY-US, V30, P648, DOI 10.1021/bi00217a009; Dell'Italia LJ, 2002, CURR OPIN CARDIOL, V17, P374, DOI 10.1097/00001573-200207000-00009; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GOLDSTEIN SM, 1989, J CLIN INVEST, V83, P1630, DOI 10.1172/JCI114061; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Kim S, 2000, PHARMACOL REV, V52, P11; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Ruiz-Ortega M, 2001, HYPERTENSION, V38, P1382, DOI 10.1161/hy1201.100589; Saito K, 2003, BIOCHEM BIOPH RES CO, V302, P773, DOI 10.1016/S0006-291X(03)00263-8; Santos RAS, 2000, REGUL PEPTIDES, V91, P45, DOI 10.1016/S0167-0115(00)00138-5; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SNYDER RA, 1986, BIOCHIM BIOPHYS ACTA, V871, P1, DOI 10.1016/0167-4838(86)90125-1; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Tchougounova E, 2001, FASEB J, V15, P2763, DOI 10.1096/fj.01-0486fje; Wei CC, 2002, AM J PHYSIOL-HEART C, V282, pH2254, DOI 10.1152/ajpheart.00191.2001	19	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32339	32344		10.1074/jbc.M405576200	http://dx.doi.org/10.1074/jbc.M405576200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173164	hybrid			2022-12-27	WOS:000222849700045
J	Meek, SEM; Lane, WS; Piwnica-Worms, H				Meek, SEM; Lane, WS; Piwnica-Worms, H			Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC25C; DNA-DAMAGE; NUCLEAR EXPORT; BINDING; CHECKPOINT; KINASE; PHOSPHORYLATION; LOCALIZATION; ASSOCIATION; TSC2	14-3-3 proteins regulate the cell division cycle and play a pivotal role in blocking cell cycle advancement after activation of the DNA replication and DNA damage checkpoints. Here we describe a global proteomics analysis to identify proteins that bind to 14-3-3s during interphase and mitosis. 14-3-3-binding proteins were purified from extracts of interphase and mitotic HeLa cells using specific peptide elution from 14-3-3zeta affinity columns. Proteins that specifically bound and eluted from the affinity columns were identified by microcapillary high pressure liquid chromatography tandem mass spectrometry analysis. Several known and novel 14-3-3-interacting proteins were identified in this screen. Identified proteins are involved in cell cycle regulation, signaling, metabolism, protein synthesis, nucleic acid binding, chromatin structure, protein folding, proteolysis, nucleolar function, and nuclear transport as well as several other cellular processes. In some cases 14-3-3 binding was cell cycle-dependent, whereas in other cases the binding was shown to be cell cycle-independent. This study adds to the growing list of human 14-3-3-binding proteins and implicates a role for 14-3-3 proteins in a plethora of essential biological processes.	Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.	hpiwnica@cellbiology.wustl.edu	Piwnica-Worms, Helen/C-5214-2012					AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Catalano CM, 2004, ELECTROPHORESIS, V25, P519, DOI 10.1002/elps.200305711; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cohen D, 2003, METHODS, V30, P269, DOI 10.1016/S1046-2023(03)00033-1; Cotelle V, 2000, EMBO J, V19, P2869, DOI 10.1093/emboj/19.12.2869; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; KASTAN MB, 1991, CANCER RES, V51, P6304; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Liu HT, 1999, CANCER LETT, V144, P45, DOI 10.1016/S0304-3835(99)00184-6; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Moorhead G, 1999, PLANT J, V18, P1, DOI 10.1046/j.1365-313X.1999.00417.x; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Rothblum-Oviatt CJ, 2001, CELL GROWTH DIFFER, V12, P581; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; Siles-Lucas MD, 2003, TRENDS PARASITOL, V19, P575, DOI 10.1016/j.pt.2003.10.003; Stavridi ES, 2001, CANCER RES, V61, P7030; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; van Hemert MJ, 2004, J CELL SCI, V117, P1411, DOI 10.1242/jcs.00990; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	51	168	174	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32046	32054		10.1074/jbc.M403044200	http://dx.doi.org/10.1074/jbc.M403044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161933	hybrid			2022-12-27	WOS:000222849700008
J	Barabas, O; Pongracz, V; Kovari, J; Wilmanns, M; Vertessy, BG				Barabas, O; Pongracz, V; Kovari, J; Wilmanns, M; Vertessy, BG			Structural insights into the catalytic mechanism of phosphate ester hydrolysis by dUTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DUTPASE; CRYSTAL-STRUCTURE; SUBSTRATE-ANALOG; KINETIC CHARACTERIZATION; METAL-BINDING; PROTEIN; PYROPHOSPHATASE; EXPRESSION; VIRUS; SITE	dUTPase is essential to keep uracil out of DNA. Crystal structures of substrate (dUTP and alpha,beta-imino-dUTP) and product complexes of wild type and mutant dUTPases were determined to reveal how an enzyme responsible for DNA integrity functions. A kinetic analysis of wild type and mutant dUTPases was performed to obtain relevant mechanistic information in solution. Substrate hydrolysis is shown to be initiated via in-line nucleophile attack of a water molecule oriented by an activating conserved aspartate residue. Substrate binding in a catalytically competent conformation is achieved by (i) multiple interactions of the triphosphate moiety with catalysis-assisting Mg2+, (ii) a concerted motion of residues from three conserved enzyme motifs as compared with the apoenzyme, and (iii) an intricate hydrogen-bonding network that includes several water molecules in the active site. Results provide an understanding for the catalytic role of conserved residues in dUTPases.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary; Eotvos Lorand Univ, Dept Theoret Chem, H-1117 Budapest, Hungary; European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; European Molecular Biology Laboratory (EMBL)	Vertessy, BG (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, Karolina Ut 29-31, H-1113 Budapest, Hungary.	vertessy@enzim.hu	Vertessy, Beata G/H-6202-2012; Barabas, Orsolya/F-3961-2012	Barabas, Orsolya/0000-0002-2873-5872; Wilmanns, Matthias/0000-0002-4643-5435; Vertessy, Beata G./0000-0002-1288-2982				Aherne G.W., 1999, ANTICANCER DRUG DEV, P409; [Anonymous], 1978, TRANSITION STATES BI; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barabas O, 2003, J BIOL CHEM, V278, P38803, DOI 10.1074/jbc.M306967200; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; CANMAN CE, 1994, CANCER RES, V54, P2296; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; Flachner B, 2004, BIOCHEMISTRY-US, V43, P3436, DOI 10.1021/bi035022n; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P108; Gonzalez A, 2001, ACTA CRYSTALLOGR D, V57, P767, DOI 10.1107/S0907444901004255; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; Kovari J, 2004, J BIOL CHEM, V279, P17932, DOI 10.1074/jbc.M313643200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LARSEN M, 1969, SCIENCE, V166, P1510, DOI 10.1126/science.166.3912.1510; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Mustafi D, 2003, P NATL ACAD SCI USA, V100, P5670, DOI 10.1073/pnas.1031504100; Ostermann N, 2000, STRUCTURE, V8, P629, DOI 10.1016/S0969-2126(00)00149-0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; Persson R, 2002, PREP BIOCHEM BIOTECH, V32, P157, DOI 10.1081/PB-120004128; Persson T, 1996, BIOORGAN MED CHEM, V4, P553, DOI 10.1016/0968-0896(96)00044-2; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; Prasad GS, 2000, ACTA CRYSTALLOGR D, V56, P1100, DOI 10.1107/S0907444900009197; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; TAYLOR JS, 1981, J BIOL CHEM, V256, P9793; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; Vertessy BG, 1998, FEBS LETT, V421, P83, DOI 10.1016/S0014-5793(97)01545-7; Williams NH, 2004, BBA-PROTEINS PROTEOM, V1697, P279, DOI 10.1016/j.bbapap.2003.11.031; Wolfenden R, 1998, J AM CHEM SOC, V120, P833, DOI 10.1021/ja9733604; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009	48	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42907	42915		10.1074/jbc.M406135200	http://dx.doi.org/10.1074/jbc.M406135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15208312	hybrid			2022-12-27	WOS:000224226400069
J	Zamurovic, N; Cappellen, D; Rohner, D; Susa, M				Zamurovic, N; Cappellen, D; Rohner, D; Susa, M			Coordinated activation of Notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis Notch - Target gene Hey1 inhibits mineralization and Runx2 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELL-DIFFERENTIATION; MC3T3-E1 CELLS; ARRAY ANALYSIS; STEM-CELLS; PROTEIN; EXPRESSION; DEFECTS; PHENOTYPE; MUTATIONS; SKELETAL	To examine early events in osteoblast differentiation, we analyzed the expression of about 9,400 genes in the murine MC3T3 cell line, whose robust differentiation was documented cytochemically and molecularly. The cells were stimulated for 1 and 3 days with the osteogenic stimulus containing bone morphogenic protein 2. Total RNA was extracted and analyzed by Affymetrix GeneChip oligonucleotide arrays. A regulated expression of 394 known genes and 295 expressed sequence tags was detected. The sensitivity and reliability of detection by microarrays was shown by confirming the expression pattern for 20 genes by radioactive quantitative reverse transcription-PCR. Functional classification of regulated genes was performed, defining the groups of regulated growth factors, receptors, and transcription factors. The most interesting finding was concomitant activation of transforming growth factor-beta, Wnt, and Notch signaling pathways, confirmed by strong up-regulation of their target genes by PCR. The transforming growth factor-beta pathway is activated by stimulated production of the growth factor itself, while the exact mechanism of Wnt and Notch activation remains elusive. We showed that bone morphogenic protein 2 stimulated expression of Hey1, a direct Notch target gene, in mouse MC3T3 and C2C12 cells, in human mesenchymal cells, and in mouse calvaria. Small interfering RNA-mediated inhibition of Hey1 induction led to an increase in osteoblast matrix mineralization, suggesting that Hey1 is a negative regulator of osteoblast maturation. This negative regulation is apparently achieved via interaction with Runx2: Hey1 completely abrogated Runx2 transcriptional activity. These findings identify the Notch-Hey1 pathway as a negative regulator of osteoblast differentiation/maturation, which is a completely novel aspect of osteogenesis and could point to possible new targets for bone anabolic agents.	Novartis Inst Biomed Res, Arthrit & Bone Metab Gastrointestinal Dis Area, CH-4002 Basel, Switzerland	Novartis	Susa, M (corresponding author), Novartis Inst Biomed Res, Arthrit & Bone Metab Gastrointestinal Dis Area, WKL-125-9-12, CH-4002 Basel, Switzerland.	mira.susa_spring@pharma.novartis.com						ALLAN EH, 1995, CLIN ORTHOP RELAT R, P54; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; Baron R., 2003, PRIMER METABOLIC BON, P1; Beck GR, 2001, CELL GROWTH DIFFER, V12, P61; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Canalis Ernesto, 1996, P619; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; Chambers TJ, 2000, J PATHOL, V192, P4; Choi Y, 2001, EUR J IMMUNOL, V31, P2179, DOI 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X; Chua CC, 2002, BBA-MOL CELL RES, V1593, P1, DOI 10.1016/S0167-4889(02)00257-4; Conover Cheryl A., 1996, P607; Dahlqvist C, 2003, DEVELOPMENT, V130, P6089, DOI 10.1242/dev.00834; Doi M, 2002, BIOCHEM BIOPH RES CO, V290, P381, DOI 10.1006/bbrc.2001.6196; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gordeladze JO, 2001, CURR PHARM DESIGN, V7, P275, DOI 10.2174/1381612013398167; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hagiwara H, 1998, J ENDOCRINOL, V156, P543, DOI 10.1677/joe.0.1560543; Harris SE, 2003, FRONT BIOSCI, V8, pS1249, DOI 10.2741/1170; Hefferan TE, 2000, J CELL BIOCHEM, V78, P380, DOI 10.1002/1097-4644(20000901)78:3<380::AID-JCB4>3.0.CO;2-L; Hurley Marja M., 1996, P627; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Jumlongras D, 2001, AM J HUM GENET, V69, P67, DOI 10.1086/321271; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; KIM SJ, 1993, CELLULAR MOL BIOL BO, P98; Korchynskyi O, 2003, J BONE MINER RES, V18, P1177, DOI 10.1359/jbmr.2003.18.7.1177; Kraus P, 1999, J CELL BIOCHEM, P133; KRAUS P, 1999, J CELL BIOCH S, V75, P32; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Leis HJ, 1997, J BONE MINER RES, V12, P541, DOI 10.1359/jbmr.1997.12.4.541; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Mackie EJ, 1998, BONE, V22, P301, DOI 10.1016/S8756-3282(97)00297-4; MAILLARD C, 1993, ENDOCRINOLOGY, V133, P668, DOI 10.1210/en.133.2.668; Malaval L, 2001, J CELL BIOCHEM, P63; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Pilbeam Carol C., 1996, P715; Puente E, 2001, J BIOL CHEM, V276, P13461, DOI 10.1074/jbc.M010981200; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647	67	178	191	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37704	37715		10.1074/jbc.M403813200	http://dx.doi.org/10.1074/jbc.M403813200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15178686	hybrid			2022-12-27	WOS:000223554600062
J	Lau, P; Nixon, SJ; Parton, RG; Muscat, GEO				Lau, P; Nixon, SJ; Parton, RG; Muscat, GEO			ROR alpha regulates the expression of genes involved in lipid homeostasis in skeletal muscle cells - Caveolin-3 and CPT-1 are direct targets of ROR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; DOMINANT-NEGATIVE MUTANT; AMINO-TERMINAL DOMAINS; REV-ERBA-ALPHA; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENT; TRANSGENIC MICE; CARDIAC MYOCYTES; STAGGERER MOUSE; ACTIN GENE	The staggerer mice carry a deletion in the RORalpha gene and have a prolonged humoral response, overproduce inflammatory cytokines, and are immunodeficient. Furthermore, the staggerer mice display lowered plasma apoA-I/-II, decreased plasma high density lipoprotein cholesterol and triglycerides, and develop hypo-alpha-lipoproteinemia and atherosclerosis. However, relatively little is known about RORalpha in the context of target tissues, target genes, and lipid homeostasis. For example, RORalpha is abundantly expressed in skeletal muscle, a major mass peripheral tissue that accounts for similar to40% of total body weight and 50% of energy expenditure. This lean tissue is a primary site of glucose disposal and fatty acid oxidation. Consequently, muscle has a significant role in insulin sensitivity, obesity, and the blood-lipid profile. In particular, the role of RORalpha in skeletal muscle metabolism has not been investigated, and the contribution of skeletal muscle to the ROR-/- phenotype has not been resolved. We utilize ectopic dominant negative RORalpha expression in skeletal muscle cells to understand the regulatory role of RORs in this major mass peripheral tissue. Exogenous dominant negative RORalpha expression in skeletal muscle cells represses the endogenous levels of RORalpha and -gamma mRNAs and ROR-dependent gene expression. Moreover, we observed attenuated expression of many genes involved in lipid homeostasis. Furthermore, we show that the muscle carnitine palmitoyltransferase-1 and caveolin-3 promoters are directly regulated by ROR and coactivated by p300 and PGC-1. This study implicates RORs in the control of lipid homeostasis in skeletal muscle. In conclusion, we speculate that ROR agonists would increase fatty acid catabolism in muscle and suggest selective activators of ROR may have therapeutic utility in the treatment of obesity and atherosclerosis.	Univ Queensland, Sch Biomed Sci, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Div Mol Genet & Dev, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Ctr Microscopy & Microanal, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Muscat, GEO (corresponding author), Univ Queensland, Sch Biomed Sci, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	g.muscat@imb.uq.edu.au	Parton, Robert G/C-5673-2009; Nixon, Susan/D-4588-2017; Muscat, George/A-6401-2017	Parton, Robert G/0000-0002-7494-5248; Nixon, Susan/0000-0003-0346-9683; Muscat, George/0000-0002-5829-5695; Lau, Patrick/0000-0002-9693-390X				Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BONNELYE E, 1994, CELL GROWTH DIFFER, V5, P1357; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Burke L, 1996, NUCLEIC ACIDS RES, V24, P3481, DOI 10.1093/nar/24.18.3481; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1995, J PINEAL RES, V18, P171, DOI 10.1111/j.1600-079X.1995.tb00157.x; Chen SL, 2000, GENE DEV, V14, P1209; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; Curlewis JD, 2002, ENDOCRINOLOGY, V143, P3984, DOI 10.1210/en.2002-220344; DOWHAN DH, 1994, ENDOCRINOLOGY, V135, P2595, DOI 10.1210/en.135.6.2595; DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; DUNWOODIE SL, 1994, J BIOL CHEM, V269, P12212; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Hailstones D, 1998, J LIPID RES, V39, P369; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Jarvis CI, 2002, MOL CELL ENDOCRINOL, V186, P1, DOI 10.1016/S0303-7207(01)00668-2; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; Lopez IP, 2004, BIOCHEM BIOPH RES CO, V318, P234, DOI 10.1016/j.bbrc.2004.04.018; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; Matsui T, 1997, GENES CELLS, V2, P263, DOI 10.1111/j.1365-2443.1997.119gc0317.x; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; Medvedev A, 1996, GENE, V181, P199, DOI 10.1016/S0378-1119(96)00504-5; Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200; ORTIZ MA, 1995, MOL ENDOCRINOL, V9, P1679, DOI 10.1210/me.9.12.1679; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; SHANI M, 1988, MOL CELL BIOL, V8, P1006, DOI 10.1128/MCB.8.2.1006; Shore P, 2002, NUCLEIC ACIDS RES, V30, P1767, DOI 10.1093/nar/30.8.1767; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Vosper H, 2002, PHARMACOL THERAPEUT, V95, P47, DOI 10.1016/S0163-7258(02)00232-2; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705	56	126	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36828	36840		10.1074/jbc.M404927200	http://dx.doi.org/10.1074/jbc.M404927200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15199055	hybrid			2022-12-27	WOS:000223453600085
J	Maliekal, TT; Anto, RJ; Karunagaran, D				Maliekal, TT; Anto, RJ; Karunagaran, D			Differential activation of Smads in HeLa and SiHa cells that differ in their response to transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL-TRANSDUCTION; CANCER-CELLS; MEDIATED APOPTOSIS; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; CROSS-TALK; MAP KINASE; II GENE	We assessed the responsiveness of six human cervical cancer cell lines to transforming growth factor (TGF)-beta with p3TP-lux reporter assay and found that HeLa and SiHa cells were highly responsive to TGF-beta. However, when pSBE4-BV/Luc reporter with four Smad binding elements was used, only the SiHa, not the HeLa, cells showed Smad activation. Smad DNA binding activity was relatively more in SiHa than in HeLa cells upon TGF-beta treatment, and the active complex contained Smad 2 and Smad 4. In 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, HeLa cells treated with 5 ng/ml of TGF-beta for 24 h showed proliferation, whereas SiHa cells showed growth inhibition under the same conditions. TGF-beta treatment resulted in G(0)/G(1) arrest with a reduction in S-phase only in SiHa cells. A chemical inhibitor of Smad activation (SB203580) blocked the growth inhibitory effect of TGF-beta in SiHa, whereas the proliferative response in HeLa was unaffected. TGF-beta-induced translocation of phospho-Smad 2 was relatively less in HeLa than in SiHa cells. MAPK activation occurred within 5 min and persisted up to 15 min upon TGF-beta treatment in HeLa but was negligible in SiHa cells. TGF-beta activated JNK in HeLa, but SiHa cells showed a down-regulation of its activity. When an inhibitor of MAPK (U0126) was used, the TGF-beta-mediated proliferative response in HeLa cells was completely abolished. SB203580 did not affect MAPK activation induced by TGF-beta in HeLa cells. We report for the first time an activation, presumably independent of Smad activation, of TGF-beta-dependent MAPK within 5 min of treatment that resulted in cell cycle progression in a cervical adenocarcinoma cell line.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.	dkarunagaran@hotmail.com	Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Maliekal, Tessy/0000-0002-7311-7950				Anto RJ, 2000, J BIOL CHEM, V275, P15601, DOI 10.1074/jbc.C000105200; Apati A, 2003, J BIOL CHEM, V278, P9235, DOI 10.1074/jbc.M205528200; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; BRAUN L, 1990, CANCER RES, V50, P7324; Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.3.CO;2-5; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Fink SP, 2001, CANCER RES, V61, P256; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Fu YX, 2003, BIOCHEM BIOPH RES CO, V310, P391, DOI 10.1016/j.bbrc.2003.09.021; Gendron S, 2003, J BIOL CHEM, V278, P48633, DOI 10.1074/jbc.M305169200; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Heldin NE, 1999, MOL CELL ENDOCRINOL, V153, P79, DOI 10.1016/S0303-7207(99)00086-6; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; JAMES GK, 1989, CANCER GENET CYTOGEN, V38, P53, DOI 10.1016/0165-4608(89)90165-9; Jonson T, 2001, INT J ONCOL, V19, P71; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.3.CO;2-5; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Lee SH, 2001, INT J CANCER, V94, P500, DOI 10.1002/ijc.1494; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Maliekal TT, 2003, ONCOGENE, V22, P4889, DOI 10.1038/sj.onc.1206806; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Muro-Cacho CA, 2001, CLIN CANCER RES, V7, P1618; Osawa H, 2000, INT J ONCOL, V17, P723; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Rich JN, 2001, MICROSC RES TECHNIQ, V52, P363, DOI 10.1002/1097-0029(20010215)52:4<363::AID-JEMT1021>3.3.CO;2-6; Riggins GJ, 1997, CANCER RES, V57, P2578; Simeone DM, 2001, AM J PHYSIOL-CELL PH, V281, pC311, DOI 10.1152/ajpcell.2001.281.1.C311; Tanaka S, 2000, BRIT J CANCER, V82, P1557; Terada Y, 1999, NEPHROL DIAL TRANSPL, V14, P45, DOI 10.1093/ndt/14.suppl_1.45; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	49	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36287	36292		10.1074/jbc.M404568200	http://dx.doi.org/10.1074/jbc.M404568200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192088	hybrid			2022-12-27	WOS:000223453600017
J	Schillo, S; Belusic, G; Hartmann, K; Franz, C; Kuhl, B; Brenner-Weiss, G; Paulsen, R; Huber, A				Schillo, S; Belusic, G; Hartmann, K; Franz, C; Kuhl, B; Brenner-Weiss, G; Paulsen, R; Huber, A			Targeted mutagenesis of the farnesylation site of Drosophila G gamma e disrupts membrane association of the G protein beta gamma complex and affects the light sensitivity of the visual system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-BETA; PDZ-DOMAIN PROTEIN; SIGNALING COMPLEX; CARBOXYL METHYLATION; SUBUNIT GENE; CA2+ CHANNEL; COMPOUND EYE; TRANSDUCTION; PHOTORECEPTORS; INAD	Activation of phototransduction in the compound eye of Drosophila is mediated by a heterotrimeric G protein that couples to the effector enzyme phospholipase Cbeta. The gamma subunit of this G protein (Ggammae) as well as gamma subunits of vertebrate transducins contain a carboxyl-terminal CAAX motif (C, cysteine; A, aliphatic amino acid; X, any amino acid) with a consensus sequence for protein farnesylation. To examine the function of Ggammae farnesylation, we mutated the farnesylation site and overexpressed the mutated Ggammae in Drosophila. Mass spectrometry of overexpressed Ggammae subunits revealed that nonmutated Ggammae is modified by farnesylation, whereas the mutated Ggammae is not farnesylated. In the transgenic flies, mutated Ggammae forms a dimeric complex with Gbetae, with the consequence that the fraction of non-membrane-bound Gbetagamma is increased. Thus, farnesylation of Ggammae facilitates the membrane attachment of the Gbetagamma complex. We also expressed human Ggammarod in Drosophila photoreceptors. Despite similarities in the primary structure between the transducin gamma subunit and Drosophila Ggammae, we observed no interaction of human Ggammarod with Drosophila Ggammae. This finding indicates that human Ggammarod and Drosophila Ggammae provide different interfaces for the interaction with Gbeta subunits. Electroretinogram recordings revealed a significant loss of light sensitivity in eyes of transgenic flies that express mutated Ggammae. This loss in light sensitivity reveals that post-translational farnesylation is a critical step for the formation of membrane-associated Galphabetagamma required for transmitting light activation from rhodopsin to phospholipase Cbeta.	Univ Karlsruhe, Inst Zool, Dept Cell & Neurobiol, D-76131 Karlsruhe, Germany; Univ Ljubljana, Dept Biol, Biotech Facil, Ljubljana 1000, Slovenia; Forschungszentrum Karlsruhe, Inst Tech Chem Wasser & Geotechnol, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology; University of Ljubljana; Helmholtz Association; Karlsruhe Institute of Technology	Huber, A (corresponding author), Univ Karlsruhe, Inst Zool, Dept Cell & Neurobiol, Haid & Neu Str 9, D-76131 Karlsruhe, Germany.	Armin.Huber@bio.uka.de	Brenner-Weiss, Gerald/H-2868-2013; Huber, Armin/GYU-6322-2022; Kuehl, Boris/I-2630-2014	Brenner-Weiss, Gerald/0000-0002-6728-5907; Belusic, Gregor/0000-0003-3571-1948; Huber, Armin/0000-0003-3977-089X				Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; Balcueva EA, 2000, EXP CELL RES, V257, P310, DOI 10.1006/excr.2000.4893; BIGAY J, 1994, METHOD ENZYMOL, V237, P449; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Dietrich A, 2003, BIOCHEM J, V376, P449, DOI 10.1042/BJ20030578; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Fogg VC, 2001, J BIOL CHEM, V276, P41797, DOI 10.1074/jbc.M107661200; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Jian XY, 2001, J BIOL CHEM, V276, P48518, DOI 10.1074/jbc.M107129200; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; McCarthy NEM, 2000, BIOCHEM J, V347, P163, DOI 10.1042/0264-6021:3470163; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; MISMER D, 1987, GENETICS, V116, P565; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; OTOUSA JE, 1992, VISUAL NEUROSCI, V8, P385, DOI 10.1017/S0952523800004910; PARISH CA, 1994, BIOCHEMISTRY-US, V33, P9986, DOI 10.1021/bi00199a023; Parish CA, 1996, BIOCHEMISTRY-US, V35, P7499, DOI 10.1021/bi960271f; PAULSEN R, 2000, SERIES BIOPHYSICS BI, P41; PAULSEN R, 2000, SERIES BIOPHYSICS BI, P60; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; RAY K, 1992, J BIOL CHEM, V267, P6086; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; Schulz S, 1999, J BIOL CHEM, V274, P37605, DOI 10.1074/jbc.274.53.37605; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAO L, 1993, EXP EYE RES, V56, P497, DOI 10.1006/exer.1993.1063; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	49	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36309	36316		10.1074/jbc.M404611200	http://dx.doi.org/10.1074/jbc.M404611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205461	hybrid			2022-12-27	WOS:000223453600020
J	Sato, K; Yamasaki, K; Daiho, T; Miyauchi, Y; Takahashi, H; Ishida-Yamamoto, A; Nakamura, S; Iizuka, H; Suzuki, H				Sato, K; Yamasaki, K; Daiho, T; Miyauchi, Y; Takahashi, H; Ishida-Yamamoto, A; Nakamura, S; Iizuka, H; Suzuki, H			Distinct types of abnormality in kinetic properties of three Darier disease-causing sarco(endo)plasmic reticulum Ca2+-ATPase mutants that exhibit normal expression and high Ca2+ transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE PHOSPHOENZYME INTERMEDIATE; MUSCLE SARCOPLASMIC-RETICULUM; ATP2A2 MUTATIONS; ADENOSINE-TRIPHOSPHATASE; CALCIUM-PUMP; PHOSPHORYLATED INTERMEDIATE; CONFORMATIONAL TRANSITION; CRYSTAL-STRUCTURE; DIVALENT-CATION; CATALYTIC SITE	The possible functional abnormalities in three different Darier disease-causing Ca2+-ATPase (SERCA2b) mutants, Ile(274) --> Val at the lumenal end of M3, Leu(321) --> Phe on the cytoplasmic part of M4, and Met(719) --> Ile in P domain, were explored, because they exhibited nearly normal expression and localization in COS-1 cells and the high ATPase and coupled Ca2+ transport activities that were essentially identical (L321F) or slightly lower (I274V by similar to35% and M719I by similar to30%) as compared with those of the wild type. These mutations happened to be in Japanese patients found previously by us. Kinetic analyses revealed that each of the mutants possesses distinct types of abnormalities; M719I and L321F possess the 2-3-fold reduced affinity for cytoplasmic Ca2+, whereas I274V possesses the normal high affinity. L321F exhibited also the remarkably reduced sensitivity to the feedback inhibition of the transport cycle by accumulated lumenal Ca2+, as demonstrated with the effect of Ca2+ ionophore on ATPase activity and more specifically with the effects of Ca2+ (up to 50 mM) on the decay of phosphoenzyme intermediates. The results on I274V and M719I suggest that the physiological requirement for Ca2+ homeostasis in keratinocytes to avoid haploinsufficiency is very strict, probably much more than considered previously. The insensitivity to lumenal Ca2+ in L321F likely brings the lumenal Ca2+ to an abnormally elevated level. The three mutants with their distinctively altered kinetic properties will thus likely cause different types of perturbation of intracellular Ca2+ homeostasis, but nevertheless all types of perturbation result in Darier disease. It might be possible that the observed unique feature of L321F could possibly be associated with the specific symptoms in the pedigree with this mutation, neuropsychiatric disorder, and behavior problems. The results also provided further insight into the global nature of conformational changes of SERCAs for ATP-driven Ca2+ transport.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; Chao SC, 2002, BRIT J DERMATOL, V146, P958, DOI 10.1046/j.1365-2133.2002.04786.x; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Daiho T, 2001, J BIOL CHEM, V276, P32771, DOI 10.1074/jbc.M101229200; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; Dhitavat J, 2003, J INVEST DERMATOL, V121, P486, DOI 10.1046/j.1523-1747.2003.12410.x; Dode L, 2003, J BIOL CHEM, V278, P47877, DOI 10.1074/jbc.M306784200; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ikeda S, 2003, J INVEST DERMATOL, V121, P475, DOI 10.1046/j.1523-1747.2003.12400.x; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Jacobsen NJO, 1999, HUM MOL GENET, V8, P1631, DOI 10.1093/hmg/8.9.1631; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; NAKAMURA Y, 1986, J BIOL CHEM, V261, P3090; OGURUSU T, 1991, J BIOCHEM-TOKYO, V109, P472, DOI 10.1093/oxfordjournals.jbchem.a123406; Onozuka T, 2004, BRIT J DERMATOL, V150, P652, DOI 10.1111/j.0007-0963.2004.05868.x; PICK U, 1982, J BIOL CHEM, V257, P6120; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; Ruiz-Perez VL, 1999, HUM MOL GENET, V8, P1621, DOI 10.1093/hmg/8.9.1621; Sakuntabhai A, 2000, J INVEST DERMATOL, V115, P1144, DOI 10.1046/j.1523-1747.2000.00182.x; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sakuntabhai A, 1999, HUM MOL GENET, V8, P1611, DOI 10.1093/hmg/8.9.1611; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P4157; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; SUZUKI H, 1989, J BIOL CHEM, V264, P920; Takahashi H, 2001, J DERMATOL SCI, V26, P169, DOI 10.1016/S0923-1811(00)00173-0; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Wada T, 2003, BRIT J DERMATOL, V149, P185, DOI 10.1046/j.1365-2133.2003.05412.x; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; WEBER K, 1969, J BIOL CHEM, V244, P4406; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200; Yang Y, 2001, J INVEST DERMATOL, V116, P482, DOI 10.1046/j.1523-1747.2001.127910.x; Youngburg GE, 1930, J LAB CLIN MED, V16, P158; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	68	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35595	35603		10.1074/jbc.M404887200	http://dx.doi.org/10.1074/jbc.M404887200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208303	hybrid, Green Submitted			2022-12-27	WOS:000223303400055
J	Yu, YM; Zeng, H; Vijay-Kumar, M; Neish, AS; Merlin, D; Sitaraman, SV; Gewirtz, AT				Yu, YM; Zeng, H; Vijay-Kumar, M; Neish, AS; Merlin, D; Sitaraman, SV; Gewirtz, AT			STAT signaling underlies difference between flagellin-induced and tumor necrosis factor-alpha-induced epithelial gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL FLAGELLIN; INTERLEUKIN-6 GENE; P38 MAPK; SALMONELLA; CELLS; SECRETION; CROSSTALK; ANALOGS	Both bacterial flagellin and the cytokine tumor necrosis factor-alpha (TNFalpha) are potent activators of intestinal epithelial cell pro-inflammatory gene expression in general; nonetheless, there seem to be distinct differences in the specific patterns of gene expression induced by these agonists. The goal of this study was to define one such difference and elucidate the signaling mechanism responsible for such differential gene induction by these agonists. We observed that expression of inducible nitric-oxide synthase is substantially induced by flagellin but only minimally expressed in response to TNFalpha. This difference seemed to be underlain by differential induction of signal transducers and activators of transcription (STAT) activation in that, whereas flagellin and TNFalpha seemed to be equipotent activators of p38 mitogen-activated protein kinase and nuclear factor-kappaB, flagellin induced substantially higher levels of STAT-1 and -3 tyrosine phosphorylation. Such flagellin-induced STAT activation exhibited delayed kinetics and was ablated by treatment with cycloheximide. Flagellin-induced activation of STAT-3 was abolished via neutralizing antibodies to interleukin (IL)-6, but not interferon (IFN)beta nor IFNgamma; none of these neutralizing antibodies had any effect on flagellin-induced STAT-1 tyrosine phosphorylation. Flagellin induced substantially more IL-6 expression than did TNFalpha, but neither agonist elicited detectable levels of IFN expression. Flagellin-induced expression of inducible nitric-oxide synthase but not IL-6, was abolished by blocking STAT activation with AG490, and was reduced by blocking STAT-3 activation with anti-IL-6. Together, these results indicate that epithelial cell induction of flagellin-specific gene expression is mediated, in part, by STAT activation that results from autocrine activation via IL-6.	Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Emory Univ, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Gewirtz, AT (corresponding author), Emory Univ, Dept Pathol & Lab Med, Pathol WRB 105H,615 Michael St, Atlanta, GA 30322 USA.	agewirt@emory.edu	Neish, Andrew/B-3895-2009; Vijay-Kumar, Matam/Q-8988-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061417, R24DK064399, R01DK061941] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061417, R01 DK002802, R24-DK064399, R01 DK061941] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 1998, J CLIN INVEST, V101, P1860, DOI 10.1172/JCI1339; Gewirtz AT, 2002, BEST PRACT RES CL GA, V16, P851, DOI 10.1053/bega.2002.0339; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; Gewirtz AT, 2002, METHOD MICROBIOL, V31, P377, DOI 10.1016/S0580-9517(02)31022-5; Gewirtz AT, 2002, J IMMUNOL, V168, P5260, DOI 10.4049/jimmunol.168.10.5260; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; McCormick B, 1998, CURR OPIN GASTROEN, V14, P492, DOI 10.1097/00001574-199811010-00013; McSorley SJ, 2002, J IMMUNOL, V169, P3914, DOI 10.4049/jimmunol.169.7.3914; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; Schmitt CK, 1996, J BACTERIOL, V178, P2911, DOI 10.1128/jb.178.10.2911-2915.1996; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Takahashi A, 2001, FEBS LETT, V508, P484, DOI 10.1016/S0014-5793(01)03088-5; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Wang LH, 1999, J IMMUNOL, V162, P3897; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Zeng H, 2003, J IMMUNOL, V171, P3668, DOI 10.4049/jimmunol.171.7.3668	21	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35210	35218		10.1074/jbc.M404064200	http://dx.doi.org/10.1074/jbc.M404064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199060	hybrid			2022-12-27	WOS:000223303400011
J	Agarwalla, S; Stroud, RM; Gaffney, BJ				Agarwalla, S; Stroud, RM; Gaffney, BJ			Redox reactions of the iron-sulfur cluster in a ribosomal RNA methyltransferase, RumA - Optical and EPR studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINELANDII FERREDOXIN-I; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ENDONUCLEASE-III; 4FE-4S CLUSTER; NITRIC-OXIDE; MOSSBAUER-SPECTROSCOPY; FERRICYANIDE OXIDATION; DNA-REPAIR; PROTEIN	An unprecedented [4Fe-4S] iron-sulfur cluster was found in RumA, the enzyme that methylates U1939 in Escherichia coli 23 S ribosomal RNA ( Agarwalla, S., Kealey, J. T., Santi, D. V., and Stroud, R. M. ( 2002) J. Biol. Chem. 277, 8835 - 8840; Lee, T. T., Agarwalla, S., and Stroud, R. M. ( 2004) Structure 12, 397 - 407). Methyltransferase reactions do not involve a redox step. To understand the structural and functional roles of the cluster in RumA, we have characterized redox reactions of the iron-sulfur cluster. As isolated aerobically, RumA exhibits a visible absorbance maximum at 390 nm and is EPR silent. It cannot be reduced by anaerobic additions of dithionite. Photoreduction by deazariboflavin/EDTA gives EPR spectra, the quantity (56% of S = 1/2 species) and details (g(av) similar to 1.96 - 1.93) of which indicate a [4Fe-4S](1+) cluster in the reduced RumA. Oxidation of RumA by ferricyanide leads to loss of the 390-nm band and appearance of lower intensity bands at 444 and 520 nm. EPR spectra of ferricyanide-oxidized RumA show a fraction (< 8%) of the FeS cluster trapped in the [3Fe-4S](1+) form (g(av) similar to 2.011) together with unusual radical-like spectrum (g' values 2.015, 2.00, and 1.95). RumA also reacts with nitric oxide to give EPR spectra characteristic of the protein-bound iron dinitrosyl species. Oxidation of the cluster leads to its decomposition and that could be a mechanism for regulating the activity of RumA under conditions of oxidative stress in the cell. Sequence data base searches revealed that RumA homologs are widespread in various kingdoms of life and contain a conserved and unique iron-sulfur cluster binding motif, CX(5)CGGC.	Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94107 USA	State University System of Florida; Florida State University; University of California System; University of California San Francisco	Gaffney, BJ (corresponding author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA.	gaffney@bio.fsu.edu	Stroud, Rhonda/GQZ-0151-2022; Gaffney, Betty J/C-9666-2015	Stroud, Rhonda/0000-0001-5242-8015; 	NIGMS NIH HHS [GM 51232, R01 GM065268, R01 GM051232, GM 65268] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051232, R01GM065268] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwalla S, 2002, J BIOL CHEM, V277, P8835, DOI 10.1074/jbc.M111825200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bentrop D, 2001, HANDBOOK ON METALLOPROTEINS, P357; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; BERTINI I, 1993, BIOCHEMISTRY-US, V32, P12887, DOI 10.1021/bi00210a042; BLANKENHORN G, 1976, EUR J BIOCHEM, V67, P67, DOI 10.1111/j.1432-1033.1976.tb10634.x; Boon EM, 2003, P NATL ACAD SCI USA, V100, P12543, DOI 10.1073/pnas.2035257100; Chen KS, 2002, J BIOL CHEM, V277, P5603, DOI 10.1074/jbc.M108916200; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; DUNHAM WR, 1991, BIOCHIM BIOPHYS ACTA, V1079, P253, DOI 10.1016/0167-4838(91)90066-9; Foster HW, 1999, J AM CHEM SOC, V121, P4093; Glaser T, 2001, J AM CHEM SOC, V123, P442, DOI 10.1021/ja002183v; Glaser T, 2001, J AM CHEM SOC, V123, P4859, DOI 10.1021/ja0155940; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Griffin M., 1999, Molecular Physics Reports, V26, P60; GU XG, 1992, BIOCHEMISTRY-US, V31, P10295, DOI 10.1021/bi00157a017; HADLEY JH, 1974, P NATL ACAD SCI USA, V71, P4409, DOI 10.1073/pnas.71.11.4409; Hinks JA, 2002, J BIOL CHEM, V277, P16936, DOI 10.1074/jbc.M200668200; HU ZG, 1994, BIOCHEMISTRY-US, V33, P14475, DOI 10.1021/bi00252a014; IVANETICH KM, 1992, PROG NUCLEIC ACID RE, V42, P127, DOI 10.1016/S0079-6603(08)60575-9; Iwasaki T, 2002, J BIOL CHEM, V277, P39642, DOI 10.1074/jbc.M207312200; Jager G, 2004, J BACTERIOL, V186, P750, DOI 10.1128/JB.186.3.750-757.2004; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Jung YS, 2000, J BIOL CHEM, V275, P36974, DOI 10.1074/jbc.M004947200; KEALEY JT, 1994, BIOCHIMIE, V76, P1133, DOI 10.1016/0300-9084(94)90042-6; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Knappe W R, 1978, Biochemistry, V17, P16; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Lee TT, 2004, STRUCTURE, V12, P397, DOI 10.1016/j.str.2004.02.009; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; Lu AL, 2003, BIOCHEMISTRY-US, V42, P3742, DOI 10.1021/bi0269198; Madsen CT, 2003, NUCLEIC ACIDS RES, V31, P4738, DOI 10.1093/nar/gkg657; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MORGAN TV, 1985, FEBS LETT, V183, P206, DOI 10.1016/0014-5793(85)80777-8; MORGAN TV, 1984, P NATL ACAD SCI-BIOL, V81, P1931, DOI 10.1073/pnas.81.7.1931; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; Rogers PA, 2003, DNA REPAIR, V2, P809, DOI 10.1016/S1568-7864(03)00065-X; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; Sridhar V, 1998, J BIOL INORG CHEM, V3, P140; SURERUS KK, 1989, P NATL ACAD SCI USA, V86, P9846, DOI 10.1073/pnas.86.24.9846; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; WALKER MC, 1991, ARCH BIOCHEM BIOPHYS, V287, P351, DOI 10.1016/0003-9861(91)90489-6; WANG TF, 1995, WELDING, V1, P8; Wu J C, 1985, Prog Clin Biol Res, V198, P119; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zhou J, 1996, J AM CHEM SOC, V118, P1966, DOI 10.1021/ja9537843	53	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34123	34129		10.1074/jbc.M405702200	http://dx.doi.org/10.1074/jbc.M405702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181002	hybrid, Green Accepted			2022-12-27	WOS:000223134800009
J	Li, XF; Song, S; Liu, Y; Ko, SH; Kao, HY				Li, XF; Song, S; Liu, Y; Ko, SH; Kao, HY			Phosphorylation of the histone deacetylase 7 modulates its stability and association with 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; PROLYL ISOMERASE PIN1; MUSCLE DIFFERENTIATION; BETA-CATENIN; 14-3-3 PROTEINS; HDAC4 DEACETYLASE; NUCLEAR EXPORT; RECEPTOR-ALPHA; P53; UBIQUITINATION	Class II histone deacetylases (HDACs) play a role in myogenesis and inhibit transcriptional activation by myocyte enhancer factors 2. A distinct feature of class II HDACs is their ability to shuttle between the nucleus and the cytoplasm in a cell type- and signal-dependent manner. We demonstrate here that treatment with the 26 S proteosome inhibitors, MG132 and ALLN, leads to detection of ubiquitinated HDAC7 and causes accumulation of cytoplasmic HDAC7. We also show that treatment with calyculin A, a protein phosphatase inhibitor, leads to a marked increase of HDAC7 but not HDAC5. The increase in HDAC7 is accompanied by enhanced interaction between 14-3-3 proteins and HDAC7. HDAC7 mutations that prevent the interaction with 14-3-3 proteins also block calyculin A-mediated stabilization. Expression of constitutively active calcium/calmodulin-dependent kinase I stabilizes HDAC7 and causes an increased association between HDAC7 and 14-3-3. Together, our results suggest that calcium/calmodulin-dependent kinase I-mediated phosphorylation of HDAC7 acts, in part, to promote association of HDAC7 with 14-3-3 and stabilizes HDAC7.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University	Kao, HY (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxk43@po.cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062985] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 62985] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajiro Kozo, 2002, Tanpakushitsu Kakusan Koso, V47, P753; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Huang EY, 2000, GENE DEV, V14, P45; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Maki CG, 1996, CANCER RES, V56, P2649; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Osburn DL, 2001, MOL CELL BIOL, V21, P4909, DOI 10.1128/MCB.21.15.4909-4918.2001; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	60	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34201	34208		10.1074/jbc.M405179200	http://dx.doi.org/10.1074/jbc.M405179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15166223	hybrid			2022-12-27	WOS:000223134800018
J	Hao, JJ; Carey, GB; Zhan, X				Hao, JJ; Carey, GB; Zhan, X			Syk-mediated tyrosine phosphorylation is required for the association of hematopoietic lineage cell-specific protein 1 with lipid rafts and B cell antigen receptor signalosome complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED MEMBRANE DOMAINS; HS1 PROTEIN; SEQUENTIAL PHOSPHORYLATION; ACTIN CYTOSKELETON; SRC; SUBSTRATE; DYNAMICS; KINASES; PATCHES; EDGE	Hematopoietic lineage cell-specific protein 1 (HS1) is an F-actin- and actin-related proteins 2 and 3 (Arp2/3)binding protein that undergoes a rapid tyrosine phosphorylation upon B cell antigen receptor (BCR) activation. Density gradient centrifugation of Triton X-100 lysates from B lymphocytes demonstrated that HS1 was translocated in response to BCR cross-linking into lipid raft microdomain along with Arp2/3 complex and Wiskott-Aldrich syndrome protein. HS1-green fluorescent protein was localized in membrane patches enriched with GM1 gangliosides and BCR in the cells treated with anti-IgM antibody. Colocalization of HS1-green fluorescent protein with BCR was also correlated with tyrosine phosphorylation of HS1. Interestingly a murine HS1 mutant at the tyrosine residues Tyr(388) and Tyr(405) targeted by Syk failed to respond to BCR cross-linking for either translocation into lipid rafts or colocalization with BCR within cells. Furthermore HS1 was unable to translocate into lipid rafts in a chicken B cell line deficient in Syk. Reintroducing a Syk construct into the Syk knock-out cells recovered effectively both tyrosine phosphorylation and translocation of HS1 into lipid rafts. In contrast, translocation of HS1 into rafts was normal in a Lyn knock-out B cell line, and an HS1 mutant at the tyrosine residue Tyr(222) targeted by Lyn maintained the ability to partition into rafts upon BCR cross-linking. These data indicate that Syk plays an important role in the translocation of HS1 into lipid rafts and may be responsible for actin assembly recruitment to rafts and subsequent antigen presentations.	Amer Red Cross, Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; Amer Red Cross, Holland Lab, Dept Immunol, Rockville, MD 20855 USA	American Red Cross; American Red Cross	Zhan, X (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	szhan001@umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA091984] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 91984-02] Funding Source: Medline; NHLBI NIH HHS [R01-HL 50753-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown BK, 2001, TRAFFIC, V2, P414, DOI 10.1034/j.1600-0854.2001.002006414.x; Brunati AM, 1999, J BIOL CHEM, V274, P7557, DOI 10.1074/jbc.274.11.7557; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Guo BC, 2000, IMMUNITY, V13, P243, DOI 10.1016/S1074-7613(00)00024-8; Gupta N, 2003, MOL BIOL CELL, V14, P432, DOI 10.1091/mbc.02-05-0078; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Jordan S, 2003, J IMMUNOL, V171, P78, DOI 10.4049/jimmunol.171.1.78; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; Kurosaki T, 1998, INT J MOL MED, V1, P515; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Rodgers W, 2001, EXP CELL RES, V267, P173, DOI 10.1006/excr.2001.5253; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; Saeki K, 2003, EMBO J, V22, P3015, DOI 10.1093/emboj/cdg293; Sawabe T, 2003, GENES IMMUN, V4, P122, DOI 10.1038/sj.gene.6363932; Shrivastava P, 2004, BLOOD, V103, P1425, DOI 10.1182/blood-2003-03-0716; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sproul TW, 2000, J IMMUNOL, V165, P6020, DOI 10.4049/jimmunol.165.11.6020; Stoddart A, 2002, IMMUNITY, V17, P451, DOI 10.1016/S1074-7613(02)00416-8; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; Takemoto Y, 1996, INT IMMUNOL, V8, P1699, DOI 10.1093/intimm/8.11.1699; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Uruno T, 2003, BIOCHEM J, V371, P485, DOI 10.1042/BJ20021791; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	39	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33413	33420		10.1074/jbc.M313564200	http://dx.doi.org/10.1074/jbc.M313564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166239	hybrid			2022-12-27	WOS:000223039700049
J	Napoli, A; Valenti, A; Salerno, V; Nadal, M; Garnier, F; Rossi, M; Ciaramella, M				Napoli, A; Valenti, A; Salerno, V; Nadal, M; Garnier, F; Rossi, M; Ciaramella, M			Reverse gyrase recruitment to DNA after UV light irradiation in Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILIC ARCHAEON-SULFOLOBUS; TOPOISOMERASE-I; RECQ HELICASE; BINDING-PROTEIN; ACTINOMYCIN-D; REPAIR; DAMAGE; MECHANISM; TOPOLOGY; RECOMBINATION	Induction of DNA damage triggers a complex biological response concerning not only repair systems but also virtually every cell function. DNA topoisomerases regulate the level of DNA supercoiling in all DNA transactions. Reverse gyrase is a peculiar DNA topoisomerase, specific to hyperthermophilic microorganisms, which contains a helicase and a topoisomerase IA domain that has the unique ability to introduce positive supercoiling into DNA molecules. We show here that reverse gyrase of the archaean Sulfolobus solfataricus is mobilized to DNA in vivo after UV irradiation. The enzyme, either purified or in cell extracts, forms stable covalent complexes with UV-damaged DNA in vitro. We also show that the reverse gyrase translocation to DNA in vivo and the stabilization of covalent complexes in vitro are specific effects of UV light irradiation and do not occur with the intercalating agent actinomycin D. Our results suggest that reverse gyrase might participate, directly or indirectly, in the cell response to UV light-induced DNA damage. This is the first direct evidence of the recruitment of a topoisomerase IA enzyme to DNA after the induction of DNA damage. The interaction between helicase and topoisomerase activities has been previously proposed to facilitate aspects of DNA replication or recombination in both Bacteria and Eukarya. Our results suggest a general role of the association of such activities in maintaining genome integrity and a mutual effect of DNA topology and repair.	CNR, Inst Prot Biochem, I-80131 Naples, Italy; Univ Versailles, Lab Genet & Biol Cellulaire, Equipe Microbiol, CNRS FRE 2445, F-78035 Versailles, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); UDICE-French Research Universities; Universite Paris Saclay	Ciaramella, M (corresponding author), CNR, Inst Prot Biochem, Via P Castellino 111, I-80131 Naples, Italy.	m.ciaramella@ibp.cnr.it	Ciaramella, Maria/O-1152-2015	Ciaramella, Maria/0000-0003-1583-1694; Valenti, Anna/0000-0002-5278-3524; Garnier, Florence/0000-0002-6299-6531; NADAL, Marc/0000-0001-9637-7694				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Chakraverty RK, 2001, MOL CELL BIOL, V21, P7150, DOI 10.1128/MCB.21.21.7150-7162.2001; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Ciaramella M, 2002, ANTON LEEUW INT J G, V81, P85, DOI 10.1023/A:1020577510469; Dai PG, 2003, J BACTERIOL, V185, P5500, DOI 10.1128/JB.185.18.5500-5507.2003; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Duguet M, 1997, J CELL SCI, V110, P1345; Dutertre S, 2002, J BIOL CHEM, V277, P6280, DOI 10.1074/jbc.M105735200; Eckardt-Schupp F, 1999, BIOCHIMIE, V81, P161, DOI 10.1016/S0300-9084(99)80049-2; Forterre P, 1996, FEMS MICROBIOL REV, V18, P237; Forterre P, 2002, TRENDS GENET, V18, P236, DOI 10.1016/S0168-9525(02)02650-1; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 2003, J BIOL CHEM, V278, P42668, DOI 10.1074/jbc.M302994200; Hjort K, 2001, MOL MICROBIOL, V40, P225, DOI 10.1046/j.1365-2958.2001.02377.x; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Jaxel C, 1999, EUR J BIOCHEM, V260, P103, DOI 10.1046/j.1432-1327.1999.00128.x; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; Laursen LV, 2003, MOL CELL BIOL, V23, P3692, DOI 10.1128/MCB.23.10.3692-3705.2003; Lilley DMJ., 1995, NUCL ACIDS MOL BIOL, P84; LopezGarcia P, 1997, MOL MICROBIOL, V23, P1267, DOI 10.1046/j.1365-2958.1997.3051668.x; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2003, DNA REPAIR, V2, P1115, DOI 10.1016/S1568-7864(03)00122-8; NADAL M, 1988, BIOCHEMISTRY-US, V27, P9102, DOI 10.1021/bi00426a006; NADAL M, 1994, J BIOL CHEM, V269, P5255; Napoli A, 2002, NUCLEIC ACIDS RES, V30, P2656, DOI 10.1093/nar/gkf377; Napoli A, 2001, J BIOL CHEM, V276, P10745, DOI 10.1074/jbc.M010611200; Park JY, 2000, FEBS LETT, V476, P174, DOI 10.1016/S0014-5793(00)01718-X; PEDRINI AM, 1983, P NATL ACAD SCI-BIOL, V80, P1787, DOI 10.1073/pnas.80.7.1787; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Rodriguez AC, 2003, BIOCHEMISTRY-US, V42, P5993, DOI 10.1021/bi034188l; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; Salerno V, 2003, NUCLEIC ACIDS RES, V31, P6127, DOI 10.1093/nar/gkg831; Subramanian D, 1998, CANCER RES, V58, P976; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WASSERMANN K, 1990, MOL PHARMACOL, V38, P38; Watt PM, 1996, CURR BIOL, V6, P265, DOI 10.1016/S0960-9822(02)00474-8; White MF, 2003, BIOCHEM SOC T, V31, P690, DOI 10.1042/BST0310690.; Wu L, 1999, CURR BIOL, V9, pR518, DOI 10.1016/S0960-9822(99)80325-X	44	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33192	33198		10.1074/jbc.M402619200	http://dx.doi.org/10.1074/jbc.M402619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15190074	hybrid			2022-12-27	WOS:000223039700023
J	Sweeney, G; Garg, RR; Ceddia, RB; Li, DL; Ishiki, M; Somwar, R; Foster, LJ; Neilsen, PO; Prestwich, GD; Rudich, A; Klip, A				Sweeney, G; Garg, RR; Ceddia, RB; Li, DL; Ishiki, M; Somwar, R; Foster, LJ; Neilsen, PO; Prestwich, GD; Rudich, A; Klip, A			Intracellular delivery of phosphatidylinositol (3,4,5)-trisphosphate causes incorporation of glucose transporter 4 into the plasma membrane of muscle and fat cells without increasing glucose uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; AKT/PROTEIN KINASE-B; AMINO-ACID-TRANSPORT; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; INSULIN-RESISTANCE; L6 MYOBLASTS; SUBCELLULAR-DISTRIBUTION; SIGNALING MECHANISMS	Insulin stimulates glucose uptake into muscle and fat cells by translocating glucose transporter 4 (GLUT4) to the cell surface, with input from phosphatidylinositol ( PI) 3-kinase and its downstream effector Akt/protein kinase B. Whether PI3,4,5-trisphosphate (PI(3,4,5)P-3) suffices to produce GLUT4 translocation is unknown. We used two strategies to deliver PI(3,4,5)P-3 intracellularly and two insulin-sensitive cell lines to examine Akt activation and GLUT4 translocation. In 3T3-L1 adipocytes, the acetoxymethyl ester of PI(3,4,5)P-3 caused GLUT4 migration to the cell periphery and increased the amount of plasma membrane-associated phospho-Akt and GLUT4. Intracellular delivery of PI(3,4,5)P-3 using polyamine carriers also induced translocation of myc-tagged GLUT4 to the surface of intact L6 myoblasts, demonstrating membrane insertion of the transporter. GLUT4 translocation caused by carrier-delivered PI(3,4,5)P-3 was not reproduced by carrier-PI 4,5-bisphosphate or carrier alone. Like insulin, carrier-mediated delivery of PI( 3,4,5) P3 elicited redistribution of perinuclear GLUT4 and Akt phosphorylation at the cell periphery. In contrast to its effect on GLUT4 mobilization, delivered PI(3,4,5) P3 did not increase 2-deoxyglucose uptake in either L6GLUT4myc myoblasts or 3T3-L1 adipocytes. The ability of exogenously delivered PI(3,4,5)P-3 to augment plasma membrane GLUT4 content without increasing glucose uptake suggests that input at the level of PI 3-kinase suffices for GLUT4 translocation but is insufficient to stimulate glucose transport.	Hosp Sick Children, Programme Cell Biol, Toronto, ON M5G 1X8, Canada; York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Echelon Biosci, Salt Lake City, UT 84108 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); York University - Canada; Utah System of Higher Education; University of Utah	Klip, A (corresponding author), Hosp Sick Children, Programme Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	amira@sickkids.ca		Rudich, Assaf/0000-0002-1366-1444	NIGMS NIH HHS [GM62734-03] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM062734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; EVANS JL, 1995, CELL SIGNAL, V7, P365, DOI 10.1016/0898-6568(95)00007-C; Fletcher LM, 1999, BIOCHEM SOC T, V27, P677, DOI 10.1042/bst0270677; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hou JCQ, 2003, MOL BIOL CELL, V14, P3578, DOI 10.1091/mbc.E03-02-0012; Ijuin T, 2003, MOL CELL BIOL, V23, P1209, DOI 10.1128/MCB.23.4.1209-1220.2003; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Khayat ZA, 2000, J CELL SCI, V113, P279; KLIP A, 2001, HDB PHYSL 7, V2, P451; KONRAD D, 2004, KEYST M DIAB MELL MO, P123; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; Mosser VA, 2001, BIOCHEM BIOPH RES CO, V288, P1011, DOI 10.1006/bbrc.2001.5876; Mueckler M, 2001, J CLIN INVEST, V107, P1211, DOI 10.1172/JCI13020; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Rudich A, 2003, DIABETOLOGIA, V46, P649, DOI 10.1007/s00125-003-1080-1; SARGEANT R, 1993, J ENDOCRINOL INVEST, V16, P147, DOI 10.1007/BF03347669; Sasaoka T, 2004, J BIOL CHEM, V279, P14835, DOI 10.1074/jbc.M311534200; Sasaoka T, 2001, DIABETOLOGIA, V44, P1258, DOI 10.1007/s001250100645; Shisheva A, 2003, DIABETOLOGIA, V46, pA213; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tengholm A, 2002, CURR BIOL, V12, P1871, DOI 10.1016/S0960-9822(02)01223-X; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; YANG J, 1992, J BIOL CHEM, V267, P10393	65	55	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32233	32242		10.1074/jbc.M402897200	http://dx.doi.org/10.1074/jbc.M402897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166230	hybrid			2022-12-27	WOS:000222849700031
J	Thomas, LR; Henson, A; Reed, JC; Salsbury, FR; Thorburn, A				Thomas, LR; Henson, A; Reed, JC; Salsbury, FR; Thorburn, A			Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX; CELL-DEATH; TRAIL RECEPTORS; CASPASE-8; PROTEIN; RECRUITMENT; ACTIVATION; FADD/MORT1; INDUCTION; INSIGHTS	Members of the tumor necrosis factor superfamily of receptors induce apoptosis by recruiting adaptor molecules through death domain interactions. The central adaptor molecule for these receptors is the death domain-containing protein Fas-associated death domain ( FADD). FADD binds a death domain on a receptor or additional adaptor and recruits caspases to the activated receptor. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signals apoptosis through two receptors, DR4 and DR5. Although there is much interest in TRAIL, the mechanism by which FADD is recruited to the TRAIL receptors is not clear. Using a reverse two-hybrid system we previously identified mutations in the death effector domain of FADD that prevented binding to Fas/CD95. Here we show that these mutations also prevent binding to DR5. FADD-deficient Jurkat cells stably expressing these FADD mutations did not transduce TRAIL or Fas/CD95 signaling. Second site compensating mutations that restore binding to and signaling through Fas/CD95 and DR5 were also in the death effector domain. We conclude that in contrast to current models where the death domain of FADD functions independently of the death effector domain, the death effector domain of FADD comes into direct contact with both TRAIL and Fas/CD95 receptors.	Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Burnham Inst, La Jolla, CA 92037 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Sanford Burnham Prebys Medical Discovery Institute; Wake Forest University	Thorburn, A (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	athorbur@wfubmc.edu	Salsbury, FR/A-5923-2008	Salsbury, FR/0000-0002-2699-829X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee MS, 2002, J CHEM PHYS, V116, P10606, DOI 10.1063/1.1480013; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	33	69	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32780	32785		10.1074/jbc.M401680200	http://dx.doi.org/10.1074/jbc.M401680200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173180	hybrid			2022-12-27	WOS:000222849700097
J	Trausch-Azar, JS; Lingbeck, J; Ciechanover, A; Schwartz, AL				Trausch-Azar, JS; Lingbeck, J; Ciechanover, A; Schwartz, AL			Ubiquitin-proteasome-mediated degradation of Id1 is modulated by MyoD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; LOOP-HELIX PROTEINS; TRANSCRIPTION FACTORS; NUCLEAR; REGULATORS; PATHWAY; BINDING; SYSTEM; PROTEOLYSIS; TRANSPORT	Degradation of many short-lived cellular proteins such as the transcription factor MyoD occurs via the ubiquitin-proteasome pathway. MyoD, similar to many rapidly degraded regulatory factors, interacts with several high affinity binding partners, including members of the Id ( inhibitors of DNA binding) family. Following transfection to HeLa cells, Id1 is localized to the nucleus and rapidly (t(1/2) similar to 1 h) degraded via the ubiquitin-proteasome system. Mutagenesis of lysine residues within the putative nuclear localization region (amino acids 68-82) directs Id1(NLS) to the cytoplasm yet confers an increased rate of degradation (t(1/2) similar to 0.5 h). Id1 in which all lysine residues were mutagenized to alanine (lysineless Id1) was also rapidly degraded (t(1/2) similar to 0.6 h). Addition of a Myc(6) tag to the N terminus of lysine-less Id1 markedly stabilized Id1 (t(1/2) > 10 h) and suggests degradation via the N terminus-dependent pathway. Co-transfection of MyoD with Id1 or Id1(NLS) increases Id1 or Id1(NLS) within the nucleus and markedly reduces the rate of Id1 or Id1(NLS) degradation. These results thus demonstrate that in vivo MyoD modulates the rate of Id1 degradation and suggest a dynamic interplay of these factors.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat & Mol Biol & Phar, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	Schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; Belletti B, 2002, EXP CELL RES, V277, P107, DOI 10.1006/excr.2002.5542; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Immink RGH, 2002, P NATL ACAD SCI USA, V99, P2416, DOI 10.1073/pnas.042677699; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lees MJ, 2003, J BIOL CHEM, V278, P35878, DOI 10.1074/jbc.M302430200; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Paulmurugan R, 2002, P NATL ACAD SCI USA, V99, P15608, DOI 10.1073/pnas.242594299; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; RODRIGUEZ MS, 1999, J BIOL CHEM, V274, P9017; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200	46	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32614	32619		10.1074/jbc.M403794200	http://dx.doi.org/10.1074/jbc.M403794200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15163661	hybrid			2022-12-27	WOS:000222849700078
J	Wright, TG; Tsai, J; Jia, ZC; Elliott, BE				Wright, TG; Tsai, J; Jia, ZC; Elliott, BE			Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor met and blockade of HGF/Met function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; C-MET; EPITHELIAL-CELLS; TYROSINE KINASE; BREAST-CANCER; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; NK1 FRAGMENT; EXPRESSION; ANTAGONIST	Overexpression of hepatocyte growth factor (HGF) and its receptor Met often occurs in carcinoma cells, leading to establishment of an HGF/Met autocrine loop. Therefore, disruption of the HGF/Met autocrine loop may lead to down-regulation of tumorigenesis. To study the HGF/Met interaction, we have developed a cell-free system to detect HGF binding to a Met fusion protein, Met-IgG, using a modified enzyme-linked immunosorbent assay methodology. Since we previously showed that HGF can be purified by copper(II) affinity chromatography, we further explored the effect of copper( II) on the HGF/Met interaction. The divalent metal cations copper( II) and zinc( II) significantly inhibited HGF binding to immobilized Met-IgG with IC50 values of 230-270 muM, respectively, whereas manganese(II) and magnesium (II) were less inhibitory with 20-60-fold higher IC50 values. Incubation of 1 mM copper( II) with HGF resulted in nondenaturing and denaturing gel-mobility shifts, indicating that copper(II) binds directly to HGF. This interaction occurs at the N terminus of HGF, as incubation of 1 mM copper( II) with both HGF and the HGF derivative NK1 yielded similar results on SDS-PAGE. HGF-induced activation of Met and cell scattering were inhibited upon addition of HGF in the presence of 1 mM and 500 muM copper(II), respectively. Chemical protonation with diethyl pyrocarbonate of HGF histidine residues impeded the ability of 500 muM copper(II) to inhibit the binding of HGF to immobilized Met-IgG. Based on the NK1 domain structure, we propose that copper( II) may interact with HGF via the histidine residues in either N-terminal or kringle domains. The inhibition of HGF/Met interaction and subsequent downstream cellular functions may be through direct interference by copper(II), such as a change in charge or an induced local conformational change. This putative copper( II) binding domain may be the basis for developing potential inhibitors of HGF/Met binding and downstream functions and could lead to novel strategies for anti-cancer treatment.	Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Elliott, BE (corresponding author), Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada.	elliottb@post.queensu.ca						ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ALITALO K, 1982, ADV CANCER RES, V37, P111, DOI 10.1016/S0065-230X(08)60883-0; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Chirgadze DY, 1998, FEBS LETT, V430, P126, DOI 10.1016/S0014-5793(98)00558-4; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; Gherardi E, 1997, CIBA F SYMP, V212, P84; Gherardi E, 1993, EXS, V65, P31; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hill BC, 2003, ARCH BIOCHEM BIOPHYS, V412, P186, DOI 10.1016/S0003-9861(03)00032-8; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuba K, 2000, BIOCHEM BIOPH RES CO, V279, P846, DOI 10.1006/bbrc.2000.4034; LEE HS, 1995, BIOCHEM BIOPH RES CO, V210, P1017, DOI 10.1006/bbrc.1995.1758; Linder MC, 2001, MUTAT RES-FUND MOL M, V475, P141, DOI 10.1016/S0027-5107(01)00076-8; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARS WM, 1993, AM J PATHOL, V143, P949; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MIZUNO K, 1994, BIOCHEM BIOPH RES CO, V198, P1161, DOI 10.1006/bbrc.1994.1164; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; Parr C, 2000, INT J CANCER, V85, P563, DOI 10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.0.CO;2-D; Parr C, 2001, BIOCHEM BIOPH RES CO, V285, P1330, DOI 10.1006/bbrc.2001.5307; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rahimi N, 1996, PROTEIN EXPRES PURIF, V7, P329, DOI 10.1006/prep.1996.0047; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; Toi M, 1998, CLIN CANCER RES, V4, P659; Tsai YH, 2002, J CHROMATOGR B, V766, P133, DOI 10.1016/S0378-4347(01)00459-5; Tuck AB, 1996, AM J PATHOL, V148, P225; Ultsch M, 1998, STRUCT FOLD DES, V6, P1383, DOI 10.1016/S0969-2126(98)00138-5; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Woodbury RL, 2002, J PROTEOME RES, V1, P233, DOI 10.1021/pr025506q; Yao Y, 1996, AM J PATHOL, V149, P1707; Zhou HJ, 1999, BIOCHEMISTRY-US, V38, P14793, DOI 10.1021/bi9908641	51	5	7	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32499	32506		10.1074/jbc.M405043200	http://dx.doi.org/10.1074/jbc.M405043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161915	hybrid			2022-12-27	WOS:000222849700064
J	Banninger, G; Reich, NC				Banninger, G; Reich, NC			STAT2 nuclear trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED TRANSCRIPTION FACTOR; INTERFERON REGULATORY FACTOR; DNA-BINDING DOMAIN; IMPORTIN-ALPHA; LOCALIZATION SIGNAL; TYROSINE PHOSPHORYLATION; TARGETED DISRUPTION; PROTEIN; ACTIVATION; TRANSPORT	STAT2 is a transcription factor critical to the signal transduction pathway of type I interferons (e.g. IFNalpha). STAT2 resides primarily in the cytoplasm and is tyrosine-phosphorylated after IFNalpha binds to cell surface receptors. In response to tyrosine phosphorylation STAT2 rapidly localizes to the nucleus and acquires the ability to bind specific DNA targets in association with two other proteins, STAT1 and IFN regulatory factor-9 (IRF-9). To elucidate the mechanisms that regulate cellular localization of STAT2, we investigated STAT2 nuclear trafficking both prior to tyrosine phosphorylation and after phosphorylation. Prior to phosphorylation, STAT2 is primarily resident in the cytoplasm, however, we found that it dynamically shuttles between nuclear and cytoplasmic compartments. The nuclear translocation of latent unphosphorylated STAT2 was found to be dependent on its constitutive association with IRF-9, and the export of STAT2 from the nucleus was contingent upon the function of an intrinsic nuclear export signal within the carboxyl terminus of STAT2. STAT2 export could be inhibited with leptomycin B, indicating a nuclear export signal within STAT2 is recognized by the CRM1 exportin carrier. In contrast, following tyrosine phosphorylation, STAT2 dimerizes with phosphorylated STAT1 and accumulates in the nucleus. In the absence of STAT1, STAT2 does not accumulate in the nucleus. In addition, subsequent to nuclear import of phosphorylated STAT2, it redistributes to the cytoplasm within an hour coordinate with its dephosphorylation in the nucleus. The regulation of STAT2 nuclear trafficking is distinct from the previously characterized STAT1 factor.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Reich, NC (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	nreich@notes.cc.sunysb.edu			NCI NIH HHS [R01CA50773] Funding Source: Medline; OAPP OPHS HHS [PPGCA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OAPP OPHS HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kraus TA, 2003, J BIOL CHEM, V278, P13033, DOI 10.1074/jbc.M212972200; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lau JF, 2000, P NATL ACAD SCI USA, V97, P7278, DOI 10.1073/pnas.97.13.7278; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Melen K, 2003, J BIOL CHEM, V278, P28193, DOI 10.1074/jbc.M303571200; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Prieve MG, 1998, MOL CELL BIOL, V18, P4819, DOI 10.1128/MCB.18.8.4819; Reich NC, 2002, J INTERF CYTOK RES, V22, P103, DOI 10.1089/107999002753452719; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	42	95	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39199	39206		10.1074/jbc.M400815200	http://dx.doi.org/10.1074/jbc.M400815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15175343	hybrid			2022-12-27	WOS:000223791500003
J	Dettwiler, S; Aringhieri, C; Cardinale, S; Keller, W; Barabino, SML				Dettwiler, S; Aringhieri, C; Cardinale, S; Keller, W; Barabino, SML			Distinct sequence motifs within the 68-kDa subunit of cleavage factor I-m mediate RNA binding, protein-protein interactions, and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLYADENYLATION SPECIFICITY FACTOR; VERTEBRATE POLY(A) POLYMERASE; SR PROTEINS; SPLICING FACTOR; SUBNUCLEAR LOCALIZATION; MOLECULAR-CLONING; CARBOXYL-TERMINUS; 3'-END CLEAVAGE; NUCLEAR EXPORT	Cleavage factor I-m (CF I-m) is required for the first step in pre-mRNA 3'-end processing and can be reconstituted in vitro from its heterologously expressed 25- and 68-kDa subunits. The binding of CF I-m to the pre-mRNA is one of the earliest steps in the assembly of the cleavage and polyadenylation machinery and facilitates the recruitment of other processing factors. We identified regions in the subunits of CF I-m involved in RNA binding, protein-protein interactions, and subcellular localization. CF I(m)68 has a modular domain organization consisting of an N-terminal RNA recognition motif and a C-terminal alternating charge domain. However, the RNA recognition motif of CF I(m)68 on its own is not sufficient to bind RNA but is necessary for association with the 25-kDa subunit. RNA binding appears to require a CF I(m)68/25 heterodimer. Whereas multiple protein interactions with other 3'-end-processing factors are detected with CF I(m)25, CF I(m)68 interacts with SRp20, 9G8, and hTra2beta, members of the SR family of splicing factors, via its C-terminal alternating charge domain. This domain is also required for targeting CF I(m)68 to the nucleus. However, CF I(m)68 does not concentrate in splicing speckles but in foci that partially colocalize with paraspeckles, a subnuclear component in which other proteins involved in transcriptional control and RNA processing have been found.	Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Milano-Bicocca; University of Basel	Barabino, SML (corresponding author), Univ Milano Bicocca, Dept Biotechnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	silvia.barabino@unimib.it	Barabino, Silvia/AAC-4674-2021	Cardinale, Stefano/0000-0003-4357-9246	Telethon [GP0020Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Awasthi S, 2003, RNA, V9, P1400, DOI 10.1261/rna.5104603; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1993, J CELL BIOL, V120, P841, DOI 10.1083/jcb.120.4.841; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Dichtl B, 2001, EMBO J, V20, P3197, DOI 10.1093/emboj/20.12.3197; Emili A, 2002, RNA, V8, P1102, DOI 10.1017/S1355838202025037; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; Kim H, 2001, BIOCHEM BIOPH RES CO, V289, P513, DOI 10.1006/bbrc.2001.5992; KRAUSE S, 1994, EXP CELL RES, V214, P75, DOI 10.1006/excr.1994.1235; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Lutz CS, 1998, RNA, V4, P1493, DOI 10.1017/S1355838298981183; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; McCracken S, 2002, MOL CELL BIOL, V22, P148, DOI 10.1128/MCB.22.1.148-160.2002; Millevoi S, 2002, EMBO REP, V3, P869, DOI 10.1093/embo-reports/kvf173; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rosonina E, 2003, J BIOL CHEM, V278, P43034, DOI 10.1074/jbc.M307289200; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Ruegsegger U, 1998, MOL CELL, V1, P243, DOI 10.1016/S1097-2765(00)80025-8; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; Schul W, 1998, EXP CELL RES, V238, P1, DOI 10.1006/excr.1997.3808; Segade F, 1996, FEBS LETT, V387, P152, DOI 10.1016/0014-5793(96)00496-6; Selenko P, 2003, MOL CELL, V11, P965, DOI 10.1016/S1097-2765(03)00115-1; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Vagner S, 2000, GENE DEV, V14, P403; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zhou ZL, 2002, P NATL ACAD SCI USA, V99, P12203, DOI 10.1073/pnas.182427099	61	112	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35788	35797		10.1074/jbc.M403927200	http://dx.doi.org/10.1074/jbc.M403927200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169763	Green Accepted, hybrid			2022-12-27	WOS:000223303400079
J	Enomoto, R; Kinebuchi, T; Sato, M; Yagi, H; Shibata, T; Kurumizaka, H; Yokoyama, S				Enomoto, R; Kinebuchi, T; Sato, M; Yagi, H; Shibata, T; Kurumizaka, H; Yokoyama, S			Positive role of the mammalian TBPIP/HOP2 protein in DMC1-mediated homologous pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED CIRCULAR DNA; RECA PROTEIN; CHROMOSOME SYNAPSIS; MOLECULAR-CLONING; FISSION YEAST; HOP2 PROTEIN; RECOMBINATION; RAD51; MOUSE; DMC1	In meiosis, homologous recombination preferentially occurs between homologous chromosomes rather than between sister chromatids, which is opposite to the bias of mitotic recombinational repair. The TBPIP/HOP2 protein is a factor that ensures the proper pairing of homologous chromosomes during meiosis. In the present study, we found that the purified mouse TBPIP/HOP2 protein stimulated homologous pairing catalyzed by the meiotic DMC1 recombinase in vitro. In contrast, TBPIP/HOP2 did not stimulate homologous pairing by RAD51, which is another homologous pairing protein acting in both meiotic and mitotic recombination. The positive effect of TBPIP/HOP2 in the DMC1-mediated homologous pairing was only observed when TBPIP/HOP2 first binds to double-stranded DNA, not to single-stranded DNA, before the initiation of the homologous pairing reaction. Deletion analyses revealed that the C-terminal basic region of TBPIP/HOP2 is required for efficient DNA binding and is also essential for its homologous pairing stimulation activity. Therefore, these results suggest that TBPIP/HOP2 directly binds to DNA and functions as an activator for DMC1 during the homologous pairing step in meiosis.	RIKEN Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Fukui, Fac Med Sci, Dept Morphol & Physiol Sci, Div Cell Biol & Neurosci, Fukui 9101193, Japan; JST, Solut Oriented Res Sci & Technol, Kawaguchi, Saitama 3320012, Japan; RIKEN Discovery Res Inst, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan; Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; RIKEN Harima Inst SPring8, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; RIKEN Harima Inst SPring8, Structurome Res Grp, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Fukui; Japan Science & Technology Agency (JST); RIKEN; Waseda University; RIKEN; RIKEN; University of Tokyo	Kurumizaka, H (corresponding author), RIKEN Genom Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	kurumizaka@waseda.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Yagi, Hideshi/0000-0002-8506-8965; Kurumizaka, Hitoshi/0000-0001-7412-3722				Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Gerton JL, 2002, P NATL ACAD SCI USA, V99, P6895, DOI 10.1073/pnas.102167899; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Ijichi H, 2000, GENE, V248, P99, DOI 10.1016/S0378-1119(00)00141-4; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Ko L, 2002, MOL CELL BIOL, V22, P357, DOI 10.1128/MCB.22.1.357-369.2002; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; Nabeshima K, 2001, EMBO J, V20, P3871, DOI 10.1093/emboj/20.14.3871; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petukhova GV, 2003, DEV CELL, V5, P927, DOI 10.1016/S1534-5807(03)00369-1; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Schommer C, 2003, PLANT J, V36, P1, DOI 10.1046/j.1365-313X.2003.01850.x; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tanaka T, 1997, BIOCHEM BIOPH RES CO, V239, P176, DOI 10.1006/bbrc.1997.7447; Tsubouchi H, 2003, DEV CELL, V5, P915, DOI 10.1016/S1534-5807(03)00357-5; Tsubouchi H, 2002, MOL CELL BIOL, V22, P3078, DOI 10.1128/MCB.22.9.3078-3088.2002; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	41	29	30	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35263	35272		10.1074/jbc.M402481200	http://dx.doi.org/10.1074/jbc.M402481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192114	hybrid			2022-12-27	WOS:000223303400017
J	Lu, ZM; Hu, XH; Li, Y; Zheng, L; Zhou, Y; Jiang, HD; Ning, T; Basang, Z; Zhang, CF; Ke, Y				Lu, ZM; Hu, XH; Li, Y; Zheng, L; Zhou, Y; Jiang, HD; Ning, T; Basang, Z; Zhang, CF; Ke, Y			Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR; GENE-PRODUCTS; CELL-GROWTH; HUMAN KERATINOCYTES; PROTEINS TARGET; TSC2; RHEB; HAMARTIN; COMPLEX	Tuberous sclerosis complex (TSC) is a genetic disorder caused by mutations in either TSC1 or TSC2 tumor suppressor gene. TSC1 and TSC2 products, Harmatin and Tuberin, form the functional complex to serve as the negative regulator for insulin-induced phosphorylation of S6 kinase and elF4E-binding protein 1. High-risk human papillomavirus (HPV) infection is the necessary cause for cervical cancer. E6 oncoprotein encoded by HPV plays a pivotal role in carcinogenesis by interference with the host intracellular protein functions. In this study, we show that HPV16 E6 interacts with tumor suppressor gene TSC2 product, Tuberin, and results in the phosphorylation of S6 kinase and S6 even in the absence of insulin. The overexpression of Tuberin overcomes the effect of E6 on S6 kinase phosphorylation. Binding with HPV16 E6 causes the proteasome-mediated degradation of Tuberin. A DILG motif and an ELVG motif located in the carboxyl-terminal of Tuberin are required for E6 binding. In addition, the Tuberin interaction region in E6 has been mapped in the amino-terminal portion of HPV16 E6, which is different from the binding domain with p53. These results provide a possible link between E6-induced oncogenesis and the insulin-stimulated cell proliferation signaling pathway.	Peking Univ, Sch Oncol, Beijing Inst Canc Res, Dept Genet, Beijing 100034, Peoples R China	Peking University	Ke, Y (corresponding author), Peking Univ, Sch Oncol, Beijing Inst Canc Res, Dept Genet, 1 Da Hong Luo Chang St,West Dist, Beijing 100034, Peoples R China.	keyang@mx.cei.gov.cn						Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; DENG GR, 1989, CANCER RES, V47, P3195; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; Filippova M, 2002, J BIOL CHEM, V277, P21730, DOI 10.1074/jbc.M200113200; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengstschlager M, 2001, MUTAT RES-REV MUTAT, V488, P233, DOI 10.1016/S1383-5742(01)00058-8; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Momose S, 2002, HUM MOL GENET, V11, P2997, DOI 10.1093/hmg/11.24.2997; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NELLIST M, 1993, CELL, V75, P1305; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Thomas M, 1996, ONCOGENE, V13, P471; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	59	85	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35664	35670		10.1074/jbc.M403385200	http://dx.doi.org/10.1074/jbc.M403385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15175323	hybrid			2022-12-27	WOS:000223303400063
J	Pinson, B; Merle, M; Franconi, JM; Daignan-Fornier, B				Pinson, B; Merle, M; Franconi, JM; Daignan-Fornier, B			Low affinity orthophosphate carriers regulate PHO gene expression independently of internal orthophosphate concentration in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; CYCLIN-CDK COMPLEX; PHOSPHATE-TRANSPORTER; INHIBITOR PHO81; PROTEIN; POLYPHOSPHATE; PHO80-PHO85; RECEPTOR; SYSTEM; KINASE	Phosphate is an essential nutrient that must be taken up from the growth medium through specific transporters. In Saccharomyces cerevisiae, both high and low affinity orthophosphate carriers allow this micro-organism to cope with environmental variations. Intriguingly, in this study we found a tight correlation between selenite resistance and expression of the high affinity orthophosphate carrier Pho84p. Our work further revealed that mutations in the low affinity orthophosphate carrier genes (PHO87, PHO90, and PHO91) cause deregulation of phosphate-repressed genes. Strikingly, the deregulation due to pho87Delta, pho90Delta, or pho91Delta mutations was neither correlated to impaired orthophosphate uptake capacity nor to a decrease of the intracellular orthophosphate or polyphosphate pools, as shown by P-31 NMR spectroscopy. Thus, our data clearly establish that the low affinity orthophosphate carriers affect phosphate regulation independently of intracellular orthophosphate concentration through a new signaling pathway that was found to strictly require the cyclin-dependent kinase inhibitor Pho81p. We propose that phosphate-regulated gene expression is under the control of two different regulatory signals as follows: the sensing of internal orthophosphate by a yet unidentified protein and the sensing of external orthophosphate by low affinity orthophosphate transporters; the former would be required to maintain phosphate homeostasis, and the latter would keep the cell informed on the medium phosphate richness.	Univ Bordeaux 2, CNRS, UMR 5095, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5536, Unite Resonance Magnet Syst Biol, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Pinson, B (corresponding author), Univ Bordeaux 2, CNRS, UMR 5095, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	benoit.pinson@ibgc.u-bordeaux2.fr		Pinson, Benoit/0000-0003-2936-9058				Auesukaree C, 2004, J BIOL CHEM, V279, P17289, DOI 10.1074/jbc.M312202200; Auesukaree C, 2003, BIOCHEM BIOPH RES CO, V306, P843, DOI 10.1016/S0006-291X(03)01068-4; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BEAUVOIT B, 1991, BIOCHEMISTRY-US, V30, P11212, DOI 10.1021/bi00111a004; BISSON LF, 1982, GENETICS, V102, P341; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; BunYa M, 1996, CURR GENET, V29, P344, DOI 10.1007/s002940050055; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; Espie P, 1997, J BIOENERG BIOMEMBR, V29, P591, DOI 10.1023/A:1022487119390; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huang SD, 2001, MOL CELL BIOL, V21, P6695, DOI 10.1128/MCB.21.19.6695-6705.2001; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Lau WTW, 2000, P NATL ACAD SCI USA, V97, P1107, DOI 10.1073/pnas.97.3.1107; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; Nishimura K, 1999, YEAST, V15, P1711, DOI 10.1002/(SICI)1097-0061(199912)15:16<1711::AID-YEA497>3.0.CO;2-8; Ogawa N, 1995, MOL GEN GENET, V249, P406, DOI 10.1007/BF00287102; Ogawa N, 2000, J BACTERIOL, V182, P6687, DOI 10.1128/JB.182.23.6687-6693.2000; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; OGAWA N, 1995, MOL CELL BIOL, V15, P997; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Persson BL, 1998, BBA-BIOENERGETICS, V1365, P23, DOI 10.1016/S0005-2728(98)00037-1; Pinson B, 2000, MOL MICROBIOL, V36, P679, DOI 10.1046/j.1365-2958.2000.01890.x; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; Sherman F., 1983, METHODS YEAST GENETI; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; SUMMER JB, 1944, SCIENCE, V100, P413; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; Van Belle D, 2001, CURR OPIN CELL BIOL, V13, P389, DOI 10.1016/S0955-0674(00)00226-X; Wykoff DD, 2001, GENETICS, V159, P1491	40	48	49	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35273	35280		10.1074/jbc.M405398200	http://dx.doi.org/10.1074/jbc.M405398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194704	hybrid			2022-12-27	WOS:000223303400018
J	Sharma, AK; Rohrer, B				Sharma, AK; Rohrer, B			RETRACTED: Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line (Retracted article. See vol. 292, pg. 13186, 2017)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							DOMINANT RETINITIS-PIGMENTOSA; RETINAL DEGENERATION; CYTOCHROME-C; DEATH; RD; MEMBRANE; MICE; PHOSPHODIESTERASE; RHODOPSIN; MUTATION	The rd mouse, an accepted animal model for photoreceptor degeneration in retinitis pigmentosa, has a recessive mutation for the gene encoding the beta-subunit of the cGMP phosphodiesterase. This mutation results in high levels of cGMP, which leaves an increased number of the cGMP-gated channels in the open state, thus allowing intracellular calcium (Ca2+) to rise to toxic levels, and rapid photoreceptor degeneration follows. To delineate the events in rd photoreceptor degeneration, we demonstrated an increase in calpain and caspase-3 activity, hypothesizing that Ca2+-mediated apoptosis in photoreceptors is mediated by calpain, involving mitochondrial depolarization and caspase-3 activation. To examine this hypothesis further, a murine photoreceptor-derived cell line (661W) was treated with the Ca2+ ionophore A23187, cGMP-gated channel agonist 8-bromoc-GMP, or phosphodiesterase inhibitor isobutylmethylxanthine to mimic the increased Ca2+ influx seen in the rd photoreceptors. Ca2+-induced cell death in 661W cells was found to be mediated by calpain and caspase-3 and could be completely inhibited by the calpain inhibitor SJA6017, implicating both calpain and caspases in the apoptotic process. The apoptotic events correlated in an SJA6017-inhibitable manner with bid cleavage, mitochondrial depolarization, cytochrome c release, and caspase-3 and -9 activation. We concluded that Ca2+ influx in the rd model of photoreceptor degeneration leads to the activation of the cysteine protease calpain, which executes apoptosis via modulation of caspase-3 activity.	Med Univ S Carolina, Dept Ophthalmol, Storm Eye Inst, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Rohrer, B (corresponding author), Med Univ S Carolina, Dept Ophthalmol, Storm Eye Inst, 167 Ashley Ave, Charleston, SC 29425 USA.	rohrer@musc.edu			NEI NIH HHS [EY014793, EY13520] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013520, R24EY014793] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BLANKS JC, 1974, J COMP NEUROL, V156, P95, DOI 10.1002/cne.901560108; CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CROSSON CE, 1990, J OCUL PHARMACOL, V6, P293, DOI 10.1089/jop.1990.6.293; Doonan F, 2003, J NEUROSCI, V23, P5723; EDWARD DP, 1991, ARCH OPHTHALMOL-CHIC, V109, P554, DOI 10.1001/archopht.1991.01080040122042; FARBER DB, 1988, EXP EYE RES, V46, P363, DOI 10.1016/S0014-4835(88)80026-5; FARRAR GJ, 1990, GENOMICS, V8, P35; FARRAR GJ, 1992, GENOMICS, V14, P805; Fox DA, 1999, ANN NY ACAD SCI, V893, P282, DOI 10.1111/j.1749-6632.1999.tb07837.x; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jomary C, 2001, MOL CELL NEUROSCI, V18, P335, DOI 10.1006/mcne.2001.1036; Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114; THIRKILL CE, 1987, ARCH OPHTHALMOL-CHIC, V105, P372; Wei MC, 2000, GENE DEV, V14, P2060	26	128	137	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35564	35572		10.1074/jbc.M401037200	http://dx.doi.org/10.1074/jbc.M401037200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208318	hybrid			2022-12-27	WOS:000223303400052
J	Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR				Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR			Glycoprotein hormone assembly in the endoplasmic reticulum - IV. Probable mechanism of subunit docking and completion of assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; BETA-SUBUNIT; BIOLOGICAL-ACTIVITY; DISULFIDE BONDS; PROTEIN; COMBINATION; ANALOGS	The unique structures of human choriogonadotropin (hCG) and related glycoprotein hormones make them well suited for studies of protein folding in the endoplasmic reticulum. hCG is stabilized by a strand of its beta-subunit that has been likened to a "seatbelt" because it surrounds alpha-subunit loop 2 and its end is "latched" by an intrasubunit disulfide bond to the beta-subunit core. As shown here, assembly begins when parts of the NH2 terminus, cysteine knot, and loops 1 and 3 of the alpha-subunit dock reversibly with parts of the NH2 terminus, cystine knot, and loop 2 of the hCG beta-subunit. Whereas the seatbelt can contribute to the stability of the docked subunit complex, it interferes with docking and/or destabilizes the docked complex when it is unlatched. This explains why most hCG is assembled by threading the glycosylated end of alpha-subunit loop 2 beneath the latched seatbelt rather than by wrapping the unlatched seatbelt around this loop. hCG assembly appears to be limited by the need to disrupt the disulfide that stabilizes the small seatbelt loop prior to threading. We postulate that assembly depends on a "zipper- like" sequential formation of intersubunit and intrasubunit hydrogen bonds between backbone atoms of several residues in the beta-subunit cystine knot, alpha-subunit loop 2, and the small seatbelt loop. The resulting intersubunit beta-sheet enhances the stability of the seatbelt loop disulfide, which shortens the seatbelt and secures the heterodimer. Formation of this disulfide also explains the ability of the seatbelt loop to facilitate latching during assembly by the wraparound pathway.	Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038547, R01HD014907, R37HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD38547, HD14907] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALOJ SM, 1973, ARCH BIOCHEM BIOPHYS, V159, P497, DOI 10.1016/0003-9861(73)90480-3; CHEN F, 1991, J BIOL CHEM, V266, P6904; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lin W, 1999, MOL CELL ENDOCRINOL, V152, P91, DOI 10.1016/S0303-7207(99)00056-8; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SLAUGHTER S, 1995, MOL CELL ENDOCRINOL, V112, P21, DOI 10.1016/0303-7207(95)03579-V; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P35449, DOI 10.1074/jbc.M403054200; Xing YN, 2004, J BIOL CHEM, V279, P35437, DOI 10.1074/jbc.M403053200; Xing YN, 2004, J BIOL CHEM, V279, P35426, DOI 10.1074/jbc.M403052200; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; Xing YN, 2001, PROTEIN SCI, V10, P226, DOI 10.1110/ps.25901	18	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35458	35468		10.1074/jbc.M403055200	http://dx.doi.org/10.1074/jbc.M403055200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15166248	hybrid			2022-12-27	WOS:000223303400039
J	Hengst, JA; Bond, AS				Hengst, JA; Bond, AS			Transport of meprin subunits through the secretory pathway - Role of the transmembrane and cytoplasmic domains and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL TAIL; ENDOPLASMIC-RETICULUM; ALPHA-SUBUNIT; BETA-SUBUNIT; RETENTION; MOTIF; GENE; IDENTIFICATION; EXPRESSION; PROTEINS	The meprin alpha subunit, a multidomain metalloproteinase, is synthesized as a type I membrane protein and proteolytically cleaved during biosynthesis in the endoplasmic reticulum (ER), consequently losing its membrane attachment and COOH-terminal domains. The meprin alpha subunit is secreted as a disulfide-linked dimer that forms higher oligomers. By contrast, the evolutionarily related meprin beta subunit retains the COOH-terminal domains during biosynthesis and travels to the plasma membrane as a disulfide-linked integral membrane dimer. Deletion of a unique 56-amino acid inserted domain (the I domain) of meprin alpha prevents COOH-terminal proteolytic processing and results in the retention of this subunit within the ER. To determine elements responsible for this retention versus transport to the cell surface, mutagenesis experiments were performed. Replacement of the meprin alpha transmembrane (alphaT) and cytoplasmic (alphaC) domains with their beta counterparts allowed rapid movement of the alpha subunit to the cell surface. The meprin alphaT and alphaC domains substituted into meprin beta delayed movement of this chimera through the secretory pathway. Replacement of glycines in the meprin alphaT domain GXXXG motif with leucine residues, alanine insertions in the meprin alphaT domain, and mutagenesis of basic residues within the meprin alphaC domain did not enhance the movement of the alpha subunit through the secretory pathway. By contrast, a mutant of meprin alpha (C320AalphaDeltaI) that did not form disulfide-linked dimers or higher order oligomers was transported through the secretory pathway, although more slowly than meprin beta. Taken together, the data indicate that the meprin alphaT and alphaC domains together contain a weak signal for retention within the ER/cis-Golgi compartments that is strengthened by oligomerization.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Bond, AS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171,500 Univ Dr, Hershey, PA 17033 USA.	jbond@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R37DK019691, R01DK019691, R01DK054625] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691, DK 54625] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Becker C, 2003, BIOL CHEM, V384, P825, DOI 10.1515/BC.2003.092; Bertenshaw GP, 2003, J BIOL CHEM, V278, P2522, DOI 10.1074/jbc.M208808200; BERTENSHAW GP, 2004, HDB PROTEOLYTIC ENZY, P599; Beynon RJ, 1996, BIOCHEM J, V315, P461, DOI 10.1042/bj3150461; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BOND JS, 1997, ASTACINS, P45; Booth A G, 1974, Biochem J, V142, P575; Carmago S, 2002, KIDNEY INT, V61, P959, DOI 10.1046/j.1523-1755.2002.00209.x; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; Chevallier S, 1996, BIOCHEM J, V317, P731, DOI 10.1042/bj3170731; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; Crisman JM, 2004, J IMMUNOL, V172, P4510, DOI 10.4049/jimmunol.172.7.4510; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Friedmann E, 2002, J BIOL CHEM, V277, P35274, DOI 10.1074/jbc.M201044200; Hahn D, 1997, EUR J BIOCHEM, V247, P933, DOI 10.1111/j.1432-1033.1997.00933.x; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; Litovchick L, 2002, J BIOL CHEM, V277, P34413, DOI 10.1074/jbc.M203986200; Litovchick L, 1998, J BIOL CHEM, V273, P29043, DOI 10.1074/jbc.273.44.29043; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Norman LP, 2003, MOL CELL BIOL, V23, P1221, DOI 10.1128/MCB.23.4.1221-1230.2003; Plemper RK, 2001, J BIOL CHEM, V276, P44239, DOI 10.1074/jbc.M105967200; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; Tsukuba T, 2002, ARCH BIOCHEM BIOPHYS, V397, P191, DOI 10.1006/abbi.2001.2672; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Villa JP, 2003, BIOCHEM SOC SYMP, V70, P53, DOI 10.1042/bss0700053; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325	42	17	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34856	34864		10.1074/jbc.M405774200	http://dx.doi.org/10.1074/jbc.M405774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187079	hybrid			2022-12-27	WOS:000223134800095
J	Kao, YY; Lai, HL; Hwang, MJ; Chern, YJ				Kao, YY; Lai, HL; Hwang, MJ; Chern, YJ			An important functional role of the N terminus domain of type VI adenylyl cyclase in G alpha(i)-mediated inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHEOCHROMOCYTOMA PC12 CELLS; CENTRAL-NERVOUS-SYSTEM; CYTOSOLIC DOMAINS; RECEPTOR ISOFORMS; ESCHERICHIA-COLI; BETA-GAMMA; G(I-ALPHA); EXPRESSION; BINDING	We show herein that removal of the first 86 amino acids (aa) of the N terminus ( designated N) of type VI adenylyl cyclase (ACVI) caused the resultant ACVI mutant (ACVI-DeltaA87) to be more greatly inhibited by a Galpha(i)-coupled receptor or activated Galpha(i) protein. Moreover, in vitro binding of the full-length N and C1a domain ( designated C1a), which interacts with Galpha(i), was detected. A truncated N terminus ( aa 1 - 86) also interacted with C1a, suggesting that the C1a-interacting region is located within aa 1 - 86. Mutation analyses further revealed that N might interact with C1a in the region ( aa 434 - 505) where Galpha(i) is bound. Mutations of two residues (Leu-472 and Val-476) located in this N-binding region of C1a suppressed the interaction between recombinant N and C1a and markedly reduced Galpha(i)-mediated inhibition of ACVI-DeltaA87. Further biochemical analyses of the effect of internal mutations of Leu-472/Val-476 on Galpha(i)-mediated inhibition of wild-type ACVI and ACVI-DeltaA87 suggested that N modulates the Galpha(i)-mediated inhibition of ACVI via binding to C1a when the level of Galpha(i) is low (i.e. around the IC50 value) and that a more complicated interfering mode results when the level of Galpha(i) is high (i.e. similar to10- to 20-fold of the IC50 value). Collectively, data presented herein suggest a novel function of the N terminus of ACVI in Galpha(i)-mediated regulation.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Chern, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.	bmychern@ibms.sinica.edu.tw	Hwang, Ming-jing/E-9210-2012; chern, yijuang/S-7013-2018	Hwang, Ming-jing/0000-0002-9657-5663; chern, yijuang/0000-0002-5842-5429				ANTONI FA, 1995, J BIOL CHEM, V270, P28055; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; Dessauer CW, 2002, J BIOL CHEM, V277, P28823, DOI 10.1074/jbc.M203962200; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Drutel G, 2001, MOL PHARMACOL, V59, P1; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; HARAZONO A, 1994, BIOCHEM BIOPH RES CO, V201, P340, DOI 10.1006/bbrc.1994.1707; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hu BA, 2002, J BIOL CHEM, V277, P33139, DOI 10.1074/jbc.M112373200; Huang CL, 1999, J NEUROCHEM, V72, P2437, DOI 10.1046/j.1471-4159.1999.0722437.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lai HL, 1999, MOL PHARMACOL, V56, P644, DOI 10.1124/mol.56.3.644; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Lin TH, 2002, J BIOL CHEM, V277, P15721, DOI 10.1074/jbc.M111537200; LINDER ME, 1991, J BIOL CHEM, V266, P4654; Liu FC, 1998, FEBS LETT, V436, P92, DOI 10.1016/S0014-5793(98)01098-9; Patel TB, 2001, GENE, V269, P13, DOI 10.1016/S0378-1119(01)00448-6; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Robinson SW, 1997, MOL PHARMACOL, V52, P508, DOI 10.1124/mol.52.3.508; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Senogles SE, 2004, J BIOL CHEM, V279, P1601, DOI 10.1074/jbc.M309792200; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; WONG YH, 1994, METHOD ENZYMOL, V238, P81; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 2001, J BIOL CHEM, V276, P8500, DOI 10.1074/jbc.M010361200	42	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34440	34448		10.1074/jbc.M401952200	http://dx.doi.org/10.1074/jbc.M401952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192109	hybrid			2022-12-27	WOS:000223134800045
J	Miyake, T; Reese, J; Loch, CM; Auble, DT; Li, R				Miyake, T; Reese, J; Loch, CM; Auble, DT; Li, R			Genome-wide analysis of ARS (autonomously replicating sequence) binding factor 1 (Abf1p)-mediated transcriptional regulation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN GENES; DNA-REPLICATION; YEAST; ACTIVATION; ABF1P; PURIFICATION; EXPRESSION; IDENTIFICATION; PROMOTER; ELEMENTS	Autonomously replicating sequence-binding factor-1 (Abf1p) is an essential sequence-specific transcription factor in Saccharomyces cerevisiae that participates in multiple nuclear events including DNA replication, transcription activation, and gene silencing. Numerous gene-specific analyses have implicated Abf1p in the transcriptional control of genes involved in a diverse range of cellular functions, leading to the notion that Abf1p acts as a global transcriptional regulator. Here we report findings from a genome-wide comparison of the gene expression profiles in the wild-type and abf1-1 temperature-sensitive mutant. The study identifies a total of 86 Abf1p-regulated genes (1.4% of the genome) of which 50 are activated and 36 are repressed by Abf1p. Interestingly, Abf1p binds to its own promoter in vivo and strongly represses its own transcription, suggesting a potential negative regulatory loop in Abf1p-mediated gene regulation. A comparison of our microarray data with the available databases reveals a significant overlap of genes regulated by Abf1p and those by several general transcription factors such as Mot1p and TAFs (TATA-binding protein-associated factors). Different mutant alleles of abf1 affect Abf1p-mediated transcription in a gene-dependent manner. Furthermore, Abf1p in vivo is associated with the promoter region of most Abf1p-activated but not with that of most Abf1p-repressed genes. Taken together, these results strongly suggest distinct underlying mechanisms by which Abf1p regulates gene expression.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, POB 800733, Charlottesville, VA 22908 USA.	rl2t@virginia.edu			NIGMS NIH HHS [GM 55763, R01 GM055763, GM 57893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055763, R01GM057893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHO GN, 1995, NUCLEIC ACIDS RES, V23, P2980, DOI 10.1093/nar/23.15.2980; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; FRANCESCONI SC, 1989, MOL CELL BIOL, V9, P2906, DOI 10.1128/MCB.9.7.2906; GALIUSDURNER V, 1996, MOL CELL BIOL, V16, P2777; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GONCALVES PM, 1995, NUCLEIC ACIDS RES, V23, P1475, DOI 10.1093/nar/23.9.1475; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNZLER M, 1995, MOL MICROBIOL, V15, P167, DOI 10.1111/j.1365-2958.1995.tb02231.x; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LOO S, 1995, GENETICS, V141, P889; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARTENS JA, 1994, J BIOL CHEM, V269, P15661; Miyake T, 2002, MOL CELL BIOL, V22, P505, DOI 10.1128/MCB.22.2.505-516.2002; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; OZSARAC N, 1995, GENE, V164, P157, DOI 10.1016/0378-1119(95)00438-C; Planta RJ, 1995, BIOCHEM CELL BIOL, V73, P825, DOI 10.1139/o95-090; RAMER SW, 1992, P NATL ACAD SCI USA, V89, P11589, DOI 10.1073/pnas.89.23.11589; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; Schroeder SC, 1998, J BIOL CHEM, V273, P19884, DOI 10.1074/jbc.273.31.19884; SILVE S, 1992, MOL CELL BIOL, V12, P4197, DOI 10.1128/MCB.12.9.4197; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wiltshire S, 1997, NUCLEIC ACIDS RES, V25, P4250, DOI 10.1093/nar/25.21.4250; YOO HY, 1995, CURR MICROBIOL, V31, P163, DOI 10.1007/BF00293548	39	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34865	34872		10.1074/jbc.M405156200	http://dx.doi.org/10.1074/jbc.M405156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192094	hybrid			2022-12-27	WOS:000223134800096
J	van den Heuvel, RHH; van den Berg, WAM; Rovida, S; van Berkel, WJH				van den Heuvel, RHH; van den Berg, WAM; Rovida, S; van Berkel, WJH			Laboratory-evolved vanillyl-alcohol oxidase produces natural vanillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED EVOLUTION; PENICILLIUM-SIMPLICISSIMUM; SUBSTRATE-SPECIFICITY; ENZYME-SUBSTRATE; PARA-CRESOL; HYDROXYLATION; ANTIOXIDANT; INHIBITION; CONVERSION; MUTATIONS	The flavoenzyme vanillyl-alcohol oxidase was subjected to random mutagenesis to generate mutants with enhanced reactivity to creosol (2-methoxy-4-methylphenol). The vanillyl-alcohol oxidase-mediated conversion of creosol proceeds via a two-step process in which the initially formed vanillyl alcohol (4-hydroxy-3-methoxybenzyl alcohol) is oxidized to the widely used flavor compound vanillin (4-hydroxy-3-methoxybenzaldehyde). The first step of this reaction is extremely slow due to the formation of a covalent FAD N-5-creosol adduct. After a single round of error-prone PCR, seven mutants were generated with increased reactivity to creosol. The single-point mutants I238T, F454Y, E502G, and T505S showed an up to 40-fold increase in catalytic efficiency (k(cat)/K-m) with creosol compared with the wild-type enzyme. This enhanced reactivity was due to a lower stability of the covalent flavin-substrate adduct, thereby promoting vanillin formation. The catalytic efficiencies of the mutants were also enhanced for other ortho-substituted 4-methylphenols, but not for p-cresol (4-methylphenol). The replaced amino acid residues are not located within a distance of direct interaction with the substrate, and the determined three-dimensional structures of the mutant enzymes are highly similar to that of the wild-type enzyme. These results clearly show the importance of remote residues, not readily predicted by rational design, for the substrate specificity of enzymes.	Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 BC Wageningen, Netherlands; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands	Wageningen University & Research; University of Pavia; Utrecht University; Utrecht University	van Berkel, WJH (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Dreijenlaan 3, NL-6703 BC Wageningen, Netherlands.	willem.vanberkel@wur.nl	van Berkel, Willem J.H./O-2431-2014	van Berkel, Willem J.H./0000-0002-6551-2782				Aruoma OI, 1999, FREE RADICAL RES, V30, P419, DOI 10.1080/10715769900300461; Benen JAE, 1998, J BIOL CHEM, V273, P7865, DOI 10.1074/jbc.273.14.7865; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Bensaid FF, 2002, J AGR FOOD CHEM, V50, P6271, DOI 10.1021/jf020316l; Bornscheuer UT, 2001, CURR OPIN CHEM BIOL, V5, P137, DOI 10.1016/S1367-5931(00)00182-4; BROWN KA, 1993, P NATL ACAD SCI USA, V90, P11753, DOI 10.1073/pnas.90.24.11753; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURRI J, 1989, J SCI FOOD AGR, V48, P49, DOI 10.1002/jsfa.2740480107; Cedrone F, 2000, CURR OPIN STRUC BIOL, V10, P405, DOI 10.1016/S0959-440X(00)00106-8; Cerrutti P, 1997, J FOOD SCI, V62, P608, DOI 10.1111/j.1365-2621.1997.tb04442.x; *COMP COLL PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760; Cunane LM, 2000, J MOL BIOL, V295, P357, DOI 10.1006/jmbi.1999.3290; Dignum MJW, 2001, FOOD REV INT, V17, P199; Fitzgerald DJ, 2003, INT J FOOD MICROBIOL, V86, P113, DOI 10.1016/S0168-1605(03)00059-X; Fraaije MW, 1998, EUR J BIOCHEM, V253, P712, DOI 10.1046/j.1432-1327.1998.2530712.x; FRAAIJE MW, 1995, EUR J BIOCHEM, V234, P271, DOI 10.1111/j.1432-1033.1995.271_c.x; Fraaije MW, 1997, J BIOL CHEM, V272, P18111, DOI 10.1074/jbc.272.29.18111; Fraaije MW, 1997, FEBS LETT, V402, P33, DOI 10.1016/S0014-5793(96)01494-9; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; HAGEDORN S, 1994, ANNU REV MICROBIOL, V48, P773, DOI 10.1146/annurev.micro.48.1.773; HOPPER DJ, 1976, BIOCHEM BIOPH RES CO, V69, P462, DOI 10.1016/0006-291X(76)90544-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Kamat JP, 2000, MOL CELL BIOCHEM, V209, P47, DOI 10.1023/A:1007048313556; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Liebeton K, 2000, CHEM BIOL, V7, P709, DOI 10.1016/S1074-5521(00)00015-6; LinGoerke JL, 1997, BIOTECHNIQUES, V23, P409, DOI 10.2144/97233bm12; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; MCINTIRE W, 1984, BIOCHEM J, V224, P617, DOI 10.1042/bj2240617; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; Podstolski A, 2002, PHYTOCHEMISTRY, V61, P611, DOI 10.1016/S0031-9422(02)00285-6; Priefert H, 2001, APPL MICROBIOL BIOT, V56, P296, DOI 10.1007/s002530100687; Rajagopalan PTR, 2002, BIOCHEMISTRY-US, V41, P12618, DOI 10.1021/bi026369d; Rao SR, 2000, J SCI FOOD AGR, V80, P289, DOI 10.1002/1097-0010(200002)80:3&lt;289::AID-JSFA543&gt;3.0.CO;2-2; Regan L, 1999, CURR OPIN STRUC BIOL, V9, P494, DOI 10.1016/S0959-440X(99)80070-0; Rod TH, 2003, P NATL ACAD SCI USA, V100, P6980, DOI 10.1073/pnas.1230801100; Schmidt-Dannert C, 2001, BIOCHEMISTRY-US, V40, P13125, DOI 10.1021/bi011310c; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Tahallah N, 2002, J BIOL CHEM, V277, P36425, DOI 10.1074/jbc.M205841200; Tao HY, 2002, CURR OPIN CHEM BIOL, V6, P858, DOI 10.1016/S1367-5931(02)00396-4; van den Heuvel RHH, 2000, P NATL ACAD SCI USA, V97, P9455, DOI 10.1073/pnas.160175897; van den Heuvel RHH, 2000, FEBS LETT, V481, P109, DOI 10.1016/S0014-5793(00)01992-X; van den Heuvel RHH, 2000, J BIOL CHEM, V275, P14799, DOI 10.1074/jbc.275.20.14799; van den Heuvel RHH, 1998, J BACTERIOL, V180, P5646, DOI 10.1128/JB.180.21.5646-5651.1998; van den Heuvel RHH, 2001, J AGR FOOD CHEM, V49, P2954, DOI 10.1021/jf010093j; Walton NJ, 2003, PHYTOCHEMISTRY, V63, P505, DOI 10.1016/S0031-9422(03)00149-3; Walton NJ, 2000, CURR OPIN BIOTECH, V11, P490, DOI 10.1016/S0958-1669(00)00125-7; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zhao HM, 1997, CURR OPIN STRUC BIOL, V7, P480, DOI 10.1016/S0959-440X(97)80110-8	57	34	36	3	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33492	33500		10.1074/jbc.M312968200	http://dx.doi.org/10.1074/jbc.M312968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169773	hybrid			2022-12-27	WOS:000223039700058
J	Moore, VD; Payne, RM				Moore, VD; Payne, RM			Transactivator of transcription fusion protein transduction causes membrane inversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; CELL-PENETRATING PEPTIDES; INTRACELLULAR DELIVERY; IN-VIVO; ANTENNAPEDIA HOMEODOMAIN; PLASMA-MEMBRANE; MAMMALIAN-CELLS; ANNEXIN-V; 3RD HELIX; INTERNALIZATION	The transactivator of transcription ( TAT) protein transduction domain is an 11-amino acid positively charged peptide that has been shown to pull diverse molecules across cell membranes in vitro and in vivo. Fusion proteins constructed with TAT rapidly enter and exit cells and have been shown to cross intracellular membranes as well. Electrostatic interactions between TAT and the cell membrane have been implicated as a part of the mechanism of transduction. Here, we report that TAT transduction causes membrane phospholipid rearrangement as evidenced by detection of phosphatidylserine on the outer surface of the cell membrane. Furthermore, these rearrangements can be blocked by positively charged polylysine, further implicating electrostatic interactions as a part of the mechanism. Neither apoptosis nor necrosis is induced in these cells after exposure to TAT. We conclude that the process of TAT.GFP transduction causes phosphatidylserine to translocate from the inner to the outer leaflet of the plasma membrane. These results provide insight into the mechanism of TAT protein transduction domain transduction.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Div Mol Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Div Cardiol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Payne, RM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Div Mol Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mpayne@wfubmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055765, R01DK067763] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK67763, DK55765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2; Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Del Gaizo V, 2003, MOL GENET METAB, V80, P170, DOI 10.1016/j.ymgme.2003.08.017; Del Gaizo V, 2003, MOL THER, V7, P720, DOI 10.1016/S1525-0016(03)00130-8; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAUTZ R, 1991, MUTAT RES, V253, P173, DOI 10.1016/0165-1161(91)90130-Z; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Levchenko TS, 2003, METHOD ENZYMOL, V372, P339; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Magzoub M, 2001, BBA-BIOMEMBRANES, V1512, P77, DOI 10.1016/S0005-2736(01)00304-2; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; van Heerde WL, 2000, CARDIOVASC RES, V45, P549, DOI 10.1016/S0008-6363(99)00396-X; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242; Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805	32	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32541	32544		10.1074/jbc.M405930200	http://dx.doi.org/10.1074/jbc.M405930200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169776	hybrid			2022-12-27	WOS:000222849700069
J	Sato, K; Hayami, R; Wu, WW; Nishikawa, T; Nishikawa, H; Okuda, Y; Ogata, H; Fukuda, M; Ohta, T				Sato, K; Hayami, R; Wu, WW; Nishikawa, T; Nishikawa, H; Okuda, Y; Ogata, H; Fukuda, M; Ohta, T			Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRCA1/BARD1 HETERODIMER; POLYUBIQUITIN CHAINS; PROTEIN B23; BRCA1; CENTROSOME; MITOSIS; COMPLEX; BINDING; CELLS; RNA	The breast and ovarian tumor suppressor BRCA1 forms a heterodimeric RING-type ubiquitin ligase with BARD1 to catalyze untraditional Lys-6-linked polyubiquitin chains. It is not clear how the BRCA1-BARD1 ligase regulates various cellular processes such as DNA repair, cell-cycle progression, transcriptional regulation, and centrosome duplication. Here we report that BRCA1-BARD1 catalyzes the polyubiquitination of nucleolar phosphoprotein nucleophosmin/B23 (NPM). Two different mass spectrometry screens for protein ubiquitinated by BRCA1-BARD1 both identified NPM. NPM interacts with N-terminal fragments of BRCA1 and BARD1 in a manner dependent upon BRCA1-BARD1 heterodimer formation. NPM colocalizes with BRCA1 and BARD1 in mitotic cells suggesting the possibility of NPM regulation by BRCA1-BARD1 during mitosis. BRCA1-BARD1 catalyzes the ubiquitination of NPM in vitro and in vivo, and BRCA1-BARD1 co-expression in cells causes NPM stabilization rather than degradation. This is consistent with the notion that this ligase catalyzes untraditional polyubiquitin chains. Given the many overlapped functions between NPM and BRCA1, we propose that NPM is a strong candidate as a substrate of the BRCA1-BARD1 ubiquitin ligase.	St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan	Saint Marianna University	Ohta, T (corresponding author), St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan.	to@marianna-u.ac.jp		Ohta, Tomohiko/0000-0002-9700-7342; WU, WENWEN/0000-0002-3654-585X				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Liu WH, 1998, ONCOGENE, V17, P3055, DOI 10.1038/sj.onc.1202234; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Szebeni A, 2003, J BIOL CHEM, V278, P9107, DOI 10.1074/jbc.M204411200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Zatsepina OV, 1999, J CELL SCI, V112, P455	22	117	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30919	30922		10.1074/jbc.C400169200	http://dx.doi.org/10.1074/jbc.C400169200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15184379	hybrid			2022-12-27	WOS:000222726800002
J	Reid, J; Svejstrup, JQ				Reid, J; Svejstrup, JQ			DNA damage-induced Def1-RNA polymerase II interaction and Def1 requirement for polymerase ubiquitylation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; NUCLEOTIDE EXCISION-REPAIR; LARGE SUBUNIT; SACCHAROMYCES-CEREVISIAE; DHFR GENE; DEGRADATION; COMPLEXES; REMOVAL; YEAST; CELLS	UV-induced DNA damage results in ubiquitylation and degradation of RNA polymerase II (RNAPII). In yeast, this requires the DEF1 gene, the product of which forms a complex with the transcription-coupling repair factor, Rad26. However, whether Def1 is directly involved in RNAPII ubiquitylation has remained unclear. Here we report the establishment of a reconstituted system for studying UV-induced RNAPII ubiquitylation, which mimics the known requirements for this process in vitro. Using this system, we show that Def1 is indeed directly required for RNAPII ubiquitylation. Moreover, Def1 interacts with RNAPII in a damage-dependent manner. These results support a model in which Def1 interacts with RNAPII in response to DNA damage, recruiting the ubiquitylation machinery to enable its modification and subsequent degradation.	Clare Hall Labs, Canc Res UK, London Res Inst, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Svejstrup, JQ (corresponding author), Clare Hall Labs, Canc Res UK, London Res Inst, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk		Svejstrup, Jesper/0000-0003-4964-6147				Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kong SE, 2002, DNA REPAIR, V1, P731, DOI 10.1016/S1568-7864(02)00080-0; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Wang GL, 1999, MOL CELL BIOL, V19, P342; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a	21	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29875	29878		10.1074/jbc.C400185200	http://dx.doi.org/10.1074/jbc.C400185200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15166235	hybrid			2022-12-27	WOS:000222531900002
J	Jensen, PE; Haldrup, A; Zhang, SP; Scheller, HV				Jensen, PE; Haldrup, A; Zhang, SP; Scheller, HV			The PSI-O subunit of plant photosystem I is involved in balancing the excitation pressure between the two photosystems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; STATE TRANSITIONS; H SUBUNIT; PROMOTER; TRANSFORMATION; IDENTIFICATION; PROTEINS; BINDING; GENES; DNA	PSI-O is a subunit of photosystem I in eukaryotes. The function of PSI-O was characterized in Arabidopsis plants using RNA interference. Several transformants with the psaO-RNAi construct were generated, and a high proportion of the plants contained only very little or virtually no residual PSI-O. Plants lacking PSI-O have a 50% reduction in state transitions indicating a role for PSI-O in the balancing of excitation energy between the two photosystems. PSI-H and -L have been shown previously to be involved in state transitions, and immunoblot analysis revealed that plants devoid of PSI-L or -H also have 80-90% reduction in the abundance of PSI-O. In contrast, down-regulation of PSI-O has no negative effect on the content of PSI-H and -L. The interaction between PSI-O and the PSI-L was confirmed by chemical cross-linking. A model of PSI is proposed in which PSI-L as the most ancient subunit is closest to the reaction center, and PSI-O is positioned close to PSI-L on the PSI-H/-L/-I side of the PSI complex. PSI-H, -L, -O, and possibly -I are all involved in forming a domain in PSI that is involved in the interaction with light-harvesting complex II.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark	University of Copenhagen	Jensen, PE (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	peje@kvl.dk	Scheller, Henrik/AAH-4770-2020; Scheller, Henrik V/A-8106-2008; Jensen, Poul Erik/A-4862-2014	Scheller, Henrik/0000-0002-6702-3560; Scheller, Henrik V/0000-0002-6702-3560; Jensen, Poul Erik/0000-0001-6524-7723; Haldrup, Anna/0000-0002-2348-7072				Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; Asamizu E, 2000, DNA RES, V7, P175, DOI 10.1093/dnares/7.3.175; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jensen PE, 2002, J BIOL CHEM, V277, P2798, DOI 10.1074/jbc.M110448200; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Lunde C, 2003, PLANT CELL PHYSIOL, V44, P44, DOI 10.1093/pcp/pcg012; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; SANDER L, 1995, PLANT MOL BIOL, V27, P165, DOI 10.1007/BF00019188; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; Varotto C, 2002, PLANT PHYSIOL, V129, P616, DOI 10.1104/pp.002089; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525; Zhang SP, 2004, J BIOL CHEM, V279, P3180, DOI 10.1074/jbc.M311640200	32	66	78	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24212	24217		10.1074/jbc.M403147200	http://dx.doi.org/10.1074/jbc.M403147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15169790	hybrid			2022-12-27	WOS:000221702500045
J	Nemoto, T; Kojima, T; Oshima, A; Bito, H; Kasai, H				Nemoto, T; Kojima, T; Oshima, A; Bito, H; Kasai, H			Stabilization of exocytosis by dynamic F-actin coating of zymogen granules in pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EXOCYTOSIS; RHO-GTPASES; RAT; CELL; CYTOSKELETON; PROTEIN; SECRETION; MEMBRANE; CALCIUM; VILLIN	Reorganization of F-actin in the apical region of mouse pancreatic acinar cells during Ca2+-dependent exocytosis of zymogen granules was investigated by two-photon excitation microscopy with intact acini. Granules were rapidly coated with F-actin in response to either agonist stimulation or photolysis of a caged-Ca2+ compound. Such F-actin coating occurred exclusively at the surface of granules undergoing exocytosis and was prevented either by latrunculin-A, which inhibits actin polymerization, or by Clostridium botulinum exoenzyme C3, which inhibits the small GTPase Rho. Latrunculin-A or exoenzyme C3 also triggered the formation of vacuoles in acinar cells, a characteristic of acute pancreatitis. Stimulation of acini with high concentrations of cholecystokinin, which cause acute pancreatitis in mice, also impaired the F-actin coating of granules and induced vacuole formation. Latrunculin-A reduced the latency to exocytosis but did not affect the total number of exocytic events, suggesting that F-actin slows and further stabilizes exocytosis by facilitating F-actin coating. Rho-dependent F-actin coating of granule membranes thus stabilizes exocytic structures and is necessary for physiological progression of sequetial compound exocytosis in the exocrine pancreas and for prevention of acute pancreatitis.	Natl Inst Physiol Sci, Dept Cell Physiol, Aichi 4448787, Japan; Grad Univ Adv Studies SOKENDAI, Aichi 4448787, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Kyoto Prefectural Univ Med, Dept Otolaryngol, Kamigyo Ku, Kyoto 6020841, Japan; Univ Tokyo, Fac Med, Dept Neurochem, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Tokyo 1130033, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST); Kyoto Prefectural University of Medicine; University of Tokyo; University of Tokyo	Nemoto, T (corresponding author), Natl Inst Physiol Sci, Dept Cell Physiol, 5-1 Higashiyama, Aichi 4448787, Japan.	tn@nips.ac.jp	Nemoto, Tomomi/B-4412-2012; Bito, Haruhiko/A-8635-2008	Nemoto, Tomomi/0000-0001-6102-1495; Bito, Haruhiko/0000-0001-6315-9594; Kasai, Haruo/0000-0003-2327-9027				Beil M, 2002, AM J PHYSIOL-GASTR L, V282, pG450, DOI 10.1152/ajpgi.00042.2001; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BURNHAM DB, 1982, CELL TISSUE RES, V222, P201; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; DECAMILLI P, 1976, J CELL BIOL, V70, P59, DOI 10.1083/jcb.70.1.59; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fuchs E, 1999, CELL, V98, P547, DOI 10.1016/S0092-8674(00)80041-0; Gaisano HY, 2001, J CLIN INVEST, V108, P1597; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halpain S, 2000, TRENDS NEUROSCI, V23, P141, DOI 10.1016/S0166-2236(00)01576-9; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; ICHIKAWA A, 1965, J CELL BIOL, V24, P369, DOI 10.1083/jcb.24.3.369; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JUNGERMANN J, 1995, AM J PHYSIOL-GASTR L, V268, pG328, DOI 10.1152/ajpgi.1995.268.2.G328; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KLOPPEL G, 1994, ACUTE PANCREATITIS D, P35; Kukor Z, 2002, J BIOL CHEM, V277, P21389, DOI 10.1074/jbc.M200878200; LAMPEL M, 1977, VIRCHOWS ARCH A, V373, P97, DOI 10.1007/BF00432156; Leser J, 2000, AM J PHYSIOL-GASTR L, V278, pG486, DOI 10.1152/ajpgi.2000.278.3.G486; Miyake K, 2001, J CELL SCI, V114, P3487; MORII N, 1995, METHOD ENZYMOL, V256, P196; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; OKONSKI MS, 1990, J CLIN INVEST, V86, P1649, DOI 10.1172/JCI114887; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Raraty M, 2000, P NATL ACAD SCI USA, V97, P13126, DOI 10.1073/pnas.97.24.13126; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; SAHARA N, 1990, CELL TISSUE RES, V261, P461, DOI 10.1007/BF00313524; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; SCHEELE G, 1987, GASTROENTEROLOGY, V92, P345, DOI 10.1016/0016-5085(87)90127-2; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Sokac AM, 2003, NAT CELL BIOL, V5, P727, DOI 10.1038/ncb1025; Steer ML, 1999, BEST PRACT RES CL GA, V13, P213, DOI 10.1053/bega.1999.0020; Takahashi N, 2004, J CELL BIOL, V165, P255, DOI 10.1083/jcb.200312033; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Torgerson RR, 2000, J CELL PHYSIOL, V182, P438, DOI 10.1002/(SICI)1097-4652(200003)182:3<438::AID-JCP15>3.0.CO;2-N; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; Valentijn JA, 2000, P NATL ACAD SCI USA, V97, P1091, DOI 10.1073/pnas.97.3.1091; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; WARD JB, 1995, LANCET, V346, P1016, DOI 10.1016/S0140-6736(95)91695-4; WATANABE O, 1984, AM J PHYSIOL, V246, pG457, DOI 10.1152/ajpgi.1984.246.4.G457; Williams JA, 2002, PHARMACOL TOXICOL, V91, P297, DOI 10.1034/j.1600-0773.2002.910606.x; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	49	105	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37544	37550		10.1074/jbc.M403976200	http://dx.doi.org/10.1074/jbc.M403976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15184362	hybrid			2022-12-27	WOS:000223554600045
J	Scaffidi, AK; Petrovic, N; Moodley, YP; Fogel-Petrovic, M; Kroeger, KM; Seeber, RM; Eidne, KA; Thompson, PJ; Knight, DA				Scaffidi, AK; Petrovic, N; Moodley, YP; Fogel-Petrovic, M; Kroeger, KM; Seeber, RM; Eidne, KA; Thompson, PJ; Knight, DA			alpha(v)beta(3) Integrin interacts with the transforming growth factor beta (TGF beta) type II receptor to potentiate the proliferative effects of TGF beta 1 in living human lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; EPITHELIAL-CELLS; INSULIN-RECEPTOR; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; INTEGRIN EXPRESSION; CYTOPLASMIC DOMAIN; HORMONE-RECEPTOR; KINASE; ACTIVATION	The alpha(v)beta(3) integrin is known to cooperate with receptor tyrosine kinases to enhance cellular responses. To determine whether alpha(v)beta(3) regulates transforming growth factor beta (TGFbeta) 1-induced responses, we investigated the interaction between alpha(v)beta(3) and TGFbeta type II receptor (TGFbetaIIR) in primary human lung fibroblasts. We report that TGFbeta1 up-regulates cell surface and mRNA expression of alpha(v)beta(3) in a time- and dose-dependent manner. Co-immunoprecipitation and confocal microscopy showed that TGFbetaRII associates and clusters with alpha(v)beta(3), following TGFbeta1 exposure. This association was not observed with alpha(v)beta(5) or alpha(5)beta(1). We also used a novel molecular proximity assay, bioluminescence resonance energy transfer (BRET), to quantify this dynamic interaction in living cells. TGFbeta1 stimulation resulted in a BRET signal within 5 min, whereas tenascin, which binds alpha(v)beta(3), did not induce a substantial BRET signal. Co-exposure to tenascin and TGFbeta1 produced no further increases in BRET than TGFbeta1 alone. Cyclin D1 was rapidly induced in cells co-exposed to TGFbeta1 and tenascin, and as a consequence proliferation induced by TGFbeta1 was dramatically enhanced in cells co-exposed to tenascin or vitronectin. Cholesterol depletion inhibited the interaction between TGFbetaRII and alpha(v)beta(3) and abrogated the proliferative effect. The cyclic RGD peptide, GpenGRGDSPCA, which blocks alpha(v)beta(3), also abolished the synergistic proliferative effect seen. These results indicate a new interaction partner for the alpha(v)beta(3) integrin, the TGFbetaIIR, in which TGFbeta1-induced responses are potentiated in the presence alpha(v)beta(3) ligands. Our data provide a novel mechanism by which TGFbeta1 may contribute to abnormal wound healing and tissue fibrosis.	Univ Western Australia, Asthma & Allergy Res Inst, Nedlands, WA 6009, Australia; Univ Western Australia, Ctr Asthma Allergy & Resp Res, Nedlands, WA 6009, Australia; Western Australian Inst Med Res, Nedlands, WA 6009, Australia; Univ Western Australia, Med Res Ctr, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Knight, DA (corresponding author), Univ British Columbia, St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V6Z 1Y6, Canada.	dknight@mrl.ubc.ca	Seeber, Ruth/AAS-9411-2021	Seeber, Ruth/0000-0003-3265-7931				Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Boute N, 2003, EMBO REP, V4, P313, DOI 10.1038/sj.embor.embor767; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Clark RAF, 1996, AM J PATHOL, V148, P1407; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Eidne KA, 2002, TRENDS ENDOCRIN MET, V13, P415, DOI 10.1016/S1043-2760(02)00669-0; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Graf K, 2000, HYPERTENSION, V35, P978, DOI 10.1161/01.HYP.35.4.978; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; Issad T, 2002, ANN NY ACAD SCI, V973, P120, DOI 10.1111/j.1749-6632.2002.tb04619.x; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; JANAT MF, 1992, J CELL PHYSIOL, V151, P588, DOI 10.1002/jcp.1041510319; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; KUMAR NM, 1995, EXP CELL RES, V221, P385, DOI 10.1006/excr.1995.1389; Levinson H, 2002, J CELL PHYSIOL, V193, P219, DOI 10.1002/jcp.10164; LINNALA A, 1995, AM J RESP CELL MOL, V13, P578, DOI 10.1165/ajrcmb.13.5.7576694; McAnulty RJ, 1997, BIOCHEM J, V321, P639, DOI 10.1042/bj3210639; Meerovitch K, 2003, VASC PHARMACOL, V40, P77, DOI 10.1016/S1537-1891(02)00339-7; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moustakas A, 1999, J CELL SCI, V112, P1169; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; POHL WR, 1991, AM REV RESPIR DIS, V143, P1369, DOI 10.1164/ajrccm/143.6.1369; Riedy MC, 1999, EXP CELL RES, V251, P194, DOI 10.1006/excr.1999.4573; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Scaffidi AK, 2002, BRIT J PHARMACOL, V136, P793, DOI 10.1038/sj.bjp.0704769; Scaffidi AK, 2001, J CELL SCI, V114, P3507; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; TESCHLER H, 1993, AM REV RESPIR DIS, V147, P332, DOI 10.1164/ajrccm/147.2.332; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	47	83	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37726	37733		10.1074/jbc.M403010200	http://dx.doi.org/10.1074/jbc.M403010200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15187087	hybrid			2022-12-27	WOS:000223554600064
J	Fischer, M; Romisch, W; Saller, S; Illarionov, B; Richter, G; Rohdich, F; Eisenreich, W; Bacher, A				Fischer, M; Romisch, W; Saller, S; Illarionov, B; Richter, G; Rohdich, F; Eisenreich, W; Bacher, A			Evolution of vitamin B-2 biosynthesis - Structural and functional similarity between pyrimidine deaminases of eubacterial and plant origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3,4-DIHYDROXY-2-BUTANONE 4-PHOSPHATE SYNTHASE; SITE-DIRECTED MUTAGENESIS; GTP CYCLOHYDROLASE-II; LUMAZINE SYNTHASE; RIBOFLAVIN SYNTHASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; KINETIC-ANALYSIS	The Arabidopsis thaliana open reading frame At4g20960 predicts a protein whose N-terminal part is similar to the eubacterial 2,5-diamino-6-ribosylamino-4-(3H)-pyrimidinone 5'-phosphate deaminase domain. A synthetic open reading frame specifying a pseudomature form of the plant enzyme directed the synthesis of a recombinant protein which was purified to apparent homogeneity and was shown by NMR spectroscopy to convert 2,5-diamino-6-ribosylamino-4(3H)-pyrimidinone 5'-phosphate into 5-amino-6-ribosylamino-2,4(1H,3H)-pyrimidinedione 5'-phosphate at a rate of 0.9 mumol mg(-1) min(-1). The substrate and product of the enzyme are both subject to spontaneous anomerization of the ribosyl side chain as shown by C-13 NMR spectroscopy. The protein contains 1 eq of Zn2+/subunit. The deaminase activity could be assigned to the N-terminal section of the plant protein. The deaminase domains of plants and eubacteria share a high degree of similarity, in contrast to deaminases from fungi. These data show that the riboflavin biosynthesis in plants proceeds by the same reaction steps as in eubacteria, whereas fungi use a different pathway.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Fischer, M (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	markus.fischer@ch.tum.de	Eisenreich, Wolfgang/A-1258-2013; Fischer, Markus J./G-9477-2012; Fischer, Markus/AFT-1856-2022; Fischer, Markus/H-2870-2012; Richter, Gerald/F-3642-2011	Eisenreich, Wolfgang/0000-0002-9832-8279; Fischer, Markus/0000-0001-7243-4199; 				Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Bacher A, 1997, METHOD ENZYMOL, V280, P382; Bacher A, 1997, METHOD ENZYMOL, V280, P389; BACHER A, 1970, J BIOL CHEM, V245, P4647; BACHER A, 1971, J BIOL CHEM, V246, P7018; BACHER A, 2001, Patent No. 11145; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Eberhardt S, 1996, EUR J BIOCHEM, V242, P712, DOI 10.1111/j.1432-1033.1996.0712r.x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Fischer M, 2003, J MOL BIOL, V326, P783, DOI 10.1016/S0022-2836(02)01473-0; Fischer M, 2002, EUR J BIOCHEM, V269, P519, DOI 10.1046/j.0014-2956.2001.02674.x; Fischer M, 2002, J BIOL CHEM, V277, P41410, DOI 10.1074/jbc.M206863200; Fischer M, 2001, P NATL ACAD SCI USA, V98, P3567, DOI 10.1073/pnas.041594798; Gerhardt S, 2002, STRUCTURE, V10, P1371, DOI 10.1016/S0969-2126(02)00864-X; Graupner M, 2002, J BACTERIOL, V184, P1952, DOI 10.1128/JB.184.7.1952-1957.2002; Haase I, 2003, J BIOL CHEM, V278, P37909, DOI 10.1074/jbc.M303090200; Haase I, 2003, EUR J BIOCHEM, V270, P1025, DOI 10.1046/j.1432-1033.2003.03478.x; Herz S, 2002, PHYTOCHEMISTRY, V60, P3, DOI 10.1016/S0031-9422(02)00056-0; Herz S, 2000, PHYTOCHEMISTRY, V53, P723, DOI 10.1016/S0031-9422(00)00013-3; HOLLANDER I, 1979, BIOCHEM BIOPH RES CO, V89, P759, DOI 10.1016/0006-291X(79)90694-6; Illarionov B, 2003, J BIOL CHEM, V278, P47700, DOI 10.1074/jbc.M305050200; Illarionov B, 2001, P NATL ACAD SCI USA, V98, P7224, DOI 10.1073/pnas.131610698; Illarionov B, 2001, J BIOL CHEM, V276, P11524, DOI 10.1074/jbc.M008931200; Ireton GC, 2003, STRUCTURE, V11, P961, DOI 10.1016/S0969-2126(03)00153-9; Jordan DB, 1999, J BIOL CHEM, V274, P22114, DOI 10.1074/jbc.274.31.22114; Kaiser J, 2002, EUR J BIOCHEM, V269, P5264, DOI 10.1046/j.1432-1033.2002.03239.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1992, EUR J BIOCHEM, V210, P711, DOI 10.1111/j.1432-1033.1992.tb17472.x; Lee J., 1985, CHEM BIOLUMINESCENCE, P401; LINGENS F, 1967, Z NATURFORSCH PT B, VB 22, P755; LOGVINENKO EM, 1993, GENETIKA+, V29, P922; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; MEIGHEN EA, 1993, FASEB J, V7, P1016, DOI 10.1096/fasebj.7.11.8370470; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; MITSUDA H, 1970, J VITAMINOL, V16, P285, DOI 10.5925/jnsv1954.16.285; Mortl S, 1996, J BIOL CHEM, V271, P33201, DOI 10.1074/jbc.271.52.33201; OLTMANNS O, 1972, J BACTERIOL, V110, P818, DOI 10.1128/JB.110.3.818-822.1972; Persson K, 1999, PROTEIN SCI, V8, P2355; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REVUELTA DJL, 1995, Patent No. 944420785; REVUELTA DJL, 1994, Patent No. 924238904; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; RICHTER G, 1992, J BACTERIOL, V174, P4050, DOI 10.1128/jb.174.12.4050-4056.1992; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; Richter G, 1997, METHOD ENZYMOL, V280, P374; Ritz H, 2001, J BIOL CHEM, V276, P22273, DOI 10.1074/jbc.M100752200; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scheuring J, 2001, J ORG CHEM, V66, P3811, DOI 10.1021/jo001739u; Schramek N, 2003, J AM CHEM SOC, V125, P4460, DOI 10.1021/ja028226k; SHAVLOVSKII G M, 1981, Mikrobiologiya, V50, P1008; Steinbacher S, 2003, J BIOL CHEM, V278, P42256, DOI 10.1074/jbc.M307301200; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972; Zhang XF, 2003, J MOL BIOL, V328, P167, DOI 10.1016/S0022-2836(03)00186-4; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435	61	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36299	36308		10.1074/jbc.M404406200	http://dx.doi.org/10.1074/jbc.M404406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208317	hybrid			2022-12-27	WOS:000223453600019
J	Uchida, T; Yamasaki, T; Eto, S; Sugawara, H; Kurisu, G; Nakagawa, A; Kusunoki, M; Hatakeyama, T				Uchida, T; Yamasaki, T; Eto, S; Sugawara, H; Kurisu, G; Nakagawa, A; Kusunoki, M; Hatakeyama, T			Crystal structure of the hemolytic lectin CEL-III isolated from the marine invertebrate Cucumaria echinata - Implications of domain structure for its membrane pore-formation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; RIBOSOME-INACTIVATING PROTEIN; AMINO-ACID-SEQUENCE; BINDING; RECOGNITION; HOLOTHUROIDEA; REFINEMENT; MOLSCRIPT; ALIGNMENT; CALCIUM	CEL-III is a Ca2+-dependent and galactose-specific lectin purified from the sea cucumber, Cucumaria echinata, which exhibits hemolytic and hemagglutinating activities. Six molecules of CEL-III are assumed to oligomerize to form an ion-permeable pore in the cell membrane. We have determined the crystal structure of CEL-III by using single isomorphous replacement aided by anomalous scattering in lead at 1.7 Angstrom resolution. CEL-III consists of three distinct domains as follows: the N-terminal two carbohydrate-binding domains (1 and 2), which adopt beta-trefoil folds such as the B-chain of ricin and are members of the (QXW) 3 motif family; and domain 3, which is a novel fold composed of two alpha-helices and one beta-sandwich. CEL-III is the first Ca2+-dependent lectin structure with two beta-trefoil folds. Despite sharing the structure of the B-chain of ricin, CEL-III binds five Ca2+ ions at five of the six subdomains in both domains 1 and 2. Considering the relatively high similarity among the five subdomains, they are putative binding sites for galactose-related carbohydrates, although it remains to be elucidated whether bound Ca2+ is directly involved in interaction with carbohydrates. The paucity of hydrophobic interactions in the interfaces between the domains and biochemical data suggest that these domains rearrange upon carbohydrate binding in the erythrocyte membrane. This conformational change may be responsible for oligomerization of CEL-III molecules and hemolysis in the erythrocyte membranes.	Osaka Univ, Inst Prot Res, Res Ctr Struct & Funct Prote, Osaka 5650871, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528521, Japan; RIKEN, Plant Sci Ctr, Lab Commun Mech, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Osaka University; Nagasaki University; RIKEN	Kusunoki, M (corresponding author), Osaka Univ, Inst Prot Res, Res Ctr Struct & Funct Prote, 3-2 Yamadaoka, Osaka 5650871, Japan.	kusunoki@protein.osaka-u.ac.jp; thata@net.nagasaki-u.ac.jp	KURISU, GENJI/ABA-5960-2020; Nakagawa, Atsushi/D-4329-2009; KURISU, GENJI/AAD-7109-2022; Nakagawa, Atsushi/M-5731-2019	KURISU, GENJI/0000-0002-5354-0807; Nakagawa, Atsushi/0000-0002-1700-7861; KURISU, GENJI/0000-0002-5354-0807; Nakagawa, Atsushi/0000-0002-1700-7861; Hatakeyama, Tomomitsu/0000-0002-9505-1980				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Cioci G, 2003, FEBS LETT, V555, P297, DOI 10.1016/S0014-5793(03)01249-3; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; HATAKEYAMA T, 1995, BIOSCI BIOTECH BIOCH, V59, P1314, DOI 10.1271/bbb.59.1314; HATAKEYAMA T, 1995, J BIOL CHEM, V270, P3560, DOI 10.1074/jbc.270.8.3560; Hatakeyama T, 1999, J BIOCHEM, V125, P277, DOI 10.1093/oxfordjournals.jbchem.a022284; HATAKEYAMA T, 1994, J BIOCHEM, V116, P209, DOI 10.1093/oxfordjournals.jbchem.a124495; Hatakeyama T, 2002, BIOSCI BIOTECH BIOCH, V66, P157, DOI 10.1271/bbb.66.157; Hatakeyama T, 2004, J BIOCHEM, V135, P65, DOI 10.1093/jb/mvh007; Hatakeyama T, 1996, J BIOL CHEM, V271, P16915, DOI 10.1074/jbc.271.28.16915; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; Kouzuma Y, 2003, J BIOCHEM, V134, P395, DOI 10.1093/jb/mvg157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauspenhaar R, 1999, BIOCHEM BIOPH RES CO, V257, P418, DOI 10.1006/bbrc.1999.0470; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; Mancheno JM, 2004, ACTA CRYSTALLOGR D, V60, P1139, DOI 10.1107/S0907444904007991; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchell E, 2002, NAT STRUCT BIOL, V9, P918, DOI 10.1038/nsb865; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Nakano M, 1999, BBA-PROTEIN STRUCT M, V1435, P167, DOI 10.1016/S0167-4838(99)00212-5; Niwa H, 2003, EUR J BIOCHEM, V270, P2739, DOI 10.1046/j.1432-1033.2003.03646.x; Oda T, 1997, J BIOCHEM, V121, P560; Oda T, 1999, J BIOCHEM, V125, P713, DOI 10.1093/oxfordjournals.jbchem.a022341; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Sallay I, 1998, BIOSCI BIOTECH BIOCH, V62, P1757, DOI 10.1271/bbb.62.1757; Sallay I, 2001, BIOSCI BIOTECH BIOCH, V65, P1347, DOI 10.1271/bbb.65.1347; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; Tateno H, 2003, J BIOL CHEM, V278, P40455, DOI 10.1074/jbc.M306836200; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	53	50	52	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37133	37141		10.1074/jbc.M404065200	http://dx.doi.org/10.1074/jbc.M404065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194688	Green Published, hybrid			2022-12-27	WOS:000223453600117
J	Winkler, DG; Yu, CP; Geoghegan, JC; Ojala, EW; Skonier, JE; Shpektor, D; Sutherland, MK; Latham, JA				Winkler, DG; Yu, CP; Geoghegan, JC; Ojala, EW; Skonier, JE; Shpektor, D; Sutherland, MK; Latham, JA			Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL ECTODERMAL RIDGE; BMP ANTAGONIST; DIFFERENTIATION; OVEREXPRESSION; OSTEOPOROSIS; EXPRESSION; INDUCTION; SKELETON; SOST; LIMB	Noggin and sclerostin are bone morphogenetic protein (BMP) antagonists that modulate mitogenic activity through sequestering BMPs. Little is known of the interactions among this class of proteins. We show that recombinant sclerostin and noggin bound to each other with high affinity (K-D = 2.92 nM). This observation has been extended to naturally expressed noggin and sclerostin from the rat osteosarcoma cell line, ROS 17/2.8, supporting a role for the complex in natural systems. The noggin-sclerostin complex was competitive with BMP binding and mutually attenuated the activity of each BMP antagonist. Collectively, the data demonstrate a novel and exquisite paradigm for the regulation of BMP activity through direct neutralization of the BMP and activation by co-localized BMP antagonist expression. The pleiotrophic nature of noggin and sclerostin represents a novel mechanism for the fine-tuning of BMP activity in bone homeostasis.	Celltech R&D Inc, Dept Gene Funct & Target Validat, Bothell, WA 98021 USA		Latham, JA (corresponding author), 2409 10th Ave W, Seattle, WA 98119 USA.	latham@alderbio.com						Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002-220918; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399-0004.2003.00036.x; Merino R, 1998, DEV BIOL, V200, P35, DOI 10.1006/dbio.1998.8946; Nifuji A, 1999, J BONE MINER RES, V14, P2057, DOI 10.1359/jbmr.1999.14.12.2057; Pizette S, 2001, DEVELOPMENT, V128, P4463; Pizette S, 1999, DEVELOPMENT, V126, P883; Sharov AA, 2003, EMBO J, V22, P2992, DOI 10.1093/emboj/cdg291; SUTHERLAND MK, 2004, IN PRESS BONE; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Wu XB, 2002, J BONE MINER RES, V17, pS143; Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543; Yu MK, 2002, NATURE, V420, P308, DOI 10.1038/nature01196; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	19	71	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36293	36298		10.1074/jbc.M400521200	http://dx.doi.org/10.1074/jbc.M400521200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15199066	hybrid			2022-12-27	WOS:000223453600018
J	Yang, XFF; Ji, YR; Schneider, BL; Reitzer, L				Yang, XFF; Ji, YR; Schneider, BL; Reitzer, L			Phosphorylation-independent dimer-dimer interactions by the enhancer-binding activator NtrC of Escherichia coli - A third function for the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN REGULATOR-I; PROTEIN NTRC; TRANSCRIPTIONAL ACTIVATION; ATPASE ACTIVITY; DNA INVERSION; SIGNAL-TRANSDUCTION; RESPONSE REGULATORS; RECEIVER DOMAIN; RNA-POLYMERASE; OPERON	The response regulator NtrC transcriptionally activates genes of the nitrogen-regulated (Ntr) response. Phosphorylation of its N-terminal receiver domain stimulates an essential oligomerization of the central domain. Deletion of the central domain reduces, but does not eliminate, intermolecular interactions as assessed by cooperative binding to DNA. To analyze the structural determinants and function of this central domain-independent as well as phosphorylation-independent oligomerization, we randomly mutagenized DNA coding for an NtrC without its central domain and isolated strains containing NtrC with defective phosphorylation-independent cooperative binding. The alterations were primarily localized to helix B of the C-terminal domain. Site-specific mutagenesis that altered surface residues of helix B confirmed this localization. The purified NtrC variants, with or without the central domain, were specifically defective in phosphorylation-independent cooperative DNA binding and had little defect, if any, on other functions, such as noncooperative DNA binding. We propose that this region forms an oligomerization interface. Full-length NtrC variants did not efficiently repress the glnA-ntrBC operon when NtrC was not phosphorylated, which suggests that phosphorylation-independent cooperative binding sets the basal level for glutamine synthetase and the regulators of the Ntr response. The NtrC variants in these cells generally, but not always, supported wild-type growth in nitrogen-limited media and wild-type activation of a variety of Ntr genes. We discuss the differences and similarities between the NtrC C-terminal domain and the homologous Fis, which is also capable of intermolecular interactions.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Reitzer, L (corresponding author), Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA.	reitzer@utdallas.edu	Yang, X. Frank/F-3266-2010; Reitzer, Larry/A-2510-2016	Reitzer, Larry/0000-0002-4406-6090	NIGMS NIH HHS [GM 47965] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047965] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; Bantscheff M, 1999, BIOCHEMISTRY-US, V38, P11012, DOI 10.1021/bi990781k; CHEN P, 1995, J BACTERIOL, V177, P2490, DOI 10.1128/jb.177.9.2490-2496.1995; Cho HS, 2001, CURR OPIN STRUC BIOL, V11, P679, DOI 10.1016/S0959-440X(01)00271-8; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; Haldimann A, 2001, J BACTERIOL, V183, P6384, DOI 10.1128/JB.183.21.6384-6393.2001; Harrod AC, 2004, J BIOL CHEM, V279, P2350, DOI 10.1074/jbc.M306181200; Hastings CA, 2003, BIOCHEMISTRY-US, V42, P9081, DOI 10.1021/bi0273866; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; Kiupakis AK, 2002, J BACTERIOL, V184, P2940, DOI 10.1128/JB.184.11.2940-2950.2002; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; Lee SY, 2003, GENE DEV, V17, P2552, DOI 10.1101/gad.1125603; Leung DW, 1989, TECHNIQUE, V1, P11; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P147; Lu CD, 1999, J BACTERIOL, V181, P1934, DOI 10.1128/JB.181.6.1934-1938.1999; McLeod SM, 1999, J MOL BIOL, V294, P333, DOI 10.1006/jmbi.1999.3262; Merickel SK, 1998, GENE DEV, V12, P2803, DOI 10.1101/gad.12.17.2803; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; Miller J. H, 1972, EXPT MOL GENETICS; MOORE JB, 1993, J BACTERIOL, V175, P2692, DOI 10.1128/JB.175.9.2692-2701.1993; Morett E, 1998, FEBS LETT, V433, P108, DOI 10.1016/S0014-5793(98)00888-6; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; OSUNA R, 1991, EMBO J, V10, P1593, DOI 10.1002/j.1460-2075.1991.tb07680.x; Park S, 2002, FASEB J, V16, P1964, DOI 10.1096/fj.02-0395fje; Park S, 2002, BIOCHEMISTRY-US, V41, P10934, DOI 10.1021/bi0260031; Pelton JG, 1999, J MOL BIOL, V292, P1095, DOI 10.1006/jmbi.1999.3140; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Pybus CA, 2002, THESIS U TEXAS DALLA; Reitzer L, 2001, MICROBIOL MOL BIOL R, V65, P422, DOI 10.1128/MMBR.65.3.422-444.2001; Reitzer L, 2003, ANNU REV MICROBIOL, V57, P155, DOI 10.1146/annurev.micro.57.030502.090820; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Rombel I, 1999, J BACTERIOL, V181, P4628, DOI 10.1128/JB.181.15.4628-4638.1999; ROTHSTEIN DM, 1980, P NATL ACAD SCI-BIOL, V77, P7372, DOI 10.1073/pnas.77.12.7372; Safo MK, 1997, EMBO J, V16, P6860, DOI 10.1093/emboj/16.22.6860; Samsonova NN, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHIAU SP, 1993, J BACTERIOL, V175, P190, DOI 10.1128/JB.175.1.190-199.1993; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	52	15	16	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36708	36714		10.1074/jbc.M405205200	http://dx.doi.org/10.1074/jbc.M405205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208307	hybrid			2022-12-27	WOS:000223453600070
J	Bulygin, VV; Duncan, TM; Cross, RL				Bulygin, VV; Duncan, TM; Cross, RL			Rotor/stator interactions of the epsilon subunit in Escherichia coli ATP synthase and implications for enzyme regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; F0F1-ATP SYNTHASE; BETA-SUBUNITS; GAMMA-SUBUNIT; ROTARY MOTOR; OXIDATIVE-PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; TERMINAL DOMAIN; CROSS-LINKING	The H+-translocating F0F1-ATP synthase of Escherichia coli functions as a rotary motor, coupling the transmembrane movement of protons through F-0 to the synthesis of ATP by F-1. Although the epsilon subunit appears to be tightly associated with the gamma subunit in the central stalk region of the rotor assembly, several studies suggest that the C-terminal domain of epsilon can undergo significant conformational change as part of a regulatory process. Here we use disulfide cross-linking of substituted cysteines on functionally coupled ATP synthase to characterize interactions of epsilon with an F-0 component of the rotor (subunit c) and with an F-1 component of the stator (subunit beta). Oxidation of the engineered F0F1 causes formation of two disulfide bonds, betaD380C-epsilonS108C and epsilonE31C-cQ42C, to give a beta-epsilon-c cross-linked product in high yield. The results demonstrate the ability of epsilon to span the central stalk region from the surface of the membrane (epsilon-c) to the bottom of F1 (beta-epsilon) and suggest that the conformation detected here is distinct from both the "closed" state seen with isolated epsilon (Uhlin, U., Cox, G. B., and Guss, J. M. (1997) Structure 5, 1219-1230) and the "open" state seen in a complex with a truncated form of the gamma subunit (Rodgers, A. J., and Wilce, M. C. (2000) Nat. Struct. Biol. 7, 1051-1054). The kinetics of beta-epsilon and epsilon-c cross-linking were studied separately using F0F1 containing one or the other matched cysteine pair. The rate of cross-linking at the epsilon/c (rotor/rotor) interface is not influenced by the type of nucleotide added. In contrast, the rate of beta-epsilon cross-linking is fastest under ATP hydrolysis conditions, intermediate with MgADP, and slowest with MgAMP-PNP. This is consistent with a regulatory role for a reversible beta/epsilon (stator/rotor) interaction that blocks rotation and inhibits catalysis. Furthermore, the rate of beta-epsilon cross-linking is much faster than that indicated by previous studies, allowing for the possibility of a rapid response to regulatory signals.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Cross, RL (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.	crossr@upstate.edu		Duncan, Thomas/0000-0002-6432-4958	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023152, R01GM023152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Borsch M, 2002, FEBS LETT, V527, P147, DOI 10.1016/S0014-5793(02)03198-8; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; Capaldi RA, 2000, BBA-BIOENERGETICS, V1458, P263, DOI 10.1016/S0005-2728(00)00078-5; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Duncan T. M., 2004, ENZYMES, VXXIII, P203; Duncan TM, 1995, BIOCHEM SOC T, V23, P736, DOI 10.1042/bst0230736; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Etzold C, 1997, EUR J BIOCHEM, V243, P336, DOI 10.1111/j.1432-1033.1997.0336a.x; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIBSON F, 1978, J BACTERIOL, V134, P728, DOI 10.1128/JB.134.3.728-736.1978; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Johnson EA, 2002, BIOCHEMISTRY-US, V41, P2446, DOI 10.1021/bi011939f; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Kaim G, 2002, FEBS LETT, V525, P156, DOI 10.1016/S0014-5793(02)03097-1; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Kato-Yamada Y, 2000, J BIOL CHEM, V275, P35746, DOI 10.1074/jbc.M006575200; KOMATSUTAKAKI M, 1992, J BIOL CHEM, V267, P2360; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; Ma JP, 2002, STRUCTURE, V10, P921, DOI 10.1016/S0969-2126(02)00789-X; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nowak KF, 2002, BIOCHEMISTRY-US, V41, P15130, DOI 10.1021/bi026594v; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Peskova YB, 2000, BIOCHEMISTRY-US, V39, P11830, DOI 10.1021/bi0013694; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; Richter ML, 2000, BBA-BIOENERGETICS, V1458, P326, DOI 10.1016/S0005-2728(00)00084-0; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; XIE DL, 1993, BIOCHIM BIOPHYS ACTA, V1172, P267, DOI 10.1016/0167-4781(93)90213-W; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	63	29	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35616	35621		10.1074/jbc.M405012200	http://dx.doi.org/10.1074/jbc.M405012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199054	hybrid			2022-12-27	WOS:000223303400057
J	Choe, CU; Harrison, KD; Grant, W; Ehrlich, BE				Choe, CU; Harrison, KD; Grant, W; Ehrlich, BE			Functional coupling of chromogranin with the inositol 1,4,5-trisphosphate receptor shapes calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID CELL SECRETION; B-LIKE IMMUNOREACTIVITY; NEUROLOGICAL DISEASES; ALZHEIMERS-DISEASE; PROTEIN; CHANNEL; PEPTIDE; GRANULES; RELEASE; NEURONS	Chromogranins A and B are high capacity, low affinity calcium (Ca2+) storage proteins that bind to the inositol 1,4,5-trisphosphate-gated receptor (InsP(3)R). Although most commonly associated with secretory granules of neuroendocrine cells, chromogranins have also been found in the lumen of the endoplasmic reticulum (ER) of many cell types. To investigate the functional consequences of the interaction between the InsP(3)R and the chromogranins, we disrupted the interaction between the two proteins by adding a chromogranin fragment, which competed with chromogranin for its binding site on the InsP(3)R. Responses were monitored at the single channel level and in intact cells. When using InsP(3)R type I incorporated into planar lipid bilayers and activated by cytoplasmic InsP(3) and luminal chromogranin, the addition of the fragment reversed the enhancing effect of chromogranin. Moreover, the expression of the fragment in the ER of neuronally differentiated PC12 cells attenuated agonist-induced intracellular Ca2+ signaling. These results show that the InsP(3)R/chromogranin interaction amplifies Ca2+ release from the ER and that chromogranin is an essential component of this intracellular channel complex.	Yale Univ, Dept Pharmacol & Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Inst Neural Signal Transduct, D-20251 Hamburg, Germany	Yale University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Ehrlich, BE (corresponding author), Yale Univ, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	barbara.ehrlich@yale.edu	/AAX-8408-2021	/0000-0001-9657-9704	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063496] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63496] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; Eder U, 1998, J NEURAL TRANSM, V105, P39, DOI 10.1007/s007020050036; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; FISCHERCOLBRIE R, 1985, NEUROSCIENCE, V16, P547, DOI 10.1016/0306-4522(85)90191-5; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HELLE KB, 1993, NEUROCHEM INT, V22, P353, DOI 10.1016/0197-0186(93)90017-Y; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; Johenning FW, 2002, J NEUROSCI, V22, P5344; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; LEWIS JJ, 1988, SURGERY, V104, P1031; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Marksteiner J, 2002, J MOL NEUROSCI, V18, P53, DOI 10.1385/JMN:18:1-2:53; Marksteiner J, 2000, ACTA NEUROPATHOL, V100, P205, DOI 10.1007/s004010000239; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; Nagase T, 2003, NEUROSCIENCE, V117, P821, DOI 10.1016/S0306-4522(02)00803-5; NISHIMURA M, 1994, BRAIN RES, V634, P339, DOI 10.1016/0006-8993(94)91940-2; Nowakowski C, 2002, SCHIZOPHR RES, V58, P43, DOI 10.1016/S0920-9964(01)00389-9; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; OCONNOR DT, 1983, REGUL PEPTIDES, V6, P263, DOI 10.1016/0167-0115(83)90145-3; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; SIMON JP, 1989, BIOCHEM J, V262, P1; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SOMOGYI P, 1984, BRAIN RES REV, V8, P193, DOI 10.1016/0165-0173(84)90007-9; Steffl M, 2003, ANN ANAT, V185, P103, DOI 10.1016/S0940-9602(03)80070-5; Strub JM, 1997, J BIOL CHEM, V272, P11928, DOI 10.1074/jbc.272.18.11928; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Thrower EC, 2003, J BIOL CHEM, V278, P49699, DOI 10.1074/jbc.M309307200; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; YASUHARA O, 1994, NEUROSCI LETT, V170, P13, DOI 10.1016/0304-3940(94)90227-5; Yoo SH, 2001, J BIOL CHEM, V276, P45806, DOI 10.1074/jbc.M107532200; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0; Yoo SH, 2000, J BIOL CHEM, V275, P30293, DOI 10.1074/jbc.M001204200	42	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35551	35556		10.1074/jbc.M311261200	http://dx.doi.org/10.1074/jbc.M311261200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194698	hybrid			2022-12-27	WOS:000223303400050
J	Saha, PK; Kojima, H; Martinez-Botas, J; Sunehag, AL; Chan, L				Saha, PK; Kojima, H; Martinez-Botas, J; Sunehag, AL; Chan, L			Metabolic adaptations in the absence of perilipin - Increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perilipin-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; FATTY-ACID OXIDATION; HUMAN NEWBORN; MUSCLE; LIPOLYSIS; GENE; INTOLERANCE; PROTEIN; INACTIVATION; ADIPONECTIN	Targeted disruption of the lipid droplet protein, perilipin, in mice leads to constitutional lipolysis associated with marked reduction in white adipose tissue as a result of unbridled lipolysis. To investigate the metabolic adaptations in response to the constitutive lipolysis, we studied perilipin-null (plin(-/-)) mice in terms of their fatty acid oxidation and glycerol and glucose metabolism homeostasis by using dynamic biochemical testing and clamp and tracer infusion methods. plin(-/-) mice showed increased beta-oxidation in muscle, liver, and adipose tissue resulting from a coordinated regulation of the enzymes and proteins involved in beta-oxidation. The increased beta-oxidation helped remove the extra free fatty acids created by the constitutive lipolysis. An increase in the expression of the transcripts for uncoupling proteins-2 and -3 also accompanied this increase in fatty acid oxidation. Adult plin(-/-) mice had normal plasma glucose but a reduced basal hepatic glucose production (46% that of plin(+/+)). Insulin infusion during low dose hyperinsulinemic-euglycemic clamp further lowered the glucose production in plin(-/-) mice, but plin(-/-) mice also showed a 36% decrease (p < 0.007) in glucose disposal rate during the low dose insulin clamp, indicating peripheral insulin resistance. However, compared with plin(-/-) mice, 14-week-old plin(-/-) mice showed no significant difference in glucose disposal rate during the high dose hyperinsulinemic clamp, whereas 42-week-old plin(-/-) mice displayed significant insulin resistance on high dose hyperinsulinemic clamp. Despite increasing insulin resistance with age, plin(-/-) mice at different ages maintained a normal glucose response during an intraperitoneal glucose tolerance curve, being compensated by the increased beta-oxidation and reduced hepatic glucose production. These experiments uncover the metabolic adaptations associated with the constitutional lipolysis in plin(-/-) mice that allowed the mice to continue to exhibit normal glucose tolerance in the presence of peripheral insulin resistance.	Baylor Coll Med, Div Diabet Endocrinol & Metab, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Div Diabet Endocrinol & Metab, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; ARS, USDA, Childrens Nutr Res Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA)	Chan, L (corresponding author), Baylor Coll Med, Div Diabet Endocrinol & Metab, Dept Med, N520-10,1 Baylor Plaza, Houston, TX 77030 USA.	lchan@bcm.tmc.edu	Martinez-Botas, Javier/AAD-8733-2021	Martinez-Botas, Javier/0000-0002-5190-3619	NHLBI NIH HHS [HL-51586] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Alam N, 1998, BIOCHEM J, V334, P233, DOI 10.1042/bj3340233; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; BIER DM, 1977, DIABETES, V26, P1005, DOI 10.2337/diabetes.26.11.1005; BOUGNERES PF, 1987, BIOL NEONATE, V52, P87; BOUGNERES PF, 1982, J CLIN INVEST, V70, P262, DOI 10.1172/JCI110613; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Chou CJ, 2002, J BIOL CHEM, V277, P24484, DOI 10.1074/jbc.M202449200; FJELD CR, 1992, PEDIATR RES, V32, P693, DOI 10.1203/00006450-199212000-00015; Fujita Y, 1998, DIABETOLOGIA, V41, P1459, DOI 10.1007/s001250051092; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Ihlemann J, 1999, AM J PHYSIOL-ENDOC M, V277, pE208, DOI 10.1152/ajpendo.1999.277.2.E208; Jones JP, 1997, AM J PHYSIOL-ENDOC M, V273, pE682, DOI 10.1152/ajpendo.1997.273.4.E682; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim JK, 2001, J CLIN INVEST, V108, P153, DOI 10.1172/JCI10294; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Ma K, 2002, J BIOL CHEM, V277, P34658, DOI 10.1074/jbc.C200362200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; PATEL D, 1992, PEDIATR RES, V31, P52, DOI 10.1203/00006450-199201000-00010; Reitman ML, 2002, ANNU REV NUTR, V22, P459, DOI 10.1146/annurev.nutr.22.010402.102849; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; SUNEHAG A, 1994, PEDIATR RES, V36, P550, DOI 10.1203/00006450-199410000-00024; Sunehag AL, 1999, DIABETES, V48, P791, DOI 10.2337/diabetes.48.4.791; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	44	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35150	35158		10.1074/jbc.M405499200	http://dx.doi.org/10.1074/jbc.M405499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15197189	hybrid			2022-12-27	WOS:000223303400005
J	Chan, Y; Fish, JE; D'Abreo, C; Lin, S; Robb, GB; Teichert, AM; Karantzoulis-Fegaras, F; Keightley, A; Steer, BM; Marsden, PA				Chan, Y; Fish, JE; D'Abreo, C; Lin, S; Robb, GB; Teichert, AM; Karantzoulis-Fegaras, F; Keightley, A; Steer, BM; Marsden, PA			The cell-specific expression of endothelial nitric-oxide synthase - A role for DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN MECP2; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; ERYTHROPOIETIN GENE; CPG ISLANDS; PROMOTER; CANCER; SITES; SP1	The basis for the endothelial cell-restricted expression of endothelial nitric-oxide synthase ( eNOS) is not known. While transgenic promoter/reporter mice demonstrated endothelium cell-specific eNOS expression, we found robust expression of episomal eNOS promoter/reporter constructs in cell types that do not express the native eNOS transcript. To explore the mechanism underlying this differential activity pattern of chromatin-versus episome-based eNOS promoters, we examined the methylation status of 5'-regulatory sequences of the human eNOS gene. DNA methylation differed dramatically between endothelial and nonendothelial cell types, including vascular smooth muscle cells. This same cell type-specific methylation pattern was observed in vivo in endothelial and vascular smooth muscle cells of the mouse aorta at the native murine eNOS promoter. We addressed the functional consequences of methylation on eNOS transcription using transient transfection of in vitro methylated promoter/reporter constructs and found that methylated constructs exhibited a marked decrease in the synergistic action of Sp1, Sp3, and Ets1 on eNOS promoter activity. The addition of methyl-CpG-binding protein 2 further reduced the transcriptional activity of methylated eNOS constructs. Importantly, chromatin immunoprecipitation demonstrated the presence of Sp1, Sp3, and Ets1 at the native eNOS promoter in endothelial cells but not in vascular smooth muscle cells. Finally, robust expression of eNOS mRNA was induced in nonendothelial cell types following inhibition of DNA methyltransferase activity with 5-azacytidine, demonstrating the importance of DNA methylation-mediated repression. This report is the first to show that promoter DNA methylation plays an important role in the cell-specific expression of a constitutively expressed gene in the vascular endothelium.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marsden, PA (corresponding author), Univ Toronto, Dept Med Biophys, Med Sci Bldg,Rm 7358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Teichert, Anouk-Martine/O-1462-2015; Lin, Steve/H-3723-2013; Marsden, Philip A/B-1441-2012	Teichert, Anouk-Martine/0000-0001-9648-8677; Lin, Steve/0000-0002-8644-9719; Robb, Gregory Brett/0000-0002-2382-2256; Fish, Jason/0000-0003-0640-7277				Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; Bestor TH, 2000, J CLIN INVEST, V105, P409, DOI 10.1172/JCI9459; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Cirino G, 2003, TRENDS PHARMACOL SCI, V24, P91, DOI 10.1016/S0165-6147(02)00049-4; Clark S. J., 1997, P151; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Guillot PV, 2000, PHYSIOL GENOMICS, V2, P77, DOI 10.1152/physiolgenomics.2000.2.2.77; Guillot PV, 1999, J CLIN INVEST, V103, P799, DOI 10.1172/JCI6017; HALL AV, 1994, J BIOL CHEM, V269, P33082; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Klose R, 2003, SCIENCE, V302, P793, DOI 10.1126/science.1091762; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Kupper D, 1997, BIOTECHNIQUES, V23, P843, DOI 10.2144/97235bm17; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lin XH, 2003, CANCER RES, V63, P498; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446; Minami T, 2002, BLOOD, V100, P4019, DOI 10.1182/blood-2002-03-0955; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; PATEL CV, 1987, ANAL BIOCHEM, V164, P164, DOI 10.1016/0003-2697(87)90381-2; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RHODES K, 1994, MOL CELL BIOL, V14, P5950, DOI 10.1128/MCB.14.9.5950; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Stancheva I, 2003, MOL CELL, V12, P425, DOI 10.1016/S1097-2765(03)00276-4; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Yin H, 2000, BLOOD, V95, P111, DOI 10.1182/blood.V95.1.111.001k20_111_119; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	59	186	197	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35087	35100		10.1074/jbc.M405063200	http://dx.doi.org/10.1074/jbc.M405063200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180995	hybrid			2022-12-27	WOS:000223134800121
J	Mayorga, M; Bahi, N; Ballester, M; Comella, JX; Sanchis, D				Mayorga, M; Bahi, N; Ballester, M; Comella, JX; Sanchis, D			Bcl-2 is a key factor for cardiac fibroblast resistance to programmed cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; OXIDATIVE STRESS; FAMILY-MEMBERS; ACTIVATION; MITOCHONDRIAL; HYPOXIA; PATHWAY; PROTEIN	Cardiac fibroblasts play an essential role in the physiology of the heart. These produce extracellular matrix proteins and synthesize angiogenic and cardioprotective factors. Although fibroblasts of cardiac origin are known to be resistant to apoptosis and to remain metabolically active in situations compromising cell survival, the underlying mechanisms are unknown. Here, we report that cardiac fibroblasts were more resistant than dermal or pulmonary fibroblasts to mitochondria-dependent cell death. Cytochrome c release was blocked in cardiac fibroblasts but not in dermal fibroblasts treated with staurosporine, etoposide, serum deprivation, or simulated ischemia, precluding caspase-3 activation and DNA fragmentation. Resistance to apoptosis of cardiac fibroblasts correlated with the expression of the anti-apoptotic protein Bcl-2, whereas skin and lung fibroblasts did not express detectable levels of this protein. Bcl-xL, Bax, and Bak were expressed at similar levels in cardiac, dermal, and lung fibroblasts. In addition, the death of cardiac fibroblasts during hypoxia was not associated with the cleavage of Bid but rather with Bcl-2 disappearance, suggesting the requirement of the mitochondrial apoptotic machinery to execute death receptor-induced programmed cell death. Knockdown of bcl-2 expression by siRNA in cardiac fibroblasts increased their apoptotic response to staurosporine, serum, and glucose deprivation and to simulated ischemia. Moreover, dermal fibroblasts overexpressing Bcl-2 achieved a similar level of resistance to these stimuli as cardiac fibroblasts. Thus, our data demonstrate that Bcl-2 is an important effector of heart fibroblast resistance to apoptosis and highlight a probable mechanism for promoting survival advantage in fibroblasts of cardiac origin.	Univ Lleida, Grp Cell Signaling & Apoptosis, Fac Med, Dept Ciencies Med Basiques, Lleida 25008, Spain; Univ Lleida, Grp Cell Signaling & Apoptosis, Fac Med, Dept Med, Lleida 25008, Spain; Hosp Arnau Vilanova, Lab Recerca, Lleida 25198, Spain	Universitat de Lleida; Universitat de Lleida; University Hospital Arnau de Vilanova	Sanchis, D (corresponding author), Univ Lleida, Grp Cell Signaling & Apoptosis, Fac Med, Dept Ciencies Med Basiques, Montserrat Roig 2, Lleida 25008, Spain.	daniel.sanchis@cmb.udl.es	Sanchis, Daniel/C-8077-2009; Sanchis, Daniel/B-5644-2009; Comella, Joan X/D-7333-2012; Bahi, Nuria/ABE-9680-2021; Pla, Nuria Bahi/B-8022-2009; Comella, Joan/GQA-4279-2022	Sanchis, Daniel/0000-0003-0047-8533; Comella, Joan X/0000-0002-6218-0786; Bahi, Nuria/0000-0003-2845-0313; Pla, Nuria Bahi/0000-0003-2845-0313; 				Abbate A, 2003, J AM COLL CARDIOL, V41, P753, DOI 10.1016/S0735-1097(02)02959-5; Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Agocha A, 1997, J MOL CELL CARDIOL, V29, P2233, DOI 10.1006/jmcc.1997.0462; Akao M, 2003, CIRC RES, V92, P186, DOI 10.1161/01.RES.0000051861.21316.E9; Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Aoyama T, 2002, CARDIOVASC RES, V55, P787, DOI 10.1016/S0008-6363(02)00493-5; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bouillet P, 2002, J CELL SCI, V115, P1567; Bruce MC, 1999, AM J RESP CELL MOL, V20, P228, DOI 10.1165/ajrcmb.20.2.3150; Chen DB, 2000, LIFE SCI, V67, P1683, DOI 10.1016/S0024-3205(00)00759-1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dammer S, 2002, CIRCULATION, V106, P309; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gardner LB, 2003, MOL CELL BIOL, V23, P9032, DOI 10.1128/MCB.23.24.9032-9045.2003; Gonzalez A, 2002, HYPERTENSION, V39, P75, DOI 10.1161/hy0102.100788; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Kang MJ, 1997, J MOL CELL CARDIOL, V29, P1767, DOI 10.1006/jmcc.1997.0450; Katz AM, 2000, HEART FAILURE; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li PF, 1999, FEBS LETT, V448, P206, DOI 10.1016/S0014-5793(99)00370-1; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; Nelson DP, 2000, J CLIN INVEST, V105, P1199, DOI 10.1172/JCI8212; NOVACK DV, 1994, AM J PATHOL, V145, P61; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; Pablos JL, 1997, J HISTOCHEM CYTOCHEM, V45, P711, DOI 10.1177/002215549704500509; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Sanchis D, 2003, CELL DEATH DIFFER, V10, P977, DOI 10.1038/sj.cdd.4401267; SCHAPER J, 1992, BASIC RES CARDIOL, V87, P303; Scheubel RJ, 2002, J AM COLL CARDIOL, V39, P481, DOI 10.1016/S0735-1097(01)01769-7; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Soler RM, 1999, J NEUROSCI, V19, P9160; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Takemura G, 1998, CIRC RES, V82, P1130, DOI 10.1161/01.RES.82.11.1130; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; van den Hoff MJB, 2000, CARDIOVASC RES, V45, P603, DOI 10.1016/S0008-6363(99)00401-0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x; Zhang XM, 2001, J AM COLL CARDIOL, V38, P2055, DOI 10.1016/S0735-1097(01)01665-5	49	70	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34882	34889		10.1074/jbc.M404616200	http://dx.doi.org/10.1074/jbc.M404616200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184368	hybrid			2022-12-27	WOS:000223134800098
J	Orth, JHC; Lang, S; Aktories, K				Orth, JHC; Lang, S; Aktories, K			Action of Pasteurella multocida toxin depends on the helical domain of G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL FRAGMENT; TYROSINE PHOSPHORYLATION; BACTERIAL TOXINS; MITOGENIC TOXIN; POTENT MITOGEN; PROTEIN; ALPHA; ACTIVATION; INCREASES; MECHANISM	Pasteurella multocida produces a 146-kDa protein toxin (PMT), which activates multiple cellular signal transduction pathways, resulting in the activation of phospholipase Cbeta, RhoA, Jun kinase, and extracellular signal-regulated kinase. Using Galpha(q)/Galpha(11)-deficient cells, it was shown that the PMT-induced pleiotropic effects are mediated by Galpha(q) but not by the highly related Galpha(11) protein (Zywietz, A., Gohla, A., Schmelz, M., Schultz, G., and Offermanns, S. ( 2001) J. Biol. Chem. 276, 3840 - 3845). Here we studied the molecular basis of the unique specificity of PMT to distinguish between Galpha(q) and/or Galpha(11). Infection of Galpha(q/11)-deficient cells with retrovirus-encoding Galpha(q) caused reconstitution of PMT-induced activation of phospholipase Cbeta, whereas Galpha(11)-encoding virus did not reconstitute PMT activity. Chimeras between Galpha(q) and/or Galpha(11) revealed that a peptide region of Galpha(q), covering amino acid residues 105 - 113, is essential for the action of PMT to activate phospholipase Cbeta. Exchange of glutamine 105 or asparagine 109 of Galpha(11), which are located in the all-helical domain of the Galpha subunit, with the equally positioned histidines of Galpha(q), renders Galpha(11) capable of transmission PMT-induced phospholipase Cbeta activation. The data indicate that the all-helical domain of Galpha(q) is essential for the action of PMT and suggest an essential functional role of this domain in signal transduction via G(q) proteins.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Baldwin MR, 2003, J BIOL CHEM, V278, P32719, DOI 10.1074/jbc.M303524200; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628-3634.2001; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CHANTER N, 1990, CAN J VET RES, V54, pS45; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; Dudet LI, 1996, J CELL PHYSIOL, V168, P173; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; KAMP EM, 1988, AM J VET RES, V49, P1844; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; Lax AJ, 2001, INT J MED MICROBIOL, V291, P261, DOI 10.1078/1438-4221-00129; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; Mullan PB, 1996, INFECT IMMUN, V64, P959, DOI 10.1128/IAI.64.3.959-965.1996; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Orth JHC, 2003, BIOCHEMISTRY-US, V42, P4971, DOI 10.1021/bi0272959; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PEDERSEN KB, 1981, NORD VET MED, V33, P513; Pullinger GD, 2001, INFECT IMMUN, V69, P7839, DOI 10.1128/IAI.69.12.7839-7850.2001; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; STADDON JM, 1991, J BIOL CHEM, V266, P4840; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Ward PN, 1998, INFECT IMMUN, V66, P5636, DOI 10.1128/IAI.66.12.5636-5642.1998; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	36	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34150	34155		10.1074/jbc.M405353200	http://dx.doi.org/10.1074/jbc.M405353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192096	hybrid			2022-12-27	WOS:000223134800012
J	Wang, SX; Skorczewski, J; Feng, X; Mei, L; Murphy-Ullrich, JE				Wang, SX; Skorczewski, J; Feng, X; Mei, L; Murphy-Ullrich, JE			Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MESANGIAL CELLS; SMOOTH-MUSCLE CELLS; FACTOR USF; NITRIC-OXIDE; EXTRACELLULAR-MATRIX; MULTIPLE FORMS; MESSENGER-RNA; ACTIVATION; EXPRESSION; GMP	Thrombospondin 1 (TSP1) transcription is stimulated by glucose, resulting in increased TGF-beta activation and matrix protein synthesis. We previously showed that inducible expression of the catalytic domain of cGMP-dependent protein kinase (PKG) inhibits glucose-regulated TSP1 transcription and transforming growth factor (TGF)-beta activity in stably transfected rat mesangial cells (RMCs(tr/cd)). However, the molecular mechanisms by which PKG represses glucose-regulated TSP1 transcription are unknown. Using a luciferase-promoter deletion assay, we now identify a single region of the human TSP1 promoter (-1172 to -878, relative to the transcription start site) that is responsive to glucose. Further characterization of this region identified an 18-bp sequence that specifically binds nuclear proteins from mesangial cells. Moreover, binding is significantly enhanced by high glucose treatment and is reduced by increased PKG activity. Gel mobility shift and supershift assays show that the nuclear proteins binding to the 18-bp sequence are USF1 and -2. USF1 and USF2 bound to the endogenous TSP1 promoter using a chromatin immunoprecipitation assay. Glucose stimulates nuclear USF2 protein accumulation through protein kinase C, p38 MAPK, and extracellular signal-regulated kinase pathways. Increased PKG activity down-regulates USF2 protein levels and its DNA binding activity under high glucose conditions, resulting in inhibition of glucose-induced TSP1 transcription and TGF-beta activity. Overexpression of USF2 reversed the inhibitory effect of PKG on glucose-induced TSP1 gene transcription and TGF-beta activity. Taken together these data present the first evidence that USF2 mediates glucose-induced TSP1 expression and TSP1-dependent TGF-beta bioactivity in mesangial cells, suggesting that USF2 is an important transcriptional regulator of diabetic complications.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, SX (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Cell Adhes & Matrix Res Ctr, Volker Hall,668C,1670 Univ Blvd, Birmingham, AL 35294 USA.	swang@path.uab.edu	Mei, Lin/G-8755-2012		NCRR NIH HHS [C06 RR 15490] Funding Source: Medline; NIAMS NIH HHS [AR 47830] Funding Source: Medline; NIDDK NIH HHS [DK 54624] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054624] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; BAYRAKTAR M, 1994, J INT MED RES, V22, P90, DOI 10.1177/030006059402200204; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; Dey NB, 1998, CIRC RES, V82, P139; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; Gudi T, 1996, J BIOL CHEM, V271, P4597; Haneda M, 2001, AM J KIDNEY DIS, V38, pS178, DOI 10.1053/ajkd.2001.27438; Haneda M, 1995, J DIABETES COMPLICAT, V9, P246, DOI 10.1016/1056-8727(95)80013-5; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; He B, 2003, EUR J BIOCHEM, V270, P2174, DOI 10.1046/j.1432-1033.2003.03574.x; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Hida K, 2000, J LIPID RES, V41, P1615; Holmes DIR, 1997, BIOCHEM BIOPH RES CO, V238, P179, DOI 10.1006/bbrc.1997.7265; HUGO C, 1995, KIDNEY INT, V48, P1846, DOI 10.1038/ki.1995.483; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Ingram AJ, 1999, KIDNEY INT, V56, P1721, DOI 10.1046/j.1523-1755.1999.00743.x; Iwano M, 1996, KIDNEY INT, V49, P1120, DOI 10.1038/ki.1996.162; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LIN Q, 1994, J BIOL CHEM, V269, P23894; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MCGREGOR B, 1994, AM J PATHOL, V144, P1281; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Pawliczak R, 2001, J BIOL CHEM, V276, P44613, DOI 10.1074/jbc.M104993200; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; Poczatek MH, 2000, AM J PATHOL, V157, P1353, DOI 10.1016/S0002-9440(10)64649-4; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; RIFKIN DB, 1993, THROMB HAEMOSTASIS, V70, P177; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; Tada H, 2001, J DIABETES COMPLICAT, V15, P193, DOI 10.1016/S1056-8727(01)00147-7; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tsiani E, 2002, AM J PHYSIOL-ENDOC M, V282, pE161, DOI 10.1152/ajpendo.2002.282.1.E161; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wang SX, 2003, DIABETES, V52, P2144, DOI 10.2337/diabetes.52.8.2144; Wang SX, 2002, J BIOL CHEM, V277, P9880, DOI 10.1074/jbc.M108360200; Weigert C, 2004, J BIOL CHEM, V279, P15908, DOI 10.1074/jbc.M313524200; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; Wilmer WA, 2001, KIDNEY INT, V60, P858, DOI 10.1046/j.1523-1755.2001.060003858.x; WOLF G, 1992, KIDNEY INT, V42, P647, DOI 10.1038/ki.1992.330; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	66	90	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34311	34322		10.1074/jbc.M401629200	http://dx.doi.org/10.1074/jbc.M401629200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184388	hybrid			2022-12-27	WOS:000223134800030
J	Wooldridge, AA; MacDonald, JA; Erdodi, F; Ma, CY; Borman, MA; Hartshorne, DJ; Haystead, TAJ				Wooldridge, AA; MacDonald, JA; Erdodi, F; Ma, CY; Borman, MA; Hartshorne, DJ; Haystead, TAJ			Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of serine 695 in response to cyclic nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN-PHOSPHATASE; DEPENDENT PROTEIN-KINASE; HORMONE-SENSITIVE LIPASE; MYOSIN-BINDING SUBUNIT; INTEGRIN-LINKED KINASE; CA2+ SENSITIZATION; CONTRACTION; INHIBITION; TELOKIN; RELAXATION	Regulation of smooth muscle myosin phosphatase (SMPP-1M) is thought to be a primary mechanism for explaining Ca2+ sensitization/desensitization in smooth muscle. Ca2+ sensitization induced by activation of G protein-coupled receptors acting through RhoA involves phosphorylation of Thr-696 ( of the human isoform) of the myosin targeting subunit (MYPT1) of SMPP-1M inhibiting activity. In contrast, agonists that elevate intracellular cGMP and cAMP promote Ca2+ desensitization in smooth muscle through apparent activation of SMPP-1M. We show that cGMP-dependent protein kinase (PKG)/cAMP-dependent protein kinase (PKA) efficiently phosphorylates MYPT1 in vitro at Ser-692, Ser-695, and Ser-852 ( numbering for human isoform). Although phosphorylation of MYPT1 by PKA/PKG has no direct effect on SMPP-1M activity, a primary site of phosphorylation is Ser-695, which is immediately adjacent to the inactivating Thr-696. In vitro, phosphorylation of Ser-695 by PKA/PKG appeared to prevent phosphorylation of Thr-696 by MYPT1K. In ileum smooth muscle, Ser-695 showed a 3-fold increase in phosphorylation in response to 8-bromo-cGMP. Addition of constitutively active recombinant MYPT1K to permeabilized smooth muscles caused phosphorylation of Thr-696 and Ca2+ sensitization; however, this phosphorylation was blocked by preincubation with 8-bromo-cGMP. These findings suggest a mechanism of Ca2+ desensitization in smooth muscle that involves mutual exclusion of phosphorylation, whereby phosphorylation of Ser-695 prevents phosphorylation of Thr-696 and therefore inhibition of SMPP-1M.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Calgary, Dept Biochem & Mol Biol, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Univ Debrecen, Med & Hlth Sci Ctr, Dept Med Chem, Debrecen, Hungary; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA	Duke University; University of Calgary; University of Debrecen; University of Arizona	Haystead, TAJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	hayst001@mc.duke.edu	Erdődi, Ferenc/B-3383-2011	MacDonald, Justin/0000-0002-9238-8473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, R01HL023615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 23615, HL 19242-24] Funding Source: Medline; NIDDK NIH HHS [DK 52378-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beall AC, 1997, J BIOL CHEM, V272, P11283; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; Chiba Y, 2001, EUR J PHARMACOL, V427, P77, DOI 10.1016/S0014-2999(01)01225-0; Chiba Y, 2001, INFLAMM RES, V50, P333, DOI 10.1007/PL00000253; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; Huang QQ, 2004, J BIOL CHEM, V279, P597, DOI 10.1074/jbc.M308496200; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Iizuka K, 2000, EUR J PHARMACOL, V406, P273, DOI 10.1016/S0014-2999(00)00504-5; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Komatsu S, 2002, AM J PHYSIOL-CELL PH, V283, pC752, DOI 10.1152/ajpcell.00501.2001; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; MacDonald JA, 2000, FEBS LETT, V479, P83, DOI 10.1016/S0014-5793(00)01884-6; MADONALD JA, 2001, P NATL ACAD SCI USA, V98, P2419; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; OMKUMAR RV, 1994, J BIOL CHEM, V269, P6810; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7; Walker LA, 2001, J BIOL CHEM, V276, P24519, DOI 10.1074/jbc.M103560200; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Woodrum DA, 2001, MOL CELL ENDOCRINOL, V177, P135, DOI 10.1016/S0303-7207(01)00407-5; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	37	165	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34496	34504		10.1074/jbc.M405957200	http://dx.doi.org/10.1074/jbc.M405957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194681	hybrid			2022-12-27	WOS:000223134800052
J	Park, SY; Avraham, HK; Avraham, S				Park, SY; Avraham, HK; Avraham, S			RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; CELL-ADHESION; PYK2; PHOSPHORYLATION; FAK; MEGAKARYOCYTES; BRAIN	The related adhesion focal tyrosine kinase ( RAFTK), also known as Pyk2, undergoes autophosphorylation upon its stimulation. This leads to cascades of intracellular signaling that result in the regulation of various cellular activities. However, the molecular mechanism of RAFTK autophosphorylation is not yet known. Using various RAFTK constructs fused with two different tags, we found that the autophosphorylation of RAFTK was mediated by a trans-acting mechanism, not a cis-acting mechanism. In addition, overexpression of kinase-mutated RAFTK inhibited wild type RAFTK autophosphorylation in a dose-dependent manner by a trans-acting interaction. Trans-acting autophosphorylation was also observed between endogenous and exogenous RAFTK upon potassium depolarization of neuroendocrine PC12 cells. Using immunoprecipitation and affinity chromatography, we detected RAFTK self-association that was not affected by deletion of a single region or domain of RAFTK. Furthermore, RAFTK autophosphorylation occurred only at site Tyr(402) in a Src kinase activity-independent manner. However, Src significantly enhanced RAFTK-mediated paxillin phosphorylation, suggesting a key role for Src in RAFTK activation and phosphorylation of downstream substrates. Our results indicate that the activation of RAFTK occurs in several steps. First, upon stimulus, RAFTK trans-autophosphorylates Tyr(402). Second, phosphorylated Tyr(402) recruits and activates Src kinase that in turn phosphorylates RAFTK and enhances its kinase activity. Lastly, the enhanced RAFTK activity induces the activation of downstream signaling molecules. Taken together, these studies provide insights into the molecular mechanism of RAFTK autophosphorylation and the specific role of Src in the regulation of RAFTK activation.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640; Park, Shin-Young/0000-0001-6385-4132	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039558] Funding Source: NIH RePORTER; NCI NIH HHS [CA97153] Funding Source: Medline; NIAMS NIH HHS [K18 PAR-02-069] Funding Source: Medline; NINDS NIH HHS [NS39558] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Bongiorno-Borbone L, 2002, J NEUROCHEM, V81, P1212, DOI 10.1046/j.1471-4159.2002.00906.x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Katagiri T, 2000, J BIOL CHEM, V275, P19645, DOI 10.1074/jbc.M909828199; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Melendez J, 2002, J BIOL CHEM, V277, P45203, DOI 10.1074/jbc.M204886200; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	22	97	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33315	33322		10.1074/jbc.M313527200	http://dx.doi.org/10.1074/jbc.M313527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166227	hybrid			2022-12-27	WOS:000223039700038
J	Segura-Pena, D; Sekulic, N; Ort, S; Konrad, M; Lavie, A				Segura-Pena, D; Sekulic, N; Ort, S; Konrad, M; Lavie, A			Substrate-induced conformational changes in human UMP/CMP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYMIDYLATE KINASE; DEOXYCYTIDINE ANALOG MONOPHOSPHATES; UMP-CMP KINASE; DICTYOSTELIUM-DISCOIDEUM; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; GUANYLATE KINASE; URIDYLATE KINASE; SPECIFICITY; MECHANISM	Human UMP/CMP kinase plays a crucial role in supplying precursors for nucleic acid synthesis by catalyzing the conversion of UMP, CMP, and dCMP into their diphosphate form. In addition, this kinase is an essential component of the activation cascade of medicinally relevant nucleoside analog prodrugs such as AraC, gemcitabine, and ddC. During the catalytic cycle the enzyme undergoes large conformational changes from open in the absence of substrates to closed in the presence of both phosphoryl donor and phosphoryl acceptor. Here we report the crystal structure of the substrate-free, open form of human UMP/CMP kinase. Comparison of the open structure with the closed state previously reported for the similar Dictyostelium discoideum UMP/CMP kinase reveals the conformational changes that occur upon substrate binding. We observe a classic example of induced fit where substrate-induced conformational changes in hinge residues result in rigid body movements of functional domains to form the catalytically competent state. In addition, a homology model of the human enzyme in the closed state based on the structure of D. discoideum UMP/CMP kinase aids to rationalize the substrate specificity of the human enzyme.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Max Planck Inst Biophys Chem, Dept Mol Genet, D-37077 Gottingen, Germany	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Max Planck Society	Lavie, A (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	lavie@uic.edu	Sekulic, Nikolina/F-8911-2013; Sekulic, Nikolina/N-5550-2016; Lavie, Arnon/H-4927-2012	Sekulic, Nikolina/0000-0001-7555-3222; Lavie, Arnon/0000-0001-5591-8722	NIAID NIH HHS [AI46943] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046943] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blaszczyk J, 2001, J MOL BIOL, V307, P247, DOI 10.1006/jmbi.2000.4427; Brundiers R, 1999, J BIOL CHEM, V274, P35289, DOI 10.1074/jbc.274.50.35289; DIAMOND R, 1992, PROTEIN SCI, V1, P1279, DOI 10.1002/pro.5560011006; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GERSTEIN M, 1991, J MOL BIOL, V220, P133, DOI 10.1016/0022-2836(91)90387-L; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hutter MC, 2000, PROTEIN SCI, V9, P2225, DOI 10.1110/ps.9.11.2225; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar S, 1999, CELL BIOCHEM BIOPHYS, V31, P141, DOI 10.1007/BF02738169; LABENZ J, 1982, ARCH VIROL, V71, P235, DOI 10.1007/BF01314875; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; LESK AM, 1984, J MOL BIOL, V174, P175, DOI 10.1016/0022-2836(84)90371-1; Liou JY, 2002, CANCER RES, V62, P1624; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; MULLERDIECKMANN HJ, 1994, J MOL BIOL, V236, P361, DOI 10.1006/jmbi.1994.1140; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ostermann N, 2003, BIOCHEMISTRY-US, V42, P2568, DOI 10.1021/bi027302t; Ostermann N, 2000, STRUCTURE, V8, P629, DOI 10.1016/S0969-2126(00)00149-0; Pasti C, 2003, EUR J BIOCHEM, V270, P1784, DOI 10.1046/j.1432-1033.2003.03537.x; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RHOADS DG, 1968, J BIOL CHEM, V243, P3963; Sabini E, 2003, NAT STRUCT BIOL, V10, P513, DOI 10.1038/nsb942; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sekulic N, 2002, J BIOL CHEM, V277, P30236, DOI 10.1074/jbc.M204668200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Van Rompay AR, 1999, MOL PHARMACOL, V56, P562, DOI 10.1124/mol.56.3.562; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; WIESMULLER L, 1995, FEBS LETT, V363, P22, DOI 10.1016/0014-5793(95)00271-A; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4	38	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33882	33889		10.1074/jbc.M401989200	http://dx.doi.org/10.1074/jbc.M401989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15163660	Green Published, hybrid			2022-12-27	WOS:000223039700098
J	Kao, MC; Di Bernardo, S; Perego, M; Nakamaru-Ogiso, E; Matsuno-Yagi, A; Yagi, T				Kao, MC; Di Bernardo, S; Perego, M; Nakamaru-Ogiso, E; Matsuno-Yagi, A; Yagi, T			Functional roles of four conserved charged residues in the membrane domain subunit NuoA of the proton-translocating NADH-quinone oxidoreductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-I; UBIQUINONE OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; RHODOBACTER-CAPSULATUS; MISSENSE MUTATION; RESPIRATORY-CHAIN; PROTEIN-STRUCTURE; READING FRAME; NDH-1; STOICHIOMETRY	The H+(Na+)-translocating NADH-quinone (Q) oxidoreductase (NDH-1) of Escherichia coli is composed of 13 different subunits (NuoA-N). Subunit NuoA (ND3, Nqo7) is one of the seven membrane domain subunits that are considered to be involved in H+(Na+) translocation. We demonstrated that in the Paracoccus denitrificans NDH-1 subunit, Nqo7 ( ND3) directly interacts with peripheral subunits Nqo6 (PSST) and Nqo4 ( 49 kDa) by using cross-linkers (Di Bernardo, S., and Yagi, T. (2001) FEBS Lett. 508, 385-388 and Kao, M.-C., Matsuno-Yagi, A., and Yagi, T. ( 2004) Biochemistry 43, 3750-3755). To investigate the structural and functional roles of conserved charged amino acid residues, a nuoA knock-out mutant and site-specific mutants K46A, E51A, D79N, D79A, E81Q, E81A, and D79N/E81Q were constructed by utilizing chromosomal DNA manipulation. In terms of immunochemical and NADH dehydrogenase activity-staining analyses, all site-specific mutants are similar to the wild type, suggesting that those NuoA site-specific mutations do not significantly affect the assembly of peripheral subunits in situ. In addition, site-specific mutants showed similar deamino-NADH-K3Fe(CN)(6) reductase activity to the wild type. The K46A mutation scarcely inhibited deamino-NADH-Q reductase activity. In contrast, E51A, D79A, D79N, E81A, and E81Q mutation partially suppressed deamino-NADH-Q reductase activity to 30, 90, 40, 40, and 50%, respectively. The double mutant D79N/E81Q almost completely lost the energy-transducing NDH-1 activities but did not display any loss of deamino-NADH-K3Fe(CN)(6) reductase activity. The possible functional roles of residues Asp-79 and Glu-81 were discussed.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Matsuno-Yagi, A (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	yagi@scripps.edu; yagi2@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055594, R01GM033712] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM33712, R01GM55594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amarneh B, 2003, BIOCHEMISTRY-US, V42, P4800, DOI 10.1021/bi0340346; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; Carelli V, 1999, ANN NEUROL, V45, P320, DOI 10.1002/1531-8249(199903)45:3<320::AID-ANA7>3.0.CO;2-L; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Chevallet M, 1997, EUR J BIOCHEM, V250, P451, DOI 10.1111/j.1432-1033.1997.0451a.x; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; Clapham DE, 1998, NAT STRUCT BIOL, V5, P342, DOI 10.1038/nsb0598-342; Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Di Bernardo S, 2000, BIOCHEMISTRY-US, V39, P9411; Di Bernardo S, 2001, FEBS LETT, V508, P385, DOI 10.1016/S0014-5793(01)03111-8; Falk-Krzesinski HJ, 1998, J BACTERIOL, V180, P1174, DOI 10.1128/JB.180.5.1174-1184.1998; Fillingame RH, 1999, SCIENCE, V286, P1687, DOI 10.1126/science.286.5445.1687; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Flemming D, 2003, J BIOL CHEM, V278, P3055, DOI 10.1074/jbc.M208849200; Friedrich T, 1998, BBA-BIOENERGETICS, V1365, P215, DOI 10.1016/S0005-2728(98)00070-X; Galkin AS, 1999, FEBS LETT, V451, P157, DOI 10.1016/S0014-5793(99)00575-X; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; HASSINEN IE, 1993, BIOCHIM BIOPHYS ACTA, V1144, P107, DOI 10.1016/0005-2728(93)90164-B; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kao MC, 2004, BIOCHEMISTRY-US, V43, P3750, DOI 10.1021/bi049927s; Kao MC, 2003, BIOCHEMISTRY-US, V42, P4534, DOI 10.1021/bi034166z; Kao MC, 2002, BIOCHEMISTRY-US, V41, P4377, DOI 10.1021/bi025525d; Kervinen M, 2004, BIOCHEMISTRY-US, V43, P773, DOI 10.1021/bi0355903; Kurki S, 2000, BIOCHEMISTRY-US, V39, P13496, DOI 10.1021/bi001134s; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Lunardi J, 1998, BBA-MOL BASIS DIS, V1407, P114, DOI 10.1016/S0925-4439(98)00036-2; Majander A, 1996, EUR J BIOCHEM, V239, P201, DOI 10.1111/j.1432-1033.1996.0201u.x; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787; MURPHY E, 1985, EMBO J, V4, P3357, DOI 10.1002/j.1460-2075.1985.tb04089.x; Nakamaru-Ogiso E, 2003, FEBS LETT, V549, P43, DOI 10.1016/S0014-5793(03)00766-X; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; Satoh T, 1996, BBA-BIOENERGETICS, V1273, P21, DOI 10.1016/0005-2728(95)00131-X; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Sorgen PL, 2002, P NATL ACAD SCI USA, V99, P14037, DOI 10.1073/pnas.182552199; Steuber J, 2003, J BIOL CHEM, V278, P26817, DOI 10.1074/jbc.M301682200; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084; Wackwitz B, 1999, MOL GEN GENET, V262, P876, DOI 10.1007/s004380051153; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; YAGI T, 1987, BIOCHEMISTRY-US, V26, P2822, DOI 10.1021/bi00384a025; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; YAGI T, 2004, RESP ARCHAEA BACTERI, P15; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; Yano T, 1999, J BIOL CHEM, V274, P28606, DOI 10.1074/jbc.274.40.28606; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; ZHANG Y, 1994, J BIOL CHEM, V269, P5473	55	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32360	32366		10.1074/jbc.M403885200	http://dx.doi.org/10.1074/jbc.M403885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175326	hybrid			2022-12-27	WOS:000222849700048
J	Lanciault, C; Champoux, JJ				Lanciault, C; Champoux, JJ			Single unpaired nucleotides facilitate HIV-1 reverse transcriptase displacement synthesis through duplex RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; IN-VITRO ANALYSIS; DNA-SYNTHESIS; NUCLEOCAPSID PROTEIN; SECONDARY STRUCTURE; STRAND TRANSFER; POLYPURINE TRACT; AVIAN RETROVIRUS; TYPE-1	During reverse transcription of viral RNA, HIV-1 reverse transcriptase (RT) encounters RNA stem-loop structures that require displacement synthesis activity in which RT disrupts the RNA helix to access the template strand. A primer extension assay was developed to assess HIV-1 RT RNA displacement synthesis activity in vitro. Initial results revealed that HIV-1 RT performs only limited amounts of RNA displacement through long stretches of RNA duplex, with the majority of synthesis stalling at sequence-dependent pause positions. DNA displacement synthesis through the same sequence, however, proceeded rapidly to the end of the template. The RNA folding algorithm mfold indicated that the presence of an unpaired nucleotide, or "bulge," along the RNA duplex would promote helix melting ahead of the DNA primer terminus to create a small gap of nondisplacement synthesis. Primer extension assays using substrates possessing single-nucleotide bulges in the nontemplate strand near pause sites resulted in diminished pausing at positions within the predicted melted region. Surprisingly, the bulges also reduced pausing distal to the bulge at positions that are expected to remain base-paired. Further analysis revealed that stalling during RNA displacement synthesis results from the displaced RNA re-annealing to the template strand thus forcing the primer terminus to become unpaired and, therefore, not extendable. Introduction of a bulge facilitates displacement synthesis through distal regions by increasing RT processivity in the vicinity of a bulge and reducing the impact of branch migration on primer extension.	Univ Washington, Dept Microbiol, Sch Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Dept Microbiol, Sch Med, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA051605, R37CA051605] Funding Source: NIH RePORTER; NCI NIH HHS [CA51605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMACKER M, 1995, J VIROL, V69, P6273, DOI 10.1128/JVI.69.10.6273-6279.1995; Amacker M, 1997, AIDS, V11, P534; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; Bibillo A, 2002, J BIOL CHEM, V277, P34836, DOI 10.1074/jbc.M204345200; BOONE LR, 1981, J VIROL, V37, P117, DOI 10.1128/JVI.37.1.117-126.1981; BUISER RG, 1993, BIOCHIM BIOPHYS ACTA, V1216, P20, DOI 10.1016/0167-4781(93)90033-A; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; COFFIN JM, 1997, RETROVIRUSES, P121; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; Fisher TS, 2003, J MOL BIOL, V325, P443, DOI 10.1016/S0022-2836(02)01225-1; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; Fuentes GM, 1996, J BIOL CHEM, V271, P29605, DOI 10.1074/jbc.271.47.29605; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; Hameau L, 2001, J VIROL, V75, P3301, DOI 10.1128/JVI.75.7.3301-3313.2001; HILLEBRAND GG, 1985, J BIOL CHEM, V260, P3116; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HUBER HE, 1989, J BIOL CHEM, V264, P4669; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; KUNG HJ, 1981, J VIROL, V37, P127, DOI 10.1128/JVI.37.1.127-138.1981; LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013; MCDONALD WF, 1994, J BIOL CHEM, V269, P31190; MOK M, 1987, J BIOL CHEM, V262, P2304; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; Pop MP, 1996, BIOCHEMISTRY-US, V35, P5054, DOI 10.1021/bi9530292; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; Tasara T, 1999, BIOCHEMISTRY-US, V38, P1633, DOI 10.1021/bi9821162; TAYLOR JM, 1983, J VIROL, V48, P654, DOI 10.1128/JVI.48.3.654-659.1983; TURCHI JJ, 1992, BIOCHEMISTRY-US, V31, P9008, DOI 10.1021/bi00152a043; Whiting SH, 1998, J MOL BIOL, V278, P559, DOI 10.1006/jmbi.1998.1720; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; Xiong Y, 2000, RNA, V6, P1316, DOI 10.1017/S135583820000090X; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	44	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32252	32261		10.1074/jbc.M404117200	http://dx.doi.org/10.1074/jbc.M404117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169769	hybrid			2022-12-27	WOS:000222849700033
J	Li, J; Wynn, RM; Machius, M; Chuang, JL; Karthikeyan, S; Tomchick, DR; Chuang, DT				Li, J; Wynn, RM; Machius, M; Chuang, JL; Karthikeyan, S; Tomchick, DR; Chuang, DT			Cross-talk between thiamin diphosphate binding and phosphorylation loop conformation in human branched-chain alpha-keto acid decarboxylase/dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRUCTURAL BASIS; ACTIVE-SITE; KINASE; RAT; RECONSTITUTION; EXPRESSION	The decarboxylase/dehydrogenase (E1b) component of the 4-megadalton human branched-chain alpha-keto acid dehydrogenase (BCKD) metabolic machine is a thiamin diphosphate (ThDP)-dependent enzyme with a heterotetrameric cofactor-binding fold. The E1b component catalyzes the decarboxylation of alpha-keto acids and the subsequent reductive acylation of the lipoic acid-bearing domain (LBD) from the 24-meric transacylase (E2b) core. In the present study, we show that the binding of cofactor ThDP to the E1b active site induces a disorder-to-order transition of the conserved phosphorylation loop carrying the two phosphorylation sites Ser(292)-alpha and Ser(302)-alpha, as deduced from the 1.80-1.85 Angstrom apoE1b and holoE1b structures. The induced loop conformation is essential for the recognition of lipoylated LBD to initiate E1b-catalyzed reductive acylation. Alterations of invariant Arg(287)-alpha, Asp(295)-alpha, Tyr(300)-alpha, and Arg(301)-alpha that form a hydrogen-bonding network in the phosphorylation loop result in the disordering of the loop conformation as elucidated by limited proteolysis, accompanied by the impaired binding and diminished reductive acylation of lipoylated LBD. In contrast, k(cat) values for E1b-catalyzed decarboxylation of the alpha-keto acid are higher in these E1b mutants than in wild-type E1b, with higher K-m values for the substrate in the mutants. ThDP binding that orders the loop prevents phosphorylation of E1b by the BCKD kinase and averts the inactivation of wild-type E1b, but not the above mutants, by this covalent modification. Our results establish that the cross-talk between the bound ThDP and the phosphorylation loop conformation serves as a feed-forward switch for multiple reaction steps in the BCKD metabolic machine.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.chuang@utsouthwestern.edu	Tomchick, Diana/HGV-2018-2022; Karthikeyan, Subramanian/F-8808-2010	Wynn, Richard/0000-0002-1879-2136; Tomchick, Diana/0000-0002-7529-4643	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062306, R56DK062306, R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26758, DK-62306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BETTENDORFF L, 1994, BBA-MOL CELL RES, V1222, P1, DOI 10.1016/0167-4889(94)90018-3; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; CHUANG DT, 2001, ENCY MOL MED, V5, P393; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Chuang JL, 2002, J BIOL CHEM, V277, P36905, DOI 10.1074/jbc.C200430200; Chuang JL, 2004, J BIOL CHEM, V279, P17792, DOI 10.1074/jbc.M313879200; Ciszak EM, 2003, J BIOL CHEM, V278, P21240, DOI 10.1074/jbc.M300339200; COOK KG, 1985, BIOCHEM J, V225, P731, DOI 10.1042/bj2250731; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fries M, 2003, EUR J BIOCHEM, V270, P861, DOI 10.1046/j.1432-1033.2003.03444.x; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; Hawes JW, 1995, J BIOL CHEM, V270, P31071, DOI 10.1074/jbc.270.52.31071; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HENNIG J, 1966, BIOCH PHYSL THIAMIN, P243; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Karthikeyan S, 2003, BIOCHEMISTRY-US, V42, P12532, DOI 10.1021/bi035450t; LAKOWICZ JR, 1983, BIOCHEMISTRY-US, V22, P1741, DOI 10.1021/bi00277a001; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; MULLINAX TR, 1985, ARCH BIOCHEM BIOPHYS, V243, P655, DOI 10.1016/0003-9861(85)90543-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAXTON R, 1982, J BIOL CHEM, V257, P4433; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SCHELLENBERGER V, 1991, EUR J BIOCHEM, V199, P623, DOI 10.1111/j.1432-1033.1991.tb16163.x; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; Song QL, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-8; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; Wynn RM, 2000, METHOD ENZYMOL, V324, P179; Wynn RM, 2003, J BIOL CHEM, V278, P43402, DOI 10.1074/jbc.M306204200	39	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32968	32978		10.1074/jbc.M403611200	http://dx.doi.org/10.1074/jbc.M403611200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166214	hybrid			2022-12-27	WOS:000222849700117
J	Li, WQ; Guan, KL				Li, WQ; Guan, KL			The Down syndrome cell adhesion molecule (DSCAM) interacts with and activates Pak	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA DSCAM; AXON GUIDANCE; KINASE; GTPASES; AUTOPHOSPHORYLATION; PHOSPHORYLATION; EXPRESSION; INHIBITOR; MECHANISM; RECEPTORS	The Down syndrome cell adhesion molecule (DSCAM) is a member of the immunoglobulin superfamily that maps to a Down syndrome region of chromosome 21q22.2-22.3. In Drosophila, Dscam functions as an axon guidance receptor regulating targeting and branching. Genetic and biochemical studies have shown that in Drosophila, Dscam activates Pak1 via the Dock adaptor molecule. The extracellular domain of human DSCAM is highly homologous to the Drosophila protein; however, the intracellular domains of both human and Drosophila DSCAM share no obvious sequence identity. To study the signaling mechanisms of human DSCAM, we investigated the interaction between DSCAM and potential downstream molecules. We found that DSCAM directly binds to Pak1 and stimulates Pak1 phosphorylation and activity, unlike Drosophila where an adaptor protein Dock mediates the interaction between Dscam and Pak1. We also observed that DSCAM activates both JNK and p38 MAP kinases. Furthermore, expression of the cytoplasmic domain of DSCAM induces a morphological change in cultured cells that is JNK-dependent. These observations suggest that human DSCAM also signals through Pak1 and may function in axon guidance similar to the Drosophila Dscam.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	Li, Weiquan/B-4897-2011					Agarwala KL, 2001, BIOCHEM BIOPH RES CO, V281, P697, DOI 10.1006/bbrc.2001.4420; Agarwala KL, 2001, J NEUROSCI RES, V66, P337, DOI 10.1002/jnr.1226; Ang LH, 2003, DEVELOPMENT, V130, P1307, DOI 10.1242/dev.00356; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Barlow GM, 2002, BIOCHEM BIOPH RES CO, V299, P1, DOI 10.1016/S0006-291X(02)02548-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Celotto AM, 2001, GENETICS, V159, P599; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; EPSTEIN CJ, 1986, EXPERIENTIA, V42, P1117, DOI 10.1007/BF01941286; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Hummel T, 2003, NEURON, V37, P221, DOI 10.1016/S0896-6273(02)01183-2; Kalil K, 2000, J NEUROBIOL, V44, P145, DOI 10.1002/1097-4695(200008)44:2<145::AID-NEU5>3.0.CO;2-X; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; KORENBERG JR, 1992, AM J HUM GENET, V50, P294; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; NEVES G, 2004, NAT GENET; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, TRENDS CELL BIOL, V9, P355, DOI 10.1016/S0962-8924(99)01642-6; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Wang J, 2002, NEURON, V33, P559, DOI 10.1016/S0896-6273(02)00570-6; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Worby CA, 2001, J BIOL CHEM, V276, P41782, DOI 10.1074/jbc.M107080200; Xu Z, 2003, J BIOL CHEM, V278, P24767, DOI 10.1074/jbc.M302454200; Yamakawa K, 1998, HUM MOL GENET, V7, P227, DOI 10.1093/hmg/7.2.227; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895	34	39	44	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32824	32831		10.1074/jbc.M401878200	http://dx.doi.org/10.1074/jbc.M401878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169762	hybrid			2022-12-27	WOS:000222849700102
J	Merkel, AB; Major, LL; Errey, JC; Burkart, MD; Field, RA; Walsh, CT; Naismith, JN				Merkel, AB; Major, LL; Errey, JC; Burkart, MD; Field, RA; Walsh, CT; Naismith, JN			The position of a key tyrosine in dTDP-4-Keto-6-deoxy-D-glucose-5-epimerase (EvaD) alters the substrate profile for this RmlC-like enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPEPTIDE ANTIBIOTICS; VANCOMYCIN-GROUP; STAPHYLOCOCCUS-AUREUS; BIOSYNTHETIC PATHWAYS; L-EPIVANCOSAMINE; MODE; DTDP; DIMERIZATION; 3,5-EPIMERASE; RESISTANCE	Vancomycin, the last line of defense antibiotic, depends upon the attachment of the carbohydrate vancosamine to an aglycone skeleton for antibacterial activity. Vancomycin is a naturally occurring secondary metabolite that can be produced by bacterial fermentation. To combat emerging resistance, it has been proposed to genetically engineer bacteria to produce analogues of vancomycin. This requires a detailed understanding of the biochemical steps in the synthesis of vancomycin. Here we report the 1.4 Angstrom structure and biochemical characterization of EvaD, an RmlC-like protein that is required for the C-5' epimerization during synthesis of dTDP-epivancosamine. EvaD, although clearly belonging to the RmlC class of enzymes, displays very low activity in the archetypal RmlC reaction ( double epimerization of dTDP-6-deoxy-4-keto-D-glucose at C-3' and C-5'). The high resolution structure of EvaD compared with the structures of authentic RmlC enzymes indicates that a subtle change in the enzyme active site repositions a key catalytic Tyr residue. A mutant designed to re-establish the normal position of the Tyr increases the RmlC-like activity of EvaD.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ E Anglia, Sch Chem Sci & Pharm, Ctr Carbohydrate Chem, Norwich NR4 7TJ, Norfolk, England; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of St Andrews; University of East Anglia; Harvard University; Harvard Medical School	Naismith, JN (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	naismith@st-and.ac.uk	Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Major, Louise/0000-0001-5287-4488; Field, Rob/0000-0001-8574-0275	Biotechnology and Biological Sciences Research Council [BBS/E/J/000C0618] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Albermann C, 2003, ORG LETT, V5, P933, DOI 10.1021/ol0341086; Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011; Blankenfeldt W, 2002, STRUCTURE, V10, P773, DOI 10.1016/S0969-2126(02)00770-0; Chen HW, 2000, P NATL ACAD SCI USA, V97, P11942, DOI 10.1073/pnas.210395097; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; Dong CJ, 2003, STRUCTURE, V11, P715, DOI 10.1016/S0969-2126(03)00098-4; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; FOLDES M, 1983, J ANTIMICROB CHEMOTH, V11, P21, DOI 10.1093/jac/11.1.21; Gaisser S, 2002, CHEM COMMUN, P618, DOI 10.1039/b200536k; Ge M, 1999, SCIENCE, V284, P507, DOI 10.1126/science.284.5413.507; Giraud MF, 2000, NAT STRUCT BIOL, V7, P398; Graninger M, 1999, J BIOL CHEM, V274, P25069, DOI 10.1074/jbc.274.35.25069; Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; Hubbard BK, 2003, ANGEW CHEM INT EDIT, V42, P730, DOI 10.1002/anie.200390202; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirkpatrick PN, 2000, CHEM COMMUN, P1565, DOI 10.1039/b004463f; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P548; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie AGW, 1992, CRYSTALLOGRAPHY, V26, P1; MACKAY JP, 1994, J AM CHEM SOC, V116, P4573, DOI 10.1021/ja00090a005; MACKAY JP, 1994, J AM CHEM SOC, V116, P4581, DOI 10.1021/ja00090a006; McAtee JJ, 2002, BIOORG MED CHEM LETT, V12, P1319, DOI 10.1016/S0960-894X(02)00130-0; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Merkel AB, 2002, ACTA CRYSTALLOGR D, V58, P1226, DOI 10.1107/S0907444902007382; Meyers CLF, 2003, BIOCHEMISTRY-US, V42, P4179, DOI 10.1021/bi0340088; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicolaou KC, 1999, ANGEW CHEM INT EDIT, V38, P240, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<240::AID-ANIE240>3.0.CO;2-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pootoolal J, 2002, ANNU REV PHARMACOL, V42, P381, DOI 10.1146/annurev.pharmtox.42.091601.142813; Rodriguez L, 2002, CHEM BIOL, V9, P721, DOI 10.1016/S1074-5521(02)00154-0; Sharman GJ, 1997, CHEM COMMUN, P723, DOI 10.1039/a608477j; Trefzer A, 2002, J AM CHEM SOC, V124, P6056, DOI 10.1021/ja017385l; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WATANAKUNAKORN C, 1984, J ANTIMICROB CHEMOTH, V14, P7, DOI 10.1093/jac/14.suppl_D.7	39	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32684	32691		10.1074/jbc.M404091200	http://dx.doi.org/10.1074/jbc.M404091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159413	hybrid			2022-12-27	WOS:000222849700087
J	Hu, TH; Exton, JH				Hu, TH; Exton, JH			Protein kinase C alpha translocates to the perinuclear region to activate phospholipase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLASMA-MEMBRANE; SELECTIVE INHIBITORS; RAT-BRAIN; IN-VIVO; PHOSPHORYLATION; LOCALIZATION; CELLS; ASSOCIATION; CLONING	The inhibition of phorbol ester activation of phospholipase D1 (PLD1) by protein kinase C (PKC) inhibitors has been considered proof of phosphorylation-dependent activation of PLD1 by PKCalpha. We studied the effect of the PKC inhibitors Ro-31-8220 and bisindolylmaleimide I on PLD1 activation and found that they inhibited the activation by interfering with PKCalpha binding to PLD1. Further studies showed that only unphosphorylated PKCalpha could bind to and activate PLD1 and that both inhibitors induced phosphorylation of PKCalpha. The phosphorylation status of either PLD1 or PKCalpha per se did not affect PLD1 activation in vitro. Immunofluorescence studies showed that PLD1 remained in the perinuclear region after phorbol ester treatment, whereas PKCalpha translocated from cytosol to both plasma membrane and perinuclear regions. Both Ro-31-8220 and bisindolylmaleimide I blocked the translocation of PKCalpha to the perinuclear region but not to the plasma membrane. Studies with okadaic acid suggested that phosphorylation regulated the relocation of PKCalpha from the plasma membrane to the perinuclear region. It is proposed that localization and interaction of PKCalpha with PLD1 in the perinuclear region is required for PLD1 activation and that PKC inhibitors inhibit this through phosphorylation of PKCalpha, which blocks its translocation.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Rm 831 Light Hall, Nashville, TN 37232 USA.	john.exton@vanderbilt.edu	Hu, T/G-3381-2010					Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Buchner K, 1997, FEBS LETT, V406, P61, DOI 10.1016/S0014-5793(97)00226-3; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Gatti A, 1996, J BIOL CHEM, V271, P31718, DOI 10.1074/jbc.271.49.31718; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Hu TH, 2003, J BIOL CHEM, V278, P2348, DOI 10.1074/jbc.M210093200; Hughes WE, 2001, BIOCHEM J, V356, P727, DOI 10.1042/0264-6021:3560727; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Sciorra VA, 2001, BIOCHEMISTRY-US, V40, P2640, DOI 10.1021/bi002528m; Singer WD, 1996, J BIOL CHEM, V271, P4504; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; Xie Z, 2000, J BIOL CHEM, V275, P24962, DOI 10.1074/jbc.M909745199; Xu LZ, 2000, BIOCHEM BIOPH RES CO, V273, P77, DOI 10.1006/bbrc.2000.2907; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	44	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35702	35708		10.1074/jbc.M402372200	http://dx.doi.org/10.1074/jbc.M402372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15187091	hybrid			2022-12-27	WOS:000223303400068
J	Kadyrov, FA; Drake, JW				Kadyrov, FA; Drake, JW			UvsX recombinase and Dda helicase rescue stalled bacteriophage T4 DNA replication forks in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRRADIATED ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; DEPENDENT ATPASE; STRAND EXCHANGE; REPAIR; PROTEIN; PURIFICATION; DAMAGE; CELLS	The rescue of stalled replication forks via a series of steps that include fork regression, template switching, and fork restoration often has been proposed as a major mechanism for accurately bypassing non-coding DNA lesions. Bacteriophage T4 encodes almost all of the proteins required for its own DNA replication, recombination, and repair. Both recombination and recombination repair in T4 rely on UvsX, a RecA-like recombinase. We show here that UvsX plus the T4-encoded helicase Dda suffice to rescue stalled T4 replication forks in vitro. This rescue is based on two sequential template-switching reactions that allow DNA replication to bypass a non-coding DNA lesion in a non-mutagenic manner.	NIEHS, Lab Mol Genet E3 01, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Drake, JW (corresponding author), NIEHS, Lab Mol Genet E3 01, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	drake@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES061055, Z01ES061055] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARRY J, 1994, J BIOL CHEM, V269, P33049; BEHME MT, 1975, J VIROL, V15, P50, DOI 10.1128/JVI.15.1.50-54.1975; BERNSTEIN H, 1989, J BACTERIOL, V171, P2265, DOI 10.1128/jb.171.5.2265-2270.1989; Bierne H, 1997, MOL MICROBIOL, V26, P557, DOI 10.1046/j.1365-2958.1997.6011973.x; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; BROOMFIELD S, 2001, MUTAT RES, V486, P176; CarlesKinch K, 1997, EMBO J, V16, P4142, DOI 10.1093/emboj/16.13.4142; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; DEBRECENI N, 1970, BIOCHEM BIOPH RES CO, V41, P115, DOI 10.1016/0006-291X(70)90476-6; DEFAIS M, 1989, J BACTERIOL, V171, P4938, DOI 10.1128/jb.171.9.4938-4944.1989; DRAKE JW, 1988, MOL GEN GENET, V214, P547, DOI 10.1007/BF00330493; Dudas KC, 2001, MOL CELL BIOL, V21, P2706, DOI 10.1128/MCB.21.8.2706-2715.2001; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GANESAN AK, 1974, J MOL BIOL, V87, P103, DOI 10.1016/0022-2836(74)90563-4; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HINTON DM, 1985, J BIOL CHEM, V260, P2851; Jaktaji RP, 2003, MOL MICROBIOL, V47, P1091, DOI 10.1046/j.1365-2958.2003.03357.x; JIANG H, 1993, J BIOL CHEM, V268, P7904; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; Kadyrov FA, 2003, J BIOL CHEM, V278, P25247, DOI 10.1074/jbc.M302564200; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; Li ZQ, 2002, P NATL ACAD SCI USA, V99, P4459, DOI 10.1073/pnas.062047799; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; RANEY KD, 1995, J BIOL CHEM, V270, P22236, DOI 10.1074/jbc.270.38.22236; RESNICK MA, 1983, GENETICS, V104, P583; RESNICK MA, 1981, J BACTERIOL, V146, P285, DOI 10.1128/JB.146.1.285-290.1981; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; Sickmier EA, 2004, STRUCTURE, V12, P583, DOI 10.1016/j.str.2004.02.016; SMITH KC, 1970, J MOL BIOL, V51, P459, DOI 10.1016/0022-2836(70)90001-X; WACHSMAN JT, 1987, GENETICS, V115, P405; WEIGLE JJ, 1953, P NATL ACAD SCI USA, V39, P628, DOI 10.1073/pnas.39.7.628; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	49	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35735	35740		10.1074/jbc.M403942200	http://dx.doi.org/10.1074/jbc.M403942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194689	hybrid			2022-12-27	WOS:000223303400072
J	Travagli, J; Letourneur, M; Bertoglio, J; Pierre, J				Travagli, J; Letourneur, M; Bertoglio, J; Pierre, J			STAT6 and Ets-1 form a stable complex that modulates Socs-1 expression by interleukin-4 in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE SIGNALING SOCS; DNA-BINDING SPECIFICITY; NF-KAPPA-B; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTIONAL ACTIVATION; TRANSLATIONAL REPRESSION; SYNERGISTIC ACTIVATION; PROTEIN INTERACTIONS; NEGATIVE REGULATOR	Supressor of cytokine signaling (SOCS)-1 is selectively and rapidly induced by appropriate agonists and modulates cytokine responses by interfering with the Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway. On the basis of the observation that interleukin (IL)-4 up-regulates Socs-1 in the keratinocyte HaCaT cell line, we investigated which sequences of the 5'-Socs-1 gene are responsive to IL-4. We therefore have cloned the 5'-flanking region of this gene, and by promoter analysis we identified a functional IL-4-responsive element located at nucleotide (-684/-570) upstream from the transcription initiation site, whose presence and integrity are necessary to ensure IL-4 responsiveness. This element contains three STAT6 and one Ets consensus binding sequences of which specific mutations abolished IL-4 responsiveness either partially or totally. We also report that Ets-1 physically interacted with STAT6. Exogenous expression of Ets-1 in conjunction with STAT6 activation strongly inhibited expression of a Socs-1 promoter-luciferase reporter. Collectively, our data demonstrated the involvement of STAT6 and Ets, via a composite DNA element, in the IL-4 regulation of Socs-1 gene expression in keratinocytes.	Fac Pharm Chatenay Malabry, INSERM, U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pierre, J (corresponding author), Fac Pharm Chatenay Malabry, INSERM, U461, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	josiane.pierre@cep.u-psud.fr						Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bennett BL, 1997, J BIOL CHEM, V272, P10212; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Daniel C, 2000, J BIOL CHEM, V275, P14255, DOI 10.1074/jbc.C000129200; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Federici M, 2002, J IMMUNOL, V169, P434, DOI 10.4049/jimmunol.169.1.434; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Goenka S, 2003, J BIOL CHEM, V278, P50362, DOI 10.1074/jbc.M305854200; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; Hebenstreit D, 2003, J IMMUNOL, V171, P5901, DOI 10.4049/jimmunol.171.11.5901; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jegalian AG, 2002, J BIOL CHEM, V277, P2345, DOI 10.1074/jbc.M105575200; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Litterst CM, 2002, J BIOL CHEM, V277, P36052, DOI 10.1074/jbc.M203556200; Losman JA, 1999, J IMMUNOL, V162, P3770; Lu J, 2004, MOL CELL BIOL, V24, P428, DOI 10.1128/MCB.24.1.428-441.2004; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Pesu M, 2003, EUR J IMMUNOL, V33, P1727, DOI 10.1002/eji.200323680; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Woelfle J, 2004, AM J PHYSIOL-ENDOC M, V286, pE393, DOI 10.1152/ajpendo.00389.2003; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	52	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35183	35192		10.1074/jbc.M403223200	http://dx.doi.org/10.1074/jbc.M403223200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199062	hybrid			2022-12-27	WOS:000223303400008
J	Weisshart, K; Pestryakov, P; Smith, RWP; Hartmann, H; Kremmer, E; Lavrik, O; Nasheuer, HP				Weisshart, K; Pestryakov, P; Smith, RWP; Hartmann, H; Kremmer, E; Lavrik, O; Nasheuer, HP			Coordinated regulation of replication protein A activities by its subunits p14 and p32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED-DNA-BINDING; POLYMERASE-ALPHA-PRIMASE; SV40 T-ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC CELLS; S-PHASE; RP-A	The heterotrimeric replication protein A (RPA) has multiple essential activities in eukaryotic DNA metabolism and in signaling pathways. Despite extensive analyses, the functions of the smallest RPA subunit p14 are still unknown. To solve this issue we produced and characterized a dimeric RPA complex lacking p14, RPADeltap14, consisting of p70 and p32. RPADeltap14 was able to bind single-stranded DNA, but its binding mode and affinity differed from those of the heterotrimeric complex. Moreover, in the RPADeltap14 complex p32 only minimally recognized the 3'-end of a primer in a primer-template junction. Partial proteolytic digests revealed that p14 and p32 together stabilize the C terminus of p70 against degradation. Although RPADeltap14 efficiently supported bidirectional unwinding of double-stranded DNA and interacted with both the simian virus 40 (SV40) large T antigen and cellular DNA polymerase alpha-primase, it did not support cell-free SV40 DNA replication. This inability manifested itself in a failure to support both the primer synthesis and primer elongation reactions. These data reveal that efficient binding and correct positioning of the RPA complex on single-stranded DNA requires all three subunits to support DNA replication.	Natl Univ Ireland Univ Coll Galway, Dept Biochem, Cell Cycle Control Lab, Galway, Ireland; Inst Mol Biotechnol, D-07745 Jena, Germany; Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Div, Novosibirsk 630090, Russia; GSF, Inst Immunol, D-81377 Munich, Germany	Ollscoil na Gaillimhe-University of Galway; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Nasheuer, HP (corresponding author), Natl Univ Ireland Univ Coll Galway, Dept Biochem, Cell Cycle Control Lab, Univ Rd, Galway, Ireland.	h.nasheuer@nuigalway.ie	Pestryakov, Pavel/AAH-2022-2020; Lavrik, Olga I/G-4641-2013; Nasheuer, Heinz P./B-9025-2008; Smith, Richard/J-8117-2019	Pestryakov, Pavel/0000-0003-3277-5321; Smith, Richard/0000-0002-6475-6910; Nasheuer, Heinz Peter/0000-0002-9218-9079; Hartmann, Hella/0000-0002-7133-7474				Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Daboussi F, 2002, CELL SIGNAL, V14, P969, DOI 10.1016/S0898-6568(02)00052-9; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Kautz AR, 2001, J VIROL, V75, P1751, DOI 10.1128/JVI.75.4.1751-1760.2001; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kneissl M, 2003, J MOL BIOL, V327, P111, DOI 10.1016/S0022-2836(03)00079-2; Kolpashchikov DM, 2001, NUCLEIC ACIDS RES, V29, P373, DOI 10.1093/nar/29.2.373; Kolpashchikov DM, 1999, FEBS LETT, V450, P131, DOI 10.1016/S0014-5793(99)00484-6; Lavrik OI, 1998, FEBS LETT, V441, P186, DOI 10.1016/S0014-5793(98)01544-0; Lavrik OI, 1998, NUCLEIC ACIDS RES, V26, P602, DOI 10.1093/nar/26.2.602; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Mass G, 1998, MOL CELL BIOL, V18, P6399, DOI 10.1128/MCB.18.11.6399; Mass G, 2001, NUCLEIC ACIDS RES, V29, P3892, DOI 10.1093/nar/29.18.3892; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; Nasheuer HP, 2002, PROG NUCLEIC ACID RE, V72, P41, DOI 10.1016/S0079-6603(02)72067-9; Nuss JE, 2004, PROTEIN SCI, V13, P1365, DOI 10.1110/ps.04616304; Pestryakov PE, 2004, NUCLEIC ACIDS RES, V32, P1894, DOI 10.1093/nar/gkh346; Pestryakov PE, 2003, J BIOL CHEM, V278, P17515, DOI 10.1074/jbc.M301265200; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOCANALE C, 1995, J MOL BIOL, V254, P595, DOI 10.1006/jmbi.1995.0641; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; STRAUSFELD U, 1989, PREP BIOCHEM, V19, P37, DOI 10.1080/10826068908544895; Taneja P, 2002, J BIOL CHEM, V277, P40853, DOI 10.1074/jbc.M208067200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; WAGA S, 1994, J BIOL CHEM, V269, P10923; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wang M, 2000, NUCLEIC ACIDS RES, V28, P4742, DOI 10.1093/nar/28.23.4742; Weisshart K, 1998, J VIROL, V72, P9771, DOI 10.1128/JVI.72.12.9771-9781.1998; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	59	20	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35368	35376		10.1074/jbc.M403825200	http://dx.doi.org/10.1074/jbc.M403825200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205463	hybrid			2022-12-27	WOS:000223303400030
J	Rothnie, A; Storm, J; Campbell, J; Linton, KJ; Kerr, ID; Callaghan, R				Rothnie, A; Storm, J; Campbell, J; Linton, KJ; Kerr, ID; Callaghan, R			The topography of transmembrane segment six is altered during the catalytic cycle of P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-BINDING SITE; CYSTEINE-SCANNING MUTAGENESIS; TERTIARY STRUCTURE CHANGES; CROSS-LINKING ANALYSIS; MULTIDRUG-RESISTANCE; NUCLEOTIDE-BINDING; CONFORMATIONAL-CHANGES; SUBSTRATE-SPECIFICITY; ATPASE ACTIVITY; TRANSPORT	Structural evidence has demonstrated that P-glycoprotein (P-gp) undergoes considerable conformational changes during catalysis, and these alterations are important in drug interaction. Knowledge of which regions in P-gp undergo conformational alterations will provide vital information to elucidate the locations of drug binding sites and the mechanism of coupling. A number of investigations have implicated transmembrane segment six (TM6) in drug-P-gp interactions, and a cysteine-scanning mutagenesis approach was directed to this segment. Introduction of cysteine residues into TM6 did not disturb basal or drug-stimulated ATPase activity per se. Under basal conditions the hydrophobic probe coumarin maleimide readily labeled all introduced cysteine residues, whereas the hydrophilic fluorescein maleimide only labeled residue Cys-343. The amphiphilic BODIPY-maleimide displayed a more complex labeling profile. The extent of labeling with coumarin maleimide did not vary during the catalytic cycle, whereas fluorescein maleimide labeling of F343C was lost after nucleotide binding or hydrolysis. BODIPY-maleimide labeling was markedly altered during the catalytic cycle and indicated that the adenosine 5'-(beta, gamma-imino) triphosphate-bound and ADP/vanadate-trapped intermediates were conformationally distinct. Our data are reconciled with a recent atomic scale model of P-gp and are consistent with a tilting of TM6 in response to nucleotide binding and ATP hydrolysis.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ Oxford, Lab Mol Biophys, Oxford OX1 3QU, England; Hammersmith Hosp, Med Res Council Clin Sci Ctr, Imperial Coll Sch Med, London W12 0NN, England; Univ Nottingham, Ctr Biochem & Cell Biol, Sch Biomed Sci, Queens Med Ctr, Nottingham NG7 2UH, England	University of Oxford; University of Oxford; Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Nottingham	Callaghan, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.	richard.callaghan@ndcls.ox.ac.uk	Kerr, Ian D/B-3803-2015; Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020; Rothnie, Alice/F-1358-2011	Kerr, Ian D/0000-0002-7544-8454; Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; Rothnie, Alice/0000-0002-4259-7015; Storm, Janet/0000-0001-7812-4220				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Blott EJ, 1999, EMBO J, V18, P6800, DOI 10.1093/emboj/18.23.6800; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dean M, 2001, J LIPID RES, V42, P1007; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; Druley TE, 2001, BIOCHEMISTRY-US, V40, P4312, DOI 10.1021/bi001371v; Ecker GF, 2002, MOL PHARMACOL, V61, P637, DOI 10.1124/mol.61.3.637; Gabriel MP, 2003, BIOCHEMISTRY-US, V42, P7780, DOI 10.1021/bi0341049; GLOSSMANN H, 1987, TRENDS PHARMACOL SCI, V8, P95, DOI 10.1016/0165-6147(87)90082-4; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; KRUPKA RM, 1993, BIOCHIM BIOPHYS ACTA, V1183, P114, DOI 10.1016/0005-2728(93)90010-D; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; Taylor AM, 2001, BRIT J PHARMACOL, V134, P1609, DOI 10.1038/sj.bjp.0704400; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956	51	52	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34913	34921		10.1074/jbc.M405336200	http://dx.doi.org/10.1074/jbc.M405336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192095	Green Accepted, hybrid			2022-12-27	WOS:000223134800102
J	Uchimura, K; Kadomatsu, K; El-Fasakhany, FM; Singer, MS; Izawa, M; Kannagi, R; Takeda, N; Rosen, SD; Muramatsu, T				Uchimura, K; Kadomatsu, K; El-Fasakhany, FM; Singer, MS; Izawa, M; Kannagi, R; Takeda, N; Rosen, SD; Muramatsu, T			N-acetylglucosamine 6-O-sulfotransferase-1 regulates expression of L-selectin ligands and lymphocyte homing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-ENDOTHELIAL VENULES; SIALYL-LEWIS-X; HEV-RESTRICTED SULFOTRANSFERASE; MOLECULAR-CLONING; CHONDROITIN 6-SULFOTRANSFERASE; P-SELECTIN; O-GLYCANS; NODES; BIOSYNTHESIS; SULFATION	Lymphocyte homing is initiated by the binding of L-selectin on lymphocytes to its ligands on high endothelial venules (HEV). Sialyl 6-sulfo Lewis X is a major capping group of L-selectin ligands. N-Acetylglucosamine ( GlcNAc) 6-sulfation is essential for the ligand activity, and is catalyzed by GlcNAc 6-O-sulfotransferases (GlcNAc6STs) of which GlcNAc6ST-1 and GlcNAc6ST-2 are expressed in HEV. Here, we report that mice deficient in GlcNAc6ST-1 were impaired in the elaboration of sialyl 6-sulfo Lewis X in HEV and that an epitope of L-selectin ligands recognized by the MECA-79 antibody was greatly reduced or abolished in the abluminal aspect of HEV. Lymphocyte homing to peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches was significantly reduced in GlcNAc6ST-1 null mice. These results demonstrate that GlcNAc6ST-1 is involved in lymphocyte homing in vivo, and indicate that GlcNAc6ST-1 and -2 play complementary roles. The importance of GlcNAc6ST-1 is particularly highlighted by its involvement in lymphocyte homing to Peyer's patches where GlcNAc6ST-2 expression is undetectable.	Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Calif San Francisco, Program Immunol, Dept Anat, San Francisco, CA 94143 USA; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8600811, Japan	Nagoya University; University of California System; University of California San Francisco; Aichi Cancer Center; Kumamoto University	Muramatsu, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tmurama@med.nagoya-u.ac.jp	Uchimura, Kenji/C-9635-2014; Kadomatsu, Kenji/G-8083-2012; Uchimura, Kenji/AFV-1802-2022; Kannagi, Reiji/Q-6459-2018; ELFASAKHANY, Fathy/ABD-2927-2021	Uchimura, Kenji/0000-0003-3009-248X; Uchimura, Kenji/0000-0003-3009-248X; Kannagi, Reiji/0000-0003-4202-2921; Rosen, Steven/0000-0002-6245-701X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM057411] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57411, R37 GM 23547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Bistrup A, 2004, AM J PATHOL, V164, P1635, DOI 10.1016/S0002-9440(10)63722-4; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Bruehl RE, 2000, J BIOL CHEM, V275, P32642, DOI 10.1074/jbc.M001703200; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; de Graffenried CL, 2003, J BIOL CHEM, V278, P40282, DOI 10.1074/jbc.M304928200; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Drayton DL, 2003, J EXP MED, V197, P1153, DOI 10.1084/jem.20021761; Fukuda M, 2001, J BIOL CHEM, V276, P47747, DOI 10.1074/jbc.R100049200; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hickey MJ, 2000, J IMMUNOL, V165, P7164, DOI 10.4049/jimmunol.165.12.7164; Hiraoka N, 2004, J BIOL CHEM, V279, P3058, DOI 10.1074/jbc.M311150200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1993, NATURE, V361, P555; Izawa M, 2000, CANCER RES, V60, P1410; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Lee JK, 2003, GLYCOBIOLOGY, V13, P245, DOI 10.1093/glycob/cwg018; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Ogawa D, 2004, J BIOL CHEM, V279, P2085, DOI 10.1074/jbc.M305809200; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; ROSEN SD, 1989, J IMMUNOL, V142, P1895; Satomaa T, 2002, BLOOD, V99, P2609, DOI 10.1182/blood.V99.7.2609; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; van Zante A, 2003, J EXP MED, V198, P1289, DOI 10.1084/jem.20030057; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	48	64	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35001	35008		10.1074/jbc.M404456200	http://dx.doi.org/10.1074/jbc.M404456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175329	hybrid			2022-12-27	WOS:000223134800112
J	Weber, ANR; Morse, MA; Gay, NJ				Weber, ANR; Morse, MA; Gay, NJ			Four N-linked glycosylation sites in human Toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; GLYCOPROTEIN IB-ALPHA; DROSOPHILA TOLL; CRYSTAL-STRUCTURE; SOLUBLE FORMS; PROTEIN; RECOGNITION; DOMAIN; FAMILY; MD-2	Most higher organisms have a system of innate immune defense that is mediated by a group of evolutionarily related, germ line-encoded receptors, so-called Toll-like receptors. In mammals Toll-like receptors signal in response to pathogen-associated microbial structures. For example, Toll-like receptor 2 appears to mediate responses to bacterial peptidoglycan and acylated lipoproteins and Toll-like receptor 4 to bacterial lipopolysaccharide. However, the structural principles that underlie recognition of these structures are poorly understood. Toll-like receptors have leucine-rich repeats in their extracellular domains and are thus believed to adopt solenoid structures, similar to that found in platelet glycoprotein Ib. Additionally, all Toll-like receptors contain N-linked glycosylation consensus sites, and Toll-like receptor 4 requires glycosylation for function. Toll-like receptor glycosylation is also likely to influence receptor surface representation, trafficking, and pattern recognition. Using circular dichroism spectroscopy, we show here that purified human Toll-like receptor 2 and 4 proteins have secondary structure contents similar to glycoprotein Ib. We have also analyzed where consensus glycosylation sites are located in the extracellular domains of other human Toll-like receptors. We found that there are significant differences in the location and degree of conservation between sites in different Toll-like receptors. Using site-directed mutagenesis, we have found that in Toll-like receptor 2 extracellular domain all four predicted glycosylation sites are substituted, although one site is inefficiently core-glycosylated and its removal drastically affects secretion. The remaining Toll-like receptor 2 glycosylation sites also contribute to efficient protein secretion, albeit to a lesser degree.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; GlaxoSmithKline Med Res Ctr, RA Pharmacol, RI CEDD, Stevenage SG1 2NY, Herts, England	University of Cambridge; GlaxoSmithKline	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	njg11@mole.bio.cam.ac.uk		Weber, Alexander/0000-0002-8627-7056				Assil IQ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1015, DOI 10.1152/ajpendo.2001.281.5.E1015; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; DUBE S, 1988, J BIOL CHEM, V263, P17516; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Hausmann M, 2002, GASTROENTEROLOGY, V122, P1987, DOI 10.1053/gast.2002.33662; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; HICKMAN S, 1978, J IMMUNOL, V121, P990; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; LeBouder E, 2003, J IMMUNOL, V171, P6680, DOI 10.4049/jimmunol.171.12.6680; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; RECNY MA, 1992, J BIOL CHEM, V267, P22428; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; Taylor WR, 1997, J MOL BIOL, V269, P902, DOI 10.1006/jmbi.1997.1008; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Wojczyk BS, 1998, GLYCOBIOLOGY, V8, P121, DOI 10.1093/glycob/8.2.121	30	98	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34589	34594		10.1074/jbc.M403830200	http://dx.doi.org/10.1074/jbc.M403830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173186	hybrid			2022-12-27	WOS:000223134800063
J	Besana, A; Barbuti, A; Tateyama, MA; Symes, AJ; Robinson, RB; Feinmark, SJ				Besana, A; Barbuti, A; Tateyama, MA; Symes, AJ; Robinson, RB; Feinmark, SJ			Activation of protein kinase C epsilon inhibits the two-pore domain K+ channel, TASK-1, inducing repolarization abnormalities in cardiac ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM LEAK; TRANSLOCATION; EXPRESSION; ARRHYTHMIAS; ISOZYME; TREK-1; HEART; BLOCK; ACID	Activation of the platelet-activating factor (PAF) receptor leads to a decrease in outward current in murine ventricular myocytes by inhibiting the TASK-1 channel. TASK-1 carries a background or "leak" current and is a member of the two-pore domain potassium channel family. Its inhibition is sufficient to delay repolarization, causing prolongation of the action potential duration, and in some cases, early after depolarizations. We set out to determine the cellular mechanisms that control regulation of TASK-1 by PAF. Inhibition of TASK-1 via activation of the PAF receptor is protein kinase C (PKC)dependent. Using isoform-specific PKC inhibitor or activator peptides in patch clamp experiments, we now demonstrate that activation of PKCepsilon is both necessary and sufficient to regulate murine TASK-1 current in a heterologous expression system and to induce repolarization abnormalities in isolated myocytes. Furthermore, site-directed mutagenesis studies have identified threonine 381, in the C-terminal tail of murine TASK-1, as a critical residue in this regulation.	Columbia Univ, Dept Pharmacol, Ctr Mol Therapeut, New York, NY 10032 USA	Columbia University	Feinmark, SJ (corresponding author), Columbia Univ, Dept Pharmacol, Ctr Mol Therapeut, 630 W 168th St, New York, NY 10032 USA.	sjf1@columbia.edu	Barbuti, Andrea/N-9805-2013; Symes, Aviva J/S-7471-2016	Barbuti, Andrea/0000-0002-4521-4913; Symes, Aviva J/0000-0003-2557-9939	NHLBI NIH HHS [HL70105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson ME, 2002, AM HEART J, V144, P769, DOI 10.1067/mhj.2002.125804; Armstrong SC, 2004, CARDIOVASC RES, V61, P427, DOI 10.1016/j.cardiores.2003.09.031; Barbuti A, 2002, AM J PHYSIOL-HEART C, V282, pH2024, DOI 10.1152/ajpheart.00956.2001; Bayliss Douglas A, 2003, Mol Interv, V3, P205, DOI 10.1124/mi.3.4.205; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Hoffman BF, 1996, J CARDIOVASC ELECTR, V7, P120, DOI 10.1111/j.1540-8167.1996.tb00507.x; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; Maingret F, 2002, BIOCHEM BIOPH RES CO, V292, P339, DOI 10.1006/bbrc.2002.6674; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Marban E, 2002, NATURE, V415, P213, DOI 10.1038/415213a; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; Sariahmetoglu M, 1998, PHARMACOL RES, V38, P173, DOI 10.1006/phrs.1998.0348; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; Zilberberg N, 2000, J GEN PHYSIOL, V116, P721, DOI 10.1085/jgp.116.5.721	28	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33154	33160		10.1074/jbc.M403525200	http://dx.doi.org/10.1074/jbc.M403525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184378	hybrid			2022-12-27	WOS:000223039700018
J	Yajima, H; Ikeshima, E; Shiraki, M; Kanaya, T; Fujiwara, D; Odai, H; Tsuboyama-Kasaoka, N; Ezaki, O; Oikawa, S; Kondo, K				Yajima, H; Ikeshima, E; Shiraki, M; Kanaya, T; Fujiwara, D; Odai, H; Tsuboyama-Kasaoka, N; Ezaki, O; Oikawa, S; Kondo, K			Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-FED RATS; PPAR-GAMMA; 3T3-L1 ADIPOCYTES; LIPID-METABOLISM; GENE-EXPRESSION; DIABETIC MICE; BEER HOP; SENSITIVITY; LIVER; OBESITY	The peroxisome proliferator-activated receptors (PPARs) are dietary lipid sensors that regulate fatty acid and carbohydrate metabolism. The hypolipidemic effects of fibrate drugs and the therapeutic benefits of the thiazolidinedione drugs are due to their activation of PPARalpha and -gamma, respectively. In this study, isohumulones, the bitter compounds derived from hops that are present in beer, were found to activate PPARalpha and -gamma in transient co-transfection studies. Among the three major isohumulone homologs, isohumulone and isocohumulone were found to activate PPARalpha and -gamma. Diabetic KK-A(y) mice that were treated with isohumulones ( isohumulone and isocohumulone) showed reduced plasma glucose, triglyceride, and free fatty acid levels (65.3, 62.6, and 73.1%, respectively, for isohumulone); similar reductions were found following treatment with the thiazolidinedione drug, pioglitazone. Isohumulone treatment did not result in significant body weight gain, although pioglitazone treatment did increase body weight (10.6% increase versus control group). C57BL/6N mice fed a high fat diet that were treated with isohumulones showed improved glucose tolerance and reduced insulin resistance. Furthermore, these animals showed increased liver fatty acid oxidation and a decrease in size and an increase in apoptosis of their hypertrophic adipocytes. A double-blind, placebo-controlled pilot study for studying the effect of isohumulones on diabetes suggested that isohumulones significantly decreased blood glucose and hemoglobin A1c levels after 8 weeks ( by 10.1 and 6.4%, respectively, versus week 0). These results suggest that isohumulones can improve insulin sensitivity in high fat diet-fed mice with insulin resistance and in patients with type 2 diabetes.	Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Kanagawa 2360004, Japan; Natl Inst Hlth & Nutr, Div Clin Nutr, Tokyo 1628636, Japan; Nippon Med Coll, Dept Med, Tokyo 1138603, Japan	Kirin Brewery Company Limited; National Institute of Health & Nutrition - Japan; Nippon Medical School	Yajima, H (corresponding author), Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, 1-13-5 Fukuura, Kanagawa 2360004, Japan.	hyajima@kirin.co.jp		Taguchi, Maho/0000-0001-7347-1514				Chakrabarti R, 2003, BRIT J PHARMACOL, V140, P527, DOI 10.1038/sj.bjp.0705463; Cohen B, 2001, J BIOL CHEM, V276, P7697, DOI 10.1074/jbc.C000634200; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Fujita H, 2001, J NUTR, V131, P2105, DOI 10.1093/jn/131.8.2105; Gerhauser C, 2002, MOL CANCER THER, V1, P959; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Ikemoto S, 1996, METABOLISM, V45, P1539, DOI 10.1016/S0026-0495(96)90185-7; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kushiro M, 2002, J NUTR BIOCHEM, V13, P289, DOI 10.1016/S0955-2863(01)00224-8; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lee HJ, 2002, BIOCHEM BIOPH RES CO, V296, P293, DOI 10.1016/S0006-291X(02)00822-7; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Ljung B, 2002, J LIPID RES, V43, P1855, DOI 10.1194/jlr.M200127-JLR200; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Milligan S, 2002, REPRODUCTION, V123, P235, DOI 10.1530/rep.0.1230235; MONDON CE, 1981, AM J PHYSIOL, V240, pE482, DOI 10.1152/ajpendo.1981.240.5.E482; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Mukherjee R, 2000, MOL ENDOCRINOL, V14, P1425, DOI 10.1210/me.14.9.1425; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Pereira MA, 2002, AM J CLIN NUTR, V75, P848, DOI 10.1093/ajcn/75.5.848; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; SAHA AK, 1994, AM J PHYSIOL, V267, pE95, DOI 10.1152/ajpendo.1994.267.1.E95; Shimamura M, 2001, BIOCHEM BIOPH RES CO, V289, P220, DOI 10.1006/bbrc.2001.5934; SIMPSON WJ, 1992, J APPL BACTERIOL, V72, P327, DOI 10.1111/j.1365-2672.1992.tb01843.x; SINGH V, 1990, PHARMACOL RES, V22, P37, DOI 10.1016/1043-6618(90)90741-U; SWANSTONFLATT SK, 1989, DIABETES RES CLIN EX, V10, P69; Takahashi N, 2002, FEBS LETT, V514, P315, DOI 10.1016/S0014-5793(02)02390-6; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Yamamoto K, 2000, FEBS LETT, V465, P103, DOI 10.1016/S0014-5793(99)01727-5; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; YASUKAWA K, 1995, ONCOLOGY, V52, P156; Ye JM, 2003, AM J PHYSIOL-ENDOC M, V284, pE531, DOI 10.1152/ajpendo.00299.2002; Ye JM, 2001, DIABETES, V50, P411, DOI 10.2337/diabetes.50.2.411	39	124	145	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33456	33462		10.1074/jbc.M403456200	http://dx.doi.org/10.1074/jbc.M403456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178687	hybrid			2022-12-27	WOS:000223039700054
J	Zhang, AH; Yeung, PL; Li, CW; Tsai, SC; Dinh, GK; Wu, XY; Li, H; Chen, JD				Zhang, AH; Yeung, PL; Li, CW; Tsai, SC; Dinh, GK; Wu, XY; Li, H; Chen, JD			Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; ESTROGEN-RECEPTOR; STEROID-RECEPTORS; HORMONE RECEPTORS; CO-REPRESSOR; ACTIVATION; PROTEIN; COREPRESSOR; COMPLEX; SMRT	Members of the p160 nuclear receptor coactivators interact with liganded nuclear receptors to enhance transcription of target genes. Here we identify a novel family of ankyrin repeats containing cofactors (ANCOs) that interact with the p160 coactivators. ANCO-1 binds to the conserved Per-Arnt-Sim ( PAS) region of the p160 coactivators. It encodes a large nuclear protein with five ankyrin repeats, and parts of its sequences have been reported as nasopharyngeal carcinoma susceptibility protein and medulloblastoma antigen. Immunofluorescence staining reveals discrete nuclear foci of ANCO-1 that are distinct from known nuclear structures. Intriguingly, ANCO-1 also colocalizes and interacts with histone deacetylases. Transient reporter gene assay shows that ANCO-1 expression inhibits ligand-dependent transactivation by both steroid and nonsteroid nuclear receptors. Taken together, we have identified a novel family of ankyrin repeats containing cofactors that may recruit histone deacetylases to the p160 coactivators/ nuclear receptor complex to inhibit ligand-dependent transactivation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Chen, JD (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 661 Hoes Lane, Piscataway, NJ 08854 USA.	chenjd@umdnj.edu	Li, Chia-Wei/AAC-8660-2019	Li, Chia-Wei/0000-0002-2531-2866	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052888, R01DK052542] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52542, DK52888, R01 DK052542-03, R01 DK052542-06, R01 DK052542-05, R01 DK052542-02, R01 DK052888-04, R01 DK052888-05, R01 DK052542-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Behrends U, 2003, INT J CANCER, V106, P244, DOI 10.1002/ijc.11208; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Bernstein E, 2001, RNA, V7, P1509; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Guenther MG, 2000, GENE DEV, V14, P1048; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAWAZ Z, 1994, MOL GEN GENET, V245, P724, DOI 10.1007/BF00297279; ONATE SA, 1995, SCIENCE, V270, P1354; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Powell JA, 2002, GENOMICS, V80, P303, DOI 10.1006/geno.2002.6828; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922	41	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33799	33805		10.1074/jbc.M403997200	http://dx.doi.org/10.1074/jbc.M403997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184363	hybrid			2022-12-27	WOS:000223039700089
J	Samuel, VT; Liu, ZX; Qu, XQ; Elder, BD; Bilz, S; Befroy, D; Romanelli, AJ; Shulman, GI				Samuel, VT; Liu, ZX; Qu, XQ; Elder, BD; Bilz, S; Befroy, D; Romanelli, AJ; Shulman, GI			Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; RECEPTOR SUBSTRATE-1; GLUCOSE-PRODUCTION; GLYCOGEN-SYNTHASE; KAPPA-B; ACTIVATION; MUSCLE; ACID; ASSOCIATION	Short term high fat feeding in rats results specifically in hepatic fat accumulation and provides a model of non-alcoholic fatty liver disease in which to study the mechanism of hepatic insulin resistance. Short term fat feeding (FF) caused a similar to3-fold increase in liver triglyceride and total fatty acyl-CoA content without any significant increase in visceral or skeletal muscle fat content. Suppression of endogenous glucose production (EGP) by insulin was diminished in the FF group, despite normal basal EGP and insulin-stimulated peripheral glucose disposal. Hepatic insulin resistance could be attributed to impaired insulin-stimulated IRS-1 and IRS-2 tyrosine phosphorylation. These changes were associated with activation of PKC-epsilon and JNK1. Ultimately, hepatic fat accumulation decreased insulin activation of glycogen synthase and increased gluconeogenesis. Treatment of the FF group with low dose 2,4-dinitrophenol to increase energy expenditure abrogated the development of fatty liver, hepatic insulin resistance, activation of PKC-epsilon and JNK1, and defects in insulin signaling. In conclusion, these data support the hypothesis hepatic steatosis leads to hepatic insulin resistance by stimulating gluconeogenesis and activating PKC-epsilon and JNK1, which may interfere with tyrosine phosphorylation of IRS-1 and IRS-2 and impair the ability of insulin to activate glycogen synthase.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Univ Technol Sydney, Dept Hlth Sci, Sydney, NSW 2007, Australia	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; University of Technology Sydney	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, S269 CAB 300 Cedar St, New Haven, CT 06510 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019; Adiels, Martin/C-9278-2011	Shulman, Gerald I./0000-0003-1529-5668; Bilz, Stefan/0000-0002-7716-2791	NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR017404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P30DK045735] Funding Source: NIH RePORTER; NCRR NIH HHS [K23 RR-17404] Funding Source: Medline; NIDDK NIH HHS [R01 DK-40936, R01 DK040936, P30 DK-45735] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; CHIASSON JL, 1976, DIABETES, V25, P283, DOI 10.2337/diabetes.25.4.283; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hundal RS, 2000, DIABETES, V49, P2063, DOI 10.2337/diabetes.49.12.2063; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Jiang GQ, 2004, BIOCHEM J, V377, P339, DOI 10.1042/BJ20031207; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Koizumi M, 2001, J Toxicol Sci, V26, P299, DOI 10.2131/jts.26.299; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE281, DOI 10.1152/ajpendo.00332.2002; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; McCullough AJ, 2002, J CLIN GASTROENTEROL, V34, P255, DOI 10.1097/00004836-200203000-00013; NUTTALL FQ, 1989, ANAL BIOCHEM, V178, P311, DOI 10.1016/0003-2697(89)90644-1; Previs SF, 1999, AM J PHYSIOL-ENDOC M, V277, pE154, DOI 10.1152/ajpendo.1999.277.1.E154; Qu X, 1999, J ENDOCRINOL, V162, P207, DOI 10.1677/joe.0.1620207; REBRIN K, 1995, DIABETES, V44, P1038, DOI 10.2337/diabetes.44.9.1038; SALORANTA C, 1993, AM J PHYSIOL, V264, pE599, DOI 10.1152/ajpendo.1993.264.4.E599; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Sanyal Arun J, 2002, Gastroenterology, V123, P1705, DOI 10.1053/gast.2002.36572; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	31	964	1034	1	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32345	32353		10.1074/jbc.M313478200	http://dx.doi.org/10.1074/jbc.M313478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166226	hybrid			2022-12-27	WOS:000222849700046
J	Torizawa, T; Ueda, T; Kuramitsu, S; Hitomi, K; Todo, T; Iwai, S; Morikawa, K; Shimada, I				Torizawa, T; Ueda, T; Kuramitsu, S; Hitomi, K; Todo, T; Iwai, S; Morikawa, K; Shimada, I			Investigation of the cyclobutane pyrimidine dimer (CPD) photolyase DNA recognition mechanism by NMR analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; EXCISION-REPAIR; ANACYSTIS-NIDULANS; STRUCTURAL BASIS; 2ND CHROMOPHORE; BASE-EXCISION; ENZYME; BINDING; SUBSTRATE	The cyclobutane pyrimidine dimer (CPD) is one of the major forms of DNA damage caused by irradiation with ultraviolet (UV) light. CPD photolyases recognize and repair UV-damaged DNA. The DNA recognition mechanism of the CPD photolyase has remained obscure because of a lack of structural information about DNA-CPD photolyase complexes. In order to elucidate the CPD photolyase DNA binding mode, we performed NMR analyses of the DNA-CPD photolyase complex. Based upon results from P-31 NMR measurements, in combination with site-directed mutagenesis, we have demonstrated the orientation of CPD-containing single-stranded DNA (ssDNA) on the CPD photolyase. In addition, chemical shift perturbation analyses, using stable isotope-labeled DNA, revealed that the CPD is buried in a cavity within CPD photolyase. Finally, NMR analyses of a double-stranded DNA (dsDNA)-CPD photolyase complex indicated that the CPD is flipped out of the dsDNA by the enzyme, to gain access to the active site.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; JBIC, JBIRC, Chuo Ku, Tokyo 1040032, Japan; Osaka Univ, Grad Sch Sci, Osaka 5600043, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan; Natl Inst Adv Ind Sci & Technol, BIRC, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Osaka University; Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp						BAER ME, 1993, J BIOL CHEM, V268, P16717; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; EKER AP, 1988, BIOCHEMISTRY-US, V27, P1758, DOI 10.1021/bi00405a056; Friedberg EC, 1995, DNA REPAIR MUTAGENES, P91; HEELIS PF, 1992, INT J RADIAT BIOL, V62, P137, DOI 10.1080/09553009214551941; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; KAY LE, 1990, J AM CHEM SOC, V112, P888, DOI 10.1021/ja00158a070; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, BIOCHEMISTRY-US, V31, P11244, DOI 10.1021/bi00160a040; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; MAHER VM, 1982, P NATL ACAD SCI-BIOL, V79, P2613, DOI 10.1073/pnas.79.8.2613; MARINO JP, 1994, J AM CHEM SOC, V116, P6472, DOI 10.1021/ja00093a073; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; Meier A, 2002, J BIOL CHEM, V277, P11845, DOI 10.1074/jbc.M110941200; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SANCAR A, 1984, J MOL BIOL, V172, P223, DOI 10.1016/S0022-2836(84)80040-6; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SETLOW RB, 1978, NATURE, V271, P713, DOI 10.1038/271713a0; SKLENAR V, 1993, J BIOMOL NMR, V3, P721, DOI 10.1007/BF00198375; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Smith DE, 1997, J BIOMOL NMR, V10, P245, DOI 10.1023/A:1018358602001; SUZUKI F, 1981, CANCER RES, V41, P4916; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Torizawa T, 1998, FEBS LETT, V429, P157, DOI 10.1016/S0014-5793(98)00582-1; Torizawa T, 2000, NUCLEIC ACIDS RES, V28, P944, DOI 10.1093/nar/28.4.944; Vande Berg BJ, 1998, J BIOL CHEM, V273, P20276, DOI 10.1074/jbc.273.32.20276; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6	39	36	39	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32950	32956		10.1074/jbc.M404536200	http://dx.doi.org/10.1074/jbc.M404536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169780	hybrid			2022-12-27	WOS:000222849700115
J	Wallace, MA; Liou, LL; Martins, J; Clement, MHS; Bailey, S; Longo, VD; Valentine, JS; Gralla, EB				Wallace, MA; Liou, LL; Martins, J; Clement, MHS; Bailey, S; Longo, VD; Valentine, JS; Gralla, EB			Superoxide inhibits 4Fe-4S cluster enzymes involved in amino acid biosynthesis - Cross-compartment protection by CuZn-superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; LYSINE BIOSYNTHESIS; INTERMEMBRANE SPACE; SULFITE REDUCTASE; YEAST-CELLS; IRON; MITOCHONDRIA; PROTEINS; SENSITIVITY	Among the phenotypes of Saccharomyces cerevisiae mutants lacking CuZn-superoxide dismutase (Sod1p) is an aerobic lysine auxotrophy; in the current work we show an additional leaky auxotrophy for leucine. The lysine and leucine biosynthetic pathways each contain a 4Fe-4S cluster enzyme homologous to aconitase and likely to be superoxide-sensitive, homoaconitase (Lys4p) and isopropylmalate dehydratase (Leu1p), respectively. We present evidence that direct aerobic inactivation of these enzymes in sod1Delta yeast results in the auxotrophies. Located in the cytosol and intermembrane space of the mitochondria, Sod1p likely provides direct protection of the cytosolic enzyme Leu1p. Surprisingly, Lys4p does not share a compartment with Sod1p but is located in the mitochondrial matrix. The activity of a second matrix protein, the tricarboxylic acid cycle enzyme aconitase, was similarly lowered in sod1Delta mutants. We measured only slight changes in total mitochondrial iron and found no detectable difference in mitochondrial "free" (EPR-detectable) iron making it unlikely that a gross defect in mitochondrial iron metabolism is the cause of the decreased enzyme activities. Thus, we conclude that when Sod1p is absent a lysine auxotrophy is induced because Lys4p is inactivated in the matrix by superoxide that originates in the intermembrane space and diffuses across the inner membrane.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Gralla, EB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	egralla@chem.ucla.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM08496] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, pCH10; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BILINSKI T, 1985, ACTA MICROBIOL POL, V34, P15; BOWLER C, 1991, EMBO J, V10, P1723, DOI 10.1002/j.1460-2075.1991.tb07696.x; Broquist HP., 1971, METHODS ENZYMOL, V17B, P112; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; Costa Vitor, 2001, Molecular Aspects of Medicine, V22, P217, DOI 10.1016/S0098-2997(01)00012-7; Crane BR, 1997, BIOCHEMISTRY-US, V36, P12101, DOI 10.1021/bi971065q; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Davis CA, 2004, J BIOL CHEM, V279, P12769, DOI 10.1074/jbc.M310623200; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRALLA EB, 1997, COLD SPRING HARBOR M, V34, P495; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HASSAN HM, 1982, CAN J PHYSIOL PHARM, V60, P1367, DOI 10.1139/y82-204; Hearn AS, 2004, J BIOL CHEM, V279, P5861, DOI 10.1074/jbc.M311310200; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; Irvin SD, 1998, J MOL EVOL, V46, P401, DOI 10.1007/PL00006319; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Liu SS, 1999, J BIOENERG BIOMEMBR, V31, P367; LIU XF, 1992, J BIOL CHEM, V267, P18298; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; NAKATANI Y, 1972, ANAL BIOCHEM, V49, P225, DOI 10.1016/0003-2697(72)90261-8; NICHOLLS DG, 2002, BIOENERGETICS, V3, P65; RASMUSSEN H, 1965, P NATL ACAD SCI USA, V53, P1069, DOI 10.1073/pnas.53.5.1069; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Srinivasan C, 2002, METHOD ENZYMOL, V349, P173, DOI 10.1016/S0076-6879(02)49333-0; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; STRASSMAN M, 1966, J BIOL CHEM, V241, P5401; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WANG L, 1989, CURR GENET, V16, P7, DOI 10.1007/BF00411077; Wei JPJ, 2001, J BIOL CHEM, V276, P44798, DOI 10.1074/jbc.M104708200; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; YOSHIMOTO A, 1968, BIOCHIM BIOPHYS ACTA, V153, P555, DOI 10.1016/0005-2728(68)90185-0	61	82	84	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32055	32062		10.1074/jbc.M403590200	http://dx.doi.org/10.1074/jbc.M403590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166213	hybrid			2022-12-27	WOS:000222849700009
J	Zou, H; Lee, J; Kilani, AF; Kim, K; Trang, P; Kim, J; Liu, FY				Zou, H; Lee, J; Kilani, AF; Kim, K; Trang, P; Kim, J; Liu, FY			Engineered RNase P ribozymes increase their cleavage activities and efficacies in inhibiting viral gene expression in cells by enhancing the rate of cleavage and binding of the target mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTERNAL GUIDE SEQUENCES; RIBONUCLEASE-P; ESCHERICHIA-COLI; SUBSTRATE-BINDING; HAIRPIN RIBOZYME; THERAPEUTIC AGENTS; CATALYTIC SUBUNIT; PROTEIN COFACTOR; ENZYME; REPLICATION	Engineered RNase P ribozymes are promising gene-targeting agents that can be used in both basic research and clinical applications. We have previously selected ribozyme variants for their activity in cleaving an mRNA substrate from a pool of ribozymes containing randomized sequences. In this study, one of the variants was used to target the mRNA encoding thymidine kinase (TK) of herpes simplex virus 1 (HSV-1). The variant exhibited enhanced cleavage and substrate binding and was at least 30 times more efficient in cleaving TK mRNA in vitro than the ribozyme derived from the wild type sequence. Our results provide the first direct evidence to suggest that a point mutation at nucleotide 95 of RNase P catalytic RNA from Escherichia coli (G(95)-->U-95) increases the rate of cleavage, whereas another mutation at nucleotide 200 (A(200)-->C-200) enhances substrate binding of the ribozyme. A reduction of about 99% in TK expression was observed in cells expressing the variant, whereas a 70% reduction was found in cells expressing the ribozyme derived from the wild type sequence. Thus, the RNase P ribozyme variant is highly effective in inhibiting HSV-1 gene expression. Our study demonstrates that ribozyme variants increase their cleavage activity and efficacy in blocking gene expression in cells through enhanced substrate binding and rate of cleavage. These results also provide insights into the mechanism of how RNase P ribozymes efficiently cleave an mRNA substrate and, furthermore, facilitate the development of highly active RNase P ribozymes for gene-targeting applications.	Univ Calif Berkeley, Sch Publ Hlth, Program Comparat Biochem, Program Infect Dis & Immun, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Liu, FY (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Program Comparat Biochem, Program Infect Dis & Immun, 140 Warren Hall, Berkeley, CA 94720 USA.	liu_fy@uclink4.berkeley.edu		Lee, Jarone/0000-0002-4532-8523				Altman S., 1999, RNA WORLD, P351; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; Bertrand E, 1997, RNA, V3, P75; Chen JL, 1998, EMBO J, V17, P1515, DOI 10.1093/emboj/17.5.1515; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; Donahue CP, 1997, RNA, V3, P961; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FRANK DN, 1994, BIOCHEMISTRY-US, V33, P10800, DOI 10.1021/bi00201a030; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; Gopalan V, 2002, J BIOL CHEM, V277, P6759, DOI 10.1074/jbc.R100067200; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Haas ES, 1998, NUCLEIC ACIDS RES, V26, P4093, DOI 10.1093/nar/26.18.4093; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; Hsu AW, 2000, NUCLEIC ACIDS RES, V28, P3105, DOI 10.1093/nar/28.16.3105; Kawa D, 1998, RNA, V4, P1397, DOI 10.1017/S1355838298980918; Kilani AF, 1999, RNA, V5, P1235, DOI 10.1017/S1355838299990672; Kilani AF, 2000, J BIOL CHEM, V275, P10611, DOI 10.1074/jbc.275.14.10611; Kim JJ, 1997, RNA, V3, P613; Kurz JC, 2000, CURR OPIN CHEM BIOL, V4, P553, DOI 10.1016/S1367-5931(00)00131-9; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1995, GENE DEV, V9, P471, DOI 10.1101/gad.9.4.471; Loria A, 1999, BIOCHEMISTRY-US, V38, P8612, DOI 10.1021/bi990691f; Massire C, 1998, J MOL BIOL, V279, P773, DOI 10.1006/jmbi.1998.1797; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Plehn-Dujowich D, 1998, P NATL ACAD SCI USA, V95, P7327, DOI 10.1073/pnas.95.13.7327; Pulitz JZ, 1999, J VIROL, V73, P5381, DOI 10.1128/JVI.73.7.5381-5387.1999; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; Scherer LJ, 2003, NAT BIOTECHNOL, V21, P1457, DOI 10.1038/nbt915; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; Trang P, 1999, NUCLEIC ACIDS RES, V27, P4590, DOI 10.1093/nar/27.23.4590; Trang P, 2000, P NATL ACAD SCI USA, V97, P5812, DOI 10.1073/pnas.100101797; Trang P, 2000, J MOL BIOL, V301, P817, DOI 10.1006/jmbi.2000.4022; Wong-Staal F, 1998, HUM GENE THER, V9, P2407, DOI 10.1089/hum.1998.9.16-2407; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZAUG AJ, 1995, RNA, V1, P363	46	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32063	32070		10.1074/jbc.M403059200	http://dx.doi.org/10.1074/jbc.M403059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169770	hybrid			2022-12-27	WOS:000222849700010
J	Macchi, P; Brownawell, AM; Grunewald, B; DesGroseillers, L; Macara, IG; Kiebler, MA				Macchi, P; Brownawell, AM; Grunewald, B; DesGroseillers, L; Macara, IG; Kiebler, MA			The brain-specific double-stranded RNA-binding protein Staufen2 - Nucleolar accumulation and isoform-specific exportin-5-dependent export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES NUCLEAR EXPORT; SOMATODENDRITIC DOMAIN; MAMMALIAN STAUFEN; TRANSPORT; LOCALIZATION; RECOGNITION; TRANSLATION; NEURONS; SIGNAL	The mammalian double-stranded RNA-binding proteins Staufen (Stau1 and Stau2) are involved in RNA localization in polarized neurons. In contrast to the more ubiquitously expressed Stau1, Stau2 is mainly expressed in the nervous system. In Drosophila, the third double-stranded RNA-binding domain (RBD3) of Staufen is essential for RNA interaction. When conserved amino acids within the RBD3 of Stau2 were mutated to render Stau2 defective for RNA binding, the mutant Stau2 proteins accumulate predominantly in the nucleolus. This is in contrast to wild type Stau2 that mostly localizes in the cytosol. The nuclear import is dependent on a nuclear localization signal in close proximity to the RBD3. The nuclear export of Stau2 is not dependent on CRM1 but rather on Exportin-5. We show that Exportin-5 interacts with the RBD3 of wild type Stau2 in an RNA-dependent manner in vitro but not with mutant Stau2. When Exportin-5 is down-regulated by RNA interference, only the largest isoform of Stau2 (Stau2(62)) preferentially accumulates in the nucleolus. It is tempting to speculate that Stau2(62) binds RNA in the nucleus and assembles into ribonucleoparticles, which are then exported via the Exportin-5 pathway to their final destination.	Max Planck Inst Dev Biol, D-72076 Tubingen, Germany; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	Max Planck Society; University of Virginia; Universite de Montreal	Kiebler, MA (corresponding author), Max Planck Inst Dev Biol, Spemannstr 35, D-72076 Tubingen, Germany.	michael.kiebler@tuebingen.mpg.de		Kiebler, Michael/0000-0002-8850-6297				Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; de Heredia ML, 2004, CURR OPIN CELL BIOL, V16, P80, DOI 10.1016/j.ceb.2003.11.002; Duchaine TF, 2002, J CELL SCI, V115, P3285; GOETZE B, 2004, IN PRESS J NEUROBIOL; GOETZE B, 2003, SCI STKE; Gwizdek C, 2003, J BIOL CHEM, V278, P5505, DOI 10.1074/jbc.C200668200; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Politz JC, 2002, J CELL BIOL, V159, P411, DOI 10.1083/jcb.200208037; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; Strehblow A, 2002, MOL BIOL CELL, V13, P3822, DOI 10.1091/mbc.E02-03-0161; Tamanini F, 1999, HUM MOL GENET, V8, P863, DOI 10.1093/hmg/8.5.863; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803	22	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31440	31444		10.1074/jbc.C400226200	http://dx.doi.org/10.1074/jbc.C400226200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15166236	hybrid			2022-12-27	WOS:000222726800065
J	Risteli, M; Niemitalo, O; Lankinen, H; Juffer, AH; Myllyla, R				Risteli, M; Niemitalo, O; Lankinen, H; Juffer, AH; Myllyla, R			Characterization of collagenous peptides bound to lysyl hydroxylase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SYNDROME TYPE-VI; CIRCULAR-DICHROISM SPECTRA; CAENORHABDITIS-ELEGANS; TISSUE DISTRIBUTION; IN-VITRO; EXPRESSION; LYSINE; GENE; GLUCOSYLTRANSFERASE	Lysyl hydroxylase (LH, EC 1.14.11.4) is the enzyme catalyzing the formation of hydroxylysyl residues in collagens and other proteins with collagenous domains. Although lower species, such as Caenorhabditis elegans, have only one LH orthologue, LH activity in higher species, such as human, rat, and mouse, is present in three molecules, LH1, LH2, and LH3, encoded by three different genes. In addition, LH2 is present in two alternatively spliced forms (LH2a, LH2b). To understand the functions of the four molecular forms of LH in vertebrates, we analyzed differences in the binding and hydroxylation of various collagenous peptides by the LH isoforms. Nine-amino acid-long synthetic peptides on Pepspot were used for the binding analysis and an activity assay to measure hydroxylation. Our data with 727 collagenous peptides indicated that a positive charge on the peptide and specific amino acid residues in close proximity to the lysyl residues in the collagenous sequences are the key factors promoting peptide binding to the LH isoforms. The data suggest that the LH binding site is not a deep hydrophobic pocket but is open and hydrophilic where acidic amino acids play an important role in the binding. The data do not indicate strict sequence specificity for the LH isoforms, but the data indicated that there was a clear preference for some sequences to be bound and hydroxylated by a certain isoform.	Univ Oulu, Vioctr Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Helsinki, Cent Hosp, Haartman Inst, Diagnost Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, Peptide & Prot Lab, FIN-00014 Helsinki, Finland	Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Myllyla, R (corresponding author), Univ Oulu, Vioctr Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	raili.myllyla@oulu.fi		Juffer, Andre/0000-0003-3533-0520				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Agrafiotis DK, 1997, PROTEIN SCI, V6, P287; ARMSTRONG LC, 1995, BBA-GENE STRUCT EXPR, V1264, P93, DOI 10.1016/0167-4781(95)00130-9; AYAD S, 1998, EXTRACELLULAR MATRIX, P43; BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; BERRY DA, 1996, STAT BAYESIAN PERSPE, P518; DEB K, 2002, COMPUTATIONALLY EFFI; Eyre D, 2002, MOL GENET METAB, V76, P211, DOI 10.1016/S1096-7192(02)00036-7; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; HEIKKINEN J, 1994, GENOMICS, V24, P464, DOI 10.1006/geno.1994.1654; Heikkinen J, 2000, J BIOL CHEM, V275, P36158, DOI 10.1074/jbc.M006203200; JIANG P, 1991, J BIOL CHEM, V266, P22960; Johnstone IL, 2000, TRENDS GENET, V16, P21, DOI 10.1016/S0168-9525(99)01857-0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KADLER K, 1994, PROTEIN PROFILE, V1, P525; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1973, BIOCHEMISTRY-US, V12, P4966, DOI 10.1021/bi00748a023; KIVIRIKKO KI, 1972, BIOCHEMISTRY-US, V11, P122, DOI 10.1021/bi00751a021; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; Mercer DK, 2003, BIOCHEM BIOPH RES CO, V307, P803, DOI 10.1016/S0006-291X(03)01262-2; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rautavuoma K, 2000, MATRIX BIOL, V19, P73, DOI 10.1016/S0945-053X(99)00058-X; Rautavuoma K, 2002, J BIOL CHEM, V277, P23084, DOI 10.1074/jbc.M112077200; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; Ruotsalainen H, 1999, MATRIX BIOL, V18, P325, DOI 10.1016/S0945-053X(99)00016-5; Ruotsalainen H, 2001, MATRIX BIOL, V20, P137, DOI 10.1016/S0945-053X(01)00130-5; RYHANEN L, 1975, BIOCHIM BIOPHYS ACTA, V397, P50; SAMMON JW, 1969, IEEE T COMPUT, VC 18, P401, DOI 10.1109/T-C.1969.222678; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Steinmann Beat, 1993, P351; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; VALTAVAARA M, 1999, ACTA U OULUENSIS; van der Slot AJ, 2003, J BIOL CHEM, V278, P40967, DOI 10.1074/jbc.M307380200; Wang CG, 2002, MATRIX BIOL, V21, P559, DOI 10.1016/S0945-053X(02)00071-9; Wang CG, 2000, DNA CELL BIOL, V19, P71, DOI 10.1089/104454900314582; Wang CG, 2002, J BIOL CHEM, V277, P18568, DOI 10.1074/jbc.M201389200; WEI L, 1997, USING RADIAL DISTRIB, P465; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	48	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37535	37543		10.1074/jbc.M405638200	http://dx.doi.org/10.1074/jbc.M405638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208310	hybrid			2022-12-27	WOS:000223554600044
J	Aronov, S; Gerst, JE				Aronov, S; Gerst, JE			Involvement of the late secretory pathway in actin regulation and mRNA transport in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS CELL POLARIZATION; UNCONVENTIONAL MYOSIN; BUDDING YEAST; LOCALIZATION; EXOCYTOSIS; PROTEIN; GROWTH; GENE; CYTOSKELETON; REQUIREMENT	Both the delivery of secretory vesicles and asymmetric distribution of mRNA to the bud are dependent upon the actin cytoskeleton in yeast. Here we examined whether components of the exocytic apparatus play a role in mRNA transport. By screening secretion mutants in situ and in vivo, we found that all had an altered pattern of ASH1 mRNA localization. These included alleles of CDC42 and RHO3 (cdc42-6 and rho3-V51) thought to regulate specifically the fusion of secretory vesicles but were found to affect strongly the cytoskeleton as well. Most interestingly, mutations in late secretion-related genes not directly involved in actin regulation also showed substantial alterations in ASH1 mRNA distribution. These included mutations in genes encoding components of the exocyst (SEC10 and SEC15), SNARE regulatory proteins (SEC1, SEC4, and SRO7), SNAREs (SEC9 and SSO1/2), and proteins involved in Golgi export (PIK1 and YPT31/32). Importantly, prominent defects in the actin cytoskeleton were observed in all of these strains, thus implicating a known causal relationship between the deregulation of actin and the inhibition of mRNA transport. Our novel observations suggest that vesicular transport regulates the actin cytoskeleton in yeast (and not just vice versa) leading to subsequent defects in mRNA transport and localization.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Gerst, JE (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	jeffrey.gerst@weizmann.ac.il	Liberman-Aronov, Stella/H-6935-2019	Liberman-Aronov, Stella/0000-0001-6938-053X				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Adamo JE, 2001, J CELL BIOL, V155, P581, DOI 10.1083/jcb.200106065; Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Beach DL, 1999, CURR BIOL, V9, P569, DOI 10.1016/S0960-9822(99)80260-7; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Bretscher A, 2003, J CELL BIOL, V160, P811, DOI 10.1083/jcb.200301035; Casamayor A, 2002, CURR OPIN MICROBIOL, V5, P179, DOI 10.1016/S1369-5274(02)00300-4; Chartrand P, 2001, ANNU REV CELL DEV BI, V17, P297, DOI 10.1146/annurev.cellbio.17.1.297; Dollar G, 2002, DEVELOPMENT, V129, P517; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Fehrenbacher KL, 2003, TRENDS CELL BIOL, V13, P472, DOI 10.1016/S0962-8924(03)00174-0; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Gao XD, 2003, J CELL BIOL, V162, P635, DOI 10.1083/jcb.200302038; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; HAARER BK, 1994, J CELL SCI, V107, P1055; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Ho J, 2001, MOL BIOL CELL, V12, P1541, DOI 10.1091/mbc.12.6.1541; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; LEW DJ, 1991, J MEMBRANE BIOL, V123, P261, DOI 10.1007/BF01870409; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Rose MD., 1990, METHODS YEAST GENETI; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; Shaw SL, 1996, DEVELOPMENT, V122, P2623; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Toi H, 2003, MOL BIOL CELL, V14, P2237, DOI 10.1091/mbc.E02-09-0616; Wedlich-Soldner R, 2003, SCIENCE, V299, P1231, DOI 10.1126/science.1080944; Wedlich-Soldner R, 2003, NAT CELL BIOL, V5, P267, DOI 10.1038/ncb0403-267; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485	45	43	45	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36962	36971		10.1074/jbc.M402068200	http://dx.doi.org/10.1074/jbc.M402068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192110	hybrid			2022-12-27	WOS:000223453600099
J	Morgan, CT; Tsivkovskii, R; Kosinsky, YA; Efremov, RG; Lutsenko, S				Morgan, CT; Tsivkovskii, R; Kosinsky, YA; Efremov, RG; Lutsenko, S			The distinct functional properties of the nucleotide-binding domain of ATP7B, the human copper-transporting ATPase - Analysis of the Wilson disease mutations E1064A, H1069Q, R1151H, AND C1104F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; ADENOSINE-TRIPHOSPHATASE ATP7B; ESCHERICHIA-COLI; OVARIAN-CARCINOMA; CALCIUM-PUMP; PROTEIN; MOTIF; NA,K-ATPASE; DIVERSITY	Copper transport by the P-1-ATPase ATP7B, or Wilson disease protein (WNDP),(1) is essential for human metabolism. Perturbation of WNDP function causes intracellular copper accumulation and severe pathology, known as Wilson disease (WD). Several WD mutations are clustered within the WNDP nucleotide-binding domain (N-domain), where they are predicted to disrupt ATP binding. The mechanism by which the N-domain coordinates ATP is presently unknown, because residues important for nucleotide binding in the better characterized P-2-ATPases are not conserved within the P-1-ATPase subfamily. To gain insight into nucleotide binding under normal and disease conditions, we generated the recombinant WNDP N-domain and several WD mutants. Using isothermal titration calorimetry, we demonstrate that the N-domain binds ATP in a Mg2+-independent manner with a relatively high affinity of 75 muM, compared with millimolar affinities observed for the P-2-ATPase N-domains. The WNDP N-domain shows minimal discrimination between ATP, ADP, and AMP, yet discriminates well between ATP and GTP. Similar results were obtained for the N-domain of ATP7A, another P-1-ATPase. Mutations of the invariant WNDP residues E1064A and H1069Q drastically reduce nucleotide affinities, pointing to the likely role of these residues in nucleotide coordination. In contrast, the R1151H mutant exhibits only a 1.3-fold reduction in affinity for ATP. The C1104F mutation significantly alters protein folding, whereas C1104A does not affect the structure or function of the N-domain. Together, the results directly demonstrate the phenotypic diversity of WD mutations within the N-domain and indicate that the nucleotide-binding properties of the P-1-ATPases are distinct from those of the P-2-ATPases.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia	Oregon Health & Science University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	lutsenko@ohsu.edu	Morgan, Clinton/AAM-7410-2021; Roman, Efremov/A-7460-2014	Roman, Efremov/0000-0002-5474-4721	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 55719] Funding Source: Medline; NIGMS NIH HHS [1P01 GM 67166-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Abed M, 2004, BIOCHEM J, V379, P235, DOI 10.1042/BJ20040168; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; Champeil P, 1998, J BIOL CHEM, V273, P6619, DOI 10.1074/jbc.273.12.6619; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Cox DW, 2002, J BIOENERG BIOMEMBR, V34, P333, DOI 10.1023/A:1021293818125; EFREMOV RG, 1995, J PHYS CHEM-US, V99, P10658, DOI 10.1021/j100026a033; EFREMOV RG, 2004, BIOCH J         0517; Fatemi N, 2002, J BIOENERG BIOMEMBR, V34, P339, DOI 10.1023/A:1021245902195; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gitlin JD, 2003, GASTROENTEROLOGY, V125, P1868, DOI 10.1053/j.gastro.2003.05.010; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; Katano K, 2003, MOL PHARMACOL, V64, P466, DOI 10.1124/mol.64.2.466; Komatsu M, 2000, CANCER RES, V60, P1312; Loudianos G, 2000, SEMIN LIVER DIS, V20, P353, DOI 10.1055/s-2000-9389; Loudianos G, 1999, J MED GENET, V36, P833; Lutsenko S, 2002, J BIOENERG BIOMEMBR, V34, P351, DOI 10.1023/A:1021297919034; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608; Okkeri J, 2004, BIOCHEM J, V377, P95, DOI 10.1042/BJ20030740; Okkeri J, 2002, EUR J BIOCHEM, V269, P1579, DOI 10.1046/j.1432-1033.2002.02810.x; Riordan SM, 2001, J HEPATOL, V34, P165, DOI 10.1016/S0168-8278(00)00028-3; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsivkovskii R, 2003, J BIOL CHEM, V278, P13302, DOI 10.1074/jbc.M300034200; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik I, 2003, BIOCHEM BIOPH RES CO, V301, P488, DOI 10.1016/S0006-291X(03)00010-X	32	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36363	36371		10.1074/jbc.M404553200	http://dx.doi.org/10.1074/jbc.M404553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205462	hybrid			2022-12-27	WOS:000223453600026
J	Yasuda, Y; Li, ZQ; Greenbaum, D; Bogyo, M; Weber, E; Bromme, D				Yasuda, Y; Li, ZQ; Greenbaum, D; Bogyo, M; Weber, E; Bromme, D			Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CYSTEINE PROTEASE; MATRIX METALLOPROTEINASES; MOLECULAR-CLONING; INVARIANT CHAIN; CLASS-II; ATHEROSCLEROSIS; LOCALIZATION; PROTEINASES; DEGRADATION	Atherosclerosis is characterized by a thickening and loss of elasticity of the arterial wall. Loss of elasticity has been attributed to the degradation of the arterial elastin matrix. Cathepsins K and S are papain-like cysteine proteases with known elastolytic activities, and both enzymes have been identified in macrophages present in plaque areas of diseased blood vessels. Here we demonstrate that macrophages express a third elastolytic cysteine protease, cathepsin V, which exhibits the most potent elastase activity yet described among human proteases and that cathepsin V is present in atherosclerotic plaque specimens. Approximately 60% of the total elastolytic activity of macrophages can be attributed to cysteine proteases with cathepsins V, K, and S contributing equally. From this 60%, two-thirds occur extracellularly and one-third intracellularly with the latter credited to cathepsin V. Ubiquitously expressed glycosaminoglycans (GAGs) such as chondroitin sulfate specifically inhibit the elastolytic activities of cathepsins V and K via the formation of specific cathepsin-GAG complexes. In contrast, cathepsin S, which does not form complexes with chondroitin sulfate is not inhibited; thus suggesting a specific regulation of elastolytic activities of cathepsins by GAGs. Because the GAG content is reduced in atherosclerotic plaques, an increase of cathepsins V and K activities may accelerate the destruction of the elastin matrix in diseased arteries.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Univ Halle Wittenberg, Inst Physiol Chem, D-06114 Halle An Der Saale, Saale, Germany	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Stanford University; Martin Luther University Halle Wittenberg	Bromme, D (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave 100th St, New York, NY 10029 USA.	dieter.bromme@mssm.edu		Bogyo, Matthew/0000-0003-3753-4412; Weber, Ekkehard/0000-0002-4014-4303	NIAMS NIH HHS [AR 46182, AR 48669] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048669, R01AR046182] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Adachi W, 1998, INVEST OPHTH VIS SCI, V39, P1789; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Bernard D, 2003, J INVEST DERMATOL, V120, P592, DOI 10.1046/j.1523-1747.2003.12086.x; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; BROMME D, 1993, J BIOL CHEM, V268, P4832; Bromme D, 2004, METHODS, V32, P199, DOI 10.1016/S1046-2023(03)00212-3; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; Caballero AR, 2001, ANAL BIOCHEM, V290, P330, DOI 10.1006/abio.2001.4999; Cheng XW, 2004, AM J PATHOL, V164, P243, DOI 10.1016/S0002-9440(10)63114-8; Fiebiger E, 2001, J EXP MED, V193, P881, DOI 10.1084/jem.193.8.881; Filippov S, 2003, J EXP MED, V198, P925, DOI 10.1084/jem.20030626; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Greenbaum DC, 2002, CHEM BIOL, V9, P1085, DOI 10.1016/S1074-5521(02)00238-7; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; Hou WS, 2002, ARTHRITIS RHEUM, V46, P663, DOI 10.1002/art.10114; Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002-9440(10)63068-4; Jormsjo S, 2002, AM J PATHOL, V161, P939, DOI 10.1016/S0002-9440(10)64254-X; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Lijnen HR, 2002, BIOCHEM SOC T, V30, P163, DOI 10.1042/bst0300163; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; Matsumoto S, 1998, AM J PATHOL, V153, P109, DOI 10.1016/S0002-9440(10)65551-4; MURATA K, 1989, ATHEROSCLEROSIS, V78, P69, DOI 10.1016/0021-9150(89)90160-3; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; Parkar AA, 2000, PROTEIN EXPRES PURIF, V20, P152, DOI 10.1006/prep.2000.1280; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; Robert L, 1998, ATHEROSCLEROSIS, V140, P281, DOI 10.1016/S0021-9150(98)00171-3; RUST L, 1994, METHOD ENZYMOL, V235, P554; Santamaria I, 1998, CANCER RES, V58, P1624; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SPERBER K, 1990, J IMMUNOL METHODS, V129, P31, DOI 10.1016/0022-1759(90)90417-T; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; Tolosa E, 2003, J CLIN INVEST, V112, P517, DOI 10.1172/JCI200318028; Tournu C, 1998, ARCH BIOCHEM BIOPHYS, V360, P15, DOI 10.1006/abbi.1998.0916; Volpi N, 1997, CHEM-BIOL INTERACT, V105, P157, DOI 10.1016/S0009-2797(97)00045-8; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; Williams KJ, 2001, CURR OPIN LIPIDOL, V12, P477, DOI 10.1097/00041433-200110000-00002; Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084	53	150	152	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36761	36770		10.1074/jbc.M403986200	http://dx.doi.org/10.1074/jbc.M403986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192101	hybrid			2022-12-27	WOS:000223453600077
J	Konas, DW; Zhu, K; Sharma, M; Aulak, KS; Brudvig, GW; Stuehr, DJ				Konas, DW; Zhu, K; Sharma, M; Aulak, KS; Brudvig, GW; Stuehr, DJ			The FAD-shielding residue Phe(1395) regulates neuronal nitric-oxide synthase catalysis by controlling NADP(+) affinity and a conformational equilibrium within the flavoprotein domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME-P450 REDUCTASE; AUTOINHIBITORY CONTROL ELEMENT; ELECTRON FLOW-THROUGH; FLAVIN DOMAIN; FERREDOXIN-NADP(+) REDUCTASE; COENZYME BINDING; P450 REDUCTASE; PHOTOSYSTEM-II; NO SYNTHASE; CALMODULIN	Phe(1395) stacks parallel to the FAD isoalloxazine ring in neuronal nitric-oxide synthase (nNOS) and is representative of conserved aromatic amino acids found in structurally related flavoproteins. This laboratory previously showed that Phe(1395) was required to obtain the electron transfer properties and calmodulin (CaM) response normally observed in wild-type nNOS. Here we characterized the F1395S mutant of the nNOS flavoprotein domain (nNOSr) regarding its physical properties, NADP(+) binding characteristics, flavin reduction kinetics, steady-state and pre-steady-state cytochrome c reduction kinetics, and ability to shield its FMN cofactor in response to CaM or NADP(H) binding. F1395S nNOSr bound NADP(+) with 65% more of the nicotinamide ring in a productive conformation with FAD for hydride transfer and had an 8-fold slower rate of NADP(+) dissociation. CaM stimulated the rates of NADPH-dependent flavin reduction in wild-type nNOSr but not in the F1395S mutant, which had flavin reduction kinetics similar to those of CaM-free wild-type nNOSr. CaM-free F1395S nNOSr lacked repression of cytochrome c reductase activity that is typically observed in nNOSr. The combined results from pre-steady-state and EPR experiments revealed that this was associated with a lesser degree of FMN shielding in the NADP(+)-bound state as compared with wild type. We conclude that Phe(1395) regulates nNOSr catalysis in two ways. It facilitates NADP(+) release to prevent this step from being rate-limiting, and it enables NADP(H) to properly regulate a conformational equilibrium involving the FMN subdomain that controls reactivity of the FMN cofactor in electron transfer.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Cleveland Clinic Foundation; Yale University	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NB-30,9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org			NIGMS NIH HHS [GM51491, GM36442] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036442, R01GM051491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CHEN X, 1990, CHEM PHARM BULL, V38, P612, DOI 10.1248/cpb.38.612; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furchgott RF, 1999, BIOSCIENCE REP, V19, P235, DOI 10.1023/A:1020537506008; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Guan ZW, 2003, J BIOL CHEM, V278, P30859, DOI 10.1074/jbc.M301929200; Guan ZW, 2003, ARCH BIOCHEM BIOPHYS, V412, P65, DOI 10.1016/S0003-9861(03)00009-2; Gutierrez A, 2003, BIOCHEM SOC T, V31, P497, DOI 10.1042/BST0310497; Gutierrez A, 2003, EUR J BIOCHEM, V270, P2612, DOI 10.1046/j.1432-1033.2003.03633.x; Gutierrez A, 2002, BIOCHEMISTRY-US, V41, P4626, DOI 10.1021/bi0159433; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; Gutierrez A, 2001, BIOCHEMISTRY-US, V40, P1964, DOI 10.1021/bi001719m; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; INNES JB, 1989, BIOCHEMISTRY-US, V28, P1116, DOI 10.1021/bi00429a028; ISOGAI Y, 1990, BIOCHIM BIOPHYS ACTA, V1017, P204, DOI 10.1016/0005-2728(90)90185-7; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KIM JJP, 1997, FASEB J SS, V11, P63; KLATT P, 1992, J BIOL CHEM, V267, P11374; Knight K, 2002, BIOCHEM J, V367, P19, DOI 10.1042/BJ20020667; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Lane P, 2000, ACTA PHYSIOL SCAND, V168, P53; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MASSEY V, 1962, J BIOL CHEM, V237, P2347; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; Mayer B., 2000, HDB EXPT PHARM, V143; MEINHARDT SW, 1992, BIOCHIM BIOPHYS ACTA, V1100, P67, DOI 10.1016/0005-2728(92)90127-N; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; NAGAMATSU T, 1984, J CHEM SOC PERK T 1, P561, DOI 10.1039/p19840000561; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Piubelli L, 2000, J BIOL CHEM, V275, P10472, DOI 10.1074/jbc.275.14.10472; Roitel O, 2003, BIOCHEMISTRY-US, V42, P10809, DOI 10.1021/bi034562h; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuart-Smith K, 2002, J CLIN PATHOL-MOL PA, V55, P360, DOI 10.1136/mp.55.6.360; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; STUEHR DJ, 2004, IN PRESS J BIOL CHEM; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WANG ZX, 1992, ANAL BIOCHEM, V206, P376, DOI 10.1016/0003-2697(92)90381-G; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	67	45	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35412	35425		10.1074/jbc.M400872200	http://dx.doi.org/10.1074/jbc.M400872200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15180983	hybrid			2022-12-27	WOS:000223303400035
J	Lemtiri-Chlieh, F; Berkowitz, GA				Lemtiri-Chlieh, F; Berkowitz, GA			Cyclic adenosine monophosphate regulates calcium channels in the plasma membrane of Arabidopsis leaf guard and mesophyll cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION-CHANNEL; ABSCISIC-ACID; CYCLASE ACTIVITY; CATION CHANNELS; NITRIC-OXIDE; K+ CHANNEL; HYPERPOLARIZATION; EXPRESSION; IDENTIFICATION; CALMODULIN	The effect of cAMP on Ca2+-permeable channels from Arabidopsis thaliana leaf guard cell and mesophyll cell protoplasts was studied using the patch clamp technique. In the whole cell configuration, dibutyryl cAMP was found to increase a hyperpolarization-activated Ba2+ conductance (I-Ba). The increase of IBa was blocked by the addition of GdCl3. In excised outside-out patches, the addition of dibutyryl cAMP consistently activated a channel with particularly fast gating kinetics. Current/voltage analyses indicated a single channel conductance of similar to13 picosiemens. In patches where we measured some channel activity prior to cAMP application, the data suggest that cAMP enhances channel activity without affecting the single channel conductance. The cAMP activation of these channels was reversible upon washout. The results obtained with excised patches indicate that the cAMP-activated IBa seen in the whole cell configuration could be explained by a direct effect of cAMP on the Ca2+ channel itself or a close entity to the channel. This work represents the first demonstration using patch clamp analysis of the presence in plant cell membranes of an ion channel directly activated by cAMP.	Univ Connecticut, Dept Plant Sci, Agr Biotechnol Lab, Storrs, CT 06269 USA	University of Connecticut	Berkowitz, GA (corresponding author), Univ Connecticut, Dept Plant Sci, Agr Biotechnol Lab, U-4067,Storrs Rd, Storrs, CT 06269 USA.	gerald.berkowitz@uconn.edu	Lemtiri-Chlieh, Fouad/S-3022-2019; Lemtiri-Chlieh, Fouad/B-5624-2008; Lemtiri-Chlieh, Fouad/Y-9683-2019; Lemtiri-Chlieh, Fouad/D-5201-2013	Lemtiri-Chlieh, Fouad/0000-0002-7418-2623				Arazi T, 2000, PLANT MOL BIOL, V42, P591, DOI 10.1023/A:1006345302589; ASSMANN SM, 1995, PLANT PHYSIOL, V108, P885, DOI 10.1104/pp.108.3.885; Balague C, 2003, PLANT CELL, V15, P365, DOI 10.1105/tpc.006999; Balasubramanian S, 1996, J MEMBRANE BIOL, V152, P13, DOI 10.1007/s002329900081; Chan CWM, 2003, PLANT PHYSIOL, V132, P728, DOI 10.1104/pp.102.019216; Clough SJ, 2000, P NATL ACAD SCI USA, V97, P9323, DOI 10.1073/pnas.150005697; Cousson A, 1998, PLANTA, V206, P308, DOI 10.1007/s004250050405; Garcia-Mata C, 2003, TRENDS PLANT SCI, V8, P20, DOI 10.1016/S1360-1385(02)00009-2; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; Gelli A, 1997, J MEMBRANE BIOL, V155, P35, DOI 10.1007/s002329900156; GORDON SE, 1995, J PHYSIOL-LONDON, V486, P533, DOI 10.1113/jphysiol.1995.sp020832; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamilton DWA, 2000, P NATL ACAD SCI USA, V97, P4967, DOI 10.1073/pnas.080068897; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; Hua BG, 2003, PLANT PHYSIOL, V132, P1353, DOI 10.1104/pp.103.020560; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Johannes E, 1994, Symp Soc Exp Biol, V48, P113; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kiegle E, 2000, PLANT J, V21, P225, DOI 10.1046/j.1365-313x.2000.00659.x; Kohler C, 2001, PLANTA, V213, P327, DOI 10.1007/s004250000510; Kohler C, 2000, FEBS LETT, V471, P133, DOI 10.1016/S0014-5793(00)01383-1; KUROSAKI F, 1993, ARCH BIOCHEM BIOPHYS, V302, P144, DOI 10.1006/abbi.1993.1192; Lemtiri-Chlieh F, 2003, P NATL ACAD SCI USA, V100, P10091, DOI 10.1073/pnas.1133289100; LemtiriChlieh F, 1996, J MEMBRANE BIOL, V153, P105, DOI 10.1007/s002329900114; Leng Q, 1999, PLANT PHYSIOL, V121, P753, DOI 10.1104/pp.121.3.753; Leng Q, 2002, PLANT PHYSIOL, V128, P400, DOI 10.1104/pp.010832; LI WW, 1994, PLANT PHYSIOL, V106, P957, DOI 10.1104/pp.106.3.957; Ludidi N, 2003, J BIOL CHEM, V278, P6490, DOI 10.1074/jbc.M210983200; Maathuis FJM, 2001, PLANT PHYSIOL, V127, P1617, DOI 10.1104/pp.010502; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; Moutinho A, 2001, P NATL ACAD SCI USA, V98, P10481, DOI 10.1073/pnas.171104598; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.010707; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pharmawati M, 2001, PLANT PHYSIOL BIOCH, V39, P385, DOI 10.1016/S0981-9428(01)01252-9; Richards H, 2002, PHYTOCHEMISTRY, V61, P531, DOI 10.1016/S0031-9422(02)00266-2; Seifert R, 1999, EMBO J, V18, P119, DOI 10.1093/emboj/18.1.119; Sunkar R, 2000, PLANT J, V24, P533, DOI 10.1046/j.1365-313x.2000.00901.x; Talke IN, 2003, TRENDS PLANT SCI, V8, P286, DOI 10.1016/S1360-1385(03)00099-2; Trewavas AJ, 2002, CURR OPIN PLANT BIOL, V5, P425, DOI 10.1016/S1369-5266(02)00281-9; Very AA, 2002, TRENDS PLANT SCI, V7, P168, DOI 10.1016/S1360-1385(02)02262-8; Very AA, 2000, P NATL ACAD SCI USA, V97, P9801, DOI 10.1073/pnas.160250397; Volotovski ID, 1998, PLANT PHYSIOL, V117, P1023, DOI 10.1104/pp.117.3.1023; Walden R, 1998, CURR OPIN PLANT BIOL, V1, P419, DOI 10.1016/S1369-5266(98)80266-5; White PJ, 2002, BBA-BIOMEMBRANES, V1564, P299, DOI 10.1016/S0005-2736(02)00509-6; Witters E, 2004, RAPID COMMUN MASS SP, V18, P499, DOI 10.1002/rcm.1365; Xu W, 1999, J MEMBRANE BIOL, V171, P117, DOI 10.1007/s002329900564; YAO XQ, 1995, P NATL ACAD SCI USA, V92, P11711, DOI 10.1073/pnas.92.25.11711	51	85	93	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35306	35312		10.1074/jbc.M400311200	http://dx.doi.org/10.1074/jbc.M400311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199067	hybrid			2022-12-27	WOS:000223303400022
J	Wang, S; Liu, Y; Adamson, CL; Valdez, G; Guo, W; Hsu, SC				Wang, S; Liu, Y; Adamson, CL; Valdez, G; Guo, W; Hsu, SC			The mammalian exocyst, a complex required for exocytosis, inhibits tubulin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC6/8 COMPLEX; COMPONENT SEC5; MEMBRANE; PURIFICATION; MICROTUBULES; PROTEINS; DYNAMICS	The exocyst is a 734-kDa complex essential for development. Perturbation of its function results in early embryonic lethality. Extensive investigation has revealed that this complex participates in multiple biological processes, including protein synthesis and vesicle/protein targeting to the plasma membrane. In this article we report that the exocyst may also play a role in modulating microtubule dynamics. Using monoclonal antibodies, we observed that endogenous exocyst subunits co-localized with microtubules and mitotic spindles in normal rat kidney cells. To test for a functional relationship between the exocyst complex and microtubules, we established an in vitro exocyst reconstitution assay and studied exocyst effect on microtubule dynamics. We found that the exocyst complex reconstituted from eight recombinant exocyst subunits inhibited tubulin polymerization in vitro. Deletion of exocyst subunit sec5, sec6, sec15, or exo70 diminished its tubulin polymerization inhibition activity. Surprisingly, exocyst subunit exo70 itself was also capable of inhibiting tubulin polymerization, although exocyst complex with exo70 deletion did not lose its activity completely. Overexpression of exo70 in NRK cells resulted in microtubule network disruption and the formation of filopodia-like plasma membrane protrusions. The formation of these membrane protrusions was greatly hampered by stabilizing microtubules with taxol. Overexpression of exo84, an exocyst subunit that did not show tubulin polymerization inhibition activity, did not cause this phenotype. Results shown in this article, along with a previous report that localized microtubule instability induces plasma membrane addition, implicates a novel role for the exocyst in modulating microtubule dynamics underlying exocytosis.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, Piscataway, NJ 08854 USA; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Neurobiol & Behav, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Brain & Spinal Cord Res, Stony Brook, NY 11794 USA; SUNY Stony Brook, WM Keck Ctr Collaborat Neurosci, Stony Brook, NY 11794 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	Rutgers State University New Brunswick; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Pennsylvania	Hsu, SC (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, Rm D419,604 Allison Rd, Piscataway, NJ 08854 USA.	hsu@biology.rutgers.edu	wang, sheng/B-1969-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018218] Funding Source: NIH RePORTER; NINDS NIH HHS [NS388892, NS18218] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews HK, 2002, TRAFFIC, V3, P906, DOI 10.1034/j.1600-0854.2002.31206.x; Awasthi S, 2001, J BIOL CHEM, V276, P31004, DOI 10.1074/jbc.M100022200; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Folsch H, 2003, J CELL BIOL, V163, P351, DOI 10.1083/jcb.200309020; Friedrich GA, 1997, DEV BIOL, V192, P364, DOI 10.1006/dbio.1997.8727; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Lipschutz JH, 2003, J BIOL CHEM, V278, P20954, DOI 10.1074/jbc.M213210200; Matern HT, 2001, P NATL ACAD SCI USA, V98, P9648, DOI 10.1073/pnas.171317898; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Murthy M, 2003, NEURON, V37, P433, DOI 10.1016/S0896-6273(03)00031-X; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Sjolinder M, 2002, FEBS LETT, V532, P211, DOI 10.1016/S0014-5793(02)03677-3; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Terbush DR, 2001, METHOD ENZYMOL, V329, P100; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; Vega IE, 2001, J NEUROSCI, V21, P3839, DOI 10.1523/JNEUROSCI.21-11-03839.2001; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088; Zakharenko S, 1998, J CELL BIOL, V143, P1077, DOI 10.1083/jcb.143.4.1077; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	30	58	61	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35958	35966		10.1074/jbc.M313778200	http://dx.doi.org/10.1074/jbc.M313778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205466	hybrid			2022-12-27	WOS:000223303400097
J	Lubelski, J; Mazurkiewicz, P; van Merkerk, R; Konings, WN; Driessen, AJM				Lubelski, J; Mazurkiewicz, P; van Merkerk, R; Konings, WN; Driessen, AJM			ydaG and ydbA of Lactococcus lactis encode a heterodimeric ATP-binding cassette-type multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DRUG EXTRUSION; ABC-TRANSPORTERS; ESCHERICHIA-COLI; RESISTANCE PROTEIN; EFFLUX PUMPS; SYSTEMS; RECONSTITUTION; MECHANISM; LMRA; MICROORGANISMS	Multidrug resistance (MDR)-type transporters mediate the active extrusion of structurally and functionally dissimilar compounds from the cells, thereby rendering cells resistant to a range of drugs. The ydaG and ydbA genes of Lactococcus lactis encode two ATP-binding cassette half-transporters, which both share homology with MDR proteins such as LmrA from L. lactis or the mammalian P-glycoprotein. The ydaG/ydbA genes were cloned and expressed separately and jointly in L. lactis using the nisin-inducible system. When both proteins are co-expressed, several structurally dissimilar drugs such as ethidium, daunomycin, and BCECF-AM are extruded from the cell. YdaG and YdbA could be co-purified as a stable heterodimer. ATPase activity was found to be associated with the YdaG/YdbA heterodimer only and not with the individual subunits. Both the ydaG and ydbA genes are up-regulated in multidrug-resistant L. lactis strains selected for growth in the presence of a variety of toxic compounds. This is the first demonstration of a functional heterodimeric ATP-binding cassette-type MDR transporter.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012; Lubelski, Jacek/D-8639-2013; Konings, Wilhelmus N./C-7063-2013	Driessen, Arnold J.M./0000-0001-9258-9104				AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; Blackmore CG, 2001, MOL MEMBR BIOL, V18, P97, DOI 10.1080/09687680010030200; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Borges-Walmsley MI, 2003, BIOCHEM J, V376, P313, DOI 10.1042/BJ20020957; Chang G, 2003, FEBS LETT, V555, P102, DOI 10.1016/S0014-5793(03)01085-8; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Croop JM, 1998, METHOD ENZYMOL, V292, P101; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Edgar R, 1997, J BACTERIOL, V179, P2274, DOI 10.1128/jb.179.7.2274-2280.1997; Ewart GD, 1998, METHOD ENZYMOL, V292, P213; Gajic O, 2003, J BIOL CHEM, V278, P34291, DOI 10.1074/jbc.M211100200; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Jenkinson HF, 1996, J DENT RES, V75, P736, DOI 10.1177/00220345960750020201; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Lage H, 2003, INT J ANTIMICROB AG, V22, P188, DOI 10.1016/S0924-8579(03)00203-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Mazurkiewicz P, 2002, J BIOL CHEM, V277, P26081, DOI 10.1074/jbc.M203141200; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ozkan P, 2002, BBA-GEN SUBJECTS, V1572, P143, DOI 10.1016/S0304-4165(02)00303-3; Paulsen IT, 2003, CURR OPIN MICROBIOL, V6, P446, DOI 10.1016/j.mib.2003.08.005; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Saier MH, 2001, SEMIN CELL DEV BIOL, V12, P205, DOI 10.1006/scdb.2000.0246; Sakamoto K, 2001, J BACTERIOL, V183, P5371, DOI 10.1128/JB.183.18.5371-5375.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; Steinfels E, 2002, BBA-BIOMEMBRANES, V1565, P1, DOI 10.1016/S0005-2736(02)00515-1; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Venter H, 2003, NATURE, V426, P866, DOI 10.1038/nature02173; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856	48	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34449	34455		10.1074/jbc.M404072200	http://dx.doi.org/10.1074/jbc.M404072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192086	Green Published, hybrid			2022-12-27	WOS:000223134800046
J	Miki, T; Okada, N; Danbara, H				Miki, T; Okada, N; Danbara, H			Two periplasmic disulfide oxidoreductases, DsbA and SrgA, target outer membrane protein SpiA, a component of the Salmonella pathogenicity island 2 type III secretion system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOND FORMATION; VIRULENCE PLASMID; SHIGELLA-FLEXNERI; IN-VIVO; TYPHIMURIUM; IDENTIFICATION; PATHWAY; INVASION; GENES	The formation of disulfide is essential for the folding, activity, and stability of many proteins secreted by Gram-negative bacteria. The disulfide oxidoreductase, DsbA, introduces disulfide bonds into proteins exported from the cytoplasm to periplasm. In pathogenic bacteria, DsbA is required to process virulence determinants for their folding and assembly. In this study, we examined the role of the Dsb enzymes in Salmonella pathogenesis, and we demonstrated that DsbA, but not DsbC, is required for the full expression of virulence in a mouse infection model of Salmonella enterica serovar Typhimurium. Salmonella strains carrying a dsbA mutation showed reduced function mediated by type III secretion systems (TTSSs) encoded on Salmonella pathogenicity islands 1 and 2 (SPI-1 and SPI-2). To obtain a more detailed understanding of the contribution of DsbA to both SPI-1 and SPI-2 TTSS function, we identified a protein component of the SPI- 2 TTSS apparatus affected by DsbA. Although we found no substrate protein for DsbA in the SPI- 1 TTSS apparatus, we identified SpiA (SsaC), an outer membrane protein of SPI- 2 TTSS, as a DsbA substrate. Site-directed mutagenesis of the two cysteine residues present in the SpiA protein resulted in the loss of SPI- 2 function in vitro and in vivo. Furthermore, we provided evidence that a second disulfide oxidoreductase, SrgA, also oxidizes SpiA. Analysis of in vivo mixed infections demonstrated that a Salmonella dsbA srgA double mutant strain was more attenuated than either single mutant, suggesting that DsbA acts in concert with SrgA in vivo.	Kitasato Univ, Sch Pharmaceut Sci, Dept Microbiol, Minato Ku, Tokyo 1088641, Japan	Kitasato University	Okada, N (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Dept Microbiol, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	okadan@pharm.kitasato-u.ac.jp						Agudo D, 2004, PROTEOMICS, V4, P355, DOI 10.1002/pmic.200300554; ALTMEYER RM, 1993, MOL MICROBIOL, V7, P89, DOI 10.1111/j.1365-2958.1993.tb01100.x; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bajaj V, 1995, MOL MICROBIOL, V18, P715, DOI 10.1111/j.1365-2958.1995.mmi_18040715.x; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; Beuzon CR, 2001, MICROBES INFECT, V3, P1345, DOI 10.1016/S1286-4579(01)01496-4; Bouwman CW, 2003, J BACTERIOL, V185, P991, DOI 10.1128/JB.185.3.991-1000.2003; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; Crago AM, 1998, MOL MICROBIOL, V30, P47, DOI 10.1046/j.1365-2958.1998.01036.x; Daefler S, 1998, MOL MICROBIOL, V28, P1367, DOI 10.1046/j.1365-2958.1998.00908.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; Ellermeier CD, 2004, J BACTERIOL, V186, P68, DOI 10.1128/JB.186.1.68-79.2004; Freeman JA, 2003, INFECT IMMUN, V71, P418, DOI 10.1128/IAI.71.1.418-427.2003; GALAN JE, 1992, J BACTERIOL, V174, P4338; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Gotoh H, 2003, MICROB PATHOGENESIS, V34, P227, DOI 10.1016/S0882-4010(03)00034-2; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Ha UH, 2003, INFECT IMMUN, V71, P1590, DOI 10.1128/IAI.71.3.1590-1595.2003; Henderson IR, 2001, INFECT IMMUN, V69, P1231, DOI 10.1128/IAI.69.3.1231-1243.2001; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jackson MW, 1999, J BACTERIOL, V181, P5126, DOI 10.1128/JB.181.16.5126-5130.1999; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KANIGA K, 1995, J BACTERIOL, V177, P3965, DOI 10.1128/jb.177.14.3965-3971.1995; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Komoriya K, 1999, MOL MICROBIOL, V34, P767, DOI 10.1046/j.1365-2958.1999.01639.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 2001, CURR OPIN STRUC BIOL, V11, P403, DOI 10.1016/S0959-440X(00)00224-4; LEONG JM, 1993, J BIOL CHEM, V268, P20524; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; MENARD R, 1993, J BACTERIOL, V175, P5899; Miller JH., 1992, SHORT COURSE BACTERI, P72; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; MORONA R, 1995, J BACTERIOL, V177, P1059, DOI 10.1128/jb.177.4.1059-1068.1995; Nikolaus T, 2001, J BACTERIOL, V183, P6036, DOI 10.1128/JB.183.20.6036-6045.2001; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; OKAMOTO K, 1995, J BACTERIOL, V177, P4579, DOI 10.1128/jb.177.16.4579-4586.1995; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rappl C, 2003, FEMS MICROBIOL LETT, V226, P363, DOI 10.1016/S0378-1097(03)00638-4; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; RodriguezPena JM, 1997, MICROBIOL-UK, V143, P1405, DOI 10.1099/00221287-143-4-1405; Ruiz-Albert J, 2002, MOL MICROBIOL, V44, P645, DOI 10.1046/j.1365-2958.2002.02912.x; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Stafford SJ, 1999, FEMS MICROBIOL LETT, V174, P179, DOI 10.1111/j.1574-6968.1999.tb13566.x; STERNBERG NL, 1991, METHOD ENZYMOL, V204, P18; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; Turcot I, 2001, CAN J MICROBIOL, V47, P711, DOI 10.1139/cjm-47-8-711; WATARAI M, 1995, P NATL ACAD SCI USA, V92, P4927, DOI 10.1073/pnas.92.11.4927; YAMANAKA H, 1994, J BACTERIOL, V176, P2906, DOI 10.1128/JB.176.10.2906-2913.1994; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x; Zhang HZ, 1996, MOL MICROBIOL, V21, P787, DOI 10.1046/j.1365-2958.1996.431403.x	72	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34631	34642		10.1074/jbc.M402760200	http://dx.doi.org/10.1074/jbc.M402760200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15169785	hybrid			2022-12-27	WOS:000223134800068
J	Milovic, S; Steinecker-Frohnwieser, B; Schreibmayer, W; Weigl, LG				Milovic, S; Steinecker-Frohnwieser, B; Schreibmayer, W; Weigl, LG			The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; GENERAL-ANESTHETICS; ADENYLATE-CYCLASE; POTASSIUM CHANNEL; GIRK2 SUBUNITS; BINDING; ANALGESIA; SITES; INHIBITION; MODULATION	G protein-activated K+ channels (GIRKs or Kir3.x) are targets for the volatile anesthetic, halothane. When coexpressed with the m(2) acetylcholine (ACh) receptor in Xenopus oocytes, agonist-activated GIRK1(F137S)- and GIRK2-mediated currents are inhibited by halothane, whereas in the absence of ACh, high concentrations of halothane induce GIRK1F137S- mediated currents. To elucidate the molecular mechanism of halothane action on GIRK currents of different subunit compositions, we constructed deletion mutants of GIRK1(F137S) (GIRK1(Delta363*)) and GIRK2 (GIRK2(Delta356)) lacking the C-terminal ends, as well as chimeric GIRK channels. Mutated GIRK channels showed normal currents when activated by ACh but exhibited different pharmacological properties toward halothane. GIRK2(Delta356) showed no sensitivity against the inhibitory action of halothane but was activated by halothane in the absence of an agonist. GIRK1(Delta363*) was activated by halothane more efficiently. Currents mediated by chimeric channels were inhibited by anesthetic concentrations that were at least 30-fold lower than those necessary to decrease GIRK2 wild type currents. Glutathione S-transferase pulldown experiments did not show displacement of bound Gbetagamma by halothane, indicating that halothane does not interfere with Gbetagamma binding. Single channel experiments revealed an influence of halothane on the gating of the channels: The agonist-induced currents of GIRK1 and GIRK2, carried mainly by brief openings, were inhibited, whereas higher concentrations of the anesthetic promoted long openings of GIRK1 channels. Because the C terminus is crucial for these effects, an interaction of halothane with the channel seems to be involved in the mechanism of current modulation.	Med Univ Vienna, Dept Anesthesia & Intens Care Med B, A-1090 Vienna, Austria; Med Univ Graz, Inst Med Phys & Biophys, A-8010 Graz, Austria	Medical University of Vienna; Medical University of Graz	Weigl, LG (corresponding author), Med Univ Vienna, Dept Anesthesia & Intens Care Med B, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	lukas.weigl@univie.ac.at		Weigl, Lukas/0000-0002-9359-536X; Steinecker-Frohnwieser, Bibiane/0000-0001-6852-4466; Schreibmayer, Wolfgang/0000-0002-4631-7922				Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Blednow YA, 2003, P NATL ACAD SCI USA, V100, P277, DOI 10.1073/pnas.012682399; BOHM M, 1994, MOL PHARMACOL, V45, P380; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Doupnik CA, 1996, NEUROPHARMACOLOGY, V35, P923, DOI 10.1016/0028-3908(96)00125-6; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Ikeda K, 2002, NEUROSCI RES, V44, P121, DOI 10.1016/S0168-0102(02)00094-9; Ivanina T, 2003, J BIOL CHEM, V278, P29174, DOI 10.1074/jbc.M304518200; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; KIRSCH GE, 1989, AM J PHYSIOL, V257, pH334, DOI 10.1152/ajpheart.1989.257.1.H334; KRESS HG, 1998, RECENT ADV ANESTHESI, V20, P1; KREYSZIG E, 1979, STAT METHODEN IHRE A, P191; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; Marker CL, 2004, J NEUROSCI, V24, P2806, DOI 10.1523/JNEUROSCI.5251-03.2004; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; Mitrovic I, 2003, P NATL ACAD SCI USA, V100, P271, DOI 10.1073/pnas.0136822100; NARAYANAN TK, 1988, BIOCHEM PHARMACOL, V37, P1219, DOI 10.1016/0006-2952(88)90774-5; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Pentyala SN, 1999, EUR J PHARMACOL, V384, P213, DOI 10.1016/S0014-2999(99)00625-1; Rebecchi MJ, 2002, BRIT J ANAESTH, V89, P62, DOI 10.1093/bja/aef160; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; Spauschus A, 1996, J NEUROSCI, V16, P930; Weigl LG, 2001, MOL PHARMACOL, V60, P282, DOI 10.1124/mol.60.2.282; Wickman K, 2000, J NEUROSCI, V20, P5608, DOI 10.1523/JNEUROSCI.20-15-05608.2000; Yamakura T, 2001, ANESTHESIOLOGY, V95, P144, DOI 10.1097/00000542-200107000-00025	38	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34240	34249		10.1074/jbc.M403448200	http://dx.doi.org/10.1074/jbc.M403448200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175324	hybrid			2022-12-27	WOS:000223134800022
J	Miyamoto, Y; Yamauchi, J; Mizuno, N; Itoh, H				Miyamoto, Y; Yamauchi, J; Mizuno, N; Itoh, H			The adaptor protein Nck1 mediates endothelin A receptor-regulated cell migration through the Cdc42-dependent c-Jun N-terminal kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JNK SIGNALING PATHWAY; RHO-GTPASES; SH3 DOMAINS; BETA-GAMMA; SRC KINASE; B RECEPTOR; ACTIVATION; MICE; GRB2; RAS	Cell migration plays key roles in physiological and pathological phenomena, such as development and oncogenesis. The adaptor proteins Grb2, CrkII, and Nck1 are composed of only a single Src homology 2 domain and some Src homology 3 domains, giving specificity to each signal transduction pathway. However, little is known about the relationships between their adaptor proteins and cell migration, which are regulated by the G protein-coupled receptor. Here we showed that Nck1, but not Grb2 or CrkII, mediated the inhibition of cell migration induced by the endothelin-1 and endothelin A receptor. The small interference RNA and dominant negative mutants of Nck1 diminished the endothelin-1-induced inhibition of cell migration. Although overexpression of wild-type Nck1 was detected in the cytosol and did not affect cell migration, expression of the myristoylation signal sequence-conjugated Nck1 was detected in the membrane and induced activation of Cdc42 and c-Jun N-terminal kinase, inhibiting cell migration. Taken together, these results suggest that the endothelin A receptor transduces the signal of inhibition of cell migration through Cdc42-dependent c-Jun N-terminal kinase activation by using Nck1.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, Nara 6300192, Japan; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Nara Institute of Science & Technology; Stanford University	Itoh, H (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, 8916-5 Takayama, Nara 6300192, Japan.	hitoh@bs.naist.jp						Abe Y, 2000, J BIOL CHEM, V275, P8664, DOI 10.1074/jbc.275.12.8664; Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Flynn DC, 2001, ONCOGENE, V20, P6270, DOI 10.1038/sj.onc.1204769; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GENARD C, 1994, ANNU REV IMMUNOL, V12, P775; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MAKMAN MH, 1995, J IMMUNOL, V154, P1323; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Ridley AJ, 2001, J CELL SCI, V114, P2713; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi J, 2002, FEBS LETT, V527, P284, DOI 10.1016/S0014-5793(02)03231-3; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V284, P1199, DOI 10.1006/bbrc.2001.5103; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	42	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34336	34342		10.1074/jbc.M402767200	http://dx.doi.org/10.1074/jbc.M402767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187089	hybrid			2022-12-27	WOS:000223134800033
J	Nguyen, TLA; Calomme, C; Wijmeersch, G; Nizet, S; Veithen, E; Portetelle, D; de Launoit, Y; Burny, A; Van Lint, C				Nguyen, TLA; Calomme, C; Wijmeersch, G; Nizet, S; Veithen, E; Portetelle, D; de Launoit, Y; Burny, A; Van Lint, C			Deacetylase inhibitors and the viral transactivator Tax(BLV) synergistically activate bovine leukemia virus gene expression via a cAMP-responsive element and cAMP-responsive element-binding protein-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TRANSCRIPTIONAL COACTIVATORS P300; INTERFERON REGULATORY FACTOR-2; I TAX PROTEIN; NF-KAPPA-B; DNA-BINDING; HISTONE ACETYLATION; HIV-1 TAT; FACTOR CREB; T-CELLS	Efficient bovine leukemia virus (BLV) transcription requires the virus-encoded transactivator Tax(BLV), which acts through three Tax(BLV)-responsive elements located in the 5' long terminal repeat. It has been proposed that the binding of the CRE-binding protein (CREB) and the activating transcription factor (ATF) to the three imperfect cAMP-responsive elements (CREs) located in each Tax(BLV)-responsive element mediates Tax(BLV) transactivation. Here we demonstrated that deacetylase inhibitors (HDACis) synergistically enhanced the transcriptional activation of the BLV promoter by Tax(BLV) in a CRE-dependent manner. Tax(BLV) was acetylated in vivo at its N-alpha terminus but not at internal lysine residues. Rather, HDACi potentiation of Tax(BLV) transactivation was mediated by an HDACi indirect action that requires new protein synthesis. Mechanistically, using a dominant-negative form of CREB, we showed that Tax(BLV) and HDACi synergistically activated BLV gene expression via a CREB-dependent mechanism. Moreover, electrophoretic mobility shift assay and Western blot experiments revealed that HDACi increased the in vitro DNA binding activity of CREB/ ATF but did not alter CREB/ ATF intranuclear presence. Remarkably, chromatin immunoprecipitation assays demonstrated that HDACi treatment increased the level of CREB bound to the BLV promoter in vivo. Our results together suggest that an increase in CREB/ ATF occupancy of the viral CREs in response to HDACi potentiates Tax(BLV) transactivation of the BLV promoter.	Free Univ Brussels, Inst Biol & Med Mol, Serv Chim Biol, Mol Virol Lab, B-6041 Gosselies, Belgium; Fac Univ Sci Agron Gembloux, Dept Biol Mol, B-5030 Gembloux, Belgium; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium; Univ Lille 1, Inst Pasteur Lille, Inst Biol Lille, CNRS,UMR 8117, F-59021 Lille, France	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Van Lint, C (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Serv Chim Biol, Mol Virol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	cvlint@ulb.ac.be						Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; ADAM E, 1994, J VIROL, V68, P5845, DOI 10.1128/JVI.68.9.5845-5853.1994; Adam E, 2003, MOL CELL BIOL, V23, P6200, DOI 10.1128/MCB.23.17.6200-6209.2003; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bondzio A, 2001, BIOL CHEM, V382, P407, DOI 10.1515/BC.2001.050; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Calomme C, 2002, J BIOL CHEM, V277, P8775, DOI 10.1074/jbc.M107441200; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chan HM, 2001, J CELL SCI, V114, P2363; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; Dormeyer W, 2003, ANAL BIOANAL CHEM, V376, P994, DOI 10.1007/s00216-003-2058-z; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Eklund EA, 1999, J IMMUNOL, V163, P6095; Gachon F, 2002, VIROLOGY, V299, P271, DOI 10.1006/viro.2002.1501; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Goren I, 2001, J MOL BIOL, V313, P695, DOI 10.1006/jmbi.2001.5064; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kawasaki H, 2000, Nucleic Acids Symp Ser, P259; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Kino T, 1999, J STEROID BIOCHEM, V70, P15, DOI 10.1016/S0960-0760(99)00100-4; KISSTOTH E, 1993, NUCLEIC ACIDS RES, V21, P3677, DOI 10.1093/nar/21.16.3677; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; Masumi A, 2003, J BIOL CHEM, V278, P25401, DOI 10.1074/jbc.M213037200; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Merezak C, 2002, J VIROL, V76, P5034, DOI 10.1128/JVI.76.10.5034-5042.2002; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Quivy V, 2002, J VIROL, V76, P11091, DOI 10.1128/JVI.76.21.11091-11103.2002; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Van den Broeke A, 1999, J VIROL, V73, P1054, DOI 10.1128/JVI.73.2.1054-1065.1999; Van Lint C, 2000, Adv Pharmacol, V48, P121; VanLint C, 1996, GENE EXPRESSION, V5, P245; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Wallberg AE, 2000, BIOCHEM SOC T, V28, P410, DOI 10.1042/0300-5127:0280410; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WILLEMS L, 1992, J VIROL, V66, P766, DOI 10.1128/JVI.66.2.766-772.1992; Willems L, 1987, Haematol Blood Transfus, V31, P482; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; Wolfl S, 1999, MOL ENDOCRINOL, V13, P659, DOI 10.1210/me.13.5.659; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xiao JQ, 1998, J VIROL, V72, P5994, DOI 10.1128/JVI.72.7.5994-6003.1998; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	78	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35025	35036		10.1074/jbc.M404081200	http://dx.doi.org/10.1074/jbc.M404081200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15163662	hybrid			2022-12-27	WOS:000223134800115
J	Onesto, C; Berra, E; Grepin, R; Pages, G				Onesto, C; Berra, E; Grepin, R; Pages, G			Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-TRANSCRIPTION; POLY(A) BINDING-PROTEIN; 3' UNTRANSLATED REGION; HYPOXIA; STABILIZATION; STABILITY; EXPRESSION; HUR; KINASE; IDENTIFICATION	Expression of vascular endothelial growth factor ( VEGF) is tightly regulated, particularly at the level of its mRNA stability, which is essentially mediated through the 3'-untranslated region (3'-UTR) of VEGF mRNA. To identify new protein partners regulating VEGF mRNA stability, we screened a cDNA expression library with an RNA probe corresponding to the entire VEGF mRNA 3'-UTR. We identified the "poly(A)-binding protein-interacting protein 2" (PAIP2) as a new VEGF mRNA 3'-UTR interacting protein. By RNA electromobility shift assays, we showed that PAIP2 binds to two distinct regions of a domain encompassing base 1 to 1280 of the VEGF 3'-UTR. Such in vitro interaction was confirmed using cell extracts in which PAIP2 expression is induced by tetracycline (Tet-on cells). Moreover, we demonstrated by RNA affinity purification as well as by ribonucleoprotein complexes immunoprecipitation, that PAIP2 interacts with VEGF mRNA in vivo. Using an in vitro RNA degradation assay, the half-life of VEGF 3'-UTR was found to be increased by overexpressing PAIP2. PAIP2 stabilizes endogenous VEGF mRNA in Tet-on cells, leading to increased VEGF secretion. Moreover, RNAi- mediated knock-down of PAIP2 significantly reduces the steady-state levels of endogenous VEGF mRNA. We also showed, by in vitro protein-protein interactions and co-immunoprecipitation experiments, that PAIP2 interacts with HuR, an already known VEGF mRNA-binding protein, suggesting cooperation of both proteins for VEGF mRNA stabilization. Hence, PAIP2 appears to be a crucial regulator of VEGF mRNA and as a consequence, any variation in its expression could modulate angiogenesis.	Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Pages, G (corresponding author), Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice 2, France.	gpages@unice.fr	Berra, Edurne/F-9692-2011; Pages, Gilles/N-7135-2017	Berra, Edurne/0000-0002-3820-5744; 				Baker DM, 2000, J BIOL CHEM, V275, P19985, DOI 10.1074/jbc.M002351200; BOADO RJ, 1993, J NEUROCHEM, V60, P2290, DOI 10.1111/j.1471-4159.1993.tb03516.x; Bonino F, 2001, BIOTECHNIQUES, V30, P1254, DOI 10.2144/01306st02; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; Feral C, 2001, NUCLEIC ACIDS RES, V29, P1872, DOI 10.1093/nar/29.9.1872; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Gouyon F, 2003, BIOCHEM J, V375, P167, DOI 10.1042/BJ20030661; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Khaleghpour K, 2001, MOL CELL BIOL, V21, P5200, DOI 10.1128/MCB.21.15.5200-5213.2001; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Steger K, 1998, MOL HUM REPROD, V4, P939, DOI 10.1093/molehr/4.10.939; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Trawick JD, 1997, J BIOL CHEM, V272, P3099, DOI 10.1074/jbc.272.5.3099; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000	38	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34217	34226		10.1074/jbc.M400219200	http://dx.doi.org/10.1074/jbc.M400219200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175342	hybrid			2022-12-27	WOS:000223134800020
J	Swingler, TE; Bess, KL; Yao, J; Stifani, S; Jayaraman, PS				Swingler, TE; Bess, KL; Yao, J; Stifani, S; Jayaraman, PS			The proline-rich homeodomain protein recruits members of the Groucho/transducin-like enhancer of split protein family to co-repress transcription in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN-LIKE-ENHANCER; MESSENGER-RNA TRANSPORT; AMINO-TERMINAL ENHANCER; HOMEOBOX GENE; MEDIATED TRANSCRIPTION; DROSOPHILA GROUCHO; HEX; EXPRESSION; INTERACTS; DOMAIN	The proline-rich homeodomain protein (PRH/Hex) is important in the control of cell proliferation and differentiation and in the regulation of multiple processes in embryonic development. We have shown previously that PRH contains two domains that can independently bring about transcriptional repression. The PRH homeodomain represses transcription by binding to TATA box sequences, whereas the proline-rich N-terminal domain of PRH can repress transcription when attached to a heterologous DNA-binding domain. The Groucho/transducin-like enhancer of split (TLE) family of proteins are transcriptional co-repressors that interact with a number of DNA-bound transcription factors and play multiple roles in development. Here we demonstrate that the proline-rich N-terminal domain of PRH binds to TLE1 in vitro and in yeast two-hybrid assays. We show that PRH and TLE proteins are co-expressed in hematopoietic cells and interact in co-immunoprecipitation assays. We demonstrate that TLE1 increases repression by PRH in transient transfection assays and that titration of endogenous TLE proteins by co-expression of Grg5, a natural trans-dominant negative protein, alleviates transcriptional repression by PRH. Finally, we show that a mutation in the PRH N-terminal domain that blocks the PRH-TLE1 interaction in vitro eliminates co-repression. We discuss these results in terms of the roles of PRH and TLE in cell differentiation and development.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Bristol; McGill University	Jayaraman, PS (corresponding author), Univ Bristol, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	Sheela.Jayaraman@bristol.ac.uk		/0000-0002-6500-9095; Stifani, Stefano/0000-0002-2376-7701				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Bess KL, 2003, BIOCHEM J, V374, P667, DOI 10.1042/BJ20030769; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bogue CW, 2000, DEV DYNAM, V219, P84, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1028>3.0.CO;2-5; Brickman JM, 2000, DEVELOPMENT, V127, P2303; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Courey AJ, 2001, GENE DEV, V15, P2786; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Dasen JS, 2001, GENE DEV, V15, P3193, DOI 10.1101/gad.932601; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1989, MOL CELL BIOL, V9, P312, DOI 10.1128/MCB.9.1.312; Du ZW, 2001, BIOCHEM BIOPH RES CO, V282, P701, DOI 10.1006/bbrc.2001.4636; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; George A, 2003, ONCOGENE, V22, P6764, DOI 10.1038/sj.onc.1206822; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grbavec D, 1999, BIOCHEM J, V337, P13, DOI 10.1042/0264-6021:3370013; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Guiral M, 2001, J BIOL CHEM, V276, P2961, DOI 10.1074/jbc.M004948200; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jayaraman PS, 2000, LEUKEMIA RES, V24, P1023, DOI 10.1016/S0145-2126(00)00072-2; Jimenez G, 1999, MOL CELL BIOL, V19, P2080; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; KOEFFLER HP, 1980, BLOOD, V56, P344; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Nakagawa T, 2003, ARTERIOSCL THROM VAS, V23, P231, DOI 10.1161/01.ATV.0000052670.55321.87; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Obinata A, 2002, DEV GROWTH DIFFER, V44, P281; Ohishi K, 2003, SEMIN CELL DEV BIOL, V14, P143, DOI 10.1016/S1084-9521(02)00183-0; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pellizzari L, 2000, NUCLEIC ACIDS RES, V28, P2503, DOI 10.1093/nar/28.13.2503; Pickles LM, 2002, STRUCTURE, V10, P751, DOI 10.1016/S0969-2126(02)00768-2; Puppin C, 2003, NUCLEIC ACIDS RES, V31, P1845, DOI 10.1093/nar/gkg295; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Smith ST, 1996, DEVELOPMENT, V122, P3141; STIFANI S, 1992, NAT GENET, V2, P343, DOI 10.1038/ng1292-343a; Tanaka T, 1999, BIOCHEM J, V339, P111, DOI 10.1042/0264-6021:3390111; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Topcu Z, 1999, ONCOGENE, V18, P7091, DOI 10.1038/sj.onc.1203201; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhang H, 2002, GENETICS, V160, P799	68	64	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34938	34947		10.1074/jbc.M404488200	http://dx.doi.org/10.1074/jbc.M404488200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187083	hybrid			2022-12-27	WOS:000223134800105
J	Wagner, KW; Engels, IH; Deveraux, QL				Wagner, KW; Engels, IH; Deveraux, QL			Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH; MITOCHONDRIA; ACTIVATION; APO2L/TRAIL; MECHANISMS; PROTEINS; RELEASE; MODEL; BAX	In many mammalian cell types, engagement of the TRAIL/Apo2L death receptors DR4 and DR5 alters mitochondrial physiology, thereby promoting the release of pro-apoptotic proteins normally contained within this organelle. A contemporary view of this process is that in so-called type II cells death receptor-activated caspase-8 cleaves the Bcl-2 family member Bid, which generates a truncated Bid fragment that collaborates with Bax, another Bcl-2 relative, to promote the release of mitochondrial factors necessary for activation of executioner caspases and apoptosis. Here we show that in some type II cells caspase-2 is necessary for optimal TRAIL-mediated cleavage of Bid. Down-regulation of caspase-2 using RNA interference significantly inhibited TRAIL-induced apoptosis. Analysis of the TRAIL proteolytic cascade following gene silencing of specific pathway components revealed that caspase-2 is necessary for efficient cleavage of Bid; however, caspase-2 proteolytic processing, which occurs downstream of Bax, is not necessary for its role in Bid cleavage.	Novartis Res Fdn, Genom Inst, Dept Canc Biol, San Diego, CA 92121 USA	Novartis	Deveraux, QL (corresponding author), GNF, Dept Canc Biol, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	deveraux@gnf.org						Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 2003, SEMIN CANCER BIOL, V13, P293, DOI 10.1016/S1044-579X(03)00043-9; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roucou Xavier, 2001, Cardiology Clinics, V19, P45, DOI 10.1016/S0733-8651(05)70194-6; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Wagner KW, 2003, CANCER BIOL THER, V2, P534, DOI 10.4161/cbt.2.5.453; Wang XD, 2001, GENE DEV, V15, P2922; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	30	97	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35047	35052		10.1074/jbc.M400708200	http://dx.doi.org/10.1074/jbc.M400708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173176	hybrid			2022-12-27	WOS:000223134800117
J	Lin, J; Yang, QY; Yan, Z; Markowitz, J; Wilder, PT; Carrier, F; Weber, DJ				Lin, J; Yang, QY; Yan, Z; Markowitz, J; Wilder, PT; Carrier, F; Weber, DJ			Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; REGULATORY DOMAIN; PROTEIN; PATHWAY; S100B(BETA-BETA); ACTIVATION; BINDING; FAMILY; GROWTH; GADD45	S100 calcium-binding proteins such as S100B are elevated in primary malignant melanoma and are used as markers for this and numerous other cancers. Wild-type p53 protein levels are relatively low in these cancer cells (i.e. when compared with cells without S100B) but are elevated when RNA antisense to S100B is introduced. This result implicates S100B in the down-regulation of p53 and is consistent with the large decreases in p53 protein levels observed previously in transient co-transfections of p53 and S100B (Lin, J., Blake, M., Tang, C., Zimmer, D., Rustandi, R. R., Weber, D. J., and Carrier, F. (2001) J. Biol. Chem. 276, 35037-35041). Down-regulation of p53 in primary malignant melanoma cells is likely the result of a direct interaction with S100B, which was observed by co-immunoprecipitation experiments. Furthermore, p53 binds regions of the S100B promoter, one of which matches the 20-nucleotide p53-binding consensus DNA sequence perfectly. Therefore, when p53 levels increase, it contributes to its own demise by up-regulating the transcription of S100B as part of a negative feedback loop. This is analogous to what is found for another protein that down-regulates p53, namely hdm2 (human double mutant 2).	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Weber, DJ (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	dweber@umaryland.edu	Weber, David J/B-5349-2011; Markowitz, Joseph/AAS-1041-2021; Carrier, France/C-3063-2008	Weber, David J/0000-0002-8824-1110; Carrier, France/0000-0002-5517-5284	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058888] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058888, GM58888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AMBURGEY JC, 1995, J BIOMOL NMR, V6, P171, DOI 10.1007/BF00211781; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Boni R, 1997, J CUTAN PATHOL, V24, P76, DOI 10.1111/j.1600-0560.1997.tb01100.x; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Carrier F, 1996, MUTAT RES-FUND MOL M, V352, P79, DOI 10.1016/0027-5107(95)00255-3; Carrier F., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P102; Castets F, 1997, MOL BRAIN RES, V46, P208, DOI 10.1016/S0169-328X(96)00298-7; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COCHRAN AJ, 1993, MELANOMA RES, V3, P325, DOI 10.1097/00008390-199310000-00004; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; MARKS A, 1990, EXP CELL RES, V187, P59, DOI 10.1016/0014-4827(90)90116-R; Meek DW, 1997, PATHOL BIOL, V45, P804; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; OConnor PM, 1997, CANCER RES, V57, P4285; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Rustandi RR, 1999, PROTEIN SCI, V8, P1743, DOI 10.1110/ps.8.9.1743; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weber DJ, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P521; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	41	102	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34071	34077		10.1074/jbc.M405419200	http://dx.doi.org/10.1074/jbc.M405419200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178678	hybrid			2022-12-27	WOS:000223039700119
J	Mukhopadhyay, S; Munshi, HG; Kambhampati, S; Sassano, A; Platanias, LC; Stack, MS				Mukhopadhyay, S; Munshi, HG; Kambhampati, S; Sassano, A; Platanias, LC; Stack, MS			Calcium-induced matrix metalloproteinase 9 gene expression is differentially regulated by ERK1/2 and p38 MAPK in oral keratinocytes and oral squamous cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MATRIX-METALLOPROTEINASE; BASEMENT-MEMBRANE; STRUCTURAL PROTEINS; SIGNAL-TRANSDUCTION; MMP-9; HEAD; PHOSPHORYLATION; MIGRATION; CASCADE	Matrix metalloproteinases ( MMPs) play an important role in the invasive behavior of a number of cancers including oral squamous cell cancer (OSCC), and increased expression of MMP-9 is correlated with invasive and metastatic OSCC. Because calcium is an important regulator of keratinocyte function, the effect of modulating extracellular calcium on MMP-9 expression in OSCC cell lines was evaluated. Increasing extracellular calcium induced a dose-dependent increase in MMP-9 expression in immortalized normal and premalignant oral keratinocytes, but not in two highly invasive OSCC cell lines. Differential activation of MAPK signaling was also induced by calcium. p38 MAPK activity was downregulated, whereas ERK1/2 activity was enhanced. Pharmacologic inhibition of p38 MAPK activity or expression of a catalytically inactive mutant of the upstream kinase MAPK kinase 3 (MKK3) increased the calcium induced MMP-9 gene expression, demonstrating that p38 MAPK activity negatively regulated this process. Interestingly blocking p38 MAPK activity enhanced ERK1/2 phosphorylation, suggesting reciprocal regulation between the ERK1/2 and p38 MAPK pathways. Together these data support a model wherein calcium-induced MMP-9 expression is differentially regulated by the ERK1/2 and p38 MAPK pathways in oral keratinocytes, and the data suggest that a loss of this regulatory mechanism accompanies malignant transformation of the oral epithelium.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA077816, T32CA070085, K08CA094877, R01CA085870, R01CA094079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA94079, R01CA77816, R01CA85870, T32 CA70085, K08CA94877] Funding Source: Medline; NIDCR NIH HHS [P01DE12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Corbetta S, 2002, J CLIN ENDOCR METAB, V87, P2201, DOI 10.1210/jc.87.5.2201; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Firth NA, 1996, AUST DENT J, V41, P83, DOI 10.1111/j.1834-7819.1996.tb05918.x; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hong SD, 2000, ORAL ONCOL, V36, P207, DOI 10.1016/S1368-8375(99)00088-3; Ikebe T, 1999, CLIN EXP METASTAS, V17, P315, DOI 10.1023/A:1006642428826; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jordan R C, 1997, J Can Dent Assoc, V63, P517; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; Kobayashi T, 1998, DERMATOLOGY, V197, P1, DOI 10.1159/000017967; Kobayashi T, 2001, EMBO REP, V2, P604, DOI 10.1093/embo-reports/kve129; KUMAGAI S, 1994, HEAD NECK-J SCI SPEC, V16, P51, DOI 10.1002/hed.2880160111; Kurahara S, 1999, HEAD NECK-J SCI SPEC, V21, P627, DOI 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.3.CO;2-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lakka SS, 2002, ONCOGENE, V21, P5601, DOI 10.1038/sj.onc.1205646; Li SP, 2003, CANCER RES, V63, P3473; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Mauro T, 1998, J INVEST DERMATOL, V111, P1198, DOI 10.1046/j.1523-1747.1998.00421.x; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MENON GK, 1994, J INVEST DERMATOL, V102, P789, DOI 10.1111/1523-1747.ep12377921; Munshi HG, 2002, J BIOL CHEM, V277, P38159, DOI 10.1074/jbc.M202384200; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Numazawa S, 2003, J BIOCHEM, V133, P599, DOI 10.1093/jb/mvg077; Oda D, 1996, EXP CELL RES, V226, P164, DOI 10.1006/excr.1996.0215; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RHEINWALD JG, 1981, CANCER RES, V41, P1657; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKR WA, 1987, HUM PATHOL, V18, P1043, DOI 10.1016/S0046-8177(87)80221-6; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Simon C, 1998, LARYNGOSCOPE, V108, P1686, DOI 10.1097/00005537-199811000-00018; Simon C, 1999, BRIT J CANCER, V80, P1412, DOI 10.1038/sj.bjc.6690537; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Wong H, 2000, METH MOL B, V151, P305, DOI 10.1385/1-59259-046-2:305; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	47	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33139	33146		10.1074/jbc.M405194200	http://dx.doi.org/10.1074/jbc.M405194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180997	hybrid			2022-12-27	WOS:000223039700016
J	Oliveira, JS; Redaelli, E; Zaharenko, AJ; Cassulini, RR; Konno, K; Pimenta, DC; Freitas, JC; Clare, JJ; Wanke, E				Oliveira, JS; Redaelli, E; Zaharenko, AJ; Cassulini, RR; Konno, K; Pimenta, DC; Freitas, JC; Clare, JJ; Wanke, E			Binding specificity of sea anemone toxins to Na(v)1.1-1.6 sodium channels - Unexpected contributions from differences in the IV/S3-S4 outer loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE ANTHOPLEURIN-B; HUMAN BRAIN; PHARMACOLOGICAL PROPERTIES; FUNCTIONAL-ANALYSIS; SCORPION TOXINS; CELL-LINE; RESIDUES; SUBUNIT; CLONING; NEURONS	Sea anemones are an important source of various biologically active peptides, and it is known that ATX-II from Anemonia sulcata slows sodium current inactivation. Using six different sodium channel genes ( from Na(v)1.1 to Na(v)1.6), we investigated the differential selectivity of the toxins AFT-II ( purified from Anthopleura fuscoviridis) and Bc-III ( purified from Bunodosoma caissarum) and compared their effects with those recorded in the presence of ATX-II. Interestingly, ATX-II and AFT-II differ by only one amino acid (L36A) and Bc-III has 70% similarity. The three toxins induced a low voltage-activated persistent component primarily in the Na(v)1.3 and Na(v)1.6 channels. An analysis showed that the 18 dose-response curves only partially fit the hypothesized binding of Lys-37 ( sea anemone toxin Anthopleurin B) to the Asp ( or Glu) residue of the extracellular IV/S3-S4 loop in cardiac ( or nervous) Na+ channels, thus suggesting the substantial contribution of some nearby amino acids that are different in the various channels. As these channels are atypically expressed in mammalian tissues, the data not only suggest that the toxicity is highly dependent on the channel type but also that these toxins and their various physiological effects should be considered prototype models for the design of new and specific pharmacological tools.	Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Univ Sao Paulo, Dept Fisiol, Inst Biosci, BR-05508900 Sao Paulo, Brazil; Inst Butantan, Ctr Toxinol Aplicada, CAT CEPID FAPESP, BR-05503900 Sao Paulo, Brazil; GlaxoSmithKline, Med Res Ctr, Gene Express & Prot Biochem, Stevenage SG1 2NY, Herts, England	University of Milano-Bicocca; Universidade de Sao Paulo; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Instituto Butantan; GlaxoSmithKline	Wanke, E (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	enzo.wanke@unimib.it	Pimenta, Daniel C/B-4361-2008; Stolarz-de-Oliveira, Joacir/AAG-4165-2020; Zaharenko, André/A-4946-2010	Pimenta, Daniel C/0000-0003-2406-0860; Stolarz-de-Oliveira, Joacir/0000-0002-0764-017X; Zaharenko, André/0000-0003-0374-1608; Konno, Katsuhiro/0000-0002-1949-1845				Benzinger GR, 1998, J BIOL CHEM, V273, P80, DOI 10.1074/jbc.273.1.80; BERESS L, 1975, FEBS LETT, V50, P311, DOI 10.1016/0014-5793(75)80517-5; Bosmans F, 2002, FEBS LETT, V532, P131, DOI 10.1016/S0014-5793(02)03653-0; Brand S, 2000, EUR J NEUROSCI, V12, P2387, DOI 10.1046/j.1460-9568.2000.00136.x; Burbidge SA, 2002, MOL BRAIN RES, V103, P80, DOI 10.1016/S0169-328X(02)00188-2; CATTERAL WA, 2002, IUPHAR COMPENDIUM VO; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chahine M, 1996, J MEMBRANE BIOL, V152, P39, DOI 10.1007/s002329900083; Chen HJ, 2002, EUR J NEUROSCI, V16, P767, DOI 10.1046/j.1460-9568.2002.02142.x; Chen YH, 2000, EUR J NEUROSCI, V12, P4281, DOI 10.1111/j.1460-9568.2000.01336.x; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; Goudet C, 2001, BRIT J PHARMACOL, V134, P1195, DOI 10.1038/sj.bjp.0704361; ISOM LI, 1995, J BIOL CHEM, V17, P3306; Khera PK, 1996, BIOCHEMISTRY-US, V35, P3503, DOI 10.1021/bi9528457; Lanio ME, 2001, TOXICON, V39, P187, DOI 10.1016/S0041-0101(00)00106-9; LORET EP, 1994, J BIOL CHEM, V269, P16785; MALPEZZI ELA, 1993, TOXICON, V31, P853, DOI 10.1016/0041-0101(93)90220-D; Mantegazza M, 1998, J PHYSIOL-LONDON, V507, P105, DOI 10.1111/j.1469-7793.1998.105bu.x; MEIER J, 1986, TOXICON, V24, P395, DOI 10.1016/0041-0101(86)90199-6; Moran O, 2000, FEBS LETT, V473, P132, DOI 10.1016/S0014-5793(00)01518-0; Mouhat S, 2004, BIOCHEM J, V378, P717, DOI 10.1042/BJ20031860; Rees S, 1996, BIOTECHNIQUES, V20, P102; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; ROMEY G, 1980, J PHARMACOL EXP THER, V213, P607; Salceda E, 2002, J PHARMACOL EXP THER, V303, P1067, DOI 10.1124/jpet.102.038570; SUNAHARA S, 1987, TOXICON, V25, P211, DOI 10.1016/0041-0101(87)90243-1; WIDMER H, 1989, PROTEINS, V6, P357, DOI 10.1002/prot.340060403; Xie XM, 2001, PFLUG ARCH EUR J PHY, V441, P425, DOI 10.1007/s004240000448	29	89	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33323	33335		10.1074/jbc.M404344200	http://dx.doi.org/10.1074/jbc.M404344200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169781	hybrid			2022-12-27	WOS:000223039700039
J	Yarmola, EG; Bubb, MR				Yarmola, EG; Bubb, MR			Effects of profilin and thymosin beta(4) on the critical concentration of actin demonstrated in vitro and in cell extracts with a novel direct assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; BARBED-END; RATE CONSTANTS; ADP-ACTIN; QUANTITATIVE-ANALYSIS; ELECTRON-MICROSCOPY; PROTEIN FUNCTION; ATP-ACTIN; FILAMENTS; POLYMERIZATION	The free actin concentration at steady state, A(c), is a variable that determines how actin regulatory proteins influence the extent of actin polymerization. We describe a novel method employing fluorescence anisotropy to directly measure A(c) in any sample after the addition of a trace amount of labeled thymosin beta(4) or thymosin beta(4) peptide. Using this assay, we confirm earlier theoretical work on the helical polymerization of actin and confirm the effects of actin filament-stabilizing drugs and capping proteins on A(c), thereby validating the assay. We also confirm a controversial prior observation that profilin lowers the critical concentration of Mg2+-actin. A general mechanism is proposed to explain this effect, and the first quantitative dose-response curve for the effect of profilin on A(c) facilitates its evaluation. This mechanism also predicts the effect of profilin on critical concentration in the presence of the limited amount of capping protein, which is the condition often found in cells, and the effect of profilin on critical concentration in cell extracts is demonstrated for the first time. Additionally, nonlinear effects of thymosin beta(4) on the steady state amount of F-actin are explained by the observed changes in A(c). This assay has potential in vivo applications that complement those demonstrated in vitro.	Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Malcom Randall Dept Vet Affairs Med Ctr, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida	Bubb, MR (corresponding author), Univ Florida, Coll Med, Dept Med, Box 100221, Gainesville, FL 32610 USA.	bubbmr@medicine.ufl.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K25AR048918] Funding Source: NIH RePORTER; NIAMS NIH HHS [5K25AR048918] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Blanchoin L, 2002, BIOCHEMISTRY-US, V41, P597, DOI 10.1021/bi011214b; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; BONDER EM, 1983, CELL, V34, P491, DOI 10.1016/0092-8674(83)90382-3; Bubb MR, 2003, J BIOL CHEM, V278, P24629, DOI 10.1074/jbc.M302796200; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; Clayton AHA, 2002, BIOPHYS J, V83, P1631, DOI 10.1016/S0006-3495(02)73932-5; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CRAIG SW, 1980, CELL, V22, P739, DOI 10.1016/0092-8674(80)90550-4; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; DiNubile MJ, 1997, CELL MOTIL CYTOSKEL, V37, P211, DOI 10.1002/(SICI)1097-0169(1997)37:3<211::AID-CM3>3.0.CO;2-9; Geese M, 2000, J CELL SCI, V113, P1415; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Hertzog M, 2002, J BIOL CHEM, V277, P14786, DOI 10.1074/jbc.M112064200; JANMEY PA, 1986, J BIOL CHEM, V261, P8357; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Kinosian HJ, 2002, BIOCHEMISTRY-US, V41, P6734, DOI 10.1021/bi016083t; NISHIDA E, 1981, J BIOCHEM-TOKYO, V89, P1197; Nyman T, 2002, J BIOL CHEM, V277, P15828, DOI 10.1074/jbc.M112195200; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; OOSAWA F, 1975, THERMODYNAMICS POLYM, P109; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1981, J CELL BIOL, V88, P654, DOI 10.1083/jcb.88.3.654; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Selden LA, 1998, BIOPHYS J, V75, P3092, DOI 10.1016/S0006-3495(98)77750-1; TARDIF M, 1995, J BIOL CHEM, V270, P28075; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P3207, DOI 10.1021/bi00256a027; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5; Yao XY, 2001, J BIOL CHEM, V276, P25598, DOI 10.1074/jbc.M011797200; Yarmola EG, 2001, J BIOL CHEM, V276, P45555, DOI 10.1074/jbc.M105723200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; YIN HL, 1980, J BIOL CHEM, V255, P9494	41	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33519	33527		10.1074/jbc.M404392200	http://dx.doi.org/10.1074/jbc.M404392200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184365	hybrid			2022-12-27	WOS:000223039700060
J	Jekabsons, MB; Nicholls, DG				Jekabsons, MB; Nicholls, DG			In situ respiration and bioenergetic status of mitochondria in primary cerebellar granule neuronal cultures exposed continuously to glutamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HIPPOCAMPAL-NEURONS; PLASMA-MEMBRANE DEPOLARIZATION; NITRIC-OXIDE; NMDA-RECEPTOR; CALCIUM HOMEOSTASIS; BRAIN NEURONS; PROTON LEAK; CELL-DEATH; NEUROTOXICITY; EXCITOTOXICITY	Mitochondria play a central role in neuronal death during pathological exposure to glutamate (excitotoxicity). To investigate the detailed bioenergetics of the in situ mitochondria, a method is described to monitor continuously the respiration of primary cerebellar granule neuron cultures while simultaneously imaging cytoplasmic Ca2+ and mitochondrial membrane potential. Coverslip-attached cells were perfused in an imaging chamber with upstream and downstream flow-through oxygen electrodes. The bioenergetic consequences of chronic glutamate exposure were investigated, including ATP supply and demand, proton leak, and mitochondrial respiratory capacity during chronic glutamate exposure. In 25 mM K+ medium supplemented with 10% dialyzed serum, cells utilized 54% of their respiratory capacity in the absence of receptor activation (37% for ATP generation, 12% to drive the mitochondrial proton leak, and the residual 5% was nonmitochondrial). Glutamate initially increased mitochondrial respiration from 51 to 68% of capacity, followed by a slow decline. It was estimated that 85% of this increased respiration was because of increased ATP demand, whereas 15% was attributable to a transient mitochondrial proton leak. N-Methyl-D-aspartate receptor activation was only responsible for 62% of the increased respiration. When adjusted for cell death over 3 h of glutamate exposure, respiration of the viable cells remained near basal and protonophore stimulated respiration to the same extent as control cells. Pyruvate-supplemented media protected cells from glutamate excitotoxicity, although this was associated with mitochondrial dysfunction. We conclude that excitotoxicity under these conditions is not because of an ATP deficit or uncoupling. Furthermore, mitochondria maintain the same respiratory capacity as in control cells.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Nicholls, DG (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	dnicholls@buckinstitute.org	NICHOLLS, DAVID G/K-4300-2012		NATIONAL INSTITUTE ON AGING [R01AG021440] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG21440] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almeida A, 1999, BRAIN RES, V816, P580, DOI 10.1016/S0006-8993(98)01240-2; Almeida A, 1998, BRAIN RES, V790, P209, DOI 10.1016/S0006-8993(98)00064-X; Atlante A, 1996, NEUROREPORT, V7, P2519, DOI 10.1097/00001756-199611040-00023; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Bal-Price A, 2002, J NEUROCHEM, V80, P73, DOI 10.1046/j.0022-3042.2001.00675.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; Castilho RF, 1998, J NEUROSCI, V18, P10277; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; Desagher S, 1997, J NEUROSCI, V17, P9060; Dienel GA, 2001, J NEUROSCI RES, V66, P824, DOI 10.1002/jnr.10079; EIMERL S, 1995, J NEUROCHEM, V65, P739; EIMERL S, 1994, J NEUROCHEM, V62, P1223; GALLO V, 1987, J NEUROSCI, V7, P2203; GARTHWAITE G, 1986, NEUROSCI LETT, V66, P193, DOI 10.1016/0304-3940(86)90189-8; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HERTZ L, 1988, NEUROCHEM RES, V13, P605, DOI 10.1007/BF00973275; HERTZ L, 1992, CAN J PHYSIOL PHARM, V70, P145; Izumi Y, 1997, J NEUROSCI, V17, P9448; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; NICHOLLS DG, 1980, BIOCHEM J, V186, P833, DOI 10.1042/bj1860833; NICHOLLS DG, 2002, BIOENERGETICS, P57; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; PLATT B, 1995, NEUROPHARMACOLOGY, V34, P1339, DOI 10.1016/0028-3908(95)00123-N; POCOCK JM, 1993, NEUROPHARMACOLOGY, V32, P1185, DOI 10.1016/0028-3908(93)90012-R; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Ruiz F, 1998, NEUROREPORT, V9, P1277; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; VILLALBA M, 1994, J BIOL CHEM, V269, P2468; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; Ward MW, 2000, J NEUROSCI, V20, P7208; White RJ, 1996, J NEUROSCI, V16, P5688	44	109	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32989	33000		10.1074/jbc.M401540200	http://dx.doi.org/10.1074/jbc.M401540200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166243	hybrid			2022-12-27	WOS:000222849700119
J	Nenquin, M; Szollosi, A; Aguilar-Bryan, L; Bryan, J; Henquin, JC				Nenquin, M; Szollosi, A; Aguilar-Bryan, L; Bryan, J; Henquin, JC			Both triggering and amplifying pathways contribute to fuel-induced insulin secretion in the absence of sulfonylurea receptor-1 in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; CYTOPLASMIC CA2+; PROTEIN-KINASE; KNOCKOUT MICE; ELECTRICAL-ACTIVITY; INTRACELLULAR CA2+; MOUSE ISLETS; B-CELLS; GLUCOSE; ATP	In normal beta-cells glucose induces insulin secretion by activating both a triggering pathway (closure of K-ATP channels, depolarization, and rise in cytosolic [Ca2+](i)) and an amplifying pathway (augmentation of Ca2+ efficacy on exocytosis). It is unclear if and how nutrients can regulate insulin secretion by beta-cells lacking K-ATP channels (Sur1 knockout mice). We compared glucose- and amino acid-induced insulin secretion and [Ca2+](i) changes in control and Sur1KO islets. In 1 mM glucose (non-stimulatory for controls), the triggering signal [Ca2+](i) was high (loss of regulation) and insulin secretion was stimulated in Sur1KO islets. This "basal" secretion was decreased or increased by imposed changes in [Ca2+](i) and was dependent on ATP production, indicating that both triggering and amplifying signals are involved. High glucose stimulated insulin secretion in Sur1KO islets, by an unsuspected, transient increase in [Ca2+](i) and a sustained activation of the amplifying pathway. Unlike controls, Sur1KO islets were insensitive to diazoxide and tolbutamide, which rules out effects of either drug at sites other than K-ATP channels. Amino acids potently increased insulin secretion by Sur1KO islets through both a further electrogenic rise in [Ca2+](i) and a metabolism-dependent activation of the amplifying pathway. After sulfonylurea blockade of their K-ATP channels, control islets qualitatively behaved like Sur1KO islets, but their insulin secretion rate was consistently lower for a similar or even higher [Ca2+](i). In conclusion, fuel secretagogues can control insulin secretion in beta-cells without K-ATP channels, partly by an unsuspected influence on the triggering [Ca2+](i) signal and mainly by the modulation of a very effective amplifying pathway.	Univ Louvain, Fac Med UCL 55 30, Unite Endocrinol & Metab, B-1200 Brussels, Belgium; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Universite Catholique Louvain; Baylor College of Medicine; Baylor College of Medicine	Henquin, JC (corresponding author), Univ Louvain, Fac Med UCL 55 30, Unite Endocrinol & Metab, Ave Hippocrate 55, B-1200 Brussels, Belgium.	henquin@endo.ucl.ac.be	Szollosi, Andras/J-5097-2013; Szollosi, Andras/P-4278-2019	Szollosi, Andras/0000-0002-5570-4609	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057671, R01DK052771] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57671, DK52771] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Aizawa T, 2002, DIABETES, V51, pS96, DOI 10.2337/diabetes.51.2007.S96; Ammala C, 2000, DIABETES, V49, pA62; Anello M, 1999, BRIT J PHARMACOL, V127, P1883, DOI 10.1038/sj.bjp.0702731; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; Barg S, 2002, DIABETES, V51, pS74, DOI 10.2337/diabetes.51.2007.S74; Bertrand G, 2002, J BIOL CHEM, V277, P32883, DOI 10.1074/jbc.M205326200; Bolea S, 1997, PFLUG ARCH EUR J PHY, V433, P699, DOI 10.1007/s004240050334; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; Doliba NM, 2004, AM J PHYSIOL-ENDOC M, V286, pE834, DOI 10.1152/ajpendo.00292.2003; Dufer M, 2004, DIABETOLOGIA, V47, P488, DOI 10.1007/s00125-004-1348-0; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Eto K, 2002, DIABETES, V51, P87, DOI 10.2337/diabetes.51.1.87; GarciaBarrado MJ, 1996, EUR J PHARMACOL, V298, P279, DOI 10.1016/0014-2999(95)00806-3; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; Geng XH, 2003, DIABETES, V52, P767, DOI 10.2337/diabetes.52.3.767; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; GILON P, 1992, J BIOL CHEM, V267, P20713; Harris TE, 2000, BIOCHEM BIOPH RES CO, V270, P1119, DOI 10.1006/bbrc.2000.2563; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HENQUIN JC, 1978, NATURE, V271, P271, DOI 10.1038/271271a0; Henquin JC, 2003, EUR J CLIN INVEST, V33, P742, DOI 10.1046/j.1365-2362.2003.01207.x; Henquin JC, 2002, DIABETES, V51, pS60, DOI 10.2337/diabetes.51.2007.S60; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HERMANS MP, 1987, DIABETOLOGIA, V30, P659; Jonas JC, 1998, DIABETES, V47, P1266, DOI 10.2337/diabetes.47.8.1266; Komatsu M, 2001, ENDOCR J, V48, P275, DOI 10.1507/endocrj.48.275; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; Liu YJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE380, DOI 10.1152/ajpendo.00008.2003; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Minami K, 2002, J BIOL CHEM, V277, P25277, DOI 10.1074/jbc.M203988200; Nakazaki M, 2002, DIABETES, V51, P3440, DOI 10.2337/diabetes.51.12.3440; Nichols CG, 2002, AM J PHYSIOL-ENDOC M, V283, pE403, DOI 10.1152/ajpendo.00168.2002; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; PANTEN U, 1984, BIOCHEM J, V219, P189, DOI 10.1042/bj2190189; PRENTKI M, 1983, J BIOL CHEM, V258, P4239; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Rutter Guy A., 2001, Molecular Aspects of Medicine, V22, P247, DOI 10.1016/S0098-2997(01)00013-9; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; Sato Y, 1999, ENDOCRINOLOGY, V140, P2252, DOI 10.1210/en.140.5.2252; Sato Y, 1998, DIABETES, V47, P1713, DOI 10.2337/diabetes.47.11.1713; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Shiota C, 2002, J BIOL CHEM, V277, P37176, DOI 10.1074/jbc.M206757200; Sieg A, 2004, AM J PHYSIOL-ENDOC M, V286, pE463, DOI 10.1152/ajpendo.00365.2003; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Takahashi N, 1999, P NATL ACAD SCI USA, V96, P760, DOI 10.1073/pnas.96.2.760; Wollheim CB, 2002, DIABETES, V51, pS37, DOI 10.2337/diabetes.51.2007.S37	56	87	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32316	32324		10.1074/jbc.M402076200	http://dx.doi.org/10.1074/jbc.M402076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175349	hybrid			2022-12-27	WOS:000222849700042
J	Jiang, HD; Liu, XY				Jiang, HD; Liu, XY			Principles of mimicking and engineering the self-organized structure of hard tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEATION; EPIPHYSEAL CARTILAGE; LIQUID NUCLEATION; HYDROXYAPATITE; MACROMOLECULES; CALCIFICATION; AGGREGATION; INDUCTION; CRYSTALS; MATRIX	The mechanism of the formation of a self-aligned hydroxyapatite (HAP) nanocrystallite structure was examined. It is found that the highly ordered HAP nanocrystallite assembly is attributed to the so-called self(homo)epitaxial nucleation and growth. On the other hand, according to this mechanism, a high supersaturation will give rise to a random assembly of HAP crystallites. The effects of ions, biosubstrate, and supersaturation on the micro/nanostructure correlation between substrate and biominerals as well as their implications in hard tissue formation were examined. Surprisingly, some biomolecules are found to be able to suppress the supersaturation-driven interfacial structure mismatch and hence promote the well aligned HAP pattern formation.	Natl Univ Singapore, Dept Phys, Singapore 117542, Singapore	National University of Singapore	Jiang, HD (corresponding author), Natl Univ Singapore, Dept Phys, 2 Sci Dr 3, Singapore 117542, Singapore.	phyliuxy@nus.edu.sg	Zhou, Weiqian/B-8991-2011; Liu, XY/E-5090-2010; Li, Jingliang/A-6039-2011	Liu, XY/0000-0002-4747-1251; Li, Jingliang/0000-0003-0709-2246; Liu, Xiang-Yang/0000-0002-5592-6885				ALI SY, 1973, BIOCHEM J, V134, P647, DOI 10.1042/bj1340647; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BERMAN A, 1993, SCIENCE, V259, P776, DOI 10.1126/science.259.5096.776; BERMAN A, 1988, NATURE, V331, P546, DOI 10.1038/331546a0; CHERNOV AA, 1984, MODERN CRYSTALLOGRAP, V3, P225; Elliott J. C., 1994, STRUCTURE CHEM APATI, V18, P111; EVERETT DH, 1994, BASIC PRINCIPLES COL, P185; Gebhardt M., 1972, CRYSTAL GROWTH INTRO, P105; GLIMCHER MJ, 1989, P 3 INT C CHEM BIOL, P617; HARRIS DC, 1999, QUANTITATIVE CHEM AN, P175; HUNTER GK, 1989, J THEOR BIOL, V138, P195, DOI 10.1016/S0022-5193(89)80139-0; KAY MI, 1964, NATURE, V204, P1050, DOI 10.1038/2041050a0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi N, 2004, KEY ENG MATER, V254-2, P537, DOI 10.4028/www.scientific.net/KEM.254-256.537; KOKUBO T, 1990, J BIOMED MATER RES, V24, P331, DOI 10.1002/jbm.820240306; LAAKSONEN A, 1995, ANNU REV PHYS CHEM, V46, P489, DOI 10.1146/annurev.pc.46.100195.002421; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; Liu JQ, 2001, BOT BULL ACAD SINICA, V42, P61; Liu XY, 1999, J CHEM PHYS, V111, P1628, DOI 10.1063/1.479391; Liu XY, 2003, J AM CHEM SOC, V125, P888, DOI 10.1021/ja020355d; Liu XY, 2000, J CHEM PHYS, V112, P9949, DOI 10.1063/1.481644; Liu XY, 2000, LANGMUIR, V16, P7337, DOI 10.1021/la991333g; Liu XY, 2000, J CHEM PHYS, V113, P4408, DOI 10.1063/1.1288030; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MCDOWELL H, 1977, J RES NBS A PHYS CH, V81, P273, DOI 10.6028/jres.081A.017; McGraw R, 1996, PHYS REV LETT, V76, P2754, DOI 10.1103/PhysRevLett.76.2754; MOSS M, 1965, ORAL SURG ORAL MED O, V20, P795, DOI 10.1016/0030-4220(65)90143-X; Oxtoby DW, 2000, NATURE, V406, P464, DOI 10.1038/35020163; Rodriguez-Clemente R, 1998, J EUR CERAM SOC, V18, P1351, DOI 10.1016/S0955-2219(98)00064-8; Saito T, 1997, BONE, V21, P305, DOI 10.1016/S8756-3282(97)00149-X; Siesser, 1994, COCCOLITHOPHORES, P51; SOHNEL O, 1988, J COLLOID INTERF SCI, V123, P43, DOI 10.1016/0021-9797(88)90219-6; Ten Cate A.R., 1985, ORAL HISTOLOGY DEV S; WEAKLIEM CL, 1994, J CHEM PHYS, V101, P2398, DOI 10.1063/1.467680; WINTER WT, 1978, J MOL BIOL, V125, P1, DOI 10.1016/0022-2836(78)90251-6; ZENG XC, 1991, J CHEM PHYS, V94, P4472, DOI 10.1063/1.460603; Zettlemoyer A. C., 1969, NUCLEATION	37	40	40	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41286	41293		10.1074/jbc.M314027200	http://dx.doi.org/10.1074/jbc.M314027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15192103	hybrid			2022-12-27	WOS:000224075500007
J	Vo, TD; Greenberg, HJ; Palsson, BO				Vo, TD; Greenberg, HJ; Palsson, BO			Reconstruction and functional characterization of the human mitochondrial metabolic network based on proteomic and biochemical data	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-COMPOSITION; FLUX-BALANCE ANALYSIS; HEART-MITOCHONDRIA; ENERGY-METABOLISM; CARRIER; TRANSPORT; PHOSPHATIDYLSERINE; ORGANIZATION; BIOGENESIS; OXIDATION	Diverse datasets including genomic, proteomic, isotopomer, and DNA sequence variation are becoming available for human mitochondria. Thus there is a need to integrate these data within an in silico modeling framework where mitochondrial biology and related disorders can be studied and analyzed. This paper reports a reconstruction and characterization of the human mitochondrial metabolic network based on proteomic and biochemical data. The 189 reactions included in this reconstruction are both elementally and charge-balanced and are assigned to their respective cellular compartments (mitochondrial, cytosol, or extracellular). The capabilities of the reconstructed network to fulfill three metabolic functions (ATP production, heme synthesis, and mixed phospholipid synthesis) were determined. Network-based analysis of the mitochondrial energy conversion process showed that the overall ATP yield per glucose is 31.5. Network flexibility, characterized by allowable variation in reaction fluxes, was evaluated using flux variability analysis and analysis of all of the possible optimal flux distributions. Results showed that the network has high flexibility for the biosynthesis of heme and phospholipids but modest flexibility for maximal ATP production. A subset of all of the optimal network flux distributions, computed with respect to the three metabolic functions individually, was found to be highly correlated, suggesting that this set may contain physiological meaningful fluxes. Examinations of optimal flux distributions also identified correlated reaction sets that form functional modules in the network.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Colorado, Dept Math, Denver, CO 80217 USA	University of California System; University of California San Diego; University of Colorado System; University of Colorado Denver	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr,POB 0412, La Jolla, CA 92093 USA.	bpalsson@be-research.ucsd.edu		Palsson, Bernhard/0000-0003-2357-6785				Aimar-Beurton M, 2002, MOL BIOL REP, V29, P227, DOI 10.1023/A:1020338115406; ANDERSON ED, 2002, MOSEK APS; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Antunes F, 2002, FREE RADICAL BIO MED, V33, P1260, DOI 10.1016/S0891-5849(02)01016-X; Atamna H, 2002, ARCH BIOCHEM BIOPHYS, V397, P345, DOI 10.1006/abbi.2001.2671; Avis D, 2000, DMV SEMINAR, V29, P177; AVIS D, 2003, IRS; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; Brown G.C.N.D.G., 1999, MITOCHONDRIA CELL DE; BUNGER R, 1993, BIOCHIM BIOPHYS ACTA, V1151, P223, DOI 10.1016/0005-2736(93)90107-B; Burgard AP, 2004, GENOME RES, V14, P301, DOI 10.1101/gr.1926504; CAREW JS, 2002, MOL CANC; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; Cortassa S, 2003, BIOPHYS J, V84, P2734, DOI 10.1016/S0006-3495(03)75079-6; Covert MW, 2001, TRENDS BIOCHEM SCI, V26, P179, DOI 10.1016/S0968-0004(00)01754-0; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Duarte NC, 2004, GENOME RES, V14, P1298, DOI 10.1101/gr.2250904; Edwards JS, 2000, BMC BIOINFORMATICS, V1, DOI 10.1186/1471-2105-1-1; Edwards JS, 2002, BIOTECHNOL BIOENG, V77, P27, DOI 10.1002/bit.10047; EDWARDS JS, 1999, METAB ENG, P13; Fiermonte G, 1999, BIOCHEM J, V344, P953, DOI 10.1042/0264-6021:3440953; Fiermonte G, 2003, J BIOL CHEM, V278, P32778, DOI 10.1074/jbc.M302317200; *GAMS DEV CORP, 2003, GAMS; *GEN, 2003, SYMPHENY; GLOSTER J, 1969, CARDIOVASC RES, V3, P45, DOI 10.1093/cvr/3.1.45; GLOSTER J, 1970, Journal of Molecular and Cellular Cardiology, V1, P459, DOI 10.1016/0022-2828(70)90042-8; Grynberg A, 1996, J CARDIOVASC PHARM, V28, pS11; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1069, P110, DOI 10.1016/0005-2736(91)90110-T; Kauffman KJ, 2003, CURR OPIN BIOTECH, V14, P491, DOI 10.1016/j.copbio.2003.08.001; Korzeniewski B, 1996, BIOCHEM J, V319, P143, DOI 10.1042/bj3190143; Lee S, 2000, COMPUT CHEM ENG, V24, P711, DOI 10.1016/S0098-1354(00)00323-9; Lehninger A., 1993, PRINCIPLES BIOCH; Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490; Mahadevan R, 2003, METAB ENG, V5, P264, DOI 10.1016/j.ymben.2003.09.002; *MATHWORKS INC, 2003, MATLAB; MURTHY MSR, 1984, J BIOL CHEM, V259, P9082; Ozawa T, 2003, NAT BIOTECHNOL, V21, P287, DOI 10.1038/nbt791; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Palsson B, 2000, NAT BIOTECHNOL, V18, P1147, DOI 10.1038/81125; Papin JA, 2002, J THEOR BIOL, V215, P67, DOI 10.1006/jtbi.2001.2499; Papin JA, 2002, GENOME RES, V12, P1889, DOI 10.1101/gr.327702; Phalakornkule C, 2001, METAB ENG, V3, P124, DOI 10.1006/mben.2000.0165; Price ND, 2002, BIOPHYS J, V83, P2879, DOI 10.1016/S0006-3495(02)75297-1; Price ND, 2002, GENOME RES, V12, P760, DOI 10.1101/gr.218002; Ramakrishna R, 2001, AM J PHYSIOL-REG I, V280, pR695, DOI 10.1152/ajpregu.2001.280.3.R695; Reed JL, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r54; ROCQUELIN G, 1989, LIPIDS, V24, P775, DOI 10.1007/BF02544583; ROCQUELIN G, 1985, J MOL CELL CARDIOL, V17, P769, DOI 10.1016/S0022-2828(85)80038-9; Salway J.G., 2017, METABOLISM GLANCE; Santos DL, 2003, MOL CELL BIOCHEM, V246, P163, DOI 10.1023/A:1023475022025; Schilling CH, 2000, J THEOR BIOL, V203, P229, DOI 10.1006/jtbi.2000.1073; Searcy DG, 2003, CELL RES, V13, P229, DOI 10.1038/sj.cr.7290168; SEDMAN R, 1982, BIOCHEM PHARMACOL, V31, P761, DOI 10.1016/0006-2952(82)90460-9; Sherry AD, 2004, METAB ENG, V6, P12, DOI 10.1016/j.ymben.2003.10.007; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Verma M, 2003, NAT REV CANCER, V3, P789, DOI 10.1038/nrc1192; Voet D, 1999, FUNDAMENTALS BIOCH; Vu TH, 2002, NEUROL CLIN, V20, P809, DOI 10.1016/S0733-8619(01)00017-2; Westermann B, 2003, NAT BIOTECHNOL, V21, P239, DOI 10.1038/nbt0303-239; Williamson J R, 1980, Ann N Y Acad Sci, V341, P593, DOI 10.1111/j.1749-6632.1980.tb47201.x	65	110	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39532	39540		10.1074/jbc.M403782200	http://dx.doi.org/10.1074/jbc.M403782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15205464	hybrid			2022-12-27	WOS:000223791500043
J	Bhattacharya, A; Lakhman, SS; Singh, S				Bhattacharya, A; Lakhman, SS; Singh, S			Modulation of L-type calcium channels in Drosophila via a pituitary adenylyl cyclase-activating polypeptide (PACAP)-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARVAL MUSCLE-FIBERS; POTASSIUM CURRENTS; CA2+ CHANNEL; PACAP; RELEASE; CELLS; NEUROPEPTIDE; RECEPTORS; SECRETION; TRANSCRIPTION	Modulation of calcium channels plays an important role in many cellular processes. Previous studies have shown that the L-type Ca2+ channels in Drosophila larval muscles are modulated via a cAMP-protein kinase A (PKA)-mediated pathway. This raises questions on the identity of the steps prior to cAMP, particularly the endogenous signal that may initiate this modulatory cascade. We now present data suggesting the possible role of a neuropeptide, pituitary adenylyl cyclase-activating polypeptide ( PACAP), in this modulation. Mutations in the amnesiac (amn) gene, which encodes a polypeptide homologous to human PACAP-38, reduced the L-type current in larval muscles. Conditional expression of a wild-type copy of the amn gene rescued the current from this reduction. Bath application of human PACAP-38 also rescued the current. PACAP-38 did not rescue the mutant current in the presence of PACAP-6 38, an antagonist at type-I PACAP receptor. 2', 5'-dideoxyadenosine, an inhibitor of adenylyl cyclase, prevented PACAP-38 from rescuing the amn current. In addition, 2', 5'-dideoxyadenosine reduced the wild-type current to the level seen in amn, whereas it failed to further reduce the current observed in amn muscles. H-89, an inhibitor of PKA, suppressed the effect of PACAP-38 on the current. The above data suggest that PACAP, the type-I PACAP receptors, and adenylyl cyclase play a role in the modulation of L-type Ca2+ channels via cAMP-PKA pathway. The data also provide support for functional homology between human PACAP-38 and the amn gene product in Drosophila.	SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Singh, S (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, 102 Farber Hall, Buffalo, NY 14214 USA.	singhs@buffalo.edu			NIGMS NIH HHS [GM-50779] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050779] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIDLEY DJ, 1998, PHYSL EXCITABLE CELS; Akiyama M, 2001, J NEUROCHEM, V78, P499, DOI 10.1046/j.1471-4159.2001.00452.x; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Ashburner M., 1989, DROSOPHILA LAB HDB; Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; Bhattacharya A, 1999, J NEUROBIOL, V39, P491, DOI 10.1002/(SICI)1097-4695(19990615)39:4<491::AID-NEU3>3.0.CO;2-6; Chang CH, 1998, AM J PHYSIOL-GASTR L, V275, pG192, DOI 10.1152/ajpgi.1998.275.2.G192; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; CHOPRA M, 1994, J NEUROBIOL, V25, P119, DOI 10.1002/neu.480250204; Cooper EC, 1999, P NATL ACAD SCI USA, V96, P4759, DOI 10.1073/pnas.96.9.4759; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; Davies NP, 2003, CURR OPIN NEUROL, V16, P559, DOI 10.1097/00019052-200310000-00001; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DeZazzo J, 1999, J NEUROSCI, V19, P8740, DOI 10.1523/JNEUROSCI.19-20-08740.1999; Dubnau J, 1998, ANNU REV NEUROSCI, V21, P407, DOI 10.1146/annurev.neuro.21.1.407; Dziema H, 2002, J NEUROPHYSIOL, V88, P1374, DOI 10.1152/jn.2002.88.3.1374; EVANS PD, 1978, J EXP BIOL, V73, P235; EVANS PD, 1988, MOL BASIS DRUG PESTI; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; Geng GJ, 1997, AM J PHYSIOL-REG I, V273, pR1339, DOI 10.1152/ajpregu.1997.273.4.R1339; GHO M, 1986, PFLUG ARCH EUR J PHY, V407, P526, DOI 10.1007/BF00657511; GIELOW ML, 1995, J NEUROSCI, V15, P6085; Gu GG, 1997, J NEUROBIOL, V33, P265, DOI 10.1002/(SICI)1097-4695(199709)33:3<265::AID-NEU5>3.0.CO;2-#; Hashimoto H, 2002, BIOCHEM BIOPH RES CO, V297, P427, DOI 10.1016/S0006-291X(02)02144-7; Hashimoto H, 2001, P NATL ACAD SCI USA, V98, P13355, DOI 10.1073/pnas.231094498; Hernandez M, 2004, BRIT J PHARMACOL, V141, P123, DOI 10.1038/sj.bjp.0705582; Hille B., 2001, IONIC CHANNELS EXCIT, P814; HOFFMAN EP, 1995, CELL, V80, P681, DOI 10.1016/0092-8674(95)90345-3; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; Lindstrom E, 2001, J PHYSIOL-LONDON, V535, P663, DOI 10.1111/j.1469-7793.2001.00663.x; Martinez-Fuentes AJ, 1998, ENDOCRINOLOGY, V139, P5116, DOI 10.1210/en.139.12.5116; Maturana A, 2002, J BIOL CHEM, V277, P39713, DOI 10.1074/jbc.M200464200; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; Miller RJ, 1997, TRENDS NEUROSCI, V20, P189, DOI 10.1016/S0166-2236(96)01037-5; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Nishiyama M, 2003, NATURE, V423, P990, DOI 10.1038/nature01751; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Shibuya I, 1998, J NEUROENDOCRINOL, V10, P31, DOI 10.1046/j.1365-2826.1998.00168.x; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; Takeuchi T, 2004, REGUL PEPTIDES, V118, P1, DOI 10.1016/j.regpep.2003.10.033; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; TRIGGLE DJ, 1990, CAN J PHYSIOL PHARM, V68, P1474, DOI 10.1139/y90-224; TSIEN RW, 1995, TRENDS NEUROSCI, V18, P52; Vaudry D, 2000, PHARMACOL REV, V52, P269; Waddell S, 2001, ANNU REV NEUROSCI, V24, P1283, DOI 10.1146/annurev.neuro.24.1.1283; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Wolfe JT, 2003, NATURE, V424, P209, DOI 10.1038/nature01772; WU CF, 1985, J NEUROSCI, V5, P2626; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Xiao D, 2002, NEUROENDOCRINOLOGY, V76, P325, DOI 10.1159/000066627; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7; Zhou CJ, 2002, CURR PROTEIN PEPT SC, V3, P423, DOI 10.2174/1389203023380576	60	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37291	37297		10.1074/jbc.M403819200	http://dx.doi.org/10.1074/jbc.M403819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201281	hybrid			2022-12-27	WOS:000223554600013
J	Li, DL; Xiao, YC; Xu, X; Xiong, XY; Lu, SY; Liu, ZH; Zhu, Q; Wang, MC; Gu, XC; Liang, SP				Li, DL; Xiao, YC; Xu, X; Xiong, XY; Lu, SY; Liu, ZH; Zhu, Q; Wang, MC; Gu, XC; Liang, SP			Structure-activity relationships of hainantoxin-IV and structure determination of active and inactive sodium channel Blockers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-CONOTOXIN-GIIIA; MOLECULAR-MECHANISMS; SECONDARY STRUCTURE; CONUS-GEOGRAPHUS; CHEMICAL-SHIFT; MUSCLE; INHIBITOR; NMR; BINDING; SITE	Hainantoxin-IV (HNTX-IV) can specifically inhibit the neuronal tetrodotoxin-sensitive sodium channels and defines a new class of depressant spider toxin. The sequence of native HNTX-IV is ECLGFGKGCNPSNDQC-CKSSNLVCSRKHRWCKYEI-NH2. In the present study, to obtain further insight into the primary and tertiary structural requirements of neuronal sodium channel blockers, we determined the solution structure of HNTX-IV as a typical inhibitor cystine knot motif and synthesized four mutants designed based on the predicted sites followed by structural elucidation of two inactive mutants. Pharmacological studies indicated that the S12A and R26A mutants had activities near that of native HNTX-IV, while K27A and R29A demonstrated activities reduced by 2 orders of magnitude. H-1 MR analysis showed the similar molecular conformations for native HNTX-IV and four synthetic mutants. Furthermore, in the determined structures of K27A and R29A, the side chains of residues 27 and 29 were located in the identical spatial position to those of native HNTX-IV. These results suggested that residues Ser(12), Arg(26), Lys(27), and Arg(29) were not responsible for stabilizing the distinct conformation of HNTX-IV, but Lys(27) and Arg(29) were critical for the bioactivities. The potency reductions produced by Ala substitutions were primarily due to the direct interaction of the essential residues Lys27 and Arg29 with sodium channels rather than to a conformational change. After comparison of these structures and activities with correlated toxins, we hypothesized that residues Lys(27), Arg(29), His(28), Lys(32), Phe(5), and Trp(30) clustered on one face of HNTX-IV were responsible for ligand binding.	Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Hunan Normal University; Peking University	Liang, SP (corresponding author), Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China.	liangsp@hunnu.edu.cn	Xiao, Yucheng/H-3600-2012					BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4; FUHRMAN FA, 1967, SCI AM, V217, P61, DOI 10.1038/scientificamerican0867-60; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hu ZH, 1997, J PHYSIOL-LONDON, V501, P67, DOI 10.1111/j.1469-7793.1997.067bo.x; Hui KY, 2002, J GEN PHYSIOL, V119, P45, DOI 10.1085/jgp.119.1.45; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li DL, 2003, FEBS LETT, V555, P616, DOI 10.1016/S0014-5793(03)01303-6; Li RA, 2002, FEBS LETT, V511, P159, DOI 10.1016/S0014-5793(01)03316-6; Li RA, 1997, BIOPHYS J, V73, P1874, DOI 10.1016/S0006-3495(97)78218-3; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Li RK, 2000, J BIOL CHEM, V275, P27551; Liu Z, 2003, CELL MOL LIFE SCI, V60, P972, DOI 10.1007/s00018-003-2354-x; Liu ZH, 2002, ACTA BIOCH BIOPH SIN, V34, P516; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; Nakamura M, 2001, FEBS LETT, V503, P107, DOI 10.1016/S0014-5793(01)02714-4; Nielsen KJ, 2002, J BIOL CHEM, V277, P27247, DOI 10.1074/jbc.M201611200; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Peng K, 2002, J BIOL CHEM, V277, P47564, DOI 10.1074/jbc.M204063200; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Safo P, 2000, J NEUROSCI, V20, P76, DOI 10.1523/JNEUROSCI.20-01-00076.2000; SATO K, 1991, J BIOL CHEM, V266, P16989; SCHANTZ EJ, 1986, ANN NY ACAD SCI, V479, P15, DOI 10.1111/j.1749-6632.1986.tb15557.x; Shon KJ, 1998, J NEUROSCI, V18, P4473; SZILAGYI L, 1989, J MAGN RESON, V83, P441, DOI 10.1016/0022-2364(89)90341-7; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; Xiao YC, 2003, TOXICON, V41, P643, DOI 10.1016/S0041-0101(02)00280-5; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009; YANAGAWA Y, 1987, J NEUROSCI, V7, P1498; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhu Q, 2002, BIOCHEMISTRY-US, V41, P11488, DOI 10.1021/bi026136m	42	55	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37734	37740		10.1074/jbc.M405765200	http://dx.doi.org/10.1074/jbc.M405765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201273	hybrid			2022-12-27	WOS:000223554600065
J	Ellis, PD; Smith, CWJ; Kemp, P				Ellis, PD; Smith, CWJ; Kemp, P			Regulated tissue-specific alternative splicing of enhanced green fluorescent protein transgenes conferred by alpha-tropomyosin regulatory elements in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; MUTUALLY EXCLUSIVE EXON; MESSENGER-RNA; SMOOTH; GENE; SELECTION; ISOFORMS; SITE; MECHANISMS; EXPRESSION	The mutually exclusive exons 2 and 3 of alpha-tropomyosin (alphaTM) have been used as a model system for strictly regulated alternative splicing. Exon 2 inclusion is only observed at high levels in smooth muscle (SM) tissues, whereas striated muscle and non-muscle cells use predominantly exon 3. Experiments in cell culture have shown that exon 2 selection results from repression of exon 3 and that this repression is mediated by regulatory elements flanking exon 3. We have now tested the cell culture-derived model in transgenic mice. We show that by harnessing the intronic splicing regulatory elements, expression of an enhanced green fluorescent protein transgene with a constitutively active promoter can be restricted to SM cells. Splicing of both endogenous alphaTM and a series of transgenes carrying regulatory element mutations was analyzed by reverse transcriptase-PCR. These studies indicated that although SM-rich tissues are equipped to regulate splicing of high levels of endogenous or transgene alphaTM RNA, other non-SM tissues such as spleen, which express lower amounts of alphaTM, also splice significant proportions of exon 2, and this splicing pattern can be recapitulated by transgenes expressed at low levels. We confirm the importance in vivo of the negatively acting regulatory elements for regulated skipping of exon 3. Moreover, we provide evidence that some of the regulatory factors responsible for exon 3 skipping appear to be titratable, with loss of regulated splicing sometimes being associated with high transgene expression levels.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Smith, CWJ (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	cwjs1@cam.ac.uk; pk@mole.bio.cam.ac.uk		Kemp, Paul/0000-0001-8975-7293				Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blanchard EM, 1997, CIRC RES, V81, P1005; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; DiDonato CJ, 2001, HUM MOL GENET, V10, P2727, DOI 10.1093/hmg/10.23.2727; Dye DT, 1998, RNA, V4, P1523, DOI 10.1017/S1355838298980360; Good PJ, 2000, J BIOL CHEM, V275, P28583, DOI 10.1074/jbc.M003083200; Gooding C, 2003, J BIOL CHEM, V278, P15201, DOI 10.1074/jbc.M210131200; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; Gromak N, 2003, EMBO J, V22, P6356, DOI 10.1093/emboj/cdg609; Gromak N, 2002, NUCLEIC ACIDS RES, V30, P3548, DOI 10.1093/nar/gkf480; Ichida M, 2000, J BIOL CHEM, V275, P15992, DOI 10.1074/jbc.275.21.15992; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; OWENS GK, 1995, PHYSIOL REV, V75, P487; Perez I, 1997, RNA, V3, P764; Rethinasamy P, 1998, CIRC RES, V82, P116; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Roberts GC, 1996, EMBO J, V15, P6301, DOI 10.1002/j.1460-2075.1996.tb01020.x; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Seipelt RL, 1998, MOL CELL BIOL, V18, P1042, DOI 10.1128/MCB.18.2.1042; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; Wagner E, 2002, J CELL SCI, V115, P3033; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; Wollerton MC, 2001, RNA, V7, P819, DOI 10.1017/S1355838201010214; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	39	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36660	36669		10.1074/jbc.M405380200	http://dx.doi.org/10.1074/jbc.M405380200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194683	hybrid			2022-12-27	WOS:000223453600065
J	Engel, M; Mazurek, S; Eigenbrodt, E; Welter, C				Engel, M; Mazurek, S; Eigenbrodt, E; Welter, C			Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; HETEROTRIMERIC G-PROTEINS; ENERGY PHOSPHATE TRANSFER; PYRUVATE-KINASE; 2,3-BISPHOSPHOGLYCERATE PHOSPHATASE; TRANSCRIPTION FACTOR; EXTRACELLULAR AMP; ENOLASE ACTIVITY; CREATINE-KINASE; NDPK-B	The putative tumor metastasis suppressor protein Nm23-H1 is a nucleoside diphosphate kinase that exhibits a novel protein kinase activity when bound to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In this study we show that the glycolytic enzyme phosphoglycerate mutase B (PGM) becomes phosphorylated in the presence of the Nm23-H1.GAPDH complex in vitro. Mutation of His-10 in PGM abolishes the Nm23-H1.GAPDH complex-induced phosphorylation. Nm23-H1, GAPDH, and PGM are known to co-localize as shown by free flow isoelectric focusing. In association with Nm23-H1 and GAPDH, PGM could be activated by dCTP, which is a substrate of Nm23-H1, in addition to the well known PGM activator 2,3-bisphosphoglycerate. A synthetic cell-penetrating peptide (PGMtide) encompassing the phosphorylated histidine and several residues from PGM (LIR (H) under bar GE) promoted growth arrest of several tumor cell lines, whereas proliferation of tested non-tumor cells was not influenced. Analysis of metabolic activity of one of the tumor cell lines, MCF-7, indicated that PGMtide inhibited glycolytic flux, consistent with in vivo inhibition of PGM. The specificity of the observed effect was further determined experimentally by testing the effect of PGMtide on cells growing in the presence of pyruvate, which helps to compensate PGM inhibition in the glycolytic pathway. Thus, growth of MCF-7 cells was not arrested by PGMtide in the presence of pyruvate. The data presented here provide evidence that inhibition of PGM activity can be achieved by exogenous addition of a polypeptide, resulting in inhibition of glycolysis and cell growth arrest in cell culture.	Univ Saarland, Dept Human Genet, Sch Med, D-66421 Homburg, Germany; Univ Giessen, Inst Biochem & Endocrinol, D-35392 Giessen, Germany	Saarland University; Justus Liebig University Giessen	Engel, M (corresponding author), PhosphoSites GmbH, Universitatskliniken Geb 7, Starterzentrum 3, D-66421 Homburg, Germany.	m.engel@phosphosites.com	Mazurek, Sybille/ABH-2089-2020					BERBERICH SJ, 1995, ONCOGENE, V10, P2343; Bergmeyer H. U., 1974, METHODEN ENZYMATISCH, VI; BERGMEYER HU, 1974, METHODEN ENZYMATISCH, V2; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; Boren J, 2003, J BIOL CHEM, V278, P28395, DOI 10.1074/jbc.M302932200; Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3; Cuello F, 2003, J BIOL CHEM, V278, P7220, DOI 10.1074/jbc.M210304200; Durany N, 1997, BRIT J CANCER, V75, P969, DOI 10.1038/bjc.1997.168; Durany N, 1997, BRIT J CANCER, V76, P1139, DOI 10.1038/bjc.1997.525; Durany N, 2000, BRIT J CANCER, V82, P20; Eigenbrodt E, 1998, ANTICANCER RES, V18, P3267; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; Hegde P, 2001, CANCER RES, V61, P7792; Hippe HJ, 2003, J BIOL CHEM, V278, P7227, DOI 10.1074/jbc.M210305200; HUGO F, 1992, J CELL PHYSIOL, V153, P539, DOI 10.1002/jcp.1041530315; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Mazurek S, 1996, J CELL PHYSIOL, V167, P238, DOI 10.1002/(SICI)1097-4652(199605)167:2<238::AID-JCP7>3.0.CO;2-Q; Mazurek S, 1997, J BIOENERG BIOMEMBR, V29, P315, DOI 10.1023/A:1022490512705; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 1998, ANTICANCER RES, V18, P3275; Mazurek S, 1997, J BIOL CHEM, V272, P4941, DOI 10.1074/jbc.272.8.4941; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; MEDINA MA, 1988, BIOCHEM INT, V16, P339; Otero AD, 2000, J BIOENERG BIOMEMBR, V32, P269, DOI 10.1023/A:1005589029959; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Roymans D, 2002, CLIN EXP METASTAS, V19, P465, DOI 10.1023/A:1020396722860; RYLL T, 1992, BIOTECHNOL BIOENG, V40, P934, DOI 10.1002/bit.260400810; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; STANKIEWICZ PJ, 1987, BIOCHEMISTRY-US, V26, P1264, DOI 10.1021/bi00379a010; Steeg PS, 2003, CANCER LETT, V190, P1, DOI 10.1016/S0304-3835(02)00499-8; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; WAGNER P, 2001, BIOCHEM J, V346, P623; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; YEOH GCT, 1980, NATURE, V285, P108, DOI 10.1038/285108a0; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	42	50	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35803	35812		10.1074/jbc.M402768200	http://dx.doi.org/10.1074/jbc.M402768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15181008	hybrid			2022-12-27	WOS:000223303400081
J	Feng, JH; Tamaskovic, R; Yang, ZZ; Brazil, DP; Merlo, A; Hess, D; Hemmings, BA				Feng, JH; Tamaskovic, R; Yang, ZZ; Brazil, DP; Merlo, A; Hess, D; Hemmings, BA			Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TUMOR-SUPPRESSOR; HEMATOPOIETIC-CELLS; P53 ACTIVATION; PATHWAY; AKT; DEGRADATION; APOPTOSIS; SURVIVAL; GROWTH	The tumor suppressor p53 is commonly inhibited under conditions in which the phosphatidylinositide 3'-OH kinase/protein kinase B (PKB) Akt pathway is activated. Intracellular levels of p53 are controlled by the E3 ubiquitin ligase Mdm2. Here we show that PKB inhibits Mdm2 self-ubiquitination via phosphorylation of Mdm2 on Ser(166) and Ser(188). Stimulation of human embryonic kidney 293 cells with insulin-like growth factor-1 increased Mdm2 phosphorylation on Ser(166) and Ser(188) in a phosphatidylinositide 3'-OH kinase-dependent manner, and the treatment of both human embryonic kidney 293 and COS-1 cells with phosphatidylinositide 3'-OH kinase inhibitor LY-294002 led to proteasome-mediated Mdm2 degradation. Introduction of a constitutively active form of PKB together with Mdm2 into cells induced phosphorylation of Mdm2 at Ser(166) and Ser(188) and stabilized Mdm2 protein. Moreover, mouse embryonic fibroblasts lacking PKBalpha displayed reduced Mdm2 protein levels with a concomitant increase of p53 and p21(Cip1), resulting in strongly elevated apoptosis after UV irradiation. In addition, activation of PKB correlated with Mdm2 phosphorylation and stability in a variety of human tumor cells. These findings suggest that PKB plays a critical role in controlling of the Mdm2.p53 signaling pathway by regulating Mdm2 stability.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Univ Basel, Dept Clin & Biol Sci, Mol Neurooncol Lab, CH-4031 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Basel	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch		Brazil, Derek/0000-0003-1375-1076				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Goetz AW, 2001, CANCER RES, V61, P7635; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HJERRILD M, 1999, BIOCHEM J, V15, P347; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hong M, 1999, CANCER RES, V59, P2847; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Moll UM, 2003, MOL CANCER RES, V1, P1001; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Pan Y, 1999, CANCER RES, V59, P2064; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shinozaki T, 2003, ONCOGENE, V22, P8870, DOI 10.1038/sj.onc.1207176; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Zeng SX, 2003, J BIOL CHEM, V278, P7453, DOI 10.1074/jbc.M209030200; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	61	218	224	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35510	35517		10.1074/jbc.M404936200	http://dx.doi.org/10.1074/jbc.M404936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169778	hybrid			2022-12-27	WOS:000223303400045
J	Bhatnagar, A; Sheffler, DJ; Kroeze, WK; Compton-Toth, B; Roth, BL				Bhatnagar, A; Sheffler, DJ; Kroeze, WK; Compton-Toth, B; Roth, BL			Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected G alpha(q)-coupled protein receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HYDROXYTRYPTAMINE(2A) RECEPTOR; IN-VITRO; INDEPENDENT INTERNALIZATION; COUPLED RECEPTORS; DOWN-REGULATION; SALVINORIN-A; CELL BIOLOGY; NULL MICE; AGONIST; TRANSDUCTION	5-Hydroxytryptamine 2A (5-HT2A) serotonin receptors are important for a variety of functions including vascular smooth muscle contraction, platelet aggregation, and the modulation of perception, cognition, and emotion. In a search for 5-HT2A receptor-interacting proteins, we discovered that caveolin-1 (Cav-1), a scaffolding protein enriched in caveolae, complexes with 5-HT2A receptors in a number of cell types including C6 glioma cells, transfected HEK-293 cells, and rat brain synaptic membrane preparations. To address the functional significance of this interaction, we performed RNA interference-mediated knockdown of Cav-1 in C6 glioma cells, a cell type that endogenously expresses both 5-HT2A receptors and Cav-1. We discovered that the in vitro knockdown of Cav-1 in C6 glioma cells nearly abolished 5-HT2A receptor-mediated signal transduction as measured by calcium flux assays. RNA interference-mediated knockdown of Cav-1 also greatly attenuated endogenous Galpha(q)-coupled P2Y purinergic receptor-mediated signaling without altering the signaling of PAR-1 thrombin receptors. Cav-1 appeared to modulate 5-HT2A signaling by facilitating the interaction of 5-HT2A receptors with Galpha(q). These studies provide compelling evidence for a prominent role of Cav-1 in regulating the functional activity of not only 5-HT2A serotonin receptors but also selected Galpha(q)-coupled receptors.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Roth, BL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Rm W441,2109 Adelbert Rd, Cleveland, OH 44106 USA.	bryan.roth@case.edu	Roth, Bryan L/F-3928-2010		NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001366, R01MH061887, R01MH057635] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 43703] Funding Source: Medline; NIMH NIH HHS [R01 MH 57635, R01 MH 61887, K02 MH 01366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Backstrom JR, 1997, J NEUROSCI METH, V77, P109, DOI 10.1016/S0165-0270(97)00102-7; Berry SA, 1996, MOL PHARMACOL, V50, P306; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DOYLE VM, 1986, N-S ARCH PHARMACOL, V333, P98, DOI 10.1007/BF00506510; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dreja K, 2002, ARTERIOSCL THROM VAS, V22, P1267, DOI 10.1161/01.ATV.0000023438.32585.A1; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GLENNON RA, 1984, LIFE SCI, V35, P2505, DOI 10.1016/0024-3205(84)90436-3; Gray JA, 2003, MOL PHARMACOL, V63, P961, DOI 10.1124/mol.63.5.961; Gray JA, 2002, SCIENCE, V297, P529, DOI 10.1126/science.1075453; Gray JA, 2001, MOL PHARMACOL, V60, P1020, DOI 10.1124/mol.60.5.1020; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Kroeze WK, 2003, J CELL SCI, V116, P4867, DOI 10.1242/jcs.00902; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Park H, 2000, AM J PHYSIOL-HEART C, V278, pH1285, DOI 10.1152/ajpheart.2000.278.4.H1285; Park WY, 2001, ANN NY ACAD SCI, V928, P79; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Raymond JR, 2001, PHARMACOL THERAPEUT, V92, P179, DOI 10.1016/S0163-7258(01)00169-3; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; ROTH BL, 1981, J BIOL CHEM, V256, P117; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rothman RB, 2003, J PHARMACOL EXP THER, V307, P138, DOI 10.1124/jpet.103.053975; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Saucier C, 1997, J NEUROCHEM, V68, P1998; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Setola V, 2003, MOL PHARMACOL, V63, P1223, DOI 10.1124/mol.63.6.1223; Sheffler DJ, 2003, TRENDS PHARMACOL SCI, V24, P107, DOI 10.1016/S0165-6147(03)00027-0; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200	44	136	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34614	34623		10.1074/jbc.M404673200	http://dx.doi.org/10.1074/jbc.M404673200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190056	hybrid, Green Published			2022-12-27	WOS:000223134800066
J	Miyazaki, M; Dobrzyn, A; Sampath, H; Lee, SH; Man, WC; Chu, K; Peters, JM; Gonzalez, FJ; Ntambi, JM				Miyazaki, M; Dobrzyn, A; Sampath, H; Lee, SH; Man, WC; Chu, K; Peters, JM; Gonzalez, FJ; Ntambi, JM			Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; CAUSES INSULIN-RESISTANCE; MESSENGER-RNA LEVELS; GENE-EXPRESSION; PROTEIN-KINASE; PPAR-GAMMA; TARGETED DISRUPTION; TISSUE DISTRIBUTION; SKELETAL-MUSCLE; UP-REGULATION	Stearoyl-CoA desaturase catalyzes the rate-limiting step in the biosynthesis of monounsaturated fatty acids, which are required for normal rates of synthesis of triglycerides, cholesterol esters, and phospholipids. Mice with a targeted disruption of the stearoyl-CoA desaturase 1 (SCD1) isoform are protected against diet and leptin deficiency-induced adiposity, have increased energy expenditure, and have up-regulated expression of hepatic genes encoding enzymes of fatty acid beta-oxidation. Because peroxisome proliferator-activated receptor-alpha( PPARalpha) is a key transcription factor that induces the transcription of fatty acid beta-oxidation and thermogenic genes, we hypothesized that the increased fatty acid oxidation observed in SCD1 deficiency is dependent on activation of the PPARalpha pathway. Here we show that mice nullizygous for SCD1 and PPARalpha are still protected against adiposity, have increased energy expenditure, and maintain high expression of PPARalpha target genes in the liver and brown adipose tissue. The SCD1 deficiency rescued hepatic steatosis of the PPARalpha(-/-) mice. The SCD1 mutation increased the phosphorylation of both AMP-activated protein kinase and acetylCoA carboxylase, thereby increasing CPT activity and stimulating the oxidation of liver palmitoyl-CoA in the PPARalpha null mice. The findings indicate that the reduced adiposity, reduced liver steatosis, increased energy expenditure, and increased expression of PPARalpha target genes associated with SCD1 deficiency are independent of activation of the PPARalpha pathway.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ntambi@biochem.wisc.edu	Peters, Jeffrey/D-8847-2011; Dobrzyn, Agnieszka/R-4073-2016	Dobrzyn, Agnieszka/0000-0002-6331-9460; Peters, Jeffrey/0000-0003-2782-2998	NIDDK NIH HHS [R01 DK 62388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Akiyama TE, 2001, J BIOL CHEM, V276, P39088, DOI 10.1074/jbc.M107073200; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; Beiraghi S, 2003, GENE, V309, P11, DOI 10.1016/S0378-1119(03)00461-x; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; Brun RP, 1997, CURR OPIN LIPIDOL, V8, P212, DOI 10.1097/00041433-199708000-00004; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Cabrero A, 2000, ARCH BIOCHEM BIOPHYS, V380, P353, DOI 10.1006/abbi.2000.1927; Chen HC, 2003, AM J PHYSIOL-ENDOC M, V284, pE213, DOI 10.1152/ajpendo.00248.2002; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Crowley V, 2001, NUTR METAB CARDIOVAS, V11, P70; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KING MT, 1985, ANAL BIOCHEM, V146, P173, DOI 10.1016/0003-2697(85)90412-9; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEE S, 2004, IN PRESS J LIPID RES; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1978, BIOCHIM BIOPHYS ACTA, V529, P201, DOI 10.1016/0005-2760(78)90063-2; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Minokoshi Y, 2003, BIOCHEM SOC T, V31, P196, DOI 10.1042/bst0310196; Miyazaki M, 2003, J BIOL CHEM, V278, P33904, DOI 10.1074/jbc.M304724200; Miyazaki M, 2001, J BIOL CHEM, V276, P39455, DOI 10.1074/jbc.M106442200; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Rosen ED, 2003, MOL CELL BIOL, V23, P7222, DOI 10.1128/MCB.23.20.7222-7229.2003; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Teruel T, 1999, BIOCHEM BIOPH RES CO, V264, P311, DOI 10.1006/bbrc.1999.1526; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WOODS A, 1994, J BIOL CHEM, V269, P19509; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864; Zhang L, 2001, BIOCHEM J, V357, P183, DOI 10.1042/0264-6021:3570183; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429	61	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35017	35024		10.1074/jbc.M405327200	http://dx.doi.org/10.1074/jbc.M405327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180999	hybrid			2022-12-27	WOS:000223134800114
J	Greschik, H; Flaig, R; Renaud, JP; Moras, D				Greschik, H; Flaig, R; Renaud, JP; Moras, D			Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; MOLECULAR-BASIS; ERR; LIGAND; ALPHA; BINDING; EXPRESSION; MEMBER; GENE	The estrogen-related receptor (ERR) gamma behaves as a constitutive activator of transcription. Although no natural ligand is known, ERRgamma is deactivated by the estrogen receptor ( ER) agonist diethylstilbestrol and the selective ER modulator 4-hydroxytamoxifen but does not significantly respond to estradiol or raloxifene. Here we report the crystal structures of the ERRgamma ligand binding domain (LBD) complexed with diethylstilbestrol or 4-hydroxytamoxifen. Antagonist binding to ERRgamma results in a rotation of the side chain of Phe-435 that partially fills the cavity of the apoLBD. The new rotamer of Phe-435 displaces the "activation helix" ( helix 12) from the agonist position observed in the absence of ligand. In contrast to the complexes of the ERalpha LBD with 4-hydroxytamoxifen or raloxifene, helix 12 of antagonist-bound ERRgamma does not occupy the coactivator groove but appears to be completely dissociated from the LBD body. Comparison of the ligand-bound LBDs of ERRgamma and ERalpha reveals small but significant differences in the architecture of the ligand binding pockets that result in a slightly shifted binding position of diethylstilbestrol and a small rotation of 4-hydroxytamoxifen in the cavity of ERRgamma relative to ERalpha. Our results provide detailed molecular insight into the conformational changes occurring upon binding of synthetic antagonists to the constitutive orphan receptor ERRgamma and reveal structural differences with ERs that explain why ERRgamma does not bind estradiol or raloxifene and will help to design new selective antagonists.	Inst Genet & Biol Mol & Cellulaire, Dept Biol & Genom Struct, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), Inst Genet & Biol Mol & Cellulaire, Dept Biol & Genom Struct, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Renaud, Jean-Paul/AAM-4879-2020	Renaud, Jean-Paul/0000-0001-9180-5426				Ariazi EA, 2002, CANCER RES, V62, P6510; Auwerx J, 1999, CELL, V97, P161; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Billas IML, 2003, NATURE, V426, P91, DOI 10.1038/nature02112; Bonnelye E, 2002, ENDOCRINOLOGY, V143, P3658, DOI 10.1210/en.2002-220095; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Eudy JD, 1998, GENOMICS, V50, P382, DOI 10.1006/geno.1998.5345; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hentschke M, 2002, BIOCHEM BIOPH RES CO, V299, P872, DOI 10.1016/S0006-291X(02)02753-5; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Hylemon PB, 1998, FEMS MICROBIOL REV, V22, P475, DOI 10.1111/j.1574-6976.1998.tb00382.x; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallenberger BC, 2003, NAT STRUCT BIOL, V10, P136, DOI 10.1038/nsb892; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Klaholz BP, 2000, ACTA CRYSTALLOGR D, V56, P933, DOI 10.1107/S090744490000634X; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kraus RJ, 2002, J BIOL CHEM, V277, P24826, DOI 10.1074/jbc.M202952200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lonard DM, 2002, STEROIDS, V67, P15, DOI 10.1016/S0039-128X(01)00133-7; Lu DS, 2001, CANCER RES, V61, P6755; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Susens U, 2000, BIOCHEM BIOPH RES CO, V267, P532, DOI 10.1006/bbrc.1999.1976; Tamrazi A, 2003, MOL ENDOCRINOL, V17, P2593, DOI 10.1210/me.2003-0239; Tremblay GB, 2001, ENDOCRINOLOGY, V142, P4572, DOI 10.1210/en.142.10.4572; Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang C, 1999, CANCER RES, V59, P4519; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795	54	105	110	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33639	33646		10.1074/jbc.M402195200	http://dx.doi.org/10.1074/jbc.M402195200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161930	hybrid			2022-12-27	WOS:000223039700073
J	Huntington, JT; Shields, JM; Der, CJ; Wyatt, CA; Benbow, U; Slingluff, CL; Brinckerhoff, CE				Huntington, JT; Shields, JM; Der, CJ; Wyatt, CA; Benbow, U; Slingluff, CL; Brinckerhoff, CE			Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells - Role of BRAF mutation and fibroblast growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SINGLE NUCLEOTIDE POLYMORPHISM; MATRIX METALLOPROTEINASE-1; METASTATIC MELANOMA; GENE-EXPRESSION; MALIGNANT MELANOMAS; TUMOR PROGRESSION; RAS MUTATIONS; I COLLAGEN; B-RAF	Melanoma progresses as a multistep process where the thickness of the lesion and depth of tumor invasion are the best prognostic indicators of clinical outcome. Degradation of the interstitial collagens in the extracellular matrix is an integral component of tumor invasion and metastasis, and much of this degradation is mediated by collagenase-1 (MMP-1), a member of the matrix metalloproteinase (MMP) family. MMP-1 levels increase during melanoma progression where they are associated with shorter disease-free survival. The Ras/Raf/ MEK/ERK mitogen-activated protein kinase ( MAPK) pathway is a major regulator of melanoma cell proliferation. Recently, BRAF has been identified as a common site of activating mutations, and, although many reports focus on its growth-promoting effects, this pathway has also been implicated in progression toward metastatic disease. In this study, we describe four melanoma cell lines that produce high levels of MMP-1 constitutively. In each cell line the Ras/Raf/ MEK/ERK pathway is constitutively active and is the dominant pathway driving the production of MMP-1. Activation of this pathway arises due to either an activating mutation in BRAF ( three cell lines) or autocrine fibroblast growth factor signaling ( one cell line). Furthermore, blocking MEK/ ERK activity inhibits melanoma cell proliferation and abrogates collagen degradation, thus decreasing their metastatic potential. Importantly, this inhibition of invasive behavior can occur in the absence of any detectable changes in cell proliferation and survival. Thus, constitutive activation of this MAPK pathway not only promotes the increased proliferation of melanoma cells but is also important for the acquisition of an invasive phenotype.	Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Biochem, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Physiol, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Med, Lebanon, NH 03756 USA; Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; University of Virginia	Brinckerhoff, CE (corresponding author), Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Biochem, 1 Med Ctr Dr,602 Rubin, Lebanon, NH 03756 USA.	brinckerhoff@dartmouth.edu		Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [T32CA009658, R01CA057653, R29CA057653, R01CA077617, R01CA063071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R37AR026599] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77617, T32-CA09658, CA-57653, CA-63071] Funding Source: Medline; NIAMS NIH HHS [AR-26599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Benbow U, 2002, J CELL BIOCHEM, V86, P307, DOI 10.1002/jcb.10225; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Brose MS, 2002, CANCER RES, V62, P6997; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Collisson EA, 2003, CANCER RES, V63, P5669; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Durko M, 1997, BBA-MOL CELL RES, V1356, P271, DOI 10.1016/S0167-4889(97)00004-9; Ge XK, 2002, CANCER LETT, V179, P133, DOI 10.1016/S0304-3835(02)00004-6; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Gorden A, 2003, CANCER RES, V63, P3955; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Hingorani SR, 2003, CANCER RES, V63, P5198; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Ishii Y, 2003, INT J CANCER, V103, P161, DOI 10.1002/ijc.10808; Johansson N, 2000, J CELL SCI, V113, P227; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Kumar R, 2004, J INVEST DERMATOL, V122, P342, DOI 10.1046/j.0022-202X.2004.22225.x; Kurschat P, 2000, CLIN EXP DERMATOL, V25, P482, DOI 10.1046/j.1365-2230.2000.00701.x; Laud K, 2003, CANCER RES, V63, P3061; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li SP, 2003, CANCER RES, V63, P3473; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Meier F, 2002, BRIT J DERMATOL, V147, P62, DOI 10.1046/j.1365-2133.2002.04867.x; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Nikkola J, 2002, INT J CANCER, V97, P432, DOI 10.1002/ijc.1636; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Rutter JL, 1998, CANCER RES, V58, P5321; Satyamoorthy K, 2003, CANCER RES, V63, P756; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Tanimura S, 2003, BIOCHEM BIOPH RES CO, V304, P801, DOI 10.1016/S0006-291X(03)00670-3; Tower GB, 2003, EUR J BIOCHEM, V270, P4216, DOI 10.1046/j.1432-1033.2003.03821.x; Tower GB, 2002, BBA-MOL BASIS DIS, V1586, P265, DOI 10.1016/S0925-4439(01)00105-3; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Walker RA, 1999, VIRCHOWS ARCH, V435, P574, DOI 10.1007/s004280050443; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Westermarck J, 2000, CANCER RES, V60, P7156; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200	66	126	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33168	33176		10.1074/jbc.M405102200	http://dx.doi.org/10.1074/jbc.M405102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184373	hybrid			2022-12-27	WOS:000223039700020
J	Jez, JM; Cahoon, RE; Chen, SX				Jez, JM; Cahoon, RE; Chen, SX			Arabidopsis thaliana glutamate-cysteine ligase - Functional properties, kinetic mechanism, and regulation of activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; GLUTATHIONE HOMEOSTASIS; MASS-SPECTROMETRY; MODIFIER SUBUNIT; PLANT; RAT; PURIFICATION; ACCUMULATION; TOLERANCE; SUBSTRATE	In plants, glutathione accumulates in response to different stress stimuli as a protective mechanism, but only limited biochemical information is available on the plant enzymes that synthesize glutathione. Glutamate-cysteine ligase (GCL) catalyzes the first step in glutathione biosynthesis and plays an important role in regulating the intracellular redox environment. Because the putative Arabidopsis thaliana GCL (AtGCL) displays no significant homology to the GCL from bacteria and other eukaryotes, the identity of this protein as a GCL has been debated. We have purified AtGCL from an Escherichia coli expression system and demonstrated that the recombinant enzyme catalyzes the ATP-dependent formation of gamma-glutamylcysteine from glutamate (K-m = 9.1 mM) and cysteine (K-m = 2.7 mM). Glutathione feedback inhibits AtGCL (K-i similar to 1.0 mM). As with other GCL, buthionine sulfoximine and cystamine inactivate the Arabidopsis enzyme but with inactivation rates much slower than those of the mammalian, bacterial, and nematode enzymes. The slower inactivation rates observed with AtGCL suggest that the active site differs structurally from that of other GCL. Global fitting analysis of initial velocity data indicates that a random terreactant mechanism with a preferred binding order best describes the kinetic mechanism of AtGCL. Unlike the mammalian GCL, which consists of a catalytic subunit and a regulatory subunit, AtGCL functions and is regulated as a monomeric protein. In response to redox environment, AtGCL undergoes a reversible conformational change that modulates the enzymatic activity of the monomer. These results explain the reported posttranslational change in AtGCL activity in response to oxidative stress.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Jez, JM (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jjez@danforthcenter.org						Abbott JJ, 2002, BIOCHEMISTRY-US, V41, P2741, DOI 10.1021/bi0159128; Barker KR, 2003, ANNU REV PHYTOPATHOL, V41, P1, DOI 10.1146/annurev.phyto.41.052002.095647; BOARD PG, 1980, BIOCHIM BIOPHYS ACTA, V613, P534, DOI 10.1016/0005-2744(80)90109-6; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; Brunold Christian, 1997, Progress in Botany, V58, P164; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Copley SD, 2002, GENOME BIOL, V3; DAVIS JS, 1973, BIOCHEM J, V133, P667, DOI 10.1042/bj1330667; Dhankher OP, 2002, NAT BIOTECHNOL, V20, P1140, DOI 10.1038/nbt747; Emanuele JJ, 1997, BIOCHEMISTRY-US, V36, P7264, DOI 10.1021/bi970266r; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Fraser JA, 2003, J BIOL CHEM, V278, P46369, DOI 10.1074/jbc.M308035200; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Gomez LD, 2004, PLANT PHYSIOL, V134, P1662, DOI 10.1104/pp.103.033027; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; GUPTA AS, 1991, PLANT PHYSIOL, V96, P650, DOI 10.1104/pp.96.2.650; HELL R, 1990, PLANTA, V180, P603, DOI 10.1007/BF02411460; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUSSEIN AS, 1995, MOL BIOCHEM PARASIT, V72, P57, DOI 10.1016/0166-6851(94)00064-T; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; KITZ R, 1962, J BIOL CHEM, V237, P3245; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; LEBO RV, 1978, J BIOL CHEM, V253, P2615; LOO JA, 1991, ANAL CHEM, V63, P2488, DOI 10.1021/ac00021a018; Loo JA, 2000, INT J MASS SPECTROM, V200, P175, DOI 10.1016/S1387-3806(00)00298-0; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; Luersen K, 2000, MOL BIOCHEM PARASIT, V111, P243, DOI 10.1016/S0166-6851(00)00325-X; MADAMANCHI NR, 1991, PLANT PHYSIOL, V97, P88, DOI 10.1104/pp.97.1.88; MATRINGE M, 1988, PLANT PHYSIOL, V86, P619, DOI 10.1104/pp.86.2.619; May MJ, 1998, P NATL ACAD SCI USA, V95, P12049, DOI 10.1073/pnas.95.20.12049; May MJ, 1998, J EXP BOT, V49, P649, DOI 10.1093/jexbot/49.321.649; MAY MJ, 1994, P NATL ACAD SCI USA, V91, P10059, DOI 10.1073/pnas.91.21.10059; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; ORLOWSKI M, 1971, J BIOL CHEM, V246, P7095; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Schafer HJ, 1997, FEBS LETT, V404, P216, DOI 10.1016/S0014-5793(97)00132-4; Schafer HJ, 1998, PLANT MOL BIOL, V37, P87, DOI 10.1023/A:1005929022061; SCHANDLE VB, 1981, J BIOL CHEM, V256, P7590; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Segel IH, 1975, ENZYME KINETICS BEHA; SEKURA R, 1977, J BIOL CHEM, V252, P2599; Tu ZH, 1998, BIOCHEM J, V336, P675, DOI 10.1042/bj3360675; VANBUSKIRK GE, 1978, EUR J BIOCHEM, V85, P589; VIOLA RE, 1982, METHOD ENZYMOL, V87, P353; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539; YIP B, 1976, J BIOL CHEM, V251, P3563; Zhu YL, 1999, PLANT PHYSIOL, V121, P1169, DOI 10.1104/pp.121.4.1169	51	109	116	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33463	33470		10.1074/jbc.M405127200	http://dx.doi.org/10.1074/jbc.M405127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180996	hybrid			2022-12-27	WOS:000223039700055
J	Lane, MD				Lane, MD			The biotin connection: Severo Ochoa, Harland Wood, and Feodor Lynen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							ENZYMES		Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Lane, MD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	dlane@jhmi.edu						KNAPPE J, 1961, BIOCHEM Z, V335, P168; KORNBERG A, 1975, REFLECTIONS BIOCH, P1; Krebs H.A., 1981, REMINISCENCES REFLEC; LANE MD, 1963, P NATL ACAD SCI USA, V49, P379, DOI 10.1073/pnas.49.3.379; LARDY HA, 1956, J BIOL CHEM, V219, P933; LYNEN F, 1959, ANGEW CHEM INT EDIT, V71, P481, DOI 10.1002/ange.19590711503; LYNEN F, 1967, BIOCHEM J, V102, P381, DOI 10.1042/bj1020381; MOSS J, 1971, ADV ENZYMOL RAMB, V35, P321; OCHOA S, 1980, ANNU REV BIOCHEM, V49, P1, DOI 10.1146/annurev.bi.49.070180.000245; WOOD HG, 1985, ANNU REV BIOCHEM, V54, P1	10	4	4	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39187	39194		10.1074/jbc.X400005200	http://dx.doi.org/10.1074/jbc.X400005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15166234	hybrid			2022-12-27	WOS:000223791500001
J	Huang, XP; Chang, WP; Koelsch, G; Turner, RT; Lupu, F; Tang, J				Huang, XP; Chang, WP; Koelsch, G; Turner, RT; Lupu, F; Tang, J			Internalization of exogenously added memapsin 2 (beta-secretase) ectodomain by cells is mediated by amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CYTOSOLIC DOMAIN; CLEAVING ENZYME; SORTING SIGNAL; VHS DOMAIN; BACE; TRAFFICKING; ENDOCYTOSIS; CLEAVAGE; SITE	Memapsin 2 (beta-secretase) is the protease that initiates cleavage of amyloid precursor protein (APP) leading to the production of amyloid-beta (Abeta) peptide and the onset of Alzheimer's disease. Both APP and memapsin 2 are Type I transmembrane proteins and are endocytosed into endosomes where APP is cleaved by memapsin 2. Separate endocytic signals are located in the cytosolic domains of these proteins. We demonstrate here that the addition of the ectodomain of memapsin 2 (M2(ED)) to cells transfected with native APP or APP Swedish mutant (APPsw) resulted in the internalization of M2(ED) into endosomes with increased Abeta production. These effects were reduced by treatment with glycosylphosphatidylinositol-specific phospholipase C. The nontransfected parental cells had little internalization of M2(ED). The internalization of M2(ED) was dependent on the endocytosis signal in APP, because the expression of a mutant APP that lacks its endocytosis signal failed to support M2(ED) internalization. These results suggest that exogenously added M2(ED) interacts with the ectodomain of APP on the cell surface leading to the internalization of M2(ED), supported by fluorescence resonance energy transfer experiments. The interactions between the two proteins is not due to the binding of substrate APPsw to the active site of memapsin 2, because neither a potent active site binding inhibitor of memapsin 2 nor an antibody directed to the beta-secretase site of APPsw had an effect on the uptake of M2(ED). In addition, full-length memapsin 2 and APP, immunoprecipitated together from cell lysates, suggested that the interaction of these two proteins is part of the native cellular processes.	Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Zapaq Inc, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Tang, J (corresponding author), Oklahoma Med Res Fdn, Prot Studies Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jordan-tang@omrf.ouhsc.edu	Lupu, Florea/AAV-3257-2021; Lupu, Florea/C-3162-2009	Lupu, Florea/0000-0003-1249-9278; Lupu, Florea/0000-0003-1249-9278	NIA NIH HHS [AG-18933] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018933] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hong L, 2002, BIOCHEMISTRY-US, V41, P10963, DOI 10.1021/bi026232n; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kametaka S, 2003, J BIOL CHEM, V278, P15239, DOI 10.1074/jbc.M208611200; Kato Y, 2002, NAT STRUCT BIOL, V9, P532, DOI 10.1038/nsb807; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Lai A, 1998, J BIOL CHEM, V273, P3732, DOI 10.1074/jbc.273.6.3732; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; Scholefield Z, 2003, J CELL BIOL, V163, P97, DOI 10.1083/jcb.200303059; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Tun H, 2002, J MOL NEUROSCI, V19, P31, DOI 10.1007/s12031-002-0007-5; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; WOLFE MS, 2002, CURR TOP MED CHEM, V4, P371; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	36	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37886	37894		10.1074/jbc.M402130200	http://dx.doi.org/10.1074/jbc.M402130200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15197182	hybrid			2022-12-27	WOS:000223554600082
J	Bodding, M; Flockerzi, V				Bodding, M; Flockerzi, V			Ca2+ dependence of the Ca(2+)selective TRPV6 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM-CHANNEL; PORE PROPERTIES; PROSTATE-CANCER; WHOLE-CELL; CAT-LIKE; PERMEATION; IDENTIFICATION; TRANSPORT; CURRENTS; PROTEIN	Microfluorimetry and patch-clamp experiments were performed on TRPV6-expressing HEK cells to determine whether this Ca2+-sensing Ca2+ channel is constitutively active. Intact cells loaded with fura-2 had an elevated intracellular free Ca2+ concentration ([Ca2+](i)), which decreased to the same level such as in non-transfected cells if external Ca2+ was chelated by EGTA. Whole cell recordings from non-transfected HEK cells and cells expressing human TRPV6 revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mM EGTA and 100 nM [Ca2+](i) or if the cytosolic Ca2+ buffering remained undisturbed in perforated patch-clamp experiments. If recombinantly expressed TRPV6 forms open channels, one would expect Ca2+-induced current inhibition, because TRPV6 is negatively regulated by internal Ca2+. However, dialyzing solutions with high [Ca2+] such as 1 muM into TRPV6-expressing cells did not block the basal inward current, which was not different from the recordings from non-transfected cells. In contrast, dialyzing 0.5 mM EGTA into TRPV6-expressing cells readily activated Ca2+ inward currents, which were undetectable in non-transfected cells. Interestingly, monovalent cations permeated the TRPV6 channels under conditions where no Ca2+ permeation was detectable, indicating that divalent cations block TRPV6 channels from the extracellular side. Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca2+-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel. In summary, no constitutive open TRPV6 channels were detected in patch-clamp experiments from transfected HEK cells. However, channel activity is highly regulated by intracellular and extracellular divalent cations.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Bodding, M (corresponding author), Univ Saarland, D-66421 Homburg, Germany.	matthias.boedding@uniklinik-saarland.de						Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hirnet D, 2003, CELL CALCIUM, V33, P509, DOI 10.1016/S0143-4160(03)00066-6; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2002, BBA-PROTEINS PROTEOM, V1600, P6, DOI 10.1016/S1570-9639(02)00438-7; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Jean K, 2002, AM J PHYSIOL-CELL PH, V282, pC665, DOI 10.1152/ajpcell.00443.2001; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Peng JB, 2003, J PHYSIOL-LONDON, V551, P729, DOI 10.1113/jphysiol.2003.043349; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	21	51	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36546	36552		10.1074/jbc.M404679200	http://dx.doi.org/10.1074/jbc.M404679200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15184369	hybrid			2022-12-27	WOS:000223453600050
J	Kersting, MC; Choi, HS; Carman, GM				Kersting, MC; Choi, HS; Carman, GM			Regulation of the yeast EKI1-encoded ethanolamine kinase by inositol and choline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLSERINE SYNTHASE; INO1 PROMOTER; GENETIC-REGULATION; PHOSPHATIDYLETHANOLAMINE; EXPRESSION; GLYCOSYLPHOSPHATIDYLINOSITOL; PHOSPHATIDYLCHOLINE; IDENTIFICATION	Regulation of the EKI1-encoded ethanolamine kinase by inositol and choline was examined in Saccharomyces cerevisiae. Transcription of the EKI1 gene was monitored by following the expression of beta-galactosidase activity driven by a P-EKI1-lacZ reporter gene. The addition of inositol to the growth medium resulted in a dose-dependent decrease in EKI1 expression. Supplementation of choline to inositol-containing growth medium brought about a further decrease in expression, whereas choline supplementation alone had no effect. Analysis of EKI1 expression in ino2Delta, ino4Delta, and opi1Delta mutants indicated that the transcription factors Ino2p, Ino4p, and Opi1p played a role in this regulation. Moreover, mutational analysis showed that the UAS(INO) element in the EKI1 promoter was required for the inositol-mediated regulation. The regulation of EKI1 expression by inositol and choline was confirmed by corresponding changes in ethanolamine kinase mRNA, protein, and activity levels. The repression of ethanolamine kinase by inositol supplementation correlated with a decrease in the incorporation of ethanolamine into CDP-ethanolamine pathway intermediates and into phosphatidylethanolamine and phosphatidylcholine.	Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; Birner R, 2003, INT REV CYTOL, V225, P273, DOI 10.1016/S0074-7696(05)25007-6; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1975, GENETICS, V80, P23; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HJELMSTAD RH, 1994, J BIOL CHEM, V269, P20995; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MENON AK, 1992, J BIOL CHEM, V267, P15277; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA JI, 1986, J BACTERIOL, V166, P328, DOI 10.1128/jb.166.1.328-330.1986; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; RATTRAY JBM, 1975, BACTERIOL REV, V39, P197, DOI 10.1128/MMBR.39.3.197-231.1975; Rose MD., 1990, METHODS YEAST GENETI; Sambrok J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x	67	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35353	35359		10.1074/jbc.M405704200	http://dx.doi.org/10.1074/jbc.M405704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201274	hybrid			2022-12-27	WOS:000223303400028
J	Sayers, I; Housden, JEM; Spivey, AC; Helm, BA				Sayers, I; Housden, JEM; Spivey, AC; Helm, BA			The importance of Lys-352 of human immunoglobulin E in Fc epsilon RII/CD23 recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-AFFINITY RECEPTOR; HUMAN IGE-FC; BINDING-SITE; CD23; IDENTIFICATION; FRAGMENT; CELLS; EXPRESSION; ANTIBODIES; SECRETION	The interaction of immunoglobulin E (IgE) with its low affinity receptor (FcepsilonRII/CD23) plays a central role in the initiation and regulation of type I hypersensitivity responses. We have previously identified the importance of amino acid residues in the A-B loop of the Cepsilon3 domain of human IgE and implicated a region close to the glycosylation site at asparagine 371 as contributing to IgE-CD23 interaction. These residues were now targeted by site-directed mutagenesis. The IgE-CD23 interaction was assessed by semiquantitative flow cytometry. Replacement of the entire Cepsilon3 A-B loop (residues 341 356) with the homologous rat IgE sequence resulted in complete loss of human CD23 recognition, as did replacement of residues 346-353, indicating that class-specific effector residue(s) are contained within these eight amino acids. Lysine 352 within the A-B loop was identified as contributing directly to human CD23 interaction. Mutation to the rodent homologue glycine or glutamate resulted in a significant reduction in binding compared with native IgE, whereas conservative substitution with arginine effected a small, but statistically significant, enhancement of CD23 binding. Mutation of the Cepsilon3 glycosylation site at asparagine 371 to threonine or glutamine did not significantly affect CD23 recognition. Our results yield new insights into the structural basis of the hIgE-CD23 interaction and hold promise for the rational design of drugs that can manipulate IgE-mediated regulation of the allergic response.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Queens Med Ctr, Div Therapeut & Mol Med, Nottingham NG7 2UH, England; Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England	University of Sheffield; University of Nottingham; Imperial College London	Helm, BA (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	B.Helm@sheffield.ac.uk		Sayers, Ian/0000-0001-5601-5410				BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BETTLER B, 1992, J BIOL CHEM, V267, P185; BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7566, DOI 10.1073/pnas.86.19.7566; Bjorklund JEM, 1999, MOL IMMUNOL, V36, P213, DOI 10.1016/S0161-5890(99)00036-X; Chen BH, 2002, IMMUNOLOGY, V107, P373, DOI 10.1046/j.1365-2567.2002.01512.x; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DIERKS SE, 1993, J IMMUNOL, V150, P2372; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; GONZALEZMOLINA A, 1976, J IMMUNOL, V117, P1838; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Helm BA, 1996, J BIOL CHEM, V271, P7494, DOI 10.1074/jbc.271.13.7494; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; Kilmon MA, 2001, J IMMUNOL, V167, P3139, DOI 10.4049/jimmunol.167.6.3139; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; NISSIM A, 1993, J IMMUNOL, V150, P1365; PADLAN EA, 1993, BIOCHEM SOC T, V21, P963, DOI 10.1042/bst0210963; POCHON S, 1992, J EXP MED, V176, P389, DOI 10.1084/jem.176.2.389; Sayers I, 1999, CLIN EXP ALLERGY, V29, P585; Sayers I, 1998, BIOCHEMISTRY-US, V37, P16152, DOI 10.1021/bi981456k; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; Shi JG, 1997, BIOCHEMISTRY-US, V36, P2112, DOI 10.1021/bi961231e; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Tsicopoulos A, 2000, CLIN EXP ALLERGY, V30, P602; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; VOGEL M, 1994, EUR J IMMUNOL, V24, P1200, DOI 10.1002/eji.1830240529; WILSON APM, 1993, EUR J IMMUNOL, V23, P240, DOI 10.1002/eji.1830230137; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6; YOUNG RJ, 1995, PROTEIN ENG, V8, P193, DOI 10.1093/protein/8.2.193	30	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35320	35325		10.1074/jbc.M404575200	http://dx.doi.org/10.1074/jbc.M404575200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199058	hybrid			2022-12-27	WOS:000223303400024
J	Chen, K; Thomas, SR; Albano, A; Murphy, MP; Keaney, JF				Chen, K; Thomas, SR; Albano, A; Murphy, MP; Keaney, JF			Mitochondrial function is required for hydrogen peroxide-induced growth factor receptor transactivation and downstream signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; STRESS-INDUCED APOPTOSIS; FACTOR-BETA RECEPTOR; OXIDATIVE STRESS; REVERSIBLE INACTIVATION; LIPID-PEROXIDATION; KINASE ACTIVATION; REDOX REGULATION; CELL-SURVIVAL; EGF RECEPTOR	The transactivation of growth factor receptors is an early event in H2O2-induced signaling, although proximal targets in this process remain unclear. We found that inhibition of flavin- or heme-containing proteins eliminated H2O2-induced transactivation of the epidermal growth factor receptor and stimulation of its downstream targets, JNK and Akt. Inhibition of mitochondrial function with rotenone, antimycin A, KCN, carbonylcyanide-m-chlorophenylhydrazone, or oligomycin reproduced this effect, as did generation of mitochondrial DNA-deficient (pseudo-rho(0)) cells. Mitochondrial function had no role in JNK activation in response to UV irradiation or tumor necrosis factor-alpha. The impact of mitochondrial function on H2O2-induced growth factor transactivation was ubiquitous and applied to both the vascular endothelial growth factor (VEGF)-2 receptor and the platelet-derived growth factor-beta receptor in endothelium and fibroblasts, respectively. In contrast, ligand-induced growth factor activation was unrelated to mitochondrial function. Growth factor receptor transactivation and its downstream signaling in response to H2O2 appeared to involve redox-sensitive mitochondrial events as they were abrogated by a mitochondrial-targeted antioxidants but not their nontargeted counterparts. Functionally, we found that mitochondrial-targeted antioxidants inhibited H2O2-induced apoptosis and cell death but had no effect with UV irradiation. These data establish a novel role for the mitochondrion as a proximal target specific to H2O2-induced signaling and growth factor transactivation.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Mem Dept Med, Boston, MA 02118 USA; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	Boston University; Boston University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Keaney, JF (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,Rm W507, Boston, MA 02118 USA.	jkeaney@bu.edu	Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Keaney, John/0000-0002-0866-1837	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060886, P01HL068758, K02HL067206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 68758, HL 60886, HL 67206] Funding Source: Medline; NIDDK NIH HHS [DK 55656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; BURTON GW, 1983, CIBA F SYMP, V101, P4; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chen K, 2003, FREE RADICAL BIO MED, V35, P117, DOI 10.1016/S0891-5849(03)00239-9; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XP, 2001, FREE RADICAL BIO MED, V31, P894, DOI 10.1016/S0891-5849(01)00665-7; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x; Pearlstein DP, 2002, ARTERIOSCL THROM VAS, V22, P566, DOI 10.1161/01.ATV.0000012262.76205.6A; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Thomas SR, 2003, ANTIOXID REDOX SIGN, V5, P181, DOI 10.1089/152308603764816541; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Wan YS, 2001, INT J ONCOL, V18, P461; WANG X, 2001, J BIOL CHEM; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	53	89	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35079	35086		10.1074/jbc.M404859200	http://dx.doi.org/10.1074/jbc.M404859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180991	hybrid			2022-12-27	WOS:000223134800120
J	Landino, LM; Skreslet, TE; Alston, JA				Landino, LM; Skreslet, TE; Alston, JA			Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite - Modulation of microtubule assembly kinetics by the thioredoxin reductase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULIN; LOCALIZATION; DAMAGE; SULFHYDRYLS; NITRATION	Alterations in the redox status of proteins have been implicated in the pathology of several neurodegenerative conditions including Alzheimer and Parkinson diseases. We report that peroxynitrite- and hydrogen peroxide-induced disulfides in the neuron-specific microtubule-associated proteins tau and microtubule-associated protein-2 are substrates for the ubiquitous thioredoxin reductase system composed of thioredoxin reductase, human or Escherichia coli thioredoxin, and NADPH. Tau and microtubule-associated protein-2 cysteine oxidation and reduction were quantitated by monitoring the incorporation of 5-iodoacetamidofluorescein, a thiol-specific labeling reagent. Cysteine oxidation of tau and microtubule-associated protein-2 to disulfides altered the ability of the proteins to promote the assembly of microtubules from purified porcine tubulin. Treatment of tau and microtubule-associated protein-2 with either the thioredoxin reductase system or small molecule reductants fully restores the ability of the MAPs to promote microtubule assembly. Thus changes in the redox state of microtubule-associated proteins may regulate microtubule polymerization in vivo.	Coll William & Mary, Dept Chem, Williamsburg, VA 23187 USA	William & Mary	Landino, LM (corresponding author), Coll William & Mary, Dept Chem, POB 8795, Williamsburg, VA 23187 USA.	lmland@wm.edu			NINDS NIH HHS [R15 NS 38885] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R15NS038885] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; ANDERSON PJ, 1979, J BIOL CHEM, V254, P2168; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BRADY ST, 1986, ANN NY ACAD SCI, V466, P199, DOI 10.1111/j.1749-6632.1986.tb38395.x; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Di Noto L, 1999, Mol Cell Biol Res Commun, V2, P71, DOI 10.1006/mcbr.1999.0153; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Landino LM, 2004, FREE RADICAL BIO MED, V36, P497, DOI 10.1016/j.freeradbiomed.2003.11.026; Landino LM, 2004, BIOCHEM BIOPH RES CO, V314, P555, DOI 10.1016/j.bbrc.2003.12.126; Landino LM, 2002, ARCH BIOCHEM BIOPHYS, V398, P213, DOI 10.1006/abbi.2001.2729; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LONG C, 1968, BIOCH HDB, P782; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; Smith MA, 1997, J NEUROSCI, V17, P2653; TRONCOSO JC, 1993, BRAIN RES, V613, P313, DOI 10.1016/0006-8993(93)90918-D; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376	32	68	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35101	35105		10.1074/jbc.M405471200	http://dx.doi.org/10.1074/jbc.M405471200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184375	hybrid			2022-12-27	WOS:000223134800122
J	Lee, AYL; Hsu, CH; Wu, SH				Lee, AYL; Hsu, CH; Wu, SH			Functional domains of Brevibacillus thermoruber Lon protease for oligomerization and DNA binding - Role of N-terminal and sensor and substrate discrimination domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MYCOBACTERIUM-SMEGMATIS; MITOCHONDRIAL LON; CRYSTAL-STRUCTURE; CLPAP PROTEASE; LIMITED PROTEOLYSIS; CAPR PROTEIN; LA	Lon protease is a multifunctional enzyme, and its functions include the degradation of damaged proteins and naturally short lived proteins, ATPase and chaperone-like activities, as well as DNA binding. A thermostable Lon protease from Brevibacillus thermoruber WR-249 (Bt-Lon) has been cloned and characterized with an N-terminal domain, a central ATPase domain that includes a sensor and substrate discrimination (SSD) domain, and a C-terminal protease domain. Here we present a detailed structure-function characterization of Bt-Lon, not only dissecting the individual roles of Bt-Lon domains in oligomerization, catalytic activities, chaperone-like activity, and DNA binding activity but also describing the nature of oligomerization. Seven truncated mutants of Bt-Lon were designed, expressed, and purified. Our results show that the N-terminal domain is essential for oligomerization. The truncation of the N-terminal domain resulted in the failure of oligomerization and led to the inactivation of proteolytic, ATPase, and chaperone-like activities but retained the DNA binding activity, suggesting that oligomerization of Bt-Lon is a prerequisite for its catalytic and chaperone-like activities. We further found that the SSD is involved in DNA binding based on gel mobility shift assays. On the other hand, the oligomerization of Bt-Lon proceeds through a dimer 7 tetramer 7 hexamer assembly model revealed by chemical cross-linking experiments. The results also showed that hydrophobic interactions may play important roles in the dimerization of Bt-Lon, and ionic interactions are mainly responsible for the assembly of hexamers.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Wu, SH (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	shwu@gate.sinica.edu.tw	Lee, Alan Yueh-Luen/A-9141-2010; Lee, Alan Yueh-Luen/B-1097-2010; HSU, CHUN-HUA/W-4554-2019	HSU, CHUN-HUA/0000-0002-0008-7383; Lee, Alan Yueh-Luen/0000-0003-0252-0571				AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Botos I, 2004, J STRUCT BIOL, V146, P113, DOI 10.1016/j.jsb.2003.09.003; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHARETTE MF, 1984, J BACTERIOL, V158, P195, DOI 10.1128/JB.158.1.195-201.1984; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1983, J BIOL CHEM, V258, P215; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; Ebel W, 1999, J BACTERIOL, V181, P2236, DOI 10.1128/JB.181.7.2236-2243.1999; FISCHER H, 1993, J BIOL CHEM, V268, P22502; Fu GK, 1997, J BIOL CHEM, V272, P534; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Fukui T, 2002, J BACTERIOL, V184, P3689, DOI 10.1128/JB.184.13.3689-3698.2002; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; GILL RE, 1993, J BACTERIOL, V175, P4538, DOI 10.1128/JB.175.14.4538-4544.1993; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee AYL, 2004, EUR J BIOCHEM, V271, P834, DOI 10.1111/j.1432-1033.2004.03988.x; LIN TH, 1991, J BIOL CHEM, V266, P1635; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Neuwald AF, 1999, GENOME RES, V9, P27; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niwa H, 2002, STRUCTURE, V10, P1415, DOI 10.1016/S0969-2126(02)00855-9; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Rasulova FS, 1998, FEBS LETT, V432, P179, DOI 10.1016/S0014-5793(98)00859-X; Roudiak SG, 1998, BIOCHEMISTRY-US, V37, P11255, DOI 10.1021/bi980945h; Roudiak SG, 1998, BIOCHEMISTRY-US, V37, P377, DOI 10.1021/bi971732f; Rudyak SG, 2000, PROTEIN SCI, V9, P1810, DOI 10.1110/ps.9.9.1810; Rudyak SG, 2001, BIOCHEMISTRY-US, V40, P9317, DOI 10.1021/bi0102508; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHMIDT R, 1994, J BACTERIOL, V176, P6528, DOI 10.1128/JB.176.21.6528-6537.1994; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shotland Y, 1997, MOL MICROBIOL, V24, P1303, DOI 10.1046/j.1365-2958.1997.4231796.x; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; Starkova NN, 1998, FEBS LETT, V422, P218, DOI 10.1016/S0014-5793(98)00012-X; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Vasilyeva OV, 2002, FEBS LETT, V526, P66, DOI 10.1016/S0014-5793(02)03117-4; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; ZEHNBAUER BA, 1981, P NATL ACAD SCI-BIOL, V78, P2043, DOI 10.1073/pnas.78.4.2043; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	64	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34903	34912		10.1074/jbc.M403562200	http://dx.doi.org/10.1074/jbc.M403562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181012	Green Published, hybrid			2022-12-27	WOS:000223134800101
J	Rouzer, CA; Kingsley, PJ; Wang, HB; Zhang, H; Morrow, JD; Dey, SK; Marnett, LJ				Rouzer, CA; Kingsley, PJ; Wang, HB; Zhang, H; Morrow, JD; Dey, SK; Marnett, LJ			Cyclooxygenase-1-dependent prostaglandin synthesis modulates tumor necrosis factor-alpha secretion in lipopolysaccharide-challenged murine resident peritoneal macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE-H SYNTHASE-1; ARACHIDONIC-ACID METABOLITES; HIGHER OXIDATION-STATES; NITRIC-OXIDE SYNTHASE; MESSENGER-RNA; ANTIINFLAMMATORY DRUGS; PROSTANOID SYNTHASES; PHOSPHOLIPASE A(2); MONONUCLEAR-CELLS; GENE DISRUPTION	Comprehensive studies of prostaglandin ( PG) synthesis in murine resident peritoneal macrophages ( RPM) responding to bacterial lipopolysaccharide (LPS) revealed that the primary PGs produced by RPM were prostacyclin and PGE(2). Detectable increases in net PG formation occurred within the first hour, and maximal PG formation had occurred by 6 - 10 h after LPS addition. Free arachidonic acid levels rose and peaked at 1 - 2 h after LPS addition and then returned to baseline. Cyclooxygenase-2 (COX-2) and microsomal PGE synthase levels markedly increased upon exposure of RPM to LPS, with the most rapid increases in protein expression occurring 2 - 6 h after addition of the stimulus. RPM constitutively expressed high levels of COX-1. Studies using isoform-selective inhibitors and RPM from mice bearing targeted deletions of ptgs-1 and ptgs-2 demonstrated that COX-1 contributes significantly to PG synthesis in RPM, especially during the initial 1 - 2 h after LPS addition. Selective inhibition of either COX isoform resulted in increased secretion of tumor necrosis factor-alpha ( TNF-alpha); however, this effect was much greater with the COX-1 than with the COX-2 inhibitor. These results demonstrate autocrine regulation of TNF-alpha secretion by endogenous PGs synthesized primarily by COX-1 in RPM and suggest that COX-1 may play a significant role in the regulation of the early response to endotoxemia.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Pharmacol & Drug Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat & Cell & Dev Biol & Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Reprod & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Clin Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Rouzer, CA (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	c.rouzer@vanderbilt.edu		Rouzer, Carol/0000-0001-6827-1534	NCI NIH HHS [CA 77839] Funding Source: Medline; NCRR NIH HHS [RR 00095] Funding Source: Medline; NICHD NIH HHS [HD 12304, HD 33994] Funding Source: Medline; NIDA NIH HHS [DA 06668] Funding Source: Medline; NIDDK NIH HHS [DK 48831] Funding Source: Medline; NIGMS NIH HHS [GM 15431] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, R37HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006668, R37DA006668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABIKO Y, 1983, FEBS LETT, V154, P297, DOI 10.1016/0014-5793(83)80170-7; BAGGIOLINI M, 1982, IMMUNOBIOLOGY, V161, P369, DOI 10.1016/S0171-2985(82)80094-6; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BONNEY RJ, 1978, BIOCHEM J, V176, P433, DOI 10.1042/bj1760433; BRAY MA, 1976, BRIT J PHARMACOL, V57, pP466; BROWN GP, 1988, AM J PHYSIOL, V254, pC809, DOI 10.1152/ajpcell.1988.254.6.C809; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; CHANG J, 1980, P NATL ACAD SCI-BIOL, V77, P4736, DOI 10.1073/pnas.77.8.4736; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; COOK HW, 1975, BIOCHEM BIOPH RES CO, V65, P464, DOI 10.1016/S0006-291X(75)80170-7; Devaux Y, 2001, J IMMUNOL, V167, P3962, DOI 10.4049/jimmunol.167.7.3962; Dieter P, 1999, MEDIAT INFLAMM, V8, P295, DOI 10.1080/09629359990306; Dieter P, 2000, BIOCHEM BIOPH RES CO, V276, P488, DOI 10.1006/bbrc.2000.3496; Dieter P, 2002, CELL SIGNAL, V14, P199, DOI 10.1016/S0898-6568(01)00243-1; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dooper MMBW, 2002, IMMUNOLOGY, V107, P152, DOI 10.1046/j.1365-2567.2002.01474.x; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Fennekohl A, 2002, J HEPATOL, V36, P328, DOI 10.1016/S0168-8278(01)00277-X; FU JY, 1990, J BIOL CHEM, V265, P16737; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMILTON JA, 1980, CANCER RES, V40, P2273; HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOMMA Y, 1985, BIOCHEM J, V229, P643, DOI 10.1042/bj2290643; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; HUMS JL, 1985, ADV PROSTAGLANDIN TH, V15, P205; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kim JG, 2000, IMMUNOL INVEST, V29, P257, DOI 10.3109/08820130009060866; Kingsley PJ, 2003, ANAL BIOCHEM, V314, P8, DOI 10.1016/S0003-2697(02)00643-7; Kirtikara K, 1998, J EXP MED, V187, P517, DOI 10.1084/jem.187.4.517; KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008-8749(87)90326-1; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kudo I, 1999, ADV EXP MED BIOL, V469, P29; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; LANDS W, 1971, ANN NY ACAD SCI, V180, P107, DOI 10.1111/j.1749-6632.1971.tb53190.x; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Liu GZ, 2003, J BIOL CHEM, V278, P14956, DOI 10.1074/jbc.M212229200; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Luttmann W, 1999, CYTOKINE, V11, P127, DOI 10.1006/cyto.1998.0410; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Marnett LJ, 2004, MIL DRUG TH, P15; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; MILANO S, 1995, PROSTAG OTH LIPID M, V49, P105, DOI 10.1016/0090-6980(94)00004-G; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Naraba H, 1998, J IMMUNOL, V160, P2974; Ndengele MM, 2000, AM J PHYSIOL-LUNG C, V278, pL1289, DOI 10.1152/ajplung.2000.278.6.L1289; Novak TE, 2003, AM J PHYSIOL-LUNG C, V284, pL84, DOI 10.1152/ajplung.00077.2002; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P5656, DOI 10.1073/pnas.79.18.5656; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; ROUZER CA, 1982, J EXP MED, V155, P720, DOI 10.1084/jem.155.3.720; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; SCALES WE, 1989, J LEUKOCYTE BIOL, V45, P416, DOI 10.1002/jlb.45.5.416; Scott KF, 1999, J LEUKOCYTE BIOL, V66, P535, DOI 10.1002/jlb.66.4.535; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SPENGLER RN, 1989, J IMMUNOL, V142, P4346; STOSSEL TP, 1974, J CLIN INVEST, V54, P638, DOI 10.1172/JCI107801; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; Tsuboi K, 2002, PROSTAG OTH LIPID M, V68-9, P535, DOI 10.1016/S0090-6980(02)00054-0; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WATANABE S, 1994, J LIPID MEDIAT CELL, V10, P283; Wong E, 1997, J BIOL CHEM, V272, P9280; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	99	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34256	34268		10.1074/jbc.M402594200	http://dx.doi.org/10.1074/jbc.M402594200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181007	hybrid			2022-12-27	WOS:000223134800024
J	Stilo, R; Liguoro, D; Di Jeso, B; Formisano, S; Consiglio, E; Leonardi, A; Vito, P				Stilo, R; Liguoro, D; Di Jeso, B; Formisano, S; Consiglio, E; Leonardi, A; Vito, P			Physical and functional interaction of CARMA1 and CARMA3 with I kappa kinase gamma-NF kappa B essential modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; LYMPHOCYTE-ACTIVATION; CONTAINING PROTEIN; T-LYMPHOCYTES; FAMILY MEMBER; PKC-THETA; BCL10; APOPTOSIS; REGULATOR; PATHWAY	CARMA proteins are scaffold molecules that contain a caspase recruitment domain and a membrane-associated guanylate kinase-like domain. CARMA1 plays a critical role in mediating activation of the NFkappaB transcription factor following antigen receptor stimulation of both B and T lymphocytes. However, the biochemical mechanism by which CARMA1 regulates activation of NFkappaB remains to be determined. Here we have shown that CARMA1 and CARMA3 physically associate with Ikappa kinase gamma/NFkappaB essential modulator (IkappaKgamma-NEMO) in lymphoid and non-lymphoid cells. CARMA1 participates to an inducible large molecular complex that contains IkappaKgamma/NEMO, Bcl10, and IkappaKalpha/beta kinases. Expression of the NEMO-binding region of CARMA3 exerts a dominant negative effect on Bcl10-mediated activation of NFkappaB. Thus, our results provide direct evidence for physical and functional interaction between CARMA and the IkappaK complex and offer a biochemical framework to understand the molecular activities controlled by CARMA-1, -2, and -3 and Bcl10.	Univ Naples Federico II, BioGeM Consortium, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Lecce, Dipartimento Sci & Tecnol Biol & Ambientali, I-73100 Lecce, Italy; Univ Studi Sannio Benevento, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy	University of Naples Federico II; University of Naples Federico II; University of Salento; University of Sannio	Vito, P (corresponding author), Univ Naples Federico II, BioGeM Consortium, Via S Pansini 5, I-80131 Naples, Italy.	vito@unisannio.it	leonardi, antonio/A-2887-2009; vito, pasquale/ABF-5505-2020	leonardi, antonio/0000-0001-8636-9623; vito, pasquale/0000-0002-5721-7716; di jeso, bruno/0000-0001-8713-5984				Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Dienz O, 2000, J BIOL CHEM, V275, P24547, DOI 10.1074/jbc.C000177200; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wang L, 2001, J BIOL CHEM, V276, P21405, DOI 10.1074/jbc.M102488200; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	31	57	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34323	34331		10.1074/jbc.M402244200	http://dx.doi.org/10.1074/jbc.M402244200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184390	hybrid			2022-12-27	WOS:000223134800031
J	Kedjouar, B; de Medina, P; Oulad-Abdelghani, M; Payre, B; Silvente-Poirot, S; Favre, G; Faye, JC; Poirot, M				Kedjouar, B; de Medina, P; Oulad-Abdelghani, M; Payre, B; Silvente-Poirot, S; Favre, G; Faye, JC; Poirot, M			Molecular characterization of the microsomal tamoxifen binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIONAL-CANCER-INSTITUTE; HIGH-AFFINITY BINDING; PROTEIN-KINASE-C; ESTROGEN-RECEPTOR; BREAST-CANCER; RAT-LIVER; CHOLESTEROL-BIOSYNTHESIS; STRUCTURAL REQUIREMENTS; EPOXIDE HYDROLASE; MASS-SPECTROMETRY	Tamoxifen is a selective estrogen receptor modulator widely used for the prophylactic treatment of breast cancer. In addition to the estrogen receptor ( ER), tamoxifen binds with high affinity to the microsomal antiestrogen binding site (AEBS), which is involved in ER-independent effects of tamoxifen. In the present study, we investigate the modulation of the biosynthesis of cholesterol in tumor cell lines by AEBS ligands. As a consequence of the treatment with the antitumoral drugs tamoxifen or PBPE, a selective AEBS ligand, we show that tumor cells produced a significant concentration- and time-dependent accumulation of cholesterol precursors. Sterols have been purified by HPLC and gas chromatography, and their chemical structures determined by mass spectrometric analysis. The major metabolites identified were 5 alpha-cholest-8-en-3beta-ol for tamoxifen treatment and 5alpha-cholest-8-en-3beta-ol and cholesta-5,7-dien-3beta-ol, for PBPE treatment, suggesting that these AEBS ligands affect at least two enzymatic steps: the 3beta-hydroxysterol-Delta(8)-Delta(7)-isomerase and the 3beta-hydroxysterol-Delta(7)-reductase. Steroidal antiestrogens such as ICI 182,780 and RU 58,668 did not affect these enzymatic steps, because they do not bind to the AEBS. Transient co-expression of human 3beta-hydroxysterol-Delta(8)-Delta(7)- isomerase and 3beta-hydroxysterol-Delta(7)-reductase and immunoprecipitation experiments showed that both enzymes were required to reconstitute the AEBS in mammalian cells. Altogether, these data provide strong evidence that the AEBS is a hetero-oligomeric complex including 3beta-hydroxysterol-Delta(8)-Delta(7)-isomerase and the 3beta-hydroxysterol-Delta(7)-reductase as subunits that are necessary and sufficient for tamoxifen binding in mammary cells. Furthermore, because selective AEBS ligands are antitumoral compounds, these data suggest a link between cholesterol metabolism at a post-lanosterol step and tumor growth control. These data afford both the identification of the AEBS and give new insight into a novel molecular mechanism of action for drugs of clinical value.	INSERM, U563, CPTP,Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, F-31052 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Poirot, M (corresponding author), INSERM, U563, CPTP,Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, 20-24 Rue Pont Saint Pierre, F-31052 Toulouse, France.	poirot@icr.fnclcc.fr	Poirot, Marc/K-3551-2012; Poirot, Sandrine/D-5448-2017; Poirot, Marc/C-7613-2009; abdelghani, mustapha oulad/A-5986-2017; FAVRE, Gilles/K-9189-2014; de Medina, Philippe/X-1358-2019	Poirot, Marc/0000-0002-5711-6624; Poirot, Marc/0000-0002-5711-6624; abdelghani, mustapha oulad/0000-0002-8381-4397; FAVRE, Gilles/0000-0002-2344-1883; Silvente-Poirot, Sandrine/0000-0003-2245-9069; de Medina, Philippe/0000-0002-9618-3133				BECKER A, 1994, ARTERIOSCLER THROMB, V14, P1346, DOI 10.1161/01.ATV.14.8.1346; Bencze W L, 1969, Prog Drug Res, V13, P217; Bitsch F, 2003, ANAL BIOCHEM, V323, P139, DOI 10.1016/j.ab.2003.08.029; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDES LJ, 1988, CANCER RES, V48, P3954; BRANDES LJ, 1984, BIOCHEM BIOPH RES CO, V124, P244, DOI 10.1016/0006-291X(84)90943-4; BRANDES LJ, 1995, J CLIN ONCOL, V13, P1398, DOI 10.1200/JCO.1995.13.6.1398; CHAILLEUX C, 1994, J RECEPTOR RES, V14, P23, DOI 10.3109/10799899409066994; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cho SY, 1998, MOL CELLS, V8, P233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Medina P, 2004, J PHARMACOL EXP THER, V308, P1165, DOI 10.1124/jpet.103.060426; Delarue F, 1999, BIOCHEM PHARMACOL, V57, P657, DOI 10.1016/S0006-2952(98)00347-5; FARGIN A, 1988, CHEM-BIOL INTERACT, V66, P101, DOI 10.1016/0009-2797(88)90044-0; Ferlini C, 1999, BRIT J CANCER, V79, P257, DOI 10.1038/sj.bjc.6690042; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Gerst N, 1997, J LIPID RES, V38, P1685; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; HWANG PLH, 1989, J LIPID RES, V30, P239; HWANG PLH, 1990, BIOCHIM BIOPHYS ACTA, V1033, P154, DOI 10.1016/0304-4165(90)90006-I; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Jetten AM, 2002, CELL DEATH DIFFER, V9, P1167, DOI 10.1038/sj.cdd.4401085; Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031; JOZAN S, 1982, BIOCHEM BIOPH RES CO, V107, P1566, DOI 10.1016/S0006-291X(82)80178-2; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kedjouar B, 1999, BIOCHEM PHARMACOL, V58, P1927, DOI 10.1016/S0006-2952(99)00285-3; Khoo K, 1999, J CLIN ONCOL, V17, P3431, DOI 10.1200/JCO.1999.17.11.3431; LaBella FS, 2000, J CELL BIOCHEM, V76, P686, DOI 10.1002/(SICI)1097-4644(20000315)76:4<686::AID-JCB16>3.3.CO;2-M; LI L, 1991, BIOCHIM BIOPHYS ACTA, V1082, P177, DOI 10.1016/0005-2760(91)90192-K; Mesange F, 1998, BIOCHEM J, V334, P107, DOI 10.1042/bj3340107; Mesange F, 2002, BIOCONJUGATE CHEM, V13, P766, DOI 10.1021/bc015588t; Moebius FF, 1998, P NATL ACAD SCI USA, V95, P1899, DOI 10.1073/pnas.95.4.1899; Moebius FF, 1998, MOL PHARMACOL, V54, P591, DOI 10.1124/mol.54.3.591; PAIK YK, 1986, J BIOL CHEM, V261, P6470; Paul R, 1998, J PHARMACOL EXP THER, V285, P1296; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; POIROT M, 1990, J BIOL CHEM, V265, P17039; Poirot M, 2000, BIOORGAN MED CHEM, V8, P2007, DOI 10.1016/S0968-0896(00)00119-X; POIROT M, 1990, BIOCHEM PHARMACOL, V40, P425, DOI 10.1016/0006-2952(90)90539-W; POPJAK G, 1989, J BIOL CHEM, V264, P6230; Porter FD, 2002, J CLIN INVEST, V110, P715, DOI 10.1172/JCI200216386; Reyno L, 2004, J CLIN ONCOL, V22, P269, DOI 10.1200/JCO.2003.04.075; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SHEEN YY, 1985, ENDOCRINOLOGY, V117, P561, DOI 10.1210/endo-117-2-561; Shefer S, 1998, J LIPID RES, V39, P2471; SHEFER S, 1995, J CLIN INVEST, V96, P1779, DOI 10.1172/JCI118223; Smith LL, 1996, LIPIDS, V31, P453, DOI 10.1007/BF02522641; SMITH LL, 1987, CHEM PHYS LIPIDS, V44, P87, DOI 10.1016/0009-3084(87)90046-6; SUTHERLAND RL, 1980, NATURE, V288, P273, DOI 10.1038/288273a0; TANG BL, 1989, BIOCHIM BIOPHYS ACTA, V1014, P162, DOI 10.1016/0167-4889(89)90029-3; VANDENKOEDIJK CDMA, 1992, BIOCHEM PHARMACOL, V43, P2511, DOI 10.1016/0006-2952(92)90138-9; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; Wassif CA, 2003, STEROIDS, V68, P497, DOI 10.1016/S0039-128X(03)00090-4; WATTS CKW, 1987, MOL PHARMACOL, V31, P541; WATTS CKW, 1984, J BIOL CHEM, V259, P4223; WAYS P, 1964, J LIPID RES, V5, P318; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200	61	72	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34048	34061		10.1074/jbc.M405230200	http://dx.doi.org/10.1074/jbc.M405230200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175332	hybrid			2022-12-27	WOS:000223039700117
J	Nogami, K; Freas, J; Manithody, C; Wakabayashi, H; Rezaie, AR; Fay, PJ				Nogami, K; Freas, J; Manithody, C; Wakabayashi, H; Rezaie, AR; Fay, PJ			Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN HIRUDIN COMPLEX; LENGTH CROSS-LINKING; LIGHT-CHAIN; HEAVY-CHAIN; HEPARIN-BINDING; A2 SUBUNITS; FACTOR-IXA; CLEAVAGE; RESIDUES; ACTIVATION	The 337 - 372 sequence of the factor VIIIa A1 subunit contains interactive sites for both zymogen factor X and the active enzyme, factor Xa. Solid phase binding studies indicated that factor Xa possessed a > 20-fold higher affinity for the isolated A1 subunit of factor VIIIa compared with factor X. Heparin completely inhibited zero-length cross-linking of the 337 - 372 peptide to factor Xa but not to factor X. In the presence of calcium, factor Xa showed greater affinity for heparin than factor X. Studies using factor Xa mutants in which heparin-binding exosite residues were individually replaced by Ala showed that the R240A mutant was defective in recognition of the Lys(36) cleavage site, generating the A1(37-372) intermediate with similar to 20% the catalytic efficiency of wild type. This defect likely resulted from an similar to 4-fold increase in K-m for the A1 substrate because k(cat) values for the wild type and mutant were equivalent. Cleavage of the A1-A2 domain junction by factor Xa R240A was not blocked by the 337 - 372 peptide. Studies using mutant factor VIII where clustered acidic residues in the 337 372 segment were replaced by Ala showed that a factor VIIIa D361A/D362A/D363A mutant possessed a similar to 1.6-fold increase in Km for factor X compared with wild type. However, similar Km values were observed for recombinant factor X and R240A substrates. These results indicate that the binding regions of factor X and factor Xa for A1 domain overlap and that both utilize acidic residues 361 - 363. Furthermore, factor Xa but not factor X interacts with high affinity at this site via residues contained within the heparin-binding exosite of the proteinase.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	University of Rochester; University of Rochester; Saint Louis University	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R01HL038199, R01HL076213, R01HL062565] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62565, HL 68571, HL 38199, HL 76213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; BETZ A, 1991, BIOCHEMISTRY-US, V30, P9848, DOI 10.1021/bi00105a006; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen L, 2004, PROTEIN SCI, V13, P431, DOI 10.1110/ps.03406904; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; Nogami K, 2004, J BIOL CHEM, V279, P15763, DOI 10.1074/jbc.M400568200; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; Nogami K, 2003, J BIOL CHEM, V278, P16502, DOI 10.1074/jbc.M213044200; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	32	28	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33104	33113		10.1074/jbc.M405537200	http://dx.doi.org/10.1074/jbc.M405537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166225	hybrid			2022-12-27	WOS:000223039700012
J	Warmka, JK; Mauro, LJ; Wattenberg, EV				Warmka, JK; Mauro, LJ; Wattenberg, EV			Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; DUAL-SPECIFICITY PHOSPHATASES; MAP KINASE; CONSTITUTIVE ACTIVATION; TYROSINE PHOSPHATASES; AP-1 TRANSACTIVATION; SKIN CARCINOGENESIS; TERMINAL KINASE; GENE-EXPRESSION	We have capitalized on the unique properties of the skin tumor promoter palytoxin, which does not activate protein kinase C, to investigate alternative mechanisms by which major signaling molecules can be modulated during carcinogenesis. We report here that palytoxin activates extracellular signal-regulated kinase (ERK) through a novel mechanism that involves inactivation of an ERK phosphatase in keratinocytes derived from initiated mouse skin ( 308 cells). Use of U0126 revealed that palytoxin requires the ERK kinase MEK to stimulate ERK activity, although palytoxin did not activate MEK. We found that 308 keratinocytes highly express mitogen-activated protein kinase phosphatase-3 (MKP-3), which selectively inactivates ERK. Palytoxin induced the loss of MKP-3 in a manner that corresponded to increased ERK phosphorylation. Complementary studies showed that sustained expression of exogenous MKP-3 inhibited palytoxin-stimulated ERK activation. As is characteristic of initiated keratinocytes, 308 cells express activated H-Ras. To investigate whether expression of oncogenic Ras is key to palytoxin-stimulated ERK activation, we determined how palytoxin affected ERK and MKP-3 in MCF10A human breast epithelial cells and in H-ras MCF10A cells, which stably express activated H-Ras. Palytoxin did not affect ERK activity in MCF10A cells, which had no detectable MKP-3. Like 308 cells, H-ras MCF10A cells highly express MKP-3. Strikingly, palytoxin stimulated ERK activity and induced a corresponding loss of MKP-3 in H-ras MCF10A cells. These studies indicate that in initiated cells palytoxin unleashes ERK activity by down-regulating MKP-3, an ERK inhibitor, and further suggest that MKP-3 may be a vulnerable target in cells that express oncogenic Ras.	Univ Minnesota, Div Environm Hlth Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Anim Sci Physiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Wattenberg, EV (corresponding author), Univ Minnesota, Div Environm Hlth Sci, Mayo Mail Code 807,420 Delaware St SE, Minneapolis, MN 55455 USA.	watte004@umn.edu						Albanell J, 2001, CANCER RES, V61, P6500; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Dowd S, 1998, J CELL SCI, V111, P3389; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FUJIKI H, 1986, CARCINOGENESIS, V7, P707, DOI 10.1093/carcin/7.5.707; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; HABERMANN E, 1989, TOXICON, V27, P1171, DOI 10.1016/0041-0101(89)90026-3; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Kuroki DW, 1997, J BIOL CHEM, V272, P23905, DOI 10.1074/jbc.272.38.23905; Kuroki DW, 1996, CANCER RES, V56, P637; Li SN, 1998, TOXICOL APPL PHARM, V151, P377, DOI 10.1006/taap.1998.8471; Li SN, 1999, TOXICOL APPL PHARM, V160, P109, DOI 10.1006/taap.1999.8754; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MOORE RE, 1981, J AM CHEM SOC, V103, P2491, DOI 10.1021/ja00399a093; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PITOT HC, 1995, PROG CLIN  BIOL, V391, P21; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; STRICKLAND JE, 1988, CANCER RES, V48, P165; Thilly WG, 2003, NAT GENET, V34, P255, DOI 10.1038/ng1205; Warmka JK, 2002, TOXICOL APPL PHARM, V185, P8, DOI 10.1006/taap.2002.9519; WATTENBERG EV, 1989, J BIOL CHEM, V264, P213; WATTENBERG EV, 1987, CANCER RES, V47, P4618; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zeliadt NA, 2004, BIOCHEM BIOPH RES CO, V317, P570, DOI 10.1016/j.bbrc.2004.03.081; Zhan XL, 2001, CHEM REV, V101, P2477, DOI 10.1021/cr000245u; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	54	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33085	33092		10.1074/jbc.M403120200	http://dx.doi.org/10.1074/jbc.M403120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159408	hybrid			2022-12-27	WOS:000223039700010
J	Sandoval, R; Xue, JP; Pilkinton, M; Salvi, D; Kiyokawa, H; Colamonici, OR				Sandoval, R; Xue, JP; Pilkinton, M; Salvi, D; Kiyokawa, H; Colamonici, OR			Different requirements for the cytostatic and apoptotic effects of type I Interferons - Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; INDEPENDENT RESPONSES; INK4A LOCUS; ALPHA; CANCER; EXPRESSION; GROWTH; CYCLE; P14(ARF); PROTEIN	The regulation of cell growth is one of the most important effects of type I interferons (IFNs). This response may involve a cytostatic effect or the induction of apoptosis depending on the cell context. Often the growth-inhibitory response of type I IFNs is studied in tumor cell lines carrying mutations of tumor suppressor genes, and therefore, the growth-inhibitory effect can be influenced by inactivation of these important regulators of cell proliferation. In this report, we explored the role of the ARF-p53 pathway in the growth-inhibitory effect of type I IFNs. We found that p53 is only induced in cells that express p14(ARF) (p19(ARF) in mouse cells). Surprisingly, mouse embryonal fibroblasts that are null for p19(ARF) or P53, even after transformation with oncogenic RAS, respond as well as wild type to the growth-inhibitory effect of type I IFNs. Similarly, human ARF(-/-) U2OS and P53(-/-) SAOS-2 cells show a significant decrease in cell proliferation. However, only SAOS-2 or U2OS reconstituted with inducible p14(ARF) undergo apoptosis in response to IFNbeta treatment, and this effect was not inhibited by expression of dominant negative p53. These data suggest that (i) at least in specific cell types, the induction of apoptosis by type I IFNs requires an ARF pathway that is p53-independent and (ii) the cytostatic and pro-apoptotic effects of type I IFNs employ different pathways.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol MC868, 835 S Wolcott Ave,Rm E403, Chicago, IL 60612 USA.	ocolamon@uic.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NATIONAL CANCER INSTITUTE [R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NCI NIH HHS [CA55079] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Erickson S, 1999, CELL GROWTH DIFFER, V10, P575; Gamero AM, 2001, J BIOL CHEM, V276, P13547, DOI 10.1074/jbc.M007948200; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; JEWELL AP, 1994, BRIT J HAEMATOL, V88, P268, DOI 10.1111/j.1365-2141.1994.tb05017.x; Kamijo T, 1999, CANCER RES, V59, P2217; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Matsuoka M, 1998, ONCOGENE, V16, P2075, DOI 10.1038/sj.onc.1201745; MILNER AE, 1995, INT J CANCER, V61, P348, DOI 10.1002/ijc.2910610313; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Munro J, 1999, CANCER RES, V59, P2516; Nakamura M, 2001, CANCER RES, V61, P6335; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Prejean C, 2000, SEMIN CANCER BIOL, V10, P83, DOI 10.1006/scbi.2000.0311; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; RODRIGUEZVILLANUEVA J, 1995, INT J CANCER, V61, P110, DOI 10.1002/ijc.2910610119; ROOS G, 1984, CANCER RES, V44, P2358; Rubinstein M, 1998, CYTOKINE GROWTH F R, V9, P175; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TIEFERBRUN N, 1996, MOL CELL BIOL, V7, P3934; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yano H, 1999, HEPATOLOGY, V29, P1708, DOI 10.1002/hep.510290624; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	53	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32275	32280		10.1074/jbc.M313830200	http://dx.doi.org/10.1074/jbc.M313830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169789	hybrid			2022-12-27	WOS:000222849700036
J	Zhong, Q; Gohil, VM; Ma, LN; Greenberg, ML				Zhong, Q; Gohil, VM; Ma, LN; Greenberg, ML			Absence of cardiolipin results in temperature sensitivity, respiratory defects, and mitochondrial DNA instability independent of pet56	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BARTH-SYNDROME; YEAST MITOCHONDRIA; SYNTHASE; MUTANT; GENE; EXPRESSION; GROWTH; ABNORMALITIES; STABILITY	Cardiolipin ( CL) is a dimeric phospholipid localized primarily in the mitochondrial membrane. Previous studies have shown that yeast cells containing a disruption of CRD1, the structural gene encoding CL synthase, exhibit temperature-sensitive colony formation and multiple mitochondrial defects. A recent report (Zhang, M., Su, X., Mileykovskaya, E., Amoscato, A. A., and Dowhan, W. ( 2003) J. Biol. Chem. 278, 35204-35210) suggested that defects associated with CL deficiency may result from the reduced expression of PET56 in crd1Delta mutant backgrounds and should be reevaluated. In the current study, we present evidence that CL deficiency leads to mitochondrial DNA instability, loss of viability, and defects in oxidative phosphorylation at elevated temperatures. The observed mutant phenotypes are characteristic of crd1Delta mutant cells of both PET56 and pet56 backgrounds and are complemented by an episomal copy of CRD1 but not by expression of the PET56 gene. Phosphatidylglycerol is elevated in crd1Delta mutant cells when grown in the presence of fermentable and non-fermentable carbon sources, although the extent of the increase is higher in nonfermentable medium. An increase in the ratio of phosphatidylethanolamine to phosphatidylcholine was also apparent in the mutant. These findings demonstrate that CRD1, independent of PET56, is required for optimal mitochondrial function and for an essential cellular function at elevated temperatures.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, 5047 GullenM all, Detroit, MI 48202 USA.	mlgreen@sun.science.wayne.edu	zhong, quan/AAE-8893-2021	Gohil, Vishal/0000-0002-9920-2563; Zhong, Quan/0000-0003-2910-5597	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Barth PG, 1996, J INHERIT METAB DIS, V19, P157, DOI 10.1007/BF01799418; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Chen R, 2002, MOL GENET METAB, V77, P319, DOI 10.1016/S1096-7192(02)00195-6; COLLART MA, 1994, CURRENT PROTOCOLS MO; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; Gu ZM, 2004, MOL MICROBIOL, V51, P149, DOI 10.1046/j.1365-2958.2003.03802.x; JAKOVCIC S, 1971, J CELL BIOL, V48, P490, DOI 10.1083/jcb.48.3.490; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; LERAY C, 1987, J CHROMATOGR-BIOMED, V420, P411, DOI 10.1016/0378-4347(87)80198-6; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Rieger KJ, 1997, YEAST, V13, P1547, DOI 10.1002/(SICI)1097-0061(199712)13:16<1547::AID-YEA230>3.3.CO;2-P; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SIKORSKI RS, 1989, GENETICS, V122, P19; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; Storey MK, 2001, BBA-MOL CELL BIOL L, V1532, P234, DOI 10.1016/S1388-1981(01)00129-9; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; Zhang M, 2003, J BIOL CHEM, V278, P35204, DOI 10.1074/jbc.M306729200	31	79	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32294	32300		10.1074/jbc.M403275200	http://dx.doi.org/10.1074/jbc.M403275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169766	hybrid			2022-12-27	WOS:000222849700039
J	Lai, MC; Tarn, WY				Lai, MC; Tarn, WY			Hypophosphorylated ASF/SF2 binds TAP and is present in messenger ribonucleoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON JUNCTION COMPLEX; RNA EXPORT; SPLICING FACTORS; SR PROTEINS; NUCLEAR IMPORT; RS DOMAIN; PHOSPHORYLATION; MEX67P; TRANSPORTIN-SR2; SURVEILLANCE	Serine/arginine-rich proteins (SR proteins) function in precursor mRNA (pre-mRNA) splicing and may also act as adaptors for mRNA export. SR proteins are dynamically phosphorylated in their RS domain, and differential phosphorylation modulates their splicing activity and subcellular localization. In this study, we investigated the influence of phosphorylation on the function of SR proteins in events occurring during mRNA maturation. Immunoprecipitation experiments showed that the mRNA export receptor TAP associates preferentially with the hypophosphorylated form of shuttling SR proteins, including ASF/SF2. Overexpression of ASF induced subnuclear relocalization of TAP to SR protein-enriched nuclear speckles, suggesting their interaction in vivo. Moreover, the ASF found in a nucleoplasmic fraction rich in heterogeneous nuclear ribonucleoprotein ( hnRNP) complexes is hyperphosphorylated, whereas mature messenger RNP (mRNP)-bound ASF is hypophosphorylated. Therefore, hypophosphorylation of ASF in mRNPs coincides with its higher affinity for TAP, suggesting that dephosphorylation of ASF promotes both its incorporation into mRNPs and recruitment of TAP for mRNA export. Thus, the phosphorylation state of RS domains may modulate the function of mammalian shuttling SR proteins during mRNA maturation or export.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Tarn, WY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	wtarn@ibms.sinica.edu.tw	Tarn, Woan-Yuh/N-8464-2018					Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gilbert W, 2004, MOL CELL, V13, P201, DOI 10.1016/S1097-2765(04)00030-9; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Herold A, 2001, RNA, V7, P1768; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Izaurralde E, 2004, NAT STRUCT MOL BIOL, V11, P210, DOI 10.1038/nsmb0304-210; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Lai MC, 2000, J BIOL CHEM, V275, P7950, DOI 10.1074/jbc.275.11.7950; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Li C, 2003, MOL CELL BIOL, V23, P7363, DOI 10.1128/MCB.23.20.7363-7376.2003; Lu SH, 2003, RNA, V9, P618, DOI 10.1261/rna.5260303; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Mili S, 2001, MOL CELL BIOL, V21, P7307, DOI 10.1128/MCB.21.21.7307-7319.2001; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Nott A, 2003, RNA, V9, P607, DOI 10.1261/rna.5250403; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Reed R, 2001, NAT CELL BIOL, V3, pE201, DOI 10.1038/ncb0901-e201; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Yun CY, 2003, J BIOL CHEM, V278, P18050, DOI 10.1074/jbc.M211714200	30	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31745	31749		10.1074/jbc.C400173200	http://dx.doi.org/10.1074/jbc.C400173200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15184380	hybrid			2022-12-27	WOS:000222726800100
J	Kondo, T; Kahn, CR				Kondo, T; Kahn, CR			Altered insulin signaling in retinal tissue in diabetic states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; INDUCED DOWN-REGULATION; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; ANIMAL-MODELS; UP-REGULATION; RISK-FACTORS; RETINOPATHY; ACTIVATION; MUSCLE	Both type 1 and type 2 diabetes can lead to altered retinal microvascular function and diabetic retinopathy. Insulin signaling may also play a role in this process, and mice lacking insulin receptors in endothelial cells are protected from retinal neovascularization. To define the role of diabetes in retinal function, we compared insulin signaling in the retinal vasculature of mouse models of type 1 ( streptozotocin) and type 2 diabetes (ob/ob). In streptozotocin mice, in both retina and liver, insulin receptor (IR) and insulin receptor substrate (IRS)-2 protein and tyrosine phosphorylation were increased by insulin, while IRS-1 protein and its phosphorylation were maintained. By contrast, in ob/ob mice, there was marked down-regulation of IR, IRS-1, and IRS-2 protein and phosphorylation in liver; these were maintained or increased in retina. In both mice, Phosphatidylinositol 3,4,5-trisphosphate generation by acute insulin stimulation was enhanced in retinal endothelial cells. On the other hand, protein levels and phosphorylation of PDK1 and Akt were decreased in retina of both mice. Interestingly, phosphorylation of p38 mitogen-activated protein kinase and ERK1 were responsive to insulin in retina of both mice but were unresponsive in liver. HIF-1alpha and vascular endothelial growth factor were increased and endothelial nitric-oxide synthase was decreased in retina. These observations indicate that, in both insulin-resistant and insulin-deficient diabetic states, there are alterations in insulin signaling, such as impaired PDK/Akt responses and enhanced mitogen-activated protein kinases responses that could contribute to the retinopathy. Furthermore, insulin signaling in retinal endothelial cells is differentially altered in diabetes and is also differentially regulated from insulin signaling in classical target tissues such as liver.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	CLIHON, Residencia Medica/K-4896-2013; Kahn, Ronald/AAY-2435-2021	CLIHON, Residencia Medica/0000-0001-6734-2513; Kahn, Ronald/0000-0002-7583-9228; Kondo, Tatsuya/0000-0003-4830-8955	NIDDK NIH HHS [DK33201, DK31036, DK53105] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053105, R01DK031036, R37DK031036, R01DK033201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler AI, 2002, DIABETES CARE, V25, P894, DOI 10.2337/diacare.25.5.894; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Cardillo C, 1999, CIRCULATION, V100, P820, DOI 10.1161/01.CIR.100.8.820; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Chaturvedi N, 2001, DIABETES CARE, V24, P284, DOI 10.2337/diacare.24.2.284; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Henricsson M, 1997, DIABETIC MED, V14, P123, DOI 10.1002/(SICI)1096-9136(199702)14:2<123::AID-DIA306>3.0.CO;2-U; Igarashi M, 2000, EUR J CLIN INVEST, V30, P668; KAHN CR, 1973, J BIOL CHEM, V248, P244; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KNUTSON VP, 1995, J BIOL CHEM, V270, P24972, DOI 10.1074/jbc.270.42.24972; Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; Lu M, 1999, INVEST OPHTH VIS SCI, V40, P3281; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; Montagnani M, 2002, J BIOL CHEM, V277, P1794, DOI 10.1074/jbc.M103728200; Niswender KD, 2003, J HISTOCHEM CYTOCHEM, V51, P275, DOI 10.1177/002215540305100302; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776; Reiter CEN, 2003, PROG RETIN EYE RES, V22, P545, DOI 10.1016/S1350-9462(03)00035-1; Rojas FA, 2001, MOL CELL ENDOCRINOL, V183, P63, DOI 10.1016/S0303-7207(01)00597-4; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; ROSENZWEIG SA, 1990, J BIOL CHEM, V265, P18030; ROYSARKAR TK, 1993, AM J OPHTHALMOL, V115, P569, DOI 10.1016/S0002-9394(14)71452-7; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; SOLL AH, 1975, J BIOL CHEM, V250, P4702; Suzuki M, 2000, J DIABETES COMPLICAT, V14, P40, DOI 10.1016/S1056-8727(00)00052-0; Ten Vadim S, 2002, Curr Opin Crit Care, V8, P242, DOI 10.1097/00075198-200206000-00008; TOZZO E, 1992, DIABETES, V41, P1609, DOI 10.2337/diabetes.41.12.1609; Vicent D, 2003, J CLIN INVEST, V111, P1373, DOI 10.1172/JCI200315211; Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209; ZETTERSTROM C, 1992, DIABETES, V41, P818, DOI 10.2337/diabetes.41.7.818	44	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37997	38006		10.1074/jbc.M401339200	http://dx.doi.org/10.1074/jbc.M401339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201286	hybrid			2022-12-27	WOS:000223554600093
J	Lisman, Q; Urli-Stam, D; Holthuis, JCM				Lisman, Q; Urli-Stam, D; Holthuis, JCM			HOR7, a multicopy suppressor of the Ca(2+)induced growth defect in sphingolipid mannosyltransferase-deficient yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; HEAT-STRESS; PROTEIN; GENE; MUTATIONS; PHOSPHATASE; TOLERANCE; REQUIRES	Yeast mutants defective in sphingolipid mannosylation accumulate inositol phosphorylceramide C (IPC-C), which renders cells Ca2+-sensitive. A screen for loss of function suppressors of the Ca2+-sensitive phenotype previously led to the identification of numerous genes involved in IPC-C synthesis. To better understand the molecular basis of the Ca2+-induced growth defect in IPC-C-overaccumulating cells, we searched for genes whose overexpression restored Ca2+ tolerance in a mutant lacking the IPC mannosyltransferases Csg1p and Csh1p. Here we report the isolation of HOR7 as a multicopy suppressor of the Ca2+-sensitive phenotype of Deltacsg1Deltacsh1 cells. HOR7 belongs to a group of hyperosmolarity-responsive genes and encodes a small (59-residue) type I membrane protein that localizes at the plasma membrane. Hor7p is not required for high Ca2+ or Na+ tolerance. Instead, we find that Hor7p-overproducing cells display an increased resistance to high salt, sensitivity to low pH, and a reduced uptake of methylammonium, an indicator of the plasma membrane potential. These phenotypes are induced through a mechanism independent of the plasma membrane H+-ATPase, Pma1p. Our findings suggest that induction of Hor7p causes a depolarization of the plasma membrane that may counteract a Ca2+-induced influx of toxic cations in IPC-C-overaccumulating cells.	Univ Utrecht, Fac Chem, Dept Membrane Enxymol, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam	Holthuis, JCM (corresponding author), Univ Utrecht, Fac Chem, Dept Membrane Enxymol, Ctr Biomembranes & Lipid Enzymol, HR Kruytgebouw N605,Padualaan 8, NL-3584 CH Utrecht, Netherlands.	j.c.holthuis@chem.uu.nl	Holthuis, Joost/AAL-9157-2020	Holthuis, Joost/0000-0001-8912-1586				Ambesi A, 2000, J EXP BIOL, V203, P155; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Dunn TM, 1998, YEAST, V14, P311, DOI 10.1002/(SICI)1097-0061(19980315)14:4<311::AID-YEA220>3.0.CO;2-B; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kobayashi N, 1996, BIOCHEM BIOPH RES CO, V229, P540, DOI 10.1006/bbrc.1996.1840; Leber A, 1997, FEBS LETT, V411, P211, DOI 10.1016/S0014-5793(97)00692-3; Lisman Q, 2004, J BIOL CHEM, V279, P1020, DOI 10.1074/jbc.M306119200; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; MCCLANAHAN T, 1984, MOL CELL BIOL, V4, P2356, DOI 10.1128/MCB.4.11.2356; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; NAVARRE C, 1992, J BIOL CHEM, V267, P6425; Navarre C, 2000, EMBO J, V19, P2515, DOI 10.1093/emboj/19.11.2515; NAVARRE C, 1994, J BIOL CHEM, V269, P21262; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Treger JM, 1998, J BIOL CHEM, V273, P26875, DOI 10.1074/jbc.273.41.26875; Uemura S, 2003, J BIOL CHEM, V278, P45049, DOI 10.1074/jbc.M305498200; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; Withee JL, 1998, GENETICS, V149, P865; ZHAO C, 1994, J BIOL CHEM, V269, P21480; Ziman M, 1996, MOL BIOL CELL, V7, P1909, DOI 10.1091/mbc.7.12.1909	40	6	6	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36390	36396		10.1074/jbc.M406197200	http://dx.doi.org/10.1074/jbc.M406197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208314	hybrid, Green Published			2022-12-27	WOS:000223453600029
J	Clarke, BR; Cuthbertson, L; Whitfield, C				Clarke, BR; Cuthbertson, L; Whitfield, C			Nonreducing terminal modifications determine the chain length of polymannose O antigens of Escherichia coli and couple chain termination to polymer export via an ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-1 CAPSULAR POLYSACCHARIDES; STEAROTHERMOPHILUS NRS 2004/3A; RHIZOBIUM-ETLI CE3; VIBRIO-CHOLERAE O1; COILED-COIL DOMAIN; SHIGELLA-FLEXNERI; KLEBSIELLA-PNEUMONIAE; SALMONELLA-ENTERICA; POLYACRYLAMIDE GELS; SERUM RESISTANCE	The chain length of bacterial lipopolysaccharide O antigens is regulated to give a modal distribution that is critical for pathogenesis. This paper describes the process of chain length determination in the ATP-binding cassette (ABC) transporter-dependent pathway, a pathway that is widespread among Gram-negative bacteria. Escherichia coli O8 and O9/O9a polymannans are synthesized in the cytoplasm, and an ABC transporter exports the nascent polymer across the inner membrane prior to completion of the LPS molecule. The polymannan O antigens have nonreducing terminal methyl groups. The 3-O-methyl group in serotype O8 is transferred from S-adenosylmethionine by the WbdD(O8) enzyme, and this modification terminates polymerization. Methyl groups are added to the O9a polymannan in a reaction dependent on preceding phosphorylation. The bifunctional WbdD(O9a) catalyzes both reactions, but only the kinase activity controls chain length. Chain termination occurs in a mutant lacking the ABC transporter, indicating that it precedes export. An E. coli wbdD(O9a) mutant accumulated O9a polymannan in the cytoplasm, indicating that WbdD activity coordinates polymannan chain termination with export across the inner membrane.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of Guelph	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca						Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; BASTIN DA, 1993, MOL MICROBIOL, V7, P725, DOI 10.1111/j.1365-2958.1993.tb01163.x; BATCHELOR RA, 1991, J BACTERIOL, V173, P5699, DOI 10.1128/jb.173.18.5699-5704.1991; Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; BRONNER D, 1994, MOL MICROBIOL, V14, P505, DOI 10.1111/j.1365-2958.1994.tb02185.x; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Burns SM, 1998, INFECT IMMUN, V66, P4244; Daniell SJ, 2001, INFECT IMMUN, V69, P4055, DOI 10.1128/IAI.69.6.4055-4064.2001; Delahay RM, 1999, J BIOL CHEM, V274, P35969, DOI 10.1074/jbc.274.50.35969; Duelli DM, 2001, J BACTERIOL, V183, P6054, DOI 10.1128/JB.183.20.6054-6064.2001; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Franco AV, 1998, J BACTERIOL, V180, P2670, DOI 10.1128/JB.180.10.2670-2675.1998; GOLDMAN RC, 1990, J BACTERIOL, V172, P5352, DOI 10.1128/jb.172.9.5352-5359.1990; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Hong M, 1997, MOL MICROBIOL, V24, P779, DOI 10.1046/j.1365-2958.1997.3731744.x; ITO T, 1994, CARBOHYD RES, V256, P113, DOI 10.1016/0008-6215(94)84231-0; JANSSON PE, 1985, CARBOHYD RES, V145, P59, DOI 10.1016/S0008-6215(00)90412-9; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; KIDO N, 1995, J BACTERIOL, V177, P2178, DOI 10.1128/jb.177.8.2178-2187.1995; Kido N, 2000, J BACTERIOL, V182, P2567, DOI 10.1128/JB.182.9.2567-2573.2000; Klee SR, 1997, J BACTERIOL, V179, P2421, DOI 10.1128/jb.179.7.2421-2425.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawton DG, 2002, J BIOL CHEM, V277, P38714, DOI 10.1074/jbc.M203632200; LAZAREVIC V, 1995, MOL MICROBIOL, V16, P345, DOI 10.1111/j.1365-2958.1995.tb02306.x; Lerouge I, 2003, MOL PLANT MICROBE IN, V16, P1085, DOI 10.1094/MPMI.2003.16.12.1085; Lerouge I, 2001, J BIOL CHEM, V276, P17190, DOI 10.1074/jbc.M101129200; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Miller J. H., 1972, EXPT MOL GENETICS, P431; Morona R, 2003, FEMS MICROBIOL LETT, V221, P173, DOI 10.1016/S0378-1097(03)00210-6; Morona R, 2003, FEMS MICROBIOL LETT, V221, P213, DOI 10.1016/S0378-1097(03)00217-9; Morona R, 2003, MICROBIOL-SGM, V149, P925, DOI 10.1099/mic.0.26141-0; MORONA R, 1995, J BACTERIOL, V177, P1059, DOI 10.1128/jb.177.4.1059-1068.1995; Murray GL, 2003, MOL MICROBIOL, V47, P1395, DOI 10.1046/j.1365-2958.2003.03383.x; Najdenski H, 2003, FEMS IMMUNOL MED MIC, V38, P97, DOI 10.1016/S0928-8244(03)00183-4; Novotny R, 2004, MICROBIOL-SGM, V150, P953, DOI 10.1099/mic.0.26672-0; ORSKOV I, 1977, BACTERIOL REV, V41, P667, DOI 10.1128/MMBR.41.3.667-710.1977; Preston A, 1999, INFECT IMMUN, V67, P3763, DOI 10.1128/IAI.67.8.3763-3767.1999; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rick P, 1996, ESCHERICHIA COLI SAL, P104; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaffer C, 2002, J BIOL CHEM, V277, P6230, DOI 10.1074/jbc.M108873200; Schaffer C, 2001, BIOCHIMIE, V83, P591, DOI 10.1016/S0300-9084(01)01299-8; SCHMIDT MA, 1982, FEMS MICROBIOL LETT, V14, P69, DOI 10.1016/0378-1097(82)90045-3; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Stricker J, 2003, J BACTERIOL, V185, P4796, DOI 10.1128/JB.185.16.4796-4805.2003; STROEHER UH, 1992, P NATL ACAD SCI USA, V89, P2566, DOI 10.1073/pnas.89.7.2566; Sugiyama T, 1997, GENE, V198, P111, DOI 10.1016/S0378-1119(97)00300-4; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VanDenBosch L, 1997, MOL MICROBIOL, V23, P765, DOI 10.1046/j.1365-2958.1997.2541625.x; Vinogradov E, 2002, CARBOHYD RES, V337, P961; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2000, EUR J BIOCHEM, V267, P7230, DOI 10.1046/j.1432-1327.2000.01835.x; Vinogradov EV, 1999, EUR J BIOCHEM, V261, P629, DOI 10.1046/j.1432-1327.1999.00280.x; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Whitfield C, 2003, CARBOHYD RES, V338, P2491, DOI 10.1016/j.carres.2003.08.010; WHITFIELD C, 1989, J GEN MICROBIOL, V135, P2589; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200; [No title captured]	67	95	98	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35709	35718		10.1074/jbc.M404738200	http://dx.doi.org/10.1074/jbc.M404738200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15184370	hybrid			2022-12-27	WOS:000223303400069
J	Liaw, SH; Chang, YJ; Lai, CT; Chang, HC; Chang, GG				Liaw, SH; Chang, YJ; Lai, CT; Chang, HC; Chang, GG			Crystal structure of Bacillus subtilis guanine deaminase - The first domain-swapped structure in the cytidine deaminase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCYTIDYLATE DEAMINASE; FUNCTIONAL-ANALYSIS; PROTEIN; INSIGHTS; ENZYMES; ASSOCIATION; MOLSCRIPT; SEQUENCE; CLONING; GENES	Guanine deaminase, a key enzyme in the nucleotide metabolism, catalyzes the hydrolytic deamination of guanine into xanthine. The crystal structure of the 156-residue guanine deaminase from Bacillus subtilis has been solved at 1.17-Angstrom resolution. Unexpectedly, the C-terminal segment is swapped to form an intersubunit active site and an intertwined dimer with an extensive interface of 3900 Angstrom(2) per monomer. The essential zinc ion is ligated by a water molecule together with His(53), Cys(83), and Cys(86). A transition state analog was modeled into the active site cavity based on the tightly bound imidazole and water molecules, allowing identification of the conserved deamination mechanism and specific substrate recognition by Asp(114) and Tyr(156'). The closed conformation also reveals that substrate binding seals the active site entrance, which is controlled by the C-terminal tail. Therefore, the domain swapping has not only facilitated the dimerization but has also ensured specific substrate recognition. Finally, a detailed structural comparison of the cytidine deaminase superfamily illustrates the functional versatility of the divergent active sites found in the guanine, cytosine, and cytidine deaminases and suggests putative specific substrate-interacting residues for other members such as dCMP deaminases.	Natl Yang Ming Univ, Struct Biol Program, Taipei 11221, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 11221, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Liaw, SH (corresponding author), Natl Yang Ming Univ, Struct Biol Program, Taipei 11221, Taiwan.	shliaw@ym.edu.tw	Lai, Cheng-Tsung/H-6728-2013	Lai, Cheng-Tsung/0000-0002-1192-2815				BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canbolat O, 1996, BREAST CANCER RES TR, V37, P189, DOI 10.1007/BF01806500; Chang YJ, 2004, ACTA CRYSTALLOGR D, V60, P1152, DOI 10.1107/S0907444904008558; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Durak I, 1997, CANCER INVEST, V15, P212, DOI 10.3109/07357909709039717; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fassbinder F, 2000, FEMS MICROBIOL LETT, V191, P191, DOI 10.1111/j.1574-6968.2000.tb09339.x; GREEN SM, 1995, NAT STRUCT BIOL, V2, P746, DOI 10.1038/nsb0995-746; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; Keefe RG, 2000, J BIOL CHEM, V275, P12598, DOI 10.1074/jbc.275.17.12598; Keegan LP, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-209; Ko TP, 2003, J BIOL CHEM, V278, P19111, DOI 10.1074/jbc.M300874200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuwahara H, 1999, J BIOL CHEM, V274, P32204, DOI 10.1074/jbc.274.45.32204; Lai WL, 2004, J BIOL CHEM, V279, P13962, DOI 10.1074/jbc.M308849200; Liou JY, 2003, MOL PHARMACOL, V63, P105, DOI 10.1124/mol.63.1.105; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Matsunaga Hiroko, 2003, Journal of Medical Investigation, V50, P64; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nygaard P, 2000, MICROBIOL-UK, V146, P3061, DOI 10.1099/00221287-146-12-3061; Paletzki RF, 2002, NEUROSCIENCE, V109, P15, DOI 10.1016/S0306-4522(01)00352-9; Roberts ELL, 2004, ANAL BIOCHEM, V324, P250, DOI 10.1016/j.ab.2003.09.041; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Schultz AC, 2001, J BACTERIOL, V183, P3293, DOI 10.1128/JB.183.11.3293-3302.2001; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; Wolan DW, 2002, BIOCHEMISTRY-US, V41, P15505, DOI 10.1021/bi020505x; Xiang SB, 1997, BIOCHEMISTRY-US, V36, P4768, DOI 10.1021/bi963091e; Yuan G, 1999, J BIOL CHEM, V274, P8175, DOI 10.1074/jbc.274.12.8175	34	45	48	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35479	35485		10.1074/jbc.M405304200	http://dx.doi.org/10.1074/jbc.M405304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15180998	hybrid			2022-12-27	WOS:000223303400041
J	Berryman, M; Bruno, J; Price, J; Edwards, JC				Berryman, M; Bruno, J; Price, J; Edwards, JC			CLIC-5A functions as a chloride channel in vitro and associates with the cortical actin cytoskeleton in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PLACENTAL MICROVILLI; EPITHELIAL-CELLS; PLASMA-MEMBRANE; PROTEIN; FAMILY; MEMBER; EZRIN; IDENTIFICATION; AKAP350	CLIC-5A is a member of the chloride intracellular channel protein family, which is comprised of six related human genes encoding putative chloride channels. In this study, we found that reconstitution of purified recombinant CLIC-5A into artificial liposomes resulted in a dose-dependent chloride efflux that was sensitive to the chloride channel blocker IAA-94. CLIC-5A was originally isolated as a component of an ezrin-containing cytoskeletal complex from human placental microvilli. Here we show that similar protein complexes can be isolated using either immobilized CLIC-5A or the C-terminal F-actin-binding domain of ezrin and that actin polymerization is required for de novo assembly of these complexes. To investigate the behavior of CLIC-5A in vivo, JEG-3 placental choriocarcinoma cells were stably transfected with epitope-tagged CLIC-5A. In fixed cells, CLIC-5A displayed a polarized distribution and colocalized with ezrin in apical microvilli. Microvillar localization of CLIC-5A was retained after Triton X-100 extraction and was disrupted by treatment with latrunculin B. In transient transfections assays, we mapped a region between residues 20 and 54 of CLIC-5A that is required for targeting of CLIC-5A to microvilli in JEG-3 cells. Interestingly, expression of CLIC-5A in JEG-3 cells did not enhance the rate of iodide efflux in intact cells, suggesting that if CLIC-5A is a chloride channel, its channel activity may be restricted to intracellular membrane compartments in these cells. Regardless of its role in ion transport, CLIC-5A, like ezrin, may play an important role in the assembly or maintenance of F-actin-based structures at the cell cortex.	Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; Ohio Univ, Mol & Cellular Biol Program, Athens, OH 45701 USA; St Louis Univ, St Louis Vet Affairs Med Ctr, St Louis, MO 63106 USA; St Louis Univ, Dept Med, St Louis, MO 63106 USA	University System of Ohio; Ohio University; University System of Ohio; Ohio University; Saint Louis University; Saint Louis University	Berryman, M (corresponding author), Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, 237 Life Sci Bldg, Athens, OH 45701 USA.	berryman@ohiou.edu	Bruno, Jonathan/HII-3034-2022		NIDDK NIH HHS [R01 DK 060551] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060551] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENZEEV A, 1986, EXP CELL RES, V164, P335, DOI 10.1016/0014-4827(86)90033-9; Berry KL, 2003, SCIENCE, V302, P2134, DOI 10.1126/science.1087667; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Berryman MA, 2003, CELL MOTIL CYTOSKEL, V56, P159, DOI 10.1002/cm.10141; BRETSCHER A, 1978, J CELL BIOL, V79, P839, DOI 10.1083/jcb.79.3.839; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CARLSON RW, 1976, J BIOL CHEM, V251, P4139; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Friedli M, 2003, GENE, V320, P31, DOI 10.1016/S0378-1119(03)00830-8; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Griffon N, 2003, MOL BRAIN RES, V117, P47, DOI 10.1016/S0169-328X(03)00283-3; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; Proutski I, 2002, BIOCHEM BIOPH RES CO, V297, P317, DOI 10.1016/S0006-291X(02)02199-X; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Shanks RA, 2002, J BIOL CHEM, V277, P40973, DOI 10.1074/jbc.M112277200; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Tulk BM, 2000, J BIOL CHEM, V275, P26986; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Warton K, 2002, J BIOL CHEM, V277, P26003, DOI 10.1074/jbc.M203666200	30	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34794	34801		10.1074/jbc.M402835200	http://dx.doi.org/10.1074/jbc.M402835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184393	hybrid			2022-12-27	WOS:000223134800087
J	Fournier, KM; Gonzalez, MI; Robinson, MB				Fournier, KM; Gonzalez, MI; Robinson, MB			Rapid trafficking of the neuronal glutamate transporter, EAAC1 - Evidence for distinct trafficking pathways differentially regulated by protein kinase C and platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTOR TRAFFICKING; CELL-SURFACE EXPRESSION; INSULIN RECRUITS GLUT4; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTER; SYNAPTIC LOCALIZATION; PLASMA-MEMBRANE; GABA SYNTHESIS; SYNTAXIN 1A; ACTIVATION	The neuronal glutamate transporter, EAAC1, appears to both limit spillover between excitatory synapses and provide precursor for the synthesis of the inhibitory neurotransmitter, gamma-aminobutyric acid. There is evidence for a large intracellular pool of EAAC1 from which transporter is redistributed to the cell surface following activation of protein kinase C ( PKC) or platelet-derived growth factor ( PDGF) receptor by seemingly independent pathways. A variety of biotinylation strategies were employed to measure trafficking of EAAC1 to and from the plasma membrane and to examine the effects of phorbol ester and PDGF on these events. Biotinylation of cell surface protein under trafficking-permissive conditions ( 37 degreesC) resulted in a 2-fold increase in the amount of biotinylated EAAC1 within 15 min in C6 glioma and in primary neuronal cultures, suggesting that EAAC1 has a half-life of similar to 5 - 7 min for residence at the plasma membrane. Both phorbol ester and PDGF increased the amount of transporter labeled under these conditions. Using a reversible biotinylation strategy, a similarly rapid internalization of EAAC1 was observed in C6 glioma. Phorbol ester, but not PDGF, blocked this measure of internalization. Incubation at 18 degreesC, which blocks some forms of intracellular membrane trafficking, inhibited PKC- and PDGF-dependent redistribution of EAAC1 but had no effect on basal trafficking of EAAC1. These studies suggest that both PKC and PDGF accelerate delivery of EAAC1 to the cell surface and that PKC has an additional effect on endocytosis. The data also suggest that basal and regulated pools of EAAC1 exist in distinct compartments.	Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Robinson, MB (corresponding author), 502N Anramson Pediat Res Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@pharm.med.upenn.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039011] Funding Source: NIH RePORTER; NIMH NIH HHS [5T32 MH 014654] Funding Source: Medline; NINDS NIH HHS [NS 39011] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara S G, 1998, Adv Pharmacol, V42, P164; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; Beckman ML, 2000, NEUROSCIENTIST, V6, P199, DOI 10.1177/107385840000600310; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Butchbach MER, 2003, J NEUROCHEM, V84, P891, DOI 10.1046/j.1471-4159.2003.01588.x; Cheatham B, 2000, TRENDS ENDOCRIN MET, V11, P356, DOI 10.1016/S1043-2760(00)00308-8; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; Clift-O'Grady L, 1998, METHODS, V16, P150, DOI 10.1006/meth.1998.0662; Conti F, 1998, CEREB CORTEX, V8, P108, DOI 10.1093/cercor/8.2.108; Crino PB, 2002, EPILEPSIA, V43, P211, DOI 10.1046/j.1528-1157.2002.35001.x; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Deken SL, 2003, J NEUROSCI, V23, P1563; Diamond JS, 2002, NAT NEUROSCI, V5, P291, DOI 10.1038/nn0402-291; Diamond JS, 2001, J NEUROSCI, V21, P8328, DOI 10.1523/JNEUROSCI.21-21-08328.2001; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Dowd LA, 1996, MOL PHARMACOL, V49, P465; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Esteban Jose A, 2003, Mol Interv, V3, P375, DOI 10.1124/mi.3.7.375; Ferguson SM, 2003, J NEUROSCI, V23, P9697; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Gonzalez MI, 2003, J NEUROSCI, V23, P5589; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; He Y, 2001, NEUROSCI LETT, V311, P161, DOI 10.1016/S0304-3940(01)02180-2; He Y, 2000, J COMP NEUROL, V418, P255; Horton N, 2001, MOL MEMBR BIOL, V18, P39; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; Levenson J, 2002, NAT NEUROSCI, V5, P155, DOI 10.1038/nn791; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Mathews GC, 2003, J NEUROSCI, V23, P2040; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Miller BT, 1997, PEPTIDES, V18, P1585, DOI 10.1016/S0196-9781(97)00225-8; Miller HP, 1997, J NEUROCHEM, V68, P1564; Moron JA, 2003, J NEUROSCI, V23, P8480; Morpurgo M, 1999, J BIOCHEM BIOPH METH, V38, P17, DOI 10.1016/S0165-022X(98)00027-X; Najimi M, 2002, FEBS LETT, V523, P224, DOI 10.1016/S0014-5793(02)02981-2; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Ribeiro FM, 2003, J NEUROCHEM, V87, P136, DOI 10.1046/j.1471-4159.2003.01974.x; Richerson GB, 2003, J NEUROPHYSIOL, V90, P1363, DOI 10.1152/jn.00317.2003; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Savchenko V, 2003, MOL CELL NEUROSCI, V24, P1131, DOI 10.1016/S1044-7431(03)00235-5; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Sung U, 2003, J NEUROSCI, V23, P1697; SUSARLA BTS, 2002, SOC NEUR ABSTR, V28; Ueda Y, 2001, J NEUROCHEM, V76, P892, DOI 10.1046/j.1471-4159.2001.00087.x; Watson RT, 2003, MOL CELL BIOL, V23, P961, DOI 10.1128/MCB.23.3.961-974.2003; WIT H, 1999, MOL BIOL CELL, V10, P4163; Yang WB, 2002, J BIOL CHEM, V277, P38350, DOI 10.1074/jbc.M202052200	69	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34505	34513		10.1074/jbc.M404032200	http://dx.doi.org/10.1074/jbc.M404032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15197183	hybrid			2022-12-27	WOS:000223134800053
J	Le Stunff, H; Mikami, A; Giussani, P; Hobson, JP; Jolly, PS; Milstien, S; Spiegel, S				Le Stunff, H; Mikami, A; Giussani, P; Hobson, JP; Jolly, PS; Milstien, S; Spiegel, S			Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; KINASE; ACTIVATION; MOTILITY; PHOSPHOHYDROLASE; TRANSACTIVATION; INVOLVEMENT	Sphingosine-1-phosphate (S1P) is the ligand for a family of specific G protein-coupled receptors that regulate a wide variety of cellular functions, including cytoskeletal rearrangements and cell motility. Because of the pivotal role of S1P, its levels are low and tightly regulated in a spatial-temporal manner through its synthesis catalyzed by sphingosine kinases and degradation by an S1P lyase and specific S1P phosphatases (SPP). Surprisingly, down-regulation of SPP-1 enhanced migration toward epidermal growth factor (EGF); conversely, overexpression of SPP-1, which is localized in the endoplasmic reticulum, attenuated migration toward EGF. To determine whether the inhibitory effect on EGF-induced migration was because of decreased S1P or increased ceramide as a consequence of acylation of increased sphingosine by ceramide synthase, we used fumonisin B1, a specific inhibitor of ceramide synthase. Although fumonisin B1 blocked ceramide production and increased sphingosine, it did not reverse the negative effect of SPP-1 expression on EGF- or S1P-induced chemotaxis. EGF activated the epidermal growth factor receptor to the same extent in SPP-1-expressing cells, yet ERK1/2 activation was impaired. In agreement, PD98059, an inhibitor of the ERK-activating enzyme MEK, decreased EGF- stimulated migration. We next examined the possibility that intracellularly generated S1P might be involved in activating a G protein-coupled S1P receptor important for EGF- directed migration. Treatment with pertussis toxin to inactivate Galpha(i) suppressed EGF- induced migration. Moreover, expression of regulator of G protein signaling 3, which inhibits S1P receptor signaling and completely prevented ERK1/2 activation mediated by S1P receptors, not only reduced migration toward S1P but also markedly reduced migration toward EGF. Collectively, these results suggest that metabolism of S1P by SPP-1 is important for EGF- directed cell migration.	Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	sspiegel@vcu.edu	LE STUNFF, Hervé/AAA-6882-2019; Giussani, Paola/R-4268-2017	Giussani, Paola/0000-0002-7793-1757	NIGMS NIH HHS [GM 43880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Auge N, 2002, ARTERIOSCL THROM VAS, V22, P1990, DOI 10.1161/01.ATV.0000043453.21629.3B; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Budnik LT, 2003, MOL ENDOCRINOL, V17, P1593, DOI 10.1210/me.2002-0371; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Cho H, 2003, BIOCHEM J, V371, P973, DOI 10.1042/BJ20021769; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gschwind A, 2002, CANCER RES, V62, P6329; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Le Stunff H, 2002, J BIOL CHEM, V277, P8920, DOI 10.1074/jbc.M109968200; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Starz-Gaiano M, 2001, DEVELOPMENT, V128, P983; Stukey J, 1997, PROTEIN SCI, V6, P469; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Tanski W, 2002, J SURG RES, V108, P98, DOI 10.1006/jsre.2002.6529; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, CANCER RES, V59, P6185; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Whatmore J, 1999, BIOCHEM J, V341, P435, DOI 10.1042/0264-6021:3410435; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	57	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34290	34297		10.1074/jbc.M404907200	http://dx.doi.org/10.1074/jbc.M404907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180992	hybrid			2022-12-27	WOS:000223134800027
J	Song, MY; Kim, HJ; Kim, EY; Shin, MS; Lee, HC; Hong, YJ; Rhee, JH; Yoon, H; Ryu, S; Lim, S; Choy, HE				Song, MY; Kim, HJ; Kim, EY; Shin, MS; Lee, HC; Hong, YJ; Rhee, JH; Yoon, H; Ryu, S; Lim, S; Choy, HE			ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; RIBONUCLEIC ACID SYNTHESIS; ARAC/XYLS FAMILY-MEMBERS; ALTERNATIVE SIGMA-FACTOR; ESCHERICHIA-COLI; INVASION GENES; GUANOSINE TETRAPHOSPHATE; HISTIDINE OPERON; HILA EXPRESSION; III SECRETION	We have examined expression of the genes on Salmonella pathogenicity island 1 (SPI1) during growth under the physiologically well defined standard growth condition of Luria-Bertani medium with aeration. We found that the central regulator hilA and the genes under its control are expressed at the onset of stationary phase. Interestingly, the two-component regulatory genes hilC/ hilD, sirA/barA, and ompR, which are known to modulate expression from the hilA promoter (hilAp) under so-called "inducing conditions" (Luria-Bertani medium containing 0.3 M NaCl without aeration), acted under standard conditions at the stationary phase induction level. The induction of hilAp depended not on RpoS, the stationary phase sigma factor, but on the stringent signal molecule ppGpp. In the ppGpp null mutant background, hilAp showed absolutely no activity. The stationary phase induction of hilAp required spoT but not relA. Consistent with this requirement, hilAp was also induced by carbon source deprivation, which is known to transiently elevate ppGpp mediated by spoT function. The observation that amino acid starvation elicited by the addition of serine hydroxamate did not induce hilAp in a RelA(+) SpoT(+) strain suggested that, in addition to ppGpp, some other alteration accompanying entry into the stationary phase might be necessary for induction. It is speculated that during the course of infection Salmonella encounters various stressful environments that are sensed and translated to the intracellular signal, ppGpp, which allows expression of Salmonella virulence genes, including SPI1 genes.	Chonnam Natl Univ, Coll Med, Genome Res Ctr Enteropathogen Bacteria, Kwangju 501746, South Korea; Chonnam Natl Univ, Coll Med, Res Inst Vibrio Infect, Kwangju 501746, South Korea; Chonnam Natl Univ, Coll Med, Dept Microbiol, Kwangju 501746, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Sch Agr Biotechnol, Dept Food Sci & Technol, Seoul 151742, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Seoul National University (SNU)	Choy, HE (corresponding author), Chonnam Natl Univ, Coll Med, Genome Res Ctr Enteropathogen Bacteria, Kwangju 501746, South Korea.	hyonchoy@chonnam.ac.kr		Shin, Minsang/0000-0001-8679-446X				Akbar S, 2003, MOL MICROBIOL, V47, P715, DOI 10.1046/j.1365-2958.2003.03322.x; Altier C, 2000, MOL MICROBIOL, V35, P635, DOI 10.1046/j.1365-2958.2000.01734.x; Altier C, 2000, INFECT IMMUN, V68, P6790, DOI 10.1128/IAI.68.12.6790-6797.2000; Bajaj V, 1996, MOL MICROBIOL, V22, P703, DOI 10.1046/j.1365-2958.1996.d01-1718.x; Bang IS, 2000, J BACTERIOL, V182, P2245, DOI 10.1128/JB.182.8.2245-2252.2000; Bang IS, 2002, MOL MICROBIOL, V44, P1235, DOI 10.1046/j.1365-2958.2002.02937.x; CARTER PB, 1974, J EXP MED, V139, P1189, DOI 10.1084/jem.139.5.1189; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1968, J MOL BIOL, V34, P317, DOI 10.1016/0022-2836(68)90256-8; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; DaCosta XJ, 1997, J BACTERIOL, V179, P5211, DOI 10.1128/jb.179.16.5211-5217.1997; Darwin KH, 1999, J BACTERIOL, V181, P4949; Darwin KH, 2000, MOL MICROBIOL, V35, P949, DOI 10.1046/j.1365-2958.2000.01772.x; Darwin KH, 2001, EMBO J, V20, P1850, DOI 10.1093/emboj/20.8.1850; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis R., 1980, ADV BACTERIAL GENETI; DEBOER HA, 1976, BIOCHIM BIOPHYS ACTA, V432, P361, DOI 10.1016/0005-2787(76)90146-5; Eichelberg K, 1999, MOL MICROBIOL, V33, P139, DOI 10.1046/j.1365-2958.1999.01458.x; Fahlen TF, 2001, J BACTERIOL, V183, P6620, DOI 10.1128/JB.183.22.6620-6629.2001; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FRIESEN JD, 1975, J BIOL CHEM, V250, P304; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; HANSEN MT, 1975, J BACTERIOL, V122, P585, DOI 10.1128/JB.122.2.585-591.1975; HARSHMAN RB, 1971, BIOCHEMISTRY-US, V10, P3980, DOI 10.1021/bi00797a027; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; Heyde M, 2000, J BACTERIOL, V182, P198, DOI 10.1128/JB.182.1.198-202.2000; HOHMANN AW, 1978, INFECT IMMUN, V22, P763, DOI 10.1128/IAI.22.3.763-770.1978; Hong KH, 1998, J BACTERIOL, V180, P1793, DOI 10.1128/JB.180.7.1793-1802.1998; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Humphreys S, 1999, INFECT IMMUN, V67, P1560; ISHIGURO EE, 1979, CAN J MICROBIOL, V25, P1206, DOI 10.1139/m79-188; Johnston C, 1996, MOL MICROBIOL, V22, P715, DOI 10.1046/j.1365-2958.1996.d01-1719.x; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAGOSKY PA, 1980, J BACTERIOL, V144, P499, DOI 10.1128/JB.144.2.499-508.1980; Lawhon SD, 2003, MOL MICROBIOL, V48, P1633, DOI 10.1046/j.1365-2958.2003.03535.x; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; Lindgren SW, 1996, P NATL ACAD SCI USA, V93, P4197, DOI 10.1073/pnas.93.9.4197; Lucas RL, 2000, MOL MICROBIOL, V36, P1024, DOI 10.1046/j.1365-2958.2000.01961.x; Lucas RL, 2001, J BACTERIOL, V183, P2733, DOI 10.1128/JB.183.9.2733-2745.2001; Lundberg U, 1999, J BACTERIOL, V181, P3433, DOI 10.1128/JB.181.11.3433-3437.1999; Magnusson LU, 2003, J BIOL CHEM, V278, P968, DOI 10.1074/jbc.M209881200; Marcus SL, 2000, MICROBES INFECT, V2, P145, DOI 10.1016/S1286-4579(00)00273-2; MILLS DM, 1995, MOL MICROBIOL, V15, P749, DOI 10.1111/j.1365-2958.1995.tb02382.x; Murray KD, 1996, J MOL BIOL, V259, P41; Murray RA, 2000, INFECT IMMUN, V68, P5050, DOI 10.1128/IAI.68.9.5050-5055.2000; Olekhnovich IN, 2002, J BACTERIOL, V184, P4148, DOI 10.1128/JB.184.15.4148-4160.2002; PRATT LA, 1995, MOL MICROBIOL, V17, P565, DOI 10.1111/j.1365-2958.1995.mmi_17030565.x; PUTNAM SL, 1975, ANAL BIOCHEM, V63, P350, DOI 10.1016/0003-2697(75)90357-7; Rakeman JL, 1999, J BACTERIOL, V181, P3096, DOI 10.1128/JB.181.10.3096-3104.1999; RYALS J, 1982, J BACTERIOL, V151, P1425, DOI 10.1128/JB.151.3.1425-1432.1982; SANDS MK, 1952, J BACTERIOL, V63, P505, DOI 10.1128/JB.63.4.505-511.1952; Schechter LM, 1999, MOL MICROBIOL, V32, P629, DOI 10.1046/j.1365-2958.1999.01381.x; Schechter LM, 2003, INFECT IMMUN, V71, P5432, DOI 10.1128/IAI.71.9.5432-5435.2003; Schechter LM, 2001, MOL MICROBIOL, V40, P1289, DOI 10.1046/j.1365-2958.2001.02462.x; SHAND RF, 1989, J BACTERIOL, V171, P737, DOI 10.1128/jb.171.2.737-743.1989; Shin D, 2001, J BIOL CHEM, V276, P25871, DOI 10.1074/jbc.M101757200; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Tedin K, 2001, J BACTERIOL, V183, P6184, DOI 10.1128/JB.183.21.6184-6196.2001; Testerman TL, 2002, MOL MICROBIOL, V43, P771, DOI 10.1046/j.1365-2958.2002.02787.x; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; Wilson RL, 2001, MOL MICROBIOL, V39, P79, DOI 10.1046/j.1365-2958.2001.02192.x; XIAO H, 1991, J BIOL CHEM, V266, P5980	68	108	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34183	34190		10.1074/jbc.M313491200	http://dx.doi.org/10.1074/jbc.M313491200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15161921	hybrid			2022-12-27	WOS:000223134800016
J	Ma, HP; Al-Khalili, O; Ramosevac, S; Saxena, S; Liang, YY; Warnock, DG; Eaton, DC				Ma, HP; Al-Khalili, O; Ramosevac, S; Saxena, S; Liang, YY; Warnock, DG; Eaton, DC			Steroids and exogenous gamma-ENaC subunit modulate cation channels formed by alpha-ENaC in human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; SODIUM-CHANNEL; BETA-SUBUNIT; II CELLS; EXPRESSION; NEDD4; CLONING; RECONSTITUTION	Previous studies using whole-cell recording methods suggest that human B lymphocytes express an amiloride-sensitive, sodium-permeable channel. The present studies aim to determine whether this channel has biophysical properties and a molecular structure related to the alpha, beta, and gamma subunits of the epithelial sodium channel ( ENaC). Reverse transcriptase polymerase chain reaction and Northern blots showed that human B lymphocytes express messages for both alpha- and beta- but not gamma-ENaC. Western blots showed that both alpha- and beta- but not gamma-ENaC proteins are expressed and strongly reduced by antisense oligonucleotides. Patch clamp experiments demonstrated that lymphocyte sodium channels are not active in cell-attached patches. However, membrane stretch can activate a 21-pS nonselective cation channel. The frequency of observance of this channel was significantly reduced by antisense oligonucleotide against alpha-ENaC but not by antisense oligonucleotide against beta-ENaC, indicating that only the alpha subunit of ENaC is necessary to form stretch-activated cation channels. Aldosterone (1.5 muM) reduced the frequency of observance of 21-pS alpha-ENaC channels and simultaneously induced the appearance of spontaneously active 10-pS channels. Antisense oligonucleotide experiments showed that this 10-pS channel is formed from alpha- and beta-ENaC. After expression of exogenous gamma-ENaC, aldosterone again reduced the frequency of observance of the 21-pS alpha-ENaC channel but induced the appearance of a 5-pS channel, presumably a alphabetagamma-ENaC channel. In the absence of aldosterone, the alpha subunit forms an alpha-cryptic channel that is activated by stretch, and in the presence of aldosterone, beta and alpha subunits together form an active channel that is modulated by aldosterone.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA; Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA; Stevens Inst Technol, Dept Chem & Biol Chem, Hoboken, NJ 07030 USA	Emory University; Emory University; University of Alabama System; University of Alabama Birmingham; Stevens Institute of Technology	Ma, HP (corresponding author), Emory Univ, Sch Med, Dept Physiol, Whitehead Biomed Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	hma@physio.eory.edu		Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053161, R37DK037963, R01DK057717, R01DK067110, R24DK064399] Funding Source: NIH RePORTER; NIDDK NIH HHS [1R01 DK067110, 1R24 DK064399, 1R01 DK57717, 1R37 DK037963, 1R01 DK53161] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achard JM, 1996, AM J PHYSIOL-CELL PH, V270, pC224, DOI 10.1152/ajpcell.1996.270.1.C224; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; BRADFORD AL, 1995, AM J PHYSIOL-CELL PH, V269, pC601, DOI 10.1152/ajpcell.1995.269.3.C601; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; Bubien JK, 2001, J BIOL CHEM, V276, P8557, DOI 10.1074/jbc.M008886200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Cui Y, 1997, P NATL ACAD SCI USA, V94, P9962, DOI 10.1073/pnas.94.18.9962; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; HAMILTON KL, 1986, MEMBRANE BIOCHEM, V6, P149, DOI 10.3109/09687688609065447; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Jain L, 1999, AM J PHYSIOL-LUNG C, V276, pL1046, DOI 10.1152/ajplung.1999.276.6.L1046; Jain L, 1998, AM J PHYSIOL-LUNG C, V274, pL475, DOI 10.1152/ajplung.1998.274.4.L475; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; Lazrak A, 2000, AM J PHYSIOL-CELL PH, V279, pC762, DOI 10.1152/ajpcell.2000.279.3.C762; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Ma HP, 2002, AM J PHYSIOL-RENAL, V282, pF501, DOI 10.1152/ajprenal.00147.2001; Malik B, 2002, FASEB J, V16, pA477; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Marunaka Y, 1999, J PHYSIOL-LONDON, V515, P669, DOI 10.1111/j.1469-7793.1999.669ab.x; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; YUE G, 1995, P NATL ACAD SCI USA, V92, P8418, DOI 10.1073/pnas.92.18.8418; Zhou ZH, 2002, J MEMBRANE BIOL, V188, P97, DOI 10.1007/s00232-001-0176-0	33	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33206	33212		10.1074/jbc.M405455200	http://dx.doi.org/10.1074/jbc.M405455200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15187080	hybrid			2022-12-27	WOS:000223039700025
J	Mercuri, PS; Garcia-Saez, I; De Vriendt, K; Thamm, I; Devreese, B; Van Beeumen, J; Dideberg, O; Rossolini, GM; Frere, JM; Galleni, M				Mercuri, PS; Garcia-Saez, I; De Vriendt, K; Thamm, I; Devreese, B; Van Beeumen, J; Dideberg, O; Rossolini, GM; Frere, JM; Galleni, M			Probing the specificity of the subclass B3FEZ-1 metallo-beta-lactamase by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; FLUORIBACTER-GORMANII; AEROMONAS-HYDROPHILA; BACTEROIDES-FRAGILIS; ACTIVE-SITE; BINDING; L1; INHIBITOR	The subclass B3 FEZ-1 beta-lactamase produced by Fluoribacter ( Legionella) gormanii is a Zn(II)-containing enzyme that hydrolyzes the beta-lactam bond in penicillins, cephalosporins, and carbapenems. FEZ-1 has been extensively studied using kinetic, computational modeling and x-ray crystallography. In an effort to probe residues potentially involved in substrate binding and zinc binding, five site-directed mutants of FEZ-1 (H121A, Y156A, S221A, N225A, and Y228A) were prepared and characterized using metal analyses and steady state kinetics. The activity of H121A is dependent on zinc ion concentration. The H121A monozinc form is less active than the dizinc form, which exhibits an activity similar to that of the wild type enzyme. Tyr(156) is not essential for binding and hydrolysis of the substrate. Substitution of residues Ser(221) and Asn(225) modifies the substrate profile by selectively decreasing the activity against carbapenems. The Y228A mutant is inhibited by the product formed upon hydrolysis of cephalosporins. A covalent bond between the side chain of Cys(200) and the hydrolyzed cephalosporins leads to the formation of an inactive and stable complex.	Univ Liege, Ctr Ingn Prot, B-4000 Liege, Belgium; UJF, CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, F-38027 Grenoble, France; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; Univ Siena, Sez Microbiol, Dipartimento Biol Mol, I-53100 Siena, Italy	University of Liege; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Ghent University; University of Siena	Galleni, M (corresponding author), Univ Liege, Ctr Ingn Prot, B6 Sart Tilman, B-4000 Liege, Belgium.	mgalleni@ulg.ac.be	Devreese, Bart/K-2841-2019; Devreese, Bart/B-2011-2009	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581; ROSSOLINI, Gian Maria/0000-0002-9386-0434				AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P3028, DOI 10.1128/AAC.44.11.3028-3034.2000; Boschi L, 2000, ANTIMICROB AGENTS CH, V44, P1538, DOI 10.1128/AAC.44.6.1538-1543.2000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Carenbauer AL, 2002, BMC BIOCHEM, V3; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; de Seny D, 2002, BIOCHEM J, V363, P687, DOI 10.1042/0264-6021:3630687; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; DEMEESTER F, 1987, BIOCHEM PHARMACOL, V36, P2393, DOI 10.1016/0006-2952(87)90609-5; Docquier JD, 2002, ANTIMICROB AGENTS CH, V46, P1823, DOI 10.1128/AAC.46.6.1823-1830.2002; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P192, DOI 10.1128/AAC.39.1.192; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; Mercuri PS, 2002, MICROB DRUG RESIST, V8, P193, DOI 10.1089/107662902760326904; Mercuri PS, 2001, ANTIMICROB AGENTS CH, V45, P1254, DOI 10.1128/AAC.45.4.1254-1262.2001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rossolini GM, 2001, ANTIMICROB AGENTS CH, V45, P837, DOI 10.1128/AAC.45.3.837-844.2001; SAMBROOOK J, 1989, MOL CLONING LAB MANU; Schnaible V, 2002, ANAL CHEM, V74, P4980, DOI 10.1021/ac025807j; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; Simm AM, 2002, J BIOL CHEM, V277, P24744, DOI 10.1074/jbc.M201524200; Simm AM, 2001, FEBS LETT, V509, P350, DOI 10.1016/S0014-5793(01)03152-0; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; TOWNS ML, 1994, CLIN INFECT DIS, V18, P265, DOI 10.1093/clinids/18.2.265; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Zervosen A, 2001, EUR J BIOCHEM, V268, P3840, DOI 10.1046/j.1432-1327.2001.02298.x	36	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33630	33638		10.1074/jbc.M403671200	http://dx.doi.org/10.1074/jbc.M403671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159411	hybrid			2022-12-27	WOS:000223039700072
J	Zhang, LL; Shimizu, S; Sakamaki, K; Yonehara, S; Tsujimoto, Y				Zhang, LL; Shimizu, S; Sakamaki, K; Yonehara, S; Tsujimoto, Y			A caspase-8-independent signaling pathway activated by fas ligation leads to exposure of the Bak N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MITOCHONDRIAL DYSFUNCTION; CELL-DEATH; CONFORMATIONAL-CHANGE; KINASE ACTIVATION; APOPTOSIS; BCL-2; PROTEIN; MEMBRANE; OLIGOMERIZATION	Bak is a pro-apoptotic member of the Bcl-2 family that is activated by apoptotic stimulation: its activation is characterized by conformational changes such as exposure of the N terminus and oligomerization. In death receptor-mediated apoptosis, the activation of Bak depends on activation of caspase-8. However, we found that exposure of the N terminus of Bak ( but not oligomerization) can occur in the absence of active caspase-8. Although exposure of the N terminus of Bak without oligomerization is not sufficient to release cytochrome c from the mitochondria and commit cells to apoptosis, this change sensitizes the mitochondria to apoptotic signals ( including Bid) and thus sensitizes cells to apoptotic death. Fas-induced, caspase-8-independent exposure of the N terminus of Bak is blocked by staurosporine, a pan protein kinase inhibitor. These results suggest that Fas stimulation not only activates caspase-8, but also a distinct signaling pathway involving protein kinase(s) to induce exposure of the N terminus of Bak.	Osaka Univ, Sch Med, Dept Postgenom & Dis, Genet Mol Lab, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Suita, Osaka 5650871, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyoto University; Kyoto University	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Postgenom & Dis, Genet Mol Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp		Sakamaki, Kazuhiro/0000-0002-7072-9628				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 2001, ONCOGENE, V20, P7668, DOI 10.1038/sj.onc.1204995; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nomura M, 1999, CANCER RES, V59, P5542; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shinohara H, 2000, CANCER RES, V60, P1766; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolf BB, 2002, CURR BIOL, V12, pR177, DOI 10.1016/S0960-9822(02)00736-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	40	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33865	33874		10.1074/jbc.M403499200	http://dx.doi.org/10.1074/jbc.M403499200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159409	hybrid			2022-12-27	WOS:000223039700096
J	Hashimoto, G; Shimoda, M; Okada, Y				Hashimoto, G; Shimoda, M; Okada, Y			ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; MATRIX METALLOPROTEINASES; GROWTH-FACTOR; SYNOVIAL-FLUID; ACTIVATION; CLEAVAGE; EXPRESSION; BINDING; FAMILY; IDENTIFICATION	ADAMTS4 (aggrecanase-1), a secreted enzyme belonging to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) gene family, is considered to play a key role in the degradation of cartilage proteoglycan (aggrecan) in osteoarthritis and rheumatoid arthritis. To clone molecules that bind to ADAMTS4, we screened a human chondrocyte cDNA library by the yeast two-hybrid system using the ADAMTS4 spacer domain as bait and obtained cDNA clones derived from fibronectin. Interaction between ADAMTS4 and fibronectin was demonstrated by chemical cross-linking. A yeast two-hybrid assay and solid-phase binding assay using wild-type fibronectin and ADAMTS4 and their mutants demonstrated that the C-terminal domain of fibronectin is capable of binding to the C-terminal spacer domain of ADAMTS4. Wild-type ADAMTS4 was co-localized with fibronectin as determined by confocal microscopy on the cell surface of stable 293T transfectants expressing ADAMTS4, although ADAMTS4 deletion mutants, including DeltaSp (DeltaArg(693)-Lys(837), lacking the spacer domain), showed negligible localization. The aggrecanase activity of wild-type ADAMTS4 was dose-dependently inhibited by fibronectin (IC50 = 110 nM), whereas no inhibition was observed with DeltaSp. The C-terminal 40-kDa fibronectin fragment also inhibited the activity of wild-type ADAMTS4 (IC50 = 170 nM). These data demonstrate for the first time that the aggrecanase activity of ADAMTS4 is inhibited by fibronectin through interaction with their C-terminal domains and suggest that this extracellular regulation mechanism of ADAMTS4 activity may be important for the degradation of aggrecan in arthritic cartilage.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Sumitomo Pharmaceut Co Ltd, Div Res, Konohana Ku, Osaka 5540022, Japan	Keio University	Okada, Y (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1600016, Japan.	okada@sc.itc.keio.ac.jp	Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; CARNEMOLLA B, 1984, ARTHRITIS RHEUM, V27, P913, DOI 10.1002/art.1780270811; *CLONT, 2001, YEAST PROT HDB; Cucuianu M, 1996, BLOOD COAGUL FIBRIN, V7, P779, DOI 10.1097/00001721-199611000-00006; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Imai K, 1997, AM J PATHOL, V151, P245; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Llamazares M, 2003, J BIOL CHEM, V278, P13382, DOI 10.1074/jbc.M211900200; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Martin JA, 2002, OSTEOARTHR CARTILAGE, V10, P556, DOI 10.1053/joca.2002.0791; Nakada M, 2001, CANCER RES, V61, P8896; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; SCOTT DL, 1981, ANN RHEUM DIS, V40, P142, DOI 10.1136/ard.40.2.142; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sugimoto K, 1999, J BIOCHEM, V126, P449, DOI 10.1093/oxfordjournals.jbchem.a022471; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Yamanaka H, 2000, LAB INVEST, V80, P677, DOI 10.1038/labinvest.3780071; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Yasuda T, 2003, ARTHRITIS RHEUM, V48, P1271, DOI 10.1002/art.10951; Zamir E, 2001, J CELL SCI, V114, P3583	36	61	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32483	32491		10.1074/jbc.M314216200	http://dx.doi.org/10.1074/jbc.M314216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161923	hybrid			2022-12-27	WOS:000222849700062
J	Noguchi, K; Fukazawa, H; Murakami, Y; Uehara, Y				Noguchi, K; Fukazawa, H; Murakami, Y; Uehara, Y			Nucleolar Nek11 is a novel target of Nek2A in G(1)/S-arrested cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC14A PHOSPHATASE; NIMA-FAMILY KINASE; PROTEIN-KINASE; DNA-REPLICATION; CHROMOSOME SEGREGATION; CENTROSOME STRUCTURE; ZYGOTIC CENTROSOME; CYCLE PROGRESSION; XENOPUS-LAEVIS; CHECKPOINT	We previously reported that Nek11, a member of the NIMA (never-in-mitosis A) family of kinases, is activated in G(1)/S-arrested cells. We provide herein several lines of evidence for a novel interaction between Nek11 and Nek2A. Both Nek11 and Nek2A, but not Nek2B, were detected at nucleoli, and the Nek2A-specific C-terminal end (amino acids 399-445) was responsible for nucleolar localization. Endogenous Nek11 coimmunoprecipitated with endogenous Nek2A, and non-catalytic regions of each kinase were involved in the complex formation. Nek11L interacted with phosphorylated Nek2A but barely with the kinase-inactive Nek2A (K37R) mutant. In addition, both Nek2A autophosphorylation activity and the Nek11L-Nek2A complex formation increased in G(1)/S-arrested cells. These results indicate that autophosphorylation of Nek2A could stimulate its interaction with Nek11L at the nucleolus. Moreover, Nek2 directly phosphorylated Nek11 in the C-terminal noncatalytic region and elevated Nek11 kinase activity. The non-catalytic region of Nek11 showed autoinhibitory activity through intramolecular interaction with its N-terminal catalytic domain. Nek2 dissociated this autoinhibitory interaction. Altogether, our studies demonstrate a unique mechanism of Nek11 activation by Nek(2)A in G(1)/S-arrested cells and suggest a novel possibility for nucleolar function of the NIMA family.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Uehara, Y (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	yuehara@nih.go.jp						Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2000, J CELL SCI, V113, P1973; Graf R, 2002, J CELL SCI, V115, P1919; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Hanrahan J, 2003, MOL CELL, V12, P663, DOI 10.1016/j.molcel.2003.08.006; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kallstrom G, 2003, MOL CELL BIOL, V23, P4344, DOI 10.1128/MCB.23.12.4344-4355.2003; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Mahjoub MR, 2002, J CELL SCI, V115, P1759; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meraldi P, 2001, J CELL SCI, V114, P3749; Noguchi K, 2002, J BIOL CHEM, V277, P39655, DOI 10.1074/jbc.M204599200; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Park JH, 2001, J CELL SCI, V114, P173; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Stegmeier F, 2004, CURR BIOL, V14, P467, DOI 10.1016/j.cub.2004.03.009; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Twomey C, 2004, DEV BIOL, V265, P384, DOI 10.1016/j.ydbio.2003.10.001; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816	40	31	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32716	32727		10.1074/jbc.M404104200	http://dx.doi.org/10.1074/jbc.M404104200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161910	hybrid			2022-12-27	WOS:000222849700091
J	Shen, RK; Olcott, MC; Kim, J; Rajagopal, I; Mathews, CK				Shen, RK; Olcott, MC; Kim, J; Rajagopal, I; Mathews, CK			Escherichia coli nucleoside diphosphate kinase interactions with T4 phage proteins of deoxyribonucleotide synthesis and possible regulatory functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-INFECTED BACTERIA; DNA-REPAIR NUCLEASE; PYRUVATE-KINASE; DEOXYCYTIDYLATE HYDROXYMETHYLASE; NUCLEOTIDE POOLS; AMBER MUTANTS; T4; BACTERIOPHAGE-T4; ENZYMOLOGY; COMPLEX	In both prokaryotic and eukaryotic organisms, nucleoside diphosphate kinase is a multifunctional protein, with well defined functions in ribo- and deoxyribonucleoside triphosphate biosynthesis and more recently described functions in genetic and metabolic regulation, signal transduction, and DNA repair. This paper concerns two unusual properties of nucleoside diphosphate (NDP) kinase from Escherichia coli: 1) its ability to interact specifically with enzymes encoded by the virulent bacteriophage T4 and 2) its roles in regulating metabolism of the host cell. By means of optical biosensor analysis, fluorescence spectroscopy, immunoprecipitation, and glutathione S-transferase pull-down assays, we have shown that E. coli NDP kinase interacts directly with T4 thymidylate synthase, aerobic ribonucleotide reductase, dCTPase-dUTPase, gene 32 single-strand DNA-binding protein, and deoxycytidylate hydroxymethylase. The interactions with ribonucleotide reductase and with gp32 are enhanced by nucleoside triphosphates, suggesting that the integrity of the T4 dNTP synthetase complex in vivo is influenced by the composition of the nucleotide pool. The other investigations in this work stem from the unexpected finding that E. coli NDP kinase is dispensable for successful T4 phage infection, and they deal with two observations suggesting that the NDP kinase protein plays a genetic role in regulating metabolism of the host cell: 1) the elevation of CTP synthetase activity in an ndk mutant, in which the structural gene for NDP kinase is disrupted, and 2) the apparent ability of NDP kinase to suppress anaerobic growth in a pyruvate kinase-negative E. coli mutant. Our data indicate that the regulatory roles are metabolic, not genetic, in nature.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.	mathewsc@onid.orst.edu			NIEHS NIH HHS [ES 00040] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Admiraal SJ, 1999, BIOCHEMISTRY-US, V38, P4701, DOI 10.1021/bi9827565; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALLEN JR, 1983, J BIOL CHEM, V258, P5746; ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; BELLO LJ, 1963, BIOCHIM BIOPHYS ACTA, V72, P647; BELLO LJ, 1963, J BIOL CHEM, V238, P1777; Bennett SE, 2004, P NATL ACAD SCI USA, V101, P6391, DOI 10.1073/pnas.0401031101; Bernard MA, 2000, J BIOENERG BIOMEMBR, V32, P259, DOI 10.1023/A:1005537013120; DUCKWORTH DH, 1967, J BIOL CHEM, V242, P2877; Ellis RJ, 2003, NATURE, V425, P27, DOI 10.1038/425027a; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; FLANEGAN JB, 1977, J BIOL CHEM, V252, P3019; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HANSON E, 1994, J BIOL CHEM, V269, P30999; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Levit MN, 2002, J BIOL CHEM, V277, P5163, DOI 10.1074/jbc.M111170200; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MATHEWS CK, 1966, BIOCHEMISTRY-US, V4, P2092; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; Postel EH, 2003, P NATL ACAD SCI USA, V100, P13247, DOI 10.1073/pnas.2333230100; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Postel EH, 1999, J BIOL CHEM, V274, P22821, DOI 10.1074/jbc.274.32.22821; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; REDDY GPV, 1977, P NATL ACAD SCI USA, V74, P3152, DOI 10.1073/pnas.74.8.3152; REDDY GPV, 1978, J BIOL CHEM, V253, P3461; SAEKI T, 1974, J BIOCHEM-TOKYO, V76, P631, DOI 10.1093/oxfordjournals.jbchem.a130607; SAEKI T, 1975, J ANTIBIOT, V28, P974, DOI 10.7164/antibiotics.28.974; Srere P, 1987, ANNU REV BIOCHEM, V56, P21; WHEELER L, 1992, J BIOL CHEM, V267, P7664; Wheeler LJ, 1996, J BIOL CHEM, V271, P11156, DOI 10.1074/jbc.271.19.11156; YOUNG JP, 1992, J BIOL CHEM, V267, P10786; Zhang XL, 1996, J BACTERIOL, V178, P4115, DOI 10.1128/jb.178.14.4115-4121.1996	35	13	13	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32225	32232		10.1074/jbc.M402750200	http://dx.doi.org/10.1074/jbc.M402750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169771	hybrid			2022-12-27	WOS:000222849700030
J	Vollbrandt, T; Tiedemann, K; El-Hallous, E; Lin, GQ; Brinckmann, J; John, H; Batge, B; Notbohm, H; Reinhardt, DP				Vollbrandt, T; Tiedemann, K; El-Hallous, E; Lin, GQ; Brinckmann, J; John, H; Batge, B; Notbohm, H; Reinhardt, DP			Consequences of cysteine mutations in calcium-binding epidermal growth factor modules of fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; MARFAN-SYNDROME; FBN1 MUTATIONS; MATRIX METALLOPROTEINASES; GENE; EXPRESSION; PATHOGENESIS; ORGANIZATION; PROTEOLYSIS; SECRETION	Mutations in fibrillin-1 lead to Marfan syndrome and some related genetic disorders. Many of the more than 600 mutations currently known in fibrillin-1 eliminate or introduce cysteine residues in epidermal growth factor-like modules. Here we report structural and functional consequences of three selected cysteine mutations (R627C, C750G, and C926R) in fibrillin-1. The mutations have been analyzed by means of recombinant polypeptides produced in mammalian expression systems. The mRNA levels for the mutation constructs were similar to wild-type levels. All three mutated polypeptides were secreted by embryonic kidney cells ( 293) into the culture medium. Purification was readily feasible for mutants R627C and C750G, but not for C926R, which restricted the availability of this mutant polypeptide to selected analyses. The overall folds of the mutant polypeptides were indistinguishable from the wild-type as judged by the ultrastructural shape, CD analysis, and reactivity with a specific antibody sensitive for intact disulfide bonds. Subtle structural changes caused by R627C and C750G, however, were monitored by proteolysis and heat denaturation experiments. These changes occurred in the vicinity of the mutations either as short range effects (R627C) or both short and long range effects (C750G). Enhanced proteolytic susceptibility was observed for R627C and C750G to a variety of proteases. These results expand and further strengthen the concept that proteolytic degradation of mutated fibrillin-1 might be an important potential mechanism in the pathogenesis of Marfan syndrome and other disorders caused by mutations in fibrillin-1.	Med Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; IPF PharmaCeut GmbH, D-30625 Hannover, Germany; Klinikum Neustadt, D-23730 Neustadt, Germany	University of Lubeck	Reinhardt, DP (corresponding author), Med Univ Lubeck, Dept Med Mol Biol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	reinhardt@molbio.uni-luebeck.de	Tiedemann, one/A-9739-2016; Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872; El-Hallous, Ehab/0000-0003-0189-3720				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; AOYAMA T, 1994, J CLIN INVEST, V94, P130, DOI 10.1172/JCI117298; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Booms P, 1999, CLIN GENET, V55, P110, DOI 10.1034/j.1399-0004.1999.550207.x; Booms P, 2000, HUM GENET, V107, P216, DOI 10.1007/s004390000368; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Collod-Beroud G, 2003, HUM MUTAT, V22, P199, DOI 10.1002/humu.10249; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Halliday D, 1999, HUM GENET, V105, P587, DOI 10.1007/s004390051150; HAYWARD C, 1994, HUM MOL GENET, V3, P373, DOI 10.1093/hmg/3.2.373; HEWETT D, 1994, AM J HUM GENET, V55, P447; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Milewicz DM, 2000, MATRIX BIOL, V19, P471, DOI 10.1016/S0945-053X(00)00099-8; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; Montgomery RA, 1998, AM J HUM GENET, V63, P1703, DOI 10.1086/302144; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pyeritz RE, 2000, ANNU REV MED, V51, P481, DOI 10.1146/annurev.med.51.1.481; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; Robinson PN, 2001, CELL MOL LIFE SCI, V58, P1698, DOI 10.1007/PL00000807; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Schrijver I, 1999, AM J HUM GENET, V65, P1007, DOI 10.1086/302582; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Whiteman P, 2003, HUM MOL GENET, V12, P727, DOI 10.1093/hmg/ddg081; Whiteman P, 2001, J BIOL CHEM, V276, P17156, DOI 10.1074/jbc.M006547200; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	41	48	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32924	32931		10.1074/jbc.M405239200	http://dx.doi.org/10.1074/jbc.M405239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161917	Green Published, hybrid			2022-12-27	WOS:000222849700112
J	Kacprzak, MM; Peinado, JR; Than, ME; Appel, J; Henrich, S; Lipkind, G; Houghten, RA; Bode, W; Lindberg, I				Kacprzak, MM; Peinado, JR; Than, ME; Appel, J; Henrich, S; Lipkind, G; Houghten, RA; Bode, W; Lindberg, I			Inhibition of furin by polyarginine-containing peptides - Nanomolar inhibition by NONA-D-arginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MEDIATED CLEAVAGE; ENDOPROTEASE; ACTIVATION; COMPLEX	Polyarginine-containing peptides represent potent inhibitors of furin, a mammalian endoprotease that plays an important role in metabolism, activation of pathogenic toxins, and viral proliferation. The therapeutic use of D-polyarginines is especially interesting because they are not cleaved by furin and possess inhibitory potency almost equal to L-polyarginines. In this study we attempted to determine the important elements within polyarginines that contribute to effective inhibition. Structure-function analyses of polyarginine peptides showed that inhibition by polyarginine-containing peptides appeared to depend on the total number of basic charges of the positively charged inhibitors bound to the negatively charged substrate binding pocket; peptide positioning did not appear to be rigorously determined. Screening of L- and D-decapeptide positional scanning combinatorial peptide libraries indicated a preference for basic residues in nearly all positions, similar to previous results with hexapeptide libraries. Length and terminal modification studies showed that the most potent D-polyarginine tested was nona-D-arginine (D9R) amide with a K-i of 1.3 nM. D9R amide was shown to protect RAW264.7 cells against anthrax toxemia with an IC50 of 3.7 muM. Because of its high stability, specificity, low toxicity, small molecular weight, and extremely low K-i against furin, D9R amide or its derivatives may represent promising compounds for therapeutic use.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Max Planck Inst Biochem, Dept Struct Res, D-82152 Martinsried, Germany; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Max Planck Society; Torrey Pines Institute for Molecular Studies, California; University of Chicago	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@lsuhsc.edu	Lindberg, Iris/Q-3825-2019; Than, Manuel/F-7536-2015; Peinado, Juan R/A-3450-2011	Than, Manuel/0000-0002-4707-9225; Peinado, Juan R/0000-0002-0004-7963	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 53517-02] Funding Source: Medline; NIDA NIH HHS [R56 DA005084, R01 DA005084] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; Chiron MF, 1997, J BIOL CHEM, V272, P31707, DOI 10.1074/jbc.272.50.31707; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fortenberry Y, 1999, J NEUROCHEM, V73, P994, DOI 10.1046/j.1471-4159.1999.0730994.x; Fortenberry Y, 2002, J BIOL CHEM, V277, P5175, DOI 10.1074/jbc.M104531200; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Komiyama T, 2003, P NATL ACAD SCI USA, V100, P8205, DOI 10.1073/pnas.1032865100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lindberg I., 1995, METH NEUROSCI, V23, P94; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; MERRITT EA, 1997, METHOD ENZYMOL, V24, P946; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Sarac MS, 2004, INFECT IMMUN, V72, P602, DOI 10.1128/IAI.72.1.602-605.2004; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; Turk D., 1992, THESIS TU MUENCHEN; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762	29	96	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36788	36794		10.1074/jbc.M400484200	http://dx.doi.org/10.1074/jbc.M400484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15197180	hybrid			2022-12-27	WOS:000223453600080
J	Sica, F; Di Fiore, A; Merlino, A; Mazzarella, L				Sica, F; Di Fiore, A; Merlino, A; Mazzarella, L			Structure and stability of the non-covalent swapped dimer of bovine seminal ribonuclease - An enzyme tailored to evade ribonuclease protein inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; OLIGOMERIC PROTEINS; ANTITUMOR ACTION; RNASE; SUBSTRATE; MOTIONS; BINDING; EVOLUTION; MOLSCRIPT; CELLS	A growing number of pancreatic-type ribonucleases (RNases) present cytotoxic activity against malignant cells. The cytoxicity of these enzymes is related to their resistance to the ribonuclease protein inhibitor (RI). In particular, bovine seminal ribonuclease (BS-RNase) is toxic to tumor cells both in vitro and in vivo. BS-RNase is a covalent dimer with two intersubunit disulfide bridges between Cys(31) of one chain and Cys(32) of the second and vice versa. The native enzyme is an equilibrium mixture of two isomers, MxM and M=M. In the former the two subunits swap their N-terminal helices. The cytotoxic action is a peculiar property of MxM. In the reducing environment of cytosol, M=M dissociates into monomers, which are strongly inhibited by RI, whereas MxM remains as a non-covalent dimer (NCD), which evades RI. We have solved the crystal structure of NCD, carboxyamidomethylated at residues Cys(31) and Cys(32) (NCD-CAM), in a complex with 2'-deoxycitidylyl(3'-5')-2'-deoxyadenosine. The molecule reveals a quaternary structural organization much closer to MxM than to other N-terminal-swapped non-covalent dimeric forms of RNases. Model building of the complexes between these non-covalent dimers and RI reveals that NCD-CAM is the only dimer equipped with a quaternary organization capable of interfering seriously with the binding of the inhibitor. Moreover, a detailed comparative structural analysis of the dimers has highlighted the residues, which are mostly important in driving the quaternary structure toward that found in NCD-CAM.	Univ Naples Federico II, Dipartimento Chim, I-80126 Naples, Italy; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy; Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, SA, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Salerno	Mazzarella, L (corresponding author), Univ Naples Federico II, Dipartimento Chim, Complesso Univ Monte Sant Angelo,Via Cynthia, I-80126 Naples, Italy.	lelio.mazzarella@unina.it	Merlino, Antonello/AAI-2114-2020; Di Fiore, Anna/AAX-5655-2020; Di Fiore, Anna/AAW-3780-2020	Di Fiore, Anna/0000-0003-2924-5194; Merlino, Antonello/0000-0002-1045-7720				Antignani A, 2001, BIOCHEMISTRY-US, V40, P3492, DOI 10.1021/bi002781m; Avitabile F, 2003, BIOCHEMISTRY-US, V42, P8704, DOI 10.1021/bi0342517; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berisio R, 2003, FEBS LETT, V554, P105, DOI 10.1016/S0014-5793(03)01114-1; Berisio R, 2002, ACTA CRYSTALLOGR D, V58, P441, DOI 10.1107/S0907444901021758; CAFARO V, 1995, FEBS LETT, V359, P31, DOI 10.1016/0014-5793(94)01450-F; Canals A, 2001, STRUCTURE, V9, P967, DOI 10.1016/S0969-2126(01)00659-1; Ciglic MI, 1998, BIOCHEMISTRY-US, V37, P4008, DOI 10.1021/bi972203e; Cinatl J, 2000, ANTICANCER RES, V20, P853; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; D'Alessio G, 1999, EUR J BIOCHEM, V266, P699, DOI 10.1046/j.1432-1327.1999.00912.x; D'Alessio G, 1999, PROG BIOPHYS MOL BIO, V72, P271, DOI 10.1016/S0079-6107(99)00009-7; D'Alessio G., 1997, RIBONUCLEASES STRUCT, P383; DIDONATO A, 1987, BIOCHEM J, V241, P435, DOI 10.1042/bj2410435; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; GILLILAND GL, 1997, RIBONUCLEASES STRUCT, P306; Haigis MC, 2003, NUCLEIC ACIDS RES, V31, P1024, DOI 10.1093/nar/gkg163; Haigis MC, 2003, J CELL SCI, V116, P313, DOI 10.1242/jcs.00214; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Makarov AA, 2003, FEBS LETT, V540, P15, DOI 10.1016/S0014-5793(03)00225-4; Matousek J, 2003, COMP BIOCHEM PHYS C, V136, P343, DOI 10.1016/j.cca.2003.10.005; Matousek J, 2003, J BIOL CHEM, V278, P23817, DOI 10.1074/jbc.M302711200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAZZARELLA L, 1995, P NATL ACAD SCI USA, V92, P3799, DOI 10.1073/pnas.92.9.3799; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; Merlino A, 2004, BIOPOLYMERS, V73, P689, DOI 10.1002/bip.20016; Merlino A, 2004, BIOPHYS J, V86, P2383, DOI 10.1016/S0006-3495(04)74295-2; Merlino A, 2003, PROTEINS, V53, P101, DOI 10.1002/prot.10466; Merlino A, 2002, BIOPOLYMERS, V65, P274, DOI 10.1002/bip.10225; MIKULSKI SM, 1995, INT J ONCOL, V7, P1415; MIKULSKI SM, 1993, INT J ONCOL, V2, P807; Mikulski SM, 2002, J CLIN ONCOL, V20, P274, DOI 10.1200/JCO.20.1.274; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; Murthy BS, 1996, BIOCHEMISTRY-US, V35, P3880, DOI 10.1021/bi952429m; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sica F, 2003, PROTEINS, V52, P263, DOI 10.1002/prot.10407; Sorrentino S, 2000, FEBS LETT, V466, P35, DOI 10.1016/S0014-5793(99)01742-1; Vitagliano L, 1998, PROTEIN SCI, V7, P1691, DOI 10.1002/pro.5560070804; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; Vitagliano L, 1999, J MOL BIOL, V293, P569, DOI 10.1006/jmbi.1999.3158; Wei CW, 2002, FEBS LETT, V531, P421, DOI 10.1016/S0014-5793(02)03577-9; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217	59	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36753	36760		10.1074/jbc.M405655200	http://dx.doi.org/10.1074/jbc.M405655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192098	hybrid			2022-12-27	WOS:000223453600076
J	Welsch, CA; Roth, LWA; Goetschy, JF; Movva, NR				Welsch, CA; Roth, LWA; Goetschy, JF; Movva, NR			Genetic, biochemical, and transcriptional responses of Saccharomyces cerevisiae to the novel immunomodulator FTY720 largely mimic those of the natural sphingolipid phytosphingosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-CHAIN BASES; POSSESSING UNIQUE MECHANISMS; SPHINGOSINE 1-PHOSPHATE; GROWTH-INHIBITION; YEAST-CELLS; PROTEINS; BIOSYNTHESIS; KINASE; SPHINGOSINE-1-PHOSPHATE; IDENTIFICATION	Sphingolipids are signaling molecules that influence diverse cellular functions from control of the cell cycle to degradation of plasma membrane proteins. The synthetic sphingolipid-like compound FTY720 is an immunomodulating agent in clinical trials for transplant graft maintenance. In this report, we compare the effects of the natural yeast sphingolipid phytosphingosine with FTY720 in Saccharomyces cerevisiae. We show that the multicopy suppressor genes that induce growth resistance to FTY720 also confer resistance to growth-inhibitory concentrations of phytosphingosine. In addition, mutants for ubiquitination pathway proteins are shown to be resistant to the growth-inhibiting effect of both FTY720 and phytosphingosine. We observe fewer similarities between sphingosine and FTY720 than between FTY720 and phytosphingosine as revealed by genetic studies. Yeast cells lacking the specific sphingosine kinase LCB4 are sensitive to phytosphingosine and FTY720 but resistant to sphingosine, suggesting that FTY720 and phytosphingosine have a more related mechanism of action. Gene expression profile comparisons of sensitive and resistant yeast cells exposed to FTY720 and phytosphingosine highlight a number of similarities. In response to treatment with these compounds, similar to77% of the genes that are regulated >2-fold by FTY720 also respond to phytosphingosine in the same direction in the parent strain. In addition, a close inspection of TAT1 and TAT2 transporters following exposure to phytosphingosine indicates that TAT1 protein is degraded in a similar fashion upon treatment with FTY720 and phytosphingosine. There were differences, however, with respect to the TAT2 protein level and the expression profiles of a subset of genes. The genetic, transcriptional, and biochemical data together indicate that FTY720 and phytosphingosine influence similar pathways in yeast cells. These findings offer further insights into the physiological pathways influenced by these compounds in all eukaryotic cells and help us to understand the therapeutic consequences of FTY720 in humans.	Novartis Pharma AG, Transplantat Res, Novartis Inst Biomed Res Autoimmun & Transplantat, CH-4002 Basel, Switzerland	Novartis	Movva, NR (corresponding author), Novartis Pharma AG, Transplantat Res, Novartis Inst Biomed Res Autoimmun & Transplantat, WSJ 386-906, CH-4002 Basel, Switzerland.	rao.movva@pharma.novartis.com						Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BAGNAT M, 2000, J BIOL CHEM, V275, P2191; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Candelore MR, 2002, BIOCHEM BIOPH RES CO, V297, P600; Chen JK, 1999, CHEM BIOL, V6, P221, DOI 10.1016/S1074-5521(99)80038-6; Chiba K, 1996, TRANSPLANT P, V28, P1056; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Cowart LA, 2003, J BIOL CHEM, V278, P30328, DOI 10.1074/jbc.M300656200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Ehrenhofer-Murray AE, 1998, YEAST, V14, P49, DOI 10.1002/(SICI)1097-0061(19980115)14:1<49::AID-YEA199>3.0.CO;2-T; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Grzanowski A, 2002, CURR GENET, V41, P142, DOI 10.1007/s00294-002-0292-0; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Hoshino Y, 1996, TRANSPLANT P, V28, P1060; Kahan BD, 1998, TRANSPLANT P, V30, P2210, DOI 10.1016/S0041-1345(98)00593-4; Kim S, 2000, GENETICS, V156, P1519; Lee J, 2002, MOL CELLS, V13, P407; LOUBBARDI A, 1995, J BACTERIOL, V177, P1817, DOI 10.1128/jb.177.7.1817-1823.1995; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Suzuki S, 1996, Transpl Immunol, V4, P252, DOI 10.1016/S0966-3274(96)80026-8; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Welsch CA, 2003, J BIOL CHEM, V278, P26976, DOI 10.1074/jbc.M213144200; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	44	22	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36720	36731		10.1074/jbc.M406179200	http://dx.doi.org/10.1074/jbc.M406179200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15190065	hybrid			2022-12-27	WOS:000223453600072
J	Liu, YC; Pelekanakis, K; Woolkalis, MJ				Liu, YC; Pelekanakis, K; Woolkalis, MJ			Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells - Regulation through c-Fos and c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAYS; FACTOR GENE; KAPPA-B; ACTIVATION; EGR-1; INFLAMMATION; COAGULATION; INHIBITION; RECEPTOR	Tissue factor is critically important for initiating the activation of coagulation zymogens leading to the generation of thrombin. Quiescent endothelial cells do not express tissue factor on their surface, but many stimuli including cytokines and coagulation proteases can elicit tissue factor synthesis. We challenged human endothelial cells simultaneously with tumor necrosis factor alpha (TNFalpha) and thrombin because many pathophysiological conditions, such as sepsis, diabetes, and coronary artery disease, result in the concurrent presence of circulating inflammatory mediators and activated thrombin. We observed a remarkable synergy in the expression of tissue factor by thrombin plus TNFalpha. This was due to altered regulation of the transcription factors c-Jun and c-Fos. The activation of c-Jun was greater and more sustained than that obtained with either thrombin or TNFalpha alone. Thrombin-stimulated expression of c-Fos was both enhanced and prolonged by the concurrent presence of TNFalpha. These changes support the increased availability of c-Jun/c-Fos AP-1 complexes for mediating transcription at the tissue factor promoter. Transcription factors downstream of the extracellular signal-regulated kinases as well as changes in NFkappaB regulation were not involved in the synergistic increase in tissue factor expression by thrombin and TNFalpha. Thus, concurrent exposure of vascular endothelial cells to cytokines and procoagulant proteases such as thrombin can result in greatly enhanced tissue factor expression on the endothelium, thereby perpetuating the prothrombotic phenotype of the endothelium.	Thomas Jefferson Univ, Dept Physiol, Philadelphia, PA 19107 USA	Jefferson University	Woolkalis, MJ (corresponding author), Thomas Jefferson Univ, Dept Physiol, 411 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Marilyn.Woolkalis@jefferson.edu						Anrather D, 1997, J IMMUNOL, V159, P5620; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Edmead C, 1999, ANAL BIOCHEM, V275, P180, DOI 10.1006/abio.1999.4313; Eto M, 2002, CIRCULATION, V105, P1756, DOI 10.1161/01.CIR.0000015465.73933.3B; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; Gonzalez MA, 2003, AM J MED, V115, P99, DOI 10.1016/j.amjmed.2003.09.016; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1990, BLOOD, V76, P1173; Levi M, 2002, CRIT CARE MED, V30, pS220, DOI 10.1097/00003246-200205001-00008; Lindmark E, 2001, THROMB RES, V103, P249, DOI 10.1016/S0049-3848(01)00313-9; Luther T, 2001, TRENDS CARDIOVAS MED, V11, P307, DOI 10.1016/S1050-1738(01)00129-3; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Matschurat S, 2003, INT J CANCER, V107, P30, DOI 10.1002/ijc.11345; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Merrill J T, 2001, Curr Rheumatol Rep, V3, P293, DOI 10.1007/s11926-001-0033-2; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; Reilly MP, 2002, CURR OPIN HEMATOL, V9, P395, DOI 10.1097/00062752-200209000-00002; Takeya H, 2003, BLOOD, V102, P1693, DOI 10.1182/blood-2002-11-3607; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Versteeg HH, 2004, SEMIN HEMATOL, V41, P168, DOI 10.1053/j.seminhematol.2003.11.028; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Xuereb JM, 2000, THROMB HAEMOSTASIS, V84, P129, DOI 10.1055/s-0037-1613980; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A	35	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36142	36147		10.1074/jbc.M405039200	http://dx.doi.org/10.1074/jbc.M405039200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201277	hybrid			2022-12-27	WOS:000223303400116
J	Suzuki, Y; Moriyoshi, E; Tsuchiya, D; Jingami, H				Suzuki, Y; Moriyoshi, E; Tsuchiya, D; Jingami, H			Negative cooperativity of glutamate binding in the dimeric metabotropic glutamate receptor subtype 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ASPARTATE RECEPTOR; PROTEIN-COUPLED RECEPTORS; TRYPTOPHAN FLUORESCENCE; STRUCTURAL BASIS; LIGAND; EXPRESSION; INTERFACE; DOMAIN; OLIGOMERIZATION; PHARMACOLOGY	Metabotropic glutamate receptor (mGluR) subtype 1 is a Class III G-protein-coupled receptor that is mainly expressed on the post-synaptic membrane of neuronal cells. The receptor has a large N-terminal extracellular ligand binding domain that forms a homodimer, however, the intersubunit communication of ligand binding in the dimer remains unknown. Here, using the intrinsic tryptophan fluorescence change as a probe for ligand binding events, we examined whether allosteric properties exist in the dimeric ligand binding domain of the receptor. The indole ring of the tryptophan 110, which resides on the upper surface of the ligand binding pocket, sensed the ligand binding events. From saturation binding curves, we have determined the apparent dissociation constants (K-0.5) of representative agonists and antagonists for this receptor (3.8, 0.46, 40, and 0.89 muM for glutamate, quisqualate, (S)-alpha-methyl-4-carboxy-phenylglycine ((S)-MCPG), and (+)-2-methyl-4-carboxy-phenylglycine (LY367385), respectively). Calcium ions functioned as a positive modulator for agonist but not for antagonist binding (K-0.5 values were 1.3, 0.21, 59, and 1.2 muM for glutamate, quisqualate, (S)-MCPG, and LY367385, respectively, in the presence of 2.0 mM calcium ion). Moreover, a Hill analysis of the saturation binding curves revealed the strong negative cooperativity of glutamate binding between each subunit in the dimeric ligand binding domain. As far as we know, this is the first direct evidence that the dimeric ligand binding domain of mGluR exhibits intersubunit cooperativity of ligand binding.	Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan		Jingami, H (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Osaka 5650874, Japan.	jingami@beri.or.jp						Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Franco R, 2003, TRENDS BIOCHEM SCI, V28, P238, DOI 10.1016/S0968-0004(03)00065-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jingami H, 2003, CURR OPIN NEUROBIOL, V13, P271, DOI 10.1016/S0959-4388(03)00067-9; Kolodziej AF, 1996, BIOCHEMISTRY-US, V35, P14782, DOI 10.1021/bi961481v; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P452; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIMBIRD LE, 1976, J BIOL CHEM, V251, P5007; Lin FF, 1997, NEUROPHARMACOLOGY, V36, P917, DOI 10.1016/S0028-3908(97)00078-6; LIU J, 1914, J BIOL CHEM, V279, P15824; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Milligan G, 2001, J CELL SCI, V114, P1265; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pizard A, 1998, J BIOL CHEM, V273, P1309, DOI 10.1074/jbc.273.3.1309; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Saunders R, 1998, NEUROPHARMACOLOGY, V37, P273, DOI 10.1016/S0028-3908(98)00027-6; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2940; Xu Y, 2003, J BIOL CHEM, V278, P13719, DOI 10.1074/jbc.M212979200; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	34	67	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35526	35534		10.1074/jbc.M404831200	http://dx.doi.org/10.1074/jbc.M404831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199056	hybrid			2022-12-27	WOS:000223303400047
J	Barlic, A; Gutierrez-Aguirre, I; Caaveiro, JMM; Cruz, A; Ruiz-Arguello, MB; Perez-Gil, J; Gonzalez-Manas, JM				Barlic, A; Gutierrez-Aguirre, I; Caaveiro, JMM; Cruz, A; Ruiz-Arguello, MB; Perez-Gil, J; Gonzalez-Manas, JM			Lipid phase coexistence favors membrane insertion of equinatoxin-II, a pore-forming toxin from Actinia equina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANEMONE STICHODACTYLA-HELIANTHUS; ATOMIC-FORCE MICROSCOPY; SEA-ANEMONE; MODEL MEMBRANES; PHOSPHOLIPASE-C; CONDENSED COMPLEXES; CELL-MEMBRANES; STICHOLYSIN-II; BIOLOGICAL-MEMBRANES; ANCHORED PROTEINS	Equinatoxin-II is a eukaryotic pore-forming toxin belonging to the family of actinoporins. Its interaction with model membranes is largely modulated by the presence of sphingomyelin. We have used large unilamellar vesicles and lipid monolayers to gain further information about this interaction. The coexistence of gel and liquid-crystal lipid phases in sphingomyelin/phosphatidylcholine mixtures and the coexistence of liquid-ordered and liquid-disordered lipid phases in phosphatidylcholine/cholesterol or sphingomyelin/phosphatidylcholine/cholesterol mixtures favor membrane insertion of equinatoxin-II. Phosphatidylcholine vesicles are not permeabilized by equinatoxin-II. However, the localized accumulation of phospholipase C-generated diacylglycerol creates conditions for toxin activity. By using epifluorescence microscopy of transferred monolayers, it seems that lipid packing defects arising at the interfaces between coexisting lipid phases may function as preferential binding sites for the toxin. The possible implications of such a mechanism in the assembly of a toroidal pore are discussed.	Univ Pais Vasco Euskal herriko Unibertsitatea, CSIC, Unidad Biofis, Bilbao 48080, Spain; Univ Pais Vasco Euskal herriko Unibertsitatea, Dept Bioquim & Biol Mol, Bilbao 48080, Spain; Univ Complutense, Fac Biol, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Complutense University of Madrid	Gonzalez-Manas, JM (corresponding author), Univ Pais Vasco Euskal herriko Unibertsitatea, CSIC, Unidad Biofis, Apdo 644, Bilbao 48080, Spain.	gbpgomaj@lg.ehu.es	Perez-Gil, Jesus/H-3102-2019; Cruz, Antonio/H-2881-2015; Caaveiro, Jose/J-2790-2013	Perez-Gil, Jesus/0000-0003-3587-7147; Cruz, Antonio/0000-0002-0465-4111; Caaveiro, Jose/0000-0001-5568-2369; Barlic, Ariana/0000-0003-4822-142X; Gutierrez Aguirre, Ion/0000-0002-8348-8616; GONZALEZ MANAS, JUAN MANUEL/0000-0002-1833-6982				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; Anderluh G, 2003, J BIOL CHEM, V278, P45216, DOI 10.1074/jbc.M305916200; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; Bai JN, 1997, BIOCHEMISTRY-US, V36, P8840, DOI 10.1021/bi970145r; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Basanez G, 1996, BIOCHEMISTRY-US, V35, P15183, DOI 10.1021/bi9616561; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; BERNHEIMER AW, 1976, P NATL ACAD SCI USA, V73, P467, DOI 10.1073/pnas.73.2.467; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; Cruz A, 2004, BIOPHYS J, V86, P308, DOI 10.1016/S0006-3495(04)74106-5; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Fivaz M, 2000, PROTOPLASMA, V212, P8, DOI 10.1007/BF01279342; Giocondi MC, 2001, ULTRAMICROSCOPY, V86, P151, DOI 10.1016/S0304-3991(00)00086-3; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; HAMILTON JA, 1991, BIOCHEMISTRY-US, V30, P2894, DOI 10.1021/bi00225a024; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Honger T, 1996, BIOCHEMISTRY-US, V35, P9003, DOI 10.1021/bi960866a; HOUSLAY MD, 1982, DYNAMICS BIOL MEMBRA, P41; IPSEN JH, 1987, BIOCHIM BIOPHYS ACTA, V905, P162; IPSEN JH, 1989, BIOPHYS J, V56, P661, DOI 10.1016/S0006-3495(89)82713-4; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; MACEK P, 1995, EUR J BIOCHEM, V234, P329, DOI 10.1111/j.1432-1033.1995.329_c.x; Malovrh P, 2003, J BIOL CHEM, V278, P22678, DOI 10.1074/jbc.M300622200; Mancheno JM, 2003, STRUCTURE, V11, P1319, DOI 10.1016/j.str.2003.09.019; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McConnell HM, 2003, BBA-BIOMEMBRANES, V1610, P159, DOI 10.1016/S0005-2736(03)00015-4; McConnell HM, 2003, ANNU REV BIOPH BIOM, V32, P469, DOI 10.1146/annurev.biophys.32.110601.141704; Netz RR, 1996, J PHYS II, V6, P1023, DOI 10.1051/jp2:1996114; Nielsen LK, 1999, BBA-BIOMEMBRANES, V1420, P266, DOI 10.1016/S0005-2736(99)00103-0; NIEVA JL, 1989, BIOCHEMISTRY-US, V28, P7364, DOI 10.1021/bi00444a032; NORTON RS, 1992, TOXICON, V30, P13, DOI 10.1016/0041-0101(92)90497-S; PAPAHADJOPOULOS D, 1972, BIOCHIM BIOPHYS ACTA, V266, P561, DOI 10.1016/0005-2736(72)90354-9; Patra SK, 1999, J LIPOSOME RES, V9, P247, DOI 10.3109/08982109909024788; Radhakrishnan A, 1999, BIOPHYS J, V77, P1507, DOI 10.1016/S0006-3495(99)76998-5; Radhakrishnan A, 2001, BBA-BIOMEMBRANES, V1511, P1, DOI 10.1016/S0005-2736(01)00274-7; RECKTENWALD DJ, 1981, BIOCHEMISTRY-US, V20, P4505, DOI 10.1021/bi00518a042; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Rinia HA, 2001, FEBS LETT, V501, P92, DOI 10.1016/S0014-5793(01)02636-9; Ruiz-Arguello MB, 1998, BIOCHEMISTRY-US, V37, P11621, DOI 10.1021/bi980615x; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; Ruiz-Arguello MB, 2002, CHEM PHYS LIPIDS, V114, P11, DOI 10.1016/S0009-3084(01)00195-5; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; Schief WR, 2000, PHYS REV E, V62, P6831, DOI 10.1103/PhysRevE.62.6831; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHIPLEY GG, 1974, J LIPID RES, V15, P126; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; THEWALT JL, 1992, BIOPHYS J, V63, P1176, DOI 10.1016/S0006-3495(92)81681-8; TURK T, 1986, PERIOD BIOL, V88, P216; UNTRACHT SH, 1977, J BIOL CHEM, V252, P4449; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101; Veiga MP, 2001, BIOCHEMISTRY-US, V40, P2614, DOI 10.1021/bi0019803; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X; ZOREC R, 1990, J MEMBRANE BIOL, V118, P243, DOI 10.1007/BF01868608	77	109	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34209	34216		10.1074/jbc.M313817200	http://dx.doi.org/10.1074/jbc.M313817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175339	hybrid			2022-12-27	WOS:000223134800019
J	Knappe, S; Wu, F; Madlansacay, MR; Wu, QY				Knappe, S; Wu, F; Madlansacay, MR; Wu, QY			Identification of domain structures in the propeptide of corin essential for the processing of proatrial natriuretic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SERINE PROTEASES; DENSITY-LIPOPROTEIN RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA MUTATIONS; SURFACE PROTEOLYTIC-ENZYMES; LDL-RECEPTOR; CARBOXYPEPTIDASE-Z; TYROSINE KINASES; CRD DOMAIN; PROTEIN; BINDING	Corin is a type II transmembrane serine protease and functions as the proatrial natriuretic peptide (pro-ANP) convertase in the heart. In the extracellular region of corin, there are two frizzled-like cysteine-rich domains, eight low density lipoprotein receptor ( LDLR) repeats, a macrophage scavenger receptor-like domain, and a trypsin-like protease domain at the C terminus. To examine the functional importance of the domain structures in the propeptide of corin for pro-ANP processing, we constructed a soluble corin, EKshortCorin, that consists of only the protease domain and contains an enterokinase (EK) recognition sequence at the conserved activation cleavage site. After being activated by EK, EKshortCorin exhibited catalytic activity toward chromogenic substrates but failed to cleave pro-ANP, indicating that certain domain structures in the propeptide are required for pro-ANP processing. We then constructed a series of corin deletion mutants and studied their functions in pro-ANP processing. Compared with that of the full-length corin, a corin mutant lacking frizzled 1 domain exhibited similar to 40% activity, whereas corin mutants lacking single LDLR repeat 1, 2, 3, or 4 had similar to 49, similar to 12, similar to 53, and similar to 77% activity, respectively. We also made corin mutants with a single mutation at a conserved Asp residue that coordinates Ca2+-binding in LDLR repeats 1, 2, 3, or 4 (D300Y, D336Y, D373Y, and D410Y) and showed that these mutants had similar to 25, similar to 11, similar to 16, and similar to 82% pro-ANP processing activity, respectively. Our results indicate that frizzled 1 domain and LDLR repeats 1 - 4 are important structural elements for corin to recognize its physiological substrate, pro-ANP.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA		Wu, QY (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 2600 Hilltop Dr, Richmond, CA 94804 USA.	qywu88@yahoo.com		Wu, Qingyu/0000-0003-0561-9315				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Cal S, 2003, P NATL ACAD SCI USA, V100, P9185, DOI 10.1073/pnas.1633392100; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Hooper JD, 2000, EUR J BIOCHEM, V267, P6931, DOI 10.1046/j.1432-1327.2000.01806.x; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Knappe S, 2003, J BIOL CHEM, V278, P52363, DOI 10.1074/jbc.M309991200; Levin ER, 1998, NEW ENGL J MED, V339, P321; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; Moeller C, 2003, DEVELOPMENT, V130, P5103, DOI 10.1242/dev.00686; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; North CL, 2000, BIOCHEMISTRY-US, V39, P13127, DOI 10.1021/bi0015156; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Song LX, 1997, J BIOL CHEM, V272, P10543; Stein B, 1998, AM HEART J, V135, P914, DOI 10.1016/S0002-8703(98)70054-7; Szabo R, 2003, THROMB HAEMOSTASIS, V90, P185, DOI 10.1160/TH03-02-0071; Tomita Y, 1998, J BIOCHEM-TOKYO, V124, P784, DOI 10.1093/oxfordjournals.jbchem.a022180; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; Wu QY, 2003, CURR TOP DEV BIOL, V54, P167, DOI 10.1016/S0070-2153(03)54009-1; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097	35	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34464	34471		10.1074/jbc.M405041200	http://dx.doi.org/10.1074/jbc.M405041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192093	hybrid			2022-12-27	WOS:000223134800048
J	Beekman, JM; Bakema, JE; van der Linden, J; Tops, B; Hinten, M; van Vugt, M; van de Winkel, JGJ; Leusen, JHW				Beekman, JM; Bakema, JE; van der Linden, J; Tops, B; Hinten, M; van Vugt, M; van de Winkel, JGJ; Leusen, JHW			Modulation of Fc gamma RI (CD64) ligand binding by blocking peptides of periplakin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE EXPRESSION; CYTOPLASMIC DOMAIN; TRANSGENIC MICE; PLAKIN FAMILY; IGE RECEPTOR; CLASS-I; CHAIN; ASSOCIATION; AFFINITY; CELLS	FcgammaRI requires both the intracellular domain of the alpha-chain and associated leukocyte Fc receptor (FcR) gamma-chains for its biological function. We recently found the C terminus of periplakin to selectively interact with the cytoplasmic domain of the FcgammaRI alpha-chain. It thereby enhances the capacity of FcgammaRI to bind, internalize, and present antigens on MHC class II. Here, we characterized the domains involved in FcgammaRI-periplakin interaction using truncated and alanine-substituted FcgammaRI mutants and randomly mutagenized periplakin. This allowed us to design TAT peptides that selectively interfered with endogenous FcgammaRI-periplakin interactions. The addition of these peptides to FcgammaRI-expressing cells modulated FcgammaRI ligand binding, as assessed by erythrocyte-antibody-rosetting. These data support a dominant-negative role of C-terminal periplakin for FcgammaRI biological activity and implicate periplakin as a novel regulator of FcgammaRI in immune cells.	Univ Med Ctr Utrecht, Dept Immunol, Immunotherapy Lab, NL-3584 EA Utrecht, Netherlands; Medarex Europe, NL-3584 EA Utrecht, Netherlands; Genmab, NL-3584 CM Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Genmab	Leusen, JHW (corresponding author), Univ Med Ctr Utrecht, Dept Immunol, Immunotherapy Lab, Lundlaan 6,KC-02-085-2, NL-3584 EA Utrecht, Netherlands.	J.H.W.leusen@lab.azu.nl	Beekman, Jeffrey M/I-7781-2014; , Jeanette/AAG-3736-2019; Leusen, Jeanette/I-9010-2014; Tops, Bastiaan/L-4697-2015	Beekman, Jeffrey M/0000-0003-4886-3756; Tops, Bastiaan/0000-0002-1699-8210; Leusen, Jeanette/0000-0003-4982-6914				Aho S, 1998, GENOMICS, V48, P242, DOI 10.1006/geno.1997.5188; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOOT JHA, 1989, J IMMUNOL, V142, P1217; Bracke M, 2001, BLOOD, V97, P3478, DOI 10.1182/blood.V97.11.3478; Curnow RT, 1997, CANCER IMMUNOL IMMUN, V45, P210, DOI 10.1007/s002620050435; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAVIS W, 1995, EMBO J, V14, P432, DOI 10.1002/j.1460-2075.1995.tb07019.x; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; Edberg JC, 2002, J BIOL CHEM, V277, P41287, DOI 10.1074/jbc.M207835200; Edberg JC, 1999, J BIOL CHEM, V274, P30328, DOI 10.1074/jbc.274.42.30328; ERNST LK, 1992, J BIOL CHEM, V267, P15692; Ernst LK, 1998, MOL IMMUNOL, V35, P943, DOI 10.1016/S0161-5890(98)00079-0; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; Gavin AL, 2000, IMMUNOGENETICS, V51, P206, DOI 10.1007/s002510050033; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; GRAZIANO RF, 1995, J IMMUNOL, V155, P4996; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; INDIK ZK, 1994, EXP HEMATOL, V22, P599; Jones SL, 1998, P NATL ACAD SCI USA, V95, P9331, DOI 10.1073/pnas.95.16.9331; Karashima T, 2002, J CELL SCI, V115, P5027, DOI 10.1242/jcs.00191; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; Leung CL, 2001, J CELL SCI, V114, P3409; MASUDA M, 1993, J IMMUNOL, V151, P7188; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; MORTON HC, 1995, J BIOL CHEM, V270, P29781; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PORGES AJ, 1992, J CLIN INVEST, V90, P2102, DOI 10.1172/JCI116094; RA C, 1989, J BIOL CHEM, V264, P15323; Radsak M, 2000, IMMUNOLOGY, V101, P521, DOI 10.1046/j.1365-2567.2000.00140.x; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Thepen T, 2000, NAT BIOTECHNOL, V18, P48, DOI 10.1038/71908; van den Heuvel APJ, 2002, J CELL SCI, V115, P3957, DOI 10.1242/jcs.00069; van Roon JAG, 2003, ARTHRITIS RHEUM-US, V48, P1229, DOI 10.1002/art.10940; van Spriel AB, 2001, J IMMUNOL, V166, P7019, DOI 10.4049/jimmunol.166.12.7019; van Vugt MJ, 1999, BLOOD, V94, P808, DOI 10.1182/blood.V94.2.808.414k31_808_817; van Vugt MJ, 1999, EUR J IMMUNOL, V29, P143; Van Vugt MJ, 1998, CLIN EXP IMMUNOL, V113, P415; VANDEWINKEL JGJ, 1996, MOL BIOL INTELLIGENC; vanVugt MJ, 1996, BLOOD, V87, P3593, DOI 10.1182/blood.V87.9.3593.bloodjournal8793593; Wallace PK, 2001, J IMMUNOL METHODS, V248, P183, DOI 10.1016/S0022-1759(00)00351-3	50	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33875	33881		10.1074/jbc.M401018200	http://dx.doi.org/10.1074/jbc.M401018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161926	hybrid			2022-12-27	WOS:000223039700097
J	Carvin, CD; Kladde, MP				Carvin, CD; Kladde, MP			Effectors of lysine 4 methylation of histone H3 in Saccharomyces cerevisiae are negative regulators of PHO5 and GAL1-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ELONGATION; GENE-EXPRESSION; PAF1 COMPLEX; IN-VIVO; ACTIVE GENES; H2B; YEAST; PROTEIN; COMPASS	Post-translational modifications of histone amino-terminal tails are a key determinant in gene expression. Histone methylation plays a dual role in gene regulation. Methylation of lysine 9 of histone H3 in higher eukaryotes is associated with transcriptionally inactive heterochromatin, whereas H3 lysine 4 methylation correlates with active chromatin. Methylation of lysine 4 of H3 via Set1, a component of the Saccharomyces cerevisiae COMPASS complex, is regulated by the transcriptional elongation Paf1-Rtf1 and histone ubiquitination Rad6-Bre1 complexes, which are required for the expression of a subset of genes. This suggests that lysine 4 methylation of histone H3 may play an activating role in transcription; however, the mechanism of Set1 function remains unclear. We show here that H3 lysine 4 methylation also negatively regulated gene expression, as strains without Set1 showed enhanced expression of PHO5, wherein chromatin structure plays an important transcriptional regulatory role. Di- and trimethylation of H3 lysine 4 was detected at the PHO5 promoter, and a strain expressing a mutant version of histone H3 with lysine 4 changed to arginine, ( which cannot be methylated) exhibited PHO5 derepression. Moreover, PHO5 was derepressed in strains that lacked components of either the Paf1-Rtf1 elongation or Rad6-Bre1 histone ubiquitination complexes. Lastly, PHO84 and GAL1 - 10 transcription was also increased in set1Delta cells. These results suggest that H3 methylation at lysine 4, in conjunction with transcriptional elongation, may function in a negative feedback pathway for basal transcription of some genes, although being a positive effector at others.	Texas A&M Univ, Dept Biochem & Biophys, TAMU 2128, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Kladde, MP (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, TAMU 2128, College Stn, TX 77843 USA.	kladde@tamu.edu			NCI NIH HHS [R01 CA095525, CA95525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Blackwell TK, 2003, CURR BIOL, V13, pR915, DOI 10.1016/j.cub.2003.11.013; Boa S, 2003, YEAST, V20, P827, DOI 10.1002/yea.995; Brachmann CB, 1998, YEAST, V14, P115; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carvin CD, 2003, P NATL ACAD SCI USA, V100, P7743, DOI 10.1073/pnas.1332672100; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Landry J, 2003, MOL CELL BIOL, V23, P5972, DOI 10.1128/MCB.23.17.5972-5978.2003; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Li YH, 2003, DEVELOPMENT, V130, P1817, DOI 10.1242/dev.00405; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Patturajan M, 1999, J BIOL CHEM, V274, P27823, DOI 10.1074/jbc.274.39.27823; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shi XM, 1996, MOL CELL BIOL, V16, P669; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Turner SD, 2002, MOL CELL BIOL, V22, P4011, DOI 10.1128/MCB.22.12.4011-4019.2002; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	44	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33057	33062		10.1074/jbc.M405033200	http://dx.doi.org/10.1074/jbc.M405033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180994	hybrid, Green Accepted			2022-12-27	WOS:000223039700006
J	Olson, LJ; Dahms, NM; Kim, JJP				Olson, LJ; Dahms, NM; Kim, JJP			The N-terminal carbohydrate recognition site of the cation-independent mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; LYSOSOMAL-ENZYMES; BINDING-SITES; RESIDUES; LOCALIZATION; CLONING; TWISTS	The 300-kDa cation-independent mannose 6-phosphate receptor (CI-MPR) plays a critical role in the trafficking of newly synthesized mannose 6-phosphate-containing acid hydrolases to the lysosome. The receptor contains two high affinity carbohydrate recognition sites within its 15-domain extracytoplasmic region, with essential residues for carbohydrate recognition located in domain 3 and domain 9. Previous studies have shown that these two sites are distinct with respect to carbohydrate specificity. In addition, expression of truncated forms of the CI-MPR demonstrated that domain 9 can be expressed as an isolated domain, retaining high affinity (K-d similar to 1 nM) carbohydrate binding, whereas expression of domain 3 alone resulted in a protein capable of only low affinity binding (K-d similar to 1 muM) toward a lysosomal enzyme. In the current report the crystal structure of the N-terminal 432 residues of the CI-MPR, encompassing domains 1-3, was solved in the presence of bound mannose 6-phosphate. The structure reveals the unique architecture of this carbohydrate binding pocket and provides insight into the ability of this site to recognize a variety of mannose-containing sugars.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	jjkim@mcw.edu			NIDDK NIH HHS [DK42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667, R29DK042667, R56DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brown J, 2002, EMBO J, V21, P1054, DOI 10.1093/emboj/21.5.1054; BRUNETTI CR, 1995, J VIROL, V69, P3517, DOI 10.1128/JVI.69.6.3517-3528.1995; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Hancock MK, 2002, J BIOL CHEM, V277, P47205, DOI 10.1074/jbc.M208534200; Hancock MK, 2002, J BIOL CHEM, V277, P11255, DOI 10.1074/jbc.M109855200; HASILIK A, 1980, J BIOL CHEM, V255, P4946; Leksa V, 2002, J BIOL CHEM, V277, P40575, DOI 10.1074/jbc.M207979200; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson LJ, 2002, J BIOL CHEM, V277, P10156, DOI 10.1074/jbc.M112230200; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; Olson LJ, 1999, J BIOL CHEM, V274, P36905, DOI 10.1074/jbc.274.52.36905; Olson LJ, 2004, EMBO J, V23, P2019, DOI 10.1038/sj.emboj.7600215; OTWINOWSKI Z, 1994, ACTA CRYSTALLOGR D, V50, P760; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROUSSEL A, 2002, TURBOFRODO MANUAL; Saris JJ, 2001, AM J PHYSIOL-HEART C, V280, pH1706, DOI 10.1152/ajpheart.2001.280.4.H1706; Sohar I, 1998, BIOCHEM J, V330, P903, DOI 10.1042/bj3300903; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WESTLUND B, 1991, J BIOL CHEM, V266, P23233	32	44	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34000	34009		10.1074/jbc.M404588200	http://dx.doi.org/10.1074/jbc.M404588200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169779	hybrid			2022-12-27	WOS:000223039700111
J	Chigaev, A; Zwartz, GJ; Buranda, T; Edwards, BS; Prossnitz, ER; Sklar, LA				Chigaev, A; Zwartz, GJ; Buranda, T; Edwards, BS; Prossnitz, ER; Sklar, LA			Conformational regulation of alpha(4)beta(1)-integrin affinity by reducing agents - "Inside-out" signaling is independent of and additive to reduction-regulated integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; T-CELL MIGRATION; CYTOPLASMIC DOMAIN; BETA(3) INTEGRINS; RECEPTOR SUBTYPES; ADHESION; BINDING; PHOSPHORYLATION; EXPRESSION; DISRUPTION	The alpha(4)beta(1)-integrin (very late antigen-4 (VLA-4), CD49d/CD29) is an adhesion receptor involved in the interaction of lymphocytes, dendritic cells, and stem cells with the extracellular matrix and endothelial cells. This and other integrins have the ability to regulate their affinity for ligands through a process termed "inside-out" signaling that affects cell adhesion avidity. Several mechanisms are known to regulate integrin affinity and conformation: conformational changes induced by separation of the C-terminal tails, divalent ions, and reducing agents. Recently, we described a fluorescent LDV-containing small molecule that was used to monitor VLA-4 affinity changes in live cells (Chigaev, A., Blenc, A. M., Braaten, J. V., Kumaraswamy, N., Kepley, C. L., Andrews, R. P., Oliver, J. M., Edwards, B. S., Prossnitz, E. R., Larson, R. S., and Sklar, L. A. (2001) J. Biol. Chem. 276, 48670-48678). Using the same molecule, we also developed a fluorescence resonance energy transfer-based assay to probe the "switchblade-like" opening of VLA-4 upon activation. Here, we investigated the effect of reducing agents on the affinity and conformational state of the VLA-4 integrin simultaneously with cell activation initiated by inside-out signaling through G protein-coupled receptors or Mn2+ in live cells in real time. We found that reducing agents ( dithiothreitol and 2,3-dimercapto-1-propanesulfonic acid) induced multiple states of high affinity of VLA-4, where the affinity change was accompanied by an extension of the integrin molecule. Bacitracin, an inhibitor of the reductive function of the plasma membrane, diminished the effect of dithiothreitol, but had no effect on inside-out signaling. Based on this result and differences in the kinetics of integrin activation, we conclude that conformational activation of VLA-4 by inside-out signaling is independent of and additive to reduction-regulated integrin activation.	Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Ctr Canc, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Los Alamos Natl Lab, Natl Flow Cytometry Resource, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; United States Department of Energy (DOE); Los Alamos National Laboratory	Sklar, LA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA.	lsklar@salud.unm.edu	Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008; Chigaev, Alexandre/A-3103-2010	Prossnitz, Eric/0000-0001-9190-8302; Chigaev, Alexandre/0000-0002-7726-638X	NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002022] Funding Source: NIH RePORTER; NCI NIH HHS [1R24 CA88339] Funding Source: Medline; NHLBI NIH HHS [P50 HL56384] Funding Source: Medline; NIBIB NIH HHS [1R01EB02022] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; Brower DL, 1997, P NATL ACAD SCI USA, V94, P9182, DOI 10.1073/pnas.94.17.9182; Butta N, 2003, BLOOD, V102, P2491, DOI 10.1182/blood-2003-01-0213; Chen C, 1999, J IMMUNOL, V162, P1084; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Chen P, 2001, J BIOL CHEM, V276, P38628, DOI 10.1074/jbc.M105737200; Chigaev A, 2003, BIOPHYS J, V85, P3951, DOI 10.1016/S0006-3495(03)74809-7; Chigaev A, 2003, J BIOL CHEM, V278, P38174, DOI 10.1074/jbc.M210472200; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165-2478(03)00108-1; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Edwards BS, 1998, J LEUKOCYTE BIOL, V63, P190, DOI 10.1002/jlb.63.2.190; EDWARDS BS, 1995, BLOOD, V86, P2288, DOI 10.1182/blood.V86.6.2288.bloodjournal8662288; Essex DW, 2001, BIOCHEMISTRY-US, V40, P6070, DOI 10.1021/bi002454e; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Han JW, 2003, J BIOL CHEM, V278, P34845, DOI 10.1074/jbc.M304691200; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Jin JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/sj.bjp.0701665; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Lahav J, 2000, FEBS LETT, V475, P89, DOI 10.1016/S0014-5793(00)01630-6; Lahav J, 2003, BLOOD, V102, P2085, DOI 10.1182/blood-2002-06-1646; Lahav J, 2002, BLOOD, V100, P2472, DOI 10.1182/blood-2001-12-0339; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Liu SC, 2002, J BIOL CHEM, V277, P20887, DOI 10.1074/jbc.M110928200; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; PEERSCHKE EI, 1995, THROMB HAEMOSTASIS, V73, P862; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; Puig-Kroger A, 2000, J IMMUNOL, V165, P4338, DOI 10.4049/jimmunol.165.8.4338; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Ruiz C, 2001, BLOOD, V98, P2432, DOI 10.1182/blood.V98.8.2432; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Zwartz G, 2004, BIOPHYS J, V86, P1243, DOI 10.1016/S0006-3495(04)74198-3	51	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32435	32443		10.1074/jbc.M404387200	http://dx.doi.org/10.1074/jbc.M404387200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166232	hybrid			2022-12-27	WOS:000222849700057
J	Dumoutier, L; Tounsi, A; Michiels, T; Sommereyns, C; Kotenko, SV; Renauld, JC				Dumoutier, L; Tounsi, A; Michiels, T; Sommereyns, C; Kotenko, SV; Renauld, JC			Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1 - Similarities with type I interferon signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT2; ACTIVATION; TRANSDUCER; EXPRESSION; DISTINCT; DOCKING; DOMAIN; IDENTIFICATION; RECRUITMENT; CLONING	Interferon (IFN)-lambda1, -lambda2, and -lambda3 are the latest members of the class II cytokine family and were shown to have antiviral activity. Their receptor is composed of two chains, interleukin-28R/likely interleukin or cytokine or receptor 2 (IL-28R/LICR2) and IL-10Rbeta, and mediates the tyrosine phosphorylation of STAT1, STAT2, STAT3, and STAT5. Here, we show that activation of this receptor by IFN-lambda1 can also inhibit cell proliferation and induce STAT4 phosphorylation, further extending functional similarities with type I IFNs. We used IL-28R/LICR2-mutated receptors to identify the tyrosines required for STAT activation, as well as antiproliferative and antiviral activities. We found that IFN-lambda1-induced STAT2 tyrosine phosphorylation is mediated through tyrosines 343 and 517 of the receptor, which showed some similarities with tyrosines from type I IFN receptors involved in STAT2 activation. These two tyrosines were also responsible for antiviral and antiproliferative activities of IFN-lambda1. By contrast, STAT4 phosphorylation ( and to some extent STAT3 activation) was independent from IL-28R/LICR2 tyrosine residues. Taken together, these observations extend the functional similarities between IFN-lambdas and type I IFNs and shed some new light on the mechanisms of activation of STAT2 and STAT4 by these cytokines.	Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium; Univ Louvain, Expt Med Unit, B-1200 Brussels, Belgium; Univ Louvain, Christian de Duce Inst Cellular Pathol, MIPA VIRO Unit, B-1200 Brussels, Belgium; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Rutgers State University New Brunswick; Rutgers State University Medical Center	Renauld, JC (corresponding author), Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, Ave Hippocrate 74, B-1200 Brussels, Belgium.	renauld@licr.ucl.ac.be	Michiels, Thomas/ABE-3203-2021; Renauld, Jean-Christophe/B-7268-2012	Michiels, Thomas/0000-0001-9615-8053; Dumoutier, Laure/0000-0002-6645-684X; Renauld, Jean-Christophe/0000-0003-1736-2131	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051139] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI051139, R01 AI51139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Clifford JL, 2003, MOL CANCER THER, V2, P453; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Decker T, 2002, J CLIN INVEST, V109, P1271, DOI 10.1172/JCI200215770; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; DUKE GM, 1989, J VIROL, V63, P1822, DOI 10.1128/JVI.63.4.1822-1826.1989; Dumoutier L, 2003, BIOCHEM J, V370, P391, DOI 10.1042/BJ20021935; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Krishnan K, 1998, J BIOL CHEM, V273, P19495, DOI 10.1074/jbc.273.31.19495; Langer JA, 2004, CYTOKINE GROWTH F R, V15, P33, DOI 10.1016/j.cytogfr.2003.10.001; Lejeune D, 2002, J BIOL CHEM, V277, P33676, DOI 10.1074/jbc.M204204200; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Naeger LK, 1999, J BIOL CHEM, V274, P1875, DOI 10.1074/jbc.274.4.1875; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Sheikh F, 2004, J IMMUNOL, V172, P2006, DOI 10.4049/jimmunol.172.4.2006; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; van Pesch V, 2003, J BIOL CHEM, V278, P46321, DOI 10.1074/jbc.M302554200; VANPESCH V, 2004, IN PRESS J VIROL; Wagner TC, 2002, J BIOL CHEM, V277, P1493, DOI 10.1074/jbc.M108928200; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x	29	256	303	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32269	32274		10.1074/jbc.M404789200	http://dx.doi.org/10.1074/jbc.M404789200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166220	hybrid			2022-12-27	WOS:000222849700035
J	Molteni, SN; Fassio, A; Ciriolo, MR; Filomeni, G; Pasqualetto, E; Fagioli, C; Sitia, R				Molteni, SN; Fassio, A; Ciriolo, MR; Filomeni, G; Pasqualetto, E; Fagioli, C; Sitia, R			Glutathione limits Ero1-dependent oxidation in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; QUALITY-CONTROL; BOND FORMATION; MOLECULAR CHAPERONES; THIOREDOXIN FAMILY; CHOLERA-TOXIN; REDOX STATE; DEGRADATION; MEMBRANE; THIOLS	Many proteins of the secretory pathway contain disulfide bonds that are essential for structure and function. In the endoplasmic reticulum (ER), Ero1alpha and Ero1beta oxidize protein disulfide isomerase (PDI), which in turn transfers oxidative equivalents to newly synthesized cargo proteins. However, oxidation must be limited, as some reduced PDI is necessary for disulfide isomerization and ER-associated degradation. Here we show that in semipermeable cells, PDI is more oxidized, disulfide bonds are formed faster, and high molecular mass covalent protein aggregates accumulate in the absence of cytosol. Addition of reduced glutathione (GSH) reduces PDI and restores normal disulfide formation rates. A higher GSH concentration is needed to balance oxidative folding in semipermeable cells overexpressing Ero1alpha, indicating that cytosolic GSH and lumenal Ero1alpha play antagonistic roles in controlling the ER redox. Moreover, the overexpression of Ero1alpha significantly increases the GSH content in HeLa cells. Our data demonstrate tight connections between ER and cytosol to guarantee redox exchange across compartments: a reducing cytosol is important to ensure disulfide isomerization in secretory proteins.	Univ Vita Salute San Raffaele, I-20132 Milan, Italy; San Raffaele Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Rome Tor Vergata	Sitia, R (corresponding author), Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.	r.sitia@hsr.it	Sitia, Roberto/AAB-5005-2019; fassio, anna/K-4482-2014; Fagioli, Claudio/AAN-4147-2020; Ciriolo, Maria Rosa/K-6572-2016	Sitia, Roberto/0000-0001-7086-4152; fassio, anna/0000-0002-8801-038X; Fagioli, Claudio/0000-0001-9889-4695; Filomeni, Giuseppe/0000-0002-2719-1412; Ciriolo, Maria Rosa/0000-0002-7863-9029; Pasqualetto, Elena/0000-0003-2130-1577	Telethon [GP0117Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fagioli C, 2001, J BIOL CHEM, V276, P40962, DOI 10.1074/jbc.M107456200; FAHEY RC, 1977, J MOL EVOL, V10, P155, DOI 10.1007/BF01751808; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pagani M, 2001, FEBS LETT, V508, P117, DOI 10.1016/S0014-5793(01)03034-4; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Yoneda T, 2002, GENE DEV, V16, P1307, DOI 10.1101/gad.1000902	39	115	125	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32667	32673		10.1074/jbc.M404992200	http://dx.doi.org/10.1074/jbc.M404992200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161913	Green Published, hybrid			2022-12-27	WOS:000222849700085
J	Sekiya, F; Poulin, B; Kim, YJ; Rhee, SG				Sekiya, F; Poulin, B; Kim, YJ; Rhee, SG			Mechanism of tyrosine phosphorylation and activation of phospholipase C-gamma 1 - Tyrosine 783 phosphorylation is not sufficient for lipase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; CELL ANTIGEN RECEPTOR; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR; ARACHIDONIC-ACID; GENETIC-EVIDENCE; SH2 DOMAINS; C-GAMMA-1	Phospholipase C-gamma1 (PLC-gamma1) is phosphorylated on three tyrosine residues: Tyr-771, Tyr-783, and Tyr-1253. With the use of antibodies specific for each of these phosphorylation sites, we have now determined the kinetics and magnitude of phosphorylation at each site. Phosphorylation of Tyr-783, which is essential for lipase activation, was observed in all stimulated cell types examined. The extent of phosphorylation of Tyr-1253 was similar to50 to 70% of that of Tyr-783 in cells stimulated with platelet-derived growth factor ( PDGF) or epidermal growth factor (EGF), but Tyr-1253 phosphorylation was not detected in B or T cell lines stimulated through Band T-cell antigen receptors, respectively. Tyr-771 was phosphorylated only at a low level in all cells studied. In cells stimulated with PDGF, phosphorylation and dephosphorylation of Tyr-783 and of Tyr-1253 occurred with similar kinetics; the receptor kinase appeared to phosphorylate both sites, albeit with Tyr-783 favored over Tyr-1253, before the bound PLC-gamma1 was released, and phosphorylation at the two sites occurred independently. PDGF and EGF induced similar levels of phosphorylation of Tyr-783 and of Tyr-1253 in a cell line that expressed receptors for both growth factors. However, only PDGF, not EGF, elicited substantial PLC activity, suggesting that Tyr-783 phosphorylation was not sufficient for enzyme activation. Finally, concurrent production of phosphatidylinositol 3,4,5-trisphosphate was found to contribute to the activation of phosphorylated PLC-gamma1.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University; Ewha Womans University	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 50,Rm 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov						Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; CUNNINGHAM TW, 1989, J BIOL CHEM, V264, P15351; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Graham LJ, 2000, FEBS LETT, V470, P273, DOI 10.1016/S0014-5793(00)01341-7; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; LAROSE L, 1993, ONCOGENE, V8, P2493; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Pawson T, 2000, GENE DEV, V14, P1027; Poulin B, 2000, J BIOL CHEM, V275, P6411, DOI 10.1074/jbc.275.9.6411; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Singh SM, 2003, PROTEIN SCI, V12, P1934, DOI 10.1110/ps.0358803; Smith AJ, 2001, J BIOL CHEM, V276, P17213, DOI 10.1074/jbc.M100417200; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUH PG, 1988, J BIOL CHEM, V263, P14497; Sung JY, 2001, J NEUROCHEM, V78, P1044, DOI 10.1046/j.1471-4159.2001.00491.x; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tvorogov D, 2002, EXP CELL RES, V277, P86, DOI 10.1006/excr.2002.5545; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL M, 1988, J BIOL CHEM, V263, P7581; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; YANG LJ, 1994, J BIOL CHEM, V269, P7156; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Zhang L, 1998, Methods Mol Biol, V105, P47; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	53	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32181	32190		10.1074/jbc.M405116200	http://dx.doi.org/10.1074/jbc.M405116200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161916	hybrid			2022-12-27	WOS:000222849700024
J	Jang, JH; Surh, YJ				Jang, JH; Surh, YJ			Bcl-2 attenuation of oxidative cell death is associated with up-regulation of gamma-glutamylcysteine ligase via constitutive NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; KINASE; SURVIVAL; OVEREXPRESSION; STRESS; EXPRESSION; ERK; PHOSPHORYLATION	Oxidative stress induced by reactive oxygen intermediates often causes cell death via apoptosis, which is regulated by many functional genes and their protein products. The evolutionarily conserved protein Bcl-2 blocks apoptosis induced by a wide array of death signals. Despite extensive research, the molecular milieu that characterizes the anti-apoptotic function of Bcl-2 has not been fully clarified. In this work, we have investigated the role of bcl-2 in protecting against oxidative death induced by H2O2 in cultured rat pheochromocytoma PC12 cells. Transfection with the bcl-2 gene rescued PC12 cells from apoptotic death caused by H2O2. Addition of NF-kappaB inhibitors such as pyrrolidine dithiocarbamate and N-tosyl-L-phenylalanine chloromethyl ketone to the medium aggravated oxidative cell death. PC12 cells overexpressing bcl-2 exhibited relatively high constitutive DNA binding and transcriptional activities of NF-kappaB compared with vector-transfected control cells. Western blot analysis and immunocytochemistry revealed that bcl-2-transfected PC12 cells retained a higher level of p65 (the functionally active subunit of NF-kappaB) in the nucleus compared with vector-transfected controls. In addition, sustained activation of ERK1/2 (upstream of NF-kappaB) was observed in bcl-2-overexpressing cells. In contrast, the cytoplasmic inhibitor IkappaBalpha was present in lower amounts in cells overexpressing bcl-2. The ectopic expression of bcl-2 increased the cellular glutathione level and gamma-glutamylcysteine ligase expression, which were attenuated by NF-kappaB inhibitors. These results suggest that NF-kappaB plays a role in bcl-2-mediated protection against H2O2-induced apoptosis in PC12 cells through augmentation of antioxidant capacity.	Seoul Natl Univ, Coll Pharm, Lab Biochem & Mol Toxicol, Seoul 151742, South Korea	Seoul National University (SNU)	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Lab Biochem & Mol Toxicol, Shinlim Dong, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr						Amstad PA, 2001, REDOX REP, V6, P351, DOI 10.1179/135100001101536535; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bhakar AL, 2002, J NEUROSCI, V22, P8466; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bian X, 2002, J BIOL CHEM, V277, P42144, DOI 10.1074/jbc.M203891200; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; Burlacu A, 2003, J CELL MOL MED, V7, P249, DOI 10.1111/j.1582-4934.2003.tb00225.x; Chau YP, 1998, FREE RADICAL BIO MED, V24, P660, DOI 10.1016/S0891-5849(97)00337-7; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; Chung KC, 2000, J NEUROSCI RES, V59, P117, DOI 10.1002/(SICI)1097-4547(20000101)59:1<117::AID-JNR14>3.0.CO;2-Q; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Foo SY, 1999, TRENDS GENET, V15, P229; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Howard S, 2002, J NEUROCHEM, V83, P914, DOI 10.1046/j.1471-4159.2002.01198.x; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kim DK, 2001, FREE RADICAL BIO MED, V30, P563, DOI 10.1016/S0891-5849(00)00504-9; Kim HJ, 2001, MOL PHARMACOL, V60, P440; Kondo T, 1999, FREE RADICAL RES, V31, P325, DOI 10.1080/10715769900300891; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Lawrence MS, 1996, J NEUROSCI, V16, P486; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Liang Y, 2003, ONCOGENE, V22, P5515, DOI 10.1038/sj.onc.1206844; Liu Q, 2003, BLOOD, V101, P4105, DOI 10.1182/blood-2002-10-3067; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Massaad CA, 2003, NEUROREPORT, V14, P1167, DOI 10.1097/00001756-200306110-00013; McConkey DJ, 1998, TOXICOL LETT, V99, P157, DOI 10.1016/S0378-4274(98)00155-6; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Poulaki V, 2002, AM J PATHOL, V161, P2229, DOI 10.1016/S0002-9440(10)64499-9; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; REGULA KM, 2000, J BIOL CHEM, V275, P38676; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Seyfried J, 2003, FREE RADICAL BIO MED, V34, P1517, DOI 10.1016/S0891-5849(03)00103-5; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WOOD KA, 1994, ANN NY ACAD SCI, V738, P400; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; Zhu Y, 2004, NEUROSCIENCE, V123, P897, DOI 10.1016/j.neuroscience.2003.10.037	65	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38779	38786		10.1074/jbc.M406371200	http://dx.doi.org/10.1074/jbc.M406371200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208316	hybrid			2022-12-27	WOS:000223684100089
J	Alonso, A; Burkhalter, S; Sasin, J; Tautz, L; Bogetz, J; Huynh, H; Bremer, MCD; Holsinger, LJ; Godzik, A; Mustelin, T				Alonso, A; Burkhalter, S; Sasin, J; Tautz, L; Bogetz, J; Huynh, H; Bremer, MCD; Holsinger, LJ; Godzik, A; Mustelin, T			The minimal essential core of a cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like phosphatase, VHZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; CRYSTAL-STRUCTURE; MAP KINASE; PHOSPHOINOSITIDE PHOSPHATASE; CATALYTIC DOMAIN; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; INHIBITION; DEPHOSPHORYLATION; PHOSPHORYLATION	The smallest active protein-tyrosine phosphatase yet (only 16 kDa) is described here and given the name VHZ for VH1-like member Z because it belongs to the group of small Vaccinia virus VH1-related dual specific phosphatases exemplified by VHR, VHX, and VHY. Human VHZ is remarkably well conserved through evolution as it has species orthologs in frogs, fish, fly, and Archaea. The gene for VHZ, which we designate as DUSP25, is located on human chromosome 1q23.1 and consists of only two coding exons. VHZ is broadly expressed in tissues and cells, including resting blood lymphocytes, Jurkat T cells, HL-60, and RAMOS. In transfected cells, VHZ was located in the cytosol and in other cells also in the nucleoli. Endogenous VHZ showed a similar but more granular distribution. We show that VHZ is an active phosphatase and analyze its structure by computer modeling, which shows that in comparison with the 185-amino acid residue VHR, the 150-residue VHZ is a shortened version of VHR and contains the minimal set of secondary structure elements conserved in all known phosphatases from this class. The surface charge distribution of VHZ differs from that of VHR and is therefore unlikely to dephosphorylate mitogen-activated protein kinases. The remarkably high degree of conservation of VHZ through evolution may indicate a role in some ancient and fundamental physiological process.	Burnham Inst, Program Signal Transduct, La Jolla, CA 92037 USA; Burnham Inst, Program Bioinformat, La Jolla, CA 92037 USA; SUGEN Inc, San Francisco, CA 94602 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Pfizer	Mustelin, T (corresponding author), Burnham Inst, Program Signal Transduct, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Alonso, Andrés/L-7523-2014; Godzik, Adam/A-7279-2009; Godzik, Adam/AAW-1467-2020; Bogetz, Jori F./U-2258-2019; Tautz, Lutz/M-9989-2014	Alonso, Andrés/0000-0001-8674-9378; Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X; Tautz, Lutz/0000-0002-4075-6238; Mustelin, Tomas/0000-0001-5912-8840	NCI NIH HHS [CA96949] Funding Source: Medline; NIAID NIH HHS [AI35603, AI53585, AI48032, AI55741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055741, R01AI053585, R01AI048032, R01AI035603] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2004, J BIOL CHEM, V279, P4922, DOI 10.1074/jbc.M308978200; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Dorfman K, 1996, ONCOGENE, V13, P925; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Hanlon N, 1998, PROTEIN SCI, V7, P508; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Hood KL, 2002, BIOCHEM BIOPH RES CO, V298, P545, DOI 10.1016/S0006-291X(02)02488-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Michalopoulos I, 2004, NUCLEIC ACIDS RES, V32, pD251, DOI 10.1093/nar/gkh060; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Munoz-Alonso MJ, 2000, J BIOL CHEM, V275, P32406, DOI 10.1074/jbc.M000841200; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Sasin JM, 2003, BIOINFORMATICS, V19, pi252, DOI 10.1093/bioinformatics/btg1035; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schumacher MA, 2002, BIOCHEMISTRY-US, V41, P3009, DOI 10.1021/bi015799l; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Wang JY, 2002, J BIOL CHEM, V277, P2377, DOI 10.1074/jbc.C100686200; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	37	31	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35768	35774		10.1074/jbc.M403412200	http://dx.doi.org/10.1074/jbc.M403412200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201283	hybrid			2022-12-27	WOS:000223303400076
J	Fera, E; O'Neil, C; Lee, W; Li, SH; Pickering, JG				Fera, E; O'Neil, C; Lee, W; Li, SH; Pickering, JG			Fibroblast growth factor-2 and remodeled type I collagen control membrane protrusion in human vascular smooth muscle cells - Biphasic activation of Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(2)BETA(1) INTEGRIN; RHO GTPASES; MIGRATION; EXPRESSION; MATRIX; CLEAVAGE; PROLIFERATION; CYTOSKELETON; ADHESION; RELEASE	Plasma membrane protrusion is fundamental to cell motility, but its regulation by the extracellular environment is not well elucidated. We have quantified lamellipodial protrusion dynamics in human vascular smooth muscle cells exposed to fibroblast growth factor 2 (FGF-2) and type I collagen, two distinct ligands presented to vascular cells during arterial remodeling. Video microscopy revealed that FGF-2 stimulated a modest increase in lamellipodial protrusion rate that peaked within 15 min. This response was associated with immediate but transient activation of Rac1 and was inhibited in cells infected with retrovirus containing cDNA encoding dominant-negative Rac1. A 1-h exposure to FGF-2 also set up a second phase of more striking lamellipodial protrusion evident at 24-36 h. This delayed response was most pronounced when cells were on type 1 collagen and was associated with FGF-2-induced expression of collagenase-1 that localized to the edge of protruding lamellipodia. Moreover, late membrane protrusion was inhibited when cells were on collagenase-resistant type I collagen, implicating degraded collagen as a mediator. For cells on collagen, the immediate activation of Rac1 by FGF-2 was followed by a sustained wave of Rac1 activation that was inhibited when cleavage of the collagen triple helix was prevented and also by blockade of alpha(v)beta(3) integrin. We conclude that lamellipodial protrusion in smooth muscle cells can be regulated by waves of Rac1 activation, corresponding to the sequential presentation of FGF-2 and remodeled collagen. The findings thus reveal a previously unrecognized level of coordination among extracellular input that enables cells to maintain protrusive activity over prolonged periods.	Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London Hlth Sci Ctr,Dept Med Cardiol, London, ON N6A 5A5, Canada; Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London Hlth Sci Ctr,Dept Biochem, London, ON N6A 5A5, Canada; Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London Hlth Sci Ctr,Dept Med Biophys, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Pickering, JG (corresponding author), Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London Hlth Sci Ctr,Dept Med Cardiol, 339 Windermere Rd, London, ON N6A 5A5, Canada.	gpickering@robarts.ca	Pickering, J. Geoffrey/G-3341-2011	Pickering, J. Geoffrey/0000-0001-6474-3274				Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BILATO C, 1995, J CLIN INVEST, V96, P1905, DOI 10.1172/JCI118236; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; JACKSON CL, 1993, AM J PATHOL, V143, P1024; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Li SH, 2000, J BIOL CHEM, V275, P35384, DOI 10.1074/jbc.M005139200; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Messent AJ, 1998, J CELL SCI, V111, P1127; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pickering JG, 1997, ARTERIOSCL THROM VAS, V17, P475, DOI 10.1161/01.ATV.17.3.475; PICKERING JG, 1993, J CLIN INVEST, V91, P724, DOI 10.1172/JCI116254; Pickering JG, 2000, AM J PATHOL, V156, P453, DOI 10.1016/S0002-9440(10)64750-5; Pickering JG, 1997, CIRC RES, V80, P627, DOI 10.1161/01.RES.80.5.627; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2003, NATURE, V422, P741, DOI 10.1038/nature01598; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Rocnik EF, 2002, J BIOL CHEM, V277, P38571, DOI 10.1074/jbc.M206689200; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	38	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35573	35582		10.1074/jbc.M400711200	http://dx.doi.org/10.1074/jbc.M400711200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15166228	hybrid			2022-12-27	WOS:000223303400053
J	Somerville, RPT; Longpre, JM; Apel, ED; Lewis, RM; Wang, LW; Sanes, JR; Leduc, R; Apte, SS				Somerville, RPT; Longpre, JM; Apel, ED; Lewis, RM; Wang, LW; Sanes, JR; Leduc, R; Apte, SS			ADAMTS7B, the full-length product of the ADAMTS7 gene, is a chondroitin sulfate proteoglycan containing a mucin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; THROMBOSPONDIN MOTIFS; MOLECULAR-CLONING; HEPARAN-SULFATE; FURIN INTERACTS; O-GLYCOSYLATION; FAMILY PROTEIN; METALLOPROTEINASE; CLEAVAGE; DISINTEGRIN	We have characterized ADAMTS7B, the authentic full-length protein product of the ADAMTS7 gene. ADAMTS7B has a domain organization similar to that of ADAMTS12, with a total of eight thrombospondin type 1 repeats in its ancillary domain. Of these, seven are arranged in two distinct clusters that are separated by a mucin domain. Unique to the ADAMTS family, ADAMTS7B is modified by attachment of the glycosaminoglycan chondroitin sulfate within the mucin domain, thus rendering it a proteoglycan. Glycosaminoglycan addition has potentially important implications for ADAMTS7B cellular localization and for substrate recognition. Although not an integral membrane protein, ADAMTS7B is retained near the cell surface of HEK293F cells via interactions involving both the ancillary domain and the prodomain. ADAMTS7B undergoes removal of the prodomain by a multistep furin-dependent mechanism. At least part of the final processing event, i.e. cleavage following Arg(220) (mouse sequence annotation), occurs at the cell surface. ADAMTS7B is an active metalloproteinase as shown by its ability to cleave alpha(2)-macroglobulin, but it does not cleave specific peptide bonds in versican and aggrecan attacked by ADAMTS proteases. Together with ADAMTS12, whose primary structure also predicts a mucin domain, ADAMTS7B constitutes a unique subgroup of the ADAMTS family.	Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthoped Res Ctr, Cleveland, OH 44195 USA; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Sherbrooke; Washington University (WUSTL)	Apte, SS (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn ND20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@bme.ri.ccf.org		Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR49930] Funding Source: Medline; NINDS NIH HHS [NS19195] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR049930, R01AR049930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019195, R37NS019195] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Christian S, 2001, J BIOL CHEM, V276, P7408, DOI 10.1074/jbc.M009604200; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Engbring JA, 2002, CANCER RES, V62, P3549; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Godl K, 2002, J BIOL CHEM, V277, P47248, DOI 10.1074/jbc.M208483200; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li CQ, 2002, THROMB HAEMOSTASIS, V88, P673, DOI 10.1055/s-0037-1613274; LOTAN R, 1975, J BIOL CHEM, V250, P8518; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; Nardi JB, 1999, INSECT BIOCHEM MOLEC, V29, P883, DOI 10.1016/S0965-1748(99)00064-8; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Somerville RPT, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-216; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Turcotte CL, 2002, DEV DYNAM, V224, P51, DOI 10.1002/dvdy.10081; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	58	76	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35159	35175		10.1074/jbc.M402380200	http://dx.doi.org/10.1074/jbc.M402380200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192113	hybrid			2022-12-27	WOS:000223303400006
J	Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR				Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR			Glycoprotein hormone assembly in the endoplasmic reticulum - II. Multiple roles of a redox sensitive beta-subunit disulfide switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; ALPHA-SUBUNIT; STIMULATING-HORMONE; PROTEIN; RECEPTOR; CHORIOGONADOTROPIN; FOLLITROPIN; LUTROPIN; BINDING; CONFORMATION	All three human glycoprotein hormone heterodimers are assembled in the endoplasmic reticulum by threading the glycosylated end of alpha-subunit loop two (alpha2) beneath a disulfide "latched" strand of the beta-subunit known as the "seatbelt." This remarkable event occurs efficiently even though the seatbelt effectively blocks the reverse process, thereby stabilizing each heterodimer. Studies described here show that assembly is facilitated by the formation, disruption, and reformation of a loop within the seatbelt that is stabilized by the most easily reduced disulfide in the free beta-subunit. We refer to this disulfide as the "tensor" because it shortens the seatbelt, thereby securing the heterodimer. Formation of the tensor disulfide appears to precede and facilitate seatbelt latching in most human choriogonadotropin beta-subunit molecules. Subsequent disruption of the tensor disulfide elongates the seatbelt, thereby increasing the space beneath the seatbelt and the beta-subunit core. This permits the formation of hydrogen bonds between backbone atoms of the beta-subunit cystine knot and the tensor loop with backbone atoms in loop alpha2, a process that causes the glycosylated end of loop alpha2 to be threaded between the seatbelt and the beta-subunit core. Contacts between the tensor loop and loop alpha2 promote reformation of the tensor disulfide, which explains why it is more stable in the heterodimer than in the uncombined beta-subunit. These findings unravel the puzzling nature of how a threading mechanism can be used in the endoplasmic reticulum to assemble glycoprotein hormones that have essential roles in vertebrate reproduction and thyroid function.	Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			NICHD NIH HHS [HD38547, HD14907] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, R37HD014907, R01HD038547] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; HUTH JR, 1993, J BIOL CHEM, V268, P16472; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lin W, 1999, MOL CELL ENDOCRINOL, V152, P91, DOI 10.1016/S0303-7207(99)00056-8; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; STRICKLAND TW, 1982, J BIOL CHEM, V257, P2954; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P35449, DOI 10.1074/jbc.M403054200; Xing YN, 2004, J BIOL CHEM, V279, P35458, DOI 10.1074/jbc.M403055200; Xing YN, 2004, J BIOL CHEM, V279, P35426, DOI 10.1074/jbc.M403052200; Xing YN, 2003, BIOCHEM BIOPH RES CO, V303, P201, DOI 10.1016/S0006-291X(03)00322-X; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; Xing YN, 2001, PROTEIN SCI, V10, P226, DOI 10.1110/ps.25901	24	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35437	35448		10.1074/jbc.M403053200	http://dx.doi.org/10.1074/jbc.M403053200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15161903	hybrid			2022-12-27	WOS:000223303400037
J	Furuyama, T; Kitayama, K; Shimoda, Y; Ogawa, M; Sone, K; Yoshida-Araki, K; Hisatsune, H; Nishikawa, S; Nakayama, K; Nakayama, K; Ikeda, K; Motoyama, N; Mori, N				Furuyama, T; Kitayama, K; Shimoda, Y; Ogawa, M; Sone, K; Yoshida-Araki, K; Hisatsune, H; Nishikawa, S; Nakayama, K; Nakayama, K; Ikeda, K; Motoyama, N; Mori, N			Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; ENDOTHELIAL GROWTH-FACTOR; FACTOR BINDING PROTEIN-1; C-ELEGANS; CAENORHABDITIS-ELEGANS; SIGNALING PATHWAY; OXIDATIVE STRESS; FAMILY-MEMBER; LIFE-SPAN; CELLS	Members of the Foxo family, Foxo1 (Fkhr), Foxo3 (Fkhrl1), and Foxo4 (Afx), are mammalian homologs of daf-16, which influences life span and energy metabolism in Caenorhabditis elegans. Mammalian FOXO proteins also play important roles in cell cycle arrest, apoptosis, stress resistance, and energy metabolism. In this study, we generated Foxo1-deficient mice to investigate the physiological role of FOXO1. The Foxo1-deficient mice died around embryonic day 11 because of defects in the branchial arches and remarkably impaired vascular development of embryos and yolk sacs. In vitro differentiation of embryonic stem cells demonstrated that endothelial cells derived from wild-type and Foxo1-deficient embryonic stem cells were able to produce comparable numbers of colonies supported by a layer of OP9 stromal cells. Although the morphology of the endothelial cell colonies was identical in both genotypes in the absence of exogenous vascular endothelial growth factor (VEGF), Foxo1-deficient endothelial cells showed a markedly different morphological response compared with wild-type endothelial cells in the presence of exogenous VEGF. These results suggest that Foxo1 is essential to the ability of endothelial cells to respond properly to a high dose of VEGF, thereby playing a critical role in normal vascular development.	Kumamoto Univ, Dept Mol Genet, Natl Inst Longev Sci, Kumamoto 8600811, Japan; Kumamoto Univ, Dept Geriatr Res, Natl inst Longev Sci, Kumamoto 8600811, Japan; Kumamoto Univ, Dept Cell Differentiat, Inst Mol Embryol & Genet, Kumamoto 8600811, Japan; Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Kyushu 8128582, Japan; RIKEN, Lab Stem Cell Biol, Ctr Dev Biol, Kyoto 6500047, Japan; Kyoto Univ, Dept Mol Genet, Grad Sch Med, Kyoto 6068501, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kyushu University; RIKEN; Kyoto University	Furuyama, T (corresponding author), Sonoda Womans Univ, Dept Food & Nutr, 7-29-1 Minami Tsukaguchi, Amagasaki, Hyogo 6618520, Japan.	furuyama@sonoda-u.ac.jp		Kitayama, Kazuko/0000-0003-2829-762X; Furuyama, Tatsuo/0000-0001-7349-103X				Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Antebi A, 2000, GENE DEV, V14, P1512; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gerety SS, 2002, DEVELOPMENT, V129, P1397; Gerisch B, 2001, DEV CELL, V1, P841, DOI 10.1016/S1534-5807(01)00085-5; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Hirashima M, 1999, BLOOD, V93, P1253, DOI 10.1182/blood.V93.4.1253.404k31_1253_1263; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Jia KL, 2002, DEVELOPMENT, V129, P221; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; Matsumura K, 2003, BLOOD, V101, P1367, DOI 10.1182/blood-2002-05-1329; Matsuyoshi N, 1997, P ASSOC AM PHYSICIAN, V109, P362; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nishikawa S, 1998, IMMUNITY, V8, P761, DOI 10.1016/S1074-7613(00)80581-6; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Simon AM, 2003, J CELL SCI, V116, P2223, DOI 10.1242/jcs.00429; Simon AM, 2002, DEV BIOL, V251, P206, DOI 10.1006/dbio.2002.0826; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Yang X, 1999, DEVELOPMENT, V126, P1571; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	45	263	271	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34741	34749		10.1074/jbc.M314214200	http://dx.doi.org/10.1074/jbc.M314214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184386	hybrid			2022-12-27	WOS:000223134800080
J	Liu, F; Dowling, M; Yang, XJ; Kao, GD				Liu, F; Dowling, M; Yang, XJ; Kao, GD			Caspase-mediated specific cleavage of human histone deacetylase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; APOPTOSIS; HDAC4; DEGRADATION; ACTIVATION; SURVIVAL; DOMAIN; PHOSPHORYLATION; COMPLEX	Histone deacetylase 4 (HDAC4) is a class II HDAC implicated in controlling gene expression important for diverse cellular functions, but little is known about how its expression and stability are regulated. We report here that this deacetylase is unusually unstable, with a half-life of less than 8 h. Consistent with the instability of HDAC4 protein, its mRNA was also highly unstable ( with a half-life of less than 4 h). The degradation of HDAC4 could be accelerated by exposure of cells to ultraviolet irradiation. HDAC4 degradation was not dependent on proteasome or CRM1-mediated export activity but instead was caspase-dependent and was detectable in diverse human cancer lines. Of two potential caspase consensus motifs in HDAC4, both lying within a region containing proline-,glutamic acid-, serine, and threonine-rich ( PEST) sequences, we identified, by site-directed mutagenesis, Asp-289 as the prime cleavage site. Notably, this residue is not conserved among other class IIa members, HDAC5, - 7, and - 9. Finally, the induced expression of caspase-cleavable HDAC4 led to markedly increased apoptosis. These results therefore unexpectedly link the regulation of HDAC4 protein stability to caspases, enzymes that are important for controlling cell death and differentiation.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	University of Pennsylvania; McGill University	Kao, GD (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, John Morgan 180 H, Philadelphia, PA 19104 USA.	Kao@xrt.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA107956] Funding Source: NIH RePORTER; NCI NIH HHS [CA 107956-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Borghi S, 2001, J CELL SCI, V114, P4477; Butts BD, 2003, HORM METAB RES, V35, P763; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hong HN, 2002, NEUROSCI LETT, V334, P63, DOI 10.1016/S0304-3940(02)01066-2; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Huang EY, 2000, GENE DEV, V14, P45; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Imai S, 2000, COLD SPRING HARB SYM, V65, P297, DOI 10.1101/sqb.2000.65.297; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim W, 2004, J BIOL CHEM, V279, P8333, DOI 10.1074/jbc.M312026200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; KRAKOFF IH, 1968, CANCER RES, V28, P1559; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang SC, 2001, CANCER RES, V61, P2838; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Xerri L, 2000, J PATHOL, V192, P194, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH685>3.0.CO;2-M; Yang XJ, 2003, CURR OPIN GENET DEV, V13, P143, DOI 10.1016/S0959-437X(03)00015-7; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	49	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34537	34546		10.1074/jbc.M402475200	http://dx.doi.org/10.1074/jbc.M402475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15205465	hybrid			2022-12-27	WOS:000223134800057
J	Mould, J; Yasuda, T; Schroeder, CI; Beedle, AM; Doering, CJ; Zamponi, GW; Adams, DJ; Lewis, RJ				Mould, J; Yasuda, T; Schroeder, CI; Beedle, AM; Doering, CJ; Zamponi, GW; Adams, DJ; Lewis, RJ			The alpha(2)delta auxiliary subunit reduces affinity of omega-conotoxins for recombinant N-type (Ca(v)2.2) calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLION; CA2+ CHANNEL; RAT-BRAIN; NEUROPATHIC PAIN; BETA-SUBUNITS; XENOPUS OOCYTES; TRANSMITTER RELEASE; GENE-EXPRESSION; IDENTIFICATION; ALPHA(1B)	The omega-conotoxins from fish-hunting cone snails are potent inhibitors of voltage-gated calcium channels. The omega-conotoxins MVIIA and CVID are selective N-type calcium channel inhibitors with potential in the treatment of chronic pain. The beta and alpha(2)delta-1 auxiliary subunits influence the expression and characteristics of the alpha(1B) subunit of N-type channels and are differentially regulated in disease states, including pain. In this study, we examined the influence of these auxiliary subunits on the ability of the omega-conotoxins GVIA, MVIIA, CVID and analogues to inhibit peripheral and central forms of the rat N-type channels. Although the beta3 subunit had little influence on the on- and off-rates of omega-conotoxins, coexpression of alpha(2)delta with alpha(1B) significantly reduced on- rates and equilibrium inhibition at both the central and peripheral isoforms of the N-type channels. The alpha(2)delta also enhanced the selectivity of MVIIA, but not CVID, for the central isoform. Similar but less pronounced trends were also observed for N-type channels expressed in human embryonic kidney cells. The influence of alpha(2)delta was not affected by oocyte deglycosylation. The extent of recovery from the omega-conotoxin block was least for GVIA, intermediate for MVIIA, and almost complete for CVID. Application of a hyperpolarizing holding potential ( - 120 mV) did not significantly enhance the extent of CVID recovery. Interestingly, [R10K] MVIIA and [O10K] GVIA had greater recovery from the block, whereas [K10R] CVID had reduced recovery from the block, indicating that position 10 had an important influence on the extent of omega-conotoxin reversibility. Recovery from CVID block was reduced in the presence of alpha(2)delta in human embryonic kidney cells and in oocytes expressing alpha(1B-b). These results may have implications for the antinociceptive properties of omega-conotoxins, given that the alpha(2)delta subunit is up-regulated in certain pain states.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	University of Queensland; University of Queensland; University of Calgary	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard J/E-8674-2013; Beedle, Aaron/AAI-7014-2020; Adams, David John/K-3578-2019; Lewis, Richard/T-8763-2019; Schroeder, Cristina I./K-2042-2014; Beedle, Aaron M/K-1902-2015	Lewis, Richard J/0000-0003-3470-923X; Adams, David John/0000-0002-7030-2288; Lewis, Richard/0000-0003-3470-923X; Schroeder, Cristina I./0000-0002-6737-6374; Beedle, Aaron M/0000-0002-1019-3235; Zamponi, Gerald W./0000-0002-0644-9066				Abe M, 2002, SPINE, V27, P1517, DOI 10.1097/00007632-200207150-00007; Adams DJ, 2003, J BIOL CHEM, V278, P4057, DOI 10.1074/jbc.M209969200; ADAMS ME, 1993, BIOCHEMISTRY-US, V32, P12566, DOI 10.1021/bi00210a003; Atanassoff PG, 2000, REGION ANESTH PAIN M, V25, P274, DOI 10.1016/S1098-7339(00)90010-5; Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; COUSINS MJ, 2003, P 10 WORLD C PAIN PR, pA615; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DUNLAP K, 1994, SCIENCE, V266, P828, DOI 10.1126/science.7973643; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; Felix R, 1997, J NEUROSCI, V17, P6884; Feng ZP, 2003, J BIOL CHEM, V278, P20171, DOI 10.1074/jbc.M300581200; Feng ZP, 2001, J BIOL CHEM, V276, P15728, DOI 10.1074/jbc.M100406200; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P2403, DOI 10.1517/13543784.9.10.2403; Jones LP, 1998, J GEN PHYSIOL, V112, P125, DOI 10.1085/jgp.112.2.125; Kaneko S, 2002, J NEUROSCI, V22, P82, DOI 10.1523/JNEUROSCI.22-01-00082.2002; Kim DS, 2001, MOL BRAIN RES, V96, P151, DOI 10.1016/S0169-328X(01)00285-6; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; Levin T, 2002, PSYCHOSOMATICS, V43, P63, DOI 10.1176/appi.psy.43.1.63; Lewis RJ, 2000, J BIOL CHEM, V275, P35335, DOI 10.1074/jbc.M002252200; Lin ZX, 1999, J NEUROSCI, V19, P5322; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Ludwig A, 1997, J NEUROSCI, V17, P1339; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; Meadows HJ, 1999, ANN NY ACAD SCI, V868, P224, DOI 10.1111/j.1749-6632.1999.tb11291.x; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Newton RA, 2001, MOL BRAIN RES, V95, P1, DOI 10.1016/S0169-328X(01)00188-7; Nielsen KJ, 1999, J MOL BIOL, V289, P1405, DOI 10.1006/jmbi.1999.2817; Nielsen KJ, 1999, BIOCHEMISTRY-US, V38, P6741, DOI 10.1021/bi982980u; Nielsen KJ, 2000, J MOL RECOGNIT, V13, P55, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Qin N, 1998, AM J PHYSIOL-CELL PH, V274, pC1324, DOI 10.1152/ajpcell.1998.274.5.C1324; Saegusa H, 2001, EMBO J, V20, P2349, DOI 10.1093/emboj/20.10.2349; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Scott DA, 2002, EUR J PHARMACOL, V451, P279, DOI 10.1016/S0014-2999(02)02247-1; Smith MT, 2002, PAIN, V96, P119, DOI 10.1016/S0304-3959(01)00436-5; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; Stocker JW, 1997, J NEUROSCI, V17, P3002; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; Wakamori M, 1999, J PHYSIOL-LONDON, V517, P659, DOI 10.1111/j.1469-7793.1999.0659s.x; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; Wu LG, 1999, J NEUROSCI, V19, P726; Xiao HS, 2002, P NATL ACAD SCI USA, V99, P8360, DOI 10.1073/pnas.122231899; YAMADA K, 1994, NEUROPHARMACOLOGY, V33, P251, DOI 10.1016/0028-3908(94)90016-7; Yasuda T, 2004, J GEN PHYSIOL, V123, P401, DOI 10.1085/jgp.200308967	53	64	71	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34705	34714		10.1074/jbc.M310848200	http://dx.doi.org/10.1074/jbc.M310848200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15166237	hybrid			2022-12-27	WOS:000223134800076
J	Rey, O; Reeve, JR; Zhukova, E; Sinnett-Smith, J; Rozengurt, E				Rey, O; Reeve, JR; Zhukova, E; Sinnett-Smith, J; Rozengurt, E			G protein-coupled receptor-mediated phosphorylation of the activation loop of protein kinase D - Dependence on plasma membrane translocation and protein kinase C-epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; PLECKSTRIN HOMOLOGY DOMAIN; SIGNAL-TRANSDUCTION PATHWAY; POTENTIATES DNA-SYNTHESIS; CYSTEINE-RICH MOTIFS; D PKD ACTIVATION; PHORBOL ESTERS; IN-VIVO; INTRACELLULAR REDISTRIBUTION; CCKB/GASTRIN RECEPTOR	Protein kinase D (PKD) is a serine/threonine protein kinase activated by G protein-coupled receptor ( GPCR) agonists through an incompletely characterized mechanism that includes its reversible plasma membrane translocation and activation loop phosphorylation via a protein kinase C (PKC)-dependent pathway. To gain a better understanding of the mechanism regulating the activation of PKD in response to GPCR stimulation, we investigated the role of its rapid plasma membrane translocation on its activation loop phosphorylation and identified the endogenous PKC isozyme that mediates that event in vivo. We had found that the activation loop of a PKD mutant, with reduced affinity for diacylglycerol and phorbol esters, was only phosphorylated upon its plasma membrane association. We also found that the activation loop phosphorylation and rapid plasma membrane dissociation of PKD were inhibited either by preventing the plasma membrane translocation of PKCepsilon, through abolition of its interaction with receptor for activated C kinase, or by suppressing the expression of PKCepsilon via specific small interfering RNAs. Thus, this study demonstrates that the plasma membrane translocation of PKD, in response to GPCR stimulation, is necessary for the PKCepsilon-mediated phosphorylation of the activation loop of PKD and that this event requires the translocation of both kinases to the plasma membrane. Based on these and previous results, we propose a model of GPCR-mediated PKD regulation that integrates its changes in distribution, catalytic activity, and multisite phosphorylation.	Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	Reeve, James/GYI-8415-2022	Rey, Osvaldo/0000-0003-1575-9864	NCI NIH HHS [P50 CA 090388, K01 CA 097956] Funding Source: Medline; NIDDK NIH HHS [DK 33580, DK 41301, DK 56930, DK 55003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388, K01CA097956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, P30DK041301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bonfanti M, 1997, CANCER RES, V57, P1442; Brooks G, 1997, J MOL CELL CARDIOL, V29, P2273, DOI 10.1006/jmcc.1997.0466; Chiu T, 2002, AM J PHYSIOL-CELL PH, V282, pC434, DOI 10.1152/ajpcell.00240.2001; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Fujimoto K, 2000, CANCER LETT, V159, P151, DOI 10.1016/S0304-3835(00)00536-X; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Guha S, 2002, CANCER RES, V62, P1632; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; Haworth RS, 2000, J MOL CELL CARDIOL, V32, P1013, DOI 10.1006/jmcc.2000.1143; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2003, J BIOL CHEM, V278, P23773, DOI 10.1074/jbc.M300226200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rey O, 2001, BIOCHEM BIOPH RES CO, V287, P21, DOI 10.1006/bbrc.2001.5530; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P945, DOI 10.1101/SQB.1988.053.01.109; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SchutzeRedelmeier MP, 1996, J IMMUNOL, V157, P650; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	79	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34361	34372		10.1074/jbc.M403265200	http://dx.doi.org/10.1074/jbc.M403265200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190080	hybrid			2022-12-27	WOS:000223134800036
J	Zhao, KS; Zhao, GM; Wu, DL; Soong, Y; Birk, AV; Schiller, PW; Szeto, HH				Zhao, KS; Zhao, GM; Wu, DL; Soong, Y; Birk, AV; Schiller, PW; Szeto, HH			Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ADENINE-NUCLEOTIDE TRANSLOCATOR; TOXIN 3-NITROPROPIONIC ACID; OXYGEN SPECIES PRODUCTION; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; TRANSITION PORE; INDUCED APOPTOSIS; CYCLOSPORINE-A; STRESS	Reactive oxygen species (ROS) play a key role in promoting mitochondrial cytochrome c release and induction of apoptosis. ROS induce dissociation of cytochrome c from cardiolipin on the inner mitochondrial membrane (IMM), and cytochrome c may then be released via mitochondrial permeability transition (MPT)dependent or MPT-independent mechanisms. We have developed peptide antioxidants that target the IMM, and we used them to investigate the role of ROS and MPT in cell death caused by t-butylhydroperoxide (tBHP) and 3-nitropropionic acid (3NP). The structural motif of these peptides centers on alternating aromatic and basic amino acid residues, with dimethyltyrosine providing scavenging properties. These peptide antioxidants are cell-permeable and concentrate 1000-fold in the IMM. They potently reduced intracellular ROS and cell death caused by tBHP in neuronal N(2)A cells (EC50 in nM range). They also decreased mitochondrial ROS production, inhibited MPT and swelling, and prevented cytochrome c release induced by Ca2+ in isolated mitochondria. In addition, they inhibited 3NP-induced MPT in isolated mitochondria and prevented mitochondrial depolarization in cells treated with 3NP. ROS and MPT have been implicated in myocardial stunning associated with reperfusion in ischemic hearts, and these peptide antioxidants potently improved contractile force in an ex vivo heart model. It is noteworthy that peptide analogs without dimethyltyrosine did not inhibit mitochondrial ROS generation or swelling and failed to prevent myocardial stunning. These results clearly demonstrate that overproduction of ROS underlies the cellular toxicity of tBHP and 3NP, and ROS mediate cytochrome c release via MPT. These IMM-targeted antioxidants may be very beneficial in the treatment of aging and diseases associated with oxidative stress.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ H2W 1R7, Canada	Cornell University; Cornell University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Szeto, HH (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA.	hhszeto@med.cornell.edu			NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008924, K01DA018268] Funding Source: NIH RePORTER; NIDA NIH HHS [K01 DA018268-01, K01 DA018268, DA 08924] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; BEAL MF, 1995, J NEUROCHEM, V65, P919; BEAL MF, 1993, J NEUROSCI, V13, P4181; Berezowska I, 2003, PEPTIDES, V24, P1195, DOI 10.1016/j.peptides.2003.07.004; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Byrne AM, 1999, HEPATOLOGY, V29, P1523, DOI 10.1002/hep.510290521; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; CROMPTON M, 1993, BASIC RES CARDIOL, V88, P513, DOI 10.1007/BF00795416; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; FLAHERTY JT, 1994, CIRCULATION, V89, P1982, DOI 10.1161/01.CIR.89.5.1982; Fontana M, 2001, BIOCHEM PHARMACOL, V61, P1253, DOI 10.1016/S0006-2952(01)00565-2; Galindo MF, 2003, BRIT J PHARMACOL, V139, P797, DOI 10.1038/sj.bjp.0705309; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kanno T, 2004, FREE RADICAL RES, V38, P27, DOI 10.1080/10715760310001626266; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Lee WT, 2002, NEUROSCIENCE, V112, P707, DOI 10.1016/S0306-4522(02)00097-0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YB, 1999, BBA-GEN SUBJECTS, V1428, P1, DOI 10.1016/S0304-4165(99)00040-9; Lim KHH, 2002, J PHYSIOL-LONDON, V545, P961, DOI 10.1113/jphysiol.2002.031484; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Longoni B, 1997, BIOCHEM BIOPH RES CO, V233, P778, DOI 10.1006/bbrc.1997.6563; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Moosmann B, 2002, MOL PHARMACOL, V61, P260, DOI 10.1124/mol.61.2.260; NAKAMURA M, 1986, J BIOL CHEM, V261, P13923; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Nishimura G, 2001, FEBS LETT, V505, P399, DOI 10.1016/S0014-5793(01)02859-9; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Pias EK, 2003, J BIOL CHEM, V278, P13294, DOI 10.1074/jbc.M208670200; PICHORNER H, 1995, ARCH BIOCHEM BIOPHYS, V323, P429, DOI 10.1006/abbi.1995.0064; Polster BM, 2001, J BIOL CHEM, V276, P37887; Pong K, 2001, EXP NEUROL, V171, P84, DOI 10.1006/exnr.2001.7747; Rosenstock TR, 2004, J NEUROCHEM, V88, P1220, DOI 10.1046/j.1471-4159.2003.02250.x; Schiller PW, 2000, EUR J MED CHEM, V35, P895, DOI 10.1016/S0223-5234(00)01171-5; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Terada T, 1999, AM J PHYSIOL-GASTR L, V276, pG1435, DOI 10.1152/ajpgi.1999.276.6.G1435; VALOTI M, 1992, BIOCHEM PHARMACOL, V43, P945, DOI 10.1016/0006-2952(92)90597-C; VARDANIS A, 1977, J BIOL CHEM, V252, P807; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wu CL, 2002, AM J PHYSIOL-HEART C, V283, pH783, DOI 10.1152/ajpheart.00193.2002; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zhao GM, 2003, J PHARMACOL EXP THER, V307, P947, DOI 10.1124/jpet.103.054775; Zhao KS, 2003, J PHARMACOL EXP THER, V304, P425, DOI 10.1124/jpet.102.040147; Zhao ZQ, 2004, CURR OPIN PHARMACOL, V4, P159, DOI 10.1016/j.coph.2003.10.010	59	594	665	3	91	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34682	34690		10.1074/jbc.M402999200	http://dx.doi.org/10.1074/jbc.M402999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15178689	hybrid			2022-12-27	WOS:000223134800073
J	Chae, C; Sharma, S; Hoskins, JR; Wickner, S				Chae, C; Sharma, S; Hoskins, JR; Wickner, S			CbpA, a DnaJ homolog, is a DnaK co-chaperone, and its activity is modulated by CbpM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; FUNCTIONAL CYCLE; REPLICATION; BINDING; HSP70; MONOMERIZATION; EXPRESSION; COMPLEX	The DnaK chaperone system, consisting of DnaK, DnaJ, and GrpE, remodels and refolds proteins during both normal growth and stress conditions. CbpA, one of several DnaJ analogs in Escherichia coli, is known to function as a multicopy suppressor for dnaJ mutations and to bind nonspecifically to DNA and preferentially to curved DNA. We found that CbpA functions as a DnaJ-like co-chaperone in vitro. CbpA acted in an ATP-dependent reaction with DnaK and GrpE to remodel inactive dimers of plasmid P1 RepA into monomers active in P1 DNA binding. Additionally, CbpA participated with DnaK in an ATP-dependent reaction to prevent aggregation of denatured rhodanese. The cbpA gene is in an operon with an open reading frame, yccD, which encodes a protein that has some homology to DafA of Thermus thermophilus. DafA is a protein required for the assembly of ring-like particles that contain trimers each of T. thermophilus DnaK, DnaJ, and DafA. The E. coli YccD was isolated because of its potential functional relationship to CbpA. Purified YccD specifically inhibited both the co-chaperone activity and the DNA binding activity of CbpA, suggesting that YccD modulates the activity of CbpA. We named the product of the yccD gene CbpM for "CbpA modulator."	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 5144,37 Convent Dr,MSC37-4264, Bethesda, MD 20892 USA.	suewick@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC008710, ZIABC008710] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tucker DL, 2002, J BACTERIOL, V184, P6551, DOI 10.1128/JB.184.23.6551-6558.2002; UEGUCHI C, 1994, P NATL ACAD SCI USA, V91, P1054, DOI 10.1073/pnas.91.3.1054; UEGUCHI C, 1995, J BACTERIOL, V177, P3894, DOI 10.1128/jb.177.13.3894-3896.1995; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMASHINO T, 1994, MOL MICROBIOL, V13, P475, DOI 10.1111/j.1365-2958.1994.tb00442.x; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	23	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33147	33153		10.1074/jbc.M404862200	http://dx.doi.org/10.1074/jbc.M404862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184371	hybrid			2022-12-27	WOS:000223039700017
J	Dodson, GE; Shi, YL; Tibbetts, RS				Dodson, GE; Shi, YL; Tibbetts, RS			DNA replication defects, spontaneous DNA damage, and ATM-dependent checkpoint activation in replication protein A-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BINDING-PROTEIN; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; KINASE-ACTIVITIES; P34 SUBUNIT; RPA; PHOSPHORYLATION; ATRIP; CHK1	Replication protein A (RPA) is a heterotrimeric, single-stranded DNA-binding complex comprised of 70-kDa (RPA1), 32-kDa (RPA2), and 14-kDa (RPA3) subunits that is essential for DNA replication, recombination, and repair in eukaryotes. In addition, recent studies using vertebrate model systems have suggested an important role for RPA in the initiation of cell cycle checkpoints following exposure to DNA replication stress. Specifically, RPA has been implicated in the recruitment and activation of the ATM-Rad3-related protein kinase, ATR, which in conjunction with the related kinase, ATM (ataxia-telangiectasia-mutated), transmits checkpoint signals via the phosphorylation of downstream effectors. In this report, we have explored the effects of RPA insufficiency on DNA replication, cell survival, and ATM/ATR-dependent signal transduction in response to genotoxic stress. RNA interference-mediated suppression of RPA1 caused a slowing of S phase progression, G(2)/M cell cycle arrest, and apoptosis in HeLa cells. RPA-deficient cells demonstrated high levels of spontaneous DNA damage and constitutive activation of ATM, which was responsible for the terminal G(2)/M arrest phenotype. Surprisingly, we found that neither RPA1 nor RPA2 were essential for the hydroxyurea- or UV-induced phosphorylation of the ATR substrates CHK1 and CREB (cyclic AMP-response element-binding protein). These findings reveal that RPA is required for genomic stability and suggest that activation of ATR can occur through RPA-independent pathways.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Tibbetts, RS (corresponding author), Univ Wisconsin, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	rstibbetts@wisc.edu		Tibbetts, Randal/0000-0003-2245-2297	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067868] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-067868-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Bomgarden RD, 2004, J BIOL CHEM, V279, P13346, DOI 10.1074/jbc.M311098200; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; Liu QH, 2000, GENE DEV, V14, P1448; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Parker AE, 1997, MOL CELL BIOL, V17, P2381, DOI 10.1128/MCB.17.5.2381; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	36	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34010	34014		10.1074/jbc.C400242200	http://dx.doi.org/10.1074/jbc.C400242200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15197179	hybrid			2022-12-27	WOS:000223039700112
J	Sheng, WY; Yan, H; Rausa, FM; Costa, RH; Liao, HB				Sheng, WY; Yan, H; Rausa, FM; Costa, RH; Liao, HB			Structure of the hepatocyte nuclear factor 6 alpha and its interaction with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRAINED MOLECULAR-DYNAMICS; COMMON AMINO-ACIDS; TRANSCRIPTION FACTOR; MAGNETIC-RESONANCE; BIOLOGICAL MACROMOLECULES; HOMEODOMAIN PROTEIN; NMR-SPECTROSCOPY; BINDING PROTEIN; GENE-EXPRESSION; CUT REPEATS	Hepatocyte nuclear factor 6 (HNF-6) belongs to the family of One Cut transcription factors ( also known as OC-1) and is essential for the development of the mouse pancreas, gall bladder, and the interhepatic bile ducts. HNF-6 binds to DNA as a monomer utilizing a single cut domain and a divergent homeodomain motif located at its C terminus. Here, we have used NMR methods to determine the solution structures of the 162 amino acid residue DNA-binding domain of the HNF-6alpha protein. The resulting overall structure of HNF-6alpha has two different distinct domains: the Cut domain and the Homeodomain connected by a long flexible linker. Our NMR structure shows that the Cut domain folds into a topology homologous to the POU DNA-binding domain, even though the sequences of these two protein families do not show homology. The DNA contact sequence of the HNF-6alpha was mapped with chemical shift perturbation methods. Our data also show that a proposed CREB-binding protein histone acetyltransferase protein-recruiting sequence, LSDLL, forms a helix and is involved in the hydrophobic core of the Cut domain. The structure implies that this sequence has to undergo structural changes when it interacts with CREB-binding protein.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Liao, HB (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC669, MBRB 3300,900 S Ashland, Chicago, IL 60607 USA.	xiubei@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043241] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-43241-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COX M, 1995, J BIOMOL NMR, V6, P23, DOI 10.1007/BF00417488; FESIK SW, 1990, Q REV BIOPHYS, V23, P97, DOI 10.1017/S0033583500005515; Gardner KH, 1998, ANNU REV BIOPH BIOM, V27, P357, DOI 10.1146/annurev.biophys.27.1.357; GEGRING WJ, 1994, CELL, V78, P211; GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HARADA R, 1994, J BIOL CHEM, V269, P2062; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 2003, DEV BIOL, V258, P105, DOI 10.1016/S0012-1606(03)00115-5; Kay LE, 2001, METHOD ENZYMOL, V339, P174, DOI 10.1016/S0076-6879(01)39314-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; Lannoy VJ, 2000, J BIOL CHEM, V275, P22098, DOI 10.1074/jbc.M000855200; Lannoy VJ, 2002, DIABETOLOGIA, V45, P1136, DOI 10.1007/s00125-002-0856-z; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moller AM, 1999, DIABETOLOGIA, V42, P1011, DOI 10.1007/s001250051261; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Razeto A, 2004, J MOL BIOL, V336, P319, DOI 10.1016/j.jmb.2003.12.057; Reid D. G., 1997, PROTEIN NMR TECHNIQU; Remenyi A, 2001, MOL CELL, V8, P569, DOI 10.1016/S1097-2765(01)00336-7; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Schonemann MD, 1998, ADV EXP MED BIOL, V449, P39; Sheng WY, 2004, J BIOMOL NMR, V28, P401, DOI 10.1023/B:JNMR.0000015376.37420.ad; TSAO DHH, 1995, J MOL BIOL, V251, P297, DOI 10.1006/jmbi.1995.0435; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	40	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33928	33936		10.1074/jbc.M403805200	http://dx.doi.org/10.1074/jbc.M403805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169783	hybrid			2022-12-27	WOS:000223039700103
J	Poso, D; Clarke, AR; Burston, SG				Poso, D; Clarke, AR; Burston, SG			Identification of a major inter-ring coupling step in the GroEL reaction cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ALLOSTERIC TRANSITIONS; INDUCED CONFORMATIONAL-CHANGES; KINETIC-ANALYSIS; CHAPERONIN GROEL; THERMOANAEROBACTER-BROCKII; CRYSTAL-STRUCTURE; FOLDING REACTION; ATPASE CYCLE; HEAT-SHOCK; BINDING	It has been shown previously that the double-ring structure of GroEL can be converted to a single-ring species by site-directed amino acid replacements at the ring interface and that the resultant molecule retains many of the crucial chaperonin properties; it is structurally stable, hydrolytically active, and can bind both the co-chaperonin, GroES, and unfolded substrate proteins. By comparing the behavior of the double- and single-ring structures in response to nucleotide binding and hydrolysis, we elucidate steps in the ATP-driven reaction cycle at which there is conformational coupling between the rings. Remarkably, the parting of the rings has little effect either on the thermodynamic properties of ATP binding or on the ATP-induced conformational changes prior to hydrolysis. However, there is a marked effect on the rate-limiting process in the steady-state cycle; a step that is coincident with bond cleavage in ATP. The effect of the ring-ring interaction is to increase its activation enthalpy from 42.0 to 94.2 kJ/mol. These results show that the major conformational coupling step, where structural rearrangements in one ring are propagated to the other, is the slowest process the ATPase cycle of GroEL.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Poso, D (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	d.poso@bristol.ac.uk; s.g.burston@bristol.ac.uk		Burston, Steven/0000-0003-1848-1853				Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; Amir A, 2004, J MOL BIOL, V338, P979, DOI 10.1016/j.jmb.2004.02.076; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Carrascosa JL, 2001, MICRON, V32, P43, DOI 10.1016/S0968-4328(00)00027-5; Case A, 2003, BIOCHEMISTRY-US, V42, P3335, DOI 10.1021/bi020668l; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Cornish-Bowden A, 2002, J BIOSCIENCES, V27, P121, DOI 10.1007/BF02703768; Ellis R J, 1990, Semin Cell Biol, V1, P1; FINZI A, 1992, J APPL RABBIT RES, V15, P745; Franzetti B, 2001, J BIOL CHEM, V276, P29906, DOI 10.1074/jbc.M102098200; Galan A, 1999, EUR J BIOCHEM, V259, P347, DOI 10.1046/j.1432-1327.1999.00045.x; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; Gibbons DL, 1996, J BIOL CHEM, V271, P31989, DOI 10.1074/jbc.271.50.31989; Grallert N, 2000, J BIOL CHEM, V275, P20424, DOI 10.1074/jbc.M002243200; Horovitz A, 2001, J STRUCT BIOL, V135, P104, DOI 10.1006/jsbi.2001.4377; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KOHL B, 1987, BIOPHYS J, V52, P271, DOI 10.1016/S0006-3495(87)83214-9; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; Llorca O, 1998, J BIOL CHEM, V273, P32587, DOI 10.1074/jbc.273.49.32587; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Poso D, 2004, J MOL BIOL, V338, P969, DOI 10.1016/j.jmb.2004.03.010; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; SITHERLAND GB, 1958, J APPL PHYSIOL, V12, P367; Sot B, 2002, J BIOL CHEM, V277, P34024, DOI 10.1074/jbc.M205733200; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; Sun Z, 2003, J MOL BIOL, V332, P715, DOI 10.1016/S0022-2836(03)00830-1; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; TRUSCOTT KN, 1994, EUR J BIOCHEM, V222, P277, DOI 10.1111/j.1432-1033.1994.tb18866.x; Walter S, 2002, CELL MOL LIFE SCI, V59, P1589, DOI 10.1007/PL00012485; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Weissman JS, 2001, MOL CELL, V8, P730, DOI 10.1016/S1097-2765(01)00359-8; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	45	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38111	38117		10.1074/jbc.M401730200	http://dx.doi.org/10.1074/jbc.M401730200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15169772	hybrid			2022-12-27	WOS:000223684100008
J	Kulanthaivel, P; Kreuzman, AJ; Strege, MA; Belvo, MD; Smitka, TA; Clemens, M; Swartling, JR; Minton, KL; Zheng, F; Angleton, EL; Mullen, D; Jungheim, LN; Klimkowski, VJ; Nicas, TI; Thompson, RC; Peng, SB				Kulanthaivel, P; Kreuzman, AJ; Strege, MA; Belvo, MD; Smitka, TA; Clemens, M; Swartling, JR; Minton, KL; Zheng, F; Angleton, EL; Mullen, D; Jungheim, LN; Klimkowski, VJ; Nicas, TI; Thompson, RC; Peng, SB			Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL ACTIVE-SITE; COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; BETA-LACTAMS; MECHANISM; SERINE; EXPRESSION; MEMBRANE; IDENTIFICATION; VANCOMYCIN	Signal peptidase (SPase) I is responsible for the cleavage of signal peptides of many secreted proteins in bacteria. Because of its unique physiological and biochemical properties, it serves as a potential target for development of novel antibacterial agents. In this study, we report the production, isolation, and structure determination of a family of structurally related novel lipoglycopeptides from a Streptomyces sp. as inhibitors of SPase I. Detailed spectroscopic analyses, including MS and NMR, revealed that these lipoglycopeptides share a common 14-membered cyclic peptide core, an acyclic tripeptide chain, and a deoxy-alpha-mannose sugar, but differ in the degree of oxidation of the N-methylphenylglycine residue and the length and branching of the fatty acyl chain. Biochemical analysis demonstrated that these peptides are potent and competitive inhibitors of SPase I with K-i 50 to 158 nM. In addition, they showed modest antibacterial activity against a panel of pathogenic Gram-positive and Gram-negative bacteria with minimal inhibitory concentration of 8-64 muM against Streptococcus pneumonniae and 4-8 muM against Escherichia coli. Notably, they mechanistically blocked the protein secretion in whole cells as demonstrated by inhibiting beta-lactamase release from Staphylococcus aureus. Taken together, the present discovery of a family of novel lipoglycopeptides as potent inhibitors of bacterial SPase I may lead to the development of a novel class of broad-spectrum antibiotics.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Peng, SB (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.	Peng_Sheng-Bin@Lilly.com						Allen NE, 2003, FEMS MICROBIOL REV, V26, P511, DOI 10.1111/j.1574-6976.2003.tb00628.x; Allsop A, 1996, J ANTIBIOT, V49, P921, DOI 10.7164/antibiotics.49.921; ALLSOP AE, 1995, BIOORG MED CHEM LETT, V5, P443, DOI 10.1016/0960-894X(95)00052-U; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; Boger DL, 2001, MED RES REV, V21, P356, DOI 10.1002/med.1014; Cregg KM, 1996, J BACTERIOL, V178, P5712, DOI 10.1128/jb.178.19.5712-5718.1996; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Ge M, 1999, SCIENCE, V284, P507, DOI 10.1126/science.284.5413.507; HIKAIDO H, 1996, J BACTERIOL, V178, P5853; Holtzel A, 2002, J ANTIBIOT, V55, P571; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; Irvine G B, 1994, Methods Mol Biol, V32, P257; KUO D, 1994, BIOCHEMISTRY-US, V33, P8347, DOI 10.1021/bi00193a023; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; Laganas V, 2003, ANTIMICROB AGENTS CH, V47, P2682, DOI 10.1128/AAC.47.8.2682-2684.2003; LEE JI, 1992, J BIOL CHEM, V267, P938; MOORE KE, 1987, J BIOL CHEM, V262, P8806; National Committee for Clinical Laboratory Standards, 1990, M7A2 NAT COMM CLIN L; NORMARK S, 1969, J BACTERIOL, V97, P1334, DOI 10.1128/JB.97.3.1334-1342.1969; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Peng SB, 2001, ANAL BIOCHEM, V293, P88, DOI 10.1006/abio.2001.5102; Peng SB, 2001, J BACTERIOL, V183, P621, DOI 10.1128/JB.183.2.621-627.2001; SCHAEFLER S, 1981, J CLIN MICROBIOL, V13, P754, DOI 10.1128/JCM.13.4.754-759.1981; Schmid D. G., 2001, PEPTIDES WAVE FUTURE, P768; SMITH MD, 1979, J BACTERIOL, V137, P735, DOI 10.1128/JB.137.2.735-739.1979; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG M, 1992, J BIOL CHEM, V267, P13154; Tally FP, 2000, J ANTIMICROB CHEMOTH, V46, P523, DOI 10.1093/jac/46.4.523; Taylor P, 1999, J BIOL CHEM, V274, P24901, DOI 10.1074/jbc.274.35.24901; Tew DG, 1998, BIOCHEMISTRY-US, V37, P10087, DOI 10.1021/bi9801412; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TSCHANTZ WR, 1994, METHOD ENZYMOL, V244, P285; Tsubery H, 2000, J MED CHEM, V43, P3085, DOI 10.1021/jm0000057; VALKENBURG CV, 1999, J BIOL CHEM, V274, P11519; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1988, MOL GEN GENET, V214, P55; Wilmouth RC, 1999, BIOCHEMISTRY-US, V38, P7989, DOI 10.1021/bi990098y; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; Zahn JA, 2001, APPL ENVIRON MICROB, V67, P377, DOI 10.1128/AEM.67.1.377-386.2001	47	81	84	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36250	36258		10.1074/jbc.M405884200	http://dx.doi.org/10.1074/jbc.M405884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15173160	hybrid			2022-12-27	WOS:000223453600013
J	Shakor, ABA; Kwiatkowska, K; Sobota, A				Shakor, ABA; Kwiatkowska, K; Sobota, A			Cell surface ceramide generation precedes and controls Fc gamma RII clustering and phosphorylation in rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACID SPHINGOMYELINASE; RICH MEMBRANE RAFTS; NEUTRAL SPHINGOMYELINASE; HUMAN-FIBROBLASTS; BINDING-PROTEIN; LIPID RAFTS; RECEPTOR-II; DOMAINS; MICRODOMAINS; IDENTIFICATION	Despite the role of sphingolipid/cholesterol rafts as signaling platforms for Fcgamma receptor II (FcgammaRII), the mechanism governing translocation of an activated receptor toward the rafts is unknown. We show that at the onset of FcgammaRII cross-linking acid sphingomyelinase is rapidly activated. This enzyme is extruded from intracellular compartments to the cell surface, and concomitantly, exofacially oriented ceramide is produced. Both non-raft and, to a lesser extent, raft sphingomyelin pools were hydrolyzed at the onset of FcgammaRII cross-linking. The time course of ceramide production preceded the recruitment of FcgammaRII to rafts and the receptor phosphorylation. Exogenous C-16-ceramide facilitated clustering of FcgammaRII and its association with rafts. In contrast, inhibition of acid sphingomyelinase diminished both the ceramide generation and clustering of crosslinked FcgammaRII. Under these conditions, tyrosine phosphorylation of FcgammaRII and receptor-accompanying proteins was also reduced. All the inhibitory effects were bypassed by treatment of cells with exogenous ceramide. These data provide evidence that the generation of cell surface ceramide is a prerequisite for fusion of cross-linked FcgammaRII and rafts, which triggers the receptor tyrosine phosphorylation and signaling.	M Nencki Inst Expt Biol, Dept Cell Biol, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Sobota, A (corresponding author), M Nencki Inst Expt Biol, Dept Cell Biol, 3 Pasteur St, PL-02093 Warsaw, Poland.	a.sobota@nencki.gov.pl	Abdel shakor, Abo bakr/R-7133-2016; Kwiatkowska, Katarzyna/ABE-9713-2021	Abdel shakor, Abo bakr/0000-0003-2792-9066; Kwiatkowska, Katarzyna/0000-0002-0550-8394				Albrektsen T, 2001, BIOCHEM J, V359, P393, DOI 10.1042/0264-6021:3590393; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; FENG SS, 1995, BIOPHYS J, V69, P460, DOI 10.1016/S0006-3495(95)79919-2; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hauck CR, 2000, FEBS LETT, V478, P260, DOI 10.1016/S0014-5793(00)01851-2; Hinkovska-Galcheva V, 1998, BLOOD, V91, P4761, DOI 10.1182/blood.V91.12.4761.412k24_4761_4769; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Katsumata O, 2001, J IMMUNOL, V167, P5814, DOI 10.4049/jimmunol.167.10.5814; KOBAYASHI H, 2001, M RIKEN FRONT RES SY; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Korzeniowski M, 2003, BIOCHEMISTRY-US, V42, P5358, DOI 10.1021/bi027135x; Kwiatkowska K, 2003, J CELL SCI, V116, P537, DOI 10.1242/jcs.00254; Kwiatkowska K, 1999, CELL MOTIL CYTOSKEL, V42, P298, DOI 10.1002/(SICI)1097-0169(1999)42:4<298::AID-CM4>3.0.CO;2-Q; Kwiatkowska K, 2001, EUR J IMMUNOL, V31, P989, DOI 10.1002/1521-4141(200104)31:4<989::AID-IMMU989>3.0.CO;2-V; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lansmann S, 2003, EUR J BIOCHEM, V270, P1076, DOI 10.1046/j.1432-1033.2003.03435.x; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Romiti E, 2000, MOL CELL BIOCHEM, V205, P75, DOI 10.1023/A:1007041329052; Romiti E, 2001, FEBS LETT, V506, P163, DOI 10.1016/S0014-5793(01)02878-2; Segui B, 1999, J BIOL CHEM, V274, P37251, DOI 10.1074/jbc.274.52.37251; Shakor ABA, 2003, FEBS LETT, V542, P1, DOI 10.1016/S0014-5793(03)00330-2; Strzelecka-Kiliszek A, 2004, MOL MEMBR BIOL, V21, P101, DOI 10.1080/09687680310001639094; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; van Blitterswijk WJ, 1998, BIOCHEM J, V331, P679; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wilson BS, 2001, J CELL BIOL, V154, P645, DOI 10.1083/jcb.200104049; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; YOSHIDA Y, 1985, J BIOCHEM-TOKYO, V98, P1669, DOI 10.1093/oxfordjournals.jbchem.a135438; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	52	86	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36778	36787		10.1074/jbc.M402170200	http://dx.doi.org/10.1074/jbc.M402170200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194692	hybrid			2022-12-27	WOS:000223453600079
J	Tanida, I; Sou, YS; Ezaki, J; Minematsu-Ikeguchi, N; Ueno, T; Kominami, E				Tanida, I; Sou, YS; Ezaki, J; Minematsu-Ikeguchi, N; Ueno, T; Kominami, E			HsAtg4B/HsApg4B/autophagin-1 cleaves the carboxyl termini of three human Atg8 homologues and delipidates microtubule-associated protein light chain 3-and GABA(A) receptor-associated protein-phospholipid conjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT MODULATOR; ACTIVATING ENZYME; AUTOPHAGY; GATE-16; YEAST; GABARAP; CELL; DEGRADATION; MAP-LC3; APG7P/CVT2P	In yeast, Atg4/Apg4 is a unique cysteine protease responsible for the cleavage of the carboxyl terminus of Atg8/Apg8/Aut7, a reaction essential for its lipidation during the formation of autophagosomes. However, it is still unclear whether four human Atg4 homologues cleave the carboxyl termini of the three human Atg8 homologues, microtubule-associated protein light chain 3 (LC3), GABARAP, and GATE-16. Using a cell-free system, we found that HsAtg4B, one of the human Atg4 homologues, cleaves the carboxyl termini of these three Atg8 homologues. In contrast, the mutant HsAtg4B(C74A), in which a predicted active site Cys(74) was changed to Ala, lacked proteolytic activity, indicating that Cys(74) is essential for the cleavage activity of cysteine protease. Using phospholipase D, we showed that the modified forms of endogenous LC3 and GABARAP are lipidated and therefore were designated LC3-PL and GABARAP-PL. When purified glutathione S-transferase-tagged HsAtg4B was incubated in vitro with a membrane fraction enriched with endogenous LC3-PL and GABARAP-PL, the mobility of LC3-PL and GABARAP-PL was changed to those of the unmodified proteins. These mobility shifts were not seen when Cys(74) of HsAtg4B was changed to Ala. Overexpression of wild-type HsAtg4B decreased the amount of LC3-PL and GABARAP-PL and increased the amount of unmodified endogenous LC3 and GABARAP in HeLa cells. Expression of CFP-tagged HsAtg4B (CFP-HsAtg4B) and YFP-tagged LC3 in HeLa cells under starvation conditions resulted in a significant decrease in the punctate pattern of distribution of YFP-tagged LC3 and an increase in its cytoplasmic distribution. RNA interference of HsAtg4B increased the amount of LC3-PL in HEK293 cells. Taken together, these results suggest that HsAtg4B negatively regulates the localization of LC3 to a membrane compartment by delipidation.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	kominami@med.juntendo.ac.jp	Kominami, Eiki/D-3802-2009; Tanida, Isei/C-8277-2009	Sou, Yu-shin/0000-0002-7219-9106; Tanida, Isei/0000-0001-8999-3990				Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; HUAN W, 1999, MOL BIOL CELL, V10, P1353; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kadowaki M, 2003, J NUTR, V133, p2052S, DOI 10.1093/jn/133.6.2052S; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Mann SS, 1996, J NEUROSCI RES, V43, P535, DOI 10.1002/(SICI)1097-4547(19960301)43:5<535::AID-JNR3>3.0.CO;2-J; MANN SS, 1994, J BIOL CHEM, V269, P11492; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Nemoto T, 2003, J BIOL CHEM, V278, P39517, DOI 10.1074/jbc.M300550200; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Scherz-Shouval R, 2003, J BIOL CHEM, V278, P14053, DOI 10.1074/jbc.M212108200; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Thumm M, 2001, MOL GENET GENOMICS, V266, P657, DOI 10.1007/s004380100585; Thummel CS, 2001, BIOESSAYS, V23, P677, DOI 10.1002/bies.1096; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	35	271	288	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36268	36276		10.1074/jbc.M401461200	http://dx.doi.org/10.1074/jbc.M401461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15187094	hybrid			2022-12-27	WOS:000223453600015
J	Auguin, D; Barthe, P; Royer, C; Stern, MH; Noguchi, M; Arold, ST; Roumestand, C				Auguin, D; Barthe, P; Royer, C; Stern, MH; Noguchi, M; Arold, ST; Roumestand, C			Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; NMR-SPECTROSCOPY; PROLYMPHOCYTIC LEUKEMIA; SIGNAL-TRANSDUCTION; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; ONCOGENE PRODUCT; BETA-GAMMA; C-AKT	Chromosomal translocations leading to overexpression of p14(TCL1) and its homologue p13(MTCP1) are hallmarks of several human T-cell malignancies (1). p14(TCL1)/p13(MTCP1) co-activate protein kinase B (PKB, also named Akt) by binding to its pleckstrin homology (PH) domain, suggesting that p14(TCL1)/p13(MTCP1) induce T-cell leukemia by promoting anti-apoptotic signals via PKB (2,3). Here we combined fluorescence anisotropy, NMR, and small angle x-ray-scattering measurements to determine the affinities, molecular interfaces, and low resolution structure of the complex formed between PKBbeta-PH and p14(TCL1)/p13(MTCP1). We show that p14(TCL1)/p13(MTCP1) target PKB-PH at a site that has not yet been observed in PH-protein interactions. Located opposite the phospholipid binding pocket and distal from known protein-protein interaction sites on PH domains, the binding of dimeric TCL1 proteins to this site would allow the cross-linking of two PKB molecules at the cellular membrane in a preactivated conformation without disrupting certain PH-ligand interactions. Thus this interaction could serve to strengthen membrane association, promote trans-phosphorylation, hinder deactivation of PKB, and involve PKB in a multi-protein complex, explaining the array of known effects of TCL1. The binding sites on both proteins present attractive drug targets against leukemia caused by TCL1 proteins.	UM1, Fac Pharm, Ctr Biochim Struct, CNRS,UMR 5048,INSERM,UMR 554, F-34093 Montpellier 5, France; Inst Curie, Sect Rech, INSERM, U509, F-75248 Paris 5, France; Hokkaido Univ, Inst Med Genet, Div Canc Biol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Hokkaido University	Arold, ST (corresponding author), UM1, Fac Pharm, Ctr Biochim Struct, CNRS,UMR 5048,INSERM,UMR 554, BP14491,15 Ave Charles Flahault, F-34093 Montpellier 5, France.	stef@cbs.cnrs.fr; roume@cbs.cnrs.fr	Arold, Stefan/T-2612-2019; Stern, Marc-Henri/A-2728-2011; Auguin, Daniel/Y-2074-2019; Royer, Catherine A/E-5266-2016	Stern, Marc-Henri/0000-0002-8100-2272; Auguin, Daniel/0000-0003-4713-9096; Royer, Catherine A/0000-0002-2670-3391; Arold, Stefan T/0000-0001-5278-0668; Barthe, Philippe/0000-0003-4282-6604; ROUMESTAND, Christian/0000-0002-4082-3293				Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Auguin D, 2004, CR CHIM, V7, P265, DOI 10.1016/j.crci.2003.10.017; Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Auguin D, 2003, J BIOMOL NMR, V27, P287, DOI 10.1023/A:1025490109384; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; FU TB, 1994, CANCER RES, V54, P6297; Fu ZQ, 1998, P NATL ACAD SCI USA, V95, P3413, DOI 10.1073/pnas.95.7.3413; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; Guignard L, 2000, J BIOMOL NMR, V17, P215, DOI 10.1023/A:1008386110930; Hoh F, 1998, STRUCTURE, V6, P147, DOI 10.1016/S0969-2126(98)00017-3; Howard MJ, 2000, J MOL BIOL, V295, P1023, DOI 10.1006/jmbi.1999.3391; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MARKUS MA, 1994, PROTEIN SCI, V3, P70; Matsuo H, 1999, J AM CHEM SOC, V121, P9903, DOI 10.1021/ja991881g; McAlister MSB, 1996, BIOCHEMISTRY-US, V35, P5982, DOI 10.1021/bi952756u; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Narducci MG, 2002, P NATL ACAD SCI USA, V99, P11712, DOI 10.1073/pnas.182412399; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Pekarsky Y, 2001, JAMA-J AM MED ASSOC, V286, P2308, DOI 10.1001/jama.286.18.2308; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; ROGERS MT, 1962, J PHYS CHEM-US, V66, P540, DOI 10.1021/j100809a043; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; SKLENAR V, 1995, J MAGN RESON SER A, V114, P132, DOI 10.1006/jmra.1995.1119; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; STERN MH, 1993, ONCOGENE, V8, P2475; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; van den Heuvel APJ, 2002, J CELL SCI, V115, P3957, DOI 10.1242/jcs.00069; VANNULAND NAJ, 1993, FEBS LETT, V315, P11, DOI 10.1016/0014-5793(93)81122-G; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Wang LC, 2001, P NATL ACAD SCI USA, V98, P7684, DOI 10.1073/pnas.121069998; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang YS, 1998, J BIOMOL NMR, V11, P337, DOI 10.1023/A:1008279616063; ZUIDERWEG ERP, 1981, EUR J BIOCHEM, V118, P95, DOI 10.1111/j.1432-1033.1981.tb05490.x; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	64	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35890	35902		10.1074/jbc.M400364200	http://dx.doi.org/10.1074/jbc.M400364200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169787	hybrid			2022-12-27	WOS:000223303400090
J	Niwa, R; Matsuda, T; Yoshiyama, T; Namiki, T; Mita, K; Fujimoto, Y; Kataoka, H				Niwa, R; Matsuda, T; Yoshiyama, T; Namiki, T; Mita, K; Fujimoto, Y; Kataoka, H			CYP306A1, a cytochrome P450 enzyme, is essential for ecdysteroid biosynthesis in the prothoracic glands of Bombyx and Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P450 ENZYMES; WING DISCS; ECDYSONE; GENES; MORPHOGENESIS; EXPRESSION; MELANOGASTER; SEQUENCES; SILKWORM; INSECTS	Ecdysteroids mediate a wide variety of developmental and physiological events in insects. In the postembryonic development of insects, ecdysone is synthesized in the prothoracic gland (PG). Although many studies have revealed the biochemical and physiological properties of the enzymes for ecdysteroid biosynthesis, most of the molecular identities of these enzymes have not been elucidated. Here we describe an uncharacterized cytochrome P450 gene, designated Cyp306a1, that is essential for ecdysteroid biosynthesis in the PGs of the silkworm Bombyx mori and fruit fly Drosophila melanogaster. Using the microarray technique for analyzing gene expression profiles in PG cells during Bombyx development, we identified two PG-specific P450 genes whose temporal expression patterns are correlated with changes in ecdysteroid titer during development. Amino acid sequence analysis showed that one of the Bombyx P450 genes belongs to the CYP306A1 subfamily. The temporal and spatial expression pattern of the Drosophila Cyp306a1 homolog is essentially the same as that of Bombyx Cyp306a1. We also found that Drosophila Cyp306a1 is disrupted in the phantom (phm) mutant, known also as the Halloween mutant. The morphological defects and decreased expression of ecdysone-inducible genes in phm suggest that this mutant cannot produce a high titer of ecdysone. Finally we demonstrate that S2 cells transfected with Cyp306a1 convert ketodiol to ketotriol via carbon 25 hydroxylation. These results strongly suggest that CYP306A1 functions as a carbon 25 hydroxylase and has an essential role in ecdysteroid biosynthesis during insect development.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan; Tokyo Inst Technol, Dept Chem & Mat Sci, Meguro Ku, Tokyo 1528551, Japan; Natl Inst Agrobiol Sci, Lab Insect Genome, Tsukuba, Ibaraki 3058643, Japan	University of Tokyo; Tokyo Institute of Technology; National Institute of Agrobiological Sciences - Japan	Niwa, R (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Rm 201,5-1-5 Kashiwanoha, Chiba 2778562, Japan.	rniwa@k.u-tokyo.ac.jp; kataoka@k.u-tokyo.ac.jp						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; BOLLENBACHER WE, 1977, STEROIDS, V29, P47, DOI 10.1016/0039-128X(77)90108-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buszczak M, 1999, DEVELOPMENT, V126, P4581; Casso D, 2000, MECH DEVELOP, V91, P449; Charles JP, 1999, EUR J BIOCHEM, V266, P181, DOI 10.1046/j.1432-1327.1999.00842.x; Chavez VM, 2000, DEVELOPMENT, V127, P4115; Feyereisen R, 1999, ANNU REV ENTOMOL, V44, P507, DOI 10.1146/annurev.ento.44.1.507; Freeman MR, 1999, DEVELOPMENT, V126, P4591; Gilbert LI, 2004, MOL CELL ENDOCRINOL, V215, P1, DOI 10.1016/j.mce.2003.11.003; Gilbert LI, 2002, ANNU REV ENTOMOL, V47, P883, DOI 10.1146/annurev.ento.47.091201.145302; GRIENEISEN ML, 1994, INSECT BIOCHEM MOLEC, V24, P115, DOI 10.1016/0965-1748(94)90078-7; HAAG T, 1987, INSECT BIOCHEM, V17, P291, DOI 10.1016/0020-1790(87)90071-0; HAAG T, 1988, J CHEM SOC PERK T 1, P2353, DOI 10.1039/p19880002353; Harvie PD, 1998, GENETICS, V149, P217; KAPPLER C, 1988, J STEROID BIOCHEM, V31, P891, DOI 10.1016/0022-4731(88)90330-5; Koyama T, 2004, J INSECT PHYSIOL, V50, P123, DOI 10.1016/j.jinsphys.2003.09.009; Kusano K, 2001, J BIOCHEM, V129, P259, DOI 10.1093/oxfordjournals.jbchem.a002853; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; MAROY P, 1988, J INSECT PHYSIOL, V34, P633, DOI 10.1016/0022-1910(88)90071-6; Matsuoka T, 2000, DEV GENES EVOL, V210, P120, DOI 10.1007/s004270050018; Mita K, 2003, P NATL ACAD SCI USA, V100, P14121, DOI 10.1073/pnas.2234984100; Mizoguchi A, 2001, INSECT BIOCHEM MOLEC, V31, P349, DOI 10.1016/S0965-1748(00)00127-2; NAGAKARI M, 1994, J CHEM SOC CHEM COMM, P1761, DOI 10.1039/c39940001761; NATZLE JE, 1992, DEV GENET, V13, P331, DOI 10.1002/dvg.1020130504; NATZLE JE, 1986, J BIOL CHEM, V261, P5575; NATZLE JE, 1988, DEV BIOL, V129, P428, DOI 10.1016/0012-1606(88)90390-9; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Noji T, 2003, INSECT BIOCHEM MOLEC, V33, P671, DOI 10.1016/S0965-1748(03)00048-1; Omura T., 1993, CYTOCHROME P 450; Petryk A, 2003, P NATL ACAD SCI USA, V100, P13773, DOI 10.1073/pnas.2336088100; Poulson D. F., 1945, TRANS CONNECTICUT ACAD ARTS AND SCI, V36, P449; REES HH, 1995, EUR J ENTOMOL, V92, P9; Riddiford Lynn M., 1993, P899; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Roth GE, 2004, P NATL ACAD SCI USA, V101, P1601, DOI 10.1073/pnas.0308212100; Sakurai S, 1998, J INSECT PHYSIOL, V44, P867, DOI 10.1016/S0022-1910(98)00075-4; STAPLETON M, 2002, GENOME BIOL; Takeuchi H, 2002, FEBS LETT, V513, P230, DOI 10.1016/S0014-5793(02)02319-0; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Thummel CS, 2001, DEV CELL, V1, P453, DOI 10.1016/S1534-5807(01)00060-0; Tijet N, 2001, GENE, V262, P189, DOI 10.1016/S0378-1119(00)00533-3; Tsruya R, 2002, GENE DEV, V16, P222, DOI 10.1101/gad.214202; Venkatesh K, 1997, CURR BIOL, V7, P500, DOI 10.1016/S0960-9822(06)00221-1; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; Wieschaus E., 1998, DROSOPHILA PRACTICAL, P179; [No title captured]	49	218	231	5	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35942	35949		10.1074/jbc.M404514200	http://dx.doi.org/10.1074/jbc.M404514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15197185	hybrid			2022-12-27	WOS:000223303400095
J	Taron, BW; Colussi, PA; Wiedman, JM; Orlean, P; Taron, CH				Taron, BW; Colussi, PA; Wiedman, JM; Orlean, P; Taron, CH			Human Smp3p adds a fourth mannose to yeast and human glycosylphosphatidylinositol precursors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOINOSITOL PHOSPHOLIPID ANCHOR; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; GPI-ANCHOR; MEMBRANE ANCHORS; 3RD MANNOSE; TRANSFERRING PHOSPHOETHANOLAMINE; STRUCTURAL-CHARACTERIZATION; CORE STRUCTURE	Yeast and human glycosylphosphatidylinositol (GPI) precursors differ in the extent to which a fourth mannose is present as a side branch of the third core mannose. A fourth mannose addition to GPIs has scarcely been detected in studies of mammalian GPI synthesis but is an essential step in the Saccharomyces cerevisiae pathway. We report that human SMP3 encodes a functional homolog of the yeast Smp3 GPI fourth mannosyltransferase. Expression of hSMP3 in yeast complements growth and biochemical defects of smp3 mutants and permits in vivo mannosylation of trimannosyl (Man(3))-GPIs. Immunolocalization shows that hSmp3p resides in the endoplasmic reticulum in human cells. Northern analysis of mRNA from human tissues and cell lines indicates that hSMP3 is expressed in most tissues, with the highest levels in brain and colon, but its mRNA is nearly absent from cultured human cell lines. Correspondingly, increasing expression of hSMP3 in cultured HeLa cells causes abundant formation of three putative tetramannosyl (Man(4))-GPIs. Our data indicate that hSmp3p functions as a mannosyltransferase that adds a fourth mannose to certain Man(3)-GPIs during biosynthesis of the human GPI precursor, and suggest it may do so in a tissue-specific manner.	New England Biolabs Inc, Beverly, MA 01915 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Taron, CH (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	taron@neb.com		Taron, Christopher/0000-0001-8149-4556	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann NA, 2000, J BIOL CHEM, V275, P7378, DOI 10.1074/jbc.275.10.7378; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DEEG MA, 1992, J BIOL CHEM, V267, P18573; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grimme SJ, 2001, J BIOL CHEM, V276, P27731, DOI 10.1074/jbc.M101986200; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; MUKASA R, 1995, ARCH BIOCHEM BIOPHYS, V318, P182, DOI 10.1006/abbi.1995.1219; NAKANO Y, 1994, ARCH BIOCHEM BIOPHYS, V311, P117, DOI 10.1006/abbi.1994.1216; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1992, J BIOL CHEM, V267, P22673; REDMAN CA, 1994, BIOCHEM J, V302, P861, DOI 10.1042/bj3020861; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; Sutterlin C, 1998, BIOCHEM J, V332, P153; TAGUCHI R, 1994, BIOCHEMISTRY-US, V33, P1017, DOI 10.1021/bi00170a021; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; Taron CH, 2000, MOL BIOL CELL, V11, P1611, DOI 10.1091/mbc.11.5.1611; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; UEDA E, 1993, J BIOL CHEM, V268, P9998; Vainauskas S, 2004, J BIOL CHEM, V279, P6540, DOI 10.1074/jbc.M312191200; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	44	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36083	36092		10.1074/jbc.M405081200	http://dx.doi.org/10.1074/jbc.M405081200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208306	hybrid			2022-12-27	WOS:000223303400110
J	Zhang, H; Shi, XQ; Paddon, H; Hampong, M; Dai, W; Pelech, S				Zhang, H; Shi, XQ; Paddon, H; Hampong, M; Dai, W; Pelech, S			B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; CENTROSOME DUPLICATION; SCHIZOSACCHAROMYCES-POMBE; SPINDLE POLES; CANCER-CELLS; PLK1; CYTOKINESIS; ACTIVATION; NUCLEOPHOSMIN; INHIBITION	Phosphoprotein profiling by Kinetworks(TM) analysis of M-phase-arrested HeLa cells by nocodazole treatment revealed that a novel mitosis-specific phosphorylation event occurred in the nucleolar protein B23/nucleophosmin at a conserved Ser-4 residue. Consistent with the resemblance of the Ser-4 phosphorylation site to the Polo-like kinase 1 (Plk1) consensus recognition sequence, inhibition of Plk1 by a kinase-defective mutation (K82M) abrogated B23 Ser-4 phosphorylation, whereas activation of Plk1 by a constitutively active mutation (T210D) enhanced its phosphorylation following in vivo transfection and in vitro phosphorylation assays. Depletion of endogenous Plk1 by RNA interference abolished B23 Ser-4 phosphorylation. The physical interaction of Plk1 and B23 was further demonstrated by their co-immunoprecipitation and glutathione S-transferase fusion protein pull-down assays. Interference of Ser-4 phosphorylation of B23 induced multiple mitotic defects in HeLa cells, including aberrant numbers of centrosomes, elongation and fragmentation of nuclei, and incomplete cytokinesis. The phenotypes of B23 mutants are reminiscent of a subset of those described previously in Plk1 mutants. Our findings provide insights into the biochemical mechanism underlying the role of Plk1 in mitosis regulation through the identification of Ser-4 in B23 as a major physiological substrate of Plk1.	Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	University of British Columbia; University of British Columbia; New York Medical College	Pelech, S (corresponding author), Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z3, Canada.	spelech@kinexus.ca						Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Donaldson MM, 2001, J CELL SCI, V114, P2357; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; KINTER M, 2000, PROTEIN SEQUENCING I, P147, DOI DOI 10.1002/0471721980; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Leung GC, 2003, CELL, V115, P3, DOI 10.1016/S0092-8674(03)00761-X; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Okano-Uchida T, 2003, EMBO J, V22, P5633, DOI 10.1093/emboj/cdg535; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Pelech Steven, 2003, Methods Mol Biol, V218, P99; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zatsepina OV, 1999, J CELL SCI, V112, P455; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	52	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35726	35734		10.1074/jbc.M403264200	http://dx.doi.org/10.1074/jbc.M403264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190079	hybrid			2022-12-27	WOS:000223303400071
J	Moon, SK; Kim, HM; Lee, YC; Kim, CH				Moon, SK; Kim, HM; Lee, YC; Kim, CH			Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNALING TRANSDUCTION PATHWAY; MONOCLONAL-ANTIBODY; MALIGNANT-MELANOMA; MOLECULAR-CLONING; GANGLIOSIDES GM1; KINASE-ACTIVITY; GROWTH; PROLIFERATION; ATHEROSCLEROSIS	Sialic acid-containing glycosphingolipids (gangliosides) have been implicated in the regulation of various biological phenomena such as atherosclerosis. Recent report suggests that exogenously supplied disialoganglioside (GD3) serves a dual role in vascular smooth muscle cells (VSMC) proliferation and apoptosis. However, the role of the GD3 synthase gene in VSMC responses has not yet been elucidated. To determine whether a ganglioside is able to modulate VSMC growth, the effect of overexpression of the GD3 synthase gene on DNA synthesis was examined. The results show that the overexpression of this gene has a potent inhibitory effect on DNA synthesis and ERK phosphorylation in cultured VSMC in the presence of PDGF. The suppression of the GD3 synthase gene was correlated with the down-regulation of cyclinE/CDK2, the up-regulation of the CDK inhibitor p21 and blocking of the p27 inhibition, whereas up-regulation of p53 as the result of GD3 synthase gene expression was not observed. Consistently, blockade of GD3 function with anti-GD3 antibody reversed VSMC proliferation and cell cycle proteins. The expression of the GD3 synthase gene also led to the inhibition of TNF-alpha-induced matrix metalloproteinase-9 (MMP-9) expression in VSMC as determined by zymography and immunoblot. Furthermore, GD3 synthase gene expression strongly decreased MMP-9 promoter activity in response to TNF-alpha. This inhibition was characterized by the downregulation of MMP-9, which was transcriptionally regulated at NF-kappaB and activation protein-1 (AP-1) sites in the MMP-9 promoter. Finally, the overexpression of MMP-9 in GD3 synthase transfectant cells rescued VSMC proliferation. However, MMP-2 overexpression was not affected by cell proliferation. These findings suggest that the GD3 synthase gene represents a physiological modulator of VSMC responses that may contribute to plaque instability in atherosclerosis.	Dongguk Univ, Coll Oriental Med, Minist Sci & Technol, NRL Glycobiol, Kyungju 780714, Kyungbuk, South Korea; Dongguk Univ, Coll Oriental Med, Dept Biochem & Mol Biol, Kyungju 780714, Kyungbuk, South Korea; Dong A Univ, Fac Biotechnol, Pusan 604714, South Korea	Dongguk University; Dongguk University; Dong A University	Kim, CH (corresponding author), Dongguk Univ, Coll Oriental Med, Minist Sci & Technol, NRL Glycobiol, Sukjang Dong 707, Kyungju 780714, Kyungbuk, South Korea.	chkimbio@dongguk.ac.kr		Kim, Cheorl-Ho/0000-0002-6323-0714				Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; CHANG HR, 1992, CANCER, V70, P633, DOI 10.1002/1097-0142(19920801)70:3<633::AID-CNCR2820700315>3.0.CO;2-F; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Furukawa K., 1990, HUMAN MELANOMA BASIC, P15; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HAMILTON WB, 1993, INT J CANCER, V53, P566, DOI 10.1002/ijc.2910530407; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; Kim KW, 2001, GENE, V273, P163, DOI 10.1016/S0378-1119(01)00595-9; Kim SW, 2002, BBA-GENE STRUCT EXPR, V1578, P84, DOI 10.1016/S0167-4781(02)00505-5; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; Kim YJ, 1997, BIOCHEM BIOPH RES CO, V235, P327, DOI 10.1006/bbrc.1997.6725; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maria R.D., 1997, SCIENCE, V277, P1652; Moon SK, 2003, BIOCHEM BIOPH RES CO, V301, P1069, DOI 10.1016/S0006-291X(03)00091-3; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Moon SK, 2003, FEBS LETT, V552, P130, DOI 10.1016/S0014-5793(03)00935-9; Moon SK, 2001, AM J PHYSIOL-HEART C, V280, pH2779, DOI 10.1152/ajpheart.2001.280.6.H2779; MUKHIN DN, 1995, ARTERIOSCL THROM VAS, V15, P1607, DOI 10.1161/01.ATV.15.10.1607; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; Nakamura K, 1999, CANCER RES, V59, P5323; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sachinidis A, 1996, EUR J CELL BIOL, V71, P79; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHINOURA N, 1992, NEUROSURGERY, V31, P541, DOI 10.1227/00006123-199209000-00017; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUCHIDA T, 1987, J NATL CANCER I, V78, P45, DOI 10.1093/jnci/78.1.45; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang SL, 1997, INT J CANCER, V73, P50, DOI 10.1002/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.3.CO;2-O	50	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33063	33070		10.1074/jbc.M313462200	http://dx.doi.org/10.1074/jbc.M313462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175338	hybrid			2022-12-27	WOS:000223039700007
J	Vertegaal, ACO; Ogg, SC; Jaffray, E; Rodriguez, MS; Hay, RT; Andersen, JS; Mann, M; Lamond, AI				Vertegaal, ACO; Ogg, SC; Jaffray, E; Rodriguez, MS; Hay, RT; Andersen, JS; Mann, M; Lamond, AI			A proteomic study of SUMO-2 target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; CONJUGATING ENZYME; SUBSTRATE RECOGNITION; E3 LIGASE; NUCLEAR; RANGAP1; SENTRIN; IDENTIFICATION; COMPLEX	The SUMO family in vertebrates includes at least three distinct proteins ( SUMO-1, -2, and -3) that are added as post-translational modifications to target proteins. A considerable number of SUMO-1 target proteins have been identified, but little is known about SUMO-2. A stable HeLa cell line expressing His(6)-tagged SUMO-2 was established and used to label and purify novel endogenous SUMO-2 target proteins. Tagged forms of SUMO-2 were functional and localized predominantly in the nucleus. His(6)-tagged SUMO-2 conjugates were affinity-purified from nuclear fractions and identified by mass spectrometry. Eight novel potential SUMO-2 target proteins were identified by at least two peptides. Three of these proteins, SART1, heterogeneous nuclear ribonucleoprotein (RNP) M, and the U5 small nuclear RNP 200-kDa helicase, play a role in RNA metabolism. SART1 and heterogeneous nuclear RNP M were both shown to be genuine SUMO targets, confirming the validity of the approach.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark	University of Dundee; University of St Andrews; University of Southern Denmark	Lamond, AI (corresponding author), Univ Dundee, Wellcome Trust Bioctr, MSI WTB Complex, Dundee DD1 5EH, Scotland.	a.i.lamond@dundee.ac.uk	Andersen, Jens S/L-2100-2015; Hay, Ronald/S-3233-2019; Vertegaal, Alfred CO/Y-3875-2018; Hay, Ronald T/F-9338-2011; Vertegaal, Alfred/ABG-8141-2021; Mann, Matthias/A-3454-2013	Andersen, Jens S/0000-0002-6091-140X; Hay, Ronald/0000-0001-7113-9024; Vertegaal, Alfred CO/0000-0002-7989-0493; Hay, Ronald T/0000-0001-7113-9024; Vertegaal, Alfred/0000-0002-7989-0493; Mann, Matthias/0000-0003-1292-4799; Lamond, Angus/0000-0001-6204-6045; Ogg, Stephen/0000-0003-4157-1654	MRC [G0301131] Funding Source: UKRI; Medical Research Council [G0301131] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Boddy MN, 1996, ONCOGENE, V13, P971; Ciechanover A, 2002, HEPATOLOGY, V35, P3, DOI 10.1053/jhep.2002.30316; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Gattoni R, 1996, NUCLEIC ACIDS RES, V24, P2535, DOI 10.1093/nar/24.13.2535; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Jones D, 2002, GENOME BIOL, V3; Joseph J, 2002, J CELL BIOL, V156, P595, DOI 10.1083/jcb.200110109; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Tatham MH, 2003, BIOCHEMISTRY-US, V42, P3168, DOI 10.1021/bi026861x; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	72	172	188	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33791	33798		10.1074/jbc.M404201200	http://dx.doi.org/10.1074/jbc.M404201200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175327	hybrid			2022-12-27	WOS:000223039700088
J	Leslie, EM; Haimeur, A; Waalkes, MP				Leslie, EM; Haimeur, A; Waalkes, MP			Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1) - Evidence that a tri-glutathione conjugate is required	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE PHOSPHORYLASE; S-TRANSFERASE-PI; ORGANIC ANION TRANSPORT; CHARGED AMINO-ACIDS; SUBSTRATE-SPECIFICITY; MEMBRANE-VESICLES; TUMOR-CELLS; PHARMACOKINETIC MODEL; VINCRISTINE TRANSPORT; MONOCLONAL-ANTIBODIES	Inorganic arsenic is an established human carcinogen, but its metabolism is incompletely defined. The ATP binding cassette protein, multidrug resistance protein (MRP1/ABCC1), transports conjugated organic anions (e.g. leukotriene C-4) and also co-transports certain unmodified xenobiotics ( e. g. vincristine) with glutathione (GSH). MRP1 also confers resistance to arsenic in association with GSH; however, the mechanism and the species of arsenic transported are unknown. Using membrane vesicles prepared from the MRP1-overexpressing lung cancer cell line, H69AR, we found that MRP1 transports arsenite (As-III) only in the presence of GSH but does not transport arsenate (As-V) ( with or without GSH). The non-reducing GSH analogs L-gamma-glutamyl-L-alpha-aminobutyryl glycine and S-methyl GSH did not support AsIII transport, indicating that the free thiol group of GSH is required. GSH-dependent transport of As-III was 2-fold higher at pH 6.5-7 than at a more basic pH, consistent with the formation and transport of the acid-stable arsenic triglutathione (As(GS)(3)). Immunoblot analysis of H69AR vesicles revealed the unexpected membrane association of GSH S-transferase P1-1 (GSTP1-1). Membrane vesicles from an MRP1-transfected HeLa cell line lacking membrane-associated GSTP1-1 did not transport AsIII even in the presence of GSH but did transport synthetic As(GS)(3). The addition of exogenous GSTP1-1 to HeLa-MRP1 vesicles resulted in GSH-dependent AsIII transport. The apparent K-m of As(GS)(3) for MRP1 was 0.32 muM, suggesting a remarkably high relative affinity. As(GS)(3) transport by MRP1 was osmotically sensitive and was inhibited by several conjugated organic anions ( MRP1 substrates) as well as the metalloid antimonite (K-i 2.8 muM). As(GS) 3 transport experiments using MRP1 mutants with substrate specificities differing from wild-type MRP1 suggested a commonality in the substrate binding pockets of As(GS)(3) and leukotriene C-4. Finally, human MRP2 also transported As(GS)(3). In conclusion, MRP1 transports inorganic arsenic as a tri-GSH conjugate, and GSTP1-1 may have a synergistic role in this process.	NIEHS, Inorgan Carcinogenesis Sect, Comparat Carcinogenesis Lab, NCI,NIH, Res Triangle Pk, NC 27709 USA; Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS); Queens University - Canada	Waalkes, MP (corresponding author), NIEHS, Inorgan Carcinogenesis Sect, Comparat Carcinogenesis Lab, NCI,NIH, POB 12233,Mail Drop F0-09,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	waalkes@niehs.nih.gov		Leslie, Elaine/0000-0003-1825-348X	NATIONAL CANCER INSTITUTE [ZIABC005488, Z01BC005488] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; AliOsman F, 1997, J BIOL CHEM, V272, P10004; Aposhian HV, 2003, TOXICOL APPL PHARM, V193, P1, DOI 10.1016/S0041-008X(03)00324-7; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008; DELNOMDEDIEU M, 1994, CHEM-BIOL INTERACT, V90, P139, DOI 10.1016/0009-2797(94)90099-X; Depeille P, 2004, MOL PHARMACOL, V65, P897, DOI 10.1124/mol.65.4.897; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1994, J BIOL CHEM, V269, P25442; Flens MJ, 1996, AM J PATHOL, V148, P1237; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; Gomez-Caminero A. P., 2001, ENV HLTH CRITERIA, V224; Gregus Z, 2002, TOXICOL SCI, V70, P13, DOI 10.1093/toxsci/70.1.13; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; GYURASICS A, 1991, BIOCHEM PHARMACOL, V42, P465, DOI 10.1016/0006-2952(91)90306-P; Haimeur A, 2004, MOL PHARMACOL, V65, P1375, DOI 10.1124/mol.65.6.1375; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Hemachand T, 2002, J CELL SCI, V115, P2053; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; Kala SV, 2004, CHEM RES TOXICOL, V17, P243, DOI 10.1021/tx0342060; Kala SV, 2000, J BIOL CHEM, V275, P33404, DOI 10.1074/jbc.M007030200; Kumana CR, 2002, EUR J CLIN PHARMACOL, V58, P521, DOI 10.1007/s00228-002-0514-x; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2003, BIOCHEMISTRY-US, V42, P5214, DOI 10.1021/bi027076n; Leslie EM, 2003, J PHARMACOL EXP THER, V304, P643, DOI 10.1124/jpet.102.044073; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; LO JF, 1992, BIOCHEM J, V288, P977, DOI 10.1042/bj2880977; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Lorico A, 2002, BIOCHEM BIOPH RES CO, V291, P617, DOI 10.1006/bbrc.2002.6489; Lorico A, 1997, CANCER RES, V57, P5238; Mann S, 1996, TOXICOL APPL PHARM, V140, P471, DOI 10.1006/taap.1996.0244; Mann S, 1996, TOXICOL APPL PHARM, V137, P8, DOI 10.1006/taap.1996.0052; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Marnell LL, 2003, CHEM RES TOXICOL, V16, P1507, DOI 10.1021/tx034149a; MORGENSTERN R, 1983, FEBS LETT, V160, P264, DOI 10.1016/0014-5793(83)80979-X; Nemeti B, 2003, TOXICOL SCI, V74, P22, DOI 10.1093/toxsci/kfg116; O'Brien ML, 1999, J PHARMACOL EXP THER, V291, P1348; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Radabaugh TR, 2002, CHEM RES TOXICOL, V15, P692, DOI 10.1021/tx0101853; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Rinaldi R, 2002, DRUG METAB DISPOS, V30, P1053, DOI 10.1124/dmd.30.10.1053; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Salerno M, 2002, J BIOENERG BIOMEMBR, V34, P135, DOI 10.1023/A:1015180026665; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Singh SP, 2002, J BIOL CHEM, V277, P4232, DOI 10.1074/jbc.M109678200; Smitherman PK, 2004, J PHARMACOL EXP THER, V308, P260, DOI 10.1124/jpet.103.057729; STYBLO M, 1995, BIOCHEM PHARMACOL, V49, P971, DOI 10.1016/0006-2952(95)00008-N; Vernhet L, 1999, FEBS LETT, V443, P321, DOI 10.1016/S0014-5793(98)01716-5; Vernhet L, 2000, TOXICOLOGY, V142, P127; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886	67	196	209	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32700	32708		10.1074/jbc.M404912200	http://dx.doi.org/10.1074/jbc.M404912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161912	hybrid			2022-12-27	WOS:000222849700089
J	Rao, KVR; Norenberg, MD				Rao, KVR; Norenberg, MD			Manganese induces the mitochondrial permeability transition in cultured astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; RAT-BRAIN; CALCIUM-TRANSPORT; INDUCED APOPTOSIS; CELL-DEATH; PORE; NEUROTOXICITY; TOXICITY; MODULATION; INHIBITION	Manganese is known to cause central nervous system injury leading to parkinsonism and to contribute to the pathogenesis of hepatic encephalopathy. Although mechanisms of manganese neurotoxicity are not completely understood, chronic exposure of various cell types to manganese has shown oxidative stress and mitochondrial energy failure, factors that are often implicated in the induction of the mitochondrial permeability transition (MPT). In this study, we examined whether exposure of cultured neurons and astrocytes to manganese induces the MPT. Cells were treated with manganese acetate (10-100 muM), and the MPT was assessed by changes in the mitochondrial membrane potential and in mitochondrial calcein fluorescence. In astrocytes, manganese caused a dissipation of the mitochondrial membrane potential and decreased the mitochondrial calcein fluorescence in a concentration- and time-dependent manner. These changes were completely blocked by pretreatment with cyclosporin A, consistent with induction of the MPT. On the other hand, similarly treated cultured cortical neurons had a delayed or reduced MPT as compared with astrocytes. The manganese-induced MPT in astrocytes was blocked by pretreatment with antioxidants, suggesting the potential involvement of oxidative stress in this process. Induction of the MPT by manganese and associated mitochondrial dysfunction in astrocytes may represent key mechanisms in manganese neurotoxicity.	Vet Affairs Med Ctr, Miami, FL 33125 USA; Univ Miami, Sch Med, Dept Pathol, Miami, FL 33125 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33125 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; University of Miami	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu			NIDDK NIH HHS [DK063311] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063311] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLSHIRE A, 1985, BIOCHIM BIOPHYS ACTA, V807, P202, DOI 10.1016/0005-2728(85)90123-9; ASCHNER M, 1992, J NEUROCHEM, V58, P730, DOI 10.1111/j.1471-4159.1992.tb09778.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BLOKHUIS GG, 1970, FEBS LETT, V11, P197, DOI 10.1016/0014-5793(70)80527-0; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Chen CJ, 2002, EXP NEUROL, V175, P216, DOI 10.1006/exnr.2002.7894; Chen JY, 2001, TOXICOL APPL PHARM, V175, P160, DOI 10.1006/taap.2001.9245; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; DESOLE MS, 1995, NEUROSCI LETT, V192, P73, DOI 10.1016/0304-3940(95)11613-2; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gavin CE, 1999, NEUROTOXICOLOGY, V20, P445; GAVIN CE, 1992, TOXICOL APPL PHARM, V115, P1, DOI 10.1016/0041-008X(92)90360-5; GAVIN CE, 1990, BIOCHEM J, V266, P329, DOI 10.1042/bj2660329; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HaMai D, 2001, FREE RADICAL BIO MED, V31, P763, DOI 10.1016/S0891-5849(01)00639-6; Hazell AS, 1997, NEUROCHEM RES, V22, P1443, DOI 10.1023/A:1021994126329; HERTZ L, 1989, NEUROCHEM RES, V14, P755, DOI 10.1007/BF00964954; Higuchi H, 2001, HEPATOLOGY, V34, P320, DOI 10.1053/jhep.2001.26380; Jou MJ, 2002, J BIOMED SCI, V9, P507; Kaiser J, 2003, SCIENCE, V300, P927, DOI 10.1126/science.300.5621.927; Kaiser J, 2003, SCIENCE, V300, P926, DOI 10.1126/science.300.5621.926; Kerr PM, 1999, AM J PHYSIOL-HEART C, V276, pH496, DOI 10.1152/ajpheart.1999.276.2.H496; KREIGER D, 1995, LANCET, V346, P270; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; Norenberg MD, 2003, ENCEPHALOPATHY AND NITROGEN METABOLISM IN LIVER FAILURE, P267; Olanow CW, 1996, NEUROLOGY, V46, P492, DOI 10.1212/WNL.46.2.492; Pal PK, 1999, NEUROTOXICOLOGY, V20, P227; PENTSCHEW A, 1963, J NEUROPATH EXP NEUR, V22, P488, DOI 10.1097/00005072-196307000-00010; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; POMIERLAYRARGUES G, 1995, LANCET, V345, P735, DOI 10.1016/S0140-6736(95)90909-5; Rao KVR, 2003, NEUROCHEM INT, V43, P517, DOI 10.1016/S0197-0186(03)00042-1; Rao KVR, 2003, METAB BRAIN DIS, V18, P113, DOI 10.1023/A:1023858902184; Reichert SA, 2001, J NEUROSCI, V21, P6608, DOI 10.1523/JNEUROSCI.21-17-06608.2001; Roth JA, 2002, J NEUROSCI RES, V68, P76, DOI 10.1002/jnr.10207; Spranger M, 1998, EXP NEUROL, V149, P277, DOI 10.1006/exnr.1997.6666; SUAREZ N, 1993, J NEUROCHEM, V61, P127, DOI 10.1111/j.1471-4159.1993.tb03546.x; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; SUN AY, 1993, ANN NY ACAD SCI, V679, P358; Takeda A, 2003, BRAIN RES REV, V41, P79, DOI 10.1016/S0165-0173(02)00234-5; THOLEY G, 1987, NEUROCHEM RES, V12, P45; Verity MA, 1999, NEUROTOXICOLOGY, V20, P489; WEDLER FC, 1989, NEUROCHEM RES, V14, P1129, DOI 10.1007/BF00965619; WEDLER FC, 1986, MANGANESE METABOLISM, P221; Zhang SR, 2004, TOXICOL IN VITRO, V18, P71, DOI 10.1016/j.tiv.2003.09.002; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	88	88	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32333	32338		10.1074/jbc.M402096200	http://dx.doi.org/10.1074/jbc.M402096200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173181	hybrid			2022-12-27	WOS:000222849700044
J	Rahn, JJ; Shen, Q; Mah, BK; Hugh, JC				Rahn, JJ; Shen, Q; Mah, BK; Hugh, JC			MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; PROTEIN-KINASE-C; BETA-CATENIN; TYROSINE PHOSPHORYLATION; BREAST-CANCER; CYTOPLASMIC DOMAIN; CELL-ADHESION; SRC	The MUC1 mucin is normally restricted to the apical surface of breast epithelial cells. In tumors, it is frequently overexpressed and underglycosylated. The MUC1 peptide core mediates firm adhesion of tumor cells to adjacent cells via binding to intercellular adhesion molecule-1 (ICAM-1). There is increasing evidence that MUC1 is involved in signaling, with current reports focusing on phosphorylation of the MUC1 cytoplasmic tail after indirect or artificial modes of stimulation. ICAM-1 is the only known direct ligand of the MUC1 extracellular domain. The data presented herein show that MUC1 expressed on the surface of breast cancer cell lines or transfected 293T cells can initiate a calcium-based oscillatory signal on contact with ICAM-1-transfected NIH 3T3 cells, and we present a novel method of quantifying and comparing calcium oscillations. The MUC1-induced signal appears to be distinct from those previously described, and may involve a Src family kinase, phosphoinositol 3-kinase, phospholipase C, and lipid rafts, but not mitogen-activated protein kinase. As calcium signaling has been associated with cytoskeletal change and motility, it is possible that the functions of MUC1 include heterotypic cell-cell adhesion followed by a calcium-based promigratory signal within tumor cells, thus facilitating metastasis.	Univ Alberta, Cross Canc Inst, Dept Lab Med & Pathol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Hugh, JC (corresponding author), Univ Alberta, Cross Canc Inst, Dept Lab Med & Pathol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	judith.hugh@cancerboard.ab.ca						Bodin S, 2003, THROMB HAEMOSTASIS, V89, P318, DOI 10.1055/s-0037-1613449; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; HORNE G, 1999, THESIS U ALBERTA EDM; Hur EM, 2004, J BIOL CHEM, V279, P5852, DOI 10.1074/jbc.M311687200; Kam JL, 1998, CANCER RES, V58, P5577; Kiely JM, 2003, J IMMUNOL, V171, P3216, DOI 10.4049/jimmunol.171.6.3216; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Meerzaman D, 2000, AM J PHYSIOL-LUNG C, V278, pL625, DOI 10.1152/ajplung.2000.278.3.L625; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Oosawa Y, 1997, CELL BIOCHEM FUNCT, V15, P113, DOI 10.1002/(SICI)1099-0844(19970601)15:2<113::AID-CBF730>3.3.CO;2-O; Ozdener F, 2002, MOL PHARMACOL, V62, P672, DOI 10.1124/mol.62.3.672; PANDEY P, 1995, CANCER RES, V55, P4000; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Quin RJ, 2000, INT J CANCER, V87, P499, DOI 10.1002/1097-0215(20000815)87:4<499::AID-IJC6>3.0.CO;2-9; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ranta-Knuuttila T, 2002, DIGEST DIS SCI, V47, P1008, DOI 10.1023/A:1015025704589; Regimbald LH, 1996, CANCER RES, V56, P4244; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shu LM, 2003, J BIOL CHEM, V278, P31419, DOI 10.1074/jbc.M303783200; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; Tokmakov AA, 2002, CELL CALCIUM, V32, P11, DOI 10.1016/S0143-4160(02)00078-7; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	30	65	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29386	29390		10.1074/jbc.C400010200	http://dx.doi.org/10.1074/jbc.C400010200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15169768	hybrid			2022-12-27	WOS:000222445300070
J	Chen, WY; Lee, WC; Hsu, NC; Huang, F; Chung, BC				Chen, WY; Lee, WC; Hsu, NC; Huang, F; Chung, BC			SUMO modification of repression domains modulates function of nuclear receptor 5A1 (steroidogenic factor-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT MODIFICATION; TRANSCRIPTIONAL ACTIVITY; BINDING PROTEIN; P450SCC GENE; UBIQUITIN; CELLS; TRANSACTIVATION; LOCALIZATION; EXPRESSION; ACTIVATION	Steroidogenic factor 1 (SF-1 or NR5A1), is a Ftz-F1 member of the nuclear receptor superfamily that plays essential roles in endocrine development, steroidogenesis, and gonad differentiation. We investigated modifications that control SF-1 function and found that SF-1 could be conjugated by SUMO-1 both in vitro and in vivo. SF-1 was modified predominantly at Lys(194) and much less at Lys(119) when free SUMO-1 was supplied. Mutations of Lys(194) and Lys(119) enhanced transcriptional activity of SF-1, although the DNA binding activity of SF-1 was not affected. Sequences around Lys(194) and Lys(119) both repressed transcription intrinsically. The Lys(194) motif repressed transcription more efficiently than the Lys(119) domain, consistent with its ability to be a better substrate for SUMO conjugation. Thus, SUMO modification of SF-1 correlates with transcriptional repression. Wild-type but not conjugation-deficient SF-1 was localized at the nuclear speckles together with SUMO-1. Thus, SUMO-1 conjugation could also target SF-1 into nuclear speckles. Collectively, these results suggest that SUMO modification at the repression domains targets SF-1 to nuclear speckles; this could be an important mechanism by which SF-1 is regulated.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Chung, BC (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	mbchung@sinica.edu.tw		Huang, Fu/0000-0001-9549-8937; Chen, Wei-Yi/0000-0002-0661-6899; Chung, Bon-chu/0000-0002-8612-0219				Auwerx J, 1999, CELL, V97, P161; Borud B, 2002, MOL ENDOCRINOL, V16, P757, DOI 10.1210/me.16.4.757; Crawford PA, 1997, MOL CELL BIOL, V17, P3997, DOI 10.1128/MCB.17.7.3997; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; GUO IC, 1994, J BIOL CHEM, V269, P6362; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hsu HJ, 2003, DEVELOPMENT, V130, P2107, DOI 10.1242/dev.00427; HU MC, 1990, MOL ENDOCRINOL, V4, P893, DOI 10.1210/mend-4-6-893; HU MC, 1991, BIOCHEM J, V274, P813, DOI 10.1042/bj2740813; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; KOMATSU T, 2004, IN PRESS MOL ENDOCRI, V18; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Li LA, 1999, MOL ENDOCRINOL, V13, P1588, DOI 10.1210/me.13.9.1588; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; LUO XR, 1995, MOL ENDOCRINOL, V9, P1233, DOI 10.1210/me.9.9.1233; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Suzuki T, 2003, MOL CELL BIOL, V23, P238, DOI 10.1128/MCB.23.1.238-249.2003; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	31	84	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38730	38735		10.1074/jbc.M405006200	http://dx.doi.org/10.1074/jbc.M405006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15192092	hybrid			2022-12-27	WOS:000223684100083
J	Harris, EN; Weigel, JA; Weigel, PH				Harris, EN; Weigel, JA; Weigel, PH			Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; ASIALOGLYCOPROTEIN RECEPTOR; BINDING PROTEINS; ACID; TISSUE; SERUM; DISEASE; LIGAND; IDENTIFICATION	The human hyaluronan receptor for endocytosis (hHARE) mediates the endocytic clearance of hyaluronan (HA) and chondroitin sulfate from lymph fluid and blood. Two hHARE isoforms (190 and 315 kDa) are present in sinusoidal endothelial cells of liver, spleen, and lymph nodes (Zhou, B., McGary, C. T., Weigel, J. A., Saxena, A., and Weigel, P. H. (2003) Glycobiology 13, 339-349). Here we report the specificity and function of the 190-kDa HARE, expressed without the larger isoform, in Flp-In 293 cell lines (190hHARE cells). Like the native protein, recombinant hHARE contains similar to25 kDa of N-linked oligosaccharides, binds HA in a ligand blot assay, cross-reacts with three anti-rat HARE monoclonal antibodies, and is inactivated by reduction. The 190hHARE cell lines mediated rapid, continuous I-125-HA endocytosis and degradation for >1 day. About 30-50% of the total cellular receptors were on the cell surface, and their recycling time for reutilization was similar to8.5 min. The average K-d for the binding of HA to the 190-kDa hHARE at 4 degreesC was 7 nM with 118,000 total HA binding sites per cell. Competition studies at 37 degreesC indicated that the 190-kDa hHARE binds HA and chondroitin better than dermatan sulfate and chondroitin sulfates A, C, D, and E, but it does not bind to heparin, heparan sulfate, or keratan sulfate. Although competition was observed at 37 degreesC, none of the glycosaminoglycans tested, except HA, competed for I-125-HA binding by 190hHARE cells at 4 degreesC. Anti-HARE monoclonal antibodies #30 and #154, which do not inhibit I-125-HA uptake mediated by the 175-kDa rat HARE, partially blocked HA endocytosis by the 190-kDa hHARE. We conclude that the 190-kDa hHARE can function independently of other hHARE isoforms to mediate the endocytosis of multiple glycosaminoglycans. Furthermore, the rat and human small HARE isoforms have different glycosaminoglycan specificities and sensitivities to inhibition by cross-reacting antibodies.	Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, BMSB,Rm 860,Box 26901, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu						ABATANGELO G, 2000, NEW FRONTIERS MED SC; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMLEY PN, 1991, J HEPATOL, V13, P8, DOI 10.1016/0168-8278(91)90856-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; EVERED D, 1989, CIBA F SYMP, V143, P1; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; Freitas JP, 1996, DERMATOLOGY, V192, P46, DOI 10.1159/000246314; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai KN, 1998, J LAB CLIN MED, V131, P354, DOI 10.1016/S0022-2143(98)90186-X; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT UBG, 1991, EXP PHYSIOL, V76, P695, DOI 10.1113/expphysiol.1991.sp003536; LEBEL L, 1988, J APPL PHYSIOL, V64, P1327, DOI 10.1152/jappl.1988.64.4.1327; LEBOEUF RD, 1987, BIOCHEMISTRY-US, V26, P6052, DOI 10.1021/bi00393a016; LEBOEUF RD, 1986, J BIOL CHEM, V261, P2586; LUNDIN A, 1985, BRIT J DERMATOL, V112, P663, DOI 10.1111/j.1365-2133.1985.tb02334.x; Manicourt DH, 1999, ARTHRITIS RHEUM, V42, P1861, DOI 10.1002/1529-0131(199909)42:9<1861::AID-ANR10>3.0.CO;2-I; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; OKA JA, 1983, J BIOL CHEM, V258, P253; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMEDSROD B, 1988, CELL TISSUE RES, V253, P39; Thylen A, 1999, CANCER-AM CANCER SOC, V86, P2000, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.3.CO;2-E; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TZAICOS C, 1989, BIOCHEM J, V264, P823, DOI 10.1042/bj2640823; Weigel JA, 2003, J BIOL CHEM, V278, P9808, DOI 10.1074/jbc.M211462200; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	44	67	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36201	36209		10.1074/jbc.M405322200	http://dx.doi.org/10.1074/jbc.M405322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208308	Green Published, hybrid			2022-12-27	WOS:000223453600007
J	Meredith, AL; Thorneloe, KS; Werner, ME; Nelson, MT; Aldrich, RW				Meredith, AL; Thorneloe, KS; Werner, ME; Nelson, MT; Aldrich, RW			Overactive bladder and incontinence in the absence of the BK large conductance Ca2+-activated K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PIG VAS-DEFERENS; RYANODINE RECEPTORS; CA2+ SPARKS; DIFFERENTIAL REGULATION; OPENING ACTIVITY; ACTIVATION; SUBUNIT; MICE	BK large conductance voltage- and calcium-activated potassium channels respond to elevations in intracellular calcium and membrane potential depolarization, braking excitability of smooth muscle. BK channels are thought to have a particularly prominent role in urinary bladder smooth muscle function and therefore are candidate targets for overactive bladder therapy. To address the role of the BK channel in urinary bladder function, the gene mSlo1 for the pore-forming subunit of the BK channel was deleted. Slo(-/-) mice were viable but exhibited moderate ataxia. Urinary bladder smooth muscle cells of Slo(-/-) mice lacked calcium- and voltage-activated BK currents, whereas local calcium transients ("calcium sparks") and voltage- dependent potassium currents were unaffected. In the absence of BK channels, urinary bladder spontaneous and nerve-evoked contractions were greatly enhanced. Consistent with increased urinary bladder contractility caused by the absence of BK currents, Slo(-/-) mice demonstrate a marked elevation in urination frequency. These results reveal a central role for BK channels in urinary bladder function and indicate that BK channel dysfunction leads to overactive bladder and urinary incontinence.	Stanford Univ, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; University of Vermont	Aldrich, RW (corresponding author), Stanford Univ, Dept Cellular & Mol Physiol, 279 Campus Dr,Beckman 173, Stanford, CA 94305 USA.	raldrich@stanford.edu	Werner, Matthias E/A-7141-2008	Nelson, Mark/0000-0002-6608-8784; Meredith, Andrea/0000-0003-1061-2302				ANWER K, 1993, AM J PHYSIOL, V265, pC976, DOI 10.1152/ajpcell.1993.265.4.C976; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Brune ME, 2002, J PHARMACOL EXP THER, V303, P387, DOI 10.1124/jpet.102.034553; Butera JA, 2001, BIOORG MED CHEM LETT, V11, P2093, DOI 10.1016/S0960-894X(01)00385-7; Christ GJ, 2001, AM J PHYSIOL-REG I, V281, pR1699, DOI 10.1152/ajpregu.2001.281.5.R1699; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, P31; Hashitani H, 2003, BRIT J PHARMACOL, V140, P159, DOI 10.1038/sj.bjp.0705320; Heppner TJ, 1997, AM J PHYSIOL-CELL PH, V273, pC110; Herrera GM, 2003, J PHYSIOL-LONDON, V551, P893, DOI 10.1113/jphysiol.2003.045914; Herrera GM, 2002, J PHYSIOL-LONDON, V541, P483, DOI 10.1113/jphysiol.2002.017707; Herrera GM, 2001, AM J PHYSIOL-CELL PH, V280, pC481, DOI 10.1152/ajpcell.2001.280.3.C481; Herrera GM, 2000, AM J PHYSIOL-REG I, V279, pR60, DOI 10.1152/ajpregu.2000.279.1.R60; Hewawasam P, 2002, BIOORG MED CHEM LETT, V12, P1117, DOI 10.1016/S0960-894X(02)00099-9; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Hu TW, 2004, UROLOGY, V63, P461, DOI 10.1016/j.urology.2003.10.037; Imaizumi Y, 1996, AM J PHYSIOL-CELL PH, V271, pC772, DOI 10.1152/ajpcell.1996.271.3.C772; Imaizumi Y, 1998, J PHYSIOL-LONDON, V510, P705, DOI 10.1111/j.1469-7793.1998.705bj.x; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V279, pC1528, DOI 10.1152/ajpcell.2000.279.5.C1528; JOYNER AL, 1993, GENE TARGETING PRACT, P1; LI JH, 1995, PHARMACOLOGY, V51, P33, DOI 10.1159/000139314; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Ohi Y, 2001, J PHYSIOL-LONDON, V534, P313, DOI 10.1111/j.1469-7793.2001.t01-3-00313.x; Perez GJ, 1999, J GEN PHYSIOL, V113, P229, DOI 10.1085/jgp.113.2.229; Petkov GV, 2001, J PHYSIOL-LONDON, V537, P443, DOI 10.1111/j.1469-7793.2001.00443.x; Sah P, 2002, PROG NEUROBIOL, V66, P345, DOI 10.1016/S0301-0082(02)00004-7; Song M, 1999, FEBS LETT, V460, P427, DOI 10.1016/S0014-5793(99)01394-0; THOR KB, 1989, DEV BRAIN RES, V46, P137, DOI 10.1016/0165-3806(89)90151-X; Thorneloe KS, 2003, J PHYSIOL-LONDON, V549, P65, DOI 10.1113/jphysiol.2003.039859; Turner SC, 2003, BIOORG MED CHEM LETT, V13, P2003, DOI 10.1016/S0960-894X(03)00324-X; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wellman GC, 2001, AM J PHYSIOL-CELL PH, V281, pC1029, DOI 10.1152/ajpcell.2001.281.3.C1029	32	276	286	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36746	36752		10.1074/jbc.M405621200	http://dx.doi.org/10.1074/jbc.M405621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15184377	hybrid			2022-12-27	WOS:000223453600075
J	Marshall, S; Nadeau, O; Yamasaki, K				Marshall, S; Nadeau, O; Yamasaki, K			Dynamic actions of glucose and glucosamine on hexosamine biosynthesis in isolated adipocytes - Differential effects on glucosamine 6-phosphate, UDP-N-acetylglucosamine, and ATP levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; GLYCOGEN-SYNTHASE; SKELETAL-MUSCLE; IN-VIVO; INDUCED DESENSITIZATION; DIFFERENT MECHANISMS; TRANSPORT SYSTEM; AKT ACTIVATION; PATHWAY; TRANSLOCATION	Glucose and glucosamine (GlcN) cause insulin resistance over several hours by increasing metabolite flux through the hexosamine biosynthesis pathway (HBP). To elucidate the early events underlying glucose-induced desensitization, we treated isolated adipocytes with either glucose or GlcN and then measured intracellular levels of glucose-6-P (G-6-P), GlcN-6-P, UDP-GlcNAc, and ATP. Glucose treatment rapidly increased G-6-P levels (t(1/2) < 1 min), which plateaued by 15 min and remained elevated for up to 4 h (glucose ED50 = 4 mM). In glucose-treated cells, GlcN-6-P was undetectable; however, GlcN treatment (2 mM) caused a rapid and massive accumulation of GlcN-6-P. Levels increased by 5 min (similar to 400 nmol/g) and continued to rise over 2 h (t(1/2) similar to 20 min) before reaching a plateau at > 1,400 nmol/g (ED50 = 900 muM). Thus, at high GlcN concentrations, unrestricted flux into the HBP greatly exceeds the biosynthetic capacity of the pathway leading to a rapid buildup of GlcN-6-P. The GlcN-induced rise in GlcN-6-P levels was correlated with ATP depletion, suggesting that ATP loss is caused by phosphate sequestration (with the formation of GlcN-6-P) or the energy demands of phosphorylation. As expected, GlcN and glucose increased UDPGlcNAc levels (t(1/2) similar to 14-18 min), but greater levels were obtained with GlcN (4-5-fold for GlcN, 2-fold for glucose). Importantly, we found that low doses of GlcN (< 250 mu M, ED50 = 80 mu M) could markedly elevate UDP-GlcNAc levels without increasing GlcN-6-P levels or depleting ATP levels. These studies on the dynamic actions of glucose and GlcN on hexosamine levels should be useful in exploring the functional role of the HBP and in avoiding the potential pitfalls in the pharmacological use of GlcN.	Hexos Inc, Woodinville, WA 98072 USA		Marshall, S (corresponding author), Hexos Inc, 18304 NE 153rd St, Woodinville, WA 98072 USA.	Hexos@comcast.net		Yamasaki, Kazumitsu/0000-0002-8414-2393				Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Ciaraldi TP, 1999, ENDOCRINOLOGY, V140, P3971, DOI 10.1210/en.140.9.3971; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; GIACCARI A, 1995, DIABETOLOGIA, V38, P518, DOI 10.1007/BF00400719; Han DH, 2003, AM J PHYSIOL-ENDOC M, V285, pE1267, DOI 10.1152/ajpendo.00255.2003; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Kang J, 2001, AM J PHYSIOL-ENDOC M, V280, pE428, DOI 10.1152/ajpendo.2001.280.3.E428; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; Lang G., 1974, METHODS ENZYMATIC AN, P1238; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P123; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MARSHALL S, 1983, DIABETES, V32, P319, DOI 10.2337/diab.32.4.319; Marshall S, 2000, DIABETES ANNUAL/13, P97; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 2002, CURR OPIN ENDOCRINOL, V9, P160; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MCCLAIN DA, 2001, CURR OPIN ENDOCRINOL, V9, P186; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; Nelson BA, 2002, AM J PHYSIOL-ENDOC M, V282, pE497, DOI 10.1152/ajpendo.00438.2001; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P122; Ross SA, 2000, BIOCHEM BIOPH RES CO, V273, P1033, DOI 10.1006/bbrc.2000.3082; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; Schleicher ED, 2000, KIDNEY INT, V58, pS13, DOI 10.1046/j.1523-1755.2000.07703.x; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; Virkamaki A, 1999, DIABETES, V48, P1101, DOI 10.2337/diabetes.48.5.1101; Virkamaki A, 1997, ENDOCRINOLOGY, V138, P2501, DOI 10.1210/en.138.6.2501; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399	36	106	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35313	35319		10.1074/jbc.M404133200	http://dx.doi.org/10.1074/jbc.M404133200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199059	hybrid			2022-12-27	WOS:000223303400023
J	Sun, WC; Yang, J; Liu, XQ				Sun, WC; Yang, J; Liu, XQ			Synthetic two-piece and three-piece split inteins for protein trans-splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HOMING ENDONUCLEASE; TRICHODESMIUM-ERYTHRAEUM; SPLICING MECHANISM; DNAB INTEIN; PI-SCEI; CYCLIZATION; EVOLUTION; PCC6803; GENE	Inteins are protein-intervening sequences that can self-excise and concomitantly splice together the flanking polypeptides. Two-piece split inteins capable of protein trans-splicing have been found in nature and engineered in laboratories, but they all have a similar split site corresponding to the endonuclease domain of the intein. Can inteins be split at other sites and do trans-splicing? After testing 13 split sites engineered into a Ssp DnaB mini-intein, we report the finding of three new split sites that each produced a two-piece split intein capable of protein trans-splicing. These three functional split sites are located in different loop regions between beta-strands of the intein structure, and one of them is just 11 amino acids from the beginning of the intein. Because different inteins have similar structures and similar beta-strands, these new split sites may be generalized to other inteins. We have also demonstrated for the first time that a three-piece split intein could function in protein trans-splicing. These findings have implications for intein structure-function, evolution, and uses in biotechnology.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Liu, XQ (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.	pxqliu@dal.ca						Amitai G, 2004, J BIOL CHEM, V279, P3121, DOI 10.1074/jbc.M311343200; Amitai G, 2003, MOL MICROBIOL, V47, P61, DOI 10.1046/j.1365-2958.2003.03283.x; Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; Caspi J, 2003, MOL MICROBIOL, V50, P1569, DOI 10.1046/j.1365-2958.2003.03825.x; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; Chen LX, 2000, J BIOL CHEM, V275, P20431, DOI 10.1074/jbc.M000178200; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; Ding Y, 2003, J BIOL CHEM, V278, P39133, DOI 10.1074/jbc.M306197200; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Gogarten JP, 2002, ANNU REV MICROBIOL, V56, P263, DOI 10.1146/annurev.micro.56.012302.160741; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240; Ichiyanagi K, 2000, J MOL BIOL, V300, P889, DOI 10.1006/jmbi.2000.3873; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Liu XQ, 1997, P NATL ACAD SCI USA, V94, P7851, DOI 10.1073/pnas.94.15.7851; Liu XQ, 2003, J BIOL CHEM, V278, P46826, DOI 10.1074/jbc.M309575200; Liu XQ, 2003, J BIOL CHEM, V278, P26315, DOI 10.1074/jbc.C300202200; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; Martin DD, 2001, BIOCHEMISTRY-US, V40, P1393, DOI 10.1021/bi001786g; Mills KV, 2004, J BIOL CHEM, V279, P20685, DOI 10.1074/jbc.M400887200; Mills KV, 1998, P NATL ACAD SCI USA, V95, P3543, DOI 10.1073/pnas.95.7.3543; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 2002, NUCLEIC ACIDS RES, V30, P383, DOI 10.1093/nar/30.1.383; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Poland BW, 2000, J BIOL CHEM, V275, P16408, DOI 10.1074/jbc.275.22.16408; Southworth MW, 2000, EMBO J, V19, P5019, DOI 10.1093/emboj/19.18.5019; Southworth MW, 1998, EMBO J, V17, P918, DOI 10.1093/emboj/17.4.918; Telenti A, 1997, J BACTERIOL, V179, P6378, DOI 10.1128/jb.179.20.6378-6382.1997; Werner E, 2002, NUCLEIC ACIDS RES, V30, P3962, DOI 10.1093/nar/gkf523; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187; Yang J, 2004, MOL MICROBIOL, V51, P1185, DOI 10.1046/j.1365-2958.2003.03902.x; Yang JJ, 2003, P NATL ACAD SCI USA, V100, P3513, DOI 10.1073/pnas.0635899100	38	83	101	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35281	35286		10.1074/jbc.M405491200	http://dx.doi.org/10.1074/jbc.M405491200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194682	hybrid			2022-12-27	WOS:000223303400019
J	Wester, MR; Yano, JK; Schoch, GA; Yang, C; Griffin, KJ; Stout, CD; Johnson, EF				Wester, MR; Yano, JK; Schoch, GA; Yang, C; Griffin, KJ; Stout, CD; Johnson, EF			The structure of human cytochrome P4502C9 complexed with flurbiprofen at 2.0-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; ANGSTROM RESOLUTION; BINDING; IDENTIFICATION; METABOLISM; RESIDUES; PROGRAM; PROTEIN; MODEL; SULFAPHENAZOLE	The structure of human P450 2C9 complexed with flurbiprofen was determined to 2.0 Angstrom by x-ray crystallography. In contrast to other structurally characterized P450 2C enzymes, 2C5, 2C8, and a 2C9 chimera, the native catalytic domain of P450 2C9 differs significantly in the conformation of the helix F to helix G region and exhibits an extra turn at the N terminus of helix A. In addition, a distinct conformation of the helix B to helix C region allows Arg-108 to hydrogen bond with Asp-293 and Asn-289 on helix I and to interact directly with the carboxylate of flurbiprofen. These interactions position the substrate for regioselective oxidation in a relatively large active site cavity and are likely to account for the high catalytic efficiency exhibited by P450 2C9 for the regioselective oxidation of several anionic non-steroidal anti-inflammatory drugs. The structure provides a basis for interpretation of a number of observations regarding the substrate selectivity of P450 2C9 and the observed effects of mutations on catalysis.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stout, CD (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,MB8, La Jolla, CA 92037 USA.	dave@scripps.edu; johnson@scripps.edu		Yano, Jason/0000-0002-9774-2611	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NIGMS NIH HHS [GM031001] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; de Groot MJ, 2002, J MED CHEM, V45, P1983, DOI 10.1021/jm0110791; Dickmann LJ, 2004, MOL PHARMACOL, V65, P842, DOI 10.1124/mol.65.4.842; Flanagan JU, 2003, BIOCHEM J, V370, P921, DOI 10.1042/BJ20021841; Fleming I, 2004, PHARMACOL RES, V49, P525, DOI 10.1016/j.phrs.2003.11.016; HELMS V, 1995, BIOPHYS J, V69, P810, DOI 10.1016/S0006-3495(95)79955-6; Hutzler JM, 2001, DRUG METAB DISPOS, V29, P1029; Hutzler JM, 2003, ARCH BIOCHEM BIOPHYS, V410, P16; Ibeanu GC, 1996, J BIOL CHEM, V271, P12496, DOI 10.1074/jbc.271.21.12496; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Jones BC, 1996, DRUG METAB DISPOS, V24, P260; Jones JP, 1996, DRUG METAB DISPOS, V24, P1; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Jung F, 1998, BIOCHEMISTRY-US, V37, P16270, DOI 10.1021/bi981704c; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Klose TS, 1998, ARCH BIOCHEM BIOPHYS, V357, P240, DOI 10.1006/abbi.1998.0826; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee CR, 2002, PHARMACOGENETICS, V12, P251, DOI 10.1097/00008571-200204000-00010; LESLIE AGW, 1996, CCP4 NEWLETTER PROTE; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; Ridderstrom M, 2000, BIOCHEM BIOPH RES CO, V270, P983, DOI 10.1006/bbrc.2000.2538; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; TRACY TS, 1995, BIOCHEM PHARMACOL, V49, P1269, DOI 10.1016/0006-2952(95)00048-5; Tsao CC, 2001, BIOCHEMISTRY-US, V40, P1937, DOI 10.1021/bi001678u; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; Wester MR, 2000, DRUG METAB DISPOS, V28, P354; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862	38	398	409	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35630	35637		10.1074/jbc.M405427200	http://dx.doi.org/10.1074/jbc.M405427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15181000	hybrid			2022-12-27	WOS:000223303400059
J	Williamson, AL; Lecchi, P; Turk, BE; Choe, Y; Hotez, PJ; McKerrow, JH; Cantley, LC; Sajid, M; Craik, CS; Loukas, A				Williamson, AL; Lecchi, P; Turk, BE; Choe, Y; Hotez, PJ; McKerrow, JH; Cantley, LC; Sajid, M; Craik, CS; Loukas, A			A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE PLASMODIUM-FALCIPARUM; ANCYLOSTOMA-CANINUM HOOKWORMS; HAEMONCHUS-CONTORTUS; SCHISTOSOMA-MANSONI; CYSTEINE PROTEINASE; MOLECULAR-CLONING; CATHEPSIN-B; SUBSTRATE-SPECIFICITY; FUNCTIONAL EXPRESSION; PROTECTIVE ANTIGENS	Blood-feeding pathogens digest hemoglobin (Hb) as a source of nutrition, but little is known about this process in multicellular parasites. The intestinal brush border membrane of the canine hookworm, Ancylostoma caninum, contains aspartic proteases (APR-1), cysteine proteases (CP-2), and metalloproteases (MEP-1), the first of which is known to digest Hb. We now show that Hb is degraded by a multi-enzyme, synergistic cascade of proteolysis. Recombinant APR-1 and CP-2, but not MEP-1, digested native Hb and denatured globin. MEP-1, however, did cleave globin fragments that had undergone prior digestion by APR-1 and CP-2. Proteolytic cleavage sites within the Hb alpha and beta chains were determined for the three enzymes, identifying a total of 131 cleavage sites. By scanning synthetic combinatorial peptide libraries with each enzyme, we compared the preferred residues cleaved in the libraries with the known cleavage sites within Hb. The semi-ordered pathway of Hb digestion described here is surprisingly similar to that used by Plasmodium to digest Hb and provides a potential mechanism by which these hemoglobinases are efficacious vaccines in animal models of hookworm infection.	Queensland Inst Med Res, Div Infect Dis & Immunol, Helminth Biol Lab, Brisbane, Qld 4006, Australia; George Washington Univ, Dept Microbiol & Trop Med, Washington, DC 20037 USA; George Washington Univ, Inst Proteom Technol & Applicat, Washington, DC 20037 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02215 USA; Univ Calif San Francisco, Trop Dis Res Unit, San Francisco, CA 94122 USA; Univ Calif San Francisco, Sandler Ctr Basic Res Parasit Dis, San Francisco, CA 94122 USA; Univ Queensland, Australian Ctr Int & Trop Hlth, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; George Washington University; George Washington University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco; QIMR Berghofer Medical Research Institute; University of Queensland	Loukas, A (corresponding author), Queensland Inst Med Res, Div Infect Dis & Immunol, Helminth Biol Lab, 300 Herston Rd, Brisbane, Qld 4006, Australia.	alexL@qimr.edu.au	Cantley, Lewis C/D-1800-2014; Loukas, Alex/B-7355-2014	Cantley, Lewis C/0000-0002-1298-7653; Loukas, Alex/0000-0002-0896-8441; Hotez, Peter/0000-0001-8770-1042	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053247] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-3276, AI-53247] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bakker N, 2004, VACCINE, V22, P618, DOI 10.1016/j.vaccine.2003.08.025; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bouchard E, 2003, MOL ECOL, V12, P2439, DOI 10.1046/j.1365-294X.2003.01919.x; Brady CP, 1999, INFECT IMMUN, V67, P368, DOI 10.1128/IAI.67.1.368-374.1999; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; BROWN A, 1995, PARASITOLOGY, V110, P555, DOI 10.1017/S0031182000065276; Caffrey CR, 2004, TRENDS PARASITOL, V20, P241, DOI 10.1016/j.pt.2004.03.004; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Choi KH, 2000, EUR J BIOCHEM, V267, P1516, DOI 10.1046/j.1432-1327.2000.01152.x; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; DON TA, 2004, IN PRESS INT J PARAS; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; Gavigan CS, 2001, MOL BIOCHEM PARASIT, V117, P37, DOI 10.1016/S0166-6851(01)00327-9; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; HARROP SA, 1995, TROP MED PARASITOL, V46, P119; Harrop SA, 1996, BIOCHEM BIOPH RES CO, V227, P294, DOI 10.1006/bbrc.1996.1503; HARROP SA, 1995, MOL BIOCHEM PARASIT, V71, P163, DOI 10.1016/0166-6851(95)00045-3; HOTEZ PJ, 2002, CHINA QUART, V172, P1029; HOTEZ PJ, 2004, IN PRESS NEW ENG J M; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; Jones BF, 2002, MOL BIOCHEM PARASIT, V119, P107, DOI 10.1016/S0166-6851(01)00409-1; Knox D.P., 2001, P247, DOI 10.1079/9780851994239.0247; Knox DP, 1999, PARASITE IMMUNOL, V21, P201, DOI 10.1046/j.1365-3024.1999.00220.x; LAWRENCE JD, 1973, J PARASITOL, V59, P60, DOI 10.2307/3278572; Lecaille F, 2003, BIOCHEM J, V375, P307, DOI 10.1042/BJ20030468; Lipps G, 1996, J BIOL CHEM, V271, P1717, DOI 10.1074/jbc.271.3.1717; Loukas A, 2004, J INFECT DIS, V189, P1952, DOI 10.1086/386346; McCarthy E, 2004, INT J PARASITOL, V34, P703, DOI 10.1016/j.ijpara.2004.01.008; Mills BJ, 1996, BIOCHEM PHARMACOL, V52, P401, DOI 10.1016/0006-2952(96)00241-9; Mulenga A, 2001, INSECT BIOCHEM MOLEC, V31, P817, DOI 10.1016/S0965-1748(00)00187-9; Murata CE, 2003, J BIOL CHEM, V278, P38022, DOI 10.1074/jbc.M306842200; Ramalho-Ortigao JM, 2003, INSECT BIOCHEM MOLEC, V33, P163, DOI 10.1016/S0965-1748(02)00187-X; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; Redmond DL, 1997, MOL BIOCHEM PARASIT, V85, P77, DOI 10.1016/S0166-6851(96)02812-5; ROCHE M, 1966, AM J TROP MED HYG, V15, P1032, DOI 10.4269/ajtmh.1966.15.1032; Sajid M, 2003, MOL BIOCHEM PARASIT, V131, P65, DOI 10.1016/S0166-6851(03)00194-4; SALAS F, 1995, INFECT IMMUN, V63, P2120, DOI 10.1128/IAI.63.6.2120-2125.1995; Serveau C, 1996, BIOCHEM J, V313, P951, DOI 10.1042/bj3130951; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Shenai BR, 2002, MOL BIOCHEM PARASIT, V122, P99, DOI 10.1016/S0166-6851(02)00075-0; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Smith WD, 2003, PARASITE IMMUNOL, V25, P521, DOI 10.1111/j.0141-9838.2004.00667.x; Smith WD, 2003, PARASITE IMMUNOL, V25, P313, DOI 10.1046/j.1365-3024.2003.00637.x; Smooker PM, 2000, PROTEIN SCI, V9, P2567, DOI 10.1110/ps.9.12.2567; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Vizioli J, 2001, EUR J BIOCHEM, V268, P4027, DOI 10.1046/j.1432-1327.2001.02315.x; Williamson AL, 2003, PARASITOLOGY, V126, P179, DOI 10.1017/S0031182002002706; Williamson AL, 2003, J INFECT DIS, V187, P484, DOI 10.1086/367708; Williamson AL, 2002, FASEB J, V16, P1458, DOI 10.1096/fj.02-0181fje; Williamson AL, 2003, TRENDS PARASITOL, V19, P417, DOI 10.1016/S1471-4922(03)00189-2; Zhan B, 2002, MOL BIOCHEM PARASIT, V120, P291, DOI 10.1016/S0166-6851(01)00453-4	59	130	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35950	35957		10.1074/jbc.M405842200	http://dx.doi.org/10.1074/jbc.M405842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199048	hybrid			2022-12-27	WOS:000223303400096
J	Hanzelmann, P; Hernandez, HL; Menzel, C; Garcia-Serres, R; Huynh, BH; Johnson, MK; Mendel, RR; Schindelin, H				Hanzelmann, P; Hernandez, HL; Menzel, C; Garcia-Serres, R; Huynh, BH; Johnson, MK; Mendel, RR; Schindelin, H			Characterization of MOCS1A, an oxygen-sensitive iron-sulfur protein involved in human molybdenum cofactor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MOLYBDOPTERIN SYNTHASE; MAGNETIC CIRCULAR-DICHROISM; LYASE ACTIVATING ENZYME; COLI BIOTIN SYNTHASE; ANAEROBIC RIBONUCLEOTIDE REDUCTASE; PYROCOCCUS-FURIOSUS FERREDOXIN; OVERLAPPING READING FRAMES; SITE-DIRECTED MUTAGENESIS; CLUSTER BINDING-SITES; GTP CYCLOHYDROLASE-I	The human proteins MOCS1A and MOCS1B catalyze the conversion of a guanosine derivative to precursor Z during molybdenum cofactor biosynthesis. MOCS1A shares homology with S-adenosylmethionine ( AdoMet)dependent radical enzymes, which catalyze the formation of protein and/or substrate radicals by reductive cleavage of AdoMet through a [4Fe-4S] cluster. Sequence analysis of MOCS1A showed two highly conserved cysteine motifs, one near the N terminus and one near the C terminus. MOCS1A was heterologously expressed in Escherichia coli and purified under aerobic and anaerobic conditions. Individual mutations of the conserved cysteines to serine revealed that all are essential for synthesis of precursor Z in vivo. The type and properties of the iron-sulfur (FeS) clusters were investigated using a combination of UV-visible absorption, variable temperature magnetic circular dichroism, resonance Raman, Mossbauer, and EPR spectroscopies coupled with iron and acid-labile sulfide analyses. The results indicated that anaerobically purified MOCS1A is a monomeric protein containing two oxygen-sensitive FeS clusters, each coordinated by only three cysteine residues. A redox-active [4Fe- 4S](2+,+) cluster is ligated by an N-terminal CX3CX2C motif as is the case with all other AdoMet-dependent radical enzymes investigated thus far. A C-terminal CX2CX13C motif that is unique to MOCS1A and its orthologs primarily ligates a [3Fe- 4S](0) cluster. However, MOCS1A could be reconstituted in vitro under anaerobic conditions to yield a form containing two [4Fe-4S] (2+) clusters. The N-terminal [4Fe- 4S](2+) cluster was rapidly degraded by oxygen via a semistable [2Fe- 2S](2+) cluster intermediate, and the C-terminal [4Fe- 4S](2+) cluster was rapidly degraded by oxygen to yield a semistable [ 3Fe- 4S](0) cluster intermediate.	SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; Tech Univ Carolo Wilhelmina Braunschweig, Inst Plant Biol, D-38023 Braunschweig, Germany; Emory Univ, Dept Phys, Atlanta, GA 30322 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Braunschweig University of Technology; Emory University	Hanzelmann, P (corresponding author), SUNY Stony Brook, Dept Biochem, CMM Bldg,Rm Nr 150, Stony Brook, NY 11794 USA.	petra@csb.sunysb.edu; hermann.schindelin@sunysb.edu	Schindelin, Hermann/Q-2697-2019; García-Serres, Ricardo/E-4344-2012	García-Serres, Ricardo/0000-0001-5203-0568	NIDDK NIH HHS [DK 54835] Funding Source: Medline; NIGMS NIH HHS [GM 47295, GM 62542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295, R01GM062542] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BENNETT DE, 1987, BIOCHIM BIOPHYS ACTA, V911, P71, DOI 10.1016/0167-4838(87)90272-X; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brereton PS, 1999, BIOCHEMISTRY-US, V38, P10594, DOI 10.1021/bi990671d; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Cosper MM, 2002, J AM CHEM SOC, V124, P14006, DOI 10.1021/ja0283044; Cosper MM, 2004, BIOCHEMISTRY-US, V43, P2007, DOI 10.1021/bi0356653; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; DROZDZEWSKI PM, 1988, APPL SPECTROSC, V42, P1575, DOI 10.1366/0003702884429841; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; EMPTAGE MH, 1980, J BIOL CHEM, V255, P1793; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; GLASER JH, 1972, MOL GEN GENET, V116, P1, DOI 10.1007/BF00334254; Hanzelmann P, 2002, J BIOL CHEM, V277, P18303, DOI 10.1074/jbc.M200947200; HUYNH BH, 1980, J BIOL CHEM, V255, P3242; Jameson GNL, 2004, BIOCHEMISTRY-US, V43, P2022, DOI 10.1021/bi035666v; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; Johnson M. K., 1988, METAL CLUSTERS PROTE, P326; Johnson MK, 1999, ADV INORG CHEM, V47, P1, DOI 10.1016/S0898-8838(08)60076-8; Johnson MK, 1982, IRON SULFUR PROTEINS, P367; Kaiser J, 2002, EUR J BIOCHEM, V269, P5264, DOI 10.1046/j.1432-1033.2002.03239.x; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Leimkuhler S, 2003, J BIOL CHEM, V278, P26127, DOI 10.1074/jbc.M303092200; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Marquet A, 2001, CURR OPIN CHEM BIOL, V5, P541, DOI 10.1016/S1367-5931(00)00249-0; Matthies A, 2004, P NATL ACAD SCI USA, V101, P5946, DOI 10.1073/pnas.0308191101; Menendez C, 1996, FEBS LETT, V391, P101, DOI 10.1016/0014-5793(96)00712-0; MENENDEZ C, 1995, ARCH MICROBIOL, V164, P142, DOI 10.1007/s002030050246; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; Mulliez E, 1999, J BIOL INORG CHEM, V4, P614, DOI 10.1007/s007750050385; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; ONATE YA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P113, DOI 10.1016/0167-4838(93)90237-L; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAVI N, 1994, J AM CHEM SOC, V116, P8007, DOI 10.1021/ja00097a007; Rebelo J, 2003, J MOL BIOL, V326, P503, DOI 10.1016/S0022-2836(02)01303-7; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; Reiss J, 2003, HUM MUTAT, V21, P569, DOI 10.1002/humu.10223; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; Santamaria-Araujo JA, 2004, J BIOL CHEM, V279, P15994, DOI 10.1074/jbc.M311815200; Sloan J, 1999, NUCLEIC ACIDS RES, V27, P854, DOI 10.1093/nar/27.3.854; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Solomon PS, 1999, MICROBIOL-UK, V145, P1421, DOI 10.1099/13500872-145-6-1421; Spiro T. G., 1988, BIOL APPLICATIONS RA, P523; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; THOMSON AJ, 1993, METHOD ENZYMOL, V226, P199, DOI 10.1016/0076-6879(93)26011-W; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Ugulava NB, 2002, J AM CHEM SOC, V124, P9050, DOI 10.1021/ja027004j; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; Walsby CJ, 2002, J AM CHEM SOC, V124, P11270, DOI 10.1021/ja027078v; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10533, DOI 10.1021/bi00498a016; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	76	113	116	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34721	34732		10.1074/jbc.M313398200	http://dx.doi.org/10.1074/jbc.M313398200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180982	hybrid			2022-12-27	WOS:000223134800078
J	Jimenez, A; Zu, W; Rawe, VY; Pelto-Huikko, M; Flickinger, CJ; Sutovsky, P; Gustafsson, JA; Oko, R; Miranda-Vizuete, A				Jimenez, A; Zu, W; Rawe, VY; Pelto-Huikko, M; Flickinger, CJ; Sutovsky, P; Gustafsson, JA; Oko, R; Miranda-Vizuete, A			Spermatocyte/spermatid-specific thioredoxin-3, a novel Golgi apparatus-associated thioredoxin, is a specific marker of aberrant spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; MOLECULAR-CLONING; FIBROUS SHEATH; HUMAN TESTIS; PROTEIN; EXPRESSION; RAT; GENE; ACROSOME; KINASE	Mammalian germ cells are endowed with a complete set of thioredoxins (Trx), a class of redox proteins located in specific structures of the spermatid and sperm tail. We report here the characterization, under normal and pathological conditions, of a novel thioredoxin with a germ line-restricted expression pattern, named spermatocyte/ spermatid-specific thioredoxin-3 (SPTRX-3). The human SPTRX-3 gene maps at 9q32, only 50 kb downstream from the TRX-1 gene from which it probably originated as genomic duplication. Therefore, human SPTRX-3 protein comprises a unique thioredoxin domain displaying high homology with the ubiquitously expressed TRX-1. Among the tissues investigated, Sptrx-3 mRNA is found exclusively in the male germ cells at pachytene spermatocyte and round spermatid stages. Light and electron microscopy show SPTRX-3 protein to be predominately located in the Golgi apparatus of pachytene spermatocytes and round and elongated spermatids, with a transient localization in the developing acrosome of round spermatids. In addition, increased levels of SPTRX-3, possibly caused by overexpression, are observed in morphologically abnormal human spermatozoa from infertile men. In addition, SPTRX-3 is identified as a novel postobstruction autoantigen. In this report, we propose that SPTRX-3 can be used as a specific marker for diverse sperm and testis pathologies. SPTRX-3 is the first thioredoxin specific to the Golgi apparatus, and its function within this organelle might be related to the post-translational modification of proteins required for germ cell-specific functions, such as acrosomal biogenesis.	Karolinska Inst, NOVUM, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Magee Womens Res Inst,Pittsburgh Dev Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Magee Womens Res Inst,Pittsburgh Dev Ctr, Pittsburgh, PA 15213 USA; Tampere Univ, Sch Med, Dept Dev Biol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Pathol, FIN-33101 Tampere, Finland; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Obstet & Gynecol, Columbia, MO 65211 USA	Karolinska Institutet; Queens University - Canada; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Tampere University; Tampere University; Tampere University Hospital; University of Virginia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Miranda-Vizuete, A (corresponding author), Karolinska Inst, NOVUM, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	anmi@biosci.ki.se	Miranda-Vizuete, Antonio/D-6927-2012; Jiménez, Alberto/A-6234-2009; IBIS, REDOX/J-7473-2017	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Jiménez, Alberto/0000-0003-3685-6479; Sutovsky, Peter/0000-0002-9231-2823	NICHD NIH HHS [HD U54 29009] Funding Source: Medline; NIDDK NIH HHS [P450 DK 45179] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045179] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abou-Haila A, 2000, ARCH BIOCHEM BIOPHYS, V379, P173, DOI 10.1006/abbi.2000.1880; Aitken RJ, 2003, MOL HUM REPROD, V9, P645, DOI 10.1093/molehr/gag086; ALEXANDER NJ, 1979, FERTIL STERIL, V32, P253; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Blobel G, 2000, CHEMBIOCHEM, V1, P87; Brede G, 2003, EXP CELL RES, V291, P299, DOI 10.1016/j.yexcr.2003.07.009; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Curry M., 1995, GAMETES SPERMATOZOON, P45; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Eddy E. M., 1994, P29; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Flickinger CJ, 2001, BIOL REPROD, V64, P1451, DOI 10.1095/biolreprod64.5.1451; Flickinger CJ, 1999, J REPROD IMMUNOL, V43, P35, DOI 10.1016/S0165-0378(98)00090-4; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; HANDLEY HH, 1988, BIOL REPROD, V39, P1239, DOI 10.1095/biolreprod39.5.1239; HERMO L, 1991, ANAT REC, V229, P31, DOI 10.1002/ar.1092290106; HIGGY NA, 1995, DEV GENET, V16, P190, DOI 10.1002/dvg.1020160211; Hirota K, 2002, ANN NY ACAD SCI, V957, P189, DOI 10.1111/j.1749-6632.2002.tb02916.x; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Jimenez A, 2002, MOL HUM REPROD, V8, P710, DOI 10.1093/molehr/8.8.710; JINNO A, 1993, MOL CELL BIOL, V13, P4146, DOI 10.1128/MCB.13.7.4146; Jurado J, 2003, J BIOL CHEM, V278, P45546, DOI 10.1074/jbc.M307866200; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Liu F, 2003, GENE, V315, P71, DOI 10.1016/S0378-1119(03)00732-7; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Miranda-Vizuete A, 1998, BIOCHEM BIOPH RES CO, V243, P284, DOI 10.1006/bbrc.1997.8003; Miranda-Vizuete A, 2004, ANTIOXID REDOX SIGN, V6, P25, DOI 10.1089/152308604771978327; Miranda-Vizuete A, 2003, J BIOL CHEM, V278, P44874, DOI 10.1074/jbc.M305475200; Miranda-Vizuete A, 2002, MOL CELLS, V13, P488; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; Moreno RD, 2000, BIOL REPROD, V63, P89, DOI 10.1095/biolreprod63.1.89; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Ogawa K, 1996, MOL BIOL CELL, V7, P1895, DOI 10.1091/mbc.7.12.1895; OHTA E, 2003, J BIOL CHEM; Oko R, 1998, ANDROLOGIA, V30, P193; OKO R, 1993, J CELL BIOL, V123, P809, DOI 10.1083/jcb.123.4.809; Oko R., 1998, ENCY REPROD, P602; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Ramalho-Santos J, 2001, EXP CELL RES, V267, P45, DOI 10.1006/excr.2000.5119; Rawe VY, 2002, HUM REPROD, V17, P2119, DOI 10.1093/humrep/17.8.2119; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Roeder GS, 2000, TRENDS GENET, V16, P395, DOI 10.1016/S0168-9525(00)02080-1; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Rundlof AK, 2004, ANTIOXID REDOX SIGN, V6, P41, DOI 10.1089/152308604771978336; Rybnikova E, 2000, EUR J NEUROSCI, V12, P1669, DOI 10.1046/j.1460-9568.2000.00059.x; Sadek CM, 2003, J BIOL CHEM, V278, P13133, DOI 10.1074/jbc.M300369200; Sadek CM, 2001, GENES CELLS, V6, P1077, DOI 10.1046/j.1365-2443.2001.00484.x; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sasagawa I, 2001, EUR J BIOCHEM, V268, P3053, DOI 10.1046/j.1432-1327.2001.02200.x; Schultz R, 2003, ENDOCRINOLOGY, V144, P767, DOI 10.1210/en.2002-220642; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Spyrou G, 2001, HUM GENET, V109, P429, DOI 10.1007/s004390100597; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sutovsky P, 2001, HUM REPROD, V16, P250, DOI 10.1093/humrep/16.2.250; Svensson MJ, 2003, CHROMOSOMA, V112, P133, DOI 10.1007/s00412-003-0253-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506	64	54	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34971	34982		10.1074/jbc.M404192200	http://dx.doi.org/10.1074/jbc.M404192200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181017	Green Submitted, hybrid			2022-12-27	WOS:000223134800109
J	Murphy, EJ; Barcelo-Coblijn, G; Binas, B; Glatz, JFC				Murphy, EJ; Barcelo-Coblijn, G; Binas, B; Glatz, JFC			Heart fatty acid uptake is decreased in heart fatty acid-binding protein gene-ablated mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; PERFORMANCE LIQUID-CHROMATOGRAPHY; ARACHIDONIC-ACID; ADULT-RAT; SKELETAL-MUSCLE; L-CELLS; LIVER; PHOSPHOLIPIDS; EXPRESSION; PLASMALOGEN	Cell culture systems have demonstrated a role for cytoplasmic fatty acid-binding proteins ( FABP) in lipid metabolism, although a similar function in intact animals is unknown. We addressed this issue using heart fatty acid-binding protein (H-FABP) gene-ablated mice. H-FABP gene ablation reduced total heart fatty acid uptake 40 and 52% for [1-C-14] 16: 0 and [1-C-14] 20: 4n-6 compared with controls, respectively. Similarly, the amount of fatty acid found in the aqueous fraction was reduced 40 and 52% for [1-C-14] 16: 0 and [1-C-14] 20: 4n-6, respectively. Less [1-C-14] 16: 0 entered the triacylglycerol pool, with significant redistribution of fatty acid between the triacylglycerol pool and the total phospholipid pool. Less [1-C-14] 20: 4n-6 entered each lipid pool measured, but these changes did not alter the distribution of tracer among these pools. In gene-ablated mice, significantly more [1-C-14] 16: 0 was targeted to choline and ethanolamine glycerophospholipids, whereas more [1-C-14] 20: 4n-6 was targeted to the phosphatidylinositol ( PtdIns) pool. H-FABP gene ablation significantly increased PtdIns mass 1.4-fold but reduced PtdIns 20: 4n-6 mass 30%. Consistent with a reported effect of FABP on plasmalogen mass, ethanolamine plasmalogen mass was reduced 30% in gene-ablated mice. Further, 20: 4n-6 mass was reduced in each of the three other major phospholipid classes, suggesting H-FABP has a role in maintaining steady-state 20: 4n-6 mass in heart. In summary, H-FABP was important for heart fatty acid uptake and targeting of fatty acids to specific heart lipid pools as well as for maintenance of phospholipid pool mass and acyl chain composition.	Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA; Texas A&M Univ, Dept Pathobiol, College Stn, TX 77843 USA; Cardiovasc Res Inst Maastricht, Dept Mol Genet, NL-6200 MD Maastricht, Netherlands	University of North Dakota Grand Forks; Texas A&M University System; Texas A&M University College Station; Maastricht University	Murphy, EJ (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 501 N Columbia Rd,Rm 3700, Grand Forks, ND 58202 USA.	emurphy@medicine.nodak.edu	Barceló-Coblijn, Gwendolyn/R-4099-2019; Barceló-Coblijn, Gwendolyn/O-1348-2019	Barceló-Coblijn, Gwendolyn/0000-0003-1017-5616				Atkinson LL, 2003, AM J PHYSIOL-ENDOC M, V284, pE923, DOI 10.1152/ajpendo.00360.2002; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Binas B, 2003, AM J PHYSIOL-ENDOC M, V285, pE481, DOI 10.1152/ajpendo.00060.2003; Brockerhoff H, 1975, Methods Enzymol, V35, P315, DOI 10.1016/0076-6879(75)35171-9; DUGAN LL, 1986, J CHROMATOGR, V378, P317, DOI 10.1016/S0378-4347(00)80728-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORD DA, 1991, J CLIN INVEST, V88, P331, DOI 10.1172/JCI115296; FREED LM, 1994, BRAIN RES, V645, P41, DOI 10.1016/0006-8993(94)91636-5; GLATZ JFC, 1989, MOL CELL BIOCHEM, V88, P37, DOI 10.1007/BF00223421; GLATZ JFC, 1994, BIOCHEM BIOPH RES CO, V199, P639, DOI 10.1006/bbrc.1994.1276; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; Hanhoff T, 2002, MOL CELL BIOCHEM, V239, P45, DOI 10.1023/A:1020502624234; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HOHL CM, 1987, BIOCHIM BIOPHYS ACTA, V921, P356, DOI 10.1016/0005-2760(87)90037-3; Holehouse EL, 1998, BBA-LIPID LIPID MET, V1390, P52, DOI 10.1016/S0005-2760(97)00176-8; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; JOLLY CA, 2002, CELLULAR PROTEINS TH; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V267, P77; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; Luiken JJFP, 2003, LIPIDS, V38, P491, DOI 10.1007/s11745-003-1089-6; LUXON BA, 1993, AM J PHYSIOL, V265, pG831, DOI 10.1152/ajpgi.1993.265.5.G831; MARCHESELLI VL, 1988, NEUROMETHODS, V7, P83; McHowat J, 2001, Cardiovasc Toxicol, V1, P253, DOI 10.1385/CT:1:4:253; McHowat J, 1997, AM J PHYSIOL-CELL PH, V272, pC450, DOI 10.1152/ajpcell.1997.272.2.C450; McHowat J, 2000, AM J PHYSIOL-HEART C, V278, pH1933, DOI 10.1152/ajpheart.2000.278.6.H1933; MEIJ JTA, 1990, CARDIOVASC RES, V24, P94, DOI 10.1093/cvr/24.2.94; MEIJ JTA, 1989, MOL CELL BIOCHEM, V88, P73; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Murphy EJ, 2000, LIPIDS, V35, P729, DOI 10.1007/s11745-000-0579-x; MURPHY EJ, 1993, LIPIDS, V28, P565, DOI 10.1007/BF02536090; Murphy EJ, 2000, LIPIDS, V35, P891, DOI 10.1007/S11745-000-0598-7; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; Pavoine C, 1999, J BIOL CHEM, V274, P628, DOI 10.1074/jbc.274.2.628; PROWS DR, 1995, LIPIDS, V30, P907, DOI 10.1007/BF02537481; Prows DR, 1996, CHEM PHYS LIPIDS, V84, P47, DOI 10.1016/S0009-3084(96)02619-9; Qian QH, 1999, CIRC RES, V84, P276, DOI 10.1161/01.RES.84.3.276; RADIN NS, 1988, NEUROMETHODS, V7, P1; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Rosenberger TA, 2002, J LIPID RES, V43, P59; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SADDIK M, 1991, BIOCHIM BIOPHYS ACTA, V1086, P217, DOI 10.1016/0005-2760(91)90010-F; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; SMITH BSW, 1970, CLIN CHIM ACTA, V27, P105, DOI 10.1016/0009-8981(70)90381-5; Steer SA, 2002, AM J PHYSIOL-CELL PH, V283, pC1621, DOI 10.1152/ajpcell.00109.2002; Steinberg SF, 1999, CIRC RES, V85, P1101; STORCH J, 1990, J BIOL CHEM, V265, P7827; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; ZSCHIESCHE W, 1995, HISTOCHEM CELL BIOL, V103, P147, DOI 10.1007/BF01454012	54	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34481	34488		10.1074/jbc.M314263200	http://dx.doi.org/10.1074/jbc.M314263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194696	hybrid			2022-12-27	WOS:000223134800050
J	Robison, JG; Elliott, J; Dixon, K; Oakley, GG				Robison, JG; Elliott, J; Dixon, K; Oakley, GG			Replication protein A and the Mre11 center dot Rad50 center dot Nbs1 complex co-localize and interact at sites of stalled replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-BINDING-PROTEIN; DEPENDENT NUCLEAR-DYNAMICS; MRE11 COMPLEX; RPA PHOSPHORYLATION; CELLULAR-RESPONSE; DAMAGE RESPONSES; WERNER-SYNDROME; ATM ACTIVATION; HISTONE H2AX	In response to replicative stress, cells relocate and activate DNA repair and cell cycle arrest proteins such as replication protein A (RPA, a three subunit protein complex required for DNA replication and DNA repair) and the MRN complex ( consisting of Mre11, Rad50, and Nbs1; involved in DNA double-strand break repair). There is increasing evidence that both of these complexes play a central role in DNA damage recognition, activation of cell cycle checkpoints, and DNA repair pathways. Here we demonstrate that RPA and the MRN complex co-localize to discrete foci and interact in response to DNA replication fork blockage induced by hydroxyurea (HU) or ultraviolet light (UV). Members of both RPA and the MRN complexes become phosphorylated during S-phase and in response to replication fork blockage. Analysis of RPA and Mre11 in fractionated lysates (cytoplasmic/nucleoplasmic, chromatin-bound, and nuclear matrix fractions) showed increased hyperphosphorylated-RPA and phosphorylated-Mre11 in the chromatin-bound fractions. HU and UV treatment also led to co-localization of hyperphosphorylated RPA and Mre11 to discrete detergent-resistant nuclear foci. An interaction between RPA and Mre11 was demonstrated by co-immunoprecipitation of both protein complexes with anti-Mre11, anti-Rad50, anti-NBS1, or anti-RPA antibodies. Phosphatase treatment with calf intestinal phosphatase or lambda-phosphatase not only de-phosphorylated RPA and Mre11 but also abrogated the ability of RPA and the MRN complex to co-immunoprecipitate. Together, these data demonstrate that RPA and the MRN complex co-localize and interact after HU- or UV-induced replication stress and suggest that protein phosphorylation may play a role in this interaction.	Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Oakley, GG (corresponding author), Univ Cincinnati, Coll Med, Dept Environm Hlth, 3223 Eden Ave, Cincinnati, OH 45267 USA.	Greg.Oakley@uc.edu		Oakley, Gregory/0000-0001-6207-0969	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, T32ES007250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034782] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES 06096, T32 ES 07250] Funding Source: Medline; NINDS NIH HHS [R02 NS 34782] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Cheng WH, 2004, J BIOL CHEM, V279, P21169, DOI 10.1074/jbc.M312770200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Digweed M, 2002, ONCOGENE, V21, P4873, DOI 10.1038/sj.onc.1205616; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Liu JS, 2001, BIOCHEMISTRY-US, V40, P14661, DOI 10.1021/bi015680c; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Mochan TA, 2003, CANCER RES, V63, P8586; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; PETRINI JHJ, 1991, P NATL ACAD SCI USA, V88, P7615, DOI 10.1073/pnas.88.17.7615; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rothstein R, 2000, GENE DEV, V14, P1; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	46	120	120	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34802	34810		10.1074/jbc.M404750200	http://dx.doi.org/10.1074/jbc.M404750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180989	hybrid			2022-12-27	WOS:000223134800088
J	Schiffler, B; Zollner, A; Bernhardt, R				Schiffler, B; Zollner, A; Bernhardt, R			Stripping down the mitochondrial cholesterol hydroxylase system, a kinetics study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL STEROID HYDROXYLASES; SITE-DIRECTED MUTAGENESIS; IRON PROTEIN ADRENODOXIN; SIDE-CHAIN CLEAVAGE; ELECTRON-TRANSPORT; BOVINE ADRENODOXIN; CYTOCHROME P450(SCC); COMPLEX-FORMATION; ESCHERICHIA-COLI; LYSINE RESIDUES	The origin of steroid hormones in mammals is cholesterol that is metabolized by the mitochondrial CYP11A1 system. The cytochrome P450 is fed with reduction equivalents via a small electron transfer chain consisting of NADPH, adrenodoxin reductase, and adrenodoxin. Though the redox behavior of the individual protein components has been studied previously, the kinetics of the system in its entirety has not yet been analyzed. In this study we combine surface plasmon resonance experiments to determine the binding constants for the different pairs of redox partners with measurements of the pre-steady-state kinetics of the different reaction steps of this system and steady-state kinetics. We could correlate the individual protein-protein interactions with the effect of distinct reduction-oxidation steps on the overall catalytic activity of the CYP11A1 system. For the first time, we were able to follow the reduction of each of the protein components of this system within one measurement when we mixed all oxidized protein components with NADPH. These measurements allowed the determination of the individual apparent rate constants for the reduction of all three proteins involved. In addition, variation of the ionic strength in these experiments revealed different optimum salt concentrations for the reduction of adrenodoxin reductase and adrenodoxin, respectively, and unraveled dramatically changing reduction rates of CYP11A1 by adrenodoxin.	Univ Saarland, Nat Wissensch Tech Fak 3, FR Biochem 88, D-66041 Saarbrucken, Germany	Saarland University	Bernhardt, R (corresponding author), Univ Saarland, Nat Wissensch Tech Fak 3, FR Biochem 88, POB 151150, D-66041 Saarbrucken, Germany.	ritabern@mx.uni-saarland.de						ADAMOVICH TB, 1989, BIOCHIM BIOPHYS ACTA, V996, P247, DOI 10.1016/0167-4838(89)90254-9; Beckert V, 1997, J BIOL CHEM, V272, P4883, DOI 10.1074/jbc.272.8.4883; Bernhardt R, 1996, REV PHYSIOL BIOCH P, V127, P137, DOI 10.1007/BFb0048267; BRANDT ME, 1993, J BIOL CHEM, V268, P17126; CHU JW, 1973, J BIOL CHEM, V248, P5183; CHU JW, 1973, J BIOL CHEM, V248, P2089; ESTABROOK RW, 1973, IRON SULPHUR PROTEIN, V1, P193; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; Hannemann F, 2001, J BIOL CHEM, V276, P1369, DOI 10.1074/jbc.M007589200; HANUKOGLU I, 1980, J BIOL CHEM, V255, P3057, DOI 10.1016/S0021-9258(19)85851-9; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; Ivanov YD, 1999, BIOCHEM MOL BIOL INT, V47, P327; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; KATAGIRI M, 1977, BIOCHEM BIOPH RES CO, V77, P804, DOI 10.1016/S0006-291X(77)80049-1; Kimura T, 1978, Methods Enzymol, V52, P132; KIMURA T, 1965, BIOCHEM BIOPH RES CO, V20, P373, DOI 10.1016/0006-291X(65)90585-1; KIMURA T, 1967, J BIOL CHEM, V242, P485; LAMBETH JD, 1980, J BIOL CHEM, V255, P4667; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1977, J BIOL CHEM, V252, P2908; LAMBETH JD, 1976, J BIOL CHEM, V251, P4299; LAMBETH JD, 1979, J BIOL CHEM, V254, P2766; LAMBETH JD, 1976, J BIOL CHEM, V251, P7545; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; Miller WL, 1995, J STEROID BIOCHEM, V55, P607, DOI 10.1016/0960-0760(95)00212-X; OMURA T, 1964, J BIOL CHEM, V239, P2370; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; SAGARA Y, 1993, BIOL PHARM BULL, V16, P627; SAGARA Y, 1987, J BIOCHEM-TOKYO, V102, P1333, DOI 10.1093/oxfordjournals.jbchem.a122178; Schiffler B, 2003, BIOCHEM BIOPH RES CO, V312, P223, DOI 10.1016/j.bbrc.2003.09.214; Schiffler B, 2001, J BIOL CHEM, V276, P36225, DOI 10.1074/jbc.M102320200; SHIKITA M, 1974, P NATL ACAD SCI USA, V71, P1441, DOI 10.1073/pnas.71.4.1441; SUGANO S, 1989, ANAL BIOCHEM, V182, P327, DOI 10.1016/0003-2697(89)90603-9; TAKIKAWA O, 1978, ARCH BIOCHEM BIOPHYS, V190, P300, DOI 10.1016/0003-9861(78)90279-5; TULS J, 1989, J BIOL CHEM, V264, P16421; TULS J, 1987, J BIOL CHEM, V262, P10020; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; UHLMANN H, 1995, THESIS HUMBOLDT U BE; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; WADA A, 1992, J BIOL CHEM, V267, P22877; WATARI H, 1966, BIOCHEM BIOPH RES CO, V24, P106, DOI 10.1016/0006-291X(66)90417-7; Zollner A, 2002, J INORG BIOCHEM, V91, P644, DOI 10.1016/S0162-0134(02)00463-4	44	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34269	34276		10.1074/jbc.M402798200	http://dx.doi.org/10.1074/jbc.M402798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181009	hybrid			2022-12-27	WOS:000223134800025
J	Bock, HH; Jossin, Y; May, P; Bergner, O; Herz, J				Bock, HH; Jossin, Y; May, P; Bergner, O; Herz, J			Apolipoprotein E receptors are required for Reelin-induced proteasomal degradation of the neuronal adaptor protein Disabled-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL PLATE DEVELOPMENT; BRAIN-DEVELOPMENT; MONOCLONAL-ANTIBODIES; SIGNALING PATHWAY; TYROSINE KINASES; NERVOUS-SYSTEM; MOUSE-BRAIN; UBIQUITIN; MICE; PHOSPHORYLATION	The cytoplasmic adaptor protein Disabled-1 (Dab1) is necessary for the regulation of neuronal positioning in the developing brain by the secreted molecule Reelin. Binding of Reelin to the neuronal apolipoprotein E receptors apoER2 and very low density lipoprotein receptor induces tyrosine phosphorylation of Dab1 and the subsequent activation or relocalization of downstream targets like phosphatidylinositol 3 (PI3)-kinase and Nckbeta. Disruption of Reelin signaling leads to the accumulation of Dab1 protein in the brains of genetically modified mice, suggesting that Reelin limits its own action in responsive neurons by down-regulating the levels of Dab1 expression. Here, we use cultured primary embryonic neurons as a model to demonstrate that Reelin treatment targets Dab1 for proteolytic degradation by the ubiquitin-proteasome pathway. We show that tyrosine phosphorylation of Dab1 but not PI3-kinase activation is required for its proteasomal targeting. Genetic deficiency in the Dab1 kinase Fyn prevents Dab1 degradation. The Reelin-induced Dab1 degradation also depends on apoER2 and very low density lipoprotein receptor in a gene-dose dependent manner. Moreover, pharmacological blockade of the proteasome prevents the formation of a proper cortical plate in an in vitro slice culture assay. Our results demonstrate that signaling through neuronal apoE receptors can activate the ubiquitin-proteasome machinery, which might have implications for the role of Reelin during neurodevelopment and in the regulation of synaptic transmission.	Univ Freiburg, Dept Med 2, D-79104 Freiburg, Germany; Univ Freiburg, Zentrum Neurowissensch, D-79104 Freiburg, Germany; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Catholic Univ Louvain, Dev Genet Unit, B-1200 Brussels, Belgium	University of Freiburg; University of Freiburg; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universite Catholique Louvain	Herz, J (corresponding author), Univ Freiburg, Dept Med 2, Albertstr 23, D-79104 Freiburg, Germany.	hans.bock@zfn.uni-freiburg.de; joachim.herz@utsouthwestern.edu	Bock, Hans/AAF-2635-2021	Jossin, Yves/0000-0001-8466-7432	NHLBI NIH HHS [HL20948, HL63762, R37 HL063762] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali S, 2003, J BIOL CHEM, V278, P52021, DOI 10.1074/jbc.M306758200; Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Arnaud L, 2003, MOL CELL BIOL, V23, P9293, DOI 10.1128/MCB.23.24.9293-9302.2003; Ballif BA, 2003, MOL BRAIN RES, V117, P152, DOI 10.1016/S0169-328X(03)00295-X; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Beffert U, 2004, J NEUROSCI, V24, P1897, DOI 10.1523/JNEUROSCI.4084-03.2004; Benhayon D, 2003, MOL BRAIN RES, V112, P33, DOI 10.1016/S0169-328X(03)00032-9; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Herrick TM, 2002, DEVELOPMENT, V129, P787; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Hisanaga S, 2003, NEUROSIGNALS, V12, P221, DOI 10.1159/000074624; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Jossin Y, 2003, J NEUROSCI, V23, P9953; Jossin Y, 2004, J NEUROSCI, V24, P514, DOI 10.1523/JNEUROSCI.3408-03.2004; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Mukherjee A, 2003, J BIOL CHEM, V278, P40806, DOI 10.1074/jbc.M306440200; Niu S, 2004, NEURON, V41, P71, DOI 10.1016/S0896-6273(03)00819-5; Ohshima T, 2001, P NATL ACAD SCI USA, V98, P2764, DOI 10.1073/pnas.051628498; Park TJ, 2003, BIOCHEM BIOPH RES CO, V302, P671, DOI 10.1016/S0006-291X(03)00247-X; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 2001, NEURON, V31, P929, DOI 10.1016/S0896-6273(01)00436-6; Rice DS, 1998, DEVELOPMENT, V125, P3719; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Strasser V, 2004, MOL CELL BIOL, V24, P1378, DOI 10.1128/MCB.24.3.1378-1386.2004; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200; Yamanouchi H, 1997, ACTA NEUROPATHOL, V93, P528, DOI 10.1007/s004010050648; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yasha TC, 1997, CLIN NEUROPATHOL, V16, P17; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	62	79	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33471	33479		10.1074/jbc.M401770200	http://dx.doi.org/10.1074/jbc.M401770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175346	hybrid			2022-12-27	WOS:000223039700056
J	Ferrandi, M; Molinari, I; Barassi, P; Minotti, E; Bianchi, G; Ferrari, P				Ferrandi, M; Molinari, I; Barassi, P; Minotti, E; Bianchi, G; Ferrari, P			Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+/K+-ATPASE; ESSENTIAL-HYPERTENSION; NA,K-ATPASE; PLASMA; CELLS; RAT; GLYCOSIDES; INHIBITOR; MECHANISM; PROTEIN	In addition to inhibition of the Na-K ATPase, ouabain activates a signal transduction function, triggering growth and proliferation of cultured cells even at nanomolar concentrations. An isomer of ouabain ( EO) circulates in mammalians at subnanomolar concentrations, and increased levels are associated with cardiac hypertrophy and hypertension. We present here a study of cardiac and renal hypertrophy induced by ouabain infused into rats for prolonged periods and relate this effect to the recently described ouabain-induced activation of the Src-EGFr-ERK signaling pathway. Ouabain infusion into rats ( 15 mu\g/kg/day for 18 weeks) doubled plasma ouabain levels from 0.3 to 0.7 nM and increased blood pressure by 20 mm Hg ( p < 0.001), cardiac left ventricle ( + 11%, p < 0.05), and kidney weight ( + 9%, p < 0.01). These effects in vivo are associated with a significant enrichment of alpha 1, beta 1, gamma a Na-K ATPase subunits together with Src and EGFr in isolated renal caveolae membranes and activation of ERK1/2. In caveolae, direct Na-K ATPase/Src interactions can be demonstrated by co-immunoprecipitation. The interaction is amplified by ouabain, at a high affinity binding site, detectable in caveolae but not in total rat renal membranes. The high affinity site for ouabain is associated with Src-dependent tyrosine phosphorylation of rat alpha 1 Na-K ATPase. The antihypertensive compound, PST 2238, antagonized all ouabain-induced effects at 10 mu g/kg/day in vivo or 10(-10) 10(-8) M in vitro. These findings provide a molecular mechanism for the in vivo pro-hypertrophic and hypertensinogenic activity of ouabain, or by analogy those of EO in humans. They also explain the pharmacological basis for PST 2238 treatment.	Prassis Sigma Tau Res Inst, I-20019 Milan, Italy; Vita & Salute Univ, Div Nephrol Dialysis & Hypertens, Hosp San Raffaele, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ferrandi, M (corresponding author), Prassis Sigma Tau Res Inst, Via Forlanini, I-20019 Milan, Italy.	mara.ferrandi@prassis.it		Bianchi, Giuseppe/0000-0002-8365-3618; BARASSI, PAOLO/0000-0002-8086-2342				Bagrov AY, 1996, AM J HYPERTENS, V9, P982, DOI 10.1016/0895-7061(96)00148-3; BAKER PF, 1970, NATURE, V226, P521, DOI 10.1038/226521a0; Balzan S, 2001, EUR J HEART FAIL, V3, P165, DOI 10.1016/S1388-9842(00)00132-X; Blaustein MP, 1998, CLIN EXP HYPERTENS, V20, P691, DOI 10.3109/10641969809053247; Bozulic LD, 2004, AM J PHYSIOL-CELL PH, V286, pC90, DOI 10.1152/ajpcell.00174.2003; Breton S, 1998, J HISTOCHEM CYTOCHEM, V46, P205, DOI 10.1177/002215549804600209; Dmitrieva RI, 2003, J BIOL CHEM, V278, P28160, DOI 10.1074/jbc.M303768200; FERRAILLE E, 1995, EUR J PHYSL, V430, P205; Ferrandi M, 1996, HYPERTENSION, V28, P1018, DOI 10.1161/01.HYP.28.6.1018; Ferrandi M, 1997, HYPERTENSION, V30, P886, DOI 10.1161/01.HYP.30.4.886; Ferrari P, 1998, J PHARMACOL EXP THER, V285, P83; Gerbi A, 1999, J MEMBRANE BIOL, V168, P19, DOI 10.1007/s002329900494; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; HAMLYN JM, 1982, NATURE, V300, P650, DOI 10.1038/300650a0; JORGENSEN PL, 1986, KIDNEY INT, V29, P10, DOI 10.1038/ki.1986.3; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2000, J BIOL CHEM, V275, P27838; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; Lucking K, 1996, AM J PHYSIOL-RENAL, V271, pF253, DOI 10.1152/ajprenal.1996.271.2.F253; Manunta P, 1999, HYPERTENSION, V34, P450, DOI 10.1161/01.HYP.34.3.450; MANUNTA P, 1994, J HYPERTENS, V12, P549; Manunta P, 2001, HYPERTENSION, V38, P198, DOI 10.1161/01.HYP.38.2.198; Miyakawa-Naito A, 2003, J BIOL CHEM, V278, P50355, DOI 10.1074/jbc.M305378200; Pierdomenico SD, 2001, AM J HYPERTENS, V14, P44, DOI 10.1016/S0895-7061(00)01225-5; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Quadri L, 1997, J MED CHEM, V40, P1561, DOI 10.1021/jm970162e; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; SHAUL P, 1998, AM J PHYSIOL, V276, pL843; Shelly DA, 2004, AM J PHYSIOL-CELL PH, V286, pC813, DOI 10.1152/ajpcell.00389.2003; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Wu BJ, 2001, J EXP BIOL, V204, P4271; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x	36	114	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33306	33314		10.1074/jbc.M402187200	http://dx.doi.org/10.1074/jbc.M402187200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161929	hybrid			2022-12-27	WOS:000223039700037
J	Maertens, G; Cherepanov, P; Debyser, Z; Engelborghs, Y; Engelman, A				Maertens, G; Cherepanov, P; Debyser, Z; Engelborghs, Y; Engelman, A			Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 PREINTEGRATION COMPLEXES; CENTRAL DNA FLAP; LARGE-T-ANTIGEN; VIRAL MATRIX PROTEIN; STRESS-RELATED GENES; NONDIVIDING CELLS; IMPORTIN-BETA; SUBCELLULAR-LOCALIZATION; LENTIVIRAL VECTOR	Human lens epithelium-derived growth factor ( LEDGF)/p75 protein forms a specific nuclear complex with human immunodeficiency virus type 1 (HIV-1) integrase and is essential for nuclear localization and chromosomal association of the viral protein. We now studied nuclear import of LEDGF/p75 in live and semipermeabilized cells. We show that nuclear import of LEDGF/p75 is GTP-, Ran-, importin-alpha/beta-, and energy-dependent and that the protein competes with the canonical SV40 large T antigen nuclear localization signal (NLS) for nuclear import receptors. We identified the NLS of LEDGF/p75 through deletion analysis and site-directed mutagenesis. The LEDGF/p75 NLS, (148)GRKR-KAEKQ(156), belongs to the canonical SV40-like family. Fusion of this short peptide to the amino terminus of Escherichia coli beta-galactosidase rendered the fusion protein nuclear, confirming that the LEDGF/p75 NLS is transferable. Moreover, a single amino acid change in the NLS was sufficient to exclude the mutant LEDGF/ p75 protein from the nucleus and abolish nuclear import of HIV-1 integrase.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Katholieke Univ Leuven, KULAK, B-3000 Louvain, Belgium	Harvard University; Dana-Farber Cancer Institute; KU Leuven; Harvard University; Harvard Medical School; KU Leuven; KU Leuven	Engelman, A (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	Alan_Engelman@dfci.harvard.edu	Cherepanov, Peter P/F-6859-2010; Maertens, Goedele/D-8628-2015	Cherepanov, Peter P/0000-0002-0634-538X; Maertens, Goedele/0000-0002-1963-8026	NIAID NIH HHS [AI52014] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052014] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Armon-Omer A, 2004, J MOL BIOL, V336, P1117, DOI 10.1016/j.jmb.2003.11.057; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; BISCHOFF FR, 1995, METHOD ENZYMOL, V257, P135; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; Dvorin JD, 2002, J VIROL, V76, P12087, DOI 10.1128/JVI.76.23.12087-12096.2002; Fassati A, 2003, EMBO J, V22, P3675, DOI 10.1093/emboj/cdg357; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GULIZIA J, 1994, J VIROL, V68, P2021, DOI 10.1128/JVI.68.3.2021-2025.1994; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Huber J, 2002, J CELL BIOL, V156, P467, DOI 10.1083/jcb.200108114; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kukolj G, 1997, J VIROL, V71, P843, DOI 10.1128/JVI.71.1.843-847.1997; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Limon A, 2002, J VIROL, V76, P12078, DOI 10.1128/JVI.76.23.12078-12086.2002; Limon A, 2002, J VIROL, V76, P10598, DOI 10.1128/JVI.76.21.10598-10607.2002; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Reil H, 1998, EMBO J, V17, P2699, DOI 10.1093/emboj/17.9.2699; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Schwamborn K, 1998, EXP CELL RES, V244, P206, DOI 10.1006/excr.1998.4177; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; Woodward CL, 2003, J VIROL, V77, P4516, DOI 10.1128/JVI.77.8.4516-4527.2003; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	74	82	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33421	33429		10.1074/jbc.M404700200	http://dx.doi.org/10.1074/jbc.M404700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15163664	hybrid, Green Published			2022-12-27	WOS:000223039700050
J	Pacheco, R; Ciruela, F; Casado, V; Mallol, J; Gallart, T; Lluis, C; Franco, R				Pacheco, R; Ciruela, F; Casado, V; Mallol, J; Gallart, T; Lluis, C; Franco, R			Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE; CAMP; ERYTHROCYTE; LYMPHOCYTES; EXPRESSION; MECHANISMS; PLASMA	Metabotropic glutamate receptors (mGluR) are present in cells of the nervous system, where they are activated by one of the main neurotransmitters, glutamate. They are also expressed in cells outside the nervous system. We identified and characterized two receptors belonging to group I mGluR, mGlu1R and mGlu5R, in human cell lines of lymphoid origin and in resting and activated lymphocytes from human peripheral blood. Both are highly expressed in the human Jurkat T cell line, whereas mGlu5R is expressed only in the human B cell line SKW6.4. In blood lymphocytes, mGlu5R is expressed constitutively, whereas mGlu1R is expressed only upon activation via the T cell receptor-CD3 complex. Group I receptors in the central nervous system are coupled to phospholipase C, whereas in blood lymphocytes, activation of mGlu5R does not trigger this signaling pathway, but instead activates adenylate cyclase. On the other hand, mGlu5R does not mediate ERK1/2 activation, whereas mGlu1R, which is coupled neither to phospholipase C nor to calcium channels and whose activation does not increase cAMP, activates the mitogen-activated protein kinase cascade. The differential expression of mGluR in resting and activated lymphocytes and the different signaling pathways that are triggered when mGlu1Rs or mGlu5Rs are activated point to a key role of glutamate in the regulation of T cell physiological function. The study of the signaling pathways ( cAMP production and ERK1/2 phosphorylation) and the proliferative response obtained in the presence of glutamate analogs suggests that mGlu1R and mGlu5R have distinct functions. mGlu5R mediates the reported inhibition of cell proliferation evoked by glutamate, which is reverted by the activation of inducible mGlu1R. This is a novel non-inhibitory action mechanism for glutamate in lymphocyte activation. mGlu1R and mGlu5R thus mediate opposite glutamate effects in human lymphocytes.	Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Univ Barcelona, Div Immunol, Hosp Clin & Prov, Fdn Clin, Barcelona 08026, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Franco, R (corresponding author), Univ Barcelona, Dept Biochem & Mol Biol, Marti Franques 1, E-08028 Barcelona, Spain.	r.franco@bq.ub.es	Franco, Rafael/C-3694-2015; Mallol, Josefa/I-4194-2015; Ciruela, F./A-5096-2013; Casadó, Vicent/K-1660-2014	Franco, Rafael/0000-0003-2549-4919; Mallol, Josefa/0000-0002-2479-4162; Ciruela, F./0000-0003-0832-3739; Casadó, Vicent/0000-0002-1764-3825; Pacheco, Rodrigo/0000-0001-8057-9806				Angelini G, 2002, P NATL ACAD SCI USA, V99, P1491, DOI 10.1073/pnas.022630299; Arslan G, 2002, N-S ARCH PHARMACOL, V365, P150, DOI 10.1007/s002100100456; BOYUM A, 1968, SCAND J CLIN LAB S21, V97, P51; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Dale LB, 2002, NEUROCHEM INT, V41, P319, DOI 10.1016/S0197-0186(02)00073-6; Divino JC, 1998, J ENDOCRINOL, V156, P519, DOI 10.1677/joe.0.1560519; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Ganor Y, 2003, J IMMUNOL, V170, P4362, DOI 10.4049/jimmunol.170.8.4362; Kostanyan IA, 1997, IMMUNOL LETT, V58, P177, DOI 10.1016/S0165-2478(97)00086-2; KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668; Lombardi G, 2001, BRIT J PHARMACOL, V133, P936, DOI 10.1038/sj.bjp.0704134; Mirabet M, 1997, BRIT J PHARMACOL, V122, P1075, DOI 10.1038/sj.bjp.0701495; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Ramstad C, 2000, CELL SIGNAL, V12, P557, DOI 10.1016/S0898-6568(00)00097-8; Sorensen SD, 2003, NEUROPHARMACOLOGY, V44, P699, DOI 10.1016/S0028-3908(03)00053-4; Storto M, 2000, J NEUROIMMUNOL, V109, P112, DOI 10.1016/S0165-5728(00)00269-1; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; Tsai PJ, 1999, METABOLISM, V48, P1455, DOI 10.1016/S0026-0495(99)90159-2; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; WINDER DG, 1993, J NEUROSCI, V13, P38	22	102	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33352	33358		10.1074/jbc.M401761200	http://dx.doi.org/10.1074/jbc.M401761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184389	hybrid, Green Published			2022-12-27	WOS:000223039700042
J	Rivas, M; Mellstrom, B; Naranjo, JR; Santisteban, P				Rivas, M; Mellstrom, B; Naranjo, JR; Santisteban, P			Transcriptional repressor DREAM interacts with thyroid transcription factor-1 and regulates thyroglobulin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; SURFACTANT PROTEIN-C; POTASSIUM CHANNELS; EPITHELIAL-CELLS; BINDING PROTEIN; NUCLEAR-PROTEIN; GROWTH-FACTOR; TSH RECEPTOR; PROMOTER; THYROTROPIN	Tissue-specific gene expression depends on the interaction between tissue-specific and general transcription factors. DREAM is a Ca2+-dependent transcriptional repressor widely expressed in the brain where it participates in nociception through its control of prodynorphin gene expression. In the periphery, DREAM is highly expressed in the thyroid gland, the immune system, and the reproductive organs. Here, we show that DREAM interacts with thyroid-specific transcription factor TTF-1 and regulates the expression of the thyroglobulin (Tg) gene. The mechanism also involves binding of DREAM to the thyroglobulin promoter and blockage of TTF-1-mediated transactivation. The TSH/cAMP pathway and Ca2+ signaling regulate DREAM-mediated transcriptional repression of the thyroglobulin gene. Furthermore, chromatin immunoprecipitation experiments in FRTL-5 cells confirmed that Tg is a bona fide target gene for DREAM transrepression in thyroid follicular cells.	CSIC, CNB, Dpto Biol Mol & Celular, Madrid 28049, Spain; CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Naranjo, JR (corresponding author), CSIC, CNB, Dpto Biol Mol & Celular, Campus Cantoblanco, Madrid 28049, Spain.	naranjo@cnb.csic.es	Santisteban, Pilar/E-7829-2016; NARANJO, Jose R/K-1950-2014	Santisteban, Pilar/0000-0002-2758-796X; NARANJO, Jose R/0000-0002-0270-3469				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1998, MOL CELL BIOL, V18, P6921, DOI 10.1128/MCB.18.12.6921; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CORDA D, 1985, J BIOL CHEM, V260, P9230; DAMANTE G, 1988, MOL CELL ENDOCRINOL, V58, P279, DOI 10.1016/0303-7207(88)90165-7; Damante G, 2001, PROG NUCLEIC ACID RE, V66, P307; De Felice M, 1998, NAT GENET, V19, P395, DOI 10.1038/1289; Decker Patrice, 2002, Current Pharmaceutical Biotechnology, V3, P275, DOI 10.2174/1389201023378265; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Ledo F, 2002, EMBO J, V21, P4583, DOI 10.1093/emboj/cdf440; Ledo F, 2000, MOL CELL BIOL, V20, P9120, DOI 10.1128/MCB.20.24.9120-9126.2000; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Medina DL, 2002, MOL ENDOCRINOL, V16, P33, DOI 10.1210/me.16.1.33; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Pellizzari L, 2000, NUCLEIC ACIDS RES, V28, P2503, DOI 10.1093/nar/28.13.2503; Perrone L, 1999, J BIOL CHEM, V274, P4640, DOI 10.1074/jbc.274.8.4640; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; Spitzweg C, 1998, J CLIN ENDOCR METAB, V83, P1746, DOI 10.1210/jc.83.5.1746; Spreafico F, 2001, MOL CELL NEUROSCI, V17, P1, DOI 10.1006/mcne.2000.0913; Sussel L, 1999, DEVELOPMENT, V126, P3359; Takahashi Y, 2000, GENE DEV, V14, P804; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Yan C, 2001, J BIOL CHEM, V276, P21686, DOI 10.1074/jbc.M011378200; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	50	59	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33114	33122		10.1074/jbc.M403526200	http://dx.doi.org/10.1074/jbc.M403526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15181011	hybrid			2022-12-27	WOS:000223039700013
J	Sinclair, JF; O'Brien, AD				Sinclair, JF; O'Brien, AD			Intimin types alpha, beta, and gamma bind to nucleolin with equivalent affinity but lower avidity than to the translocated intimin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; MURINE COLONIC HYPERPLASIA; CITROBACTER-FREUNDII BIOTYPE; ACTIVATED PROTEIN-KINASES; SITE-DIRECTED MUTAGENESIS; TISSUE-CULTURE CELLS; NF-KAPPA-B; EAE GENE; INFLAMMATORY RESPONSE; ENTEROCYTE EFFACEMENT	The outer membrane adhesins of enteropathogenic Escherichia coli, Citrobacter rodentium, and enterohemorrhagic E. coli (EHEC) O157: H7 that mediate attach and efface intestinal lesions are classified as intimin alpha, beta, and gamma, respectively. Each of these intimin types binds to its cognate, bacterially encoded receptor ( called Tir for translocated intimin receptor) to promote tight adherence of the organism to the host-cell plasma membrane. We previously reported that gamma intimin of EHEC O157: H7 also bound to a eucaryotic receptor that we determined was nucleolin. The objective of this study was to investigate in vitro and in vivo the interactions of intimins alpha, beta, and gamma with nucleolin in the presence of Tir from EHEC O157: H7. Protein binding experiments demonstrated that intimin of types alpha, beta, and gamma bound nucleolin with similar affinity. Moreover, all three intimin types co-localized with regions of nucleolin expressed on the surface of HEp-2 cells. When intimin alpha, beta, or gamma bound to Tir in vitro, the intimin interaction with nucleolin was blocked. Both Tir and nucleolin accumulated beneath intimin-presenting bacteria that had attached to the surface of HEp-2 cells. Taken together, these findings suggest that nucleolin is involved in bacterial adherence promoted by all intimin types and that Tir and nucleolin compete for intimin during adherence.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	O'Brien, AD (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aobrien@usuhs.mil		O'Brien, Alison/0000-0002-1315-3204	NIAID NIH HHS [AI20148-21] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020148, R22AI020148, R01AI020148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTHOLD SW, 1976, LAB ANIM SCI, V26, P889; Batchelor M, 2000, EMBO J, V19, P2452, DOI 10.1093/emboj/19.11.2452; Berin MC, 2002, CELL MICROBIOL, V4, P635, DOI 10.1046/j.1462-5822.2002.00218.x; Celli J, 2000, CELL MICROBIOL, V2, P1, DOI 10.1046/j.1462-5822.2000.00033.x; Czerucka D, 2001, INFECT IMMUN, V69, P1298, DOI 10.1128/IAI.69.3.1298-1305.2001; Dahan S, 2002, INFECT IMMUN, V70, P2304, DOI 10.1128/IAI.70.5.2304-2310.2002; De Grado M, 2001, INFECT IMMUN, V69, P6217, DOI 10.1128/IAI.69.10.6217-6224.2001; Deng WY, 2003, MOL MICROBIOL, V48, P95, DOI 10.1046/j.1365-2958.2003.03429.x; Deng WY, 2001, INFECT IMMUN, V69, P6323, DOI 10.1128/IAI.69.10.6323-6335.2001; DeVinney R, 1999, INFECT IMMUN, V67, P2389, DOI 10.1128/IAI.67.5.2389-2398.1999; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1418, DOI 10.1172/JCI116718; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Fitzhenry RJ, 2002, GUT, V50, P180, DOI 10.1136/gut.50.2.180; Frankel G, 1998, MOL MICROBIOL, V29, P559, DOI 10.1046/j.1365-2958.1998.00950.x; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1995, INFECT IMMUN, V63, P4323, DOI 10.1128/IAI.63.11.4323-4328.1995; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Hartland EL, 2000, INFECT IMMUN, V68, P4637, DOI 10.1128/IAI.68.8.4637-4646.2000; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; Higgins LM, 1999, SCIENCE, V285, P588, DOI 10.1126/science.285.5427.588; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JARVIS KG, 1995, P NATL ACAD SCI USA, V92, P7996, DOI 10.1073/pnas.92.17.7996; JERSE AE, 1991, INFECT IMMUN, V59, P4302, DOI 10.1128/IAI.59.12.4302-4309.1991; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; LEVINE MM, 1978, LANCET, V1, P1119; Liu H, 1999, MOL MICROBIOL, V34, P67, DOI 10.1046/j.1365-2958.1999.01574.x; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; McGraw EA, 1999, MOL BIOL EVOL, V16, P12, DOI 10.1093/oxfordjournals.molbev.a026032; MCKEE ML, 1995, INFECT IMMUN, V63, P3739, DOI 10.1128/IAI.63.9.3739-3744.1995; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; Phillips AD, 2000, MICROBIOL-SGM, V146, P1333, DOI 10.1099/00221287-146-6-1333; Phillips AD, 2000, J INFECT DIS, V181, P1496, DOI 10.1086/315404; Ramachandran V, 2003, J CLIN MICROBIOL, V41, P5022, DOI 10.1128/JCM.41.11.5022-5032.2003; Reece S, 2002, MICROBES INFECT, V4, P1389, DOI 10.1016/S1286-4579(02)00021-7; Reece S, 2001, MOL MICROBIOL, V40, P86, DOI 10.1046/j.1365-2958.2001.02371.x; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; Savkovic SD, 2003, AM J PHYSIOL-CELL PH, V285, pC512, DOI 10.1152/ajpcell.00444.2002; Savkovic SD, 2001, AM J PHYSIOL-GASTR L, V281, pG890, DOI 10.1152/ajpgi.2001.281.4.G890; SCHAUER DB, 1993, INFECT IMMUN, V61, P2486, DOI 10.1128/IAI.61.6.2486-2492.1993; SCHAUER DB, 1993, INFECT IMMUN, V61, P4654, DOI 10.1128/IAI.61.11.4654-4661.1993; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; Sinclair JF, 2002, J BIOL CHEM, V277, P2876, DOI 10.1074/jbc.M110230200; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Tarr CL, 2002, J BACTERIOL, V184, P479, DOI 10.1128/JB.184.2.479-487.2002; Torres AG, 2003, INFECT IMMUN, V71, P4985, DOI 10.1128/IAI.71.9.4985-4995.2003; TZIPORI S, 1995, INFECT IMMUN, V63, P3621, DOI 10.1128/IAI.63.9.3621-3627.1995; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x; Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	57	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33751	33758		10.1074/jbc.M401616200	http://dx.doi.org/10.1074/jbc.M401616200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173179	hybrid			2022-12-27	WOS:000223039700084
J	Vijayan, KV; Liu, Y; Li, TT; Bray, PF				Vijayan, KV; Liu, Y; Li, TT; Bray, PF			Protein phosphatase 1 associates with the integrin alpha(IIb) subunit and regulates signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-CELLS; INTEGRIN ALPHA(IIB)BETA(3); DEPHOSPHORYLATION EVENTS; BINDING PROTEIN; PLATELET; KINASE; ACTIVATION; PHOSPHORYLATION; ADHESION; AVIDITY	Regulation of integrin activation occurs by specific interactions among cytoplasmic proteins and integrin alpha and beta cytoplasmic tails. We report that the catalytic subunit of protein phosphatase 1 (PP1c) constitutively associates with the prototypic integrin alpha(IIb)beta(3) in platelets and in cell lines overexpressing the integrin. PP1c binds directly to the cytoplasmic domain of integrin alpha(IIb) subunit containing a conserved PP1c binding motif (989)KVGF(992). Anchored PP1c is inactive, while thrombin-induced platelet aggregation or fibrinogen-alpha(IIb)beta(3) engagement caused PP1c dissociation and concomitant activation as revealed by dephosphorylation of PP1c substrate, myosin light chain. Inhibition of ligand binding to activated alpha(IIb)beta(3) blocks PP1c dissociation and represses PP1c activation. These studies reveal a previously unrecognized role for integrins whereby the alpha subunit cytoplasmic tail localizes the machinery for initiating and temporally maintaining the regulatory signaling activity of a phosphatase.	Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA	Baylor College of Medicine	Vijayan, KV (corresponding author), Baylor Coll Med, Dept Med, Thrombosis Res Sect, 1 Baylor Plaza,BCM 286,N1319, Houston, TX 77030 USA.	vvijayan@bcm.tmc.edu; pbray@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057488, P50HL065967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57488, HL65967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Barry WT, 2002, J BIOL CHEM, V277, P28877, DOI 10.1074/jbc.M202983200; Bettoun DJ, 2002, J BIOL CHEM, V277, P24847, DOI 10.1074/jbc.C200187200; Bugaud F, 1999, BLOOD, V94, P3800, DOI 10.1182/blood.V94.11.3800.423k25_3800_3805; Cohen PTW, 2002, J CELL SCI, V115, P241; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hedman H, 1996, SCAND J IMMUNOL, V44, P239, DOI 10.1046/j.1365-3083.1996.d01-305.x; HEDMAN H, 1992, J IMMUNOL, V149, P2295; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Larkin D, 2004, J BIOL CHEM, V279, P27286, DOI 10.1074/jbc.M402159200; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Mauco G, 1997, CELL SIGNAL, V9, P117, DOI 10.1016/S0898-6568(96)00119-2; Michelson AD, 2000, CIRCULATION, V101, P1013, DOI 10.1161/01.CIR.101.9.1013; MURATA K, 1995, J CELL BIOCHEM, V57, P120, DOI 10.1002/jcb.240570112; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; Naik UP, 2003, BLOOD, V102, P1355, DOI 10.1182/blood-2003-02-0591; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; Obergfell A, 2002, BLOOD, V100, p122A; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shock David D., 1994, Journal of Tissue Culture Methods, V16, P249, DOI 10.1007/BF01540661; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Vijayan KV, 2003, J BIOL CHEM, V278, P3860, DOI 10.1074/jbc.M208680200	29	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33039	33042		10.1074/jbc.C400239200	http://dx.doi.org/10.1074/jbc.C400239200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15205468	hybrid			2022-12-27	WOS:000223039700002
J	Alexander, DE; Kaczorowski, DJ; Jackson-Fisher, AJ; Lowery, DM; Zanton, SJ; Pugh, BF				Alexander, DE; Kaczorowski, DJ; Jackson-Fisher, AJ; Lowery, DM; Zanton, SJ; Pugh, BF			Inhibition of TATA binding protein dimerization by RNA polymerase III transcription initiation factor Brf1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TFIIIB-DNA COMPLEXES; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; DIMER DISSOCIATION; TERNARY COMPLEX; YEAST TFIIIB; TBP; PROMOTER; GENE; MUTATIONS	The Brf1 subunit of TFIIIB plays an important role in recruiting the TATA-binding protein (TBP) to the upstream region of genes transcribed by RNA polymerase III. When TBP is not bound to promoters, it sequesters its DNA binding domain through dimerization. Promoter assembly factors therefore might be required to dissociate TBP into productively binding monomers. Here we show that Saccharomyces cerevisiae Brf1 induces TBP dimers to dissociate. The high affinity TBP binding domain of Brf1 is not sufficient to promote TBP dimer dissociation but in addition requires the TFIIB homology domain of Brf1. A model is proposed to explain how two distinct functional domains of Brf1 work in concert to dissociate TBP into monomers.	Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pugh, BF (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, N Frear Lab 452, University Pk, PA 16803 USA.	bfp2@psu.edu			NIGMS NIH HHS [R01 GM059055, GM059055] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059055] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; Daugherty MA, 1999, J MOL BIOL, V285, P1389, DOI 10.1006/jmbi.1998.2427; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hahn S, 2000, GENE DEV, V14, P719; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; ICARDLIEPKALNS C, 1993, BIOCHEM BIOPH RES CO, V193, P453, DOI 10.1006/bbrc.1993.1645; Jackson-Fisher AJ, 1999, BIOCHEMISTRY-US, V38, P11340, DOI 10.1021/bi990911p; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Juo ZS, 2003, NATURE, V422, P534, DOI 10.1038/nature01534; KAISER MW, 1995, J BIOL CHEM, V270, P11398, DOI 10.1074/jbc.270.19.11398; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; Kassavetis GA, 2003, J BIOL CHEM, V278, P17912, DOI 10.1074/jbc.M300743200; KASSAVETIS GA, 1994, RAV S MOL C, V3, P107; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kou HP, 2004, J BIOL CHEM, V279, P20966, DOI 10.1074/jbc.M401535200; Kou HP, 2003, MOL CELL BIOL, V23, P3186, DOI 10.1128/MCB.23.9.3186-3201.2003; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Persinger J, 1999, MOL CELL BIOL, V19, P5218; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1994, RNA POLYM 3 TRANSCRI; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x	46	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32401	32406		10.1074/jbc.M405782200	http://dx.doi.org/10.1074/jbc.M405782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15190063	hybrid			2022-12-27	WOS:000222849700053
J	Araki, S; Ito, M; Soyano, T; Nishihama, R; Machida, Y				Araki, S; Ito, M; Soyano, T; Nishihama, R; Machida, Y			Mitotic cyclins stimulate the activity of c-Myb-like factors for transactivation of G(2)/M phase-specific genes in tobacco	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; B-MYB; TRANSCRIPTIONAL ACTIVATION; S-PHASE; PLANT CYTOKINESIS; KINASE COMPLEX; A-TYPE; EXPRESSION; PHOSPHORYLATION; REPRESSION	Myb transcription factors, which contain three imperfect repeats in the Myb domain, are evolutionarily conserved members of the Myb superfamily. Vertebrate Myb proteins with three repeats, c-Myb, A-Myb, and B-Myb, play important roles at the G(1)/S transition in the cell cycle. In plants, this type of Myb protein controls the G(2)/M phase by activating or repressing the transcription of cyclin B genes and a variety of other G(2)/M phase-specific genes. In tobacco, two genes for Myb activators, NtmybA1 and NtmybA2, are transcriptionally controlled and are expressed specifically at the G(2)/M phase. As we showed here, in addition to the control at the transcriptional level, activity of NtmybA2 is also controlled at the post-translational level. We found that the transactivation potential of NtmybA2 is repressed by a regulatory domain located at its carboxyl terminus and that specific classes of cyclins A and B enhanced NtmybA2 activity possibly by relieving this inhibitory effect. Mutations at the 20 potential sites of phosphorylation by cyclin-dependent kinase (CDK) in NtmybA2 blocked the enhancing effects of the cyclins on NtmybA2 activity. Recombinant NtmybA2 was phosphorylated in vitro by a CDK fraction prepared from tobacco BY2 cells. The kinase activity for NtmybA2 in the CDK fraction was cell cycle-regulated in BY2 cells, peaking at the G(2)/M phase when the level of transcripts of cyclin B is maximal. Taken together, our data suggest that NtmybA2 is phosphorylated by a specific cyclin/CDK complex(es) at G2/M and that this phosphorylation removes the inhibitory effect of its C-terminal region, thereby activating NtmybA2 specifically at G(2)/M.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan	Nagoya University; University of Tokyo	Ito, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Regulat Biol Signals, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	masakito@agr.nagoya-u.ac.jp	Nishihama, Ryuichi/X-8623-2019; Ito, Masaki/G-4252-2013	Nishihama, Ryuichi/0000-0002-7032-732X; Ito, Masaki/0000-0002-9635-9709; Soyano, Takashi/0000-0002-0620-6734				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Breeden LL, 2000, CURR BIOL, V10, pR586, DOI 10.1016/S0960-9822(00)00634-5; Breyne P, 2002, P NATL ACAD SCI USA, V99, P14825, DOI 10.1073/pnas.222561199; Chaboute ME, 2002, J BIOL CHEM, V277, P17845, DOI 10.1074/jbc.M200959200; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Dohna CLZ, 2000, FEBS LETT, V484, P77, DOI 10.1016/S0014-5793(00)02133-5; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVANS DA, 1983, INT REV CYTOL S, V16, P33; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; Genschik P, 1998, PLANT CELL, V10, P2063; Guerineau F., 1993, Plant molecular biology labfax., P121; Gutierrez C, 2002, CURR OPIN PLANT BIOL, V5, P480, DOI 10.1016/S1369-5266(02)00301-1; Ito M, 2000, PLANT MOL BIOL, V43, P677, DOI 10.1023/A:1006336005587; Ito M, 1997, PLANT J, V11, P983, DOI 10.1046/j.1365-313X.1997.11050983.x; Ito M, 1998, PLANT CELL, V10, P331; Ito M, 2001, PLANT CELL, V13, P1891, DOI 10.1105/tpc.13.8.1891; Kosugi S, 2002, PLANT J, V29, P45, DOI 10.1046/j.1365-313x.2002.01196.x; Kranz H, 2000, PLANT J, V21, P231, DOI 10.1046/j.1365-313x.2000.00666.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lavia P, 1999, BIOESSAYS, V21, P221; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; Menges M, 2002, J BIOL CHEM, V277, P41987, DOI 10.1074/jbc.M207570200; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Nakagami H, 2002, PLANT CELL, V14, P1847, DOI 10.1105/tpc.002550; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; Nishihama R, 2002, CELL, V109, P87, DOI 10.1016/S0092-8674(02)00691-8; Okada M, 2002, EMBO J, V21, P675, DOI 10.1093/emboj/21.4.675; Potrykus, 1994, PLANT MOL BIOL MAN A, P1; Reindl A, 1997, PLANT PHYSIOL, V115, P93, DOI 10.1104/pp.115.1.93; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Renaudin JP, 1996, PLANT MOL BIOL, V32, P1003, DOI 10.1007/BF00041384; Reynolds D, 2003, GENE DEV, V17, P1789, DOI 10.1101/gad.1074103; Robinson C, 1996, ONCOGENE, V12, P1855; Rosinski JA, 1998, J MOL EVOL, V46, P74, DOI 10.1007/PL00006285; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Schwechheimer C, 1998, PLANT MOL BIOL, V36, P195, DOI 10.1023/A:1005990321918; Setiady YY, 1996, PLANT CELL PHYSIOL, V37, P369, DOI 10.1093/oxfordjournals.pcp.a028955; Setiady YY, 1995, PLANT J, V8, P949, DOI 10.1046/j.1365-313X.1995.8060949.x; Soyano T, 2003, GENE DEV, V17, P1055, DOI 10.1101/gad.1071103; Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vandepoele K, 2002, PLANT CELL, V14, P903, DOI 10.1105/tpc.010445; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	53	92	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32979	32988		10.1074/jbc.M403171200	http://dx.doi.org/10.1074/jbc.M403171200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175336	hybrid			2022-12-27	WOS:000222849700118
J	Lozach, PY; Amara, A; Bartosch, B; Virelizier, JL; Arenzana-Seisdedos, F; Cosset, FL; Altmeyer, R				Lozach, PY; Amara, A; Bartosch, B; Virelizier, JL; Arenzana-Seisdedos, F; Cosset, FL; Altmeyer, R			C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC CELLS; GLYCOPROTEIN E2; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; EFFICIENT INFECTION; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; ENVELOPE PROTEIN; DNA FLAP; B VIRUS	The molecular mechanisms involved in the hepatic tropism of hepatitis C virus (HCV) have not been identified. We have shown previously that liver-expressed C-type lectins L-SIGN and DC-SIGN bind the HCV E2 glycoprotein with high affinity (Lozach, P. Y., Lortat-Jacob, H., de Lacroix de Lavalette, A., Staropoli, I., Foung, S., Amara, A., Houles, C., Fieschi, F., Schwartz, O., Virelizier, J. L., Arenzana-Seisdedos, F., and Altmeyer, R. ( 2003) J. Biol. Chem. 278, 20358-20366). To analyze the functional relevance of this interaction, we generated pseudotyped lentivirus particles presenting HCV glycoproteins E1 and E2 at the virion surface (HCV-pp). High mannose N-glycans are present on E1 and, to a lesser extent, on E2 proteins of mature infectious HCV-pp. Such particles bind to both L-SIGN and DC-SIGN, but they cannot use these receptors for entry into cells. However, infectious virus is transmitted efficiently when permissive Huh-7 cells are cocultured with HCV-pp bound to L-SIGN or to DC-SIGN-positive cell lines. HCV-pp transmission via L-SIGN or DC-SIGN is inhibited by characteristic inhibitors such as the calcium chelator EGTA and monoclonal antibodies directed against lectin carbohydrate recognition domains of both lectins. In support of the biological relevance of this phenomenon, dendritic cells expressing endogenous DC-SIGN transmitted HCV-pp with high efficiency in a DC-SIGN-dependent manner. Our results support the hypothesis that C-type lectins such as the liver sinusoidal endothelial cell-expressed L-SIGN could act as a capture receptor for HCV in the liver and transmit infectious virions to neighboring hepatocytes.	Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France; Ecole Normale Super Lyon, Inst Federat Rech 74, Lab Vectorol Retrovirale & Therapie Genique, INSERM,U412, F-69364 Lyon 07, France; Univ Hong Kong, Pasteur Res Ctr, Hong Kong, Hong Kong, Peoples R China	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Hong Kong	Altmeyer, R (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75015 Paris, France.	altmeyer@hkucc.hku.hk	Bartosch, Birke/I-7255-2018; Lozach, Pierre-Yves/H-7072-2015	Bartosch, Birke/0000-0001-6354-4660; AMARA, Ali/0000-0002-0283-1815; Cosset, Francois-Loic/0000-0001-8842-3726; Lozach, Pierre-Yves/0000-0002-9966-1452				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Agnello V, 1998, HEPATOLOGY, V28, P573, DOI 10.1002/hep.510280240; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Amara A, 2003, J VIROL, V77, P2550, DOI 10.1128/JVI.77.4.2550-2558.2003; Barth H, 2003, J BIOL CHEM, V278, P41003, DOI 10.1074/jbc.M302267200; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; BLIGHT K, 1993, AM J PATHOL, V143, P1568; Breiner KM, 2001, HEPATOLOGY, V34, P803, DOI 10.1053/jhep.2001.27810; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Goutagny N, 2003, J INFECT DIS, V187, P1951, DOI 10.1086/375350; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; KEMPKA G, 1988, EXP CELL RES, V176, P38, DOI 10.1016/0014-4827(88)90118-8; Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Limmer A, 1998, EUR J IMMUNOL, V28, P2395, DOI 10.1002/(SICI)1521-4141(199808)28:08<2395::AID-IMMU2395>3.0.CO;2-D; Liu WL, 2004, J BIOL CHEM, V279, P18748, DOI 10.1074/jbc.M311227200; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Navas MC, 2002, J MED VIROL, V67, P152, DOI 10.1002/jmv.2204; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Royer C, 2003, J HEPATOL, V38, P250, DOI 10.1016/S0168-8278(02)00418-X; Saunier B, 2003, J VIROL, V77, P546, DOI 10.1128/JVI.77.1.546-559.2003; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Schwartz AJ, 2002, AIDS RES HUM RETROV, V18, P1021, DOI 10.1089/08892220260235380; Swameye I, 1997, J VIROL, V71, P9434, DOI 10.1128/JVI.71.12.9434-9441.1997; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Wu L, 2004, VIROLOGY, V318, P17, DOI 10.1016/j.virol.2003.09.028; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; YONEYAMA H, 2003, 10 INT M HEP C VIR R, P26; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115	48	146	159	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32035	32045		10.1074/jbc.M402296200	http://dx.doi.org/10.1074/jbc.M402296200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166245	hybrid, Green Published			2022-12-27	WOS:000222849700007
J	Sakamoto, S; Potla, R; Larner, AC				Sakamoto, S; Potla, R; Larner, AC			Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; DNA; PROTEIN; GAMMA; EXPRESSION; INDUCTION; ELEMENT; ALPHA; STAT1	Posttranslational modification of histones by acetylation, methylation or phosphorylation has emerged as a major mechanism to modify chromatin structure and gene expression. In most cases, transcriptionally active genes display enhanced binding of acetylated histones in their promoters. Activation of histone acetyltransferases or inhibition of histone deacetylases (HDACs) allows chromatin to assume a more open state permitting transcriptional activators to form a preinitiation complex. To our surprise, treatment of cells with the HDAC inhibitor, trichostatin A (TSA), inhibits selected interferon beta (IFNbeta)-stimulated immediate early genes that are activated by the transcription factors Stat1 and Stat2. However, IFNbeta activation of IRF-1, which requires tyrosine-phosphorylated Stat1 homodimers binding to a gamma interferon activation sequence in its promoter is not affected by TSA. Exposure of cells to TSA does not alter tyrosine phosphorylation of Stat1 or Stat2. TSA treatment of cells also does not alter the binding of Stat 1 or Stat2 to the endogenous ISG54 promoter. However, IFNbeta-stimulated binding of RNA polymerase II to the ISG54 promoter is prevented by TSA. Interestingly, ectopic expression of IRF9 reverses the inhibitory actions of TSA, suggesting that IRF9 functions to recruit RNA polymerase II to the promoter of interferon-stimulated genes. This particular function of IRF9 requires the activity of histone deacetylases.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Larner, AC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	larnera@ccf.org			NCI NIH HHS [CA77366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kraus TA, 2003, J BIOL CHEM, V278, P13033, DOI 10.1074/jbc.M212972200; Larner AC, 2000, CANC DRUG DISC DEV, V5, P393; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Masumi A, 2003, J BIOL CHEM, V278, P25401, DOI 10.1074/jbc.M213037200; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Sakamoto S, 2004, J BIOL CHEM, V279, P3245, DOI 10.1074/jbc.M309631200; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	22	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40362	40367		10.1074/jbc.M406400200	http://dx.doi.org/10.1074/jbc.M406400200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15194680	hybrid			2022-12-27	WOS:000223916800019
J	Hao, G; Xie, LJ; Gross, SS				Hao, G; Xie, LJ; Gross, SS			Argininosuccinate synthetase is reversibly inactivated by S-nitrosylation in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; VASCULAR SMOOTH-MUSCLE; ARGININE METABOLISM; MESSENGER-RNAS; L-CITRULLINE; LYASE; MITOCHONDRIA; CELLS; NO; LOCALIZATION	Prior studies have demonstrated that the substrate for NO synthesis, L-arginine, can be regenerated from the NOS co-product L-citrulline. This requires the sequential action of two enzymes, argininosuccinate synthetase (AS) and argininosuccinate lyase (AL). AS activity has been shown to be rate-limiting for high output NO synthesis by immunostimulant-activated cells and represents a potential site for metabolic control of NO synthesis. We now demonstrate that NO mediates reversible S-nitrosylation and inactivation of AS in vitro and in lipopolysaccharide-treated cells and mice. Using a novel mass spectrometry-based method, we show that Cys-132 in human AS is the sole target for S-nitrosylation among five Cys residues. Mutagenesis studies confirm that S-nitrosylation of Cys-132 is both necessary and sufficient for the inhibition of AS by NO donors. S-nitroso-AS content is regulated by cellular glutathione levels and selectively influences NO production when citrulline is provided to cells as a protosubstrate of NOS but not when L-arginine is provided. A phylogenetic comparison of AS sequences suggests that Cys-132 evolved as a site for post-translational regulation of activity in the AS in NOS-expressing species, endowing NO with the capacity to limit its own synthesis by restricting arginine availability.	Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Program Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Program Biochem & Struct Biol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Gross, SS (corresponding author), Cornell Univ, Weill Med Coll, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.	ssgross@mail.med.cornell.edu			NHLBI NIH HHS [HL 50656, HL 46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050656, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Cohen NS, 1996, J CELL BIOCHEM, V61, P81, DOI 10.1002/(SICI)1097-4644(19960401)61:1<81::AID-JCB10>3.3.CO;2-Z; Farghali H, 1999, METHOD FIND EXP CLIN, V21, P395, DOI 10.1358/mf.1999.21.6.541919; Flam BR, 2001, NITRIC OXIDE-BIOL CH, V5, P187, DOI 10.1006/niox.2001.0340; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GROSS SS, 1993, ADV EXP MED BIOL, V338, P295; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Gross SS, 1996, METHOD ENZYMOL, V268, P159; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1995, BIOCHEM BIOPH RES CO, V215, P148, DOI 10.1006/bbrc.1995.2445; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Kolb JP, 2000, LEUKEMIA, V14, P1685, DOI 10.1038/sj.leu.2401896; KUMAR S, 1985, P NATL ACAD SCI USA, V82, P6745, DOI 10.1073/pnas.82.20.6745; Kurz S, 1997, J CLIN INVEST, V99, P369, DOI 10.1172/JCI119166; Lane P, 1999, SEMIN NEPHROL, V19, P215; Lipton SA, 1996, TRENDS PHARMACOL SCI, V17, P186, DOI 10.1016/0165-6147(96)20028-8; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; ROSENTHAL GA, 1969, BIOCHEM J, V112, P415, DOI 10.1042/bj1120415; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Shiloh MU, 2000, CURR OPIN MICROBIOL, V3, P35, DOI 10.1016/S1369-5274(99)00048-X; SHUTTLEWORTH CWR, 1995, NEUROSCIENCE, V68, P1295, DOI 10.1016/0306-4522(95)00193-M; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624; Xie LJ, 2000, SEMIN PERINATOL, V24, P42, DOI 10.1016/S0146-0005(00)80054-3; Yoon JH, 2000, FEBS LETT, V474, P175, DOI 10.1016/S0014-5793(00)01599-4	41	66	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36192	36200		10.1074/jbc.M404866200	http://dx.doi.org/10.1074/jbc.M404866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192091	hybrid			2022-12-27	WOS:000223453600006
J	Tkach, JM; Glover, JR				Tkach, JM; Glover, JR			Amino acid substitutions in the C-terminal AAA(+) module of Hsp104 prevent substrate recognition by disrupting oligomerization and cause high temperature inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-LOCALIZATION; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ATPASE DOMAIN; YEAST; PROPAGATION; CLPB	Hsp104 is an important determinant of thermotolerance in yeast and is an unusual molecular chaperone that specializes in the remodeling of aggregated proteins. The structural requirements for Hsp104-substrate interactions remain unclear. Upon mild heat shock Hsp104 formed cytosolic foci in live cells that indicated co-localization of the chaperone with aggregates of thermally denatured proteins. We generated random amino acid substitutions in the C-terminal 199 amino acid residues of a GFP-Hsp104 fusion protein, and we used a visual screen to identify mutants that remained diffusely distributed immediately after heat shock. Multiple amino acid substitutions were required for loss of heat-inducible redistribution, and this correlated with complete loss of nucleotide-dependent oligomerization. Based on the multiply substituted proteins, several single amino acid substitutions were generated by site-directed mutagenesis. The singly substituted proteins retained the ability to oligomerize and detect substrates. Intriguingly, some derivatives of Hsp104 functioned well in prion propagation and multiple stress tolerance but failed to protect yeast from extreme thermal stress. We demonstrate that these proteins co-aggregate in the presence of other thermolabile proteins during heat treatment both in vitro and in vivo suggesting a novel mechanism for uncoupling the function of Hsp104 in acute severe heat shock from its functions at moderate temperatures.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Glover, JR (corresponding author), Univ Toronto, Dept Biochem, Rm 5302 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	john.glover@utoronto.ca						Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Chernoff YO, 1999, MOL CELL BIOL, V19, P8103; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Fujita K, 1998, BIOCHEM BIOPH RES CO, V248, P542, DOI 10.1006/bbrc.1998.9008; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Kawai R, 1999, CELL STRESS CHAPERON, V4, P46, DOI 10.1054/csac.1999.0076; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; LinGoerke JL, 1997, BIOTECHNIQUES, V23, P409, DOI 10.2144/97233bm12; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Santoro N, 1998, MOL CELL BIOL, V18, P6340, DOI 10.1128/MCB.18.11.6340; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; Schirmer EC, 1998, METHOD ENZYMOL, V290, P430, DOI 10.1016/S0076-6879(98)90036-2; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Tuite MF, 1996, TRENDS GENET, V12, P467, DOI 10.1016/0168-9525(96)10045-7; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001; Weibezahn J, 2003, J BIOL CHEM, V278, P32608, DOI 10.1074/jbc.M303653200; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	52	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35692	35701		10.1074/jbc.M400782200	http://dx.doi.org/10.1074/jbc.M400782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15178690	hybrid			2022-12-27	WOS:000223303400067
J	Igarashi, RY; Dos Santos, PC; Niehaus, WG; Dance, IG; Dean, DR; Seefeldt, LC				Igarashi, RY; Dos Santos, PC; Niehaus, WG; Dance, IG; Dean, DR; Seefeldt, LC			Localization of a catalytic intermediate bound to the FeMo-cofactor of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; MOLYBDENUM IRON PROTEIN; MOFE-PROTEIN; ANGSTROM RESOLUTION; SUBSTRATE REDUCTION; ALPHA-SUBUNIT; BINDING; HISTIDINE-195; ACETYLENE; INHIBITOR	Nitrogenase catalyzes the biological reduction of N-2 to ammonia ( nitrogen fixation) as well as the reduction of a number of alternative substrates, including acetylene (HC = CH) to ethylene (H2C = CH2). It is known that the metallocluster FeMo-cofactor located within the nitrogenase MoFe protein component provides the site of substrate reduction, but the exact site where substrates bind and are reduced on the FeMo-cofactor remains unknown. We have recently shown that the alpha-70 residue of the MoFe protein plays a significant role in defining substrate access to the active site; alpha-70 approaches one face of the FeMo-cofactor, and when valine is substituted by alanine at this position, the substituted nitrogenase is able to accommodate a reduction of the larger alkyne propargyl alcohol (HC = CCH2OH, propargyl-OH). During this reduction, a substrate-derived intermediate can be trapped on the FeMo-cofactor resulting in an S = 1/2 spin system with a novel electron paramagnetic resonance spectrum. In the present work, trapping of the propargyl-OH-derived or propargyl amine (HC = CCH2NH2, propargyl-NH2)- derived intermediates is shown to be dependent on pH and the presence of histidine at position alpha-195. It is concluded that these catalytic intermediates are stabilized and thereby trapped by H-bonding interactions between either the - OH group or the - NH3+ group and the imidazole epsilon-NH of alpha-195(His). Thus, for the first time it is possible to establish the location of a bound substrate-derived intermediate on the FeMo-cofactor. Refinement of the binding mode and site was accomplished by the use of density functional and force field calculations pointing to an eta(2) coordination at Fe-6 of the FeMo-cofactor.	Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA; Univ New S Wales, Sch Chem Sci, Sydney, NSW 2052, Australia	Virginia Polytechnic Institute & State University; Utah System of Higher Education; Utah State University; University of New South Wales Sydney	Dean, DR (corresponding author), Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA.	deandr@vt.edu; seefeldt@cc.usu.edu		Dos Santos, Patricia/0000-0002-3364-0931; Seefeldt, Lance/0000-0002-6457-9504	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059087] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59087] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benton PMC, 2003, BIOCHEMISTRY-US, V42, P9102, DOI 10.1021/bi034595x; Benton PMC, 2001, BIOCHEMISTRY-US, V40, P13816, DOI 10.1021/bi011571m; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; Chang FC, 1997, BIOCHEMISTRY-US, V36, P9013, DOI 10.1021/bi970783+; Christiansen J, 2000, PROKARYOTIC NITROGEN FIXATION, P101; Christiansen J, 2000, J BIOL CHEM, V275, P36104, DOI 10.1074/jbc.M004889200; Christiansen J, 2000, J BIOL CHEM, V275, P11459, DOI 10.1074/jbc.275.15.11459; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dance I, 2003, CHEM COMMUN, P324, DOI 10.1039/b211036a; DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452; Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015; Delley B., 1995, MODERN DENSITY FUNCT, V2, P221; Demadis KD, 1996, INORG CHEM, V35, P4038, DOI 10.1021/ic960098b; Dilworth MJ, 1998, BIOCHEMISTRY-US, V37, P17495, DOI 10.1021/bi9812017; Durrant MC, 2002, BIOCHEMISTRY-US, V41, P13934, DOI 10.1021/bi025623z; Edgcomb SP, 2002, PROTEINS, V49, P1, DOI 10.1002/prot.10177; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Fisher K, 2000, BIOCHEMISTRY-US, V39, P15570, DOI 10.1021/bi0017834; Graton J, 1999, J CHEM SOC PERK T 2, P997, DOI 10.1039/a809265f; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LEE HI, 2004, IN PRESS J AM CHEM S; Malinak SM, 1997, J AM CHEM SOC, V119, P1662, DOI 10.1021/ja963475s; Mayer SM, 1999, J MOL BIOL, V292, P871, DOI 10.1006/jmbi.1999.3107; Mayer SM, 2002, J CHEM SOC DALTON, P802, DOI 10.1039/b107336b; PHAM DN, 1993, BIOCHEMISTRY-US, V32, P13725, DOI 10.1021/bi00212a043; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; SCHROCK RR, 1988, INORG CHEM, V27, P3574, DOI 10.1021/ic00293a027; Seefeldt LC, 2004, BIOCHEMISTRY-US, V43, P1401, DOI 10.1021/bi036038g; SEEFELDT LC, 1995, BIOCHEMISTRY-US, V34, P5382, DOI 10.1021/bi00016a009; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100	36	68	69	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34770	34775		10.1074/jbc.M403194200	http://dx.doi.org/10.1074/jbc.M403194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181010	hybrid			2022-12-27	WOS:000223134800084
J	Jette, C; Peterson, PW; Sandoval, IT; Manos, EJ; Hadley, E; Ireland, CM; Jones, DA				Jette, C; Peterson, PW; Sandoval, IT; Manos, EJ; Hadley, E; Ireland, CM; Jones, DA			The tumor suppressor adenomatous polyposis coli and caudal related homeodomain protein regulate expression of retinol dehydrogenase L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; ABERRANT CRYPT FOCI; EPITHELIAL STEM-CELL; BETA-CATENIN; DOWN-REGULATION; CYCLIN D1; SODIUM-BUTYRATE; CDX2 EXPRESSION; ACID SYNTHESIS; HOMEOBOX GENE	Development of normal colon epithelial cells proceeds through a systematic differentiation of cells that emerge from stem cells within the base of colon crypts. Genetic mutations in the adenomatous polyposis coli (APC) gene are thought to cause colon adenoma and carcinoma formation by enhancing colonocyte proliferation and impairing differentiation. We currently have a limited understanding of the cellular mechanisms that promote colonocyte differentiation. Herein, we present evidence supporting a lack of retinoic acid biosynthesis as a mechanism contributing to the development of colon adenomas and carcinomas. Microarray and reverse transcriptase-PCR analyses revealed reduced expression of two retinoid biosynthesis genes: retinol dehydrogenase 5 (RDH5) and retinol dehydrogenase L (RDHL) in colon adenomas and carcinomas as compared with normal colon. Consistent with the adenoma and carcinomas samples, seven colon carcinoma cell lines also lacked expression of RDH5 and RDHL. Assessment of RDH enzymatic activity within these seven cell lines showed poor conversion of retinol into retinoic acid when compared with normal cells such as normal human mammary epithelial cells. Reintroduction of wild type APC into an APC-deficient colon carcinoma cell line (HT29) resulted in increased expression of RDHL without affecting RDH5. APC-mediated induction of RDHL was paralleled by increased production of retinoic acid. Investigations into the mechanism responsible for APC induction of RDHL indicated that beta-catenin fails to repress RDHL. The colon-specific transcription factor CDX2, however, activated an RDHL promoter construct and induced endogenous RDHL. Finally, the induction of RDHL by APC appears dependent on the presence of CDX2. We propose a novel role for APC and CDX2 in controlling retinoic acid biosynthesis and in promoting a retinoid-induced program of colonocyte differentiation.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope,Rm 5262, Salt Lake City, UT 84112 USA.	david.jones@hci.utah.edu			NIGMS NIH HHS [5T32 GM 07464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Adachi Y, 2001, TUMOR BIOL, V22, P247, DOI 10.1159/000050623; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BLANER WS, 1999, RETINOIDS BIOCH MOL, P117; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Buckhaults P, 2001, CANCER RES, V61, P6996; Cerignoli F, 2002, CANCER RES, V62, P1196; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Clatworthy JP, 2001, MECH DEVELOP, V101, P3, DOI 10.1016/S0925-4773(00)00557-8; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; DE LUCA LM, 1994, NUTR REV, V52, P45; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; EE HC, 1995, AM J PATHOL, V147, P586; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; GLICK AB, 1991, DEVELOPMENT, V111, P1081; Guo XJ, 2002, CANCER RES, V62, P1654; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Maden M, 1999, BIOESSAYS, V21, P809, DOI 10.1002/(SICI)1521-1878(199910)21:10<809::AID-BIES2>3.0.CO;2-0; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mariadason JM, 2001, CANCER RES, V61, P3465; Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murakami R, 1999, CELL MOL BIOL, V45, P661; NARISAWA T, 1976, CANCER RES, V36, P1379; Nicke B, 1999, BIOCHEM BIOPH RES CO, V261, P572, DOI 10.1006/bbrc.1999.1086; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; NILES RM, 1988, CANCER INVEST, V6, P39, DOI 10.3109/07357908809077027; NOY N, 1999, HANDB EXP PHARM, V139, P3; NZEGWU H, 1991, GUT, V32, P1324, DOI 10.1136/gut.32.11.1324; NZEGWU HC, 1992, GUT, V33, P794, DOI 10.1136/gut.33.6.794; OTORI K, 1995, CANCER RES, V55, P4743; Pereira MA, 1999, ADV EXP MED BIOL, V470, P55; PERUMAL AS, 1968, BIOCHIM BIOPHYS ACTA, V170, P399, DOI 10.1016/0304-4165(68)90019-6; PERUMAL AS, 1966, BIOCHIM BIOPHYS ACTA, V124, P95, DOI 10.1016/0304-4165(66)90316-3; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Rexer BN, 2001, CANCER RES, V61, P7065; Reynolds S, 1998, CANCER LETT, V134, P53, DOI 10.1016/S0304-3835(98)00242-0; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Soref CM, 2001, J BIOL CHEM, V276, P24194, DOI 10.1074/jbc.M100332200; Sparks AB, 1998, CANCER RES, V58, P1130; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; VOGEL S, 1999, RETINOIDS BIOCH MOL, P31; Wargovich MJ, 2000, CARCINOGENESIS, V21, P1149, DOI 10.1093/carcin/21.6.1149; Wright NA, 2000, INT J EXP PATHOL, V81, P117, DOI 10.1046/j.1365-2613.2000.00146.x; Zheng Y, 1997, CARCINOGENESIS, V18, P2119, DOI 10.1093/carcin/18.11.2119; Zheng Y, 1999, CARCINOGENESIS, V20, P255, DOI 10.1093/carcin/20.2.255; ZILE M, 1977, J NUTR, V107, P552, DOI 10.1093/jn/107.4.552; ZILE M, 1970, ARCH BIOCHEM BIOPHYS, V140, P210, DOI 10.1016/0003-9861(70)90024-X	68	54	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34397	34405		10.1074/jbc.M314021200	http://dx.doi.org/10.1074/jbc.M314021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190067	hybrid			2022-12-27	WOS:000223134800040
J	Mitsushima, M; Suwa, A; Amachi, T; Ueda, K; Kioka, N				Mitsushima, M; Suwa, A; Amachi, T; Ueda, K; Kioka, N			Extracellular signal-regulated kinase activated by epidermal growth factor and cell adhesion interacts with and phosphorylates vinexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCULIN-BINDING PROTEIN; MAP KINASE; CYTOSKELETAL ORGANIZATION; TRANSCRIPTION FACTORS; ESTROGEN-RECEPTOR; STRESS FIBERS; DOCKING SITES; IN-VIVO; MITOGEN; INTEGRIN	Extracellular signal-regulated kinase 1/2 (ERK1/2) is activated by various extracellular stimuli including growth factors and cytokines and plays a pivotal role in regulating cell proliferation and differentiation by phosphorylating nuclear transcription factors. Recently, it was reported that activated ERK1/2 also concentrates at adhesion sites and regulates cell spreading and migration. Vinexin is a focal adhesion protein regulating both cell spreading and growth factor signaling. We show here that vinexin was directly phosphorylated by ERK1/2 upon stimulation with growth factors. ERK1/2 phosphorylated the linker region of vinexin between the second and third SH3 domains. Site-directed mutagenesis revealed that ERK2 mainly phosphorylated the serine 189 residue of vinexin beta. Furthermore, vinexin beta interacted with ERK1/2 both in vitro and in vivo. Vinexin interacted with the active but not inactive form of ERK1/2. A putative DEF ( docking for ERK FXFP) domain located in the linker region of vinexin was required for the interaction with ERK1/2 and efficient phosphorylation of vinexin beta by ERK2. Finally, we showed that cell adhesion to fibronectin also induced the association of vinexin beta with ERK2 and the phosphorylation of vinexin beta. Furthermore, vinexin and ERK were co-localized to the periphery of cells during cell spreading on fibronectin. Together, these results suggest that vinexin is a novel substrate of ERK2 and may play roles in ERK-dependent cell regulation during cell spreading as well as in growth factor-induced responses.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Kioka, N (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	nkioka@kais.kyoto-u.ac.jp		Ueda, Kazumitsu/0000-0003-2980-6078; Kioka, Noriyuki/0000-0002-2708-537X				Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; SCHLAEPFER DD, 1994, NATURE, V372, P786; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; TUJAGUE M, 2003, J BIOL CHEM; UEKI K, 1994, J BIOL CHEM, V269, P15756; Wakabayashi M, 2003, J BIOL CHEM, V278, P21709, DOI 10.1074/jbc.M211004200; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	48	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34570	34577		10.1074/jbc.M402304200	http://dx.doi.org/10.1074/jbc.M402304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184391	hybrid			2022-12-27	WOS:000223134800061
J	Joly, N; Bohm, A; Boos, W; Richet, E				Joly, N; Bohm, A; Boos, W; Richet, E			MalK, the ATP-binding cassette component of the Escherichia coli maltodextrin transporter, inhibits the transcriptional activator MalT by antagonizing inducer binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABC TRANSPORTER; GENE-EXPRESSION; PROTEIN; REGULON; REGULATOR; SYSTEM; DOMAIN; ENZYME; MOTIF; ENCODES	MalK, the ATP-binding cassette component of the Escherichia coli maltodextrin transporter, has long been known to control negatively the activity of MalT, a transcriptional activator dedicated to the maltose regulon. By using a biochemical approach and the soluble form of MalK as a model substrate, we demonstrate that MalK alone inhibits transcription activation by MalT in a purified transcription system. The inhibitory effect observed in vitro is relieved by maltotriose and by two malT mutations and one malK mutation known to interfere with MalT repression by MalK in vivo. MalK interacts directly with the activator in the absence of maltotriose but not in the presence of maltotriose. Conversely, MalK inhibits maltotriose binding by MalT. Altogether, these data strongly suggest that MalK and maltotriose compete for MalT binding. Part, if not all, of the MalK-binding site is located on DT1, the N-terminal domain of MalT. All of these features indicate that MalK inhibits MalT by the same mechanism as two other proteins, MalY and Aes, that also act as negative effectors of MalT by antagonizing maltotriose binding by MalT. These results offer new insights into the mechanism by which gene regulation can be accomplished by the ATPase component of a bacterial ATP-binding cassette-type importer.	Inst Pasteur, Unite Genet Mol, CNRS, URA 2172, F-75724 Paris 15, France; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Konstanz	Richet, E (corresponding author), Inst Pasteur, Unite Genet Mol, CNRS, URA 2172, 25 Rue Dr Roux, F-75724 Paris 15, France.	erichet@pasteur.fr	Joly, Nicolas/H-6851-2018	Joly, Nicolas/0000-0003-2731-3827				Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Boos W, 2000, TRENDS GENET, V16, P404, DOI 10.1016/S0168-9525(00)02086-2; Braun V, 2003, CURR OPIN MICROBIOL, V6, P173, DOI 10.1016/S1369-5274(03)00022-5; BUKAU B, 1986, J BACTERIOL, V166, P884, DOI 10.1128/jb.166.3.884-891.1986; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Clausen T, 2000, EMBO J, V19, P831, DOI 10.1093/emboj/19.5.831; Danot O, 1996, J MOL BIOL, V262, P1, DOI 10.1006/jmbi.1996.0493; DANOT O, 1994, MOL MICROBIOL, V14, P335, DOI 10.1111/j.1365-2958.1994.tb01294.x; Danot O, 2001, P NATL ACAD SCI USA, V98, P435, DOI 10.1073/pnas.98.2.435; DARDONVILLE B, 1990, J BACTERIOL, V172, P1846, DOI 10.1128/jb.172.4.1846-1852.1990; Davidson AL, 2002, SCIENCE, V296, P1038, DOI 10.1126/science.1072484; De Schrijver A, 1999, MICROBIOL-UK, V145, P1287, DOI 10.1099/13500872-145-6-1287; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; HOFNUNG M, 1974, J BACTERIOL, V117, P40, DOI 10.1128/JB.117.1.40-47.1974; Joly N, 2002, J BIOL CHEM, V277, P16606, DOI 10.1074/jbc.M200991200; Lopian L, 2003, P NATL ACAD SCI USA, V100, P7099, DOI 10.1073/pnas.1037608100; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; Peist R, 1997, J BACTERIOL, V179, P7679, DOI 10.1128/jb.179.24.7679-7686.1997; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; RICHET E, 1987, J BIOL CHEM, V262, P12647; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schlegel A, 2002, J BACTERIOL, V184, P3069, DOI 10.1128/JB.184.11.3069-3077.2002; Schreiber V, 1999, J BIOL CHEM, V274, P33220, DOI 10.1074/jbc.274.47.33220; Schreiber V, 2000, MOL MICROBIOL, V35, P765, DOI 10.1046/j.1365-2958.2000.01747.x; Steegborn C, 2001, STRUCTURE, V9, P1051, DOI 10.1016/S0969-2126(01)00665-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Valdez F, 1999, MICROBIOL-UK, V145, P2365, DOI 10.1099/00221287-145-9-2365; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I	33	45	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33123	33130		10.1074/jbc.M403615200	http://dx.doi.org/10.1074/jbc.M403615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180985	hybrid			2022-12-27	WOS:000223039700014
J	Longpre, JM; Leduc, R				Longpre, JM; Leduc, R			Identification of prodomain determinants involved in ADAMTS-1 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; PROPROTEIN CONVERTASE; THROMBOSPONDIN MOTIFS; FURIN; DISINTEGRIN; ACTIVATION; BINDING; CLONING; FAMILY; GENE	The metalloprotease ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin type I motif), similarly to other members of the ADAMTS family, is initially synthesized as a zymogen, proADAMTS-1, that undergoes proteolytic processing at the prodomain/catalytic domain junction by serine proteinases of the furin-like family of proprotein convertases. The goals of this study were to identify residues of the prodomain that play an essential role in ADAMTS-1 processing and to determine the identity of the convertase required for zymogen processing. To gain insight into the putative roles of specific prodomain residues in ADAMTS-1 biosynthesis, we performed biosynthetic labeling experiments in transiently transfected human embryonic kidney 293 cells expressing wild-type and prodomain mutants of proADAMTS-1. Cells expressing wild-type ADAMTS-1 initially produced a 110-kDa zymogen form that was later converted to an 87-kDa form, which was also detected in the media. Although convertases such as PACE4 and PC6B processed proADAMTS-1, we found that furin was the most efficient enzyme at producing the mature ADAMTS-1 87-kDa moiety. Site-directed mutagenesis of the two putative furin recognition sequences found within the ADAMTS-1 prodomain (RRNR173 and RKKR235) revealed that Arg(235) was the sole processing site. Use of the Golgi disturbing agent, Brefeldin A, and monensin suggests that the cleavage of proADAMTS-1 takes place in the Golgi apparatus prior to its secretion. Conserved residues within the prodomain of other ADAMTS members hinted that they might act as maturation determinants. Replacement with alanine of selected residues Cys(106), Tyr(108), Gly(110), Cys(125), and Cys(181) and residues encompassing the 137-144 sequence significantly affected the biosynthetic profile of the enzyme. Our results suggest that conserved residues other than the furin cleavage site in the prodomain of ADAMTS-1 are involved in its biosynthesis.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Leduc, R (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.	Richard.Leduc@USherbrooke.ca						Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Bissonnette L, 2004, BIOCHEM J, V379, P757, DOI 10.1042/BJ20031902; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Denault JB, 2000, PROTEIN EXPRES PURIF, V19, P113, DOI 10.1006/prep.2000.1215; Denault JB, 2002, FEBS LETT, V527, P309, DOI 10.1016/S0014-5793(02)03249-0; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Pavlaki M, 2002, J BIOL CHEM, V277, P2740, DOI 10.1074/jbc.M108987200; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Taniguchi T, 2002, BIOCHEM BIOPH RES CO, V290, P878, DOI 10.1006/bbrc.2001.6282; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tsuji A, 2003, BBA-PROTEINS PROTEOM, V1645, P95, DOI 10.1016/S1570-9639(02)00532-0; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33237	33245		10.1074/jbc.M313151200	http://dx.doi.org/10.1074/jbc.M313151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184385	hybrid			2022-12-27	WOS:000223039700029
J	Lorkovic, ZJ; Lopato, S; Pexa, M; Lehner, R; Barta, A				Lorkovic, ZJ; Lopato, S; Pexa, M; Lehner, R; Barta, A			Interactions of Arabidopsis RS domain containing cyclophilins with SR proteins and U1 and U11 small nuclear ribonucleoprotein-specific proteins suggest their involvement in pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOMIC ANALYSIS; PROLYL ISOMERASES; PHOSPHORYLATION; ORGANIZATION; IDENTIFICATION; SPLICEOSOME; COMPLEX; MATRIX; STEPS; UBP1	Ser/Arg (SR)-rich proteins are important splicing factors in both general and alternative splicing. By binding to specific sequences on pre-mRNA and interacting with other splicing factors via their RS domain they mediate different intraspliceosomal contacts, thereby helping in splice site selection and spliceosome assembly. While characterizing new members of this protein family in Arabidopsis, we have identified two proteins, termed CypRS64 and CypRS92, consisting of an N-terminal peptidylprolyl cis/trans isomerase domain and a C-terminal domain with many SR/SP dipeptides. Cyclophilins possess a peptidyl-prolyl cis/trans isomerase activity and are implicated in protein folding, assembly, and transport. CypRS64 interacts in vivo and in vitro with a subset of Arabidopsis SR proteins, including SRp30 and SRp34/SR1, two homologs of mammalian SF2/ASF, known to be important for 5' splice site recognition. In addition, both cyclophilins interact with U1-70K and U11-35K, which in turn are binding partners of SRp34/ SR1. CypRS64 is a nucleoplasmic protein, but in most cells expressing CypRS64-GFP fusion it was also found in one to six round nuclear bodies. However, co-expression of CypRS64 with its binding partners resulted in re-localization of CypRS64 from the nuclear bodies to nuclear speckles, indicating functional interactions. These findings together with the observation that binding of SRp34/ SR1 to CypRS64 is phosphorylation-dependent indicate an involvement of CypRS64 in nuclear pre-mRNA splicing, possibly by regulating phosphorylation/dephosphorylation of SR proteins and other spliceosomal components. Alternatively, binding of CypRS64 to proteins important for 5' splice site recognition suggests its involvement in the dynamics of spliceosome assembly.	Med Univ Vienna, Dept Biochem, Vienna Bioctr,Univ Dept, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Lorkovic, ZJ (corresponding author), Med Univ Vienna, Dept Biochem, Vienna Bioctr,Univ Dept, Max F Perutz Labs, Dr Bohrgasse 9-3, A-1030 Vienna, Austria.	zdravko.lorkovic@univie.ac.at		Barta, Andrea/0000-0002-8851-406X; Lorkovic, Zdravko/0000-0002-3074-7258				BEVEN AF, 1995, J CELL SCI, V108, P509; Boudonck K, 1998, J CELL SCI, V111, P3687; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; Brown JWS, 2002, BIOCHEM SOC T, V30, P146, DOI 10.1042/BST0300146; Burge CB, 1999, RNA WORLD, P525; Cavarec L, 2002, J BIOL CHEM, V277, P41171, DOI 10.1074/jbc.M203757200; FU XD, 1995, RNA, V1, P663; Golovkin M, 1996, PLANT CELL, V8, P1421, DOI 10.1105/tpc.8.8.1421; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hamm J, 1998, CURR BIOL, V8, pR532, DOI 10.1016/S0960-9822(07)00340-5; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hastings ML, 2001, RNA, V7, P471, DOI 10.1017/S1355838201002552; Horowitz DS, 1997, RNA, V3, P1374; Horowitz DS, 2002, EMBO J, V21, P470, DOI 10.1093/emboj/21.3.470; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lambermon MHL, 2000, EMBO J, V19, P1638, DOI 10.1093/emboj/19.7.1638; Lambermon MHL, 2002, MOL CELL BIOL, V22, P4346, DOI 10.1128/MCB.22.12.4346-4357.2002; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lopato S, 2002, J BIOL CHEM, V277, P39989, DOI 10.1074/jbc.M206455200; Lopato S, 1999, GENE DEV, V13, P987, DOI 10.1101/gad.13.8.987; Lorkovic ZJ, 1997, MOL CELL BIOL, V17, P2257, DOI 10.1128/MCB.17.4.2257; Lorkovic ZJ, 2000, TRENDS PLANT SCI, V5, P160, DOI 10.1016/S1360-1385(00)01595-8; Lorkovic ZJ, 2004, MOL BIOL CELL, V15, P3233, DOI 10.1091/mbc.E04-01-0055; Lorkovic ZJ, 2002, NUCLEIC ACIDS RES, V30, P623, DOI 10.1093/nar/30.3.623; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Meskiene I, 2003, J BIOL CHEM, V278, P18945, DOI 10.1074/jbc.M300878200; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 2000, J CELL SCI, V113, P1841; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Mortillaro MJ, 1998, J BIOL CHEM, V273, P8183, DOI 10.1074/jbc.273.14.8183; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; ROMANO PGN, 2004, PLANT PHYSIOL, V134, P1; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; Teigelkamp S, 1998, RNA, V4, P127; Will CL, 1999, SCIENCE, V284, P2003, DOI 10.1126/science.284.5422.2003; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	52	51	65	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33890	33898		10.1074/jbc.M400270200	http://dx.doi.org/10.1074/jbc.M400270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166240	hybrid			2022-12-27	WOS:000223039700099
J	Ajenjo, N; Canon, E; Sanchez-Perez, I; Matallanas, D; Leon, J; Perona, R; Crespo, P				Ajenjo, N; Canon, E; Sanchez-Perez, I; Matallanas, D; Leon, J; Perona, R; Crespo, P			Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE KINASE; SIGNAL-REGULATED KINASE; ABL TYROSINE KINASE; RIBOSOMAL S6 KINASE; EPIDERMAL-GROWTH-FACTOR; NUCLEAR EXPORT SIGNAL; MAP KINASE; BCR-ABL; CONSTITUTIVE ACTIVATION	ERKs, mitogen-activated protein kinases, are well characterized as key mediators in the conveyance of signals that promote cell survival in cells of hemopoietic origin, a key factor in the upbringing of leukemogenesis. It is also well known that ERKs phosphorylate a wide array of substrates distributed throughout distinct cellular locations such as the nucleus, cytoplasm, and cell periphery, but the relative contribution of these compartmentalized signal components to the overall survival signal generated by activation of ERKs has yet to be established. To this end, we have utilized constitutively activated forms of ERK2, whose expression is restricted to the nucleus or to the cytoplasm, to investigate the consequences of compartmentalized activation of ERK in the survival of chronic myelogenous leukemia cells subjected to distinct apoptogenic stimuli. We show that cytoplasmic ERK2 activity protected against apoptosis caused by prolonged serum starvation, whereas ERK2 activation restricted to the nucleus antagonized apoptosis induced by the Bcr-Abl inhibitor STI571. On the other hand, neither cytoplasmic nor nuclear ERK2 activities were effective in counteracting apoptosis induced by UV light. These results demonstrate that the protective effects of ERK2 against defined apoptogenic stimuli are strictly dependent on the cellular localization where ERK activation takes place. Furthermore, we present evidence suggesting that the complex IkappaB-NFkappaB participates on ERK2-mediated survival mechanisms, in a fashion dependent on the cellular location where ERK2 is active and on the causative apoptogenic stimulus.	Univ Cantabria, Fac Med, Dept Biol Mol, CSIC,Inst Invest Biomed,Unidad Biomed, Santander 39011, Spain; CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Crespo, P (corresponding author), Univ Cantabria, Fac Med, Dept Biol Mol, CSIC,Inst Invest Biomed,Unidad Biomed, C Cardenal Herrera Oria S-N, Santander 39011, Spain.	pcrespo@iib.uam.es	Leon, Javier/K-4615-2014; Sánchez-Pérez, Isabel/R-4107-2016; gomez, david/U-9465-2019; Crespo, Piero/M-3273-2014	Sánchez-Pérez, Isabel/0000-0002-4829-201X; gomez, david/0000-0002-2360-3141; Ajenjo Diez, Nuria/0000-0002-9435-6467; Crespo, Piero/0000-0003-2825-7783; Leon, Javier/0000-0001-5803-0112				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BEDI A, 1994, BLOOD, V83, P2038; Benito A, 1997, LEUKEMIA, V11, P940, DOI 10.1038/sj.leu.2400699; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; GRENDINER E, 1998, J BIOL CHEM, V2273, P10436; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Henderson C, 2003, DRUG RESIST UPDATE, V6, P247, DOI 10.1016/S1368-7646(03)00067-0; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Iida M, 1999, LEUKEMIA, V13, P585, DOI 10.1038/sj.leu.2401369; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Lai JM, 2002, MOL CELL BIOL, V22, P7581, DOI 10.1128/MCB.22.21.7581-7592.2002; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Lerga A, 1999, BIOCHEM BIOPH RES CO, V260, P256, DOI 10.1006/bbrc.1999.0852; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; OKA H, 1995, CANCER RES, V55, P4182; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RACKE FK, 1997, J BIOL CHEM, V272, P23336; Renault F, 2003, BIOCHEM PHARMACOL, V66, P1581, DOI 10.1016/S0006-2952(03)00514-8; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sanz-Moreno V, 2003, MOL CELL BIOL, V23, P3079, DOI 10.1128/MCB.23.9.3079-3090.2003; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Schramek H, 1997, J BIOL CHEM, V272, P11426; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Viatour P, 2003, J BIOL CHEM, V278, P46541, DOI 10.1074/jbc.M306381200; Wang SJ, 1998, BIOCHEM PHARMACOL, V56, P635, DOI 10.1016/S0006-2952(98)00188-9; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124; Yu CR, 2002, CANCER RES, V62, P188; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	77	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32813	32823		10.1074/jbc.M313656200	http://dx.doi.org/10.1074/jbc.M313656200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173174	hybrid			2022-12-27	WOS:000222849700101
J	Sun, XJ; Zhang, H; Wang, D; Ma, DL; Shen, Y; Shang, YF				Sun, XJ; Zhang, H; Wang, D; Ma, DL; Shen, Y; Shang, YF			DLP, a novel Dim1 family protein implicated in pre-mRNA splicing and cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN PARTICLE; SCHIZOSACCHAROMYCES-POMBE; U5 SNRNP; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; MAMMALIAN HOMOLOG; BINDING PROTEIN; MITOTIC ENTRY; GENE ENCODES; IDENTIFICATION	In eukaryotes, primary transcripts undergo a splicing process that removes intronic sequences by a macromolecular enzyme known as the spliceosome. Both genetic and biochemical studies have revealed that essential components of the spliceosome include five small RNAs, U1, U2, U4, U5, and U6, and as many as 300 distinct proteins. Here we report the molecular cloning and functional analysis of a novel cDNA encoding for a protein of 149 amino acids. This protein has 38% amino acid sequence identity with and is evolutionally related to yeast Dim1 protein. Hence we named this protein DLP for Dim1-like protein. We showed that DLP is required for S/G(2) transition. We also demonstrated that DLP functions in cell nucleus and interacts with the U5-102-kDa protein subunit of the spliceosome, and blocking DLP protein activity led to an insufficient pre-mRNA splicing, suggesting that DLP is yet another protein component involved in pre-mRNA splicing. Collectively, our experiments indicated that DLP is implicated in not only cell cycle progression but also in a more specific molecular process such as pre-mRNA splicing.	Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Chinese Natl Human Genome Ctr, Beijing 100176, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Peking University	Shen, Y (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.	sheny@ms.imicams.ac.cn; jason@bjmu.edu.cn						ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Ajuh P, 2002, EMBO J, V21, P6590, DOI 10.1093/emboj/cdf652; Ajuh P, 2001, J BIOL CHEM, V276, P42370, DOI 10.1074/jbc.M105453200; ALLEY MC, 1988, CANCER RES, V48, P589; Beales M, 2000, YEAST, V16, P1001, DOI 10.1002/1097-0061(200008)16:11<1001::AID-YEA605>3.0.CO;2-6; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; Berry LD, 1997, J CELL BIOL, V137, P1337, DOI 10.1083/jcb.137.6.1337; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Chawla G, 2003, NUCLEIC ACIDS RES, V31, P2333, DOI 10.1093/nar/gkg333; Engemann H, 2002, NUCLEIC ACIDS RES, V30, P1408, DOI 10.1093/nar/30.6.1408; Gottschalk A, 1999, EMBO J, V18, P4535, DOI 10.1093/emboj/18.16.4535; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gross T, 1997, NUCLEIC ACIDS RES, V25, P1028, DOI 10.1093/nar/25.5.1028; Habara Y, 2001, RNA, V7, P671, DOI 10.1017/S1355838201001200; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Komuro A, 1999, NUCLEIC ACIDS RES, V27, P1957, DOI 10.1093/nar/27.9.1957; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lei XH, 2000, J CELL SCI, V113, P4523; Lundgren K, 1996, MOL BIOL CELL, V7, P1083, DOI 10.1091/mbc.7.7.1083; Makarov EM, 2000, J MOL BIOL, V298, P567, DOI 10.1006/jmbi.2000.3685; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; Potashkin J, 1998, CURR GENET, V34, P153, DOI 10.1007/s002940050381; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; Reuter K, 1999, J MOL BIOL, V294, P515, DOI 10.1006/jmbi.1999.3258; Russell CS, 2000, RNA, V6, P1565, DOI 10.1017/S1355838200000984; Schwelnus W, 2001, EMBO REP, V2, P35, DOI 10.1093/embo-reports/kve009; Shao WL, 2002, MOL CELL BIOL, V22, P3358, DOI 10.1128/MCB.22.10.3358-3372.2002; SHEA JE, 1994, NUCLEIC ACIDS RES, V22, P5555, DOI 10.1093/nar/22.25.5555; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Zhang YZ, 1999, PHYSIOL GENOMICS, V1, P109, DOI 10.1152/physiolgenomics.1999.1.3.109; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	42	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32839	32847		10.1074/jbc.M402522200	http://dx.doi.org/10.1074/jbc.M402522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161931	hybrid			2022-12-27	WOS:000222849700104
J	Volk, DE; Beasley, DWC; Kallick, DA; Holbrook, MR; Barrett, ADT; Gorenstein, DG				Volk, DE; Beasley, DWC; Kallick, DA; Holbrook, MR; Barrett, ADT; Gorenstein, DG			Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORNE ENCEPHALITIS-VIRUS; DENGUE-VIRUS; NEUTRALIZING-ANTIBODY; SEROLOGIC EVIDENCE; NMR; MEXICO; GLYCOPROTEIN; RESOLUTION; INFECTION; HORSES	The solution structure of domain III from the New York West Nile virus strain 385-99 (WN-rED3) has been determined by NMR methods. The West Nile domain III structure is a beta-barrel structure formed from seven anti-parallel beta-strands in two beta-sheets. One anti-parallel beta-sheet consists of beta-strands beta1 (Phe(299)-Asp(307)), beta2 (Val(313)-Tyr(319)), beta4 (Arg(354)-Leu(355)), and beta5 (Lys(370)-Glu(376)) arranged so that beta2 is flanked on either side by beta1 and beta5. The short beta4 flanks the end of the remaining side of beta5. The remaining anti-parallel beta-sheet is formed from strands beta3 (Ile(340)-Val(343)), beta6 (Gly(380)-Arg(388)), and beta7 (Gln(391)-Lys(399)) arranged with beta6 at the center. Residues implicated in antigenic differences between different West Nile virus strains (and other flaviviruses) and neutralization are located on the outer surface of the protein. Characterization of the binding of monoclonal antibodies to WN-rED3 mutants, which were identified through neutralization escape experiments, indicate that antibody neutralization directly correlates with binding affinities. These studies provide an insight into theoretical virus-receptor interaction points, structure of immunogenic determinants, and potential targets for antiviral agents against West Nile virus and highlight differences between West Nile virus and other flavivirus structures that may represent critical determinants of virulence.	Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Gorenstein, DG (corresponding author), Univ Texas, Med Branch, Sealy Ctr Struct Biol, Route 1147, Galveston, TX 77555 USA.	david@nmr.utmb.edu	Holbrook, Michael/AAT-6865-2020; Volk, David/H-7956-2019	Holbrook, Michael/0000-0002-0824-2667; Volk, David/0000-0002-4372-6915; Kallick, Deborah/0000-0003-4241-2532	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007536] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI007536-06] Funding Source: Medline; PHS HHS [U01 A1054827] Funding Source: Medline; ODCDC CDC HHS [U90CCU618754] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ODCDC CDC HHS		Beasley DWC, 2002, J VIROL, V76, P13097, DOI 10.1128/JVI.76.24.13097-13100.2002; Blitvich BJ, 2003, EMERG INFECT DIS, V9, P853; CASE DA, 1999, AMBER6; CLORE GM, 1994, METHOD ENZYMOL, V239, P249; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Estrada-Franco JG, 2003, EMERG INFECT DIS, V9, P1604, DOI 10.3201/eid0912.030564; Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee YC, 2004, J BIOMOL NMR, V29, P399, DOI 10.1023/B:JNMR.0000032617.88899.4b; Lin CW, 2003, J VIROL, V77, P2600, DOI 10.1128/JVI.77.4.2600-2606.2003; Lorono-Pino MA, 2003, EMERG INFECT DIS, V9, P857; MANDL CW, 1989, J VIROL, V63, P564, DOI 10.1128/JVI.63.2.564-571.1989; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Wu KP, 2003, J BIOL CHEM, V278, P46007, DOI 10.1074/jbc.M307776200; Zeller HG, 2004, EUR J CLIN MICROBIOL, V23, P147, DOI 10.1007/s10096-003-1085-1	25	91	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38755	38761		10.1074/jbc.M402385200	http://dx.doi.org/10.1074/jbc.M402385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15190071	hybrid			2022-12-27	WOS:000223684100086
J	Seye, CI; Yu, NP; Gonzalez, FA; Erb, L; Weisman, GA				Seye, CI; Yu, NP; Gonzalez, FA; Erb, L; Weisman, GA			The P2Y(2) nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; TRANSACTIVATION; MIGRATION; RHOA; PHOSPHORYLATION; FAMILY; CDC42	UTP stimulates the expression of pro-inflammatory vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells through activation of the P2Y(2) nucleotide receptor P2Y(2)R. Here, we demonstrated that activation of the P2Y(2)R induced rapid tyrosine phosphorylation of vascular endothelial growth factor receptor (VEGFR)-2 in human coronary artery endothelial cells (HCAEC). RNA interference targeting VEGFR-2 or inhibition of VEGFR-2 tyrosine kinase activity abolishes P2Y(2)R-mediated VCAM-1 expression. Furthermore, VEGFR-2 and the P2Y(2)R co-localize upon UTP stimulation. Deletion or mutation of two Src homology-3-binding sites in the C-terminal tail of the P2Y(2)R or inhibition of Src kinase activity abolished the P2Y(2)R-mediated transactivation of VEGFR-2 and subsequently inhibited UTP-induced VCAM-1 expression. Moreover, activation of VEGFR-2 by UTP leads to the phosphorylation of Vav2, a guanine nucleotide exchange factor for Rho family GTPases. Using a binding assay to measure the activity of the small GTPases Rho, we found that stimulation of HCAEC by UTP increased the activity of RhoA and Rac1 (but not Cdc42). Significantly, a dominant negative form of RhoA inhibited P2Y(2)R-mediated VCAM-1 expression, whereas expression of dominant negative forms of Cdc42 and Rac1 had no effect. These data indicate a novel mechanism whereby a nucleotide receptor transactivates a receptor tyrosine kinase to generate an inflammatory response associated with atherosclerosis.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Seye, CI (corresponding author), Univ Missouri, Dept Biochem, M743 Med Sci Bldg, Columbia, MO 65212 USA.	seyec@missouri.edu	Yu, Ningpu/D-4266-2009	Erb, Laurie/0000-0001-6372-3378	NCRR NIH HHS [RR15565] Funding Source: Medline; NIA NIH HHS [AG18357] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chaulet H, 2001, CIRC RES, V89, P772, DOI 10.1161/hh2101.098617; Di Virgilio F, 2002, BRIT J PHARMACOL, V135, P831, DOI 10.1038/sj.bjp.0704524; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; ERLINGE D, 1995, EUR J PHARM-MOLEC PH, V289, P135, DOI 10.1016/0922-4106(95)90178-7; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; MalamSouley R, 1996, J CELL PHYSIOL, V166, P57, DOI 10.1002/(SICI)1097-4652(199601)166:1<57::AID-JCP7>3.0.CO;2-F; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sauzeau V, 2000, AM J PHYSIOL-HEART C, V278, pH1751, DOI 10.1152/ajpheart.2000.278.6.H1751; Seta K, 2003, J BIOL CHEM, V278, P9019, DOI 10.1074/jbc.M208017200; Seye CI, 2003, J BIOL CHEM, V278, P24960, DOI 10.1074/jbc.M301439200; Seye CI, 2002, CIRCULATION, V106, P2720, DOI 10.1161/01.CIR.0000038111.00518.35; Seye CI, 1997, ARTERIOSCL THROM VAS, V17, P3602, DOI 10.1161/01.ATV.17.12.3602; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; [No title captured]	31	105	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35679	35686		10.1074/jbc.M401799200	http://dx.doi.org/10.1074/jbc.M401799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15175347	hybrid			2022-12-27	WOS:000223303400065
J	Cheng, GJ; Ritsick, D; Lambeth, JD				Cheng, GJ; Ritsick, D; Lambeth, JD			Nox3 regulation by NOXO1, p47(phox), and p67(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SUPEROXIDE-GENERATING OXIDASE; PHAGOCYTE NADPH OXIDASE; COLON EPITHELIAL-CELLS; NAD(P)H OXIDASE; ACTIVATION DOMAIN; SH3 DOMAIN; GROWTH; PROTEINS; PHOSPHORYLATION	gp91(phox) (Nox2), the catalytic subunit of the superoxide-generating respiratory burst oxidase, is regulated by subunits p47(phox) and p67(phox). Nox1, a homolog of gp91(phox), is regulated by NOXO1 and NOXA1, homologs of p47(phox) and p67(phox), respectively. For both Nox1 and gp91(phox), an organizer protein ( NOXO1 or p47(phox)) cooperates with an activator protein ( NOXA1 or p67(phox)) to regulate the catalytic subunit. Herein, we investigate the subunit regulation of Nox3 compared with that of other Nox enzymes. Nox3, like gp91(phox), was activated by p47(phox) plus p67(phox). Whereas gp91(phox) activity required the protein kinase C activator phorbol myristate acetate (PMA), Nox3 activity was already high without PMA, but was further stimulated similar to 30% by PMA. gp91(phox) was also activated by NOXO1/NOXA1 and required PMA for high activity. gp91(phox) regulation required an intact activation domain in the activator protein, as neither p67(phox)( V204A) nor NOXA1(V205A) were effective. In contrast, p67(phox)( V204A) was effective ( along with p47(phox)) in activating Nox3. Unexpectedly, Nox3 was strongly activated by NOXO1 in the absence of NOXA1 or p67(phox). Nox3 activity was regulated by PMA only when p47(phox) but not NOXO1 was present, consistent with the phosphorylation-regulated autoinhibitory region in p47(phox) but not in NOXO1. Deletion of the autoinhibitory region from p47(phox) rendered this subunit highly active in the absence of PMA toward both gp91(phox) and Nox3, and high activity required an activator subunit. The unique regulation of Nox3 supports a model in which multiple interactions with regulatory subunits stabilize an active conformation of the catalytic subunit.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.	dlambe@emory.edu		Cheng, Guangjie/0000-0002-9368-379X	NATIONAL CANCER INSTITUTE [R01CA084138] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Chamulitrat W, 2003, ONCOGENE, V22, P6045, DOI 10.1038/sj.onc.1206654; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; ElBenna J, 1995, BLOOD CELL MOL DIS, V21, P201, DOI 10.1006/bcmd.1995.0023; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; LAMBETH JD, 2003, RECENT ADV RES UPDAT, V4, P31; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Perner A, 2003, GUT, V52, P231, DOI 10.1136/gut.52.2.231; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Teshima S, 2000, AM J PHYSIOL-GASTR L, V279, pG1169, DOI 10.1152/ajpgi.2000.279.6.G1169; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Yang S, 2001, J BIOL CHEM, V276, P5452, DOI 10.1074/jbc.M001004200; Yuzawa S, 2003, ACTA CRYSTALLOGR D, V59, P1479, DOI 10.1107/S0907444903011636	43	118	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34250	34255		10.1074/jbc.M400660200	http://dx.doi.org/10.1074/jbc.M400660200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181005	hybrid			2022-12-27	WOS:000223134800023
J	Ng, Y; Tan, I; Lim, L; Leung, T				Ng, Y; Tan, I; Lim, L; Leung, T			Expression of the human myotonic dystrophy kinase-related Cdc42-binding kinase gamma is regulated by promoter DNA methylation and Sp1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN PHOSPHATASE; CATALYTIC-ACTIVITY; CDC42 EFFECTOR; RHO-KINASE; ALPHA; TRANSCRIPTION; GENE; PHOSPHORYLATION; LOCALIZATION; PROTEINS	Myotonic dystrophy kinase-related Cdc42 binding kinases (MRCKs) are family members most related to the myotonic dystrophy kinase (DMPK), RhoA-binding kinase (ROK), and citron kinase. Two highly conserved members, MRCKalpha and -beta, have been previously identified and characterized. We now describe a novel isoform, MRCKgamma, which is functionally and structurally related to members of this kinase family. We show these kinases to have marked similarities in their genomic organization, substrate phosphorylation, and catalytic autoinhibition. Unlike MRCKalpha and -beta, which are expressed ubiquitously, MRCKgamma mRNA was only expressed in heart and skeletal muscle. In cultured cells, MRCKgamma showed differential expression with high levels of expression only in certain cell lines. DNA analysis showed that lack of expression is correlated with promoter DNA methylation. We have mapped the methylation sites in the MRCKgamma promoter. Significantly, agents that suppressed DNA methylation caused increases in the expression of the kinase in low-expressing cells, further supporting the notion that promoter DNA methylation plays an important role in the expression of MRCKgamma. Analysis of the MRCKgamma promoter has also revealed two proximal Sp1 sites that are essential for transcriptional activity. We conclude that both promoter DNA methylation and Sp1 binding are important regulators for MRCKgamma expression.	Natl Univ Singapore, Dept Anat, Inst Mol & Cell Biol, GSK IMCB Grp, Singapore 138673, Singapore; UCL, Inst Neurol, Dept Mol Neurosci, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; National University of Singapore; University of London; University College London	Leung, T (corresponding author), Natl Univ Singapore, Dept Anat, Inst Mol & Cell Biol, GSK IMCB Grp, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbthoml@imcb.a-star.edu.sg						Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bush EW, 2000, BIOCHEMISTRY-US, V39, P8480, DOI 10.1021/bi992142f; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; Chotai KA, 1998, J MED GENET, V35, P472, DOI 10.1136/jmg.35.6.472; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; GARG LC, 1989, J BIOL CHEM, V264, P2134; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KRUGER T, 1995, EMBO J, V14, P2661, DOI 10.1002/j.1460-2075.1995.tb07264.x; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Moncrieff CL, 1999, GENOMICS, V57, P297, DOI 10.1006/geno.1999.5769; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; Pirone DM, 2001, TRENDS GENET, V17, P370, DOI 10.1016/S0168-9525(01)02311-3; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Suetsugu S, 2003, INT REV CYTOL, V229, P245, DOI 10.1016/S0074-7696(03)29006-9; Sumi T, 2001, J BIOL CHEM, V276, P23092, DOI 10.1074/jbc.C100196200; Tan I, 2003, GENE, V304, P107, DOI 10.1016/S0378-1119(02)01185-X; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Turner CE, 2000, J CELL SCI, V113, P4139; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; Zhao SJ, 2003, CANCER RES, V63, P2624; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	32	13	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34156	34164		10.1074/jbc.M405252200	http://dx.doi.org/10.1074/jbc.M405252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194684	hybrid			2022-12-27	WOS:000223134800013
J	Solovyov, A; Xiao, RY; Gilbert, HF				Solovyov, A; Xiao, RY; Gilbert, HF			Sulfhydryl oxidation, not disulfide isomerization, is the principal function of protein disulfide isomerase in yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BOND FORMATION; DOMAINS	Protein disulfide isomerase (PDI) is an essential protein folding assistant of the eukaryotic endoplasmic reticulum that catalyzes both the formation of disulfides during protein folding ( oxidase activity) and the isomerization of disulfides that may form incorrectly ( isomerase activity). Catalysis of thiol-disulfide exchange by PDI is required for cell viability in Saccharomyces cerevisiae, but there has been some uncertainty as to whether the essential role of PDI in the cell is oxidase or isomerase. We have studied the ability of PDI constructs with high oxidase activity and very low isomerase activity to complement the chromosomal deletion of PDI1 in S. cerevisiae. A single catalytic domain of yeast PDI (PDIa') has 50% of the oxidase activity but only 5% of the isomerase activity of wild-type PDI in vitro. Titrating the expression of PDI using the inducible/repressible GAL1-10 promoter shows that the amount of wild-type PDI protein needed to sustain a normal growth rate is 60% or more of the amount normally expressed from the PDI1 chromosomal location. A single catalytic domain (PDIa') is needed in molar amounts that are approximately twice as high as those required for wild-type PDI, which contains two catalytic domains. This comparison suggests that high (> 60%) PDI oxidase activity is critical to yeast growth and viability, whereas less than 6% of its isomerase activity is needed.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Baylor College of Medicine; Karolinska Institutet	Gilbert, HF (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, 1 Baylor Plaza, Houston, TX 77030 USA.	hgilbert@bcm.tmc.edu			NIGMS NIH HHS [GM 40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Guthrie C, 1991, GUIDE YEAST GENETICS; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Jung GM, 1999, J BIOCHEM-TOKYO, V126, P1; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; SIKORSKI RS, 1989, GENETICS, V122, P19; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Xiao R, 2001, J BIOL CHEM, V276, P27975, DOI 10.1074/jbc.M104203200; Zhan XM, 1999, BIOTECHNOL PROGR, V15, P1033, DOI 10.1021/bp990083r	19	28	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34095	34100		10.1074/jbc.M405640200	http://dx.doi.org/10.1074/jbc.M405640200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175335	hybrid			2022-12-27	WOS:000223134800005
J	Ichida, F; Nishimura, R; Hata, K; Matsubara, T; Ikeda, F; Hisada, K; Yatani, H; Cao, X; Komori, T; Yamaguchi, A; Yoneda, T				Ichida, F; Nishimura, R; Hata, K; Matsubara, T; Ikeda, F; Hisada, K; Yatani, H; Cao, X; Komori, T; Yamaguchi, A; Yoneda, T			Reciprocal roles of Msx2 in regulation of osteoblast and adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RECEPTOR-GAMMA; BONE-FORMATION; HOMEOBOX GENE; CELLS; MICE; PROTEIN; BINDING; MARROW; CBFA1	Mice deficient in the Msx2 gene manifest defects in skull ossification and a marked reduction in bone formation associated with decreases in osteoblast numbers, thus suggesting that Msx2 is involved in bone formation. However, the precise role of Msx2 during osteoblast differentiation is not fully understood. In the present study, we investigated the role of Msx2 in the regulation of osteoblast differentiation in the multipotent mesenchymal cell lines C3H10T1/2 and C2C12 and in murine primary osteoblasts. Introduction of Msx2 induced alkaline phosphatase activity in C3H10T1/2 and C2C12 cells and promoted the calcification of murine primary osteoblasts. This effect of Msx2 was also observed in mesenchymal cells isolated from Runx2-deficient mice. Interestingly the expression of Msx2 was induced by bone morphogenetic protein 2 treatment in Runx2-deficient mesenchymal cells. In contrast, Msx2 diminished peroxisome proliferator-activated receptor gamma (PPARgamma) expression and adipogenesis of the preadipocytic cell line 3T3-F442A. Moreover Msx2 inhibited the transcriptional activity of PPARgamma, CCAAT/enhancer-binding protein beta (C/EBPbeta), and C/EBPdelta and blocked adipocyte differentiation of mesenchymal cells induced by overexpression of PPARgamma, C/EBPalpha, C/EBPbeta, or C/EBPdelta. These data indicate that Msx2 promotes osteoblast differentiation independently of Runx2 and negatively regulates adipocyte differentiation through inhibition of PPARgamma and the C/EBP family.	Osaka Univ, Grad Sch Dent, Dept Biochem, Osaka 5650871, Japan; Univ Alabama, Sch Med, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Osaka Univ, Sch Med, Dept Mol Med, Osaka 5650871, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Oral Pathol & Bone Metab, Nagasaki 8528588, Japan	Osaka University; University of Alabama System; University of Alabama Birmingham; Osaka University; Nagasaki University	Nishimura, R (corresponding author), Osaka Univ, Grad Sch Dent, Dept Biochem, 1-8 Yamadaoka, Osaka 5650871, Japan.	rikonisi@dent.osaka-u.ac.jp	Matsubara, Takuma/B-5031-2019; Ikeda, Fumiyo/AAD-3770-2020	Matsubara, Takuma/0000-0002-8505-0431; Ikeda, Fumiyo/0000-0003-0407-2768; Nishimura, Riko/0000-0001-7279-8363				AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756-3282(87)90015-9; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02-06-0356; Hirata K, 2003, BONE, V32, P502, DOI 10.1016/S8756-3282(03)00054-1; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LIU YH, 1995, P NATL ACAD SCI USA, V92, P6137, DOI 10.1073/pnas.92.13.6137; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; MEUNIER P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086-197110000-00021; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MORIKAWA M, 1986, J CELL PHYSIOL, V128, P293, DOI 10.1002/jcp.1041280222; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756-3282(02)00826-8; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Winograd J, 1997, HUM MOL GENET, V6, P369, DOI 10.1093/hmg/6.3.369; Wuyts W, 2000, HUM MOL GENET, V9, P1251, DOI 10.1093/hmg/9.8.1251; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200	33	157	161	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34015	34022		10.1074/jbc.M403621200	http://dx.doi.org/10.1074/jbc.M403621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175325	hybrid			2022-12-27	WOS:000223039700113
J	Doeven, MK; Abele, R; Tampe, R; Poolman, B				Doeven, MK; Abele, R; Tampe, R; Poolman, B			The binding specificity of OppA determines the selectivity of the oligopeptide ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; ABC TRANSPORTERS; SYSTEM; PROTEIN; MECHANISM; PEPTIDES; RECONSTITUTION; SEQUENCE; RECEPTOR	The purification and functional reconstitution of a five-component oligopeptide ATP-binding cassette transporter with a remarkably wide substrate specificity are described. High-affinity peptide uptake was dependent on liganded substrate-binding protein OppA, which interacts with the translocator OppBCDF with higher affinity than unliganded OppA. Transport screening with combinatorial peptide libraries revealed that (i) the Opp transporter is not selective with respect to amino acid side chains of the transported peptides; (ii) any peptide that can bind to OppA is transported via Opp, including very long peptides up to 35 residues long; and (iii) the binding specificity of OppA largely determines the overall transport selectivity.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Goethe Univ Frankfurt, Inst Biochem, Bioctr, D-60439 Frankfurt, Germany	University of Groningen; Goethe University Frankfurt	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@chem.rug.nl	Poolman, Bert/D-1882-2012; Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Charbonnel P, 2003, J BIOL CHEM, V278, P14832, DOI 10.1074/jbc.M212454200; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; DEAN DA, 1992, MOL MICROBIOL, V6, P2033, DOI 10.1111/j.1365-2958.1992.tb01376.x; Detmers FJM, 2000, P NATL ACAD SCI USA, V97, P12487, DOI 10.1073/pnas.220308797; Detmers FJM, 1998, BIOCHEMISTRY-US, V37, P16671, DOI 10.1021/bi981712t; Detmers FJM, 2001, RES MICROBIOL, V152, P245, DOI 10.1016/S0923-2508(01)01196-2; Helinck S, 2003, J APPL MICROBIOL, V94, P900, DOI 10.1046/j.1365-2672.2003.01922.x; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Kunji ERS, 2003, BBA-BIOMEMBRANES, V1610, P97, DOI 10.1016/S0005-2736(02)00712-5; Kunji ERS, 1996, MOL MICROBIOL, V21, P123, DOI 10.1046/j.1365-2958.1996.6231339.x; Lanfermeijer FC, 2000, EMBO J, V19, P3649, DOI 10.1093/emboj/19.14.3649; Lanfermeijer FC, 1999, BIOCHEMISTRY-US, V38, P14440, DOI 10.1021/bi9914715; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOWRY OH, 1951, J BIOL CHEM, V193, P275; MERINO G, 1995, J THEOR BIOL, V177, P171, DOI 10.1006/jtbi.1995.0236; Patzlaff JS, 2003, J BIOL CHEM, V278, P29546, DOI 10.1074/jbc.M304796200; Picon A, 2000, J BACTERIOL, V182, P1600, DOI 10.1128/JB.182.6.1600-1608.2000; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; van der Heide T, 2002, EMBO REP, V3, P938, DOI 10.1093/embo-reports/kvf201; van Montfort BA, 2002, BBA-BIOENERGETICS, V1555, P111, DOI 10.1016/S0005-2728(02)00264-5	27	63	63	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32301	32307		10.1074/jbc.M404343200	http://dx.doi.org/10.1074/jbc.M404343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169767	Green Published, hybrid			2022-12-27	WOS:000222849700040
J	Inacio, A; Silva, AL; Pinto, J; Ji, XJ; Morgado, A; Almeida, F; Faustino, P; Lavinha, J; Liebhaber, SA; Romao, L				Inacio, A; Silva, AL; Pinto, J; Ji, XJ; Morgado, A; Almeida, F; Faustino, P; Lavinha, J; Liebhaber, SA; Romao, L			Nonsense mutations in close proximity to the initiation codon fail to trigger full nonsense-mediated mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; PREMATURE TERMINATION CODONS; PROTEIN ALPHA-CP; SPLICE-SITE; TRANSLATION; EXON; SURVEILLANCE; PHOSPHORYLATION; POSITION; CELLS	Nonsense-mediated mRNA decay (NMD) is a surveillance mechanism that degrades mRNAs containing premature translation termination codons. In mammalian cells, a termination codon is ordinarily recognized as "premature" if it is located greater than 50-54 nucleotides 5' to the final exon-exon junction. We have described a set of naturally occurring human beta-globin gene mutations that apparently contradict this rule. The corresponding beta-thalassemia genes contain nonsense mutations within exon 1, and yet their encoded mRNAs accumulate to levels approaching wild-type beta-globin (beta(WT)) mRNA. In the present report we demonstrate that the stabilities of these mRNAs with nonsense mutations in exon 1 are intermediate between beta(WT) mRNA and beta-globin mRNA carrying a prototype NMD-sensitive mutation in exon 2 (codon 39 nonsense; beta39). Functional analyses of these mRNAs with 5'-proximal nonsense mutations demonstrate that their relative resistance to NMD does not reflect abnormal RNA splicing or translation re-initiation and is independent of promoter identity and erythroid specificity. Instead, the proximity of the nonsense codon to the translation initiation AUG constitutes a major determinant of NMD. Positioning a termination mutation at the 5' terminus of the coding region blunts mRNA destabilization, and this effect is dominant to the "50-54 nt boundary rule." These observations impact on current models of NMD.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Instituto Nacional de Saude Dr. Ricardo Jorge; University of Pennsylvania; University of Pennsylvania	Romao, L (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Av Padre Cruz, P-1649016 Lisbon, Portugal.	luisa.romao@insa.min-saude.pt	Faustino, Paula/E-4546-2010; Romão, Luísa/A-2289-2016	Faustino, Paula/0000-0002-6269-4867; Romão, Luísa/0000-0002-5061-5287; Inacio, Angela/0000-0003-0396-6743; Silva, Ana Luisa/0000-0002-4839-8279; Morgado, Ana/0000-0002-8909-3615; Lavinha, Joao/0000-0002-7474-6871	NHLBI NIH HHS [R01-HL 65449] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065449] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asselta R, 2001, BLOOD, V98, P3685, DOI 10.1182/blood.V98.13.3685; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Buzina A, 1999, MOL BIOL CELL, V10, P515, DOI 10.1091/mbc.10.3.515; Couttet P, 2004, NUCLEIC ACIDS RES, V32, P488, DOI 10.1093/nar/gkh218; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; Denecke J, 2004, HUM MUTAT, V23, P477, DOI 10.1002/humu.20026; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; GOLDSMITH ME, 1983, P NATL ACAD SCI-BIOL, V80, P2318, DOI 10.1073/pnas.80.8.2318; HALL GW, 1994, BLOOD, V83, P2031; He F, 1997, MOL CELL BIOL, V17, P1580, DOI 10.1128/MCB.17.3.1580; HINNEBUSCH AG, 1993, MOL MICROBIOL, V10, P215, DOI 10.1111/j.1365-2958.1993.tb01947.x; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Janzen DM, 2002, MOL CELL BIOL, V22, P8562, DOI 10.1128/MCB.22.24.8562-8570.2002; Ji XJ, 2003, MOL CELL BIOL, V23, P899, DOI 10.1128/MCB.23.3.899-907.2003; Kataoka N, 2004, J BIOL CHEM, V279, P7009, DOI 10.1074/jbc.M307692200; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Kong J, 2003, MOL CELL BIOL, V23, P1125, DOI 10.1128/MCB.23.4.1125-1134.2003; Kozak M, 2002, MAMM GENOME, V13, P401, DOI 10.1007/s00335-002-4002-5; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Liebhaber SA, 1996, MOL CELL BIOL, V16, P2637; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; MAQUAT LE, 1995, RNA, V1, P453; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; Mendell JT, 2000, MOL CELL BIOL, V20, P8944, DOI 10.1128/MCB.20.23.8944-8957.2000; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; ORKIN SH, 1984, BLOOD, V64, P311; ORKIN SH, 1982, NATURE, V300, P768, DOI 10.1038/300768a0; Pal M, 2001, RNA, V7, P5, DOI 10.1017/S1355838201000127; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Romao L, 2000, BLOOD, V96, P2895; Schell T, 2003, BIOCHEM J, V373, P775, DOI 10.1042/BJ20021920; Serin G, 2001, MOL CELL BIOL, V21, P209, DOI 10.1128/MCB.21.1.209-223.2001; Stevens A, 2002, P NATL ACAD SCI USA, V99, P12741, DOI 10.1073/pnas.192442399; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; THEIN SL, 1990, P NATL ACAD SCI USA, V87, P3924, DOI 10.1073/pnas.87.10.3924; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Wagner E, 2002, J CELL SCI, V115, P3033; Wang J, 2002, EMBO REP, V3, P274, DOI 10.1093/embo-reports/kvf036; YANG KG, 1989, BRIT J HAEMATOL, V72, P73, DOI 10.1111/j.1365-2141.1989.tb07655.x; Yu X, 2001, J BIOL CHEM, V276, P33821, DOI 10.1074/jbc.M103772200; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272; Zhang J, 1998, RNA, V4, P801, DOI 10.1017/S1355838298971849; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	56	96	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32170	32180		10.1074/jbc.M405024200	http://dx.doi.org/10.1074/jbc.M405024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161914	hybrid			2022-12-27	WOS:000222849700023
J	Mishra, SK; Talukder, AH; Guraraj, AE; Yang, ZB; Singh, RR; Mahoney, MG; Franci, C; Vadlamudi, RK; Kumar, R				Mishra, SK; Talukder, AH; Guraraj, AE; Yang, ZB; Singh, RR; Mahoney, MG; Franci, C; Vadlamudi, RK; Kumar, R			Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN EXPRESSION; MTA1 MESSENGER-RNA; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; PROTEIN; COMPLEX; CANCER; SNAIL; ROLES; OVEREXPRESSION	Although recent studies have shown a role of estrogen receptor-alpha (ER) in the regulation of epithelial-to-mesenchymal transition via MTA3, the role of upstream determinants of ER regulation of MTA3 and the underlying molecular mechanism remains unknown. Here we show that MTA3 gene regulation by ER is influenced by dynamic changes in levels of nuclear coregulators. MTA3 promoter has a functional ER element half-site with which MTA1 and HDACs interact under basal conditions. Upon estrogen stimulation, these corepressors are derecruited with concomitant recruitment of ER, leading to increased MTA3 transcription and expression. Genetic inactivation of MTA1 pathway promotes the ability of ER to up-regulate MTA3 expression, whereas knockdown of ER enhances MTA1 association with MTA3 gene. Modulation of ER functions, by corepressors (i.e. MTA1 and MTA1s) or coactivators (i.e. AIB1 and PELP1/MNAR), alters ER recruitment to MTA3 chromatin, MTA3 transcription, and expression of downstream epithelial-to-mesenchymal transition components. These studies provide novel insights into the transregulation of the MTA3 gene and reveal novel roles of upstream determinants in modifying the outcome of MTA3 axis and cell differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular Mol, Barcelona 08003, Spain	University of Texas System; UTMD Anderson Cancer Center; Jefferson University; Pompeu Fabra University	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Mahoney, My/A-2716-2009	Mishra, Sandip/0000-0002-0776-6581	NCI NIH HHS [R01 CA090970, CA098823, CA90970, CA095681, R01 CA095681, R01 CA098823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095681, R01CA098823, R01CA090970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Liao L, 2002, J STEROID BIOCHEM, V83, P3, DOI 10.1016/S0960-0760(02)00254-6; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mercer JA, 2000, SEMIN CELL DEV BIOL, V11, P309, DOI 10.1006/scdb.2000.0181; Sasaki H, 2002, LUNG CANCER-J IASLC, V35, P149, DOI 10.1016/S0169-5002(01)00329-4; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; TATA JR, 1993, J STEROID BIOCHEM, V46, P105, DOI 10.1016/0960-0760(93)90286-6; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3	28	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32709	32715		10.1074/jbc.M402942200	http://dx.doi.org/10.1074/jbc.M402942200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169784	hybrid, Green Accepted			2022-12-27	WOS:000222849700090
J	Zhou, WD; Ryan, JJ; Zhou, HL				Zhou, WD; Ryan, JJ; Zhou, HL			Global analyses of sumoylated proteins in Saccharomyces cerevisiae - Induction of protein sumoylation by cellular stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; SUMO-1 MODIFICATION; CONJUGATING ENZYME; UBIQUITIN; YEAST; SMT3P; GENE; IDENTIFICATION; ACTIVATION; MODIFIERS	We have undertaken a global analysis of sumoylated proteins in Saccharomyces cerevisiae by tandem mass spectrometry. Exposure of cells to oxidative and ethanol stresses caused large increases in protein sumoylation. A large number of new sumoylated proteins were identified in untreated, hydrogen peroxide-treated, and ethanol-treated cells. These proteins are known to be involved in diverse cellular processes, including gene transcription, protein translation, DNA replication, chromosome segregation, metabolic processes, and stress responses. Additionally, the known enzymes, including E1, E2, and E3 of the sumoylation cascade were found to be auto-sumoylated. Taken together, these results show that protein sumoylation is broadly involved in many cellular functions and this mass spectrometry-based proteomic approach is useful in studying the regulation of protein sumoylation in the cells.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Zhou, HL (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, 9500 Gilman Dr,CMM-E,Rm 3050, La Jolla, CA 92093 USA.	huzhou@ucsd.edu		Zhou, Huilin/0000-0002-1350-4430; Ryan, Jennifer/0000-0001-6324-9186	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG002604] Funding Source: NIH RePORTER; NHGRI NIH HHS [K22 HG002604-02, K22 HG002604] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARNOLD JE, 1990, BIOCHEM J, V267, P751, DOI 10.1042/bj2670751; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Krogan NJ, 2001, MOL CELL BIOL, V21, P8203, DOI 10.1128/MCB.21.23.8203-8212.2001; Kurepa J, 2003, J BIOL CHEM, V278, P6862, DOI 10.1074/jbc.M209694200; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yoon HJ, 1999, P NATL ACAD SCI USA, V96, P13208, DOI 10.1073/pnas.96.23.13208	35	249	270	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32262	32268		10.1074/jbc.M404173200	http://dx.doi.org/10.1074/jbc.M404173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166219	hybrid, Green Accepted			2022-12-27	WOS:000222849700034
J	Meng, TC; Buckley, DA; Galic, S; Tiganis, T; Tonks, NK				Meng, TC; Buckley, DA; Galic, S; Tiganis, T; Tonks, NK			Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; REDOX REGULATION; IN-VIVO; FACTOR RECEPTOR; HYDROGEN-PEROXIDE; TRANSDUCTION; INACTIVATION; 1B; PHOSPHORYLATION; INTERMEDIATE	Many studies have illustrated that the production of reactive oxygen species (ROS) is important for optimal tyrosine phosphorylation and signaling in response to diverse stimuli. Protein-tyrosine phosphatases (PTPs), which are important regulators of signal transduction, are exquisitely sensitive to inhibition after generation of ROS, and reversible oxidation is becoming recognized as a general physiological mechanism for regulation of PTP function. Thus, production of ROS facilitates a tyrosine phosphorylation-dependent cellular signaling response by transiently inactivating those PTPs that normally suppress the signal. In this study, we have explored the importance of reversible PTP oxidation in the signaling response to insulin. Using a modified in-gel PTP assay, we show that stimulation of cells with insulin resulted in the rapid and transient oxidation and inhibition of two distinct PTPs, which we have identified as PTP1B and TC45, the 45-kDa spliced variant of the T cell protein-tyrosine phosphatase. We investigated further the role of TC45 as a regulator of insulin signaling by combining RNA interference and the use of substrate-trapping mutants. We have shown that TC45 is an inhibitor of insulin signaling, recognizing the beta-subunit of the insulin receptor as a substrate. The data also suggest that this strategy, using ligand-induced oxidation to tag specific PTPs and using interference RNA and substrate-trapping mutants to illustrate their role as regulators of particular signal transduction pathways, may be applied broadly across the PTP family to explore function.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Cold Spring Harbor Laboratory; Monash University	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.edu	Galic, Sandra/C-6098-2014; Meng, Tzu-Ching/G-5426-2019; Tiganis, Tony/AAV-3495-2020	Galic, Sandra/0000-0002-7611-5619; Meng, Tzu-Ching/0000-0001-7693-2021; Tiganis, Tony/0000-0002-8065-9942	NATIONAL CANCER INSTITUTE [T32CA009311, R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09311-23, CA53840] Funding Source: Medline; NIGMS NIH HHS [GM55989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Andersen JN, 2004, TOP CURR GENET, V5, P201; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Berhanu P, 1997, J BIOL CHEM, V272, P22884, DOI 10.1074/jbc.272.36.22884; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Cantrell DA, 2001, J CELL SCI, V114, P1439; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Huang DS, 2002, J BIOL CHEM, V277, P18151, DOI 10.1074/jbc.M104252200; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ibarra-Sanchez MD, 2001, ONCOGENE, V20, P4728, DOI 10.1038/sj.onc.1204648; Isomaa B, 2003, LIFE SCI, V73, P2395, DOI 10.1016/S0024-3205(03)00646-5; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Meng TC, 2003, METHOD ENZYMOL, V366, P304; Moller N P, 2000, Curr Opin Drug Discov Devel, V3, P527; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Persson C, 2004, P NATL ACAD SCI USA, V101, P1886, DOI 10.1073/pnas.0304403101; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; SALMEEN A, 2004, IN PRESS ANTIOXID RE; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Tennagels N, 2000, FEBS LETT, V479, P67, DOI 10.1016/S0014-5793(00)01879-2; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; TONKS NK, 2003, HDB CELL SIGNALLING, V108, P641; van der Wijk T, 2003, J BIOL CHEM, V278, P13968, DOI 10.1074/jbc.M300632200; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161	60	219	227	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37716	37725		10.1074/jbc.M404606200	http://dx.doi.org/10.1074/jbc.M404606200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15192089	Green Accepted, hybrid			2022-12-27	WOS:000223554600063
J	Kaabeche, K; Lemonnier, J; Le Mee, S; Caverzasio, J; Marie, PJ				Kaabeche, K; Lemonnier, J; Le Mee, S; Caverzasio, J; Marie, PJ			Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE KINASE; SRC-FAMILY; NEGATIVE REGULATION; CELL-PROLIFERATION; COUPLED RECEPTORS; FGF RECEPTORS; EGF RECEPTOR; RING FINGER; PHOSPHORYLATION	Fibroblast growth factors (FGFs) play an important regulatory role in skeletal development and bone formation. However, the FGF signaling mechanisms controlling osteoblast function are poorly understood. Here, we identified a role for the Src family members Lyn and Fyn in osteoblast differentiation promoted by constitutive activation of FGF receptor-2 (FGFR2). We show that the overactive FGFR2 S252W mutation induced decreased Src family kinase tyrosine phosphorylation and activity associated with decreased Lyn and Fyn protein expression in human osteoblasts. Pharmacological stimulation of Src family kinases or transfection with Lyn or Fyn vectors repressed alkaline phosphatase (ALP) up-regulation induced by overactive FGFR2. Inhibition of proteasome activity restored normal Lyn and Fyn expression and ALP activity in FGFR2 mutant osteoblasts. Immunoprecipitation studies showed that Lyn, Fyn, and FGFR2 interacted with the ubiquitin ligase c-Cbl and ubiquitin. Transfection with c-Cbl in which the RING finger was disrupted or with c-Cbl with a point mutation that abolishes the binding ability of the Cbl phosphotyrosine-binding domain restored Src kinase activity and Lyn, Fyn, and FGFR2 levels and reduced ALP up-regulation in mutant osteoblasts. Thus, constitutive FGFR2 activation induces c-Cbl-dependent Lyn and Fyn proteasome degradation, resulting in reduced Lyn and Fyn kinase activity, increased ALP expression, and FGFR2 down-regulation. This reveals a common Cbl-mediated negative feedback mechanism controlling Lyn, Fyn, and FGFR2 degradation in response to overactive FGFR2 and indicates a role for Cbl-dependent down-regulation of Lyn and Fyn in osteoblast differentiation induced by constitutive FGFR2 activation.	Univ Paris 07, Hop Lariboisiere, INSERM, U606,Lab Osteoblast Biol & Pathol, F-75475 Paris 10, France; Serv Bone Dis, CH-1211 Geneva 14, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marie, PJ (corresponding author), Univ Paris 07, Hop Lariboisiere, INSERM, U606,Lab Osteoblast Biol & Pathol, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	pierre.marie@larib.inserm.fr						Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Bresnick S, 1998, J CRANIOFAC SURG, V9, P92, DOI 10.1097/00001665-199801000-00020; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Chen L, 2003, BONE, V33, P169, DOI 10.1016/S8756-3282(03)00222-9; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hay E, 2004, J BIOL CHEM, V279, P1650, DOI 10.1074/jbc.M300969200; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; HURLEY MM, 2001, PRINCIPLES BONE BIOL, V1, P825; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kilkenny DM, 2003, J BIOL CHEM, V278, P17448, DOI 10.1074/jbc.M209698200; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kyo S, 2003, GENES CELLS, V8, P825, DOI 10.1046/j.1365-2443.2003.00679.x; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Lemonnier J, 2001, J BONE MINER RES, V16, P832, DOI 10.1359/jbmr.2001.16.5.832; Lemonnier J, 2000, EXP CELL RES, V256, P158, DOI 10.1006/excr.2000.4820; Leu TH, 2003, FRONT BIOSCI-LANDMRK, V8, pS28, DOI 10.2741/980; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li Y, 1997, LEUKEMIA RES, V21, P391, DOI 10.1016/S0145-2126(96)00078-1; Lomri A, 1998, J CLIN INVEST, V101, P1310; Lomri A, 2001, J BONE MINER RES, V16, P705, DOI 10.1359/jbmr.2001.16.4.705; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378-1119(03)00748-0; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Maschberger P, 2000, J BIOL CHEM, V275, P19159, DOI 10.1074/jbc.M910257199; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Monsonego-Ornan E, 2002, FEBS LETT, V528, P83, DOI 10.1016/S0014-5793(02)03255-6; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sanjay A., 2001, SCI STKE; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; ZAISI SK, 2004, EMBO J, V23, P790; ZHAN X, 1994, J BIOL CHEM, V269, P20221	65	65	70	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36259	36267		10.1074/jbc.M402469200	http://dx.doi.org/10.1074/jbc.M402469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15190072	hybrid			2022-12-27	WOS:000223453600014
J	Debaigt, C; Hirling, H; Steiner, P; Vincent, JP; Mazella, J				Debaigt, C; Hirling, H; Steiner, P; Vincent, JP; Mazella, J			Crucial role of neuron-enriched endosomal protein of 21 kDa in sorting between degradation and recycling of internalized G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTENSIN RECEPTORS; BINDING-PROPERTIES; ENDOCYTIC PATHWAY; SYNTAXIN 13; TRAFFICKING; EXPRESSION; COMPLEXES; TERMINUS; RESIDUE; MOUSE	Recycling of endocytosed G-protein-coupled receptors involves a series of molecular events through early and recycling endosomes. The purpose of this work was to study the role of neuron-enriched endosomal protein of 21 kDa (NEEP21) in the recycling process of neurotensin receptors-1 and -2. Here we showed that suppression of NEEP21 expression does not modify the internalization rate of both receptors but strongly inhibited the recycling of the neurotensin receptor-2. In contrast, overexpression of NEEP21 changes the behavior of the neurotensin receptor-1 from a non-recycling to a recycling state. Recycling of the neurotensin receptor-2 involves both the phosphatidylinositol 3-kinase and the recycling endosome pathways, whereas recycling of the neurotensin receptor-1 induced by overexpression of NEEP21 only occurs by the phosphatidylinositol 3-kinase-dependent pathway. Taken together, these results confirm the essential role of NEEP21 in the recycling mechanism and show that this protein acts at the level of early endosomes to promote sorting of receptors toward a recycling pathway.	CNRS, Inst Pharmacol Mol & Cellulaire, Unite Mixte Rech 6097, F-06560 Valbonne, France; Ecole Polytech Fed Lausanne, Fac Sci Vie, CH-1015 Lausanne, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Mazella, J (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, Unite Mixte Rech 6097, 660 Route Lucioles, F-06560 Valbonne, France.	mazella@ipmc.cnrs.fr	Mazella, Jean/A-6767-2012					Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hermanns S, 1997, GLIA, V21, P299; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Liang W, 2003, J BIOL CHEM, V278, P39773, DOI 10.1074/jbc.M304482200; Martin S, 2002, J CELL SCI, V115, P165; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; SADOUL JL, 1984, BIOCHEM BIOPH RES CO, V120, P812, DOI 10.1016/S0006-291X(84)80179-5; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7; Trejo J, 2003, J PHARMACOL EXP THER, V307, P437, DOI 10.1124/jpet.103.052100; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Zhu JJ, 2000, NAT NEUROSCI, V3, P1098, DOI 10.1038/80614	21	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35687	35691		10.1074/jbc.M402751200	http://dx.doi.org/10.1074/jbc.M402751200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15187090	hybrid			2022-12-27	WOS:000223303400066
J	Longo, KA; Wright, WS; Kang, S; Gerin, I; Chiang, SH; Lucas, PC; Opp, MR; MacDougald, OA				Longo, KA; Wright, WS; Kang, S; Gerin, I; Chiang, SH; Lucas, PC; Opp, MR; MacDougald, OA			Wnt10b inhibits development of white and brown adipose tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESISTANCE; BETA-CATENIN; GENE FAMILY; ADAPTIVE THERMOGENESIS; DIABETES-MELLITUS; TRANSGENIC MICE; GROWTH-FACTORS; CELL-GROWTH; ADIPOGENESIS; LIPODYSTROPHY	Wnt is a family of secreted signaling proteins that regulate diverse developmental processes. Activation of canonical Wnt signaling by Wnt10b inhibits differentiation of preadipocytes in vitro. To determine whether Wnt signaling blocks adipogenesis in vivo, we created transgenic mice in which Wnt10b is expressed from the FABP4 promoter. Expression of Wnt10b in adipose impairs development of this tissue throughout the body, with a decline of similar to50% in total body fat and a reduction of similar to60% in weight of epididymal and perirenal depots. FABP4-Wnt10b mice resist accumulation of adipose tissue when fed a high fat diet. Furthermore, transgenic mice are more glucose-tolerant and insulin-sensitive than wild type mice. Expression of Wnt10b from the FABP4 promoter also blocks development of brown adipose tissue. Interscapular tissue of FABP4-Wnt10b mice has the visual appearance of white adipose tissue but expresses neither brown (e.g. uncoupling protein 1) nor white adipocyte markers. Transgenic mice are unable to maintain a core body temperature when placed in a cold environment, providing further evidence that Wnt10b inhibits development of brown adipose tissue. Although food intake is not altered in FABP4-Wnt10b mice, oxygen consumption is decreased. Thus, FABP4-Wnt10b mice on a chow diet gain more weight than controls, largely because of an increase in weight of skin. In summary, inhibition by Wnt10b of white and brown adipose tissue development results in lean mice without lipodystrophic diabetes.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, 7620 Med Sci 2,1301 E Catherine Dr, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Longo, Kenneth A/A-5631-2010	MacDougald, Ormond/0000-0001-6907-7960; Hahn, Wendy/0000-0002-4374-5876; Opp, Mark/0000-0002-9831-9866; Lucas, Peter/0000-0003-4880-7172	NIDDK NIH HHS [DK51563, DK62876] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062876, R01DK051563, R01DK062876] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Feely RS, 2000, EXP GERONTOL, V35, P417, DOI 10.1016/S0531-5565(00)00095-4; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kennell JA, 2003, MOL CELL BIOL, V23, P5366, DOI 10.1128/MCB.23.15.5366-5375.2003; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4	39	266	286	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35503	35509		10.1074/jbc.M402937200	http://dx.doi.org/10.1074/jbc.M402937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190075	hybrid			2022-12-27	WOS:000223303400044
J	Reuben, PM; Sun, YB; Cheung, HS				Reuben, PM; Sun, YB; Cheung, HS			Basic calcium phosphate crystals activate p44/42 MAPK signal transduction pathway via protein kinase C mu in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; ANGIOTENSIN-II; INDUCTION; ANTISENSE; COLLAGENASE; INHIBITION; GROWTH; OLIGODEOXYNUCLEOTIDES; METALLOPROTEINASE-1	Although basic calcium phosphate (BCP) crystals are common in osteoarthritis, the crystal-induced signal transduction pathways in human fibroblasts have not been fully comprehended. We have previously demonstrated that the induction of matrix metalloproteinases (MMP) 1 and 3 by BCP crystals follows both the calcium-dependent protein kinase C (PKC) pathway and the calcium-independent p44/42 mitogen-activated protein kinase (p44/42 MAPK) pathway. Although we showed that the calcium-dependent PKC pathway was characterized by calcium-dependent PKCalpha, here we show that the calcium-independent p44/42 MAPK pathway is mediated by calcium-independent PKCmu. Inhibition of PKCmu synthesis and activity by antisense oligodeoxynucleotides and H-89 (N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide), respectively, results in the inhibition of p44/42 MAPK activation, thus demonstrating that p44/42 MAPK activity is dependent upon PKCmu. Reverse transcription-polymerase chain reaction and Western blotting also show that inhibition of PKCmu results in the inhibition of MMP-1 and MMP-3 mRNA and protein expression as a result of p44/42 MAPK inhibition. These results now lead us to the conclusion that BCP crystal activation of human fibroblasts follows two pathways: 1) the calcium-dependent PKC pathway characterized by PKCalpha and 2) the calcium-independent p44/42 MAPK pathway mediated by PKCmu, which operate independently leading to an increase in mitogenesis and MMP synthesis and ultimately complementing each other for the efficient regulation of cellular responses to BCP crystal stimulation of human fibroblasts.	Vet Adm Med Ctr, Res Serv, Miami, FL 33125 USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Miami, FL 33125 USA; Univ Miami, Dept Biomed Engn, Coral Gables, FL 33146 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33101 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; University of Miami	Cheung, HS (corresponding author), Vet Adm Med Ctr, Res Serv, 1201 NW 16th St, Miami, FL 33125 USA.	hcheung@med.miami.edu			NIAMS NIH HHS [AR38421-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; Bai G, 2001, OSTEOARTHR CARTILAGE, V9, P416, DOI 10.1053/joca.2000.0407; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Berts A, 1999, MOL PHARMACOL, V55, P296, DOI 10.1124/mol.55.2.296; Brogley MA, 1999, J CELL PHYSIOL, V180, P215, DOI 10.1002/(SICI)1097-4652(199908)180:2<215::AID-JCP9>3.0.CO;2-J; Buchner K, 2000, J CANCER RES CLIN, V126, P1, DOI 10.1007/PL00008458; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Cheung, 1980, J TISS CULT METHODS, V6, P39, DOI 10.1007/BF01665905; CHEUNG HS, 1993, JOINT CARTILAGE DEGR, P209; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cohen RI, 1996, MOL BRAIN RES, V43, P193, DOI 10.1016/S0169-328X(96)00176-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; EVANS RW, 1994, CALCIFIED TISSUE INT, V36, P645; Fleming I, 1998, BIOCHEM J, V333, P719, DOI 10.1042/bj3330719; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HALVERSON PB, 1986, ANN RHEUM DIS, V45, P603, DOI 10.1136/ard.45.7.603; Halverson PB, 1998, OSTEOARTHR CARTILAGE, V6, P324, DOI 10.1053/joca.1998.0131; HALVERSON PB, 2001, ARTHRITIS ALLIED CON, P2371; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; IZANT JG, 1989, CELL MOTIL CYTOSKEL, V14, P81, DOI 10.1002/cm.970140117; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Larocca JN, 1997, J NEUROSCI RES, V50, P743, DOI 10.1002/(SICI)1097-4547(19971201)50:5<743::AID-JNR11>3.0.CO;2-2; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; MCCARTHY GM, 1991, ARTHRITIS RHEUM-US, V34, P1021, DOI 10.1002/art.1780340812; MCCARTHY GM, 1992, J CELL PHYSIOL, V153, P140, DOI 10.1002/jcp.1041530118; McCarthy GM, 2001, ANN RHEUM DIS, V60, P399, DOI 10.1136/ard.60.4.399; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Reuben PM, 2002, J BIOL CHEM, V277, P15190, DOI 10.1074/jbc.M200278200; Reuben PM, 2001, CONNECT TISSUE RES, V42, P1, DOI 10.3109/03008200109014244; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROTHENBERG RJ, 1988, AM J PHYSIOL-CELL PH, V23, pC554; Ryan LM, 1999, RHEUM DIS CLIN N AM, V25, P257, DOI 10.1016/S0889-857X(05)70066-1; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHUMACHER HR, 1968, ARTHRITIS RHEUM-US, V11, P426, DOI 10.1002/art.1780110308; STEIN CA, 1988, CANCER RES, V48, P2659; Sun YB, 2002, J BIOL CHEM, V277, P1544, DOI 10.1074/jbc.M100567200; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Wagner S, 2000, EXP CELL RES, V258, P204, DOI 10.1006/excr.2000.4925; ZON G, 1988, PHARM RES-DORDR, V5, P539, DOI 10.1023/A:1015985728434; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	58	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35719	35725		10.1074/jbc.M403406200	http://dx.doi.org/10.1074/jbc.M403406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190081	hybrid			2022-12-27	WOS:000223303400070
J	Tzameli, I; Fang, H; Ollero, M; Shi, H; Hamm, JK; Kievit, P; Hollenberg, AN; Flier, JS				Tzameli, I; Fang, H; Ollero, M; Shi, H; Hamm, JK; Kievit, P; Hollenberg, AN; Flier, JS			Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-GENE-EXPRESSION; ENHANCER BINDING-PROTEIN; PPAR-GAMMA; INSULIN-RESISTANCE; LIPID-METABOLISM; OXIDIZED LDL; FATTY-ACIDS; C/EBP-BETA; ADIPOGENESIS; ALPHA	Peroxisome proliferator-activated receptor-gamma(PPARgamma) is a nuclear hormone receptor that is critical for adipogenesis and insulin sensitivity. Ligands for PPARgamma include some polyunsaturated fatty acids and prostanoids and the synthetic high affinity antidiabetic agents thiazolidinediones. However, the identity of a biologically relevant endogenous PPARgamma ligand is unknown, and limited insight exists into the factors that may regulate production of endogenous PPARgamma ligands during adipocyte development. To address this question, we created a line of 3T3-L1 preadipocytes that carry a beta-galactosidase-based PPARgamma ligand-sensing vector system. In this system, induction of adipogenesis resulted in elevated beta-galactosidase activity that signifies activation of PPARgamma via its ligand-binding domain (LBD) and suggests generation and/or accumulation of a ligand moiety. The putative endogenous ligand appeared early in adipogenesis in response to increases in cAMP, accumulated in the medium, and dissipated later in adipogenesis. Organically extracted and high pressure liquid chromatography-fractionated conditioned media from differentiating cells, but not from mature adipocytes, were enriched in this activity. One or more components within the organic extract activated PPARgamma through interaction with its LBD, induced lipid accumulation in 3T3-L1 cells as efficiently as the differentiation mixture, and competed for binding of rosiglitazone to the LBD of PPARgamma. The active species appears to be different from other PPARgamma ligands identified previously. Our findings suggest that a novel biologically relevant PPARgamma ligand is transiently produced in 3T3-L1 cells during adipogenesis.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Obstet & Gynecol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Flier, JS (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Finard 202,330 Brookline Ave, Boston, MA 02215 USA.	jflier@caregroup.harvard.edu	Ollero, Mario/AAJ-3545-2020; Flier, jeffrey/AAG-6223-2019; Ollero, Mario/Q-6147-2018	Ollero, Mario/0000-0003-3590-706X	NIDDK NIH HHS [2P30 DK46200-11, DKR3728082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082, P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Camp HS, 1999, FEBS LETT, V447, P186, DOI 10.1016/S0014-5793(99)00268-9; Camp HS, 2001, ENDOCRINOLOGY, V142, P3207, DOI 10.1210/en.142.7.3207; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; de Urquiza AM, 1999, P NATL ACAD SCI USA, V96, P13270, DOI 10.1073/pnas.96.23.13270; Fajas L, 2003, J LIPID RES, V44, P1652, DOI 10.1194/jlr.M300248-JLR200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Funk CD, 2000, AM J RESP CRIT CARE, V161, pS120, DOI 10.1164/ajrccm.161.supplement_1.ltta-24; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lebovitz HE, 2001, RECENT PROG HORM RES, V56, P265, DOI 10.1210/rp.56.1.265; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lenhard JM, 1997, BIOCHEM PHARMACOL, V54, P801, DOI 10.1016/S0006-2952(97)00229-3; Madsen L, 2003, BIOCHEM J, V375, P539, DOI 10.1042/BJ20030503; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Micheal LF, 1997, ENDOCRINOLOGY, V138, P3695, DOI 10.1210/en.138.9.3695; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pages C, 2000, ANN NY ACAD SCI, V905, P159; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SPARKS RL, 1991, J CELL PHYSIOL, V146, P101, DOI 10.1002/jcp.1041460114; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; Takamura T, 2001, EUR J PHARMACOL, V422, P23, DOI 10.1016/S0014-2999(01)01053-6; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; WONG WT, 1992, AM J PHYSIOL, V262, pC91, DOI 10.1152/ajpcell.1992.262.1.C91; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	58	151	175	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36093	36102		10.1074/jbc.M405346200	http://dx.doi.org/10.1074/jbc.M405346200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190061	hybrid			2022-12-27	WOS:000223303400111
J	Fitzsimons, CP; Monczor, F; Fernandez, N; Shayo, C; Davio, C				Fitzsimons, CP; Monczor, F; Fernandez, N; Shayo, C; Davio, C			Mepyramine, a histamine H-1 receptor inverse agonist, binds preferentially to a G protein-coupled form of the receptor and sequesters G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCUPANCY MODEL; ANTAGONIST; ACTIVATION; AFFINITY; DESENSITIZATION; PHARMACOLOGY; MECHANISMS; EXPRESSION; TIOTIDINE; CALCIUM	Accurate characterization of the molecular mechanisms of the action of ligands is an extremely important issue for their appropriate research, pharmacological, and therapeutic uses. In view of this fact, the aim of the present work was to investigate the mechanisms involved in the actions of mepyramine at the guinea pig H-1 receptor stably expressed in Chinese hamster ovary cells. We found that mepyramine is able to decrease the basal constitutive activity of the guinea pig H-1 receptor, to bind with high affinity to a G(q/11) protein-coupled form of the receptor and to promote a G protein-coupled inactive state of the H-1 receptor that interferes with the G(q/11)-mediated signaling of the endogenously expressed ATP receptor, as predicted by the Cubic Ternary Complex Model of receptor occupancy. The effect of mepyramine on ATP-induced signaling was specifically neutralized by Galpha(11) overexpression, indicating that mepyramine is able to reduce G protein availability for other non-related receptors associated with the same signaling pathway. Finally, we found a loss of mepyramine efficacy in decreasing basal levels of intracellular calcium at high Galpha(11) expression levels, which can be theoretically explained in terms of high H-1 receptor constitutive activity. The whole of the present work sheds new light on H-1 receptor pharmacology and the mechanisms H-1 receptor inverse agonists could use to exert their observed negative efficacy.	Univ Buenos Aires, Fac Farm & Bioquim, Catedra Fis, Lab Radioisotopos, RA-1113 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol Biol Mol & Celular, RA-1113 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1113 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Davio, C (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Catedra Fis, Lab Radioisotopos, Junin 956,PB, RA-1113 Buenos Aires, DF, Argentina.	cardavio@ffyb.uba.ar		Fitzsimons, Carlos P./0000-0002-1556-2650				Anthes JC, 2002, EUR J PHARMACOL, V449, P229, DOI 10.1016/S0014-2999(02)02049-6; Asghar AUR, 2000, EUR J PHARMACOL, V398, P131, DOI 10.1016/S0014-2999(00)00281-8; Bakker RA, 2000, EUR J PHARMACOL, V387, pR5, DOI 10.1016/S0014-2999(99)00803-1; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; Brown GP, 1998, J PHARMACOL EXP THER, V286, P376; CarmanKrzan M, 1997, N-S ARCH PHARMACOL, V355, P431, DOI 10.1007/PL00004965; Carrillo JJ, 2003, J BIOL CHEM, V278, P42578, DOI 10.1074/jbc.M306165200; CASALE TB, 1985, BIOCHEM PHARMACOL, V34, P3285, DOI 10.1016/0006-2952(85)90347-8; Chen G, 2000, MOL PHARMACOL, V57, P125; DELEAN A, 1982, MOL PHARMACOL, V22, P290; Dickenson JM, 1998, BRIT J PHARMACOL, V124, P1491, DOI 10.1038/sj.bjp.0701977; DINI S, 1991, AGENTS ACTIONS, V33, P181, DOI 10.1007/BF01993161; Fernandez N, 2002, MOL PHARMACOL, V62, P1506, DOI 10.1124/mol.62.6.1506; Fitzsimons C, 2002, BIOCHEM PHARMACOL, V63, P1785, DOI 10.1016/S0006-2952(02)00975-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATTORI Y, 1991, BRIT J PHARMACOL, V103, P1573, DOI 10.1111/j.1476-5381.1991.tb09829.x; Hill SJ, 1997, PHARMACOL REV, V49, P253; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; Kakiuchi M, 1997, JPN J PHARMACOL, V73, P291, DOI 10.1254/jjp.73.291; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LIU YJ, 1992, BRIT J PHARMACOL, V106, P233, DOI 10.1111/j.1476-5381.1992.tb14322.x; MARTIN MW, 1984, J PHARMACOL EXP THER, V230, P424; McLoughlin DJ, 2000, J NEUROCHEM, V74, P347, DOI 10.1046/j.1471-4159.2000.0740347.x; Megson AC, 2001, MOL PHARMACOL, V59, P1012, DOI 10.1124/mol.59.5.1012; Miller TR, 1999, J BIOMOL SCREEN, V4, P249, DOI 10.1177/108705719900400506; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Monczor F, 2003, MOL PHARMACOL, V64, P512, DOI 10.1124/mol.64.2.512; ROBERTSON MJ, 1994, TRENDS PHARMACOL SCI, V15, P364, DOI 10.1016/0165-6147(94)90156-2; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seifert R, 2003, J PHARMACOL EXP THER, V305, P1104, DOI 10.1124/jpet.103.049619; Shayo C, 2001, MOL PHARMACOL, V60, P1049, DOI 10.1124/mol.60.5.1049; Strange PG, 2002, TRENDS PHARMACOL SCI, V23, P89, DOI 10.1016/S0165-6147(02)01993-4; TRAIFFORT E, 1994, J NEUROCHEM, V62, P507; van der Goot H, 2000, EUR J MED CHEM, V35, P5, DOI 10.1016/S0223-5234(00)00101-X; Vauquelin G, 2001, TRENDS PHARMACOL SCI, V22, P343, DOI 10.1016/S0165-6147(00)01739-9; Wade SM, 2001, MOL PHARMACOL, V59, P532, DOI 10.1124/mol.59.3.532; Walsh Garry M, 2002, Expert Opin Drug Saf, V1, P225, DOI 10.1517/14740338.1.3.225; Weiss JM, 1996, J THEOR BIOL, V178, P169, DOI 10.1006/jtbi.1996.0015; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Weiss JM, 1996, J THEOR BIOL, V181, P381, DOI 10.1006/jtbi.1996.0139; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; Wieland K, 1999, J BIOL CHEM, V274, P29994, DOI 10.1074/jbc.274.42.29994; Yakuo I, 2001, PHARMACOL TOXICOL, V89, P171, DOI 10.1111/j.0901-9928.2001.890405.x	45	51	52	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34431	34439		10.1074/jbc.M400738200	http://dx.doi.org/10.1074/jbc.M400738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192105	Green Published, hybrid			2022-12-27	WOS:000223134800044
J	Huang, SC; Jagadeeswaran, R; Liu, ES; Benz, EJ				Huang, SC; Jagadeeswaran, R; Liu, ES; Benz, EJ			Protein 4.1R, a microtubule-associated protein involved in microtubule aster assembly in mammalian mitotic extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTRIN-ACTIN-BINDING; CYTOPLASMIC DYNEIN; FUNCTIONAL-CHARACTERIZATION; NONERYTHROID ISOFORM; MESSENGER-RNA; CELL-CYCLE; IN-VITRO; SPINDLE; TUBULIN; ORGANIZATION	Non-erythroid protein 4.1R ( 4.1R) consists of a complex family of isoforms. We have shown that 4.1R isoforms localize at the mitotic spindle/spindle poles and associate in a complex with the mitotic-spindle organization proteins Nuclear Mitotic Apparatus protein ( NuMA), dynein, and dynactin. We addressed the mitotic function of 4.1R by investigating its association with microtubules, the main component of the mitotic spindles, and its role in mitotic aster assembly in vitro. 4.1R appears to partially co-localize with microtubules throughout the mitotic stages of the cell cycle. In vitro sedimentation assays showed that 4.1R isoforms directly interact with microtubules. Glutathione S-transferase (GST) pull-down assays using GST-4.1R fusions and mitotic cell extracts further showed that the association of 4.1R with tubulin results from both the membrane-binding domain and C-terminal domain of 4.1R. Moreover, 4.1R, but not actin, is a mitotic microtubule-associated protein; 4.1R associates with microtubules in the microtubule pellet of the mitotic asters assembled in mammalian cell-free mitotic extract. The organization of microtubules into asters depends on 4.1R in that immunodepletion of 4.1R from the extract resulted in randomly dispersed microtubules. Furthermore, adding a 135-kDa recombinant 4.1R reconstituted the mitotic asters. Finally, we demonstrated that a mitotic 4.1R isoform appears to form a complex in vivo with tubulin and NuMA in highly synchronized mitotic HeLa extracts. Our results suggest that a 135-kDa non-erythroid 4.1R is important to cell division, because it participates in the formation of mitotic spindles and spindle poles through its interaction with mitotic microtubules.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp Boston, Dept Pediat, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital	Huang, SC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, D610,44 Binney St, Boston, MA 02115 USA.	shu-ching_huang@dfci.harvard.edu	Jagadeeswaran, Ramasamy/C-9987-2013	Ramasamy, Jagadeesh/0000-0002-7906-4239	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL061295, R01HL044985, R01HL061295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61295, HL 44985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; BENZ EJ, 1994, MOL BASIS BLOOD DIS, P257; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; Chasis JA, 1996, BLOOD, V87, P5324, DOI 10.1182/blood.V87.12.5324.bloodjournal87125324; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1988, BIOCHEM J, V255, P217; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; Dionne MA, 2000, J BIOL CHEM, V275, P12346, DOI 10.1074/jbc.275.16.12346; DISCHER DE, 1995, J CELL BIOL, V130, P897, DOI 10.1083/jcb.130.4.897; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Haren L, 2002, J CELL SCI, V115, P1815; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; HEIDEMANN SR, 1980, NATURE, V286, P517, DOI 10.1038/286517a0; HUANG SC, 1992, T ASSOC AM PHYSICIAN, V105, P165; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; Kontrogianni-Konstantopoulos A, 2000, MOL BIOL CELL, V11, P3805, DOI 10.1091/mbc.11.11.3805; Kontrogianni-Konstantopoulos A, 2001, J BIOL CHEM, V276, P20679, DOI 10.1074/jbc.M010581200; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Krauss SW, 2004, J BIOL CHEM, V279, P27591, DOI 10.1074/jbc.M402813200; Lallena MJ, 1997, J CELL SCI, V110, P239; Mack GJ, 2001, P NATL ACAD SCI USA, V98, P14434, DOI 10.1073/pnas.261371298; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; OCONNOR PM, 1995, CELL CYCLE MAT METHO, P63; Ohara R, 1999, DEV BRAIN RES, V117, P127, DOI 10.1016/S0165-3806(99)00110-8; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Parra MK, 2003, BLOOD, V101, P4164, DOI 10.1182/blood-2002-06-1796; Perez-Ferreiro CM, 2001, J BIOL CHEM, V276, P44785, DOI 10.1074/jbc.M107369200; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Ramez M, 2003, KIDNEY INT, V63, P1321, DOI 10.1046/j.1523-1755.2003.00870.x; Rusan NM, 2002, J CELL BIOL, V158, P997, DOI 10.1083/jcb.200204109; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shi ZT, 1999, J CLIN INVEST, V103, P331, DOI 10.1172/JCI3858; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; Tran YK, 1999, CANCER RES, V59, P35; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; Walensky LD, 1999, J NEUROSCI, V19, P6457; Whitehead CM, 1998, J CELL SCI, V111, P2551	51	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34595	34602		10.1074/jbc.M404051200	http://dx.doi.org/10.1074/jbc.M404051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184364	hybrid			2022-12-27	WOS:000223134800064
J	Lariviere, L; Morera, S				Lariviere, L; Morera, S			Structural evidence of a passive base-flipping mechanism for beta-glucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; CRYSTAL-STRUCTURES; RECOGNITION; BINDING; REPAIR; SUBSTRATE; ACID; IDENTIFICATION; KINETICS; EXCISION	beta-Glucosyltransferase (BGT) is a DNA-modifying enzyme and a glycosyltransferase. This inverting enzyme transfers glucose from UDP-glucose to the 5-hydroxymethyl cytosine bases of T4 phage DNA. From previous structural analyses we showed that Asp-100 and Asn-70 were, respectively, the catalytic base and the key residue for specific DNA recognition (Lariviere, L., Gueguen-Chaignon, V., and Morera, S. ( 2003) J. Mol. Biol. 330, 1077 - 1086). Here, we supply biochemical evidence supporting their essential roles in catalysis. We have also shown previously that BGT uses a base-flipping mechanism to access 5-hydroxymethyl cytosine (Lariviere, L., and Morera, S. ( 2002) J. Mol. Biol. 324, 483 - 490). Whether it is an active or a passive process remains unclear, as is the case for all DNA cleaving and modifying enzymes. Here, we report two crystal structures: (i) BGT in complex with a 13-mer DNA containing an A: G mismatch and (ii) BGT in a ternary complex with UDP and an oligonucleotide containing a single central G: C base pair. The binary structure reveals a specific complex with the flipped-out, mismatched adenine exposed to the active site. Unexpectedly, the other structure shows the non-productive binding of an intermediate flipped-out base. Our structural analysis provides clear evidence for a passive process.	CNRS, Unite Propre Rech 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Morera, S (corresponding author), CNRS, Unite Propre Rech 9063, Lab Enzymol & Biochim Struct, Batiment 34,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	morera@lebs.cnrs-gif.fr						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN X, 2001, NUCLEIC ACIDS RES, V19, P3784; DeLano W.L, PYMOL MOL GRAPHICS S; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; Gueron M, 1995, METHOD ENZYMOL, V261, P383; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Hosfield DJ, 2001, PROG NUCLEIC ACID RE, V68, P315; JOSSE J, 1962, J BIOL CHEM, V237, P1968; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; Kurzeck J., 2002, THESIS RUHR U BOCHUM; Lariviere L, 2003, J MOL BIOL, V330, P1077, DOI 10.1016/S0022-2836(03)00635-1; Lariviere L, 2002, J MOL BIOL, V324, P483, DOI 10.1016/S0022-2836(02)01091-4; Lariviere L, 2002, ACTA CRYSTALLOGR D, V58, P1484, DOI 10.1107/S0907444902012969; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LESLIE AGW, 1992, JOINT CCP4 ESRF EAMC, V26; Luscombe NM, 1997, NUCLEIC ACIDS RES, V25, P4940, DOI 10.1093/nar/25.24.4940; MI S, 1995, NUCLEIC ACIDS RES, V23, P620, DOI 10.1093/nar/23.4.620; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Morera S, 2001, J MOL BIOL, V311, P569, DOI 10.1006/jmbi.2001.4905; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Nadassy K, 1999, BIOCHEMISTRY-US, V38, P1999, DOI 10.1021/bi982362d; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pasternack LB, 1996, NUCLEIC ACIDS RES, V24, P2740, DOI 10.1093/nar/24.14.2740; Quevillon-Cheruel S, 2003, J SYNCHROTRON RADIAT, V10, P4, DOI 10.1107/S0909049502017284; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wibley JEA, 2003, MOL CELL, V11, P1647, DOI 10.1016/S1097-2765(03)00235-1; WINKLER FK, 1994, STRUCTURE, V2, P79, DOI 10.1016/S0969-2126(00)00009-5; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200	40	16	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34715	34720		10.1074/jbc.M404394200	http://dx.doi.org/10.1074/jbc.M404394200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15178685	hybrid			2022-12-27	WOS:000223134800077
J	Ruiz, A; Munoz, I; Serrano, R; Gonzalez, A; Simon, E; Arino, J				Ruiz, A; Munoz, I; Serrano, R; Gonzalez, A; Simon, E; Arino, J			Functional characterization of the Saccharomyces cerevisiae VHS3 gene - A regulatory subunit of the Ppz1 protein phosphatase with novel, phosphatase-unrelated functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PSEUDOHYPHAL DIFFERENTIATION; SALT TOLERANCE; INVASIVE GROWTH; MOLECULAR CHARACTERIZATION; MOONLIGHTING PROTEINS; SIGNAL-TRANSDUCTION; SURFACE FLOCCULIN; ION HOMEOSTASIS; FISSION YEAST	The yeast gene VHS3 (YOR054c) has been recently identified as a multicopy suppressor of the G(1)/S cell cycle blockade of a conditional sit4 and hal3 mutant. Vhs3 is structurally related to Hal3, a negative regulatory subunit of the Ser/Thr protein phosphatase Ppz1 important for cell integrity, salt tolerance, and cell cycle control. Phenotypic analyses using vhs3 mutants and overexpressing strains clearly show that Vhs3 has functions reminiscent to those of Hal3 and contrary to those of Ppz1. Mutation of Vhs3 His(459), equivalent to the supposedly functionally relevant His(90) in the plant homolog AtHal3a, did not affect Vhs3 functions mentioned above. Similarly to Hal3, Vhs3 binds in vivo to the C-terminal catalytic moiety of Ppz1 and inhibits in vitro its phosphatase activity. Therefore, our results indicate that Vhs3 plays a role as an inhibitory subunit of Ppz1. We have found that the vhs3 and hal3 mutations are synthetically lethal. Remarkably, lethality is not suppressed by deletion of PPZ1, PPZ2, or both phosphatase genes, indicating that it is not because of an excess of Ppz phosphatase activity. Furthermore, a Vhs3 version carrying the H459A mutation did not rescue the synthetically lethal phenotype. A conditional vhs3 tetO: HAL3 double mutant displays, in the presence of doxycycline, a flocculation phenotype that is dependent on the presence of Flo8 and Flo11. These results indicate that, besides its role as Ppz1 inhibitory subunit, Vhs3 ( and probably Hal3) might have important Ppz-independent functions.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain	Autonomous University of Barcelona	Arino, J (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Ed 5, E-08193 Barcelona, Spain.	Joaquin.Arino@uab.es	Zhang, Ning/F-1387-2014; González, Asier/A-7064-2012; Arino, Joaquin/D-3756-2011; Ruiz, Amparo/AAZ-2317-2021	Arino, Joaquin/0000-0002-6774-2987; Ruiz, Amparo/0000-0002-3947-4540; Munoz Munoz, Ivan/0000-0002-1606-5445; Arino Carmona, Joaquin/0000-0002-0390-4270				ADAMS A, 1997, METHODS YEAST GENETI, P147; Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Arino J, 2002, EUR J BIOCHEM, V269, P1072, DOI 10.1046/j.0014-2956.2002.02753.x; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Bony M, 1998, YEAST, V14, P25, DOI 10.1002/(SICI)1097-0061(19980115)14:1<25::AID-YEA197>3.3.CO;2-3; Calero F, 2000, J BACTERIOL, V182, P394, DOI 10.1128/JB.182.2.394-399.2000; Clotet J, 1999, MOL CELL BIOL, V19, P2408; Clotet J, 1996, J BIOL CHEM, V271, P26349, DOI 10.1074/jbc.271.42.26349; Davydenko SG, 2004, YEAST, V21, P463, DOI 10.1002/yea.1063; de Nadal E, 1999, J BACTERIOL, V181, P6456, DOI 10.1128/JB.181.20.6456-6462.1999; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; de Nadal E, 2001, J BIOL CHEM, V276, P14829, DOI 10.1074/jbc.M010824200; DICOMO CJ, 1995, GENETICS, V139, P95; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; Gagiano M, 2003, MOL MICROBIOL, V47, P119, DOI 10.1046/j.1365-2958.2003.03247.x; Gagiano M, 2002, FEMS YEAST RES, V2, P433, DOI 10.1016/S1567-1356(02)00133-2; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; Garcia-Gimeno MA, 2003, J BIOL CHEM, V278, P47744, DOI 10.1074/jbc.M306157200; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; HUGHES V, 1993, EUR J BIOCHEM, V216, P269, DOI 10.1111/j.1432-1033.1993.tb18142.x; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jeffery CJ, 2003, TRENDS GENET, V19, P415, DOI 10.1016/S0168-9525(03)00167-7; Kuchin S, 2002, MOL CELL BIOL, V22, P3994, DOI 10.1128/MCB.22.12.3994-4000.2002; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Lambrechts MG, 1996, P NATL ACAD SCI USA, V93, P8419, DOI 10.1073/pnas.93.16.8419; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LIU HP, 1992, GENETICS, V132, P665; Lo WS, 1996, J BACTERIOL, V178, P7144, DOI 10.1128/jb.178.24.7144-7151.1996; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Munoz I, 2003, YEAST, V20, P157, DOI 10.1002/yea.938; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Palecek SP, 2002, MICROBIOL-SGM, V148, P893, DOI 10.1099/00221287-148-4-893; Pan XW, 2000, CURR OPIN MICROBIOL, V3, P567, DOI 10.1016/S1369-5274(00)00142-9; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; POSAS F, 1993, FEBS LETT, V318, P282, DOI 10.1016/0014-5793(93)80529-4; POSAS F, 1992, J BIOL CHEM, V267, P11734; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Ruiz A, 2003, EUKARYOT CELL, V2, P937, DOI 10.1128/EC.2.5.937-948.2003; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Simon E, 2001, J BIOL CHEM, V276, P29740, DOI 10.1074/jbc.M101992200; Steinbacher S, 2003, J MOL BIOL, V327, P193, DOI 10.1016/S0022-2836(03)00092-5; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TRECO DA, 1998, CURRENT PROTOCOLS MO; Venturi GM, 2000, GENETICS, V155, P69; Verstrepen KJ, 2003, APPL MICROBIOL BIOT, V61, P197, DOI 10.1007/s00253-002-1200-8; Vissi E, 2001, YEAST, V18, P115, DOI 10.1002/1097-0061(20010130)18:2<115::AID-YEA653>3.0.CO;2-G; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Williams-Hart T, 2002, GENETICS, V160, P1423; Yenush L, 2002, EMBO J, V21, P920, DOI 10.1093/emboj/21.5.920; Zhang NS, 2003, GENE, V303, P121, DOI 10.1016/S0378-1119(02)01142-3; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037	61	37	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34421	34430		10.1074/jbc.M400572200	http://dx.doi.org/10.1074/jbc.M400572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192104	hybrid			2022-12-27	WOS:000223134800043
J	Bowman, EJ; Graham, LA; Stevens, TH; Bowman, BJ				Bowman, EJ; Graham, LA; Stevens, TH; Bowman, BJ			The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from Neurospora crassa and Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTEOLIPID SUBUNIT; PROTON PUMP; YEAST; GENE; SYNTHASE; BAFILOMYCINS; INHIBITORS; MUTATIONS; IDENTIFICATION	The vacuolar H+-ATPase is inhibited with high specificity and potency by bafilomycin and concanamycin, macrolide antibiotics with similar structures. We previously reported that mutation at three residues in subunit c of the vacuolar ATPase from Neurospora crassa conferred strong resistance to bafilomycin but little or no resistance to concanamycin ( Bowman, B. J., and Bowman, E. J. ( 2002) J. Biol. Chem. 277, 3965 - 3972). We have identified additional mutated sites in subunit c that confer resistance to bafilomycin. Furthermore, by subjecting a resistant mutant to a second round of mutation we isolated strains with increased resistance to both bafilomycin and concanamycin. In all of these strains the second mutation is also in subunit c, suggesting it forms at least part of the concanamycin binding site. Site-directed mutagenesis of the gene encoding subunit c in Saccharomyces cerevisiae showed that single mutations in each of the residues identified in one of the double mutants of N. crassa conferred resistance to both bafilomycin and concanamycin. Mutations at the corresponding sites in the VMA11 and VMA16 genes of S. cerevisiae, which encode the c' and c" subunits, did not confer resistance to the drugs. In all, nine residues of subunit c have been implicated in drug binding. The positions of these residues support a model in which the drug binding site is a pocket formed by helices 1, 2, and 4. We hypothesize that the drugs inhibit by preventing the rotation of the c subunits.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of California System; University of California Santa Cruz; University of Oregon	Bowman, BJ (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.	bowman@biology.ucsc.edu		Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006, R25GM058903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006, GM58903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI H, 1988, J BIOL CHEM, V263, P8796; Beutler JA, 2003, CURR MED CHEM, V10, P787, DOI 10.2174/0929867033457827; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2000, J BIOL CHEM, V275, P167, DOI 10.1074/jbc.275.1.167; Bowman EJ, 2003, J BIOL CHEM, V278, P44147, DOI 10.1074/jbc.M306595200; Bowman EJ, 1997, J BIOL CHEM, V272, P14776, DOI 10.1074/jbc.272.23.14776; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOWMAN EJ, 1997, BIOMEMBRANE, P861; Boyd MR, 2001, J PHARMACOL EXP THER, V297, P114; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Drose S, 1997, J EXP BIOL, V200, P1; Farina C, 2001, FARMACO, V56, P113, DOI 10.1016/S0014-827X(01)01013-8; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gibson LCD, 2002, BIOCHEM J, V366, P911, DOI 10.1042/BJ20020171; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; Harrison M, 2003, J BIOENERG BIOMEMBR, V35, P337, DOI 10.1023/A:1025728915565; Harrison M, 2000, BIOCHEMISTRY-US, V39, P7531, DOI 10.1021/bi000159o; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; Hayami K, 2001, GENE, V273, P199, DOI 10.1016/S0378-1119(01)00590-X; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Mattsson JP, 1996, BBA-BIOMEMBRANES, V1280, P98, DOI 10.1016/0005-2736(95)00285-5; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; RAUTIALA TJ, 1993, BIOCHEM BIOPH RES CO, V194, P50, DOI 10.1006/bbrc.1993.1783; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Shen RC, 2003, J AM CHEM SOC, V125, P7889, DOI 10.1021/ja0352350; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sun-Wada GH, 2003, J BIOENERG BIOMEMBR, V35, P347, DOI 10.1023/A:1025780932403; Torigoe T, 2002, ANTI-CANCER DRUG, V13, P237, DOI 10.1097/00001813-200203000-00005; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	48	108	116	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33131	33138		10.1074/jbc.M404638200	http://dx.doi.org/10.1074/jbc.M404638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180988	hybrid			2022-12-27	WOS:000223039700015
J	Hor, S; Pirzer, H; Dumoutier, L; Bauer, F; Wittmann, S; Sticht, H; Renauld, JC; Malefyt, RD; Fickenscher, H				Hor, S; Pirzer, H; Dumoutier, L; Bauer, F; Wittmann, S; Sticht, H; Renauld, JC; Malefyt, RD; Fickenscher, H			The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-ASSOCIATED GENE; HERPESVIRUS SAIMIRI; INTERFERON-GAMMA; INDUCIBLE FACTOR; CUTTING EDGE; MELANOMA DIFFERENTIATION; GROWTH TRANSFORMATION; IL-TIF; CYTOKINE; IL-10	The cellular members of the interleukin-10 (IL-10) cytokine family share sequence homology with IL-10, whereas their sites of expression and their functions are divergent. One of these factors, AK155 or IL-26, was discovered because of its overexpression in human T lymphocytes after growth transformation by the simian rhadinovirus herpesvirus saimiri. In addition, the gene is transcribed in various types of primary and immortalized T-cells. Here we describe epithelial cells, namely colon carcinoma cells and keratinocytes, as targets of this T-cellular lymphokine. Purified recombinant IL-26 induced the rapid phosphorylation of the signal transducer and activator of transcription factors 1 and 3. As a result, secretion of IL-10 and IL-8, as well as cell surface expression of CD54 were enhanced. Moreover, we show that the IL-26 protein binds to heparin, is released from the cell surface, and can be functionally inhibited by heparin. The sensitivity to recombinant IL-26 of various cell lines strictly correlated with the expression of the long chain of the IL-20 receptor. Because blocking antibodies against either the short chain of the IL-10 receptor or the long chain of the IL-20 receptor inhibited IL-26-dependent signal transduction, and transient expression of these receptor chains induced IL-26 responsivity in non-sensitive cells, we propose that the IL-20 receptor 1 and IL-10 receptor 2 chains participate in forming the IL-26 receptor. Targeting epithelial cells, the T-cell lymphokine IL-26 is likely to play a role in local mechanisms of mucosal and cutaneous immunity.	Heidelberg Univ, Dept Virol, D-69120 Heidelberg, Germany; Cambridge Inst Med Res, Cambridge CB2 2XY, England; Catholic Univ Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Erlangen Nurnberg, Bioinformat Unit, Dept Biochem, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; DNAX Res Inst Mol & Cellular Biol Inc, Dept Pharmacol, Palo Alto, CA 94304 USA	Ruprecht Karls University Heidelberg; University of Cambridge; Ludwig Institute for Cancer Research; Universite Catholique Louvain; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Fickenscher, H (corresponding author), Heidelberg Univ, Dept Virol, Im Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	helmut.fickenscher@med.uni-heidelberg.de	Fickenscher, Helmut/J-9655-2019; Fickenscher, Helmut/A-3004-2010; Renauld, Jean-Christophe/B-7268-2012	Fickenscher, Helmut/0000-0003-0043-1153; Sticht, Heinrich/0000-0001-5644-045X; de Waal Malefyt, Rene/0000-0002-2663-383X; Dumoutier, Laure/0000-0002-6645-684X; Renauld, Jean-Christophe/0000-0003-1736-2131				BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; Dumoutier L, 2003, BIOCHEM J, V370, P391, DOI 10.1042/BJ20021935; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Dumoutier L, 2002, EUR CYTOKINE NETW, V13, P5; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; Dumoutier L, 2000, GENES IMMUN, V1, P488, DOI 10.1038/sj.gene.6363716; Fernandez-Botran R, 1999, CYTOKINE, V11, P313, DOI 10.1006/cyto.1998.0438; Fickenscher H, 2002, METHOD MICROBIOL, V32, P657; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Goris A, 2002, GENES IMMUN, V3, P470, DOI 10.1038/sj.gene.6363913; Goris A, 2001, GENES IMMUN, V2, P284, DOI 10.1038/sj.gene.6363772; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Knappe A, 1997, J VIROL, V71, P9124, DOI 10.1128/JVI.71.12.9124-9133.1997; Kotenko SV, 2002, CYTOKINE GROWTH F R, V13, P223, DOI 10.1016/S1359-6101(02)00012-6; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; Liao YC, 2002, J IMMUNOL, V169, P4288, DOI 10.4049/jimmunol.169.8.4288; LIU Y, 1994, J IMMUNOL, V152, P1821; Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Salek-Ardakani S, 2000, BLOOD, V96, P1879, DOI 10.1182/blood.V96.5.1879.h8001879_1879_1888; Sheikh F, 2004, J IMMUNOL, V172, P2006, DOI 10.4049/jimmunol.172.4.2006; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	45	110	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33343	33351		10.1074/jbc.M405000200	http://dx.doi.org/10.1074/jbc.M405000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178681	hybrid			2022-12-27	WOS:000223039700041
J	Xu, B; Koenig, RJ				Xu, B; Koenig, RJ			An RNA-binding domain in the thyroid hormone receptor enhances transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTORS; RESPONSE ELEMENT; ESCHERICHIA-COLI; GENE-EXPRESSION; MESSENGER-RNA; COACTIVATOR; PROTEINS; PURIFICATION; SEQUENCES; COMPLEX	Thyroid hormone plays important roles in development, differentiation, and metabolic homeostasis by binding to nuclear thyroid hormone receptors, which regulate target gene expression by interacting with DNA response elements and coregulatory proteins. We show that thyroid hormone receptors also are single-stranded RNA binding proteins and that this binding is functionally significant. By using a series of deletion mutants, a novel RNA-binding domain was localized to a 41-amino acid segment of thyroid hormone receptor alpha1 between the second zinc finger and the ligand-binding domain. This RNA-binding domain was necessary and sufficient for thyroid hormone receptor binding to the steroid receptor RNA activator (SRA). Although SRA does not bind directly to steroid receptors, it has been identified as a steroid receptor coactivator, and was thought not to be a coactivator for thyroid hormone receptors. However, transfection studies revealed that SRA enhances thyroid hormone induction of appropriate reporter genes and that the thyroid hormone receptor RNA-binding domain is important for this enhancement. We conclude that thyroid hormone receptors bind RNA through a novel domain and that the interaction of this domain with SRA, and perhaps other RNAs, enhances thyroid hormone receptor function.	Univ Michigan, Med Ctr, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Koenig, RJ (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol Diabet & Metab, 5560 MSRB-2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	rkoenig@umich.edu			NIDDK NIH HHS [DK44155, P60 DK20572] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155, P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; Cusack Stephen, 1999, Current Opinion in Structural Biology, V9, P66; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Glass CK, 2000, GENE DEV, V14, P121; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Olson DP, 1997, J BIOL CHEM, V272, P9907; ONATE SA, 1995, SCIENCE, V270, P1354; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Wu YF, 2001, J BIOL CHEM, V276, P3929, DOI 10.1074/jbc.M006743200; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	31	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33051	33056		10.1074/jbc.M404930200	http://dx.doi.org/10.1074/jbc.M404930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180993	hybrid			2022-12-27	WOS:000223039700005
J	Xu, X; Zhao, JY; Xu, Z; Peng, BZ; Huang, QH; Arnold, E; Ding, JP				Xu, X; Zhao, JY; Xu, Z; Peng, BZ; Huang, QH; Arnold, E; Ding, JP			Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; CRYSTAL-STRUCTURE; CELLULAR DEFENSE; FATTY-ACIDS; PHOSPHORYLATION; ENZYME; DAMAGE; SITE; KINASE/PHOSPHATASE; INACTIVATION	Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, and regulation of the enzymatic activity of IDHs is crucial for their biological functions. Bacterial IDHs are reversibly regulated by phosphorylation of a strictly conserved serine residue at the active site. Eukaryotic NADP-dependent IDHs (NADP-IDHs) have been shown to have diverse important biological functions; however, their regulatory mechanism remains unclear. Structural studies of human cytosolic NADP-IDH (HcIDH) in complex with NADP and in complex with NADP, isocitrate, and Ca2+ reveal three biologically relevant conformational states of the enzyme that differ substantially in the structure of the active site and in the overall structure. A structural segment at the active site that forms a conserved alpha-helix in all known NADP-IDH structures assumes a loop conformation in the open, inactive form of HcIDH; a partially unraveled alpha-helix in the semi-open, intermediate form; and an alpha-helix in the closed, active form. The side chain of Asp(279) of this segment occupies the isocitrate-binding site and forms hydrogen bonds with Ser(94) ( the equivalent of the phosphorylation site in bacterial IDHs) in the inactive form and chelates the metal ion in the active form. The structural data led us to propose a novel self-regulatory mechanism for HcIDH that mimics the phosphorylation mechanism used by the bacterial homologs, consistent with biochemical and biological data. This mechanism might be applicable to other eukaryotic NADP-IDHs. The results also provide insights into the recognition and specificity of substrate and cofactor by eukaryotic NADP-IDHs.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Prote, Shanghai 200031, Peoples R China; Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Gen, Shanghai 200025, Peoples R China; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Ding, JP (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Prote, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jpding@sibs.ac.cn	Xu, Xiang/G-5528-2012	ding, jian ping/0000-0001-7029-7346	NIAID NIH HHS [AI27690] Funding Source: Medline; NIGMS NIH HHS [GM 66671] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027690, R37AI027690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM066671] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benderdour M, 2003, J BIOL CHEM, V278, P45154, DOI 10.1074/jbc.M306285200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; FARRELL HM, 1990, J BIOL CHEM, V265, P17637; FinerMoore J, 1997, BIOCHEMISTRY-US, V36, P13890, DOI 10.1021/bi9711691; Geisbrecht BV, 1999, J BIOL CHEM, V274, P30527, DOI 10.1074/jbc.274.43.30527; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Huang YC, 2002, BIOCHEMISTRY-US, V41, P5637, DOI 10.1021/bi0200716; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JENNINGS GT, 1994, J BIOL CHEM, V269, P23128; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim SY, 2003, FREE RADICAL RES, V37, P309, DOI 10.1080/1071576021000050429; LAPORTE DC, 1993, J CELL BIOCHEM, V51, P14, DOI 10.1002/jcb.240510104; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Minard KI, 1999, J BIOL CHEM, V274, P3402, DOI 10.1074/jbc.274.6.3402; Nekrutenko A, 1998, MOL BIOL EVOL, V15, P1674, DOI 10.1093/oxfordjournals.molbev.a025894; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; SEERY VL, 1990, J BIOL CHEM, V265, P17644; Singh SK, 2002, J BIOL CHEM, V277, P7567, DOI 10.1074/jbc.M107908200; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; SMYTH GE, 1991, J BIOL CHEM, V266, P14918; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; Yang ES, 2002, FREE RADICAL BIO MED, V33, P927, DOI 10.1016/S0891-5849(02)00981-4; Yoshihara T, 2001, J HISTOCHEM CYTOCHEM, V49, P1123, DOI 10.1177/002215540104900906	35	281	300	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33946	33957		10.1074/jbc.M404298200	http://dx.doi.org/10.1074/jbc.M404298200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173171	hybrid			2022-12-27	WOS:000223039700105
J	Anindya, R; Savithri, HS				Anindya, R; Savithri, HS			Potyviral NIa proteinase, a proteinase with novel deoxyribonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO ETCH POTYVIRUS; TURNIP MOSAIC POTYVIRUS; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; CATALYTIC-ACTIVITY; STRUCTURAL BASIS; RNASE ACTIVITY; CLEAVAGE SITE; PROTEASE	The NIa proteinase from pepper vein banding virus (PVBV) is a sequence-specific proteinase required for processing of viral polyprotein in the cytoplasm. It accumulates in the nucleus of the infected plant cell and forms inclusion bodies. The function of this protein in the nucleus is not clear. The purified recombinant NIa proteinase was active, and the mutation of the catalytic residues His-46, Asp-81, and Cys-151 resulted in complete loss of activity. Most interesting, the PVBV NIa proteinase exhibited previously unidentified activity, namely nonspecific double-stranded DNA degradation. This DNase activity of the NIa proteinase showed an absolute requirement for Mg2+. Site-specific mutational analysis showed that of the three catalytic residues, Asp-81 was the crucial residue for DNase activity. Mutation of His-46 and Cys-151 had no effect on the DNase activity, whereas mutant D81N was partially active, and D81G was completely inactive. Based on kinetic analysis and molecular modeling, a metal ion-dependent catalysis similar to that observed in other nonspecific DNases is proposed. Similar results were obtained with glutathione S-transferase-fused PVBV NIa proteinase and tobacco etch virus NIa proteinase, confirming that the DNase function is an intrinsic property of potyviral NIa proteinase. The NIa protein present in the infected plant nuclear extract also showed the proteinase and the DNase activities, suggesting that the PVBV NIa protein that accumulates in the nucleus late in the infection cycle might serve to degrade the host DNA. Thus the dual function of the NIa proteinase could play an important role in the life cycle of the virus.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Savithri, HS (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	bchss@biochem.iisc.ernet.in	Anindya, Roy/ABD-1326-2020; Anindya, Roy/F-8241-2012	Anindya, Roy/0000-0001-8561-907X; Anindya, Roy/0000-0001-8561-907X				Anindya R, 2004, ARCH VIROL, V149, P625, DOI 10.1007/s00705-003-0236-0; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CARRINGTON JC, 1989, EMBO J, V8, P365, DOI 10.1002/j.1460-2075.1989.tb03386.x; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CARRINGTON JC, 1993, J VIROL, V67, P6995, DOI 10.1128/JVI.67.12.6995-7000.1993; CHEAH KSE, 1977, BIOCHEM J, V163, P141, DOI 10.1042/bj1630141; Daros JA, 1997, VIROLOGY, V237, P327, DOI 10.1006/viro.1997.8802; DOUGHERTY WG, 1988, EMBO J, V7, P1281, DOI 10.1002/j.1460-2075.1988.tb02942.x; GARCIA JA, 1990, J GEN VIROL, V71, P2773, DOI 10.1099/0022-1317-71-12-2773; Gautier-Bert K, 2003, MOL BIOL REP, V30, P1, DOI 10.1023/A:1022261925117; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; Hajimorad MR, 1996, VIROLOGY, V224, P368, DOI 10.1006/viro.1996.0544; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hull R., 2002, MATTHEWS PLANT VIROL; Jarrousse AS, 1999, J BIOL CHEM, V274, P5925, DOI 10.1074/jbc.274.9.5925; Joseph J, 1999, ARCH VIROL, V144, P1679, DOI 10.1007/s007050050696; Joseph J, 2000, ARCH VIROL, V145, P2493, DOI 10.1007/s007050070004; Kim DH, 1996, VIROLOGY, V221, P245, DOI 10.1006/viro.1996.0372; Kim DH, 1996, VIROLOGY, V226, P183, DOI 10.1006/viro.1996.0645; KNUHTSEN H, 1974, VIROLOGY, V61, P200, DOI 10.1016/0042-6822(74)90254-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CL, 2003, EMBO J, V22, P4014, DOI 10.1093/emboj/cdg377; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; Patel D, 2001, BIOTECHNIQUES, V31, P1194, DOI 10.2144/01315dd04; Petit F, 1997, MOL BIOL REP, V24, P113, DOI 10.1023/A:1006886911852; Phan J, 2002, J BIOL CHEM, V277, P50564, DOI 10.1074/jbc.M207224200; POUCH MN, 1995, J BIOL CHEM, V270, P22023, DOI 10.1074/jbc.270.37.22023; Rashid N, 1997, NUCLEIC ACIDS RES, V25, P719, DOI 10.1093/nar/25.4.719; RIECHMANN JL, 1992, J GEN VIROL, V73, P1, DOI 10.1099/0022-1317-73-1-1; Schaad MC, 1996, J VIROL, V70, P7039, DOI 10.1128/JVI.70.10.7039-7048.1996; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6	37	29	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32159	32169		10.1074/jbc.M404135200	http://dx.doi.org/10.1074/jbc.M404135200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15163663	Green Accepted, hybrid			2022-12-27	WOS:000222849700022
J	Eissing, T; Conzelmann, H; Gilles, ED; Allgower, F; Bullinger, E; Scheurich, P				Eissing, T; Conzelmann, H; Gilles, ED; Allgower, F; Bullinger, E; Scheurich, P			Bistability analyses of a caspase activation model for receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; CYTOCHROME-C; CATALYTIC-PROPERTIES; SIGNALING PATHWAYS; POSITIVE-FEEDBACK; IAP PROTEINS; CELL-DEATH; INHIBITOR; COMPLEX; MITOCHONDRIA	Apoptosis is an important physiological process crucially involved in development and homeostasis of multicellular organisms. Although the major signaling pathways have been unraveled, a detailed mechanistic understanding of the complex underlying network remains elusive. We have translated here the current knowledge of the molecular mechanisms of the death-receptor-activated caspase cascade into a mathematical model. A reduction down to the apoptotic core machinery enables the application of analytical mathematical methods to evaluate the system behavior within a wide range of parameters. Using parameter values from the literature, the model reveals an unstable status of survival indicating the need for further control. Based on recent publications we tested one additional regulatory mechanism at the level of initiator caspase activation and demonstrated that the resulting system displays desired characteristics such as bistability. In addition, the results from our model studies allowed us to reconcile the fast kinetics of caspase 3 activation observed at the single cell level with the much slower kinetics found at the level of a cell population.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Stuttgart, Inst Syst Theory Engn, D-70550 Stuttgart, Germany; Univ Stuttgart, Inst Syst Dynam & Control, D-70550 Stuttgart, Germany; Max Planck Inst Dynam Complex Tech Syst, D-39106 Magdeburg, Germany	University of Stuttgart; University of Stuttgart; University of Stuttgart; Max Planck Society	Scheurich, P (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Peter.Scheurich@izi.uni-stuttgart.de	Allgöwer, Frank/F-3909-2011; Bullinger, Eric/B-6772-2008	Allgöwer, Frank/0000-0002-3702-3658; Bullinger, Eric/0000-0002-8889-8286; Eissing, Thomas/0000-0003-4378-3423				Angeli D, 2004, P NATL ACAD SCI USA, V101, P1822, DOI 10.1073/pnas.0308265100; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Ditzel M, 2002, TRENDS CELL BIOL, V12, P449, DOI 10.1016/S0962-8924(02)02366-8; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Ferrell JE, 2001, CHAOS, V11, P227, DOI 10.1063/1.1349894; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P768, DOI 10.1038/77589; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254; Krippner-Heidenreich A, 2002, J BIOL CHEM, V277, P44155, DOI 10.1074/jbc.M207399200; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Luo KQ, 2003, BIOCHEM BIOPH RES CO, V304, P217, DOI 10.1016/S0006-291X(03)00559-X; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Newton K, 2003, GENE DEV, V17, P819, DOI 10.1101/gad.1077403; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tyas L, 2000, EMBO REP, V1, P266, DOI 10.1093/embo-reports/kvd050; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; [No title captured]	46	225	228	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36892	36897		10.1074/jbc.M404893200	http://dx.doi.org/10.1074/jbc.M404893200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208304	Green Published, hybrid			2022-12-27	WOS:000223453600091
J	Horn, NA; Hurst, GB; Mayasundari, A; Whittemore, NA; Serpersu, EH; Peterson, CB				Horn, NA; Hurst, GB; Mayasundari, A; Whittemore, NA; Serpersu, EH; Peterson, CB			Assignment of the four disulfides in the N-terminal somatomedin B domain of native vitronectin isolated from human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; CYSTINE-KNOT; CELL-ADHESION; ALPHA-SUBUNIT; PROTEINS; BINDING; PAI-1; RESOLUTION; BRIDGES; BONDS	The primary sequence of the N-terminal somatomedin B (SMB) domain of native vitronectin contains 44 amino acids, including a framework of four disulfide bonds formed by 8 closely spaced cysteines in sequence patterns similar to those found in the cystine knot family of proteins. The SMB domain of vitronectin was isolated by digesting the protein with endoproteinase Glu-C and purifying the N-terminal 1-55 peptide by reverse-phase high performance liquid chromatography. Through a combination of techniques, including stepwise reduction and alkylation at acidic pH, peptide mapping with matrix-assisted laser desorption ionization mass spectrometry and NMR, the disulfide bonds contained in the SMB domain have been determined to be Cys(5):Cys(9), Cys(19):Cys(31), Cys(21):Cys(32), and Cys(25):Cys(39). This pattern of disulfides differs from two other connectivities that have been reported previously for recombinant forms of the SMB domain expressed in Escherichia coli. This arrangement of disulfide bonds in the SMB domain from native vitronectin forms a rigid core around the Cys(19):Cys(31) and Cys(21):Cys(32) disulfides. A small positively charged loop is created at the N terminus by the Cys(5):Cys(9) cystine. The most prominent feature of this disulfide-bonding pattern is a loop between Cys(25) and Cys(39) similar to cystine-stabilized alpha-helical structures commonly observed in cystine knots. This alpha-helix has been confirmed in the solution structure determined for this domain using NMR (Mayasundari, A., Whittemore, N. A., Serpersu, E. H., and Peterson, C. B. (2004) J. Biol. Chem. 279, 29359-29366). It confers function on the SMB domain, comprising the site for binding to plasminogen activator inhibitor type-1 and the urokinase receptor.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Excellence Struct Biol, Knoxville, TN 37996 USA; Oak Ridge Natl Lab, Div Chem Sci, Oak Ridge, TN 37831 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.	cynthia_peterson@utk.edu		Serpersu, Engin H./0000-0003-1420-455X; Hurst, Gregory/0000-0002-7650-8009	NHLBI NIH HHS [HL50676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Calabro V, 1997, J PEPT RES, V50, P39; Cemazar M, 2004, J BIOL CHEM, V279, P16697, DOI 10.1074/jbc.M312328200; Cemazar M, 2003, P NATL ACAD SCI USA, V100, P5754, DOI 10.1073/pnas.2225470100; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; Daly NL, 2003, J BIOL CHEM, V278, P6314, DOI 10.1074/jbc.M210492200; Darling RJ, 2000, J BIOL CHEM, V275, P15413, DOI 10.1074/jbc.275.20.15413; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Escoubas P, 2004, TOXICON, V43, P555, DOI 10.1016/j.toxicon.2004.02.007; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; Hiro'oka T, 2000, ENDOCRINOLOGY, V141, P4751, DOI 10.1210/en.141.12.4751; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kamikubo Y, 2004, BIOCHEMISTRY-US, V43, P6519, DOI 10.1021/bi049647c; Kamikubo Y, 2002, J BIOL CHEM, V277, P27109, DOI 10.1074/jbc.M200354200; KARL R, 1999, ANAL CHEM, V71, P2871; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Mayasundari A, 2004, J BIOL CHEM, V279, P29359, DOI 10.1074/jbc.M401279200; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; Mousa Shaker A, 2002, Curr Opin Investig Drugs, V3, P1191; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; Schroeck F, 2002, BIOL CHEM, V383, P1143, DOI 10.1515/BC.2002.125; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; Taylor WR, 2003, COMPUT BIOL CHEM, V27, P11, DOI 10.1016/S1476-9271(02)00099-3; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Wechsler-Reya RJ, 2001, TRENDS NEUROSCI, V24, P680, DOI 10.1016/S0166-2236(00)02058-0; Wilken JA, 2004, BIOCHEMISTRY-US, V43, P5109, DOI 10.1021/bi049856x; Wu Jiang, 2002, Methods Mol Biol, V194, P1; Xu D, 2001, PROTEINS, V44, P312, DOI 10.1002/prot.1096; Yen TY, 2002, J MASS SPECTROM, V37, P15, DOI 10.1002/jms.241; Young Y, 1999, J PEPT RES, V54, P514, DOI 10.1034/j.1399-3011.1999.00126.x; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943; Zhu Q, 2002, BIOCHEMISTRY-US, V41, P11488, DOI 10.1021/bi026136m; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333	59	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35867	35878		10.1074/jbc.M405716200	http://dx.doi.org/10.1074/jbc.M405716200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15173163	hybrid, Green Published			2022-12-27	WOS:000223303400088
J	Otto, VI; Schurpf, T; Folkers, G; Cummings, RD				Otto, VI; Schurpf, T; Folkers, G; Cummings, RD			Sialylated complex-type N-glycans enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; GOLGI VESICLE MEMBRANES; LINKED OLIGOSACCHARIDES; CEREBROSPINAL-FLUID; GLYCOSYLATION SITES; CIRCULATING ICAM-1; ENDOTHELIAL-CELLS; MUTANT DEFICIENT; INTERFERON-GAMMA	Intercellular adhesion molecule-1 (ICAM-1) occurs as both a membrane and a soluble, secreted glycoprotein (sICAM-1). ICAM-1 on endothelial cells mediates leukocyte adhesion by binding to leukocyte function associated antigen-1 (LFA-1) and macrophage antigen-1 (Mac-1). Recombinant mouse sICAM-1 induces the production of macrophage inflammatory protein-2 (MIP-2) in mouse astrocytes by a novel LFA-1- and Mac-1-independent mechanism. Here we showed that N-glycan structures of sICAM-1 influence its ability to induce MIP-2 production. sICAM-1 expressed in Chinese hamster ovary (CHO) cells was a more potent inducer of MIP-2 production than sICAM-1 expressed in HEK 293 cells, suggesting that post-translational modification of sICAM-1 could influence its signaling activity. To explore the roles of glycosylation in sICAM-1 activity, we expressed sICAM-1 in mutant CHO cell lines differing in glycosylation, including Lec2, Lec8, and Lec1 as well as in CHO cells cultured in the presence of the alpha-mannosidase-I inhibitor kifunensine. Signaling activity of sICAM-1 lacking sialic acid was reduced 3-fold compared with sICAM-1 from CHO cells. The activity of sICAM-1 lacking both sialic acid and galactose was reduced 12-fold, whereas the activity of sICAM-1 carrying only high mannose-type N-glycans was reduced 12-26-fold. sICAM-1 glycoforms carrying truncated glycans retained full ability to bind to LFA-1 on leukocytes. Thus, sialylated and galactosylated complex-type N-glycans strongly enhanced the ability of sICAM-1 to induce MIP-2 production in astrocytes but did not alter its binding to LFA-1 on leukocytes. Glycosylation could therefore serve as a means to regulate specifically the signaling function of sICAM-1 in vivo.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8057 Zurich, Switzerland	University of Oklahoma System; University of Oklahoma Health Sciences Center; Swiss Federal Institutes of Technology Domain; ETH Zurich	Otto, VI (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.	vivianne.otto@pharma.ethz.ch	Schürpf, Thomas/E-7380-2012	Otto, Vivianne/0000-0002-1157-0186; Folkers, Gerd/0000-0002-3620-705X; Schurpf, Thomas/0000-0003-3023-1136	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI48075] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLANTYNE CM, 1989, NUCLEIC ACIDS RES, V17, P5853, DOI 10.1093/nar/17.14.5853; BALLANTYNE CM, 1992, GENOMICS, V14, P1076, DOI 10.1016/S0888-7543(05)80132-6; Bloom JW, 1996, BIOCHEMISTRY-US, V35, P1856, DOI 10.1021/bi952354m; Bragonzi A, 2000, BBA-GEN SUBJECTS, V1474, P273, DOI 10.1016/S0304-4165(00)00023-4; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Fisher KL, 1997, MOL BIOL CELL, V8, P501, DOI 10.1091/mbc.8.3.501; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; GREEN ED, 1988, J BIOL CHEM, V263, P18253; Greenwood J, 2002, VASC PHARMACOL, V38, P315, DOI 10.1016/S1537-1891(02)00199-4; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kusterer K, 1998, AM J PHYSIOL-GASTR L, V275, pG377, DOI 10.1152/ajpgi.1998.275.2.G377; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARTIN S, 1993, ANTIMICROB AGENTS CH, V37, P1278, DOI 10.1128/AAC.37.6.1278; Massa PT, 1996, J NEUROCHEM, V67, P1831; MCCABE SM, 1993, CELL IMMUNOL, V150, P364, DOI 10.1006/cimm.1993.1204; MCEVER RP, 1997, J CLIN INVEST, V100, P97; MEYER DM, 1995, J IMMUNOL, V155, P3578; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; NEMANSKY M, 1995, EUR J BIOCHEM, V227, P880, DOI 10.1111/j.1432-1033.1995.tb20214.x; Nyame AK, 2002, J PARASITOL, V88, P890, DOI 10.1645/0022-3395(2002)088[0890:DEOLFL]2.0.CO;2; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Otto VI, 2002, J NEUROCHEM, V80, P824, DOI 10.1046/j.0022-3042.2001.00748.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; PLOEGH HL, 2002, CURRENT PROTOCOLS PR; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; ROHRER JS, 1993, ANAL BIOCHEM, V212, P7, DOI 10.1006/abio.1993.1283; Rossi P, 2002, BIOCHEM CELL BIOL, V80, P41, DOI 10.1139/o01-209; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shrikant P, 1996, J IMMUNOL, V157, P1819; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; STANLEY P, 1985, MOL CELL BIOL, V5, P1204, DOI 10.1128/MCB.5.6.1204; Stanley P, 2000, BIOCHEM J, V351, P79, DOI 10.1042/0264-6021:3510079; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; WINZLER R J, 1955, Methods Biochem Anal, V2, P279, DOI 10.1002/9780470110188.ch10	59	33	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35201	35209		10.1074/jbc.M404947200	http://dx.doi.org/10.1074/jbc.M404947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201278	hybrid			2022-12-27	WOS:000223303400010
J	Sharma, C; Pradeep, A; Wong, L; Rana, A; Rana, B				Sharma, C; Pradeep, A; Wong, L; Rana, A; Rana, B			Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; GASTRIC-CANCER CELLS; PPAR-GAMMA; GENE-EXPRESSION; COLORECTAL-CANCER; NUCLEAR RECEPTORS; ADIPOCYTE DIFFERENTIATION; HEPATOCELLULAR CARCINOMAS; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTORS	The transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) belongs to the family of nuclear hormone receptors and consists of two isotypes, PPARgamma1 and PPARgamma2. Our earlier studies have shown that troglitazone (TZD)-mediated activation of PPARgamma2 in hepatocytes inhibits growth and attenuates cyclin D1 transcription via modulating CREB levels. Because this process of growth inhibition was also associated with an inhibition of beta-catenin expression at a post-translational level, our aim was to elucidate the mechanism involved. beta-Catenin is a multifunctional protein, which can regulate cell-cell adhesion by interacting with E-cadherin and other cellular processes via regulating target gene transcription in association with TCF/LEF transcription factors. Two adenomatous polyposis coli (APC)-dependent proteasomal degradation pathways, one involving glycogen synthase kinase 3beta (GSK3beta) and the other involving p53-Siah-1, degrade excess beta-catenin in normal cells. Our immunofluorescence and Western blot studies indicated a TZD-dependent decrease in cytoplasmic and membrane-bound beta-catenin, indicating no increase in its membrane translocation. This was associated with a reduction in E-cadherin expression. PPARgamma2 activation inhibited GSK3beta kinase activity, and pharmacological inhibition of GSK3beta activity was unable to restore beta-catenin expression following PPARgamma2 activation. Additionally, this beta-catenin degradation pathway was operative in cells, with inactivating mutations of both APC and p53. Inhibition of the proteasomal pathway inhibited PPARgamma2-mediated degradation of beta-catenin, and incubation with TZD increased ubiquitination of beta-catenin. We conclude that PPARgamma2-mediated suppression of beta-catenin levels involves a novel APC/GSK3beta/p53-independent ubiquitination-mediated proteasomal degradation pathway.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Cardiovasc Res Inst, Temple, TX 76504 USA; Scott & White Mem Hosp & Clin, Div Hematol Oncol, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center	Rana, B (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Cardiovasc Res Inst, 1901 S 1st St,Bldg 205, Temple, TX 76504 USA.	brana@medicine.tamu.edu	Rana, Ajay/ABE-3739-2020	Rana, Ajay/0000-0003-0951-2566	NIGMS NIH HHS [R01GM055835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABARZUA P, 1995, CANCER RES, V55, P3490; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Edvardsson U, 1999, J LIPID RES, V40, P1177; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Harada N, 2002, CANCER RES, V62, P1971; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitamura S, 1999, BIOCHEM BIOPH RES CO, V265, P453, DOI 10.1006/bbrc.1999.1715; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Miyoshi Y, 1998, CANCER RES, V58, P2524; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Ohta T, 2002, INT J ONCOL, V21, P37; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Qin CH, 2003, CANCER RES, V63, P958; Rahimian R, 2001, MOL CELL BIOCHEM, V224, P29, DOI 10.1023/A:1011927113563; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rumi MAK, 2001, BRIT J CANCER, V84, P1640, DOI 10.1054/bjoc.2001.1821; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Schoonjans K, 1996, J LIPID RES, V37, P907; Shah S, 2003, J BIOL CHEM, V278, P48137, DOI 10.1074/jbc.M307154200; Sharma C, 2004, J BIOL CHEM, V279, P16927, DOI 10.1074/jbc.M309045200; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	73	117	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35583	35594		10.1074/jbc.M403143200	http://dx.doi.org/10.1074/jbc.M403143200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190077	hybrid			2022-12-27	WOS:000223303400054
J	Mate, MJ; Kleanthous, C				Mate, MJ; Kleanthous, C			Structure-based analysis of the metal-dependent mechanism of H-N-H endonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW CONFORMATIONAL DYNAMICS; DNA-BINDING; TRANSITION-METALS; CRYSTAL-STRUCTURE; DUAL RECOGNITION; NUCLEASE DOMAIN; COLICIN E9; HNH MOTIF; COMPLEX; IMMUNITY	Controversy surrounds the metal-dependent mechanism of H-N-H endonucleases, enzymes involved in a variety of biological functions, including intron homing and DNA repair. To address this issue we determined the crystal structures for complexes of the H-N-H motif containing bacterial toxin colicin E9 with Zn2+, Zn2+ . DNA, and Mg2+ . DNA. The structures show that the rigid V-shaped architecture of the active site does not undergo any major conformational changes on binding to the minor groove of DNA and that the same interactions are made to the nucleic acid regardless of which metal ion is bound to the enzyme. The scissile phosphate contacts the single metal ion of the motif through distortion of the DNA brought about by the insertion of the Arg-96-Glu-100 salt bridge into the minor groove and a network of contacts to the DNA phosphate backbone that straddle the metal site. The Mg2+-bound structure reveals an unusual coordination scheme involving two H-N-H histidine residues, His-102 and His-127. The mechanism of DNA cleavage is likely related to that of other single metal ion-dependent endonucleases, such as I-PpoI and Vvn, although in these enzymes the single alkaline earth metal ion is coordinated by oxygen-bearing amino acids. The structures also provide a rationale as to why H-N-H endonucleases are inactive in the presence of Zn2+ but active with other transition metal ions such as Ni2+. This is because of coordination of the Zn2+ ion through a third histidine, His-131." Active" transition metal ions are those that bind more weakly to the H-N-H motif because of the disengagement of His-131, which we suggest allows a water molecule to complete the catalytic cycle.	Univ York, Dept Biol, Heslington YO10 5Y2, England	University of York - UK	Kleanthous, C (corresponding author), Univ York, Dept Biol, Area 10,POB 373, Heslington YO10 5Y2, England.	ck11@york.ac.uk						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; DeLano WL, 2002, PYMOL USERS MANUAL; Drouin M, 2000, NUCLEIC ACIDS RES, V28, P4566, DOI 10.1093/nar/28.22.4566; Dudev T, 2001, J PHYS CHEM B, V105, P4446, DOI 10.1021/jp004602g; Filippo Joseph San, 2002, Journal of Molecular Biology, V324, P933; Friedhoff P, 1999, NAT STRUCT BIOL, V6, P112; Galburt EA, 1999, NAT STRUCT BIOL, V6, P1096, DOI 10.1038/70027; Galburt EA, 2002, BIOCHEMISTRY-US, V41, P13851, DOI 10.1021/bi020467h; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Hsia KC, 2004, STRUCTURE, V12, P205, DOI 10.1016/j.str.2004.01.004; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; Keeble AH, 2002, BIOCHEMISTRY-US, V41, P10234, DOI 10.1021/bi020174o; Kleanthous C, 1999, NAT STRUCT BIOL, V6, P243, DOI 10.1038/6683; Kleanthous C, 2001, TRENDS BIOCHEM SCI, V26, P624, DOI 10.1016/S0968-0004(01)01941-7; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Ku WY, 2002, NUCLEIC ACIDS RES, V30, P1670, DOI 10.1093/nar/30.7.1670; Kuhlmann UC, 2000, J MOL BIOL, V301, P1163, DOI 10.1006/jmbi.2000.3945; Kuhlmann UC, 1999, FEBS LETT, V463, P1, DOI 10.1016/S0014-5793(99)01499-4; LAVIE A, 1994, BIOCHEMISTRY-US, V33, P5469, DOI 10.1021/bi00184a016; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Li CL, 2003, EMBO J, V22, P4014, DOI 10.1093/emboj/cdg377; Malik HS, 2000, TRENDS BIOCHEM SCI, V25, P414, DOI 10.1016/S0968-0004(00)01623-6; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pommer AJ, 1999, J BIOL CHEM, V274, P27153, DOI 10.1074/jbc.274.38.27153; Pommer AJ, 2001, J MOL BIOL, V314, P735, DOI 10.1006/jmbi.2001.5189; Pommer AJ, 1998, BIOCHEM J, V334, P387, DOI 10.1042/bj3340387; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Scharff EI, 2001, STRUCTURE, V9, P493, DOI 10.1016/S0969-2126(01)00610-4; Sui MJ, 2002, PROTEIN SCI, V11, P2947, DOI 10.1110/ps.0220602; Walker DC, 2002, NUCLEIC ACIDS RES, V30, P3225, DOI 10.1093/nar/gkf420; Whittaker SBM, 1998, J BIOMOL NMR, V12, P145, DOI 10.1023/A:1008272928173; Whittaker SBM, 2000, PROTEIN SCI, V9, P713	38	53	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34763	34769		10.1074/jbc.M403719200	http://dx.doi.org/10.1074/jbc.M403719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190054	hybrid			2022-12-27	WOS:000223134800083
J	Davis, HR; Zhu, LJ; Hoos, LM; Tetzloff, G; Maguire, M; Liu, JJ; Yao, XR; Iyer, SPN; Lam, MH; Lund, EG; Detmers, PA; Graziano, MP; Altmann, SW				Davis, HR; Zhu, LJ; Hoos, LM; Tetzloff, G; Maguire, M; Liu, JJ; Yao, XR; Iyer, SPN; Lam, MH; Lund, EG; Detmers, PA; Graziano, MP; Altmann, SW			Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSORPTION INHIBITOR; DIETARY-CHOLESTEROL; MESSENGER-RNA; EZETIMIBE; IDENTIFICATION; POTENT; ABCG5; EXPRESSION; DISCOVERY; EFFLUX	Niemann-Pick C1 Like 1 (NPC1L1) is a protein localized in jejunal enterocytes that is critical for intestinal cholesterol absorption. The uptake of intestinal phytosterols and cholesterol into absorptive enterocytes in the intestine is not fully defined on a molecular level, and the role of NPC1L1 in maintaining whole body cholesterol homeostasis is not known. NPC1L1 null mice had substantially reduced intestinal uptake of cholesterol and sitosterol, with dramatically reduced plasma phytosterol levels. The NPC1L1 null mice were completely resistant to diet-induced hypercholesterolemia, with plasma lipoprotein and hepatic cholesterol profiles similar to those of wild type mice treated with the cholesterol absorption inhibitor ezetimibe. Cholesterol/cholate feeding resulted in down-regulation of intestinal NPC1L1 mRNA expression in wild type mice. NPC1L1 deficiency resulted in up-regulation of intestinal hydroxymethylglutaryl-CoA synthase mRNA and an increase in intestinal cholesterol synthesis, down-regulation of ABCA1 mRNA, and no change in ABCG5 and ABCG8 mRNA expression. NPC1L1 is required for intestinal uptake of both cholesterol and phytosterols and plays a major role in cholesterol homeostasis. Thus, NPC1L1 may be a useful drug target for the treatment of hypercholesterolemia and sitosterolemia.	Schering Plough Corp, Res Inst, Dept Cardiovasc Metab Dis, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Discovery Technol, Kenilworth, NJ 07033 USA; Merck Res Labs, Dept Cardiovasc Dis, Rahway, NJ 07065 USA; Merck Res Labs, Dept Immunol, Rahway, NJ 07065 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Merck & Company	Davis, HR (corresponding author), Schering Plough Corp, Res Inst, Dept Cardiovasc Metab Dis, K15-2-2600,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	harry.davis@spcorp.com						Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Altmann SW, 2002, BBA-MOL CELL BIOL L, V1580, P77, DOI 10.1016/S1388-1981(01)00190-1; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; BURRIER RE, 1994, BIOCHEM PHARMACOL, V47, P1545, DOI 10.1016/0006-2952(94)90530-4; Davies JP, 2000, GENOMICS, V65, P137, DOI 10.1006/geno.2000.6151; Davis HR, 2001, ARTERIOSCL THROM VAS, V21, P2032, DOI 10.1161/hq1201.100260; Davis HR, 2001, METABOLISM, V50, P1234, DOI 10.1053/meta.2001.26737; Gagne C, 2002, AM J CARDIOL, V90, P1084, DOI 10.1016/S0002-9149(02)02774-1; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Repa JJ, 2002, J LIPID RES, V43, P1864, DOI 10.1194/jlr.M200144-JLR200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rosenblum SB, 1998, J MED CHEM, V41, P973, DOI 10.1021/jm970701f; Salen G, 2004, CIRCULATION, V109, P966, DOI 10.1161/01.CIR.0000116766.31036.03; Sudhop T, 2002, CIRCULATION, V106, P1943, DOI 10.1161/01.CIR.0000034044.95911.DC; van Heek M, 2003, BRIT J PHARMACOL, V138, P1459, DOI 10.1038/sj.bjp.0705187; van Heek M, 2001, EUR J PHARMACOL, V415, P79, DOI 10.1016/S0014-2999(01)00825-1; van Heek M, 2001, BRIT J PHARMACOL, V134, P409, DOI 10.1038/sj.bjp.0704260; VanHeek M, 1997, J PHARMACOL EXP THER, V283, P157; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	22	525	549	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33586	33592		10.1074/jbc.M405817200	http://dx.doi.org/10.1074/jbc.M405817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173162	hybrid			2022-12-27	WOS:000223039700067
J	Vadaie, N; Jarvis, DL				Vadaie, N; Jarvis, DL			Molecular cloning and functional characterization of a lepidopteran insect beta 4-N-acetylgalactosaminyltransferase with broad substrate specificity, a functional role in glycoprotein biosynthesis, and a potential functional role in glycolipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SPODOPTERA-FRUGIPERDA CELLS; ALPHA-MANNOSIDASE-II; N-GLYCOSYLATION PATHWAY; BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; ASPARAGINE-LINKED OLIGOSACCHARIDES; BACULOVIRUS EXPRESSION VECTORS; RECOMBINANT HUMAN PROTEIN; GLCNAC-BETA-R; DROSOPHILA-MELANOGASTER; UDP-GALACTOSE	A degenerate PCR approach was used to isolate a lepidopteran insect cDNA encoding a beta4-galactosyl-transferase family member. The isolation and initial identification of this cDNA was based on bioinformatics, but its identification as a beta4-galactosyltransferase family member was experimentally confirmed. The newly identified beta4-galactosyltransferase family member had unusually broad donor and acceptor substrate specificities in vitro, as transfered galactose, N-acetylglucosamine, and N-acetylgalactosamine to carbohydrate, glycoprotein, and glycolipid acceptors. However, the enzyme preferentially utilized N-acetylgalactosamine as the donor for all three acceptors, and its derived amino acid sequence was closely related to a known N-acetylgalactosaminyltransferase. These data suggested that the newly isolated cDNA encodes a beta4-N-acetylgalactosaminyltransferase that functions in insect cell glycoprotein biosynthesis, glycolipid biosynthesis, or both. The remainder of this study focused on the role of this enzyme in N-glycoprotein biosynthesis. The results showed that the purified enzyme transferred N-acetylgalactosamine, but no detectable galactose or N-acetylglucosamine, to a synthetic N-glycan in vitro. The structure of the reaction product was confirmed by chromatographic, mass spectroscopic, and nuclear magnetic resonance analyses. Co-expression of the new cDNA product in insect cells with an N-glycoprotein reporter showed that it transferred N-acetylgalactosamine, but no detectable galactose or N-acetylglucosamine, to this N-glycoprotein in vivo. Confocal microscopy showed that a GFP-tagged version of the enzyme was localized in the insect cell Golgi apparatus. In summary, this study demonstrated that lepidopteran insect cells encode and express a beta4-N-acetylgalactosaminyltransferase that functions in N-glycoprotein biosynthesis and perhaps in glycolipid biosynthesis, as well. The isolation and characterization of this gene and its product contribute to our basic understanding of insect protein N-glycosylation pathways and to the growing body of evidence that insects can produce glycoproteins with complex N-glycans.	Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA	University of Wyoming	Jarvis, DL (corresponding author), Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA.	DLJarvis@uwyo.edu		Jarvis, Donald/0000-0002-8104-7155	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049734] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015640, P20 RR016474, P20 RR015553] Funding Source: Medline; NIGMS NIH HHS [R01 GM049734, GM49734] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Aumiller JJ, 2003, GLYCOBIOLOGY, V13, P497, DOI 10.1093/glycob/cwg051; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAKKER H, 1994, J BIOL CHEM, V269, P30326; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Breton C, 1998, J BIOCHEM, V123, P1000; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cummings RD, 1999, BBA-MOL BASIS DIS, V1455, P363, DOI 10.1016/S0925-4439(99)00063-0; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P9811, DOI 10.1021/bi00105a001; Donaldson M, 1999, BIOTECHNOL PROGR, V15, P168, DOI 10.1021/bp9900211; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; FOSTER JM, 1995, GENE, V154, P183, DOI 10.1016/0378-1119(94)00867-R; Francis BR, 2002, GLYCOBIOLOGY, V12, P369, DOI 10.1093/glycob/12.6.369; GORISCH H, 1988, ANAL BIOCHEM, V173, P393, DOI 10.1016/0003-2697(88)90205-9; Gotoh M, 2004, FEBS LETT, V562, P134, DOI 10.1016/S0014-5793(04)00219-4; Griffitts JS, 2001, SCIENCE, V293, P860, DOI 10.1126/science.1062441; Griffitts JS, 2003, J BIOL CHEM, V278, P45594, DOI 10.1074/jbc.M308142200; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; Hollister J, 2003, GLYCOBIOLOGY, V13, P487, DOI 10.1093/glycob/cwg053; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; Hollister JR, 1998, GLYCOBIOLOGY, V8, P473, DOI 10.1093/glycob/8.5.473; Hollister JR, 2001, GLYCOBIOLOGY, V11, P1; Hsu TA, 1997, J BIOL CHEM, V272, P9062; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JARVIS DL, 1990, BIO-TECHNOL, V8, P950, DOI 10.1038/nbt1090-950; Jarvis DL, 1996, PROTEIN EXPRES PURIF, V8, P191, DOI 10.1006/prep.1996.0092; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; Jarvis DL, 1998, CURR OPIN BIOTECH, V9, P528, DOI 10.1016/S0958-1669(98)80041-4; Jarvis DL, 1996, NAT BIOTECHNOL, V14, P1288, DOI 10.1038/nbt1096-1288; JARVIS DL, 1987, J VIROL, V61, P3950, DOI 10.1128/JVI.61.12.3950-3959.1987; Jarvis DL, 2003, VIROLOGY, V310, P1, DOI 10.1016/S0042-6822(03)00120-X; Jarvis DL, 1997, GLYCOBIOLOGY, V7, P113, DOI 10.1093/glycob/7.1.113; JARVIS DL, 1997, BACULOVIRUSES, P389; Joosten CE, 2003, BIOTECHNOL PROGR, V19, P193, DOI 10.1021/bp025695h; Joshi L, 2001, BIOTECHNOL PROGR, V17, P822, DOI 10.1021/bp010071h; Joshi L, 2000, BIOTECHNOL PROGR, V16, P650, DOI 10.1021/bp000057p; Kawar Z, 2001, J BIOL CHEM, V276, P16335, DOI 10.1074/jbc.M100119200; Kawar Z, 2000, GLYCOBIOLOGY, V10, P347, DOI 10.1093/glycob/10.4.347; Kawar Z, 1997, GLYCOBIOLOGY, V7, P433, DOI 10.1093/glycob/7.3.433; Kawar Z, 2001, INSECT BIOCHEM MOLEC, V31, P289, DOI 10.1016/S0965-1748(00)00121-1; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; KERSCHER S, 1995, DEV BIOL, V168, P613, DOI 10.1006/dbio.1995.1106; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; MARZ L, 1995, GLYCOPROTEINS A, V29, P543; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MURHAMMER DW, 1988, BIO-TECHNOL, V6, P1411, DOI 10.1038/nbt1288-1411; Nakamura Y, 2002, J BIOL CHEM, V277, P46280, DOI 10.1074/jbc.M203873200; Nobiron I, 2003, J GEN VIROL, V84, P3029, DOI 10.1099/vir.0.19270-0; Ogonah OW, 1996, BIO-TECHNOL, V14, P197, DOI 10.1038/nbt0296-197; Ohtsuka I, 2002, CARBOHYD RES, V337, P2037, DOI 10.1016/S0008-6215(02)00295-1; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Palomares LA, 2003, BIOTECHNOL PROGR, V19, P185, DOI 10.1021/bp025598o; Park YI, 1999, GLYCOCONJUGATE J, V16, P629, DOI 10.1023/A:1007029017400; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Rabouille C, 1999, J CELL SCI, V112, P3319; REN J, 1997, BIOCHEM J, V15, P951; REN JX, 1995, BIOCHEMISTRY-US, V34, P2489, DOI 10.1021/bi00008a012; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROUX KH, 1994, BIOTECHNIQUES, V16, P812; Rudd PM, 2000, BIOCHEMISTRY-US, V39, P1596, DOI 10.1021/bi9918285; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Sato T, 2003, J BIOL CHEM, V278, P47534, DOI 10.1074/jbc.M308857200; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SMITH PL, 1993, J BIOL CHEM, V268, P795; STAUDACHER E, 1992, EUR J BIOCHEM, V207, P987, DOI 10.1111/j.1432-1033.1992.tb17134.x; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Takemae H, 2003, J BIOL CHEM, V278, P15571, DOI 10.1074/jbc.M301123200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomiya N, 2003, ACCOUNTS CHEM RES, V36, P613, DOI 10.1021/ar020202v; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vadaie N, 2002, GLYCOBIOLOGY, V12, P589, DOI 10.1093/glycob/cwf074; van den Elsen JMH, 2001, EMBO J, V20, P3008, DOI 10.1093/emboj/20.12.3008; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; VanDie I, 1997, GLYCOBIOLOGY, V7, pR5; vanDie I, 1996, GLYCOBIOLOGY, V6, P157, DOI 10.1093/glycob/6.2.157; VANHALBEEK H, 1994, METHOD ENZYMOL, V230, P132; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; VELARDO MA, 1993, J BIOL CHEM, V268, P17902; Wagner R, 1996, J VIROL, V70, P4103, DOI 10.1128/JVI.70.6.4103-4109.1996; Watanabe S, 2002, J BIOL CHEM, V277, P5090, DOI 10.1074/jbc.M110548200; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; Wilson IBH, 2002, CURR OPIN STRUC BIOL, V12, P569, DOI 10.1016/S0959-440X(02)00367-6; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597	106	39	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33501	33518		10.1074/jbc.M404925200	http://dx.doi.org/10.1074/jbc.M404925200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173167	Green Accepted, hybrid			2022-12-27	WOS:000223039700059
J	Midwinter, RG; Peskin, AV; Vissers, MCM; Winterbourn, CC				Midwinter, RG; Peskin, AV; Vissers, MCM; Winterbourn, CC			Extracellular oxidation by taurine chloramine activates ERK via the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; HYDROGEN PEROXIDE-CHLORIDE; HYPOCHLOROUS ACID; ENDOTHELIAL-CELLS; NITRIC-OXIDE; KINASE-ACTIVITY; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; INFLAMMATORY MEDIATORS; SIGNAL-TRANSDUCTION	Taurine is present in high concentrations in neutrophils, and when the cells are stimulated taurine can react with hypochlorous acid (HOCl) to form taurine-chloramine (Tau-Cl). This compound retains oxidant activity and can affect the neutrophil itself or surrounding tissue cells. We have investigated the effects of Tau-Cl on MAPK signaling in human umbilical vein endothelial cells ( HUVEC). Tau-Cl caused no loss in intracellular glutathione or inactivation of the thiol-sensitive enzyme glyceral-dehyde-3-phosphate dehydrogenase, indicating that it had not entered the cells. However, stimulation of HUVEC with Tau-Cl (20-100 muM) induced the rapid activation of ERK within 10 min. This activation was abolished by inhibition of MEK by U0126, indicating that it was not because of direct oxidation of ERK. No activation of p38 was detected. These results suggest that Tau-Cl reacts with a cell membrane target that results in intracellular ERK activation. Tau-Cl over the same concentration range and time scale stimulated epidermal growth factor (EGF) receptor tyrosine phosphorylation in A431 cells and HUVEC. The EGF receptor inhibitor PD158780 significantly attenuated Tau-Cl-induced phosphorylation of both the EGF receptor and ERK. This implicates the EGF receptor in the upstream activation of ERK. The Src tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolol[3,4-d]pyrimidine had no effect on Tau-Cl-induced EGF receptor or ERK activation. We propose that Tau-Cl acts on an oxidant-sensitive target on the cell surface, this being either the EGF receptor itself or another target that can interact with the EGF receptor, with consequential activation of ERK.	Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, Christchurch 8001, New Zealand	University of Otago	Midwinter, RG (corresponding author), Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, POB 4345, Christchurch 8001, New Zealand.	robyn.midwinter@chmeds.ac.nz	Peskin, alexander/R-6457-2019; Vissers, Margreet C M/T-4159-2017	peskin, alexander/0000-0001-9890-6043				Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barua M, 2001, J IMMUNOL, V167, P2275, DOI 10.4049/jimmunol.167.4.2275; Beutler E., 1984, RED CELL METABOLISM, P51; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Chorazy M, 2002, AMINO ACIDS, V23, P407, DOI 10.1007/s00726-002-0204-0; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; Englert RP, 2002, J BIOL CHEM, V277, P20518, DOI 10.1074/jbc.M200212200; FUKUDA K, 1982, CLIN CHEM, V28, P1758; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; GRISHAM MB, 1984, J BIOL CHEM, V259, P6676; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jope RS, 2000, ARCH BIOCHEM BIOPHYS, V376, P365, DOI 10.1006/abbi.2000.1728; Kanayama A, 2002, J BIOL CHEM, V277, P24049, DOI 10.1074/jbc.M110832200; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Liu Y, 2003, ADV EXP MED BIOL, V526, P365; Marcinkiewicz J, 2003, IMMUNOL LETT, V89, P187, DOI 10.1016/S0165-2478(03)00140-8; Marcinkiewicz J, 1995, J LEUKOCYTE BIOL, V58, P667, DOI 10.1002/jlb.58.6.667; Midwinter RG, 2001, ARCH BIOCHEM BIOPHYS, V394, P13, DOI 10.1006/abbi.2001.2530; Milligan SA, 1998, ARCH BIOCHEM BIOPHYS, V352, P255, DOI 10.1006/abbi.1998.0603; NAITO Y, 1997, J CLIN GASTRONETE S1, V25, P179; Oliveira CJR, 2003, FREE RADICAL BIO MED, V35, P381, DOI 10.1016/S0891-5849(03)00311-3; PARK E, 1995, J IMMUNOL, V154, P4778; Park S, 2001, BIOCHEM PHARMACOL, V62, P1107, DOI 10.1016/S0006-2952(01)00741-9; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Prutz WA, 1996, ARCH BIOCHEM BIOPHYS, V332, P110, DOI 10.1006/abbi.1996.0322; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Pullar JM, 2000, IUBMB LIFE, V50, P259, DOI 10.1080/15216540051080958; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; TATSUMI T, 1994, AM J PHYSIOL-HEART C, V267, pH1597, DOI 10.1152/ajpheart.1994.267.4.H1597; Thomas E L, 1986, Methods Enzymol, V132, P569; Thomas E L, 1986, Methods Enzymol, V132, P585; THOMAS EL, 1979, INFECT IMMUN, V25, P110, DOI 10.1128/IAI.25.1.110-116.1979; Thomas EL, 2000, REDOX REP, V5, P191, DOI 10.1179/135100000101535744; THOMAS EL, 1985, J BIOL CHEM, V260, P3321; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vile GF, 2000, ARCH BIOCHEM BIOPHYS, V377, P122, DOI 10.1006/abbi.2000.1706; Vissers MCM, 1999, BIOCHEM J, V344, P443, DOI 10.1042/0264-6021:3440443; Vissers MCM, 2001, J BIOL CHEM, V276, P46835, DOI 10.1074/jbc.M107664200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v; Zhang P, 2000, J BIOL CHEM, V275, P22479, DOI 10.1074/jbc.M910425199	52	40	40	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32205	32211		10.1074/jbc.M402070200	http://dx.doi.org/10.1074/jbc.M402070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166244	hybrid			2022-12-27	WOS:000222849700027
J	Koo, BM; Yoon, MJ; Lee, CR; Nam, TW; Choe, YJ; Jaffe, H; Peterkofsky, A; Seok, YJ				Koo, BM; Yoon, MJ; Lee, CR; Nam, TW; Choe, YJ; Jaffe, H; Peterkofsky, A; Seok, YJ			A novel fermentation/respiration switch protein regulated by enzyme IIA(Glc) in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; PHOSPHORYL TRANSFER COMPLEX; GLOBAL REPRESSOR MLC; GLUCOSE-TRANSPORTER; INDUCER EXCLUSION; TERMINAL DOMAIN; GLYCEROL KINASE; SALMONELLA-TYPHIMURIUM; GLYCOGEN-PHOSPHORYLASE; ALLOSTERIC REGULATION	The bacterial phosphoenolpyruvate: sugar phosphotransferase system regulates a variety of physiological processes as well as effecting sugar transport. The crr gene product (enzyme IIA(Glc) (IIA(Glc))) mediates some of these regulatory phenomena. In this report, we characterize a novel IIA(Glc)-binding protein from Escherichia coli extracts, discovered using ligand-fishing with surface plasmon resonance spectroscopy. This protein, which we named FrsA ( fermentation/respiration switch protein), is the 47-kDa product of the yafA gene, previously denoted as "function unknown." FrsA forms a 1: 1 complex specifically with the unphosphorylated form of IIA(Glc), with the highest affinity of any protein thus far shown to interact with IIA(Glc). Orthologs of FrsA have been found to exist only in facultative anaerobes belonging to the gamma-proteobacterial group. Disruption of frsA increased cellular respiration on several sugars including glucose, while increased FrsA expression resulted in an increased fermentation rate on these sugars with the concomitant accumulation of mixed-acid fermentation products. These results suggest that IIA(Glc) regulates the flux between respiration and fermentation pathways by sensing the available sugar species via a phosphorylation state-dependent interaction with FrsA.	Seoul Natl Univ, Sch Biol Sci, Lab Macromol Interact, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; NINDS, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Seok, YJ (corresponding author), Seoul Natl Univ, Sch Biol Sci, Lab Macromol Interact, Seoul 151742, South Korea.	yjseok@plaza.snu.ac.kr		Choe, Young Jun/0000-0003-3062-057X; Koo, Byoung-Mo/0000-0003-1001-6367; Seok, Yeong-Jae/0000-0003-0379-3619	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bochner BR, 2001, GENOME RES, V11, P1246, DOI 10.1101/gr.186501; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CLARKE PM, 1983, ANAL BIOCHEM, V130, P402, DOI 10.1016/0003-2697(83)90607-3; DEAN DA, 1990, J BIOL CHEM, V265, P21005; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Hogema BM, 1998, MOL MICROBIOL, V30, P487, DOI 10.1046/j.1365-2958.1998.01053.x; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; Jaffe H, 1998, BIOCHEMISTRY-US, V37, P3931, DOI 10.1021/bi972518u; Koo BM, 2001, J MICROBIOL, V39, P24; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; LEVY S, 1990, GENE, V86, P27, DOI 10.1016/0378-1119(90)90110-D; LUX R, 1995, P NATL ACAD SCI USA, V92, P11583, DOI 10.1073/pnas.92.25.11583; MORITZ RL, 1995, TECH PROT CHEM, V6, P311, DOI 10.1016/S1080-8914(06)80039-6; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; NYSTROM T, 1994, MOL MICROBIOL, V12, P833, DOI 10.1111/j.1365-2958.1994.tb01069.x; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; Pettigrew DW, 1998, BIOCHEMISTRY-US, V37, P4875, DOI 10.1021/bi971634u; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; SAIER MH, 1983, J BACTERIOL, V155, P1351, DOI 10.1128/JB.155.3.1351-1357.1983; Seok YJ, 1997, J BIOL CHEM, V272, P26511, DOI 10.1074/jbc.272.42.26511; Seok YJ, 1996, P NATL ACAD SCI USA, V93, P347, DOI 10.1073/pnas.93.1.347; Seok YJ, 2001, J MOL MICROB BIOTECH, V3, P385; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; TITGEMEYER F, 1994, J BACTERIOL, V176, P543, DOI 10.1128/JB.176.2.543-546.1994; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhou L, 2003, J BACTERIOL, V185, P4956, DOI 10.1128/JB.185.16.4956-4972.2003	34	57	61	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31613	31621		10.1074/jbc.M405048200	http://dx.doi.org/10.1074/jbc.M405048200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15169777	hybrid			2022-12-27	WOS:000222726800085
J	Skowronek, KR; Guo, F; Zheng, Y; Nassar, N				Skowronek, KR; Guo, F; Zheng, Y; Nassar, N			The C-terminal basic tail of RhoG assists the guanine nucleotide exchange factor trio in binding to phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; STRUCTURAL BASIS; DBL FAMILY; GUANOSINE TRIPHOSPHATASES; CRYSTAL-STRUCTURE; AXON GUIDANCE; HIGH-AFFINITY; GEF TRIO; PROTEIN; RAC	The multidomain protein Trio regulates among others neuronal outgrowth and axonal guidance in vertebrates and invertebrates. Trio contains two Dbl-homology/pleckstrin homology (DH/PH) tandem domains that activate several RhoGTPases. Here, we present the x-ray structure of the N-terminal DH/PH, hereafter TrioN, refined to 1.7-Angstrom resolution. We show that the relative orientations of the DH and PH domains of TrioN and free Dbs are similar. However, this relative orientation is dissimilar to Dbs in the Dbs/Cdc42 structure. In vitro nucleotide exchange experiments catalyzed by TrioN show that RhoG is similar to 3 x more efficiently exchanged than Rac and support the conclusion that RhoG is likely the downstream target of TrioN. Residues 54 and 69, which are not conserved between the two GTPases, are responsible for this specificity. Dot-blot assay reveals that the TrioN-PH domain does not detectably bind phosphatidylinositol 3,4-bisphosphate, PtdIns(3,4) P-2, or other phospholipids. This finding is supported by our three-dimensional structure and affinity binding experiments. Interestingly, the presence of RhoG but not Rac or a C-terminal-truncated RhoG mutant allows TrioN to bind PtdIns( 3,4) P2 with a micromolar affinity constant. We conclude the variable C-terminal basic tail of RhoG specifically assists the recruitment of the TrioN-PH domain to specific membrane-bound phospholipids. Our data suggest a role for the phosphoinositide 3-kinase, PI 3-kinase, in modulating the Trio/RhoG signaling pathway.	SUNY Stony Brook, Dept Physiol & Biophys, Hlth Sci Ctr, Stony Brook, NY 11794 USA; Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Nassar, N (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Hlth Sci Ctr, Basic Sci Tower, Stony Brook, NY 11794 USA.	nicolas.nassar@sunysb.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NCRR NIH HHS [RR-01646] Funding Source: Medline; NIDDK NIH HHS [T32-DK07521-16] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Ahmadian Mohammad Reza, 2002, Methods Mol Biol, V189, P45; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bateman J, 2001, J CELL SCI, V114, P1973; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bellanger JM, 2003, BIOL CELL, V95, P625, DOI 10.1016/j.biolcel.2003.10.002; Blangy A, 2000, J CELL SCI, V113, P729; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Gallo G, 1999, CURR BIOL, V9, pR490, DOI 10.1016/S0960-9822(99)80304-2; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Seipel K, 2001, J CELL SCI, V114, P389; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Skowronek K, 2003, ACTA CRYSTALLOGR D, V59, P1273, DOI 10.1107/S0907444903009442; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VAN AL, 1997, GENE DEV, V11, P2295; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	69	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37895	37907		10.1074/jbc.M312677200	http://dx.doi.org/10.1074/jbc.M312677200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15199069	hybrid			2022-12-27	WOS:000223554600083
J	Gavard, J; Marthiens, V; Monnet, C; Lambert, M; Mege, RM				Gavard, J; Marthiens, V; Monnet, C; Lambert, M; Mege, RM			N-cadherin activation substitutes for the cell contact control in cell cycle arrest and myogenic differentiation - Involvement of p120 AND beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; RHO-FAMILY GTPASES; 3-DIMENSIONAL CULTURES; ACTIN CYTOSKELETON; STRIATED-MUSCLE; EXPRESSION; ADHESION; GROWTH; LOCALIZATION; INHIBITION	N-cadherin is expressed throughout skeletal myogenesis and has been proposed to be involved in the differentiation program of myogenic precursors. Here, we further characterize the N-cadherin involvement and its mechanism of action at the onset of differentiation, through controlled N-cadherin activation by plating isolated C2 myoblasts on surfaces coated with a chimeric Ncad-Fc homophilic ligand (N-cadherin ectodomain fused to the immunoglobulin G Fc fragment). We show that N-cadherin activation substitutes for the cell density in myogenic differentiation by promoting myogenin and troponin T expression. In addition, N-cadherin adhesion participates to the associated cell cycle arrest through the nuclear accumulation of cyclin-dependent kinase inhibitors p21 and p27. Mouse primary myoblast cultures exhibited similar responses to N-cadherin as C2 cells. RNA interference knockdowns of the N-cadherin-associated cytoplasmic proteins p120 and beta-catenin produced opposite effects on the differentiation pathway. p120 silencing resulted in a decreased myogenic differentiation, associated with a reduction in cadherin-catenin content, which may explain its action on myogenic differentiation. beta-Catenin silencing led to a stimulatory effect on myogenin expression, without any effect on cell cycle. Our results demonstrate that N-cadherin adhesion may account for cell-cell contact-dependent cell cycle arrest and differentiation of myogenic cells, involving regulation through p120 and beta-catenins.	Inst Fer Moulin, INSERM, U440, UPMC, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mege, RM (corresponding author), Inst Fer Moulin, INSERM, U440, UPMC, 17 Rue Fer Moulin, F-75005 Paris, France.	mege@fer-a-moulin.inserm.fr	Marthiens, Veronique/D-8673-2017; Mege, Rene Marc/M-9569-2013; Gavard, Julie/I-5487-2012; Gavard, Julie/I-5487-2012	Gavard, Julie/0000-0002-7985-9007; Mege, Rene-Marc/0000-0001-8128-5543; MONNET, Celine/0000-0003-0492-5062; marthiens, veronique/0000-0002-1360-0617; Gavard, Julie/0000-0003-3107-2026				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Brand-Saberi B, 1999, CELL TISSUE RES, V296, P199, DOI 10.1007/s004410051281; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157; Charlton CA, 1997, J CELL BIOL, V138, P331, DOI 10.1083/jcb.138.2.331; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; CIFUENTESDIAZ C, 1995, MECH DEVELOP, V50, P85, DOI 10.1016/0925-4773(94)00327-J; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; GeorgeWeinstein M, 1997, DEV BIOL, V185, P14, DOI 10.1006/dbio.1997.8542; Goichberg P, 2001, J CELL SCI, V114, P1309; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; HOLT CE, 1994, P NATL ACAD SCI USA, V91, P10844, DOI 10.1073/pnas.91.23.10844; IRINTCHEV A, 1994, DEV DYNAM, V199, P326, DOI 10.1002/aja.1001990407; Kang JS, 2003, P NATL ACAD SCI USA, V100, P3989, DOI 10.1073/pnas.0736565100; Kaufmann U, 1999, CELL TISSUE RES, V296, P191, DOI 10.1007/s004410051280; Knudsen KA, 1990, CURR OPIN CELL BIOL, V2, P902, DOI 10.1016/0955-0674(90)90090-2; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lambert M, 2000, J CELL SCI, V113, P2207; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Marthiens V, 2002, MOL CELL NEUROSCI, V20, P458, DOI 10.1006/mcne.2002.1130; Marthiens W, 2002, BIOL CELL, V94, P315, DOI 10.1016/S0248-4900(02)00005-9; MEGE RM, 1992, J CELL SCI, V103, P897; Monnet C, 2003, EUR J NEUROSCI, V18, P542, DOI 10.1046/j.1460-9568.2003.02777.x; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Redfield A, 1997, J CELL BIOL, V138, P1323, DOI 10.1083/jcb.138.6.1323; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Rosenberg P, 1997, DEV BIOL, V187, P55, DOI 10.1006/dbio.1997.8602; Seghatoleslami MR, 2000, J CELL BIOCHEM, V77, P252, DOI 10.1002/(SICI)1097-4644(20000501)77:2<252::AID-JCB8>3.0.CO;2-J; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TASSIN AM, 1988, DEV BIOL, V129, P37, DOI 10.1016/0012-1606(88)90159-5; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; ZESCHNIGK M, 1995, J CELL SCI, V108, P2973	57	50	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36795	36802		10.1074/jbc.M401705200	http://dx.doi.org/10.1074/jbc.M401705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194693	hybrid			2022-12-27	WOS:000223453600081
J	Elad-Sfadia, G; Haklai, R; Balan, E; Kloog, Y				Elad-Sfadia, G; Haklai, R; Balan, E; Kloog, Y			Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; H-RAS; ROD PHOSPHODIESTERASE; DELTA-SUBUNIT; CELL-LINES; N-RAS; BINDING; FAMILY; EXPRESSION; PROTEINS	Depending on the cellular context, Ras can activate characteristic effectors by mechanisms still poorly understood. Promotion by galectin-1 of Ras activation of Raf-1 but not of phosphoinositide 3-kinase (PI3-K) is one such mechanism. In this report, we describe a mechanism controlling selectivity of K-Ras4B (K-Ras), the most important Ras oncoprotein. We show that galectin-3 acts as a selective binding partner of activated K-Ras. Galectin-3 co-immunoprecipitated significantly better with K-Ras-GTP than with K-Ras-GDP, H-Ras, or N-Ras and colocalized with green fluorescent protein-K-Ras(G12V), not with green fluorescent protein-H-Ras(G12V), in the cell membrane. Co-transfectants of K-Ras/galectin-3, but not of H-Ras/galectin-3, exhibited enhanced and prolonged epidermal growth factor-stimulated increases in Ras-GTP, Raf-1 activity, and PI3-K activity. Extracellular signal-regulated kinase (ERK) activity, however, was attenuated in K-Ras/galectin-3 and in K-Ras(G12V)/galectin-3 co-transfectants. Galectin-3 antisense RNA inhibited the epidermal growth factor-stimulated increase in K-Ras-GTP but enhanced ERK activation and augmented K-Ras(G12V) transformation activity. Thus, unlike galectin-1, which prolongs Ras activation of ERK and inhibits PI3-K, K-Ras-GTP/galectin-3 interactions promote, in addition to PI3-K and Raf-1 activation, a third inhibitory signal that attenuates active ERK. These experiments established a novel and specific mechanism controlling the duration and selectivity of signals of active K-Ras, which is extremely important in many human tumors.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	kloog@post.tau.ac.il						Akahani S, 1997, CANCER RES, V57, P5272; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Bresalier RS, 1997, CANCER, V80, P776; Camby I, 2001, BRAIN PATHOL, V11, P12; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Elad G, 1999, BBA-MOL CELL RES, V1452, P228, DOI 10.1016/S0167-4889(99)00144-5; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; Goi T, 1999, MOL CELL BIOL, V19, P1731; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; HUBERT M, 1995, EXP CELL RES, V220, P397, DOI 10.1006/excr.1995.1331; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kayser K, 2000, VIRCHOWS ARCH, V437, P284, DOI 10.1007/s004280000207; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rotblat B, 2004, CANCER RES, V64, P3112, DOI 10.1158/0008-5472.CAN-04-0026; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; van den Brule FA, 2001, J PATHOL, V193, P80, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2; VICIANA PR, 1996, EMBO J, V15, P2442; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271	52	219	224	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34922	34930		10.1074/jbc.M312697200	http://dx.doi.org/10.1074/jbc.M312697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15205467	hybrid			2022-12-27	WOS:000223134800103
J	Jeong, SM; Lee, KY; Shin, DH; Chung, HY; Jeon, SH; Seong, RH				Jeong, SM; Lee, KY; Shin, DH; Chung, HY; Jeon, SH; Seong, RH			Nitric oxide inhibits glucocorticoid-induced apoptosis of thymocytes by repressing the SRG3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; DENDRITIC CELLS; GENE-EXPRESSION; UP-REGULATION; SYNTHASE; RECEPTOR; ACTIVATION; DEATH; TRANSCRIPTION; LYMPHOCYTES	Nitric oxide ( NO) plays many roles in the immune system. It has been known that NO rescues thymocytes from glucocorticoid (GC)-induced apoptosis. However, the downstream target of NO in the protection from GC-induced thymocyte apoptosis has yet to be identified. We previously reported that GC sensitivity of developing thymocytes is dependent on the expression level of SRG3. In the present report, we found that NO repressed the SRG3 expression in both primary thymocytes and 16610D9 thymoma cells. Specifically, NO down-regulated the transcription of SRG3 via the inactivation of the transcription factor Sp1 DNA-binding activity to the SRG3 promoter. In addition, overexpression of SRG3 by a heterologous promoter reduced NO-mediated rescue of thymocytes from GC-induced apoptosis. These observations strongly suggest that NO may be involved in protecting immature thymocytes from GC-induced apoptosis by repressing the SRG3 expression in thymus.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Hanyang Univ, Sch Med, Dept Pathol, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University	Jeon, SH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	jeonsho@snu.ac.kr; rhseong@plaza.snu.ac.kr		Seong, Rho/0000-0001-5699-0718				Aiello S, 2000, J IMMUNOL, V164, P4649, DOI 10.4049/jimmunol.164.9.4649; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Ashwell JD, 1996, STEM CELLS, V14, P490, DOI 10.1002/stem.140490; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Chen Y, 2001, CELL IMMUNOL, V214, P72, DOI 10.1006/cimm.2001.1880; Choi YI, 2001, P NATL ACAD SCI USA, V98, P10267, DOI 10.1073/pnas.181076198; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Galigniana MD, 1999, MOL PHARMACOL, V55, P317, DOI 10.1124/mol.55.2.317; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; Iwata M, 1996, EUR J IMMUNOL, V26, P2081, DOI 10.1002/eji.1830260918; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; Jondal M, 1995, Curr Top Microbiol Immunol, V200, P67; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Ko M, 2004, J BIOL CHEM, V279, P21916, DOI 10.1074/jbc.M402145200; Ko M, 2004, J BIOL CHEM, V279, P21903, DOI 10.1074/jbc.M402144200; Kroncke KD, 2002, J BIOL CHEM, V277, P13294, DOI 10.1074/jbc.M111216200; Kroncke KD, 2001, FASEB J, V15, P2503, DOI 10.1096/fj.01-0240hyp; Lu LN, 1996, J IMMUNOL, V157, P3577; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Pazirandeh A, 2002, FASEB J, V16, P727, DOI 10.1096/fj.01-0891fje; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Tai XG, 1997, J IMMUNOL, V158, P4696; Wagner DH, 1996, J EXP MED, V184, P1631, DOI 10.1084/jem.184.5.1631; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZHAO Y, 1995, J IMMUNOL, V154, P6346	36	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34373	34379		10.1074/jbc.M403461200	http://dx.doi.org/10.1074/jbc.M403461200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187086	hybrid			2022-12-27	WOS:000223134800037
J	Liger, D; Graille, M; Zhou, CZ; Leulliot, N; Quevillon-Cheruel, S; Blondeau, K; Janin, J; van Tilbeurgh, H				Liger, D; Graille, M; Zhou, CZ; Leulliot, N; Quevillon-Cheruel, S; Blondeau, K; Janin, J; van Tilbeurgh, H			Crystal structure and functional characterization of yeast YLR011wp, an enzyme with NAD(P)H-FMN and ferric iron reductase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED FLAVODOXIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; FLAVIN REDUCTASE; PROTEIN; AZOREDUCTASE; PURIFICATION; ACTIVATION; RESOLUTION	Flavodoxins are involved in a variety of electron transfer reactions that are essential for life. Although FMN-binding proteins are well characterized in prokaryotic organisms, information is scarce for eukaryotic flavodoxins. We describe the 2.0-Angstrom resolution crystal structure of the Saccharomyces cerevisiae YLR011w gene product, a predicted flavoprotein. YLR011wp indeed adopts a flavodoxin fold, binds the FMN cofactor, and self-associates as a homodimer. Despite the absence of the flavodoxin key fingerprint motif involved in FMN binding, YLR011wp binds this cofactor in a manner very analogous to classical flavodoxins. YLR011wp closest structural homologue is the homodimeric Bacillus subtilis Yhda protein (25% sequence identity) whose homodimer perfectly superimposes onto the YLR011wp one. Yhda, whose function is not documented, has 53% sequence identity with the Bacillus sp. OY1-2 azoreductase. We show that YLR011wp has an NAD(P)H-dependent FMN reductase and a strong ferricyanide reductase activity. We further demonstrate a weak but specific reductive activity on azo dyes and nitrocompounds.	Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619, F-91405 Orsay, France; CNRS, Lab Enzymol & Biochim Struct, Unite Propre Rech 9063, F-91198 Gif Sur Yvette, France; Univ Paris 11, Inst Genet & Microbiol, CNRS, UMR 8621, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619, Batiment 430, F-91405 Orsay, France.	herman@lebs.cnrs-gif.fr	GRAILLE, Marc/D-3242-2014; Zhou, Cong-Zhao/E-9174-2011; Leulliot, Nicolas/AAA-7160-2019; Janin, Joel/I-2958-2012	GRAILLE, Marc/0000-0002-7853-5852; Zhou, Cong-Zhao/0000-0002-6881-7151; Leulliot, Nicolas/0000-0003-0283-4298; 				BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; Chen HZ, 2004, PROTEIN EXPRES PURIF, V34, P302, DOI 10.1016/j.pep.2003.12.016; CHIKUBA K, 1994, BIOCHEM BIOPH RES CO, V198, P1170, DOI 10.1006/bbrc.1994.1165; Drennan CL, 1999, J MOL BIOL, V294, P711, DOI 10.1006/jmbi.1999.3151; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Freigang J, 2002, PROTEIN SCI, V11, P253, DOI 10.1110/ps.28602; FUKUYAMA K, 1992, J MOL BIOL, V225, P775, DOI 10.1016/0022-2836(92)90400-E; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESUISSE E, 1990, BIOCHIM BIOPHYS ACTA, V1038, P253, DOI 10.1016/0167-4838(90)90213-Y; MAYHEW SG, 1975, FLAVODOXINS ELECT TR; Moutaouakkil A, 2003, ARCH BIOCHEM BIOPHYS, V413, P139, DOI 10.1016/S0003-9861(03)00096-1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakanishi M, 2001, J BIOL CHEM, V276, P46394, DOI 10.1074/jbc.M104483200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; Roth M, 2002, ACTA CRYSTALLOGR D, V58, P805, DOI 10.1107/S0907444902003943; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Schroder I, 2003, FEMS MICROBIOL REV, V27, P427, DOI 10.1016/S0168-6445(03)00043-3; SIMONDSEN RP, 1980, MOL CELL BIOCHEM, V33, P13; Suzuki Y, 2001, J BIOL CHEM, V276, P9059, DOI 10.1074/jbc.M008083200; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Watanabe M, 1998, J BIOL CHEM, V273, P23922, DOI 10.1074/jbc.273.37.23922; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; YANG WP, 1993, P NATL ACAD SCI USA, V90, P5796, DOI 10.1073/pnas.90.12.5796; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996; Zhang L, 2001, BIOCHEM BIOPH RES CO, V283, P531, DOI 10.1006/bbrc.2001.4776	34	63	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34890	34897		10.1074/jbc.M405404200	http://dx.doi.org/10.1074/jbc.M405404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184374	Green Published, hybrid			2022-12-27	WOS:000223134800099
J	Randau, L; Schauer, S; Ambrogelly, A; Salazar, JC; Moser, J; Sekine, S; Yokoyama, S; Soll, D; Jahn, D				Randau, L; Schauer, S; Ambrogelly, A; Salazar, JC; Moser, J; Sekine, S; Yokoyama, S; Soll, D; Jahn, D			tRNA recognition by glutamyl-tRNA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; DELTA-AMINOLEVULINIC-ACID; ESCHERICHIA-COLI; 1-SEMIALDEHYDE AMINOTRANSFERASE; IDENTITY DETERMINANTS; TRANSFER RNA(GLU); CRYSTAL-STRUCTURE; ACCEPTOR STEM; SYNTHETASE; NUCLEOTIDES	During the first step of porphyrin biosynthesis in Archaea, most bacteria, and in chloroplasts glutamyl-tRNA reductase (GluTR) catalyzes the NADPH-dependent reduction of glutamyl-tRNA to glutamate-1-semialdehyde. Elements in tRNA(Glu) important for utilization by Escherichia coli GluTR were determined by kinetic analysis of 51 variant transcripts of E. coli Glu-tRNA(Glu). Base U8, the U13*G22**A46 base triple, the tertiary Watson-Crick base pair 19*56, and the lack of residue 47 are required for GluTR recognition. All of these bases contribute to the formation of the unique tertiary core of E. coli tRNAGlu. Two tRNA(Glu) molecules lacking the entire anticodon stem/loop but retaining the tertiary core structure remained substrates for GluTR, while further decreasing tRNA size toward a minihelix abolished GluTR activity. RNA footprinting experiments revealed the physical interaction of GluTR with the tertiary core of Glu-tRNA(Glu). E. coli GluTR showed clear selectivity against mischarged Glu-tRNA(Gln). We concluded that the unique tertiary core structure of E. coli tRNA(Glu) was sufficient for E. coli GluTR to distinguish specifically its glutamyl-tRNA substrate.	Tech Univ Braunschweig, Inst Mikrobiol, D-38023 Braunschweig, Germany; Yale Univ, Dept Mol Biophys, New Haven, CT 06520 USA; Yale Univ, Dept Biochem, New Haven, CT 06520 USA; SPring 8, RIKEN Harima Inst, Cellular Signaling Lab, Mikazuki, Hyogo 6795148, Japan; SPring 8, RIKEN Harima Inst, Structurome Grp, Mikazuki, Hyogo 6795148, Japan	Braunschweig University of Technology; Yale University; Yale University; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu; d.jahn@tu-bs.de	Salazar, Juan/D-9368-2014; Yokoyama, Shigeyuki/N-6911-2015; Garrido, Juan Carlos Salazar/H-2672-2017; Sekine, Shun-ichi/N-5450-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Garrido, Juan Carlos Salazar/0000-0002-2096-2050; Sekine, Shun-ichi/0000-0001-8174-8704; Jahn, Dieter/0000-0002-4064-9205; Randau, Lennart/0000-0002-2780-2076				AVISSAR YJ, 1990, J BACTERIOL, V172, P1656, DOI 10.1128/jb.172.3.1656-1659.1990; BARON C, 1991, J BIOL CHEM, V266, P20375; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BERESTEN S, 1992, NUCLEIC ACIDS RES, V20, P1523, DOI 10.1093/nar/20.7.1523; CHAPMAN KT, 1993, J MED CHEM, V36, P4293, DOI 10.1021/jm00078a019; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Freist W, 1997, BIOL CHEM, V378, P1313; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HOBEN P, 1985, METHOD ENZYMOL, V113, P55; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; ILAG LL, 1992, BIOCHEMISTRY-US, V31, P7143, DOI 10.1021/bi00146a016; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JAHN D, 1992, PLANT PHYSIOL BIOCH, V30, P245; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; LADNER JE, 1975, P NATL ACAD SCI USA, V72, P4414, DOI 10.1073/pnas.72.11.4414; LEE CP, 1991, J BIOL CHEM, V266, P18012; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P71, DOI 10.1016/1046-5928(92)90058-5; Mayer C, 2002, NUCLEIC ACIDS RES, V30, P2844, DOI 10.1093/nar/gkf411; Moser J, 2002, BIOCHEM SOC T, V30, P579, DOI 10.1042/bst0300579; Moser J, 2001, EMBO J, V20, P6583, DOI 10.1093/emboj/20.23.6583; Moser J, 1999, J BIOL CHEM, V274, P30679, DOI 10.1074/jbc.274.43.30679; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; ONEILL GP, 1988, J BACTERIOL, V170, P3810, DOI 10.1128/jb.170.9.3810-3816.1988; PETERSON D, 1988, PLANT MOL BIOL, V11, P293, DOI 10.1007/BF00027386; ROGERS KC, 1993, BIOCHEMISTRY-US, V32, P14210, DOI 10.1021/bi00214a021; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; Schauer S, 2003, PROTEIN EXPRES PURIF, V31, P271, DOI 10.1016/S1046-5928(03)00184-0; Schauer S, 2002, J BIOL CHEM, V277, P48657, DOI 10.1074/jbc.M206924200; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; Sekine S, 1999, EUR J BIOCHEM, V261, P354, DOI 10.1046/j.1432-1327.1999.00293.x; Sekine S, 2003, EMBO J, V22, P676, DOI 10.1093/emboj/cdg053; Sekine S, 1996, J MOL BIOL, V256, P685, DOI 10.1006/jmbi.1996.0118; Sekine S, 2001, NAT STRUCT BIOL, V8, P203, DOI 10.1038/84927; SMITH MA, 1992, BIOCHEMISTRY-US, V31, P11249, DOI 10.1021/bi00160a041; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STANGETHOMANN N, 1994, P NATL ACAD SCI USA, V91, P7947, DOI 10.1073/pnas.91.17.7947; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; WAKAO H, 1989, J BIOL CHEM, V264, P20363; WEINSTEIN JD, 1986, PLANT PHYSIOL, V82, P1096, DOI 10.1104/pp.82.4.1096; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WILLOWS RD, 1995, BBA-GENE STRUCT EXPR, V1263, P228, DOI 10.1016/0167-4781(95)00105-P	45	25	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34931	34937		10.1074/jbc.M401529200	http://dx.doi.org/10.1074/jbc.M401529200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194701	hybrid			2022-12-27	WOS:000223134800104
J	Sinkins, WG; Goel, M; Estacion, M; Schilling, WP				Sinkins, WG; Goel, M; Estacion, M; Schilling, WP			Association of immunophilins with mammalian TRPC channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR; FK506-BINDING PROTEIN; POTENTIAL CHANNELS; RELEASE CHANNEL; FKBP12; CALCINEURIN; BINDS; FK506; COMPLEX	Drosophila photoreceptor channels TRP and TRPL are held in a large signalplex by the scaffolding protein, INAD. Immunophilin FKBP59, another member of the signalplex, binds to both INAD and TRPL. Mutation P702Q or P709Q in the highly conserved TRPL sequence (LPPPFNVLP709)-L-701, eliminates TRPL interaction with FKBP59. The first leucylprolyl (LP) dipeptide in this region is conserved in mammalian TRPC channel proteins. However, the second LP is changed to isoleucylprolyl (IP) in TRPC1, - C4, and - C5, and valylprolyl (VP) in TRPC3, - C6, and - C7. The purpose of the present study was to determine if mammalian FKBP12 or FKBP52 interact with TRPC channel proteins. Using TRPC-specific antibodies, immunoprecipitations from Sf9 cells individually co-expressing each of the TRPC proteins along with the immunophilins showed that TRPC3, - C6, and - C7 interact with FKBP12, whereas TRPC1, - C4, and - C5 interact with FKBP52. The binding of FKBP12 and FKBP52 was specific and could be displaced by the immunosuppressant drug FK506, at concentrations of 0.5 and 10 muM, respectively. To evaluate TRPC-immunophilin interactions in vivo, immunoprecipitations were performed using membrane lysates of rat cerebral cortex. FKBP12 co-immunoprecipitated with TRPC3, - C6, and - C7 from rat brain, whereas FKBP52 was found to associate with TRPC1, - C4, and - C5. The association of immunophilins with the TRPC channels in rat brain lysates could be displaced by FK506. Receptor-mediated activation of TRPC6, stably expressed in HEK cells, was significantly inhibited by FK506, which also disrupted interaction between TRPC6 and the endogenous immunophilin found in HEK cells. Pro to Gln mutations in the first LP dipeptide in the putative FKBP binding domain eliminated FKBP12 and FKBP52 interaction with TRPC3 and - C6, and TRPC1 and - C4, respectively. However, mutual swap of VP and IP in TRPC3 and TRPC5 did not alter the association or the selectivity of the channels for their respective immunophilin binding partner. These results suggest that immunophilins are TRPC channel accessory proteins that play an important role in the mechanism of channel activation following receptor stimulation.	Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University	Schilling, WP (corresponding author), Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res, Rm R322,2500 MetroHlth Dr, Cleveland, OH 44109 USA.	wschilling@metrohealth.org	Estacion, Mark/H-2444-2011	Estacion, Mark/0000-0002-7271-1165	NIGMS NIH HHS [GM 52019] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052019] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Carmody M, 2001, FEBS LETT, V505, P97, DOI 10.1016/S0014-5793(01)02787-9; Dargan SL, 2002, BIOCHEM J, V361, P401, DOI 10.1042/0264-6021:3610401; Estacion M, 2004, J BIOL CHEM, V279, P22047, DOI 10.1074/jbc.M402320200; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Goel M, 2001, J BIOL CHEM, V276, P38762, DOI 10.1074/jbc.M104125200; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; Marks Andrew R., 1996, Methods (Orlando), V9, P177, DOI 10.1006/meth.1996.0024; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; MONTELL C, 2001, SCI STKE, V90, P1; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Shin DW, 2002, BIOPHYS J, V83, P2539, DOI 10.1016/S0006-3495(02)75265-X; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	38	83	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34521	34529		10.1074/jbc.M401156200	http://dx.doi.org/10.1074/jbc.M401156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15199065	hybrid			2022-12-27	WOS:000223134800055
J	Zhang, Y; Karas, M; Zhao, H; Yakar, S; LeRoith, D				Zhang, Y; Karas, M; Zhao, H; Yakar, S; LeRoith, D			14-3-3 sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FORKHEAD TRANSCRIPTION FACTOR; ACCELERATES G(1) PHASE; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; CYCLIN-D1 EXPRESSION; SIGNAL TRANSDUCTION; DNA-DAMAGE; IGF-I	We investigated the role of 14-3-3sigma protein in insulin-like growth factor-I (IGF-I) receptor signaling. It has been previously shown that 14-3-3sigma negatively regulates cell cycle especially in response to p53-sensitive DNA damage. In this study we demonstrated that 14-3-3sigma is a positive mediator of IGF-I receptor-induced cell proliferation. Treatment with IGF-I increased 14-3-3sigma mRNA and protein levels about 4-fold, in a time-dependent manner in MCF-7 breast cancer cells. Preincubation with the phosphoinositide 3'-kinase inhibitor LY294002 significantly reduced the effects of IGF-I on 14-3-3sigma gene expression in these cells, suggesting that this effect of IGF-I occurs via the phosphoinositide 3'-kinase pathway. 14-3-3sigma is induced by IGF-I in MCF-7 cells, which express wild-type p53, as well as in MCF-7 cells transfected with a small interference RNA targeting duplex that reduced p53 expression levels. These results suggest that IGF-I induces 14-3-3sigma expression in a manner that is independent of p53. Using the small interference RNA strategy, we demonstrated that a 70-75% reduction of 14-3-3sigma mRNA levels resulted in a similar decrease in the effects of IGF-I on cell cycle progression and proliferation in MCF-7 cells. This effect was also associated with a reduction in IGF-I-induced cyclin D1 expression. Taken together, these results suggest that 14-3-3sigma positively mediates IGF-I-induced cell cycle progression.	NIDDK, Diabet Branch, NIH, Sect Mol & Cellular Physiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Diabet Branch, NIH, Sect Mol & Cellular Physiol, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.	derek@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055017] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chakravarthy MV, 2000, J BIOL CHEM, V275, P35942, DOI 10.1074/jbc.M005832200; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FILMUS J, 1994, ONCOGENE, V9, P3627; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; GILLETT C, 1994, CANCER RES, V54, P1812; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Lai A, 2001, J BIOL CHEM, V276, P25823, DOI 10.1074/jbc.M100925200; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; Murray SA, 2003, ONCOGENE, V22, P1703, DOI 10.1038/sj.onc.1206327; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Ozes ON, 1999, NATURE, V401, P82; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Perry JE, 1998, PROSTATE, V35, P117; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Sfacteria A, 2003, J COMP PATHOL, V128, P245, DOI 10.1053/jcpa.2002.0622; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang WF, 1996, J MOL EVOL, V43, P384; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	59	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34353	34360		10.1074/jbc.M401300200	http://dx.doi.org/10.1074/jbc.M401300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187095	hybrid			2022-12-27	WOS:000223134800035
J	Erikson, E; Haystead, TAJ; Qian, YW; Maller, JL				Erikson, E; Haystead, TAJ; Qian, YW; Maller, JL			A feedback loop in the polo-like kinase activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS CDC25 PHOSPHATASE; PROTEIN-KINASE; CELL-CYCLE; PHOSPHORYLATION SITES; PLX1; TRANSITION; PLK1; BOX; IDENTIFICATION; AMPLIFICATION	The Xenopus polo-like kinase Plx1 plays important roles during entry into and exit from mitosis ( M phase). Previous studies revealed that Plx1 is activated by phosphorylation on serine and threonine residues, and purification of an activating enzyme from mitotic Xenopus egg extracts led to cloning and characterization of Xenopus polo-like kinase kinase (xPlkk1), which can phosphorylate and activate Plx1 in vitro. In the present study, a positive feedback loop between Plx1 and xPlkk1 was shown to result in each kinase phosphorylating and activating the other. Sequencing of radiolabeled xPlkk1 after phosphorylation by Plx1 in vitro identified three phosphorylation sites each spaced three amino acids apart, two of which have the consensus acidic-X-pSer-hydrophobic described for other polo-like kinase substrates. In addition, endogenous xPlkk1 in oocytes was phosphorylated on these sites in M phase but not in interphase. A mutant xPlkk1 in which these three amino acids were changed to alanine (xPlkk1(SA3)) was unable to be phosphorylated or activated in vitro by Plxl. Depletion of Plx1 from oocyte extracts prior to stimulation of the G(2)/M transition blocked the activation of xPlkk1, but depletion of xPlkk1 before stimulation did not block Plx1 activation. These results indicate that xPlkk1 may function downstream as a target of Plx1 rather than as an upstream activating kinase during the G(2)/M transition.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Duke University	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	Jim.Maller@uchsc.edu			NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NIDDK NIH HHS [DK52378-08] Funding Source: Medline; NIGMS NIH HHS [GM26743-24] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL SCI, V114, P2357; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Gross SD, 2001, J BIOL CHEM, V276, P46099, DOI 10.1074/jbc.C100496200; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Liu JJ, 2004, J BIOL CHEM, V279, P21367, DOI 10.1074/jbc.M400482200; LIU X, 2004, IN PRESS J CELL SCI; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Perdiguero E, 2004, CELL CYCLE, V3, P733; Perdiguero E, 2003, EMBO J, V22, P5746, DOI 10.1093/emboj/cdg559; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SUL HS, 1982, J BIOL CHEM, V257, P3484; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	44	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32219	32224		10.1074/jbc.M403840200	http://dx.doi.org/10.1074/jbc.M403840200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166215	hybrid			2022-12-27	WOS:000222849700029
J	Lorch, JH; Klessner, J; Park, JK; Getsios, S; Wu, YL; Stack, MS; Green, KJ				Lorch, JH; Klessner, J; Park, JK; Getsios, S; Wu, YL; Stack, MS; Green, KJ			Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITOR; BETA-CATENIN; E-CADHERIN; MONOCLONAL-ANTIBODY; PROSTATE-CANCER; DOWN-REGULATION; ZD1839 IRESSA; FACTOR-ALPHA; DESMOPLAKIN; PLAKOGLOBIN	The epidermal growth factor receptor (EGFR) has been proposed as a key modulator of cadherin-containing intercellular junctions, particularly in tumors that overexpress this tyrosine kinase. Here the EGFR tyrosine kinase inhibitor PKI166 and EGFR blocking antibody C225, both of which are used clinically to treat head and neck cancers, were used to determine the effects of EGFR inhibition on intercellular junction assembly and adhesion in oral squamous cell carcinoma cells. EGFR inhibition resulted in a transition from a fibroblastic morphology to a more epithelial phenotype in cells grown in low calcium; under these conditions cadherin-mediated cell-cell adhesion is normally reduced, and desmosomes are absent. The accumulated levels of desmoglein 2 (Dsg2) and desmocollin 2 increased 1.7-2.0-fold, and both desmosomal cadherin and plaque components were recruited to cell-cell borders. This redistribution was paralleled by an increase in Dsg2 and desmoplakin in the Triton-insoluble cell fraction, suggesting that EGFR blockade promotes desmosome assembly. Importantly, E-cadherin expression and solubility were unchanged. Furthermore, PKI166 blocked tyrosine phosphorylation of Dsg2 and plakoglobin following epidermal growth factor stimulation, whereas no change in phosphorylation was detected for E-cadherin and beta-catenin. The increase in Dsg2 protein was in part due to the inhibition of matrix metalloproteinase-dependent proteolysis of this desmosomal cadherin. These morphological and biochemical changes were accompanied by an increase in intercellular adhesion based on functional assays at all calcium concentrations tested. Our results suggest that EGFR inhibition promotes desmosome assembly in oral squamous cell carcinoma cells, resulting in increased cell-cell adhesion.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Lorch, JH (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	kgreen@northwestern.edu			NATIONAL CANCER INSTITUTE [T32CA080621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80621] Funding Source: Medline; NIAMS NIH HHS [R01 AR 41836] Funding Source: Medline; NIDCR NIH HHS [P01 DE 12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Al Moustafa AE, 2002, LUNG CANCER, V37, P49, DOI 10.1016/S0169-5002(02)00025-9; Al Moustafa AE, 1999, CLIN CANCER RES, V5, P681; Anderson NG, 2002, FRONT BIOSCI-LANDMRK, V7, pD1926, DOI 10.2741/anderson; Anderson NG, 2001, INT J CANCER, V94, P774, DOI 10.1002/ijc.1557; ANGST BD, 1990, J CELL SCI, V97, P247; Bruns CJ, 2000, CANCER RES, V60, P2926; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; Depondt J, 1999, EUR J ORAL SCI, V107, P183, DOI 10.1046/j.0909-8836.1999.eos1070305.x; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Ellerbroek SM, 1998, INT J CANCER, V78, P331, DOI 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; Gaudry CA, 2001, J BIOL CHEM, V276, P24871, DOI 10.1074/jbc.M102731200; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Ghosh S, 2002, CANCER-AM CANCER SOC, V95, P2524, DOI 10.1002/cncr.10997; GRANDIS JR, 1993, CANCER RES, V53, P3579; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Herbst RS, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.35644; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Ishii K, 2001, J INVEST DERMATOL, V117, P26, DOI 10.1046/j.0022-202x.2001.01400.x; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Janmaat ML, 2003, DRUG TODAY, V39, P61; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Laird AD, 2003, EXPERT OPIN INV DRUG, V12, P51, DOI 10.1517/eoid.12.1.51.21253; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Mellinghoff IK, 2002, CANCER RES, V62, P5254; Miravet S, 2003, MOL CELL BIOL, V23, P7391, DOI 10.1128/MCB.23.20.7391-7402.2003; Motoyama AB, 2002, CANCER RES, V62, P3151; Myers JN, 2002, ARCH OTOLARYNGOL, V128, P875, DOI 10.1001/archotol.128.8.875; Noe V, 2001, J CELL SCI, V114, P111; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shimizu T, 2001, DERMATOLOGY, V202, P203, DOI 10.1159/000051637; Shiozaki H, 1995, Nihon Rinsho, V53, P1602; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; VALLES AM, 1990, CELL REGUL, V1, P975, DOI 10.1091/mbc.1.13.975; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Weiske J, 2001, J BIOL CHEM, V276, P41175, DOI 10.1074/jbc.M105769200; Wells A, 2000, ADV CANCER RES, V78, P31; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yang ZB, 2004, CLIN CANCER RES, V10, P658, DOI 10.1158/1078-0432.CCR-0382-03	54	118	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37191	37200		10.1074/jbc.M405123200	http://dx.doi.org/10.1074/jbc.M405123200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205458	hybrid			2022-12-27	WOS:000223453600123
J	Bocharov, AV; Baranova, IN; Vishnyakova, TG; Remaley, AT; Csako, G; Thomas, F; Patterson, AP; Eggerman, TL				Bocharov, AV; Baranova, IN; Vishnyakova, TG; Remaley, AT; Csako, G; Thomas, F; Patterson, AP; Eggerman, TL			Targeting of scavenger receptor class B type I by synthetic amphipathic alpha-helical-containing peptides blocks lipopolysaccharide (LPS) uptake and LPS-induced pro-inflammatory cytokine responses in THP-1 monocyte cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; TOLL-LIKE RECEPTOR-4; APOLIPOPROTEIN-A-I; INTESTINAL EPITHELIAL-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; GOLGI-APPARATUS; SR-BI; SIGNAL-TRANSDUCTION; MEDIATED ACTIVATION; CHOLESTERYL ESTER	Human scavenger receptor class B type I, CLA-1, mediates lipopolysaccharide (LPS) binding and internalization (Vishnyakova, T.G., Bocharov, A.V., Baranova, I.N., Chen, Z., Remaley, A.T., Csako, G., Eggerman, T.L., and Patterson, A. P. (2003) J. Biol. Chem. 278, 22771-22780). Because one of the recognition motifs in SR-B1 ligands is the anionic amphipathic alpha-helix, we analyzed the effects of model amphipathic alpha-helical-containing peptides on LPS uptake and LPS-stimulated cytokine production. The L-37pA model peptide, containing two class A amphipathic helices, bound with high affinity (K-d=0.94 mug/ml) to CLA-1-expressing HeLa cells with a 10-fold increased capacity when compared with mock transfected HeLa cells. Both LPS and L-37pA colocalized with anti-CLA-1 antibody and directly bound CLA-1 as determined by cross-linking. SR-BI/CLA-1 ligands such as HDL, apoA-I, and L-37pA efficiently competed against iodinated L-37pA. Bacterial LPS, lipoteichoic acid, and hsp60 also competed against iodinated L-37pA. Model peptides blocked uptake of iodinated LPS in both mock transfected and CLA-1-overexpressing HeLa cells. Bound and internalized Alexa-L-37pA and BODIPY-LPS colocalized at the cell surface and perinuclear compartment. Both ligands were predominantly transported to the Golgi complex, colocalizing with the Golgi markers bovine serum albumin-ceramide, anti-Golgin97 antibody, and cholera toxin subunit B. A 100-fold excess of L-37pA nearly eliminated BODIPY-LPS binding and internalization. L-37pA and its D-amino acid analogue, D-37pA peptide were similarly effective in blocking LPS, Gram-positive bacterial wall component lipoteichoic acid and bacterial heat shock protein Gro-EL-stimulated cytokine secretion in THP-1 cells. In the same culture media used for the cytokine stimulation study, neither L-37pA nor D-37pA affected the Limulus amebocyte lysate activity of LPS, indicating that LPS uptake and cytokine stimulation were blocked independently of LPS neutralization. These results demonstrate that amphipathic helices of exchangeable apolipoproteins may represent a general host defense mechanism against inflammation.	NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA; NIH, Dept Lab Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bocharov, AV (corresponding author), NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, 6707 Democracy Blvd,Rm 697,MSC5460, Bethesda, MD 20892 USA.	abocharov@mail.cc.nih.gov; eggermant@extra.niddk.nih.gov			CLINICAL CENTER [Z01CL010306] Funding Source: NIH RePORTER	CLINICAL CENTER		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002; Chen W, 1999, J IMMUNOL, V162, P3212; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cockerill GW, 2001, CIRCULATION, V103, P108; COHEN J, 1985, LANCET, V2, P1069; Dunzendorfer S, 2004, FASEB J, V18, P1117, DOI 10.1096/fj.03-1263fje; FAIRWELL T, 1987, P NATL ACAD SCI USA, V84, P4796, DOI 10.1073/pnas.84.14.4796; Garber DW, 2001, J LIPID RES, V42, P545; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Han Chang-Hoon, 2002, J Vet Sci, V3, P265; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; Hirata M, 1995, Prog Clin Biol Res, V392, P317; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Hyka N, 2001, BLOOD, V97, P2381, DOI 10.1182/blood.V97.8.2381; KANG YH, 1990, J LEUKOCYTE BIOL, V48, P316, DOI 10.1002/jlb.48.4.316; KRIEGSMANN J, 1993, CELL MOL BIOL, V39, P791; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Levels JHM, 2001, INFECT IMMUN, V69, P2821, DOI 10.1128/IAI.69.5.2821-2828.2001; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Magee T, 2002, BIOL RES, V35, P127, DOI 10.4067/S0716-97602002000200003; Matveev S, 2001, EUR J BIOCHEM, V268, P5609, DOI 10.1046/j.1432-1033.2001.02496.x; MERRIFIELD RB, 1969, ADV ENZYMOL RAMB, V32, P221; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Moudry R, 1997, SHOCK, V7, P175, DOI 10.1097/00024382-199703000-00004; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; Ogata M, 1997, INFECT IMMUN, V65, P2160, DOI 10.1128/IAI.65.6.2160-2167.1997; Periti P, 1999, INT J ANTIMICROB AG, V12, P97, DOI 10.1016/S0924-8579(99)00044-8; Poussin C, 1998, J BIOL CHEM, V273, P20285, DOI 10.1074/jbc.273.32.20285; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Risso A, 1998, CELL IMMUNOL, V189, P107, DOI 10.1006/cimm.1998.1358; Schulthess G, 2000, BIOCHEMISTRY-US, V39, P12623, DOI 10.1021/bi0011633; Seternes T, 2001, J EXP BIOL, V204, P4055; Shah PK, 2001, CIRCULATION, V104, P2376, DOI 10.1161/hc4401.098467; SHNYRA A, 1995, INFECT IMMUN, V63, P865, DOI 10.1128/IAI.63.3.865-873.1995; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tsuneyama K, 2001, J HEPATOL, V35, P156, DOI 10.1016/S0168-8278(01)00084-8; ULEVITCH RJ, 1978, IMMUNOCHEMISTRY, V15, P157, DOI 10.1016/0161-5890(78)90144-X; Ulevitch RJ, 2000, IMMUNOL RES, V21, P49, DOI 10.1385/IR:21:2-3:49; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Van Lenten BJ, 2002, CIRCULATION, V106, P1127, DOI 10.1161/01.CIR.0000030182.35880.3E; Van Lenten BJ, 2001, CIRCULATION, V103, P2283; van OOsten M, 2001, J ENDOTOXIN RES, V7, P381, DOI 10.1177/09680519010070050601; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Zhang GH, 1995, APMIS, V103, P721	58	51	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36072	36082		10.1074/jbc.M314264200	http://dx.doi.org/10.1074/jbc.M314264200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199068	hybrid			2022-12-27	WOS:000223303400109
J	Goldschmidt, V; Paillart, JC; Rigourd, ML; Ehresmann, B; Aubertin, AM; Ehresmann, C; Marquet, R				Goldschmidt, V; Paillart, JC; Rigourd, ML; Ehresmann, B; Aubertin, AM; Ehresmann, C; Marquet, R			Structural variability of the initiation complex of HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BINDING-SITE COMPLEMENTARY; PRIMER ACTIVATION SIGNAL; STRAND DNA-SYNTHESIS; PSI-C LOOP; TRANSFER-RNA; SECONDARY STRUCTURE; VIRAL-RNA; EFFICIENT INITIATION; NUCLEOCAPSID PROTEIN	HIV-1 reverse transcription is initiated from a tRNA(3)(Lys) molecule annealed to the viral RNA at the primer binding site (PBS), but the structure of the initiation complex of reverse transcription remains controversial. Here, we performed in situ structural probing, as well as in vitro structural and functional studies, of the initiation complexes formed by highly divergent isolates (MAL and NL4.3/HXB2). Our results show that the structure of the initiation complex is not conserved. In MAL, and according to sequence analysis in 14% of HIV-1 isolates, formation of the initiation complex is accompanied by complex rearrangements of the viral RNA, and extensive interactions with tRNA(3)(Lys) are required for efficient initiation of reverse transcription. In NL4.3, HXB2, and most isolates, tRNA(3)(Lys) annealing minimally affects the viral RNA structure and no interaction outside the PBS is required for optimal initiation of reverse transcription. We suggest that in MAL, extensive interactions with tRNA(3)(Lys) are required to drive the structural rearrangements generating the structural elements ultimately recognized by reverse transcriptase. In NL4.3 and HXB2, these elements are already present in the viral RNA prior to tRNA(3)(Lys) annealing, thus explaining that extensive interactions with the primer are not required. Interestingly, such interactions are required in HXB2 mutants designed to use a non-cognate tRNA as primer (tRNA(His)). In the latter case, the extended interactions are required to counteract a negative contribution associate with the alternate primer.	Univ Strasbourg, IBMC, CNRS Conventionnee, Unite Propre Rech 9002, F-67084 Strasbourg, France; Univ Strasbourg, Inst Virol, INSERM, UMR544, F-67000 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Marquet, R (corresponding author), Univ Strasbourg, IBMC, CNRS Conventionnee, Unite Propre Rech 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	r.marquet@ibmc.u-strasbg.fr	Paillart, Jean-Christophe/A-4171-2010	Paillart, Jean-Christophe/0000-0003-1647-8917; Marquet, Roland/0000-0002-4209-3976				AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beerens N, 2000, J BIOL CHEM, V275, P15474, DOI 10.1074/jbc.275.20.15474; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Beerens N, 2000, J VIROL, V74, P2227, DOI 10.1128/JVI.74.5.2227-2238.2000; Benas P, 2000, RNA, V6, P1347, DOI 10.1017/S1355838200000911; Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Dupuy LC, 2003, J VIROL, V77, P8756, DOI 10.1128/JVI.77.16.8756-8764.2003; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Fosse P, 1998, J MOL BIOL, V275, P731, DOI 10.1006/jmbi.1997.1487; Freund F, 2001, NUCLEIC ACIDS RES, V29, P2757, DOI 10.1093/nar/29.13.2757; Gabor J, 2002, J VIROL, V76, P9096, DOI 10.1128/JVI.76.18.9096-9102.2002; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Goldschmidt V, 2003, NUCLEIC ACIDS RES, V31, P850, DOI 10.1093/nar/gkg187; Goldschmidt V, 2002, J BIOL CHEM, V277, P43233, DOI 10.1074/jbc.M205295200; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; Iwatani Y, 2003, J BIOL CHEM, V278, P14185, DOI 10.1074/jbc.M211618200; Kang SM, 1999, VIROLOGY, V257, P95, DOI 10.1006/viro.1999.9615; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; Kuiken C, 2000, HUMAN RETROVIRUSES A; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Le Grice SFJ, 2003, BIOCHEMISTRY-US, V42, P14349, DOI 10.1021/bi030201q; Li Y, 1997, J VIROL, V71, P6315, DOI 10.1128/JVI.71.9.6315-6322.1997; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; Miller JT, 2001, J BIOL CHEM, V276, P27721, DOI 10.1074/jbc.M100513200; MOOG C, 1994, ANTIVIR RES, V24, P275, DOI 10.1016/0166-3542(94)90075-2; Morris S, 2002, J VIROL, V76, P7571, DOI 10.1128/JVI.76.15.7571-7577.2002; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; Rigourd M, 2003, NUCLEIC ACIDS RES, V31, P5764, DOI 10.1093/nar/gkg754; VICENZI E, 1994, J VIROL, V68, P7879, DOI 10.1128/JVI.68.12.7879-7890.1994; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Zhang ZJ, 1998, RNA, V4, P394; Zhang ZJ, 1996, VIROLOGY, V226, P306, DOI 10.1006/viro.1996.0658; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	49	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35923	35931		10.1074/jbc.M404473200	http://dx.doi.org/10.1074/jbc.M404473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194685	hybrid			2022-12-27	WOS:000223303400093
J	Marz, P; Probst, A; Lang, S; Schwager, M; Rose-John, S; Otten, U; Ozbek, S				Marz, P; Probst, A; Lang, S; Schwager, M; Rose-John, S; Otten, U; Ozbek, S			Ataxin-10, the spinocerebellar ataxia type 10 neurodegenerative disorder protein, is essential for survival of cerebellar neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLINICAL-FEATURES; REPEAT EXPANSION; ATTCT REPEAT; PATHOGENESIS; FRATAXIN; REGION	Spinocerebellar ataxia (SCA) type 10, an autosomal dominant disease characterized by cerebellar ataxia, is caused by a novel pentanucleotide (ATTCT) repeat expansion in the SCA10 gene. Although clinical features of the disease are well characterized, nothing is known so far about the affected SCA10 gene product, ataxin-10 (Atx-10). We have cloned the rat SCA10 gene and expressed the corresponding protein in HEK293 cells. Atx-10 has an apparent molecular mass of similar to55 kDa and belongs to the family of armadillo repeat proteins. In solution, it tends to form homotrimeric complexes, which associate via a tip-to-tip contact with the concave sides of the molecules facing each other. Atx-10 immunostaining of mouse and human brain sections revealed a predominantly cytoplasmic and perinuclear localization with a clear restriction to olivocerebellar regions. Knock down of SCA10 in primary neuronal cells by small interfering RNAs resulted in an increased apoptosis of cerebellar neurons, arguing for a loss-of-function phenotype in SCA10 patients.	Univ Basel, Inst Physiol, CH-4051 Basel, Switzerland; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	University of Basel; University of Basel; University of Kiel; University of Basel	Marz, P (corresponding author), Univ Basel, Inst Physiol, Vesalgasse 1, CH-4051 Basel, Switzerland.	p.maerz@unibas.ch	Özbek, Suat/D-3701-2014; Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279; Ozbek, Suat/0000-0003-2569-3942				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; HARDING AE, 1981, J MED GENET, V18, P436, DOI 10.1136/jmg.18.6.436; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JUCKER M, 1994, NEUROSCIENCE, V60, P875, DOI 10.1016/0306-4522(94)90269-0; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Lin X, 2003, CYTOGENET GENOME RES, V100, P184, DOI 10.1159/000072853; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Marz P, 1999, GLIA, V26, P191, DOI 10.1002/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#; Matsuura T, 2000, NAT GENET, V26, P191, DOI 10.1038/79911; Matsuura T, 2004, AM J HUM GENET, V74, P1216, DOI 10.1086/421526; Paulson H, 2002, LANCET NEUROL, V1, P471, DOI 10.1016/S1474-4422(02)00234-X; Ranum LPW, 2002, CURR OPIN GENET DEV, V12, P266, DOI 10.1016/S0959-437X(02)00297-6; Rasmussen A, 2001, ANN NEUROL, V50, P234, DOI 10.1002/ana.1081; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Scheel H, 2003, HUM MOL GENET, V12, P2845, DOI 10.1093/hmg/ddg297; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Tapscott SJ, 2000, SCIENCE, V289, P1701, DOI 10.1126/science.289.5485.1701; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zoghbi HY, 2000, NEUROBIOL DIS, V7, P523, DOI 10.1006/nbdi.2000.0346	26	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35542	35550		10.1074/jbc.M405865200	http://dx.doi.org/10.1074/jbc.M405865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201271	hybrid			2022-12-27	WOS:000223303400049
J	Singh, A; Rosenthal, PJ				Singh, A; Rosenthal, PJ			Selection of cysteine protease inhibitor-resistant malaria parasites is accompanied by amplification of falcipain genes and alteration in inhibitor transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; HALOFANTRINE RESISTANCE; CHLOROQUINE RESISTANCE; DRUG-RESISTANCE; PROTEINASE; MEFLOQUINE; MUTATIONS; ANTIMALARIALS; EXPRESSION; INDUCTION	Cysteine protease inhibitors are being studied as possible new antimalarial agents. To evaluate the potential for resistance to these compounds, we subjected chloroquine-resistant (W2 strain) Plasmodium falciparum to increasing concentrations of a vinyl sulfone cysteine protease inhibitor. After incubation with 1-200 nM morpholine urea-leucine-homophenylalanine-phenyl vinyl sulfone over approximately 8 months, highly resistant parasites (similar to100-fold increases in IC50) were selected. The vinyl sulfone-resistant parasites were also resistant to related peptidyl inhibitors, but had only modest (similar to2-fold) decreases in sensitivity to other cysteine protease inhibitors. Compared with the parental strain, resistant parasites showed no changes in multiplication rates, but elevations in cysteine protease activity, falcipain-2 and falcipain-3 copy numbers, transcription of falcipain genes, and levels of these target proteases in trophozoites. Resistant parasites grown in the absence of the vinyl sulfone for 12 weeks showed partial reversion, with increased inhibitor sensitivity and apparent decreases in copy numbers of falcipain-2 and falcipain-3. The sequences of falcipain-1, falcipain-2, and falcipain-3 were identical in sensitive and resistant parasites. The accumulation of a vinyl sulfone inhibitor was decreased approximately 9-fold in resistant parasites. In summary, parasites resistant to a cysteine protease inhibitor were selected, although the acquisition of high level resistance required extended exposure to the inhibitor and this resistance was somewhat unstable. Resistance was specific for the type of protease inhibitor used for the selection and appeared to be mediated both by alterations in inhibitor transport and by a previously unidentified mechanism in P. falciparum, the amplification of genes encoding targets of enzyme inhibitors.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Rosenthal, PJ (corresponding author), Univ Calif San Francisco, Box 0811, San Francisco, CA 94143 USA.	rosnthl@itsa.ucsf.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035800, R29AI035800, R01AI035800] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01081] Funding Source: Medline; NIAID NIH HHS [AI35800] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; BANYAL HS, 1986, EXP PARASITOL, V62, P61, DOI 10.1016/0014-4894(86)90008-1; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; ODUOLA AMJ, 1988, EXP PARASITOL, V67, P354, DOI 10.1016/0014-4894(88)90082-3; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; PEEL SA, 1994, AM J TROP MED HYG, V51, P648, DOI 10.4269/ajtmh.1994.51.648; Pickard AL, 2003, ANTIMICROB AGENTS CH, V47, P2418, DOI 10.1128/AAC.47.8.2418-2423.2003; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; Rosenthal PJ, 2001, INFEC DIS S, P325; Rosenthal PJ, 2002, CURR PHARM DESIGN, V8, P1659, DOI 10.2174/1381612023394197; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Singh A, 2002, BIOCHEM J, V368, P273, DOI 10.1042/BJ20020753; Singh A, 2001, ANTIMICROB AGENTS CH, V45, P949, DOI 10.1128/AAC.45.3.949-951.2001; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; WILSON CM, 1993, MOL BIOCHEM PARASIT, V57, P151, DOI 10.1016/0166-6851(93)90252-S; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6	36	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35236	35241		10.1074/jbc.M404235200	http://dx.doi.org/10.1074/jbc.M404235200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192087	hybrid			2022-12-27	WOS:000223303400014
J	Albinsson, S; Nordstrom, I; Hellstrand, P				Albinsson, S; Nordstrom, I; Hellstrand, P			Stretch of the vascular wall induces smooth muscle differentiation by promoting actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; TERNARY COMPLEX FACTORS; RAT PORTAL-VEIN; GENE-EXPRESSION; PROTEIN-KINASE; INTRALUMINAL PRESSURE; MOLECULAR-MECHANISMS; ORGAN-CULTURE; LIM-KINASE; ACTIVATION	Stretch of the vascular wall by the intraluminal blood pressure stimulates protein synthesis and contributes to the maintenance of the smooth muscle contractile phenotype. The expression of most smooth muscle specific genes has been shown to be regulated by serum response factor and stimulated by increased actin polymerization. Hence we hypothesized that stretch-induced differentiation is promoted by actin polymerization. Intact mouse portal veins were cultured under longitudinal stress and compared with unstretched controls. In unstretched veins the rates of synthesis of several proteins associated with the contractile/cytoskeletal system (alpha-actin, calponin, SM22alpha, tropomyosin, and desmin) were dramatically lower than in stretched veins, whereas other proteins (beta-actin and heat shock proteins) were synthesized at similar rates. The cytoskeletal proteins beta-actin and vimentin were weakly stretch-sensitive. Inhibition of Rho-associated kinase by culture of stretched veins with Y-27632 produced similar but weaker effects compared with the absence of mechanical stress. Induction of actin polymerization by jasplakinolide increased SM22alpha synthesis in unstretched veins to the level in stretched veins. Stretch stimulated Rho activity and phosphorylation of the actin-severing protein cofilin-2, although both effects were slow in onset (Rho-GTP, > 15 min; cofilin-P, > 1 h). Cofilin-2 phosphorylation of stretched veins was inhibited by Y-27632. The F/G-actin ratio after 24 h of culture was significantly greater in stretched than in unstretched veins, as shown by both ultracentrifugation and confocal imaging with phalloidin/DNase I labeling. The results show that stretch of the vascular wall stimulates increased actin polymerization, activating synthesis of smooth muscle-specific proteins. The effect is partially, but probably not completely, mediated via Rho-associated kinase and cofilin downstream of Rho.	Lund Univ, Div Mol & Cellular Physiol, Dept Physiol Sci, Ctr Biomed, SE-22184 Lund, Sweden	Lund University	Hellstrand, P (corresponding author), BMC F12, SE-22184 Lund, Sweden.	Per.Hellstrand@mphy.lu	Albinsson, Sebastian/B-4105-2010	Albinsson, Sebastian/0000-0001-6936-3967				ADAM LP, 1995, CIRC RES, V76, P183, DOI 10.1161/01.RES.76.2.183; Birukov KG, 1997, CIRC RES, V81, P895; Birukov KG, 1998, ARTERIOSCL THROM VAS, V18, P922, DOI 10.1161/01.ATV.18.6.922; Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Cipolla MJ, 2002, FASEB J, V16, P72, DOI 10.1096/cj.01-0104hyp; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Halayko AJ, 2001, J APPL PHYSIOL, V90, P358, DOI 10.1152/jappl.2001.90.1.358; Jakkaraju S, 2003, TRENDS CARDIOVAS MED, V13, P330, DOI 10.1016/j.tcm.2003.08.004; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; KNOWLES GC, 1992, J HISTOCHEM CYTOCHEM, V40, P1605, DOI 10.1177/40.10.1527379; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Lehoux S, 2003, J BIOMECH, V36, P631, DOI 10.1016/S0021-9290(02)00441-4; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MALMQVIST U, 1990, CIRC RES, V66, P832, DOI 10.1161/01.RES.66.3.832; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Numaguchi K, 1999, CIRC RES, V85, P5; OWENS GK, 1995, PHYSIOL REV, V75, P487; Putnam AJ, 2003, AM J PHYSIOL-CELL PH, V284, pC627, DOI 10.1152/ajpcell.00137.2002; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Seasholtz TM, 2001, CIRC RES, V89, P488, DOI 10.1161/hh1801.096337; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vartiainen MK, 2002, MOL BIOL CELL, V13, P183, DOI 10.1091/mbc.01-07-0331; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang L, 2004, AM J RESP CELL MOL, V31, P54, DOI 10.1165/rcmb.2003-0240OC; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zeidan A, 2000, CIRC RES, V87, P228, DOI 10.1161/01.RES.87.3.228; Zeidan A, 2004, FEBS LETT, V562, P141, DOI 10.1016/S0014-5793(04)00220-0; Zeidan A, 2003, ARTERIOSCL THROM VAS, V23, P1528, DOI 10.1161/01.ATV.0000090129.75275.C2; Zeidan A, 2003, AM J PHYSIOL-CELL PH, V284, pC1387, DOI 10.1152/ajpcell.00508.2002; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	43	124	127	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34849	34855		10.1074/jbc.M403370200	http://dx.doi.org/10.1074/jbc.M403370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184395	hybrid			2022-12-27	WOS:000223134800094
J	Argast, GM; Campbell, JS; Brooling, JT; Fausto, N				Argast, GM; Campbell, JS; Brooling, JT; Fausto, N			Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FACTOR-ALPHA; EGF RECEPTOR; TRANSFORMING GROWTH; LIVER-REGENERATION; EPITHELIAL-CELLS; DNA-REPLICATION; TGF-ALPHA; MICE; PROLIFERATION	Tumor necrosis factor (TNF) has multiple biological effects such as participating in inflammation, apoptosis, and cell proliferation, but the mechanisms of its effects on epithelial cell proliferation have not been examined in detail. At the early stages of liver regeneration, TNF functions as a priming agent for hepatocyte replication and increases the sensitivity of hepatocytes to growth factors such as transforming growth factor alpha (TGFalpha); however, the mechanisms by which TNF interacts with growth factors and enhances hepatocyte replication are not known. Using the AML-12 hepatocyte cell line, we show that TNF stimulates proliferation of these cells through transactivation of the epidermal growth factor receptor ( EGFR). The transactivation mechanism involves the release of TGFalpha into the medium through activation of the metalloproteinase TNFalpha-converting enzyme ( also known as ADAM 17). Binding of the ligand to EGFR initiates a mitogenic cascade through extracellular signal-regulated kinases 1 and 2 and the partial involvement of protein kinase B. TNF-induced release of TGFalpha and activation of EGFR signaling were inhibited by TNFalpha protease inhibitor-1, an agent that interferes with TNFalpha-converting enzyme activity. We suggest that TNF-induced transactivation of EGFR may provide an early signal for the entry of hepatocytes into the cell cycle and may integrate proliferative and survival pathways at the start of liver regeneration.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Boulder	Fausto, N (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.	nfausto@u.washington.edu		Campbell, Jean/0000-0002-9187-2204	NCI NIH HHS [CA 23226] Funding Source: Medline; NIEHS NIH HHS [T32 ES 07032-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA023226, R37CA023226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blindenbacher A, 2003, HEPATOLOGY, V38, P674, DOI 10.1053/jhep.2003.50378; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Chen WNU, 2004, J BIOL CHEM, V279, P18488, DOI 10.1074/jbc.M310874200; Chiu H, 2003, TOXICOL APPL PHARM, V193, P218, DOI 10.1016/j.taap.2003.07.003; Chobotova K, 2002, J CLIN ENDOCR METAB, V87, P5769, DOI 10.1210/jc.2002-020069; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Doedens JR, 2003, BIOCHEM BIOPH RES CO, V308, P331, DOI 10.1016/S0006-291X(03)01381-0; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Gallucci RM, 2000, J IMMUNOL, V164, P872, DOI 10.4049/jimmunol.164.2.872; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Kalmes A, 2001, ANN NY ACAD SCI, V947, P42; Kheradmand F, 2002, J CELL SCI, V115, P839; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Kirillova I, 1999, CELL GROWTH DIFFER, V10, P819; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; SEGER R, 1994, J BIOL CHEM, V269, P25699; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wallenius V, 2001, ENDOCRINOLOGY, V142, P2953, DOI 10.1210/en.142.7.2953; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Xiao ZQ, 2001, AM J PHYSIOL-GASTR L, V281, pG111, DOI 10.1152/ajpgi.2001.281.1.G111; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200	39	88	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34530	34536		10.1074/jbc.M405703200	http://dx.doi.org/10.1074/jbc.M405703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15199050	hybrid			2022-12-27	WOS:000223134800056
J	Nadeau, KJ; Leitner, JW; Gurerich, I; Draznin, B				Nadeau, KJ; Leitner, JW; Gurerich, I; Draznin, B			Insulin regulation of sterol regulatory element-binding protein-1 expression in L-6 muscle cells and 3T3 L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; GENE-EXPRESSION; SKELETAL-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; DIABETES-MELLITUS; GLUCOSE-TRANSPORT; RECEPTOR SUBSTRATE-1; ADIPOSE-TISSUE; FATTY RATS; KINASE	Sterol regulatory element-binding proteins (SREBPs) are transcription factors that regulate enzymes required for cholesterol and fatty acid synthesis. Expression of SREBP-1 is enhanced by insulin; however, the actual insulin-signaling cascades employed are yet unclear. We determined the roles of the phosphatidylinositol (PI) 3-kinase and mitogen-activated protein (MAP) kinase-dependent pathways in the effect of mediating insulin on SREBP-1 in L-6 skeletal muscle cells and 3T3 L1 adipocytes, using wortmannin or LY294002 to inhibit the PI 3-kinase pathway, and PD98059 to inhibit the MAP kinase-dependent pathway. In myocytes, insulin increased SREBP-1 protein in a dose-dependent manner. 1 and 10 nM insulin significantly increased expression of total cellular SREBP-1 protein at 24 and 48 h, nuclear SREBP-1 protein at 24 h, and SREBP-1a mRNA at 24 h. Although wortmannin and LY294002 had no effect on this aspect of insulin action, PD98059 completely blocked each of these responses. Transfection of a dominant negative mutant of Ras similarly blocked the insulin effect on SREBP-1. In contrast, in adipocytes, the insulin effect on SREBP-1 was mediated via the PI 3-kinase and not the MAP kinase pathway. In conclusion, although insulin increases skeletal muscle SREBP-1 expression in a dose-dependent fashion via the MAP kinase-dependent signaling pathway, insulin action on adipocyte SREBP-1 is mediated via the PI 3-kinase signaling pathway. In the state of insulin resistance, characterized by selective inhibition of the PI 3-kinase pathway, the usual stimulation of lipogenesis by insulin in adipocytes may be inhibited, whereas intramyocellular lipogenesis via the MAP kinase pathway of insulin may continue unabated.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol Metab & Diabet, Denver, CO 80262 USA; Denver VA Med Ctr, Vet Affairs Res Serv, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Nadeau, KJ (corresponding author), Pediat Endocrinol Box 256,1056 E 19th Ave, Denver, CO 80218 USA.	kristen.nadeau@UCHSC.edu						Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; Bajaj M, 2003, DIABETES, V52, P1364, DOI 10.2337/diabetes.52.6.1364; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Guillet-Deniau I, 2002, DIABETES, V51, P1722, DOI 10.2337/diabetes.51.6.1722; Gunton JE, 2003, J CLIN ENDOCR METAB, V88, P1323, DOI 10.1210/jc.2002-021394; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim SJ, 1997, BIOCHEM J, V323, P621, DOI 10.1042/bj3230621; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kim YB, 2002, DIABETES, V51, P443, DOI 10.2337/diabetes.51.2.443; Kotzka J, 2000, J LIPID RES, V41, P99; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Kuhlmann J, 2003, DIABETES, V52, P138, DOI 10.2337/diabetes.52.1.138; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Montagnani M, 2002, J BIOL CHEM, V277, P1794, DOI 10.1074/jbc.M103728200; OBERKOFLER H, 2002, BIOCHIM BIOPHYS ACTA, V3, P19353; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; Sewter C, 2002, DIABETES, V51, P1035, DOI 10.2337/diabetes.51.4.1035; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598	40	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34380	34387		10.1074/jbc.M403596200	http://dx.doi.org/10.1074/jbc.M403596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187085	hybrid			2022-12-27	WOS:000223134800038
J	Oorni, K; Sneck, M; Bromme, D; Pentikainen, MO; Lindstedt, KA; Mayranpaa, M; Aitio, H; Kovanen, PT				Oorni, K; Sneck, M; Bromme, D; Pentikainen, MO; Lindstedt, KA; Mayranpaa, M; Aitio, H; Kovanen, PT			Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-RETENTION HYPOTHESIS; APO-B LIPOPROTEINS; ARTERIAL PROTEOGLYCANS; FUNCTIONAL EXPRESSION; CHOLESTEROL ESTERIFICATION; PHOSPHOLIPASE A(2); APOLIPOPROTEIN-B; FUSION; LDL; GLYCOSAMINOGLYCANS	During atherogenesis, low density lipoprotein (LDL) particles in the arterial intima become modified and fuse to form extracellular lipid droplets. Proteolytic modification of apolipoprotein (apo) B-100 may be one mechanism of droplet formation from LDL. Here we studied whether the newly described acid protease cathepsin F can generate LDL-derived lipid droplets in vitro. Treatment of LDL particles with human recombinant cathepsin F led to extensive degradation of apoB-100, which, as determined by rate zonal flotation, electron microscopy, and NMR spectroscopy, triggered both aggregation and fusion of the LDL particles. Two other acid cysteine proteases, cathepsins S and K, which have been shown to be present in the arterial intima, were also capable of degrading apoB-100, albeit less efficiently. Cathepsin F treatment resulted also in enhanced retention of LDL to human arterial proteoglycans in vitro. Cultured monocyte-derived macrophages were found to secrete active cathepsin F. In addition, similarly with cathepsins S and K, cathepsin F was found to be localized mainly within the macrophage-rich areas of the human coronary atherosclerotic plaques. These results suggest that proteolytic modification of LDL by cathepsin F may be one mechanism leading to the extracellular accumulation of LDL-derived lipid droplets within the proteoglycan-rich extracellular matrix of the arterial intima during atherogenesis.	Wihuri Res Inst, FIN-00140 Helsinki, Finland; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Univ Helsinki, Natl Biol NMR Lab Finland, FIN-00014 Helsinki, Finland	Wihuri Research Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Helsinki	Oorni, K (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, FIN-00140 Helsinki, Finland.	kati.oorni@wri.fi	Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250; Mayranpaa, Mikko/0000-0002-0877-9640	NIAMS NIH HHS [AR 46182, AR 48669] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046182, R01AR048669] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ala-Korpela M, 1998, J LIPID RES, V39, P1705; Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; Almeida PC, 1999, J BIOL CHEM, V274, P30433, DOI 10.1074/jbc.274.43.30433; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BROMME D, 1993, J BIOL CHEM, V268, P4832; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; CAMEJO G, 1991, BIOCHIM BIOPHYS ACTA, V1096, P253, DOI 10.1016/0925-4439(91)90013-Y; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; CLEVIDENCE BA, 1984, ARTERIOSCLEROSIS, V4, P196, DOI 10.1161/01.ATV.4.3.196; De Vries HE, 1998, FASEB J, V12, P111, DOI 10.1096/fasebj.12.1.111; Forte T, 1972, Adv Lipid Res, V10, P1; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; Hakala JK, 2001, ARTERIOSCL THROM VAS, V21, P1053, DOI 10.1161/01.ATV.21.6.1053; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; Hurt-Camejo E, 2001, CIRC RES, V89, P298, DOI 10.1161/hh1601.095598; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; Jormsjo S, 2002, AM J PATHOL, V161, P939, DOI 10.1016/S0002-9440(10)64254-X; KOVANEN PT, 1991, J BIOL CHEM, V266, P4430; Kruth H S, 1997, Subcell Biochem, V28, P319; KRUTH HS, 1994, ATHEROSCLEROSIS, V105, P227, DOI 10.1016/0021-9150(94)90053-1; Leake DS, 1997, ATHEROSCLEROSIS, V129, P149, DOI 10.1016/S0021-9150(96)06035-2; Levin M, 2003, ARTERIOSCL THROM VAS, V23, P1801, DOI 10.1161/01.ATV.0000092872.54026.8D; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAROUDAS A, 1988, BIOPHYS CHEM, V32, P257, DOI 10.1016/0301-4622(88)87012-1; Naghavi M, 2002, ATHEROSCLEROSIS, V164, P27, DOI 10.1016/S0021-9150(02)00018-7; Oorni K, 2000, J LIPID RES, V41, P1703; Oorni K, 1997, J BIOL CHEM, V272, P21303, DOI 10.1074/jbc.272.34.21303; PAANANEN K, 1994, J BIOL CHEM, V269, P2023; PAANANEN K, 1995, J BIOL CHEM, V270, P12257, DOI 10.1074/jbc.270.20.12257; PASQUINELLI G, 1989, SCANNING MICROSCOPY, V3, P1151; Pentikainen MO, 1997, J BIOL CHEM, V272, P25283, DOI 10.1074/jbc.272.40.25283; Pentikainen MO, 1996, J LIPID RES, V37, P2638; Pentikainen MO, 2001, J LIPID RES, V42, P916; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; POLACEK D, 1988, J LIPID RES, V29, P797; PRICE CA, 1982, CENTRIFUGATION DENSI, P18; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Saren P, 1996, J IMMUNOL, V157, P4159; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; TAILLEUX A, 1993, J LIPID RES, V34, P719; TIRZIU D, 1995, ATHEROSCLEROSIS, V112, P101, DOI 10.1016/0021-9150(94)05405-8; TURIK B, 2000, BIOCH BIOPYYS ACTA, V1477, P98; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, P421; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	69	82	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34776	34784		10.1074/jbc.M310814200	http://dx.doi.org/10.1074/jbc.M310814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184381	hybrid			2022-12-27	WOS:000223134800085
J	Qiu, ZH; Hyman, BT; Rebeck, GW				Qiu, ZH; Hyman, BT; Rebeck, GW			Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PEPTIDE; METHYL-D-ASPARTATE; GROWTH CONE MOTILITY; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; ALZHEIMERS-DISEASE; SIGNALING PATHWAY; CALCIUM RESPONSES; ALPHA(2)-MACROGLOBULIN; CREB	Several ligands of the endocytic low density lipoprotein receptor-related protein (LRP), such as apoE-containing lipoproteins and activated alpha2-macroglobulin (alpha2M*), promote neurite outgrowth, suggesting that LRP may have signaling functions. In this study, we found that the treatment of neurons with alpha2M* significantly increased the individual length (by 71%) and numbers (by 139%) of neurites of primary mouse cortical neurons. These effects were blocked by the LRP antagonist, the receptor-associated protein. We found similar neurite outgrowth with purified apoE3 and a tandem apoE peptide containing only the receptor-binding domain. To investigate the intracellular pathway of the LRP signaling involved in neurite outgrowth, we tested the effects of alpha2M* on the phosphorylation of the mitogen-activated protein (MAP) extracellular signal-regulated kinases 1 and 2 (ERK1/2). We found that 1) phospho-MAP kinase levels were altered within 30 min after treatment with alpha2M*, 2) the MAP kinase inhibitor, PD98059, specifically blocked the alpha2M*-induced neurite outgrowth, 3) manipulating intracellular calcium by BayK or BAPTA altered the neurite outgrowth and associated changes in the phospho-MAP kinase levels, which were blunted by alpha2M*, 4) alpha2M* promoted the phosphorylation of the transcription factor CREB through MAP kinase, and 5) LRP-specific antibodies increased levels of phosphorylated MAP kinase and phosphorylated CREB. The effects of alpha2M*, apoE3, and apoE peptides increased LRP levels in the cortical neurons, whereas LRP receptor-associated protein reduced dendritic LRP expression. These results demonstrate that p44/42 MAP kinase plays an important role in LRP-mediated neurite outgrowth with activation involving the effects on calcium homeostasis and downstream effects involving the activation of gene transcription through CREB.	Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA	Georgetown University; Harvard University; Massachusetts General Hospital	Rebeck, GW (corresponding author), Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA.	gwr2@georgetown.edu	Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X	NIA NIH HHS [R37 AG 12406, R01 AG 14773] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG012406] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; BERRIDGE MJ, 1979, J EXP BIOL, V81, P217; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; Doherty P, 2000, MOL CELL NEUROSCI, V16, P283, DOI 10.1006/mcne.2000.0907; Du YS, 1998, J NEUROCHEM, V70, P1182; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; GOMEZ TM, 1995, NEURON, V14, P1233, DOI 10.1016/0896-6273(95)90270-8; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Kater S. B., 1995, Current Opinion in Neurobiology, V5, P68, DOI 10.1016/0959-4388(95)80089-1; KATER SB, 1991, J NEUROSCI, V11, P891; Kim SN, 2000, J CELL BIOCHEM, V76, P386, DOI 10.1002/(SICI)1097-4644(20000301)76:3<386::AID-JCB6>3.0.CO;2-9; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Kolkova K, 2000, J NEUROSCI, V20, P2238; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Larsen JO, 1998, J NEUROSCI METH, V85, P107, DOI 10.1016/S0165-0270(98)00129-0; Lautermilch NJ, 2000, J NEUROSCI, V20, P315, DOI 10.1523/JNEUROSCI.20-01-00315.2000; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; MATTSON MP, 1988, NEURON, V1, P865, DOI 10.1016/0896-6273(88)90134-1; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Narita M, 1997, J NEUROCHEM, V68, P587; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Narita M, 1997, J NEUROCHEM, V69, P1904; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; Postuma RB, 1998, FEBS LETT, V428, P13, DOI 10.1016/S0014-5793(98)00475-X; Przewlocki R, 1999, J NEUROSCI, V19, P9705; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; Qiu ZH, 2003, J NEUROIMMUNOL, V139, P51, DOI 10.1016/S0165-5728(03)00158-9; Qiu ZH, 2001, J NEUROPATH EXP NEUR, V60, P430, DOI 10.1093/jnen/60.5.430; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; Schmid RS, 2000, J NEUROSCI, V20, P4177; SOLEM M, 1995, J NEUROSCI, V15, P5966; Spitzer NC, 1997, SCIENCE, V277, P1060, DOI 10.1126/science.277.5329.1060; Stadheim TA, 1998, BIOCHEM BIOPH RES CO, V245, P266, DOI 10.1006/bbrc.1998.8410; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; Thal DR, 1997, BRAIN RES, V777, P223, DOI 10.1016/S0006-8993(97)01021-4; Tolar M, 1997, J NEUROSCI, V17, P5678; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Veinbergs I, 2001, EXP NEUROL, V170, P15, DOI 10.1006/exnr.2001.7684; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; Williams KR, 1998, NEUROBIOL DIS, V5, P271, DOI 10.1006/nbdi.1998.0198; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Zhao LX, 2003, J NEUROSCI, V23, P4228	64	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34948	34956		10.1074/jbc.M401055200	http://dx.doi.org/10.1074/jbc.M401055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15169786	hybrid			2022-12-27	WOS:000223134800106
J	Shi, H; Tzameli, I; Bjorbaek, C; Flier, JS				Shi, H; Tzameli, I; Bjorbaek, C; Flier, JS			Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SOCS-BOX MOTIF; RECEPTOR SUBSTRATE-1; ADIPOSE-TISSUE; MICE LACKING; OBESITY; RESISTANCE; GROWTH; DEGRADATION; PHOSPHORYLATION	Many proinflammatory cytokines and hormones have been demonstrated to be involved in insulin resistance. However, the molecular mechanisms whereby these cytokines and hormones inhibit insulin signaling are not completely understood. We observed that several cytokines and hormones that induce insulin resistance also stimulate SOCS3 expression in 3T3-L1 adipocytes and that SOCS3 mRNA is increased in adipose tissue of obese/diabetic mice. We then hypothesized that SOCS3 may mediate cytokine- and hormone-induced insulin resistance. By using SOCS3-deficient adipocytes differentiated from mouse embryonic fibroblasts, we found that SOCS3 deficiency increases insulin-stimulated IRS1 and IRS2 phosphorylation, IRS-associated phosphatidylinositol 3-kinase activity, and insulin-stimulated glucose uptake. Moreover, lack of SOCS3 substantially limits the inhibitory effects of tumor necrosis factor-alpha to suppress IRS1 and IRS2 tyrosine phosphorylation, phosphatidylinositol 3-kinase activity, and glucose uptake in adipocytes. The ameliorated insulin signaling in SOCS3-deficient adipocytes is mainly due to the suppression of tumor necrosis factor-alpha-induced IRS1 and IRS2 protein degradation. Therefore, our data suggest that endogenous SOCS3 expression is a key determinant of basal insulin signaling and is an important molecular mediator of cytokine- induced insulin resistance in adipocytes. We conclude that SOCS3 plays an important role in mediating insulin resistance and may be an excellent target for therapeutic intervention in insulin resistance and type II diabetes.	Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Flier, JS (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol, 330 Brookline Ave,Finard 202, Boston, MA 02215 USA.	jflier@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019; Bjorbaek, Christian/S-4727-2019					Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Chen XL, 2001, BIOCHEM BIOPH RES CO, V283, P933, DOI 10.1006/bbrc.2001.4882; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Krebs DL, 2000, J CELL SCI, V113, P2813; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Peraldi P, 2001, J BIOL CHEM, V276, P24614, DOI 10.1074/jbc.M102209200; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Shi H, 2002, FASEB J, V16, P1808, DOI 10.1096/fj.02-0255fje; Shiba T, 1998, DIABETIC MED, V15, P435, DOI 10.1002/(SICI)1096-9136(199805)15:5<435::AID-DIA566>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Takano A, 2001, DIABETES, V50, P1891, DOI 10.2337/diabetes.50.8.1891; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wang ZW, 2000, BIOCHEM BIOPH RES CO, V277, P20, DOI 10.1006/bbrc.2000.3615; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YAMAKAWA T, 1995, CLIN IMMUNOL IMMUNOP, V75, P51, DOI 10.1006/clin.1995.1052; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	39	179	187	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34733	34740		10.1074/jbc.M403886200	http://dx.doi.org/10.1074/jbc.M403886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181014	hybrid			2022-12-27	WOS:000223134800079
J	Clark, KD; Garczynski, SF; Arora, A; Crim, JW; Strand, MR				Clark, KD; Garczynski, SF; Arora, A; Crim, JW; Strand, MR			Specific residues in plasmatocyte-spreading peptide are required for receptor binding and functional antagonism of insect immune cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; IDENTIFIES CRITICAL RESIDUES; BIOLOGICAL-ACTIVITY; FOREIGN TARGETS; MOTH; ENCAPSULATION; HEMOCYTES; HEMOLYMPH; CYTOKINE	Plasmatocyte-spreading peptide (PSP) is a 23-amino acid cytokine that activates a class of insect immune cells called plasmatocytes. PSP consists of two regions: an unstructured N terminus (1-6) and a highly structured core (7-23). Prior studies identified specific residues in both the structured and unstructured regions required for biological activity. Most important for function were Arg(13), Phe(3), Cys(7), Cys(19), and the N-terminal amine of Glu(1). Here we have built on these results by conducting cell binding and functional antagonism studies. Alanine replacement of Met(12) (M12A) resulted in a peptide with biological activity indistinguishable from PSP. Competitive binding experiments using unlabeled and I-125-M12A generated an IC50 of 0.71 nM and indicated that unlabeled M12A, at concentrations greater than or equal to100 nM, completely blocked binding of label to hemocytes. We then tested the ability of other peptide mutants to displace I-125-M12A at a concentration of 100 nM. In the structured core, we found that Cys(7) and Cys(19) were essential for cell binding and functional antagonism, but these effects were likely because of the importance of these residues for maintaining the tertiary structure of PSP. Arg(13), in contrast, was also essential for binding and activity but is not required for maintenance of structure. In the unstructured N-terminal region, deletion of the phenyl group from Phe(3) yielded a peptide that reduced binding of I-125-M12A 326-fold. This and all other mutants of Phe(3) we bioassayed were unable to antagonize PSP. Deletion of Glu1 in contrast had almost no effect on binding and was a strong functional antagonist. Experiments using a photoaffinity analog indicated that PSP binds to a single 190-kDa protein.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Wisconsin System; University of Wisconsin Madison	Strand, MR (corresponding author), Univ Georgia, Dept Entomol, Athens, GA 30602 USA.	mrstrand@bugs.ent.uga.edu	Clark, Kevin/GQA-9811-2022; Crim, Joe/GWC-6878-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032917] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Breslav M, 1997, TETRAHEDRON LETT, V38, P2219, DOI 10.1016/S0040-4039(97)00328-6; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 1998, BIOCHEM BIOPH RES CO, V250, P479, DOI 10.1006/bbrc.1998.9145; Clark KD, 2001, J BIOL CHEM, V276, P37431, DOI 10.1074/jbc.M105235200; Clark KD, 2001, J BIOL CHEM, V276, P18491, DOI 10.1074/jbc.M100579200; Crim JW, 2002, PEPTIDES, V23, P2045, DOI 10.1016/S0196-9781(02)00192-4; Gardiner EMM, 1999, J INSECT PHYSIOL, V45, P113, DOI 10.1016/S0022-1910(98)00092-4; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hrabal R, 1996, PROTEIN SCI, V5, P195; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Lavine MD, 2001, J INSECT PHYSIOL, V47, P965, DOI 10.1016/S0022-1910(01)00071-3; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; Pech LL, 1996, J CELL SCI, V109, P2053; PECH LL, 1994, CELL TISSUE RES, V277, P159, DOI 10.1007/BF00303092; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Strand MR, 1999, ARCH INSECT BIOCHEM, V42, P213, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;213::AID-ARCH5&gt;3.0.CO;2-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; STRAND MR, 1990, ANN ENTOMOL SOC AM, V83, P538, DOI 10.1093/aesa/83.3.538; Tada M, 2003, J BIOL CHEM, V278, P10778, DOI 10.1074/jbc.M211251200; Vergnolle N, 2003, TRENDS NEUROSCI, V26, P496, DOI 10.1016/S0166-2236(03)00208-X; Volkman BF, 1999, J BIOL CHEM, V274, P4493, DOI 10.1074/jbc.274.8.4493; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7	26	27	28	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33246	33252		10.1074/jbc.M401157200	http://dx.doi.org/10.1074/jbc.M401157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15192108	hybrid			2022-12-27	WOS:000223039700030
J	Nofer, JR; Herminghaus, G; Brodde, M; Morgenstern, E; Rust, S; Engel, T; Seedorf, U; Assmann, G; Bluethmann, H; Kehrel, BE				Nofer, JR; Herminghaus, G; Brodde, M; Morgenstern, E; Rust, S; Engel, T; Seedorf, U; Assmann, G; Bluethmann, H; Kehrel, BE			Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER 1; CHOLESTEROL EFFLUX; PLASMA-MEMBRANE; GLYCOPROTEIN-VI; PROCOAGULANT ACTIVITY; LIPID-COMPOSITION; THROMBIN-BINDING; APOPTOTIC CELLS; BLOOD PLATELETS; SCOTT-SYNDROME	ATP binding cassette transporter A1 (ABCA1) is involved in regulation of intracellular lipid trafficking and export of cholesterol from cells to high density lipoproteins. ABCA1 defects cause Tangier disease, a disorder characterized by absence of high density lipoprotein and thrombocytopenia. In the present study we have demonstrated that ABCA1 is expressed in human platelets and that fibrinogen binding and CD62 surface expression in response to collagen and low concentrations of thrombin, but not to ADP, are defective in platelets from Tangier patients and ABCA1-deficient animals. The expression of platelet membrane receptors such as GPVI, alpha(2)beta(1) integrin, and GPIIb/IIIa, the collagen-induced changes in phosphatidylserine and cholesterol distribution, and the collagen-induced signal transduction examined by phosphorylation of LAT and p72(syk) and by intracellular Ca2+ mobilization were unaltered in Tangier platelets. The electron microscopy of Tangier platelets revealed reduced numbers of dense bodies and the presence of giant granules typically encountered in platelets from Chediak-Higashi syndrome. Further studies demonstrated impaired release of dense body content in platelets from Tangier patients and ABCA1-deficient animals. In addition, Tangier platelets were characterized by defective surface exposure of dense body and lysosomal markers (CD63, LAMP-1, LAMP-2, CD68) during collagen- and thrombin-induced stimulation and by abnormally high lysosomal pH. We conclude that intact ABCA1 function is necessary for proper maturation of dense bodies in platelets. The impaired release of the content of dense bodies may explain the defective activation of Tangier platelets by collagen and low concentrations of thrombin, but not by ADP.	Univ Munster, Inst Klin Chem & Lab Med, D-48129 Munster, Germany; Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Univ Munster, Klin & Poliklin Anaesthesiol & Operat Intens Med, D-48129 Munster, Germany; Univ Saarland, D-66421 Homburg, Germany; F Hoffmann La Roche, Roche Ctr Med Gen, CH-4070 Basel, Switzerland	University of Munster; University of Munster; University of Munster; Saarland University; Roche Holding	Nofer, JR (corresponding author), Univ Munster, Inst Klin Chem & Lab Med, Albert Schweitzer Str 33, D-48129 Munster, Germany.	nofer@uni-muenster.de		Seedorf, Udo/0000-0003-4652-5358				ARDLIE NG, 1986, THROMB RES, V42, P115, DOI 10.1016/0049-3848(86)90288-4; ASSMAN G, 2000, METABOLIC MOL BASES, P2053; Atkinson BT, 2001, EUR J BIOCHEM, V268, P5242, DOI 10.1046/j.0014-2956.2001.02448.x; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Dachary-Prigent J, 1997, BRIT J HAEMATOL, V99, P959, DOI 10.1046/j.1365-2141.1997.5003302.x; Dean M, 2001, J LIPID RES, V42, P1007; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Dormann D, 2000, BLOOD, V96, P2469, DOI 10.1182/blood.V96.7.2469.h8002469_2469_2478; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARMON JT, 1986, BLOOD, V68, P498; Heijnen HFG, 1998, BLOOD, V91, P2313, DOI 10.1182/blood.V91.7.2313.2313_2313_2325; Hirano K, 2000, FEBS LETT, V484, P275, DOI 10.1016/S0014-5793(00)02171-2; Huizing M, 2001, THROMB HAEMOSTASIS, V86, P233, DOI 10.1055/s-0037-1616221; Kehrel B, 1998, BLOOD, V91, P491; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; LEGRAND C, 1985, THROMB HAEMOSTASIS, V54, P603; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; MCINTYRE JC, 1999, BIOCHEMISTRY-US, V32, P12420; MORGENSTERN E, 1987, EUR J CELL BIOL, V43, P273; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Nofer JR, 1997, J BIOL CHEM, V272, P32861, DOI 10.1074/jbc.272.52.32861; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Oram JF, 2002, TRENDS MOL MED, V8, P168, DOI 10.1016/S1471-4914(02)02289-X; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SHASTRI KM, 1980, J LIPID RES, V21, P467; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; VERGANI CG, 1984, EUR J CLIN INVEST, V14, P49, DOI 10.1111/j.1365-2362.1984.tb00703.x; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Xia Z, 1996, BRIT J HAEMATOL, V93, P204, DOI 10.1046/j.1365-2141.1996.445980.x	40	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34032	34037		10.1074/jbc.M405174200	http://dx.doi.org/10.1074/jbc.M405174200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15163665	hybrid			2022-12-27	WOS:000223039700115
J	Ono, S; Sone, N; Yoshida, M; Suzuki, T				Ono, S; Sone, N; Yoshida, M; Suzuki, T			ATP synthase that lacks F-0 alpha-subunit - Isolation, properties, and indication of F(0)b(2)-subunits as an anchor rail of a rotating c-ring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING PROTON MOVEMENTS; ESCHERICHIA-COLI; CROSS-LINKING; THERMOPHILIC BACTERIUM; EPSILON-SUBUNIT; ROTARY MOTOR; F-0 COMPLEX; ADENOSINE-TRIPHOSPHATASE; MOLECULAR ARCHITECTURE; F1F0-ATP SYNTHASE	In a rotary motor F1F0-ATP synthase, F-0 works as a proton motor; the oligomer ring of F(0)c-subunits (c-ring) rotates relative to the F(0)ab(2) domain as protons pass through F-0 down the gradient. F(0)ab(2) must exert dual functions during rotation, that is, sliding the c-ring ( motor drive) while keeping the association with the c-ring ( anchor rail). Here we have isolated thermophilic F1F0(- a) which lacks F(0)a. F1F0(-a) has no proton transport activity, and F-0(-a) does not work as a proton channel. Interestingly, ATPase activity of F1F0(-a) is greatly suppressed, even though its F-1 sector is intact. Most likely, F(0)b(2) associates with the c-ring as an anchor rail in the intact F1F0; without F(0)a, this association prevents rotation of the c-ring ( and hence the gamma-subunit), which disables ATP hydrolysis at F-1. Functional F1F0 is easily reconstituted from purified F(0)a and F1F0(-a), and thus F(0)a can bind to its proper location on F1F0( - a) without a large rearrangement of other-subunits.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, ERATO, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp						Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aksimentiev A, 2004, BIOPHYS J, V86, P1332, DOI 10.1016/S0006-3495(04)74205-8; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Greie JC, 2000, J BIOENERG BIOMEMBR, V32, P357, DOI 10.1023/A:1005523902800; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; MITOME N, 2004, IN PRESS P NATL ACAD; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OKAMOTO H, 1977, J BIOL CHEM, V252, P6125; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SONE N, 1977, J BIOL CHEM, V252, P2956; Stalz WD, 2003, J BIOL CHEM, V278, P27068, DOI 10.1074/jbc.M302027200; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Suzuki T, 2002, J BIOL CHEM, V277, P13281, DOI 10.1074/jbc.M111210200; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1987, J BIOL CHEM, V262, P8340; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	38	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33409	33412		10.1074/jbc.M404993200	http://dx.doi.org/10.1074/jbc.M404993200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175330	hybrid			2022-12-27	WOS:000223039700048
J	Sordet, O; Liao, ZY; Liu, H; Antony, S; Stevens, EV; Kohlhagen, G; Fu, HQ; Pommier, Y				Sordet, O; Liao, ZY; Liu, H; Antony, S; Stevens, EV; Kohlhagen, G; Fu, HQ; Pommier, Y			Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; CLEAVAGE COMPLEXES; CELL APOPTOSIS; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; DAMAGE; GLUTATHIONE; ACTIVATION; CAMPTOTHECIN; INDUCTION	Topoisomerase I is an essential enzyme that relaxes DNA supercoiling by forming covalent DNA cleavage complexes, which are normally transient. Topoisomerase I-DNA complexes can be trapped by anticancer drugs (camptothecins) as well as by endogenous and exogenous DNA lesions. We show here that arsenic trioxide (a potent inducer of apoptosis that induces the intracellular accumulation of reactive oxygen species and targets mitochondria) induces cellular topoisomerase I cleavage complexes. Bcl-2 overexpression and quenching of reactive oxygen species, which prevent arsenic trioxide-induced apoptosis, also prevent the formation of topoisomerase I-DNA complexes, whereas enhancement of reactive oxygen species accumulation promotes these complexes. The caspase inhibitor, benzyloxycarbonyl-VAD partially prevents arsenic trioxide-induced topoisomerase I-DNA complexes and apoptosis, suggesting that activated caspases further maintain intracellular levels of reactive oxygen species that induce the formation of topoisomerase I-DNA complexes. Down-regulation of topoisomerase I expression decreases arsenic trioxide-induced apoptotic DNA fragmentation. Thus, we propose that arsenic trioxide induces topoisomerase I-DNA complexes that participate in chromatin fragmentation and programmed cell death during apoptosis.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; NCI, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 37,Rm 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	Sordet, Olivier/M-3271-2014	Sordet, Olivier/0000-0001-6027-4925	NATIONAL CANCER INSTITUTE [ZIABC006150, Z01BC006150] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KC, 2002, CANCER J, V8, P12, DOI 10.1097/00130404-200201000-00003; Antony S, 2003, CANCER RES, V63, P7428; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen GQ, 1996, BLOOD, V88, P1052; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Daroui P, 2004, J BIOL CHEM, V279, P14587, DOI 10.1074/jbc.M311370200; Davison K, 2004, BLOOD, V103, P3496, DOI 10.1182/blood-2003-05-1412; Davison K, 2003, LEUKEMIA, V17, P931, DOI 10.1038/sj.leu.2402876; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Jia PM, 2001, CHINESE MED J-PEKING, V114, P19; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kessel M, 2002, MOL CELL BIOCHEM, V234, P301, DOI 10.1023/A:1015927406142; Kinjo K, 2000, LEUKEMIA, V14, P431, DOI 10.1038/sj.leu.2401646; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Li DS, 2001, ENVIRON HEALTH PERSP, V109, P523, DOI 10.2307/3454712; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Matsui M, 1999, J INVEST DERMATOL, V113, P26, DOI 10.1046/j.1523-1747.1999.00630.x; MATTERN MR, 1993, ONCOL RES, V5, P467; McCafferty-Grad J, 2003, MOL CANCER THER, V2, P1155; Miller WH, 2002, CANCER RES, V62, P3893; Pommier Y, 1999, DRUG RESIST UPDATE, V2, P307, DOI 10.1054/drup.1999.0102; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Pourquier Philippe, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P303; Pulido MD, 2003, MUTAT RES-FUND MOL M, V533, P227, DOI 10.1016/j.mrfmmm.2003.07.015; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rojewski MT, 2004, CHEM RES TOXICOL, V17, P119, DOI 10.1021/tx034104+; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Schwerdtle T, 2003, CARCINOGENESIS, V24, P967, DOI 10.1093/carcin/bgg018; SCOTT N, 1993, CHEM RES TOXICOL, V6, P102, DOI 10.1021/tx00031a016; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Zhang Y, 2003, CELL BIOL INT, V27, P953, DOI 10.1016/S1065-6995(03)00164-1; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053	55	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33968	33975		10.1074/jbc.M404620200	http://dx.doi.org/10.1074/jbc.M404620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178684	hybrid			2022-12-27	WOS:000223039700107
J	Mohan, S; Bruns, JR; Weixel, KM; Edinger, RS; Bruns, JB; Kleyman, TR; Johnson, JP; Weisz, OA				Mohan, S; Bruns, JR; Weixel, KM; Edinger, RS; Bruns, JB; Kleyman, TR; Johnson, JP; Weisz, OA			Differential current decay profiles of epithelial sodium channel subunit combinations in polarized renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; APICAL MEMBRANE; A6 CELLS; XENOPUS OOCYTES; GAMMA-SUBUNIT; ALPHA-SUBUNIT; BETA-SUBUNIT; ENAC; EXPRESSION; ALDOSTERONE	In many epithelial tissues in the body, the rate of Na+ reabsorption is governed by the activity of the epithelial sodium channel (ENaC). The assembly, trafficking, and turnover of the three ENaC subunits (alpha, beta, and gamma) is complex and not well understood. Recent experiments suggest that ENaC must be proteolytically cleaved for maximal activity and may explain the discrepancies reported in prior biochemical approaches focused on quantitating the trafficking and half-life of full-length subunits. As an alternative approach to examining the dynamics of ENaC subunits, we have generated doxycycline-repressible replication-defective recombinant adenoviruses encoding individual epitope-tagged mouse ENaC subunits and expressed these in polarized MDCK I cells. Co-infection with these viruses encoding all three subunits generates robust amiloride-sensitive currents in polarized MDCK cells. Significant current was also observed in cells expressing alpha- and gamma-mENaC in the absence of beta-mENaC. These currents did not appear to result from association with endogenous canine beta-ENaC. Treatment of alphabetagamma-expressing cells with cycloheximide (CHX) resulted in the rapid inhibition (within 3 h) of similar to50-80% of the initial current; however, a sizable fraction of the initial current remained even after 6 h of CHX. By contrast, CHX addition to cells expressing only alpha- and gamma-mENaC resulted in rapid decay in current with no residual fraction. Our data suggest that ENaC channels of differing stoichiometries are differentially trafficked and degraded and provide support for the possibility that noncoordinate trafficking of ENaC subunits may function in vivo as a mechanism to modulate ENaC activity.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK065161, R01DK057718] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK57718, R01 DK65161, T32-DK61296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2001, J AM SOC NEPHROL, V12, P1114, DOI 10.1681/ASN.V1261114; Auberson M, 2003, AM J PHYSIOL-RENAL, V285, pF459, DOI 10.1152/ajprenal.00071.2003; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Hao MM, 2004, J BIOL CHEM, V279, P14171, DOI 10.1074/jbc.M309793200; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hill WG, 2002, J BIOL CHEM, V277, P33541, DOI 10.1074/jbc.C200309200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Kleyman TR, 2001, AM J PHYSIOL-RENAL, V281, pF213, DOI 10.1152/ajprenal.2001.281.2.F213; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Weisz OA, 2003, AM J PHYSIOL-RENAL, V285, pF833, DOI 10.1152/ajprenal.00088.2003; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	29	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32071	32078		10.1074/jbc.M405091200	http://dx.doi.org/10.1074/jbc.M405091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166222	hybrid			2022-12-27	WOS:000222849700011
J	Reverter-Branchat, G; Cabiscol, E; Tamarit, J; Ros, J				Reverter-Branchat, G; Cabiscol, E; Tamarit, J; Ros, J			Oxidative damage to specific proteins in replicative and chronological-aged Saccharomyces cerevisiae - Common targets and prevention by calorie restriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY-PHASE; LIFE-SPAN; STRESS; LONGEVITY; EXTENDS; DISEASE; ENZYME; CELLS; IDENTIFICATION; RESISTANCE	Oxidative modifications of cellular components have been described as one of the main contributions to aged phenotype. In Saccharomyces cerevisiae, two distinct life spans can be considered, replicative and chronological. The relationship between both aging models is still not clear despite suggestions that these phenomena may be related. In this work, we show that replicative and chronological-aged yeast cells are affected by an oxidative stress situation demonstrated by increased protein carbonylation when compared with young cells. The data on the identification of these oxidatively modified proteins gives clues to better understand cellular dysfunction that occurs during aging. Strikingly, although in both aging models metabolic differences are important, major targets are almost the same. Common targets include stress resistance proteins (Hsp60 and Hsp70) and enzymes involved in glucose metabolism such as enolase, glyceraldehydes-3-P dehydrogenase, fructose-1,6-biphosphate aldolase, pyruvate decarboxylase, and alcohol dehydrogenase. In both aging models, calorie restriction results in decreased damage to these proteins. In addition, chronological-aged cells grown under glucose restriction displayed lowered levels of lipid peroxidation product lipofuscin. Intracellular iron concentration is kept almost unchanged, whereas in non-restricted cells, the values increase up 4 - 5 times. The pro-oxidant effects of such increased iron concentration would account for the damage observed. Also, calorie-restricted cells show undamaged catalase, which clearly appears carbonylated in cells grown at a high glucose concentration. These results may explain lengthening of the viability of chronological-aged cells and could have an important role in replicative life span extension by calorie restriction.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25008, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Montserrat Roig 2, Lleida 25008, Spain.	joaquim.ros@cmb.udl.es	ROS, Joaquim/ABG-7487-2020; Cabiscol, Elisa/A-4584-2009; Tamarit, Jordi/C-6316-2008; Ros, Joaquim/A-7507-2010	ROS, Joaquim/0000-0003-0901-8648; Cabiscol, Elisa/0000-0003-2795-7999; Tamarit, Jordi/0000-0003-3227-6928; 				Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Ashrafi K, 1999, P NATL ACAD SCI USA, V96, P9100, DOI 10.1073/pnas.96.16.9100; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bitterman KJ, 2003, MICROBIOL MOL BIOL R, V67, P376, DOI 10.1128/MMBR.67.3.376-399.2003; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Brown RK, 1996, FREE RADICALS PRACTI, P119; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Butterfield DA, 2004, BRAIN RES, V1000, P1, DOI 10.1016/j.brainres.2003.12.012; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Cabiscol E, 2002, J BIOL CHEM, V277, P44531, DOI 10.1074/jbc.M206525200; Choi J, 2004, FREE RADICAL BIO MED, V36, P1155, DOI 10.1016/j.freeradbiomed.2004.02.002; Costa WMV, 2002, FREE RADICAL BIO MED, V33, P1507, DOI 10.1016/S0891-5849(02)01086-9; Fabrizio P, 2003, GENETICS, V163, P35; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GELLER BL, 1984, METHOD ENZYMOL, V105, P105; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Harris N, 2003, FREE RADICAL BIO MED, V34, P1599, DOI 10.1016/S0891-5849(03)00210-7; Harris N, 2001, MOL GENET GENOMICS, V265, P258, DOI 10.1007/s004380000409; Herman PK, 2002, CURR OPIN MICROBIOL, V5, P602, DOI 10.1016/S1369-5274(02)00377-6; Jakubowski W, 2000, FREE RADICAL BIO MED, V28, P659, DOI 10.1016/S0891-5849(99)00266-X; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; LARDINOIS OM, 1995, FREE RADICAL RES, V22, P251, DOI 10.3109/10715769509147544; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MacLean M, 2001, YEAST, V18, P499, DOI 10.1002/yea.701; MAITRA PK, 1971, J BIOL CHEM, V246, P475; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; Park PU, 2002, METHOD ENZYMOL, V351, P468; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; Roth GS, 1999, J AM GERIATR SOC, V47, P896, DOI 10.1111/j.1532-5415.1999.tb03851.x; Shanmuganathan A, 2004, FEBS LETT, V556, P253, DOI 10.1016/S0014-5793(03)01428-5; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993	52	170	177	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31983	31989		10.1074/jbc.M404849200	http://dx.doi.org/10.1074/jbc.M404849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15166233	hybrid, Green Published			2022-12-27	WOS:000222726800127
